data_2rlq_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2rlq _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.415 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 30.6 Cg_endo . . . . . 0 CA--C 1.542 0.907 0 CA-C-O 121.436 0.515 . . . . 0.0 111.761 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.1 m -85.03 -37.68 20.09 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 177.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.08 -92.41 0.48 Allowed Glycine 0 N--CA 1.41 -3.095 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 173.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.9 t60 -177.24 123.73 0.28 Allowed Pre-proline 0 C--N 1.26 -3.314 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 -177.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.433 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 34.8 Cg_endo -66.72 -49.91 1.42 Allowed 'Trans proline' 0 C--O 1.209 -0.933 0 C-N-CA 121.33 1.353 . . . . 0.0 110.722 -177.179 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 150.32 169.18 16.08 Favored Glycine 0 N--CA 1.401 -3.642 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 -177.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -136.03 139.93 43.46 Favored 'General case' 0 C--N 1.264 -3.113 0 CA-C-N 117.31 0.555 . . . . 0.0 109.688 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.5 t -99.9 128.97 29.58 Favored Pre-proline 0 N--CA 1.409 -2.525 0 CA-C-N 115.111 -0.949 . . . . 0.0 111.304 -172.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -69.04 -24.01 33.44 Favored 'Trans proline' 0 C--O 1.24 0.591 0 C-N-CA 122.884 2.389 . . . . 0.0 110.214 175.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -75.06 -28.28 60.31 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 114.014 -1.448 . . . . 0.0 110.763 -176.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.433 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -151.0 -133.21 2.03 Favored Glycine 0 N--CA 1.409 -3.159 0 C-N-CA 119.071 -1.538 . . . . 0.0 112.783 -177.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.0 p -144.1 170.67 15.51 Favored 'General case' 0 C--N 1.275 -2.64 0 CA-C-N 113.885 -1.157 . . . . 0.0 108.896 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -140.69 153.55 46.0 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 172.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -127.26 160.12 32.27 Favored 'General case' 0 C--N 1.274 -2.705 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -116.72 118.63 33.07 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 121.293 0.568 . . . . 0.0 109.874 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 26.2 p -111.88 133.64 53.95 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.755 -174.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 111.98 -53.13 0.6 Allowed Glycine 0 N--CA 1.434 -1.478 0 C-N-CA 120.865 -0.683 . . . . 0.0 111.557 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -131.31 -7.21 3.23 Favored Glycine 0 N--CA 1.441 -0.999 0 C-N-CA 120.196 -1.002 . . . . 0.0 113.109 -179.008 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 48.4 m-80 61.17 17.4 8.08 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.53 ' O ' HG11 ' A' ' 108' ' ' VAL . 19.7 m -149.01 -170.07 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.205 -1.286 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -177.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -103.47 45.57 0.95 Allowed 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 118.422 0.556 . . . . 0.0 110.083 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.757 ' O ' HG13 ' A' ' 108' ' ' VAL . 11.9 pt-20 -86.08 176.28 8.09 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 114.957 -1.019 . . . . 0.0 111.58 177.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . 0.429 ' CE1' ' HA ' ' A' ' 131' ' ' THR . 46.0 m-85 -72.91 133.23 44.29 Favored 'General case' 0 C--N 1.293 -1.859 0 O-C-N 121.976 -0.453 . . . . 0.0 111.273 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.36 -8.7 69.42 Favored Glycine 0 N--CA 1.434 -1.453 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.232 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.757 HG13 ' O ' ' A' ' 105' ' ' GLU . 14.2 p -80.67 147.69 6.19 Favored 'Isoleucine or valine' 0 C--O 1.238 0.481 0 CA-C-N 117.553 0.676 . . . . 0.0 109.946 -176.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 16.8 mtpp -112.38 119.08 37.03 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -87.91 96.49 10.5 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.434 HG13 ' HB3' ' A' ' 126' ' ' TYR . 18.8 m -94.81 115.82 34.59 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.327 0 CA-C-O 122.036 0.922 . . . . 0.0 109.979 -177.02 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 33.3 m-85 -83.07 144.43 29.9 Favored 'General case' 0 C--N 1.265 -3.072 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.524 -178.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.4 t -143.64 127.79 17.6 Favored 'General case' 0 N--CA 1.427 -1.621 0 CA-C-N 115.275 -0.875 . . . . 0.0 108.803 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 81.4 m -73.71 163.39 28.04 Favored 'General case' 0 C--N 1.292 -1.891 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.317 -176.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.433 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 95.4 m-20 -95.25 -179.15 4.69 Favored 'General case' 0 CA--C 1.476 -1.887 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.72 -178.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -69.09 93.96 0.63 Allowed 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 124.573 1.171 . . . . 0.0 109.753 177.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 133.66 2.13 3.64 Favored Glycine 0 C--N 1.259 -3.698 0 CA-C-N 112.961 -1.927 . . . . 0.0 111.781 177.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.416 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 87.8 m-85 -133.49 158.7 42.44 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -177.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -142.11 158.06 44.18 Favored 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 -177.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 13.9 tp -83.07 146.27 28.8 Favored 'General case' 0 N--CA 1.413 -2.282 0 C-N-CA 119.491 -0.884 . . . . 0.0 109.169 -177.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.09 121.64 38.33 Favored 'General case' 0 N--CA 1.405 -2.709 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.359 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 100.4 174.93 29.96 Favored Glycine 0 C--N 1.292 -1.897 0 N-CA-C 110.914 -0.875 . . . . 0.0 110.914 -174.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -88.05 -37.89 15.9 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.255 0.55 . . . . 0.0 110.112 -177.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.3 mm -66.7 124.47 21.96 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.758 -177.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -127.13 -4.34 6.23 Favored 'General case' 0 C--O 1.204 -1.317 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.434 ' HB3' HG13 ' A' ' 111' ' ' VAL . 11.9 p90 -137.23 161.83 35.14 Favored 'General case' 0 C--N 1.293 -1.888 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.496 -170.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 49.9 mtp180 -125.28 136.11 53.19 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 106.112 -1.81 . . . . 0.0 106.112 171.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -115.32 130.94 57.05 Favored 'General case' 0 C--N 1.273 -2.719 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 33.0 t -86.49 112.26 21.35 Favored 'General case' 0 C--N 1.293 -1.869 0 C-N-CA 119.109 -1.036 . . . . 0.0 110.83 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.464 ' OD2' HG22 ' A' ' 131' ' ' THR . 14.9 t70 -103.24 -171.26 1.91 Allowed 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 175.339 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.464 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -71.16 -17.78 62.53 Favored 'General case' 0 C--N 1.291 -1.946 0 CA-C-O 121.874 0.845 . . . . 0.0 110.309 -175.027 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -87.9 -8.77 55.34 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.691 179.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 112.78 -164.32 12.07 Favored Glycine 0 N--CA 1.427 -1.936 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -177.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.433 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 97.8 m95 -60.97 123.34 17.32 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 117.255 0.527 . . . . 0.0 110.579 176.037 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.6 p -64.46 -71.77 0.17 Allowed 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 123.554 0.742 . . . . 0.0 111.99 -178.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -81.58 177.66 8.8 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.175 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -106.12 177.84 4.74 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.282 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 65.0 mt -61.38 121.11 61.21 Favored Pre-proline 0 C--O 1.245 0.861 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 176.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.13 166.89 23.48 Favored 'Trans proline' 0 C--O 1.26 1.625 0 C-N-CA 122.424 2.083 . . . . 0.0 111.637 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 55.7 mt -90.06 127.02 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.03 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -177.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.416 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 53.6 t -121.07 115.62 23.46 Favored 'General case' 0 C--N 1.269 -2.916 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 174.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.18 151.95 23.43 Favored 'General case' 0 C--N 1.282 -2.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 109.864 -177.236 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.5 p -68.88 137.52 24.18 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.105 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 41.5 t -63.95 125.91 21.58 Favored 'Isoleucine or valine' 0 C--O 1.247 0.951 0 CA-C-O 121.111 0.482 . . . . 0.0 109.74 178.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -119.13 133.55 55.72 Favored 'General case' 0 N--CA 1.418 -2.074 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -179.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 72.8 m -99.63 141.18 32.77 Favored 'General case' 0 C--N 1.261 -3.267 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -58.63 138.5 86.12 Favored Pre-proline 0 N--CA 1.427 -1.579 0 N-CA-C 114.209 1.188 . . . . 0.0 114.209 -175.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -58.25 107.4 0.32 Allowed 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 123.346 2.698 . . . . 0.0 111.117 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 5.9 p -69.26 140.58 18.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 20.5 p -71.9 -71.81 0.26 Allowed 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 111.405 0.15 . . . . 0.0 111.405 -178.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.38 162.3 0.21 Allowed Pre-proline 0 C--O 1.248 1.005 0 C-N-CA 125.748 1.619 . . . . 0.0 106.712 177.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -74.3 170.88 19.19 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 121.512 1.475 . . . . 0.0 109.469 169.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . 0.487 ' HG3' ' ND2' ' A' ' 154' ' ' ASN . 11.4 pt-20 -60.67 -48.92 79.62 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 114.055 1.132 . . . . 0.0 114.055 -173.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . 0.487 ' ND2' ' HG3' ' A' ' 153' ' ' GLU . 60.2 m-80 -117.31 32.39 6.19 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.505 0.669 . . . . 0.0 109.668 -177.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.06 -176.59 18.22 Favored Glycine 0 C--N 1.303 -1.269 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.477 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.4 ptmt -145.21 173.27 12.09 Favored 'General case' 0 N--CA 1.434 -1.231 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -178.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 69.0 mt -88.22 138.49 19.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 CA-C-O 121.3 0.572 . . . . 0.0 110.957 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.6 t -89.29 -39.71 12.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 C-N-CA 124.426 1.09 . . . . 0.0 109.402 176.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 9.9 m . . . . . 0 C--N 1.313 -1.02 0 C-N-CA 123.512 0.725 . . . . 0.0 111.09 -178.128 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 . . . . . 0 N--CA 1.424 -1.768 0 CA-C-O 121.53 0.681 . . . . 0.0 111.198 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 47.2 m170 -84.32 164.07 19.21 Favored 'General case' 0 C--O 1.248 1.019 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.115 -179.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 72.4 t80 -52.63 134.64 35.68 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 123.697 0.799 . . . . 0.0 110.765 173.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 102.01 -23.34 34.92 Favored Glycine 0 C--N 1.314 -0.674 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.305 179.02 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -72.85 133.97 44.67 Favored 'General case' 0 N--CA 1.434 -1.229 0 CA-C-O 121.085 0.469 . . . . 0.0 111.991 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . 0.411 ' HB3' ' NE2' ' A' ' 191' ' ' HIS . . . -106.28 115.73 30.72 Favored 'General case' 0 N--CA 1.421 -1.889 0 CA-C-N 114.733 -1.122 . . . . 0.0 109.142 178.403 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 48.3 t -91.27 108.75 20.25 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 175.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.432 ' HD2' ' OE2' ' A' ' 188' ' ' GLU . 20.4 ttp180 -99.4 153.79 18.72 Favored 'General case' 0 N--CA 1.403 -2.82 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 177.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 83.4 m-85 -127.24 158.9 35.93 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 123.24 0.616 . . . . 0.0 109.533 -174.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.9 p -140.57 140.32 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.579 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 77.1 m -89.62 149.61 22.74 Favored 'General case' 0 C--N 1.278 -2.54 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.186 -179.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 81.8 m-20 -76.15 179.4 5.72 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.307 -178.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 25.2 p -53.72 111.26 0.7 Allowed 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 124.027 0.931 . . . . 0.0 112.511 -176.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 97.38 2.31 58.98 Favored Glycine 0 N--CA 1.433 -1.544 0 CA-C-N 115.846 -0.615 . . . . 0.0 113.847 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -111.6 149.09 31.97 Favored 'General case' 0 CA--C 1.484 -1.573 0 CA-C-N 117.971 0.886 . . . . 0.0 110.704 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . 0.408 ' HZ3' ' HA ' ' A' ' 185' ' ' GLU . 0.1 OUTLIER -122.38 145.86 47.88 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -178.678 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.6 tt -76.3 137.01 23.5 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 CA-C-O 122.049 0.928 . . . . 0.0 111.798 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . 0.408 ' HA ' ' HZ3' ' A' ' 183' ' ' LYS . 5.2 tp10 -84.33 -48.66 9.48 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.171 -176.382 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -91.09 -136.2 6.75 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.315 177.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . 0.432 ' OD1' ' HG3' ' A' ' 189' ' ' GLU . 12.2 t70 -102.58 163.68 12.09 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 178.443 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . 0.432 ' OE2' ' HD2' ' A' ' 175' ' ' ARG . 15.8 pt-20 -91.15 -13.85 32.22 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 118.887 0.767 . . . . 0.0 112.668 -174.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . 0.432 ' HG3' ' OD1' ' A' ' 187' ' ' ASP . 0.0 OUTLIER -120.03 144.92 47.28 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 112.84 0.682 . . . . 0.0 112.84 -176.724 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 37.0 ttm -135.97 124.33 23.35 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 124.864 1.266 . . . . 0.0 109.075 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . 0.411 ' NE2' ' HB3' ' A' ' 173' ' ' ALA . 30.7 m80 -97.86 155.44 17.06 Favored 'General case' 0 C--N 1.276 -2.618 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 40.6 t -94.94 116.88 29.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 173.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 8.4 p -100.23 170.21 8.61 Favored 'General case' 0 N--CA 1.437 -1.122 0 O-C-N 123.354 0.409 . . . . 0.0 111.174 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -60.01 -21.26 61.08 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 123.607 0.763 . . . . 0.0 112.064 -175.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 13.7 m-20 -64.51 -17.54 63.99 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.741 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 80.94 20.48 65.24 Favored Glycine 0 CA--C 1.488 -1.656 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -130.48 153.44 48.79 Favored 'General case' 0 N--CA 1.407 -2.597 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 -174.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 78.2 m95 -76.84 131.47 38.65 Favored 'General case' 0 C--N 1.291 -1.971 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.34 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.5 m -69.06 -38.33 79.01 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 115.639 -0.709 . . . . 0.0 112.289 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -103.73 156.95 17.41 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 20.0 pm0 -78.83 157.91 28.27 Favored 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 177.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -68.05 116.62 40.71 Favored Pre-proline 0 C--O 1.246 0.908 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 175.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -76.98 161.5 32.86 Favored 'Trans proline' 0 N--CA 1.433 -2.088 0 C-N-CA 122.218 1.945 . . . . 0.0 110.998 -178.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -104.52 161.83 13.77 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 120.226 -0.589 . . . . 0.0 109.6 178.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 88.9 m -122.19 108.55 13.43 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 172.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.1 m . . . . . 0 C--N 1.291 -1.957 0 O-C-N 124.405 1.066 . . . . 0.0 108.818 -173.788 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.418 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 19.1 Cg_endo . . . . . 0 CA--C 1.537 0.657 0 CA-C-O 120.859 0.274 . . . . 0.0 112.205 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 50.0 m -71.67 -43.98 65.07 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.756 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 97.07 112.44 2.94 Favored Glycine 0 C--O 1.187 -2.791 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 -179.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -34.36 119.52 0.54 Allowed Pre-proline 0 C--N 1.296 -1.734 0 C-N-CA 127.235 2.214 . . . . 0.0 112.129 -173.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -60.67 -43.32 32.99 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.283 2.655 . . . . 0.0 113.305 -172.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 139.73 -174.98 22.06 Favored Glycine 0 N--CA 1.421 -2.336 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -133.78 156.66 47.6 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-N 117.403 0.602 . . . . 0.0 109.691 -178.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.1 t -115.3 126.63 27.59 Favored Pre-proline 0 C--N 1.305 -1.368 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.282 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -66.97 -18.8 52.29 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.555 2.17 . . . . 0.0 112.556 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -87.7 -15.05 38.21 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.37 -175.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.493 ' HA2' ' ND2' ' A' ' 115' ' ' ASN . . . -163.62 -133.43 1.48 Allowed Glycine 0 N--CA 1.409 -3.136 0 C-N-CA 118.635 -1.745 . . . . 0.0 113.004 -177.413 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.1 p -144.2 179.59 7.13 Favored 'General case' 0 C--N 1.284 -2.249 0 CA-C-N 114.439 -0.881 . . . . 0.0 109.264 -176.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -141.5 157.65 44.86 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 172.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.4 m -127.56 162.53 26.24 Favored 'General case' 0 C--N 1.278 -2.524 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.0 mt -118.43 117.03 27.94 Favored 'General case' 0 C--N 1.277 -2.579 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.487 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 19.5 p -109.16 127.63 54.35 Favored 'General case' 0 C--N 1.282 -2.364 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.245 -172.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 113.97 -37.92 3.38 Favored Glycine 0 N--CA 1.433 -1.567 0 C-N-CA 120.406 -0.902 . . . . 0.0 111.975 179.212 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -144.28 -7.14 0.5 Allowed Glycine 0 C--N 1.315 -0.588 0 C-N-CA 119.715 -1.231 . . . . 0.0 113.756 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 92.6 m-20 61.14 15.11 6.01 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.517 ' O ' HG11 ' A' ' 108' ' ' VAL . 24.0 m -146.52 -169.42 0.24 Allowed 'Isoleucine or valine' 0 C--O 1.209 -1.027 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -176.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -106.46 40.29 1.65 Allowed 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 118.29 0.496 . . . . 0.0 110.227 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.771 ' O ' HG13 ' A' ' 108' ' ' VAL . 10.1 pt-20 -83.04 176.48 9.21 Favored 'General case' 0 C--O 1.205 -1.24 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.046 178.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . 0.418 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 35.5 m-85 -72.88 133.26 44.33 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.218 177.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.51 5.05 63.6 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.34 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.771 HG13 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -94.97 147.16 5.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.171 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.487 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 51.8 mtpt -110.76 118.47 36.25 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 178.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -83.28 92.48 7.51 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.301 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.543 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 35.0 m -89.1 117.71 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.824 0 CA-C-O 122.151 0.977 . . . . 0.0 109.903 -178.521 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 31.5 m-85 -85.88 139.48 31.21 Favored 'General case' 0 C--N 1.263 -3.182 0 CA-C-N 115.129 -0.941 . . . . 0.0 108.896 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.2 t -138.96 124.6 19.54 Favored 'General case' 0 N--CA 1.407 -2.603 0 CA-C-O 121.999 0.904 . . . . 0.0 109.671 -178.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 74.3 m -71.74 161.79 30.44 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-N 115.0 -1.0 . . . . 0.0 112.455 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.493 ' ND2' ' HA2' ' A' ' 94' ' ' GLY . 81.3 m-20 -86.31 -176.59 5.95 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.479 179.098 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -46.87 -50.94 17.81 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 126.513 1.925 . . . . 0.0 114.008 -177.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -91.19 28.36 8.17 Favored Glycine 0 C--N 1.305 -1.158 0 C-N-CA 119.736 -1.221 . . . . 0.0 113.179 -177.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.451 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 98.8 m-85 -149.37 167.51 25.94 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -173.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . 0.42 HE22 HD21 ' A' ' 121' ' ' LEU . 1.0 OUTLIER -153.88 156.87 38.37 Favored 'General case' 0 N--CA 1.435 -1.195 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.81 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . 0.465 ' HG ' ' CB ' ' A' ' 125' ' ' ASN . 0.5 OUTLIER -85.99 128.39 34.84 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -175.182 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.42 HD21 HE22 ' A' ' 119' ' ' GLN . 0.3 OUTLIER -102.1 130.1 48.62 Favored 'General case' 0 N--CA 1.422 -1.864 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 -175.741 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.74 -159.7 13.83 Favored Glycine 0 C--N 1.297 -1.63 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.296 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -106.03 -41.63 5.33 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 121.835 0.826 . . . . 0.0 109.267 -178.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 51.1 mm -85.17 122.92 38.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 CA-C-N 114.772 -1.104 . . . . 0.0 110.069 -176.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.465 ' CB ' ' HG ' ' A' ' 120' ' ' LEU . 3.9 p-10 -127.59 7.12 6.27 Favored 'General case' 0 C--O 1.202 -1.41 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 176.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.543 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 15.4 p90 -134.25 168.21 19.3 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -171.784 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.446 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 36.3 mtp180 -130.67 119.89 23.1 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 170.399 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -92.32 126.76 37.54 Favored 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.846 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 49.3 t -84.7 108.04 17.21 Favored 'General case' 0 N--CA 1.434 -1.266 0 C-N-CA 119.142 -1.023 . . . . 0.0 109.249 174.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -101.76 -171.22 1.94 Allowed 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 105.354 -2.091 . . . . 0.0 105.354 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 15.3 t -64.37 -15.34 60.26 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.841 0.829 . . . . 0.0 110.593 -178.511 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -97.88 -2.17 41.35 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.255 -178.686 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 103.48 -159.44 16.93 Favored Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -177.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 86.9 m95 -68.64 108.47 3.37 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 177.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 41.7 p -67.71 -57.51 6.23 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 115.439 -0.8 . . . . 0.0 112.655 -175.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . 0.446 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 6.4 m120 -71.83 171.22 12.07 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.957 -178.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 25.2 m-20 -100.74 176.61 5.24 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 176.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 88.6 mt -66.35 119.07 59.39 Favored Pre-proline 0 C--O 1.237 0.407 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 173.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -64.46 164.7 22.48 Favored 'Trans proline' 0 N--CA 1.451 -0.993 0 C-N-CA 122.601 2.2 . . . . 0.0 112.986 -177.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 50.0 mm -96.49 124.47 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.766 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.903 -175.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.451 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 48.9 t -105.66 136.12 45.83 Favored 'General case' 0 C--N 1.27 -2.882 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 177.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -124.91 141.8 51.88 Favored 'General case' 0 N--CA 1.413 -2.28 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -177.236 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 6.2 p -68.34 139.19 21.09 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 O-C-N 123.874 0.734 . . . . 0.0 109.573 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.618 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 21.1 m -65.83 129.44 30.14 Favored 'Isoleucine or valine' 0 C--O 1.251 1.168 0 C-N-CA 120.48 -0.488 . . . . 0.0 110.094 178.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 89.4 mttt -114.79 166.6 11.58 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -178.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 82.0 m -129.43 -174.22 3.23 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-O 121.135 0.493 . . . . 0.0 111.457 -175.081 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 31.1 mt -77.72 137.0 62.76 Favored Pre-proline 0 N--CA 1.439 -0.991 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.315 177.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -70.86 112.51 3.29 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 C-N-CA 122.279 1.986 . . . . 0.0 109.683 175.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 27.8 t -82.81 136.61 22.51 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 -179.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.6 p -76.93 -73.71 0.28 Allowed 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 123.104 0.252 . . . . 0.0 111.518 179.371 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 167.9 160.19 0.15 Allowed Pre-proline 0 C--O 1.239 0.548 0 C-N-CA 126.128 1.771 . . . . 0.0 106.95 -179.368 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -77.49 170.05 19.99 Favored 'Trans proline' 0 CA--C 1.542 0.883 0 C-N-CA 121.586 1.524 . . . . 0.0 110.26 170.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -63.14 -52.6 61.87 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 -176.126 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -106.48 33.45 3.87 Favored 'General case' 0 CA--C 1.499 -1.011 0 CA-C-O 121.363 0.601 . . . . 0.0 109.981 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -151.59 -167.35 14.85 Favored Glycine 0 N--CA 1.42 -2.406 0 C-N-CA 120.133 -1.032 . . . . 0.0 112.062 178.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . 0.454 ' HG3' HG21 ' A' ' 177' ' ' VAL . 59.6 pttt -154.55 176.19 12.7 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -179.435 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 49.3 mt -98.31 145.05 10.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -179.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.447 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.5 m -89.12 -31.39 5.42 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.081 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 6.7 m . . . . . 0 C--N 1.313 -1.02 0 C-N-CA 124.603 1.161 . . . . 0.0 110.951 -175.325 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 . . . . . 0 N--CA 1.463 0.184 0 CA-C-O 121.623 0.725 . . . . 0.0 112.181 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.406 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 35.9 m80 -141.61 162.44 35.48 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -177.086 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . 0.618 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 91.6 t80 -48.25 139.43 8.58 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-O 121.194 0.521 . . . . 0.0 112.104 175.342 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 87.37 -15.22 55.31 Favored Glycine 0 N--CA 1.423 -2.217 0 CA-C-O 119.204 -0.776 . . . . 0.0 113.867 175.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . 0.41 ' O ' ' HA ' ' A' ' 191' ' ' HIS . 29.2 mm-40 -65.0 135.76 56.01 Favored 'General case' 0 CA--C 1.496 -1.127 0 CA-C-N 118.233 1.017 . . . . 0.0 111.157 -178.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -104.71 113.96 27.87 Favored 'General case' 0 C--N 1.287 -2.148 0 CA-C-N 114.518 -1.219 . . . . 0.0 108.325 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 98.0 t -105.5 102.28 13.62 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.447 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 40.9 ttm180 -97.06 146.97 24.5 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.437 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -116.06 156.54 26.19 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.14 0.495 . . . . 0.0 110.217 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.454 HG21 ' HG3' ' A' ' 156' ' ' LYS . 0.1 OUTLIER -127.76 135.18 63.75 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.131 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.146 177.583 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 77.7 m -93.91 139.25 31.13 Favored 'General case' 0 C--N 1.262 -3.231 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 173.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -56.02 157.55 4.47 Favored 'General case' 0 C--N 1.294 -1.829 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.208 176.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.8 m -52.25 111.12 0.57 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 124.319 1.012 . . . . 0.0 112.07 -174.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 106.6 1.71 37.35 Favored Glycine 0 N--CA 1.426 -1.984 0 C-N-CA 120.317 -0.944 . . . . 0.0 112.863 177.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -113.41 158.81 20.17 Favored 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 117.994 0.897 . . . . 0.0 110.169 176.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 15.6 pttm -120.62 153.38 36.91 Favored 'General case' 0 N--CA 1.428 -1.573 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 2.1 tt -84.67 131.06 34.93 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.911 0 C-N-CA 119.28 -0.968 . . . . 0.0 109.728 176.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -82.43 -48.33 11.22 Favored 'General case' 0 C--N 1.286 -2.165 0 CA-C-N 114.717 -1.129 . . . . 0.0 109.747 -175.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -83.89 -151.66 12.62 Favored Glycine 0 C--N 1.304 -1.213 0 CA-C-N 114.847 -1.07 . . . . 0.0 110.528 176.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -80.62 164.56 22.78 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -89.32 -3.27 58.55 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.91 -172.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -157.89 162.48 38.32 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.57 -176.257 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 17.8 ptp -137.06 153.67 50.53 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 114.81 -1.086 . . . . 0.0 108.16 176.103 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . 0.41 ' HA ' ' O ' ' A' ' 172' ' ' GLN . 22.0 m80 -125.64 151.66 46.22 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.652 0.263 . . . . 0.0 110.676 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 18.9 m -76.21 112.6 12.86 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 171.062 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 23.3 t -82.24 171.05 14.71 Favored 'General case' 0 N--CA 1.422 -1.85 0 O-C-N 124.383 1.052 . . . . 0.0 110.038 -176.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -50.54 -34.92 27.32 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 125.448 1.499 . . . . 0.0 112.198 -178.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -69.48 -14.24 62.77 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.155 -0.93 . . . . 0.0 113.367 -177.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 83.7 29.25 32.81 Favored Glycine 0 C--O 1.225 -0.466 0 C-N-CA 120.439 -0.886 . . . . 0.0 110.893 -174.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -138.33 172.64 12.6 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 70.6 m95 -80.16 136.28 36.48 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 120.816 0.341 . . . . 0.0 111.252 -179.342 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 25.7 p -73.88 -22.57 59.68 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.197 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . 0.529 ' HE2' ' HA ' ' A' ' 200' ' ' LYS . 3.9 mmpt? -122.62 166.49 14.78 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.483 0.658 . . . . 0.0 111.572 -179.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -89.71 164.68 14.59 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 179.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 43.7 mtpt -66.63 122.76 83.54 Favored Pre-proline 0 C--N 1.309 -1.155 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.038 174.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -77.58 163.38 29.47 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 C-N-CA 122.03 1.82 . . . . 0.0 111.155 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 53.7 tttp -120.22 152.09 38.23 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -178.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 88.8 m -114.81 114.81 26.05 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 176.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 19.5 m . . . . . 0 C--N 1.3 -1.582 0 O-C-N 124.277 0.985 . . . . 0.0 109.175 -175.447 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo . . . . . 0 CA--C 1.538 0.689 0 CA-C-O 122.001 0.751 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 37.2 m -88.33 -36.49 16.61 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 177.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 120.53 -91.36 0.49 Allowed Glycine 0 CA--C 1.458 -3.484 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 172.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -176.11 127.6 0.35 Allowed Pre-proline 0 C--N 1.266 -3.05 0 N-CA-C 104.77 -2.308 . . . . 0.0 104.77 -176.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.406 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 61.5 Cg_endo -74.1 -17.5 21.96 Favored 'Trans proline' 0 C--N 1.329 -0.478 0 C-N-CA 122.44 2.093 . . . . 0.0 113.977 -175.301 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 131.0 -173.78 20.16 Favored Glycine 0 N--CA 1.427 -1.909 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 -176.432 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -147.39 144.13 28.47 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.7 t -122.32 130.08 24.83 Favored Pre-proline 0 C--N 1.305 -1.352 0 CA-C-O 121.194 0.521 . . . . 0.0 111.279 -178.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.74 -12.21 24.23 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.689 2.259 . . . . 0.0 111.676 178.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -95.04 14.36 22.11 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.717 -176.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 160.22 -122.33 1.12 Allowed Glycine 0 N--CA 1.421 -2.366 0 N-CA-C 111.084 -0.807 . . . . 0.0 111.084 178.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 t -172.31 -168.23 0.52 Allowed 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -177.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -147.56 170.2 17.97 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.7 m -138.46 156.83 47.19 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.481 HD11 ' CE1' ' A' ' 104' ' ' PHE . 14.6 mt -106.65 133.41 51.37 Favored 'General case' 0 C--N 1.276 -2.601 0 CA-C-O 121.213 0.53 . . . . 0.0 110.375 -176.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.448 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 23.8 p -121.23 116.68 25.36 Favored 'General case' 0 C--N 1.294 -1.813 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.59 -176.382 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.56 -58.93 0.7 Allowed Glycine 0 N--CA 1.434 -1.47 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -179.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -127.23 -4.51 5.9 Favored Glycine 0 N--CA 1.437 -1.247 0 C-N-CA 120.159 -1.019 . . . . 0.0 112.479 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 63.05 12.91 6.31 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 123.706 0.803 . . . . 0.0 112.517 -177.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.534 ' O ' HG13 ' A' ' 108' ' ' VAL . 30.6 m -145.12 -171.86 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 -176.633 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.481 ' CE1' HD11 ' A' ' 98' ' ' LEU . 27.1 m-85 -101.01 44.45 1.01 Allowed 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 118.648 0.658 . . . . 0.0 110.074 -176.03 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.736 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.6 pt-20 -84.68 179.28 7.4 Favored 'General case' 0 C--O 1.209 -1.035 0 CA-C-N 114.639 -1.164 . . . . 0.0 112.101 178.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -78.57 132.2 37.06 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.359 0.6 . . . . 0.0 111.345 178.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 101.06 -8.67 57.64 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 115.067 -0.97 . . . . 0.0 112.475 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.736 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -86.29 143.7 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 CA-C-O 121.418 0.628 . . . . 0.0 110.726 -174.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.448 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 19.6 mtpp -110.05 119.57 39.72 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.634 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -85.57 95.08 9.21 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 177.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 55.3 t -90.33 114.93 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.58 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 -177.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -83.94 138.92 32.9 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.94 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.3 t -134.07 116.73 15.8 Favored 'General case' 0 N--CA 1.42 -1.957 0 CA-C-N 115.032 -0.986 . . . . 0.0 108.672 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 21.0 m -72.88 160.06 32.74 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.49 -175.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -68.63 -179.72 1.47 Allowed 'General case' 0 C--N 1.315 -0.911 0 C-N-CA 122.95 0.5 . . . . 0.0 111.392 -177.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -59.43 -50.96 71.94 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 123.828 0.851 . . . . 0.0 111.212 -177.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -87.56 31.16 4.63 Favored Glycine 0 C--N 1.309 -0.924 0 C-N-CA 120.984 -0.627 . . . . 0.0 113.094 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -145.76 161.44 39.92 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -177.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -142.22 173.67 11.31 Favored 'General case' 0 C--N 1.271 -2.845 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 -179.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 11.9 tp -92.4 149.92 21.12 Favored 'General case' 0 C--N 1.273 -2.753 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.51 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -132.65 130.91 40.76 Favored 'General case' 0 N--CA 1.415 -2.204 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 177.9 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 116.49 -153.41 17.44 Favored Glycine 0 N--CA 1.433 -1.547 0 C-N-CA 120.646 -0.788 . . . . 0.0 111.526 179.08 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -112.3 -41.69 3.86 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 121.82 0.819 . . . . 0.0 110.068 -178.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.406 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.5 mm -85.97 144.34 9.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.782 -173.735 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 22.4 p-10 -135.24 4.32 3.18 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-O 120.79 0.328 . . . . 0.0 110.595 175.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 5.4 p90 -145.95 165.98 27.38 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.232 -172.381 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.406 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 44.8 mtp180 -128.56 125.67 38.74 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.409 -1.7 . . . . 0.0 106.409 171.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 55.9 tt0 -103.71 136.04 44.15 Favored 'General case' 0 C--N 1.286 -2.19 0 C-N-CA 118.352 -1.339 . . . . 0.0 110.378 179.411 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . 0.419 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 21.2 t -87.33 106.93 18.27 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.237 175.336 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -102.62 -166.76 1.31 Allowed 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 104.621 -2.363 . . . . 0.0 104.621 175.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 10.6 t -61.21 -29.83 70.05 Favored 'General case' 0 C--N 1.295 -1.769 0 CA-C-N 118.93 0.786 . . . . 0.0 112.81 -175.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -78.76 -16.53 57.08 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 121.743 0.782 . . . . 0.0 110.798 177.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.419 ' HA2' ' SG ' ' A' ' 129' ' ' CYS . . . 116.02 -148.16 18.9 Favored Glycine 0 N--CA 1.416 -2.676 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 -175.237 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 86.7 m95 -66.92 109.66 3.03 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 117.092 0.446 . . . . 0.0 109.858 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.1 p -64.82 -69.58 0.28 Allowed 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 124.219 1.008 . . . . 0.0 112.037 -176.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -75.79 167.94 20.94 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 114.012 -1.449 . . . . 0.0 108.94 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -104.23 178.13 4.65 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 123.629 0.58 . . . . 0.0 110.393 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 64.6 mt -64.31 126.19 89.91 Favored Pre-proline 0 C--N 1.314 -0.941 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.625 -178.565 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . 0.406 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 48.2 Cg_endo -70.36 170.77 16.5 Favored 'Trans proline' 0 C--O 1.251 1.172 0 C-N-CA 122.654 2.236 . . . . 0.0 112.404 178.362 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.51 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 56.1 mt -97.6 127.43 49.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.742 -178.232 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 61.2 m -106.82 123.83 48.72 Favored 'General case' 0 C--N 1.273 -2.737 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 169.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -111.8 151.4 29.06 Favored 'General case' 0 C--N 1.276 -2.618 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.17 142.49 15.48 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.563 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.4 m -68.52 113.69 4.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 119.93 -0.708 . . . . 0.0 109.462 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 87.8 mttt -105.46 133.99 49.31 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.189 -177.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.3 m -97.32 149.97 21.48 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -59.44 143.83 85.13 Favored Pre-proline 0 N--CA 1.42 -1.937 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 177.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -56.94 114.37 1.89 Allowed 'Trans proline' 0 C--O 1.252 1.204 0 C-N-CA 123.479 2.786 . . . . 0.0 111.429 179.121 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.4 HG23 ' SD ' ' A' ' 190' ' ' MET . 14.4 p -89.0 137.64 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.723 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.713 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' THR . . . . . 0.401 ' O ' HD12 ' A' ' 157' ' ' ILE . 15.3 p -94.12 -158.74 0.65 Allowed 'General case' 0 N--CA 1.414 -2.262 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.065 177.271 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -122.44 160.21 49.23 Favored Pre-proline 0 C--N 1.291 -1.944 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 -173.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -71.3 -170.21 0.48 Allowed 'Trans proline' 0 CA--C 1.555 1.545 0 C-N-CA 121.171 1.247 . . . . 0.0 110.61 176.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . 0.516 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.0 OUTLIER -79.27 -46.5 17.66 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 112.557 0.577 . . . . 0.0 112.557 -171.942 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . 0.516 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 57.5 m-80 -110.52 14.59 22.45 Favored 'General case' 0 CA--C 1.502 -0.901 0 CA-C-O 121.435 0.636 . . . . 0.0 110.586 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -127.96 -176.2 14.36 Favored Glycine 0 N--CA 1.423 -2.212 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 45.6 pttt -151.56 -178.83 6.92 Favored 'General case' 0 C--N 1.292 -1.913 0 C-N-CA 123.451 0.7 . . . . 0.0 109.229 -175.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.401 HD12 ' O ' ' A' ' 150' ' ' THR . 56.1 mt -103.3 135.04 42.71 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 CA-C-N 118.018 0.372 . . . . 0.0 111.193 -176.1 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.46 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.7 m -79.0 -32.17 15.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.03 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.0 m . . . . . 0 C--N 1.32 -0.708 0 C-N-CA 124.588 1.155 . . . . 0.0 110.013 -176.304 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 64.5 m-85 . . . . . 0 N--CA 1.429 -1.501 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 45.6 m170 -120.77 163.78 17.6 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -176.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . 0.563 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 93.7 t80 -46.83 126.55 8.84 Favored 'General case' 0 C--O 1.237 0.416 0 O-C-N 124.284 0.99 . . . . 0.0 109.964 172.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 115.75 -34.63 4.67 Favored Glycine 0 N--CA 1.424 -2.152 0 C-N-CA 120.097 -1.049 . . . . 0.0 111.656 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -67.41 134.33 51.24 Favored 'General case' 0 C--O 1.25 1.097 0 CA-C-O 121.519 0.676 . . . . 0.0 112.669 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -124.87 107.32 10.76 Favored 'General case' 0 N--CA 1.431 -1.419 0 CA-C-N 114.284 -1.325 . . . . 0.0 107.934 179.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 64.9 t -92.64 116.92 34.87 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.088 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.938 -176.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.46 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 39.8 ttm180 -106.44 147.8 28.89 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 176.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -111.99 160.32 17.58 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 123.589 0.755 . . . . 0.0 110.228 -177.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.65 155.66 41.54 Favored 'Isoleucine or valine' 0 CA--C 1.469 -2.163 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.531 178.411 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 10.0 m -111.89 145.19 39.95 Favored 'General case' 0 N--CA 1.396 -3.162 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.24 172.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -64.28 171.99 2.76 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.993 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.9 m -48.2 -25.73 1.62 Allowed 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 116.677 2.103 . . . . 0.0 116.677 -169.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -112.51 8.9 26.29 Favored Glycine 0 C--N 1.298 -1.533 0 C-N-CA 120.2 -1.0 . . . . 0.0 113.568 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -126.84 178.87 5.68 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 117.3 0.55 . . . . 0.0 111.793 -176.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 15.0 pttp -150.68 165.13 34.36 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.7 tp -71.86 151.92 8.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.232 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -80.17 -73.12 0.37 Allowed 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.196 176.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -102.35 -100.18 2.51 Favored Glycine 0 CA--C 1.5 -0.887 0 C-N-CA 120.156 -1.021 . . . . 0.0 112.001 -177.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -86.43 154.28 21.27 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 177.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -108.68 3.6 22.94 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.991 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -153.05 158.71 42.36 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -174.362 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.4 ' SD ' HG23 ' A' ' 149' ' ' VAL . 13.3 ptp -135.8 156.08 49.36 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 124.695 1.198 . . . . 0.0 108.787 178.652 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.1 t-80 -137.5 142.25 41.49 Favored 'General case' 0 C--N 1.31 -1.124 0 O-C-N 122.305 -0.247 . . . . 0.0 110.659 -176.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 30.1 m -80.31 123.38 27.94 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 123.691 0.619 . . . . 0.0 111.398 174.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 67.6 m -111.62 -175.93 2.82 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 175.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.02 -17.61 53.19 Favored 'General case' 0 N--CA 1.504 2.229 0 C-N-CA 122.84 0.456 . . . . 0.0 111.843 -173.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -55.97 -35.56 66.87 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 124.441 1.096 . . . . 0.0 111.053 177.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 87.09 17.07 59.88 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 -173.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -137.07 165.74 25.33 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.0 m95 -77.16 140.64 40.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 O-C-N 123.755 0.659 . . . . 0.0 109.279 178.182 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.3 m -81.16 -6.0 58.35 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.504 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 17.2 tppt? -136.9 161.63 35.49 Favored 'General case' 0 N--CA 1.427 -1.611 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -104.25 178.08 4.66 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 117.554 0.161 . . . . 0.0 110.771 -177.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? -64.11 117.36 35.57 Favored Pre-proline 0 C--O 1.243 0.723 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 177.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -76.96 -169.06 0.66 Allowed 'Trans proline' 0 N--CA 1.446 -1.265 0 C-N-CA 122.107 1.872 . . . . 0.0 110.651 176.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . 0.427 ' HG2' ' N ' ' A' ' 205' ' ' CYS . 46.5 tttm -131.14 160.26 35.25 Favored 'General case' 0 N--CA 1.42 -1.972 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -177.111 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.427 ' N ' ' HG2' ' A' ' 204' ' ' LYS . 9.4 t -110.88 129.68 55.8 Favored 'General case' 0 N--CA 1.423 -1.789 0 N-CA-C 105.697 -1.964 . . . . 0.0 105.697 176.261 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 11.0 m . . . . . 0 C--N 1.301 -1.535 0 CA-C-O 118.491 -0.766 . . . . 0.0 111.578 -174.657 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo . . . . . 0 N--CA 1.483 0.907 0 CA-C-O 121.581 0.576 . . . . 0.0 112.658 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 59.6 m -71.63 -24.71 61.92 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.787 -178.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 96.43 14.72 43.43 Favored Glycine 0 C--N 1.302 -1.359 0 CA-C-N 115.444 -0.798 . . . . 0.0 114.808 171.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 59.2 t-80 69.23 115.39 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.764 0 C-N-CA 123.96 0.904 . . . . 0.0 109.835 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.408 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 42.7 Cg_endo -67.48 -42.25 7.51 Favored 'Trans proline' 0 C--O 1.221 -0.358 0 C-N-CA 122.141 1.894 . . . . 0.0 112.644 -174.434 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 136.07 174.64 13.45 Favored Glycine 0 N--CA 1.422 -2.286 0 N-CA-C 107.592 -2.203 . . . . 0.0 107.592 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 48.1 t0 -134.32 169.02 17.83 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 -177.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.0 t -131.56 126.43 21.09 Favored Pre-proline 0 C--N 1.285 -2.197 0 CA-C-N 117.897 0.317 . . . . 0.0 110.927 -177.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -69.72 -11.39 30.8 Favored 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 122.888 2.392 . . . . 0.0 111.477 177.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -91.84 4.12 53.59 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.06 -178.425 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.588 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.9 -131.36 1.95 Allowed Glycine 0 N--CA 1.401 -3.691 0 C-N-CA 119.637 -1.268 . . . . 0.0 112.475 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.7 p -153.83 -179.17 7.58 Favored 'General case' 0 C--N 1.287 -2.113 0 C-N-CA 124.4 1.08 . . . . 0.0 109.708 -177.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -145.68 160.34 41.84 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 172.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.3 m -125.4 159.93 30.64 Favored 'General case' 0 C--N 1.283 -2.3 0 N-CA-C 107.111 -1.441 . . . . 0.0 107.111 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 16.7 mt -116.97 115.82 26.19 Favored 'General case' 0 C--N 1.273 -2.733 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.517 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 31.9 p -106.76 133.04 52.04 Favored 'General case' 0 C--N 1.271 -2.843 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.257 -173.719 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 108.04 -67.67 0.23 Allowed Glycine 0 N--CA 1.429 -1.828 0 N-CA-C 110.611 -0.995 . . . . 0.0 110.611 -179.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -106.58 -14.83 18.74 Favored Glycine 0 C--N 1.309 -0.926 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.784 -176.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 59.81 19.09 7.94 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.206 1.002 . . . . 0.0 112.787 -178.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.466 ' O ' HG11 ' A' ' 108' ' ' VAL . 27.8 m -150.24 -172.19 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 -177.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -100.47 41.37 1.18 Allowed 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 118.642 0.655 . . . . 0.0 111.164 -176.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.762 ' O ' HG13 ' A' ' 108' ' ' VAL . 10.9 pt-20 -85.64 179.94 7.0 Favored 'General case' 0 C--O 1.207 -1.145 0 C-N-CA 123.971 0.908 . . . . 0.0 112.577 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -75.13 132.7 41.39 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.808 -0.557 . . . . 0.0 111.128 176.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.06 -5.42 63.38 Favored Glycine 0 N--CA 1.438 -1.206 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.681 178.064 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.762 HG13 ' O ' ' A' ' 105' ' ' GLU . 13.7 p -85.27 145.66 7.63 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.517 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 19.0 mtpp -111.55 113.96 26.71 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -81.4 94.23 6.76 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 177.255 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 33.0 m -92.19 120.11 40.83 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.193 0 CA-C-O 121.969 0.89 . . . . 0.0 108.897 -177.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -87.79 138.58 31.34 Favored 'General case' 0 C--N 1.262 -3.199 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.794 -177.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.0 t -137.36 110.23 7.65 Favored 'General case' 0 N--CA 1.407 -2.61 0 CA-C-O 122.381 1.086 . . . . 0.0 109.214 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 15.8 m -67.87 159.24 30.84 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.473 -1.239 . . . . 0.0 110.465 -177.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.588 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 92.0 m-20 -77.26 -179.11 5.46 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 120.746 0.308 . . . . 0.0 111.322 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -46.58 -52.51 13.37 Favored 'General case' 0 C--N 1.31 -1.138 0 C-N-CA 126.266 1.826 . . . . 0.0 114.428 -177.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -82.19 6.25 68.5 Favored Glycine 0 C--N 1.315 -0.589 0 C-N-CA 120.543 -0.837 . . . . 0.0 113.178 -176.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -128.19 166.96 17.53 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -176.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -145.35 165.73 27.62 Favored 'General case' 0 C--N 1.283 -2.312 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 176.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.07 123.68 29.73 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -178.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -106.85 126.31 52.14 Favored 'General case' 0 N--CA 1.416 -2.151 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 178.113 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 110.9 174.6 20.21 Favored Glycine 0 C--N 1.299 -1.486 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -176.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -85.6 -44.02 12.99 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 -178.114 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.7 mm -72.08 125.15 30.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 CA-C-N 114.175 -1.375 . . . . 0.0 110.39 -177.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -125.4 5.06 7.67 Favored 'General case' 0 C--O 1.202 -1.398 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 175.123 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 15.7 p90 -143.27 163.06 34.02 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.288 -171.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 50.9 mtp180 -126.96 130.51 50.22 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 174.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -106.14 130.25 54.06 Favored 'General case' 0 C--N 1.29 -2.0 0 C-N-CA 119.707 -0.797 . . . . 0.0 108.978 -179.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 26.5 t -84.31 108.51 17.2 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.466 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.428 ' OD1' HG23 ' A' ' 131' ' ' THR . 6.5 t70 -107.98 -167.22 1.22 Allowed 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.38 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.428 HG23 ' OD1' ' A' ' 130' ' ' ASP . 12.4 t -74.53 -12.61 60.52 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-O 121.861 0.838 . . . . 0.0 109.646 -178.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -86.46 -8.93 57.2 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.96 175.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 100.95 -153.56 19.14 Favored Glycine 0 N--CA 1.427 -1.963 0 N-CA-C 108.63 -1.788 . . . . 0.0 108.63 -175.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.408 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 95.2 m95 -67.33 111.25 3.92 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 117.565 0.683 . . . . 0.0 110.003 175.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 33.3 p -54.25 -58.88 5.72 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 124.877 1.271 . . . . 0.0 112.551 -176.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -92.98 -175.62 3.93 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.449 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . 0.4 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 47.0 t0 -117.19 177.96 4.53 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.4 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 76.2 mt -57.39 118.79 27.29 Favored Pre-proline 0 C--N 1.286 -2.189 0 C-N-CA 125.65 1.58 . . . . 0.0 109.343 177.078 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -73.24 -177.58 3.07 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.901 2.4 . . . . 0.0 111.914 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 67.1 mt -105.32 133.18 50.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-O 120.903 0.382 . . . . 0.0 111.716 -172.065 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 90.6 m -111.4 91.15 3.55 Favored 'General case' 0 C--N 1.297 -1.682 0 CA-C-O 121.693 0.758 . . . . 0.0 109.039 174.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -86.85 148.54 25.33 Favored 'General case' 0 N--CA 1.424 -1.77 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -177.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.8 p -70.07 137.51 23.9 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 177.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 95.4 t -64.62 126.01 22.61 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -115.44 143.98 44.5 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.033 -176.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -120.75 159.59 25.09 Favored 'General case' 0 C--N 1.281 -2.41 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.147 177.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -68.46 147.08 98.11 Favored Pre-proline 0 N--CA 1.421 -1.899 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -175.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -71.93 116.42 4.7 Favored 'Trans proline' 0 N--CA 1.442 -1.522 0 C-N-CA 122.701 2.268 . . . . 0.0 110.546 178.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.425 HG21 ' SD ' ' A' ' 190' ' ' MET . 60.1 t -74.81 144.46 12.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.319 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.4 p -66.57 -84.85 0.02 OUTLIER 'General case' 0 N--CA 1.438 -1.026 0 O-C-N 123.379 0.424 . . . . 0.0 111.629 177.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 168.01 162.58 0.15 Allowed Pre-proline 0 CA--C 1.513 -0.46 0 C-N-CA 126.106 1.763 . . . . 0.0 106.463 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -76.54 168.3 23.98 Favored 'Trans proline' 0 N--CA 1.446 -1.313 0 C-N-CA 121.324 1.349 . . . . 0.0 110.001 171.267 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -60.02 -50.9 71.92 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 113.862 1.06 . . . . 0.0 113.862 -176.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 55.0 m-80 -110.67 32.61 5.09 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.563 0.696 . . . . 0.0 109.791 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -149.15 -176.79 22.73 Favored Glycine 0 N--CA 1.425 -2.081 0 C-N-CA 120.219 -0.991 . . . . 0.0 111.384 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -144.45 169.37 18.07 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -178.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.512 HG12 ' CD2' ' A' ' 176' ' ' PHE . 51.6 mt -98.47 137.45 25.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.461 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.8 m -84.5 -28.02 6.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 CA-C-O 121.986 0.898 . . . . 0.0 108.701 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 12.9 m . . . . . 0 C--N 1.312 -1.038 0 CA-C-N 114.704 -1.135 . . . . 0.0 112.496 -176.303 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 69.7 m-85 . . . . . 0 N--CA 1.429 -1.491 0 CA-C-O 121.682 0.753 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 46.8 m170 -115.29 163.51 15.58 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.744 -176.175 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -51.93 127.46 21.25 Favored 'General case' 0 C--O 1.245 0.843 0 O-C-N 124.134 0.896 . . . . 0.0 108.983 172.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 108.23 -22.81 26.4 Favored Glycine 0 N--CA 1.435 -1.422 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.306 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 30.1 mm-40 -71.67 144.67 49.28 Favored 'General case' 0 C--O 1.256 1.398 0 CA-C-N 117.185 0.492 . . . . 0.0 110.314 178.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -123.03 104.99 9.57 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.55 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 54.4 t -79.85 106.62 11.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.832 -178.023 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.461 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 25.9 ttp85 -98.62 143.45 29.0 Favored 'General case' 0 N--CA 1.41 -2.452 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.736 179.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.512 ' CD2' HG12 ' A' ' 157' ' ' ILE . 64.0 m-85 -112.85 165.75 12.02 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -178.107 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.7 p -146.73 138.25 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.291 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.5 m -92.67 148.28 22.19 Favored 'General case' 0 C--N 1.265 -3.101 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.391 -178.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -69.64 162.41 27.71 Favored 'General case' 0 CA--C 1.497 -1.063 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.664 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 16.3 m -52.08 109.44 0.38 Allowed 'General case' 0 C--N 1.303 -1.439 0 O-C-N 124.404 1.065 . . . . 0.0 112.368 -175.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.58 -9.17 30.36 Favored Glycine 0 N--CA 1.435 -1.385 0 CA-C-N 115.715 -0.675 . . . . 0.0 113.073 178.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -108.81 153.12 23.94 Favored 'General case' 0 CA--C 1.497 -1.059 0 CA-C-N 117.886 0.843 . . . . 0.0 110.886 -178.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 16.9 pttp -115.71 159.54 21.25 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 7.0 tp -74.36 146.19 10.23 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 176.309 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -91.46 -61.21 1.7 Allowed 'General case' 0 C--N 1.27 -2.876 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -90.99 -130.48 4.68 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 177.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -87.8 153.14 21.58 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 176.141 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -92.55 8.19 39.95 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 120.365 -0.534 . . . . 0.0 110.465 -177.088 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . 0.55 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 2.0 pt-20 -155.94 143.76 19.64 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 121.123 0.487 . . . . 0.0 111.925 -179.505 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.425 ' SD ' HG21 ' A' ' 149' ' ' VAL . 13.9 ptp -125.65 138.28 53.9 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.01 -0.995 . . . . 0.0 109.336 176.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 50.1 t-80 -100.56 138.77 37.17 Favored 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 123.089 0.556 . . . . 0.0 110.045 -176.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 23.6 t -82.76 107.08 15.12 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 174.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 50.7 m -100.21 -178.59 3.87 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 114.046 1.128 . . . . 0.0 114.046 -171.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -49.17 -34.97 15.7 Favored 'General case' 0 N--CA 1.51 2.541 0 C-N-CA 125.908 1.683 . . . . 0.0 113.179 -174.153 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -81.8 -7.67 59.62 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 113.456 0.909 . . . . 0.0 113.456 -176.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 83.42 10.19 82.39 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.15 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -112.96 169.76 8.69 Favored 'General case' 0 N--CA 1.427 -1.599 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 177.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.3 m95 -83.66 134.99 34.76 Favored 'General case' 0 N--CA 1.417 -2.087 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.24 178.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 35.9 p -63.38 -32.26 73.64 Favored 'General case' 0 C--O 1.249 1.063 0 CA-C-O 121.523 0.677 . . . . 0.0 112.229 -177.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . 0.403 ' HD3' ' HA ' ' A' ' 200' ' ' LYS . 26.3 mmtp -116.49 157.08 25.76 Favored 'General case' 0 CA--C 1.483 -1.601 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.352 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -86.43 172.13 10.61 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.684 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 7.6 mmmm -55.13 119.9 26.13 Favored Pre-proline 0 C--N 1.321 -0.634 0 O-C-N 123.697 0.623 . . . . 0.0 111.786 178.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -86.5 -173.44 1.21 Allowed 'Trans proline' 0 N--CA 1.424 -2.589 0 C-N-CA 122.061 1.841 . . . . 0.0 109.987 178.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 24.5 ttmm -148.08 164.41 33.93 Favored 'General case' 0 C--N 1.278 -2.506 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -176.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 98.4 m -126.06 116.04 20.79 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 174.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--N 1.3 -1.574 0 O-C-N 124.416 1.072 . . . . 0.0 109.747 -175.392 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo . . . . . 0 N--CA 1.477 0.528 0 CA-C-O 121.313 0.464 . . . . 0.0 112.159 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.6 m -84.25 -29.97 26.05 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.37 -98.1 0.74 Allowed Glycine 0 N--CA 1.398 -3.891 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.919 171.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -177.08 110.75 0.23 Allowed Pre-proline 0 C--N 1.258 -3.407 0 N-CA-C 105.759 -1.941 . . . . 0.0 105.759 -176.075 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.45 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 45.0 Cg_endo -64.76 -30.82 59.04 Favored 'Trans proline' 0 N--CA 1.474 0.334 0 C-N-CA 122.92 2.414 . . . . 0.0 112.963 -171.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.95 -174.39 19.13 Favored Glycine 0 N--CA 1.419 -2.483 0 N-CA-C 108.481 -1.848 . . . . 0.0 108.481 -176.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -142.57 164.64 29.56 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 107.815 -1.179 . . . . 0.0 107.815 -176.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.4 t -125.05 127.31 25.1 Favored Pre-proline 0 C--N 1.295 -1.769 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 -178.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -68.64 -22.38 37.91 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.483 2.122 . . . . 0.0 110.667 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -81.24 -1.64 45.72 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.219 -1.355 . . . . 0.0 111.984 -175.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.417 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 177.38 -130.66 1.66 Allowed Glycine 0 N--CA 1.414 -2.791 0 C-N-CA 119.695 -1.241 . . . . 0.0 111.84 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 24.4 p -146.59 179.16 7.75 Favored 'General case' 0 C--N 1.285 -2.225 0 O-C-N 124.119 0.541 . . . . 0.0 110.096 -178.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -143.07 155.28 44.58 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 171.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.5 m -121.24 163.65 18.2 Favored 'General case' 0 C--N 1.279 -2.482 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.57 ' HA ' ' O ' ' A' ' 109' ' ' LYS . 32.0 mt -120.82 124.0 43.97 Favored 'General case' 0 C--N 1.277 -2.561 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.236 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.651 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 34.1 p -115.93 125.56 52.73 Favored 'General case' 0 C--N 1.285 -2.235 0 O-C-N 123.625 0.578 . . . . 0.0 110.793 -175.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 99.95 11.76 42.13 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.828 178.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -178.91 -28.76 0.05 OUTLIER Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 119.371 -1.395 . . . . 0.0 113.813 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 69.6 10.88 7.81 Favored 'General case' 0 N--CA 1.5 2.073 0 CA-C-O 122.674 1.226 . . . . 0.0 110.599 -177.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.451 ' O ' HG11 ' A' ' 108' ' ' VAL . 35.9 m -143.72 -169.79 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 114.684 -1.144 . . . . 0.0 107.937 -174.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 36.4 m-85 -110.87 43.9 1.36 Allowed 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.489 0.662 . . . . 0.0 110.567 -175.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.732 ' O ' HG13 ' A' ' 108' ' ' VAL . 11.1 pt-20 -86.23 -176.58 5.97 Favored 'General case' 0 C--O 1.207 -1.165 0 CA-C-N 114.445 -1.252 . . . . 0.0 112.474 177.388 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.2 m-85 -78.82 131.99 36.69 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 122.021 -0.425 . . . . 0.0 111.467 178.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.48 5.33 61.82 Favored Glycine 0 N--CA 1.438 -1.214 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.659 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.732 HG13 ' O ' ' A' ' 105' ' ' GLU . 9.9 p -101.75 148.66 7.23 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.651 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 89.2 mttt -108.83 138.89 44.44 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 176.042 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -97.14 86.55 3.97 Favored 'General case' 0 C--N 1.264 -3.12 0 N-CA-C 105.515 -2.031 . . . . 0.0 105.515 169.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 21.2 m -85.61 118.17 31.85 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 -177.066 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -88.04 141.04 28.88 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.725 -0.609 . . . . 0.0 111.22 -175.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -139.36 114.36 9.49 Favored 'General case' 0 N--CA 1.412 -2.352 0 CA-C-O 122.129 0.966 . . . . 0.0 108.777 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 10.5 m -73.43 159.6 33.0 Favored 'General case' 0 C--N 1.289 -2.064 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.976 -175.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.417 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 68.6 m-20 -69.18 179.1 2.05 Favored 'General case' 0 C--O 1.216 -0.683 0 C-N-CA 123.023 0.529 . . . . 0.0 111.299 178.441 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -55.73 -46.57 77.74 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.556 0.742 . . . . 0.0 112.072 -178.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -81.92 7.8 61.88 Favored Glycine 0 C--N 1.308 -1.014 0 CA-C-N 115.839 -0.619 . . . . 0.0 113.95 -177.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -129.98 152.3 49.6 Favored 'General case' 0 N--CA 1.426 -1.63 0 CA-C-O 121.495 0.664 . . . . 0.0 110.072 -178.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.44 158.43 36.04 Favored 'General case' 0 C--N 1.271 -2.824 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.3 tt -89.56 129.47 36.02 Favored 'General case' 0 C--N 1.272 -2.8 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.552 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.64 128.18 55.98 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -175.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 116.06 173.48 17.21 Favored Glycine 0 C--N 1.294 -1.751 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 -176.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -87.73 -35.72 17.76 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -179.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 47.4 mm -85.73 137.04 21.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.288 -176.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -123.93 2.46 8.72 Favored 'General case' 0 C--O 1.21 -0.998 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.307 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.514 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 50.0 p90 -145.47 169.44 18.35 Favored 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -170.523 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 54.9 mtp180 -126.17 115.52 19.91 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 170.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -91.91 124.22 35.87 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 119.749 -0.781 . . . . 0.0 109.426 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.8 t -83.93 104.03 13.68 Favored 'General case' 0 CA--C 1.498 -1.056 0 C-N-CA 118.819 -1.152 . . . . 0.0 108.858 176.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.439 ' OD1' HG22 ' A' ' 131' ' ' THR . 7.9 t70 -99.53 -171.07 2.0 Allowed 'General case' 0 C--N 1.288 -2.103 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 178.634 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.439 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.3 t -61.42 -14.77 30.77 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 124.408 1.083 . . . . 0.0 112.508 -174.346 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -98.52 -15.34 19.59 Favored 'General case' 0 C--N 1.315 -0.913 0 O-C-N 121.757 -0.59 . . . . 0.0 110.637 178.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 124.18 -161.09 18.7 Favored Glycine 0 C--N 1.305 -1.188 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 -177.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.45 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 89.3 m95 -64.91 101.3 0.48 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.889 0.345 . . . . 0.0 110.173 176.77 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.5 p -58.31 -57.19 14.0 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 124.105 0.962 . . . . 0.0 112.254 -176.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -81.36 177.53 8.92 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.19 -0.914 . . . . 0.0 109.321 -177.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -111.11 179.6 4.0 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 176.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 84.4 mt -72.53 117.95 63.46 Favored Pre-proline 0 C--N 1.317 -0.843 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -66.35 157.79 58.44 Favored 'Trans proline' 0 C--O 1.253 1.267 0 C-N-CA 122.513 2.142 . . . . 0.0 110.624 178.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 62.4 mt -92.24 129.48 42.79 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-O 120.877 0.37 . . . . 0.0 110.722 -173.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 84.5 m -99.41 105.4 17.34 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 171.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -92.94 150.14 20.77 Favored 'General case' 0 N--CA 1.407 -2.601 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 -179.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 5.8 p -74.4 131.02 35.65 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.645 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 84.7 t -52.7 132.05 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 O-C-N 123.906 0.754 . . . . 0.0 110.89 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.411 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 85.0 mttt -106.32 153.91 21.52 Favored 'General case' 0 N--CA 1.433 -1.295 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.016 -176.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.9 m -124.03 165.06 18.12 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.639 -178.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . 0.506 HD21 ' HD2' ' A' ' 148' ' ' PRO . 0.5 OUTLIER -62.58 130.85 93.85 Favored Pre-proline 0 N--CA 1.426 -1.64 0 C-N-CA 125.154 1.382 . . . . 0.0 110.777 178.099 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.506 ' HD2' HD21 ' A' ' 147' ' ' LEU . 24.1 Cg_endo -65.91 110.26 1.67 Allowed 'Trans proline' 0 C--N 1.314 -1.244 0 C-N-CA 123.174 2.582 . . . . 0.0 111.635 175.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 7.8 p -86.59 143.94 10.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 38.9 p -82.49 -83.48 0.13 Allowed 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -177.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.3 161.74 0.46 Allowed Pre-proline 0 C--N 1.326 -0.429 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 -179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . 0.461 ' HD3' ' CD2' ' A' ' 176' ' ' PHE . 43.5 Cg_endo -73.51 -169.39 0.53 Allowed 'Trans proline' 0 CA--C 1.546 1.125 0 C-N-CA 121.654 1.569 . . . . 0.0 111.27 172.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . 0.586 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.2 OUTLIER -88.44 -37.2 16.02 Favored 'General case' 0 C--N 1.287 -2.131 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -174.899 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . 0.586 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 49.8 m-80 -120.86 22.82 10.98 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 122.074 0.94 . . . . 0.0 109.827 179.345 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -146.49 178.97 23.81 Favored Glycine 0 N--CA 1.425 -2.041 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.431 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . 0.41 ' HG3' HG22 ' A' ' 177' ' ' VAL . 21.9 pttm -145.62 -176.66 5.22 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -178.093 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.419 HG23 ' N ' ' A' ' 159' ' ' SER . 64.4 mt -95.56 141.2 15.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 C-N-CA 122.505 0.322 . . . . 0.0 110.703 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.477 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.3 m -79.91 -35.39 16.11 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.461 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 177.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' SER . . . . . 0.419 ' N ' HG23 ' A' ' 157' ' ' ILE . 5.3 m . . . . . 0 CA--C 1.55 0.946 0 C-N-CA 125.429 1.492 . . . . 0.0 111.375 -174.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . 0.411 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 82.6 m-85 . . . . . 0 CA--C 1.494 -1.202 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 49.7 m170 -117.83 161.06 20.35 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.691 -175.351 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 42.5 t80 -55.72 125.27 20.5 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 174.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 109.86 -14.13 31.87 Favored Glycine 0 N--CA 1.42 -2.398 0 C-N-CA 120.047 -1.073 . . . . 0.0 111.492 -177.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 87.1 mm-40 -86.71 139.38 30.81 Favored 'General case' 0 N--CA 1.433 -1.305 0 C-N-CA 119.533 -0.867 . . . . 0.0 109.822 176.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -120.59 116.14 24.77 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.616 178.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 88.1 t -90.29 106.04 16.88 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.477 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 46.1 ttm180 -104.65 142.47 34.61 Favored 'General case' 0 N--CA 1.405 -2.689 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.461 ' CD2' ' HD3' ' A' ' 152' ' ' PRO . 88.5 m-85 -108.81 157.44 18.58 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 121.431 0.634 . . . . 0.0 110.922 -175.852 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.419 HG23 HG11 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -130.69 133.12 63.82 Favored 'Isoleucine or valine' 0 CA--C 1.471 -2.078 0 CA-C-N 114.908 -1.042 . . . . 0.0 108.507 178.626 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 93.4 m -95.33 128.34 42.1 Favored 'General case' 0 C--N 1.259 -3.337 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 177.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 77.1 m-20 -60.09 160.09 8.62 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 114.95 -1.023 . . . . 0.0 111.419 -178.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 14.9 m -37.38 102.82 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 126.484 1.914 . . . . 0.0 114.91 -174.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 111.66 -18.39 24.78 Favored Glycine 0 N--CA 1.441 -0.982 0 C-N-CA 120.998 -0.62 . . . . 0.0 113.066 177.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -96.12 156.0 16.52 Favored 'General case' 0 N--CA 1.434 -1.233 0 CA-C-N 117.094 0.447 . . . . 0.0 111.394 -177.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -123.18 155.15 37.64 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.3 tp -72.42 142.84 14.7 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.2 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -71.83 -71.24 0.28 Allowed 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.852 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -100.02 -105.86 2.73 Favored Glycine 0 N--CA 1.431 -1.665 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -99.34 163.28 12.6 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -105.88 0.8 26.24 Favored 'General case' 0 CA--C 1.499 -1.008 0 C-N-CA 119.351 -0.94 . . . . 0.0 111.249 -173.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -148.12 152.63 37.65 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 114.085 1.142 . . . . 0.0 114.085 -175.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.5 ptp -131.15 138.23 49.37 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.233 -1.349 . . . . 0.0 108.496 177.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 45.6 t-80 -123.42 137.42 54.81 Favored 'General case' 0 C--N 1.292 -1.902 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.448 -176.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 16.2 m -61.93 113.81 3.01 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.994 176.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 14.9 m -102.76 174.15 6.01 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.054 178.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -48.74 140.79 8.04 Favored 'General case' 0 N--CA 1.488 1.433 0 C-N-CA 123.833 0.853 . . . . 0.0 112.352 178.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 26.2 t70 76.47 -6.45 2.0 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 125.944 1.698 . . . . 0.0 111.937 178.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 93.04 50.94 2.35 Favored Glycine 0 N--CA 1.434 -1.499 0 C-N-CA 120.529 -0.844 . . . . 0.0 112.087 177.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -116.7 141.61 47.98 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 176.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 67.1 m95 -79.78 132.06 36.06 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 171.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.1 p -65.85 -20.34 66.2 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.245 0.545 . . . . 0.0 112.172 -179.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . 0.47 ' HA ' ' HE3' ' A' ' 200' ' ' LYS . 0.0 OUTLIER -134.17 171.1 14.7 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.597 178.43 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -108.57 170.25 8.14 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.492 -178.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 5.5 tppp? -56.06 114.87 8.34 Favored Pre-proline 0 C--O 1.233 0.237 0 O-C-N 124.047 0.842 . . . . 0.0 110.814 -178.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -80.76 -167.78 0.55 Allowed 'Trans proline' 0 N--CA 1.434 -2.0 0 C-N-CA 122.145 1.897 . . . . 0.0 110.625 176.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . 0.428 ' HZ1' ' HB2' ' A' ' 204' ' ' LYS . 5.0 ttmp? -146.38 160.31 42.23 Favored 'General case' 0 C--N 1.28 -2.422 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -174.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 87.0 m -117.41 105.93 12.66 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-O 121.518 0.675 . . . . 0.0 110.693 177.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.2 m . . . . . 0 N--CA 1.433 -1.314 0 CA-C-N 115.003 -0.998 . . . . 0.0 110.079 -176.2 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 CA--C 1.53 0.325 0 CA-C-O 121.565 0.569 . . . . 0.0 111.322 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 36.2 m -89.1 -42.16 11.87 Favored 'General case' 0 N--CA 1.426 -1.633 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 121.4 -86.0 0.39 Allowed Glycine 0 CA--C 1.472 -2.603 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 172.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -179.59 127.13 0.24 Allowed Pre-proline 0 C--N 1.274 -2.691 0 N-CA-C 104.078 -2.564 . . . . 0.0 104.078 -177.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -77.58 4.85 5.64 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 C-N-CA 123.355 2.703 . . . . 0.0 115.584 -170.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.75 -168.86 12.91 Favored Glycine 0 C--N 1.287 -2.167 0 N-CA-C 107.688 -2.165 . . . . 0.0 107.688 -174.248 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -151.12 -175.42 5.15 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 118.439 1.119 . . . . 0.0 108.846 -176.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 t -155.33 125.85 3.41 Favored Pre-proline 0 N--CA 1.424 -1.739 0 CA-C-O 121.065 0.46 . . . . 0.0 111.395 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -78.73 -5.95 14.99 Favored 'Trans proline' 0 C--O 1.239 0.556 0 C-N-CA 123.088 2.526 . . . . 0.0 112.069 178.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.431 ' HB2' ' HB2' ' A' ' 141' ' ' CYS . 27.0 m-85 -99.46 1.28 43.96 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.325 -177.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.447 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.86 -136.59 3.52 Favored Glycine 0 N--CA 1.405 -3.385 0 C-N-CA 118.817 -1.659 . . . . 0.0 113.043 -178.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.9 p -146.37 -176.85 5.33 Favored 'General case' 0 C--N 1.283 -2.311 0 CA-C-N 114.655 -0.773 . . . . 0.0 110.795 -174.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 44.6 p90 -146.58 161.53 40.31 Favored 'General case' 0 N--CA 1.431 -1.422 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 171.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.7 m -131.81 154.51 49.04 Favored 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 179.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.478 ' HB2' ' HA ' ' A' ' 102' ' ' ASN . 16.1 mt -110.07 127.68 54.99 Favored 'General case' 0 C--N 1.272 -2.78 0 CA-C-O 120.995 0.426 . . . . 0.0 110.064 -177.039 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.482 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 24.1 p -120.45 132.94 55.45 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.136 -177.613 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.44 19.34 32.86 Favored Glycine 0 C--N 1.307 -1.065 0 C-N-CA 120.599 -0.81 . . . . 0.0 111.809 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 167.92 -27.04 0.14 Allowed Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.612 178.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . 0.478 ' HA ' ' HB2' ' A' ' 98' ' ' LEU . 7.5 t30 61.28 20.07 10.71 Favored 'General case' 0 CA--C 1.56 1.338 0 CA-C-O 122.699 1.238 . . . . 0.0 110.519 -178.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.552 ' O ' HG12 ' A' ' 108' ' ' VAL . 31.1 m -144.55 -170.57 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.207 -1.164 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 -179.035 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -106.53 45.19 0.99 Allowed 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 118.394 0.543 . . . . 0.0 110.392 -178.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.721 ' O ' HG11 ' A' ' 108' ' ' VAL . 12.4 pt-20 -90.43 -177.97 5.21 Favored 'General case' 0 C--O 1.207 -1.143 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.769 177.483 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 46.9 m-85 -77.61 133.24 38.48 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.859 -0.526 . . . . 0.0 111.456 178.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.84 0.12 64.33 Favored Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.895 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.721 HG11 ' O ' ' A' ' 105' ' ' GLU . 12.7 p -94.22 145.71 7.61 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.482 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 15.1 mtpp -109.94 124.39 51.31 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.458 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.65 91.13 8.63 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 176.094 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 62.5 t -88.63 112.24 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.962 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -177.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -81.39 134.9 35.62 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-O 121.19 0.519 . . . . 0.0 111.681 -178.627 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.1 t -132.55 104.91 6.92 Favored 'General case' 0 N--CA 1.421 -1.916 0 CA-C-O 122.157 0.979 . . . . 0.0 109.16 -178.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 13.4 m -66.83 157.98 31.62 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.62 -1.173 . . . . 0.0 110.826 -178.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.447 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 95.4 m-20 -75.55 178.44 5.99 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.748 -0.206 . . . . 0.0 111.548 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -45.7 -54.63 7.54 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.945 1.298 . . . . 0.0 113.324 -177.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.546 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -85.16 25.94 5.85 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 120.3 -0.953 . . . . 0.0 113.626 -176.357 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.586 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 81.1 m-85 -145.98 154.89 42.4 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 117.321 0.56 . . . . 0.0 110.092 -176.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.03 161.84 33.3 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 176.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.28 115.4 21.33 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 -178.384 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -98.31 129.74 45.0 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 179.461 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 121.35 166.74 13.03 Favored Glycine 0 C--N 1.29 -1.99 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -177.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.0 mt-10 -88.99 -21.3 23.57 Favored 'General case' 0 C--N 1.295 -1.799 0 CA-C-O 121.955 0.883 . . . . 0.0 109.306 -177.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.461 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.5 mm -107.76 131.21 58.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.804 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.815 -178.443 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -123.57 11.5 9.21 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -177.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.458 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 15.5 p90 -152.03 161.42 42.67 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -175.24 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 62.9 mtp180 -126.43 129.02 47.9 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 172.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -105.87 132.19 52.27 Favored 'General case' 0 C--N 1.279 -2.492 0 C-N-CA 119.101 -1.039 . . . . 0.0 109.461 -178.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.1 t -82.11 101.8 10.64 Favored 'General case' 0 C--N 1.293 -1.876 0 C-N-CA 118.219 -1.392 . . . . 0.0 109.927 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.542 ' OD2' HG22 ' A' ' 131' ' ' THR . 13.3 t70 -101.83 -171.35 1.96 Allowed 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.542 HG22 ' OD2' ' A' ' 130' ' ' ASP . 8.8 t -54.93 -31.99 60.84 Favored 'General case' 0 CA--C 1.56 1.331 0 C-N-CA 124.182 0.993 . . . . 0.0 112.805 -175.47 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -85.72 -15.36 42.45 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.908 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 122.98 -159.89 17.55 Favored Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -176.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.0 m95 -62.23 112.17 2.28 Favored 'General case' 0 C--O 1.248 0.983 0 CA-C-N 117.173 0.486 . . . . 0.0 110.39 177.051 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 68.4 p -71.08 162.82 28.78 Favored 'General case' 0 C--O 1.266 1.932 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 65.6 -171.16 0.19 Allowed 'General case' 0 CA--C 1.509 -0.629 0 O-C-N 124.209 0.943 . . . . 0.0 111.451 174.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -108.51 171.79 7.21 Favored 'General case' 0 C--N 1.295 -1.804 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.566 177.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 66.2 mt -67.68 118.5 58.05 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 171.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . 0.461 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 35.0 Cg_endo -66.2 159.06 51.58 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 122.056 1.837 . . . . 0.0 111.114 178.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 74.5 mt -109.39 134.59 50.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 C-N-CA 120.68 -0.408 . . . . 0.0 109.953 -171.303 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.431 ' HB2' ' HB2' ' A' ' 93' ' ' PHE . 94.9 m -102.96 110.73 22.76 Favored 'General case' 0 C--N 1.277 -2.57 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 175.144 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.86 152.17 20.04 Favored 'General case' 0 CA--C 1.462 -2.41 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.586 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 2.8 t -69.12 142.2 16.42 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.044 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.546 -177.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.546 HG22 ' C ' ' A' ' 117' ' ' GLY . 10.4 m -66.82 122.52 18.01 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 178.072 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.448 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 49.7 mtmt -121.81 127.18 50.28 Favored 'General case' 0 N--CA 1.408 -2.565 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.923 -172.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 60.8 m -84.2 153.68 23.5 Favored 'General case' 0 C--N 1.28 -2.436 0 CA-C-N 113.981 -1.463 . . . . 0.0 108.504 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . 0.418 ' C ' HD12 ' A' ' 147' ' ' LEU . 3.6 pp -67.52 160.72 70.74 Favored Pre-proline 0 CA--C 1.553 1.075 0 O-C-N 123.236 0.335 . . . . 0.0 110.229 -178.075 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.437 ' HA ' ' CE2' ' A' ' 168' ' ' TYR . 39.4 Cg_endo -74.28 123.21 8.08 Favored 'Trans proline' 0 N--CA 1.446 -1.297 0 C-N-CA 122.499 2.133 . . . . 0.0 112.348 -175.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.638 HG12 ' O ' ' A' ' 150' ' ' THR . 62.0 t -75.07 137.68 22.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.977 -178.554 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' THR . . . . . 0.638 ' O ' HG12 ' A' ' 149' ' ' VAL . 25.4 p -95.95 -158.01 0.62 Allowed 'General case' 0 N--CA 1.417 -2.105 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 172.183 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -127.38 151.39 74.73 Favored Pre-proline 0 C--N 1.274 -2.682 0 O-C-N 120.406 -1.434 . . . . 0.0 110.352 -171.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -68.76 161.44 45.42 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.615 1.543 . . . . 0.0 112.259 177.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -60.04 -43.64 95.22 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 -174.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 57.6 m-80 -117.49 29.36 7.91 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -148.31 -167.21 13.4 Favored Glycine 0 N--CA 1.435 -1.42 0 C-N-CA 119.989 -1.101 . . . . 0.0 112.081 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -154.85 177.14 11.62 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.424 HD13 ' O ' ' A' ' 150' ' ' THR . 58.9 mt -88.75 129.7 39.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 CA-C-O 120.833 0.349 . . . . 0.0 110.713 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.406 ' CG2' ' HB ' ' A' ' 177' ' ' VAL . 34.9 t -64.34 -35.61 74.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.555 0 C-N-CA 123.902 0.881 . . . . 0.0 109.947 178.562 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 37.3 t . . . . . 0 N--CA 1.43 -1.472 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 173.75 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . 0.448 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 99.6 m-85 . . . . . 0 CA--C 1.501 -0.922 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -97.4 160.23 14.45 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -177.337 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . 0.441 ' HB2' HG21 ' A' ' 144' ' ' VAL . 53.6 t80 -54.83 111.66 0.87 Allowed 'General case' 0 C--O 1.241 0.62 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 171.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 137.55 -12.82 3.73 Favored Glycine 0 N--CA 1.425 -2.064 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -173.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -82.98 143.97 30.29 Favored 'General case' 0 C--O 1.248 1.009 0 CA-C-O 121.436 0.636 . . . . 0.0 112.116 177.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -134.88 111.1 9.59 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 172.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 76.7 t -97.75 111.53 27.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 CA-C-O 120.983 0.42 . . . . 0.0 110.083 -177.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 79.6 ttt180 -95.33 153.84 17.49 Favored 'General case' 0 N--CA 1.426 -1.644 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.05 178.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -125.49 153.56 43.37 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 124.264 1.026 . . . . 0.0 109.458 -175.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.406 ' HB ' ' CG2' ' A' ' 158' ' ' VAL . 14.7 p -135.59 143.02 37.78 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 72.6 m -96.17 146.57 24.57 Favored 'General case' 0 C--N 1.272 -2.802 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.508 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -87.71 168.38 13.03 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.762 -176.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 32.4 t 50.06 -113.2 0.63 Allowed 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 124.058 0.943 . . . . 0.0 113.357 178.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -118.87 23.83 8.61 Favored Glycine 0 N--CA 1.417 -2.577 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -79.87 158.12 26.81 Favored 'General case' 0 C--O 1.249 1.046 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.117 -176.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 20.9 ptmt -121.14 160.56 23.48 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 115.503 -0.771 . . . . 0.0 109.476 -178.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.415 HD12 ' CG ' ' A' ' 203' ' ' PRO . 3.6 tp -79.29 145.91 8.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.449 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -69.61 -66.96 0.52 Allowed 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.617 178.484 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -115.69 -98.54 2.15 Favored Glycine 0 N--CA 1.433 -1.548 0 C-N-CA 120.442 -0.885 . . . . 0.0 111.364 -179.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -98.84 145.38 27.03 Favored 'General case' 0 CA--C 1.483 -1.604 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -178.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -102.97 12.08 36.54 Favored 'General case' 0 C--N 1.287 -2.138 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.915 -175.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -149.05 132.51 16.65 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 121.555 0.693 . . . . 0.0 112.552 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.7 ptp -114.21 125.33 53.81 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.282 176.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 27.3 t-80 -103.85 148.33 26.26 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 -178.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 5.0 m -75.02 140.88 43.89 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 177.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 50.7 m -96.71 154.95 16.99 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 171.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -73.77 -2.67 24.42 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.754 0.788 . . . . 0.0 110.882 -177.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -81.29 -10.43 59.58 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.827 178.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 94.48 26.51 13.41 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.769 -0.729 . . . . 0.0 113.514 178.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 19.5 p90 -147.78 173.44 12.8 Favored 'General case' 0 C--N 1.309 -1.155 0 O-C-N 122.263 -0.551 . . . . 0.0 110.376 177.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -83.05 145.15 29.45 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 123.433 0.458 . . . . 0.0 110.486 -179.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 6.7 m -82.91 -0.52 48.82 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.847 0.356 . . . . 0.0 111.336 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 15.7 tppt? -140.14 153.5 46.69 Favored 'General case' 0 N--CA 1.424 -1.731 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -177.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -87.87 155.04 20.06 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.68 175.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . 0.417 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 38.9 mtpt -59.95 126.67 84.08 Favored Pre-proline 0 N--CA 1.434 -1.261 0 O-C-N 123.731 0.645 . . . . 0.0 110.042 174.669 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . 0.415 ' CG ' HD12 ' A' ' 184' ' ' ILE . 90.9 Cg_endo -82.93 -167.95 0.53 Allowed 'Trans proline' 0 N--CA 1.436 -1.901 0 C-N-CA 122.514 2.143 . . . . 0.0 110.66 177.313 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -132.25 170.47 15.0 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.482 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 89.2 m -120.42 112.67 19.28 Favored 'General case' 0 C--N 1.274 -2.689 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 172.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 28.2 m . . . . . 0 C--N 1.281 -2.375 0 CA-C-N 114.105 -1.407 . . . . 0.0 109.206 -172.216 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.453 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 32.7 Cg_endo . . . . . 0 CA--C 1.546 1.11 0 CA-C-O 120.902 0.293 . . . . 0.0 112.201 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . 0.597 ' HB3' ' NE1' ' A' ' 134' ' ' TRP . 0.9 OUTLIER -87.7 -16.79 33.31 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.37 0.605 . . . . 0.0 110.133 175.132 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 102.72 -93.8 1.09 Allowed Glycine 1 N--CA 1.391 -4.357 0 N-CA-C 108.748 -1.741 . . . . 0.0 108.748 174.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -170.38 132.06 0.96 Allowed Pre-proline 0 C--N 1.253 -3.628 0 N-CA-C 105.571 -2.011 . . . . 0.0 105.571 -175.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -73.27 -28.72 12.19 Favored 'Trans proline' 0 N--CA 1.477 0.512 0 C-N-CA 122.152 1.901 . . . . 0.0 113.481 -173.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 133.41 150.28 6.29 Favored Glycine 0 N--CA 1.425 -2.036 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -178.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -111.89 125.89 54.52 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -178.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.6 t -89.5 125.59 60.98 Favored Pre-proline 0 C--N 1.3 -1.557 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 178.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -70.1 -10.42 28.25 Favored 'Trans proline' 0 C--O 1.221 -0.371 0 C-N-CA 122.833 2.355 . . . . 0.0 111.911 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -92.44 -2.55 56.21 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.398 0.618 . . . . 0.0 110.616 -178.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.492 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -178.71 -119.5 0.61 Allowed Glycine 0 N--CA 1.422 -2.294 0 C-N-CA 119.948 -1.12 . . . . 0.0 111.952 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.2 t -170.25 -162.55 0.3 Allowed 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.441 ' CB ' ' HA ' ' A' ' 112' ' ' TYR . 52.5 p90 -148.37 170.93 16.88 Favored 'General case' 0 C--N 1.311 -1.106 0 O-C-N 121.61 -0.681 . . . . 0.0 110.844 178.564 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -123.47 163.31 21.14 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 177.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.2 mt -121.99 129.42 52.46 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 32.6 p -122.84 124.63 43.71 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -176.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 92.99 30.18 9.68 Favored Glycine 0 C--N 1.298 -1.548 0 C-N-CA 120.325 -0.941 . . . . 0.0 111.185 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 167.25 -33.16 0.21 Allowed Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 119.464 -1.35 . . . . 0.0 113.417 176.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 65.46 14.79 9.68 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 123.577 0.751 . . . . 0.0 112.995 -177.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.534 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.4 m -151.7 -168.89 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.213 -0.85 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -177.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -106.52 38.14 2.14 Favored 'General case' 0 C--O 1.252 1.217 0 CA-C-N 118.737 0.699 . . . . 0.0 110.445 -175.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.712 ' O ' HG13 ' A' ' 108' ' ' VAL . 12.1 pt-20 -78.49 178.74 7.52 Favored 'General case' 0 C--O 1.2 -1.521 0 CA-C-N 114.22 -1.354 . . . . 0.0 111.003 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . 0.663 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 23.7 m-85 -79.63 134.04 36.43 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-O 120.958 0.408 . . . . 0.0 111.276 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.49 4.55 60.74 Favored Glycine 0 N--CA 1.44 -1.056 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.638 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.712 HG13 ' O ' ' A' ' 105' ' ' GLU . 14.5 p -99.44 145.11 11.06 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 C-N-CA 120.425 -0.51 . . . . 0.0 109.876 -179.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 58.7 mtpt -108.1 125.09 51.18 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.609 176.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.82 94.06 9.65 Favored 'General case' 0 C--N 1.289 -2.055 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.334 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 32.8 m -94.07 116.12 34.55 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.188 0 CA-C-O 122.599 1.19 . . . . 0.0 108.434 -178.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . 0.441 ' HA ' ' CB ' ' A' ' 96' ' ' PHE . 13.4 m-85 -78.74 141.75 37.6 Favored 'General case' 0 C--N 1.267 -2.985 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.667 -174.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.7 t -133.57 106.99 7.73 Favored 'General case' 0 N--CA 1.411 -2.386 0 CA-C-N 115.114 -0.948 . . . . 0.0 108.772 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 95.4 m -63.67 160.45 16.92 Favored 'General case' 0 C--N 1.296 -1.737 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.261 177.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.492 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 78.9 m-20 -74.35 -177.87 3.23 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.656 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -58.56 -45.29 89.3 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 123.58 0.752 . . . . 0.0 112.719 -174.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.36 24.13 6.63 Favored Glycine 0 C--O 1.212 -1.249 0 C-N-CA 120.747 -0.739 . . . . 0.0 113.302 179.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -147.82 169.93 18.71 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.99 -0.712 . . . . 0.0 109.952 -173.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -152.13 162.98 40.29 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -78.45 140.84 38.61 Favored 'General case' 0 C--N 1.288 -2.069 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.516 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.4 OUTLIER -119.24 126.52 51.71 Favored 'General case' 0 N--CA 1.409 -2.488 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.244 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.52 -170.24 14.27 Favored Glycine 0 C--N 1.289 -2.061 0 C-N-CA 120.69 -0.766 . . . . 0.0 111.607 -178.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -98.66 -38.81 8.97 Favored 'General case' 0 C--N 1.309 -1.195 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 -177.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.5 mm -78.62 120.48 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.716 0 CA-C-N 114.668 -1.151 . . . . 0.0 109.098 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -123.36 6.33 9.04 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.464 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 25.8 p90 -143.29 165.4 27.57 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -171.265 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 34.4 mtp180 -129.09 143.19 50.78 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 169.126 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -113.6 130.21 56.42 Favored 'General case' 0 C--N 1.287 -2.135 0 C-N-CA 119.426 -0.909 . . . . 0.0 109.895 -178.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . 0.663 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 37.8 t -80.35 90.39 5.58 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 176.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.484 ' OD2' HG22 ' A' ' 131' ' ' THR . 16.9 t70 -97.21 -170.62 2.05 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 179.017 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.484 HG22 ' OD2' ' A' ' 130' ' ' ASP . 15.1 t -59.03 -32.36 69.67 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 123.485 0.714 . . . . 0.0 112.875 -172.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -75.86 -34.09 60.03 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 121.488 0.661 . . . . 0.0 110.393 178.012 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.469 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 140.0 -153.91 23.57 Favored Glycine 0 N--CA 1.417 -2.602 0 N-CA-C 107.81 -2.116 . . . . 0.0 107.81 -174.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.597 ' NE1' ' HB3' ' A' ' 85' ' ' CYS . 98.3 m95 -65.86 116.61 7.21 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 117.655 0.728 . . . . 0.0 111.326 176.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 54.4 p -74.74 171.13 14.49 Favored 'General case' 0 C--O 1.269 2.119 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.036 176.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 87.0 m-20 59.05 -158.3 0.31 Allowed 'General case' 0 CA--C 1.515 -0.391 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -136.58 -179.48 5.71 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 172.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.9 mt -57.5 121.21 46.67 Favored Pre-proline 0 C--N 1.273 -2.721 0 C-N-CA 123.945 0.898 . . . . 0.0 108.595 175.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -63.49 169.68 9.35 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 122.663 2.242 . . . . 0.0 112.386 -179.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.516 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 52.8 mt -95.83 139.89 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.856 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -173.608 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 38.3 t -126.59 136.57 52.71 Favored 'General case' 0 C--N 1.276 -2.628 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -130.64 154.55 47.78 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -178.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 4.2 p -70.64 147.96 11.07 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 2.3 m -67.57 107.58 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.521 176.412 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -89.9 137.16 32.57 Favored 'General case' 0 N--CA 1.436 -1.168 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.72 -178.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.8 m -102.89 138.14 40.17 Favored 'General case' 0 C--N 1.282 -2.328 0 N-CA-C 106.111 -1.811 . . . . 0.0 106.111 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -63.0 148.22 92.89 Favored Pre-proline 0 N--CA 1.433 -1.275 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -177.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -61.2 121.84 10.25 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 122.911 2.408 . . . . 0.0 110.571 175.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.6 p -93.22 151.82 3.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.2 p -88.68 -177.16 5.49 Favored 'General case' 0 N--CA 1.431 -1.385 0 C-N-CA 120.9 -0.32 . . . . 0.0 110.291 175.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -108.79 158.94 32.77 Favored Pre-proline 0 C--N 1.294 -1.832 0 C-N-CA 122.415 0.286 . . . . 0.0 111.412 -171.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.78 157.39 61.43 Favored 'Trans proline' 0 C--N 1.362 1.247 0 C-N-CA 122.779 2.32 . . . . 0.0 111.292 175.252 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -59.02 -57.25 13.91 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 113.737 1.014 . . . . 0.0 113.737 -175.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 -102.5 36.56 2.13 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -178.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -150.91 -154.56 6.56 Favored Glycine 0 N--CA 1.413 -2.851 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.399 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . 0.46 ' HG3' HG23 ' A' ' 177' ' ' VAL . 17.5 ptmt -163.84 -177.55 5.18 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 123.658 0.783 . . . . 0.0 109.002 -178.799 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 55.2 mt -100.22 135.8 34.43 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.457 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.6 m -82.5 -33.71 11.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.539 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 7.2 m . . . . . 0 N--CA 1.425 -1.696 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.356 -173.771 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 . . . . . 0 N--CA 1.424 -1.738 0 CA-C-O 121.58 0.705 . . . . 0.0 109.269 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 30.5 m170 -114.36 160.1 19.5 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -53.99 120.85 6.93 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 174.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 122.17 -23.92 7.13 Favored Glycine 0 N--CA 1.428 -1.86 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -177.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 15.6 mm100 -70.53 145.32 50.92 Favored 'General case' 0 C--O 1.256 1.423 0 CA-C-O 121.656 0.741 . . . . 0.0 110.783 178.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -116.01 112.59 22.02 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 173.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 8.4 p -95.64 112.91 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.316 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.457 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 79.5 ttt180 -110.61 143.68 40.67 Favored 'General case' 0 C--N 1.28 -2.417 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.005 -175.229 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -114.18 159.65 19.87 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.053 -174.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.46 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.0 OUTLIER -129.8 154.06 39.75 Favored 'Isoleucine or valine' 0 CA--C 1.469 -2.148 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.746 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 82.7 m -115.22 140.07 49.4 Favored 'General case' 0 N--CA 1.395 -3.19 0 CA-C-N 114.158 -1.383 . . . . 0.0 108.787 174.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -67.97 161.64 26.12 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.286 177.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 17.3 t -55.12 117.39 3.44 Favored 'General case' 0 C--N 1.311 -1.09 0 O-C-N 124.167 0.917 . . . . 0.0 111.287 -173.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 113.41 -20.98 17.93 Favored Glycine 0 N--CA 1.429 -1.802 0 CA-C-N 115.066 -0.97 . . . . 0.0 111.743 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -104.2 157.36 17.18 Favored 'General case' 0 N--CA 1.432 -1.358 0 O-C-N 122.397 -0.472 . . . . 0.0 111.572 -177.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -124.17 154.35 40.21 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.9 tp -69.25 148.59 11.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 176.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -55.91 -59.77 4.42 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 123.842 0.857 . . . . 0.0 110.758 177.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -134.16 -83.6 0.2 Allowed Glycine 0 N--CA 1.437 -1.283 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.238 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . 0.454 ' OD2' ' HD2' ' A' ' 200' ' ' LYS . 74.2 m-20 -102.56 134.94 45.09 Favored 'General case' 0 CA--C 1.499 -0.985 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -85.33 -1.76 57.33 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.536 -178.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . 0.512 ' O ' ' HG3' ' A' ' 200' ' ' LYS . 0.0 OUTLIER -134.42 143.08 47.36 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-O 121.253 0.549 . . . . 0.0 111.157 -175.878 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.419 ' HG3' ' H ' ' A' ' 200' ' ' LYS . 31.8 ttm -126.14 115.26 19.52 Favored 'General case' 0 N--CA 1.416 -2.167 0 C-N-CA 125.039 1.335 . . . . 0.0 108.07 178.232 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 8.1 m80 -94.62 154.9 17.13 Favored 'General case' 0 C--N 1.267 -3.013 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.045 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 45.0 t -98.76 142.42 30.33 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 13.7 p -119.52 -174.51 2.75 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -173.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -56.56 -22.21 31.86 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 125.317 1.447 . . . . 0.0 111.806 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -64.57 -21.01 66.58 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.338 -178.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 81.67 14.87 77.07 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -174.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -141.04 177.83 7.79 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.428 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -81.16 147.06 30.21 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.14 -176.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 26.6 m -82.3 -29.62 31.0 Favored 'General case' 0 N--CA 1.422 -1.831 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.117 177.129 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . 0.512 ' HG3' ' O ' ' A' ' 189' ' ' GLU . 6.4 mmpt? -98.47 166.12 11.51 Favored 'General case' 0 N--CA 1.441 -0.881 0 C-N-CA 117.974 -1.491 . . . . 0.0 112.913 177.037 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -96.74 163.84 12.83 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 104.365 -2.457 . . . . 0.0 104.365 171.121 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . 0.441 ' HZ1' ' HB3' ' A' ' 202' ' ' LYS . 4.9 mtpm? -66.69 125.59 90.89 Favored Pre-proline 0 C--N 1.304 -1.388 0 C-N-CA 119.862 -0.735 . . . . 0.0 112.406 178.366 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 7.3 Cg_endo -89.46 -174.08 0.86 Allowed 'Trans proline' 0 N--CA 1.42 -2.838 0 C-N-CA 121.746 1.631 . . . . 0.0 109.767 171.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 20.5 pttm -149.67 175.94 11.11 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 73.6 m -113.26 113.9 25.96 Favored 'General case' 0 C--N 1.283 -2.287 0 O-C-N 123.683 0.615 . . . . 0.0 109.524 -178.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.5 m . . . . . 0 N--CA 1.422 -1.832 0 CA-C-N 113.765 -1.561 . . . . 0.0 109.005 -174.104 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo . . . . . 0 CA--C 1.533 0.47 0 CA-C-O 121.444 0.518 . . . . 0.0 111.728 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 33.9 m -79.37 -33.31 43.0 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.21 -92.72 0.55 Allowed Glycine 1 N--CA 1.394 -4.159 0 CA-C-N 114.104 -1.407 . . . . 0.0 109.717 172.748 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -174.8 133.54 0.5 Allowed Pre-proline 0 C--N 1.255 -3.543 0 N-CA-C 103.85 -2.648 . . . . 0.0 103.85 -175.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.404 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 86.9 Cg_endo -80.61 3.0 8.09 Favored 'Trans proline' 0 C--N 1.328 -0.502 0 C-N-CA 122.643 2.228 . . . . 0.0 113.899 -173.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.3 -166.08 17.26 Favored Glycine 0 C--N 1.287 -2.163 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 -175.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -145.1 151.25 38.2 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -177.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 t -120.98 130.33 24.9 Favored Pre-proline 0 N--CA 1.429 -1.503 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -78.83 -7.59 15.55 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.59 2.194 . . . . 0.0 111.908 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -96.64 19.0 13.05 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.482 -179.168 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 155.97 -119.07 0.89 Allowed Glycine 0 N--CA 1.42 -2.378 0 C-N-CA 119.941 -1.124 . . . . 0.0 111.995 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.7 t -168.6 -169.85 1.12 Allowed 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -176.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -143.48 163.28 33.56 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 177.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.1 m -124.61 162.83 23.27 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 106.349 -1.723 . . . . 0.0 106.349 178.299 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 15.4 mt -123.37 125.2 44.55 Favored 'General case' 0 C--N 1.279 -2.493 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.409 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 44.1 p -119.68 134.09 55.37 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 -176.184 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.31 25.72 42.62 Favored Glycine 0 C--N 1.312 -0.775 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.19 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 172.87 -35.71 0.13 Allowed Glycine 0 CA--C 1.486 -1.768 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 61.18 18.97 9.61 Favored 'General case' 0 CA--C 1.521 -0.144 0 C-N-CA 124.394 1.077 . . . . 0.0 112.2 178.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.548 ' O ' HG13 ' A' ' 108' ' ' VAL . 31.1 m -154.12 -167.3 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.208 -1.103 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 -178.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 21.3 m-85 -105.42 42.71 1.2 Allowed 'General case' 0 C--N 1.311 -1.109 0 CA-C-N 119.392 0.996 . . . . 0.0 110.139 -176.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.728 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.1 pt-20 -86.23 179.14 6.97 Favored 'General case' 0 C--O 1.205 -1.251 0 CA-C-N 114.564 -1.198 . . . . 0.0 111.733 178.166 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.1 m-85 -74.9 136.18 41.47 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 122.017 -0.427 . . . . 0.0 111.391 177.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.09 6.93 70.9 Favored Glycine 0 C--N 1.31 -0.88 0 CA-C-N 115.914 -0.585 . . . . 0.0 113.034 177.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.728 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.8 p -97.9 145.64 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.062 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.409 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 59.4 mtpt -110.25 122.84 48.61 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 177.641 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.432 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -85.5 85.37 7.43 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.513 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 31.8 m -83.39 107.0 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.027 0 CA-C-O 122.812 1.291 . . . . 0.0 109.558 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 31.8 m-85 -73.17 134.84 44.54 Favored 'General case' 0 C--N 1.276 -2.606 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.964 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.6 t -129.81 114.55 16.07 Favored 'General case' 0 N--CA 1.408 -2.529 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 87.2 m -66.66 161.68 22.81 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 115.596 -0.729 . . . . 0.0 112.518 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 5.0 t-20 -68.85 -173.54 0.49 Allowed 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.136 -177.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -58.38 -52.17 66.73 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 123.109 0.564 . . . . 0.0 111.902 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.04 12.56 63.81 Favored Glycine 0 N--CA 1.437 -1.297 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.99 -177.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.505 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.6 m-85 -129.44 159.09 37.33 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 117.157 0.478 . . . . 0.0 110.72 -177.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.79 152.84 45.52 Favored 'General case' 0 C--N 1.288 -2.102 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . 0.432 ' HG ' ' CB ' ' A' ' 125' ' ' ASN . 0.5 OUTLIER -78.29 126.36 30.68 Favored 'General case' 0 C--N 1.281 -2.401 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 179.17 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.425 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.3 OUTLIER -108.01 130.61 55.05 Favored 'General case' 0 N--CA 1.418 -2.044 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -178.791 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 114.69 -169.41 12.86 Favored Glycine 0 C--N 1.292 -1.91 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -103.82 -31.77 9.64 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-O 121.52 0.676 . . . . 0.0 109.763 -179.108 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.413 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.9 mm -89.16 120.59 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.562 -178.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.432 ' CB ' ' HG ' ' A' ' 120' ' ' LEU . 3.7 p-10 -125.6 9.59 7.75 Favored 'General case' 0 C--O 1.203 -1.368 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.513 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 22.4 p90 -140.67 168.39 19.91 Favored 'General case' 0 C--N 1.282 -2.347 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -170.359 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.414 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 48.7 mtp180 -132.5 117.9 18.59 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 169.34 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -91.89 128.33 37.69 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 118.881 -1.128 . . . . 0.0 109.969 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 47.8 t -84.62 109.74 18.21 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.183 -1.007 . . . . 0.0 109.652 175.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.429 ' OD2' HG21 ' A' ' 131' ' ' THR . 9.9 t70 -111.71 -164.35 0.91 Allowed 'General case' 0 C--N 1.287 -2.126 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.429 HG21 ' OD2' ' A' ' 130' ' ' ASP . 12.0 t -63.4 -21.35 66.24 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -174.567 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -82.32 -22.77 35.46 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-O 121.87 0.843 . . . . 0.0 109.551 177.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 118.55 -145.25 18.28 Favored Glycine 0 N--CA 1.419 -2.44 0 N-CA-C 107.227 -2.349 . . . . 0.0 107.227 -171.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -69.92 111.42 5.63 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 108.984 -0.746 . . . . 0.0 108.984 177.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 37.8 p -66.65 -57.23 7.62 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-O 121.394 0.616 . . . . 0.0 111.499 -177.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . 0.414 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 4.9 m120 -75.94 169.96 17.17 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.733 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 22.0 m-20 -106.51 -178.2 3.58 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.8 mt -64.89 123.71 84.46 Favored Pre-proline 0 C--N 1.318 -0.791 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 177.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . 0.413 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 35.5 Cg_endo -67.97 174.06 8.38 Favored 'Trans proline' 0 C--O 1.242 0.7 0 C-N-CA 122.867 2.378 . . . . 0.0 112.971 -179.103 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.425 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 63.1 mt -96.13 139.08 19.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 -176.475 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.505 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 33.9 t -128.21 125.21 38.53 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 13.7 tp10 -120.02 155.57 32.62 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -174.352 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 8.6 p -75.41 134.51 29.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 169' ' ' HIS . 83.0 t -60.21 123.91 13.6 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.711 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.171 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.406 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 51.2 mttm -106.12 158.39 16.85 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 120.944 0.402 . . . . 0.0 110.457 -175.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.475 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 60.6 m -117.46 161.6 19.32 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 2.2 pp -72.47 155.38 91.24 Favored Pre-proline 0 C--N 1.307 -1.259 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -78.23 126.02 7.47 Favored 'Trans proline' 0 N--CA 1.439 -1.683 0 C-N-CA 122.294 1.996 . . . . 0.0 113.152 -175.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.492 HG12 ' O ' ' A' ' 150' ' ' THR . 54.3 t -69.46 135.67 27.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-N 114.041 -1.436 . . . . 0.0 110.349 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' THR . . . . . 0.492 ' O ' HG12 ' A' ' 149' ' ' VAL . 11.5 p -93.7 170.85 9.27 Favored 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 171.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -93.46 156.75 39.54 Favored Pre-proline 0 C--N 1.267 -2.995 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -174.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -74.35 152.96 44.88 Favored 'Trans proline' 0 N--CA 1.428 -2.371 0 C-N-CA 120.761 0.974 . . . . 0.0 110.905 172.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -54.66 -44.34 73.17 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 114.72 1.378 . . . . 0.0 114.72 -172.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.8 m-80 -122.71 31.41 6.08 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 122.154 0.978 . . . . 0.0 108.746 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -139.57 -161.79 8.86 Favored Glycine 0 N--CA 1.428 -1.888 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 40.6 pttt -157.64 163.14 38.55 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 -178.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 49.3 mt -89.36 132.33 34.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-O 121.005 0.431 . . . . 0.0 110.029 -177.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.7 t -74.85 -48.22 34.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-O 122.182 0.991 . . . . 0.0 108.393 177.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' SER . . . . . 0.478 ' CB ' ' HA ' ' A' ' 174' ' ' VAL . 6.3 m . . . . . 0 C--N 1.289 -2.039 0 CA-C-N 114.553 -1.203 . . . . 0.0 111.388 -175.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 . . . . . 0 N--CA 1.406 -2.647 0 N-CA-C 105.874 -1.899 . . . . 0.0 105.874 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.409 ' HB2' ' O ' ' A' ' 144' ' ' VAL . 2.1 p-80 -145.46 168.72 19.87 Favored 'General case' 0 C--N 1.279 -2.47 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.675 -176.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -51.76 121.04 5.9 Favored 'General case' 0 C--O 1.242 0.695 0 O-C-N 124.31 1.006 . . . . 0.0 110.307 -176.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 123.49 -17.46 7.85 Favored Glycine 0 N--CA 1.427 -1.952 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.202 -175.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 25.3 mm-40 -78.67 135.34 37.17 Favored 'General case' 0 C--O 1.255 1.371 0 CA-C-O 121.716 0.77 . . . . 0.0 112.254 178.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -125.7 109.8 13.01 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 105.582 -2.007 . . . . 0.0 105.582 173.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.478 ' HA ' ' CB ' ' A' ' 159' ' ' SER . 53.6 t -107.4 122.61 61.85 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.687 -173.14 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.414 ' HG3' ' O ' ' A' ' 188' ' ' GLU . 24.0 ttp180 -111.66 161.51 16.17 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.322 177.163 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -130.73 162.47 29.39 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 124.397 1.079 . . . . 0.0 110.296 -174.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.79 143.9 35.1 Favored 'Isoleucine or valine' 0 CA--C 1.471 -2.093 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.45 176.692 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 76.7 m -105.68 131.52 52.95 Favored 'General case' 0 N--CA 1.395 -3.216 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 173.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -54.1 164.36 0.65 Allowed 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.309 177.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 26.7 t -33.71 -47.88 0.26 Allowed 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 116.771 2.137 . . . . 0.0 116.771 -168.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -104.28 15.36 50.63 Favored Glycine 0 C--N 1.288 -2.136 0 C-N-CA 120.056 -1.069 . . . . 0.0 115.025 -173.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -120.09 162.14 19.79 Favored 'General case' 0 CA--C 1.497 -1.065 0 CA-C-N 118.344 1.072 . . . . 0.0 112.424 -176.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . 0.444 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 25.5 pttm -123.28 154.2 39.16 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.474 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 2.8 tp -72.47 145.09 12.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -82.16 -71.16 0.5 Allowed 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 120.962 -0.295 . . . . 0.0 110.481 179.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.0 -89.58 0.63 Allowed Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.948 -177.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . 0.43 ' CG ' ' HZ2' ' A' ' 200' ' ' LYS . 12.0 t70 -136.36 159.99 40.1 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 -177.809 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . 0.414 ' O ' ' HG3' ' A' ' 175' ' ' ARG . 1.0 OUTLIER -103.37 3.26 34.99 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 118.999 -1.08 . . . . 0.0 112.707 -171.979 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . 0.584 ' O ' ' HG3' ' A' ' 200' ' ' LYS . 4.3 pt-20 -149.75 143.57 25.5 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 113.572 0.953 . . . . 0.0 113.572 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.421 ' CB ' ' HB2' ' A' ' 200' ' ' LYS . 12.8 ptp -133.37 144.14 49.4 Favored 'General case' 0 C--N 1.315 -0.898 0 C-N-CA 124.146 0.978 . . . . 0.0 111.275 -176.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 49.4 t-80 -125.69 141.05 52.21 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.506 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 13.2 m -65.32 129.55 40.13 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 177.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 193' ' ' SER . . . . . 0.414 ' OG ' ' HB3' ' A' ' 199' ' ' SER . 14.5 m -104.45 167.26 9.86 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.931 177.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -48.18 -37.23 15.22 Favored 'General case' 0 N--CA 1.496 1.874 0 C-N-CA 125.529 1.532 . . . . 0.0 113.535 -176.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -68.74 -16.01 63.68 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -176.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . 0.475 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 99.33 27.79 7.95 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.195 -1.002 . . . . 0.0 113.248 178.287 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -150.21 179.2 8.3 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 122.391 -0.476 . . . . 0.0 110.356 176.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -84.84 135.77 33.95 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 123.924 0.765 . . . . 0.0 110.881 -176.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 199' ' ' SER . . . . . 0.414 ' HB3' ' OG ' ' A' ' 193' ' ' SER . 9.5 p -73.26 -24.24 60.42 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.682 0.753 . . . . 0.0 111.136 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . 0.584 ' HG3' ' O ' ' A' ' 189' ' ' GLU . 28.2 mmtp -94.9 179.88 5.08 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 115.026 -0.988 . . . . 0.0 112.909 -177.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -100.75 148.87 24.41 Favored 'General case' 0 C--N 1.292 -1.925 0 CA-C-N 113.557 -1.656 . . . . 0.0 110.735 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . 0.46 ' HE2' ' HD2' ' A' ' 203' ' ' PRO . 0.1 OUTLIER -75.03 107.98 4.76 Favored Pre-proline 0 C--N 1.323 -0.563 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 175.123 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . 0.46 ' HD2' ' HE2' ' A' ' 202' ' ' LYS . 71.8 Cg_endo -88.81 174.25 4.0 Favored 'Trans proline' 0 N--CA 1.435 -1.915 0 C-N-CA 122.743 2.296 . . . . 0.0 114.898 -172.121 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -124.36 174.27 7.85 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -176.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.444 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 91.1 m -128.77 101.38 6.09 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 174.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 21.1 m . . . . . 0 C--N 1.294 -1.832 0 CA-C-N 114.226 -1.352 . . . . 0.0 108.679 -173.176 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo . . . . . 0 CA--C 1.542 0.908 0 CA-C-O 121.056 0.357 . . . . 0.0 112.008 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 61.7 m -82.67 -29.92 29.64 Favored 'General case' 0 CA--C 1.507 -0.675 0 CA-C-O 122.418 1.104 . . . . 0.0 108.228 177.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 113.2 -91.45 0.58 Allowed Glycine 0 N--CA 1.4 -3.737 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 173.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.8 t60 -175.1 135.26 0.51 Allowed Pre-proline 0 C--N 1.257 -3.453 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 -176.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.489 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 94.0 Cg_endo -80.9 2.04 8.86 Favored 'Trans proline' 0 C--N 1.324 -0.754 0 C-N-CA 122.364 2.043 . . . . 0.0 113.156 -175.714 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 94.42 176.07 38.81 Favored Glycine 0 C--N 1.287 -2.14 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -173.093 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -144.46 159.28 43.01 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 117.444 0.622 . . . . 0.0 109.453 -176.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.7 t -120.18 131.3 24.47 Favored Pre-proline 0 C--N 1.298 -1.645 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.25 -177.256 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -71.7 -19.12 28.1 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.337 2.025 . . . . 0.0 110.561 176.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -86.58 16.0 5.06 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.755 -1.112 . . . . 0.0 110.481 -174.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 164.78 -131.94 2.55 Favored Glycine 1 N--CA 1.396 -4.001 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.591 178.339 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.3 p -154.77 175.52 13.61 Favored 'General case' 0 C--N 1.288 -2.104 0 C-N-CA 124.182 0.993 . . . . 0.0 109.896 -173.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -144.95 154.07 42.2 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 171.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.8 m -126.13 162.14 26.04 Favored 'General case' 0 C--N 1.275 -2.648 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 17.6 mt -112.47 135.95 52.56 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 18.8 p -129.03 126.93 40.54 Favored 'General case' 0 C--N 1.281 -2.386 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.893 -178.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.47 29.23 14.55 Favored Glycine 0 C--N 1.302 -1.319 0 C-N-CA 120.407 -0.902 . . . . 0.0 111.978 179.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 172.12 -36.58 0.15 Allowed Glycine 0 N--CA 1.431 -1.699 0 C-N-CA 119.964 -1.112 . . . . 0.0 112.7 178.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 70.73 1.94 3.93 Favored 'General case' 0 N--CA 1.511 2.582 0 CA-C-O 122.206 1.003 . . . . 0.0 110.728 -178.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.458 ' O ' HG11 ' A' ' 108' ' ' VAL . 34.3 m -143.94 -171.24 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -173.439 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -105.45 45.41 0.97 Allowed 'General case' 0 C--N 1.304 -1.401 0 CA-C-O 121.269 0.557 . . . . 0.0 110.216 -176.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.739 ' O ' HG13 ' A' ' 108' ' ' VAL . 10.7 pt-20 -83.01 177.65 8.52 Favored 'General case' 0 C--O 1.213 -0.857 0 CA-C-N 114.585 -1.189 . . . . 0.0 111.607 177.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 43.6 m-85 -77.42 130.92 37.68 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-O 120.941 0.401 . . . . 0.0 110.801 176.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.87 2.37 58.39 Favored Glycine 0 N--CA 1.437 -1.238 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.555 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.739 HG13 ' O ' ' A' ' 105' ' ' GLU . 11.7 p -94.77 145.89 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.285 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 19.7 mtpp -111.94 120.77 43.03 Favored 'General case' 0 C--N 1.286 -2.157 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -86.86 92.8 9.11 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 77.2 t -86.39 118.41 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.611 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -178.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -85.99 145.58 27.04 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.289 -178.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.9 t -144.34 110.66 5.52 Favored 'General case' 0 N--CA 1.407 -2.61 0 CA-C-O 122.208 1.004 . . . . 0.0 108.446 -179.408 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 41.7 m -71.22 158.81 35.75 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.813 -173.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -60.24 171.9 0.94 Allowed 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 125.128 1.371 . . . . 0.0 111.33 -177.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -59.44 -41.87 90.6 Favored 'General case' 0 C--N 1.297 -1.685 0 C-N-CA 124.568 1.147 . . . . 0.0 110.017 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.454 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -86.63 19.82 26.66 Favored Glycine 0 CA--C 1.529 0.932 0 CA-C-N 115.368 -0.833 . . . . 0.0 113.739 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.443 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 97.9 m-85 -147.11 173.85 12.11 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -143.68 165.44 27.64 Favored 'General case' 0 C--N 1.281 -2.403 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.3 tt -94.51 137.88 33.1 Favored 'General case' 0 C--N 1.28 -2.447 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -178.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -124.74 135.15 52.75 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 -177.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.66 159.5 15.39 Favored Glycine 0 N--CA 1.438 -1.191 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -78.99 -27.33 43.32 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.719 0.771 . . . . 0.0 109.085 -177.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 47.2 mm -89.76 132.78 33.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 114.814 -1.085 . . . . 0.0 108.311 -177.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -133.07 12.94 4.28 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -177.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . . . . . . . . . 2.8 p90 -152.65 169.21 23.26 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 -173.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.489 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 54.1 mtp180 -131.84 120.1 22.13 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 169.115 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -94.53 138.35 32.53 Favored 'General case' 0 C--N 1.287 -2.128 0 C-N-CA 118.893 -1.123 . . . . 0.0 110.565 177.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.0 t -89.69 104.35 16.92 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 118.881 -1.128 . . . . 0.0 109.61 174.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.439 ' OD2' HG21 ' A' ' 131' ' ' THR . 12.1 t70 -97.08 -172.22 2.39 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 176.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.439 HG21 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -67.25 -11.44 57.47 Favored 'General case' 0 C--N 1.293 -1.855 0 C-N-CA 123.259 0.623 . . . . 0.0 112.274 -174.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -94.6 -12.5 27.35 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.82 0.819 . . . . 0.0 109.412 176.558 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.15 -159.25 13.86 Favored Glycine 0 N--CA 1.431 -1.685 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -175.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.0 m95 -63.65 105.23 0.76 Allowed 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 120.894 0.378 . . . . 0.0 111.259 178.088 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 24.9 p -61.32 -64.89 0.8 Allowed 'General case' 0 C--O 1.241 0.652 0 C-N-CA 124.955 1.302 . . . . 0.0 112.87 -175.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . 0.42 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.3 m120 -71.18 173.42 7.7 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.211 -177.099 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -106.55 176.43 5.17 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 175.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 77.5 mt -69.2 125.98 92.38 Favored Pre-proline 0 C--N 1.311 -1.085 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -70.68 168.69 22.04 Favored 'Trans proline' 0 C--O 1.249 1.073 0 C-N-CA 122.719 2.279 . . . . 0.0 111.145 177.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.6 mm -97.93 129.53 47.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 120.436 -0.506 . . . . 0.0 111.245 -173.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 99.5 m -101.93 103.34 13.98 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 171.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -95.09 152.39 18.38 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 -179.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.443 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 3.2 t -76.69 145.51 10.2 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.514 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 -175.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.454 HG22 ' C ' ' A' ' 117' ' ' GLY . 5.9 m -73.71 108.39 5.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 174.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -104.75 127.2 52.45 Favored 'General case' 0 N--CA 1.412 -2.352 0 CA-C-N 114.45 -1.25 . . . . 0.0 111.095 -174.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.549 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 3.4 m -85.44 148.5 25.96 Favored 'General case' 0 C--N 1.282 -2.356 0 CA-C-N 113.738 -1.574 . . . . 0.0 110.078 -173.444 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 59.4 mt -56.36 132.46 76.19 Favored Pre-proline 0 C--N 1.319 -0.75 0 N-CA-C 112.677 0.621 . . . . 0.0 112.677 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_endo -62.49 111.4 1.3 Allowed 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 123.499 2.799 . . . . 0.0 112.391 -178.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.3 t -79.05 139.16 18.81 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.5 p -79.02 -75.9 0.22 Allowed 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 123.868 0.73 . . . . 0.0 111.51 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 166.42 159.62 0.11 Allowed Pre-proline 0 C--O 1.24 0.59 0 C-N-CA 126.248 1.819 . . . . 0.0 107.054 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -73.73 171.81 17.07 Favored 'Trans proline' 0 CA--C 1.535 0.569 0 C-N-CA 121.519 1.479 . . . . 0.0 109.572 169.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -69.67 -62.57 1.33 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -177.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.5 m-80 -95.82 38.43 1.17 Allowed 'General case' 0 C--N 1.313 -1.01 0 O-C-N 121.562 -0.711 . . . . 0.0 110.488 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -155.1 -168.57 18.5 Favored Glycine 0 N--CA 1.426 -1.973 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.964 178.189 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -153.0 174.79 13.71 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 -178.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 52.5 mt -91.58 139.62 17.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -178.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.422 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 4.7 m -77.46 -37.17 24.55 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.576 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 178.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 28.6 t . . . . . 0 N--CA 1.435 -1.199 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -178.88 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 . . . . . 0 N--CA 1.434 -1.228 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 55.2 m80 -121.61 155.81 34.3 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 -175.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 81.7 t80 -49.68 121.09 4.78 Favored 'General case' 0 C--O 1.244 0.798 0 O-C-N 123.686 0.616 . . . . 0.0 110.56 175.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 132.28 -29.65 3.29 Favored Glycine 0 N--CA 1.42 -2.41 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 -177.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.8 mm-40 -63.24 128.85 37.73 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 179.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -118.06 82.66 1.87 Allowed 'General case' 0 N--CA 1.423 -1.813 0 N-CA-C 104.32 -2.474 . . . . 0.0 104.32 170.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 14.9 p -77.63 111.56 14.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.004 -169.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.422 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 40.1 ttm180 -97.74 148.29 23.5 Favored 'General case' 0 N--CA 1.416 -2.159 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.716 -177.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.49 ' HZ ' ' SD ' ' A' ' 190' ' ' MET . 51.2 m-85 -115.46 150.98 35.61 Favored 'General case' 0 N--CA 1.42 -1.967 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 -179.38 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 13.7 p -126.49 141.05 47.08 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.749 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 178.273 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.4 m -99.64 163.59 12.43 Favored 'General case' 0 C--N 1.262 -3.207 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.001 -178.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -66.52 172.63 3.95 Favored 'General case' 0 CA--C 1.497 -1.066 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.204 179.227 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 21.8 m -42.99 -31.95 0.59 Allowed 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 116.335 1.976 . . . . 0.0 116.335 -172.033 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -126.42 24.02 5.64 Favored Glycine 0 C--N 1.289 -2.069 0 C-N-CA 119.376 -1.393 . . . . 0.0 113.377 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -118.42 151.94 36.83 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.815 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . 0.516 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 50.9 pttt -115.27 157.03 24.33 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 -179.68 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.44 HD11 ' HA ' ' A' ' 188' ' ' GLU . 5.0 tt -86.1 143.59 11.17 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.506 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.224 175.403 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -77.56 -68.16 0.65 Allowed 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -173.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -80.63 -109.61 0.3 Allowed Glycine 0 C--O 1.245 0.798 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.976 -177.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -95.93 175.8 6.36 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 176.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . 0.44 ' HA ' HD11 ' A' ' 184' ' ' ILE . 10.3 pt-20 -104.28 -19.09 14.22 Favored 'General case' 0 C--N 1.28 -2.435 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -177.316 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . 0.445 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 5.3 pt-20 -141.45 150.21 41.98 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.053 -176.184 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.49 ' SD ' ' HZ ' ' A' ' 176' ' ' PHE . 0.1 OUTLIER -117.39 125.72 51.46 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.174 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -97.26 132.7 42.76 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 176.137 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . 0.453 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 48.7 t -80.39 136.8 36.44 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.114 179.422 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 193' ' ' SER . . . . . 0.418 ' HB2' ' OD1' ' A' ' 195' ' ' ASP . 11.1 m -98.99 173.54 6.79 Favored 'General case' 0 N--CA 1.423 -1.792 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.643 179.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -67.41 -8.85 36.23 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 124.157 0.983 . . . . 0.0 112.47 -176.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . 0.418 ' OD1' ' HB2' ' A' ' 193' ' ' SER . 11.8 p-10 -94.25 4.99 53.13 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 122.223 -0.298 . . . . 0.0 111.406 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . 0.549 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 79.49 11.63 84.64 Favored Glycine 0 CA--C 1.526 0.73 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.486 178.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -117.92 150.76 38.68 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 122.345 -0.503 . . . . 0.0 110.3 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . 0.453 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 82.3 m95 -78.9 135.59 37.03 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.037 177.671 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 26.4 t -74.43 -16.91 60.86 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-O 121.19 0.519 . . . . 0.0 110.547 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 24.5 mmtp -108.82 158.14 17.93 Favored 'General case' 0 CA--C 1.5 -0.978 0 O-C-N 122.123 -0.361 . . . . 0.0 110.551 178.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -97.58 170.44 9.02 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 123.477 0.486 . . . . 0.0 110.66 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 7.6 mmmm -69.06 115.8 35.43 Favored Pre-proline 0 CA--C 1.516 -0.354 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -178.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_endo -88.15 168.28 6.52 Favored 'Trans proline' 0 N--CA 1.446 -1.313 0 C-N-CA 122.862 2.375 . . . . 0.0 112.159 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -115.73 165.93 12.51 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.516 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 86.6 m -114.71 109.83 18.81 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 172.779 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 30.8 m . . . . . 0 C--O 1.254 1.302 0 O-C-N 124.332 1.02 . . . . 0.0 109.444 -173.858 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo . . . . . 0 CA--C 1.535 0.543 0 CA-C-O 121.74 0.642 . . . . 0.0 110.866 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.0 m -86.65 -35.6 19.26 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 117.46 -88.53 0.46 Allowed Glycine 0 N--CA 1.404 -3.49 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 174.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.5 t-80 -176.67 135.9 0.42 Allowed Pre-proline 0 C--N 1.255 -3.509 0 N-CA-C 104.458 -2.423 . . . . 0.0 104.458 -175.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -82.15 -0.29 10.18 Favored 'Trans proline' 0 C--N 1.329 -0.494 0 C-N-CA 121.993 1.795 . . . . 0.0 112.791 -176.197 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.33 -155.82 15.9 Favored Glycine 0 N--CA 1.42 -2.387 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -177.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -156.02 157.41 36.1 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 178.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.5 t -122.91 127.51 25.69 Favored Pre-proline 0 C--N 1.293 -1.875 0 CA-C-N 118.226 0.467 . . . . 0.0 110.822 -177.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -65.47 -16.01 52.16 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.772 2.315 . . . . 0.0 111.64 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -86.7 -9.37 56.11 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.335 -178.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 173.14 -125.29 1.13 Allowed Glycine 0 N--CA 1.433 -1.549 0 C-N-CA 118.755 -1.688 . . . . 0.0 113.907 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.8 t -148.88 -169.76 3.45 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -176.046 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -151.81 162.4 41.09 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 177.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -126.02 162.51 25.11 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.4 mt -113.93 138.74 49.92 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.403 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 26.5 p -132.68 137.64 47.02 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -178.123 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.2 24.25 52.32 Favored Glycine 0 C--N 1.309 -0.921 0 N-CA-C 108.556 -1.818 . . . . 0.0 108.556 -173.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 145.6 154.3 6.12 Favored Glycine 1 N--CA 1.39 -4.398 0 N-CA-C 107.334 -2.306 . . . . 0.0 107.334 -177.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -108.6 29.07 7.75 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 177.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.41 ' O ' HG21 ' A' ' 108' ' ' VAL . 35.6 m -144.31 -175.17 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 CA-C-N 114.686 -1.143 . . . . 0.0 109.068 -173.418 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -108.4 47.13 0.92 Allowed 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 121.464 0.649 . . . . 0.0 109.543 -177.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.722 ' O ' HG11 ' A' ' 108' ' ' VAL . 12.2 pt-20 -82.41 178.13 8.39 Favored 'General case' 0 C--O 1.213 -0.828 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.248 178.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -76.44 132.77 39.83 Favored 'General case' 0 C--N 1.289 -2.05 0 O-C-N 122.059 -0.401 . . . . 0.0 110.149 175.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.35 5.06 63.86 Favored Glycine 0 N--CA 1.431 -1.644 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.633 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.722 HG11 ' O ' ' A' ' 105' ' ' GLU . 10.4 p -96.69 144.4 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.403 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 20.5 mtpp -112.38 118.08 34.22 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -179.407 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -82.83 92.1 7.2 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 177.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 75.9 t -82.73 111.68 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.618 0 C-N-CA 123.942 0.897 . . . . 0.0 109.44 -178.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -80.6 144.12 32.62 Favored 'General case' 0 C--N 1.293 -1.858 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.672 -179.225 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.1 t -145.87 112.43 5.9 Favored 'General case' 0 N--CA 1.418 -2.041 0 CA-C-N 115.048 -0.978 . . . . 0.0 108.677 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 83.0 m -70.46 163.24 27.19 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.127 -178.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 -68.38 174.36 4.12 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.514 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -59.96 -39.09 84.43 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 112.781 0.659 . . . . 0.0 112.781 -174.238 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -85.61 9.96 66.28 Favored Glycine 0 C--N 1.3 -1.43 0 C-N-CA 121.275 -0.488 . . . . 0.0 113.668 179.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -131.44 163.12 28.63 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.16 134.86 22.27 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 9.5 tt -70.3 138.46 51.53 Favored 'General case' 0 C--N 1.293 -1.873 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.621 -177.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.45 140.75 49.02 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.018 -172.322 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 108.37 -172.81 17.28 Favored Glycine 0 C--N 1.303 -1.252 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.272 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 30.0 mm-40 -99.68 -19.63 16.7 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 117.084 0.442 . . . . 0.0 111.18 -177.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.9 mm -98.59 135.99 31.32 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -178.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -130.52 13.3 5.47 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.355 178.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.403 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 11.4 p90 -145.34 169.96 17.25 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -174.166 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.423 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 46.6 mtp180 -131.01 120.83 24.04 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 169.33 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -95.04 136.61 35.15 Favored 'General case' 0 C--N 1.28 -2.418 0 C-N-CA 119.228 -0.989 . . . . 0.0 110.223 178.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 27.1 t -92.61 109.19 20.6 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.923 -1.111 . . . . 0.0 109.473 173.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -110.3 -167.52 1.2 Allowed 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 105.004 -2.221 . . . . 0.0 105.004 175.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 14.8 t -67.03 -13.8 62.27 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 119.056 0.844 . . . . 0.0 111.409 -177.394 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -79.21 -15.68 57.67 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 121.745 0.784 . . . . 0.0 109.646 174.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 104.19 -154.62 17.64 Favored Glycine 0 N--CA 1.431 -1.69 0 N-CA-C 107.181 -2.368 . . . . 0.0 107.181 -173.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.9 m95 -64.36 106.72 1.17 Allowed 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 118.12 0.96 . . . . 0.0 108.535 172.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.0 p -63.52 -66.01 0.6 Allowed 'General case' 0 C--O 1.253 1.269 0 C-N-CA 124.001 0.92 . . . . 0.0 111.647 -174.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . 0.423 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.6 m120 -67.09 167.88 11.16 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-N 114.84 -1.073 . . . . 0.0 109.036 -179.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -100.7 -178.97 3.94 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 176.37 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 82.1 mt -72.13 120.69 81.73 Favored Pre-proline 0 C--N 1.313 -1.0 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 175.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.29 137.81 53.1 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 122.062 1.842 . . . . 0.0 110.911 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 69.7 mt -63.88 141.55 18.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.989 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 46.2 t -131.39 140.61 49.7 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -123.72 157.33 34.19 Favored 'General case' 0 N--CA 1.408 -2.551 0 CA-C-O 121.102 0.477 . . . . 0.0 110.324 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 5.7 p -75.1 137.9 22.06 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 97.5 t -58.55 117.52 1.82 Allowed 'Isoleucine or valine' 0 C--O 1.251 1.154 0 O-C-N 123.566 0.541 . . . . 0.0 110.18 -178.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 53.9 mttp -93.09 142.44 27.29 Favored 'General case' 0 N--CA 1.425 -1.704 0 CA-C-N 115.254 -0.885 . . . . 0.0 108.78 179.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.0 m -109.25 151.35 26.66 Favored 'General case' 0 C--N 1.278 -2.532 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -179.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 64.9 mt -56.17 137.45 74.22 Favored Pre-proline 0 C--N 1.319 -0.722 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.416 ' HA ' ' CD2' ' A' ' 168' ' ' TYR . 34.8 Cg_endo -66.71 94.87 0.33 Allowed 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 123.317 2.678 . . . . 0.0 111.6 179.202 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 9.5 p -69.41 142.78 15.61 Favored 'Isoleucine or valine' 0 C--O 1.25 1.119 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.01 -177.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 11.6 p -97.59 -166.25 1.36 Allowed 'General case' 0 N--CA 1.42 -1.961 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.882 177.45 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -119.61 156.35 53.64 Favored Pre-proline 0 C--N 1.297 -1.716 0 O-C-N 122.119 -0.363 . . . . 0.0 110.714 -171.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.4 175.36 6.03 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 122.224 1.949 . . . . 0.0 111.446 174.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . 0.479 ' OE1' ' HG3' ' A' ' 204' ' ' LYS . 0.0 OUTLIER -82.72 -43.57 16.66 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 120.999 0.428 . . . . 0.0 111.068 -174.801 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . 0.432 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 55.9 m-80 -98.86 18.86 16.07 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.348 0.594 . . . . 0.0 110.488 -179.676 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -147.31 -166.34 12.41 Favored Glycine 0 N--CA 1.424 -2.118 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.664 -178.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 62.5 pttt -154.68 -179.42 7.98 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -177.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 50.0 mt -100.95 132.07 47.4 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.207 0 CA-C-N 117.745 0.248 . . . . 0.0 110.859 -177.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.443 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.3 m -78.02 -29.19 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 15.4 m . . . . . 0 C--N 1.311 -1.101 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.954 -177.063 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . 0.416 ' CD2' ' HA ' ' A' ' 148' ' ' PRO . 79.7 m-85 . . . . . 0 N--CA 1.429 -1.513 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -130.95 164.62 24.92 Favored 'General case' 0 C--N 1.291 -1.953 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -178.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 92.5 t80 -58.07 111.61 1.24 Allowed 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 173.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 134.19 -23.76 3.65 Favored Glycine 0 N--CA 1.426 -1.981 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -174.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 81.0 mm-40 -78.53 140.51 38.54 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-O 121.339 0.59 . . . . 0.0 111.339 177.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -131.17 109.62 10.57 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 176.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.464 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 97.6 t -94.14 118.29 39.75 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.206 0 CA-C-N 115.472 -0.786 . . . . 0.0 110.578 -173.688 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.443 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 41.7 ttm180 -105.46 144.86 31.65 Favored 'General case' 0 N--CA 1.426 -1.654 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.604 176.174 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -114.24 159.27 20.33 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 123.586 0.754 . . . . 0.0 109.948 -176.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.03 145.04 35.45 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.284 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.951 178.49 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 84.2 m -109.81 136.45 49.1 Favored 'General case' 0 C--N 1.268 -2.954 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 55.5 m-80 -60.51 164.76 4.2 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.082 178.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 24.1 m -48.05 108.19 0.16 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 124.799 1.312 . . . . 0.0 113.282 -175.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.78 -9.6 29.92 Favored Glycine 0 N--CA 1.421 -2.331 0 C-N-CA 120.543 -0.836 . . . . 0.0 112.737 177.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -109.36 155.49 21.16 Favored 'General case' 0 N--CA 1.423 -1.819 0 CA-C-N 117.219 0.51 . . . . 0.0 110.282 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . 0.516 ' HE2' ' O ' ' A' ' 184' ' ' ILE . 18.7 ptmt -130.26 163.23 27.21 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.516 ' O ' ' HE2' ' A' ' 183' ' ' LYS . 3.7 tp -74.32 148.17 8.37 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.046 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -85.65 -74.29 0.41 Allowed 'General case' 0 C--N 1.289 -2.048 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.042 178.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -79.48 -97.88 0.28 Allowed Glycine 0 N--CA 1.442 -0.937 0 C-N-CA 121.043 -0.598 . . . . 0.0 112.443 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -118.19 150.92 38.6 Favored 'General case' 0 CA--C 1.484 -1.566 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.349 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -95.15 -1.92 50.91 Favored 'General case' 0 CA--C 1.499 -1.007 0 C-N-CA 120.155 -0.618 . . . . 0.0 111.049 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . 0.464 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.5 pt-20 -146.35 146.72 30.77 Favored 'General case' 0 C--N 1.294 -1.844 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.437 -178.086 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.0 ptp -131.98 131.43 42.56 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.117 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 42.4 t-80 -102.83 138.52 39.61 Favored 'General case' 0 C--N 1.29 -1.989 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 177.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . 0.404 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 42.7 t -81.95 135.41 35.39 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.711 177.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.0 m -99.21 165.07 11.88 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 178.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -75.43 4.52 7.22 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.219 0.533 . . . . 0.0 111.621 -176.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -68.45 -32.51 72.58 Favored 'General case' 0 CA--C 1.507 -0.706 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.286 172.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 109.4 8.82 26.41 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 111.079 -0.808 . . . . 0.0 111.079 -175.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -142.06 173.23 11.7 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-O 120.691 0.282 . . . . 0.0 110.651 177.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . 0.404 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 66.2 m95 -82.95 148.25 27.73 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.056 -175.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 20.3 m -67.51 -25.27 65.76 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.654 0.74 . . . . 0.0 110.754 178.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -124.63 148.88 47.65 Favored 'General case' 0 CA--C 1.487 -1.456 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.947 179.064 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -82.05 161.51 22.9 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 175.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . 0.441 ' HE2' ' HB2' ' A' ' 202' ' ' LYS . 10.5 ptmm? -63.51 137.95 97.23 Favored Pre-proline 0 N--CA 1.431 -1.396 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.6 -178.359 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 63.7 Cg_endo -86.89 -169.98 0.58 Allowed 'Trans proline' 0 N--CA 1.434 -1.985 0 C-N-CA 122.815 2.343 . . . . 0.0 113.919 -175.267 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . 0.479 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 61.2 tttp -134.42 158.61 43.44 Favored 'General case' 0 N--CA 1.424 -1.753 0 CA-C-N 113.948 -1.478 . . . . 0.0 107.669 -176.519 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.412 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 89.3 m -116.08 115.58 26.34 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 174.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.563 -175.51 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 33.0 Cg_endo . . . . . 0 CA--C 1.538 0.723 0 CA-C-O 121.107 0.378 . . . . 0.0 112.012 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.0 m -84.86 -32.62 23.12 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 121.891 0.853 . . . . 0.0 109.347 177.526 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.91 -92.05 0.53 Allowed Glycine 0 N--CA 1.405 -3.408 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 175.337 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.2 t-80 -174.44 139.45 0.69 Allowed Pre-proline 0 C--N 1.265 -3.089 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 -176.371 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.423 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 88.1 Cg_endo -85.91 -0.1 8.48 Favored 'Trans proline' 0 N--CA 1.473 0.274 0 C-N-CA 122.093 1.862 . . . . 0.0 112.947 -175.222 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.59 -172.64 16.19 Favored Glycine 0 C--N 1.296 -1.692 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -176.06 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -146.96 163.61 35.64 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.8 t -141.32 139.19 18.55 Favored Pre-proline 0 C--N 1.3 -1.556 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.528 -176.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -77.4 -12.7 16.99 Favored 'Trans proline' 0 CA--C 1.529 0.267 0 C-N-CA 122.696 2.264 . . . . 0.0 111.288 176.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -88.48 2.46 52.79 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.771 -175.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 159.59 -133.66 3.42 Favored Glycine 0 N--CA 1.41 -3.093 0 C-N-CA 120.213 -0.994 . . . . 0.0 111.859 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 14.1 p -148.85 -172.89 4.21 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -173.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -144.11 167.15 23.08 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 173.18 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -131.59 157.76 42.78 Favored 'General case' 0 C--N 1.279 -2.457 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 178.207 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 22.7 mt -110.9 138.84 46.79 Favored 'General case' 0 C--N 1.265 -3.099 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.2 p -129.96 131.02 45.79 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.342 -178.094 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.18 16.19 45.0 Favored Glycine 0 CA--C 1.501 -0.797 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -175.046 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 147.77 160.46 8.95 Favored Glycine 1 N--CA 1.376 -5.305 0 N-CA-C 106.212 -2.755 . . . . 0.0 106.212 -175.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -114.09 35.77 4.0 Favored 'General case' 0 C--N 1.25 -3.739 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 -179.579 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.459 ' O ' HG12 ' A' ' 108' ' ' VAL . 16.7 m -144.96 -173.82 0.49 Allowed 'Isoleucine or valine' 0 C--O 1.204 -1.291 0 CA-C-N 114.371 -1.286 . . . . 0.0 109.623 -175.126 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.423 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 29.5 m-85 -110.02 46.6 1.01 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 121.392 0.615 . . . . 0.0 109.554 -178.015 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.725 ' O ' HG11 ' A' ' 108' ' ' VAL . 11.0 pt-20 -86.91 178.74 6.87 Favored 'General case' 0 C--O 1.212 -0.892 0 CA-C-N 114.909 -1.041 . . . . 0.0 111.427 178.209 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -75.54 132.26 40.6 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.223 177.44 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 90.69 10.49 63.19 Favored Glycine 0 N--CA 1.438 -1.194 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.969 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.725 HG11 ' O ' ' A' ' 105' ' ' GLU . 11.5 p -102.29 148.07 8.2 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 176.67 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 52.4 mtpt -117.12 123.22 46.22 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 120.907 0.384 . . . . 0.0 110.532 -179.092 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.39 91.62 8.57 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.17 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.8 t -85.16 110.97 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.31 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -78.17 143.24 37.4 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 112.462 0.542 . . . . 0.0 112.462 -177.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.8 t -142.98 112.94 7.06 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 121.712 0.768 . . . . 0.0 109.461 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 89.8 m -65.81 162.17 19.41 Favored 'General case' 0 C--N 1.311 -1.09 0 N-CA-C 114.329 1.233 . . . . 0.0 114.329 -178.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -68.71 -179.97 1.57 Allowed 'General case' 0 N--CA 1.433 -1.293 0 C-N-CA 125.612 1.565 . . . . 0.0 109.892 178.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -59.95 -52.65 64.48 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 124.099 0.959 . . . . 0.0 111.145 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -86.81 33.1 3.81 Favored Glycine 0 C--N 1.308 -1.007 0 C-N-CA 120.426 -0.892 . . . . 0.0 113.791 -176.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.499 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 86.3 m-85 -150.54 170.43 19.13 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 123.725 0.81 . . . . 0.0 110.024 -177.142 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.34 156.89 42.37 Favored 'General case' 0 N--CA 1.427 -1.617 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 176.659 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 8.2 tt -87.42 136.68 32.84 Favored 'General case' 0 C--N 1.27 -2.881 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.51 130.34 56.37 Favored 'General case' 0 N--CA 1.428 -1.54 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -176.578 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 120.97 172.14 14.45 Favored Glycine 0 N--CA 1.43 -1.733 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 -178.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 57.2 mm-40 -88.57 -25.43 22.5 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-O 121.256 0.55 . . . . 0.0 109.942 178.473 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.7 mm -87.44 127.78 40.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-N 114.604 -1.18 . . . . 0.0 108.528 -179.589 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -133.52 14.98 4.07 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.042 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 30.3 p90 -153.65 159.84 42.2 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-O 121.031 0.443 . . . . 0.0 110.558 -175.549 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -122.7 134.65 54.46 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 171.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -112.56 126.49 55.4 Favored 'General case' 0 C--N 1.278 -2.524 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -176.556 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 28.8 t -82.63 99.53 9.62 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 117.738 -1.585 . . . . 0.0 110.675 177.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.485 ' OD2' HG22 ' A' ' 131' ' ' THR . 14.1 t70 -95.87 -168.35 1.75 Allowed 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 175.112 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.485 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -64.65 -23.58 67.3 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -172.707 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -78.76 -28.13 44.76 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.778 0.799 . . . . 0.0 109.787 176.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 130.65 -154.35 20.66 Favored Glycine 0 N--CA 1.422 -2.257 0 N-CA-C 108.614 -1.795 . . . . 0.0 108.614 -175.07 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 97.5 m95 -65.06 112.47 3.37 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 117.112 0.456 . . . . 0.0 111.411 178.127 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 76.5 p -73.47 159.94 32.46 Favored 'General case' 0 C--O 1.271 2.227 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 175.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 89.3 m-20 63.4 -163.15 0.27 Allowed 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . 0.482 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 17.1 t70 -141.25 -173.24 3.69 Favored 'General case' 0 C--N 1.283 -2.291 0 N-CA-C 106.114 -1.809 . . . . 0.0 106.114 173.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.482 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 67.1 mt -66.32 120.53 70.89 Favored Pre-proline 0 C--N 1.266 -3.027 0 C-N-CA 124.643 1.177 . . . . 0.0 108.727 179.753 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -68.31 139.25 45.16 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 122.238 1.958 . . . . 0.0 111.126 -179.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 73.6 mt -62.49 125.89 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 CA-C-O 121.742 0.782 . . . . 0.0 110.732 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.499 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 43.1 t -102.48 123.95 47.16 Favored 'General case' 0 N--CA 1.406 -2.652 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 176.6 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -105.09 154.47 20.11 Favored 'General case' 0 N--CA 1.413 -2.291 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 -174.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 15.0 p -80.39 143.37 12.5 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.768 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.285 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.505 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 6.4 m -65.3 130.86 30.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 176.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.446 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 96.2 mttt -120.03 141.62 49.56 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.291 -174.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.4 m -108.92 160.06 16.3 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 124.199 0.937 . . . . 0.0 108.568 177.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -76.63 149.69 81.22 Favored Pre-proline 0 N--CA 1.418 -2.074 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -68.19 114.76 3.53 Favored 'Trans proline' 0 N--CA 1.442 -1.503 0 C-N-CA 122.679 2.253 . . . . 0.0 110.242 175.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.416 HG21 ' SD ' ' A' ' 190' ' ' MET . 41.5 t -71.36 147.19 11.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.142 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.27 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 22.8 p -71.57 -80.4 0.06 Allowed 'General case' 0 N--CA 1.435 -1.221 0 O-C-N 123.117 0.26 . . . . 0.0 111.353 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.6 161.02 0.48 Allowed Pre-proline 0 C--O 1.24 0.587 0 C-N-CA 125.607 1.563 . . . . 0.0 107.612 177.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -78.84 -158.03 0.08 OUTLIER 'Trans proline' 0 CA--C 1.547 1.17 0 C-N-CA 121.555 1.503 . . . . 0.0 111.048 171.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . 0.433 ' OE1' ' HG2' ' A' ' 204' ' ' LYS . 0.0 OUTLIER -99.91 -52.16 3.51 Favored 'General case' 0 C--N 1.31 -1.148 0 O-C-N 121.861 -0.524 . . . . 0.0 112.271 -175.668 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 61.8 m-80 -107.19 25.58 11.23 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.605 0.716 . . . . 0.0 110.141 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -151.13 -176.78 24.33 Favored Glycine 0 N--CA 1.417 -2.633 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 16.5 pttm -145.82 168.93 19.6 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 -179.334 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.432 HG12 ' CD2' ' A' ' 176' ' ' PHE . 52.1 mt -91.6 141.84 13.9 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.439 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.5 m -90.98 -30.65 4.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 178.319 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 10.4 m . . . . . 0 C--N 1.311 -1.073 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.472 -174.075 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . 0.446 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 79.6 m-85 . . . . . 0 N--CA 1.432 -1.327 0 CA-C-O 121.506 0.669 . . . . 0.0 109.897 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 20.0 m170 -106.36 160.44 15.38 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 114.538 -1.21 . . . . 0.0 108.249 -175.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . 0.505 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 65.0 t80 -50.02 123.99 9.25 Favored 'General case' 0 N--CA 1.47 0.539 0 O-C-N 123.287 0.367 . . . . 0.0 110.107 172.179 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 102.43 -0.83 49.87 Favored Glycine 0 N--CA 1.428 -1.839 0 C-N-CA 119.497 -1.335 . . . . 0.0 112.919 178.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 30.3 mm-40 -88.13 145.02 26.15 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 175.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -113.47 117.77 32.64 Favored 'General case' 0 C--N 1.281 -2.409 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.511 -179.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.427 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 54.5 t -98.71 101.24 11.87 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 176.305 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.439 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 16.2 ttm180 -93.45 145.98 24.1 Favored 'General case' 0 N--CA 1.415 -2.219 0 CA-C-N 114.906 -1.043 . . . . 0.0 110.54 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.432 ' CD2' HG12 ' A' ' 157' ' ' ILE . 68.6 m-85 -114.89 156.15 25.52 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 14.6 p -137.01 139.84 43.76 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.212 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.6 m -95.5 138.75 32.73 Favored 'General case' 0 C--N 1.269 -2.934 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.237 -176.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . 0.471 ' O ' ' HD2' ' A' ' 182' ' ' TYR . 58.9 m-20 -82.72 165.42 19.95 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 -179.349 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.7 t 49.07 -142.55 0.55 Allowed 'General case' 0 CA--C 1.548 0.867 0 O-C-N 124.057 0.848 . . . . 0.0 110.805 178.265 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -93.49 32.44 5.76 Favored Glycine 0 N--CA 1.428 -1.865 0 C-N-CA 121.19 -0.529 . . . . 0.0 111.876 178.454 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . 0.471 ' HD2' ' O ' ' A' ' 179' ' ' ASN . 96.9 m-85 -84.23 160.49 20.78 Favored 'General case' 0 N--CA 1.443 -0.802 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.378 -179.216 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -126.54 155.03 43.03 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 2.6 tp -71.82 144.77 12.91 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 178.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -85.71 -65.85 0.96 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.363 179.092 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -86.26 -113.88 0.87 Allowed Glycine 0 N--CA 1.439 -1.162 0 N-CA-C 111.817 -0.513 . . . . 0.0 111.817 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -100.05 157.47 16.53 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.827 -1.545 . . . . 0.0 106.827 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -93.51 -8.7 40.7 Favored 'General case' 0 N--CA 1.433 -1.283 0 C-N-CA 119.305 -0.958 . . . . 0.0 109.401 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . 0.427 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 2.9 pt-20 -146.23 130.41 17.48 Favored 'General case' 0 N--CA 1.43 -1.442 0 CA-C-O 121.932 0.872 . . . . 0.0 112.835 178.698 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.416 ' SD ' HG21 ' A' ' 149' ' ' VAL . 12.8 ptp -102.01 143.16 32.21 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.514 177.182 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -113.66 150.11 33.69 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 2.4 m -74.04 123.18 23.87 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 123.685 0.615 . . . . 0.0 110.795 173.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 193' ' ' SER . . . . . 0.424 ' HB2' ' OG ' ' A' ' 199' ' ' SER . 34.4 t -83.94 167.52 16.88 Favored 'General case' 0 N--CA 1.423 -1.795 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 176.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -71.81 -5.16 32.21 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 123.534 0.734 . . . . 0.0 111.351 -177.141 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -84.82 -18.87 33.6 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.412 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 88.81 27.46 24.04 Favored Glycine 0 N--CA 1.451 -0.309 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 -173.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -131.94 161.55 32.82 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 179.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -77.87 131.06 37.35 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 176.464 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 199' ' ' SER . . . . . 0.424 ' OG ' ' HB2' ' A' ' 193' ' ' SER . 15.0 m -68.04 -39.45 83.05 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-O 121.548 0.69 . . . . 0.0 110.064 -179.353 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 21.5 mmtp -96.33 150.27 20.76 Favored 'General case' 0 C--N 1.307 -1.247 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.75 177.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 22.9 mm-40 -86.3 166.23 15.81 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 176.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 28.3 ttmt -67.47 121.85 80.68 Favored Pre-proline 0 C--N 1.324 -0.519 0 C-N-CA 119.51 -0.876 . . . . 0.0 109.47 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.5 -174.86 2.44 Favored 'Trans proline' 0 N--CA 1.437 -1.834 0 C-N-CA 121.996 1.797 . . . . 0.0 111.759 179.183 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . 0.433 ' HG2' ' OE1' ' A' ' 153' ' ' GLU . 48.2 mttm -127.9 162.58 26.39 Favored 'General case' 0 C--N 1.287 -2.124 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.295 179.217 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 77.5 m -113.32 106.28 14.42 Favored 'General case' 0 C--N 1.281 -2.408 0 O-C-N 124.057 0.848 . . . . 0.0 109.137 170.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.5 m . . . . . 0 N--CA 1.431 -1.415 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.313 -173.759 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.4 ' HG2' ' HA ' ' A' ' 105' ' ' GLU . 33.9 Cg_endo . . . . . 0 CA--C 1.536 0.608 0 CA-C-O 121.113 0.38 . . . . 0.0 111.934 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.8 m -86.49 -33.69 20.27 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 176.085 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.74 -96.66 0.67 Allowed Glycine 0 N--CA 1.402 -3.593 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 173.035 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 56.0 t-80 -173.1 121.03 0.41 Allowed Pre-proline 0 C--N 1.263 -3.169 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -175.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.08 -30.79 13.05 Favored 'Trans proline' 0 C--O 1.219 -0.436 0 C-N-CA 121.909 1.74 . . . . 0.0 113.369 -171.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.22 176.13 14.34 Favored Glycine 0 CA--C 1.483 -1.936 0 N-CA-C 108.347 -1.901 . . . . 0.0 108.347 -176.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -134.7 -175.49 3.91 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -177.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 2.1 t -141.47 133.5 13.78 Favored Pre-proline 0 C--N 1.303 -1.43 0 CA-C-O 121.234 0.54 . . . . 0.0 112.131 -178.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -71.83 -18.1 28.53 Favored 'Trans proline' 0 C--O 1.238 0.513 0 C-N-CA 122.554 2.169 . . . . 0.0 111.389 175.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -86.72 -3.42 59.04 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.072 -176.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.46 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.89 -123.47 0.94 Allowed Glycine 0 N--CA 1.424 -2.157 0 C-N-CA 120.033 -1.079 . . . . 0.0 112.04 179.234 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 11.7 t -157.93 -166.48 1.98 Allowed 'General case' 0 C--N 1.285 -2.205 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -149.77 162.15 40.83 Favored 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 177.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 7.0 m -128.34 161.41 29.47 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 -178.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 25.4 mt -117.11 128.6 55.29 Favored 'General case' 0 C--N 1.266 -3.042 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.426 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 32.0 p -123.76 135.17 53.67 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -175.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 105.95 -45.33 1.32 Allowed Glycine 0 C--N 1.305 -1.19 0 N-CA-C 111.69 -0.564 . . . . 0.0 111.69 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -131.9 -16.59 1.41 Allowed Glycine 0 C--O 1.219 -0.784 0 C-N-CA 120.263 -0.97 . . . . 0.0 113.524 -177.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 64.5 12.97 7.84 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 123.657 0.783 . . . . 0.0 113.014 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.513 ' O ' HG13 ' A' ' 108' ' ' VAL . 23.4 m -145.95 -169.4 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 -177.201 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -105.14 45.54 0.96 Allowed 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 118.692 0.678 . . . . 0.0 110.461 -178.232 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.73 ' O ' HG12 ' A' ' 108' ' ' VAL . 9.3 pt-20 -89.68 -176.18 4.9 Favored 'General case' 0 C--O 1.208 -1.094 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.884 178.231 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -79.08 138.63 38.04 Favored 'General case' 0 C--N 1.31 -1.132 0 O-C-N 121.648 -0.657 . . . . 0.0 111.119 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 85.59 4.31 85.6 Favored Glycine 0 N--CA 1.439 -1.155 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.992 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.73 HG12 ' O ' ' A' ' 105' ' ' GLU . 15.0 p -93.39 143.67 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.943 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 177.552 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.426 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 54.9 mtpt -108.08 118.38 36.6 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.368 178.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -83.08 91.87 7.29 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 175.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.476 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 32.3 m -91.83 117.58 35.44 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.405 0 CA-C-O 122.19 0.995 . . . . 0.0 108.735 -178.042 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 36.4 m-85 -84.42 146.71 27.51 Favored 'General case' 0 C--N 1.264 -3.143 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.918 -176.606 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.1 t -144.06 118.54 9.7 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-O 122.102 0.954 . . . . 0.0 108.919 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 3.8 m -75.12 160.93 29.87 Favored 'General case' 0 C--N 1.284 -2.25 0 CA-C-N 115.29 -0.868 . . . . 0.0 108.966 -176.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.46 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 75.4 m-20 -73.15 171.03 13.72 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 177.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -48.06 -49.37 31.72 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.553 1.141 . . . . 0.0 113.525 -176.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.537 ' HA2' ' CD2' ' A' ' 170' ' ' PHE . . . -80.61 8.46 54.8 Favored Glycine 0 C--N 1.309 -0.95 0 CA-C-N 116.025 -0.534 . . . . 0.0 113.37 -176.635 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.46 ' CE1' HG22 ' A' ' 143' ' ' VAL . 94.0 m-85 -130.71 150.61 51.81 Favored 'General case' 0 N--CA 1.434 -1.249 0 CA-C-O 121.501 0.667 . . . . 0.0 110.397 -178.478 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -119.08 163.5 16.92 Favored 'General case' 0 C--N 1.276 -2.614 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . 0.409 HD13 ' HB2' ' A' ' 139' ' ' PRO . 13.4 tp -83.48 141.53 31.59 Favored 'General case' 0 C--N 1.282 -2.361 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 177.273 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.72 116.94 30.92 Favored 'General case' 0 N--CA 1.408 -2.57 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.149 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.6 -169.33 13.14 Favored Glycine 0 C--N 1.276 -2.777 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.02 -174.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -100.53 -48.93 4.37 Favored 'General case' 0 C--N 1.287 -2.111 0 CA-C-N 114.926 -0.637 . . . . 0.0 109.304 -174.779 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.6 mm -68.0 126.67 28.27 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 CA-C-N 114.589 -1.187 . . . . 0.0 109.874 -176.085 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -122.91 3.13 9.42 Favored 'General case' 0 C--O 1.198 -1.654 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.219 176.346 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 20.9 p90 -138.28 161.85 35.84 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.068 -173.441 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 58.1 mtp180 -126.5 131.18 51.68 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 170.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -107.62 132.18 53.58 Favored 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 -177.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 43.1 t -81.02 104.5 11.57 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 118.02 -1.472 . . . . 0.0 110.303 176.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.517 ' OD1' HG21 ' A' ' 131' ' ' THR . 15.0 t70 -97.23 -169.43 1.85 Allowed 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.517 HG21 ' OD1' ' A' ' 130' ' ' ASP . 15.0 t -68.73 -17.02 63.98 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.631 0.729 . . . . 0.0 110.921 -175.614 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -87.9 -24.01 23.77 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.694 177.011 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 122.65 -154.03 16.95 Favored Glycine 0 N--CA 1.416 -2.646 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -174.335 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.9 m95 -63.34 115.1 4.27 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 179.419 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 55.4 p -76.66 168.87 19.32 Favored 'General case' 0 C--O 1.261 1.689 0 N-CA-C 109.287 -0.635 . . . . 0.0 109.287 176.531 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 61.53 -170.75 0.16 Allowed 'General case' 0 C--O 1.242 0.672 0 O-C-N 123.94 0.775 . . . . 0.0 111.918 177.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.64 171.29 7.61 Favored 'General case' 0 CA--C 1.469 -2.163 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 175.339 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.6 mt -67.57 113.4 14.0 Favored Pre-proline 0 C--N 1.297 -1.708 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 170.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . 0.409 ' HB2' HD13 ' A' ' 120' ' ' LEU . 45.2 Cg_endo -66.46 131.69 27.06 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 122.052 1.835 . . . . 0.0 111.711 -176.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 69.3 mt -80.58 131.58 33.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.887 -176.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 74.3 m -103.52 149.56 24.74 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 174.191 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -125.49 168.37 13.73 Favored 'General case' 0 C--N 1.287 -2.117 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 174.226 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.46 HG22 ' CE1' ' A' ' 118' ' ' TYR . 99.6 t -67.65 143.3 15.51 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 177.028 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 72.6 t -61.5 130.7 25.99 Favored 'Isoleucine or valine' 0 C--O 1.242 0.668 0 N-CA-C 107.877 -1.156 . . . . 0.0 107.877 174.509 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.422 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 84.0 mttt -120.28 152.19 38.14 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 -175.264 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 59.0 m -118.42 160.04 22.4 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 64.4 mt -69.72 144.73 94.06 Favored Pre-proline 0 C--O 1.24 0.603 0 N-CA-C 112.282 0.475 . . . . 0.0 112.282 178.597 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -64.68 131.48 29.59 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 123.197 2.598 . . . . 0.0 112.449 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 44.2 t -90.94 136.82 23.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 179.245 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 15.3 p -73.55 -85.93 0.03 OUTLIER 'General case' 0 C--N 1.314 -0.965 0 CA-C-O 120.636 0.255 . . . . 0.0 111.55 178.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 177.0 150.24 0.35 Allowed Pre-proline 0 C--O 1.242 0.672 0 C-N-CA 125.627 1.571 . . . . 0.0 107.493 177.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.88 171.16 17.75 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.008 1.805 . . . . 0.0 111.263 174.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -65.06 -59.96 3.55 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 114.645 1.35 . . . . 0.0 114.645 -174.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . 0.413 ' HB2' ' O ' ' A' ' 205' ' ' CYS . 44.2 m-80 -107.52 29.88 6.78 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-O 121.845 0.831 . . . . 0.0 110.161 -178.198 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.88 178.14 22.89 Favored Glycine 0 N--CA 1.419 -2.438 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 57.5 pttt -145.79 166.14 26.79 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.178 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 56.9 mt -83.69 134.13 27.62 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 CA-C-O 121.348 0.594 . . . . 0.0 111.005 -178.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.5 t -68.81 -43.1 82.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.131 -0.94 . . . . 0.0 109.595 178.044 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 35.0 t . . . . . 0 N--CA 1.443 -0.781 0 CA-C-O 121.676 0.75 . . . . 0.0 109.464 176.392 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 . . . . . 0 C--O 1.24 0.575 0 CA-C-O 121.777 0.798 . . . . 0.0 112.79 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.414 ' HB3' HG13 ' A' ' 143' ' ' VAL . 38.0 m80 -95.43 152.02 18.78 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 114.399 -1.273 . . . . 0.0 112.057 -178.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . 0.537 ' CD2' ' HA2' ' A' ' 117' ' ' GLY . 0.9 OUTLIER -62.56 106.04 0.72 Allowed 'General case' 0 C--O 1.239 0.535 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 172.731 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 138.35 -12.53 3.52 Favored Glycine 0 N--CA 1.428 -1.884 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -174.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 31.7 mm-40 -99.34 160.74 14.06 Favored 'General case' 0 C--O 1.259 1.57 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 177.131 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -140.78 135.24 31.28 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 178.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.487 HG23 ' CH2' ' A' ' 198' ' ' TRP . 92.7 t -99.34 106.03 18.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.631 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.418 ' HA ' ' HA ' ' A' ' 189' ' ' GLU . 56.3 ttt180 -97.95 158.17 15.69 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 178.24 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -130.45 153.49 48.72 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -172.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.2 p -134.97 143.19 38.07 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 81.9 m -99.03 145.3 27.23 Favored 'General case' 0 C--N 1.283 -2.296 0 CA-C-N 115.607 -0.724 . . . . 0.0 112.218 -175.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -69.79 159.49 33.48 Favored 'General case' 0 N--CA 1.434 -1.257 0 CA-C-N 115.383 -0.826 . . . . 0.0 108.885 175.089 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 38.4 m -58.44 112.3 1.53 Allowed 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.805 -175.096 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 114.72 -13.43 20.3 Favored Glycine 0 N--CA 1.438 -1.218 0 CA-C-N 115.145 -0.934 . . . . 0.0 111.761 -178.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -107.83 160.96 15.33 Favored 'General case' 0 N--CA 1.433 -1.305 0 CA-C-O 120.876 0.369 . . . . 0.0 111.733 -177.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . 0.503 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 22.3 pttm -131.24 152.75 50.2 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 178.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.403 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.4 tt -80.61 136.05 24.05 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.285 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.332 175.738 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -75.0 -54.95 6.29 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.078 -176.502 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -91.38 -144.61 13.22 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.519 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -77.92 157.9 29.6 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . 0.403 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.4 pt-20 -89.91 -5.63 56.58 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.557 -174.538 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . 0.418 ' HA ' ' HA ' ' A' ' 175' ' ' ARG . 3.6 pt-20 -147.77 142.28 26.47 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.17 0.51 . . . . 0.0 111.977 -175.465 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.45 ' CG ' ' HB ' ' A' ' 174' ' ' VAL . 14.3 ptp -120.29 134.79 55.19 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.105 -0.952 . . . . 0.0 108.537 175.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 21.9 t-80 -112.36 147.01 37.29 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 110.56 -0.163 . . . . 0.0 110.56 -175.257 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . 0.423 ' HB3' ' HA ' ' A' ' 170' ' ' PHE . 1.5 m -70.68 120.01 15.66 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 116.663 -0.244 . . . . 0.0 110.542 173.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.1 m -98.7 163.95 12.43 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.836 178.104 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -47.17 -32.66 4.55 Favored 'General case' 0 N--CA 1.498 1.926 0 C-N-CA 126.533 1.933 . . . . 0.0 114.078 -178.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -73.1 -17.08 61.44 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 94.99 28.35 10.08 Favored Glycine 0 C--N 1.307 -1.069 0 C-N-CA 119.917 -1.135 . . . . 0.0 112.093 -178.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 2.5 p90 -140.62 172.05 13.25 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 176.45 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . 0.487 ' CH2' HG23 ' A' ' 174' ' ' VAL . 87.5 m95 -82.22 143.3 31.47 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 123.717 0.636 . . . . 0.0 111.129 -178.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 5.0 m -69.13 -6.46 28.72 Favored 'General case' 0 CA--C 1.549 0.937 0 C-N-CA 124.109 0.964 . . . . 0.0 111.245 178.197 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 25.9 mmmt -140.52 150.99 44.41 Favored 'General case' 0 CA--C 1.482 -1.666 0 C-N-CA 123.863 0.865 . . . . 0.0 109.467 -178.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -89.65 157.62 17.94 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 104.561 -2.385 . . . . 0.0 104.561 169.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 25.9 ttpp -60.85 114.44 10.4 Favored Pre-proline 0 C--O 1.243 0.759 0 N-CA-C 114.479 1.289 . . . . 0.0 114.479 -172.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -78.89 165.58 24.21 Favored 'Trans proline' 0 N--CA 1.435 -1.936 0 C-N-CA 123.113 2.542 . . . . 0.0 109.786 176.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.9 pttt -139.08 162.76 34.15 Favored 'General case' 0 C--N 1.285 -2.209 0 C-N-CA 120.005 -0.678 . . . . 0.0 111.543 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 73.6 m -96.29 121.4 38.04 Favored 'General case' 0 N--CA 1.406 -2.628 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.052 179.378 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 13.4 m . . . . . 0 C--N 1.295 -1.775 0 C-N-CA 125.384 1.474 . . . . 0.0 108.181 -177.02 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo . . . . . 0 CA--C 1.538 0.703 0 CA-C-O 121.201 0.417 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 34.2 m -75.54 -37.18 60.21 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.674 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 120.41 -95.86 0.6 Allowed Glycine 0 N--CA 1.4 -3.742 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 173.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.2 t60 -173.26 123.67 0.43 Allowed Pre-proline 0 C--N 1.253 -3.596 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 -175.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -76.02 -3.52 13.96 Favored 'Trans proline' 0 C--O 1.213 -0.75 0 C-N-CA 122.766 2.31 . . . . 0.0 113.841 -171.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 112.97 -175.58 16.78 Favored Glycine 0 C--N 1.285 -2.295 0 N-CA-C 108.296 -1.921 . . . . 0.0 108.296 -176.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -152.92 118.52 5.31 Favored 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -176.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.1 t -91.22 133.85 30.91 Favored Pre-proline 0 C--N 1.304 -1.389 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -173.124 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -77.65 -13.73 16.17 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 122.725 2.283 . . . . 0.0 111.453 173.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -81.01 -10.32 59.72 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.934 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.523 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -178.41 -133.74 1.96 Allowed Glycine 0 N--CA 1.407 -3.299 0 C-N-CA 119.583 -1.294 . . . . 0.0 112.494 -178.746 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 21.0 p -143.39 -177.5 5.41 Favored 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -177.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 37.7 p90 -149.92 157.24 42.97 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 173.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.5 m -131.81 152.21 51.14 Favored 'General case' 0 C--N 1.289 -2.065 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.437 HD11 ' CE1' ' A' ' 104' ' ' PHE . 16.2 mt -106.12 131.49 53.32 Favored 'General case' 0 C--N 1.273 -2.731 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 20.5 p -123.01 137.92 54.82 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.0 -175.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 101.99 -56.96 0.66 Allowed Glycine 0 N--CA 1.436 -1.318 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -177.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -110.04 -30.5 3.4 Favored Glycine 0 C--O 1.21 -1.383 0 C-N-CA 120.991 -0.623 . . . . 0.0 113.121 -178.216 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 42.0 m-80 70.6 11.4 7.28 Favored 'General case' 0 N--CA 1.506 2.329 0 C-N-CA 123.879 0.872 . . . . 0.0 110.96 -177.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.502 ' O ' HG12 ' A' ' 108' ' ' VAL . 24.3 m -148.8 -175.14 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.76 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 -179.385 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.437 ' CE1' HD11 ' A' ' 98' ' ' LEU . 24.4 m-85 -99.17 42.42 1.1 Allowed 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 119.25 0.932 . . . . 0.0 111.049 -176.151 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.745 ' O ' HG11 ' A' ' 108' ' ' VAL . 9.6 pt-20 -83.01 -179.67 7.51 Favored 'General case' 0 C--O 1.208 -1.128 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.877 177.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -75.61 132.96 40.98 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.743 -0.598 . . . . 0.0 111.827 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.52 3.87 66.4 Favored Glycine 0 N--CA 1.435 -1.383 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.842 177.583 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.745 HG11 ' O ' ' A' ' 105' ' ' GLU . 11.9 p -90.28 143.7 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 C-N-CA 119.993 -0.683 . . . . 0.0 109.223 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.7 mtpt -107.81 119.36 39.24 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 178.47 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.483 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.44 93.3 9.1 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 177.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 79.4 t -85.37 113.94 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.506 0 C-N-CA 123.478 0.711 . . . . 0.0 109.231 -178.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -87.16 134.75 33.49 Favored 'General case' 0 C--N 1.282 -2.335 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.843 179.205 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -132.01 130.12 40.99 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 10.1 m -82.34 154.43 25.28 Favored 'General case' 0 C--N 1.278 -2.535 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.659 -173.117 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.523 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 86.5 m-20 -71.26 177.24 3.98 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-N 116.765 -0.198 . . . . 0.0 111.47 179.445 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . 0.403 ' O ' ' HB2' ' A' ' 194' ' ' ASP . 45.6 tt0 -52.41 -54.59 30.1 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 123.845 0.858 . . . . 0.0 112.021 -174.759 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.94 34.69 3.17 Favored Glycine 0 C--N 1.308 -0.992 0 C-N-CA 120.787 -0.72 . . . . 0.0 113.171 -179.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -147.09 156.4 42.97 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.103 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -133.91 169.1 17.59 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 15.4 tp -92.2 142.66 27.24 Favored 'General case' 0 C--N 1.28 -2.42 0 C-N-CA 119.574 -0.851 . . . . 0.0 109.006 177.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -124.58 122.49 37.72 Favored 'General case' 0 N--CA 1.414 -2.239 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 177.077 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.5 171.6 15.63 Favored Glycine 0 C--N 1.286 -2.201 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.691 -176.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -95.91 -25.9 15.81 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.396 0.617 . . . . 0.0 109.808 -176.209 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.6 mm -90.2 137.36 21.69 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 23.0 p-10 -135.69 8.02 3.29 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 120.715 0.293 . . . . 0.0 110.639 179.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.483 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 28.8 p90 -146.29 171.35 15.11 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.067 -173.57 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.485 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 33.3 mtp180 -129.05 119.76 24.78 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 173.275 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -90.6 128.42 36.59 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.198 -1.001 . . . . 0.0 109.395 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 42.3 t -84.64 113.05 20.99 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.859 -1.136 . . . . 0.0 110.554 175.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -103.48 -172.33 2.09 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 10.8 t -64.19 -25.76 68.22 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.489 0.551 . . . . 0.0 112.489 -174.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -84.96 -23.94 28.54 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.13 0.491 . . . . 0.0 111.186 178.454 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 138.09 -158.01 24.59 Favored Glycine 0 N--CA 1.435 -1.381 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -177.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.4 m95 -68.57 113.04 5.74 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 178.441 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.2 p -64.49 -65.25 0.7 Allowed 'General case' 0 C--O 1.243 0.724 0 C-N-CA 123.049 0.54 . . . . 0.0 111.607 -176.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . 0.485 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 4.1 m120 -72.38 167.82 19.72 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . 0.442 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 10.4 t70 -104.66 -171.65 1.96 Allowed 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 176.329 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.442 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 78.8 mt -72.92 121.6 85.48 Favored Pre-proline 0 C--N 1.274 -2.686 0 C-N-CA 124.497 1.119 . . . . 0.0 108.256 179.674 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.69 160.7 48.73 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 122.027 1.818 . . . . 0.0 110.763 177.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.1 mm -95.91 124.64 48.66 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 CA-C-O 121.523 0.677 . . . . 0.0 110.95 -175.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 68.2 m -100.22 120.27 39.64 Favored 'General case' 0 C--N 1.271 -2.806 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 171.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 16.4 tp10 -102.36 146.1 28.54 Favored 'General case' 0 C--N 1.272 -2.777 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 -178.683 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.15 136.79 25.58 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.882 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.466 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.1 m -59.77 128.44 20.71 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 CA-C-O 121.22 0.533 . . . . 0.0 110.378 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 59.8 mttm -112.68 145.92 39.59 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.56 -174.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.2 m -118.33 137.95 52.74 Favored 'General case' 0 C--N 1.277 -2.551 0 N-CA-C 106.157 -1.794 . . . . 0.0 106.157 -179.34 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 78.3 mt -62.32 143.42 95.63 Favored Pre-proline 0 C--N 1.313 -1.008 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -176.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -66.04 122.81 10.44 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.039 2.493 . . . . 0.0 110.408 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 51.7 t -76.33 149.25 6.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.941 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 6.3 p -68.95 -84.46 0.03 OUTLIER 'General case' 0 N--CA 1.439 -0.999 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.922 176.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 166.0 159.81 0.1 OUTLIER Pre-proline 0 CA--C 1.501 -0.94 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 177.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -72.28 156.11 55.36 Favored 'Trans proline' 0 N--CA 1.431 -2.167 0 CA-C-N 119.801 0.965 . . . . 0.0 109.89 171.094 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -64.92 -33.25 75.58 Favored 'General case' 0 C--N 1.28 -2.43 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -173.136 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -125.59 25.44 6.98 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-O 122.626 1.203 . . . . 0.0 109.045 -174.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.89 -155.8 6.59 Favored Glycine 0 N--CA 1.415 -2.738 0 CA-C-N 113.519 -1.673 . . . . 0.0 110.432 178.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . 0.41 ' HG3' HG21 ' A' ' 177' ' ' VAL . 24.1 pttm -157.79 174.41 15.34 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 41.7 mt -94.45 133.64 34.72 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.422 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.454 ' CG2' HG22 ' A' ' 177' ' ' VAL . 58.2 t -73.53 -48.45 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 177.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.9 m . . . . . 0 N--CA 1.429 -1.504 0 CA-C-N 115.019 -0.991 . . . . 0.0 109.021 -179.857 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 . . . . . 0 N--CA 1.408 -2.538 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 27.7 m170 -128.71 175.67 8.41 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -175.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . 0.466 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 70.8 t80 -53.93 135.42 42.44 Favored 'General case' 0 C--N 1.306 -1.302 0 O-C-N 124.185 0.928 . . . . 0.0 110.052 172.777 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 101.3 -27.3 21.17 Favored Glycine 0 N--CA 1.43 -1.752 0 C-N-CA 120.126 -1.035 . . . . 0.0 112.306 178.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -68.14 147.21 52.62 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 117.28 0.54 . . . . 0.0 111.177 -178.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -128.44 116.13 19.26 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-N 114.457 -1.247 . . . . 0.0 107.794 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 69.5 t -100.18 110.31 26.97 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.928 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.237 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 64.1 ttt180 -97.07 155.64 16.71 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -178.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -128.27 161.87 28.34 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 123.669 0.787 . . . . 0.0 109.714 -174.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.454 HG22 ' CG2' ' A' ' 158' ' ' VAL . 0.1 OUTLIER -134.52 150.71 30.79 Favored 'Isoleucine or valine' 0 CA--C 1.474 -1.949 0 O-C-N 124.04 0.838 . . . . 0.0 109.111 178.659 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.2 m -110.83 137.5 48.41 Favored 'General case' 0 N--CA 1.395 -3.21 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 175.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -65.9 177.05 1.41 Allowed 'General case' 0 C--N 1.287 -2.136 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.853 -177.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.0 m -39.6 -36.11 0.37 Allowed 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 127.351 2.26 . . . . 0.0 116.823 -172.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -118.18 21.43 10.13 Favored Glycine 0 C--N 1.29 -2.005 0 C-N-CA 119.553 -1.308 . . . . 0.0 113.604 -178.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -126.92 156.36 41.59 Favored 'General case' 0 N--CA 1.436 -1.167 0 CA-C-N 117.754 0.777 . . . . 0.0 112.975 -177.17 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . 0.463 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 25.0 pttm -124.96 153.07 43.31 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 179.105 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.3 tp -72.93 146.91 10.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.472 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -83.04 -62.23 1.65 Allowed 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -103.15 -115.72 4.1 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -85.61 154.37 21.75 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -98.11 2.53 48.72 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 -178.277 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -155.79 149.61 25.24 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -176.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.0 ptp -126.82 126.14 42.87 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 114.945 -1.025 . . . . 0.0 111.331 179.154 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -95.76 148.28 22.74 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 177.096 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . 0.45 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 34.5 t -95.31 135.8 36.47 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 119.803 -0.759 . . . . 0.0 111.238 178.682 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 19.5 m -84.94 162.28 19.49 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 124.281 1.033 . . . . 0.0 109.294 177.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . 0.431 ' O ' HG13 ' A' ' 144' ' ' VAL . 4.5 p-10 -72.84 -7.72 52.14 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.247 0.546 . . . . 0.0 112.29 -174.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . 0.404 ' HB2' ' CD2' ' A' ' 197' ' ' PHE . 2.8 m-20 -77.81 -12.59 59.99 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 174.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 89.74 39.98 6.07 Favored Glycine 0 N--CA 1.438 -1.188 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.795 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . 0.404 ' CD2' ' HB2' ' A' ' 195' ' ' ASP . 42.1 p90 -144.69 156.78 44.26 Favored 'General case' 0 C--N 1.318 -0.771 0 O-C-N 122.121 -0.634 . . . . 0.0 109.506 177.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . 0.45 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 81.9 m95 -76.12 128.85 35.83 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.4 m -63.07 -33.65 75.9 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.264 0.554 . . . . 0.0 110.078 -178.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 28.0 mmtp -108.68 148.35 30.56 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.85 177.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -87.42 178.17 6.9 Favored 'General case' 0 C--N 1.289 -2.059 0 CA-C-N 114.835 -1.075 . . . . 0.0 110.683 -178.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 8.7 mmmm -59.84 120.34 49.05 Favored Pre-proline 0 N--CA 1.442 -0.855 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.283 177.165 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -90.49 178.89 1.97 Allowed 'Trans proline' 0 N--CA 1.427 -2.386 0 C-N-CA 122.467 2.111 . . . . 0.0 110.179 176.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -128.98 165.84 20.35 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.463 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 88.9 m -122.25 104.59 9.55 Favored 'General case' 0 N--CA 1.415 -2.205 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 172.108 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--N 1.297 -1.695 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.049 -174.728 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo . . . . . 0 CA--C 1.535 0.545 0 CA-C-O 121.404 0.502 . . . . 0.0 111.396 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 39.6 m -85.22 -33.85 22.15 Favored 'General case' 0 C--N 1.315 -0.921 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 177.337 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.72 -94.07 0.58 Allowed Glycine 0 N--CA 1.398 -3.848 0 CA-C-N 114.467 -1.242 . . . . 0.0 110.005 171.495 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.0 t-80 -175.07 123.9 0.36 Allowed Pre-proline 0 C--N 1.252 -3.649 0 N-CA-C 104.422 -2.436 . . . . 0.0 104.422 -174.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -79.0 -23.61 7.67 Favored 'Trans proline' 0 C--N 1.329 -0.473 0 C-N-CA 122.031 1.821 . . . . 0.0 112.906 -175.193 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.1 176.77 20.45 Favored Glycine 0 CA--C 1.475 -2.459 0 N-CA-C 108.263 -1.935 . . . . 0.0 108.263 -175.159 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.1 t0 -136.87 155.15 50.16 Favored 'General case' 0 C--N 1.275 -2.663 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -176.337 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.4 t -99.57 127.2 34.84 Favored Pre-proline 0 C--N 1.294 -1.805 0 CA-C-O 120.836 0.35 . . . . 0.0 110.302 -176.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.9 -13.67 39.09 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.695 2.263 . . . . 0.0 112.3 -178.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -94.62 1.48 55.6 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.72 -177.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.474 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 179.98 -129.94 1.42 Allowed Glycine 0 N--CA 1.416 -2.657 0 C-N-CA 119.234 -1.46 . . . . 0.0 112.482 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 22.0 p -149.13 -176.38 5.34 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 124.216 0.598 . . . . 0.0 110.0 -177.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -144.71 164.33 31.33 Favored 'General case' 0 C--N 1.313 -1.022 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 172.043 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.2 m -129.29 160.48 32.87 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 179.237 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.7 mt -117.51 125.01 50.13 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.121 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.456 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 21.7 p -117.86 137.87 52.49 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.442 -175.462 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 102.25 -47.72 1.13 Allowed Glycine 0 C--N 1.299 -1.497 0 N-CA-C 111.126 -0.789 . . . . 0.0 111.126 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -122.85 -21.17 2.68 Favored Glycine 0 N--CA 1.438 -1.168 0 C-N-CA 120.37 -0.919 . . . . 0.0 113.361 -178.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 64.25 14.72 8.89 Favored 'General case' 0 N--CA 1.5 2.048 0 C-N-CA 123.357 0.663 . . . . 0.0 112.666 -178.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.507 ' O ' HG12 ' A' ' 108' ' ' VAL . 30.0 m -152.1 -172.89 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -178.232 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -99.9 43.87 1.04 Allowed 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 119.368 0.986 . . . . 0.0 111.061 -177.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.744 ' O ' HG11 ' A' ' 108' ' ' VAL . 11.0 pt-20 -84.64 178.21 7.77 Favored 'General case' 0 C--O 1.205 -1.268 0 CA-C-N 114.681 -1.145 . . . . 0.0 111.983 178.225 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -71.91 135.83 46.66 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 122.076 -0.39 . . . . 0.0 110.798 177.021 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.63 -7.65 71.14 Favored Glycine 0 N--CA 1.435 -1.378 0 C-N-CA 120.148 -1.025 . . . . 0.0 113.418 178.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.744 HG11 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -85.31 143.48 11.52 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 119.709 -0.797 . . . . 0.0 110.581 -176.274 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.456 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.8 mtpt -108.82 117.0 33.05 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.474 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -83.3 92.41 7.5 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.482 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 89.5 t -87.33 114.23 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.587 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -176.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -86.33 139.32 31.09 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-O 121.409 0.623 . . . . 0.0 111.013 -177.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -133.66 109.13 8.98 Favored 'General case' 0 N--CA 1.407 -2.587 0 CA-C-O 122.334 1.064 . . . . 0.0 109.387 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 12.8 m -67.57 153.17 44.31 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.423 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.474 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 86.8 m-20 -68.71 178.77 1.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.869 0.366 . . . . 0.0 111.558 -179.012 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -57.38 -37.21 72.3 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -176.166 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -86.61 18.16 35.67 Favored Glycine 0 C--N 1.304 -1.237 0 C-N-CA 120.68 -0.771 . . . . 0.0 113.322 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -145.79 166.34 26.19 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -175.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -140.55 163.9 31.61 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -87.18 120.37 28.39 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 179.357 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.6 129.89 47.8 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 -178.154 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.8 -176.51 22.18 Favored Glycine 0 C--N 1.301 -1.366 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -91.46 -38.58 12.47 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.316 0.579 . . . . 0.0 110.0 -179.052 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.5 mm -78.08 120.62 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -176.26 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -129.16 8.05 5.53 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -177.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 22.8 p90 -151.19 169.68 21.3 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 -174.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.493 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 57.8 mtp180 -129.14 122.57 30.11 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 173.472 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -94.65 127.29 40.51 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 119.557 -0.857 . . . . 0.0 110.316 178.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 47.4 t -83.27 113.1 20.46 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.087 175.029 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.524 ' OD1' HG22 ' A' ' 131' ' ' THR . 8.4 t70 -110.3 -164.33 0.92 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.524 HG22 ' OD1' ' A' ' 130' ' ' ASP . 5.9 t -52.65 -33.45 46.98 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 -172.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -102.26 -10.39 19.59 Favored 'General case' 0 C--N 1.316 -0.875 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.83 -177.349 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 133.32 -153.96 21.01 Favored Glycine 0 N--CA 1.421 -2.346 0 N-CA-C 110.781 -0.927 . . . . 0.0 110.781 -178.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 86.2 m95 -67.65 119.93 13.21 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 122.527 0.331 . . . . 0.0 110.228 -178.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.0 p -71.58 -63.76 1.06 Allowed 'General case' 0 C--O 1.251 1.17 0 CA-C-O 121.544 0.687 . . . . 0.0 111.1 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . 0.493 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.8 m120 -69.99 164.36 24.1 Favored 'General case' 0 CA--C 1.489 -1.383 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.828 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . 0.441 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 12.1 t70 -103.35 -171.84 2.01 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 176.042 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.441 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 64.1 mt -69.48 120.68 78.7 Favored Pre-proline 0 C--N 1.28 -2.427 0 C-N-CA 124.439 1.096 . . . . 0.0 109.625 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -69.77 172.76 12.06 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.558 2.172 . . . . 0.0 112.485 178.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 49.1 mm -109.36 130.5 62.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.051 -173.245 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 89.1 m -109.06 114.34 28.0 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 174.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -103.09 157.23 17.14 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 176.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 13.6 p -70.62 145.43 12.79 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.069 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.577 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.4 m -72.35 136.28 25.99 Favored 'Isoleucine or valine' 0 C--O 1.248 1.015 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 175.841 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 64.4 mmtt -105.8 151.82 24.0 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -174.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 39.6 m -114.91 145.77 41.85 Favored 'General case' 0 C--N 1.28 -2.43 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 176.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.75 145.89 91.44 Favored Pre-proline 0 N--CA 1.418 -2.05 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -179.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -69.95 125.1 11.66 Favored 'Trans proline' 0 N--CA 1.444 -1.431 0 C-N-CA 122.885 2.39 . . . . 0.0 111.532 -178.546 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.8 t -97.98 137.82 24.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 13.5 p -76.74 -81.7 0.08 Allowed 'General case' 0 C--N 1.314 -0.962 0 O-C-N 123.126 0.267 . . . . 0.0 110.96 177.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.07 156.22 0.24 Allowed Pre-proline 0 C--O 1.24 0.566 0 C-N-CA 125.403 1.481 . . . . 0.0 107.895 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . 0.46 ' HB3' ' O ' ' A' ' 203' ' ' PRO . 37.1 Cg_endo -71.02 162.1 43.84 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 121.966 1.777 . . . . 0.0 110.17 172.475 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . 0.486 ' CD ' ' HZ3' ' A' ' 204' ' ' LYS . 9.6 pt-20 -55.51 -44.99 77.15 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -174.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 56.0 m-80 -116.45 28.0 8.85 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.242 0.544 . . . . 0.0 109.73 -177.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -143.32 -174.6 15.72 Favored Glycine 0 N--CA 1.439 -1.162 0 C-N-CA 120.181 -1.009 . . . . 0.0 112.661 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 31.7 pttt -152.9 161.02 43.06 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 123.193 0.597 . . . . 0.0 109.638 -176.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 58.2 mt -82.44 134.11 27.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 O-C-N 123.27 0.356 . . . . 0.0 110.773 -179.052 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.465 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.7 m -85.69 -32.14 6.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 CA-C-O 121.216 0.531 . . . . 0.0 110.585 -178.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 8.8 t . . . . . 0 N--CA 1.44 -0.957 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.431 -172.273 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . 0.412 ' CB ' ' HB2' ' A' ' 146' ' ' CYS . 97.5 m-85 . . . . . 0 N--CA 1.421 -1.893 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 21.3 m80 -130.31 166.44 20.38 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -175.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . 0.577 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 76.7 t80 -54.36 124.2 15.25 Favored 'General case' 0 C--O 1.247 0.945 0 C-N-CA 120.651 -0.42 . . . . 0.0 109.909 174.288 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 124.59 -26.43 5.71 Favored Glycine 0 N--CA 1.423 -2.218 0 C-N-CA 120.441 -0.885 . . . . 0.0 111.391 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 16.0 mm100 -59.08 131.56 51.39 Favored 'General case' 0 C--O 1.248 1.013 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -179.23 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -119.33 96.1 5.07 Favored 'General case' 0 N--CA 1.424 -1.735 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 73.4 t -88.89 101.6 12.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.25 -176.102 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.465 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 40.5 ttm180 -91.85 146.35 23.82 Favored 'General case' 0 N--CA 1.417 -2.084 0 CA-C-N 114.557 -1.201 . . . . 0.0 109.422 176.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -116.5 150.44 37.9 Favored 'General case' 0 N--CA 1.416 -2.135 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.6 p -129.84 142.45 43.83 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 177.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 70.3 m -94.1 148.41 22.2 Favored 'General case' 0 C--N 1.264 -3.114 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.344 -177.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -62.33 158.15 18.06 Favored 'General case' 0 CA--C 1.495 -1.166 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.578 178.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.2 m -42.11 103.92 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.22 0 O-C-N 125.173 1.545 . . . . 0.0 113.891 -174.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.02 -10.56 31.78 Favored Glycine 0 N--CA 1.432 -1.625 0 C-N-CA 120.469 -0.872 . . . . 0.0 113.731 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -97.63 160.38 14.35 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 117.809 0.805 . . . . 0.0 111.611 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.21 148.46 52.46 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.408 HD11 ' HA ' ' A' ' 188' ' ' GLU . 2.4 tt -79.77 144.99 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.148 0 CA-C-O 121.428 0.632 . . . . 0.0 110.817 -175.492 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -81.6 -65.27 1.03 Allowed 'General case' 0 C--N 1.294 -1.822 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.915 -176.534 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -78.52 -110.21 0.2 Allowed Glycine 0 C--N 1.309 -0.932 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.978 -178.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -106.59 179.46 4.26 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . 0.408 ' HA ' HD11 ' A' ' 184' ' ' ILE . 12.7 pt-20 -100.16 -11.9 20.06 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 118.974 0.806 . . . . 0.0 110.518 -174.288 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -152.61 164.38 37.79 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -173.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.2 ptp -133.79 136.89 44.8 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.079 176.176 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 44.6 t-80 -112.69 147.81 36.01 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 116.63 -0.259 . . . . 0.0 110.496 -178.104 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 61.1 m -75.08 121.2 21.67 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 123.067 0.547 . . . . 0.0 112.097 175.317 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 48.8 m -88.54 -175.23 4.88 Favored 'General case' 0 C--N 1.31 -1.136 0 C-N-CA 123.394 0.678 . . . . 0.0 110.205 174.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -51.81 -34.89 42.16 Favored 'General case' 0 N--CA 1.5 2.04 0 C-N-CA 125.073 1.349 . . . . 0.0 113.05 -178.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -78.06 -4.02 45.13 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 123.347 0.659 . . . . 0.0 112.608 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 69.25 28.42 72.71 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 108.051 -2.019 . . . . 0.0 108.051 -168.191 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -105.72 148.22 27.68 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-N 114.177 -1.012 . . . . 0.0 108.447 -176.16 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 83.6 m95 -81.97 123.67 29.08 Favored 'General case' 0 C--N 1.292 -1.906 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 10.9 m -62.4 -29.01 70.18 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 122.989 0.516 . . . . 0.0 111.837 -178.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -118.93 155.75 30.76 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 107.078 -1.452 . . . . 0.0 107.078 -178.103 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -95.3 164.06 13.0 Favored 'General case' 0 C--N 1.288 -2.105 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 176.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 54.6 mtpt -54.42 115.87 9.48 Favored Pre-proline 0 C--N 1.319 -0.76 0 O-C-N 123.815 0.697 . . . . 0.0 112.586 -176.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . 0.46 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 5.7 Cg_exo -78.06 162.56 28.86 Favored 'Trans proline' 0 N--CA 1.432 -2.093 0 C-N-CA 121.813 1.675 . . . . 0.0 111.231 177.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . 0.486 ' HZ3' ' CD ' ' A' ' 153' ' ' GLU . 50.7 tttp -109.0 157.94 18.19 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 -177.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 95.0 m -114.33 120.96 42.16 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 175.167 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.9 m . . . . . 0 C--N 1.307 -1.271 0 O-C-N 124.284 0.99 . . . . 0.0 109.318 -177.223 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.447 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 19.3 Cg_endo . . . . . 0 CA--C 1.532 0.412 0 CA-C-O 120.648 0.186 . . . . 0.0 112.308 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . 0.452 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 26.8 m -83.85 -26.55 29.38 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-O 121.465 0.65 . . . . 0.0 110.245 176.323 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.8 -86.65 0.44 Allowed Glycine 0 CA--C 1.452 -3.888 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 170.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.2 t60 -175.03 131.41 0.44 Allowed Pre-proline 0 C--N 1.26 -3.32 0 N-CA-C 104.81 -2.292 . . . . 0.0 104.81 -174.349 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -82.0 6.42 5.7 Favored 'Trans proline' 0 N--CA 1.484 0.963 0 C-N-CA 122.627 2.218 . . . . 0.0 114.641 -172.014 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 108.89 -167.19 12.91 Favored Glycine 0 C--N 1.289 -2.046 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -176.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -154.97 155.47 34.27 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 1.7 t -129.51 129.54 23.21 Favored Pre-proline 0 C--N 1.297 -1.675 0 CA-C-O 120.757 0.313 . . . . 0.0 110.561 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.49 -10.05 18.79 Favored 'Trans proline' 0 C--O 1.223 -0.258 0 C-N-CA 122.523 2.148 . . . . 0.0 111.451 -179.588 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -96.78 -52.11 4.03 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 122.213 1.006 . . . . 0.0 108.656 -179.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -106.49 -155.17 20.82 Favored Glycine 0 N--CA 1.401 -3.642 0 C-N-CA 119.78 -1.2 . . . . 0.0 112.502 -176.181 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.8 p -146.48 177.38 9.09 Favored 'General case' 0 C--N 1.261 -3.281 0 C-N-CA 125.226 1.411 . . . . 0.0 107.304 178.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.402 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 44.3 p90 -142.47 164.44 30.12 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.79 174.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -129.12 159.16 36.88 Favored 'General case' 0 C--N 1.284 -2.277 0 N-CA-C 106.641 -1.614 . . . . 0.0 106.641 -179.682 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.3 mt -118.25 119.09 33.63 Favored 'General case' 0 C--N 1.274 -2.713 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 177.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.487 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 37.3 p -116.49 136.85 52.64 Favored 'General case' 0 C--N 1.273 -2.759 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.551 -174.676 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.0 17.99 56.8 Favored Glycine 0 N--CA 1.429 -1.792 0 C-N-CA 119.593 -1.289 . . . . 0.0 111.107 -178.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 173.72 -31.85 0.1 Allowed Glycine 0 N--CA 1.436 -1.36 0 C-N-CA 119.229 -1.462 . . . . 0.0 113.596 -179.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 6.6 t30 66.28 9.73 6.61 Favored 'General case' 0 CA--C 1.556 1.175 0 CA-C-O 122.09 0.948 . . . . 0.0 111.728 -178.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.513 ' O ' HG12 ' A' ' 108' ' ' VAL . 23.3 m -142.75 -168.92 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.459 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 -177.46 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -108.51 36.54 2.79 Favored 'General case' 0 C--O 1.25 1.092 0 CA-C-N 119.29 0.95 . . . . 0.0 110.796 -176.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.746 ' O ' HG11 ' A' ' 108' ' ' VAL . 10.3 pt-20 -79.0 177.68 8.61 Favored 'General case' 0 C--O 1.195 -1.765 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.159 179.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . 0.45 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 48.2 m-85 -72.98 130.76 41.08 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 120.858 0.361 . . . . 0.0 111.641 178.771 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.42 -0.55 63.61 Favored Glycine 0 N--CA 1.437 -1.248 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.997 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.746 HG11 ' O ' ' A' ' 105' ' ' GLU . 12.4 p -90.28 145.67 7.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.487 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 16.4 mtpp -109.75 127.18 54.45 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.745 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -88.76 85.19 6.72 Favored 'General case' 0 C--N 1.284 -2.272 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 175.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 29.4 m -87.07 114.64 26.52 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 CA-C-O 122.568 1.175 . . . . 0.0 109.461 -179.108 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . 0.402 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 31.4 m-85 -77.99 144.86 36.37 Favored 'General case' 0 C--N 1.27 -2.853 0 CA-C-N 115.098 -0.955 . . . . 0.0 110.833 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.2 t -142.02 118.08 10.64 Favored 'General case' 0 N--CA 1.413 -2.29 0 N-CA-C 107.108 -1.442 . . . . 0.0 107.108 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 38.0 m -75.34 158.51 32.69 Favored 'General case' 0 C--N 1.279 -2.479 0 O-C-N 121.992 -0.443 . . . . 0.0 110.651 -175.459 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -77.65 -179.09 5.68 Favored 'General case' 0 CA--C 1.495 -1.151 0 C-N-CA 119.993 -0.683 . . . . 0.0 111.05 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -52.12 -52.73 49.71 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 124.099 0.874 . . . . 0.0 112.323 -176.306 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.476 ' C ' HG23 ' A' ' 144' ' ' VAL . . . -83.94 25.29 5.41 Favored Glycine 0 C--N 1.304 -1.219 0 C-N-CA 120.625 -0.798 . . . . 0.0 113.831 -178.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.5 ' CE1' HG11 ' A' ' 143' ' ' VAL . 87.6 m-85 -144.31 152.01 40.16 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 122.268 -0.548 . . . . 0.0 110.08 -176.665 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.78 162.05 26.76 Favored 'General case' 0 C--N 1.276 -2.613 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 -179.386 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 3.1 tt -93.06 128.24 38.88 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.07 -178.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -111.5 126.03 54.53 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 -177.364 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 113.52 164.79 15.76 Favored Glycine 0 C--N 1.286 -2.228 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -175.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 13.6 mm-40 -91.97 -31.48 15.6 Favored 'General case' 0 C--N 1.3 -1.543 0 CA-C-O 121.987 0.899 . . . . 0.0 109.382 -177.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.493 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.0 mm -82.57 127.47 39.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 178.328 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.42 2.8 9.69 Favored 'General case' 0 C--O 1.204 -1.339 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -177.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.491 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 10.8 p90 -143.54 164.08 31.36 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 120.506 -0.478 . . . . 0.0 109.817 -170.323 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -131.12 132.27 44.7 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 171.544 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -106.0 133.23 51.05 Favored 'General case' 0 C--N 1.284 -2.257 0 C-N-CA 118.533 -1.267 . . . . 0.0 110.773 -178.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . 0.45 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 39.7 t -75.72 96.88 3.7 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.443 ' OD1' HG22 ' A' ' 131' ' ' THR . 8.0 t70 -94.26 -175.05 3.54 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 178.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.447 ' HA ' ' CE1' ' A' ' 106' ' ' TYR . 13.9 t -68.28 -23.4 64.75 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-O 121.898 0.856 . . . . 0.0 109.889 -176.56 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -77.59 -39.06 46.87 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.613 177.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.452 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 145.21 -159.47 27.89 Favored Glycine 0 N--CA 1.421 -2.355 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -174.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 98.1 m95 -67.98 122.48 18.31 Favored 'General case' 0 C--N 1.309 -1.193 0 CA-C-N 117.639 0.719 . . . . 0.0 110.517 178.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 76.2 p -76.63 170.76 15.83 Favored 'General case' 0 C--O 1.265 1.885 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 74.4 m-20 61.91 -165.34 0.23 Allowed 'General case' 0 C--O 1.246 0.894 0 O-C-N 123.951 0.782 . . . . 0.0 111.474 174.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -122.53 168.83 11.66 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 80.6 mt -67.54 119.63 67.14 Favored Pre-proline 0 C--N 1.307 -1.252 0 O-C-N 123.247 0.342 . . . . 0.0 110.089 176.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . 0.493 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 33.9 Cg_endo -65.99 150.09 85.69 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 122.733 2.288 . . . . 0.0 110.527 177.317 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 61.8 mt -96.46 130.27 45.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-O 121.106 0.479 . . . . 0.0 111.034 -174.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 93.1 m -99.38 107.69 20.01 Favored 'General case' 0 C--N 1.284 -2.273 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 172.08 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -91.96 154.41 18.83 Favored 'General case' 0 N--CA 1.412 -2.362 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 177.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.5 HG11 ' CE1' ' A' ' 118' ' ' TYR . 4.5 t -80.02 141.36 15.39 Favored 'Isoleucine or valine' 0 C--N 1.256 -3.494 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -175.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.528 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 15.9 m -68.4 100.12 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-O 121.85 0.833 . . . . 0.0 109.987 -178.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.427 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 94.9 mttt -100.69 136.56 40.36 Favored 'General case' 0 N--CA 1.421 -1.879 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.053 -174.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 60.6 m -98.96 167.87 10.46 Favored 'General case' 0 C--N 1.291 -1.955 0 CA-C-N 114.321 -1.309 . . . . 0.0 109.056 -177.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 2.2 pp -79.73 154.92 75.96 Favored Pre-proline 0 N--CA 1.427 -1.612 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 178.239 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -79.64 118.82 3.92 Favored 'Trans proline' 0 N--CA 1.441 -1.564 0 C-N-CA 122.46 2.106 . . . . 0.0 111.719 -177.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.0 t -67.65 144.61 14.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.1 p -77.17 -83.54 0.07 Allowed 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 119.644 -0.217 . . . . 0.0 111.496 176.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 173.51 162.69 0.3 Allowed Pre-proline 0 N--CA 1.473 0.715 0 C-N-CA 125.171 1.388 . . . . 0.0 108.361 178.162 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . 0.405 ' HB3' ' HA ' ' A' ' 204' ' ' LYS . 72.6 Cg_endo -84.04 166.46 12.9 Favored 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 122.361 2.041 . . . . 0.0 110.997 170.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -72.11 -62.56 1.39 Allowed 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 114.099 1.148 . . . . 0.0 114.099 -176.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . 0.424 ' HB2' ' O ' ' A' ' 205' ' ' CYS . 43.7 m-80 -97.24 31.35 2.49 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 121.943 0.878 . . . . 0.0 110.075 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -150.87 -169.99 17.36 Favored Glycine 0 N--CA 1.422 -2.274 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 21.9 pttm -151.84 171.62 17.47 Favored 'General case' 0 C--N 1.289 -2.034 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 54.3 mt -90.87 135.09 27.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-O 120.951 0.405 . . . . 0.0 111.415 -178.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.464 ' CG2' HG22 ' A' ' 177' ' ' VAL . 57.0 t -70.83 -50.03 46.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 C-N-CA 124.214 1.006 . . . . 0.0 108.468 177.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 1.7 m . . . . . 0 C--N 1.303 -1.432 0 C-N-CA 124.558 1.143 . . . . 0.0 111.018 -176.513 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . 0.427 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 74.4 m-85 . . . . . 0 C--O 1.2 -1.516 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.45 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 44.6 p-80 -153.21 171.44 18.51 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-O 118.675 -0.678 . . . . 0.0 109.19 -172.641 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . 0.528 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 62.0 t80 -50.77 133.2 26.39 Favored 'General case' 0 C--O 1.239 0.528 0 O-C-N 123.732 0.645 . . . . 0.0 110.512 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 106.06 -26.99 18.91 Favored Glycine 0 N--CA 1.434 -1.48 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -177.369 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -76.12 140.43 41.8 Favored 'General case' 0 CA--C 1.503 -0.838 0 CA-C-O 121.629 0.728 . . . . 0.0 110.413 178.727 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . 0.435 ' HB2' ' CD2' ' A' ' 191' ' ' HIS . . . -129.62 119.91 24.37 Favored 'General case' 0 C--N 1.279 -2.495 0 CA-C-N 114.139 -1.391 . . . . 0.0 107.315 176.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.478 HG22 ' CH2' ' A' ' 198' ' ' TRP . 68.1 t -93.65 108.38 20.45 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.992 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 176.021 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 76.2 ttt180 -103.24 156.29 17.82 Favored 'General case' 0 N--CA 1.409 -2.479 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -127.96 153.15 47.04 Favored 'General case' 0 C--N 1.291 -1.972 0 C-N-CA 123.179 0.591 . . . . 0.0 110.158 -170.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.464 HG22 ' CG2' ' A' ' 158' ' ' VAL . 0.1 OUTLIER -127.91 141.15 47.22 Favored 'Isoleucine or valine' 0 CA--C 1.467 -2.212 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.262 179.04 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 72.1 m -95.96 132.75 40.96 Favored 'General case' 0 N--CA 1.389 -3.487 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.08 176.238 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 -67.12 170.03 7.59 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 113.985 -1.462 . . . . 0.0 109.711 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.3 m -49.84 109.47 0.29 Allowed 'General case' 0 C--N 1.297 -1.7 0 O-C-N 124.394 1.059 . . . . 0.0 113.463 -174.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 97.16 18.21 29.68 Favored Glycine 0 N--CA 1.433 -1.527 0 CA-C-N 115.234 -0.894 . . . . 0.0 114.633 174.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -128.53 164.9 21.8 Favored 'General case' 0 C--O 1.241 0.645 0 CA-C-N 118.457 1.128 . . . . 0.0 112.572 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 56.7 pttt -122.12 154.84 36.86 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 106.741 -1.578 . . . . 0.0 106.741 178.77 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 5.4 tp -72.67 145.9 11.5 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 174.453 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -70.4 -69.73 0.34 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 120.983 0.421 . . . . 0.0 110.108 -177.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -109.65 -82.76 1.39 Allowed Glycine 0 N--CA 1.431 -1.66 0 C-N-CA 120.24 -0.981 . . . . 0.0 111.851 178.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -113.99 151.81 31.85 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -177.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -109.82 9.71 24.64 Favored 'General case' 0 C--N 1.3 -1.587 0 CA-C-N 118.448 0.567 . . . . 0.0 110.708 -179.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -148.73 130.35 14.96 Favored 'General case' 0 C--N 1.295 -1.788 0 CA-C-O 122.012 0.911 . . . . 0.0 113.315 -178.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.414 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 16.5 ptp -121.46 144.72 48.53 Favored 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.21 178.003 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . 0.435 ' CD2' ' HB2' ' A' ' 173' ' ' ALA . 34.5 m80 -117.25 147.77 42.24 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 120.469 0.176 . . . . 0.0 111.032 -179.411 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 4.9 m -76.17 115.92 16.37 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.475 172.61 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 193' ' ' SER . . . . . 0.505 ' HB2' ' OD1' ' A' ' 195' ' ' ASP . 13.0 m -85.55 177.19 7.83 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.458 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -76.85 3.43 12.0 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 121.348 0.595 . . . . 0.0 112.272 -176.254 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . 0.505 ' OD1' ' HB2' ' A' ' 193' ' ' SER . 43.4 p-10 -92.61 -15.68 26.56 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 123.267 0.627 . . . . 0.0 109.755 177.077 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 90.93 19.47 43.14 Favored Glycine 0 N--CA 1.432 -1.603 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.586 -178.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -128.47 168.94 14.92 Favored 'General case' 0 C--N 1.314 -0.96 0 O-C-N 122.152 -0.617 . . . . 0.0 111.458 178.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . 0.478 ' CH2' HG22 ' A' ' 174' ' ' VAL . 85.9 m95 -82.46 131.03 35.22 Favored 'General case' 0 N--CA 1.436 -1.172 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.646 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 31.0 p -62.53 -29.66 70.72 Favored 'General case' 0 C--N 1.312 -1.025 0 C-N-CA 124.579 1.152 . . . . 0.0 113.108 -177.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 3.1 tppp? -126.17 158.18 36.25 Favored 'General case' 0 N--CA 1.432 -1.329 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -81.12 174.24 11.78 Favored 'General case' 0 C--N 1.312 -1.041 0 O-C-N 123.318 0.386 . . . . 0.0 110.033 -178.466 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 37.5 mtpt -70.0 121.35 82.61 Favored Pre-proline 0 N--CA 1.438 -1.064 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.301 176.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -89.08 -162.36 0.13 Allowed 'Trans proline' 0 N--CA 1.431 -2.153 0 C-N-CA 122.388 2.059 . . . . 0.0 109.44 173.642 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . 0.405 ' HA ' ' HB3' ' A' ' 152' ' ' PRO . 18.0 ptpt -166.39 174.09 9.36 Favored 'General case' 0 N--CA 1.416 -2.141 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.504 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 80.7 m -114.03 128.89 56.58 Favored 'General case' 0 C--N 1.276 -2.607 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 177.727 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.8 m . . . . . 0 C--N 1.28 -2.432 0 O-C-N 124.49 1.118 . . . . 0.0 108.542 -172.642 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.405 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 39.7 Cg_endo . . . . . 0 CA--C 1.54 0.804 0 CA-C-O 121.245 0.435 . . . . 0.0 111.977 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 61.3 m -90.07 -32.5 16.68 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 122.148 0.975 . . . . 0.0 108.654 176.168 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 111.82 -83.84 0.34 Allowed Glycine 0 CA--C 1.455 -3.715 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 171.043 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 9.3 t60 -179.83 130.83 0.25 Allowed Pre-proline 0 C--N 1.267 -2.979 0 N-CA-C 104.928 -2.249 . . . . 0.0 104.928 -175.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.41 ' HB3' ' CD2' ' A' ' 134' ' ' TRP . 88.1 Cg_endo -84.12 1.48 8.74 Favored 'Trans proline' 0 N--CA 1.485 1.008 0 C-N-CA 122.677 2.251 . . . . 0.0 113.915 -172.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 94.19 179.75 38.25 Favored Glycine 0 N--CA 1.429 -1.831 0 N-CA-C 108.492 -1.843 . . . . 0.0 108.492 -173.112 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -140.7 -179.66 6.17 Favored 'General case' 0 C--N 1.29 -2.005 0 CA-C-N 117.628 0.714 . . . . 0.0 109.767 -178.178 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.0 t -126.53 138.47 32.49 Favored Pre-proline 0 C--N 1.307 -1.245 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -77.34 -20.89 12.2 Favored 'Trans proline' 0 CA--C 1.534 0.514 0 C-N-CA 122.537 2.158 . . . . 0.0 112.255 -179.097 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.404 ' O ' ' HB2' ' A' ' 115' ' ' ASN . 59.0 m-85 -80.82 -50.4 9.87 Favored 'General case' 0 CA--C 1.5 -0.967 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.477 -176.287 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -122.49 -136.45 4.89 Favored Glycine 0 N--CA 1.421 -2.338 0 C-N-CA 120.558 -0.829 . . . . 0.0 111.115 -178.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.7 p -148.21 -172.51 4.09 Favored 'General case' 0 C--N 1.294 -1.813 0 C-N-CA 123.594 0.758 . . . . 0.0 109.073 -178.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 38.5 p90 -145.01 163.76 33.23 Favored 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 120.381 -0.528 . . . . 0.0 109.984 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.6 m -135.75 158.91 43.22 Favored 'General case' 0 C--N 1.288 -2.084 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 178.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.4 HD13 ' CE1' ' A' ' 104' ' ' PHE . 18.1 mt -110.18 122.05 46.71 Favored 'General case' 0 C--N 1.28 -2.414 0 CA-C-O 120.94 0.4 . . . . 0.0 110.384 -178.029 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 19.2 p -114.43 136.27 53.19 Favored 'General case' 0 C--N 1.286 -2.162 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.924 -176.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 95.78 11.74 54.52 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 120.035 -1.078 . . . . 0.0 112.174 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 171.59 -23.96 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 119.274 -1.441 . . . . 0.0 113.818 -178.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 65.4 17.3 10.92 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 179.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.5 ' O ' HG13 ' A' ' 108' ' ' VAL . 30.3 m -148.97 -176.23 0.41 Allowed 'Isoleucine or valine' 0 C--O 1.205 -1.242 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -175.726 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.4 ' CE1' HD13 ' A' ' 98' ' ' LEU . 41.2 m-85 -102.84 47.32 0.89 Allowed 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 118.299 0.5 . . . . 0.0 110.401 -179.452 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.751 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.8 pt-20 -88.44 179.54 6.29 Favored 'General case' 0 C--O 1.207 -1.147 0 CA-C-N 115.477 -0.783 . . . . 0.0 111.092 177.467 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -79.36 135.76 36.8 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.075 176.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.52 1.3 62.27 Favored Glycine 0 N--CA 1.434 -1.449 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.832 -179.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.751 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.5 p -97.54 150.67 4.53 Favored 'Isoleucine or valine' 0 C--O 1.246 0.908 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 14.6 mtpp -113.82 127.87 56.18 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -179.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -90.34 93.05 9.17 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 175.773 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 44.0 t -88.19 114.95 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.662 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.1 m-85 -85.15 133.48 34.2 Favored 'General case' 0 C--N 1.284 -2.246 0 CA-C-N 115.496 -0.775 . . . . 0.0 109.632 179.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.8 t -125.82 127.43 46.08 Favored 'General case' 0 N--CA 1.409 -2.508 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -177.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 79.6 m -75.32 159.99 30.83 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.404 ' HB2' ' O ' ' A' ' 93' ' ' PHE . 6.7 t-20 -69.53 -175.84 0.9 Allowed 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 114.053 -1.431 . . . . 0.0 109.487 178.148 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -67.1 -44.38 80.11 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 120.998 0.427 . . . . 0.0 111.081 -179.555 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.21 8.12 68.8 Favored Glycine 0 C--N 1.31 -0.878 0 CA-C-N 115.965 -0.561 . . . . 0.0 113.14 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.589 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 70.7 m-85 -127.95 160.64 31.26 Favored 'General case' 0 C--N 1.311 -1.073 0 O-C-N 122.534 -0.392 . . . . 0.0 110.955 178.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.33 144.26 30.62 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -178.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -75.6 126.95 32.01 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -174.657 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -110.79 130.92 55.44 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 -177.391 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.02 174.81 20.18 Favored Glycine 0 C--N 1.301 -1.408 0 N-CA-C 111.528 -0.629 . . . . 0.0 111.528 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -83.31 -36.22 24.62 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.5 mm -87.97 125.0 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.862 0 CA-C-N 113.977 -1.465 . . . . 0.0 109.247 -175.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -127.54 3.96 6.19 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.414 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 17.9 p90 -144.05 165.11 28.7 Favored 'General case' 0 N--CA 1.422 -1.848 0 C-N-CA 119.901 -0.72 . . . . 0.0 110.757 -171.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -126.19 132.79 51.71 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 173.093 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -108.76 134.15 51.86 Favored 'General case' 0 C--N 1.277 -2.586 0 C-N-CA 119.464 -0.895 . . . . 0.0 108.864 -177.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 17.5 t -85.74 99.96 11.69 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 118.292 -1.363 . . . . 0.0 109.403 177.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.448 ' OD2' HG21 ' A' ' 131' ' ' THR . 8.5 t70 -104.32 -167.84 1.41 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 177.123 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.448 HG21 ' OD2' ' A' ' 130' ' ' ASP . 9.6 t -65.14 -15.87 62.88 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 119.048 0.84 . . . . 0.0 111.633 -177.072 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -81.79 -13.49 57.64 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.697 0.76 . . . . 0.0 109.839 176.104 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 102.49 -157.46 18.24 Favored Glycine 0 N--CA 1.428 -1.847 0 N-CA-C 107.522 -2.231 . . . . 0.0 107.522 -174.445 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.41 ' CD2' ' HB3' ' A' ' 88' ' ' PRO . 94.6 m95 -62.28 106.64 0.77 Allowed 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 117.714 0.757 . . . . 0.0 110.405 173.766 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 62.3 p -71.8 171.48 11.57 Favored 'General case' 0 C--O 1.269 2.086 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.192 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 1.8 m-20 62.87 -158.57 0.32 Allowed 'General case' 0 C--O 1.245 0.83 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.029 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 29.0 t0 -141.11 173.03 11.87 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 173.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 70.1 mt -59.36 121.71 58.46 Favored Pre-proline 0 C--N 1.269 -2.915 0 C-N-CA 125.14 1.376 . . . . 0.0 108.352 175.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -64.78 178.32 1.85 Allowed 'Trans proline' 0 C--O 1.251 1.17 0 C-N-CA 123.097 2.531 . . . . 0.0 113.614 -176.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 63.5 mt -98.37 129.52 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.066 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.69 -176.094 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.589 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 33.6 t -114.69 107.12 15.04 Favored 'General case' 0 C--N 1.273 -2.735 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 178.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -99.35 152.1 20.33 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-O 121.625 0.726 . . . . 0.0 110.933 -176.105 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.559 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 3.3 t -73.1 136.52 25.32 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.049 0 CA-C-N 113.902 -1.499 . . . . 0.0 108.609 -179.703 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.87 125.02 20.9 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.097 0 O-C-N 124.957 1.411 . . . . 0.0 108.064 177.052 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 45.6 mttp -122.9 162.62 21.88 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.382 -174.863 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 57.0 m -124.58 168.34 13.26 Favored 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 114.309 -1.314 . . . . 0.0 107.734 175.036 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 71.5 mt -74.73 143.59 78.76 Favored Pre-proline 0 C--N 1.307 -1.244 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -179.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.438 ' HA ' ' CE2' ' A' ' 168' ' ' TYR . 17.5 Cg_endo -62.73 122.36 10.65 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.945 2.43 . . . . 0.0 110.761 178.283 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 48.0 t -91.81 142.02 13.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.005 -175.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 21.0 p -79.95 -82.67 0.11 Allowed 'General case' 0 N--CA 1.43 -1.47 0 CA-C-N 116.727 -0.215 . . . . 0.0 110.907 176.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.49 165.7 0.45 Allowed Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 124.051 0.94 . . . . 0.0 108.724 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . 0.495 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 55.6 Cg_endo -76.57 160.93 34.63 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.024 1.816 . . . . 0.0 109.742 167.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -53.3 -50.77 64.21 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 114.287 1.218 . . . . 0.0 114.287 -175.055 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 55.6 m-80 -113.3 38.06 2.99 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -154.78 -167.43 16.56 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.918 -1.134 . . . . 0.0 112.53 177.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -153.04 170.24 20.95 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 -177.347 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 73.3 mt -86.02 137.67 20.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 177.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.471 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 14.5 m -69.11 -32.68 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-O 121.597 0.713 . . . . 0.0 110.872 -177.766 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 24.3 t . . . . . 0 N--CA 1.424 -1.741 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -178.099 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . 0.521 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 67.4 m-85 . . . . . 0 CA--C 1.506 -0.736 0 CA-C-O 120.861 0.363 . . . . 0.0 110.628 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 28.1 m80 -98.02 161.45 13.72 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.534 -173.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -58.0 135.69 56.99 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.868 172.525 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 103.5 -18.26 48.39 Favored Glycine 0 N--CA 1.429 -1.803 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.62 -179.292 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.9 tp60 -76.96 128.83 35.24 Favored 'General case' 0 N--CA 1.398 -3.037 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -110.6 131.14 55.31 Favored 'General case' 0 N--CA 1.418 -2.027 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 172.468 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.468 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 55.5 t -107.87 99.56 8.88 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.32 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.471 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 41.7 ttm180 -89.76 144.09 26.26 Favored 'General case' 0 N--CA 1.42 -1.928 0 CA-C-N 115.043 -0.981 . . . . 0.0 109.025 178.124 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.495 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 78.1 m-85 -113.93 160.42 18.82 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -178.171 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.9 p -139.53 150.45 22.52 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.057 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 63.9 m -109.7 157.64 18.9 Favored 'General case' 0 C--N 1.287 -2.123 0 O-C-N 123.39 0.431 . . . . 0.0 111.602 -175.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -78.41 170.7 16.21 Favored 'General case' 0 N--CA 1.439 -1.018 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.534 179.284 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 23.1 t -49.64 105.93 0.1 Allowed 'General case' 0 C--N 1.313 -1.013 0 C-N-CA 124.88 1.272 . . . . 0.0 112.918 -175.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 111.74 -15.08 26.75 Favored Glycine 0 N--CA 1.43 -1.719 0 CA-C-N 115.285 -0.87 . . . . 0.0 113.252 175.328 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . 0.402 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 93.5 m-85 -103.84 159.84 15.3 Favored 'General case' 0 N--CA 1.433 -1.323 0 CA-C-N 117.783 0.791 . . . . 0.0 111.353 -176.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 53.4 pttt -135.04 155.7 50.3 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 175.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.447 HD11 ' HA ' ' A' ' 188' ' ' GLU . 12.5 tt -81.95 141.98 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.57 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.568 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -66.16 -79.02 0.05 OUTLIER 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 114.283 1.216 . . . . 0.0 114.283 -171.631 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -83.64 -92.87 0.67 Allowed Glycine 0 CA--C 1.496 -1.135 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.183 -175.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -94.32 173.71 7.5 Favored 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . 0.447 ' HA ' HD11 ' A' ' 184' ' ' ILE . 12.7 pt-20 -122.82 4.83 9.43 Favored 'General case' 0 N--CA 1.438 -1.029 0 C-N-CA 120.613 -0.435 . . . . 0.0 110.205 178.074 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . 0.468 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 7.1 pt-20 -163.46 120.02 1.77 Allowed 'General case' 0 N--CA 1.432 -1.345 0 CA-C-O 121.943 0.877 . . . . 0.0 112.144 -175.013 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 12.8 ptp -100.53 132.12 46.08 Favored 'General case' 0 C--N 1.281 -2.41 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.501 177.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 23.8 t-80 -107.24 143.46 35.43 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.918 -177.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 2.5 m -70.21 116.79 10.97 Favored 'General case' 0 CA--C 1.5 -0.946 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.944 172.546 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 2.6 m -83.39 151.73 25.37 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -67.75 -8.92 39.53 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 121.17 0.51 . . . . 0.0 112.362 -175.079 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . 0.402 ' HB3' ' CE1' ' A' ' 197' ' ' PHE . 26.0 t70 -82.87 -16.81 46.11 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-O 121.279 0.562 . . . . 0.0 110.638 177.464 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 99.78 38.62 3.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.669 -0.777 . . . . 0.0 113.724 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . 0.402 ' CE1' ' HB3' ' A' ' 195' ' ' ASP . 44.7 p90 -149.08 156.18 41.83 Favored 'General case' 0 C--O 1.249 1.04 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.707 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 83.4 m95 -72.79 128.33 35.2 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 175.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.0 m -51.74 -36.65 47.89 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.047 0.539 . . . . 0.0 111.621 -178.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 28.3 mmtp -116.24 163.79 15.47 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.463 177.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -88.18 162.57 16.62 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.652 178.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -57.55 105.09 0.48 Allowed Pre-proline 0 CA--C 1.57 1.731 0 C-N-CA 125.667 1.587 . . . . 0.0 112.758 -176.548 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -89.0 170.89 4.88 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 124.005 3.136 . . . . 0.0 113.671 -176.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 20.1 pttm -135.06 162.21 33.13 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.046 -176.462 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.402 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 83.2 m -100.72 119.43 38.59 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 124.264 0.978 . . . . 0.0 108.537 177.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 25.5 m . . . . . 0 C--N 1.287 -2.128 0 O-C-N 124.441 1.088 . . . . 0.0 109.776 -174.188 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 18.4 Cg_endo . . . . . 0 CA--C 1.543 0.938 0 CA-C-O 121.4 0.5 . . . . 0.0 111.882 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . 0.472 ' HB3' ' NE1' ' A' ' 134' ' ' TRP . 23.6 m -89.42 -27.3 20.49 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.035 0.445 . . . . 0.0 111.606 176.303 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.62 -83.14 0.32 Allowed Glycine 0 CA--C 1.456 -3.652 0 C-N-CA 120.292 -0.956 . . . . 0.0 111.249 170.405 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -175.66 129.21 0.39 Allowed Pre-proline 0 C--N 1.269 -2.934 0 N-CA-C 106.498 -1.667 . . . . 0.0 106.498 -176.002 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -82.81 7.97 4.86 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 123.231 2.62 . . . . 0.0 114.476 -171.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 120.69 164.92 12.59 Favored Glycine 0 C--N 1.292 -1.881 0 N-CA-C 108.316 -1.914 . . . . 0.0 108.316 -175.477 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -145.82 111.93 5.7 Favored 'General case' 0 C--N 1.293 -1.859 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -177.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 8.2 t -98.92 140.65 21.89 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -172.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -85.38 -9.02 8.42 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.853 2.369 . . . . 0.0 111.548 173.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -94.81 16.41 15.95 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.251 0.548 . . . . 0.0 110.593 -176.149 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 156.43 -121.95 1.14 Allowed Glycine 0 N--CA 1.41 -3.072 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 t -171.85 -160.33 0.16 Allowed 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.652 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -149.94 164.82 34.43 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.364 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.8 m -125.33 160.76 28.55 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 178.268 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.0 mt -119.71 131.82 55.49 Favored 'General case' 0 C--N 1.277 -2.578 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -179.023 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 38.9 p -126.21 131.28 52.0 Favored 'General case' 0 C--N 1.286 -2.178 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -177.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 87.71 24.98 33.88 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.503 -0.856 . . . . 0.0 111.68 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 176.1 -37.8 0.1 OUTLIER Glycine 0 N--CA 1.434 -1.447 0 C-N-CA 119.93 -1.129 . . . . 0.0 112.799 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 67.39 11.36 8.34 Favored 'General case' 0 N--CA 1.498 1.925 0 C-N-CA 124.354 1.062 . . . . 0.0 109.694 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.512 ' O ' HG13 ' A' ' 108' ' ' VAL . 25.1 m -150.56 -168.38 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.085 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 -177.539 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 24.4 m-85 -104.75 38.25 1.95 Allowed 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 118.347 0.521 . . . . 0.0 110.788 -175.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.751 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.2 pt-20 -79.19 173.81 12.2 Favored 'General case' 0 C--O 1.195 -1.763 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.782 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . 0.482 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 41.8 m-85 -72.44 133.14 44.71 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.975 178.668 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.34 -0.1 71.09 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 115.739 -0.664 . . . . 0.0 113.064 178.293 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.751 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.5 p -89.45 148.77 4.31 Favored 'Isoleucine or valine' 0 C--O 1.243 0.763 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.753 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -112.16 131.52 55.42 Favored 'General case' 0 C--N 1.283 -2.295 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.362 177.657 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -94.96 94.93 8.3 Favored 'General case' 0 C--N 1.285 -2.213 0 CA-C-N 115.382 -0.826 . . . . 0.0 108.791 176.411 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 91.8 t -86.54 106.84 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.812 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . 0.519 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 18.4 t80 -74.14 138.19 43.7 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 123.495 0.718 . . . . 0.0 109.19 -177.559 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.2 t -142.07 114.68 8.48 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.097 0.951 . . . . 0.0 110.09 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 73.6 m -71.35 163.19 28.16 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 115.374 -0.83 . . . . 0.0 112.193 -179.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -73.42 -175.04 1.82 Allowed 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.862 178.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -62.13 -45.93 91.25 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-O 121.228 0.537 . . . . 0.0 111.748 -177.324 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -79.82 4.32 66.0 Favored Glycine 0 C--N 1.313 -0.716 0 CA-C-N 115.879 -0.601 . . . . 0.0 114.285 -179.093 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.404 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.1 m-85 -129.77 166.25 20.27 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 -177.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 7.8 pt20 -150.49 160.87 43.47 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -77.59 133.94 38.34 Favored 'General case' 0 N--CA 1.424 -1.774 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.503 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -120.89 132.12 54.78 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 177.683 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 112.1 -170.14 13.44 Favored Glycine 0 N--CA 1.43 -1.76 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -178.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -100.77 -37.34 8.75 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.528 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 49.3 mm -80.97 125.53 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.071 0 CA-C-N 114.865 -1.061 . . . . 0.0 110.284 -177.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -132.03 11.05 4.64 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.499 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.502 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 24.3 p90 -142.88 161.09 39.02 Favored 'General case' 0 C--N 1.312 -1.058 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -178.364 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 54.8 mtp180 -129.88 138.02 50.72 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 172.196 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -109.07 128.56 55.09 Favored 'General case' 0 C--N 1.281 -2.403 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.552 -178.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . 0.482 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 38.9 t -76.84 96.06 4.21 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.033 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.412 ' OD2' HG23 ' A' ' 131' ' ' THR . 11.2 t70 -103.12 -171.6 1.97 Allowed 'General case' 0 N--CA 1.426 -1.65 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 179.181 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.412 HG23 ' OD2' ' A' ' 130' ' ' ASP . 14.8 t -69.48 -20.35 63.74 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.054 0.454 . . . . 0.0 111.873 -173.05 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -82.02 -25.37 34.72 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 121.516 0.674 . . . . 0.0 109.5 175.171 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 130.11 -154.37 20.52 Favored Glycine 0 N--CA 1.422 -2.254 0 N-CA-C 108.291 -1.923 . . . . 0.0 108.291 -174.377 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.472 ' NE1' ' HB3' ' A' ' 85' ' ' CYS . 98.5 m95 -68.93 118.7 12.18 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 117.519 0.66 . . . . 0.0 110.977 178.572 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 75.7 p -70.42 166.16 20.97 Favored 'General case' 0 C--O 1.277 2.552 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 175.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 60.81 -162.94 0.26 Allowed 'General case' 0 C--O 1.246 0.896 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -129.72 -176.02 3.78 Favored 'General case' 0 C--N 1.283 -2.298 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 173.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 75.1 mt -63.42 117.8 37.76 Favored Pre-proline 0 C--N 1.278 -2.519 0 C-N-CA 124.219 1.008 . . . . 0.0 108.289 176.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . 0.528 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 24.0 Cg_exo -55.7 158.36 13.67 Favored 'Trans proline' 0 C--O 1.251 1.172 0 C-N-CA 122.346 2.031 . . . . 0.0 111.904 178.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.503 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 46.6 mm -87.76 134.24 28.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 C-N-CA 120.192 -0.603 . . . . 0.0 109.885 -172.048 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.404 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 12.3 t -118.75 112.11 19.34 Favored 'General case' 0 C--N 1.28 -2.445 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.638 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -108.86 155.66 20.56 Favored 'General case' 0 C--N 1.278 -2.542 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -178.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.6 p -75.8 140.01 18.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 176.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 71.3 t -60.21 130.78 24.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 179.341 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -118.6 136.88 53.63 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -178.416 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 77.1 m -97.21 160.58 14.25 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.052 -177.638 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . 0.46 HD12 ' HD2' ' A' ' 148' ' ' PRO . 15.0 tp -71.75 125.91 91.58 Favored Pre-proline 0 N--CA 1.384 -3.725 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -178.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.46 ' HD2' HD12 ' A' ' 147' ' ' LEU . 14.2 Cg_endo -58.34 131.29 42.06 Favored 'Trans proline' 0 C--O 1.24 0.585 0 C-N-CA 123.839 3.026 . . . . 0.0 113.025 -176.091 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.7 t -93.51 139.59 17.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.0 p -74.98 -76.89 0.13 Allowed 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 111.657 0.243 . . . . 0.0 111.657 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.56 158.38 0.21 Allowed Pre-proline 0 CA--C 1.508 -0.665 0 N-CA-C 106.703 -1.592 . . . . 0.0 106.703 178.109 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -77.56 167.46 24.21 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 121.388 1.392 . . . . 0.0 109.33 171.597 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . 0.495 ' OE1' ' HG3' ' A' ' 204' ' ' LYS . 0.1 OUTLIER -74.68 -46.83 35.32 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -173.109 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . 0.433 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 55.2 m-80 -106.45 23.76 13.66 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.766 0.793 . . . . 0.0 110.748 -177.682 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -145.07 -157.43 7.23 Favored Glycine 0 N--CA 1.421 -2.337 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.826 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 21.4 pttp -157.78 169.58 24.3 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 43.3 mt -95.94 124.87 48.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 CA-C-O 121.4 0.619 . . . . 0.0 111.199 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 80.7 t -67.64 -46.29 83.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 C-N-CA 124.486 1.114 . . . . 0.0 109.661 179.385 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 14.9 m . . . . . 0 C--N 1.311 -1.093 0 N-CA-C 114.017 1.117 . . . . 0.0 114.017 -173.977 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 . . . . . 0 N--CA 1.441 -0.894 0 CA-C-O 121.983 0.897 . . . . 0.0 110.58 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 51.4 m170 -88.1 155.73 19.64 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.268 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 52.9 t80 -54.35 113.51 1.3 Allowed 'General case' 0 CA--C 1.509 -0.602 0 CA-C-O 121.484 0.659 . . . . 0.0 110.15 176.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 132.44 -25.33 3.83 Favored Glycine 0 N--CA 1.407 -3.243 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 -177.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . 0.418 ' HA ' HE21 ' A' ' 172' ' ' GLN . 0.0 OUTLIER -68.41 137.63 54.68 Favored 'General case' 0 C--O 1.256 1.402 0 CA-C-O 121.845 0.831 . . . . 0.0 111.747 -178.776 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -112.94 117.76 32.97 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 175.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 53.3 t -99.47 105.32 17.28 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 CA-C-O 121.336 0.589 . . . . 0.0 110.089 -178.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 27.3 ttm180 -94.92 152.8 18.05 Favored 'General case' 0 N--CA 1.414 -2.237 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.694 178.13 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -125.04 157.63 35.73 Favored 'General case' 0 C--N 1.284 -2.249 0 C-N-CA 124.491 1.116 . . . . 0.0 108.869 -175.312 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.37 151.44 35.62 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.958 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.912 175.636 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 7.7 m -118.06 135.2 54.33 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 114.136 -1.393 . . . . 0.0 108.154 173.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -62.63 161.39 12.3 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 124.233 0.958 . . . . 0.0 110.421 178.386 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 7.5 t -62.37 109.76 1.45 Allowed 'General case' 0 C--N 1.299 -1.597 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.323 -174.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 122.97 -19.93 7.72 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -177.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . 0.58 ' HB3' ' SG ' ' A' ' 205' ' ' CYS . 82.6 m-85 -107.69 160.86 15.38 Favored 'General case' 0 N--CA 1.429 -1.495 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.83 146.9 33.39 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.436 HD13 ' HA ' ' A' ' 188' ' ' GLU . 9.5 tt -80.72 140.02 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.808 0 CA-C-O 121.8 0.81 . . . . 0.0 111.513 -176.446 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -83.02 -51.02 7.93 Favored 'General case' 0 C--N 1.294 -1.829 0 CA-C-N 115.164 -0.925 . . . . 0.0 109.26 -176.112 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.58 -158.91 25.18 Favored Glycine 0 C--N 1.298 -1.573 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 173.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -79.74 160.36 26.26 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 122.283 -0.539 . . . . 0.0 110.108 177.485 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . 0.436 ' HA ' HD13 ' A' ' 184' ' ' ILE . 10.5 pt-20 -91.17 9.33 31.55 Favored 'General case' 0 C--O 1.205 -1.241 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.362 -176.167 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.2 pt-20 -155.37 138.82 15.87 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.225 0.536 . . . . 0.0 111.431 -178.767 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.423 ' HG2' ' HB ' ' A' ' 174' ' ' VAL . 6.2 ptm -127.37 144.78 51.0 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 178.401 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 52.5 t-80 -126.48 142.33 51.57 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.593 -0.692 . . . . 0.0 110.742 -175.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 6.4 m -59.32 125.21 22.7 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 176.219 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 12.1 m -104.02 165.43 11.05 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.111 179.441 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -54.06 -30.59 48.73 Favored 'General case' 0 N--CA 1.498 1.943 0 C-N-CA 123.975 0.91 . . . . 0.0 111.901 179.481 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -54.98 -30.03 58.28 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 124.906 1.282 . . . . 0.0 111.39 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 98.06 11.73 48.4 Favored Glycine 0 CA--C 1.497 -1.057 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -174.123 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -130.54 -170.88 2.42 Favored 'General case' 0 N--CA 1.429 -1.475 0 CA-C-N 114.526 -0.837 . . . . 0.0 109.281 -178.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 85.7 m95 -96.25 154.14 17.42 Favored 'General case' 0 N--CA 1.426 -1.658 0 CA-C-O 121.094 0.473 . . . . 0.0 111.335 -175.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 13.7 p -75.14 -17.78 60.35 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.626 176.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 23.9 mmtp -128.62 159.03 36.84 Favored 'General case' 0 CA--C 1.492 -1.254 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.176 179.118 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -87.15 -175.86 5.47 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 3.8 tppp? -72.49 115.14 36.39 Favored Pre-proline 0 C--O 1.249 1.053 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 173.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.73 177.5 8.74 Favored 'Trans proline' 0 N--CA 1.43 -2.231 0 C-N-CA 121.755 1.636 . . . . 0.0 110.645 177.519 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . 0.495 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 23.7 ttmm -128.56 152.75 47.94 Favored 'General case' 0 C--N 1.275 -2.654 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.45 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.58 ' SG ' ' HB3' ' A' ' 182' ' ' TYR . 18.2 t -111.42 117.83 34.14 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 179.209 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--N 1.305 -1.342 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.33 -174.39 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 28.9 Cg_endo . . . . . 0 CA--C 1.543 0.931 0 CA-C-O 121.988 0.745 . . . . 0.0 111.786 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 63.8 m -81.64 -27.97 33.86 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-O 122.066 0.936 . . . . 0.0 109.144 177.134 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.95 -91.37 0.56 Allowed Glycine 0 N--CA 1.4 -3.712 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 173.213 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -179.4 125.5 0.24 Allowed Pre-proline 0 C--N 1.256 -3.47 0 N-CA-C 103.906 -2.627 . . . . 0.0 103.906 -176.113 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.454 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 72.3 Cg_endo -76.82 5.09 5.13 Favored 'Trans proline' 0 N--CA 1.488 1.204 0 C-N-CA 122.649 2.233 . . . . 0.0 113.343 -173.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 97.98 -160.38 20.84 Favored Glycine 0 N--CA 1.419 -2.453 0 N-CA-C 106.725 -2.55 . . . . 0.0 106.725 -173.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -155.31 -168.66 2.91 Favored 'General case' 0 C--N 1.281 -2.389 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.6 t -143.42 120.32 6.72 Favored Pre-proline 0 C--N 1.289 -2.055 0 CA-C-N 118.867 0.758 . . . . 0.0 110.596 -178.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.86 -0.08 9.83 Favored 'Trans proline' 0 CA--C 1.53 0.315 0 C-N-CA 122.831 2.354 . . . . 0.0 111.047 178.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -107.25 13.74 26.88 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.379 178.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 164.77 -128.38 1.79 Allowed Glycine 0 N--CA 1.422 -2.262 0 C-N-CA 119.516 -1.326 . . . . 0.0 112.684 179.036 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.3 p -151.52 173.54 14.48 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 123.322 0.649 . . . . 0.0 110.303 -174.097 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -140.62 161.48 37.65 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 169.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.9 m -127.0 159.99 32.46 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.435 HD12 ' CE1' ' A' ' 104' ' ' PHE . 20.8 mt -117.03 122.89 45.5 Favored 'General case' 0 C--N 1.28 -2.414 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 -179.167 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 29.8 p -115.55 122.08 44.59 Favored 'General case' 0 C--N 1.286 -2.162 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.557 -176.518 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.91 -54.98 0.77 Allowed Glycine 0 N--CA 1.421 -2.339 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -178.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -141.81 3.86 2.09 Favored Glycine 0 N--CA 1.437 -1.28 0 C-N-CA 120.14 -1.029 . . . . 0.0 113.316 -178.004 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 59.99 18.51 7.65 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.524 ' O ' HG12 ' A' ' 108' ' ' VAL . 30.4 m -147.48 -173.86 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 -174.032 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.435 ' CE1' HD12 ' A' ' 98' ' ' LEU . 26.9 m-85 -102.89 45.9 0.94 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 118.447 0.567 . . . . 0.0 109.665 -179.412 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.69 ' O ' HG11 ' A' ' 108' ' ' VAL . 13.0 pt-20 -86.57 -175.03 5.29 Favored 'General case' 0 C--O 1.211 -0.924 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.211 178.124 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -80.36 137.14 36.52 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.86 -0.525 . . . . 0.0 111.455 179.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 88.65 -0.97 83.39 Favored Glycine 0 N--CA 1.439 -1.129 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.849 178.723 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.69 HG11 ' O ' ' A' ' 105' ' ' GLU . 11.4 p -90.08 147.53 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -176.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.4 mtpt -111.37 125.89 54.34 Favored 'General case' 0 N--CA 1.413 -2.281 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.706 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.405 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -89.57 93.25 9.42 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 174.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 54.1 t -88.2 116.43 30.08 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.454 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -179.315 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -87.52 141.59 28.51 Favored 'General case' 0 C--N 1.282 -2.341 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.109 -177.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.3 t -139.04 110.53 7.03 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-O 122.265 1.031 . . . . 0.0 108.488 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 33.2 m -68.75 163.03 24.96 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.114 -174.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -65.97 177.22 1.4 Allowed 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 124.31 1.044 . . . . 0.0 110.439 -178.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -58.92 -46.77 87.13 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 123.98 0.912 . . . . 0.0 112.086 -178.357 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.15 24.47 6.16 Favored Glycine 0 CA--C 1.524 0.609 0 C-N-CA 121.325 -0.464 . . . . 0.0 113.342 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -146.38 164.94 30.84 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 -177.134 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.4 pt20 -145.45 170.0 17.24 Favored 'General case' 0 C--N 1.275 -2.653 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 176.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.5 124.18 31.78 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 179.267 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.73 128.42 55.27 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 106.212 -1.773 . . . . 0.0 106.212 178.046 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 110.81 167.94 19.13 Favored Glycine 0 C--N 1.292 -1.886 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.605 -177.6 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -87.15 -26.57 23.53 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-O 121.816 0.817 . . . . 0.0 109.855 -175.443 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.9 mm -91.17 129.7 41.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.989 -1.005 . . . . 0.0 108.526 179.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 24.2 p-10 -130.81 9.62 4.98 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 120.845 0.355 . . . . 0.0 110.46 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.405 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 36.3 p90 -150.7 164.25 36.58 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.703 -173.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.454 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 45.3 mtp180 -123.66 134.47 53.74 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 173.313 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -110.13 134.03 52.6 Favored 'General case' 0 C--N 1.29 -1.987 0 C-N-CA 119.524 -0.87 . . . . 0.0 108.72 179.549 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.6 t -85.98 109.06 18.51 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.076 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -102.78 -169.36 1.65 Allowed 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 177.422 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 15.0 t -66.19 -15.39 63.11 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 123.119 0.567 . . . . 0.0 112.074 -175.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -99.09 -7.0 27.37 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-O 121.446 0.641 . . . . 0.0 109.979 177.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 114.25 -163.12 12.2 Favored Glycine 0 N--CA 1.439 -1.133 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 90.9 m95 -62.67 109.0 1.27 Allowed 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 116.681 0.24 . . . . 0.0 110.842 177.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 30.6 p -59.11 -73.56 0.08 Allowed 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 125.265 1.426 . . . . 0.0 113.076 -176.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -73.57 177.88 5.06 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.857 -177.498 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -100.97 175.6 5.55 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.951 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 87.1 mt -70.16 125.4 91.97 Favored Pre-proline 0 C--N 1.309 -1.165 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.76 172.1 8.75 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 122.716 2.277 . . . . 0.0 112.73 179.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 46.2 mm -101.77 124.94 55.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-O 121.231 0.539 . . . . 0.0 111.562 -173.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 94.7 m -97.71 99.29 10.64 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 174.335 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -92.19 146.08 24.0 Favored 'General case' 0 N--CA 1.416 -2.13 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.68 130.3 35.21 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.48 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 12.1 m -59.22 141.01 16.68 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 CA-C-O 121.138 0.494 . . . . 0.0 112.001 -176.575 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 83.4 mttt -121.12 136.94 54.88 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.081 -175.013 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 89.1 m -103.67 152.25 22.01 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 172.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 1.8 pp -60.39 154.05 56.09 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-O 120.868 0.366 . . . . 0.0 110.867 -177.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -78.12 102.95 1.62 Allowed 'Trans proline' 0 N--CA 1.441 -1.578 0 C-N-CA 122.504 2.136 . . . . 0.0 112.506 -176.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 7.7 p -73.36 134.28 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.301 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.534 177.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.1 p -75.62 -75.31 0.18 Allowed 'General case' 0 N--CA 1.439 -0.988 0 CA-C-N 116.162 -0.472 . . . . 0.0 112.217 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 171.81 159.96 0.24 Allowed Pre-proline 0 C--O 1.239 0.51 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 -177.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . 0.44 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 56.5 Cg_endo -75.57 161.06 37.64 Favored 'Trans proline' 0 N--CA 1.443 -1.459 0 C-N-CA 121.263 1.309 . . . . 0.0 109.55 171.791 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -57.89 -41.5 82.69 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 114.414 1.265 . . . . 0.0 114.414 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 56.0 m-80 -113.33 23.47 13.21 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.581 0.705 . . . . 0.0 110.041 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -139.48 -163.3 9.46 Favored Glycine 0 N--CA 1.433 -1.536 0 C-N-CA 119.93 -1.129 . . . . 0.0 112.017 -178.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -160.62 177.18 10.75 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.416 HG12 ' CE1' ' A' ' 176' ' ' PHE . 38.4 mt -95.47 140.42 17.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 123.278 0.361 . . . . 0.0 111.806 -175.545 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.447 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.8 m -92.13 -36.1 7.48 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 175.617 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.4 m . . . . . 0 N--CA 1.436 -1.162 0 CA-C-N 115.66 -0.7 . . . . 0.0 109.832 -177.055 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 . . . . . 0 N--CA 1.433 -1.28 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -96.2 167.62 11.09 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.48 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . 0.48 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 91.0 t80 -50.04 133.62 22.65 Favored 'General case' 0 N--CA 1.468 0.466 0 O-C-N 123.622 0.576 . . . . 0.0 111.019 178.184 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 111.69 -32.71 6.21 Favored Glycine 0 N--CA 1.427 -1.932 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -69.66 114.9 8.3 Favored 'General case' 0 N--CA 1.416 -2.173 0 CA-C-O 122.287 1.041 . . . . 0.0 112.303 178.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -101.95 103.44 14.08 Favored 'General case' 0 N--CA 1.416 -2.128 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 174.35 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.491 HG12 ' HG3' ' A' ' 190' ' ' MET . 6.8 p -86.04 108.34 17.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.274 0 CA-C-O 121.579 0.704 . . . . 0.0 110.263 -175.227 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.447 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 43.2 ttp180 -100.12 147.29 25.83 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.476 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.44 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 74.2 m-85 -111.93 167.8 10.09 Favored 'General case' 0 C--N 1.293 -1.857 0 CA-C-O 121.784 0.802 . . . . 0.0 111.408 -177.333 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -136.99 151.65 27.52 Favored 'Isoleucine or valine' 0 CA--C 1.455 -2.678 0 CA-C-N 114.152 -1.385 . . . . 0.0 108.766 177.265 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.8 m -112.41 122.36 47.49 Favored 'General case' 0 N--CA 1.392 -3.348 0 O-C-N 124.474 1.109 . . . . 0.0 108.068 177.618 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 48.3 m-80 -53.92 168.73 0.19 Allowed 'General case' 0 C--N 1.307 -1.263 0 O-C-N 124.761 1.288 . . . . 0.0 112.301 -179.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 16.8 m -49.86 104.66 0.07 Allowed 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 125.273 1.429 . . . . 0.0 112.259 -175.673 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.01 3.16 31.75 Favored Glycine 0 N--CA 1.435 -1.409 0 C-N-CA 120.837 -0.697 . . . . 0.0 113.261 178.438 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -124.67 158.58 32.82 Favored 'General case' 0 CA--C 1.484 -1.564 0 CA-C-N 117.341 0.57 . . . . 0.0 110.725 178.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . 0.493 ' HG2' ' OXT' ' A' ' 206' ' ' VAL . 25.2 pttm -133.39 162.23 32.4 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 106.757 -1.571 . . . . 0.0 106.757 179.239 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.4 tp -76.4 149.16 6.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -81.35 -59.12 2.74 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.987 179.584 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -115.96 -110.32 2.7 Favored Glycine 0 C--N 1.304 -1.205 0 C-N-CA 120.464 -0.874 . . . . 0.0 111.965 179.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . 0.436 ' CG ' ' HD3' ' A' ' 200' ' ' LYS . 1.5 p-10 -77.36 150.02 35.18 Favored 'General case' 0 C--O 1.193 -1.873 0 C-N-CA 124.161 0.984 . . . . 0.0 108.939 177.444 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -107.21 5.68 27.94 Favored 'General case' 0 C--N 1.296 -1.751 0 C-N-CA 121.009 -0.276 . . . . 0.0 110.871 -178.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -152.1 152.22 32.07 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 113.57 0.952 . . . . 0.0 113.57 -172.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.491 ' HG3' HG12 ' A' ' 174' ' ' VAL . 0.0 OUTLIER -128.57 137.46 51.73 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.876 -1.056 . . . . 0.0 108.306 177.454 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 40.3 t-80 -105.49 130.02 53.65 Favored 'General case' 0 C--N 1.291 -1.953 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.124 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 51.3 t -70.74 113.93 8.31 Favored 'General case' 0 C--O 1.243 0.734 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 175.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 25.1 m -85.85 163.49 18.08 Favored 'General case' 0 N--CA 1.437 -1.086 0 C-N-CA 123.217 0.607 . . . . 0.0 111.689 -176.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -67.57 -10.87 55.91 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 -173.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 19.4 m-20 -91.79 -0.99 57.56 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.402 0.62 . . . . 0.0 110.109 177.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 81.38 42.28 9.41 Favored Glycine 0 N--CA 1.436 -1.362 0 C-N-CA 120.993 -0.622 . . . . 0.0 113.282 179.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 45.5 p90 -149.65 166.71 28.5 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 175.249 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.5 m95 -83.82 125.86 32.38 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 123.146 0.279 . . . . 0.0 110.484 -178.712 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 35.9 t -57.62 -38.98 75.88 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.597 177.068 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . 0.436 ' HD3' ' CG ' ' A' ' 187' ' ' ASP . 1.8 mmpt? -101.91 178.6 4.57 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 115.718 -0.673 . . . . 0.0 111.039 177.5 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -113.69 178.78 4.16 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 179.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 51.5 mtpt -79.2 114.51 45.38 Favored Pre-proline 0 C--N 1.295 -1.802 0 C-N-CA 120.771 -0.372 . . . . 0.0 111.593 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.49 -171.73 1.19 Allowed 'Trans proline' 0 N--CA 1.437 -1.812 0 C-N-CA 122.001 1.801 . . . . 0.0 110.898 176.354 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 34.0 ttpt -141.66 153.48 44.74 Favored 'General case' 0 N--CA 1.405 -2.722 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.738 -175.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.425 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 81.1 m -104.81 121.54 43.86 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 174.648 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . 0.493 ' OXT' ' HG2' ' A' ' 183' ' ' LYS . 25.0 m . . . . . 0 C--N 1.305 -1.365 0 O-C-N 124.191 0.932 . . . . 0.0 110.101 -175.387 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo . . . . . 0 CA--C 1.54 0.812 0 CA-C-O 121.423 0.51 . . . . 0.0 111.764 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 39.3 m -82.27 -36.23 27.28 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 122.264 1.031 . . . . 0.0 108.235 177.224 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.48 -92.62 0.48 Allowed Glycine 0 N--CA 1.406 -3.327 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 174.375 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.8 t60 -177.42 129.55 0.32 Allowed Pre-proline 0 C--N 1.261 -3.248 0 N-CA-C 103.991 -2.596 . . . . 0.0 103.991 -176.255 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.441 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 90.5 Cg_endo -80.24 2.55 8.38 Favored 'Trans proline' 0 C--N 1.327 -0.582 0 C-N-CA 122.446 2.098 . . . . 0.0 113.387 -173.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.48 -178.49 41.39 Favored Glycine 0 N--CA 1.422 -2.287 0 N-CA-C 109.037 -1.625 . . . . 0.0 109.037 -175.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -139.83 159.68 41.61 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 117.477 0.639 . . . . 0.0 110.177 -177.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.7 t -108.52 139.6 20.97 Favored Pre-proline 0 C--N 1.299 -1.59 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.632 -178.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -82.41 -14.32 9.37 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.546 2.164 . . . . 0.0 111.155 178.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -86.79 -1.22 57.59 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.642 -175.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 172.17 -131.89 2.26 Favored Glycine 0 N--CA 1.408 -3.226 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 -178.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 35.8 p -145.62 -175.62 4.8 Favored 'General case' 0 C--N 1.289 -2.036 0 O-C-N 123.864 0.391 . . . . 0.0 110.012 -177.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -138.21 166.56 23.87 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 173.223 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -134.79 161.46 35.12 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.47 HD12 ' CE1' ' A' ' 104' ' ' PHE . 13.2 mt -119.14 124.16 46.16 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 -178.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.431 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 29.5 p -108.98 144.2 37.27 Favored 'General case' 0 C--N 1.284 -2.242 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -177.727 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 102.64 -70.36 0.32 Allowed Glycine 0 N--CA 1.432 -1.598 0 C-N-CA 120.01 -1.09 . . . . 0.0 110.671 -178.19 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -110.47 -18.61 8.44 Favored Glycine 0 C--N 1.307 -1.08 0 C-N-CA 120.283 -0.96 . . . . 0.0 112.187 -178.313 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . 0.408 ' HA ' ' HB2' ' A' ' 98' ' ' LEU . 42.3 m-80 64.04 22.62 12.99 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 123.336 0.655 . . . . 0.0 111.163 -178.563 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.496 ' O ' HG21 ' A' ' 108' ' ' VAL . 18.4 m -151.1 -171.75 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.198 -1.623 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -178.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.47 ' CE1' HD12 ' A' ' 98' ' ' LEU . 22.1 m-85 -101.9 43.99 1.04 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 119.095 0.862 . . . . 0.0 110.568 -177.025 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.721 ' O ' HG13 ' A' ' 108' ' ' VAL . 11.7 pt-20 -84.11 -179.66 7.28 Favored 'General case' 0 C--O 1.206 -1.222 0 CA-C-N 114.476 -1.238 . . . . 0.0 111.663 178.357 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 40.2 m-85 -76.7 135.55 39.08 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 122.029 -0.419 . . . . 0.0 110.881 176.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.62 9.3 75.42 Favored Glycine 0 N--CA 1.44 -1.057 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.704 178.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.721 HG13 ' O ' ' A' ' 105' ' ' GLU . 11.9 p -95.6 148.8 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.484 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.431 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.7 mtpt -115.17 121.96 44.59 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.458 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.454 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -88.01 93.82 9.6 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.265 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 91.5 t -90.53 114.43 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.93 0 C-N-CA 124.414 1.086 . . . . 0.0 108.431 -177.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -84.76 139.44 31.96 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.511 -177.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.9 t -136.16 112.24 9.68 Favored 'General case' 0 N--CA 1.423 -1.796 0 CA-C-O 122.156 0.979 . . . . 0.0 109.943 -179.152 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 84.8 m -69.43 156.21 39.21 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.47 -0.786 . . . . 0.0 111.998 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 -67.7 172.93 4.69 Favored 'General case' 0 C--O 1.218 -0.573 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.069 176.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -53.33 -47.8 69.03 Favored 'General case' 0 C--N 1.313 -1.007 0 C-N-CA 124.022 0.929 . . . . 0.0 113.115 -174.132 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -85.02 15.35 44.17 Favored Glycine 0 C--N 1.307 -1.039 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.784 -179.569 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -130.34 162.27 29.43 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.77 145.34 31.62 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 -179.701 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.5 tt -79.94 140.91 36.47 Favored 'General case' 0 C--N 1.279 -2.471 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.263 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.97 133.07 56.33 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -173.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 103.73 -169.41 18.08 Favored Glycine 0 C--N 1.306 -1.121 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.46 179.283 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -94.19 -47.45 6.64 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -178.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.0 mm -69.05 122.95 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 CA-C-N 114.464 -1.244 . . . . 0.0 109.626 -176.331 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -128.53 6.24 5.69 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.397 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.454 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 25.0 p90 -150.56 162.39 40.72 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 120.433 -0.507 . . . . 0.0 110.23 -173.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.441 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 39.9 mtp180 -121.78 132.97 54.89 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 106.226 -1.768 . . . . 0.0 106.226 173.235 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -108.7 128.9 55.27 Favored 'General case' 0 C--N 1.289 -2.035 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.7 t -85.35 107.33 17.3 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.087 -1.045 . . . . 0.0 109.642 177.116 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.441 ' CG ' ' H ' ' A' ' 131' ' ' THR . 34.1 t0 -103.86 -170.6 1.8 Allowed 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 178.27 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.441 ' H ' ' CG ' ' A' ' 130' ' ' ASP . 11.1 t -54.81 -29.49 54.71 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 124.56 1.144 . . . . 0.0 113.204 -177.033 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -81.82 -30.16 32.31 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 121.4 0.619 . . . . 0.0 110.382 176.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 132.86 -151.78 20.11 Favored Glycine 0 N--CA 1.42 -2.409 0 N-CA-C 108.744 -1.743 . . . . 0.0 108.744 -174.364 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 92.3 m95 -65.46 113.16 3.94 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 117.386 0.593 . . . . 0.0 109.778 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 22.3 p -64.65 -70.88 0.2 Allowed 'General case' 0 C--O 1.247 0.922 0 CA-C-O 121.6 0.714 . . . . 0.0 111.738 -178.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 -71.82 173.87 7.67 Favored 'General case' 0 CA--C 1.484 -1.559 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.959 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -110.01 -174.62 2.53 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -177.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.2 mt -66.58 118.56 55.25 Favored Pre-proline 0 C--O 1.244 0.814 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.405 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.61 155.93 63.96 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.788 2.325 . . . . 0.0 111.706 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 67.5 mt -84.81 136.15 23.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.032 -177.657 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 43.7 t -126.06 138.75 53.73 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 176.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.56 157.32 40.49 Favored 'General case' 0 N--CA 1.414 -2.243 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -178.498 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 11.5 p -75.09 136.34 25.3 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.88 178.365 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.96 130.53 25.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 C-N-CA 123.303 0.641 . . . . 0.0 109.303 178.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.536 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 44.0 mttp -131.46 159.11 39.02 Favored 'General case' 0 CA--C 1.499 -1.007 0 CA-C-O 121.564 0.697 . . . . 0.0 112.64 -177.429 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 39.5 m -123.28 149.53 44.68 Favored 'General case' 0 N--CA 1.42 -1.974 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 176.312 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 80.5 mt -65.38 148.76 97.81 Favored Pre-proline 0 C--N 1.309 -1.154 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -61.6 122.34 10.89 Favored 'Trans proline' 0 N--CA 1.459 -0.524 0 C-N-CA 123.199 2.599 . . . . 0.0 110.479 178.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.554 HG12 ' O ' ' A' ' 150' ' ' THR . 21.0 t -83.73 145.78 7.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -175.705 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' THR . . . . . 0.554 ' O ' HG12 ' A' ' 149' ' ' VAL . 15.6 p -88.13 -164.93 1.19 Allowed 'General case' 0 N--CA 1.411 -2.425 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 171.53 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . 0.421 ' HB2' ' HA ' ' A' ' 156' ' ' LYS . . . -113.09 156.37 42.97 Favored Pre-proline 0 C--N 1.266 -3.057 0 O-C-N 121.511 -0.743 . . . . 0.0 110.392 -172.494 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 28.9 Cg_endo -65.26 158.51 51.95 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 122.252 1.968 . . . . 0.0 110.276 173.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -53.78 -36.43 62.4 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 114.463 1.282 . . . . 0.0 114.463 -174.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 48.4 m-80 -127.7 36.1 4.4 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.789 0.804 . . . . 0.0 109.043 -179.493 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . 0.441 ' HA3' ' O ' ' A' ' 177' ' ' VAL . . . -152.7 -160.76 9.82 Favored Glycine 0 N--CA 1.429 -1.802 0 C-N-CA 119.628 -1.272 . . . . 0.0 113.231 178.103 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . 0.421 ' HA ' ' HB2' ' A' ' 151' ' ' ALA . 20.2 pttm -159.12 176.61 12.04 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 123.936 0.894 . . . . 0.0 109.863 -177.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 59.8 mt -94.52 142.1 13.96 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 122.24 0.216 . . . . 0.0 110.705 -178.656 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.527 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 12.2 m -99.83 -23.57 4.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 CA-C-O 121.722 0.772 . . . . 0.0 110.479 179.055 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' SER . . . . . 0.412 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 33.4 m . . . . . 0 C--N 1.298 -1.659 0 N-CA-C 114.742 1.386 . . . . 0.0 114.742 -168.496 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 . . . . . 0 N--CA 1.426 -1.648 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.536 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 21.4 p-80 -96.5 171.1 8.77 Favored 'General case' 0 C--N 1.291 -1.968 0 C-N-CA 120.137 -0.625 . . . . 0.0 111.082 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -51.51 125.6 15.02 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 123.872 0.733 . . . . 0.0 110.948 179.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.48 -10.23 21.89 Favored Glycine 0 N--CA 1.424 -2.111 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -177.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.2 mm-40 -85.26 136.96 33.28 Favored 'General case' 0 N--CA 1.438 -1.072 0 CA-C-O 121.537 0.684 . . . . 0.0 112.041 -179.636 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -115.11 120.38 39.59 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 176.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.45 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 83.3 t -108.1 110.98 33.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.598 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 72.7 ttt180 -106.37 147.72 28.91 Favored 'General case' 0 N--CA 1.425 -1.696 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -119.41 165.97 13.66 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.025 0.441 . . . . 0.0 111.134 -175.142 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.441 ' O ' ' HA3' ' A' ' 155' ' ' GLY . 0.0 OUTLIER -130.28 156.65 42.52 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.715 0 CA-C-N 115.069 -0.969 . . . . 0.0 109.745 175.21 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.7 m -111.81 142.98 43.5 Favored 'General case' 0 C--N 1.278 -2.531 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 171.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -44.74 -80.68 0.01 OUTLIER 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 114.331 1.234 . . . . 0.0 114.331 -177.173 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 64.6 m -149.24 -42.05 0.14 Allowed 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 114.018 1.118 . . . . 0.0 114.018 -178.364 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -102.29 2.22 50.53 Favored Glycine 0 C--N 1.291 -1.928 0 C-N-CA 120.152 -1.023 . . . . 0.0 114.742 -174.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -110.35 175.73 5.32 Favored 'General case' 0 CA--C 1.487 -1.445 0 CA-C-N 117.643 0.721 . . . . 0.0 111.122 -176.33 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 37.6 pttt -136.63 152.56 50.57 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 173.427 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 6.9 tt -70.97 143.2 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.473 0 CA-C-O 121.821 0.82 . . . . 0.0 112.71 -176.706 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -39.78 -59.63 1.13 Allowed 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 127.862 2.465 . . . . 0.0 113.061 179.046 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -145.24 -89.58 0.1 OUTLIER Glycine 0 CA--C 1.48 -2.122 0 C-N-CA 120.107 -1.044 . . . . 0.0 111.293 -177.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . 0.415 ' HB3' ' HG3' ' A' ' 200' ' ' LYS . 6.9 t0 -95.03 158.42 15.47 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.349 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . 0.598 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 13.4 pt-20 -111.28 -9.48 14.29 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 121.084 -0.246 . . . . 0.0 110.772 -177.443 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . 0.45 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.9 pt-20 -131.49 124.67 30.62 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-O 121.816 0.817 . . . . 0.0 112.869 -178.096 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 17.4 ptp -109.65 151.01 27.41 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.811 178.412 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 63.4 m80 -127.37 156.73 41.57 Favored 'General case' 0 CA--C 1.498 -1.043 0 C-N-CA 122.403 0.281 . . . . 0.0 110.66 -178.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 5.1 m -81.75 117.14 21.82 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.066 176.287 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 37.2 m -82.1 152.54 26.5 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.398 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -72.1 78.51 0.94 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 122.852 1.31 . . . . 0.0 112.257 -176.532 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -175.36 -47.16 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.627 0 CA-C-N 112.986 -1.915 . . . . 0.0 106.186 -179.175 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 121.28 66.34 0.25 Allowed Glycine 0 N--CA 1.427 -1.901 0 CA-C-N 114.547 -1.206 . . . . 0.0 112.21 -178.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -167.29 161.94 14.59 Favored 'General case' 0 C--O 1.248 0.979 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 176.58 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.9 m95 -85.15 139.46 31.68 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 124.005 0.816 . . . . 0.0 110.846 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.7 p -71.51 -18.64 62.27 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.252 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . 0.582 ' HE3' ' O ' ' A' ' 201' ' ' GLU . 0.0 OUTLIER -123.94 153.49 41.13 Favored 'General case' 0 N--CA 1.426 -1.626 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 -179.879 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . 0.582 ' O ' ' HE3' ' A' ' 200' ' ' LYS . 3.2 mp0 -77.55 168.4 20.05 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 106.532 -1.655 . . . . 0.0 106.532 177.261 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -68.89 114.91 26.14 Favored Pre-proline 0 C--N 1.311 -1.084 0 C-N-CA 119.915 -0.714 . . . . 0.0 109.722 176.566 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_endo -82.79 166.94 14.93 Favored 'Trans proline' 0 N--CA 1.431 -2.173 0 C-N-CA 121.95 1.766 . . . . 0.0 111.645 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 9.8 ptpp? -131.08 179.06 6.22 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.16 -177.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 87.6 m -115.32 114.18 24.81 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 178.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.9 m . . . . . 0 C--N 1.302 -1.471 0 CA-C-N 114.796 -1.093 . . . . 0.0 109.692 -174.096 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.415 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 39.9 Cg_endo . . . . . 0 CA--C 1.538 0.711 0 CA-C-O 122.19 0.829 . . . . 0.0 110.772 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.9 m -92.41 -33.09 14.69 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.696 -1.138 . . . . 0.0 108.295 175.661 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.04 -91.79 0.58 Allowed Glycine 0 N--CA 1.402 -3.618 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 174.317 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.5 t-80 -174.7 132.61 0.49 Allowed Pre-proline 0 C--N 1.268 -2.973 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 -176.058 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -81.97 5.75 6.12 Favored 'Trans proline' 0 N--CA 1.475 0.439 0 C-N-CA 122.363 2.042 . . . . 0.0 113.405 -172.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 113.58 -173.77 15.25 Favored Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -177.44 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -151.68 160.51 43.59 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 178.22 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.5 t -140.05 144.59 38.64 Favored Pre-proline 0 C--N 1.294 -1.809 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.723 -174.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -83.09 -16.77 7.13 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 122.692 2.261 . . . . 0.0 110.611 174.12 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 40.4 m-85 -87.53 2.37 50.91 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.772 -175.018 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.511 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 164.4 -127.1 1.6 Allowed Glycine 0 N--CA 1.415 -2.726 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.756 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.2 t -161.08 -161.97 0.87 Allowed 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -178.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -155.02 159.43 40.31 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 177.45 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 16.2 m -121.34 163.35 18.78 Favored 'General case' 0 C--N 1.278 -2.527 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.449 HD12 ' CE1' ' A' ' 104' ' ' PHE . 20.6 mt -121.64 129.24 52.66 Favored 'General case' 0 C--N 1.284 -2.259 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -178.377 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.2 p -124.79 130.22 51.97 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.879 -176.071 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.33 20.97 28.4 Favored Glycine 0 C--N 1.303 -1.278 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.373 -178.63 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.94 -31.74 0.14 Allowed Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 119.907 -1.139 . . . . 0.0 113.128 177.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 6.7 m120 67.8 10.27 7.67 Favored 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 123.267 0.627 . . . . 0.0 112.461 -177.1 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.527 ' O ' HG12 ' A' ' 108' ' ' VAL . 27.3 m -143.34 -171.67 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.501 -0.909 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 -176.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.449 ' CE1' HD12 ' A' ' 98' ' ' LEU . 23.4 m-85 -104.71 46.36 0.92 Allowed 'General case' 0 C--N 1.311 -1.083 0 CA-C-O 121.092 0.473 . . . . 0.0 110.162 -177.509 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.762 ' O ' HG11 ' A' ' 108' ' ' VAL . 14.9 pt-20 -87.88 175.74 7.67 Favored 'General case' 0 C--O 1.212 -0.884 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.408 178.016 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . 0.415 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 42.4 m-85 -74.69 131.57 40.98 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-O 121.088 0.47 . . . . 0.0 111.441 178.661 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 96.72 -1.13 61.42 Favored Glycine 0 N--CA 1.437 -1.239 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.112 178.413 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.762 HG11 ' O ' ' A' ' 105' ' ' GLU . 14.7 p -90.29 146.57 6.03 Favored 'Isoleucine or valine' 0 C--O 1.243 0.749 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.3 mtpt -109.5 122.97 48.59 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.543 178.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.506 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.46 93.17 9.07 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 176.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 75.7 t -86.46 108.03 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.745 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . 0.51 ' CG ' ' HG2' ' A' ' 139' ' ' PRO . 66.4 t80 -78.3 140.55 38.82 Favored 'General case' 0 C--N 1.268 -2.942 0 CA-C-N 114.121 -1.4 . . . . 0.0 109.952 -174.59 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -143.48 132.38 22.78 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-O 121.9 0.857 . . . . 0.0 109.858 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 57.0 m -85.69 159.64 19.75 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.817 -176.198 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.511 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 54.9 m-20 -65.85 176.97 1.41 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.726 178.523 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -56.12 -49.3 74.27 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 123.522 0.729 . . . . 0.0 112.396 -175.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.21 33.34 4.09 Favored Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.256 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.401 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 84.5 m-85 -146.56 158.21 43.86 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 124.224 1.01 . . . . 0.0 109.043 -178.33 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -136.1 169.75 17.12 Favored 'General case' 0 C--N 1.279 -2.457 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 177.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 10.5 tp -86.97 153.72 21.35 Favored 'General case' 0 C--N 1.287 -2.121 0 C-N-CA 119.259 -0.977 . . . . 0.0 108.397 178.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.05 125.31 31.11 Favored 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 176.218 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.68 175.8 20.04 Favored Glycine 0 C--N 1.292 -1.876 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -176.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -94.73 -28.9 15.06 Favored 'General case' 0 CA--C 1.5 -0.943 0 CA-C-O 121.26 0.553 . . . . 0.0 111.0 -177.327 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.559 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 48.8 mm -81.1 129.78 36.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.178 -178.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -133.21 9.15 4.06 Favored 'General case' 0 C--O 1.213 -0.851 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 178.158 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.506 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 22.6 p90 -147.54 158.75 44.13 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.19 0.519 . . . . 0.0 110.425 -176.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 59.7 mtp180 -125.12 132.11 53.16 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 172.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -107.3 130.82 54.72 Favored 'General case' 0 C--N 1.275 -2.65 0 C-N-CA 119.408 -0.917 . . . . 0.0 109.715 -177.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 35.8 t -82.52 101.57 10.81 Favored 'General case' 0 N--CA 1.428 -1.536 0 C-N-CA 118.098 -1.441 . . . . 0.0 110.454 177.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.409 ' OD1' HG21 ' A' ' 131' ' ' THR . 6.4 t70 -98.79 -169.56 1.8 Allowed 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 105.496 -2.038 . . . . 0.0 105.496 175.505 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.409 HG21 ' OD1' ' A' ' 130' ' ' ASP . 13.2 t -65.33 -24.36 67.24 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 118.362 0.528 . . . . 0.0 110.965 -176.869 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -70.51 -24.18 62.78 Favored 'General case' 0 C--O 1.249 1.03 0 CA-C-O 122.105 0.955 . . . . 0.0 110.558 175.243 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.62 -148.11 18.91 Favored Glycine 0 N--CA 1.411 -2.985 0 N-CA-C 107.577 -2.209 . . . . 0.0 107.577 -172.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 97.4 m95 -71.12 112.78 7.54 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 117.235 0.518 . . . . 0.0 110.822 177.722 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 65.0 p -70.5 168.12 16.9 Favored 'General case' 0 C--O 1.269 2.116 0 N-CA-C 109.001 -0.741 . . . . 0.0 109.001 176.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 63.44 -163.1 0.27 Allowed 'General case' 0 C--O 1.242 0.674 0 O-C-N 124.07 0.856 . . . . 0.0 108.992 177.163 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -126.31 178.73 5.65 Favored 'General case' 0 C--N 1.279 -2.478 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 173.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 57.0 mt -67.2 119.77 67.21 Favored Pre-proline 0 C--N 1.298 -1.638 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 175.264 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . 0.559 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 1.5 Cg_endo -58.18 165.09 7.6 Favored 'Trans proline' 0 C--O 1.24 0.606 0 C-N-CA 122.451 2.101 . . . . 0.0 111.834 177.762 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 61.8 mt -102.18 135.8 37.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.236 -172.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.432 ' SG ' ' CE2' ' A' ' 112' ' ' TYR . 90.2 m -103.28 148.47 25.79 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 171.699 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -128.5 151.76 49.05 Favored 'General case' 0 C--N 1.266 -3.052 0 N-CA-C 105.261 -2.125 . . . . 0.0 105.261 174.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.542 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 7.3 p -71.45 147.35 10.97 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.607 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.131 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.541 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 11.6 m -67.18 121.92 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.911 0 C-N-CA 118.478 -1.289 . . . . 0.0 109.243 176.132 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.542 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 52.3 mtmt -115.97 142.91 46.17 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.307 -0.861 . . . . 0.0 111.312 -172.208 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 19.0 m -110.35 142.82 41.48 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 178.079 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.1 mm? -60.95 144.42 90.51 Favored Pre-proline 0 N--CA 1.426 -1.661 0 N-CA-C 113.653 0.983 . . . . 0.0 113.653 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 31.4 Cg_exo -57.61 142.47 95.66 Favored 'Trans proline' 0 C--O 1.246 0.878 0 C-N-CA 123.493 2.796 . . . . 0.0 111.857 177.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.2 t -110.67 149.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 16.9 p -80.72 -83.57 0.11 Allowed 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 122.131 0.172 . . . . 0.0 111.093 178.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.35 153.51 0.23 Allowed Pre-proline 0 C--O 1.237 0.44 0 C-N-CA 125.883 1.673 . . . . 0.0 106.729 179.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.14 160.94 46.04 Favored 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 121.548 1.498 . . . . 0.0 111.574 175.118 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . 0.412 ' HG3' ' ND2' ' A' ' 154' ' ' ASN . 11.0 pt-20 -65.4 -32.68 74.44 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 114.582 1.326 . . . . 0.0 114.582 -173.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . 0.412 ' ND2' ' HG3' ' A' ' 153' ' ' GLU . 58.5 m-80 -126.26 32.79 5.14 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 121.777 0.799 . . . . 0.0 108.901 -179.226 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -156.59 -168.09 18.81 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.413 178.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 24.0 pttm -150.02 171.66 16.49 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 117.178 0.489 . . . . 0.0 109.705 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 53.5 mt -94.92 129.22 45.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.493 HG22 ' O ' ' A' ' 175' ' ' ARG . 10.5 m -82.09 -24.71 9.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-O 121.369 0.604 . . . . 0.0 110.569 -177.328 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 6.5 m . . . . . 0 N--CA 1.443 -0.801 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.409 -177.466 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 . . . . . 0 N--CA 1.434 -1.247 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.484 ' CD2' ' HG2' ' A' ' 145' ' ' LYS . 39.0 m170 -119.26 157.55 27.82 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 119.325 -0.369 . . . . 0.0 110.407 -172.143 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . 0.541 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 85.7 t80 -35.15 127.75 0.54 Allowed 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 176.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 103.41 -30.31 10.58 Favored Glycine 0 N--CA 1.427 -1.943 0 CA-C-N 114.783 -1.099 . . . . 0.0 112.82 177.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -72.3 145.28 47.95 Favored 'General case' 0 N--CA 1.402 -2.827 0 CA-C-N 117.266 0.533 . . . . 0.0 110.248 -177.635 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -122.39 122.54 39.25 Favored 'General case' 0 N--CA 1.414 -2.241 0 CA-C-N 115.205 -0.907 . . . . 0.0 108.835 178.506 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 54.9 t -93.71 105.01 16.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.254 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 174.705 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.493 ' O ' HG22 ' A' ' 158' ' ' VAL . 19.3 ttp180 -103.37 146.64 28.18 Favored 'General case' 0 N--CA 1.402 -2.847 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -178.498 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -117.13 166.76 11.85 Favored 'General case' 0 C--N 1.279 -2.485 0 CA-C-O 121.102 0.477 . . . . 0.0 109.945 -174.182 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.0 p -145.43 139.8 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.21 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 174.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . 0.402 ' SG ' ' HB ' ' A' ' 184' ' ' ILE . 77.5 m -101.72 157.2 17.01 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -65.71 163.4 16.59 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 177.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 15.3 t -46.83 -33.45 4.48 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -169.453 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -108.52 18.04 32.97 Favored Glycine 0 C--N 1.289 -2.04 0 C-N-CA 120.427 -0.892 . . . . 0.0 114.203 -177.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -119.29 158.86 25.21 Favored 'General case' 0 CA--C 1.486 -1.519 0 CA-C-N 118.28 1.04 . . . . 0.0 110.795 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . 0.447 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 14.8 pttm -120.14 150.97 39.76 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.316 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.402 ' HB ' ' SG ' ' A' ' 178' ' ' CYS . 8.3 tt -84.32 136.31 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.313 0 C-N-CA 119.279 -0.969 . . . . 0.0 108.902 174.485 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -86.65 -45.65 10.81 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.967 -1.015 . . . . 0.0 109.226 -174.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -78.46 -157.57 10.59 Favored Glycine 0 C--N 1.302 -1.33 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 173.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -82.04 169.34 16.82 Favored 'General case' 0 C--N 1.314 -0.977 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.132 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -81.44 -13.57 58.07 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-N 118.778 0.717 . . . . 0.0 110.865 -173.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -147.47 170.77 16.7 Favored 'General case' 0 N--CA 1.423 -1.779 0 CA-C-O 121.513 0.673 . . . . 0.0 111.431 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.0 ptp -141.8 125.66 17.09 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.911 175.372 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 1.9 m80 -98.54 147.27 24.95 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.526 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 1.7 m -73.62 110.78 8.18 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.834 171.272 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 28.8 m -83.61 160.02 21.48 Favored 'General case' 0 N--CA 1.428 -1.574 0 O-C-N 123.925 0.766 . . . . 0.0 109.342 -179.269 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -70.37 1.56 4.84 Favored 'General case' 0 N--CA 1.486 1.34 0 CA-C-O 121.261 0.553 . . . . 0.0 112.423 -176.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -84.6 -17.53 38.44 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.376 174.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 90.1 23.3 32.71 Favored Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.288 -0.958 . . . . 0.0 110.865 -174.273 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -131.01 164.5 25.26 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 58.0 m95 -79.59 143.37 34.8 Favored 'General case' 0 N--CA 1.426 -1.642 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 174.638 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.1 m -63.77 -20.77 66.02 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-O 121.153 0.502 . . . . 0.0 111.104 177.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -133.74 158.78 42.44 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.058 -177.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 25.3 mm-40 -79.63 168.0 19.95 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 114.554 -1.203 . . . . 0.0 108.392 171.742 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 17.2 tptm -55.43 117.26 14.21 Favored Pre-proline 0 N--CA 1.439 -0.989 0 O-C-N 123.863 0.727 . . . . 0.0 110.02 176.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -87.5 158.4 7.94 Favored 'Trans proline' 0 N--CA 1.423 -2.639 0 C-N-CA 122.066 1.844 . . . . 0.0 111.663 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -122.42 149.08 44.32 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.709 -175.678 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 92.7 m -108.38 115.67 30.54 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 176.244 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 9.4 m . . . . . 0 C--N 1.29 -1.981 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.126 -175.177 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo . . . . . 0 CA--C 1.534 0.477 0 CA-C-O 121.796 0.665 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 59.5 m -88.23 -36.99 16.44 Favored 'General case' 0 N--CA 1.435 -1.204 0 CA-C-N 114.813 -1.085 . . . . 0.0 109.29 175.79 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 115.98 -87.72 0.44 Allowed Glycine 0 CA--C 1.463 -3.206 0 N-CA-C 110.081 -1.207 . . . . 0.0 110.081 174.34 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 3.5 t60 -177.72 127.77 0.29 Allowed Pre-proline 0 C--N 1.269 -2.922 0 N-CA-C 104.901 -2.259 . . . . 0.0 104.901 -175.642 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -79.99 12.26 2.52 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 123.043 2.495 . . . . 0.0 114.342 -171.909 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 106.03 -169.63 15.98 Favored Glycine 0 N--CA 1.424 -2.126 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -176.305 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -160.27 139.59 10.88 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 177.717 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.3 t -110.87 131.74 21.98 Favored Pre-proline 0 C--N 1.303 -1.449 0 C-N-CA 120.631 -0.428 . . . . 0.0 111.758 -175.85 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -70.02 -18.3 35.85 Favored 'Trans proline' 0 C--N 1.351 0.681 0 C-N-CA 122.826 2.351 . . . . 0.0 111.695 176.596 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -83.57 -2.5 56.18 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.329 -176.721 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.492 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.09 -124.49 1.04 Allowed Glycine 0 N--CA 1.414 -2.817 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.328 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 14.8 t -164.8 -165.27 0.89 Allowed 'General case' 0 C--N 1.285 -2.228 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.55 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.7 p90 -146.18 165.65 28.54 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.896 -0.503 . . . . 0.0 109.758 178.203 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -126.12 162.44 25.34 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.962 -1.495 . . . . 0.0 106.962 176.64 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 16.5 mt -114.88 132.91 56.37 Favored 'General case' 0 C--N 1.278 -2.51 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.314 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 19.9 p -128.9 128.48 43.9 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 -177.161 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 93.41 30.13 9.49 Favored Glycine 0 C--N 1.292 -1.863 0 C-N-CA 119.994 -1.098 . . . . 0.0 111.253 -178.302 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 164.17 -35.51 0.29 Allowed Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.705 -1.236 . . . . 0.0 111.974 177.396 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 68.85 14.25 8.91 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.547 0.739 . . . . 0.0 112.338 179.96 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.515 ' O ' HG12 ' A' ' 108' ' ' VAL . 29.3 m -147.74 -168.92 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.211 -0.951 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 -178.616 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -106.34 42.78 1.22 Allowed 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 119.118 0.872 . . . . 0.0 110.238 -178.115 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.742 ' O ' HG11 ' A' ' 108' ' ' VAL . 10.8 pt-20 -79.27 173.91 12.11 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 114.641 -1.163 . . . . 0.0 111.588 178.262 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -75.98 127.59 33.3 Favored 'General case' 0 C--N 1.295 -1.762 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.059 176.201 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 104.17 -7.58 48.04 Favored Glycine 0 N--CA 1.435 -1.414 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.489 179.694 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.742 HG11 ' O ' ' A' ' 105' ' ' GLU . 13.9 p -87.76 148.9 4.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -178.32 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -112.03 123.72 50.86 Favored 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.574 179.181 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.419 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.85 96.99 10.4 Favored 'General case' 0 C--N 1.291 -1.939 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 176.523 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.416 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 22.6 m -95.24 111.18 25.32 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.511 0 CA-C-O 122.564 1.174 . . . . 0.0 109.457 -179.168 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -78.92 148.96 32.5 Favored 'General case' 0 C--N 1.26 -3.32 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.813 -177.62 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.9 t -145.35 130.94 18.85 Favored 'General case' 0 N--CA 1.422 -1.839 0 CA-C-N 115.012 -0.995 . . . . 0.0 108.895 177.295 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 20.5 m -82.47 160.61 22.63 Favored 'General case' 0 C--N 1.284 -2.277 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.314 -175.732 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.492 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 71.1 m-20 -73.19 -178.06 2.75 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.952 178.812 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -53.31 -53.09 56.02 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 125.02 1.328 . . . . 0.0 113.375 -175.43 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.25 31.81 4.64 Favored Glycine 0 C--N 1.305 -1.18 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.414 -177.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -146.1 153.65 40.94 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -175.044 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -133.13 171.88 13.4 Favored 'General case' 0 C--N 1.272 -2.776 0 N-CA-C 105.923 -1.881 . . . . 0.0 105.923 175.663 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 13.1 tp -87.47 149.87 24.13 Favored 'General case' 0 C--N 1.282 -2.357 0 C-N-CA 119.135 -1.026 . . . . 0.0 108.563 179.216 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -122.51 121.83 37.48 Favored 'General case' 0 N--CA 1.408 -2.539 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 176.81 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.92 171.52 23.44 Favored Glycine 0 C--N 1.284 -2.33 0 C-N-CA 120.796 -0.716 . . . . 0.0 111.943 -175.434 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -86.27 -34.72 20.3 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.65 0.738 . . . . 0.0 109.495 -176.927 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.3 mm -77.97 126.67 38.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-N 114.988 -1.006 . . . . 0.0 109.814 -175.925 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -127.57 1.93 6.19 Favored 'General case' 0 C--O 1.201 -1.454 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 176.899 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.419 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 18.2 p90 -136.51 162.43 33.12 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.42 -171.64 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 63.3 mtp180 -130.78 131.12 44.51 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 170.341 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -103.9 132.31 50.28 Favored 'General case' 0 C--N 1.292 -1.899 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.698 179.509 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 23.9 t -82.22 97.78 8.42 Favored 'General case' 0 N--CA 1.425 -1.681 0 C-N-CA 118.238 -1.385 . . . . 0.0 109.257 175.741 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -94.83 -173.41 2.98 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 106.673 -1.602 . . . . 0.0 106.673 178.163 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 14.1 t -67.01 -14.39 62.85 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.69 0.757 . . . . 0.0 111.277 -175.192 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -86.73 -28.64 22.94 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.017 177.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 132.13 -163.85 23.86 Favored Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 -175.405 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.423 ' CH2' HG13 ' A' ' 108' ' ' VAL . 98.5 m95 -63.62 113.55 3.4 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 117.85 0.825 . . . . 0.0 110.858 175.714 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 51.9 p -70.67 166.84 19.93 Favored 'General case' 0 C--O 1.267 2.006 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 177.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 62.24 -163.39 0.26 Allowed 'General case' 0 C--O 1.251 1.145 0 O-C-N 123.921 0.763 . . . . 0.0 109.383 178.061 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . 0.406 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 37.6 t0 -131.59 177.88 7.17 Favored 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 174.419 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.406 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 71.7 mt -62.68 114.98 13.84 Favored Pre-proline 0 C--N 1.27 -2.873 0 C-N-CA 124.774 1.229 . . . . 0.0 108.036 175.193 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -65.07 151.31 86.13 Favored 'Trans proline' 0 N--CA 1.447 -1.264 0 C-N-CA 122.479 2.119 . . . . 0.0 112.062 -177.929 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 48.2 mt -87.16 134.37 27.77 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.118 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.512 -174.165 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 93.5 m -107.82 148.13 29.95 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 171.165 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -129.8 144.85 51.51 Favored 'General case' 0 C--N 1.284 -2.266 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -179.824 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 4.8 p -73.26 129.43 36.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.846 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.6 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 27.6 m -54.19 130.02 15.71 Favored 'Isoleucine or valine' 0 C--O 1.243 0.741 0 O-C-N 123.848 0.717 . . . . 0.0 112.209 -174.827 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 94.8 mttt -112.54 170.08 8.43 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.533 -175.985 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.0 p -150.41 158.82 44.58 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.052 176.33 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . 0.432 HD23 ' HD2' ' A' ' 148' ' ' PRO . 1.4 tt -55.48 131.6 70.76 Favored Pre-proline 0 N--CA 1.429 -1.515 0 C-N-CA 125.59 1.556 . . . . 0.0 111.992 -178.258 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.432 ' HD2' HD23 ' A' ' 147' ' ' LEU . 37.8 Cg_endo -69.08 100.6 0.74 Allowed 'Trans proline' 0 N--CA 1.445 -1.334 0 C-N-CA 122.846 2.364 . . . . 0.0 111.806 176.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 10.2 p -64.07 140.05 20.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.935 0 CA-C-N 115.428 -0.805 . . . . 0.0 108.948 176.607 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 15.6 p -73.12 -82.38 0.05 Allowed 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -174.529 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 175.45 162.62 0.41 Allowed Pre-proline 0 CA--C 1.517 -0.311 0 C-N-CA 124.771 1.228 . . . . 0.0 107.843 179.403 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -74.05 -178.16 3.69 Favored 'Trans proline' 0 N--CA 1.446 -1.301 0 C-N-CA 121.353 1.369 . . . . 0.0 110.254 170.57 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . 0.574 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.0 OUTLIER -93.15 -41.07 10.13 Favored 'General case' 0 C--N 1.289 -2.04 0 O-C-N 122.051 -0.406 . . . . 0.0 111.413 -176.394 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . 0.574 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 42.3 m-80 -107.59 21.12 17.92 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.529 0.68 . . . . 0.0 110.259 179.736 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -148.54 -172.68 18.65 Favored Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.677 -178.274 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 58.8 pttt -145.98 164.38 32.25 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -176.621 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 63.5 mt -88.51 136.01 24.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 177.866 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.588 HG23 ' O ' ' A' ' 175' ' ' ARG . 11.5 m -84.73 -25.82 6.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.128 0.489 . . . . 0.0 110.81 -178.004 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.432 -1.338 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.761 -174.98 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . 0.438 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 95.1 m-85 . . . . . 0 N--CA 1.443 -0.812 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.467 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 36.0 m80 -136.31 169.61 17.37 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.642 -173.747 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . 0.6 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 91.7 t80 -50.11 128.94 20.16 Favored 'General case' 0 C--O 1.24 0.573 0 O-C-N 124.2 0.937 . . . . 0.0 110.571 173.468 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 101.14 -14.08 58.52 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 119.972 -1.108 . . . . 0.0 112.751 175.95 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . 0.451 HE21 ' HA ' ' A' ' 172' ' ' GLN . 0.0 OUTLIER -77.19 143.45 39.02 Favored 'General case' 0 C--O 1.251 1.143 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.154 178.272 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -124.86 101.19 6.96 Favored 'General case' 0 C--N 1.285 -2.228 0 CA-C-N 114.767 -1.106 . . . . 0.0 108.859 -179.697 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 69.2 t -81.38 96.62 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.648 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.252 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.588 ' O ' HG23 ' A' ' 158' ' ' VAL . 26.4 ttp180 -96.81 142.99 28.15 Favored 'General case' 0 N--CA 1.4 -2.936 0 CA-C-N 114.55 -1.204 . . . . 0.0 108.052 177.191 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -113.07 162.14 16.27 Favored 'General case' 0 C--N 1.278 -2.502 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -176.243 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 14.5 p -143.86 137.15 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.346 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 175.761 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 80.8 m -92.7 152.37 19.56 Favored 'General case' 0 C--N 1.257 -3.438 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.586 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 51.2 m-80 -70.6 166.16 21.26 Favored 'General case' 0 CA--C 1.493 -1.22 0 C-N-CA 120.368 -0.533 . . . . 0.0 110.176 179.546 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 12.6 t -53.61 110.31 0.56 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 124.274 0.984 . . . . 0.0 111.163 -176.082 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 116.44 -13.88 15.59 Favored Glycine 0 N--CA 1.435 -1.383 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.706 179.307 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -110.7 163.25 13.94 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 117.482 0.641 . . . . 0.0 110.876 -179.007 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 18.1 ptmt -135.39 157.26 47.34 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.692 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.8 tt -84.98 137.53 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.766 0 CA-C-O 121.609 0.718 . . . . 0.0 111.127 -179.367 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -72.2 -53.48 12.51 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.091 -177.455 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -93.9 -134.8 7.38 Favored Glycine 0 C--N 1.296 -1.674 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.087 -177.781 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -81.35 169.66 16.96 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 178.462 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -100.63 -15.76 17.65 Favored 'General case' 0 C--N 1.289 -2.048 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -176.338 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -144.19 138.32 28.01 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 -175.394 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.8 ptp -117.45 130.2 56.31 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.713 174.883 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -102.49 137.19 41.06 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.965 -177.031 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . 0.468 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 19.6 t -88.1 107.99 19.03 Favored 'General case' 0 C--O 1.253 1.274 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 174.515 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 21.7 m -102.81 -176.64 3.15 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 112.964 0.727 . . . . 0.0 112.964 -171.148 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -44.37 -39.32 4.56 Favored 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 126.148 1.779 . . . . 0.0 113.491 -176.973 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -63.54 -17.28 62.63 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.862 -177.047 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 78.57 32.91 40.23 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -174.092 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -144.11 171.92 13.62 Favored 'General case' 0 C--O 1.249 1.034 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 -179.544 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . 0.468 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 81.9 m95 -87.32 137.6 32.2 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 175.778 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 44.7 m -83.35 -3.31 57.38 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.168 0.509 . . . . 0.0 111.941 179.881 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 20.2 mmtp -128.54 162.15 27.91 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.581 179.471 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -95.65 166.09 12.0 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.935 179.86 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 9.8 tptm -65.34 116.97 35.71 Favored Pre-proline 0 CA--C 1.547 0.834 0 C-N-CA 123.337 0.655 . . . . 0.0 111.299 179.168 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_endo -90.54 177.87 2.17 Favored 'Trans proline' 0 CA--C 1.547 1.148 0 C-N-CA 122.658 2.238 . . . . 0.0 112.85 177.198 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . 0.536 ' HG3' ' OE2' ' A' ' 153' ' ' GLU . 22.1 ttmm -131.25 157.11 44.13 Favored 'General case' 0 C--N 1.318 -0.804 0 C-N-CA 124.319 1.048 . . . . 0.0 109.531 -177.238 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 87.8 m -104.06 119.22 38.47 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 173.857 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.296 -1.758 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.754 -174.693 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo . . . . . 0 CA--C 1.531 0.373 0 CA-C-O 121.665 0.611 . . . . 0.0 110.683 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.9 m -88.43 -32.96 18.04 Favored 'General case' 0 N--CA 1.436 -1.125 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 176.332 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.99 -85.72 0.4 Allowed Glycine 0 CA--C 1.453 -3.839 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 171.58 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.2 t-80 -173.75 133.75 0.6 Allowed Pre-proline 0 C--N 1.266 -3.037 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 -174.328 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.477 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 89.9 Cg_endo -87.24 -5.07 7.63 Favored 'Trans proline' 0 C--O 1.242 0.686 0 C-N-CA 122.252 1.968 . . . . 0.0 112.94 -176.364 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.402 ' HA3' HD11 ' A' ' 138' ' ' ILE . . . 126.38 -161.72 20.67 Favored Glycine 0 N--CA 1.42 -2.379 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 -178.375 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -158.48 150.52 21.53 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 177.86 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.9 t -131.53 127.04 21.43 Favored Pre-proline 0 C--N 1.301 -1.519 0 C-N-CA 119.746 -0.781 . . . . 0.0 111.994 -177.382 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -71.37 -16.6 31.06 Favored 'Trans proline' 0 CA--C 1.534 0.522 0 C-N-CA 122.541 2.161 . . . . 0.0 111.502 177.075 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 71.5 m-85 -83.45 -6.6 59.51 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.988 -177.458 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.424 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 171.89 -129.94 1.84 Allowed Glycine 0 N--CA 1.414 -2.79 0 C-N-CA 118.838 -1.648 . . . . 0.0 113.48 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.5 p -141.21 178.6 7.28 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 114.989 -0.606 . . . . 0.0 111.288 -174.804 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.458 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 36.5 p90 -148.66 155.23 40.77 Favored 'General case' 0 N--CA 1.431 -1.383 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 171.327 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -123.98 153.15 41.69 Favored 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 -178.316 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -110.74 126.67 54.82 Favored 'General case' 0 C--N 1.271 -2.814 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -179.774 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.412 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 17.2 p -121.26 134.14 55.17 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.265 -176.508 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 108.14 -45.92 1.24 Allowed Glycine 0 C--N 1.311 -0.811 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.989 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -128.3 -18.21 1.88 Allowed Glycine 0 C--N 1.311 -0.842 0 C-N-CA 120.382 -0.913 . . . . 0.0 113.009 -179.901 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 63.27 16.55 9.54 Favored 'General case' 0 N--CA 1.494 1.731 0 C-N-CA 124.388 1.075 . . . . 0.0 110.868 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.532 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.6 m -148.41 -171.86 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.211 -0.965 0 N-CA-C 106.967 -1.494 . . . . 0.0 106.967 -178.912 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.477 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 32.6 m-85 -101.47 44.66 1.0 Allowed 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 118.794 0.725 . . . . 0.0 110.648 -177.486 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.719 ' O ' HG13 ' A' ' 108' ' ' VAL . 12.2 pt-20 -86.51 -175.73 5.57 Favored 'General case' 0 C--O 1.207 -1.143 0 CA-C-N 114.837 -1.074 . . . . 0.0 111.468 177.638 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -81.05 139.65 35.59 Favored 'General case' 0 C--N 1.308 -1.226 0 O-C-N 121.686 -0.634 . . . . 0.0 111.085 178.786 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.44 4.29 80.55 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.655 -0.702 . . . . 0.0 112.529 179.122 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.719 HG13 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -94.25 142.92 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 C-N-CA 119.763 -0.775 . . . . 0.0 109.123 -179.628 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.412 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -107.67 121.23 44.26 Favored 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.708 178.441 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -86.81 89.67 8.04 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 175.575 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 94.6 t -85.71 115.13 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.638 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -177.647 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . 0.458 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 43.2 m-85 -86.63 145.77 26.59 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 116.605 -0.271 . . . . 0.0 111.116 -177.061 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.1 t -145.44 116.74 7.95 Favored 'General case' 0 N--CA 1.427 -1.602 0 CA-C-O 122.404 1.097 . . . . 0.0 109.471 178.11 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 28.4 m -72.89 164.95 25.86 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 114.901 -1.045 . . . . 0.0 111.191 -174.887 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.424 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 81.0 m-20 -75.31 171.71 13.73 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.505 177.143 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -58.49 -39.4 79.9 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 113.269 0.84 . . . . 0.0 113.269 -174.331 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.442 ' C ' HG23 ' A' ' 144' ' ' VAL . . . -75.39 12.41 7.55 Favored Glycine 0 CA--C 1.526 0.752 0 C-N-CA 120.838 -0.696 . . . . 0.0 113.063 179.733 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.473 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 83.5 m-85 -147.09 170.09 17.9 Favored 'General case' 0 N--CA 1.427 -1.582 0 C-N-CA 124.56 1.144 . . . . 0.0 108.95 -177.51 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -140.58 173.5 11.43 Favored 'General case' 0 C--N 1.266 -3.058 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 175.699 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.9 tt -99.92 137.5 38.29 Favored 'General case' 0 C--N 1.27 -2.851 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -179.713 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.413 ' HB2' ' HB2' ' A' ' 142' ' ' GLU . 0.2 OUTLIER -127.52 135.83 50.89 Favored 'General case' 0 N--CA 1.423 -1.818 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -176.978 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 130.02 179.29 15.92 Favored Glycine 0 N--CA 1.421 -2.311 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 178.397 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 61.7 mm-40 -95.88 -17.05 21.4 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 122.282 1.039 . . . . 0.0 109.078 177.102 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.6 mm -101.5 142.84 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.588 0 CA-C-N 114.184 -1.371 . . . . 0.0 108.233 179.032 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -141.14 9.61 2.11 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-O 121.278 0.561 . . . . 0.0 109.517 177.795 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . . . . . . . . . 32.8 p90 -157.55 159.57 37.28 Favored 'General case' 0 N--CA 1.427 -1.602 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.747 -172.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 56.4 mtp180 -121.16 129.85 53.44 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 172.507 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -105.43 130.61 53.48 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -178.512 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.6 t -83.1 105.35 14.01 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 117.625 -1.63 . . . . 0.0 110.206 176.643 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.432 ' OD2' HG21 ' A' ' 131' ' ' THR . 22.5 t70 -94.38 -178.59 4.63 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 178.297 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.432 HG21 ' OD2' ' A' ' 130' ' ' ASP . 11.0 t -63.28 -22.49 66.91 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 121.728 0.775 . . . . 0.0 110.38 -177.729 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -76.59 -37.12 56.99 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.769 177.735 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 139.28 -159.49 25.69 Favored Glycine 0 N--CA 1.434 -1.462 0 N-CA-C 107.982 -2.047 . . . . 0.0 107.982 -173.938 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -66.38 122.99 18.77 Favored 'General case' 0 C--O 1.248 0.979 0 CA-C-N 118.258 1.029 . . . . 0.0 110.539 177.653 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 67.7 p -80.89 163.32 23.47 Favored 'General case' 0 N--CA 1.416 -2.167 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 175.814 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 61.74 -165.21 0.23 Allowed 'General case' 0 C--N 1.323 -0.582 0 O-C-N 124.017 0.823 . . . . 0.0 110.579 175.21 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -129.57 -179.92 5.45 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 175.678 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.402 HD11 ' HA3' ' A' ' 89' ' ' GLY . 62.3 mt -66.6 122.24 81.06 Favored Pre-proline 0 C--N 1.298 -1.648 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 173.245 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.55 158.15 54.59 Favored 'Trans proline' 0 C--O 1.243 0.742 0 C-N-CA 122.67 2.247 . . . . 0.0 111.416 179.275 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 68.0 mt -84.95 131.65 33.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 CA-C-O 121.03 0.443 . . . . 0.0 111.016 -174.051 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 91.4 m -98.45 102.01 13.62 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 173.263 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.413 ' HB2' ' HB2' ' A' ' 121' ' ' LEU . 1.0 OUTLIER -87.88 154.5 20.47 Favored 'General case' 0 CA--C 1.461 -2.443 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.147 178.693 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.473 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 4.3 t -80.7 137.34 21.58 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.367 0 CA-C-N 114.82 -1.082 . . . . 0.0 108.661 -177.197 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.442 HG23 ' C ' ' A' ' 117' ' ' GLY . 3.7 m -69.83 98.34 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.153 177.407 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.461 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 49.2 mttm -88.07 131.81 34.53 Favored 'General case' 0 N--CA 1.417 -2.094 0 CA-C-N 113.754 -1.566 . . . . 0.0 109.387 -176.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.417 ' O ' ' HB2' ' A' ' 168' ' ' TYR . 61.6 m -94.16 127.43 39.99 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 107.17 -1.419 . . . . 0.0 107.17 177.026 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -50.24 138.94 19.69 Favored Pre-proline 0 N--CA 1.438 -1.071 0 N-CA-C 114.655 1.354 . . . . 0.0 114.655 -176.264 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -69.7 123.38 10.07 Favored 'Trans proline' 0 N--CA 1.444 -1.425 0 C-N-CA 122.926 2.417 . . . . 0.0 112.304 -175.522 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 21.2 t -91.84 130.75 40.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.4 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.3 m -74.93 -67.96 0.59 Allowed 'General case' 0 N--CA 1.414 -2.268 0 C-N-CA 122.764 0.425 . . . . 0.0 111.16 -177.866 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.96 150.12 0.22 Allowed Pre-proline 0 CA--C 1.509 -0.599 0 C-N-CA 124.686 1.194 . . . . 0.0 108.079 -178.934 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -77.07 174.7 12.41 Favored 'Trans proline' 0 N--CA 1.446 -1.315 0 C-N-CA 121.836 1.691 . . . . 0.0 110.811 173.947 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -61.58 -51.78 67.14 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 114.215 1.191 . . . . 0.0 114.215 -174.913 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -123.29 23.27 9.14 Favored 'General case' 0 CA--C 1.496 -1.108 0 CA-C-O 122.032 0.92 . . . . 0.0 109.891 -172.411 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . 0.456 ' HA3' ' SG ' ' A' ' 205' ' ' CYS . . . -140.47 -178.15 16.76 Favored Glycine 0 C--N 1.281 -2.516 0 CA-C-N 114.071 -1.422 . . . . 0.0 109.906 178.716 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 47.6 pttt -143.91 162.52 35.91 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 -177.146 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.407 HG21 ' H ' ' A' ' 159' ' ' SER . 46.7 mt -92.25 135.98 25.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 -179.632 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.46 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 10.8 m -71.19 -23.14 22.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-O 121.872 0.844 . . . . 0.0 111.382 -175.281 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 159' ' ' SER . . . . . 0.407 ' H ' HG21 ' A' ' 157' ' ' ILE . 20.8 t . . . . . 0 C--N 1.296 -1.724 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -178.849 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . 0.461 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 95.5 m-85 . . . . . 0 N--CA 1.444 -0.74 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 23.3 m80 -129.28 161.5 30.08 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -174.469 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . 0.411 ' HB2' HG22 ' A' ' 144' ' ' VAL . 87.1 t80 -51.9 107.74 0.22 Allowed 'General case' 0 N--CA 1.469 0.513 0 O-C-N 123.82 0.7 . . . . 0.0 110.675 174.54 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 139.05 -24.57 2.83 Favored Glycine 0 N--CA 1.433 -1.557 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -175.681 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -78.34 160.91 27.57 Favored 'General case' 0 N--CA 1.429 -1.523 0 CA-C-O 121.602 0.715 . . . . 0.0 112.897 -179.43 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . 0.414 ' HA ' ' O ' ' A' ' 190' ' ' MET . . . -148.28 118.46 7.28 Favored 'General case' 0 N--CA 1.423 -1.775 0 CA-C-N 114.376 -1.283 . . . . 0.0 109.027 179.793 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.475 HG22 ' CH2' ' A' ' 198' ' ' TRP . 46.2 t -86.18 107.41 16.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.13 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.46 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 78.9 ttt180 -99.64 140.57 33.65 Favored 'General case' 0 N--CA 1.42 -1.954 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 178.067 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -114.49 161.09 18.45 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 -176.468 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 7.7 p -140.9 128.06 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.812 0 CA-C-N 115.22 -0.9 . . . . 0.0 109.931 175.948 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 71.7 m -89.11 152.24 21.76 Favored 'General case' 0 C--N 1.276 -2.607 0 CA-C-N 114.915 -1.038 . . . . 0.0 110.138 -179.549 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -68.9 -179.92 1.62 Allowed 'General case' 0 C--O 1.239 0.532 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.714 178.663 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 8.8 p -47.02 -39.67 13.14 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 115.945 1.832 . . . . 0.0 115.945 -172.097 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -109.51 15.5 32.25 Favored Glycine 0 C--N 1.286 -2.212 0 C-N-CA 120.328 -0.939 . . . . 0.0 113.239 -176.626 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -116.12 157.97 23.94 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 117.974 0.887 . . . . 0.0 111.571 -178.24 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -126.93 158.05 37.82 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 106.557 -1.645 . . . . 0.0 106.557 175.763 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.419 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.5 tt -91.28 139.45 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.23 0 C-N-CA 119.167 -1.013 . . . . 0.0 110.806 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -50.04 -58.95 4.42 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 126.08 1.752 . . . . 0.0 113.106 -177.657 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -128.64 -103.88 1.15 Allowed Glycine 0 CA--C 1.493 -1.331 0 C-N-CA 120.247 -0.978 . . . . 0.0 111.276 -178.394 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -80.52 159.12 25.62 Favored 'General case' 0 CA--C 1.486 -1.497 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 177.815 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . 0.419 ' HA ' HD13 ' A' ' 184' ' ' ILE . 15.0 pt-20 -103.45 4.45 36.08 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.428 -0.909 . . . . 0.0 109.507 178.34 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -148.44 146.61 28.5 Favored 'General case' 0 N--CA 1.426 -1.654 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.018 -175.715 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.414 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 12.3 ptp -124.44 121.21 34.25 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.11 174.279 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 46.0 t-80 -98.77 145.41 26.97 Favored 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.069 -176.661 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 12.8 m -62.01 148.52 43.67 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 177.133 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 31.5 m -127.9 159.95 33.34 Favored 'General case' 0 N--CA 1.423 -1.813 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 173.074 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -69.97 -1.46 9.77 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -172.65 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -75.84 -15.91 60.16 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.039 0.447 . . . . 0.0 109.901 175.458 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 88.12 22.19 42.62 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -172.454 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -135.81 169.38 17.66 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -179.917 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . 0.475 ' CH2' HG22 ' A' ' 174' ' ' VAL . 78.1 m95 -87.13 151.42 23.22 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.818 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 39.6 t -71.1 -50.1 37.28 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 121.531 0.682 . . . . 0.0 109.186 177.739 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 25.4 mmtp -88.49 148.99 23.88 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-O 121.417 0.627 . . . . 0.0 111.623 -179.798 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -89.11 150.65 22.63 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.813 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 27.3 ttpp -58.73 112.95 5.69 Favored Pre-proline 0 C--O 1.237 0.4 0 N-CA-C 114.443 1.275 . . . . 0.0 114.443 -173.306 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -72.01 171.38 16.8 Favored 'Trans proline' 0 N--CA 1.451 -1.014 0 C-N-CA 123.395 2.73 . . . . 0.0 110.631 175.322 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.4 mttp -123.36 167.06 14.29 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -177.753 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.456 ' SG ' ' HA3' ' A' ' 155' ' ' GLY . 94.5 m -106.59 104.65 14.39 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 172.195 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 11.4 m . . . . . 0 C--N 1.296 -1.751 0 CA-C-N 114.782 -1.099 . . . . 0.0 112.327 -171.924 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo . . . . . 0 CA--C 1.536 0.611 0 CA-C-O 121.783 0.66 . . . . 0.0 111.082 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.5 m -82.5 -32.86 28.57 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.309 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.53 -85.86 0.4 Allowed Glycine 0 CA--C 1.458 -3.508 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 173.073 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.2 t60 179.42 130.43 0.23 Allowed Pre-proline 0 C--N 1.271 -2.818 0 N-CA-C 104.153 -2.536 . . . . 0.0 104.153 -176.056 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.4 -33.07 5.81 Favored 'Trans proline' 0 N--CA 1.474 0.363 0 C-N-CA 121.625 1.55 . . . . 0.0 112.744 -175.423 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 134.52 177.26 14.82 Favored Glycine 0 N--CA 1.419 -2.445 0 N-CA-C 107.021 -2.432 . . . . 0.0 107.021 -176.017 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -134.91 162.96 30.95 Favored 'General case' 0 C--N 1.287 -2.14 0 CA-C-N 118.36 1.08 . . . . 0.0 109.433 179.848 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.7 t -119.35 131.44 24.37 Favored Pre-proline 0 N--CA 1.416 -2.153 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.183 -178.516 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.02 -11.69 17.85 Favored 'Trans proline' 0 N--CA 1.459 -0.509 0 C-N-CA 122.563 2.176 . . . . 0.0 111.616 177.872 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -88.93 -2.89 58.81 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.216 -177.814 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.445 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 175.57 -128.02 1.34 Allowed Glycine 0 N--CA 1.414 -2.793 0 C-N-CA 118.961 -1.59 . . . . 0.0 113.63 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.1 p -138.56 170.5 15.89 Favored 'General case' 0 C--N 1.291 -1.96 0 CA-C-N 114.841 -0.68 . . . . 0.0 110.972 -174.641 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.2 p90 -140.74 145.65 36.71 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 171.023 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.7 m -120.32 161.23 21.49 Favored 'General case' 0 C--N 1.271 -2.843 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -176.894 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.5 mt -119.56 120.97 38.29 Favored 'General case' 0 C--N 1.28 -2.448 0 CA-C-O 121.028 0.442 . . . . 0.0 109.867 -177.443 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.468 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 24.0 p -109.99 129.02 55.73 Favored 'General case' 0 C--N 1.285 -2.218 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.52 -175.383 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 113.38 -54.91 0.54 Allowed Glycine 0 N--CA 1.432 -1.593 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.073 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -121.24 -12.63 5.67 Favored Glycine 0 C--N 1.305 -1.19 0 C-N-CA 119.965 -1.112 . . . . 0.0 113.335 -179.514 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 47.7 m-80 61.26 18.55 9.28 Favored 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 123.485 0.714 . . . . 0.0 112.22 -178.168 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.557 ' O ' HG13 ' A' ' 108' ' ' VAL . 18.7 m -151.32 -174.48 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.206 -1.21 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -175.806 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -99.71 46.05 0.98 Allowed 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 118.732 0.696 . . . . 0.0 110.619 -177.339 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.738 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.1 pt-20 -86.91 179.79 6.65 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.632 177.019 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 41.2 m-85 -76.12 137.28 40.01 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 122.039 -0.413 . . . . 0.0 111.301 177.089 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.98 -7.96 70.11 Favored Glycine 0 N--CA 1.441 -0.969 0 CA-C-N 115.603 -0.726 . . . . 0.0 113.048 178.003 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.738 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.9 p -87.14 146.8 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.881 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 -175.163 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.468 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.9 mtpt -110.25 125.84 53.53 Favored 'General case' 0 N--CA 1.419 -2.011 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.248 178.129 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -88.42 95.99 10.42 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 175.442 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 77.5 t -90.08 113.65 26.55 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.901 0 C-N-CA 123.988 0.915 . . . . 0.0 108.819 -177.451 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -88.48 134.6 33.8 Favored 'General case' 0 C--N 1.285 -2.228 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.992 -178.948 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.1 t -142.82 124.04 14.6 Favored 'General case' 0 N--CA 1.428 -1.561 0 CA-C-O 122.067 0.937 . . . . 0.0 109.399 179.51 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 78.0 m -75.35 166.46 23.57 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.949 -174.064 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.445 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 85.2 m-20 -85.46 -177.03 6.34 Favored 'General case' 0 C--O 1.216 -0.698 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.295 178.393 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -42.93 -54.44 4.21 Favored 'General case' 0 C--N 1.311 -1.072 0 C-N-CA 126.163 1.785 . . . . 0.0 114.527 -177.435 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -92.41 17.34 57.64 Favored Glycine 0 C--N 1.299 -1.495 0 C-N-CA 119.497 -1.335 . . . . 0.0 112.859 -175.111 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.598 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 77.8 m-85 -133.95 147.32 51.04 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.182 -177.304 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . 0.435 ' OE1' ' HB3' ' A' ' 142' ' ' GLU . 0.0 OUTLIER -136.3 160.07 39.84 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -178.849 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 10.4 tp -83.7 141.44 31.47 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 118.915 -1.114 . . . . 0.0 109.947 -176.309 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.05 122.91 43.21 Favored 'General case' 0 N--CA 1.411 -2.381 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 179.177 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.66 -160.42 13.7 Favored Glycine 0 C--N 1.293 -1.855 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.77 -176.568 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -105.9 -48.31 3.65 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.129 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.5 mm -73.4 129.51 36.16 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.132 -173.458 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -130.0 12.99 5.73 Favored 'General case' 0 C--O 1.213 -0.838 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 177.516 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.462 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 34.0 p90 -149.67 161.74 41.59 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.85 -176.48 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 44.3 mtp180 -127.46 131.78 50.13 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 172.069 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -108.06 131.98 54.03 Favored 'General case' 0 C--N 1.283 -2.301 0 C-N-CA 119.202 -0.999 . . . . 0.0 109.5 -178.405 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 21.6 t -81.4 99.27 8.62 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.829 -1.149 . . . . 0.0 109.155 176.533 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.423 ' OD2' HG21 ' A' ' 131' ' ' THR . 8.6 t70 -96.35 -167.13 1.52 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 178.447 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.423 HG21 ' OD2' ' A' ' 130' ' ' ASP . 9.0 t -59.37 -28.46 66.9 Favored 'General case' 0 C--N 1.31 -1.121 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -174.733 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -85.95 -23.65 26.85 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.549 0.69 . . . . 0.0 110.213 179.596 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 128.96 -153.96 20.01 Favored Glycine 0 N--CA 1.421 -2.362 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -175.646 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -64.87 113.38 3.79 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -179.878 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 65.0 p -73.09 172.48 10.97 Favored 'General case' 0 C--O 1.27 2.154 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 176.188 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 63.6 m-20 59.68 -156.74 0.34 Allowed 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 175.984 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -141.15 -177.51 5.15 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 173.092 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 57.0 mt -65.73 116.88 36.17 Favored Pre-proline 0 C--N 1.273 -2.728 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 174.806 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -68.61 160.83 47.77 Favored 'Trans proline' 0 C--O 1.246 0.91 0 C-N-CA 122.418 2.079 . . . . 0.0 112.308 -176.01 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 48.7 mm -90.67 131.52 37.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.364 -176.382 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.598 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 36.6 t -114.08 137.62 51.49 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 105.752 -1.944 . . . . 0.0 105.752 175.697 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.435 ' HB3' ' OE1' ' A' ' 119' ' ' GLN . 9.7 tp10 -119.1 157.59 27.56 Favored 'General case' 0 C--N 1.277 -2.557 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.473 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 24.0 t -79.84 138.54 19.72 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.073 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 -178.908 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 70.6 t -60.01 122.01 9.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 124.305 1.003 . . . . 0.0 108.399 179.331 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 59.9 mttm -120.33 156.06 32.07 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.899 -178.815 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 80.1 m -108.65 -171.54 1.87 Allowed 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 123.825 0.85 . . . . 0.0 110.677 -179.827 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . 0.474 HD12 ' HD2' ' A' ' 148' ' ' PRO . 1.5 tp -95.56 134.34 24.39 Favored Pre-proline 0 N--CA 1.421 -1.913 0 O-C-N 122.027 -0.421 . . . . 0.0 110.023 -177.181 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.474 ' HD2' HD12 ' A' ' 147' ' ' LEU . 12.7 Cg_endo -58.2 121.51 10.12 Favored 'Trans proline' 0 CA--C 1.535 0.543 0 C-N-CA 123.23 2.62 . . . . 0.0 111.563 177.333 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 28.7 t -85.94 143.65 11.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 -177.975 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 19.5 p -77.98 -83.12 0.08 Allowed 'General case' 0 N--CA 1.42 -1.974 0 CA-C-N 116.806 -0.179 . . . . 0.0 111.308 175.436 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.96 156.56 0.21 Allowed Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 125.143 1.377 . . . . 0.0 107.757 179.604 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -69.79 162.93 40.18 Favored 'Trans proline' 0 C--N 1.353 0.816 0 C-N-CA 121.723 1.615 . . . . 0.0 110.896 172.915 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -62.3 -50.6 71.02 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -174.926 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 55.4 m-80 -113.76 38.17 3.04 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 -177.96 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -154.06 -164.41 12.75 Favored Glycine 0 N--CA 1.425 -2.051 0 CA-C-N 115.026 -0.988 . . . . 0.0 111.189 178.353 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -156.0 173.24 17.09 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -178.601 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 49.7 mt -88.98 134.73 27.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 CA-C-O 121.148 0.499 . . . . 0.0 110.499 -179.251 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 55.1 t -73.98 -43.38 52.27 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 C-N-CA 124.149 0.98 . . . . 0.0 109.455 178.779 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 2.1 m . . . . . 0 C--N 1.29 -1.994 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -179.86 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 . . . . . 0 CA--C 1.49 -1.355 0 CA-C-O 121.074 0.464 . . . . 0.0 111.681 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 20.9 p-80 -96.34 159.52 14.9 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.623 -179.135 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 50.3 t80 -50.78 123.29 8.73 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 125.311 1.444 . . . . 0.0 109.59 176.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.62 -10.93 21.39 Favored Glycine 0 N--CA 1.425 -2.092 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.621 -178.068 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.0 mm-40 -89.65 143.64 26.64 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-N 117.805 0.802 . . . . 0.0 111.195 179.585 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -111.86 126.44 55.09 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.468 -1.242 . . . . 0.0 107.826 177.848 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.507 HG11 ' CG ' ' A' ' 190' ' ' MET . 0.3 OUTLIER -117.76 118.5 58.57 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.246 0 C-N-CA 119.249 -0.981 . . . . 0.0 108.384 178.73 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 43.9 ttm180 -104.54 157.52 17.12 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 -179.275 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -129.12 154.35 46.79 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -176.031 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.5 p -135.82 152.13 30.47 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.158 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.581 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 74.8 m -105.48 146.29 29.74 Favored 'General case' 0 C--N 1.274 -2.716 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.871 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -65.88 172.93 3.23 Favored 'General case' 0 CA--C 1.503 -0.832 0 O-C-N 123.732 0.645 . . . . 0.0 110.473 -177.441 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 6.0 p -53.75 104.9 0.11 Allowed 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 124.317 1.047 . . . . 0.0 112.939 -177.764 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.18 -3.64 31.47 Favored Glycine 0 N--CA 1.433 -1.508 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.457 177.889 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -112.64 150.27 31.68 Favored 'General case' 0 N--CA 1.42 -1.946 0 O-C-N 122.162 -0.611 . . . . 0.0 110.397 179.89 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 65.0 pttt -123.36 160.3 27.06 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 1.7 tp -76.18 142.2 14.72 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -179.787 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -88.5 -69.1 0.72 Allowed 'General case' 0 C--N 1.287 -2.114 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -77.8 -128.22 0.42 Allowed Glycine 0 N--CA 1.437 -1.251 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.717 176.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . 0.421 ' O ' ' HB3' ' A' ' 203' ' ' PRO . 5.6 t70 -98.28 162.04 13.39 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.281 -1.378 . . . . 0.0 107.281 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -99.78 1.1 42.84 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 119.513 1.051 . . . . 0.0 112.23 -170.618 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -152.01 153.84 34.83 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 121.398 0.618 . . . . 0.0 112.475 -177.154 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.507 ' CG ' HG11 ' A' ' 174' ' ' VAL . 16.7 ptp -132.72 148.51 52.33 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.289 178.659 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 47.6 m80 -115.17 145.44 42.39 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.604 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 42.8 t -81.58 102.25 10.51 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 177.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 51.9 m -121.66 158.0 29.63 Favored 'General case' 0 N--CA 1.425 -1.688 0 N-CA-C 114.096 1.147 . . . . 0.0 114.096 -168.607 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 21.98 -76.87 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 129.483 3.113 . . . . 0.0 116.973 174.389 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -62.76 -21.2 65.66 Favored 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 125.014 1.325 . . . . 0.0 113.58 -172.059 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 101.73 20.72 12.38 Favored Glycine 0 N--CA 1.435 -1.42 0 C-N-CA 119.62 -1.276 . . . . 0.0 110.913 -175.819 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 21.9 p90 -146.67 173.18 12.58 Favored 'General case' 0 N--CA 1.426 -1.649 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 175.068 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.3 m95 -69.18 138.44 54.1 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 123.651 0.594 . . . . 0.0 111.62 -175.366 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 13.0 p -68.31 -33.4 74.26 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.656 178.841 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 59.5 mmtt -107.23 149.57 27.59 Favored 'General case' 0 N--CA 1.432 -1.352 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.617 -179.765 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -79.84 163.89 24.03 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 114.463 -1.244 . . . . 0.0 109.018 176.467 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 9.6 mtpm? -64.89 128.52 93.78 Favored Pre-proline 0 CA--C 1.502 -0.867 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.964 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . 0.421 ' HB3' ' O ' ' A' ' 187' ' ' ASP . 95.3 Cg_endo -78.78 166.95 22.97 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 C-N-CA 122.247 1.964 . . . . 0.0 111.975 179.55 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.2 tttp -122.44 156.74 33.42 Favored 'General case' 0 N--CA 1.414 -2.268 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 -179.493 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 92.3 m -118.07 116.27 26.53 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 176.796 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 27.4 m . . . . . 0 C--N 1.301 -1.542 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.546 -176.571 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo . . . . . 0 CA--C 1.542 0.915 0 CA-C-O 120.948 0.312 . . . . 0.0 112.113 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.8 m -80.33 -31.9 37.97 Favored 'General case' 0 CA--C 1.502 -0.898 0 CA-C-O 122.262 1.03 . . . . 0.0 108.338 177.787 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.42 -87.97 0.46 Allowed Glycine 1 N--CA 1.395 -4.064 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 173.444 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 26.7 t-80 -176.47 133.22 0.4 Allowed Pre-proline 0 C--N 1.262 -3.213 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 -175.273 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.4 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 85.7 Cg_endo -81.91 1.04 9.49 Favored 'Trans proline' 0 N--CA 1.475 0.422 0 C-N-CA 122.58 2.187 . . . . 0.0 113.464 -174.819 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 100.72 -169.24 21.06 Favored Glycine 0 C--N 1.291 -1.96 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 -175.394 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -151.06 178.37 9.26 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.521 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.9 t -142.99 139.09 16.43 Favored Pre-proline 0 N--CA 1.427 -1.596 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.813 -176.984 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.97 -11.87 21.55 Favored 'Trans proline' 0 CA--C 1.534 0.5 0 C-N-CA 122.635 2.223 . . . . 0.0 111.349 176.227 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -89.63 -4.15 57.93 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.228 -177.021 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.56 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 173.83 -123.73 0.99 Allowed Glycine 0 N--CA 1.419 -2.444 0 C-N-CA 119.823 -1.18 . . . . 0.0 112.371 179.766 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.1 t -165.22 -163.25 0.67 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.28 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.433 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 54.4 p90 -145.72 175.07 10.66 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 178.593 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.8 m -136.01 163.43 30.32 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 176.645 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 23.8 mt -118.94 120.89 38.61 Favored 'General case' 0 C--N 1.285 -2.22 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -178.885 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.401 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 26.1 p -114.13 128.75 56.52 Favored 'General case' 0 C--N 1.285 -2.21 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -175.411 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 97.36 19.67 24.93 Favored Glycine 0 C--N 1.299 -1.48 0 C-N-CA 119.849 -1.167 . . . . 0.0 111.149 -179.523 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.52 -32.16 0.15 Allowed Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 118.911 -1.614 . . . . 0.0 114.417 179.445 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 65.93 19.45 11.26 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 123.205 0.602 . . . . 0.0 111.174 -176.242 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.469 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.3 m -149.23 -177.86 0.47 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.084 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -175.552 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 38.1 m-85 -103.88 47.8 0.87 Allowed 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 118.726 0.694 . . . . 0.0 110.171 -179.772 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.706 ' O ' HG13 ' A' ' 108' ' ' VAL . 10.7 pt-20 -83.63 177.8 8.24 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.311 -1.313 . . . . 0.0 111.554 179.226 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 45.5 m-85 -77.67 130.42 36.8 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.645 174.064 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 91.23 15.72 55.09 Favored Glycine 0 N--CA 1.434 -1.491 0 C-N-CA 120.203 -0.999 . . . . 0.0 112.377 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.706 HG13 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -106.38 149.5 9.77 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 176.06 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.401 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.2 mtpt -113.95 125.69 54.31 Favored 'General case' 0 N--CA 1.418 -2.048 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.485 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -90.01 89.27 7.63 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.225 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 28.5 m -84.91 112.28 21.74 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.981 0 CA-C-O 122.164 0.983 . . . . 0.0 109.565 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . 0.433 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 33.8 m-85 -78.92 142.21 36.94 Favored 'General case' 0 C--N 1.269 -2.9 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.123 -179.569 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.9 t -138.84 122.58 17.57 Favored 'General case' 0 N--CA 1.411 -2.422 0 CA-C-N 115.135 -0.938 . . . . 0.0 108.822 -179.639 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 88.0 m -73.68 160.8 31.04 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 115.487 -0.778 . . . . 0.0 112.0 -178.383 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.56 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 81.2 m-20 -76.44 -176.53 3.72 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.293 179.703 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -52.46 -48.52 65.8 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 124.655 1.182 . . . . 0.0 113.491 -177.28 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.32 10.53 70.98 Favored Glycine 0 C--N 1.3 -1.437 0 C-N-CA 119.786 -1.197 . . . . 0.0 113.306 -177.971 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.53 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 93.6 m-85 -127.62 161.02 29.85 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 122.166 -0.608 . . . . 0.0 111.419 -175.753 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.49 150.43 43.75 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.026 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.21 133.03 39.01 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 -179.681 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.03 127.54 55.92 Favored 'General case' 0 N--CA 1.414 -2.241 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.143 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.2 -163.27 12.62 Favored Glycine 0 C--N 1.296 -1.666 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.811 -179.804 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -108.96 -30.05 8.29 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 178.632 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.7 mm -88.16 127.06 41.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.513 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -129.56 9.84 5.57 Favored 'General case' 0 C--O 1.202 -1.44 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.034 176.777 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 22.1 p90 -139.08 165.52 26.94 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.397 -171.916 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.508 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 52.2 mtp180 -128.57 126.82 41.11 Favored 'General case' 0 C--O 1.204 -1.311 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 171.395 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -98.17 133.11 43.05 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.542 -0.863 . . . . 0.0 109.947 179.187 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 36.2 t -89.86 110.62 21.54 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.31 174.555 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.45 ' CG ' ' H ' ' A' ' 131' ' ' THR . 36.1 t70 -113.44 -167.21 1.17 Allowed 'General case' 0 C--N 1.289 -2.033 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 175.485 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.45 ' H ' ' CG ' ' A' ' 130' ' ' ASP . 15.3 t -67.09 -20.53 65.81 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.319 1.057 . . . . 0.0 109.69 -179.318 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -70.22 -23.73 62.98 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 114.279 -1.328 . . . . 0.0 109.233 175.001 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 105.9 -154.87 16.93 Favored Glycine 0 N--CA 1.42 -2.39 0 N-CA-C 107.169 -2.373 . . . . 0.0 107.169 -173.313 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 96.1 m95 -65.33 99.18 0.38 Allowed 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 117.666 0.733 . . . . 0.0 109.83 172.776 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.6 p -58.64 -67.58 0.35 Allowed 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 124.74 1.216 . . . . 0.0 112.839 -173.009 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . 0.508 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 3.0 m-20 -70.37 167.13 18.81 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.33 178.868 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . 0.41 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 21.9 t0 -98.64 175.55 5.95 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.537 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.41 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 68.7 mt -63.92 121.83 73.52 Favored Pre-proline 0 C--N 1.273 -2.741 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 175.079 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -63.73 174.35 3.8 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 122.482 2.121 . . . . 0.0 112.791 -179.102 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 65.8 mt -98.9 140.73 17.81 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -175.307 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.53 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 42.4 t -128.92 119.5 24.48 Favored 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 -179.784 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -103.14 140.9 36.74 Favored 'General case' 0 C--N 1.279 -2.476 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 -175.901 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.413 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 10.8 p -70.9 138.74 21.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 173.932 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 92.7 t -59.61 114.66 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.73 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -176.371 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 92.4 mttt -113.73 144.55 42.76 Favored 'General case' 0 N--CA 1.426 -1.67 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.274 -177.787 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 82.9 m -112.03 160.95 17.0 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 114.732 -1.122 . . . . 0.0 109.165 179.778 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 59.7 mt -64.82 138.19 97.39 Favored Pre-proline 0 C--N 1.318 -0.781 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -179.183 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -63.48 127.47 19.97 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.821 2.347 . . . . 0.0 111.103 179.376 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.4 t -85.21 142.42 13.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -179.788 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.9 p -67.45 -82.98 0.03 OUTLIER 'General case' 0 N--CA 1.425 -1.704 0 O-C-N 123.604 0.565 . . . . 0.0 111.223 177.412 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 168.41 159.52 0.16 Allowed Pre-proline 0 CA--C 1.513 -0.474 0 C-N-CA 125.554 1.542 . . . . 0.0 106.99 179.716 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -82.88 169.11 13.46 Favored 'Trans proline' 0 N--CA 1.448 -1.196 0 C-N-CA 121.643 1.562 . . . . 0.0 111.352 173.688 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -60.54 -57.02 14.5 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -176.827 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -112.02 25.19 11.82 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.12 0.962 . . . . 0.0 109.798 -172.908 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -146.02 -172.03 16.01 Favored Glycine 0 C--N 1.284 -2.324 0 CA-C-N 114.421 -1.263 . . . . 0.0 110.984 179.04 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.0 pttm -149.79 169.12 21.83 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 178.504 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.546 HG12 ' CE2' ' A' ' 176' ' ' PHE . 62.8 mt -88.2 130.58 37.54 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.879 179.453 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.479 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 12.9 m -87.15 -29.04 5.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.324 0.583 . . . . 0.0 109.628 179.8 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 159' ' ' SER . . . . . 0.414 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 25.2 m . . . . . 0 C--N 1.308 -1.233 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.631 -174.812 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 . . . . . 0 CA--C 1.476 -1.896 0 CA-C-O 121.194 0.521 . . . . 0.0 109.876 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 56.7 p-80 -130.44 167.93 17.81 Favored 'General case' 0 C--N 1.281 -2.395 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.038 -174.496 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 79.8 t80 -47.69 132.12 14.34 Favored 'General case' 0 CA--C 1.506 -0.73 0 O-C-N 124.418 1.074 . . . . 0.0 110.612 178.755 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 108.67 -26.11 17.11 Favored Glycine 0 N--CA 1.418 -2.55 0 C-N-CA 120.378 -0.915 . . . . 0.0 111.781 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -76.83 134.05 39.17 Favored 'General case' 0 N--CA 1.414 -2.247 0 CA-C-O 121.664 0.745 . . . . 0.0 110.524 -179.061 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -110.57 90.83 3.44 Favored 'General case' 0 C--N 1.269 -2.893 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 173.959 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.414 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 14.6 p -73.15 105.1 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.9 0 CA-C-O 121.706 0.765 . . . . 0.0 109.257 -176.127 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.506 ' HD2' ' OE2' ' A' ' 188' ' ' GLU . 12.4 ttp180 -97.11 152.73 18.49 Favored 'General case' 0 N--CA 1.411 -2.387 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.387 -175.503 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.546 ' CE2' HG12 ' A' ' 157' ' ' ILE . 81.7 m-85 -121.2 153.22 37.88 Favored 'General case' 0 N--CA 1.428 -1.563 0 C-N-CA 124.173 0.989 . . . . 0.0 109.151 -177.462 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.445 ' HB ' ' CG1' ' A' ' 158' ' ' VAL . 10.3 p -135.7 149.59 28.24 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . 0.421 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 76.6 m -90.06 141.07 29.04 Favored 'General case' 0 C--N 1.268 -2.959 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.464 178.314 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -70.91 -52.6 19.06 Favored 'General case' 0 CA--C 1.477 -1.855 0 CA-C-N 115.298 -0.864 . . . . 0.0 112.338 -175.347 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 180' ' ' SER . . . . . 0.431 ' HB3' ' CE2' ' A' ' 182' ' ' TYR . 34.3 t -116.01 -158.88 0.7 Allowed 'General case' 0 C--N 1.26 -3.287 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -177.183 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -71.77 51.03 1.18 Allowed Glycine 0 C--O 1.229 -0.203 0 O-C-N 123.473 0.483 . . . . 0.0 113.294 -177.975 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . 0.431 ' CE2' ' HB3' ' A' ' 180' ' ' SER . 90.5 m-85 -103.51 170.64 7.83 Favored 'General case' 0 C--N 1.292 -1.913 0 C-N-CA 123.137 0.575 . . . . 0.0 109.539 177.463 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . 0.451 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 39.4 pttt -126.5 150.92 48.46 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 176.374 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.5 tp -65.31 142.68 16.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 CA-C-O 121.427 0.632 . . . . 0.0 110.025 176.096 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -67.23 -58.41 4.89 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.915 -178.362 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -120.96 -111.03 2.22 Favored Glycine 0 N--CA 1.42 -2.396 0 N-CA-C 110.589 -1.005 . . . . 0.0 110.589 -178.941 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -88.91 144.9 25.88 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.225 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . 0.506 ' OE2' ' HD2' ' A' ' 175' ' ' ARG . 12.8 pt-20 -87.62 1.27 54.13 Favored 'General case' 0 C--O 1.205 -1.282 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.986 -176.045 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -145.16 151.18 38.05 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 121.191 0.52 . . . . 0.0 111.312 -179.186 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.408 ' CG ' ' HE1' ' A' ' 176' ' ' PHE . 0.0 OUTLIER -123.4 140.82 52.62 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 175.966 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 26.3 m80 -100.42 140.39 34.74 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.835 -0.346 . . . . 0.0 110.313 176.899 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 52.6 t -86.56 104.41 15.98 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 174.301 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 18.0 m -74.94 156.88 35.86 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-N 115.225 -0.898 . . . . 0.0 111.095 -177.524 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -68.63 1.84 2.89 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.794 1.238 . . . . 0.0 114.163 -174.371 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . 0.417 ' HB3' ' CE2' ' A' ' 197' ' ' PHE . 36.9 t70 -102.1 -17.37 16.06 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 121.33 0.586 . . . . 0.0 109.69 175.609 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 101.34 53.75 0.99 Allowed Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.935 179.912 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . 0.417 ' CE2' ' HB3' ' A' ' 195' ' ' ASP . 52.1 p90 -154.76 156.95 37.25 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.918 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 78.8 m95 -83.96 130.5 34.89 Favored 'General case' 0 N--CA 1.431 -1.394 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 175.39 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 7.7 m -63.8 -29.21 70.44 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.53 -179.81 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . 0.433 ' HD2' ' H ' ' A' ' 201' ' ' GLU . 4.0 mmmt -117.89 152.79 34.69 Favored 'General case' 0 N--CA 1.411 -2.395 0 O-C-N 121.943 -0.473 . . . . 0.0 110.882 -179.516 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . 0.433 ' H ' ' HD2' ' A' ' 200' ' ' LYS . 12.8 pt-20 -71.28 165.63 23.28 Favored 'General case' 0 C--O 1.252 1.205 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 174.875 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . 0.403 ' HB3' ' HE2' ' A' ' 202' ' ' LYS . 41.6 mtpt -61.32 125.3 83.83 Favored Pre-proline 0 N--CA 1.447 -0.602 0 C-N-CA 120.341 -0.544 . . . . 0.0 110.136 174.919 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -88.84 175.04 3.74 Favored 'Trans proline' 0 N--CA 1.419 -2.854 0 C-N-CA 121.791 1.661 . . . . 0.0 110.001 172.932 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.6 mttp -137.91 177.22 8.04 Favored 'General case' 0 C--N 1.284 -2.276 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 -177.073 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.451 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 68.1 m -118.76 104.27 10.43 Favored 'General case' 0 C--N 1.283 -2.324 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 171.776 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.9 m . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 114.306 -1.316 . . . . 0.0 111.337 -172.27 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo . . . . . 0 CA--C 1.536 0.595 0 CA-C-O 120.926 0.303 . . . . 0.0 112.269 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . 0.406 ' HB3' ' CD1' ' A' ' 134' ' ' TRP . 4.5 m -93.16 -24.56 18.19 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.242 0.544 . . . . 0.0 111.558 175.003 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.94 -93.55 0.59 Allowed Glycine 0 CA--C 1.46 -3.345 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 173.196 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 -170.23 132.77 1.02 Allowed Pre-proline 0 C--N 1.262 -3.201 0 N-CA-C 104.02 -2.585 . . . . 0.0 104.02 -175.478 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.478 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 87.9 Cg_endo -81.32 -19.81 7.58 Favored 'Trans proline' 0 C--N 1.332 -0.341 0 C-N-CA 121.637 1.558 . . . . 0.0 113.553 -173.189 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 130.1 -165.39 22.47 Favored Glycine 0 N--CA 1.426 -2.013 0 N-CA-C 110.186 -1.166 . . . . 0.0 110.186 -177.358 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -151.04 151.34 31.89 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 -178.659 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.1 t -131.07 127.5 22.0 Favored Pre-proline 0 C--N 1.303 -1.456 0 C-N-CA 120.338 -0.545 . . . . 0.0 110.553 179.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.46 -18.37 26.08 Favored 'Trans proline' 0 C--O 1.237 0.445 0 C-N-CA 122.523 2.149 . . . . 0.0 111.554 178.843 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.492 ' CB ' ' HB2' ' A' ' 141' ' ' CYS . 59.7 m-85 -78.92 -17.26 55.83 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.192 -177.461 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.462 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -168.97 -126.76 0.87 Allowed Glycine 0 CA--C 1.477 -2.284 0 C-N-CA 120.212 -0.994 . . . . 0.0 111.167 -178.933 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.1 t -160.07 -169.87 2.65 Favored 'General case' 0 C--N 1.284 -2.243 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.651 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.421 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 37.8 p90 -147.11 165.46 29.89 Favored 'General case' 0 N--CA 1.432 -1.331 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 177.582 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.7 m -132.81 161.75 33.32 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 177.879 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 26.6 mt -109.93 137.54 47.57 Favored 'General case' 0 C--N 1.271 -2.837 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.47 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.521 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 11.1 p -134.11 141.6 47.2 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -173.979 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 100.33 -42.37 1.97 Allowed Glycine 0 C--N 1.303 -1.304 0 N-CA-C 108.148 -1.981 . . . . 0.0 108.148 -173.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.449 ' HA3' ' OE2' ' A' ' 105' ' ' GLU . . . -139.63 -143.09 4.33 Favored Glycine 0 N--CA 1.406 -3.358 0 N-CA-C 108.029 -2.028 . . . . 0.0 108.029 176.085 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -151.61 16.22 0.69 Allowed 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.41 1.1 . . . . 0.0 109.829 -178.51 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.543 ' O ' HG13 ' A' ' 108' ' ' VAL . 28.7 m -147.5 -170.57 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 -175.511 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.478 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 30.5 m-85 -96.17 39.11 1.16 Allowed 'General case' 0 C--N 1.307 -1.255 0 CA-C-O 121.99 0.9 . . . . 0.0 110.022 -177.832 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.7 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.2 pt-20 -71.83 178.03 3.89 Favored 'General case' 0 C--O 1.202 -1.44 0 C-N-CA 127.197 2.199 . . . . 0.0 111.888 179.009 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . 0.532 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 27.6 m-85 -79.32 135.9 36.86 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-O 121.008 0.432 . . . . 0.0 110.971 176.49 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.24 3.24 82.34 Favored Glycine 0 N--CA 1.442 -0.91 0 C-N-CA 121.001 -0.618 . . . . 0.0 112.349 178.804 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.7 HG12 ' O ' ' A' ' 105' ' ' GLU . 8.5 p -92.75 142.81 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.549 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.521 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -107.52 126.82 53.0 Favored 'General case' 0 C--N 1.28 -2.437 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 177.682 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -89.32 87.98 7.32 Favored 'General case' 0 C--N 1.28 -2.436 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 174.896 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.442 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 30.0 m -84.97 116.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.383 0 CA-C-O 121.989 0.899 . . . . 0.0 109.403 -179.423 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . 0.421 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 33.9 m-85 -85.73 142.59 28.89 Favored 'General case' 0 C--N 1.27 -2.877 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.42 179.754 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -138.0 124.61 20.9 Favored 'General case' 0 N--CA 1.405 -2.725 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -178.92 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.7 m -74.08 155.61 38.3 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 115.3 -0.863 . . . . 0.0 112.262 -175.498 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.462 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 72.2 m-20 -68.09 173.81 4.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.175 178.482 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -50.75 -48.21 59.17 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 123.78 0.832 . . . . 0.0 112.547 -177.922 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.477 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -89.8 30.88 5.53 Favored Glycine 0 N--CA 1.438 -1.222 0 C-N-CA 120.778 -0.725 . . . . 0.0 113.05 -178.417 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -146.65 157.4 43.7 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 122.177 -0.602 . . . . 0.0 109.555 -176.424 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.5 150.7 47.74 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 122.688 0.395 . . . . 0.0 110.334 177.076 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.99 117.21 15.51 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -175.336 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -103.13 126.13 50.16 Favored 'General case' 0 N--CA 1.407 -2.593 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -178.876 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 120.33 176.54 15.77 Favored Glycine 0 C--N 1.29 -1.98 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.706 -177.551 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -93.77 -24.77 17.68 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.906 0.86 . . . . 0.0 109.02 -178.384 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.428 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.2 mm -104.03 129.22 56.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 114.851 -1.068 . . . . 0.0 109.213 -176.538 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -119.0 -2.49 10.8 Favored 'General case' 0 C--O 1.201 -1.493 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 177.611 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 39.8 p90 -138.46 162.18 35.13 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 120.945 0.402 . . . . 0.0 110.526 -169.374 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 61.1 mtp180 -123.53 135.24 53.91 Favored 'General case' 0 C--N 1.282 -2.328 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 170.989 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -110.45 130.58 55.53 Favored 'General case' 0 C--N 1.284 -2.253 0 C-N-CA 119.046 -1.061 . . . . 0.0 110.215 -178.517 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . 0.532 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 36.9 t -75.99 98.96 4.41 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.328 0.585 . . . . 0.0 109.918 177.878 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.446 ' OD2' HG22 ' A' ' 131' ' ' THR . 20.3 t70 -100.14 -175.43 2.94 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 178.172 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.446 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -69.26 -19.49 63.92 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-O 121.997 0.904 . . . . 0.0 109.237 179.441 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -83.12 -12.79 56.69 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.304 -1.316 . . . . 0.0 109.326 179.831 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 110.37 -164.19 12.29 Favored Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -175.942 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.406 ' CD1' ' HB3' ' A' ' 85' ' ' CYS . 98.5 m95 -64.26 114.79 4.47 Favored 'General case' 0 C--O 1.248 0.978 0 CA-C-N 117.922 0.861 . . . . 0.0 109.88 175.363 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 68.6 p -71.29 164.87 24.86 Favored 'General case' 0 N--CA 1.417 -2.108 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 177.702 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 55.8 m-20 65.53 -158.87 0.28 Allowed 'General case' 0 C--O 1.245 0.826 0 O-C-N 123.843 0.714 . . . . 0.0 109.276 173.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -136.48 176.28 8.85 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 175.866 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.1 mt -64.29 120.44 64.81 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 124.271 0.982 . . . . 0.0 108.368 175.338 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . 0.428 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 45.6 Cg_endo -67.68 176.52 4.99 Favored 'Trans proline' 0 C--O 1.248 1.024 0 C-N-CA 123.034 2.489 . . . . 0.0 112.583 -179.256 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.1 mm -111.71 137.0 46.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 CA-C-O 121.108 0.48 . . . . 0.0 110.318 -173.234 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.492 ' HB2' ' CB ' ' A' ' 93' ' ' PHE . 99.3 m -113.52 111.12 21.38 Favored 'General case' 0 C--N 1.279 -2.47 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 172.83 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -93.67 151.63 19.53 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 179.211 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 8.9 p -74.09 141.26 16.37 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.553 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . 0.477 HG22 ' C ' ' A' ' 117' ' ' GLY . 15.6 m -67.09 101.14 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.776 0 CA-C-O 121.967 0.889 . . . . 0.0 110.024 177.843 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -85.18 123.51 30.77 Favored 'General case' 0 N--CA 1.407 -2.599 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.314 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.491 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 62.6 m -83.2 122.28 28.2 Favored 'General case' 0 C--N 1.273 -2.758 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 178.02 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 80.6 mt -53.36 131.69 52.94 Favored Pre-proline 0 C--N 1.313 -0.985 0 N-CA-C 113.629 0.974 . . . . 0.0 113.629 -175.693 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -56.44 121.03 9.31 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 123.33 2.687 . . . . 0.0 110.989 -178.575 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.5 p -89.28 149.48 4.01 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.973 -175.878 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.4 p -81.73 -173.45 4.44 Favored 'General case' 0 N--CA 1.422 -1.837 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 175.245 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -123.37 155.63 64.98 Favored Pre-proline 0 C--N 1.285 -2.238 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -172.802 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -77.35 169.72 20.73 Favored 'Trans proline' 0 CA--C 1.543 0.97 0 C-N-CA 121.92 1.746 . . . . 0.0 112.491 178.277 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -64.31 -57.5 9.21 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -178.816 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 -97.87 20.09 12.7 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.846 0.831 . . . . 0.0 110.269 -174.145 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -142.79 -173.27 14.41 Favored Glycine 0 N--CA 1.412 -2.903 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.985 179.878 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 19.8 pttp -156.76 178.31 10.49 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -179.187 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 59.5 mt -101.09 138.35 25.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 CA-C-N 117.83 0.286 . . . . 0.0 111.066 -177.33 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.444 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.7 m -84.69 -33.64 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 177.426 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 6.1 m . . . . . 0 N--CA 1.444 -0.742 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.943 -174.584 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 . . . . . 0 CA--C 1.502 -0.902 0 CA-C-O 120.984 0.421 . . . . 0.0 110.088 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -125.49 165.05 19.17 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -177.3 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . 0.462 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 92.4 t80 -51.57 134.86 29.16 Favored 'General case' 0 C--O 1.239 0.526 0 O-C-N 123.885 0.741 . . . . 0.0 109.11 170.586 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 109.94 -10.05 31.89 Favored Glycine 0 N--CA 1.424 -2.103 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.732 -179.112 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 -99.55 159.29 15.14 Favored 'General case' 0 N--CA 1.433 -1.291 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.916 -178.842 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' A' ' 190' ' ' MET . . . -138.73 123.98 19.21 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 175.688 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.532 HG23 ' CH2' ' A' ' 198' ' ' TRP . 85.0 t -87.68 109.71 19.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.047 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.444 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 41.2 ttm180 -96.71 142.57 28.58 Favored 'General case' 0 N--CA 1.416 -2.162 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 177.781 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -110.19 159.59 17.24 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 -177.294 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.435 HG21 ' CG1' ' A' ' 158' ' ' VAL . 0.1 OUTLIER -130.76 139.79 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.467 -2.247 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.675 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . 0.483 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 77.4 m -84.79 129.52 34.81 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 173.501 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -53.28 -51.63 61.69 Favored 'General case' 0 CA--C 1.48 -1.713 0 C-N-CA 124.76 1.224 . . . . 0.0 112.584 -175.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 13.3 t -123.63 -154.58 0.61 Allowed 'General case' 0 N--CA 1.402 -2.837 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 -177.052 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -74.22 51.11 2.06 Favored Glycine 0 N--CA 1.443 -0.838 0 O-C-N 123.588 0.555 . . . . 0.0 113.78 -176.468 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . 0.483 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 98.4 m-85 -100.89 168.39 9.66 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 176.114 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 50.6 pttt -121.41 146.05 47.29 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.794 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.465 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.8 tt -76.86 141.8 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.766 0 C-N-CA 119.691 -0.804 . . . . 0.0 110.276 176.403 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -53.75 -61.13 2.5 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 125.086 1.354 . . . . 0.0 113.228 -176.227 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -123.89 -97.81 1.27 Allowed Glycine 0 CA--C 1.496 -1.147 0 C-N-CA 120.33 -0.938 . . . . 0.0 112.814 -178.654 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -85.07 159.97 20.08 Favored 'General case' 0 CA--C 1.48 -1.728 0 N-CA-C 106.876 -1.527 . . . . 0.0 106.876 176.75 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . 0.465 ' HA ' HD13 ' A' ' 184' ' ' ILE . 14.5 pt-20 -102.47 3.86 38.08 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 118.114 -1.434 . . . . 0.0 109.468 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 8.7 pt-20 -151.45 147.37 26.78 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-N 115.547 -0.751 . . . . 0.0 112.386 -176.216 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.47 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 13.9 ptp -113.79 128.25 56.34 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.649 175.446 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 34.1 t-80 -110.56 146.56 35.85 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 116.746 -0.206 . . . . 0.0 110.473 -174.646 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 88.6 m -75.06 155.04 37.63 Favored 'General case' 0 C--O 1.241 0.642 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 178.436 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 60.6 m -126.17 171.46 10.86 Favored 'General case' 0 C--O 1.256 1.395 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 169.387 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -78.4 91.56 4.49 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.261 1.029 . . . . 0.0 112.496 -172.347 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 9.5 t70 174.22 -38.18 0.01 OUTLIER 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 113.15 -1.841 . . . . 0.0 106.293 176.508 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . 0.491 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 119.65 18.69 4.33 Favored Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.196 -179.534 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -109.65 158.13 18.38 Favored 'General case' 0 C--O 1.251 1.168 0 O-C-N 122.226 -0.573 . . . . 0.0 109.969 176.418 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . 0.532 ' CH2' HG23 ' A' ' 174' ' ' VAL . 87.6 m95 -87.31 144.69 26.67 Favored 'General case' 0 N--CA 1.423 -1.815 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 176.18 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.2 m -92.94 7.59 43.33 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-O 121.879 0.847 . . . . 0.0 110.926 -178.176 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . 0.468 ' HG3' ' N ' ' A' ' 201' ' ' GLU . 0.8 OUTLIER -139.39 153.28 47.61 Favored 'General case' 0 N--CA 1.417 -2.102 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 177.096 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . 0.468 ' N ' ' HG3' ' A' ' 200' ' ' LYS . 0.2 OUTLIER -105.28 171.93 7.06 Favored 'General case' 0 C--N 1.279 -2.461 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 178.9 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . 0.402 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 45.8 mtpt -63.38 117.61 35.74 Favored Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 114.154 1.168 . . . . 0.0 114.154 -174.865 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -82.33 171.31 12.58 Favored 'Trans proline' 0 N--CA 1.445 -1.369 0 C-N-CA 122.793 2.329 . . . . 0.0 108.953 172.246 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . 0.43 ' O ' ' HA ' ' A' ' 184' ' ' ILE . 38.8 mtpt -122.38 174.55 6.95 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.966 -0.694 . . . . 0.0 109.432 179.681 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 57.3 m -115.39 107.56 15.37 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 173.19 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m . . . . . 0 C--N 1.281 -2.413 0 CA-C-N 114.371 -1.286 . . . . 0.0 109.736 -173.638 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo . . . . . 0 N--CA 1.477 0.548 0 CA-C-O 121.078 0.366 . . . . 0.0 112.766 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 65.1 m -73.32 -27.15 61.36 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.547 0.689 . . . . 0.0 110.677 178.027 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.19 13.12 40.19 Favored Glycine 0 C--N 1.3 -1.417 0 CA-C-N 115.206 -0.907 . . . . 0.0 114.832 172.724 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.7 t60 68.77 125.37 0.03 OUTLIER Pre-proline 0 N--CA 1.489 1.484 0 C-N-CA 123.841 0.856 . . . . 0.0 108.931 -179.234 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.418 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 92.7 Cg_endo -75.97 7.77 3.09 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 123.059 2.506 . . . . 0.0 114.862 -171.998 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 97.94 -166.0 22.25 Favored Glycine 0 C--N 1.277 -2.715 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -175.514 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -143.37 140.21 30.38 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 -179.036 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.3 t -102.64 129.53 25.73 Favored Pre-proline 0 C--N 1.299 -1.624 0 CA-C-O 121.234 0.54 . . . . 0.0 110.829 -178.366 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.25 -11.55 25.0 Favored 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 122.544 2.163 . . . . 0.0 111.474 177.599 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -87.25 -3.02 59.03 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.518 -178.285 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 167.69 -120.85 0.93 Allowed Glycine 0 N--CA 1.43 -1.717 0 C-N-CA 120.271 -0.966 . . . . 0.0 111.797 179.235 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.4 t -151.49 -172.86 4.33 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 123.71 0.3 . . . . 0.0 110.361 179.447 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.6 p90 -146.13 156.42 43.42 Favored 'General case' 0 N--CA 1.436 -1.168 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 176.65 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 5.5 m -121.92 166.52 14.29 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 178.041 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.441 HD11 ' CE1' ' A' ' 104' ' ' PHE . 14.8 mt -120.14 128.83 53.78 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.897 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.431 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 33.7 p -115.91 135.72 53.72 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 -178.262 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 114.53 -65.04 0.29 Allowed Glycine 0 N--CA 1.429 -1.781 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -179.243 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -119.69 -5.93 10.72 Favored Glycine 0 C--N 1.309 -0.938 0 C-N-CA 119.98 -1.105 . . . . 0.0 113.143 -178.991 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 59.79 19.62 8.44 Favored 'General case' 0 N--CA 1.495 1.809 0 C-N-CA 123.04 0.536 . . . . 0.0 112.373 -178.079 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.506 ' O ' HG12 ' A' ' 108' ' ' VAL . 23.0 m -146.67 -171.12 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.203 -1.379 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -176.028 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.441 ' CE1' HD11 ' A' ' 98' ' ' LEU . 54.0 m-85 -106.42 39.41 1.83 Allowed 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 118.565 0.62 . . . . 0.0 110.635 -175.756 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.736 ' O ' HG11 ' A' ' 108' ' ' VAL . 11.5 pt-20 -85.43 -176.61 6.18 Favored 'General case' 0 C--O 1.202 -1.443 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.52 179.165 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 -75.63 137.29 40.64 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.935 -0.478 . . . . 0.0 111.143 177.702 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.35 4.93 73.23 Favored Glycine 0 N--CA 1.433 -1.536 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.962 178.132 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.736 HG11 ' O ' ' A' ' 105' ' ' GLU . 13.9 p -95.02 146.22 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 C-N-CA 119.854 -0.738 . . . . 0.0 109.179 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.431 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 56.3 mtpt -110.17 123.75 50.32 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.591 179.198 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.508 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.3 93.63 9.13 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 176.469 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 76.7 t -86.03 109.62 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.772 0 C-N-CA 123.972 0.909 . . . . 0.0 109.208 -177.803 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -82.99 139.22 33.42 Favored 'General case' 0 C--N 1.286 -2.17 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.773 -179.566 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 11.1 t -136.83 127.78 27.57 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.738 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 82.3 m -81.31 160.18 24.25 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.822 -174.593 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -72.46 177.21 4.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.9 175.926 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -56.57 -47.02 80.39 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -176.14 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -78.01 11.1 23.32 Favored Glycine 0 CA--C 1.522 0.495 0 CA-C-N 116.186 -0.461 . . . . 0.0 114.236 -178.876 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.598 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 82.5 m-85 -133.45 156.73 47.19 Favored 'General case' 0 C--N 1.311 -1.094 0 O-C-N 122.368 -0.489 . . . . 0.0 110.713 -179.195 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -143.44 147.97 35.4 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.006 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 7.2 tp -76.95 144.03 39.08 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-O 120.978 0.418 . . . . 0.0 110.834 -173.158 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.82 125.38 46.36 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -179.778 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 108.12 -176.28 20.34 Favored Glycine 0 C--N 1.291 -1.919 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -174.532 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -101.07 -24.95 14.21 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.363 0.602 . . . . 0.0 110.288 -179.726 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.2 mm -80.96 127.25 39.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -178.578 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -134.42 11.38 3.79 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 -178.561 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.508 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 32.8 p90 -149.01 167.71 25.08 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 -172.135 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.498 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 46.7 mtp180 -129.2 119.37 23.93 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 171.769 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -91.23 128.68 37.15 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.755 -0.778 . . . . 0.0 110.149 178.687 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 35.2 t -87.07 107.13 18.3 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.338 -0.945 . . . . 0.0 109.89 175.126 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.439 ' OD1' HG22 ' A' ' 131' ' ' THR . 7.2 t70 -100.61 -168.73 1.61 Allowed 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 176.342 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.439 HG22 ' OD1' ' A' ' 130' ' ' ASP . 11.1 t -69.84 -18.15 63.43 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 122.445 1.117 . . . . 0.0 109.176 178.279 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -80.67 -7.0 59.18 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 114.294 -1.321 . . . . 0.0 109.327 177.036 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 97.34 -158.57 21.08 Favored Glycine 0 N--CA 1.429 -1.77 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -176.316 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . 0.416 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 90.0 m95 -65.32 108.48 1.94 Allowed 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 175.963 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 30.0 p -64.05 -55.2 23.93 Favored 'General case' 0 C--N 1.317 -0.84 0 C-N-CA 123.705 0.802 . . . . 0.0 111.581 -176.251 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . 0.498 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.3 m120 -78.64 167.22 21.56 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 114.857 -1.065 . . . . 0.0 109.04 -179.708 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -99.86 179.12 4.62 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 175.162 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.7 mt -65.63 118.98 56.45 Favored Pre-proline 0 C--N 1.325 -0.494 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 174.113 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.7 146.64 84.5 Favored 'Trans proline' 0 C--O 1.25 1.101 0 C-N-CA 122.322 2.015 . . . . 0.0 112.802 -176.292 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 66.0 mt -72.4 130.35 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.58 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.0 -179.783 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.598 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 45.3 t -121.48 142.42 50.07 Favored 'General case' 0 C--N 1.274 -2.678 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 176.354 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 6.1 tp10 -121.43 152.97 38.48 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -174.73 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.453 HG23 ' NE2' ' A' ' 169' ' ' HIS . 8.1 p -73.74 141.73 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.5 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.019 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 74.7 t -60.95 119.82 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.882 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 52.8 mtmt -125.42 138.43 54.02 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.477 -177.504 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 2.1 p -110.75 160.61 16.56 Favored 'General case' 0 C--N 1.287 -2.112 0 CA-C-N 115.298 -0.865 . . . . 0.0 112.18 -179.186 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . 0.403 HD13 ' HD2' ' A' ' 148' ' ' PRO . 0.3 OUTLIER -77.97 135.6 62.87 Favored Pre-proline 0 N--CA 1.426 -1.65 0 C-N-CA 124.573 1.149 . . . . 0.0 111.302 -173.533 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.403 ' HD2' HD13 ' A' ' 147' ' ' LEU . 12.1 Cg_endo -55.97 126.87 23.84 Favored 'Trans proline' 0 C--O 1.244 0.784 0 C-N-CA 123.812 3.008 . . . . 0.0 112.661 179.304 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 10.8 p -91.21 150.31 3.8 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.128 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 19.9 p -71.53 -88.34 0.02 OUTLIER 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 113.505 0.928 . . . . 0.0 113.505 -177.324 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 171.91 164.3 0.25 Allowed Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 179.738 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . 0.431 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 73.7 Cg_endo -78.45 166.02 24.61 Favored 'Trans proline' 0 N--CA 1.454 -0.849 0 C-N-CA 121.688 1.592 . . . . 0.0 110.419 171.624 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -64.94 -61.53 2.11 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -179.754 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -91.34 35.56 0.93 Allowed 'General case' 0 C--O 1.247 0.963 0 O-C-N 121.773 -0.579 . . . . 0.0 111.24 179.709 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -156.85 -161.78 11.02 Favored Glycine 0 N--CA 1.425 -2.053 0 C-N-CA 120.145 -1.026 . . . . 0.0 112.384 178.263 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 59.5 pttt -159.07 -178.48 7.26 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -178.394 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 58.2 mt -96.62 141.3 15.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 117.577 0.171 . . . . 0.0 111.159 -178.604 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.443 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.3 m -88.77 -31.98 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.931 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 176.317 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.8 m . . . . . 0 N--CA 1.442 -0.849 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.027 -176.07 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . 0.438 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 73.2 m-85 . . . . . 0 C--O 1.218 -0.593 0 N-CA-C 112.446 0.536 . . . . 0.0 112.446 . . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.453 ' NE2' HG23 ' A' ' 143' ' ' VAL . 54.9 t-80 -86.32 146.23 26.58 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.023 -0.99 . . . . 0.0 108.687 179.817 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 83.6 t80 -54.64 129.73 37.66 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.714 176.32 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 112.91 -22.17 16.85 Favored Glycine 0 N--CA 1.432 -1.602 0 C-N-CA 120.155 -1.021 . . . . 0.0 111.994 -178.006 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -70.35 150.88 45.85 Favored 'General case' 0 C--O 1.251 1.149 0 CA-C-O 120.87 0.367 . . . . 0.0 110.276 178.359 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -134.65 103.1 5.52 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.604 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 95.7 t -76.79 108.92 10.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.617 -178.025 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.443 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 29.5 ttp180 -101.49 142.2 33.22 Favored 'General case' 0 N--CA 1.407 -2.612 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.459 177.813 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . 0.431 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 62.8 m-85 -113.26 153.32 28.6 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.664 -174.809 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -121.29 152.54 24.75 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.275 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.996 179.296 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 67.9 m -99.51 138.87 35.99 Favored 'General case' 0 N--CA 1.403 -2.786 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 172.396 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -55.41 -52.41 63.67 Favored 'General case' 0 CA--C 1.486 -1.49 0 N-CA-C 114.192 1.182 . . . . 0.0 114.192 -175.131 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 58.9 m -150.33 -100.32 0.07 Allowed 'General case' 0 C--N 1.286 -2.153 0 C-N-CA 120.144 -0.622 . . . . 0.0 112.042 -177.005 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -87.5 44.68 3.29 Favored Glycine 0 CA--C 1.494 -1.254 0 CA-C-O 121.264 0.369 . . . . 0.0 112.343 -177.654 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -123.9 158.59 31.58 Favored 'General case' 0 N--CA 1.415 -2.2 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.531 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . 0.433 ' O ' ' HD2' ' A' ' 183' ' ' LYS . 1.2 pptp? -132.01 143.13 49.85 Favored 'General case' 0 C--N 1.288 -2.066 0 O-C-N 123.878 0.736 . . . . 0.0 109.178 179.118 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . 0.424 HD11 ' HA ' ' A' ' 188' ' ' GLU . 4.2 tt -71.57 142.47 15.4 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.26 0 CA-C-O 121.489 0.661 . . . . 0.0 111.626 -178.299 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -76.59 -57.08 4.06 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.735 -175.845 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -93.05 -126.42 4.16 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 120.277 -0.963 . . . . 0.0 111.954 -177.776 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -93.28 158.83 15.55 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 176.677 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . 0.424 ' HA ' HD11 ' A' ' 184' ' ' ILE . 14.5 pt-20 -95.1 -7.81 38.33 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 118.915 -1.114 . . . . 0.0 110.976 -174.333 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -138.91 135.79 34.81 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.163 0.506 . . . . 0.0 112.339 -176.497 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 12.8 ptp -116.12 124.05 49.38 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.398 176.301 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 52.0 t-80 -97.95 135.99 38.87 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.702 -176.234 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 16.4 t -71.15 118.61 14.15 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.34 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.5 m -97.56 165.33 12.04 Favored 'General case' 0 N--CA 1.437 -1.112 0 O-C-N 123.606 0.567 . . . . 0.0 110.445 -175.756 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -65.51 -6.76 11.6 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 124.514 1.126 . . . . 0.0 112.316 -177.573 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -74.25 -22.2 59.43 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.565 175.532 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 92.44 14.51 55.53 Favored Glycine 0 N--CA 1.435 -1.418 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -174.521 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -136.6 176.81 8.37 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.587 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 88.1 m95 -84.78 152.28 23.78 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.92 -177.521 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 21.0 p -80.23 -14.58 58.31 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.508 179.835 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -124.36 165.98 16.75 Favored 'General case' 0 CA--C 1.477 -1.846 0 CA-C-O 122.141 0.972 . . . . 0.0 113.6 -173.957 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -91.47 166.44 12.86 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 113.053 -1.885 . . . . 0.0 109.337 176.322 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 6.1 mmmm -65.96 109.78 3.68 Favored Pre-proline 0 C--N 1.318 -0.787 0 O-C-N 124.053 0.846 . . . . 0.0 112.939 178.854 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -92.04 156.85 3.28 Favored 'Trans proline' 0 N--CA 1.424 -2.612 0 C-N-CA 122.42 2.08 . . . . 0.0 110.412 177.687 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . 0.403 ' HA ' ' HB3' ' A' ' 152' ' ' PRO . 19.1 ptpt -135.68 155.81 49.83 Favored 'General case' 0 C--N 1.287 -2.126 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.005 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 97.5 m -93.29 118.52 31.37 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 177.569 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.1 m . . . . . 0 C--N 1.291 -1.951 0 CA-C-N 114.007 -1.451 . . . . 0.0 107.326 -178.267 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.452 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 41.0 Cg_endo . . . . . 0 CA--C 1.534 0.505 0 CA-C-O 121.181 0.409 . . . . 0.0 111.642 . . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . 0.547 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 3.2 m -94.36 -17.9 22.11 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 122.1 0.952 . . . . 0.0 110.211 174.176 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.73 -87.72 0.54 Allowed Glycine 2 N--CA 1.391 -4.356 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 172.364 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.4 t-80 -171.85 138.24 1.02 Allowed Pre-proline 0 C--N 1.247 -3.854 0 N-CA-C 105.735 -1.95 . . . . 0.0 105.735 -172.739 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.49 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 91.9 Cg_endo -87.45 2.06 6.87 Favored 'Trans proline' 0 C--N 1.322 -0.837 0 C-N-CA 121.946 1.764 . . . . 0.0 112.764 -177.76 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.07 -166.37 13.1 Favored Glycine 0 N--CA 1.428 -1.875 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 -179.708 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -159.27 124.12 4.08 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 177.659 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.8 t -110.56 137.32 20.69 Favored Pre-proline 0 C--N 1.296 -1.735 0 CA-C-O 120.895 0.379 . . . . 0.0 111.749 -178.585 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -83.07 -10.11 10.39 Favored 'Trans proline' 0 CA--C 1.544 1.0 0 C-N-CA 122.742 2.295 . . . . 0.0 112.062 174.063 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -88.81 6.76 37.42 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.414 0.626 . . . . 0.0 111.143 -178.624 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.412 ' HA2' ' ND2' ' A' ' 115' ' ' ASN . . . 161.95 -123.86 1.24 Allowed Glycine 0 N--CA 1.415 -2.751 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.607 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.6 t -164.29 -159.72 0.5 Allowed 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 -178.592 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.6 p90 -152.88 165.53 35.17 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 176.987 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -127.83 159.52 34.61 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 177.906 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.1 mt -117.18 132.18 56.7 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -178.54 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 16.5 p -125.53 129.77 50.39 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -176.388 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.57 27.74 34.68 Favored Glycine 0 C--N 1.313 -0.703 0 C-N-CA 120.353 -0.927 . . . . 0.0 111.653 -179.447 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 178.37 -45.81 0.09 OUTLIER Glycine 0 N--CA 1.433 -1.542 0 C-N-CA 119.69 -1.243 . . . . 0.0 112.8 -179.158 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 70.44 8.42 6.6 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 124.195 0.998 . . . . 0.0 109.965 -178.304 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.559 ' O ' HG13 ' A' ' 108' ' ' VAL . 25.2 m -148.82 -175.74 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.125 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 -177.864 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.49 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 23.5 m-85 -98.9 38.08 1.43 Allowed 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 118.995 0.816 . . . . 0.0 110.782 -176.296 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.747 ' O ' HG12 ' A' ' 108' ' ' VAL . 15.2 pt-20 -79.86 175.54 10.54 Favored 'General case' 0 C--O 1.195 -1.765 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.815 -179.344 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . 0.522 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 43.0 m-85 -74.73 126.24 30.45 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 122.144 -0.347 . . . . 0.0 111.536 179.404 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 102.21 -1.22 50.66 Favored Glycine 0 N--CA 1.439 -1.16 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.618 179.713 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.747 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -92.45 147.55 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.053 0 C-N-CA 120.068 -0.653 . . . . 0.0 109.626 -179.447 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -114.19 123.51 49.75 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 177.8 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.81 94.85 9.88 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 177.86 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 76.8 t -84.16 108.36 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.921 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -179.439 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . 0.53 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 37.6 t80 -74.82 140.99 44.32 Favored 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 123.563 0.745 . . . . 0.0 109.37 -177.012 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 3.3 t -144.3 111.49 5.9 Favored 'General case' 0 N--CA 1.426 -1.632 0 CA-C-O 121.919 0.866 . . . . 0.0 110.492 -179.637 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.514 ' SG ' ' HE1' ' A' ' 112' ' ' TYR . 74.7 m -71.46 162.17 29.86 Favored 'General case' 0 C--O 1.255 1.365 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.803 178.501 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.412 ' ND2' ' HA2' ' A' ' 94' ' ' GLY . 37.6 m-20 -74.99 -177.37 3.31 Favored 'General case' 0 C--O 1.211 -0.942 0 CA-C-N 115.817 -0.628 . . . . 0.0 109.905 175.582 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -66.86 -35.05 79.14 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -174.947 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.415 ' HA2' ' CD2' ' A' ' 170' ' ' PHE . . . -73.98 -6.19 72.64 Favored Glycine 0 C--N 1.311 -0.829 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.741 178.948 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.541 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 87.8 m-85 -129.88 167.91 17.43 Favored 'General case' 0 N--CA 1.441 -0.903 0 O-C-N 122.427 -0.455 . . . . 0.0 110.189 -176.615 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -146.27 157.55 43.81 Favored 'General case' 0 C--N 1.289 -2.033 0 CA-C-O 120.908 0.385 . . . . 0.0 110.682 -178.325 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -78.93 125.78 29.83 Favored 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 178.236 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.563 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -115.45 134.26 55.26 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 178.2 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.03 -178.07 20.6 Favored Glycine 0 C--N 1.289 -2.036 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -178.501 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -96.46 -40.53 9.03 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 -178.699 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.579 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 46.8 mm -77.26 124.06 34.99 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.696 -178.271 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -131.54 9.27 4.66 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 -176.615 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.47 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 18.5 p90 -143.88 166.99 23.38 Favored 'General case' 0 N--CA 1.425 -1.689 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -174.978 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . 0.435 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 63.3 mtp180 -131.95 122.58 25.82 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 171.345 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -91.84 124.8 36.24 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 119.889 -0.724 . . . . 0.0 111.166 178.386 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . 0.522 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 36.0 t -80.0 105.03 10.98 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 175.2 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.437 ' OD2' HG21 ' A' ' 131' ' ' THR . 6.9 t70 -118.9 -169.92 1.82 Allowed 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -178.448 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.437 HG21 ' OD2' ' A' ' 130' ' ' ASP . 12.4 t -57.75 -26.01 61.25 Favored 'General case' 0 CA--C 1.563 1.45 0 C-N-CA 123.803 0.841 . . . . 0.0 112.266 -174.19 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -84.36 -24.86 29.53 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.882 0.848 . . . . 0.0 110.585 -179.731 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.547 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 125.52 -152.55 17.92 Favored Glycine 0 N--CA 1.419 -2.484 0 N-CA-C 106.811 -2.515 . . . . 0.0 106.811 -171.641 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -70.48 114.75 8.9 Favored 'General case' 0 N--CA 1.433 -1.321 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 175.281 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.3 p -64.94 -54.77 25.42 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.762 0.791 . . . . 0.0 111.456 -176.606 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . 0.435 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.8 m120 -78.96 167.77 20.65 Favored 'General case' 0 C--N 1.296 -1.758 0 CA-C-N 114.703 -1.135 . . . . 0.0 108.619 -178.716 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -98.96 -179.91 4.42 Favored 'General case' 0 C--N 1.29 -2.018 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 175.004 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.1 mt -65.17 121.17 72.9 Favored Pre-proline 0 C--N 1.309 -1.175 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 177.526 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . 0.579 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 23.2 Cg_exo -57.67 167.29 4.09 Favored 'Trans proline' 0 C--O 1.245 0.853 0 C-N-CA 122.709 2.273 . . . . 0.0 112.179 177.909 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.563 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 3.6 mp -94.27 132.25 38.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 -171.019 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.541 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 8.5 t -112.62 119.39 37.97 Favored 'General case' 0 N--CA 1.423 -1.792 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 176.233 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -108.96 156.02 20.19 Favored 'General case' 0 C--N 1.274 -2.717 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 178.566 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.645 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 15.0 t -80.18 149.81 5.09 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.315 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 177.348 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 57.1 t -67.66 115.65 6.09 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.622 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.568 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.645 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 39.8 mtpt -123.23 157.67 32.58 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.799 -173.745 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 p -134.12 155.51 49.95 Favored 'General case' 0 C--N 1.286 -2.167 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.443 -179.228 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -55.69 147.09 42.77 Favored Pre-proline 0 N--CA 1.443 -0.807 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -177.086 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -71.77 129.9 16.16 Favored 'Trans proline' 0 N--CA 1.444 -1.43 0 C-N-CA 122.841 2.361 . . . . 0.0 111.914 -178.59 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 46.9 t -95.75 129.19 46.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.595 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.5 p -74.04 -73.93 0.21 Allowed 'General case' 0 N--CA 1.428 -1.551 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 178.215 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 175.82 156.68 0.39 Allowed Pre-proline 0 C--N 1.328 -0.347 0 C-N-CA 125.034 1.334 . . . . 0.0 107.526 178.613 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -66.76 167.04 20.37 Favored 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.532 1.488 . . . . 0.0 109.605 170.852 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . 0.556 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.0 OUTLIER -62.52 -45.16 94.26 Favored 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -175.181 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . 0.556 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 42.7 m-80 -116.51 26.92 9.54 Favored 'General case' 0 CA--C 1.504 -0.813 0 CA-C-O 121.552 0.692 . . . . 0.0 109.689 179.881 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -142.09 -171.7 13.18 Favored Glycine 0 N--CA 1.423 -2.211 0 C-N-CA 120.233 -0.984 . . . . 0.0 111.814 179.834 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 44.2 pttt -153.26 171.1 19.06 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -177.39 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 53.2 mt -96.02 139.34 19.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 120.606 0.241 . . . . 0.0 111.372 -176.151 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.523 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 5.0 m -99.03 -28.32 3.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 CA-C-O 121.269 0.556 . . . . 0.0 110.09 178.305 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 159' ' ' SER . . . . . 0.441 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 46.3 m . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.374 -172.041 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 . . . . . 0 N--CA 1.437 -1.089 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -135.08 160.41 38.44 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -178.737 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . 0.415 ' CD2' ' HA2' ' A' ' 117' ' ' GLY . 0.9 OUTLIER -61.55 114.67 3.38 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 172.259 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 135.3 -21.16 3.68 Favored Glycine 0 N--CA 1.427 -1.919 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 -176.198 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 25.7 tp60 -76.81 124.04 27.11 Favored 'General case' 0 N--CA 1.401 -2.89 0 C-N-CA 122.883 0.473 . . . . 0.0 109.986 178.271 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -112.07 118.07 34.38 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 171.262 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . 0.441 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 72.0 t -98.41 113.76 34.02 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -177.712 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.523 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 72.2 ttt180 -104.02 149.48 25.13 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 -179.678 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -122.45 162.74 21.12 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 121.579 0.704 . . . . 0.0 111.346 -174.455 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.42 149.33 33.56 Favored 'Isoleucine or valine' 0 CA--C 1.475 -1.942 0 CA-C-N 113.998 -1.455 . . . . 0.0 109.644 174.097 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 73.1 m -111.72 128.38 56.07 Favored 'General case' 0 N--CA 1.406 -2.674 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 176.062 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -50.45 159.74 0.47 Allowed 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 114.62 -1.173 . . . . 0.0 111.713 177.291 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 48.1 t -47.88 113.32 0.7 Allowed 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.42 -175.891 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.55 -17.3 30.95 Favored Glycine 0 N--CA 1.429 -1.796 0 C-N-CA 120.593 -0.813 . . . . 0.0 113.574 178.237 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -99.63 159.57 14.94 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 117.939 0.87 . . . . 0.0 110.965 -177.803 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 16.1 pttm -124.55 150.22 46.12 Favored 'General case' 0 N--CA 1.42 -1.958 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 175.615 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -74.93 133.58 31.21 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.468 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 174.807 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -77.47 -54.71 6.11 Favored 'General case' 0 C--N 1.282 -2.353 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -176.875 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -88.1 -134.65 4.7 Favored Glycine 0 C--N 1.301 -1.372 0 C-N-CA 120.958 -0.639 . . . . 0.0 111.836 177.558 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -87.36 158.7 18.97 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 178.83 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -96.37 6.17 49.34 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.067 -176.154 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -147.38 146.22 29.55 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 121.058 0.456 . . . . 0.0 111.981 -177.109 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 12.9 ptp -126.05 132.06 52.03 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.55 176.465 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 24.0 t-80 -105.84 136.09 46.11 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -177.876 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 8.6 t -74.22 124.55 26.6 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 177.338 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 27.1 t -97.18 171.55 8.38 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 122.91 0.484 . . . . 0.0 110.732 -176.361 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -68.14 -11.41 59.11 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 125.027 1.331 . . . . 0.0 114.439 -173.05 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . 0.502 ' HB3' ' CD1' ' A' ' 197' ' ' PHE . 29.3 t70 -94.23 -3.35 50.88 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 122.415 1.102 . . . . 0.0 109.959 177.68 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 82.81 49.81 4.93 Favored Glycine 0 N--CA 1.434 -1.497 0 C-N-CA 120.443 -0.884 . . . . 0.0 111.442 179.894 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . 0.502 ' CD1' ' HB3' ' A' ' 195' ' ' ASP . 3.1 p90 -151.77 158.97 44.05 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 178.322 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 87.4 m95 -76.38 135.22 39.49 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 176.551 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.9 p -61.1 -28.32 69.01 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.736 0.779 . . . . 0.0 111.291 -177.295 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 40.0 mmtt -113.71 162.83 15.79 Favored 'General case' 0 N--CA 1.418 -2.042 0 CA-C-N 114.729 -1.123 . . . . 0.0 111.062 -178.946 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -75.38 172.28 12.76 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 105.845 -1.909 . . . . 0.0 105.845 172.483 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . 0.478 ' HZ1' ' HB3' ' A' ' 202' ' ' LYS . 3.1 ttpm? -85.2 116.4 65.32 Favored Pre-proline 0 N--CA 1.421 -1.922 0 C-N-CA 117.321 -1.751 . . . . 0.0 107.773 179.18 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -67.08 166.42 23.1 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 122.774 2.316 . . . . 0.0 112.885 -174.733 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . 0.536 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 87.0 tttt -123.2 153.19 40.42 Favored 'General case' 0 C--N 1.286 -2.155 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.627 -173.627 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 99.9 m -109.82 112.85 25.14 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 177.009 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--N 1.304 -1.381 0 CA-C-N 115.173 -0.921 . . . . 0.0 108.871 -177.127 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo . . . . . 0 CA--C 1.536 0.611 0 CA-C-O 121.783 0.659 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.6 m -90.28 -32.89 16.34 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.001 178.86 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 109.68 -78.02 0.23 Allowed Glycine 0 CA--C 1.457 -3.538 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.333 168.833 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.0 t60 179.93 128.49 0.24 Allowed Pre-proline 0 C--N 1.274 -2.705 0 N-CA-C 105.08 -2.193 . . . . 0.0 105.08 -176.811 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -75.98 -0.99 10.88 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 C-N-CA 123.647 2.898 . . . . 0.0 114.448 -172.236 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.66 179.64 16.93 Favored Glycine 0 N--CA 1.41 -3.093 0 N-CA-C 107.362 -2.295 . . . . 0.0 107.362 -173.495 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -150.16 160.26 43.8 Favored 'General case' 0 C--N 1.275 -2.641 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 -177.584 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.0 t -142.18 136.38 14.89 Favored Pre-proline 0 C--N 1.297 -1.676 0 C-N-CA 120.118 -0.633 . . . . 0.0 111.459 -176.778 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -79.67 -8.94 14.72 Favored 'Trans proline' 0 CA--C 1.533 0.432 0 C-N-CA 123.127 2.551 . . . . 0.0 112.022 176.631 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -93.23 4.28 54.26 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 121.315 0.579 . . . . 0.0 111.202 -176.858 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.613 ' HA2' ' OD1' ' A' ' 115' ' ' ASN . . . 170.19 -131.49 2.26 Favored Glycine 0 N--CA 1.401 -3.636 0 C-N-CA 120.278 -0.963 . . . . 0.0 110.921 -179.548 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.9 t -162.14 -166.64 1.45 Allowed 'General case' 0 C--N 1.277 -2.572 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -178.951 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -148.14 163.17 37.76 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 178.191 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -123.12 160.08 27.19 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 178.858 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -119.7 117.15 27.49 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.865 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.513 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 30.8 p -107.03 130.9 54.59 Favored 'General case' 0 C--N 1.279 -2.496 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.441 -174.04 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 112.86 -67.44 0.24 Allowed Glycine 0 N--CA 1.424 -2.123 0 N-CA-C 110.871 -0.891 . . . . 0.0 110.871 -178.689 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -114.58 -8.84 15.57 Favored Glycine 0 C--N 1.314 -0.66 0 C-N-CA 120.109 -1.043 . . . . 0.0 113.335 -176.097 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 47.9 m-80 61.1 18.63 9.2 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 123.253 0.621 . . . . 0.0 112.371 -178.334 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.497 ' O ' HG12 ' A' ' 108' ' ' VAL . 20.6 m -148.47 -176.73 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 -175.76 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -98.8 43.28 1.06 Allowed 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.13 0.491 . . . . 0.0 110.4 -177.237 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.668 ' O ' HG11 ' A' ' 108' ' ' VAL . 17.8 pt-20 -82.63 -175.95 6.02 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.772 -1.104 . . . . 0.0 111.549 177.394 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -80.71 140.26 35.68 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.393 175.285 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.12 -4.89 84.68 Favored Glycine 0 N--CA 1.443 -0.887 0 CA-C-N 115.77 -0.65 . . . . 0.0 113.298 177.691 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.668 HG11 ' O ' ' A' ' 105' ' ' GLU . 15.0 p -88.02 148.21 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -178.237 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.513 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 58.4 mtpt -109.87 128.93 55.65 Favored 'General case' 0 N--CA 1.414 -2.267 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 177.096 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.474 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -91.27 90.69 7.86 Favored 'General case' 0 C--N 1.281 -2.397 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 175.423 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 26.5 m -90.74 110.52 22.33 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-O 122.645 1.212 . . . . 0.0 109.461 -177.361 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 27.5 m-85 -76.9 144.55 38.84 Favored 'General case' 0 C--N 1.272 -2.768 0 CA-C-N 115.074 -0.966 . . . . 0.0 112.324 -178.243 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.2 t -139.7 116.45 10.86 Favored 'General case' 0 N--CA 1.421 -1.912 0 CA-C-N 114.799 -1.091 . . . . 0.0 108.731 -179.28 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 91.4 m -70.82 161.28 31.23 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -179.307 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.613 ' OD1' ' HA2' ' A' ' 94' ' ' GLY . 4.9 m-20 -74.89 -176.73 3.01 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.003 -0.999 . . . . 0.0 110.955 177.552 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -56.03 -49.92 72.36 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 123.68 0.792 . . . . 0.0 112.746 -177.599 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -89.44 19.01 42.5 Favored Glycine 0 N--CA 1.438 -1.217 0 C-N-CA 120.804 -0.712 . . . . 0.0 113.539 -177.802 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.607 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 87.2 m-85 -137.5 159.21 42.59 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 117.287 0.544 . . . . 0.0 110.488 -179.982 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . 0.527 ' OE1' ' HB3' ' A' ' 142' ' ' GLU . 0.0 OUTLIER -145.35 159.17 43.45 Favored 'General case' 0 N--CA 1.425 -1.714 0 C-N-CA 121.087 -0.245 . . . . 0.0 110.348 179.129 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.92 122.71 27.58 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 -176.902 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -107.9 127.62 53.9 Favored 'General case' 0 N--CA 1.414 -2.233 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 179.853 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 113.48 179.41 19.24 Favored Glycine 0 C--N 1.291 -1.93 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -178.182 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -94.49 -30.19 14.55 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.852 0.834 . . . . 0.0 108.77 -177.793 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.2 mm -87.14 122.8 39.44 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.56 0 CA-C-N 114.922 -1.035 . . . . 0.0 109.101 -179.331 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -124.4 1.24 8.36 Favored 'General case' 0 C--O 1.203 -1.38 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 178.811 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 40.4 p90 -139.34 164.74 29.05 Favored 'General case' 0 C--N 1.288 -2.087 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -170.432 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 43.1 mtp180 -127.87 133.63 49.35 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 171.706 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -103.98 128.14 51.53 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 -178.485 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 13.7 t -82.85 105.22 13.69 Favored 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 117.749 -1.58 . . . . 0.0 110.332 177.18 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.458 ' OD1' HG22 ' A' ' 131' ' ' THR . 9.1 t70 -97.84 -168.68 1.71 Allowed 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 177.483 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.458 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.3 t -66.83 -22.57 66.0 Favored 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 118.161 0.437 . . . . 0.0 111.468 -175.123 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -88.95 -9.29 52.03 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.681 0.753 . . . . 0.0 110.03 178.67 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 114.72 -160.8 13.0 Favored Glycine 0 N--CA 1.428 -1.838 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -176.808 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -64.22 113.57 3.66 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 122.543 0.337 . . . . 0.0 111.819 -179.044 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 66.3 p -73.61 176.03 6.56 Favored 'General case' 0 C--O 1.269 2.124 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.408 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 35.1 m-20 60.68 -149.08 0.43 Allowed 'General case' 0 C--O 1.244 0.787 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 179.281 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -144.2 -173.11 3.92 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 171.343 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 73.5 mt -66.01 119.29 60.18 Favored Pre-proline 0 C--N 1.272 -2.798 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 174.877 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -62.15 163.19 20.61 Favored 'Trans proline' 0 C--O 1.253 1.266 0 C-N-CA 122.686 2.257 . . . . 0.0 112.011 -178.918 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.7 mm -93.83 123.72 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 CA-C-O 121.505 0.669 . . . . 0.0 109.939 -173.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.606 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 22.0 t -107.51 110.1 21.94 Favored 'General case' 0 C--N 1.263 -3.187 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 176.607 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.527 ' HB3' ' OE1' ' A' ' 119' ' ' GLN . 10.5 tp10 -101.2 150.77 22.62 Favored 'General case' 0 N--CA 1.409 -2.478 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -175.898 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.607 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 8.6 t -75.63 137.01 23.69 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.385 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.129 -177.696 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 42.9 t -67.96 112.15 2.88 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.933 0 N-CA-C 106.538 -1.652 . . . . 0.0 106.538 174.888 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . 0.426 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 35.3 mtmm -129.86 161.57 30.51 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-N 115.5 -0.773 . . . . 0.0 108.951 -175.609 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -129.62 164.5 23.75 Favored 'General case' 0 C--N 1.271 -2.831 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.896 -178.138 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 85.4 mt -70.63 142.38 88.67 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 113.931 1.085 . . . . 0.0 113.931 -175.67 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_endo -63.39 119.66 6.8 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 123.05 2.5 . . . . 0.0 110.178 175.811 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.401 HG22 ' SD ' ' A' ' 190' ' ' MET . 3.7 t -80.29 151.84 4.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.249 -174.398 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 150' ' ' THR . . . . . 0.429 ' O ' HD11 ' A' ' 157' ' ' ILE . 27.9 p -87.93 -159.08 0.5 Allowed 'General case' 0 N--CA 1.414 -2.24 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 170.971 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -128.9 151.59 77.69 Favored Pre-proline 0 C--N 1.283 -2.306 0 O-C-N 121.142 -0.973 . . . . 0.0 109.53 -172.277 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . 0.428 ' HB3' ' O ' ' A' ' 203' ' ' PRO . 24.0 Cg_endo -66.86 160.7 45.56 Favored 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.055 1.836 . . . . 0.0 112.419 178.072 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -48.88 -45.79 41.64 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 126.0 1.72 . . . . 0.0 114.389 -175.516 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.5 m-80 -126.84 27.15 6.06 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-O 122.077 0.941 . . . . 0.0 109.49 -178.477 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . 0.406 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -132.15 -169.41 12.3 Favored Glycine 0 N--CA 1.42 -2.382 0 CA-C-N 114.714 -1.13 . . . . 0.0 111.066 179.572 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . 0.401 ' HG3' HG23 ' A' ' 177' ' ' VAL . 45.3 pttt -157.94 171.78 19.65 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -177.746 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.429 HD11 ' O ' ' A' ' 150' ' ' THR . 58.6 mt -97.2 131.84 43.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 C-N-CA 122.022 0.129 . . . . 0.0 110.743 -177.613 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.473 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.5 m -75.19 -38.33 41.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.321 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 CA--C 1.537 0.468 0 C-N-CA 124.87 1.268 . . . . 0.0 109.134 -176.501 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 62.0 m-85 . . . . . 0 N--CA 1.448 -0.553 0 CA-C-O 121.668 0.747 . . . . 0.0 111.557 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -105.86 164.24 12.1 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 179.023 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 90.7 t80 -52.14 128.16 23.92 Favored 'General case' 0 C--N 1.317 -0.807 0 C-N-CA 123.123 0.569 . . . . 0.0 109.827 174.516 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.46 -33.95 5.15 Favored Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.382 -179.129 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -70.12 151.62 45.25 Favored 'General case' 0 C--O 1.259 1.557 0 CA-C-O 121.244 0.545 . . . . 0.0 109.825 179.863 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -135.09 131.16 36.59 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-N 115.344 -0.843 . . . . 0.0 109.467 179.339 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 95.3 t -100.12 114.68 39.4 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -178.594 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.538 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 43.2 ttm180 -101.49 142.99 32.05 Favored 'General case' 0 N--CA 1.419 -1.981 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 177.366 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -111.99 160.52 17.38 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 123.138 0.575 . . . . 0.0 110.876 -176.613 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.452 HG21 ' CG1' ' A' ' 158' ' ' VAL . 0.1 OUTLIER -131.52 143.29 40.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.933 178.962 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 93.4 m -102.17 132.1 48.28 Favored 'General case' 0 C--N 1.276 -2.603 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 174.168 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 59.0 m-80 -61.09 163.12 6.38 Favored 'General case' 0 CA--C 1.491 -1.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.569 -178.715 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 10.9 m -46.89 106.67 0.09 Allowed 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 125.51 1.524 . . . . 0.0 112.569 -175.723 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 115.79 -16.52 16.16 Favored Glycine 0 N--CA 1.435 -1.396 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.323 178.99 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -103.8 155.07 18.89 Favored 'General case' 0 CA--C 1.495 -1.138 0 CA-C-N 117.269 0.535 . . . . 0.0 111.609 -177.664 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -125.16 147.34 49.08 Favored 'General case' 0 N--CA 1.423 -1.785 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 177.981 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 9.1 tt -79.96 136.64 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.934 0 CA-C-O 121.802 0.811 . . . . 0.0 111.287 -177.296 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -81.87 -52.14 7.39 Favored 'General case' 0 C--N 1.292 -1.916 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.736 -177.707 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -86.4 -152.75 21.54 Favored Glycine 0 N--CA 1.433 -1.553 0 CA-C-N 114.97 -1.014 . . . . 0.0 111.042 178.487 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . 0.442 ' OD1' ' HD2' ' A' ' 200' ' ' LYS . 1.6 p-10 -92.7 163.11 13.88 Favored 'General case' 0 C--N 1.289 -2.024 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 177.955 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . 0.538 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 0.8 OUTLIER -99.87 3.74 44.75 Favored 'General case' 0 C--N 1.286 -2.181 0 C-N-CA 118.509 -1.277 . . . . 0.0 113.165 -171.683 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -144.39 121.81 11.67 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -173.986 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 190' ' ' MET . . . . . 0.401 ' SD ' HG22 ' A' ' 149' ' ' VAL . 15.0 ptp -105.46 131.19 53.19 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.403 177.955 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 25.1 t-80 -106.16 135.42 47.65 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.446 -176.952 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 7.3 t -72.74 112.48 8.83 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.043 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 193' ' ' SER . . . . . 0.422 ' OG ' ' HB3' ' A' ' 199' ' ' SER . 17.5 m -94.56 172.2 8.33 Favored 'General case' 0 N--CA 1.442 -0.856 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.289 -173.467 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -43.02 -43.1 4.11 Favored 'General case' 0 N--CA 1.495 1.775 0 C-N-CA 127.02 2.128 . . . . 0.0 114.538 -171.713 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -92.26 12.73 21.43 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 113.675 0.991 . . . . 0.0 113.675 -174.798 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 78.97 46.95 7.98 Favored Glycine 0 CA--C 1.496 -1.128 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.8 176.052 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -145.0 160.29 41.6 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.633 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -82.23 132.03 35.23 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 177.389 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 199' ' ' SER . . . . . 0.422 ' HB3' ' OG ' ' A' ' 193' ' ' SER . 23.8 p -66.06 -22.49 66.43 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.551 0.691 . . . . 0.0 111.11 -178.945 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . 0.442 ' HD2' ' OD1' ' A' ' 187' ' ' ASP . 26.5 mmtp -120.75 151.0 40.11 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.534 -177.829 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 73.0 mm-40 -89.42 166.53 13.66 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.211 176.928 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . 0.403 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 39.6 mtpt -63.95 119.04 51.63 Favored Pre-proline 0 C--N 1.319 -0.73 0 O-C-N 123.464 0.477 . . . . 0.0 111.057 179.513 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . 0.428 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 95.4 Cg_endo -77.39 168.1 23.43 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 122.642 2.228 . . . . 0.0 112.056 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 37.1 ttpt -119.9 150.86 39.79 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.86 -176.653 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 83.8 m -110.93 118.72 36.87 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 177.388 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 30.4 m . . . . . 0 C--N 1.3 -1.555 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.574 -175.325 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo . . . . . 0 CA--C 1.537 0.666 0 CA-C-O 121.603 0.585 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.7 m -82.83 -32.89 27.33 Favored 'General case' 0 CA--C 1.504 -0.814 0 CA-C-O 122.005 0.907 . . . . 0.0 108.612 179.024 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.75 -87.85 0.43 Allowed Glycine 0 N--CA 1.396 -3.967 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.366 174.415 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.0 t-80 -175.02 135.39 0.52 Allowed Pre-proline 0 C--N 1.264 -3.135 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 -173.711 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.524 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 66.9 Cg_endo -93.69 -5.18 2.76 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.497 2.131 . . . . 0.0 113.031 -178.139 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 106.73 175.93 23.08 Favored Glycine 0 CA--C 1.485 -1.826 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 178.787 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -151.43 152.88 33.66 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 177.319 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.415 HG22 ' CZ ' ' A' ' 112' ' ' TYR . 9.6 t -125.18 141.12 37.72 Favored Pre-proline 0 C--N 1.29 -1.994 0 O-C-N 123.385 0.428 . . . . 0.0 112.043 -175.218 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -79.84 -12.69 13.36 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 122.913 2.409 . . . . 0.0 111.405 173.511 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -85.98 2.26 46.93 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 121.744 0.783 . . . . 0.0 110.861 -178.7 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.6 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.48 -126.56 1.21 Allowed Glycine 0 N--CA 1.402 -3.571 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 -178.737 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.8 t -164.5 -166.23 1.06 Allowed 'General case' 0 C--N 1.27 -2.878 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.847 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -153.01 158.05 41.44 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 177.691 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.8 m -127.17 158.98 35.65 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 179.991 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 22.0 mt -116.55 127.49 54.56 Favored 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 -179.736 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.498 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 21.2 p -117.61 125.82 51.45 Favored 'General case' 0 C--N 1.29 -1.991 0 CA-C-O 121.311 0.577 . . . . 0.0 111.063 -175.728 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 121.55 -58.18 0.59 Allowed Glycine 0 N--CA 1.432 -1.602 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.306 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -130.82 -3.02 4.64 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.632 -0.794 . . . . 0.0 113.678 -177.868 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 2.3 t30 54.13 29.29 10.15 Favored 'General case' 0 CA--C 1.559 1.315 0 C-N-CA 125.776 1.631 . . . . 0.0 112.016 -178.922 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.531 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.7 m -149.74 -174.77 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.209 -1.043 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 179.699 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.524 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 20.6 m-85 -100.8 44.48 1.01 Allowed 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 118.767 0.712 . . . . 0.0 110.359 -178.174 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 105' ' ' GLU . . . . . 0.741 ' O ' HG13 ' A' ' 108' ' ' VAL . 9.7 pt-20 -85.06 177.59 7.86 Favored 'General case' 0 C--O 1.211 -0.967 0 CA-C-N 114.639 -1.164 . . . . 0.0 111.89 178.413 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -76.58 133.13 39.76 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.219 177.372 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.02 5.06 64.4 Favored Glycine 0 N--CA 1.438 -1.232 0 CA-C-N 115.791 -0.64 . . . . 0.0 112.679 179.85 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.741 HG13 ' O ' ' A' ' 105' ' ' GLU . 11.0 p -97.44 147.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 -179.92 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 109' ' ' LYS . . . . . 0.498 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -109.64 130.64 55.5 Favored 'General case' 0 N--CA 1.42 -1.938 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 177.249 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . 0.529 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -94.49 95.71 9.0 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 175.034 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 78.7 t -89.3 112.9 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.859 0 C-N-CA 123.768 0.827 . . . . 0.0 108.8 -178.327 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 112' ' ' TYR . . . . . 0.501 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 9.6 t80 -81.9 138.39 35.03 Favored 'General case' 0 C--N 1.276 -2.597 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -177.785 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -138.55 120.56 15.56 Favored 'General case' 0 N--CA 1.424 -1.739 0 CA-C-O 121.785 0.802 . . . . 0.0 109.309 177.64 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 114' ' ' CYS . . . . . 0.453 ' SG ' ' HE1' ' A' ' 112' ' ' TYR . 75.8 m -73.94 160.28 31.58 Favored 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.597 -179.244 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.6 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 82.2 m-20 -78.32 177.12 8.69 Favored 'General case' 0 C--O 1.212 -0.884 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.111 176.706 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . 0.467 ' HG3' ' OD2' ' A' ' 194' ' ' ASP . 39.9 tt0 -44.81 -46.62 10.73 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 124.956 1.303 . . . . 0.0 114.308 -177.305 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.91 5.33 82.96 Favored Glycine 0 C--N 1.311 -0.858 0 C-N-CA 120.309 -0.948 . . . . 0.0 114.048 -176.663 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 118' ' ' TYR . . . . . 0.498 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.3 m-85 -130.61 164.28 25.29 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 -176.506 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -148.1 155.77 41.84 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-O 120.988 0.423 . . . . 0.0 110.242 179.495 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -77.38 130.91 37.72 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 179.351 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 121' ' ' LEU . . . . . 0.577 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -119.45 130.41 55.24 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.83 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.17 -175.07 21.82 Favored Glycine 0 C--N 1.295 -1.717 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.521 -179.597 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -91.8 -29.04 16.98 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 121.53 0.681 . . . . 0.0 109.646 -178.331 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 124' ' ' ILE . . . . . 0.582 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 46.9 mm -82.95 114.51 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.553 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.869 -177.778 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 -130.42 7.67 4.95 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.896 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 126' ' ' TYR . . . . . 0.529 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 17.8 p90 -151.57 156.43 40.46 Favored 'General case' 0 N--CA 1.425 -1.689 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.415 -173.446 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 52.1 mtp180 -121.34 125.29 46.65 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 105.14 -2.17 . . . . 0.0 105.14 171.538 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -101.73 126.88 48.67 Favored 'General case' 0 C--N 1.275 -2.65 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.074 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . 0.46 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 25.5 t -86.03 100.81 12.41 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 118.498 -1.281 . . . . 0.0 110.075 176.166 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.425 ' OD1' HG23 ' A' ' 131' ' ' THR . 9.2 t70 -98.71 -165.28 1.22 Allowed 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 105.456 -2.053 . . . . 0.0 105.456 175.602 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.425 HG23 ' OD1' ' A' ' 130' ' ' ASP . 10.2 t -63.5 -22.95 67.18 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 119.131 0.878 . . . . 0.0 112.143 -177.02 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -80.23 -13.57 59.11 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.652 0.739 . . . . 0.0 110.692 176.357 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.46 ' HA2' ' SG ' ' A' ' 129' ' ' CYS . . . 105.49 -148.51 16.52 Favored Glycine 0 N--CA 1.421 -2.339 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -175.375 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 85.0 m95 -69.13 109.55 4.09 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 176.908 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 28.9 p -61.14 -68.8 0.28 Allowed 'General case' 0 N--CA 1.438 -1.039 0 O-C-N 123.792 0.682 . . . . 0.0 111.48 -178.126 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 74.4 m-20 -75.62 177.13 7.02 Favored 'General case' 0 CA--C 1.489 -1.368 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.513 178.035 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -108.13 -168.91 1.43 Allowed 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 178.511 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.2 mt -60.87 117.98 30.76 Favored Pre-proline 0 C--N 1.295 -1.775 0 O-C-N 123.986 0.804 . . . . 0.0 109.33 177.272 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 139' ' ' PRO . . . . . 0.582 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 53.3 Cg_exo -52.77 165.99 0.99 Allowed 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.867 3.045 . . . . 0.0 113.916 178.644 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 140' ' ' ILE . . . . . 0.577 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 3.6 mp -90.73 130.7 39.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.172 -174.801 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 141' ' ' CYS . . . . . 0.498 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 25.4 t -123.6 114.93 20.68 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.318 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -110.41 149.79 29.76 Favored 'General case' 0 N--CA 1.405 -2.711 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 -177.961 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 9.6 p -73.69 143.53 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.898 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.572 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 89.3 t -68.69 123.05 21.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 177.155 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -109.3 140.14 43.36 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.149 -176.421 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 57.5 m -102.13 144.66 30.41 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.9 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 147' ' ' LEU . . . . . 0.4 HD23 ' HD2' ' A' ' 148' ' ' PRO . 1.4 tt -49.59 130.03 19.4 Favored Pre-proline 0 N--CA 1.432 -1.36 0 C-N-CA 125.275 1.43 . . . . 0.0 110.748 179.491 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.581 ' HA ' ' CD2' ' A' ' 168' ' ' TYR . 12.4 Cg_endo -57.74 110.59 0.65 Allowed 'Trans proline' 0 N--CA 1.454 -0.813 0 C-N-CA 123.557 2.838 . . . . 0.0 113.35 -178.522 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 13.6 p -83.81 142.72 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 CA-C-N 115.176 -0.92 . . . . 0.0 108.865 177.397 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 10.2 p -105.22 -156.4 0.57 Allowed 'General case' 0 C--N 1.288 -2.069 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.37 176.172 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -100.85 151.25 37.56 Favored Pre-proline 0 C--N 1.298 -1.649 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -170.636 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -75.62 170.24 20.64 Favored 'Trans proline' 0 N--CA 1.436 -1.906 0 C-N-CA 121.442 1.428 . . . . 0.0 110.914 175.25 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -50.41 -55.24 16.62 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 114.306 1.224 . . . . 0.0 114.306 -175.992 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 154' ' ' ASN . . . . . 0.438 ' HB2' ' O ' ' A' ' 205' ' ' CYS . 57.4 m-80 -113.95 27.04 9.82 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.19 0.519 . . . . 0.0 110.725 -177.544 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.7 -173.1 15.71 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 120.081 -1.057 . . . . 0.0 111.726 179.768 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 50.3 pttt -153.33 172.67 16.68 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -178.14 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 62.5 mt -86.04 132.1 32.91 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 CA-C-O 121.169 0.509 . . . . 0.0 111.058 -176.46 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.442 ' CG2' ' HB ' ' A' ' 177' ' ' VAL . 47.9 t -76.52 -40.31 33.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 C-N-CA 123.974 0.91 . . . . 0.0 108.907 177.172 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 C--N 1.301 -1.519 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.446 179.933 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 168' ' ' TYR . . . . . 0.581 ' CD2' ' HA ' ' A' ' 148' ' ' PRO . 98.0 m-85 . . . . . 0 CA--C 1.508 -0.658 0 CA-C-O 121.661 0.743 . . . . 0.0 112.087 . . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 27.7 m80 -98.38 155.47 17.21 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 114.506 -1.224 . . . . 0.0 107.966 -179.463 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -56.77 131.5 49.45 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 172.012 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 113.43 -15.03 22.64 Favored Glycine 0 N--CA 1.414 -2.768 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.234 -177.682 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 172' ' ' GLN . . . . . 0.402 ' O ' ' HA ' ' A' ' 191' ' ' HIS . 15.5 mm100 -74.58 134.38 42.13 Favored 'General case' 0 N--CA 1.423 -1.788 0 C-N-CA 120.223 -0.591 . . . . 0.0 111.976 179.55 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -115.15 94.34 4.69 Favored 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 173.562 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 66.2 t -81.61 109.02 15.36 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 CA-C-N 115.243 -0.889 . . . . 0.0 108.963 -176.121 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 175' ' ' ARG . . . . . 0.427 ' HD2' ' OE1' ' A' ' 188' ' ' GLU . 14.5 ttp180 -97.1 156.27 16.45 Favored 'General case' 0 N--CA 1.411 -2.387 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 179.055 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -127.09 156.35 41.85 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 124.038 0.935 . . . . 0.0 109.399 -175.006 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.442 ' HB ' ' CG2' ' A' ' 158' ' ' VAL . 12.2 p -133.56 141.07 45.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.461 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 80.5 m -102.54 153.63 19.89 Favored 'General case' 0 C--N 1.265 -3.105 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.961 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -64.62 163.46 13.68 Favored 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 119.972 -0.691 . . . . 0.0 110.153 176.73 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 15.8 m -43.54 -32.74 0.98 Allowed 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 116.37 1.989 . . . . 0.0 116.37 -170.724 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -113.36 21.09 17.87 Favored Glycine 0 C--N 1.293 -1.847 0 C-N-CA 120.1 -1.047 . . . . 0.0 113.375 -179.048 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -122.32 151.06 41.53 Favored 'General case' 0 N--CA 1.432 -1.335 0 O-C-N 122.129 -0.63 . . . . 0.0 111.356 179.28 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -124.15 143.59 50.4 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.158 -178.93 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.4 tt -74.87 140.55 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.928 0 CA-C-O 121.476 0.655 . . . . 0.0 111.288 -176.695 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -67.01 -64.57 0.83 Allowed 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.318 -177.261 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -103.41 -123.59 5.3 Favored Glycine 0 N--CA 1.436 -1.32 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.283 -179.558 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 187' ' ' ASP . . . . . 0.51 ' HB2' ' HG3' ' A' ' 200' ' ' LYS . 5.5 m-20 -91.63 153.4 19.73 Favored 'General case' 0 CA--C 1.491 -1.291 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -177.495 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 188' ' ' GLU . . . . . 0.427 ' OE1' ' HD2' ' A' ' 175' ' ' ARG . 14.2 pt-20 -91.65 -4.04 55.67 Favored 'General case' 0 C--O 1.205 -1.286 0 C-N-CA 119.944 -0.702 . . . . 0.0 111.174 -172.027 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -134.34 132.31 39.35 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 -177.72 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 14.4 ptp -112.68 123.54 50.53 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.271 174.881 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 191' ' ' HIS . . . . . 0.402 ' HA ' ' O ' ' A' ' 172' ' ' GLN . 16.4 t-80 -110.36 139.01 45.99 Favored 'General case' 0 C--N 1.279 -2.498 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.954 -177.317 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 22.0 m -62.64 130.14 43.69 Favored 'General case' 0 C--N 1.32 -0.705 0 O-C-N 123.657 0.598 . . . . 0.0 111.668 175.207 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 37.5 t -101.78 166.92 10.41 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.137 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 194' ' ' ASP . . . . . 0.467 ' OD2' ' HG3' ' A' ' 116' ' ' GLU . 6.3 t70 -52.41 -33.22 42.82 Favored 'General case' 0 N--CA 1.511 2.613 0 C-N-CA 124.236 1.014 . . . . 0.0 110.332 178.925 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -56.94 -26.21 59.14 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 113.75 -1.568 . . . . 0.0 111.742 179.807 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 89.59 15.53 58.2 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -174.97 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -125.27 170.54 11.19 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.064 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -85.39 142.49 29.24 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 123.678 0.611 . . . . 0.0 110.944 -177.699 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 30.7 t -60.64 -50.29 74.11 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.725 176.593 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 200' ' ' LYS . . . . . 0.51 ' HG3' ' HB2' ' A' ' 187' ' ' ASP . 12.9 mmmm -104.61 156.14 18.23 Favored 'General case' 0 CA--C 1.485 -1.548 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 174.227 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -89.06 171.73 9.63 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 170.546 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 34.9 ttmt -61.9 122.25 70.67 Favored Pre-proline 0 C--O 1.243 0.724 0 CA-C-N 118.985 0.811 . . . . 0.0 110.492 -176.246 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.04 -173.49 1.9 Allowed 'Trans proline' 0 N--CA 1.437 -1.833 0 C-N-CA 122.039 1.826 . . . . 0.0 111.067 179.122 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 66.0 mttm -126.58 160.88 29.39 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.118 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 205' ' ' CYS . . . . . 0.438 ' O ' ' HB2' ' A' ' 154' ' ' ASN . 97.4 m -116.62 105.19 12.17 Favored 'General case' 0 C--N 1.27 -2.887 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 170.852 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 23.7 m . . . . . 0 C--N 1.286 -2.176 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.033 -173.547 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.415 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 30.6 Cg_endo . . . . . 0 CA--C 1.542 0.907 0 CA-C-O 121.436 0.515 . . . . 0.0 111.761 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.1 m -85.03 -37.68 20.09 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 177.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.08 -92.41 0.48 Allowed Glycine 0 N--CA 1.41 -3.095 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 173.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.9 t60 -177.24 123.73 0.28 Allowed Pre-proline 0 C--N 1.26 -3.314 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 -177.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.433 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 34.8 Cg_endo -66.72 -49.91 1.42 Allowed 'Trans proline' 0 C--O 1.209 -0.933 0 C-N-CA 121.33 1.353 . . . . 0.0 110.722 -177.179 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 150.32 169.18 16.08 Favored Glycine 0 N--CA 1.401 -3.642 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 -177.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -136.03 139.93 43.46 Favored 'General case' 0 C--N 1.264 -3.113 0 CA-C-N 117.31 0.555 . . . . 0.0 109.688 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.5 t -99.9 128.97 29.58 Favored Pre-proline 0 N--CA 1.409 -2.525 0 CA-C-N 115.111 -0.949 . . . . 0.0 111.304 -172.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -69.04 -24.01 33.44 Favored 'Trans proline' 0 C--O 1.24 0.591 0 C-N-CA 122.884 2.389 . . . . 0.0 110.214 175.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -75.06 -28.28 60.31 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 114.014 -1.448 . . . . 0.0 110.763 -176.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.433 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -151.0 -133.21 2.03 Favored Glycine 0 N--CA 1.409 -3.159 0 C-N-CA 119.071 -1.538 . . . . 0.0 112.783 -177.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.0 p -144.1 170.67 15.51 Favored 'General case' 0 C--N 1.275 -2.64 0 CA-C-N 113.885 -1.157 . . . . 0.0 108.896 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -140.69 153.55 46.0 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 172.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -127.26 160.12 32.27 Favored 'General case' 0 C--N 1.274 -2.705 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -116.72 118.63 33.07 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 121.293 0.568 . . . . 0.0 109.874 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 26.2 p -111.88 133.64 53.95 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.755 -174.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 111.98 -53.13 0.6 Allowed Glycine 0 N--CA 1.434 -1.478 0 C-N-CA 120.865 -0.683 . . . . 0.0 111.557 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -131.31 -7.21 3.23 Favored Glycine 0 N--CA 1.441 -0.999 0 C-N-CA 120.196 -1.002 . . . . 0.0 113.109 -179.008 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 48.4 m-80 61.17 17.4 8.08 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.53 ' O ' HG11 ' A' ' 108' ' ' VAL . 19.7 m -149.01 -170.07 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.205 -1.286 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -177.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -103.47 45.57 0.95 Allowed 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 118.422 0.556 . . . . 0.0 110.083 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.757 ' O ' HG13 ' A' ' 108' ' ' VAL . 11.9 pt-20 -86.08 176.28 8.09 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 114.957 -1.019 . . . . 0.0 111.58 177.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . 0.429 ' CE1' ' HA ' ' A' ' 131' ' ' THR . 46.0 m-85 -72.91 133.23 44.29 Favored 'General case' 0 C--N 1.293 -1.859 0 O-C-N 121.976 -0.453 . . . . 0.0 111.273 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.36 -8.7 69.42 Favored Glycine 0 N--CA 1.434 -1.453 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.232 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.757 HG13 ' O ' ' A' ' 105' ' ' GLU . 14.2 p -80.67 147.69 6.19 Favored 'Isoleucine or valine' 0 C--O 1.238 0.481 0 CA-C-N 117.553 0.676 . . . . 0.0 109.946 -176.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 16.8 mtpp -112.38 119.08 37.03 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -87.91 96.49 10.5 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.434 HG13 ' HB3' ' A' ' 126' ' ' TYR . 18.8 m -94.81 115.82 34.59 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.327 0 CA-C-O 122.036 0.922 . . . . 0.0 109.979 -177.02 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 33.3 m-85 -83.07 144.43 29.9 Favored 'General case' 0 C--N 1.265 -3.072 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.524 -178.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.4 t -143.64 127.79 17.6 Favored 'General case' 0 N--CA 1.427 -1.621 0 CA-C-N 115.275 -0.875 . . . . 0.0 108.803 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 81.4 m -73.71 163.39 28.04 Favored 'General case' 0 C--N 1.292 -1.891 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.317 -176.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.433 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 95.4 m-20 -95.25 -179.15 4.69 Favored 'General case' 0 CA--C 1.476 -1.887 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.72 -178.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -69.09 93.96 0.63 Allowed 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 124.573 1.171 . . . . 0.0 109.753 177.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 133.66 2.13 3.64 Favored Glycine 0 C--N 1.259 -3.698 0 CA-C-N 112.961 -1.927 . . . . 0.0 111.781 177.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.416 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 87.8 m-85 -133.49 158.7 42.44 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -177.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -142.11 158.06 44.18 Favored 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 -177.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 13.9 tp -83.07 146.27 28.8 Favored 'General case' 0 N--CA 1.413 -2.282 0 C-N-CA 119.491 -0.884 . . . . 0.0 109.169 -177.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.09 121.64 38.33 Favored 'General case' 0 N--CA 1.405 -2.709 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.359 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 100.4 174.93 29.96 Favored Glycine 0 C--N 1.292 -1.897 0 N-CA-C 110.914 -0.875 . . . . 0.0 110.914 -174.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -88.05 -37.89 15.9 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.255 0.55 . . . . 0.0 110.112 -177.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.3 mm -66.7 124.47 21.96 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.758 -177.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -127.13 -4.34 6.23 Favored 'General case' 0 C--O 1.204 -1.317 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.434 ' HB3' HG13 ' A' ' 111' ' ' VAL . 11.9 p90 -137.23 161.83 35.14 Favored 'General case' 0 C--N 1.293 -1.888 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.496 -170.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 49.9 mtp180 -125.28 136.11 53.19 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 106.112 -1.81 . . . . 0.0 106.112 171.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -115.32 130.94 57.05 Favored 'General case' 0 C--N 1.273 -2.719 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 33.0 t -86.49 112.26 21.35 Favored 'General case' 0 C--N 1.293 -1.869 0 C-N-CA 119.109 -1.036 . . . . 0.0 110.83 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.464 ' OD2' HG22 ' A' ' 131' ' ' THR . 14.9 t70 -103.24 -171.26 1.91 Allowed 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 175.339 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.464 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -71.16 -17.78 62.53 Favored 'General case' 0 C--N 1.291 -1.946 0 CA-C-O 121.874 0.845 . . . . 0.0 110.309 -175.027 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -87.9 -8.77 55.34 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.691 179.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 112.78 -164.32 12.07 Favored Glycine 0 N--CA 1.427 -1.936 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -177.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.433 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 97.8 m95 -60.97 123.34 17.32 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 117.255 0.527 . . . . 0.0 110.579 176.037 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.6 p -64.46 -71.77 0.17 Allowed 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 123.554 0.742 . . . . 0.0 111.99 -178.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -81.58 177.66 8.8 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.175 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -106.12 177.84 4.74 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.282 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 65.0 mt -61.38 121.11 61.21 Favored Pre-proline 0 C--O 1.245 0.861 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 176.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.13 166.89 23.48 Favored 'Trans proline' 0 C--O 1.26 1.625 0 C-N-CA 122.424 2.083 . . . . 0.0 111.637 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 55.7 mt -90.06 127.02 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.03 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -177.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.416 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 53.6 t -121.07 115.62 23.46 Favored 'General case' 0 C--N 1.269 -2.916 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 174.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.18 151.95 23.43 Favored 'General case' 0 C--N 1.282 -2.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 109.864 -177.236 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.5 p -68.88 137.52 24.18 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.105 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 41.5 t -63.95 125.91 21.58 Favored 'Isoleucine or valine' 0 C--O 1.247 0.951 0 CA-C-O 121.111 0.482 . . . . 0.0 109.74 178.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -119.13 133.55 55.72 Favored 'General case' 0 N--CA 1.418 -2.074 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -179.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 72.8 m -99.63 141.18 32.77 Favored 'General case' 0 C--N 1.261 -3.267 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -58.63 138.5 86.12 Favored Pre-proline 0 N--CA 1.427 -1.579 0 N-CA-C 114.209 1.188 . . . . 0.0 114.209 -175.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -58.25 107.4 0.32 Allowed 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 123.346 2.698 . . . . 0.0 111.117 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 5.9 p -69.26 140.58 18.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 20.5 p -71.9 -71.81 0.26 Allowed 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 111.405 0.15 . . . . 0.0 111.405 -178.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.38 162.3 0.21 Allowed Pre-proline 0 C--O 1.248 1.005 0 C-N-CA 125.748 1.619 . . . . 0.0 106.712 177.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -74.3 170.88 19.19 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 121.512 1.475 . . . . 0.0 109.469 169.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . 0.487 ' HG3' ' ND2' ' A' ' 154' ' ' ASN . 11.4 pt-20 -60.67 -48.92 79.62 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 114.055 1.132 . . . . 0.0 114.055 -173.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . 0.487 ' ND2' ' HG3' ' A' ' 153' ' ' GLU . 60.2 m-80 -117.31 32.39 6.19 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.505 0.669 . . . . 0.0 109.668 -177.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.06 -176.59 18.22 Favored Glycine 0 C--N 1.303 -1.269 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.477 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.4 ptmt -145.21 173.27 12.09 Favored 'General case' 0 N--CA 1.434 -1.231 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -178.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 69.0 mt -88.22 138.49 19.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 CA-C-O 121.3 0.572 . . . . 0.0 110.957 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.6 t -89.29 -39.71 12.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 C-N-CA 124.426 1.09 . . . . 0.0 109.402 176.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 9.9 m -85.46 45.61 1.21 Allowed 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 123.512 0.725 . . . . 0.0 111.09 -178.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 25.4 m -77.45 -30.17 53.17 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-O 121.019 0.438 . . . . 0.0 111.185 -178.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -123.12 156.25 35.36 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.28 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 22.3 ptp 174.53 -33.69 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.804 1.241 . . . . 0.0 107.7 -177.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -146.18 160.15 43.6 Favored Pre-proline 0 C--N 1.311 -1.104 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 178.068 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -82.8 -6.95 11.48 Favored 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 122.199 1.933 . . . . 0.0 110.178 172.271 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -96.33 -49.39 5.21 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.172 -1.377 . . . . 0.0 108.817 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . 0.383 7.5 ppt_? 35.52 75.67 0.06 Allowed 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 119.064 2.987 . . . . 0.0 119.064 178.022 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -95.49 148.67 22.23 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 104.228 -2.508 . . . . 0.0 104.228 167.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -87.33 91.7 8.82 Favored 'General case' 0 C--N 1.276 -2.606 0 C-N-CA 119.119 -1.032 . . . . 0.0 111.198 178.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 47.2 m170 -84.32 164.07 19.21 Favored 'General case' 0 C--O 1.248 1.019 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.115 -179.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 72.4 t80 -52.63 134.64 35.68 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 123.697 0.799 . . . . 0.0 110.765 173.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 102.01 -23.34 34.92 Favored Glycine 0 C--N 1.314 -0.674 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.305 179.02 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -72.85 133.97 44.67 Favored 'General case' 0 N--CA 1.434 -1.229 0 CA-C-O 121.085 0.469 . . . . 0.0 111.991 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . 0.411 ' HB3' ' NE2' ' A' ' 191' ' ' HIS . . . -106.28 115.73 30.72 Favored 'General case' 0 N--CA 1.421 -1.889 0 CA-C-N 114.733 -1.122 . . . . 0.0 109.142 178.403 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 48.3 t -91.27 108.75 20.25 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 175.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.432 ' HD2' ' OE2' ' A' ' 188' ' ' GLU . 20.4 ttp180 -99.4 153.79 18.72 Favored 'General case' 0 N--CA 1.403 -2.82 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 177.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 83.4 m-85 -127.24 158.9 35.93 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 123.24 0.616 . . . . 0.0 109.533 -174.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.9 p -140.57 140.32 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.579 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 77.1 m -89.62 149.61 22.74 Favored 'General case' 0 C--N 1.278 -2.54 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.186 -179.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 81.8 m-20 -76.15 179.4 5.72 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.307 -178.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 25.2 p -53.72 111.26 0.7 Allowed 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 124.027 0.931 . . . . 0.0 112.511 -176.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 97.38 2.31 58.98 Favored Glycine 0 N--CA 1.433 -1.544 0 CA-C-N 115.846 -0.615 . . . . 0.0 113.847 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -111.6 149.09 31.97 Favored 'General case' 0 CA--C 1.484 -1.573 0 CA-C-N 117.971 0.886 . . . . 0.0 110.704 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . 0.408 ' HZ3' ' HA ' ' A' ' 185' ' ' GLU . 0.1 OUTLIER -122.38 145.86 47.88 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -178.678 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.6 tt -76.3 137.01 23.5 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 CA-C-O 122.049 0.928 . . . . 0.0 111.798 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . 0.408 ' HA ' ' HZ3' ' A' ' 183' ' ' LYS . 5.2 tp10 -84.33 -48.66 9.48 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.171 -176.382 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -91.09 -136.2 6.75 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.315 177.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . 0.432 ' OD1' ' HG3' ' A' ' 189' ' ' GLU . 12.2 t70 -102.58 163.68 12.09 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 178.443 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . 0.432 ' OE2' ' HD2' ' A' ' 175' ' ' ARG . 15.8 pt-20 -91.15 -13.85 32.22 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 118.887 0.767 . . . . 0.0 112.668 -174.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . 0.432 ' HG3' ' OD1' ' A' ' 187' ' ' ASP . 0.0 OUTLIER -120.03 144.92 47.28 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 112.84 0.682 . . . . 0.0 112.84 -176.724 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 37.0 ttm -135.97 124.33 23.35 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 124.864 1.266 . . . . 0.0 109.075 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . 0.411 ' NE2' ' HB3' ' A' ' 173' ' ' ALA . 30.7 m80 -97.86 155.44 17.06 Favored 'General case' 0 C--N 1.276 -2.618 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 40.6 t -94.94 116.88 29.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 173.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 8.4 p -100.23 170.21 8.61 Favored 'General case' 0 N--CA 1.437 -1.122 0 O-C-N 123.354 0.409 . . . . 0.0 111.174 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -60.01 -21.26 61.08 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 123.607 0.763 . . . . 0.0 112.064 -175.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 13.7 m-20 -64.51 -17.54 63.99 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.741 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 80.94 20.48 65.24 Favored Glycine 0 CA--C 1.488 -1.656 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -130.48 153.44 48.79 Favored 'General case' 0 N--CA 1.407 -2.597 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 -174.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 78.2 m95 -76.84 131.47 38.65 Favored 'General case' 0 C--N 1.291 -1.971 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.34 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.5 m -69.06 -38.33 79.01 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 115.639 -0.709 . . . . 0.0 112.289 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -103.73 156.95 17.41 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 20.0 pm0 -78.83 157.91 28.27 Favored 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 177.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -68.05 116.62 40.71 Favored Pre-proline 0 C--O 1.246 0.908 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 175.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -76.98 161.5 32.86 Favored 'Trans proline' 0 N--CA 1.433 -2.088 0 C-N-CA 122.218 1.945 . . . . 0.0 110.998 -178.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -104.52 161.83 13.77 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 120.226 -0.589 . . . . 0.0 109.6 178.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 88.9 m -122.19 108.55 13.43 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 172.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.1 m . . . . . 0 C--N 1.291 -1.957 0 O-C-N 124.405 1.066 . . . . 0.0 108.818 -173.788 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.418 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 19.1 Cg_endo . . . . . 0 CA--C 1.537 0.657 0 CA-C-O 120.859 0.274 . . . . 0.0 112.205 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 50.0 m -71.67 -43.98 65.07 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.756 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 97.07 112.44 2.94 Favored Glycine 0 C--O 1.187 -2.791 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 -179.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -34.36 119.52 0.54 Allowed Pre-proline 0 C--N 1.296 -1.734 0 C-N-CA 127.235 2.214 . . . . 0.0 112.129 -173.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -60.67 -43.32 32.99 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.283 2.655 . . . . 0.0 113.305 -172.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 139.73 -174.98 22.06 Favored Glycine 0 N--CA 1.421 -2.336 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -133.78 156.66 47.6 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-N 117.403 0.602 . . . . 0.0 109.691 -178.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.1 t -115.3 126.63 27.59 Favored Pre-proline 0 C--N 1.305 -1.368 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.282 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -66.97 -18.8 52.29 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.555 2.17 . . . . 0.0 112.556 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -87.7 -15.05 38.21 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.37 -175.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.493 ' HA2' ' ND2' ' A' ' 115' ' ' ASN . . . -163.62 -133.43 1.48 Allowed Glycine 0 N--CA 1.409 -3.136 0 C-N-CA 118.635 -1.745 . . . . 0.0 113.004 -177.413 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.1 p -144.2 179.59 7.13 Favored 'General case' 0 C--N 1.284 -2.249 0 CA-C-N 114.439 -0.881 . . . . 0.0 109.264 -176.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -141.5 157.65 44.86 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 172.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.4 m -127.56 162.53 26.24 Favored 'General case' 0 C--N 1.278 -2.524 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.0 mt -118.43 117.03 27.94 Favored 'General case' 0 C--N 1.277 -2.579 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.487 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 19.5 p -109.16 127.63 54.35 Favored 'General case' 0 C--N 1.282 -2.364 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.245 -172.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 113.97 -37.92 3.38 Favored Glycine 0 N--CA 1.433 -1.567 0 C-N-CA 120.406 -0.902 . . . . 0.0 111.975 179.212 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -144.28 -7.14 0.5 Allowed Glycine 0 C--N 1.315 -0.588 0 C-N-CA 119.715 -1.231 . . . . 0.0 113.756 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 92.6 m-20 61.14 15.11 6.01 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.517 ' O ' HG11 ' A' ' 108' ' ' VAL . 24.0 m -146.52 -169.42 0.24 Allowed 'Isoleucine or valine' 0 C--O 1.209 -1.027 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -176.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -106.46 40.29 1.65 Allowed 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 118.29 0.496 . . . . 0.0 110.227 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.771 ' O ' HG13 ' A' ' 108' ' ' VAL . 10.1 pt-20 -83.04 176.48 9.21 Favored 'General case' 0 C--O 1.205 -1.24 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.046 178.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . 0.418 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 35.5 m-85 -72.88 133.26 44.33 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.218 177.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.51 5.05 63.6 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.34 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.771 HG13 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -94.97 147.16 5.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.171 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.487 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 51.8 mtpt -110.76 118.47 36.25 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 178.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -83.28 92.48 7.51 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.301 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.543 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 35.0 m -89.1 117.71 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.824 0 CA-C-O 122.151 0.977 . . . . 0.0 109.903 -178.521 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 31.5 m-85 -85.88 139.48 31.21 Favored 'General case' 0 C--N 1.263 -3.182 0 CA-C-N 115.129 -0.941 . . . . 0.0 108.896 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.2 t -138.96 124.6 19.54 Favored 'General case' 0 N--CA 1.407 -2.603 0 CA-C-O 121.999 0.904 . . . . 0.0 109.671 -178.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 74.3 m -71.74 161.79 30.44 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-N 115.0 -1.0 . . . . 0.0 112.455 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.493 ' ND2' ' HA2' ' A' ' 94' ' ' GLY . 81.3 m-20 -86.31 -176.59 5.95 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.479 179.098 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -46.87 -50.94 17.81 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 126.513 1.925 . . . . 0.0 114.008 -177.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -91.19 28.36 8.17 Favored Glycine 0 C--N 1.305 -1.158 0 C-N-CA 119.736 -1.221 . . . . 0.0 113.179 -177.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.451 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 98.8 m-85 -149.37 167.51 25.94 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -173.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . 0.42 HE22 HD21 ' A' ' 121' ' ' LEU . 1.0 OUTLIER -153.88 156.87 38.37 Favored 'General case' 0 N--CA 1.435 -1.195 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.81 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . 0.465 ' HG ' ' CB ' ' A' ' 125' ' ' ASN . 0.5 OUTLIER -85.99 128.39 34.84 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -175.182 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.42 HD21 HE22 ' A' ' 119' ' ' GLN . 0.3 OUTLIER -102.1 130.1 48.62 Favored 'General case' 0 N--CA 1.422 -1.864 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 -175.741 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.74 -159.7 13.83 Favored Glycine 0 C--N 1.297 -1.63 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.296 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -106.03 -41.63 5.33 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 121.835 0.826 . . . . 0.0 109.267 -178.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 51.1 mm -85.17 122.92 38.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 CA-C-N 114.772 -1.104 . . . . 0.0 110.069 -176.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.465 ' CB ' ' HG ' ' A' ' 120' ' ' LEU . 3.9 p-10 -127.59 7.12 6.27 Favored 'General case' 0 C--O 1.202 -1.41 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 176.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.543 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 15.4 p90 -134.25 168.21 19.3 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -171.784 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.446 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 36.3 mtp180 -130.67 119.89 23.1 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 170.399 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -92.32 126.76 37.54 Favored 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.846 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 49.3 t -84.7 108.04 17.21 Favored 'General case' 0 N--CA 1.434 -1.266 0 C-N-CA 119.142 -1.023 . . . . 0.0 109.249 174.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -101.76 -171.22 1.94 Allowed 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 105.354 -2.091 . . . . 0.0 105.354 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 15.3 t -64.37 -15.34 60.26 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.841 0.829 . . . . 0.0 110.593 -178.511 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -97.88 -2.17 41.35 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.255 -178.686 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 103.48 -159.44 16.93 Favored Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -177.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 86.9 m95 -68.64 108.47 3.37 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 177.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 41.7 p -67.71 -57.51 6.23 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 115.439 -0.8 . . . . 0.0 112.655 -175.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . 0.446 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 6.4 m120 -71.83 171.22 12.07 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.957 -178.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 25.2 m-20 -100.74 176.61 5.24 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 176.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 88.6 mt -66.35 119.07 59.39 Favored Pre-proline 0 C--O 1.237 0.407 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 173.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -64.46 164.7 22.48 Favored 'Trans proline' 0 N--CA 1.451 -0.993 0 C-N-CA 122.601 2.2 . . . . 0.0 112.986 -177.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 50.0 mm -96.49 124.47 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.766 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.903 -175.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.451 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 48.9 t -105.66 136.12 45.83 Favored 'General case' 0 C--N 1.27 -2.882 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 177.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -124.91 141.8 51.88 Favored 'General case' 0 N--CA 1.413 -2.28 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -177.236 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 6.2 p -68.34 139.19 21.09 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 O-C-N 123.874 0.734 . . . . 0.0 109.573 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.618 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 21.1 m -65.83 129.44 30.14 Favored 'Isoleucine or valine' 0 C--O 1.251 1.168 0 C-N-CA 120.48 -0.488 . . . . 0.0 110.094 178.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 89.4 mttt -114.79 166.6 11.58 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -178.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 82.0 m -129.43 -174.22 3.23 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-O 121.135 0.493 . . . . 0.0 111.457 -175.081 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 31.1 mt -77.72 137.0 62.76 Favored Pre-proline 0 N--CA 1.439 -0.991 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.315 177.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -70.86 112.51 3.29 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 C-N-CA 122.279 1.986 . . . . 0.0 109.683 175.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 27.8 t -82.81 136.61 22.51 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 -179.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.6 p -76.93 -73.71 0.28 Allowed 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 123.104 0.252 . . . . 0.0 111.518 179.371 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 167.9 160.19 0.15 Allowed Pre-proline 0 C--O 1.239 0.548 0 C-N-CA 126.128 1.771 . . . . 0.0 106.95 -179.368 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -77.49 170.05 19.99 Favored 'Trans proline' 0 CA--C 1.542 0.883 0 C-N-CA 121.586 1.524 . . . . 0.0 110.26 170.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -63.14 -52.6 61.87 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 -176.126 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -106.48 33.45 3.87 Favored 'General case' 0 CA--C 1.499 -1.011 0 CA-C-O 121.363 0.601 . . . . 0.0 109.981 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -151.59 -167.35 14.85 Favored Glycine 0 N--CA 1.42 -2.406 0 C-N-CA 120.133 -1.032 . . . . 0.0 112.062 178.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . 0.454 ' HG3' HG21 ' A' ' 177' ' ' VAL . 59.6 pttt -154.55 176.19 12.7 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -179.435 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 49.3 mt -98.31 145.05 10.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -179.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.447 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.5 m -89.12 -31.39 5.42 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.081 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 6.7 m -93.95 45.3 1.14 Allowed 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 124.603 1.161 . . . . 0.0 110.951 -175.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.4 m -82.18 4.98 21.27 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -176.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -136.07 134.01 37.96 Favored 'General case' 0 N--CA 1.434 -1.267 0 CA-C-O 120.773 0.32 . . . . 0.0 110.518 179.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 21.4 ptp -176.59 -42.11 0.01 OUTLIER 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 126.29 1.836 . . . . 0.0 106.084 178.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -136.63 148.64 64.44 Favored Pre-proline 0 N--CA 1.437 -1.11 0 N-CA-C 103.958 -2.608 . . . . 0.0 103.958 166.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.81 -8.1 22.74 Favored 'Trans proline' 0 CA--C 1.542 0.917 0 C-N-CA 122.082 1.855 . . . . 0.0 110.977 175.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . 0.454 ' C ' ' HG3' ' A' ' 166' ' ' ARG . 4.4 m-20 -103.34 -19.73 14.34 Favored 'General case' 0 CA--C 1.469 -2.137 0 CA-C-N 114.309 -1.314 . . . . 0.0 108.789 -179.19 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.484 ' HD2' ' O ' ' A' ' 166' ' ' ARG 0.289 0.0 OUTLIER 37.17 75.36 0.07 Allowed 'General case' 0 N--CA 1.434 -1.268 0 C-N-CA 125.362 1.465 . . . . 0.0 114.026 -175.207 . . . . . . . . 4 4 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -91.31 -23.39 20.13 Favored 'General case' 0 C--N 1.298 -1.671 0 CA-C-N 113.66 -1.609 . . . . 0.0 110.712 -178.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 72.2 152.33 0.12 Allowed 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 113.255 -1.793 . . . . 0.0 112.181 177.257 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.406 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 35.9 m80 -141.61 162.44 35.48 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -177.086 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . 0.618 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 91.6 t80 -48.25 139.43 8.58 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-O 121.194 0.521 . . . . 0.0 112.104 175.342 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 87.37 -15.22 55.31 Favored Glycine 0 N--CA 1.423 -2.217 0 CA-C-O 119.204 -0.776 . . . . 0.0 113.867 175.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . 0.41 ' O ' ' HA ' ' A' ' 191' ' ' HIS . 29.2 mm-40 -65.0 135.76 56.01 Favored 'General case' 0 CA--C 1.496 -1.127 0 CA-C-N 118.233 1.017 . . . . 0.0 111.157 -178.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -104.71 113.96 27.87 Favored 'General case' 0 C--N 1.287 -2.148 0 CA-C-N 114.518 -1.219 . . . . 0.0 108.325 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 98.0 t -105.5 102.28 13.62 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.447 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 40.9 ttm180 -97.06 146.97 24.5 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.437 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -116.06 156.54 26.19 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.14 0.495 . . . . 0.0 110.217 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.454 HG21 ' HG3' ' A' ' 156' ' ' LYS . 0.1 OUTLIER -127.76 135.18 63.75 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.131 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.146 177.583 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 77.7 m -93.91 139.25 31.13 Favored 'General case' 0 C--N 1.262 -3.231 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 173.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -56.02 157.55 4.47 Favored 'General case' 0 C--N 1.294 -1.829 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.208 176.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.8 m -52.25 111.12 0.57 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 124.319 1.012 . . . . 0.0 112.07 -174.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 106.6 1.71 37.35 Favored Glycine 0 N--CA 1.426 -1.984 0 C-N-CA 120.317 -0.944 . . . . 0.0 112.863 177.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -113.41 158.81 20.17 Favored 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 117.994 0.897 . . . . 0.0 110.169 176.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 15.6 pttm -120.62 153.38 36.91 Favored 'General case' 0 N--CA 1.428 -1.573 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 2.1 tt -84.67 131.06 34.93 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.911 0 C-N-CA 119.28 -0.968 . . . . 0.0 109.728 176.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -82.43 -48.33 11.22 Favored 'General case' 0 C--N 1.286 -2.165 0 CA-C-N 114.717 -1.129 . . . . 0.0 109.747 -175.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -83.89 -151.66 12.62 Favored Glycine 0 C--N 1.304 -1.213 0 CA-C-N 114.847 -1.07 . . . . 0.0 110.528 176.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -80.62 164.56 22.78 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -89.32 -3.27 58.55 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.91 -172.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -157.89 162.48 38.32 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.57 -176.257 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 17.8 ptp -137.06 153.67 50.53 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 114.81 -1.086 . . . . 0.0 108.16 176.103 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . 0.41 ' HA ' ' O ' ' A' ' 172' ' ' GLN . 22.0 m80 -125.64 151.66 46.22 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.652 0.263 . . . . 0.0 110.676 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 18.9 m -76.21 112.6 12.86 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 171.062 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 23.3 t -82.24 171.05 14.71 Favored 'General case' 0 N--CA 1.422 -1.85 0 O-C-N 124.383 1.052 . . . . 0.0 110.038 -176.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -50.54 -34.92 27.32 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 125.448 1.499 . . . . 0.0 112.198 -178.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -69.48 -14.24 62.77 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.155 -0.93 . . . . 0.0 113.367 -177.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 83.7 29.25 32.81 Favored Glycine 0 C--O 1.225 -0.466 0 C-N-CA 120.439 -0.886 . . . . 0.0 110.893 -174.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -138.33 172.64 12.6 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 70.6 m95 -80.16 136.28 36.48 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 120.816 0.341 . . . . 0.0 111.252 -179.342 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 25.7 p -73.88 -22.57 59.68 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.197 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . 0.529 ' HE2' ' HA ' ' A' ' 200' ' ' LYS . 3.9 mmpt? -122.62 166.49 14.78 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.483 0.658 . . . . 0.0 111.572 -179.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -89.71 164.68 14.59 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 179.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 43.7 mtpt -66.63 122.76 83.54 Favored Pre-proline 0 C--N 1.309 -1.155 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.038 174.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -77.58 163.38 29.47 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 C-N-CA 122.03 1.82 . . . . 0.0 111.155 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 53.7 tttp -120.22 152.09 38.23 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -178.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 88.8 m -114.81 114.81 26.05 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 176.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 19.5 m . . . . . 0 C--N 1.3 -1.582 0 O-C-N 124.277 0.985 . . . . 0.0 109.175 -175.447 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo . . . . . 0 CA--C 1.538 0.689 0 CA-C-O 122.001 0.751 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 37.2 m -88.33 -36.49 16.61 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 177.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 120.53 -91.36 0.49 Allowed Glycine 0 CA--C 1.458 -3.484 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 172.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -176.11 127.6 0.35 Allowed Pre-proline 0 C--N 1.266 -3.05 0 N-CA-C 104.77 -2.308 . . . . 0.0 104.77 -176.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.406 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 61.5 Cg_endo -74.1 -17.5 21.96 Favored 'Trans proline' 0 C--N 1.329 -0.478 0 C-N-CA 122.44 2.093 . . . . 0.0 113.977 -175.301 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 131.0 -173.78 20.16 Favored Glycine 0 N--CA 1.427 -1.909 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 -176.432 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -147.39 144.13 28.47 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.7 t -122.32 130.08 24.83 Favored Pre-proline 0 C--N 1.305 -1.352 0 CA-C-O 121.194 0.521 . . . . 0.0 111.279 -178.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.74 -12.21 24.23 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.689 2.259 . . . . 0.0 111.676 178.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -95.04 14.36 22.11 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.717 -176.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 160.22 -122.33 1.12 Allowed Glycine 0 N--CA 1.421 -2.366 0 N-CA-C 111.084 -0.807 . . . . 0.0 111.084 178.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 t -172.31 -168.23 0.52 Allowed 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -177.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -147.56 170.2 17.97 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.7 m -138.46 156.83 47.19 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.481 HD11 ' CE1' ' A' ' 104' ' ' PHE . 14.6 mt -106.65 133.41 51.37 Favored 'General case' 0 C--N 1.276 -2.601 0 CA-C-O 121.213 0.53 . . . . 0.0 110.375 -176.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.448 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 23.8 p -121.23 116.68 25.36 Favored 'General case' 0 C--N 1.294 -1.813 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.59 -176.382 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.56 -58.93 0.7 Allowed Glycine 0 N--CA 1.434 -1.47 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -179.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -127.23 -4.51 5.9 Favored Glycine 0 N--CA 1.437 -1.247 0 C-N-CA 120.159 -1.019 . . . . 0.0 112.479 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 63.05 12.91 6.31 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 123.706 0.803 . . . . 0.0 112.517 -177.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.534 ' O ' HG13 ' A' ' 108' ' ' VAL . 30.6 m -145.12 -171.86 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 -176.633 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.481 ' CE1' HD11 ' A' ' 98' ' ' LEU . 27.1 m-85 -101.01 44.45 1.01 Allowed 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 118.648 0.658 . . . . 0.0 110.074 -176.03 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.736 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.6 pt-20 -84.68 179.28 7.4 Favored 'General case' 0 C--O 1.209 -1.035 0 CA-C-N 114.639 -1.164 . . . . 0.0 112.101 178.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -78.57 132.2 37.06 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.359 0.6 . . . . 0.0 111.345 178.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 101.06 -8.67 57.64 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 115.067 -0.97 . . . . 0.0 112.475 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.736 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -86.29 143.7 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 CA-C-O 121.418 0.628 . . . . 0.0 110.726 -174.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.448 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 19.6 mtpp -110.05 119.57 39.72 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.634 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -85.57 95.08 9.21 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 177.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 55.3 t -90.33 114.93 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.58 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 -177.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -83.94 138.92 32.9 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.94 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.3 t -134.07 116.73 15.8 Favored 'General case' 0 N--CA 1.42 -1.957 0 CA-C-N 115.032 -0.986 . . . . 0.0 108.672 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 21.0 m -72.88 160.06 32.74 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.49 -175.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -68.63 -179.72 1.47 Allowed 'General case' 0 C--N 1.315 -0.911 0 C-N-CA 122.95 0.5 . . . . 0.0 111.392 -177.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -59.43 -50.96 71.94 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 123.828 0.851 . . . . 0.0 111.212 -177.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -87.56 31.16 4.63 Favored Glycine 0 C--N 1.309 -0.924 0 C-N-CA 120.984 -0.627 . . . . 0.0 113.094 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -145.76 161.44 39.92 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -177.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -142.22 173.67 11.31 Favored 'General case' 0 C--N 1.271 -2.845 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 -179.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 11.9 tp -92.4 149.92 21.12 Favored 'General case' 0 C--N 1.273 -2.753 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.51 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -132.65 130.91 40.76 Favored 'General case' 0 N--CA 1.415 -2.204 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 177.9 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 116.49 -153.41 17.44 Favored Glycine 0 N--CA 1.433 -1.547 0 C-N-CA 120.646 -0.788 . . . . 0.0 111.526 179.08 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -112.3 -41.69 3.86 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 121.82 0.819 . . . . 0.0 110.068 -178.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.406 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.5 mm -85.97 144.34 9.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.782 -173.735 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 22.4 p-10 -135.24 4.32 3.18 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-O 120.79 0.328 . . . . 0.0 110.595 175.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 5.4 p90 -145.95 165.98 27.38 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.232 -172.381 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.406 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 44.8 mtp180 -128.56 125.67 38.74 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.409 -1.7 . . . . 0.0 106.409 171.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 55.9 tt0 -103.71 136.04 44.15 Favored 'General case' 0 C--N 1.286 -2.19 0 C-N-CA 118.352 -1.339 . . . . 0.0 110.378 179.411 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . 0.419 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 21.2 t -87.33 106.93 18.27 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.237 175.336 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -102.62 -166.76 1.31 Allowed 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 104.621 -2.363 . . . . 0.0 104.621 175.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 10.6 t -61.21 -29.83 70.05 Favored 'General case' 0 C--N 1.295 -1.769 0 CA-C-N 118.93 0.786 . . . . 0.0 112.81 -175.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -78.76 -16.53 57.08 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 121.743 0.782 . . . . 0.0 110.798 177.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.419 ' HA2' ' SG ' ' A' ' 129' ' ' CYS . . . 116.02 -148.16 18.9 Favored Glycine 0 N--CA 1.416 -2.676 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 -175.237 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 86.7 m95 -66.92 109.66 3.03 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 117.092 0.446 . . . . 0.0 109.858 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.1 p -64.82 -69.58 0.28 Allowed 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 124.219 1.008 . . . . 0.0 112.037 -176.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -75.79 167.94 20.94 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 114.012 -1.449 . . . . 0.0 108.94 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -104.23 178.13 4.65 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 123.629 0.58 . . . . 0.0 110.393 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 64.6 mt -64.31 126.19 89.91 Favored Pre-proline 0 C--N 1.314 -0.941 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.625 -178.565 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . 0.406 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 48.2 Cg_endo -70.36 170.77 16.5 Favored 'Trans proline' 0 C--O 1.251 1.172 0 C-N-CA 122.654 2.236 . . . . 0.0 112.404 178.362 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.51 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 56.1 mt -97.6 127.43 49.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.742 -178.232 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 61.2 m -106.82 123.83 48.72 Favored 'General case' 0 C--N 1.273 -2.737 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 169.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -111.8 151.4 29.06 Favored 'General case' 0 C--N 1.276 -2.618 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.17 142.49 15.48 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.563 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.4 m -68.52 113.69 4.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 119.93 -0.708 . . . . 0.0 109.462 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 87.8 mttt -105.46 133.99 49.31 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.189 -177.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.3 m -97.32 149.97 21.48 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -59.44 143.83 85.13 Favored Pre-proline 0 N--CA 1.42 -1.937 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 177.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -56.94 114.37 1.89 Allowed 'Trans proline' 0 C--O 1.252 1.204 0 C-N-CA 123.479 2.786 . . . . 0.0 111.429 179.121 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.4 HG23 ' SD ' ' A' ' 190' ' ' MET . 14.4 p -89.0 137.64 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.723 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.713 179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' THR . . . . . 0.401 ' O ' HD12 ' A' ' 157' ' ' ILE . 15.3 p -94.12 -158.74 0.65 Allowed 'General case' 0 N--CA 1.414 -2.262 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.065 177.271 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -122.44 160.21 49.23 Favored Pre-proline 0 C--N 1.291 -1.944 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 -173.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -71.3 -170.21 0.48 Allowed 'Trans proline' 0 CA--C 1.555 1.545 0 C-N-CA 121.171 1.247 . . . . 0.0 110.61 176.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . 0.516 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.0 OUTLIER -79.27 -46.5 17.66 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 112.557 0.577 . . . . 0.0 112.557 -171.942 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . 0.516 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 57.5 m-80 -110.52 14.59 22.45 Favored 'General case' 0 CA--C 1.502 -0.901 0 CA-C-O 121.435 0.636 . . . . 0.0 110.586 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -127.96 -176.2 14.36 Favored Glycine 0 N--CA 1.423 -2.212 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 45.6 pttt -151.56 -178.83 6.92 Favored 'General case' 0 C--N 1.292 -1.913 0 C-N-CA 123.451 0.7 . . . . 0.0 109.229 -175.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.401 HD12 ' O ' ' A' ' 150' ' ' THR . 56.1 mt -103.3 135.04 42.71 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 CA-C-N 118.018 0.372 . . . . 0.0 111.193 -176.1 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.46 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.7 m -79.0 -32.17 15.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.03 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.0 m -95.62 42.68 1.09 Allowed 'General case' 0 C--N 1.32 -0.708 0 C-N-CA 124.588 1.155 . . . . 0.0 110.013 -176.304 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 59.0 m -75.4 88.5 2.61 Favored 'General case' 0 C--N 1.323 -0.543 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -176.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -158.18 72.13 0.61 Allowed 'General case' 0 CA--C 1.496 -1.11 0 CA-C-O 122.09 0.948 . . . . 0.0 110.829 174.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 20.9 ttp -97.65 111.1 23.52 Favored 'General case' 0 C--N 1.27 -2.867 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 172.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.463 ' HB2' ' HG3' ' A' ' 166' ' ' ARG . 47.5 mt-10 -123.81 161.16 48.03 Favored Pre-proline 0 C--N 1.279 -2.464 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -174.536 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -73.55 10.31 1.31 Allowed 'Trans proline' 0 C--O 1.242 0.686 0 C-N-CA 122.851 2.367 . . . . 0.0 113.475 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -126.13 -61.76 1.2 Allowed 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 178.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.485 ' O ' ' HD3' ' A' ' 166' ' ' ARG . 0.1 OUTLIER -91.22 99.52 12.5 Favored 'General case' 0 N--CA 1.416 -2.141 0 CA-C-O 122.825 1.298 . . . . 0.0 109.613 175.923 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -96.77 -176.89 3.72 Favored 'General case' 0 C--N 1.283 -2.321 0 CA-C-N 113.725 -1.579 . . . . 0.0 107.795 -177.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 64.5 m-85 -77.52 105.86 8.92 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 45.6 m170 -120.77 163.78 17.6 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -176.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . 0.563 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 93.7 t80 -46.83 126.55 8.84 Favored 'General case' 0 C--O 1.237 0.416 0 O-C-N 124.284 0.99 . . . . 0.0 109.964 172.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 115.75 -34.63 4.67 Favored Glycine 0 N--CA 1.424 -2.152 0 C-N-CA 120.097 -1.049 . . . . 0.0 111.656 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -67.41 134.33 51.24 Favored 'General case' 0 C--O 1.25 1.097 0 CA-C-O 121.519 0.676 . . . . 0.0 112.669 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -124.87 107.32 10.76 Favored 'General case' 0 N--CA 1.431 -1.419 0 CA-C-N 114.284 -1.325 . . . . 0.0 107.934 179.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 64.9 t -92.64 116.92 34.87 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.088 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.938 -176.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.46 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 39.8 ttm180 -106.44 147.8 28.89 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 176.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -111.99 160.32 17.58 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 123.589 0.755 . . . . 0.0 110.228 -177.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -132.65 155.66 41.54 Favored 'Isoleucine or valine' 0 CA--C 1.469 -2.163 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.531 178.411 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 10.0 m -111.89 145.19 39.95 Favored 'General case' 0 N--CA 1.396 -3.162 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.24 172.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -64.28 171.99 2.76 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.993 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.9 m -48.2 -25.73 1.62 Allowed 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 116.677 2.103 . . . . 0.0 116.677 -169.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -112.51 8.9 26.29 Favored Glycine 0 C--N 1.298 -1.533 0 C-N-CA 120.2 -1.0 . . . . 0.0 113.568 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -126.84 178.87 5.68 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 117.3 0.55 . . . . 0.0 111.793 -176.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 15.0 pttp -150.68 165.13 34.36 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.7 tp -71.86 151.92 8.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.232 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -80.17 -73.12 0.37 Allowed 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.196 176.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -102.35 -100.18 2.51 Favored Glycine 0 CA--C 1.5 -0.887 0 C-N-CA 120.156 -1.021 . . . . 0.0 112.001 -177.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -86.43 154.28 21.27 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 177.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -108.68 3.6 22.94 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.991 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -153.05 158.71 42.36 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -174.362 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.4 ' SD ' HG23 ' A' ' 149' ' ' VAL . 13.3 ptp -135.8 156.08 49.36 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 124.695 1.198 . . . . 0.0 108.787 178.652 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.1 t-80 -137.5 142.25 41.49 Favored 'General case' 0 C--N 1.31 -1.124 0 O-C-N 122.305 -0.247 . . . . 0.0 110.659 -176.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 30.1 m -80.31 123.38 27.94 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 123.691 0.619 . . . . 0.0 111.398 174.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 67.6 m -111.62 -175.93 2.82 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 175.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.02 -17.61 53.19 Favored 'General case' 0 N--CA 1.504 2.229 0 C-N-CA 122.84 0.456 . . . . 0.0 111.843 -173.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -55.97 -35.56 66.87 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 124.441 1.096 . . . . 0.0 111.053 177.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 87.09 17.07 59.88 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 -173.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -137.07 165.74 25.33 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.0 m95 -77.16 140.64 40.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 O-C-N 123.755 0.659 . . . . 0.0 109.279 178.182 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.3 m -81.16 -6.0 58.35 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.504 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 17.2 tppt? -136.9 161.63 35.49 Favored 'General case' 0 N--CA 1.427 -1.611 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -104.25 178.08 4.66 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 117.554 0.161 . . . . 0.0 110.771 -177.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? -64.11 117.36 35.57 Favored Pre-proline 0 C--O 1.243 0.723 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 177.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -76.96 -169.06 0.66 Allowed 'Trans proline' 0 N--CA 1.446 -1.265 0 C-N-CA 122.107 1.872 . . . . 0.0 110.651 176.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . 0.427 ' HG2' ' N ' ' A' ' 205' ' ' CYS . 46.5 tttm -131.14 160.26 35.25 Favored 'General case' 0 N--CA 1.42 -1.972 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -177.111 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.427 ' N ' ' HG2' ' A' ' 204' ' ' LYS . 9.4 t -110.88 129.68 55.8 Favored 'General case' 0 N--CA 1.423 -1.789 0 N-CA-C 105.697 -1.964 . . . . 0.0 105.697 176.261 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 11.0 m . . . . . 0 C--N 1.301 -1.535 0 CA-C-O 118.491 -0.766 . . . . 0.0 111.578 -174.657 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo . . . . . 0 N--CA 1.483 0.907 0 CA-C-O 121.581 0.576 . . . . 0.0 112.658 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 59.6 m -71.63 -24.71 61.92 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.787 -178.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 96.43 14.72 43.43 Favored Glycine 0 C--N 1.302 -1.359 0 CA-C-N 115.444 -0.798 . . . . 0.0 114.808 171.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 59.2 t-80 69.23 115.39 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.764 0 C-N-CA 123.96 0.904 . . . . 0.0 109.835 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.408 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 42.7 Cg_endo -67.48 -42.25 7.51 Favored 'Trans proline' 0 C--O 1.221 -0.358 0 C-N-CA 122.141 1.894 . . . . 0.0 112.644 -174.434 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 136.07 174.64 13.45 Favored Glycine 0 N--CA 1.422 -2.286 0 N-CA-C 107.592 -2.203 . . . . 0.0 107.592 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 48.1 t0 -134.32 169.02 17.83 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 -177.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.0 t -131.56 126.43 21.09 Favored Pre-proline 0 C--N 1.285 -2.197 0 CA-C-N 117.897 0.317 . . . . 0.0 110.927 -177.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -69.72 -11.39 30.8 Favored 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 122.888 2.392 . . . . 0.0 111.477 177.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -91.84 4.12 53.59 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.06 -178.425 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.588 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.9 -131.36 1.95 Allowed Glycine 0 N--CA 1.401 -3.691 0 C-N-CA 119.637 -1.268 . . . . 0.0 112.475 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.7 p -153.83 -179.17 7.58 Favored 'General case' 0 C--N 1.287 -2.113 0 C-N-CA 124.4 1.08 . . . . 0.0 109.708 -177.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -145.68 160.34 41.84 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 172.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.3 m -125.4 159.93 30.64 Favored 'General case' 0 C--N 1.283 -2.3 0 N-CA-C 107.111 -1.441 . . . . 0.0 107.111 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 16.7 mt -116.97 115.82 26.19 Favored 'General case' 0 C--N 1.273 -2.733 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.517 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 31.9 p -106.76 133.04 52.04 Favored 'General case' 0 C--N 1.271 -2.843 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.257 -173.719 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 108.04 -67.67 0.23 Allowed Glycine 0 N--CA 1.429 -1.828 0 N-CA-C 110.611 -0.995 . . . . 0.0 110.611 -179.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -106.58 -14.83 18.74 Favored Glycine 0 C--N 1.309 -0.926 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.784 -176.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 59.81 19.09 7.94 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.206 1.002 . . . . 0.0 112.787 -178.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.466 ' O ' HG11 ' A' ' 108' ' ' VAL . 27.8 m -150.24 -172.19 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 -177.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -100.47 41.37 1.18 Allowed 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 118.642 0.655 . . . . 0.0 111.164 -176.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.762 ' O ' HG13 ' A' ' 108' ' ' VAL . 10.9 pt-20 -85.64 179.94 7.0 Favored 'General case' 0 C--O 1.207 -1.145 0 C-N-CA 123.971 0.908 . . . . 0.0 112.577 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -75.13 132.7 41.39 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.808 -0.557 . . . . 0.0 111.128 176.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.06 -5.42 63.38 Favored Glycine 0 N--CA 1.438 -1.206 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.681 178.064 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.762 HG13 ' O ' ' A' ' 105' ' ' GLU . 13.7 p -85.27 145.66 7.63 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.517 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 19.0 mtpp -111.55 113.96 26.71 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -81.4 94.23 6.76 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 177.255 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 33.0 m -92.19 120.11 40.83 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.193 0 CA-C-O 121.969 0.89 . . . . 0.0 108.897 -177.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -87.79 138.58 31.34 Favored 'General case' 0 C--N 1.262 -3.199 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.794 -177.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.0 t -137.36 110.23 7.65 Favored 'General case' 0 N--CA 1.407 -2.61 0 CA-C-O 122.381 1.086 . . . . 0.0 109.214 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 15.8 m -67.87 159.24 30.84 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.473 -1.239 . . . . 0.0 110.465 -177.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.588 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 92.0 m-20 -77.26 -179.11 5.46 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 120.746 0.308 . . . . 0.0 111.322 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -46.58 -52.51 13.37 Favored 'General case' 0 C--N 1.31 -1.138 0 C-N-CA 126.266 1.826 . . . . 0.0 114.428 -177.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -82.19 6.25 68.5 Favored Glycine 0 C--N 1.315 -0.589 0 C-N-CA 120.543 -0.837 . . . . 0.0 113.178 -176.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -128.19 166.96 17.53 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -176.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -145.35 165.73 27.62 Favored 'General case' 0 C--N 1.283 -2.312 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 176.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.07 123.68 29.73 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -178.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -106.85 126.31 52.14 Favored 'General case' 0 N--CA 1.416 -2.151 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 178.113 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 110.9 174.6 20.21 Favored Glycine 0 C--N 1.299 -1.486 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -176.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -85.6 -44.02 12.99 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 -178.114 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.7 mm -72.08 125.15 30.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 CA-C-N 114.175 -1.375 . . . . 0.0 110.39 -177.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -125.4 5.06 7.67 Favored 'General case' 0 C--O 1.202 -1.398 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 175.123 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 15.7 p90 -143.27 163.06 34.02 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.288 -171.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 50.9 mtp180 -126.96 130.51 50.22 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 174.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -106.14 130.25 54.06 Favored 'General case' 0 C--N 1.29 -2.0 0 C-N-CA 119.707 -0.797 . . . . 0.0 108.978 -179.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 26.5 t -84.31 108.51 17.2 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.466 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.428 ' OD1' HG23 ' A' ' 131' ' ' THR . 6.5 t70 -107.98 -167.22 1.22 Allowed 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.38 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.428 HG23 ' OD1' ' A' ' 130' ' ' ASP . 12.4 t -74.53 -12.61 60.52 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-O 121.861 0.838 . . . . 0.0 109.646 -178.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -86.46 -8.93 57.2 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.96 175.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 100.95 -153.56 19.14 Favored Glycine 0 N--CA 1.427 -1.963 0 N-CA-C 108.63 -1.788 . . . . 0.0 108.63 -175.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.408 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 95.2 m95 -67.33 111.25 3.92 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 117.565 0.683 . . . . 0.0 110.003 175.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 33.3 p -54.25 -58.88 5.72 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 124.877 1.271 . . . . 0.0 112.551 -176.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -92.98 -175.62 3.93 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.449 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . 0.4 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 47.0 t0 -117.19 177.96 4.53 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.4 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 76.2 mt -57.39 118.79 27.29 Favored Pre-proline 0 C--N 1.286 -2.189 0 C-N-CA 125.65 1.58 . . . . 0.0 109.343 177.078 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -73.24 -177.58 3.07 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.901 2.4 . . . . 0.0 111.914 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 67.1 mt -105.32 133.18 50.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-O 120.903 0.382 . . . . 0.0 111.716 -172.065 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 90.6 m -111.4 91.15 3.55 Favored 'General case' 0 C--N 1.297 -1.682 0 CA-C-O 121.693 0.758 . . . . 0.0 109.039 174.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -86.85 148.54 25.33 Favored 'General case' 0 N--CA 1.424 -1.77 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -177.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.8 p -70.07 137.51 23.9 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 177.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 95.4 t -64.62 126.01 22.61 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -115.44 143.98 44.5 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.033 -176.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -120.75 159.59 25.09 Favored 'General case' 0 C--N 1.281 -2.41 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.147 177.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -68.46 147.08 98.11 Favored Pre-proline 0 N--CA 1.421 -1.899 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -175.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -71.93 116.42 4.7 Favored 'Trans proline' 0 N--CA 1.442 -1.522 0 C-N-CA 122.701 2.268 . . . . 0.0 110.546 178.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.425 HG21 ' SD ' ' A' ' 190' ' ' MET . 60.1 t -74.81 144.46 12.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.319 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.4 p -66.57 -84.85 0.02 OUTLIER 'General case' 0 N--CA 1.438 -1.026 0 O-C-N 123.379 0.424 . . . . 0.0 111.629 177.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 168.01 162.58 0.15 Allowed Pre-proline 0 CA--C 1.513 -0.46 0 C-N-CA 126.106 1.763 . . . . 0.0 106.463 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -76.54 168.3 23.98 Favored 'Trans proline' 0 N--CA 1.446 -1.313 0 C-N-CA 121.324 1.349 . . . . 0.0 110.001 171.267 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -60.02 -50.9 71.92 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 113.862 1.06 . . . . 0.0 113.862 -176.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 55.0 m-80 -110.67 32.61 5.09 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.563 0.696 . . . . 0.0 109.791 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -149.15 -176.79 22.73 Favored Glycine 0 N--CA 1.425 -2.081 0 C-N-CA 120.219 -0.991 . . . . 0.0 111.384 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -144.45 169.37 18.07 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -178.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.512 HG12 ' CD2' ' A' ' 176' ' ' PHE . 51.6 mt -98.47 137.45 25.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.461 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.8 m -84.5 -28.02 6.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 CA-C-O 121.986 0.898 . . . . 0.0 108.701 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 12.9 m -91.34 14.95 13.11 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 114.704 -1.135 . . . . 0.0 112.496 -176.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' SER . . . . . 0.448 ' OG ' ' HB ' ' A' ' 157' ' ' ILE . 70.6 m -89.31 -78.09 0.36 Allowed 'General case' 0 C--N 1.313 -0.997 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.48 178.104 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -80.89 89.68 5.87 Favored 'General case' 0 N--CA 1.434 -1.243 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.383 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 53.4 mtm -118.68 -49.44 2.44 Favored 'General case' 0 C--N 1.283 -2.283 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 174.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 69.6 mm-40 -157.94 147.45 15.07 Favored Pre-proline 0 C--N 1.316 -0.886 0 N-CA-C 105.176 -2.157 . . . . 0.0 105.176 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -79.63 -11.54 14.1 Favored 'Trans proline' 0 CA--C 1.545 1.072 0 C-N-CA 122.298 1.999 . . . . 0.0 113.419 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 29.8 m-20 -96.27 -16.32 21.44 Favored 'General case' 0 CA--C 1.496 -1.119 0 CA-C-O 120.969 0.414 . . . . 0.0 110.602 -177.141 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 29.2 mmm180 -77.53 107.55 10.06 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.776 -176.311 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . 0.459 ' HB2' ' NE2' ' A' ' 169' ' ' HIS . 32.6 mt-10 -87.24 164.52 16.28 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.118 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 69.7 m-85 -83.33 110.05 17.79 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.682 0.753 . . . . 0.0 109.563 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.459 ' NE2' ' HB2' ' A' ' 167' ' ' GLU . 46.8 m170 -115.29 163.51 15.58 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.744 -176.175 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -51.93 127.46 21.25 Favored 'General case' 0 C--O 1.245 0.843 0 O-C-N 124.134 0.896 . . . . 0.0 108.983 172.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 108.23 -22.81 26.4 Favored Glycine 0 N--CA 1.435 -1.422 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.306 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 30.1 mm-40 -71.67 144.67 49.28 Favored 'General case' 0 C--O 1.256 1.398 0 CA-C-N 117.185 0.492 . . . . 0.0 110.314 178.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -123.03 104.99 9.57 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.55 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 54.4 t -79.85 106.62 11.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.832 -178.023 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.461 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 25.9 ttp85 -98.62 143.45 29.0 Favored 'General case' 0 N--CA 1.41 -2.452 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.736 179.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.512 ' CD2' HG12 ' A' ' 157' ' ' ILE . 64.0 m-85 -112.85 165.75 12.02 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -178.107 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.7 p -146.73 138.25 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.291 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.5 m -92.67 148.28 22.19 Favored 'General case' 0 C--N 1.265 -3.101 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.391 -178.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -69.64 162.41 27.71 Favored 'General case' 0 CA--C 1.497 -1.063 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.664 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 16.3 m -52.08 109.44 0.38 Allowed 'General case' 0 C--N 1.303 -1.439 0 O-C-N 124.404 1.065 . . . . 0.0 112.368 -175.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.58 -9.17 30.36 Favored Glycine 0 N--CA 1.435 -1.385 0 CA-C-N 115.715 -0.675 . . . . 0.0 113.073 178.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -108.81 153.12 23.94 Favored 'General case' 0 CA--C 1.497 -1.059 0 CA-C-N 117.886 0.843 . . . . 0.0 110.886 -178.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 16.9 pttp -115.71 159.54 21.25 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 7.0 tp -74.36 146.19 10.23 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 176.309 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -91.46 -61.21 1.7 Allowed 'General case' 0 C--N 1.27 -2.876 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -90.99 -130.48 4.68 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 177.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -87.8 153.14 21.58 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 176.141 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -92.55 8.19 39.95 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 120.365 -0.534 . . . . 0.0 110.465 -177.088 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . 0.55 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 2.0 pt-20 -155.94 143.76 19.64 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 121.123 0.487 . . . . 0.0 111.925 -179.505 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.425 ' SD ' HG21 ' A' ' 149' ' ' VAL . 13.9 ptp -125.65 138.28 53.9 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.01 -0.995 . . . . 0.0 109.336 176.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 50.1 t-80 -100.56 138.77 37.17 Favored 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 123.089 0.556 . . . . 0.0 110.045 -176.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 23.6 t -82.76 107.08 15.12 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 174.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 50.7 m -100.21 -178.59 3.87 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 114.046 1.128 . . . . 0.0 114.046 -171.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -49.17 -34.97 15.7 Favored 'General case' 0 N--CA 1.51 2.541 0 C-N-CA 125.908 1.683 . . . . 0.0 113.179 -174.153 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -81.8 -7.67 59.62 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 113.456 0.909 . . . . 0.0 113.456 -176.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 83.42 10.19 82.39 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.15 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -112.96 169.76 8.69 Favored 'General case' 0 N--CA 1.427 -1.599 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 177.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.3 m95 -83.66 134.99 34.76 Favored 'General case' 0 N--CA 1.417 -2.087 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.24 178.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 35.9 p -63.38 -32.26 73.64 Favored 'General case' 0 C--O 1.249 1.063 0 CA-C-O 121.523 0.677 . . . . 0.0 112.229 -177.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . 0.403 ' HD3' ' HA ' ' A' ' 200' ' ' LYS . 26.3 mmtp -116.49 157.08 25.76 Favored 'General case' 0 CA--C 1.483 -1.601 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.352 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -86.43 172.13 10.61 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.684 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 7.6 mmmm -55.13 119.9 26.13 Favored Pre-proline 0 C--N 1.321 -0.634 0 O-C-N 123.697 0.623 . . . . 0.0 111.786 178.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -86.5 -173.44 1.21 Allowed 'Trans proline' 0 N--CA 1.424 -2.589 0 C-N-CA 122.061 1.841 . . . . 0.0 109.987 178.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 24.5 ttmm -148.08 164.41 33.93 Favored 'General case' 0 C--N 1.278 -2.506 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -176.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 98.4 m -126.06 116.04 20.79 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 174.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--N 1.3 -1.574 0 O-C-N 124.416 1.072 . . . . 0.0 109.747 -175.392 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo . . . . . 0 N--CA 1.477 0.528 0 CA-C-O 121.313 0.464 . . . . 0.0 112.159 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.6 m -84.25 -29.97 26.05 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.37 -98.1 0.74 Allowed Glycine 0 N--CA 1.398 -3.891 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.919 171.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -177.08 110.75 0.23 Allowed Pre-proline 0 C--N 1.258 -3.407 0 N-CA-C 105.759 -1.941 . . . . 0.0 105.759 -176.075 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.45 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 45.0 Cg_endo -64.76 -30.82 59.04 Favored 'Trans proline' 0 N--CA 1.474 0.334 0 C-N-CA 122.92 2.414 . . . . 0.0 112.963 -171.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.95 -174.39 19.13 Favored Glycine 0 N--CA 1.419 -2.483 0 N-CA-C 108.481 -1.848 . . . . 0.0 108.481 -176.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -142.57 164.64 29.56 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 107.815 -1.179 . . . . 0.0 107.815 -176.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.4 t -125.05 127.31 25.1 Favored Pre-proline 0 C--N 1.295 -1.769 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 -178.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -68.64 -22.38 37.91 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.483 2.122 . . . . 0.0 110.667 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -81.24 -1.64 45.72 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.219 -1.355 . . . . 0.0 111.984 -175.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.417 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 177.38 -130.66 1.66 Allowed Glycine 0 N--CA 1.414 -2.791 0 C-N-CA 119.695 -1.241 . . . . 0.0 111.84 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 24.4 p -146.59 179.16 7.75 Favored 'General case' 0 C--N 1.285 -2.225 0 O-C-N 124.119 0.541 . . . . 0.0 110.096 -178.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -143.07 155.28 44.58 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 171.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.5 m -121.24 163.65 18.2 Favored 'General case' 0 C--N 1.279 -2.482 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.57 ' HA ' ' O ' ' A' ' 109' ' ' LYS . 32.0 mt -120.82 124.0 43.97 Favored 'General case' 0 C--N 1.277 -2.561 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.236 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.651 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 34.1 p -115.93 125.56 52.73 Favored 'General case' 0 C--N 1.285 -2.235 0 O-C-N 123.625 0.578 . . . . 0.0 110.793 -175.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 99.95 11.76 42.13 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.828 178.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -178.91 -28.76 0.05 OUTLIER Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 119.371 -1.395 . . . . 0.0 113.813 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 69.6 10.88 7.81 Favored 'General case' 0 N--CA 1.5 2.073 0 CA-C-O 122.674 1.226 . . . . 0.0 110.599 -177.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.451 ' O ' HG11 ' A' ' 108' ' ' VAL . 35.9 m -143.72 -169.79 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 114.684 -1.144 . . . . 0.0 107.937 -174.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 36.4 m-85 -110.87 43.9 1.36 Allowed 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.489 0.662 . . . . 0.0 110.567 -175.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.732 ' O ' HG13 ' A' ' 108' ' ' VAL . 11.1 pt-20 -86.23 -176.58 5.97 Favored 'General case' 0 C--O 1.207 -1.165 0 CA-C-N 114.445 -1.252 . . . . 0.0 112.474 177.388 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.2 m-85 -78.82 131.99 36.69 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 122.021 -0.425 . . . . 0.0 111.467 178.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.48 5.33 61.82 Favored Glycine 0 N--CA 1.438 -1.214 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.659 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.732 HG13 ' O ' ' A' ' 105' ' ' GLU . 9.9 p -101.75 148.66 7.23 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.651 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 89.2 mttt -108.83 138.89 44.44 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 176.042 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -97.14 86.55 3.97 Favored 'General case' 0 C--N 1.264 -3.12 0 N-CA-C 105.515 -2.031 . . . . 0.0 105.515 169.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 21.2 m -85.61 118.17 31.85 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 -177.066 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -88.04 141.04 28.88 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.725 -0.609 . . . . 0.0 111.22 -175.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -139.36 114.36 9.49 Favored 'General case' 0 N--CA 1.412 -2.352 0 CA-C-O 122.129 0.966 . . . . 0.0 108.777 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 10.5 m -73.43 159.6 33.0 Favored 'General case' 0 C--N 1.289 -2.064 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.976 -175.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.417 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 68.6 m-20 -69.18 179.1 2.05 Favored 'General case' 0 C--O 1.216 -0.683 0 C-N-CA 123.023 0.529 . . . . 0.0 111.299 178.441 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -55.73 -46.57 77.74 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.556 0.742 . . . . 0.0 112.072 -178.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -81.92 7.8 61.88 Favored Glycine 0 C--N 1.308 -1.014 0 CA-C-N 115.839 -0.619 . . . . 0.0 113.95 -177.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -129.98 152.3 49.6 Favored 'General case' 0 N--CA 1.426 -1.63 0 CA-C-O 121.495 0.664 . . . . 0.0 110.072 -178.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.44 158.43 36.04 Favored 'General case' 0 C--N 1.271 -2.824 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.3 tt -89.56 129.47 36.02 Favored 'General case' 0 C--N 1.272 -2.8 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.552 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.64 128.18 55.98 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -175.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 116.06 173.48 17.21 Favored Glycine 0 C--N 1.294 -1.751 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 -176.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -87.73 -35.72 17.76 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -179.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 47.4 mm -85.73 137.04 21.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.288 -176.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -123.93 2.46 8.72 Favored 'General case' 0 C--O 1.21 -0.998 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.307 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.514 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 50.0 p90 -145.47 169.44 18.35 Favored 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -170.523 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 54.9 mtp180 -126.17 115.52 19.91 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 170.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -91.91 124.22 35.87 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 119.749 -0.781 . . . . 0.0 109.426 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.8 t -83.93 104.03 13.68 Favored 'General case' 0 CA--C 1.498 -1.056 0 C-N-CA 118.819 -1.152 . . . . 0.0 108.858 176.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.439 ' OD1' HG22 ' A' ' 131' ' ' THR . 7.9 t70 -99.53 -171.07 2.0 Allowed 'General case' 0 C--N 1.288 -2.103 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 178.634 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.439 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.3 t -61.42 -14.77 30.77 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 124.408 1.083 . . . . 0.0 112.508 -174.346 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -98.52 -15.34 19.59 Favored 'General case' 0 C--N 1.315 -0.913 0 O-C-N 121.757 -0.59 . . . . 0.0 110.637 178.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 124.18 -161.09 18.7 Favored Glycine 0 C--N 1.305 -1.188 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 -177.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.45 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 89.3 m95 -64.91 101.3 0.48 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.889 0.345 . . . . 0.0 110.173 176.77 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.5 p -58.31 -57.19 14.0 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 124.105 0.962 . . . . 0.0 112.254 -176.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -81.36 177.53 8.92 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.19 -0.914 . . . . 0.0 109.321 -177.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -111.11 179.6 4.0 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 176.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 84.4 mt -72.53 117.95 63.46 Favored Pre-proline 0 C--N 1.317 -0.843 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -66.35 157.79 58.44 Favored 'Trans proline' 0 C--O 1.253 1.267 0 C-N-CA 122.513 2.142 . . . . 0.0 110.624 178.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 62.4 mt -92.24 129.48 42.79 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-O 120.877 0.37 . . . . 0.0 110.722 -173.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 84.5 m -99.41 105.4 17.34 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 171.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -92.94 150.14 20.77 Favored 'General case' 0 N--CA 1.407 -2.601 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 -179.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 5.8 p -74.4 131.02 35.65 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.645 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 84.7 t -52.7 132.05 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 O-C-N 123.906 0.754 . . . . 0.0 110.89 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.411 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 85.0 mttt -106.32 153.91 21.52 Favored 'General case' 0 N--CA 1.433 -1.295 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.016 -176.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.9 m -124.03 165.06 18.12 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.639 -178.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . 0.506 HD21 ' HD2' ' A' ' 148' ' ' PRO . 0.5 OUTLIER -62.58 130.85 93.85 Favored Pre-proline 0 N--CA 1.426 -1.64 0 C-N-CA 125.154 1.382 . . . . 0.0 110.777 178.099 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.506 ' HD2' HD21 ' A' ' 147' ' ' LEU . 24.1 Cg_endo -65.91 110.26 1.67 Allowed 'Trans proline' 0 C--N 1.314 -1.244 0 C-N-CA 123.174 2.582 . . . . 0.0 111.635 175.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 7.8 p -86.59 143.94 10.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 38.9 p -82.49 -83.48 0.13 Allowed 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -177.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.3 161.74 0.46 Allowed Pre-proline 0 C--N 1.326 -0.429 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 -179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . 0.461 ' HD3' ' CD2' ' A' ' 176' ' ' PHE . 43.5 Cg_endo -73.51 -169.39 0.53 Allowed 'Trans proline' 0 CA--C 1.546 1.125 0 C-N-CA 121.654 1.569 . . . . 0.0 111.27 172.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . 0.586 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.2 OUTLIER -88.44 -37.2 16.02 Favored 'General case' 0 C--N 1.287 -2.131 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -174.899 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . 0.586 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 49.8 m-80 -120.86 22.82 10.98 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 122.074 0.94 . . . . 0.0 109.827 179.345 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -146.49 178.97 23.81 Favored Glycine 0 N--CA 1.425 -2.041 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.431 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . 0.41 ' HG3' HG22 ' A' ' 177' ' ' VAL . 21.9 pttm -145.62 -176.66 5.22 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -178.093 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.419 HG23 ' N ' ' A' ' 159' ' ' SER . 64.4 mt -95.56 141.2 15.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 C-N-CA 122.505 0.322 . . . . 0.0 110.703 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.477 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.3 m -79.91 -35.39 16.11 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.461 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 177.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' SER . . . . . 0.419 ' N ' HG23 ' A' ' 157' ' ' ILE . 5.3 m -79.74 31.98 0.25 Allowed 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 125.429 1.492 . . . . 0.0 111.375 -174.435 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 19.7 m -82.41 76.13 9.29 Favored 'General case' 0 N--CA 1.435 -1.206 0 CA-C-O 121.688 0.756 . . . . 0.0 112.363 -176.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -133.21 87.89 2.44 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 105.9 -1.889 . . . . 0.0 105.9 173.082 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -97.94 94.55 6.94 Favored 'General case' 0 N--CA 1.408 -2.566 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.494 -170.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.449 ' HB2' ' HG2' ' A' ' 166' ' ' ARG . 42.7 mt-10 -99.73 153.47 37.75 Favored Pre-proline 0 C--N 1.27 -2.877 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 173.056 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -73.6 -6.0 17.99 Favored 'Trans proline' 0 N--CA 1.476 0.493 0 C-N-CA 122.307 2.005 . . . . 0.0 111.164 178.265 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -97.05 -30.82 12.83 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.449 ' HG2' ' HB2' ' A' ' 163' ' ' GLU . 28.8 mmt180 -93.6 89.03 6.08 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.782 -1.099 . . . . 0.0 109.298 -177.461 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . 0.484 ' HB2' ' NE2' ' A' ' 169' ' ' HIS . 27.2 mt-10 -88.4 171.61 10.0 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 174.364 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . 0.411 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 82.6 m-85 -72.0 106.09 4.15 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.489 -0.884 . . . . 0.0 108.711 175.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.484 ' NE2' ' HB2' ' A' ' 167' ' ' GLU . 49.7 m170 -117.83 161.06 20.35 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.691 -175.351 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 42.5 t80 -55.72 125.27 20.5 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 174.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 109.86 -14.13 31.87 Favored Glycine 0 N--CA 1.42 -2.398 0 C-N-CA 120.047 -1.073 . . . . 0.0 111.492 -177.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 87.1 mm-40 -86.71 139.38 30.81 Favored 'General case' 0 N--CA 1.433 -1.305 0 C-N-CA 119.533 -0.867 . . . . 0.0 109.822 176.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -120.59 116.14 24.77 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.616 178.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 88.1 t -90.29 106.04 16.88 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.477 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 46.1 ttm180 -104.65 142.47 34.61 Favored 'General case' 0 N--CA 1.405 -2.689 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.461 ' CD2' ' HD3' ' A' ' 152' ' ' PRO . 88.5 m-85 -108.81 157.44 18.58 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 121.431 0.634 . . . . 0.0 110.922 -175.852 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.419 HG23 HG11 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -130.69 133.12 63.82 Favored 'Isoleucine or valine' 0 CA--C 1.471 -2.078 0 CA-C-N 114.908 -1.042 . . . . 0.0 108.507 178.626 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 93.4 m -95.33 128.34 42.1 Favored 'General case' 0 C--N 1.259 -3.337 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 177.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 77.1 m-20 -60.09 160.09 8.62 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 114.95 -1.023 . . . . 0.0 111.419 -178.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 14.9 m -37.38 102.82 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 126.484 1.914 . . . . 0.0 114.91 -174.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 111.66 -18.39 24.78 Favored Glycine 0 N--CA 1.441 -0.982 0 C-N-CA 120.998 -0.62 . . . . 0.0 113.066 177.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -96.12 156.0 16.52 Favored 'General case' 0 N--CA 1.434 -1.233 0 CA-C-N 117.094 0.447 . . . . 0.0 111.394 -177.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -123.18 155.15 37.64 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.3 tp -72.42 142.84 14.7 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.2 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -71.83 -71.24 0.28 Allowed 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.852 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -100.02 -105.86 2.73 Favored Glycine 0 N--CA 1.431 -1.665 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -99.34 163.28 12.6 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -105.88 0.8 26.24 Favored 'General case' 0 CA--C 1.499 -1.008 0 C-N-CA 119.351 -0.94 . . . . 0.0 111.249 -173.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -148.12 152.63 37.65 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 114.085 1.142 . . . . 0.0 114.085 -175.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.5 ptp -131.15 138.23 49.37 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.233 -1.349 . . . . 0.0 108.496 177.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 45.6 t-80 -123.42 137.42 54.81 Favored 'General case' 0 C--N 1.292 -1.902 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.448 -176.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 16.2 m -61.93 113.81 3.01 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.994 176.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 14.9 m -102.76 174.15 6.01 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.054 178.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -48.74 140.79 8.04 Favored 'General case' 0 N--CA 1.488 1.433 0 C-N-CA 123.833 0.853 . . . . 0.0 112.352 178.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 26.2 t70 76.47 -6.45 2.0 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 125.944 1.698 . . . . 0.0 111.937 178.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 93.04 50.94 2.35 Favored Glycine 0 N--CA 1.434 -1.499 0 C-N-CA 120.529 -0.844 . . . . 0.0 112.087 177.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -116.7 141.61 47.98 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 176.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 67.1 m95 -79.78 132.06 36.06 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 171.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.1 p -65.85 -20.34 66.2 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.245 0.545 . . . . 0.0 112.172 -179.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . 0.47 ' HA ' ' HE3' ' A' ' 200' ' ' LYS . 0.0 OUTLIER -134.17 171.1 14.7 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.597 178.43 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -108.57 170.25 8.14 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.492 -178.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 5.5 tppp? -56.06 114.87 8.34 Favored Pre-proline 0 C--O 1.233 0.237 0 O-C-N 124.047 0.842 . . . . 0.0 110.814 -178.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -80.76 -167.78 0.55 Allowed 'Trans proline' 0 N--CA 1.434 -2.0 0 C-N-CA 122.145 1.897 . . . . 0.0 110.625 176.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . 0.428 ' HZ1' ' HB2' ' A' ' 204' ' ' LYS . 5.0 ttmp? -146.38 160.31 42.23 Favored 'General case' 0 C--N 1.28 -2.422 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -174.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 87.0 m -117.41 105.93 12.66 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-O 121.518 0.675 . . . . 0.0 110.693 177.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.2 m . . . . . 0 N--CA 1.433 -1.314 0 CA-C-N 115.003 -0.998 . . . . 0.0 110.079 -176.2 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 CA--C 1.53 0.325 0 CA-C-O 121.565 0.569 . . . . 0.0 111.322 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 36.2 m -89.1 -42.16 11.87 Favored 'General case' 0 N--CA 1.426 -1.633 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 121.4 -86.0 0.39 Allowed Glycine 0 CA--C 1.472 -2.603 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 172.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -179.59 127.13 0.24 Allowed Pre-proline 0 C--N 1.274 -2.691 0 N-CA-C 104.078 -2.564 . . . . 0.0 104.078 -177.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -77.58 4.85 5.64 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 C-N-CA 123.355 2.703 . . . . 0.0 115.584 -170.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.75 -168.86 12.91 Favored Glycine 0 C--N 1.287 -2.167 0 N-CA-C 107.688 -2.165 . . . . 0.0 107.688 -174.248 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -151.12 -175.42 5.15 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 118.439 1.119 . . . . 0.0 108.846 -176.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 t -155.33 125.85 3.41 Favored Pre-proline 0 N--CA 1.424 -1.739 0 CA-C-O 121.065 0.46 . . . . 0.0 111.395 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -78.73 -5.95 14.99 Favored 'Trans proline' 0 C--O 1.239 0.556 0 C-N-CA 123.088 2.526 . . . . 0.0 112.069 178.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.431 ' HB2' ' HB2' ' A' ' 141' ' ' CYS . 27.0 m-85 -99.46 1.28 43.96 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.325 -177.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.447 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.86 -136.59 3.52 Favored Glycine 0 N--CA 1.405 -3.385 0 C-N-CA 118.817 -1.659 . . . . 0.0 113.043 -178.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.9 p -146.37 -176.85 5.33 Favored 'General case' 0 C--N 1.283 -2.311 0 CA-C-N 114.655 -0.773 . . . . 0.0 110.795 -174.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 44.6 p90 -146.58 161.53 40.31 Favored 'General case' 0 N--CA 1.431 -1.422 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 171.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.7 m -131.81 154.51 49.04 Favored 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 179.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.478 ' HB2' ' HA ' ' A' ' 102' ' ' ASN . 16.1 mt -110.07 127.68 54.99 Favored 'General case' 0 C--N 1.272 -2.78 0 CA-C-O 120.995 0.426 . . . . 0.0 110.064 -177.039 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.482 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 24.1 p -120.45 132.94 55.45 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.136 -177.613 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.44 19.34 32.86 Favored Glycine 0 C--N 1.307 -1.065 0 C-N-CA 120.599 -0.81 . . . . 0.0 111.809 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 167.92 -27.04 0.14 Allowed Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.612 178.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . 0.478 ' HA ' ' HB2' ' A' ' 98' ' ' LEU . 7.5 t30 61.28 20.07 10.71 Favored 'General case' 0 CA--C 1.56 1.338 0 CA-C-O 122.699 1.238 . . . . 0.0 110.519 -178.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.552 ' O ' HG12 ' A' ' 108' ' ' VAL . 31.1 m -144.55 -170.57 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.207 -1.164 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 -179.035 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -106.53 45.19 0.99 Allowed 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 118.394 0.543 . . . . 0.0 110.392 -178.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.721 ' O ' HG11 ' A' ' 108' ' ' VAL . 12.4 pt-20 -90.43 -177.97 5.21 Favored 'General case' 0 C--O 1.207 -1.143 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.769 177.483 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 46.9 m-85 -77.61 133.24 38.48 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.859 -0.526 . . . . 0.0 111.456 178.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.84 0.12 64.33 Favored Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.895 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.721 HG11 ' O ' ' A' ' 105' ' ' GLU . 12.7 p -94.22 145.71 7.61 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.482 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 15.1 mtpp -109.94 124.39 51.31 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.458 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.65 91.13 8.63 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 176.094 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 62.5 t -88.63 112.24 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.962 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -177.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -81.39 134.9 35.62 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-O 121.19 0.519 . . . . 0.0 111.681 -178.627 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.1 t -132.55 104.91 6.92 Favored 'General case' 0 N--CA 1.421 -1.916 0 CA-C-O 122.157 0.979 . . . . 0.0 109.16 -178.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 13.4 m -66.83 157.98 31.62 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.62 -1.173 . . . . 0.0 110.826 -178.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.447 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 95.4 m-20 -75.55 178.44 5.99 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.748 -0.206 . . . . 0.0 111.548 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -45.7 -54.63 7.54 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.945 1.298 . . . . 0.0 113.324 -177.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.546 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -85.16 25.94 5.85 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 120.3 -0.953 . . . . 0.0 113.626 -176.357 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.586 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 81.1 m-85 -145.98 154.89 42.4 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 117.321 0.56 . . . . 0.0 110.092 -176.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.03 161.84 33.3 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 176.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.28 115.4 21.33 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 -178.384 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -98.31 129.74 45.0 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 179.461 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 121.35 166.74 13.03 Favored Glycine 0 C--N 1.29 -1.99 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -177.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.0 mt-10 -88.99 -21.3 23.57 Favored 'General case' 0 C--N 1.295 -1.799 0 CA-C-O 121.955 0.883 . . . . 0.0 109.306 -177.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.461 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.5 mm -107.76 131.21 58.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.804 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.815 -178.443 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -123.57 11.5 9.21 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -177.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.458 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 15.5 p90 -152.03 161.42 42.67 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -175.24 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 62.9 mtp180 -126.43 129.02 47.9 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 172.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -105.87 132.19 52.27 Favored 'General case' 0 C--N 1.279 -2.492 0 C-N-CA 119.101 -1.039 . . . . 0.0 109.461 -178.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.1 t -82.11 101.8 10.64 Favored 'General case' 0 C--N 1.293 -1.876 0 C-N-CA 118.219 -1.392 . . . . 0.0 109.927 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.542 ' OD2' HG22 ' A' ' 131' ' ' THR . 13.3 t70 -101.83 -171.35 1.96 Allowed 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.542 HG22 ' OD2' ' A' ' 130' ' ' ASP . 8.8 t -54.93 -31.99 60.84 Favored 'General case' 0 CA--C 1.56 1.331 0 C-N-CA 124.182 0.993 . . . . 0.0 112.805 -175.47 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -85.72 -15.36 42.45 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.908 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 122.98 -159.89 17.55 Favored Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -176.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.0 m95 -62.23 112.17 2.28 Favored 'General case' 0 C--O 1.248 0.983 0 CA-C-N 117.173 0.486 . . . . 0.0 110.39 177.051 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 68.4 p -71.08 162.82 28.78 Favored 'General case' 0 C--O 1.266 1.932 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 65.6 -171.16 0.19 Allowed 'General case' 0 CA--C 1.509 -0.629 0 O-C-N 124.209 0.943 . . . . 0.0 111.451 174.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -108.51 171.79 7.21 Favored 'General case' 0 C--N 1.295 -1.804 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.566 177.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 66.2 mt -67.68 118.5 58.05 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 171.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . 0.461 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 35.0 Cg_endo -66.2 159.06 51.58 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 122.056 1.837 . . . . 0.0 111.114 178.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 74.5 mt -109.39 134.59 50.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 C-N-CA 120.68 -0.408 . . . . 0.0 109.953 -171.303 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.431 ' HB2' ' HB2' ' A' ' 93' ' ' PHE . 94.9 m -102.96 110.73 22.76 Favored 'General case' 0 C--N 1.277 -2.57 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 175.144 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.86 152.17 20.04 Favored 'General case' 0 CA--C 1.462 -2.41 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.586 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 2.8 t -69.12 142.2 16.42 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.044 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.546 -177.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.546 HG22 ' C ' ' A' ' 117' ' ' GLY . 10.4 m -66.82 122.52 18.01 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 178.072 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.448 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 49.7 mtmt -121.81 127.18 50.28 Favored 'General case' 0 N--CA 1.408 -2.565 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.923 -172.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 60.8 m -84.2 153.68 23.5 Favored 'General case' 0 C--N 1.28 -2.436 0 CA-C-N 113.981 -1.463 . . . . 0.0 108.504 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . 0.418 ' C ' HD12 ' A' ' 147' ' ' LEU . 3.6 pp -67.52 160.72 70.74 Favored Pre-proline 0 CA--C 1.553 1.075 0 O-C-N 123.236 0.335 . . . . 0.0 110.229 -178.075 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.437 ' HA ' ' CE2' ' A' ' 168' ' ' TYR . 39.4 Cg_endo -74.28 123.21 8.08 Favored 'Trans proline' 0 N--CA 1.446 -1.297 0 C-N-CA 122.499 2.133 . . . . 0.0 112.348 -175.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.638 HG12 ' O ' ' A' ' 150' ' ' THR . 62.0 t -75.07 137.68 22.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.977 -178.554 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' THR . . . . . 0.638 ' O ' HG12 ' A' ' 149' ' ' VAL . 25.4 p -95.95 -158.01 0.62 Allowed 'General case' 0 N--CA 1.417 -2.105 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 172.183 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -127.38 151.39 74.73 Favored Pre-proline 0 C--N 1.274 -2.682 0 O-C-N 120.406 -1.434 . . . . 0.0 110.352 -171.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -68.76 161.44 45.42 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.615 1.543 . . . . 0.0 112.259 177.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -60.04 -43.64 95.22 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 -174.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 57.6 m-80 -117.49 29.36 7.91 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -148.31 -167.21 13.4 Favored Glycine 0 N--CA 1.435 -1.42 0 C-N-CA 119.989 -1.101 . . . . 0.0 112.081 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -154.85 177.14 11.62 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.424 HD13 ' O ' ' A' ' 150' ' ' THR . 58.9 mt -88.75 129.7 39.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 CA-C-O 120.833 0.349 . . . . 0.0 110.713 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.406 ' CG2' ' HB ' ' A' ' 177' ' ' VAL . 34.9 t -64.34 -35.61 74.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.555 0 C-N-CA 123.902 0.881 . . . . 0.0 109.947 178.562 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 37.3 t -79.89 65.93 5.21 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 173.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 20.7 m -69.8 -27.19 64.69 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.72 179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -71.56 98.79 1.93 Allowed 'General case' 0 N--CA 1.432 -1.368 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 171.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 36.0 tpp -154.21 89.54 1.29 Allowed 'General case' 0 N--CA 1.416 -2.136 0 CA-C-N 115.124 -0.944 . . . . 0.0 108.997 -173.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.42 ' HG2' ' HG3' ' A' ' 166' ' ' ARG . 0.6 OUTLIER -84.57 134.31 42.6 Favored Pre-proline 0 C--N 1.278 -2.503 0 CA-C-N 114.11 -1.405 . . . . 0.0 109.315 176.745 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.72 20.66 0.38 Allowed 'Trans proline' 0 N--CA 1.486 1.085 0 C-N-CA 123.962 3.108 . . . . 0.0 114.494 -171.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 29.8 m-20 -106.48 -23.09 12.6 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-O 121.172 0.51 . . . . 0.0 110.186 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.522 ' HD3' ' O ' ' A' ' 166' ' ' ARG . 0.0 OUTLIER -99.89 114.12 27.13 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-O 121.743 0.782 . . . . 0.0 111.952 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 37.8 mt-10 -74.78 156.63 36.33 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.288 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . 0.448 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 99.6 m-85 -78.15 101.64 7.14 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -97.4 160.23 14.45 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -177.337 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . 0.441 ' HB2' HG21 ' A' ' 144' ' ' VAL . 53.6 t80 -54.83 111.66 0.87 Allowed 'General case' 0 C--O 1.241 0.62 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 171.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 137.55 -12.82 3.73 Favored Glycine 0 N--CA 1.425 -2.064 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -173.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -82.98 143.97 30.29 Favored 'General case' 0 C--O 1.248 1.009 0 CA-C-O 121.436 0.636 . . . . 0.0 112.116 177.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -134.88 111.1 9.59 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 172.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 76.7 t -97.75 111.53 27.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 CA-C-O 120.983 0.42 . . . . 0.0 110.083 -177.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 79.6 ttt180 -95.33 153.84 17.49 Favored 'General case' 0 N--CA 1.426 -1.644 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.05 178.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -125.49 153.56 43.37 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 124.264 1.026 . . . . 0.0 109.458 -175.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.406 ' HB ' ' CG2' ' A' ' 158' ' ' VAL . 14.7 p -135.59 143.02 37.78 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 72.6 m -96.17 146.57 24.57 Favored 'General case' 0 C--N 1.272 -2.802 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.508 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -87.71 168.38 13.03 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.762 -176.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 32.4 t 50.06 -113.2 0.63 Allowed 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 124.058 0.943 . . . . 0.0 113.357 178.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -118.87 23.83 8.61 Favored Glycine 0 N--CA 1.417 -2.577 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -79.87 158.12 26.81 Favored 'General case' 0 C--O 1.249 1.046 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.117 -176.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 20.9 ptmt -121.14 160.56 23.48 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 115.503 -0.771 . . . . 0.0 109.476 -178.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.415 HD12 ' CG ' ' A' ' 203' ' ' PRO . 3.6 tp -79.29 145.91 8.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.449 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -69.61 -66.96 0.52 Allowed 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.617 178.484 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -115.69 -98.54 2.15 Favored Glycine 0 N--CA 1.433 -1.548 0 C-N-CA 120.442 -0.885 . . . . 0.0 111.364 -179.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -98.84 145.38 27.03 Favored 'General case' 0 CA--C 1.483 -1.604 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -178.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -102.97 12.08 36.54 Favored 'General case' 0 C--N 1.287 -2.138 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.915 -175.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -149.05 132.51 16.65 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 121.555 0.693 . . . . 0.0 112.552 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.7 ptp -114.21 125.33 53.81 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.282 176.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 27.3 t-80 -103.85 148.33 26.26 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 -178.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 5.0 m -75.02 140.88 43.89 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 177.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 50.7 m -96.71 154.95 16.99 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 171.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -73.77 -2.67 24.42 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.754 0.788 . . . . 0.0 110.882 -177.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -81.29 -10.43 59.58 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.827 178.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 94.48 26.51 13.41 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.769 -0.729 . . . . 0.0 113.514 178.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 19.5 p90 -147.78 173.44 12.8 Favored 'General case' 0 C--N 1.309 -1.155 0 O-C-N 122.263 -0.551 . . . . 0.0 110.376 177.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -83.05 145.15 29.45 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 123.433 0.458 . . . . 0.0 110.486 -179.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 6.7 m -82.91 -0.52 48.82 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.847 0.356 . . . . 0.0 111.336 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 15.7 tppt? -140.14 153.5 46.69 Favored 'General case' 0 N--CA 1.424 -1.731 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -177.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -87.87 155.04 20.06 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.68 175.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . 0.417 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 38.9 mtpt -59.95 126.67 84.08 Favored Pre-proline 0 N--CA 1.434 -1.261 0 O-C-N 123.731 0.645 . . . . 0.0 110.042 174.669 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . 0.415 ' CG ' HD12 ' A' ' 184' ' ' ILE . 90.9 Cg_endo -82.93 -167.95 0.53 Allowed 'Trans proline' 0 N--CA 1.436 -1.901 0 C-N-CA 122.514 2.143 . . . . 0.0 110.66 177.313 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -132.25 170.47 15.0 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.482 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 89.2 m -120.42 112.67 19.28 Favored 'General case' 0 C--N 1.274 -2.689 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 172.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 28.2 m . . . . . 0 C--N 1.281 -2.375 0 CA-C-N 114.105 -1.407 . . . . 0.0 109.206 -172.216 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.453 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 32.7 Cg_endo . . . . . 0 CA--C 1.546 1.11 0 CA-C-O 120.902 0.293 . . . . 0.0 112.201 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . 0.597 ' HB3' ' NE1' ' A' ' 134' ' ' TRP . 0.9 OUTLIER -87.7 -16.79 33.31 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.37 0.605 . . . . 0.0 110.133 175.132 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 102.72 -93.8 1.09 Allowed Glycine 1 N--CA 1.391 -4.357 0 N-CA-C 108.748 -1.741 . . . . 0.0 108.748 174.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -170.38 132.06 0.96 Allowed Pre-proline 0 C--N 1.253 -3.628 0 N-CA-C 105.571 -2.011 . . . . 0.0 105.571 -175.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -73.27 -28.72 12.19 Favored 'Trans proline' 0 N--CA 1.477 0.512 0 C-N-CA 122.152 1.901 . . . . 0.0 113.481 -173.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 133.41 150.28 6.29 Favored Glycine 0 N--CA 1.425 -2.036 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -178.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -111.89 125.89 54.52 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -178.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.6 t -89.5 125.59 60.98 Favored Pre-proline 0 C--N 1.3 -1.557 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 178.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -70.1 -10.42 28.25 Favored 'Trans proline' 0 C--O 1.221 -0.371 0 C-N-CA 122.833 2.355 . . . . 0.0 111.911 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -92.44 -2.55 56.21 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.398 0.618 . . . . 0.0 110.616 -178.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.492 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -178.71 -119.5 0.61 Allowed Glycine 0 N--CA 1.422 -2.294 0 C-N-CA 119.948 -1.12 . . . . 0.0 111.952 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.2 t -170.25 -162.55 0.3 Allowed 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.441 ' CB ' ' HA ' ' A' ' 112' ' ' TYR . 52.5 p90 -148.37 170.93 16.88 Favored 'General case' 0 C--N 1.311 -1.106 0 O-C-N 121.61 -0.681 . . . . 0.0 110.844 178.564 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -123.47 163.31 21.14 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 177.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.2 mt -121.99 129.42 52.46 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 32.6 p -122.84 124.63 43.71 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -176.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 92.99 30.18 9.68 Favored Glycine 0 C--N 1.298 -1.548 0 C-N-CA 120.325 -0.941 . . . . 0.0 111.185 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 167.25 -33.16 0.21 Allowed Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 119.464 -1.35 . . . . 0.0 113.417 176.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 65.46 14.79 9.68 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 123.577 0.751 . . . . 0.0 112.995 -177.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.534 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.4 m -151.7 -168.89 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.213 -0.85 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -177.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -106.52 38.14 2.14 Favored 'General case' 0 C--O 1.252 1.217 0 CA-C-N 118.737 0.699 . . . . 0.0 110.445 -175.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.712 ' O ' HG13 ' A' ' 108' ' ' VAL . 12.1 pt-20 -78.49 178.74 7.52 Favored 'General case' 0 C--O 1.2 -1.521 0 CA-C-N 114.22 -1.354 . . . . 0.0 111.003 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . 0.663 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 23.7 m-85 -79.63 134.04 36.43 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-O 120.958 0.408 . . . . 0.0 111.276 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.49 4.55 60.74 Favored Glycine 0 N--CA 1.44 -1.056 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.638 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.712 HG13 ' O ' ' A' ' 105' ' ' GLU . 14.5 p -99.44 145.11 11.06 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 C-N-CA 120.425 -0.51 . . . . 0.0 109.876 -179.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 58.7 mtpt -108.1 125.09 51.18 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.609 176.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.82 94.06 9.65 Favored 'General case' 0 C--N 1.289 -2.055 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.334 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 32.8 m -94.07 116.12 34.55 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.188 0 CA-C-O 122.599 1.19 . . . . 0.0 108.434 -178.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . 0.441 ' HA ' ' CB ' ' A' ' 96' ' ' PHE . 13.4 m-85 -78.74 141.75 37.6 Favored 'General case' 0 C--N 1.267 -2.985 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.667 -174.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.7 t -133.57 106.99 7.73 Favored 'General case' 0 N--CA 1.411 -2.386 0 CA-C-N 115.114 -0.948 . . . . 0.0 108.772 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 95.4 m -63.67 160.45 16.92 Favored 'General case' 0 C--N 1.296 -1.737 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.261 177.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.492 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 78.9 m-20 -74.35 -177.87 3.23 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.656 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -58.56 -45.29 89.3 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 123.58 0.752 . . . . 0.0 112.719 -174.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.36 24.13 6.63 Favored Glycine 0 C--O 1.212 -1.249 0 C-N-CA 120.747 -0.739 . . . . 0.0 113.302 179.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -147.82 169.93 18.71 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.99 -0.712 . . . . 0.0 109.952 -173.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -152.13 162.98 40.29 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -78.45 140.84 38.61 Favored 'General case' 0 C--N 1.288 -2.069 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.516 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.4 OUTLIER -119.24 126.52 51.71 Favored 'General case' 0 N--CA 1.409 -2.488 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.244 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.52 -170.24 14.27 Favored Glycine 0 C--N 1.289 -2.061 0 C-N-CA 120.69 -0.766 . . . . 0.0 111.607 -178.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -98.66 -38.81 8.97 Favored 'General case' 0 C--N 1.309 -1.195 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 -177.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.5 mm -78.62 120.48 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.716 0 CA-C-N 114.668 -1.151 . . . . 0.0 109.098 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -123.36 6.33 9.04 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.464 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 25.8 p90 -143.29 165.4 27.57 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -171.265 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 34.4 mtp180 -129.09 143.19 50.78 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 169.126 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -113.6 130.21 56.42 Favored 'General case' 0 C--N 1.287 -2.135 0 C-N-CA 119.426 -0.909 . . . . 0.0 109.895 -178.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . 0.663 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 37.8 t -80.35 90.39 5.58 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 176.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.484 ' OD2' HG22 ' A' ' 131' ' ' THR . 16.9 t70 -97.21 -170.62 2.05 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 179.017 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.484 HG22 ' OD2' ' A' ' 130' ' ' ASP . 15.1 t -59.03 -32.36 69.67 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 123.485 0.714 . . . . 0.0 112.875 -172.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -75.86 -34.09 60.03 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 121.488 0.661 . . . . 0.0 110.393 178.012 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.469 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 140.0 -153.91 23.57 Favored Glycine 0 N--CA 1.417 -2.602 0 N-CA-C 107.81 -2.116 . . . . 0.0 107.81 -174.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.597 ' NE1' ' HB3' ' A' ' 85' ' ' CYS . 98.3 m95 -65.86 116.61 7.21 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 117.655 0.728 . . . . 0.0 111.326 176.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 54.4 p -74.74 171.13 14.49 Favored 'General case' 0 C--O 1.269 2.119 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.036 176.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 87.0 m-20 59.05 -158.3 0.31 Allowed 'General case' 0 CA--C 1.515 -0.391 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -136.58 -179.48 5.71 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 172.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.9 mt -57.5 121.21 46.67 Favored Pre-proline 0 C--N 1.273 -2.721 0 C-N-CA 123.945 0.898 . . . . 0.0 108.595 175.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -63.49 169.68 9.35 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 122.663 2.242 . . . . 0.0 112.386 -179.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.516 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 52.8 mt -95.83 139.89 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.856 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -173.608 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 38.3 t -126.59 136.57 52.71 Favored 'General case' 0 C--N 1.276 -2.628 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -130.64 154.55 47.78 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -178.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 4.2 p -70.64 147.96 11.07 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 2.3 m -67.57 107.58 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.521 176.412 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -89.9 137.16 32.57 Favored 'General case' 0 N--CA 1.436 -1.168 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.72 -178.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.8 m -102.89 138.14 40.17 Favored 'General case' 0 C--N 1.282 -2.328 0 N-CA-C 106.111 -1.811 . . . . 0.0 106.111 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -63.0 148.22 92.89 Favored Pre-proline 0 N--CA 1.433 -1.275 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -177.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -61.2 121.84 10.25 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 122.911 2.408 . . . . 0.0 110.571 175.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.6 p -93.22 151.82 3.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.2 p -88.68 -177.16 5.49 Favored 'General case' 0 N--CA 1.431 -1.385 0 C-N-CA 120.9 -0.32 . . . . 0.0 110.291 175.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -108.79 158.94 32.77 Favored Pre-proline 0 C--N 1.294 -1.832 0 C-N-CA 122.415 0.286 . . . . 0.0 111.412 -171.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.78 157.39 61.43 Favored 'Trans proline' 0 C--N 1.362 1.247 0 C-N-CA 122.779 2.32 . . . . 0.0 111.292 175.252 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -59.02 -57.25 13.91 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 113.737 1.014 . . . . 0.0 113.737 -175.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 -102.5 36.56 2.13 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -178.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -150.91 -154.56 6.56 Favored Glycine 0 N--CA 1.413 -2.851 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.399 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . 0.46 ' HG3' HG23 ' A' ' 177' ' ' VAL . 17.5 ptmt -163.84 -177.55 5.18 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 123.658 0.783 . . . . 0.0 109.002 -178.799 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 55.2 mt -100.22 135.8 34.43 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.457 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.6 m -82.5 -33.71 11.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.539 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 7.2 m -82.7 79.21 9.17 Favored 'General case' 0 N--CA 1.425 -1.696 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.356 -173.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 15.9 m -77.09 75.29 3.66 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.751 178.34 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -125.77 94.36 4.1 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 114.628 -1.169 . . . . 0.0 109.37 -179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 38.0 tpp -157.3 86.85 0.96 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 176.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.439 ' CG ' ' HB2' ' A' ' 166' ' ' ARG . 8.5 pt-20 -150.66 165.52 17.21 Favored Pre-proline 0 C--N 1.288 -2.071 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.396 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -44.44 -28.73 2.75 Favored 'Trans proline' 0 N--CA 1.485 0.978 0 C-N-CA 124.67 3.58 . . . . 0.0 116.127 -177.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -108.47 -44.83 4.0 Favored 'General case' 0 C--N 1.311 -1.084 0 C-N-CA 119.219 -0.992 . . . . 0.0 110.396 -177.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.439 ' HB2' ' CG ' ' A' ' 163' ' ' GLU . 4.7 mmp_? -87.42 95.38 9.99 Favored 'General case' 0 N--CA 1.427 -1.597 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.237 -177.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . 0.463 ' HB2' ' NE2' ' A' ' 169' ' ' HIS . 27.7 mt-10 -110.97 -177.78 3.3 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 105.469 -2.048 . . . . 0.0 105.469 174.53 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -86.15 105.33 16.48 Favored 'General case' 0 C--N 1.295 -1.791 0 CA-C-O 121.58 0.705 . . . . 0.0 109.269 175.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.463 ' NE2' ' HB2' ' A' ' 167' ' ' GLU . 30.5 m170 -114.36 160.1 19.5 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -178.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -53.99 120.85 6.93 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 174.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 122.17 -23.92 7.13 Favored Glycine 0 N--CA 1.428 -1.86 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -177.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 15.6 mm100 -70.53 145.32 50.92 Favored 'General case' 0 C--O 1.256 1.423 0 CA-C-O 121.656 0.741 . . . . 0.0 110.783 178.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -116.01 112.59 22.02 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 173.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 8.4 p -95.64 112.91 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.316 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.457 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 79.5 ttt180 -110.61 143.68 40.67 Favored 'General case' 0 C--N 1.28 -2.417 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.005 -175.229 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -114.18 159.65 19.87 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.053 -174.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.46 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.0 OUTLIER -129.8 154.06 39.75 Favored 'Isoleucine or valine' 0 CA--C 1.469 -2.148 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.746 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 82.7 m -115.22 140.07 49.4 Favored 'General case' 0 N--CA 1.395 -3.19 0 CA-C-N 114.158 -1.383 . . . . 0.0 108.787 174.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -67.97 161.64 26.12 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.286 177.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 17.3 t -55.12 117.39 3.44 Favored 'General case' 0 C--N 1.311 -1.09 0 O-C-N 124.167 0.917 . . . . 0.0 111.287 -173.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 113.41 -20.98 17.93 Favored Glycine 0 N--CA 1.429 -1.802 0 CA-C-N 115.066 -0.97 . . . . 0.0 111.743 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -104.2 157.36 17.18 Favored 'General case' 0 N--CA 1.432 -1.358 0 O-C-N 122.397 -0.472 . . . . 0.0 111.572 -177.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -124.17 154.35 40.21 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.9 tp -69.25 148.59 11.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 176.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -55.91 -59.77 4.42 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 123.842 0.857 . . . . 0.0 110.758 177.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -134.16 -83.6 0.2 Allowed Glycine 0 N--CA 1.437 -1.283 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.238 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . 0.454 ' OD2' ' HD2' ' A' ' 200' ' ' LYS . 74.2 m-20 -102.56 134.94 45.09 Favored 'General case' 0 CA--C 1.499 -0.985 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -85.33 -1.76 57.33 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.536 -178.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . 0.512 ' O ' ' HG3' ' A' ' 200' ' ' LYS . 0.0 OUTLIER -134.42 143.08 47.36 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-O 121.253 0.549 . . . . 0.0 111.157 -175.878 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.419 ' HG3' ' H ' ' A' ' 200' ' ' LYS . 31.8 ttm -126.14 115.26 19.52 Favored 'General case' 0 N--CA 1.416 -2.167 0 C-N-CA 125.039 1.335 . . . . 0.0 108.07 178.232 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 8.1 m80 -94.62 154.9 17.13 Favored 'General case' 0 C--N 1.267 -3.013 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.045 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 45.0 t -98.76 142.42 30.33 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 13.7 p -119.52 -174.51 2.75 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -173.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -56.56 -22.21 31.86 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 125.317 1.447 . . . . 0.0 111.806 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -64.57 -21.01 66.58 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.338 -178.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 81.67 14.87 77.07 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -174.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -141.04 177.83 7.79 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.428 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -81.16 147.06 30.21 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.14 -176.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 26.6 m -82.3 -29.62 31.0 Favored 'General case' 0 N--CA 1.422 -1.831 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.117 177.129 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . 0.512 ' HG3' ' O ' ' A' ' 189' ' ' GLU . 6.4 mmpt? -98.47 166.12 11.51 Favored 'General case' 0 N--CA 1.441 -0.881 0 C-N-CA 117.974 -1.491 . . . . 0.0 112.913 177.037 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -96.74 163.84 12.83 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 104.365 -2.457 . . . . 0.0 104.365 171.121 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . 0.441 ' HZ1' ' HB3' ' A' ' 202' ' ' LYS . 4.9 mtpm? -66.69 125.59 90.89 Favored Pre-proline 0 C--N 1.304 -1.388 0 C-N-CA 119.862 -0.735 . . . . 0.0 112.406 178.366 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 7.3 Cg_endo -89.46 -174.08 0.86 Allowed 'Trans proline' 0 N--CA 1.42 -2.838 0 C-N-CA 121.746 1.631 . . . . 0.0 109.767 171.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 20.5 pttm -149.67 175.94 11.11 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 73.6 m -113.26 113.9 25.96 Favored 'General case' 0 C--N 1.283 -2.287 0 O-C-N 123.683 0.615 . . . . 0.0 109.524 -178.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.5 m . . . . . 0 N--CA 1.422 -1.832 0 CA-C-N 113.765 -1.561 . . . . 0.0 109.005 -174.104 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo . . . . . 0 CA--C 1.533 0.47 0 CA-C-O 121.444 0.518 . . . . 0.0 111.728 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 33.9 m -79.37 -33.31 43.0 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.21 -92.72 0.55 Allowed Glycine 1 N--CA 1.394 -4.159 0 CA-C-N 114.104 -1.407 . . . . 0.0 109.717 172.748 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -174.8 133.54 0.5 Allowed Pre-proline 0 C--N 1.255 -3.543 0 N-CA-C 103.85 -2.648 . . . . 0.0 103.85 -175.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.404 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 86.9 Cg_endo -80.61 3.0 8.09 Favored 'Trans proline' 0 C--N 1.328 -0.502 0 C-N-CA 122.643 2.228 . . . . 0.0 113.899 -173.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.3 -166.08 17.26 Favored Glycine 0 C--N 1.287 -2.163 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 -175.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -145.1 151.25 38.2 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -177.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 t -120.98 130.33 24.9 Favored Pre-proline 0 N--CA 1.429 -1.503 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -78.83 -7.59 15.55 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.59 2.194 . . . . 0.0 111.908 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -96.64 19.0 13.05 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.482 -179.168 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 155.97 -119.07 0.89 Allowed Glycine 0 N--CA 1.42 -2.378 0 C-N-CA 119.941 -1.124 . . . . 0.0 111.995 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.7 t -168.6 -169.85 1.12 Allowed 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -176.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -143.48 163.28 33.56 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 177.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.1 m -124.61 162.83 23.27 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 106.349 -1.723 . . . . 0.0 106.349 178.299 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 15.4 mt -123.37 125.2 44.55 Favored 'General case' 0 C--N 1.279 -2.493 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.409 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 44.1 p -119.68 134.09 55.37 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 -176.184 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.31 25.72 42.62 Favored Glycine 0 C--N 1.312 -0.775 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.19 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 172.87 -35.71 0.13 Allowed Glycine 0 CA--C 1.486 -1.768 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 61.18 18.97 9.61 Favored 'General case' 0 CA--C 1.521 -0.144 0 C-N-CA 124.394 1.077 . . . . 0.0 112.2 178.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.548 ' O ' HG13 ' A' ' 108' ' ' VAL . 31.1 m -154.12 -167.3 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.208 -1.103 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 -178.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 21.3 m-85 -105.42 42.71 1.2 Allowed 'General case' 0 C--N 1.311 -1.109 0 CA-C-N 119.392 0.996 . . . . 0.0 110.139 -176.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.728 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.1 pt-20 -86.23 179.14 6.97 Favored 'General case' 0 C--O 1.205 -1.251 0 CA-C-N 114.564 -1.198 . . . . 0.0 111.733 178.166 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.1 m-85 -74.9 136.18 41.47 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 122.017 -0.427 . . . . 0.0 111.391 177.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.09 6.93 70.9 Favored Glycine 0 C--N 1.31 -0.88 0 CA-C-N 115.914 -0.585 . . . . 0.0 113.034 177.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.728 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.8 p -97.9 145.64 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.062 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.409 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 59.4 mtpt -110.25 122.84 48.61 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 177.641 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.432 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -85.5 85.37 7.43 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.513 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 31.8 m -83.39 107.0 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.027 0 CA-C-O 122.812 1.291 . . . . 0.0 109.558 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 31.8 m-85 -73.17 134.84 44.54 Favored 'General case' 0 C--N 1.276 -2.606 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.964 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.6 t -129.81 114.55 16.07 Favored 'General case' 0 N--CA 1.408 -2.529 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 87.2 m -66.66 161.68 22.81 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 115.596 -0.729 . . . . 0.0 112.518 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 5.0 t-20 -68.85 -173.54 0.49 Allowed 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.136 -177.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -58.38 -52.17 66.73 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 123.109 0.564 . . . . 0.0 111.902 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.04 12.56 63.81 Favored Glycine 0 N--CA 1.437 -1.297 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.99 -177.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.505 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.6 m-85 -129.44 159.09 37.33 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 117.157 0.478 . . . . 0.0 110.72 -177.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.79 152.84 45.52 Favored 'General case' 0 C--N 1.288 -2.102 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . 0.432 ' HG ' ' CB ' ' A' ' 125' ' ' ASN . 0.5 OUTLIER -78.29 126.36 30.68 Favored 'General case' 0 C--N 1.281 -2.401 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 179.17 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.425 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.3 OUTLIER -108.01 130.61 55.05 Favored 'General case' 0 N--CA 1.418 -2.044 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -178.791 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 114.69 -169.41 12.86 Favored Glycine 0 C--N 1.292 -1.91 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -103.82 -31.77 9.64 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-O 121.52 0.676 . . . . 0.0 109.763 -179.108 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.413 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.9 mm -89.16 120.59 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.562 -178.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.432 ' CB ' ' HG ' ' A' ' 120' ' ' LEU . 3.7 p-10 -125.6 9.59 7.75 Favored 'General case' 0 C--O 1.203 -1.368 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.513 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 22.4 p90 -140.67 168.39 19.91 Favored 'General case' 0 C--N 1.282 -2.347 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -170.359 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.414 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 48.7 mtp180 -132.5 117.9 18.59 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 169.34 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -91.89 128.33 37.69 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 118.881 -1.128 . . . . 0.0 109.969 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 47.8 t -84.62 109.74 18.21 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.183 -1.007 . . . . 0.0 109.652 175.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.429 ' OD2' HG21 ' A' ' 131' ' ' THR . 9.9 t70 -111.71 -164.35 0.91 Allowed 'General case' 0 C--N 1.287 -2.126 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.429 HG21 ' OD2' ' A' ' 130' ' ' ASP . 12.0 t -63.4 -21.35 66.24 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -174.567 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -82.32 -22.77 35.46 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-O 121.87 0.843 . . . . 0.0 109.551 177.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 118.55 -145.25 18.28 Favored Glycine 0 N--CA 1.419 -2.44 0 N-CA-C 107.227 -2.349 . . . . 0.0 107.227 -171.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -69.92 111.42 5.63 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 108.984 -0.746 . . . . 0.0 108.984 177.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 37.8 p -66.65 -57.23 7.62 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-O 121.394 0.616 . . . . 0.0 111.499 -177.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . 0.414 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 4.9 m120 -75.94 169.96 17.17 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.733 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 22.0 m-20 -106.51 -178.2 3.58 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.8 mt -64.89 123.71 84.46 Favored Pre-proline 0 C--N 1.318 -0.791 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 177.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . 0.413 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 35.5 Cg_endo -67.97 174.06 8.38 Favored 'Trans proline' 0 C--O 1.242 0.7 0 C-N-CA 122.867 2.378 . . . . 0.0 112.971 -179.103 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.425 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 63.1 mt -96.13 139.08 19.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 -176.475 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.505 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 33.9 t -128.21 125.21 38.53 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 13.7 tp10 -120.02 155.57 32.62 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -174.352 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 8.6 p -75.41 134.51 29.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 169' ' ' HIS . 83.0 t -60.21 123.91 13.6 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.711 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.171 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.423 ' HZ1' ' CD ' ' A' ' 167' ' ' GLU . 51.2 mttm -106.12 158.39 16.85 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 120.944 0.402 . . . . 0.0 110.457 -175.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.475 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 60.6 m -117.46 161.6 19.32 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 2.2 pp -72.47 155.38 91.24 Favored Pre-proline 0 C--N 1.307 -1.259 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -78.23 126.02 7.47 Favored 'Trans proline' 0 N--CA 1.439 -1.683 0 C-N-CA 122.294 1.996 . . . . 0.0 113.152 -175.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.492 HG12 ' O ' ' A' ' 150' ' ' THR . 54.3 t -69.46 135.67 27.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-N 114.041 -1.436 . . . . 0.0 110.349 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' THR . . . . . 0.492 ' O ' HG12 ' A' ' 149' ' ' VAL . 11.5 p -93.7 170.85 9.27 Favored 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 171.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -93.46 156.75 39.54 Favored Pre-proline 0 C--N 1.267 -2.995 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -174.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -74.35 152.96 44.88 Favored 'Trans proline' 0 N--CA 1.428 -2.371 0 C-N-CA 120.761 0.974 . . . . 0.0 110.905 172.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -54.66 -44.34 73.17 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 114.72 1.378 . . . . 0.0 114.72 -172.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.8 m-80 -122.71 31.41 6.08 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 122.154 0.978 . . . . 0.0 108.746 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -139.57 -161.79 8.86 Favored Glycine 0 N--CA 1.428 -1.888 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 40.6 pttt -157.64 163.14 38.55 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 -178.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 49.3 mt -89.36 132.33 34.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-O 121.005 0.431 . . . . 0.0 110.029 -177.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.7 t -74.85 -48.22 34.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-O 122.182 0.991 . . . . 0.0 108.393 177.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' SER . . . . . 0.478 ' CB ' ' HA ' ' A' ' 174' ' ' VAL . 6.3 m -94.73 43.06 1.09 Allowed 'General case' 0 C--N 1.289 -2.039 0 CA-C-N 114.553 -1.203 . . . . 0.0 111.388 -175.611 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 32.0 t -68.5 102.29 1.42 Allowed 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.723 -0.217 . . . . 0.0 111.076 -177.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 43.06 78.81 0.05 OUTLIER 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.438 1.495 . . . . 0.0 113.923 177.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 17.0 ptp -85.36 -19.1 31.94 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.468 0.651 . . . . 0.0 110.261 -177.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -77.13 148.81 78.8 Favored Pre-proline 0 C--N 1.313 -0.991 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.588 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.6 -4.18 14.89 Favored 'Trans proline' 0 N--CA 1.479 0.665 0 C-N-CA 123.21 2.606 . . . . 0.0 111.156 178.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . 0.522 ' C ' ' H ' ' A' ' 167' ' ' GLU . 4.0 m-20 -93.59 -29.41 15.49 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 105.122 -2.177 . . . . 0.0 105.122 178.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 69.32 -2.14 1.96 Allowed 'General case' 0 CA--C 1.501 -0.91 0 C-N-CA 127.287 2.235 . . . . 0.0 113.414 -177.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . 0.522 ' H ' ' C ' ' A' ' 165' ' ' ASP . 45.4 mt-10 -70.44 145.33 51.08 Favored 'General case' 0 C--N 1.274 -2.693 0 CA-C-N 113.53 -1.668 . . . . 0.0 107.326 172.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -90.74 126.32 35.96 Favored 'General case' 0 C--N 1.27 -2.881 0 N-CA-C 105.874 -1.899 . . . . 0.0 105.874 168.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.409 ' HB2' ' O ' ' A' ' 144' ' ' VAL . 2.1 p-80 -145.46 168.72 19.87 Favored 'General case' 0 C--N 1.279 -2.47 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.675 -176.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -51.76 121.04 5.9 Favored 'General case' 0 C--O 1.242 0.695 0 O-C-N 124.31 1.006 . . . . 0.0 110.307 -176.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 123.49 -17.46 7.85 Favored Glycine 0 N--CA 1.427 -1.952 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.202 -175.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 25.3 mm-40 -78.67 135.34 37.17 Favored 'General case' 0 C--O 1.255 1.371 0 CA-C-O 121.716 0.77 . . . . 0.0 112.254 178.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -125.7 109.8 13.01 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 105.582 -2.007 . . . . 0.0 105.582 173.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.478 ' HA ' ' CB ' ' A' ' 159' ' ' SER . 53.6 t -107.4 122.61 61.85 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.687 -173.14 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.414 ' HG3' ' O ' ' A' ' 188' ' ' GLU . 24.0 ttp180 -111.66 161.51 16.17 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.322 177.163 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -130.73 162.47 29.39 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 124.397 1.079 . . . . 0.0 110.296 -174.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.79 143.9 35.1 Favored 'Isoleucine or valine' 0 CA--C 1.471 -2.093 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.45 176.692 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 76.7 m -105.68 131.52 52.95 Favored 'General case' 0 N--CA 1.395 -3.216 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 173.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -54.1 164.36 0.65 Allowed 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.309 177.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 26.7 t -33.71 -47.88 0.26 Allowed 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 116.771 2.137 . . . . 0.0 116.771 -168.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -104.28 15.36 50.63 Favored Glycine 0 C--N 1.288 -2.136 0 C-N-CA 120.056 -1.069 . . . . 0.0 115.025 -173.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -120.09 162.14 19.79 Favored 'General case' 0 CA--C 1.497 -1.065 0 CA-C-N 118.344 1.072 . . . . 0.0 112.424 -176.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . 0.444 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 25.5 pttm -123.28 154.2 39.16 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.474 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 2.8 tp -72.47 145.09 12.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -82.16 -71.16 0.5 Allowed 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 120.962 -0.295 . . . . 0.0 110.481 179.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.0 -89.58 0.63 Allowed Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.948 -177.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . 0.43 ' CG ' ' HZ2' ' A' ' 200' ' ' LYS . 12.0 t70 -136.36 159.99 40.1 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 -177.809 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . 0.414 ' O ' ' HG3' ' A' ' 175' ' ' ARG . 1.0 OUTLIER -103.37 3.26 34.99 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 118.999 -1.08 . . . . 0.0 112.707 -171.979 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . 0.584 ' O ' ' HG3' ' A' ' 200' ' ' LYS . 4.3 pt-20 -149.75 143.57 25.5 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 113.572 0.953 . . . . 0.0 113.572 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.421 ' CB ' ' HB2' ' A' ' 200' ' ' LYS . 12.8 ptp -133.37 144.14 49.4 Favored 'General case' 0 C--N 1.315 -0.898 0 C-N-CA 124.146 0.978 . . . . 0.0 111.275 -176.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 49.4 t-80 -125.69 141.05 52.21 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.506 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 13.2 m -65.32 129.55 40.13 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 177.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 193' ' ' SER . . . . . 0.414 ' OG ' ' HB3' ' A' ' 199' ' ' SER . 14.5 m -104.45 167.26 9.86 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.931 177.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -48.18 -37.23 15.22 Favored 'General case' 0 N--CA 1.496 1.874 0 C-N-CA 125.529 1.532 . . . . 0.0 113.535 -176.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -68.74 -16.01 63.68 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -176.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . 0.475 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 99.33 27.79 7.95 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.195 -1.002 . . . . 0.0 113.248 178.287 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -150.21 179.2 8.3 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 122.391 -0.476 . . . . 0.0 110.356 176.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -84.84 135.77 33.95 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 123.924 0.765 . . . . 0.0 110.881 -176.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 199' ' ' SER . . . . . 0.414 ' HB3' ' OG ' ' A' ' 193' ' ' SER . 9.5 p -73.26 -24.24 60.42 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.682 0.753 . . . . 0.0 111.136 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . 0.584 ' HG3' ' O ' ' A' ' 189' ' ' GLU . 28.2 mmtp -94.9 179.88 5.08 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 115.026 -0.988 . . . . 0.0 112.909 -177.526 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -100.75 148.87 24.41 Favored 'General case' 0 C--N 1.292 -1.925 0 CA-C-N 113.557 -1.656 . . . . 0.0 110.735 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . 0.46 ' HE2' ' HD2' ' A' ' 203' ' ' PRO . 0.1 OUTLIER -75.03 107.98 4.76 Favored Pre-proline 0 C--N 1.323 -0.563 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 175.123 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . 0.46 ' HD2' ' HE2' ' A' ' 202' ' ' LYS . 71.8 Cg_endo -88.81 174.25 4.0 Favored 'Trans proline' 0 N--CA 1.435 -1.915 0 C-N-CA 122.743 2.296 . . . . 0.0 114.898 -172.121 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -124.36 174.27 7.85 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -176.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.444 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 91.1 m -128.77 101.38 6.09 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 174.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 21.1 m . . . . . 0 C--N 1.294 -1.832 0 CA-C-N 114.226 -1.352 . . . . 0.0 108.679 -173.176 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo . . . . . 0 CA--C 1.542 0.908 0 CA-C-O 121.056 0.357 . . . . 0.0 112.008 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 61.7 m -82.67 -29.92 29.64 Favored 'General case' 0 CA--C 1.507 -0.675 0 CA-C-O 122.418 1.104 . . . . 0.0 108.228 177.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 113.2 -91.45 0.58 Allowed Glycine 0 N--CA 1.4 -3.737 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 173.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.8 t60 -175.1 135.26 0.51 Allowed Pre-proline 0 C--N 1.257 -3.453 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 -176.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.489 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 94.0 Cg_endo -80.9 2.04 8.86 Favored 'Trans proline' 0 C--N 1.324 -0.754 0 C-N-CA 122.364 2.043 . . . . 0.0 113.156 -175.714 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 94.42 176.07 38.81 Favored Glycine 0 C--N 1.287 -2.14 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -173.093 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -144.46 159.28 43.01 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 117.444 0.622 . . . . 0.0 109.453 -176.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.7 t -120.18 131.3 24.47 Favored Pre-proline 0 C--N 1.298 -1.645 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.25 -177.256 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -71.7 -19.12 28.1 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.337 2.025 . . . . 0.0 110.561 176.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -86.58 16.0 5.06 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.755 -1.112 . . . . 0.0 110.481 -174.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 164.78 -131.94 2.55 Favored Glycine 1 N--CA 1.396 -4.001 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.591 178.339 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.3 p -154.77 175.52 13.61 Favored 'General case' 0 C--N 1.288 -2.104 0 C-N-CA 124.182 0.993 . . . . 0.0 109.896 -173.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -144.95 154.07 42.2 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 171.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.8 m -126.13 162.14 26.04 Favored 'General case' 0 C--N 1.275 -2.648 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 17.6 mt -112.47 135.95 52.56 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 18.8 p -129.03 126.93 40.54 Favored 'General case' 0 C--N 1.281 -2.386 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.893 -178.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.47 29.23 14.55 Favored Glycine 0 C--N 1.302 -1.319 0 C-N-CA 120.407 -0.902 . . . . 0.0 111.978 179.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 172.12 -36.58 0.15 Allowed Glycine 0 N--CA 1.431 -1.699 0 C-N-CA 119.964 -1.112 . . . . 0.0 112.7 178.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 70.73 1.94 3.93 Favored 'General case' 0 N--CA 1.511 2.582 0 CA-C-O 122.206 1.003 . . . . 0.0 110.728 -178.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.458 ' O ' HG11 ' A' ' 108' ' ' VAL . 34.3 m -143.94 -171.24 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -173.439 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -105.45 45.41 0.97 Allowed 'General case' 0 C--N 1.304 -1.401 0 CA-C-O 121.269 0.557 . . . . 0.0 110.216 -176.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.739 ' O ' HG13 ' A' ' 108' ' ' VAL . 10.7 pt-20 -83.01 177.65 8.52 Favored 'General case' 0 C--O 1.213 -0.857 0 CA-C-N 114.585 -1.189 . . . . 0.0 111.607 177.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 43.6 m-85 -77.42 130.92 37.68 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-O 120.941 0.401 . . . . 0.0 110.801 176.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.87 2.37 58.39 Favored Glycine 0 N--CA 1.437 -1.238 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.555 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.739 HG13 ' O ' ' A' ' 105' ' ' GLU . 11.7 p -94.77 145.89 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.285 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 19.7 mtpp -111.94 120.77 43.03 Favored 'General case' 0 C--N 1.286 -2.157 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -86.86 92.8 9.11 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 77.2 t -86.39 118.41 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.611 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -178.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -85.99 145.58 27.04 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.289 -178.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.9 t -144.34 110.66 5.52 Favored 'General case' 0 N--CA 1.407 -2.61 0 CA-C-O 122.208 1.004 . . . . 0.0 108.446 -179.408 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 41.7 m -71.22 158.81 35.75 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.813 -173.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -60.24 171.9 0.94 Allowed 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 125.128 1.371 . . . . 0.0 111.33 -177.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -59.44 -41.87 90.6 Favored 'General case' 0 C--N 1.297 -1.685 0 C-N-CA 124.568 1.147 . . . . 0.0 110.017 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.454 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -86.63 19.82 26.66 Favored Glycine 0 CA--C 1.529 0.932 0 CA-C-N 115.368 -0.833 . . . . 0.0 113.739 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.443 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 97.9 m-85 -147.11 173.85 12.11 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -143.68 165.44 27.64 Favored 'General case' 0 C--N 1.281 -2.403 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.3 tt -94.51 137.88 33.1 Favored 'General case' 0 C--N 1.28 -2.447 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -178.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -124.74 135.15 52.75 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 -177.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.66 159.5 15.39 Favored Glycine 0 N--CA 1.438 -1.191 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -78.99 -27.33 43.32 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.719 0.771 . . . . 0.0 109.085 -177.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 47.2 mm -89.76 132.78 33.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 114.814 -1.085 . . . . 0.0 108.311 -177.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -133.07 12.94 4.28 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -177.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . . . . . . . . . 2.8 p90 -152.65 169.21 23.26 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 -173.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.489 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 54.1 mtp180 -131.84 120.1 22.13 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 169.115 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -94.53 138.35 32.53 Favored 'General case' 0 C--N 1.287 -2.128 0 C-N-CA 118.893 -1.123 . . . . 0.0 110.565 177.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.0 t -89.69 104.35 16.92 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 118.881 -1.128 . . . . 0.0 109.61 174.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.439 ' OD2' HG21 ' A' ' 131' ' ' THR . 12.1 t70 -97.08 -172.22 2.39 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 176.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.439 HG21 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -67.25 -11.44 57.47 Favored 'General case' 0 C--N 1.293 -1.855 0 C-N-CA 123.259 0.623 . . . . 0.0 112.274 -174.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -94.6 -12.5 27.35 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.82 0.819 . . . . 0.0 109.412 176.558 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.15 -159.25 13.86 Favored Glycine 0 N--CA 1.431 -1.685 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -175.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.0 m95 -63.65 105.23 0.76 Allowed 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 120.894 0.378 . . . . 0.0 111.259 178.088 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 24.9 p -61.32 -64.89 0.8 Allowed 'General case' 0 C--O 1.241 0.652 0 C-N-CA 124.955 1.302 . . . . 0.0 112.87 -175.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . 0.42 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.3 m120 -71.18 173.42 7.7 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.211 -177.099 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -106.55 176.43 5.17 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 175.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 77.5 mt -69.2 125.98 92.38 Favored Pre-proline 0 C--N 1.311 -1.085 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -70.68 168.69 22.04 Favored 'Trans proline' 0 C--O 1.249 1.073 0 C-N-CA 122.719 2.279 . . . . 0.0 111.145 177.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.6 mm -97.93 129.53 47.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 120.436 -0.506 . . . . 0.0 111.245 -173.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 99.5 m -101.93 103.34 13.98 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 171.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -95.09 152.39 18.38 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 -179.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.443 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 3.2 t -76.69 145.51 10.2 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.514 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 -175.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.454 HG22 ' C ' ' A' ' 117' ' ' GLY . 5.9 m -73.71 108.39 5.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 174.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -104.75 127.2 52.45 Favored 'General case' 0 N--CA 1.412 -2.352 0 CA-C-N 114.45 -1.25 . . . . 0.0 111.095 -174.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.549 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 3.4 m -85.44 148.5 25.96 Favored 'General case' 0 C--N 1.282 -2.356 0 CA-C-N 113.738 -1.574 . . . . 0.0 110.078 -173.444 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 59.4 mt -56.36 132.46 76.19 Favored Pre-proline 0 C--N 1.319 -0.75 0 N-CA-C 112.677 0.621 . . . . 0.0 112.677 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_endo -62.49 111.4 1.3 Allowed 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 123.499 2.799 . . . . 0.0 112.391 -178.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.3 t -79.05 139.16 18.81 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.5 p -79.02 -75.9 0.22 Allowed 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 123.868 0.73 . . . . 0.0 111.51 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 166.42 159.62 0.11 Allowed Pre-proline 0 C--O 1.24 0.59 0 C-N-CA 126.248 1.819 . . . . 0.0 107.054 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -73.73 171.81 17.07 Favored 'Trans proline' 0 CA--C 1.535 0.569 0 C-N-CA 121.519 1.479 . . . . 0.0 109.572 169.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -69.67 -62.57 1.33 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -177.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.5 m-80 -95.82 38.43 1.17 Allowed 'General case' 0 C--N 1.313 -1.01 0 O-C-N 121.562 -0.711 . . . . 0.0 110.488 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -155.1 -168.57 18.5 Favored Glycine 0 N--CA 1.426 -1.973 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.964 178.189 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -153.0 174.79 13.71 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 -178.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 52.5 mt -91.58 139.62 17.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -178.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.422 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 4.7 m -77.46 -37.17 24.55 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.576 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 178.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 28.6 t -115.95 79.64 1.33 Allowed 'General case' 0 N--CA 1.435 -1.199 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 32.3 m -77.98 74.2 4.54 Favored 'General case' 0 N--CA 1.43 -1.43 0 CA-C-O 121.751 0.786 . . . . 0.0 109.388 179.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -74.84 5.63 4.84 Favored 'General case' 0 C--O 1.211 -0.957 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.403 -175.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' MET . . . . . 0.673 ' O ' ' HA ' ' A' ' 166' ' ' ARG . 19.0 ptp -67.1 -15.27 63.61 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 124.356 1.062 . . . . 0.0 111.439 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 24.4 mm-40 -125.46 -55.1 0.03 OUTLIER Pre-proline 0 N--CA 1.48 1.027 0 N-CA-C 115.687 1.736 . . . . 0.0 115.687 -178.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -57.57 -27.15 75.6 Favored 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 121.431 1.42 . . . . 0.0 111.536 177.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . 0.451 ' C ' ' H ' ' A' ' 167' ' ' GLU . 23.0 t0 -127.76 -9.43 5.55 Favored 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.673 ' HA ' ' O ' ' A' ' 162' ' ' MET 0.253 72.8 mtt-85 62.83 -42.13 0.18 Allowed 'General case' 0 C--N 1.37 1.495 0 N-CA-C 117.543 2.423 . . . . 0.0 117.543 -179.328 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . 0.451 ' H ' ' C ' ' A' ' 165' ' ' ASP . 29.9 mt-10 -116.84 145.04 43.82 Favored 'General case' 1 C--N 1.22 -5.024 0 CA-C-N 114.84 -1.073 . . . . 0.0 108.999 -174.814 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -88.9 129.35 35.62 Favored 'General case' 0 C--N 1.295 -1.761 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 176.073 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 55.2 m80 -121.61 155.81 34.3 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 -175.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 81.7 t80 -49.68 121.09 4.78 Favored 'General case' 0 C--O 1.244 0.798 0 O-C-N 123.686 0.616 . . . . 0.0 110.56 175.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 132.28 -29.65 3.29 Favored Glycine 0 N--CA 1.42 -2.41 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 -177.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.8 mm-40 -63.24 128.85 37.73 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 179.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -118.06 82.66 1.87 Allowed 'General case' 0 N--CA 1.423 -1.813 0 N-CA-C 104.32 -2.474 . . . . 0.0 104.32 170.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 14.9 p -77.63 111.56 14.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.004 -169.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.422 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 40.1 ttm180 -97.74 148.29 23.5 Favored 'General case' 0 N--CA 1.416 -2.159 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.716 -177.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.49 ' HZ ' ' SD ' ' A' ' 190' ' ' MET . 51.2 m-85 -115.46 150.98 35.61 Favored 'General case' 0 N--CA 1.42 -1.967 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 -179.38 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 13.7 p -126.49 141.05 47.08 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.749 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 178.273 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.4 m -99.64 163.59 12.43 Favored 'General case' 0 C--N 1.262 -3.207 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.001 -178.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -66.52 172.63 3.95 Favored 'General case' 0 CA--C 1.497 -1.066 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.204 179.227 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 21.8 m -42.99 -31.95 0.59 Allowed 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 116.335 1.976 . . . . 0.0 116.335 -172.033 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -126.42 24.02 5.64 Favored Glycine 0 C--N 1.289 -2.069 0 C-N-CA 119.376 -1.393 . . . . 0.0 113.377 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -118.42 151.94 36.83 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.815 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . 0.516 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 50.9 pttt -115.27 157.03 24.33 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 -179.68 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.44 HD11 ' HA ' ' A' ' 188' ' ' GLU . 5.0 tt -86.1 143.59 11.17 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.506 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.224 175.403 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -77.56 -68.16 0.65 Allowed 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -173.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -80.63 -109.61 0.3 Allowed Glycine 0 C--O 1.245 0.798 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.976 -177.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -95.93 175.8 6.36 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 176.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . 0.44 ' HA ' HD11 ' A' ' 184' ' ' ILE . 10.3 pt-20 -104.28 -19.09 14.22 Favored 'General case' 0 C--N 1.28 -2.435 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -177.316 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . 0.445 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 5.3 pt-20 -141.45 150.21 41.98 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.053 -176.184 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.49 ' SD ' ' HZ ' ' A' ' 176' ' ' PHE . 0.1 OUTLIER -117.39 125.72 51.46 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.174 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -97.26 132.7 42.76 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 176.137 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . 0.453 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 48.7 t -80.39 136.8 36.44 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.114 179.422 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 193' ' ' SER . . . . . 0.418 ' HB2' ' OD1' ' A' ' 195' ' ' ASP . 11.1 m -98.99 173.54 6.79 Favored 'General case' 0 N--CA 1.423 -1.792 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.643 179.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -67.41 -8.85 36.23 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 124.157 0.983 . . . . 0.0 112.47 -176.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . 0.418 ' OD1' ' HB2' ' A' ' 193' ' ' SER . 11.8 p-10 -94.25 4.99 53.13 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 122.223 -0.298 . . . . 0.0 111.406 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . 0.549 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 79.49 11.63 84.64 Favored Glycine 0 CA--C 1.526 0.73 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.486 178.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -117.92 150.76 38.68 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 122.345 -0.503 . . . . 0.0 110.3 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . 0.453 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 82.3 m95 -78.9 135.59 37.03 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.037 177.671 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 26.4 t -74.43 -16.91 60.86 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-O 121.19 0.519 . . . . 0.0 110.547 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 24.5 mmtp -108.82 158.14 17.93 Favored 'General case' 0 CA--C 1.5 -0.978 0 O-C-N 122.123 -0.361 . . . . 0.0 110.551 178.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -97.58 170.44 9.02 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 123.477 0.486 . . . . 0.0 110.66 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 7.6 mmmm -69.06 115.8 35.43 Favored Pre-proline 0 CA--C 1.516 -0.354 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -178.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_endo -88.15 168.28 6.52 Favored 'Trans proline' 0 N--CA 1.446 -1.313 0 C-N-CA 122.862 2.375 . . . . 0.0 112.159 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -115.73 165.93 12.51 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.516 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 86.6 m -114.71 109.83 18.81 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 172.779 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 30.8 m . . . . . 0 C--O 1.254 1.302 0 O-C-N 124.332 1.02 . . . . 0.0 109.444 -173.858 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo . . . . . 0 CA--C 1.535 0.543 0 CA-C-O 121.74 0.642 . . . . 0.0 110.866 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.0 m -86.65 -35.6 19.26 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 117.46 -88.53 0.46 Allowed Glycine 0 N--CA 1.404 -3.49 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 174.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.5 t-80 -176.67 135.9 0.42 Allowed Pre-proline 0 C--N 1.255 -3.509 0 N-CA-C 104.458 -2.423 . . . . 0.0 104.458 -175.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -82.15 -0.29 10.18 Favored 'Trans proline' 0 C--N 1.329 -0.494 0 C-N-CA 121.993 1.795 . . . . 0.0 112.791 -176.197 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.33 -155.82 15.9 Favored Glycine 0 N--CA 1.42 -2.387 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -177.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -156.02 157.41 36.1 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 178.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.5 t -122.91 127.51 25.69 Favored Pre-proline 0 C--N 1.293 -1.875 0 CA-C-N 118.226 0.467 . . . . 0.0 110.822 -177.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -65.47 -16.01 52.16 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.772 2.315 . . . . 0.0 111.64 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -86.7 -9.37 56.11 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.335 -178.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 173.14 -125.29 1.13 Allowed Glycine 0 N--CA 1.433 -1.549 0 C-N-CA 118.755 -1.688 . . . . 0.0 113.907 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.8 t -148.88 -169.76 3.45 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -176.046 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -151.81 162.4 41.09 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 177.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -126.02 162.51 25.11 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.4 mt -113.93 138.74 49.92 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.403 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 26.5 p -132.68 137.64 47.02 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -178.123 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.2 24.25 52.32 Favored Glycine 0 C--N 1.309 -0.921 0 N-CA-C 108.556 -1.818 . . . . 0.0 108.556 -173.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 145.6 154.3 6.12 Favored Glycine 1 N--CA 1.39 -4.398 0 N-CA-C 107.334 -2.306 . . . . 0.0 107.334 -177.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -108.6 29.07 7.75 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 177.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.41 ' O ' HG21 ' A' ' 108' ' ' VAL . 35.6 m -144.31 -175.17 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 CA-C-N 114.686 -1.143 . . . . 0.0 109.068 -173.418 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -108.4 47.13 0.92 Allowed 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 121.464 0.649 . . . . 0.0 109.543 -177.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.722 ' O ' HG11 ' A' ' 108' ' ' VAL . 12.2 pt-20 -82.41 178.13 8.39 Favored 'General case' 0 C--O 1.213 -0.828 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.248 178.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -76.44 132.77 39.83 Favored 'General case' 0 C--N 1.289 -2.05 0 O-C-N 122.059 -0.401 . . . . 0.0 110.149 175.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.35 5.06 63.86 Favored Glycine 0 N--CA 1.431 -1.644 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.633 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.722 HG11 ' O ' ' A' ' 105' ' ' GLU . 10.4 p -96.69 144.4 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.403 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 20.5 mtpp -112.38 118.08 34.22 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -179.407 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -82.83 92.1 7.2 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 177.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 75.9 t -82.73 111.68 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.618 0 C-N-CA 123.942 0.897 . . . . 0.0 109.44 -178.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -80.6 144.12 32.62 Favored 'General case' 0 C--N 1.293 -1.858 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.672 -179.225 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.1 t -145.87 112.43 5.9 Favored 'General case' 0 N--CA 1.418 -2.041 0 CA-C-N 115.048 -0.978 . . . . 0.0 108.677 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 83.0 m -70.46 163.24 27.19 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.127 -178.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 -68.38 174.36 4.12 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.514 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -59.96 -39.09 84.43 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 112.781 0.659 . . . . 0.0 112.781 -174.238 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -85.61 9.96 66.28 Favored Glycine 0 C--N 1.3 -1.43 0 C-N-CA 121.275 -0.488 . . . . 0.0 113.668 179.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -131.44 163.12 28.63 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.16 134.86 22.27 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 9.5 tt -70.3 138.46 51.53 Favored 'General case' 0 C--N 1.293 -1.873 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.621 -177.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.45 140.75 49.02 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.018 -172.322 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 108.37 -172.81 17.28 Favored Glycine 0 C--N 1.303 -1.252 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.272 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 30.0 mm-40 -99.68 -19.63 16.7 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 117.084 0.442 . . . . 0.0 111.18 -177.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.9 mm -98.59 135.99 31.32 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -178.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -130.52 13.3 5.47 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.355 178.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.403 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 11.4 p90 -145.34 169.96 17.25 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -174.166 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.423 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 46.6 mtp180 -131.01 120.83 24.04 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 169.33 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -95.04 136.61 35.15 Favored 'General case' 0 C--N 1.28 -2.418 0 C-N-CA 119.228 -0.989 . . . . 0.0 110.223 178.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 27.1 t -92.61 109.19 20.6 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.923 -1.111 . . . . 0.0 109.473 173.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -110.3 -167.52 1.2 Allowed 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 105.004 -2.221 . . . . 0.0 105.004 175.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 14.8 t -67.03 -13.8 62.27 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 119.056 0.844 . . . . 0.0 111.409 -177.394 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -79.21 -15.68 57.67 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 121.745 0.784 . . . . 0.0 109.646 174.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 104.19 -154.62 17.64 Favored Glycine 0 N--CA 1.431 -1.69 0 N-CA-C 107.181 -2.368 . . . . 0.0 107.181 -173.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.9 m95 -64.36 106.72 1.17 Allowed 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 118.12 0.96 . . . . 0.0 108.535 172.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.0 p -63.52 -66.01 0.6 Allowed 'General case' 0 C--O 1.253 1.269 0 C-N-CA 124.001 0.92 . . . . 0.0 111.647 -174.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . 0.423 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.6 m120 -67.09 167.88 11.16 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-N 114.84 -1.073 . . . . 0.0 109.036 -179.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -100.7 -178.97 3.94 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 176.37 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 82.1 mt -72.13 120.69 81.73 Favored Pre-proline 0 C--N 1.313 -1.0 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 175.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.29 137.81 53.1 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 122.062 1.842 . . . . 0.0 110.911 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 69.7 mt -63.88 141.55 18.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.989 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 46.2 t -131.39 140.61 49.7 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -123.72 157.33 34.19 Favored 'General case' 0 N--CA 1.408 -2.551 0 CA-C-O 121.102 0.477 . . . . 0.0 110.324 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 5.7 p -75.1 137.9 22.06 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 97.5 t -58.55 117.52 1.82 Allowed 'Isoleucine or valine' 0 C--O 1.251 1.154 0 O-C-N 123.566 0.541 . . . . 0.0 110.18 -178.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 53.9 mttp -93.09 142.44 27.29 Favored 'General case' 0 N--CA 1.425 -1.704 0 CA-C-N 115.254 -0.885 . . . . 0.0 108.78 179.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.0 m -109.25 151.35 26.66 Favored 'General case' 0 C--N 1.278 -2.532 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -179.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 64.9 mt -56.17 137.45 74.22 Favored Pre-proline 0 C--N 1.319 -0.722 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.416 ' HA ' ' CD2' ' A' ' 168' ' ' TYR . 34.8 Cg_endo -66.71 94.87 0.33 Allowed 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 123.317 2.678 . . . . 0.0 111.6 179.202 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 9.5 p -69.41 142.78 15.61 Favored 'Isoleucine or valine' 0 C--O 1.25 1.119 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.01 -177.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 11.6 p -97.59 -166.25 1.36 Allowed 'General case' 0 N--CA 1.42 -1.961 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.882 177.45 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -119.61 156.35 53.64 Favored Pre-proline 0 C--N 1.297 -1.716 0 O-C-N 122.119 -0.363 . . . . 0.0 110.714 -171.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.4 175.36 6.03 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 122.224 1.949 . . . . 0.0 111.446 174.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . 0.479 ' OE1' ' HG3' ' A' ' 204' ' ' LYS . 0.0 OUTLIER -82.72 -43.57 16.66 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 120.999 0.428 . . . . 0.0 111.068 -174.801 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . 0.432 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 55.9 m-80 -98.86 18.86 16.07 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.348 0.594 . . . . 0.0 110.488 -179.676 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -147.31 -166.34 12.41 Favored Glycine 0 N--CA 1.424 -2.118 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.664 -178.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 62.5 pttt -154.68 -179.42 7.98 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -177.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 50.0 mt -100.95 132.07 47.4 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.207 0 CA-C-N 117.745 0.248 . . . . 0.0 110.859 -177.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.443 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.3 m -78.02 -29.19 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 15.4 m -98.77 40.37 1.2 Allowed 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.954 -177.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 15.4 t -67.39 -27.29 66.97 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -102.16 97.76 8.02 Favored 'General case' 0 N--CA 1.422 -1.839 0 N-CA-C 105.982 -1.858 . . . . 0.0 105.982 170.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' MET . . . . . 0.413 ' SD ' ' N ' ' A' ' 162' ' ' MET . 0.0 OUTLIER -71.07 -60.13 2.4 Favored 'General case' 0 CA--C 1.498 -1.054 0 CA-C-O 121.794 0.807 . . . . 0.0 110.007 -172.747 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.404 ' CD ' ' HD1' ' A' ' 169' ' ' HIS . 10.0 pt-20 -161.09 165.75 16.5 Favored Pre-proline 0 C--N 1.314 -0.942 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 -175.388 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -65.41 1.88 1.84 Allowed 'Trans proline' 0 N--CA 1.49 1.322 0 C-N-CA 123.056 2.504 . . . . 0.0 114.091 178.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -108.05 -9.4 15.63 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-O 122.645 1.212 . . . . 0.0 108.063 178.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 18.4 mmm180 57.61 30.37 18.7 Favored 'General case' 0 C--O 1.245 0.836 0 N-CA-C 117.287 2.328 . . . . 0.0 117.287 167.164 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . 0.518 ' HB2' ' CE1' ' A' ' 169' ' ' HIS . 60.1 mt-10 -126.26 170.33 11.98 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 171.087 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . 0.416 ' CD2' ' HA ' ' A' ' 148' ' ' PRO . 79.7 m-85 -93.84 123.34 37.13 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 174.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.518 ' CE1' ' HB2' ' A' ' 167' ' ' GLU . 37.4 m80 -130.95 164.62 24.92 Favored 'General case' 0 C--N 1.291 -1.953 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -178.161 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 92.5 t80 -58.07 111.61 1.24 Allowed 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 173.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 134.19 -23.76 3.65 Favored Glycine 0 N--CA 1.426 -1.981 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -174.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 81.0 mm-40 -78.53 140.51 38.54 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-O 121.339 0.59 . . . . 0.0 111.339 177.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -131.17 109.62 10.57 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 176.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.464 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 97.6 t -94.14 118.29 39.75 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.206 0 CA-C-N 115.472 -0.786 . . . . 0.0 110.578 -173.688 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.443 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 41.7 ttm180 -105.46 144.86 31.65 Favored 'General case' 0 N--CA 1.426 -1.654 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.604 176.174 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -114.24 159.27 20.33 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 123.586 0.754 . . . . 0.0 109.948 -176.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.03 145.04 35.45 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.284 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.951 178.49 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 84.2 m -109.81 136.45 49.1 Favored 'General case' 0 C--N 1.268 -2.954 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 55.5 m-80 -60.51 164.76 4.2 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.082 178.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 24.1 m -48.05 108.19 0.16 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 124.799 1.312 . . . . 0.0 113.282 -175.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.78 -9.6 29.92 Favored Glycine 0 N--CA 1.421 -2.331 0 C-N-CA 120.543 -0.836 . . . . 0.0 112.737 177.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -109.36 155.49 21.16 Favored 'General case' 0 N--CA 1.423 -1.819 0 CA-C-N 117.219 0.51 . . . . 0.0 110.282 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . 0.516 ' HE2' ' O ' ' A' ' 184' ' ' ILE . 18.7 ptmt -130.26 163.23 27.21 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.516 ' O ' ' HE2' ' A' ' 183' ' ' LYS . 3.7 tp -74.32 148.17 8.37 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.046 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -85.65 -74.29 0.41 Allowed 'General case' 0 C--N 1.289 -2.048 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.042 178.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -79.48 -97.88 0.28 Allowed Glycine 0 N--CA 1.442 -0.937 0 C-N-CA 121.043 -0.598 . . . . 0.0 112.443 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -118.19 150.92 38.6 Favored 'General case' 0 CA--C 1.484 -1.566 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.349 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -95.15 -1.92 50.91 Favored 'General case' 0 CA--C 1.499 -1.007 0 C-N-CA 120.155 -0.618 . . . . 0.0 111.049 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . 0.464 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.5 pt-20 -146.35 146.72 30.77 Favored 'General case' 0 C--N 1.294 -1.844 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.437 -178.086 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.0 ptp -131.98 131.43 42.56 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.117 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 42.4 t-80 -102.83 138.52 39.61 Favored 'General case' 0 C--N 1.29 -1.989 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 177.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . 0.404 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 42.7 t -81.95 135.41 35.39 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.711 177.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.0 m -99.21 165.07 11.88 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 178.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -75.43 4.52 7.22 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.219 0.533 . . . . 0.0 111.621 -176.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -68.45 -32.51 72.58 Favored 'General case' 0 CA--C 1.507 -0.706 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.286 172.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 109.4 8.82 26.41 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 111.079 -0.808 . . . . 0.0 111.079 -175.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -142.06 173.23 11.7 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-O 120.691 0.282 . . . . 0.0 110.651 177.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . 0.404 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 66.2 m95 -82.95 148.25 27.73 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.056 -175.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 20.3 m -67.51 -25.27 65.76 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.654 0.74 . . . . 0.0 110.754 178.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -124.63 148.88 47.65 Favored 'General case' 0 CA--C 1.487 -1.456 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.947 179.064 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -82.05 161.51 22.9 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 175.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . 0.441 ' HE2' ' HB2' ' A' ' 202' ' ' LYS . 10.5 ptmm? -63.51 137.95 97.23 Favored Pre-proline 0 N--CA 1.431 -1.396 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.6 -178.359 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 63.7 Cg_endo -86.89 -169.98 0.58 Allowed 'Trans proline' 0 N--CA 1.434 -1.985 0 C-N-CA 122.815 2.343 . . . . 0.0 113.919 -175.267 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . 0.479 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 61.2 tttp -134.42 158.61 43.44 Favored 'General case' 0 N--CA 1.424 -1.753 0 CA-C-N 113.948 -1.478 . . . . 0.0 107.669 -176.519 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.412 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 89.3 m -116.08 115.58 26.34 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 174.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.563 -175.51 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 33.0 Cg_endo . . . . . 0 CA--C 1.538 0.723 0 CA-C-O 121.107 0.378 . . . . 0.0 112.012 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.0 m -84.86 -32.62 23.12 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 121.891 0.853 . . . . 0.0 109.347 177.526 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.91 -92.05 0.53 Allowed Glycine 0 N--CA 1.405 -3.408 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 175.337 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.2 t-80 -174.44 139.45 0.69 Allowed Pre-proline 0 C--N 1.265 -3.089 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 -176.371 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.423 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 88.1 Cg_endo -85.91 -0.1 8.48 Favored 'Trans proline' 0 N--CA 1.473 0.274 0 C-N-CA 122.093 1.862 . . . . 0.0 112.947 -175.222 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.59 -172.64 16.19 Favored Glycine 0 C--N 1.296 -1.692 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -176.06 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -146.96 163.61 35.64 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.8 t -141.32 139.19 18.55 Favored Pre-proline 0 C--N 1.3 -1.556 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.528 -176.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -77.4 -12.7 16.99 Favored 'Trans proline' 0 CA--C 1.529 0.267 0 C-N-CA 122.696 2.264 . . . . 0.0 111.288 176.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -88.48 2.46 52.79 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.771 -175.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 159.59 -133.66 3.42 Favored Glycine 0 N--CA 1.41 -3.093 0 C-N-CA 120.213 -0.994 . . . . 0.0 111.859 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 14.1 p -148.85 -172.89 4.21 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -173.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -144.11 167.15 23.08 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 173.18 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -131.59 157.76 42.78 Favored 'General case' 0 C--N 1.279 -2.457 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 178.207 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 22.7 mt -110.9 138.84 46.79 Favored 'General case' 0 C--N 1.265 -3.099 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.2 p -129.96 131.02 45.79 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.342 -178.094 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.18 16.19 45.0 Favored Glycine 0 CA--C 1.501 -0.797 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -175.046 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 147.77 160.46 8.95 Favored Glycine 1 N--CA 1.376 -5.305 0 N-CA-C 106.212 -2.755 . . . . 0.0 106.212 -175.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -114.09 35.77 4.0 Favored 'General case' 0 C--N 1.25 -3.739 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 -179.579 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.459 ' O ' HG12 ' A' ' 108' ' ' VAL . 16.7 m -144.96 -173.82 0.49 Allowed 'Isoleucine or valine' 0 C--O 1.204 -1.291 0 CA-C-N 114.371 -1.286 . . . . 0.0 109.623 -175.126 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.423 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 29.5 m-85 -110.02 46.6 1.01 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 121.392 0.615 . . . . 0.0 109.554 -178.015 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.725 ' O ' HG11 ' A' ' 108' ' ' VAL . 11.0 pt-20 -86.91 178.74 6.87 Favored 'General case' 0 C--O 1.212 -0.892 0 CA-C-N 114.909 -1.041 . . . . 0.0 111.427 178.209 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -75.54 132.26 40.6 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.223 177.44 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 90.69 10.49 63.19 Favored Glycine 0 N--CA 1.438 -1.194 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.969 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.725 HG11 ' O ' ' A' ' 105' ' ' GLU . 11.5 p -102.29 148.07 8.2 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 176.67 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 52.4 mtpt -117.12 123.22 46.22 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 120.907 0.384 . . . . 0.0 110.532 -179.092 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.39 91.62 8.57 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.17 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.8 t -85.16 110.97 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.31 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -78.17 143.24 37.4 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 112.462 0.542 . . . . 0.0 112.462 -177.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.8 t -142.98 112.94 7.06 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 121.712 0.768 . . . . 0.0 109.461 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 89.8 m -65.81 162.17 19.41 Favored 'General case' 0 C--N 1.311 -1.09 0 N-CA-C 114.329 1.233 . . . . 0.0 114.329 -178.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -68.71 -179.97 1.57 Allowed 'General case' 0 N--CA 1.433 -1.293 0 C-N-CA 125.612 1.565 . . . . 0.0 109.892 178.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -59.95 -52.65 64.48 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 124.099 0.959 . . . . 0.0 111.145 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -86.81 33.1 3.81 Favored Glycine 0 C--N 1.308 -1.007 0 C-N-CA 120.426 -0.892 . . . . 0.0 113.791 -176.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.499 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 86.3 m-85 -150.54 170.43 19.13 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 123.725 0.81 . . . . 0.0 110.024 -177.142 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.34 156.89 42.37 Favored 'General case' 0 N--CA 1.427 -1.617 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 176.659 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 8.2 tt -87.42 136.68 32.84 Favored 'General case' 0 C--N 1.27 -2.881 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.51 130.34 56.37 Favored 'General case' 0 N--CA 1.428 -1.54 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -176.578 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 120.97 172.14 14.45 Favored Glycine 0 N--CA 1.43 -1.733 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 -178.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 57.2 mm-40 -88.57 -25.43 22.5 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-O 121.256 0.55 . . . . 0.0 109.942 178.473 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.7 mm -87.44 127.78 40.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-N 114.604 -1.18 . . . . 0.0 108.528 -179.589 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -133.52 14.98 4.07 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.042 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 30.3 p90 -153.65 159.84 42.2 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-O 121.031 0.443 . . . . 0.0 110.558 -175.549 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -122.7 134.65 54.46 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 171.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -112.56 126.49 55.4 Favored 'General case' 0 C--N 1.278 -2.524 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -176.556 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 28.8 t -82.63 99.53 9.62 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 117.738 -1.585 . . . . 0.0 110.675 177.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.485 ' OD2' HG22 ' A' ' 131' ' ' THR . 14.1 t70 -95.87 -168.35 1.75 Allowed 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 175.112 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.485 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -64.65 -23.58 67.3 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -172.707 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -78.76 -28.13 44.76 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.778 0.799 . . . . 0.0 109.787 176.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 130.65 -154.35 20.66 Favored Glycine 0 N--CA 1.422 -2.257 0 N-CA-C 108.614 -1.795 . . . . 0.0 108.614 -175.07 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 97.5 m95 -65.06 112.47 3.37 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 117.112 0.456 . . . . 0.0 111.411 178.127 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 76.5 p -73.47 159.94 32.46 Favored 'General case' 0 C--O 1.271 2.227 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 175.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 89.3 m-20 63.4 -163.15 0.27 Allowed 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . 0.482 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 17.1 t70 -141.25 -173.24 3.69 Favored 'General case' 0 C--N 1.283 -2.291 0 N-CA-C 106.114 -1.809 . . . . 0.0 106.114 173.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.482 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 67.1 mt -66.32 120.53 70.89 Favored Pre-proline 0 C--N 1.266 -3.027 0 C-N-CA 124.643 1.177 . . . . 0.0 108.727 179.753 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -68.31 139.25 45.16 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 122.238 1.958 . . . . 0.0 111.126 -179.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 73.6 mt -62.49 125.89 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 CA-C-O 121.742 0.782 . . . . 0.0 110.732 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.499 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 43.1 t -102.48 123.95 47.16 Favored 'General case' 0 N--CA 1.406 -2.652 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 176.6 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -105.09 154.47 20.11 Favored 'General case' 0 N--CA 1.413 -2.291 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 -174.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 15.0 p -80.39 143.37 12.5 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.768 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.285 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.505 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 6.4 m -65.3 130.86 30.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 176.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.446 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 96.2 mttt -120.03 141.62 49.56 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.291 -174.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.4 m -108.92 160.06 16.3 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 124.199 0.937 . . . . 0.0 108.568 177.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -76.63 149.69 81.22 Favored Pre-proline 0 N--CA 1.418 -2.074 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -68.19 114.76 3.53 Favored 'Trans proline' 0 N--CA 1.442 -1.503 0 C-N-CA 122.679 2.253 . . . . 0.0 110.242 175.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.416 HG21 ' SD ' ' A' ' 190' ' ' MET . 41.5 t -71.36 147.19 11.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.142 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.27 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 22.8 p -71.57 -80.4 0.06 Allowed 'General case' 0 N--CA 1.435 -1.221 0 O-C-N 123.117 0.26 . . . . 0.0 111.353 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.6 161.02 0.48 Allowed Pre-proline 0 C--O 1.24 0.587 0 C-N-CA 125.607 1.563 . . . . 0.0 107.612 177.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -78.84 -158.03 0.08 OUTLIER 'Trans proline' 0 CA--C 1.547 1.17 0 C-N-CA 121.555 1.503 . . . . 0.0 111.048 171.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . 0.433 ' OE1' ' HG2' ' A' ' 204' ' ' LYS . 0.0 OUTLIER -99.91 -52.16 3.51 Favored 'General case' 0 C--N 1.31 -1.148 0 O-C-N 121.861 -0.524 . . . . 0.0 112.271 -175.668 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 61.8 m-80 -107.19 25.58 11.23 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.605 0.716 . . . . 0.0 110.141 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -151.13 -176.78 24.33 Favored Glycine 0 N--CA 1.417 -2.633 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 16.5 pttm -145.82 168.93 19.6 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 -179.334 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.448 ' HB ' ' OG ' ' A' ' 160' ' ' SER . 52.1 mt -91.6 141.84 13.9 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.439 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.5 m -90.98 -30.65 4.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 178.319 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 10.4 m -98.85 36.79 1.61 Allowed 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.472 -174.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' SER . . . . . 0.448 ' OG ' ' HB ' ' A' ' 157' ' ' ILE . 29.6 m -77.64 69.91 3.94 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 117.741 0.246 . . . . 0.0 111.179 -179.649 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 46.24 79.67 0.05 Allowed 'General case' 0 C--O 1.234 0.289 0 C-N-CA 124.807 1.243 . . . . 0.0 112.278 -177.597 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 4.0 mpp? -56.9 -43.65 81.57 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-O 121.617 0.723 . . . . 0.0 109.665 -179.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.415 ' HG3' ' HG2' ' A' ' 166' ' ' ARG . 9.0 pt-20 -118.71 138.65 26.16 Favored Pre-proline 0 C--N 1.298 -1.666 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 176.668 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -77.58 16.0 1.15 Allowed 'Trans proline' 0 N--CA 1.48 0.706 0 C-N-CA 123.039 2.493 . . . . 0.0 113.444 -175.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -105.09 -32.7 8.58 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 121.416 0.627 . . . . 0.0 109.905 -176.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.415 ' HG2' ' HG3' ' A' ' 163' ' ' GLU . 12.5 ptp180 -96.7 118.98 34.32 Favored 'General case' 0 N--CA 1.391 -3.391 0 C-N-CA 118.659 -1.216 . . . . 0.0 112.986 -174.131 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 30.4 mm-40 -82.64 168.88 16.85 Favored 'General case' 0 C--N 1.276 -2.625 0 CA-C-N 113.552 -1.658 . . . . 0.0 108.534 171.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . 0.446 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 79.6 m-85 -75.58 104.96 6.37 Favored 'General case' 0 C--N 1.293 -1.868 0 CA-C-O 121.506 0.669 . . . . 0.0 109.897 -179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 20.0 m170 -106.36 160.44 15.38 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 114.538 -1.21 . . . . 0.0 108.249 -175.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . 0.505 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 65.0 t80 -50.02 123.99 9.25 Favored 'General case' 0 N--CA 1.47 0.539 0 O-C-N 123.287 0.367 . . . . 0.0 110.107 172.179 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 102.43 -0.83 49.87 Favored Glycine 0 N--CA 1.428 -1.839 0 C-N-CA 119.497 -1.335 . . . . 0.0 112.919 178.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 30.3 mm-40 -88.13 145.02 26.15 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 175.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -113.47 117.77 32.64 Favored 'General case' 0 C--N 1.281 -2.409 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.511 -179.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.427 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 54.5 t -98.71 101.24 11.87 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 176.305 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.439 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 16.2 ttm180 -93.45 145.98 24.1 Favored 'General case' 0 N--CA 1.415 -2.219 0 CA-C-N 114.906 -1.043 . . . . 0.0 110.54 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.432 ' CD2' HG12 ' A' ' 157' ' ' ILE . 68.6 m-85 -114.89 156.15 25.52 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 14.6 p -137.01 139.84 43.76 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.212 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.6 m -95.5 138.75 32.73 Favored 'General case' 0 C--N 1.269 -2.934 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.237 -176.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . 0.471 ' O ' ' HD2' ' A' ' 182' ' ' TYR . 58.9 m-20 -82.72 165.42 19.95 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 -179.349 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.7 t 49.07 -142.55 0.55 Allowed 'General case' 0 CA--C 1.548 0.867 0 O-C-N 124.057 0.848 . . . . 0.0 110.805 178.265 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -93.49 32.44 5.76 Favored Glycine 0 N--CA 1.428 -1.865 0 C-N-CA 121.19 -0.529 . . . . 0.0 111.876 178.454 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . 0.471 ' HD2' ' O ' ' A' ' 179' ' ' ASN . 96.9 m-85 -84.23 160.49 20.78 Favored 'General case' 0 N--CA 1.443 -0.802 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.378 -179.216 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -126.54 155.03 43.03 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 2.6 tp -71.82 144.77 12.91 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 178.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -85.71 -65.85 0.96 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.363 179.092 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -86.26 -113.88 0.87 Allowed Glycine 0 N--CA 1.439 -1.162 0 N-CA-C 111.817 -0.513 . . . . 0.0 111.817 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -100.05 157.47 16.53 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.827 -1.545 . . . . 0.0 106.827 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -93.51 -8.7 40.7 Favored 'General case' 0 N--CA 1.433 -1.283 0 C-N-CA 119.305 -0.958 . . . . 0.0 109.401 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . 0.427 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 2.9 pt-20 -146.23 130.41 17.48 Favored 'General case' 0 N--CA 1.43 -1.442 0 CA-C-O 121.932 0.872 . . . . 0.0 112.835 178.698 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.416 ' SD ' HG21 ' A' ' 149' ' ' VAL . 12.8 ptp -102.01 143.16 32.21 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.514 177.182 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -113.66 150.11 33.69 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 2.4 m -74.04 123.18 23.87 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 123.685 0.615 . . . . 0.0 110.795 173.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 193' ' ' SER . . . . . 0.424 ' HB2' ' OG ' ' A' ' 199' ' ' SER . 34.4 t -83.94 167.52 16.88 Favored 'General case' 0 N--CA 1.423 -1.795 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 176.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -71.81 -5.16 32.21 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 123.534 0.734 . . . . 0.0 111.351 -177.141 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -84.82 -18.87 33.6 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.412 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 88.81 27.46 24.04 Favored Glycine 0 N--CA 1.451 -0.309 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 -173.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -131.94 161.55 32.82 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 179.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -77.87 131.06 37.35 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 176.464 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 199' ' ' SER . . . . . 0.424 ' OG ' ' HB2' ' A' ' 193' ' ' SER . 15.0 m -68.04 -39.45 83.05 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-O 121.548 0.69 . . . . 0.0 110.064 -179.353 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 21.5 mmtp -96.33 150.27 20.76 Favored 'General case' 0 C--N 1.307 -1.247 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.75 177.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 22.9 mm-40 -86.3 166.23 15.81 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 176.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 28.3 ttmt -67.47 121.85 80.68 Favored Pre-proline 0 C--N 1.324 -0.519 0 C-N-CA 119.51 -0.876 . . . . 0.0 109.47 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.5 -174.86 2.44 Favored 'Trans proline' 0 N--CA 1.437 -1.834 0 C-N-CA 121.996 1.797 . . . . 0.0 111.759 179.183 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . 0.433 ' HG2' ' OE1' ' A' ' 153' ' ' GLU . 48.2 mttm -127.9 162.58 26.39 Favored 'General case' 0 C--N 1.287 -2.124 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.295 179.217 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 77.5 m -113.32 106.28 14.42 Favored 'General case' 0 C--N 1.281 -2.408 0 O-C-N 124.057 0.848 . . . . 0.0 109.137 170.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.5 m . . . . . 0 N--CA 1.431 -1.415 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.313 -173.759 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.4 ' HG2' ' HA ' ' A' ' 105' ' ' GLU . 33.9 Cg_endo . . . . . 0 CA--C 1.536 0.608 0 CA-C-O 121.113 0.38 . . . . 0.0 111.934 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.8 m -86.49 -33.69 20.27 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 176.085 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.74 -96.66 0.67 Allowed Glycine 0 N--CA 1.402 -3.593 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 173.035 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 56.0 t-80 -173.1 121.03 0.41 Allowed Pre-proline 0 C--N 1.263 -3.169 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -175.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.08 -30.79 13.05 Favored 'Trans proline' 0 C--O 1.219 -0.436 0 C-N-CA 121.909 1.74 . . . . 0.0 113.369 -171.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.22 176.13 14.34 Favored Glycine 0 CA--C 1.483 -1.936 0 N-CA-C 108.347 -1.901 . . . . 0.0 108.347 -176.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -134.7 -175.49 3.91 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -177.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 2.1 t -141.47 133.5 13.78 Favored Pre-proline 0 C--N 1.303 -1.43 0 CA-C-O 121.234 0.54 . . . . 0.0 112.131 -178.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -71.83 -18.1 28.53 Favored 'Trans proline' 0 C--O 1.238 0.513 0 C-N-CA 122.554 2.169 . . . . 0.0 111.389 175.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -86.72 -3.42 59.04 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.072 -176.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.46 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.89 -123.47 0.94 Allowed Glycine 0 N--CA 1.424 -2.157 0 C-N-CA 120.033 -1.079 . . . . 0.0 112.04 179.234 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 11.7 t -157.93 -166.48 1.98 Allowed 'General case' 0 C--N 1.285 -2.205 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -149.77 162.15 40.83 Favored 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 177.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 7.0 m -128.34 161.41 29.47 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 -178.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 25.4 mt -117.11 128.6 55.29 Favored 'General case' 0 C--N 1.266 -3.042 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.426 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 32.0 p -123.76 135.17 53.67 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -175.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 105.95 -45.33 1.32 Allowed Glycine 0 C--N 1.305 -1.19 0 N-CA-C 111.69 -0.564 . . . . 0.0 111.69 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -131.9 -16.59 1.41 Allowed Glycine 0 C--O 1.219 -0.784 0 C-N-CA 120.263 -0.97 . . . . 0.0 113.524 -177.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 64.5 12.97 7.84 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 123.657 0.783 . . . . 0.0 113.014 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.513 ' O ' HG13 ' A' ' 108' ' ' VAL . 23.4 m -145.95 -169.4 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 -177.201 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -105.14 45.54 0.96 Allowed 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 118.692 0.678 . . . . 0.0 110.461 -178.232 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.73 ' O ' HG12 ' A' ' 108' ' ' VAL . 9.3 pt-20 -89.68 -176.18 4.9 Favored 'General case' 0 C--O 1.208 -1.094 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.884 178.231 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -79.08 138.63 38.04 Favored 'General case' 0 C--N 1.31 -1.132 0 O-C-N 121.648 -0.657 . . . . 0.0 111.119 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 85.59 4.31 85.6 Favored Glycine 0 N--CA 1.439 -1.155 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.992 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.73 HG12 ' O ' ' A' ' 105' ' ' GLU . 15.0 p -93.39 143.67 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.943 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 177.552 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.426 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 54.9 mtpt -108.08 118.38 36.6 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.368 178.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -83.08 91.87 7.29 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 175.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.476 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 32.3 m -91.83 117.58 35.44 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.405 0 CA-C-O 122.19 0.995 . . . . 0.0 108.735 -178.042 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 36.4 m-85 -84.42 146.71 27.51 Favored 'General case' 0 C--N 1.264 -3.143 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.918 -176.606 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.1 t -144.06 118.54 9.7 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-O 122.102 0.954 . . . . 0.0 108.919 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 3.8 m -75.12 160.93 29.87 Favored 'General case' 0 C--N 1.284 -2.25 0 CA-C-N 115.29 -0.868 . . . . 0.0 108.966 -176.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.46 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 75.4 m-20 -73.15 171.03 13.72 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 177.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -48.06 -49.37 31.72 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.553 1.141 . . . . 0.0 113.525 -176.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.537 ' HA2' ' CD2' ' A' ' 170' ' ' PHE . . . -80.61 8.46 54.8 Favored Glycine 0 C--N 1.309 -0.95 0 CA-C-N 116.025 -0.534 . . . . 0.0 113.37 -176.635 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.46 ' CE1' HG22 ' A' ' 143' ' ' VAL . 94.0 m-85 -130.71 150.61 51.81 Favored 'General case' 0 N--CA 1.434 -1.249 0 CA-C-O 121.501 0.667 . . . . 0.0 110.397 -178.478 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -119.08 163.5 16.92 Favored 'General case' 0 C--N 1.276 -2.614 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . 0.409 HD13 ' HB2' ' A' ' 139' ' ' PRO . 13.4 tp -83.48 141.53 31.59 Favored 'General case' 0 C--N 1.282 -2.361 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 177.273 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.72 116.94 30.92 Favored 'General case' 0 N--CA 1.408 -2.57 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.149 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.6 -169.33 13.14 Favored Glycine 0 C--N 1.276 -2.777 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.02 -174.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -100.53 -48.93 4.37 Favored 'General case' 0 C--N 1.287 -2.111 0 CA-C-N 114.926 -0.637 . . . . 0.0 109.304 -174.779 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.6 mm -68.0 126.67 28.27 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 CA-C-N 114.589 -1.187 . . . . 0.0 109.874 -176.085 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -122.91 3.13 9.42 Favored 'General case' 0 C--O 1.198 -1.654 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.219 176.346 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 20.9 p90 -138.28 161.85 35.84 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.068 -173.441 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 58.1 mtp180 -126.5 131.18 51.68 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 170.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -107.62 132.18 53.58 Favored 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 -177.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 43.1 t -81.02 104.5 11.57 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 118.02 -1.472 . . . . 0.0 110.303 176.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.517 ' OD1' HG21 ' A' ' 131' ' ' THR . 15.0 t70 -97.23 -169.43 1.85 Allowed 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.517 HG21 ' OD1' ' A' ' 130' ' ' ASP . 15.0 t -68.73 -17.02 63.98 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.631 0.729 . . . . 0.0 110.921 -175.614 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -87.9 -24.01 23.77 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.694 177.011 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 122.65 -154.03 16.95 Favored Glycine 0 N--CA 1.416 -2.646 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -174.335 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.9 m95 -63.34 115.1 4.27 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 179.419 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 55.4 p -76.66 168.87 19.32 Favored 'General case' 0 C--O 1.261 1.689 0 N-CA-C 109.287 -0.635 . . . . 0.0 109.287 176.531 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 61.53 -170.75 0.16 Allowed 'General case' 0 C--O 1.242 0.672 0 O-C-N 123.94 0.775 . . . . 0.0 111.918 177.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.64 171.29 7.61 Favored 'General case' 0 CA--C 1.469 -2.163 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 175.339 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.6 mt -67.57 113.4 14.0 Favored Pre-proline 0 C--N 1.297 -1.708 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 170.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . 0.409 ' HB2' HD13 ' A' ' 120' ' ' LEU . 45.2 Cg_endo -66.46 131.69 27.06 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 122.052 1.835 . . . . 0.0 111.711 -176.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 69.3 mt -80.58 131.58 33.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.887 -176.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 74.3 m -103.52 149.56 24.74 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 174.191 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -125.49 168.37 13.73 Favored 'General case' 0 C--N 1.287 -2.117 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 174.226 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.46 HG22 ' CE1' ' A' ' 118' ' ' TYR . 99.6 t -67.65 143.3 15.51 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 177.028 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 72.6 t -61.5 130.7 25.99 Favored 'Isoleucine or valine' 0 C--O 1.242 0.668 0 N-CA-C 107.877 -1.156 . . . . 0.0 107.877 174.509 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.422 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 84.0 mttt -120.28 152.19 38.14 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 -175.264 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 59.0 m -118.42 160.04 22.4 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 64.4 mt -69.72 144.73 94.06 Favored Pre-proline 0 C--O 1.24 0.603 0 N-CA-C 112.282 0.475 . . . . 0.0 112.282 178.597 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -64.68 131.48 29.59 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 123.197 2.598 . . . . 0.0 112.449 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 44.2 t -90.94 136.82 23.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 179.245 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 15.3 p -73.55 -85.93 0.03 OUTLIER 'General case' 0 C--N 1.314 -0.965 0 CA-C-O 120.636 0.255 . . . . 0.0 111.55 178.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 177.0 150.24 0.35 Allowed Pre-proline 0 C--O 1.242 0.672 0 C-N-CA 125.627 1.571 . . . . 0.0 107.493 177.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.88 171.16 17.75 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.008 1.805 . . . . 0.0 111.263 174.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -65.06 -59.96 3.55 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 114.645 1.35 . . . . 0.0 114.645 -174.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . 0.413 ' HB2' ' O ' ' A' ' 205' ' ' CYS . 44.2 m-80 -107.52 29.88 6.78 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-O 121.845 0.831 . . . . 0.0 110.161 -178.198 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.88 178.14 22.89 Favored Glycine 0 N--CA 1.419 -2.438 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 57.5 pttt -145.79 166.14 26.79 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.178 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 56.9 mt -83.69 134.13 27.62 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 CA-C-O 121.348 0.594 . . . . 0.0 111.005 -178.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.5 t -68.81 -43.1 82.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.131 -0.94 . . . . 0.0 109.595 178.044 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 35.0 t -79.67 82.7 5.74 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 121.676 0.75 . . . . 0.0 109.464 176.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 45.3 m -94.81 149.07 21.63 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.106 178.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 68.44 86.12 0.13 Allowed 'General case' 0 CA--C 1.501 -0.924 0 CA-C-O 122.637 1.208 . . . . 0.0 112.418 -177.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' MET . . . . . 0.466 ' O ' ' HA ' ' A' ' 166' ' ' ARG . 57.2 mmm -95.37 86.64 4.56 Favored 'General case' 0 N--CA 1.406 -2.666 0 CA-C-N 114.422 -1.263 . . . . 0.0 109.47 -179.079 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.429 ' H ' ' HD2' ' A' ' 164' ' ' PRO . 8.2 mm-40 -142.68 -41.5 0.01 OUTLIER Pre-proline 0 C--N 1.289 -2.057 0 CA-C-N 113.642 -1.617 . . . . 0.0 111.966 -178.255 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . 0.429 ' HD2' ' H ' ' A' ' 163' ' ' GLU . 7.4 Cg_endo -56.52 -22.76 44.47 Favored 'Trans proline' 0 C--N 1.373 1.828 0 CA-C-N 120.403 1.179 . . . . 0.0 111.02 166.681 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -125.66 -20.48 4.68 Favored 'General case' 0 C--O 1.213 -0.832 0 CA-C-N 116.024 -0.534 . . . . 0.0 109.777 178.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.466 ' HA ' ' O ' ' A' ' 162' ' ' MET . 24.2 mtp180 58.97 -81.57 0.02 OUTLIER 'General case' 0 C--N 1.362 1.129 0 N-CA-C 114.821 1.415 . . . . 0.0 114.821 -178.252 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -97.19 133.38 41.91 Favored 'General case' 1 C--N 1.243 -4.056 0 C-N-CA 126.403 1.881 . . . . 0.0 109.235 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -61.32 110.03 1.3 Allowed 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.777 0.798 . . . . 0.0 112.79 -175.526 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.414 ' HB3' HG13 ' A' ' 143' ' ' VAL . 38.0 m80 -95.43 152.02 18.78 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 114.399 -1.273 . . . . 0.0 112.057 -178.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . 0.537 ' CD2' ' HA2' ' A' ' 117' ' ' GLY . 0.9 OUTLIER -62.56 106.04 0.72 Allowed 'General case' 0 C--O 1.239 0.535 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 172.731 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 138.35 -12.53 3.52 Favored Glycine 0 N--CA 1.428 -1.884 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -174.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 31.7 mm-40 -99.34 160.74 14.06 Favored 'General case' 0 C--O 1.259 1.57 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 177.131 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -140.78 135.24 31.28 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 178.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.487 HG23 ' CH2' ' A' ' 198' ' ' TRP . 92.7 t -99.34 106.03 18.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.631 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.418 ' HA ' ' HA ' ' A' ' 189' ' ' GLU . 56.3 ttt180 -97.95 158.17 15.69 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 178.24 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -130.45 153.49 48.72 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -172.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.2 p -134.97 143.19 38.07 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 81.9 m -99.03 145.3 27.23 Favored 'General case' 0 C--N 1.283 -2.296 0 CA-C-N 115.607 -0.724 . . . . 0.0 112.218 -175.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -69.79 159.49 33.48 Favored 'General case' 0 N--CA 1.434 -1.257 0 CA-C-N 115.383 -0.826 . . . . 0.0 108.885 175.089 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 38.4 m -58.44 112.3 1.53 Allowed 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.805 -175.096 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 114.72 -13.43 20.3 Favored Glycine 0 N--CA 1.438 -1.218 0 CA-C-N 115.145 -0.934 . . . . 0.0 111.761 -178.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -107.83 160.96 15.33 Favored 'General case' 0 N--CA 1.433 -1.305 0 CA-C-O 120.876 0.369 . . . . 0.0 111.733 -177.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . 0.503 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 22.3 pttm -131.24 152.75 50.2 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 178.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.403 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.4 tt -80.61 136.05 24.05 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.285 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.332 175.738 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -75.0 -54.95 6.29 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.078 -176.502 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -91.38 -144.61 13.22 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.519 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -77.92 157.9 29.6 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . 0.403 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.4 pt-20 -89.91 -5.63 56.58 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.557 -174.538 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . 0.418 ' HA ' ' HA ' ' A' ' 175' ' ' ARG . 3.6 pt-20 -147.77 142.28 26.47 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.17 0.51 . . . . 0.0 111.977 -175.465 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.45 ' CG ' ' HB ' ' A' ' 174' ' ' VAL . 14.3 ptp -120.29 134.79 55.19 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.105 -0.952 . . . . 0.0 108.537 175.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 21.9 t-80 -112.36 147.01 37.29 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 110.56 -0.163 . . . . 0.0 110.56 -175.257 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . 0.423 ' HB3' ' HA ' ' A' ' 170' ' ' PHE . 1.5 m -70.68 120.01 15.66 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 116.663 -0.244 . . . . 0.0 110.542 173.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.1 m -98.7 163.95 12.43 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.836 178.104 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -47.17 -32.66 4.55 Favored 'General case' 0 N--CA 1.498 1.926 0 C-N-CA 126.533 1.933 . . . . 0.0 114.078 -178.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -73.1 -17.08 61.44 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 94.99 28.35 10.08 Favored Glycine 0 C--N 1.307 -1.069 0 C-N-CA 119.917 -1.135 . . . . 0.0 112.093 -178.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 2.5 p90 -140.62 172.05 13.25 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 176.45 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . 0.487 ' CH2' HG23 ' A' ' 174' ' ' VAL . 87.5 m95 -82.22 143.3 31.47 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 123.717 0.636 . . . . 0.0 111.129 -178.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 5.0 m -69.13 -6.46 28.72 Favored 'General case' 0 CA--C 1.549 0.937 0 C-N-CA 124.109 0.964 . . . . 0.0 111.245 178.197 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 25.9 mmmt -140.52 150.99 44.41 Favored 'General case' 0 CA--C 1.482 -1.666 0 C-N-CA 123.863 0.865 . . . . 0.0 109.467 -178.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -89.65 157.62 17.94 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 104.561 -2.385 . . . . 0.0 104.561 169.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 25.9 ttpp -60.85 114.44 10.4 Favored Pre-proline 0 C--O 1.243 0.759 0 N-CA-C 114.479 1.289 . . . . 0.0 114.479 -172.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -78.89 165.58 24.21 Favored 'Trans proline' 0 N--CA 1.435 -1.936 0 C-N-CA 123.113 2.542 . . . . 0.0 109.786 176.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.9 pttt -139.08 162.76 34.15 Favored 'General case' 0 C--N 1.285 -2.209 0 C-N-CA 120.005 -0.678 . . . . 0.0 111.543 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 73.6 m -96.29 121.4 38.04 Favored 'General case' 0 N--CA 1.406 -2.628 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.052 179.378 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 13.4 m . . . . . 0 C--N 1.295 -1.775 0 C-N-CA 125.384 1.474 . . . . 0.0 108.181 -177.02 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo . . . . . 0 CA--C 1.538 0.703 0 CA-C-O 121.201 0.417 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 34.2 m -75.54 -37.18 60.21 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.674 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 120.41 -95.86 0.6 Allowed Glycine 0 N--CA 1.4 -3.742 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 173.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.2 t60 -173.26 123.67 0.43 Allowed Pre-proline 0 C--N 1.253 -3.596 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 -175.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_endo -76.02 -3.52 13.96 Favored 'Trans proline' 0 C--O 1.213 -0.75 0 C-N-CA 122.766 2.31 . . . . 0.0 113.841 -171.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 112.97 -175.58 16.78 Favored Glycine 0 C--N 1.285 -2.295 0 N-CA-C 108.296 -1.921 . . . . 0.0 108.296 -176.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -152.92 118.52 5.31 Favored 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -176.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.1 t -91.22 133.85 30.91 Favored Pre-proline 0 C--N 1.304 -1.389 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -173.124 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -77.65 -13.73 16.17 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 122.725 2.283 . . . . 0.0 111.453 173.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -81.01 -10.32 59.72 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.934 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.523 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -178.41 -133.74 1.96 Allowed Glycine 0 N--CA 1.407 -3.299 0 C-N-CA 119.583 -1.294 . . . . 0.0 112.494 -178.746 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 21.0 p -143.39 -177.5 5.41 Favored 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -177.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 37.7 p90 -149.92 157.24 42.97 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 173.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.5 m -131.81 152.21 51.14 Favored 'General case' 0 C--N 1.289 -2.065 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.437 HD11 ' CE1' ' A' ' 104' ' ' PHE . 16.2 mt -106.12 131.49 53.32 Favored 'General case' 0 C--N 1.273 -2.731 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 20.5 p -123.01 137.92 54.82 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.0 -175.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 101.99 -56.96 0.66 Allowed Glycine 0 N--CA 1.436 -1.318 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -177.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -110.04 -30.5 3.4 Favored Glycine 0 C--O 1.21 -1.383 0 C-N-CA 120.991 -0.623 . . . . 0.0 113.121 -178.216 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 42.0 m-80 70.6 11.4 7.28 Favored 'General case' 0 N--CA 1.506 2.329 0 C-N-CA 123.879 0.872 . . . . 0.0 110.96 -177.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.502 ' O ' HG12 ' A' ' 108' ' ' VAL . 24.3 m -148.8 -175.14 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.76 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 -179.385 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.437 ' CE1' HD11 ' A' ' 98' ' ' LEU . 24.4 m-85 -99.17 42.42 1.1 Allowed 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 119.25 0.932 . . . . 0.0 111.049 -176.151 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.745 ' O ' HG11 ' A' ' 108' ' ' VAL . 9.6 pt-20 -83.01 -179.67 7.51 Favored 'General case' 0 C--O 1.208 -1.128 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.877 177.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -75.61 132.96 40.98 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.743 -0.598 . . . . 0.0 111.827 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.52 3.87 66.4 Favored Glycine 0 N--CA 1.435 -1.383 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.842 177.583 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.745 HG11 ' O ' ' A' ' 105' ' ' GLU . 11.9 p -90.28 143.7 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 C-N-CA 119.993 -0.683 . . . . 0.0 109.223 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.7 mtpt -107.81 119.36 39.24 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 178.47 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.483 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.44 93.3 9.1 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 177.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 79.4 t -85.37 113.94 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.506 0 C-N-CA 123.478 0.711 . . . . 0.0 109.231 -178.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -87.16 134.75 33.49 Favored 'General case' 0 C--N 1.282 -2.335 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.843 179.205 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -132.01 130.12 40.99 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 10.1 m -82.34 154.43 25.28 Favored 'General case' 0 C--N 1.278 -2.535 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.659 -173.117 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.523 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 86.5 m-20 -71.26 177.24 3.98 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-N 116.765 -0.198 . . . . 0.0 111.47 179.445 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . 0.403 ' O ' ' HB2' ' A' ' 194' ' ' ASP . 45.6 tt0 -52.41 -54.59 30.1 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 123.845 0.858 . . . . 0.0 112.021 -174.759 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.94 34.69 3.17 Favored Glycine 0 C--N 1.308 -0.992 0 C-N-CA 120.787 -0.72 . . . . 0.0 113.171 -179.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -147.09 156.4 42.97 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.103 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -133.91 169.1 17.59 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 15.4 tp -92.2 142.66 27.24 Favored 'General case' 0 C--N 1.28 -2.42 0 C-N-CA 119.574 -0.851 . . . . 0.0 109.006 177.622 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -124.58 122.49 37.72 Favored 'General case' 0 N--CA 1.414 -2.239 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 177.077 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.5 171.6 15.63 Favored Glycine 0 C--N 1.286 -2.201 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.691 -176.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -95.91 -25.9 15.81 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.396 0.617 . . . . 0.0 109.808 -176.209 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.6 mm -90.2 137.36 21.69 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 23.0 p-10 -135.69 8.02 3.29 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 120.715 0.293 . . . . 0.0 110.639 179.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.483 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 28.8 p90 -146.29 171.35 15.11 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.067 -173.57 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.485 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 33.3 mtp180 -129.05 119.76 24.78 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 173.275 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -90.6 128.42 36.59 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.198 -1.001 . . . . 0.0 109.395 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 42.3 t -84.64 113.05 20.99 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.859 -1.136 . . . . 0.0 110.554 175.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -103.48 -172.33 2.09 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 10.8 t -64.19 -25.76 68.22 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.489 0.551 . . . . 0.0 112.489 -174.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -84.96 -23.94 28.54 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.13 0.491 . . . . 0.0 111.186 178.454 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 138.09 -158.01 24.59 Favored Glycine 0 N--CA 1.435 -1.381 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -177.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.4 m95 -68.57 113.04 5.74 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 178.441 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.2 p -64.49 -65.25 0.7 Allowed 'General case' 0 C--O 1.243 0.724 0 C-N-CA 123.049 0.54 . . . . 0.0 111.607 -176.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . 0.485 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 4.1 m120 -72.38 167.82 19.72 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . 0.442 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 10.4 t70 -104.66 -171.65 1.96 Allowed 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 176.329 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.442 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 78.8 mt -72.92 121.6 85.48 Favored Pre-proline 0 C--N 1.274 -2.686 0 C-N-CA 124.497 1.119 . . . . 0.0 108.256 179.674 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.69 160.7 48.73 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 122.027 1.818 . . . . 0.0 110.763 177.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.1 mm -95.91 124.64 48.66 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 CA-C-O 121.523 0.677 . . . . 0.0 110.95 -175.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 68.2 m -100.22 120.27 39.64 Favored 'General case' 0 C--N 1.271 -2.806 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 171.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 16.4 tp10 -102.36 146.1 28.54 Favored 'General case' 0 C--N 1.272 -2.777 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 -178.683 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.15 136.79 25.58 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.882 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.466 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.1 m -59.77 128.44 20.71 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 CA-C-O 121.22 0.533 . . . . 0.0 110.378 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 59.8 mttm -112.68 145.92 39.59 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.56 -174.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.2 m -118.33 137.95 52.74 Favored 'General case' 0 C--N 1.277 -2.551 0 N-CA-C 106.157 -1.794 . . . . 0.0 106.157 -179.34 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 78.3 mt -62.32 143.42 95.63 Favored Pre-proline 0 C--N 1.313 -1.008 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -176.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -66.04 122.81 10.44 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.039 2.493 . . . . 0.0 110.408 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 51.7 t -76.33 149.25 6.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.941 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 6.3 p -68.95 -84.46 0.03 OUTLIER 'General case' 0 N--CA 1.439 -0.999 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.922 176.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 166.0 159.81 0.1 OUTLIER Pre-proline 0 CA--C 1.501 -0.94 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 177.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -72.28 156.11 55.36 Favored 'Trans proline' 0 N--CA 1.431 -2.167 0 CA-C-N 119.801 0.965 . . . . 0.0 109.89 171.094 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -64.92 -33.25 75.58 Favored 'General case' 0 C--N 1.28 -2.43 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -173.136 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -125.59 25.44 6.98 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-O 122.626 1.203 . . . . 0.0 109.045 -174.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.89 -155.8 6.59 Favored Glycine 0 N--CA 1.415 -2.738 0 CA-C-N 113.519 -1.673 . . . . 0.0 110.432 178.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . 0.41 ' HG3' HG21 ' A' ' 177' ' ' VAL . 24.1 pttm -157.79 174.41 15.34 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 41.7 mt -94.45 133.64 34.72 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.422 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.454 ' CG2' HG22 ' A' ' 177' ' ' VAL . 58.2 t -73.53 -48.45 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 177.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.9 m -79.62 85.4 5.35 Favored 'General case' 0 N--CA 1.429 -1.504 0 CA-C-N 115.019 -0.991 . . . . 0.0 109.021 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 37.0 t -121.71 -34.91 3.31 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.328 -175.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -113.25 91.17 3.55 Favored 'General case' 0 C--N 1.315 -0.92 0 O-C-N 121.924 -0.485 . . . . 0.0 110.919 -179.498 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 3.5 mpp? -112.87 -40.36 4.02 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.525 0.678 . . . . 0.0 109.994 178.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -156.88 168.09 13.18 Favored Pre-proline 0 C--N 1.306 -1.317 0 N-CA-C 104.907 -2.257 . . . . 0.0 104.907 -178.147 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -75.98 -22.73 12.89 Favored 'Trans proline' 0 CA--C 1.545 1.044 0 C-N-CA 121.262 1.308 . . . . 0.0 110.78 169.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -94.77 -55.87 2.97 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -178.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.482 ' O ' ' HD2' ' A' ' 166' ' ' ARG 0.297 0.6 OUTLIER 37.85 75.36 0.07 Allowed 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 179.058 . . . . . . . . 4 4 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . 0.5 ' HB2' ' NE2' ' A' ' 169' ' ' HIS . 48.3 mt-10 -80.73 140.2 35.7 Favored 'General case' 0 N--CA 1.423 -1.782 0 N-CA-C 105.851 -1.907 . . . . 0.0 105.851 172.384 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -83.49 126.52 32.86 Favored 'General case' 0 C--N 1.271 -2.835 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.5 ' NE2' ' HB2' ' A' ' 167' ' ' GLU . 27.7 m170 -128.71 175.67 8.41 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -175.679 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . 0.466 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 70.8 t80 -53.93 135.42 42.44 Favored 'General case' 0 C--N 1.306 -1.302 0 O-C-N 124.185 0.928 . . . . 0.0 110.052 172.777 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 101.3 -27.3 21.17 Favored Glycine 0 N--CA 1.43 -1.752 0 C-N-CA 120.126 -1.035 . . . . 0.0 112.306 178.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -68.14 147.21 52.62 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 117.28 0.54 . . . . 0.0 111.177 -178.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -128.44 116.13 19.26 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-N 114.457 -1.247 . . . . 0.0 107.794 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 69.5 t -100.18 110.31 26.97 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.928 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.237 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 64.1 ttt180 -97.07 155.64 16.71 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -178.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -128.27 161.87 28.34 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 123.669 0.787 . . . . 0.0 109.714 -174.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.454 HG22 ' CG2' ' A' ' 158' ' ' VAL . 0.1 OUTLIER -134.52 150.71 30.79 Favored 'Isoleucine or valine' 0 CA--C 1.474 -1.949 0 O-C-N 124.04 0.838 . . . . 0.0 109.111 178.659 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.2 m -110.83 137.5 48.41 Favored 'General case' 0 N--CA 1.395 -3.21 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 175.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -65.9 177.05 1.41 Allowed 'General case' 0 C--N 1.287 -2.136 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.853 -177.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.0 m -39.6 -36.11 0.37 Allowed 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 127.351 2.26 . . . . 0.0 116.823 -172.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -118.18 21.43 10.13 Favored Glycine 0 C--N 1.29 -2.005 0 C-N-CA 119.553 -1.308 . . . . 0.0 113.604 -178.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -126.92 156.36 41.59 Favored 'General case' 0 N--CA 1.436 -1.167 0 CA-C-N 117.754 0.777 . . . . 0.0 112.975 -177.17 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . 0.463 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 25.0 pttm -124.96 153.07 43.31 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 179.105 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.3 tp -72.93 146.91 10.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.472 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -83.04 -62.23 1.65 Allowed 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -103.15 -115.72 4.1 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -85.61 154.37 21.75 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -98.11 2.53 48.72 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 -178.277 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -155.79 149.61 25.24 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -176.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.0 ptp -126.82 126.14 42.87 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 114.945 -1.025 . . . . 0.0 111.331 179.154 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -95.76 148.28 22.74 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 177.096 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . 0.45 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 34.5 t -95.31 135.8 36.47 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 119.803 -0.759 . . . . 0.0 111.238 178.682 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 19.5 m -84.94 162.28 19.49 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 124.281 1.033 . . . . 0.0 109.294 177.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . 0.431 ' O ' HG13 ' A' ' 144' ' ' VAL . 4.5 p-10 -72.84 -7.72 52.14 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.247 0.546 . . . . 0.0 112.29 -174.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . 0.404 ' HB2' ' CD2' ' A' ' 197' ' ' PHE . 2.8 m-20 -77.81 -12.59 59.99 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 174.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 89.74 39.98 6.07 Favored Glycine 0 N--CA 1.438 -1.188 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.795 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . 0.404 ' CD2' ' HB2' ' A' ' 195' ' ' ASP . 42.1 p90 -144.69 156.78 44.26 Favored 'General case' 0 C--N 1.318 -0.771 0 O-C-N 122.121 -0.634 . . . . 0.0 109.506 177.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . 0.45 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 81.9 m95 -76.12 128.85 35.83 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.4 m -63.07 -33.65 75.9 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.264 0.554 . . . . 0.0 110.078 -178.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 28.0 mmtp -108.68 148.35 30.56 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.85 177.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -87.42 178.17 6.9 Favored 'General case' 0 C--N 1.289 -2.059 0 CA-C-N 114.835 -1.075 . . . . 0.0 110.683 -178.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 8.7 mmmm -59.84 120.34 49.05 Favored Pre-proline 0 N--CA 1.442 -0.855 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.283 177.165 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -90.49 178.89 1.97 Allowed 'Trans proline' 0 N--CA 1.427 -2.386 0 C-N-CA 122.467 2.111 . . . . 0.0 110.179 176.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -128.98 165.84 20.35 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.463 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 88.9 m -122.25 104.59 9.55 Favored 'General case' 0 N--CA 1.415 -2.205 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 172.108 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--N 1.297 -1.695 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.049 -174.728 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo . . . . . 0 CA--C 1.535 0.545 0 CA-C-O 121.404 0.502 . . . . 0.0 111.396 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 39.6 m -85.22 -33.85 22.15 Favored 'General case' 0 C--N 1.315 -0.921 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 177.337 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.72 -94.07 0.58 Allowed Glycine 0 N--CA 1.398 -3.848 0 CA-C-N 114.467 -1.242 . . . . 0.0 110.005 171.495 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.0 t-80 -175.07 123.9 0.36 Allowed Pre-proline 0 C--N 1.252 -3.649 0 N-CA-C 104.422 -2.436 . . . . 0.0 104.422 -174.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -79.0 -23.61 7.67 Favored 'Trans proline' 0 C--N 1.329 -0.473 0 C-N-CA 122.031 1.821 . . . . 0.0 112.906 -175.193 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.1 176.77 20.45 Favored Glycine 0 CA--C 1.475 -2.459 0 N-CA-C 108.263 -1.935 . . . . 0.0 108.263 -175.159 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.1 t0 -136.87 155.15 50.16 Favored 'General case' 0 C--N 1.275 -2.663 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -176.337 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.4 t -99.57 127.2 34.84 Favored Pre-proline 0 C--N 1.294 -1.805 0 CA-C-O 120.836 0.35 . . . . 0.0 110.302 -176.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.9 -13.67 39.09 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.695 2.263 . . . . 0.0 112.3 -178.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -94.62 1.48 55.6 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.72 -177.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.474 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 179.98 -129.94 1.42 Allowed Glycine 0 N--CA 1.416 -2.657 0 C-N-CA 119.234 -1.46 . . . . 0.0 112.482 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 22.0 p -149.13 -176.38 5.34 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 124.216 0.598 . . . . 0.0 110.0 -177.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -144.71 164.33 31.33 Favored 'General case' 0 C--N 1.313 -1.022 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 172.043 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.2 m -129.29 160.48 32.87 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 179.237 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.7 mt -117.51 125.01 50.13 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.121 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.456 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 21.7 p -117.86 137.87 52.49 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.442 -175.462 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 102.25 -47.72 1.13 Allowed Glycine 0 C--N 1.299 -1.497 0 N-CA-C 111.126 -0.789 . . . . 0.0 111.126 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -122.85 -21.17 2.68 Favored Glycine 0 N--CA 1.438 -1.168 0 C-N-CA 120.37 -0.919 . . . . 0.0 113.361 -178.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 64.25 14.72 8.89 Favored 'General case' 0 N--CA 1.5 2.048 0 C-N-CA 123.357 0.663 . . . . 0.0 112.666 -178.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.507 ' O ' HG12 ' A' ' 108' ' ' VAL . 30.0 m -152.1 -172.89 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -178.232 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -99.9 43.87 1.04 Allowed 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 119.368 0.986 . . . . 0.0 111.061 -177.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.744 ' O ' HG11 ' A' ' 108' ' ' VAL . 11.0 pt-20 -84.64 178.21 7.77 Favored 'General case' 0 C--O 1.205 -1.268 0 CA-C-N 114.681 -1.145 . . . . 0.0 111.983 178.225 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -71.91 135.83 46.66 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 122.076 -0.39 . . . . 0.0 110.798 177.021 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.63 -7.65 71.14 Favored Glycine 0 N--CA 1.435 -1.378 0 C-N-CA 120.148 -1.025 . . . . 0.0 113.418 178.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.744 HG11 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -85.31 143.48 11.52 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 119.709 -0.797 . . . . 0.0 110.581 -176.274 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.456 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.8 mtpt -108.82 117.0 33.05 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.474 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -83.3 92.41 7.5 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.482 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 89.5 t -87.33 114.23 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.587 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -176.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -86.33 139.32 31.09 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-O 121.409 0.623 . . . . 0.0 111.013 -177.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -133.66 109.13 8.98 Favored 'General case' 0 N--CA 1.407 -2.587 0 CA-C-O 122.334 1.064 . . . . 0.0 109.387 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 12.8 m -67.57 153.17 44.31 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.423 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.474 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 86.8 m-20 -68.71 178.77 1.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.869 0.366 . . . . 0.0 111.558 -179.012 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -57.38 -37.21 72.3 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -176.166 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -86.61 18.16 35.67 Favored Glycine 0 C--N 1.304 -1.237 0 C-N-CA 120.68 -0.771 . . . . 0.0 113.322 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -145.79 166.34 26.19 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -175.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -140.55 163.9 31.61 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -87.18 120.37 28.39 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 179.357 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.6 129.89 47.8 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 -178.154 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.8 -176.51 22.18 Favored Glycine 0 C--N 1.301 -1.366 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -91.46 -38.58 12.47 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.316 0.579 . . . . 0.0 110.0 -179.052 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.5 mm -78.08 120.62 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -176.26 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -129.16 8.05 5.53 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -177.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 22.8 p90 -151.19 169.68 21.3 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 -174.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.493 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 57.8 mtp180 -129.14 122.57 30.11 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 173.472 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -94.65 127.29 40.51 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 119.557 -0.857 . . . . 0.0 110.316 178.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 47.4 t -83.27 113.1 20.46 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.087 175.029 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.524 ' OD1' HG22 ' A' ' 131' ' ' THR . 8.4 t70 -110.3 -164.33 0.92 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.524 HG22 ' OD1' ' A' ' 130' ' ' ASP . 5.9 t -52.65 -33.45 46.98 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 -172.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -102.26 -10.39 19.59 Favored 'General case' 0 C--N 1.316 -0.875 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.83 -177.349 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 133.32 -153.96 21.01 Favored Glycine 0 N--CA 1.421 -2.346 0 N-CA-C 110.781 -0.927 . . . . 0.0 110.781 -178.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 86.2 m95 -67.65 119.93 13.21 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 122.527 0.331 . . . . 0.0 110.228 -178.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.0 p -71.58 -63.76 1.06 Allowed 'General case' 0 C--O 1.251 1.17 0 CA-C-O 121.544 0.687 . . . . 0.0 111.1 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . 0.493 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.8 m120 -69.99 164.36 24.1 Favored 'General case' 0 CA--C 1.489 -1.383 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.828 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . 0.441 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 12.1 t70 -103.35 -171.84 2.01 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 176.042 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.441 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 64.1 mt -69.48 120.68 78.7 Favored Pre-proline 0 C--N 1.28 -2.427 0 C-N-CA 124.439 1.096 . . . . 0.0 109.625 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -69.77 172.76 12.06 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.558 2.172 . . . . 0.0 112.485 178.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 49.1 mm -109.36 130.5 62.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.051 -173.245 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 89.1 m -109.06 114.34 28.0 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 174.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -103.09 157.23 17.14 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 176.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 13.6 p -70.62 145.43 12.79 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.069 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.577 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.4 m -72.35 136.28 25.99 Favored 'Isoleucine or valine' 0 C--O 1.248 1.015 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 175.841 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 64.4 mmtt -105.8 151.82 24.0 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -174.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 39.6 m -114.91 145.77 41.85 Favored 'General case' 0 C--N 1.28 -2.43 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 176.84 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.75 145.89 91.44 Favored Pre-proline 0 N--CA 1.418 -2.05 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -179.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -69.95 125.1 11.66 Favored 'Trans proline' 0 N--CA 1.444 -1.431 0 C-N-CA 122.885 2.39 . . . . 0.0 111.532 -178.546 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.8 t -97.98 137.82 24.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 13.5 p -76.74 -81.7 0.08 Allowed 'General case' 0 C--N 1.314 -0.962 0 O-C-N 123.126 0.267 . . . . 0.0 110.96 177.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.07 156.22 0.24 Allowed Pre-proline 0 C--O 1.24 0.566 0 C-N-CA 125.403 1.481 . . . . 0.0 107.895 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . 0.46 ' HB3' ' O ' ' A' ' 203' ' ' PRO . 37.1 Cg_endo -71.02 162.1 43.84 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 121.966 1.777 . . . . 0.0 110.17 172.475 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . 0.486 ' CD ' ' HZ3' ' A' ' 204' ' ' LYS . 9.6 pt-20 -55.51 -44.99 77.15 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -174.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 56.0 m-80 -116.45 28.0 8.85 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.242 0.544 . . . . 0.0 109.73 -177.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -143.32 -174.6 15.72 Favored Glycine 0 N--CA 1.439 -1.162 0 C-N-CA 120.181 -1.009 . . . . 0.0 112.661 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 31.7 pttt -152.9 161.02 43.06 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 123.193 0.597 . . . . 0.0 109.638 -176.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 58.2 mt -82.44 134.11 27.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 O-C-N 123.27 0.356 . . . . 0.0 110.773 -179.052 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.465 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.7 m -85.69 -32.14 6.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 CA-C-O 121.216 0.531 . . . . 0.0 110.585 -178.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 8.8 t -83.98 102.14 12.23 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.431 -172.273 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 45.2 m 65.09 -174.9 0.18 Allowed 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 123.98 0.912 . . . . 0.0 110.948 -176.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -108.19 167.6 9.89 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.272 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 34.5 tpp -80.75 90.41 5.82 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-O 122.045 0.926 . . . . 0.0 110.214 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.478 ' C ' ' H ' ' A' ' 165' ' ' ASP . 34.4 mt-10 -128.13 152.0 77.0 Favored Pre-proline 0 C--N 1.298 -1.637 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 -178.705 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -77.72 13.76 1.6 Allowed 'Trans proline' 0 N--CA 1.479 0.64 0 C-N-CA 122.993 2.462 . . . . 0.0 110.378 177.213 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . 0.478 ' H ' ' C ' ' A' ' 163' ' ' GLU . 10.2 t70 -98.67 -39.04 8.87 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 114.364 -1.289 . . . . 0.0 108.877 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.408 ' HD2' ' OD2' ' A' ' 165' ' ' ASP . 18.6 mmm180 -78.19 103.03 7.88 Favored 'General case' 0 N--CA 1.42 -1.967 0 CA-C-N 114.932 -1.031 . . . . 0.0 111.195 -176.172 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -83.91 160.99 20.98 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 173.233 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . 0.412 ' CB ' ' HB2' ' A' ' 146' ' ' CYS . 97.5 m-85 -109.4 130.3 55.5 Favored 'General case' 0 C--N 1.284 -2.271 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 173.504 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 21.3 m80 -130.31 166.44 20.38 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -175.187 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . 0.577 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 76.7 t80 -54.36 124.2 15.25 Favored 'General case' 0 C--O 1.247 0.945 0 C-N-CA 120.651 -0.42 . . . . 0.0 109.909 174.288 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 124.59 -26.43 5.71 Favored Glycine 0 N--CA 1.423 -2.218 0 C-N-CA 120.441 -0.885 . . . . 0.0 111.391 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 16.0 mm100 -59.08 131.56 51.39 Favored 'General case' 0 C--O 1.248 1.013 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -179.23 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -119.33 96.1 5.07 Favored 'General case' 0 N--CA 1.424 -1.735 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 73.4 t -88.89 101.6 12.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.25 -176.102 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.465 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 40.5 ttm180 -91.85 146.35 23.82 Favored 'General case' 0 N--CA 1.417 -2.084 0 CA-C-N 114.557 -1.201 . . . . 0.0 109.422 176.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -116.5 150.44 37.9 Favored 'General case' 0 N--CA 1.416 -2.135 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.6 p -129.84 142.45 43.83 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 177.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 70.3 m -94.1 148.41 22.2 Favored 'General case' 0 C--N 1.264 -3.114 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.344 -177.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -62.33 158.15 18.06 Favored 'General case' 0 CA--C 1.495 -1.166 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.578 178.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.2 m -42.11 103.92 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.22 0 O-C-N 125.173 1.545 . . . . 0.0 113.891 -174.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.02 -10.56 31.78 Favored Glycine 0 N--CA 1.432 -1.625 0 C-N-CA 120.469 -0.872 . . . . 0.0 113.731 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -97.63 160.38 14.35 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 117.809 0.805 . . . . 0.0 111.611 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.21 148.46 52.46 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.408 HD11 ' HA ' ' A' ' 188' ' ' GLU . 2.4 tt -79.77 144.99 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.148 0 CA-C-O 121.428 0.632 . . . . 0.0 110.817 -175.492 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -81.6 -65.27 1.03 Allowed 'General case' 0 C--N 1.294 -1.822 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.915 -176.534 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -78.52 -110.21 0.2 Allowed Glycine 0 C--N 1.309 -0.932 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.978 -178.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -106.59 179.46 4.26 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . 0.408 ' HA ' HD11 ' A' ' 184' ' ' ILE . 12.7 pt-20 -100.16 -11.9 20.06 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 118.974 0.806 . . . . 0.0 110.518 -174.288 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -152.61 164.38 37.79 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -173.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.2 ptp -133.79 136.89 44.8 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.079 176.176 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 44.6 t-80 -112.69 147.81 36.01 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 116.63 -0.259 . . . . 0.0 110.496 -178.104 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 61.1 m -75.08 121.2 21.67 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 123.067 0.547 . . . . 0.0 112.097 175.317 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 48.8 m -88.54 -175.23 4.88 Favored 'General case' 0 C--N 1.31 -1.136 0 C-N-CA 123.394 0.678 . . . . 0.0 110.205 174.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -51.81 -34.89 42.16 Favored 'General case' 0 N--CA 1.5 2.04 0 C-N-CA 125.073 1.349 . . . . 0.0 113.05 -178.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -78.06 -4.02 45.13 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 123.347 0.659 . . . . 0.0 112.608 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 69.25 28.42 72.71 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 108.051 -2.019 . . . . 0.0 108.051 -168.191 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -105.72 148.22 27.68 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-N 114.177 -1.012 . . . . 0.0 108.447 -176.16 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 83.6 m95 -81.97 123.67 29.08 Favored 'General case' 0 C--N 1.292 -1.906 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 10.9 m -62.4 -29.01 70.18 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 122.989 0.516 . . . . 0.0 111.837 -178.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -118.93 155.75 30.76 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 107.078 -1.452 . . . . 0.0 107.078 -178.103 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -95.3 164.06 13.0 Favored 'General case' 0 C--N 1.288 -2.105 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 176.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 54.6 mtpt -54.42 115.87 9.48 Favored Pre-proline 0 C--N 1.319 -0.76 0 O-C-N 123.815 0.697 . . . . 0.0 112.586 -176.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . 0.46 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 5.7 Cg_exo -78.06 162.56 28.86 Favored 'Trans proline' 0 N--CA 1.432 -2.093 0 C-N-CA 121.813 1.675 . . . . 0.0 111.231 177.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . 0.486 ' HZ3' ' CD ' ' A' ' 153' ' ' GLU . 50.7 tttp -109.0 157.94 18.19 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 -177.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 95.0 m -114.33 120.96 42.16 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 175.167 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.9 m . . . . . 0 C--N 1.307 -1.271 0 O-C-N 124.284 0.99 . . . . 0.0 109.318 -177.223 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.447 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 19.3 Cg_endo . . . . . 0 CA--C 1.532 0.412 0 CA-C-O 120.648 0.186 . . . . 0.0 112.308 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . 0.452 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 26.8 m -83.85 -26.55 29.38 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-O 121.465 0.65 . . . . 0.0 110.245 176.323 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.8 -86.65 0.44 Allowed Glycine 0 CA--C 1.452 -3.888 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 170.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.2 t60 -175.03 131.41 0.44 Allowed Pre-proline 0 C--N 1.26 -3.32 0 N-CA-C 104.81 -2.292 . . . . 0.0 104.81 -174.349 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -82.0 6.42 5.7 Favored 'Trans proline' 0 N--CA 1.484 0.963 0 C-N-CA 122.627 2.218 . . . . 0.0 114.641 -172.014 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 108.89 -167.19 12.91 Favored Glycine 0 C--N 1.289 -2.046 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -176.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -154.97 155.47 34.27 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 1.7 t -129.51 129.54 23.21 Favored Pre-proline 0 C--N 1.297 -1.675 0 CA-C-O 120.757 0.313 . . . . 0.0 110.561 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.49 -10.05 18.79 Favored 'Trans proline' 0 C--O 1.223 -0.258 0 C-N-CA 122.523 2.148 . . . . 0.0 111.451 -179.588 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -96.78 -52.11 4.03 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 122.213 1.006 . . . . 0.0 108.656 -179.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -106.49 -155.17 20.82 Favored Glycine 0 N--CA 1.401 -3.642 0 C-N-CA 119.78 -1.2 . . . . 0.0 112.502 -176.181 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.8 p -146.48 177.38 9.09 Favored 'General case' 0 C--N 1.261 -3.281 0 C-N-CA 125.226 1.411 . . . . 0.0 107.304 178.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.402 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 44.3 p90 -142.47 164.44 30.12 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.79 174.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -129.12 159.16 36.88 Favored 'General case' 0 C--N 1.284 -2.277 0 N-CA-C 106.641 -1.614 . . . . 0.0 106.641 -179.682 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.3 mt -118.25 119.09 33.63 Favored 'General case' 0 C--N 1.274 -2.713 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 177.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.487 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 37.3 p -116.49 136.85 52.64 Favored 'General case' 0 C--N 1.273 -2.759 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.551 -174.676 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.0 17.99 56.8 Favored Glycine 0 N--CA 1.429 -1.792 0 C-N-CA 119.593 -1.289 . . . . 0.0 111.107 -178.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 173.72 -31.85 0.1 Allowed Glycine 0 N--CA 1.436 -1.36 0 C-N-CA 119.229 -1.462 . . . . 0.0 113.596 -179.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 6.6 t30 66.28 9.73 6.61 Favored 'General case' 0 CA--C 1.556 1.175 0 CA-C-O 122.09 0.948 . . . . 0.0 111.728 -178.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.513 ' O ' HG12 ' A' ' 108' ' ' VAL . 23.3 m -142.75 -168.92 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.459 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 -177.46 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -108.51 36.54 2.79 Favored 'General case' 0 C--O 1.25 1.092 0 CA-C-N 119.29 0.95 . . . . 0.0 110.796 -176.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.746 ' O ' HG11 ' A' ' 108' ' ' VAL . 10.3 pt-20 -79.0 177.68 8.61 Favored 'General case' 0 C--O 1.195 -1.765 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.159 179.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . 0.45 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 48.2 m-85 -72.98 130.76 41.08 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 120.858 0.361 . . . . 0.0 111.641 178.771 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.42 -0.55 63.61 Favored Glycine 0 N--CA 1.437 -1.248 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.997 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.746 HG11 ' O ' ' A' ' 105' ' ' GLU . 12.4 p -90.28 145.67 7.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.487 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 16.4 mtpp -109.75 127.18 54.45 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.745 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -88.76 85.19 6.72 Favored 'General case' 0 C--N 1.284 -2.272 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 175.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 29.4 m -87.07 114.64 26.52 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 CA-C-O 122.568 1.175 . . . . 0.0 109.461 -179.108 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . 0.402 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 31.4 m-85 -77.99 144.86 36.37 Favored 'General case' 0 C--N 1.27 -2.853 0 CA-C-N 115.098 -0.955 . . . . 0.0 110.833 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.2 t -142.02 118.08 10.64 Favored 'General case' 0 N--CA 1.413 -2.29 0 N-CA-C 107.108 -1.442 . . . . 0.0 107.108 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 38.0 m -75.34 158.51 32.69 Favored 'General case' 0 C--N 1.279 -2.479 0 O-C-N 121.992 -0.443 . . . . 0.0 110.651 -175.459 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -77.65 -179.09 5.68 Favored 'General case' 0 CA--C 1.495 -1.151 0 C-N-CA 119.993 -0.683 . . . . 0.0 111.05 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -52.12 -52.73 49.71 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 124.099 0.874 . . . . 0.0 112.323 -176.306 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.476 ' C ' HG23 ' A' ' 144' ' ' VAL . . . -83.94 25.29 5.41 Favored Glycine 0 C--N 1.304 -1.219 0 C-N-CA 120.625 -0.798 . . . . 0.0 113.831 -178.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.5 ' CE1' HG11 ' A' ' 143' ' ' VAL . 87.6 m-85 -144.31 152.01 40.16 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 122.268 -0.548 . . . . 0.0 110.08 -176.665 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.78 162.05 26.76 Favored 'General case' 0 C--N 1.276 -2.613 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 -179.386 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 3.1 tt -93.06 128.24 38.88 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.07 -178.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -111.5 126.03 54.53 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 -177.364 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 113.52 164.79 15.76 Favored Glycine 0 C--N 1.286 -2.228 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -175.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 13.6 mm-40 -91.97 -31.48 15.6 Favored 'General case' 0 C--N 1.3 -1.543 0 CA-C-O 121.987 0.899 . . . . 0.0 109.382 -177.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.493 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.0 mm -82.57 127.47 39.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 178.328 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.42 2.8 9.69 Favored 'General case' 0 C--O 1.204 -1.339 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -177.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.491 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 10.8 p90 -143.54 164.08 31.36 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 120.506 -0.478 . . . . 0.0 109.817 -170.323 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -131.12 132.27 44.7 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 171.544 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -106.0 133.23 51.05 Favored 'General case' 0 C--N 1.284 -2.257 0 C-N-CA 118.533 -1.267 . . . . 0.0 110.773 -178.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . 0.45 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 39.7 t -75.72 96.88 3.7 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.443 ' OD1' HG22 ' A' ' 131' ' ' THR . 8.0 t70 -94.26 -175.05 3.54 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 178.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.447 ' HA ' ' CE1' ' A' ' 106' ' ' TYR . 13.9 t -68.28 -23.4 64.75 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-O 121.898 0.856 . . . . 0.0 109.889 -176.56 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -77.59 -39.06 46.87 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.613 177.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.452 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 145.21 -159.47 27.89 Favored Glycine 0 N--CA 1.421 -2.355 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -174.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 98.1 m95 -67.98 122.48 18.31 Favored 'General case' 0 C--N 1.309 -1.193 0 CA-C-N 117.639 0.719 . . . . 0.0 110.517 178.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 76.2 p -76.63 170.76 15.83 Favored 'General case' 0 C--O 1.265 1.885 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 74.4 m-20 61.91 -165.34 0.23 Allowed 'General case' 0 C--O 1.246 0.894 0 O-C-N 123.951 0.782 . . . . 0.0 111.474 174.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -122.53 168.83 11.66 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 80.6 mt -67.54 119.63 67.14 Favored Pre-proline 0 C--N 1.307 -1.252 0 O-C-N 123.247 0.342 . . . . 0.0 110.089 176.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . 0.493 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 33.9 Cg_endo -65.99 150.09 85.69 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 122.733 2.288 . . . . 0.0 110.527 177.317 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 61.8 mt -96.46 130.27 45.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-O 121.106 0.479 . . . . 0.0 111.034 -174.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 93.1 m -99.38 107.69 20.01 Favored 'General case' 0 C--N 1.284 -2.273 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 172.08 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -91.96 154.41 18.83 Favored 'General case' 0 N--CA 1.412 -2.362 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 177.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.5 HG11 ' CE1' ' A' ' 118' ' ' TYR . 4.5 t -80.02 141.36 15.39 Favored 'Isoleucine or valine' 0 C--N 1.256 -3.494 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -175.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.528 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 15.9 m -68.4 100.12 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-O 121.85 0.833 . . . . 0.0 109.987 -178.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.427 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 94.9 mttt -100.69 136.56 40.36 Favored 'General case' 0 N--CA 1.421 -1.879 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.053 -174.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 60.6 m -98.96 167.87 10.46 Favored 'General case' 0 C--N 1.291 -1.955 0 CA-C-N 114.321 -1.309 . . . . 0.0 109.056 -177.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 2.2 pp -79.73 154.92 75.96 Favored Pre-proline 0 N--CA 1.427 -1.612 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 178.239 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -79.64 118.82 3.92 Favored 'Trans proline' 0 N--CA 1.441 -1.564 0 C-N-CA 122.46 2.106 . . . . 0.0 111.719 -177.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.0 t -67.65 144.61 14.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.1 p -77.17 -83.54 0.07 Allowed 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 119.644 -0.217 . . . . 0.0 111.496 176.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 173.51 162.69 0.3 Allowed Pre-proline 0 N--CA 1.473 0.715 0 C-N-CA 125.171 1.388 . . . . 0.0 108.361 178.162 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . 0.405 ' HB3' ' HA ' ' A' ' 204' ' ' LYS . 72.6 Cg_endo -84.04 166.46 12.9 Favored 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 122.361 2.041 . . . . 0.0 110.997 170.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -72.11 -62.56 1.39 Allowed 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 114.099 1.148 . . . . 0.0 114.099 -176.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . 0.424 ' HB2' ' O ' ' A' ' 205' ' ' CYS . 43.7 m-80 -97.24 31.35 2.49 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 121.943 0.878 . . . . 0.0 110.075 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -150.87 -169.99 17.36 Favored Glycine 0 N--CA 1.422 -2.274 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 21.9 pttm -151.84 171.62 17.47 Favored 'General case' 0 C--N 1.289 -2.034 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 54.3 mt -90.87 135.09 27.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-O 120.951 0.405 . . . . 0.0 111.415 -178.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.464 ' CG2' HG22 ' A' ' 177' ' ' VAL . 57.0 t -70.83 -50.03 46.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 C-N-CA 124.214 1.006 . . . . 0.0 108.468 177.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 1.7 m -82.52 27.86 0.49 Allowed 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 124.558 1.143 . . . . 0.0 111.018 -176.513 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 7.2 p -68.5 -69.49 0.32 Allowed 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -174.11 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -94.59 77.83 3.78 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.923 0.868 . . . . 0.0 113.216 -174.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' MET . . . . . 0.568 ' O ' ' HG2' ' A' ' 163' ' ' GLU . 62.6 mtm -90.09 -55.51 3.58 Favored 'General case' 0 C--N 1.293 -1.887 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 170.448 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.568 ' HG2' ' O ' ' A' ' 162' ' ' MET . 10.5 mm-40 -175.36 145.66 0.86 Allowed Pre-proline 0 CA--C 1.503 -0.855 0 C-N-CA 129.412 3.085 . . . . 0.0 104.935 175.316 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -84.29 -7.3 10.01 Favored 'Trans proline' 0 C--N 1.316 -1.137 0 C-N-CA 122.436 2.091 . . . . 0.0 111.787 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -97.62 -19.47 18.28 Favored 'General case' 0 CA--C 1.47 -2.117 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.261 -176.034 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -81.72 126.94 32.4 Favored 'General case' 0 N--CA 1.398 -3.036 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.204 -179.635 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -86.91 143.55 27.36 Favored 'General case' 0 C--N 1.272 -2.791 0 CA-C-N 114.783 -1.099 . . . . 0.0 109.279 -179.213 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . 0.427 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 74.4 m-85 -67.83 136.91 54.86 Favored 'General case' 0 C--O 1.2 -1.516 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.724 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.45 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 44.6 p-80 -153.21 171.44 18.51 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-O 118.675 -0.678 . . . . 0.0 109.19 -172.641 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . 0.528 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 62.0 t80 -50.77 133.2 26.39 Favored 'General case' 0 C--O 1.239 0.528 0 O-C-N 123.732 0.645 . . . . 0.0 110.512 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 106.06 -26.99 18.91 Favored Glycine 0 N--CA 1.434 -1.48 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -177.369 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -76.12 140.43 41.8 Favored 'General case' 0 CA--C 1.503 -0.838 0 CA-C-O 121.629 0.728 . . . . 0.0 110.413 178.727 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . 0.435 ' HB2' ' CD2' ' A' ' 191' ' ' HIS . . . -129.62 119.91 24.37 Favored 'General case' 0 C--N 1.279 -2.495 0 CA-C-N 114.139 -1.391 . . . . 0.0 107.315 176.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.478 HG22 ' CH2' ' A' ' 198' ' ' TRP . 68.1 t -93.65 108.38 20.45 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.992 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 176.021 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 76.2 ttt180 -103.24 156.29 17.82 Favored 'General case' 0 N--CA 1.409 -2.479 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -127.96 153.15 47.04 Favored 'General case' 0 C--N 1.291 -1.972 0 C-N-CA 123.179 0.591 . . . . 0.0 110.158 -170.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.464 HG22 ' CG2' ' A' ' 158' ' ' VAL . 0.1 OUTLIER -127.91 141.15 47.22 Favored 'Isoleucine or valine' 0 CA--C 1.467 -2.212 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.262 179.04 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 72.1 m -95.96 132.75 40.96 Favored 'General case' 0 N--CA 1.389 -3.487 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.08 176.238 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 -67.12 170.03 7.59 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 113.985 -1.462 . . . . 0.0 109.711 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.3 m -49.84 109.47 0.29 Allowed 'General case' 0 C--N 1.297 -1.7 0 O-C-N 124.394 1.059 . . . . 0.0 113.463 -174.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 97.16 18.21 29.68 Favored Glycine 0 N--CA 1.433 -1.527 0 CA-C-N 115.234 -0.894 . . . . 0.0 114.633 174.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -128.53 164.9 21.8 Favored 'General case' 0 C--O 1.241 0.645 0 CA-C-N 118.457 1.128 . . . . 0.0 112.572 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 56.7 pttt -122.12 154.84 36.86 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 106.741 -1.578 . . . . 0.0 106.741 178.77 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 5.4 tp -72.67 145.9 11.5 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 174.453 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -70.4 -69.73 0.34 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 120.983 0.421 . . . . 0.0 110.108 -177.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -109.65 -82.76 1.39 Allowed Glycine 0 N--CA 1.431 -1.66 0 C-N-CA 120.24 -0.981 . . . . 0.0 111.851 178.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -113.99 151.81 31.85 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -177.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -109.82 9.71 24.64 Favored 'General case' 0 C--N 1.3 -1.587 0 CA-C-N 118.448 0.567 . . . . 0.0 110.708 -179.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -148.73 130.35 14.96 Favored 'General case' 0 C--N 1.295 -1.788 0 CA-C-O 122.012 0.911 . . . . 0.0 113.315 -178.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.414 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 16.5 ptp -121.46 144.72 48.53 Favored 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.21 178.003 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . 0.435 ' CD2' ' HB2' ' A' ' 173' ' ' ALA . 34.5 m80 -117.25 147.77 42.24 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 120.469 0.176 . . . . 0.0 111.032 -179.411 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 4.9 m -76.17 115.92 16.37 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.475 172.61 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 193' ' ' SER . . . . . 0.505 ' HB2' ' OD1' ' A' ' 195' ' ' ASP . 13.0 m -85.55 177.19 7.83 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.458 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -76.85 3.43 12.0 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 121.348 0.595 . . . . 0.0 112.272 -176.254 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . 0.505 ' OD1' ' HB2' ' A' ' 193' ' ' SER . 43.4 p-10 -92.61 -15.68 26.56 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 123.267 0.627 . . . . 0.0 109.755 177.077 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 90.93 19.47 43.14 Favored Glycine 0 N--CA 1.432 -1.603 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.586 -178.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -128.47 168.94 14.92 Favored 'General case' 0 C--N 1.314 -0.96 0 O-C-N 122.152 -0.617 . . . . 0.0 111.458 178.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . 0.478 ' CH2' HG22 ' A' ' 174' ' ' VAL . 85.9 m95 -82.46 131.03 35.22 Favored 'General case' 0 N--CA 1.436 -1.172 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.646 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 31.0 p -62.53 -29.66 70.72 Favored 'General case' 0 C--N 1.312 -1.025 0 C-N-CA 124.579 1.152 . . . . 0.0 113.108 -177.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 3.1 tppp? -126.17 158.18 36.25 Favored 'General case' 0 N--CA 1.432 -1.329 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -81.12 174.24 11.78 Favored 'General case' 0 C--N 1.312 -1.041 0 O-C-N 123.318 0.386 . . . . 0.0 110.033 -178.466 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 37.5 mtpt -70.0 121.35 82.61 Favored Pre-proline 0 N--CA 1.438 -1.064 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.301 176.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -89.08 -162.36 0.13 Allowed 'Trans proline' 0 N--CA 1.431 -2.153 0 C-N-CA 122.388 2.059 . . . . 0.0 109.44 173.642 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . 0.405 ' HA ' ' HB3' ' A' ' 152' ' ' PRO . 18.0 ptpt -166.39 174.09 9.36 Favored 'General case' 0 N--CA 1.416 -2.141 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.504 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 80.7 m -114.03 128.89 56.58 Favored 'General case' 0 C--N 1.276 -2.607 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 177.727 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.8 m . . . . . 0 C--N 1.28 -2.432 0 O-C-N 124.49 1.118 . . . . 0.0 108.542 -172.642 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.405 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 39.7 Cg_endo . . . . . 0 CA--C 1.54 0.804 0 CA-C-O 121.245 0.435 . . . . 0.0 111.977 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 61.3 m -90.07 -32.5 16.68 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 122.148 0.975 . . . . 0.0 108.654 176.168 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 111.82 -83.84 0.34 Allowed Glycine 0 CA--C 1.455 -3.715 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 171.043 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 9.3 t60 -179.83 130.83 0.25 Allowed Pre-proline 0 C--N 1.267 -2.979 0 N-CA-C 104.928 -2.249 . . . . 0.0 104.928 -175.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.41 ' HB3' ' CD2' ' A' ' 134' ' ' TRP . 88.1 Cg_endo -84.12 1.48 8.74 Favored 'Trans proline' 0 N--CA 1.485 1.008 0 C-N-CA 122.677 2.251 . . . . 0.0 113.915 -172.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 94.19 179.75 38.25 Favored Glycine 0 N--CA 1.429 -1.831 0 N-CA-C 108.492 -1.843 . . . . 0.0 108.492 -173.112 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -140.7 -179.66 6.17 Favored 'General case' 0 C--N 1.29 -2.005 0 CA-C-N 117.628 0.714 . . . . 0.0 109.767 -178.178 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.0 t -126.53 138.47 32.49 Favored Pre-proline 0 C--N 1.307 -1.245 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -77.34 -20.89 12.2 Favored 'Trans proline' 0 CA--C 1.534 0.514 0 C-N-CA 122.537 2.158 . . . . 0.0 112.255 -179.097 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.404 ' O ' ' HB2' ' A' ' 115' ' ' ASN . 59.0 m-85 -80.82 -50.4 9.87 Favored 'General case' 0 CA--C 1.5 -0.967 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.477 -176.287 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -122.49 -136.45 4.89 Favored Glycine 0 N--CA 1.421 -2.338 0 C-N-CA 120.558 -0.829 . . . . 0.0 111.115 -178.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.7 p -148.21 -172.51 4.09 Favored 'General case' 0 C--N 1.294 -1.813 0 C-N-CA 123.594 0.758 . . . . 0.0 109.073 -178.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 38.5 p90 -145.01 163.76 33.23 Favored 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 120.381 -0.528 . . . . 0.0 109.984 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.6 m -135.75 158.91 43.22 Favored 'General case' 0 C--N 1.288 -2.084 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 178.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.4 HD13 ' CE1' ' A' ' 104' ' ' PHE . 18.1 mt -110.18 122.05 46.71 Favored 'General case' 0 C--N 1.28 -2.414 0 CA-C-O 120.94 0.4 . . . . 0.0 110.384 -178.029 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 19.2 p -114.43 136.27 53.19 Favored 'General case' 0 C--N 1.286 -2.162 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.924 -176.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 95.78 11.74 54.52 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 120.035 -1.078 . . . . 0.0 112.174 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 171.59 -23.96 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 119.274 -1.441 . . . . 0.0 113.818 -178.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 65.4 17.3 10.92 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 179.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.5 ' O ' HG13 ' A' ' 108' ' ' VAL . 30.3 m -148.97 -176.23 0.41 Allowed 'Isoleucine or valine' 0 C--O 1.205 -1.242 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -175.726 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.4 ' CE1' HD13 ' A' ' 98' ' ' LEU . 41.2 m-85 -102.84 47.32 0.89 Allowed 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 118.299 0.5 . . . . 0.0 110.401 -179.452 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.751 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.8 pt-20 -88.44 179.54 6.29 Favored 'General case' 0 C--O 1.207 -1.147 0 CA-C-N 115.477 -0.783 . . . . 0.0 111.092 177.467 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -79.36 135.76 36.8 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.075 176.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.52 1.3 62.27 Favored Glycine 0 N--CA 1.434 -1.449 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.832 -179.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.751 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.5 p -97.54 150.67 4.53 Favored 'Isoleucine or valine' 0 C--O 1.246 0.908 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 14.6 mtpp -113.82 127.87 56.18 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -179.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -90.34 93.05 9.17 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 175.773 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 44.0 t -88.19 114.95 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.662 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.063 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.1 m-85 -85.15 133.48 34.2 Favored 'General case' 0 C--N 1.284 -2.246 0 CA-C-N 115.496 -0.775 . . . . 0.0 109.632 179.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.8 t -125.82 127.43 46.08 Favored 'General case' 0 N--CA 1.409 -2.508 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -177.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 79.6 m -75.32 159.99 30.83 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.404 ' HB2' ' O ' ' A' ' 93' ' ' PHE . 6.7 t-20 -69.53 -175.84 0.9 Allowed 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 114.053 -1.431 . . . . 0.0 109.487 178.148 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -67.1 -44.38 80.11 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 120.998 0.427 . . . . 0.0 111.081 -179.555 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.21 8.12 68.8 Favored Glycine 0 C--N 1.31 -0.878 0 CA-C-N 115.965 -0.561 . . . . 0.0 113.14 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.589 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 70.7 m-85 -127.95 160.64 31.26 Favored 'General case' 0 C--N 1.311 -1.073 0 O-C-N 122.534 -0.392 . . . . 0.0 110.955 178.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.33 144.26 30.62 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -178.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -75.6 126.95 32.01 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -174.657 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -110.79 130.92 55.44 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 -177.391 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.02 174.81 20.18 Favored Glycine 0 C--N 1.301 -1.408 0 N-CA-C 111.528 -0.629 . . . . 0.0 111.528 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -83.31 -36.22 24.62 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.5 mm -87.97 125.0 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.862 0 CA-C-N 113.977 -1.465 . . . . 0.0 109.247 -175.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -127.54 3.96 6.19 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.414 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 17.9 p90 -144.05 165.11 28.7 Favored 'General case' 0 N--CA 1.422 -1.848 0 C-N-CA 119.901 -0.72 . . . . 0.0 110.757 -171.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 45.9 mtp180 -126.19 132.79 51.71 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 173.093 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -108.76 134.15 51.86 Favored 'General case' 0 C--N 1.277 -2.586 0 C-N-CA 119.464 -0.895 . . . . 0.0 108.864 -177.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 17.5 t -85.74 99.96 11.69 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 118.292 -1.363 . . . . 0.0 109.403 177.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.448 ' OD2' HG21 ' A' ' 131' ' ' THR . 8.5 t70 -104.32 -167.84 1.41 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 177.123 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.448 HG21 ' OD2' ' A' ' 130' ' ' ASP . 9.6 t -65.14 -15.87 62.88 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 119.048 0.84 . . . . 0.0 111.633 -177.072 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -81.79 -13.49 57.64 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.697 0.76 . . . . 0.0 109.839 176.104 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 102.49 -157.46 18.24 Favored Glycine 0 N--CA 1.428 -1.847 0 N-CA-C 107.522 -2.231 . . . . 0.0 107.522 -174.445 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.41 ' CD2' ' HB3' ' A' ' 88' ' ' PRO . 94.6 m95 -62.28 106.64 0.77 Allowed 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 117.714 0.757 . . . . 0.0 110.405 173.766 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 62.3 p -71.8 171.48 11.57 Favored 'General case' 0 C--O 1.269 2.086 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.192 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 1.8 m-20 62.87 -158.57 0.32 Allowed 'General case' 0 C--O 1.245 0.83 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.029 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 29.0 t0 -141.11 173.03 11.87 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 173.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 70.1 mt -59.36 121.71 58.46 Favored Pre-proline 0 C--N 1.269 -2.915 0 C-N-CA 125.14 1.376 . . . . 0.0 108.352 175.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -64.78 178.32 1.85 Allowed 'Trans proline' 0 C--O 1.251 1.17 0 C-N-CA 123.097 2.531 . . . . 0.0 113.614 -176.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 63.5 mt -98.37 129.52 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.066 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.69 -176.094 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.589 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 33.6 t -114.69 107.12 15.04 Favored 'General case' 0 C--N 1.273 -2.735 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 178.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -99.35 152.1 20.33 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-O 121.625 0.726 . . . . 0.0 110.933 -176.105 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.559 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 3.3 t -73.1 136.52 25.32 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.049 0 CA-C-N 113.902 -1.499 . . . . 0.0 108.609 -179.703 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.87 125.02 20.9 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.097 0 O-C-N 124.957 1.411 . . . . 0.0 108.064 177.052 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 45.6 mttp -122.9 162.62 21.88 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.382 -174.863 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 57.0 m -124.58 168.34 13.26 Favored 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 114.309 -1.314 . . . . 0.0 107.734 175.036 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 71.5 mt -74.73 143.59 78.76 Favored Pre-proline 0 C--N 1.307 -1.244 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -179.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.438 ' HA ' ' CE2' ' A' ' 168' ' ' TYR . 17.5 Cg_endo -62.73 122.36 10.65 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.945 2.43 . . . . 0.0 110.761 178.283 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 48.0 t -91.81 142.02 13.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.005 -175.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 21.0 p -79.95 -82.67 0.11 Allowed 'General case' 0 N--CA 1.43 -1.47 0 CA-C-N 116.727 -0.215 . . . . 0.0 110.907 176.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.49 165.7 0.45 Allowed Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 124.051 0.94 . . . . 0.0 108.724 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . 0.495 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 55.6 Cg_endo -76.57 160.93 34.63 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.024 1.816 . . . . 0.0 109.742 167.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -53.3 -50.77 64.21 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 114.287 1.218 . . . . 0.0 114.287 -175.055 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 55.6 m-80 -113.3 38.06 2.99 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -154.78 -167.43 16.56 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.918 -1.134 . . . . 0.0 112.53 177.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -153.04 170.24 20.95 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 -177.347 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 73.3 mt -86.02 137.67 20.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 177.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.471 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 14.5 m -69.11 -32.68 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-O 121.597 0.713 . . . . 0.0 110.872 -177.766 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 24.3 t -113.25 -163.32 0.85 Allowed 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -178.099 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 28.9 p -151.69 -67.39 0.17 Allowed 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 121.022 -0.271 . . . . 0.0 111.076 177.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 60.58 23.75 13.48 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.526 1.131 . . . . 0.0 110.589 -178.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' MET . . . . . 0.451 ' CE ' ' HA ' ' A' ' 162' ' ' MET . 0.0 OUTLIER -99.53 87.52 3.61 Favored 'General case' 0 N--CA 1.428 -1.553 0 CA-C-O 121.697 0.76 . . . . 0.0 110.783 -174.709 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -129.33 159.39 69.43 Favored Pre-proline 0 C--N 1.294 -1.825 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 177.022 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -53.53 -34.93 74.67 Favored 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 122.81 2.34 . . . . 0.0 113.905 178.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -92.11 -23.58 19.4 Favored 'General case' 0 N--CA 1.476 0.843 0 CA-C-O 122.164 0.983 . . . . 0.0 109.768 -178.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 34.6 mmt180 -94.82 93.35 7.43 Favored 'General case' 0 N--CA 1.417 -2.11 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.989 -175.524 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -89.11 163.34 15.51 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.201 -1.778 . . . . 0.0 106.201 169.446 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . 0.521 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 67.4 m-85 -64.97 109.83 2.25 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 119.098 0.863 . . . . 0.0 110.628 179.453 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 28.1 m80 -98.02 161.45 13.72 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.534 -173.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -58.0 135.69 56.99 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.868 172.525 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 103.5 -18.26 48.39 Favored Glycine 0 N--CA 1.429 -1.803 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.62 -179.292 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.9 tp60 -76.96 128.83 35.24 Favored 'General case' 0 N--CA 1.398 -3.037 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -110.6 131.14 55.31 Favored 'General case' 0 N--CA 1.418 -2.027 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 172.468 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.468 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 55.5 t -107.87 99.56 8.88 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.32 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.471 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 41.7 ttm180 -89.76 144.09 26.26 Favored 'General case' 0 N--CA 1.42 -1.928 0 CA-C-N 115.043 -0.981 . . . . 0.0 109.025 178.124 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.495 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 78.1 m-85 -113.93 160.42 18.82 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -178.171 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.9 p -139.53 150.45 22.52 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.057 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 63.9 m -109.7 157.64 18.9 Favored 'General case' 0 C--N 1.287 -2.123 0 O-C-N 123.39 0.431 . . . . 0.0 111.602 -175.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -78.41 170.7 16.21 Favored 'General case' 0 N--CA 1.439 -1.018 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.534 179.284 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 23.1 t -49.64 105.93 0.1 Allowed 'General case' 0 C--N 1.313 -1.013 0 C-N-CA 124.88 1.272 . . . . 0.0 112.918 -175.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 111.74 -15.08 26.75 Favored Glycine 0 N--CA 1.43 -1.719 0 CA-C-N 115.285 -0.87 . . . . 0.0 113.252 175.328 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . 0.402 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 93.5 m-85 -103.84 159.84 15.3 Favored 'General case' 0 N--CA 1.433 -1.323 0 CA-C-N 117.783 0.791 . . . . 0.0 111.353 -176.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 53.4 pttt -135.04 155.7 50.3 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 175.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.447 HD11 ' HA ' ' A' ' 188' ' ' GLU . 12.5 tt -81.95 141.98 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.57 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.568 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -66.16 -79.02 0.05 OUTLIER 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 114.283 1.216 . . . . 0.0 114.283 -171.631 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -83.64 -92.87 0.67 Allowed Glycine 0 CA--C 1.496 -1.135 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.183 -175.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -94.32 173.71 7.5 Favored 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . 0.447 ' HA ' HD11 ' A' ' 184' ' ' ILE . 12.7 pt-20 -122.82 4.83 9.43 Favored 'General case' 0 N--CA 1.438 -1.029 0 C-N-CA 120.613 -0.435 . . . . 0.0 110.205 178.074 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . 0.468 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 7.1 pt-20 -163.46 120.02 1.77 Allowed 'General case' 0 N--CA 1.432 -1.345 0 CA-C-O 121.943 0.877 . . . . 0.0 112.144 -175.013 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 12.8 ptp -100.53 132.12 46.08 Favored 'General case' 0 C--N 1.281 -2.41 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.501 177.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 23.8 t-80 -107.24 143.46 35.43 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.918 -177.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 2.5 m -70.21 116.79 10.97 Favored 'General case' 0 CA--C 1.5 -0.946 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.944 172.546 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 2.6 m -83.39 151.73 25.37 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -67.75 -8.92 39.53 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 121.17 0.51 . . . . 0.0 112.362 -175.079 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . 0.402 ' HB3' ' CE1' ' A' ' 197' ' ' PHE . 26.0 t70 -82.87 -16.81 46.11 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-O 121.279 0.562 . . . . 0.0 110.638 177.464 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 99.78 38.62 3.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.669 -0.777 . . . . 0.0 113.724 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . 0.402 ' CE1' ' HB3' ' A' ' 195' ' ' ASP . 44.7 p90 -149.08 156.18 41.83 Favored 'General case' 0 C--O 1.249 1.04 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.707 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 83.4 m95 -72.79 128.33 35.2 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 175.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.0 m -51.74 -36.65 47.89 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.047 0.539 . . . . 0.0 111.621 -178.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 28.3 mmtp -116.24 163.79 15.47 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.463 177.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -88.18 162.57 16.62 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.652 178.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -57.55 105.09 0.48 Allowed Pre-proline 0 CA--C 1.57 1.731 0 C-N-CA 125.667 1.587 . . . . 0.0 112.758 -176.548 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -89.0 170.89 4.88 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 124.005 3.136 . . . . 0.0 113.671 -176.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 20.1 pttm -135.06 162.21 33.13 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.046 -176.462 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.402 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 83.2 m -100.72 119.43 38.59 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 124.264 0.978 . . . . 0.0 108.537 177.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 25.5 m . . . . . 0 C--N 1.287 -2.128 0 O-C-N 124.441 1.088 . . . . 0.0 109.776 -174.188 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 18.4 Cg_endo . . . . . 0 CA--C 1.543 0.938 0 CA-C-O 121.4 0.5 . . . . 0.0 111.882 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . 0.472 ' HB3' ' NE1' ' A' ' 134' ' ' TRP . 23.6 m -89.42 -27.3 20.49 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.035 0.445 . . . . 0.0 111.606 176.303 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.62 -83.14 0.32 Allowed Glycine 0 CA--C 1.456 -3.652 0 C-N-CA 120.292 -0.956 . . . . 0.0 111.249 170.405 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -175.66 129.21 0.39 Allowed Pre-proline 0 C--N 1.269 -2.934 0 N-CA-C 106.498 -1.667 . . . . 0.0 106.498 -176.002 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -82.81 7.97 4.86 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 123.231 2.62 . . . . 0.0 114.476 -171.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 120.69 164.92 12.59 Favored Glycine 0 C--N 1.292 -1.881 0 N-CA-C 108.316 -1.914 . . . . 0.0 108.316 -175.477 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -145.82 111.93 5.7 Favored 'General case' 0 C--N 1.293 -1.859 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -177.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 8.2 t -98.92 140.65 21.89 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -172.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -85.38 -9.02 8.42 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.853 2.369 . . . . 0.0 111.548 173.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -94.81 16.41 15.95 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.251 0.548 . . . . 0.0 110.593 -176.149 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 156.43 -121.95 1.14 Allowed Glycine 0 N--CA 1.41 -3.072 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 t -171.85 -160.33 0.16 Allowed 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.652 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -149.94 164.82 34.43 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.364 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.8 m -125.33 160.76 28.55 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 178.268 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.0 mt -119.71 131.82 55.49 Favored 'General case' 0 C--N 1.277 -2.578 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -179.023 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 38.9 p -126.21 131.28 52.0 Favored 'General case' 0 C--N 1.286 -2.178 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -177.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 87.71 24.98 33.88 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.503 -0.856 . . . . 0.0 111.68 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 176.1 -37.8 0.1 OUTLIER Glycine 0 N--CA 1.434 -1.447 0 C-N-CA 119.93 -1.129 . . . . 0.0 112.799 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 67.39 11.36 8.34 Favored 'General case' 0 N--CA 1.498 1.925 0 C-N-CA 124.354 1.062 . . . . 0.0 109.694 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.512 ' O ' HG13 ' A' ' 108' ' ' VAL . 25.1 m -150.56 -168.38 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.085 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 -177.539 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 24.4 m-85 -104.75 38.25 1.95 Allowed 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 118.347 0.521 . . . . 0.0 110.788 -175.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.751 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.2 pt-20 -79.19 173.81 12.2 Favored 'General case' 0 C--O 1.195 -1.763 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.782 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . 0.482 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 41.8 m-85 -72.44 133.14 44.71 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.975 178.668 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.34 -0.1 71.09 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 115.739 -0.664 . . . . 0.0 113.064 178.293 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.751 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.5 p -89.45 148.77 4.31 Favored 'Isoleucine or valine' 0 C--O 1.243 0.763 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.753 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -112.16 131.52 55.42 Favored 'General case' 0 C--N 1.283 -2.295 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.362 177.657 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -94.96 94.93 8.3 Favored 'General case' 0 C--N 1.285 -2.213 0 CA-C-N 115.382 -0.826 . . . . 0.0 108.791 176.411 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 91.8 t -86.54 106.84 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.812 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . 0.519 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 18.4 t80 -74.14 138.19 43.7 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 123.495 0.718 . . . . 0.0 109.19 -177.559 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.2 t -142.07 114.68 8.48 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.097 0.951 . . . . 0.0 110.09 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 73.6 m -71.35 163.19 28.16 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 115.374 -0.83 . . . . 0.0 112.193 -179.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -73.42 -175.04 1.82 Allowed 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.862 178.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -62.13 -45.93 91.25 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-O 121.228 0.537 . . . . 0.0 111.748 -177.324 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -79.82 4.32 66.0 Favored Glycine 0 C--N 1.313 -0.716 0 CA-C-N 115.879 -0.601 . . . . 0.0 114.285 -179.093 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.404 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.1 m-85 -129.77 166.25 20.27 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 -177.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 7.8 pt20 -150.49 160.87 43.47 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -77.59 133.94 38.34 Favored 'General case' 0 N--CA 1.424 -1.774 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.503 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -120.89 132.12 54.78 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 177.683 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 112.1 -170.14 13.44 Favored Glycine 0 N--CA 1.43 -1.76 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -178.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -100.77 -37.34 8.75 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.528 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 49.3 mm -80.97 125.53 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.071 0 CA-C-N 114.865 -1.061 . . . . 0.0 110.284 -177.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -132.03 11.05 4.64 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.499 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.502 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 24.3 p90 -142.88 161.09 39.02 Favored 'General case' 0 C--N 1.312 -1.058 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -178.364 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 54.8 mtp180 -129.88 138.02 50.72 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 172.196 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -109.07 128.56 55.09 Favored 'General case' 0 C--N 1.281 -2.403 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.552 -178.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . 0.482 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 38.9 t -76.84 96.06 4.21 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.033 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.412 ' OD2' HG23 ' A' ' 131' ' ' THR . 11.2 t70 -103.12 -171.6 1.97 Allowed 'General case' 0 N--CA 1.426 -1.65 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 179.181 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.412 HG23 ' OD2' ' A' ' 130' ' ' ASP . 14.8 t -69.48 -20.35 63.74 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.054 0.454 . . . . 0.0 111.873 -173.05 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -82.02 -25.37 34.72 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 121.516 0.674 . . . . 0.0 109.5 175.171 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 130.11 -154.37 20.52 Favored Glycine 0 N--CA 1.422 -2.254 0 N-CA-C 108.291 -1.923 . . . . 0.0 108.291 -174.377 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.472 ' NE1' ' HB3' ' A' ' 85' ' ' CYS . 98.5 m95 -68.93 118.7 12.18 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 117.519 0.66 . . . . 0.0 110.977 178.572 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 75.7 p -70.42 166.16 20.97 Favored 'General case' 0 C--O 1.277 2.552 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 175.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 60.81 -162.94 0.26 Allowed 'General case' 0 C--O 1.246 0.896 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -129.72 -176.02 3.78 Favored 'General case' 0 C--N 1.283 -2.298 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 173.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 75.1 mt -63.42 117.8 37.76 Favored Pre-proline 0 C--N 1.278 -2.519 0 C-N-CA 124.219 1.008 . . . . 0.0 108.289 176.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . 0.528 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 24.0 Cg_exo -55.7 158.36 13.67 Favored 'Trans proline' 0 C--O 1.251 1.172 0 C-N-CA 122.346 2.031 . . . . 0.0 111.904 178.903 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.503 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 46.6 mm -87.76 134.24 28.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 C-N-CA 120.192 -0.603 . . . . 0.0 109.885 -172.048 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.404 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 12.3 t -118.75 112.11 19.34 Favored 'General case' 0 C--N 1.28 -2.445 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.638 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -108.86 155.66 20.56 Favored 'General case' 0 C--N 1.278 -2.542 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -178.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.6 p -75.8 140.01 18.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 176.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 71.3 t -60.21 130.78 24.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 179.341 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -118.6 136.88 53.63 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -178.416 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 77.1 m -97.21 160.58 14.25 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.052 -177.638 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . 0.46 HD12 ' HD2' ' A' ' 148' ' ' PRO . 15.0 tp -71.75 125.91 91.58 Favored Pre-proline 0 N--CA 1.384 -3.725 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -178.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.46 ' HD2' HD12 ' A' ' 147' ' ' LEU . 14.2 Cg_endo -58.34 131.29 42.06 Favored 'Trans proline' 0 C--O 1.24 0.585 0 C-N-CA 123.839 3.026 . . . . 0.0 113.025 -176.091 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.7 t -93.51 139.59 17.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.0 p -74.98 -76.89 0.13 Allowed 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 111.657 0.243 . . . . 0.0 111.657 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.56 158.38 0.21 Allowed Pre-proline 0 CA--C 1.508 -0.665 0 N-CA-C 106.703 -1.592 . . . . 0.0 106.703 178.109 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -77.56 167.46 24.21 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 121.388 1.392 . . . . 0.0 109.33 171.597 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . 0.495 ' OE1' ' HG3' ' A' ' 204' ' ' LYS . 0.1 OUTLIER -74.68 -46.83 35.32 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -173.109 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . 0.433 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 55.2 m-80 -106.45 23.76 13.66 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.766 0.793 . . . . 0.0 110.748 -177.682 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -145.07 -157.43 7.23 Favored Glycine 0 N--CA 1.421 -2.337 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.826 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 21.4 pttp -157.78 169.58 24.3 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 43.3 mt -95.94 124.87 48.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 CA-C-O 121.4 0.619 . . . . 0.0 111.199 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 80.7 t -67.64 -46.29 83.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 C-N-CA 124.486 1.114 . . . . 0.0 109.661 179.385 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 14.9 m -78.51 4.33 13.6 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 114.017 1.117 . . . . 0.0 114.017 -173.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 69.1 m -91.88 -27.2 18.09 Favored 'General case' 0 C--N 1.291 -1.961 0 C-N-CA 120.156 -0.618 . . . . 0.0 110.088 176.165 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -88.81 79.61 7.37 Favored 'General case' 0 N--CA 1.435 -1.188 0 CA-C-O 121.738 0.78 . . . . 0.0 111.125 -178.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 57.9 mtm -157.92 -31.32 0.08 Allowed 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 126.107 1.763 . . . . 0.0 107.042 178.492 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -166.3 145.7 4.98 Favored Pre-proline 0 N--CA 1.441 -0.881 0 CA-C-N 114.168 -1.378 . . . . 0.0 107.95 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -81.61 -8.98 12.4 Favored 'Trans proline' 0 C--N 1.323 -0.777 0 C-N-CA 121.877 1.718 . . . . 0.0 112.485 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -80.88 -63.61 1.37 Allowed 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 -172.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . 0.322 4.7 ppt_? 23.65 83.18 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 117.809 2.522 . . . . 0.0 117.809 176.853 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -76.11 -12.24 60.08 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 115.281 -0.872 . . . . 0.0 111.263 178.153 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 68.08 85.08 0.14 Allowed 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 125.778 1.631 . . . . 0.0 110.58 -176.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 51.4 m170 -88.1 155.73 19.64 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.268 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 52.9 t80 -54.35 113.51 1.3 Allowed 'General case' 0 CA--C 1.509 -0.602 0 CA-C-O 121.484 0.659 . . . . 0.0 110.15 176.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 132.44 -25.33 3.83 Favored Glycine 0 N--CA 1.407 -3.243 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 -177.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . 0.418 ' HA ' HE21 ' A' ' 172' ' ' GLN . 0.0 OUTLIER -68.41 137.63 54.68 Favored 'General case' 0 C--O 1.256 1.402 0 CA-C-O 121.845 0.831 . . . . 0.0 111.747 -178.776 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -112.94 117.76 32.97 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 175.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 53.3 t -99.47 105.32 17.28 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 CA-C-O 121.336 0.589 . . . . 0.0 110.089 -178.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 27.3 ttm180 -94.92 152.8 18.05 Favored 'General case' 0 N--CA 1.414 -2.237 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.694 178.13 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -125.04 157.63 35.73 Favored 'General case' 0 C--N 1.284 -2.249 0 C-N-CA 124.491 1.116 . . . . 0.0 108.869 -175.312 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.37 151.44 35.62 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.958 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.912 175.636 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 7.7 m -118.06 135.2 54.33 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 114.136 -1.393 . . . . 0.0 108.154 173.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -62.63 161.39 12.3 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 124.233 0.958 . . . . 0.0 110.421 178.386 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 7.5 t -62.37 109.76 1.45 Allowed 'General case' 0 C--N 1.299 -1.597 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.323 -174.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 122.97 -19.93 7.72 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -177.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . 0.58 ' HB3' ' SG ' ' A' ' 205' ' ' CYS . 82.6 m-85 -107.69 160.86 15.38 Favored 'General case' 0 N--CA 1.429 -1.495 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.83 146.9 33.39 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.436 HD13 ' HA ' ' A' ' 188' ' ' GLU . 9.5 tt -80.72 140.02 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.808 0 CA-C-O 121.8 0.81 . . . . 0.0 111.513 -176.446 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -83.02 -51.02 7.93 Favored 'General case' 0 C--N 1.294 -1.829 0 CA-C-N 115.164 -0.925 . . . . 0.0 109.26 -176.112 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.58 -158.91 25.18 Favored Glycine 0 C--N 1.298 -1.573 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 173.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -79.74 160.36 26.26 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 122.283 -0.539 . . . . 0.0 110.108 177.485 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . 0.436 ' HA ' HD13 ' A' ' 184' ' ' ILE . 10.5 pt-20 -91.17 9.33 31.55 Favored 'General case' 0 C--O 1.205 -1.241 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.362 -176.167 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.2 pt-20 -155.37 138.82 15.87 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.225 0.536 . . . . 0.0 111.431 -178.767 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.423 ' HG2' ' HB ' ' A' ' 174' ' ' VAL . 6.2 ptm -127.37 144.78 51.0 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 178.401 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 52.5 t-80 -126.48 142.33 51.57 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.593 -0.692 . . . . 0.0 110.742 -175.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 6.4 m -59.32 125.21 22.7 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 176.219 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 12.1 m -104.02 165.43 11.05 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.111 179.441 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -54.06 -30.59 48.73 Favored 'General case' 0 N--CA 1.498 1.943 0 C-N-CA 123.975 0.91 . . . . 0.0 111.901 179.481 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -54.98 -30.03 58.28 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 124.906 1.282 . . . . 0.0 111.39 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 98.06 11.73 48.4 Favored Glycine 0 CA--C 1.497 -1.057 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -174.123 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -130.54 -170.88 2.42 Favored 'General case' 0 N--CA 1.429 -1.475 0 CA-C-N 114.526 -0.837 . . . . 0.0 109.281 -178.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 85.7 m95 -96.25 154.14 17.42 Favored 'General case' 0 N--CA 1.426 -1.658 0 CA-C-O 121.094 0.473 . . . . 0.0 111.335 -175.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 13.7 p -75.14 -17.78 60.35 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.626 176.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 23.9 mmtp -128.62 159.03 36.84 Favored 'General case' 0 CA--C 1.492 -1.254 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.176 179.118 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -87.15 -175.86 5.47 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 3.8 tppp? -72.49 115.14 36.39 Favored Pre-proline 0 C--O 1.249 1.053 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 173.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.73 177.5 8.74 Favored 'Trans proline' 0 N--CA 1.43 -2.231 0 C-N-CA 121.755 1.636 . . . . 0.0 110.645 177.519 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . 0.495 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 23.7 ttmm -128.56 152.75 47.94 Favored 'General case' 0 C--N 1.275 -2.654 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.45 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.58 ' SG ' ' HB3' ' A' ' 182' ' ' TYR . 18.2 t -111.42 117.83 34.14 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 179.209 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--N 1.305 -1.342 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.33 -174.39 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 28.9 Cg_endo . . . . . 0 CA--C 1.543 0.931 0 CA-C-O 121.988 0.745 . . . . 0.0 111.786 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 63.8 m -81.64 -27.97 33.86 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-O 122.066 0.936 . . . . 0.0 109.144 177.134 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.95 -91.37 0.56 Allowed Glycine 0 N--CA 1.4 -3.712 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 173.213 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -179.4 125.5 0.24 Allowed Pre-proline 0 C--N 1.256 -3.47 0 N-CA-C 103.906 -2.627 . . . . 0.0 103.906 -176.113 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.454 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 72.3 Cg_endo -76.82 5.09 5.13 Favored 'Trans proline' 0 N--CA 1.488 1.204 0 C-N-CA 122.649 2.233 . . . . 0.0 113.343 -173.905 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 97.98 -160.38 20.84 Favored Glycine 0 N--CA 1.419 -2.453 0 N-CA-C 106.725 -2.55 . . . . 0.0 106.725 -173.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -155.31 -168.66 2.91 Favored 'General case' 0 C--N 1.281 -2.389 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.6 t -143.42 120.32 6.72 Favored Pre-proline 0 C--N 1.289 -2.055 0 CA-C-N 118.867 0.758 . . . . 0.0 110.596 -178.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.86 -0.08 9.83 Favored 'Trans proline' 0 CA--C 1.53 0.315 0 C-N-CA 122.831 2.354 . . . . 0.0 111.047 178.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -107.25 13.74 26.88 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.379 178.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 164.77 -128.38 1.79 Allowed Glycine 0 N--CA 1.422 -2.262 0 C-N-CA 119.516 -1.326 . . . . 0.0 112.684 179.036 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.3 p -151.52 173.54 14.48 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 123.322 0.649 . . . . 0.0 110.303 -174.097 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -140.62 161.48 37.65 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 169.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.9 m -127.0 159.99 32.46 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.435 HD12 ' CE1' ' A' ' 104' ' ' PHE . 20.8 mt -117.03 122.89 45.5 Favored 'General case' 0 C--N 1.28 -2.414 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 -179.167 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 29.8 p -115.55 122.08 44.59 Favored 'General case' 0 C--N 1.286 -2.162 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.557 -176.518 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.91 -54.98 0.77 Allowed Glycine 0 N--CA 1.421 -2.339 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -178.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -141.81 3.86 2.09 Favored Glycine 0 N--CA 1.437 -1.28 0 C-N-CA 120.14 -1.029 . . . . 0.0 113.316 -178.004 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 59.99 18.51 7.65 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.524 ' O ' HG12 ' A' ' 108' ' ' VAL . 30.4 m -147.48 -173.86 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 -174.032 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.435 ' CE1' HD12 ' A' ' 98' ' ' LEU . 26.9 m-85 -102.89 45.9 0.94 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 118.447 0.567 . . . . 0.0 109.665 -179.412 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.69 ' O ' HG11 ' A' ' 108' ' ' VAL . 13.0 pt-20 -86.57 -175.03 5.29 Favored 'General case' 0 C--O 1.211 -0.924 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.211 178.124 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -80.36 137.14 36.52 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.86 -0.525 . . . . 0.0 111.455 179.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 88.65 -0.97 83.39 Favored Glycine 0 N--CA 1.439 -1.129 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.849 178.723 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.69 HG11 ' O ' ' A' ' 105' ' ' GLU . 11.4 p -90.08 147.53 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -176.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.4 mtpt -111.37 125.89 54.34 Favored 'General case' 0 N--CA 1.413 -2.281 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.706 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.405 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -89.57 93.25 9.42 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 174.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 54.1 t -88.2 116.43 30.08 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.454 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -179.315 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -87.52 141.59 28.51 Favored 'General case' 0 C--N 1.282 -2.341 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.109 -177.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.3 t -139.04 110.53 7.03 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-O 122.265 1.031 . . . . 0.0 108.488 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 33.2 m -68.75 163.03 24.96 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.114 -174.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -65.97 177.22 1.4 Allowed 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 124.31 1.044 . . . . 0.0 110.439 -178.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -58.92 -46.77 87.13 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 123.98 0.912 . . . . 0.0 112.086 -178.357 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.15 24.47 6.16 Favored Glycine 0 CA--C 1.524 0.609 0 C-N-CA 121.325 -0.464 . . . . 0.0 113.342 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -146.38 164.94 30.84 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 -177.134 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.4 pt20 -145.45 170.0 17.24 Favored 'General case' 0 C--N 1.275 -2.653 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 176.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.5 124.18 31.78 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 179.267 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.73 128.42 55.27 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 106.212 -1.773 . . . . 0.0 106.212 178.046 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 110.81 167.94 19.13 Favored Glycine 0 C--N 1.292 -1.886 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.605 -177.6 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -87.15 -26.57 23.53 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-O 121.816 0.817 . . . . 0.0 109.855 -175.443 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.9 mm -91.17 129.7 41.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.989 -1.005 . . . . 0.0 108.526 179.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 24.2 p-10 -130.81 9.62 4.98 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 120.845 0.355 . . . . 0.0 110.46 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.405 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 36.3 p90 -150.7 164.25 36.58 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.703 -173.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.454 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 45.3 mtp180 -123.66 134.47 53.74 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 173.313 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -110.13 134.03 52.6 Favored 'General case' 0 C--N 1.29 -1.987 0 C-N-CA 119.524 -0.87 . . . . 0.0 108.72 179.549 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.6 t -85.98 109.06 18.51 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.076 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -102.78 -169.36 1.65 Allowed 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 177.422 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 15.0 t -66.19 -15.39 63.11 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 123.119 0.567 . . . . 0.0 112.074 -175.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -99.09 -7.0 27.37 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-O 121.446 0.641 . . . . 0.0 109.979 177.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 114.25 -163.12 12.2 Favored Glycine 0 N--CA 1.439 -1.133 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 90.9 m95 -62.67 109.0 1.27 Allowed 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 116.681 0.24 . . . . 0.0 110.842 177.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 30.6 p -59.11 -73.56 0.08 Allowed 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 125.265 1.426 . . . . 0.0 113.076 -176.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -73.57 177.88 5.06 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.857 -177.498 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -100.97 175.6 5.55 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.951 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 87.1 mt -70.16 125.4 91.97 Favored Pre-proline 0 C--N 1.309 -1.165 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.76 172.1 8.75 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 122.716 2.277 . . . . 0.0 112.73 179.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 46.2 mm -101.77 124.94 55.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-O 121.231 0.539 . . . . 0.0 111.562 -173.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 94.7 m -97.71 99.29 10.64 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 174.335 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -92.19 146.08 24.0 Favored 'General case' 0 N--CA 1.416 -2.13 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.68 130.3 35.21 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.48 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 12.1 m -59.22 141.01 16.68 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 CA-C-O 121.138 0.494 . . . . 0.0 112.001 -176.575 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 83.4 mttt -121.12 136.94 54.88 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.081 -175.013 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 89.1 m -103.67 152.25 22.01 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 172.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 1.8 pp -60.39 154.05 56.09 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-O 120.868 0.366 . . . . 0.0 110.867 -177.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -78.12 102.95 1.62 Allowed 'Trans proline' 0 N--CA 1.441 -1.578 0 C-N-CA 122.504 2.136 . . . . 0.0 112.506 -176.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 7.7 p -73.36 134.28 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.301 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.534 177.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.1 p -75.62 -75.31 0.18 Allowed 'General case' 0 N--CA 1.439 -0.988 0 CA-C-N 116.162 -0.472 . . . . 0.0 112.217 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 171.81 159.96 0.24 Allowed Pre-proline 0 C--O 1.239 0.51 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 -177.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . 0.44 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 56.5 Cg_endo -75.57 161.06 37.64 Favored 'Trans proline' 0 N--CA 1.443 -1.459 0 C-N-CA 121.263 1.309 . . . . 0.0 109.55 171.791 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -57.89 -41.5 82.69 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 114.414 1.265 . . . . 0.0 114.414 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 56.0 m-80 -113.33 23.47 13.21 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.581 0.705 . . . . 0.0 110.041 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -139.48 -163.3 9.46 Favored Glycine 0 N--CA 1.433 -1.536 0 C-N-CA 119.93 -1.129 . . . . 0.0 112.017 -178.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -160.62 177.18 10.75 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.416 HG12 ' CE1' ' A' ' 176' ' ' PHE . 38.4 mt -95.47 140.42 17.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 123.278 0.361 . . . . 0.0 111.806 -175.545 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.447 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.8 m -92.13 -36.1 7.48 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 175.617 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.4 m -89.71 66.42 7.12 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 115.66 -0.7 . . . . 0.0 109.832 -177.055 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 45.6 m -82.99 89.87 6.94 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.305 1.05 . . . . 0.0 110.636 -177.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . 0.462 ' HA ' ' HG2' ' A' ' 164' ' ' PRO . . . -108.88 27.73 9.18 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.647 -177.652 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' MET . . . . . 0.504 ' CE ' ' HA ' ' A' ' 162' ' ' MET . 0.0 OUTLIER -67.01 -2.08 4.93 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 123.784 0.833 . . . . 0.0 112.968 -173.179 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -140.54 -50.24 0.02 OUTLIER Pre-proline 0 C--N 1.305 -1.357 0 C-N-CA 124.02 0.928 . . . . 0.0 113.095 178.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . 0.462 ' HG2' ' HA ' ' A' ' 161' ' ' ALA . 10.3 Cg_endo -55.74 -25.84 53.45 Favored 'Trans proline' 0 C--N 1.375 1.932 0 CA-C-N 121.011 1.397 . . . . 0.0 112.144 174.137 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . 0.451 ' C ' ' H ' ' A' ' 167' ' ' GLU . 25.5 t0 -124.54 -9.22 7.41 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 176.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.456 ' O ' ' HE1' ' A' ' 162' ' ' MET . 51.3 mtt180 65.3 -45.67 0.36 Allowed 'General case' 0 C--N 1.363 1.162 0 C-N-CA 126.602 1.961 . . . . 0.0 115.965 179.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . 0.451 ' H ' ' C ' ' A' ' 165' ' ' ASP . 42.5 mt-10 -121.65 -167.16 1.48 Allowed 'General case' 1 C--N 1.22 -5.063 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 -179.002 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -113.39 102.02 9.93 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 172.209 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -96.2 167.62 11.09 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.48 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . 0.48 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 91.0 t80 -50.04 133.62 22.65 Favored 'General case' 0 N--CA 1.468 0.466 0 O-C-N 123.622 0.576 . . . . 0.0 111.019 178.184 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 111.69 -32.71 6.21 Favored Glycine 0 N--CA 1.427 -1.932 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -69.66 114.9 8.3 Favored 'General case' 0 N--CA 1.416 -2.173 0 CA-C-O 122.287 1.041 . . . . 0.0 112.303 178.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -101.95 103.44 14.08 Favored 'General case' 0 N--CA 1.416 -2.128 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 174.35 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.491 HG12 ' HG3' ' A' ' 190' ' ' MET . 6.8 p -86.04 108.34 17.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.274 0 CA-C-O 121.579 0.704 . . . . 0.0 110.263 -175.227 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.447 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 43.2 ttp180 -100.12 147.29 25.83 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.476 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.44 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 74.2 m-85 -111.93 167.8 10.09 Favored 'General case' 0 C--N 1.293 -1.857 0 CA-C-O 121.784 0.802 . . . . 0.0 111.408 -177.333 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -136.99 151.65 27.52 Favored 'Isoleucine or valine' 0 CA--C 1.455 -2.678 0 CA-C-N 114.152 -1.385 . . . . 0.0 108.766 177.265 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.8 m -112.41 122.36 47.49 Favored 'General case' 0 N--CA 1.392 -3.348 0 O-C-N 124.474 1.109 . . . . 0.0 108.068 177.618 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 48.3 m-80 -53.92 168.73 0.19 Allowed 'General case' 0 C--N 1.307 -1.263 0 O-C-N 124.761 1.288 . . . . 0.0 112.301 -179.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 16.8 m -49.86 104.66 0.07 Allowed 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 125.273 1.429 . . . . 0.0 112.259 -175.673 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.01 3.16 31.75 Favored Glycine 0 N--CA 1.435 -1.409 0 C-N-CA 120.837 -0.697 . . . . 0.0 113.261 178.438 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -124.67 158.58 32.82 Favored 'General case' 0 CA--C 1.484 -1.564 0 CA-C-N 117.341 0.57 . . . . 0.0 110.725 178.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . 0.493 ' HG2' ' OXT' ' A' ' 206' ' ' VAL . 25.2 pttm -133.39 162.23 32.4 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 106.757 -1.571 . . . . 0.0 106.757 179.239 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.4 tp -76.4 149.16 6.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -81.35 -59.12 2.74 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.987 179.584 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -115.96 -110.32 2.7 Favored Glycine 0 C--N 1.304 -1.205 0 C-N-CA 120.464 -0.874 . . . . 0.0 111.965 179.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . 0.436 ' CG ' ' HD3' ' A' ' 200' ' ' LYS . 1.5 p-10 -77.36 150.02 35.18 Favored 'General case' 0 C--O 1.193 -1.873 0 C-N-CA 124.161 0.984 . . . . 0.0 108.939 177.444 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -107.21 5.68 27.94 Favored 'General case' 0 C--N 1.296 -1.751 0 C-N-CA 121.009 -0.276 . . . . 0.0 110.871 -178.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -152.1 152.22 32.07 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 113.57 0.952 . . . . 0.0 113.57 -172.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.491 ' HG3' HG12 ' A' ' 174' ' ' VAL . 0.0 OUTLIER -128.57 137.46 51.73 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.876 -1.056 . . . . 0.0 108.306 177.454 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 40.3 t-80 -105.49 130.02 53.65 Favored 'General case' 0 C--N 1.291 -1.953 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.124 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 51.3 t -70.74 113.93 8.31 Favored 'General case' 0 C--O 1.243 0.734 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 175.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 25.1 m -85.85 163.49 18.08 Favored 'General case' 0 N--CA 1.437 -1.086 0 C-N-CA 123.217 0.607 . . . . 0.0 111.689 -176.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -67.57 -10.87 55.91 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 -173.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 19.4 m-20 -91.79 -0.99 57.56 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.402 0.62 . . . . 0.0 110.109 177.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 81.38 42.28 9.41 Favored Glycine 0 N--CA 1.436 -1.362 0 C-N-CA 120.993 -0.622 . . . . 0.0 113.282 179.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 45.5 p90 -149.65 166.71 28.5 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 175.249 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.5 m95 -83.82 125.86 32.38 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 123.146 0.279 . . . . 0.0 110.484 -178.712 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 35.9 t -57.62 -38.98 75.88 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.597 177.068 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . 0.436 ' HD3' ' CG ' ' A' ' 187' ' ' ASP . 1.8 mmpt? -101.91 178.6 4.57 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 115.718 -0.673 . . . . 0.0 111.039 177.5 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -113.69 178.78 4.16 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 179.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 51.5 mtpt -79.2 114.51 45.38 Favored Pre-proline 0 C--N 1.295 -1.802 0 C-N-CA 120.771 -0.372 . . . . 0.0 111.593 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.49 -171.73 1.19 Allowed 'Trans proline' 0 N--CA 1.437 -1.812 0 C-N-CA 122.001 1.801 . . . . 0.0 110.898 176.354 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 34.0 ttpt -141.66 153.48 44.74 Favored 'General case' 0 N--CA 1.405 -2.722 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.738 -175.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.425 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 81.1 m -104.81 121.54 43.86 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 174.648 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . 0.493 ' OXT' ' HG2' ' A' ' 183' ' ' LYS . 25.0 m . . . . . 0 C--N 1.305 -1.365 0 O-C-N 124.191 0.932 . . . . 0.0 110.101 -175.387 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo . . . . . 0 CA--C 1.54 0.812 0 CA-C-O 121.423 0.51 . . . . 0.0 111.764 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 39.3 m -82.27 -36.23 27.28 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 122.264 1.031 . . . . 0.0 108.235 177.224 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.48 -92.62 0.48 Allowed Glycine 0 N--CA 1.406 -3.327 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 174.375 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.8 t60 -177.42 129.55 0.32 Allowed Pre-proline 0 C--N 1.261 -3.248 0 N-CA-C 103.991 -2.596 . . . . 0.0 103.991 -176.255 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.441 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 90.5 Cg_endo -80.24 2.55 8.38 Favored 'Trans proline' 0 C--N 1.327 -0.582 0 C-N-CA 122.446 2.098 . . . . 0.0 113.387 -173.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.48 -178.49 41.39 Favored Glycine 0 N--CA 1.422 -2.287 0 N-CA-C 109.037 -1.625 . . . . 0.0 109.037 -175.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -139.83 159.68 41.61 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 117.477 0.639 . . . . 0.0 110.177 -177.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.7 t -108.52 139.6 20.97 Favored Pre-proline 0 C--N 1.299 -1.59 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.632 -178.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -82.41 -14.32 9.37 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.546 2.164 . . . . 0.0 111.155 178.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -86.79 -1.22 57.59 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.642 -175.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 172.17 -131.89 2.26 Favored Glycine 0 N--CA 1.408 -3.226 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 -178.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 35.8 p -145.62 -175.62 4.8 Favored 'General case' 0 C--N 1.289 -2.036 0 O-C-N 123.864 0.391 . . . . 0.0 110.012 -177.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -138.21 166.56 23.87 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 173.223 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -134.79 161.46 35.12 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.47 HD12 ' CE1' ' A' ' 104' ' ' PHE . 13.2 mt -119.14 124.16 46.16 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 -178.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.431 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 29.5 p -108.98 144.2 37.27 Favored 'General case' 0 C--N 1.284 -2.242 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -177.727 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 102.64 -70.36 0.32 Allowed Glycine 0 N--CA 1.432 -1.598 0 C-N-CA 120.01 -1.09 . . . . 0.0 110.671 -178.19 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -110.47 -18.61 8.44 Favored Glycine 0 C--N 1.307 -1.08 0 C-N-CA 120.283 -0.96 . . . . 0.0 112.187 -178.313 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . 0.408 ' HA ' ' HB2' ' A' ' 98' ' ' LEU . 42.3 m-80 64.04 22.62 12.99 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 123.336 0.655 . . . . 0.0 111.163 -178.563 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.496 ' O ' HG21 ' A' ' 108' ' ' VAL . 18.4 m -151.1 -171.75 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.198 -1.623 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -178.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.47 ' CE1' HD12 ' A' ' 98' ' ' LEU . 22.1 m-85 -101.9 43.99 1.04 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 119.095 0.862 . . . . 0.0 110.568 -177.025 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.721 ' O ' HG13 ' A' ' 108' ' ' VAL . 11.7 pt-20 -84.11 -179.66 7.28 Favored 'General case' 0 C--O 1.206 -1.222 0 CA-C-N 114.476 -1.238 . . . . 0.0 111.663 178.357 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 40.2 m-85 -76.7 135.55 39.08 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 122.029 -0.419 . . . . 0.0 110.881 176.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.62 9.3 75.42 Favored Glycine 0 N--CA 1.44 -1.057 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.704 178.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.721 HG13 ' O ' ' A' ' 105' ' ' GLU . 11.9 p -95.6 148.8 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.484 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.431 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.7 mtpt -115.17 121.96 44.59 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.458 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.454 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -88.01 93.82 9.6 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.265 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 91.5 t -90.53 114.43 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.93 0 C-N-CA 124.414 1.086 . . . . 0.0 108.431 -177.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -84.76 139.44 31.96 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.511 -177.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.9 t -136.16 112.24 9.68 Favored 'General case' 0 N--CA 1.423 -1.796 0 CA-C-O 122.156 0.979 . . . . 0.0 109.943 -179.152 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 84.8 m -69.43 156.21 39.21 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.47 -0.786 . . . . 0.0 111.998 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 -67.7 172.93 4.69 Favored 'General case' 0 C--O 1.218 -0.573 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.069 176.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -53.33 -47.8 69.03 Favored 'General case' 0 C--N 1.313 -1.007 0 C-N-CA 124.022 0.929 . . . . 0.0 113.115 -174.132 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -85.02 15.35 44.17 Favored Glycine 0 C--N 1.307 -1.039 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.784 -179.569 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -130.34 162.27 29.43 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.77 145.34 31.62 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 -179.701 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.5 tt -79.94 140.91 36.47 Favored 'General case' 0 C--N 1.279 -2.471 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.263 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.97 133.07 56.33 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -173.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 103.73 -169.41 18.08 Favored Glycine 0 C--N 1.306 -1.121 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.46 179.283 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -94.19 -47.45 6.64 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -178.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.0 mm -69.05 122.95 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 CA-C-N 114.464 -1.244 . . . . 0.0 109.626 -176.331 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -128.53 6.24 5.69 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.397 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.454 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 25.0 p90 -150.56 162.39 40.72 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 120.433 -0.507 . . . . 0.0 110.23 -173.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.441 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 39.9 mtp180 -121.78 132.97 54.89 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 106.226 -1.768 . . . . 0.0 106.226 173.235 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -108.7 128.9 55.27 Favored 'General case' 0 C--N 1.289 -2.035 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.7 t -85.35 107.33 17.3 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.087 -1.045 . . . . 0.0 109.642 177.116 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.441 ' CG ' ' H ' ' A' ' 131' ' ' THR . 34.1 t0 -103.86 -170.6 1.8 Allowed 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 178.27 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.441 ' H ' ' CG ' ' A' ' 130' ' ' ASP . 11.1 t -54.81 -29.49 54.71 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 124.56 1.144 . . . . 0.0 113.204 -177.033 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -81.82 -30.16 32.31 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 121.4 0.619 . . . . 0.0 110.382 176.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 132.86 -151.78 20.11 Favored Glycine 0 N--CA 1.42 -2.409 0 N-CA-C 108.744 -1.743 . . . . 0.0 108.744 -174.364 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 92.3 m95 -65.46 113.16 3.94 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 117.386 0.593 . . . . 0.0 109.778 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 22.3 p -64.65 -70.88 0.2 Allowed 'General case' 0 C--O 1.247 0.922 0 CA-C-O 121.6 0.714 . . . . 0.0 111.738 -178.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 -71.82 173.87 7.67 Favored 'General case' 0 CA--C 1.484 -1.559 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.959 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -110.01 -174.62 2.53 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -177.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.2 mt -66.58 118.56 55.25 Favored Pre-proline 0 C--O 1.244 0.814 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.405 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.61 155.93 63.96 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.788 2.325 . . . . 0.0 111.706 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 67.5 mt -84.81 136.15 23.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.032 -177.657 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 43.7 t -126.06 138.75 53.73 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 176.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.56 157.32 40.49 Favored 'General case' 0 N--CA 1.414 -2.243 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -178.498 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 11.5 p -75.09 136.34 25.3 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.88 178.365 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.96 130.53 25.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 C-N-CA 123.303 0.641 . . . . 0.0 109.303 178.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.536 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 44.0 mttp -131.46 159.11 39.02 Favored 'General case' 0 CA--C 1.499 -1.007 0 CA-C-O 121.564 0.697 . . . . 0.0 112.64 -177.429 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 39.5 m -123.28 149.53 44.68 Favored 'General case' 0 N--CA 1.42 -1.974 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 176.312 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 80.5 mt -65.38 148.76 97.81 Favored Pre-proline 0 C--N 1.309 -1.154 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -61.6 122.34 10.89 Favored 'Trans proline' 0 N--CA 1.459 -0.524 0 C-N-CA 123.199 2.599 . . . . 0.0 110.479 178.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.554 HG12 ' O ' ' A' ' 150' ' ' THR . 21.0 t -83.73 145.78 7.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -175.705 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' THR . . . . . 0.554 ' O ' HG12 ' A' ' 149' ' ' VAL . 15.6 p -88.13 -164.93 1.19 Allowed 'General case' 0 N--CA 1.411 -2.425 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 171.53 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . 0.421 ' HB2' ' HA ' ' A' ' 156' ' ' LYS . . . -113.09 156.37 42.97 Favored Pre-proline 0 C--N 1.266 -3.057 0 O-C-N 121.511 -0.743 . . . . 0.0 110.392 -172.494 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 28.9 Cg_endo -65.26 158.51 51.95 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 122.252 1.968 . . . . 0.0 110.276 173.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -53.78 -36.43 62.4 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 114.463 1.282 . . . . 0.0 114.463 -174.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 48.4 m-80 -127.7 36.1 4.4 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.789 0.804 . . . . 0.0 109.043 -179.493 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . 0.441 ' HA3' ' O ' ' A' ' 177' ' ' VAL . . . -152.7 -160.76 9.82 Favored Glycine 0 N--CA 1.429 -1.802 0 C-N-CA 119.628 -1.272 . . . . 0.0 113.231 178.103 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . 0.421 ' HA ' ' HB2' ' A' ' 151' ' ' ALA . 20.2 pttm -159.12 176.61 12.04 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 123.936 0.894 . . . . 0.0 109.863 -177.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 59.8 mt -94.52 142.1 13.96 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 122.24 0.216 . . . . 0.0 110.705 -178.656 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.527 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 12.2 m -99.83 -23.57 4.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 CA-C-O 121.722 0.772 . . . . 0.0 110.479 179.055 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' SER . . . . . 0.412 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 33.4 m -108.18 133.61 52.2 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 114.742 1.386 . . . . 0.0 114.742 -168.496 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' SER . . . . . 0.642 ' HA ' ' SD ' ' A' ' 162' ' ' MET . 58.2 m 55.13 34.79 23.36 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.953 1.464 . . . . 0.0 114.953 166.64 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -106.38 22.5 15.67 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.605 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' MET . . . . . 0.642 ' SD ' ' HA ' ' A' ' 160' ' ' SER . 3.7 mpp? -57.94 -43.68 86.51 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.503 -178.484 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 24.0 mm-40 -123.55 145.61 47.55 Favored Pre-proline 0 C--N 1.311 -1.084 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 -177.334 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -82.67 -12.33 10.01 Favored 'Trans proline' 0 CA--C 1.547 1.154 0 C-N-CA 122.423 2.082 . . . . 0.0 113.188 -179.147 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -104.08 -10.29 18.12 Favored 'General case' 0 CA--C 1.487 -1.446 0 CA-C-O 121.138 0.494 . . . . 0.0 110.939 -174.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -84.52 124.87 31.86 Favored 'General case' 0 N--CA 1.419 -1.993 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -79.07 -173.98 3.85 Favored 'General case' 0 C--N 1.283 -2.308 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.306 179.229 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -120.47 107.25 12.66 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.536 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 21.4 p-80 -96.5 171.1 8.77 Favored 'General case' 0 C--N 1.291 -1.968 0 C-N-CA 120.137 -0.625 . . . . 0.0 111.082 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -51.51 125.6 15.02 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 123.872 0.733 . . . . 0.0 110.948 179.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.48 -10.23 21.89 Favored Glycine 0 N--CA 1.424 -2.111 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -177.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.2 mm-40 -85.26 136.96 33.28 Favored 'General case' 0 N--CA 1.438 -1.072 0 CA-C-O 121.537 0.684 . . . . 0.0 112.041 -179.636 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -115.11 120.38 39.59 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 176.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.45 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 83.3 t -108.1 110.98 33.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.598 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 72.7 ttt180 -106.37 147.72 28.91 Favored 'General case' 0 N--CA 1.425 -1.696 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -119.41 165.97 13.66 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.025 0.441 . . . . 0.0 111.134 -175.142 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.441 ' O ' ' HA3' ' A' ' 155' ' ' GLY . 0.0 OUTLIER -130.28 156.65 42.52 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.715 0 CA-C-N 115.069 -0.969 . . . . 0.0 109.745 175.21 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.7 m -111.81 142.98 43.5 Favored 'General case' 0 C--N 1.278 -2.531 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 171.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -44.74 -80.68 0.01 OUTLIER 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 114.331 1.234 . . . . 0.0 114.331 -177.173 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 64.6 m -149.24 -42.05 0.14 Allowed 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 114.018 1.118 . . . . 0.0 114.018 -178.364 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -102.29 2.22 50.53 Favored Glycine 0 C--N 1.291 -1.928 0 C-N-CA 120.152 -1.023 . . . . 0.0 114.742 -174.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -110.35 175.73 5.32 Favored 'General case' 0 CA--C 1.487 -1.445 0 CA-C-N 117.643 0.721 . . . . 0.0 111.122 -176.33 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 37.6 pttt -136.63 152.56 50.57 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 173.427 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 6.9 tt -70.97 143.2 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.473 0 CA-C-O 121.821 0.82 . . . . 0.0 112.71 -176.706 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -39.78 -59.63 1.13 Allowed 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 127.862 2.465 . . . . 0.0 113.061 179.046 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -145.24 -89.58 0.1 OUTLIER Glycine 0 CA--C 1.48 -2.122 0 C-N-CA 120.107 -1.044 . . . . 0.0 111.293 -177.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . 0.415 ' HB3' ' HG3' ' A' ' 200' ' ' LYS . 6.9 t0 -95.03 158.42 15.47 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.349 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . 0.598 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 13.4 pt-20 -111.28 -9.48 14.29 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 121.084 -0.246 . . . . 0.0 110.772 -177.443 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . 0.45 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.9 pt-20 -131.49 124.67 30.62 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-O 121.816 0.817 . . . . 0.0 112.869 -178.096 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 17.4 ptp -109.65 151.01 27.41 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.811 178.412 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 63.4 m80 -127.37 156.73 41.57 Favored 'General case' 0 CA--C 1.498 -1.043 0 C-N-CA 122.403 0.281 . . . . 0.0 110.66 -178.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 5.1 m -81.75 117.14 21.82 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.066 176.287 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 37.2 m -82.1 152.54 26.5 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.398 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -72.1 78.51 0.94 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 122.852 1.31 . . . . 0.0 112.257 -176.532 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -175.36 -47.16 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.627 0 CA-C-N 112.986 -1.915 . . . . 0.0 106.186 -179.175 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 121.28 66.34 0.25 Allowed Glycine 0 N--CA 1.427 -1.901 0 CA-C-N 114.547 -1.206 . . . . 0.0 112.21 -178.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -167.29 161.94 14.59 Favored 'General case' 0 C--O 1.248 0.979 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 176.58 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.9 m95 -85.15 139.46 31.68 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 124.005 0.816 . . . . 0.0 110.846 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.7 p -71.51 -18.64 62.27 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.252 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . 0.582 ' HE3' ' O ' ' A' ' 201' ' ' GLU . 0.0 OUTLIER -123.94 153.49 41.13 Favored 'General case' 0 N--CA 1.426 -1.626 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 -179.879 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.582 ' O ' ' HE3' ' A' ' 200' ' ' LYS . 3.2 mp0 -77.55 168.4 20.05 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 106.532 -1.655 . . . . 0.0 106.532 177.261 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -68.89 114.91 26.14 Favored Pre-proline 0 C--N 1.311 -1.084 0 C-N-CA 119.915 -0.714 . . . . 0.0 109.722 176.566 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_endo -82.79 166.94 14.93 Favored 'Trans proline' 0 N--CA 1.431 -2.173 0 C-N-CA 121.95 1.766 . . . . 0.0 111.645 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 9.8 ptpp? -131.08 179.06 6.22 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.16 -177.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 87.6 m -115.32 114.18 24.81 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 178.497 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.9 m . . . . . 0 C--N 1.302 -1.471 0 CA-C-N 114.796 -1.093 . . . . 0.0 109.692 -174.096 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.415 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 39.9 Cg_endo . . . . . 0 CA--C 1.538 0.711 0 CA-C-O 122.19 0.829 . . . . 0.0 110.772 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.9 m -92.41 -33.09 14.69 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.696 -1.138 . . . . 0.0 108.295 175.661 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.04 -91.79 0.58 Allowed Glycine 0 N--CA 1.402 -3.618 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 174.317 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.5 t-80 -174.7 132.61 0.49 Allowed Pre-proline 0 C--N 1.268 -2.973 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 -176.058 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -81.97 5.75 6.12 Favored 'Trans proline' 0 N--CA 1.475 0.439 0 C-N-CA 122.363 2.042 . . . . 0.0 113.405 -172.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 113.58 -173.77 15.25 Favored Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -177.44 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -151.68 160.51 43.59 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 178.22 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.5 t -140.05 144.59 38.64 Favored Pre-proline 0 C--N 1.294 -1.809 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.723 -174.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -83.09 -16.77 7.13 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 122.692 2.261 . . . . 0.0 110.611 174.12 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 40.4 m-85 -87.53 2.37 50.91 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.772 -175.018 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.511 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 164.4 -127.1 1.6 Allowed Glycine 0 N--CA 1.415 -2.726 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.756 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.2 t -161.08 -161.97 0.87 Allowed 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -178.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -155.02 159.43 40.31 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 177.45 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 16.2 m -121.34 163.35 18.78 Favored 'General case' 0 C--N 1.278 -2.527 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.449 HD12 ' CE1' ' A' ' 104' ' ' PHE . 20.6 mt -121.64 129.24 52.66 Favored 'General case' 0 C--N 1.284 -2.259 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -178.377 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.2 p -124.79 130.22 51.97 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.879 -176.071 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.33 20.97 28.4 Favored Glycine 0 C--N 1.303 -1.278 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.373 -178.63 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.94 -31.74 0.14 Allowed Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 119.907 -1.139 . . . . 0.0 113.128 177.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 6.7 m120 67.8 10.27 7.67 Favored 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 123.267 0.627 . . . . 0.0 112.461 -177.1 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.527 ' O ' HG12 ' A' ' 108' ' ' VAL . 27.3 m -143.34 -171.67 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.501 -0.909 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 -176.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.449 ' CE1' HD12 ' A' ' 98' ' ' LEU . 23.4 m-85 -104.71 46.36 0.92 Allowed 'General case' 0 C--N 1.311 -1.083 0 CA-C-O 121.092 0.473 . . . . 0.0 110.162 -177.509 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.762 ' O ' HG11 ' A' ' 108' ' ' VAL . 14.9 pt-20 -87.88 175.74 7.67 Favored 'General case' 0 C--O 1.212 -0.884 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.408 178.016 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . 0.415 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 42.4 m-85 -74.69 131.57 40.98 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-O 121.088 0.47 . . . . 0.0 111.441 178.661 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 96.72 -1.13 61.42 Favored Glycine 0 N--CA 1.437 -1.239 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.112 178.413 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.762 HG11 ' O ' ' A' ' 105' ' ' GLU . 14.7 p -90.29 146.57 6.03 Favored 'Isoleucine or valine' 0 C--O 1.243 0.749 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.3 mtpt -109.5 122.97 48.59 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.543 178.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.506 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.46 93.17 9.07 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 176.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 75.7 t -86.46 108.03 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.745 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . 0.51 ' CG ' ' HG2' ' A' ' 139' ' ' PRO . 66.4 t80 -78.3 140.55 38.82 Favored 'General case' 0 C--N 1.268 -2.942 0 CA-C-N 114.121 -1.4 . . . . 0.0 109.952 -174.59 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -143.48 132.38 22.78 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-O 121.9 0.857 . . . . 0.0 109.858 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 57.0 m -85.69 159.64 19.75 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.817 -176.198 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.511 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 54.9 m-20 -65.85 176.97 1.41 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.726 178.523 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -56.12 -49.3 74.27 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 123.522 0.729 . . . . 0.0 112.396 -175.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.21 33.34 4.09 Favored Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.256 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.401 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 84.5 m-85 -146.56 158.21 43.86 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 124.224 1.01 . . . . 0.0 109.043 -178.33 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -136.1 169.75 17.12 Favored 'General case' 0 C--N 1.279 -2.457 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 177.129 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 10.5 tp -86.97 153.72 21.35 Favored 'General case' 0 C--N 1.287 -2.121 0 C-N-CA 119.259 -0.977 . . . . 0.0 108.397 178.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.05 125.31 31.11 Favored 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 176.218 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.68 175.8 20.04 Favored Glycine 0 C--N 1.292 -1.876 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -176.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -94.73 -28.9 15.06 Favored 'General case' 0 CA--C 1.5 -0.943 0 CA-C-O 121.26 0.553 . . . . 0.0 111.0 -177.327 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.559 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 48.8 mm -81.1 129.78 36.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.178 -178.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -133.21 9.15 4.06 Favored 'General case' 0 C--O 1.213 -0.851 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 178.158 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.506 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 22.6 p90 -147.54 158.75 44.13 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.19 0.519 . . . . 0.0 110.425 -176.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 59.7 mtp180 -125.12 132.11 53.16 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 172.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -107.3 130.82 54.72 Favored 'General case' 0 C--N 1.275 -2.65 0 C-N-CA 119.408 -0.917 . . . . 0.0 109.715 -177.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 35.8 t -82.52 101.57 10.81 Favored 'General case' 0 N--CA 1.428 -1.536 0 C-N-CA 118.098 -1.441 . . . . 0.0 110.454 177.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.409 ' OD1' HG21 ' A' ' 131' ' ' THR . 6.4 t70 -98.79 -169.56 1.8 Allowed 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 105.496 -2.038 . . . . 0.0 105.496 175.505 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.409 HG21 ' OD1' ' A' ' 130' ' ' ASP . 13.2 t -65.33 -24.36 67.24 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 118.362 0.528 . . . . 0.0 110.965 -176.869 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -70.51 -24.18 62.78 Favored 'General case' 0 C--O 1.249 1.03 0 CA-C-O 122.105 0.955 . . . . 0.0 110.558 175.243 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.62 -148.11 18.91 Favored Glycine 0 N--CA 1.411 -2.985 0 N-CA-C 107.577 -2.209 . . . . 0.0 107.577 -172.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 97.4 m95 -71.12 112.78 7.54 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 117.235 0.518 . . . . 0.0 110.822 177.722 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 65.0 p -70.5 168.12 16.9 Favored 'General case' 0 C--O 1.269 2.116 0 N-CA-C 109.001 -0.741 . . . . 0.0 109.001 176.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 63.44 -163.1 0.27 Allowed 'General case' 0 C--O 1.242 0.674 0 O-C-N 124.07 0.856 . . . . 0.0 108.992 177.163 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -126.31 178.73 5.65 Favored 'General case' 0 C--N 1.279 -2.478 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 173.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 57.0 mt -67.2 119.77 67.21 Favored Pre-proline 0 C--N 1.298 -1.638 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 175.264 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . 0.559 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 1.5 Cg_endo -58.18 165.09 7.6 Favored 'Trans proline' 0 C--O 1.24 0.606 0 C-N-CA 122.451 2.101 . . . . 0.0 111.834 177.762 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 61.8 mt -102.18 135.8 37.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.236 -172.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.432 ' SG ' ' CE2' ' A' ' 112' ' ' TYR . 90.2 m -103.28 148.47 25.79 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 171.699 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -128.5 151.76 49.05 Favored 'General case' 0 C--N 1.266 -3.052 0 N-CA-C 105.261 -2.125 . . . . 0.0 105.261 174.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.542 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 7.3 p -71.45 147.35 10.97 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.607 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.131 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.541 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 11.6 m -67.18 121.92 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.911 0 C-N-CA 118.478 -1.289 . . . . 0.0 109.243 176.132 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.542 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 52.3 mtmt -115.97 142.91 46.17 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.307 -0.861 . . . . 0.0 111.312 -172.208 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 19.0 m -110.35 142.82 41.48 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 178.079 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.1 mm? -60.95 144.42 90.51 Favored Pre-proline 0 N--CA 1.426 -1.661 0 N-CA-C 113.653 0.983 . . . . 0.0 113.653 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 31.4 Cg_exo -57.61 142.47 95.66 Favored 'Trans proline' 0 C--O 1.246 0.878 0 C-N-CA 123.493 2.796 . . . . 0.0 111.857 177.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.2 t -110.67 149.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 16.9 p -80.72 -83.57 0.11 Allowed 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 122.131 0.172 . . . . 0.0 111.093 178.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.35 153.51 0.23 Allowed Pre-proline 0 C--O 1.237 0.44 0 C-N-CA 125.883 1.673 . . . . 0.0 106.729 179.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.14 160.94 46.04 Favored 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 121.548 1.498 . . . . 0.0 111.574 175.118 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . 0.412 ' HG3' ' ND2' ' A' ' 154' ' ' ASN . 11.0 pt-20 -65.4 -32.68 74.44 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 114.582 1.326 . . . . 0.0 114.582 -173.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . 0.412 ' ND2' ' HG3' ' A' ' 153' ' ' GLU . 58.5 m-80 -126.26 32.79 5.14 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 121.777 0.799 . . . . 0.0 108.901 -179.226 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -156.59 -168.09 18.81 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.413 178.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 24.0 pttm -150.02 171.66 16.49 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 117.178 0.489 . . . . 0.0 109.705 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 53.5 mt -94.92 129.22 45.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.493 HG22 ' O ' ' A' ' 175' ' ' ARG . 10.5 m -82.09 -24.71 9.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-O 121.369 0.604 . . . . 0.0 110.569 -177.328 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 6.5 m -82.83 -6.83 59.62 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.409 -177.466 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 15.5 p 55.07 160.93 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 126.378 1.871 . . . . 0.0 115.119 -178.239 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -87.29 117.67 26.2 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 176.471 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 65.8 mtm -65.29 -76.57 0.07 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.328 0.585 . . . . 0.0 110.197 -177.006 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -144.14 150.12 47.71 Favored Pre-proline 0 C--N 1.298 -1.654 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 178.665 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -63.86 -18.5 64.17 Favored 'Trans proline' 0 CA--C 1.547 1.141 0 C-N-CA 122.794 2.329 . . . . 0.0 113.684 -179.53 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -96.01 -25.14 16.04 Favored 'General case' 0 CA--C 1.501 -0.939 0 CA-C-O 121.085 0.469 . . . . 0.0 110.152 179.342 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 5.0 mmp_? -84.16 113.35 21.01 Favored 'General case' 0 N--CA 1.421 -1.921 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.698 -176.384 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -82.23 168.81 17.26 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.149 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -88.13 140.32 29.61 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 177.183 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.484 ' CD2' ' HG2' ' A' ' 145' ' ' LYS . 39.0 m170 -119.26 157.55 27.82 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 119.325 -0.369 . . . . 0.0 110.407 -172.143 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . 0.541 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 85.7 t80 -35.15 127.75 0.54 Allowed 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 176.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 103.41 -30.31 10.58 Favored Glycine 0 N--CA 1.427 -1.943 0 CA-C-N 114.783 -1.099 . . . . 0.0 112.82 177.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -72.3 145.28 47.95 Favored 'General case' 0 N--CA 1.402 -2.827 0 CA-C-N 117.266 0.533 . . . . 0.0 110.248 -177.635 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -122.39 122.54 39.25 Favored 'General case' 0 N--CA 1.414 -2.241 0 CA-C-N 115.205 -0.907 . . . . 0.0 108.835 178.506 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 54.9 t -93.71 105.01 16.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.254 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 174.705 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.493 ' O ' HG22 ' A' ' 158' ' ' VAL . 19.3 ttp180 -103.37 146.64 28.18 Favored 'General case' 0 N--CA 1.402 -2.847 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -178.498 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -117.13 166.76 11.85 Favored 'General case' 0 C--N 1.279 -2.485 0 CA-C-O 121.102 0.477 . . . . 0.0 109.945 -174.182 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.0 p -145.43 139.8 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.21 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 174.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . 0.402 ' SG ' ' HB ' ' A' ' 184' ' ' ILE . 77.5 m -101.72 157.2 17.01 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -65.71 163.4 16.59 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 177.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 15.3 t -46.83 -33.45 4.48 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -169.453 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -108.52 18.04 32.97 Favored Glycine 0 C--N 1.289 -2.04 0 C-N-CA 120.427 -0.892 . . . . 0.0 114.203 -177.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -119.29 158.86 25.21 Favored 'General case' 0 CA--C 1.486 -1.519 0 CA-C-N 118.28 1.04 . . . . 0.0 110.795 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . 0.447 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 14.8 pttm -120.14 150.97 39.76 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.316 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.402 ' HB ' ' SG ' ' A' ' 178' ' ' CYS . 8.3 tt -84.32 136.31 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.313 0 C-N-CA 119.279 -0.969 . . . . 0.0 108.902 174.485 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -86.65 -45.65 10.81 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.967 -1.015 . . . . 0.0 109.226 -174.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -78.46 -157.57 10.59 Favored Glycine 0 C--N 1.302 -1.33 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 173.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -82.04 169.34 16.82 Favored 'General case' 0 C--N 1.314 -0.977 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.132 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -81.44 -13.57 58.07 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-N 118.778 0.717 . . . . 0.0 110.865 -173.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -147.47 170.77 16.7 Favored 'General case' 0 N--CA 1.423 -1.779 0 CA-C-O 121.513 0.673 . . . . 0.0 111.431 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.0 ptp -141.8 125.66 17.09 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.911 175.372 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 1.9 m80 -98.54 147.27 24.95 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.526 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 1.7 m -73.62 110.78 8.18 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.834 171.272 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 28.8 m -83.61 160.02 21.48 Favored 'General case' 0 N--CA 1.428 -1.574 0 O-C-N 123.925 0.766 . . . . 0.0 109.342 -179.269 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -70.37 1.56 4.84 Favored 'General case' 0 N--CA 1.486 1.34 0 CA-C-O 121.261 0.553 . . . . 0.0 112.423 -176.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -84.6 -17.53 38.44 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.376 174.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 90.1 23.3 32.71 Favored Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.288 -0.958 . . . . 0.0 110.865 -174.273 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -131.01 164.5 25.26 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 58.0 m95 -79.59 143.37 34.8 Favored 'General case' 0 N--CA 1.426 -1.642 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 174.638 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.1 m -63.77 -20.77 66.02 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-O 121.153 0.502 . . . . 0.0 111.104 177.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 30.5 mmmt -133.74 158.78 42.44 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.058 -177.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 25.3 mm-40 -79.63 168.0 19.95 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 114.554 -1.203 . . . . 0.0 108.392 171.742 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 17.2 tptm -55.43 117.26 14.21 Favored Pre-proline 0 N--CA 1.439 -0.989 0 O-C-N 123.863 0.727 . . . . 0.0 110.02 176.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -87.5 158.4 7.94 Favored 'Trans proline' 0 N--CA 1.423 -2.639 0 C-N-CA 122.066 1.844 . . . . 0.0 111.663 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -122.42 149.08 44.32 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.709 -175.678 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 92.7 m -108.38 115.67 30.54 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 176.244 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 9.4 m . . . . . 0 C--N 1.29 -1.981 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.126 -175.177 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo . . . . . 0 CA--C 1.534 0.477 0 CA-C-O 121.796 0.665 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 59.5 m -88.23 -36.99 16.44 Favored 'General case' 0 N--CA 1.435 -1.204 0 CA-C-N 114.813 -1.085 . . . . 0.0 109.29 175.79 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 115.98 -87.72 0.44 Allowed Glycine 0 CA--C 1.463 -3.206 0 N-CA-C 110.081 -1.207 . . . . 0.0 110.081 174.34 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 3.5 t60 -177.72 127.77 0.29 Allowed Pre-proline 0 C--N 1.269 -2.922 0 N-CA-C 104.901 -2.259 . . . . 0.0 104.901 -175.642 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -79.99 12.26 2.52 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 123.043 2.495 . . . . 0.0 114.342 -171.909 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 106.03 -169.63 15.98 Favored Glycine 0 N--CA 1.424 -2.126 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -176.305 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -160.27 139.59 10.88 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 177.717 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.3 t -110.87 131.74 21.98 Favored Pre-proline 0 C--N 1.303 -1.449 0 C-N-CA 120.631 -0.428 . . . . 0.0 111.758 -175.85 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -70.02 -18.3 35.85 Favored 'Trans proline' 0 C--N 1.351 0.681 0 C-N-CA 122.826 2.351 . . . . 0.0 111.695 176.596 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -83.57 -2.5 56.18 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.329 -176.721 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.492 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.09 -124.49 1.04 Allowed Glycine 0 N--CA 1.414 -2.817 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.328 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 14.8 t -164.8 -165.27 0.89 Allowed 'General case' 0 C--N 1.285 -2.228 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.55 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.7 p90 -146.18 165.65 28.54 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.896 -0.503 . . . . 0.0 109.758 178.203 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -126.12 162.44 25.34 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.962 -1.495 . . . . 0.0 106.962 176.64 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 16.5 mt -114.88 132.91 56.37 Favored 'General case' 0 C--N 1.278 -2.51 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.314 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 19.9 p -128.9 128.48 43.9 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 -177.161 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 93.41 30.13 9.49 Favored Glycine 0 C--N 1.292 -1.863 0 C-N-CA 119.994 -1.098 . . . . 0.0 111.253 -178.302 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 164.17 -35.51 0.29 Allowed Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.705 -1.236 . . . . 0.0 111.974 177.396 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 68.85 14.25 8.91 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.547 0.739 . . . . 0.0 112.338 179.96 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.515 ' O ' HG12 ' A' ' 108' ' ' VAL . 29.3 m -147.74 -168.92 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.211 -0.951 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 -178.616 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -106.34 42.78 1.22 Allowed 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 119.118 0.872 . . . . 0.0 110.238 -178.115 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.742 ' O ' HG11 ' A' ' 108' ' ' VAL . 10.8 pt-20 -79.27 173.91 12.11 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 114.641 -1.163 . . . . 0.0 111.588 178.262 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -75.98 127.59 33.3 Favored 'General case' 0 C--N 1.295 -1.762 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.059 176.201 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 104.17 -7.58 48.04 Favored Glycine 0 N--CA 1.435 -1.414 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.489 179.694 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.742 HG11 ' O ' ' A' ' 105' ' ' GLU . 13.9 p -87.76 148.9 4.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -178.32 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -112.03 123.72 50.86 Favored 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.574 179.181 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.419 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.85 96.99 10.4 Favored 'General case' 0 C--N 1.291 -1.939 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 176.523 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.416 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 22.6 m -95.24 111.18 25.32 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.511 0 CA-C-O 122.564 1.174 . . . . 0.0 109.457 -179.168 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -78.92 148.96 32.5 Favored 'General case' 0 C--N 1.26 -3.32 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.813 -177.62 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.9 t -145.35 130.94 18.85 Favored 'General case' 0 N--CA 1.422 -1.839 0 CA-C-N 115.012 -0.995 . . . . 0.0 108.895 177.295 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 20.5 m -82.47 160.61 22.63 Favored 'General case' 0 C--N 1.284 -2.277 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.314 -175.732 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.492 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 71.1 m-20 -73.19 -178.06 2.75 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.952 178.812 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -53.31 -53.09 56.02 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 125.02 1.328 . . . . 0.0 113.375 -175.43 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.25 31.81 4.64 Favored Glycine 0 C--N 1.305 -1.18 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.414 -177.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -146.1 153.65 40.94 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -175.044 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -133.13 171.88 13.4 Favored 'General case' 0 C--N 1.272 -2.776 0 N-CA-C 105.923 -1.881 . . . . 0.0 105.923 175.663 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 13.1 tp -87.47 149.87 24.13 Favored 'General case' 0 C--N 1.282 -2.357 0 C-N-CA 119.135 -1.026 . . . . 0.0 108.563 179.216 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -122.51 121.83 37.48 Favored 'General case' 0 N--CA 1.408 -2.539 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 176.81 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.92 171.52 23.44 Favored Glycine 0 C--N 1.284 -2.33 0 C-N-CA 120.796 -0.716 . . . . 0.0 111.943 -175.434 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -86.27 -34.72 20.3 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.65 0.738 . . . . 0.0 109.495 -176.927 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.3 mm -77.97 126.67 38.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-N 114.988 -1.006 . . . . 0.0 109.814 -175.925 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -127.57 1.93 6.19 Favored 'General case' 0 C--O 1.201 -1.454 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 176.899 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.419 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 18.2 p90 -136.51 162.43 33.12 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.42 -171.64 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 63.3 mtp180 -130.78 131.12 44.51 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 170.341 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -103.9 132.31 50.28 Favored 'General case' 0 C--N 1.292 -1.899 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.698 179.509 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 23.9 t -82.22 97.78 8.42 Favored 'General case' 0 N--CA 1.425 -1.681 0 C-N-CA 118.238 -1.385 . . . . 0.0 109.257 175.741 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -94.83 -173.41 2.98 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 106.673 -1.602 . . . . 0.0 106.673 178.163 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 14.1 t -67.01 -14.39 62.85 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.69 0.757 . . . . 0.0 111.277 -175.192 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -86.73 -28.64 22.94 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.017 177.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 132.13 -163.85 23.86 Favored Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 -175.405 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.423 ' CH2' HG13 ' A' ' 108' ' ' VAL . 98.5 m95 -63.62 113.55 3.4 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 117.85 0.825 . . . . 0.0 110.858 175.714 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 51.9 p -70.67 166.84 19.93 Favored 'General case' 0 C--O 1.267 2.006 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 177.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 62.24 -163.39 0.26 Allowed 'General case' 0 C--O 1.251 1.145 0 O-C-N 123.921 0.763 . . . . 0.0 109.383 178.061 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . 0.406 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 37.6 t0 -131.59 177.88 7.17 Favored 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 174.419 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.406 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 71.7 mt -62.68 114.98 13.84 Favored Pre-proline 0 C--N 1.27 -2.873 0 C-N-CA 124.774 1.229 . . . . 0.0 108.036 175.193 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -65.07 151.31 86.13 Favored 'Trans proline' 0 N--CA 1.447 -1.264 0 C-N-CA 122.479 2.119 . . . . 0.0 112.062 -177.929 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 48.2 mt -87.16 134.37 27.77 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.118 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.512 -174.165 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 93.5 m -107.82 148.13 29.95 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 171.165 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -129.8 144.85 51.51 Favored 'General case' 0 C--N 1.284 -2.266 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -179.824 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 4.8 p -73.26 129.43 36.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.846 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.6 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 27.6 m -54.19 130.02 15.71 Favored 'Isoleucine or valine' 0 C--O 1.243 0.741 0 O-C-N 123.848 0.717 . . . . 0.0 112.209 -174.827 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 94.8 mttt -112.54 170.08 8.43 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.533 -175.985 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.0 p -150.41 158.82 44.58 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.052 176.33 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . 0.432 HD23 ' HD2' ' A' ' 148' ' ' PRO . 1.4 tt -55.48 131.6 70.76 Favored Pre-proline 0 N--CA 1.429 -1.515 0 C-N-CA 125.59 1.556 . . . . 0.0 111.992 -178.258 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.432 ' HD2' HD23 ' A' ' 147' ' ' LEU . 37.8 Cg_endo -69.08 100.6 0.74 Allowed 'Trans proline' 0 N--CA 1.445 -1.334 0 C-N-CA 122.846 2.364 . . . . 0.0 111.806 176.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 10.2 p -64.07 140.05 20.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.935 0 CA-C-N 115.428 -0.805 . . . . 0.0 108.948 176.607 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 15.6 p -73.12 -82.38 0.05 Allowed 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -174.529 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 175.45 162.62 0.41 Allowed Pre-proline 0 CA--C 1.517 -0.311 0 C-N-CA 124.771 1.228 . . . . 0.0 107.843 179.403 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -74.05 -178.16 3.69 Favored 'Trans proline' 0 N--CA 1.446 -1.301 0 C-N-CA 121.353 1.369 . . . . 0.0 110.254 170.57 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . 0.574 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.0 OUTLIER -93.15 -41.07 10.13 Favored 'General case' 0 C--N 1.289 -2.04 0 O-C-N 122.051 -0.406 . . . . 0.0 111.413 -176.394 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . 0.574 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 42.3 m-80 -107.59 21.12 17.92 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.529 0.68 . . . . 0.0 110.259 179.736 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -148.54 -172.68 18.65 Favored Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.677 -178.274 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 58.8 pttt -145.98 164.38 32.25 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -176.621 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 63.5 mt -88.51 136.01 24.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 177.866 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.588 HG23 ' O ' ' A' ' 175' ' ' ARG . 11.5 m -84.73 -25.82 6.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.128 0.489 . . . . 0.0 110.81 -178.004 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 21.4 t -128.58 92.4 3.41 Favored 'General case' 0 N--CA 1.432 -1.338 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.761 -174.98 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 32.2 t -148.78 97.54 2.73 Favored 'General case' 0 N--CA 1.426 -1.632 0 CA-C-O 121.108 0.48 . . . . 0.0 109.972 -178.627 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -100.09 90.88 4.53 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 176.364 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 162' ' ' MET . . . . . 0.462 ' HA ' ' HE3' ' A' ' 162' ' ' MET . 0.5 OUTLIER -84.22 84.3 7.67 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.815 0.817 . . . . 0.0 109.732 -177.825 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.438 ' HB2' ' HB2' ' A' ' 166' ' ' ARG . 45.8 mm-40 -109.1 163.42 17.04 Favored Pre-proline 0 C--N 1.296 -1.754 0 CA-C-N 114.311 -1.313 . . . . 0.0 108.67 -178.058 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.86 -12.61 19.86 Favored 'Trans proline' 0 C--O 1.221 -0.338 0 C-N-CA 121.954 1.77 . . . . 0.0 110.83 174.67 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -103.51 -38.74 7.03 Favored 'General case' 0 CA--C 1.494 -1.194 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.663 -178.145 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.438 ' HB2' ' HB2' ' A' ' 163' ' ' GLU . 9.9 mmt180 -98.43 100.33 11.58 Favored 'General case' 0 N--CA 1.416 -2.142 0 CA-C-N 115.195 -0.911 . . . . 0.0 113.45 -174.202 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.68 179.7 5.42 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 105.361 -2.088 . . . . 0.0 105.361 167.313 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . 0.438 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 95.1 m-85 -77.24 138.46 39.43 Favored 'General case' 0 C--N 1.296 -1.759 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.139 178.575 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.467 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 36.0 m80 -136.31 169.61 17.37 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.642 -173.747 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . 0.6 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 91.7 t80 -50.11 128.94 20.16 Favored 'General case' 0 C--O 1.24 0.573 0 O-C-N 124.2 0.937 . . . . 0.0 110.571 173.468 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 101.14 -14.08 58.52 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 119.972 -1.108 . . . . 0.0 112.751 175.95 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . 0.451 ' HA ' HE21 ' A' ' 172' ' ' GLN . 0.0 OUTLIER -77.19 143.45 39.02 Favored 'General case' 0 C--O 1.251 1.143 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.154 178.272 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -124.86 101.19 6.96 Favored 'General case' 0 C--N 1.285 -2.228 0 CA-C-N 114.767 -1.106 . . . . 0.0 108.859 -179.697 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 69.2 t -81.38 96.62 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.648 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.252 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.588 ' O ' HG23 ' A' ' 158' ' ' VAL . 26.4 ttp180 -96.81 142.99 28.15 Favored 'General case' 0 N--CA 1.4 -2.936 0 CA-C-N 114.55 -1.204 . . . . 0.0 108.052 177.191 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -113.07 162.14 16.27 Favored 'General case' 0 C--N 1.278 -2.502 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -176.243 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 14.5 p -143.86 137.15 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.346 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 175.761 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 80.8 m -92.7 152.37 19.56 Favored 'General case' 0 C--N 1.257 -3.438 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.586 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 51.2 m-80 -70.6 166.16 21.26 Favored 'General case' 0 CA--C 1.493 -1.22 0 C-N-CA 120.368 -0.533 . . . . 0.0 110.176 179.546 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 12.6 t -53.61 110.31 0.56 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 124.274 0.984 . . . . 0.0 111.163 -176.082 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 116.44 -13.88 15.59 Favored Glycine 0 N--CA 1.435 -1.383 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.706 179.307 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -110.7 163.25 13.94 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 117.482 0.641 . . . . 0.0 110.876 -179.007 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 18.1 ptmt -135.39 157.26 47.34 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.692 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.8 tt -84.98 137.53 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.766 0 CA-C-O 121.609 0.718 . . . . 0.0 111.127 -179.367 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -72.2 -53.48 12.51 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.091 -177.455 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -93.9 -134.8 7.38 Favored Glycine 0 C--N 1.296 -1.674 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.087 -177.781 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -81.35 169.66 16.96 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 178.462 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -100.63 -15.76 17.65 Favored 'General case' 0 C--N 1.289 -2.048 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -176.338 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -144.19 138.32 28.01 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 -175.394 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.8 ptp -117.45 130.2 56.31 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.713 174.883 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -102.49 137.19 41.06 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.965 -177.031 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . 0.468 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 19.6 t -88.1 107.99 19.03 Favored 'General case' 0 C--O 1.253 1.274 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 174.515 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 21.7 m -102.81 -176.64 3.15 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 112.964 0.727 . . . . 0.0 112.964 -171.148 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -44.37 -39.32 4.56 Favored 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 126.148 1.779 . . . . 0.0 113.491 -176.973 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -63.54 -17.28 62.63 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.862 -177.047 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 78.57 32.91 40.23 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -174.092 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -144.11 171.92 13.62 Favored 'General case' 0 C--O 1.249 1.034 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 -179.544 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . 0.468 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 81.9 m95 -87.32 137.6 32.2 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 175.778 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 44.7 m -83.35 -3.31 57.38 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.168 0.509 . . . . 0.0 111.941 179.881 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 20.2 mmtp -128.54 162.15 27.91 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.581 179.471 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -95.65 166.09 12.0 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.935 179.86 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 9.8 tptm -65.34 116.97 35.71 Favored Pre-proline 0 CA--C 1.547 0.834 0 C-N-CA 123.337 0.655 . . . . 0.0 111.299 179.168 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_endo -90.54 177.87 2.17 Favored 'Trans proline' 0 CA--C 1.547 1.148 0 C-N-CA 122.658 2.238 . . . . 0.0 112.85 177.198 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . 0.536 ' HG3' ' OE2' ' A' ' 153' ' ' GLU . 22.1 ttmm -131.25 157.11 44.13 Favored 'General case' 0 C--N 1.318 -0.804 0 C-N-CA 124.319 1.048 . . . . 0.0 109.531 -177.238 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 87.8 m -104.06 119.22 38.47 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 173.857 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.296 -1.758 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.754 -174.693 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo . . . . . 0 CA--C 1.531 0.373 0 CA-C-O 121.665 0.611 . . . . 0.0 110.683 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.9 m -88.43 -32.96 18.04 Favored 'General case' 0 N--CA 1.436 -1.125 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 176.332 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.99 -85.72 0.4 Allowed Glycine 0 CA--C 1.453 -3.839 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 171.58 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.2 t-80 -173.75 133.75 0.6 Allowed Pre-proline 0 C--N 1.266 -3.037 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 -174.328 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.477 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 89.9 Cg_endo -87.24 -5.07 7.63 Favored 'Trans proline' 0 C--O 1.242 0.686 0 C-N-CA 122.252 1.968 . . . . 0.0 112.94 -176.364 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.402 ' HA3' HD11 ' A' ' 138' ' ' ILE . . . 126.38 -161.72 20.67 Favored Glycine 0 N--CA 1.42 -2.379 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 -178.375 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -158.48 150.52 21.53 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 177.86 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.9 t -131.53 127.04 21.43 Favored Pre-proline 0 C--N 1.301 -1.519 0 C-N-CA 119.746 -0.781 . . . . 0.0 111.994 -177.382 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -71.37 -16.6 31.06 Favored 'Trans proline' 0 CA--C 1.534 0.522 0 C-N-CA 122.541 2.161 . . . . 0.0 111.502 177.075 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 71.5 m-85 -83.45 -6.6 59.51 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.988 -177.458 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.424 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 171.89 -129.94 1.84 Allowed Glycine 0 N--CA 1.414 -2.79 0 C-N-CA 118.838 -1.648 . . . . 0.0 113.48 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.5 p -141.21 178.6 7.28 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 114.989 -0.606 . . . . 0.0 111.288 -174.804 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.458 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 36.5 p90 -148.66 155.23 40.77 Favored 'General case' 0 N--CA 1.431 -1.383 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 171.327 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -123.98 153.15 41.69 Favored 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 -178.316 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -110.74 126.67 54.82 Favored 'General case' 0 C--N 1.271 -2.814 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -179.774 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.412 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 17.2 p -121.26 134.14 55.17 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.265 -176.508 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 108.14 -45.92 1.24 Allowed Glycine 0 C--N 1.311 -0.811 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.989 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -128.3 -18.21 1.88 Allowed Glycine 0 C--N 1.311 -0.842 0 C-N-CA 120.382 -0.913 . . . . 0.0 113.009 -179.901 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 63.27 16.55 9.54 Favored 'General case' 0 N--CA 1.494 1.731 0 C-N-CA 124.388 1.075 . . . . 0.0 110.868 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.532 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.6 m -148.41 -171.86 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.211 -0.965 0 N-CA-C 106.967 -1.494 . . . . 0.0 106.967 -178.912 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.477 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 32.6 m-85 -101.47 44.66 1.0 Allowed 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 118.794 0.725 . . . . 0.0 110.648 -177.486 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.719 ' O ' HG13 ' A' ' 108' ' ' VAL . 12.2 pt-20 -86.51 -175.73 5.57 Favored 'General case' 0 C--O 1.207 -1.143 0 CA-C-N 114.837 -1.074 . . . . 0.0 111.468 177.638 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -81.05 139.65 35.59 Favored 'General case' 0 C--N 1.308 -1.226 0 O-C-N 121.686 -0.634 . . . . 0.0 111.085 178.786 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.44 4.29 80.55 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.655 -0.702 . . . . 0.0 112.529 179.122 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.719 HG13 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -94.25 142.92 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 C-N-CA 119.763 -0.775 . . . . 0.0 109.123 -179.628 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.412 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -107.67 121.23 44.26 Favored 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.708 178.441 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -86.81 89.67 8.04 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 175.575 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 94.6 t -85.71 115.13 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.638 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -177.647 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . 0.458 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 43.2 m-85 -86.63 145.77 26.59 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 116.605 -0.271 . . . . 0.0 111.116 -177.061 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.1 t -145.44 116.74 7.95 Favored 'General case' 0 N--CA 1.427 -1.602 0 CA-C-O 122.404 1.097 . . . . 0.0 109.471 178.11 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 28.4 m -72.89 164.95 25.86 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 114.901 -1.045 . . . . 0.0 111.191 -174.887 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.424 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 81.0 m-20 -75.31 171.71 13.73 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.505 177.143 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -58.49 -39.4 79.9 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 113.269 0.84 . . . . 0.0 113.269 -174.331 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.442 ' C ' HG23 ' A' ' 144' ' ' VAL . . . -75.39 12.41 7.55 Favored Glycine 0 CA--C 1.526 0.752 0 C-N-CA 120.838 -0.696 . . . . 0.0 113.063 179.733 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.473 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 83.5 m-85 -147.09 170.09 17.9 Favored 'General case' 0 N--CA 1.427 -1.582 0 C-N-CA 124.56 1.144 . . . . 0.0 108.95 -177.51 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -140.58 173.5 11.43 Favored 'General case' 0 C--N 1.266 -3.058 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 175.699 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.9 tt -99.92 137.5 38.29 Favored 'General case' 0 C--N 1.27 -2.851 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -179.713 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.413 ' HB2' ' HB2' ' A' ' 142' ' ' GLU . 0.2 OUTLIER -127.52 135.83 50.89 Favored 'General case' 0 N--CA 1.423 -1.818 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -176.978 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 130.02 179.29 15.92 Favored Glycine 0 N--CA 1.421 -2.311 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 178.397 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 61.7 mm-40 -95.88 -17.05 21.4 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 122.282 1.039 . . . . 0.0 109.078 177.102 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.6 mm -101.5 142.84 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.588 0 CA-C-N 114.184 -1.371 . . . . 0.0 108.233 179.032 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -141.14 9.61 2.11 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-O 121.278 0.561 . . . . 0.0 109.517 177.795 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . . . . . . . . . 32.8 p90 -157.55 159.57 37.28 Favored 'General case' 0 N--CA 1.427 -1.602 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.747 -172.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 56.4 mtp180 -121.16 129.85 53.44 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 172.507 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -105.43 130.61 53.48 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -178.512 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.6 t -83.1 105.35 14.01 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 117.625 -1.63 . . . . 0.0 110.206 176.643 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.432 ' OD2' HG21 ' A' ' 131' ' ' THR . 22.5 t70 -94.38 -178.59 4.63 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 178.297 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.432 HG21 ' OD2' ' A' ' 130' ' ' ASP . 11.0 t -63.28 -22.49 66.91 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 121.728 0.775 . . . . 0.0 110.38 -177.729 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -76.59 -37.12 56.99 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.769 177.735 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 139.28 -159.49 25.69 Favored Glycine 0 N--CA 1.434 -1.462 0 N-CA-C 107.982 -2.047 . . . . 0.0 107.982 -173.938 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -66.38 122.99 18.77 Favored 'General case' 0 C--O 1.248 0.979 0 CA-C-N 118.258 1.029 . . . . 0.0 110.539 177.653 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 67.7 p -80.89 163.32 23.47 Favored 'General case' 0 N--CA 1.416 -2.167 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 175.814 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 61.74 -165.21 0.23 Allowed 'General case' 0 C--N 1.323 -0.582 0 O-C-N 124.017 0.823 . . . . 0.0 110.579 175.21 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -129.57 -179.92 5.45 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 175.678 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.402 HD11 ' HA3' ' A' ' 89' ' ' GLY . 62.3 mt -66.6 122.24 81.06 Favored Pre-proline 0 C--N 1.298 -1.648 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 173.245 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.55 158.15 54.59 Favored 'Trans proline' 0 C--O 1.243 0.742 0 C-N-CA 122.67 2.247 . . . . 0.0 111.416 179.275 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 68.0 mt -84.95 131.65 33.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 CA-C-O 121.03 0.443 . . . . 0.0 111.016 -174.051 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 91.4 m -98.45 102.01 13.62 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 173.263 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.413 ' HB2' ' HB2' ' A' ' 121' ' ' LEU . 1.0 OUTLIER -87.88 154.5 20.47 Favored 'General case' 0 CA--C 1.461 -2.443 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.147 178.693 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.473 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 4.3 t -80.7 137.34 21.58 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.367 0 CA-C-N 114.82 -1.082 . . . . 0.0 108.661 -177.197 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.442 HG23 ' C ' ' A' ' 117' ' ' GLY . 3.7 m -69.83 98.34 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.153 177.407 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.461 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 49.2 mttm -88.07 131.81 34.53 Favored 'General case' 0 N--CA 1.417 -2.094 0 CA-C-N 113.754 -1.566 . . . . 0.0 109.387 -176.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.417 ' O ' ' HB2' ' A' ' 168' ' ' TYR . 61.6 m -94.16 127.43 39.99 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 107.17 -1.419 . . . . 0.0 107.17 177.026 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -50.24 138.94 19.69 Favored Pre-proline 0 N--CA 1.438 -1.071 0 N-CA-C 114.655 1.354 . . . . 0.0 114.655 -176.264 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -69.7 123.38 10.07 Favored 'Trans proline' 0 N--CA 1.444 -1.425 0 C-N-CA 122.926 2.417 . . . . 0.0 112.304 -175.522 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 21.2 t -91.84 130.75 40.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.4 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.3 m -74.93 -67.96 0.59 Allowed 'General case' 0 N--CA 1.414 -2.268 0 C-N-CA 122.764 0.425 . . . . 0.0 111.16 -177.866 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.96 150.12 0.22 Allowed Pre-proline 0 CA--C 1.509 -0.599 0 C-N-CA 124.686 1.194 . . . . 0.0 108.079 -178.934 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -77.07 174.7 12.41 Favored 'Trans proline' 0 N--CA 1.446 -1.315 0 C-N-CA 121.836 1.691 . . . . 0.0 110.811 173.947 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -61.58 -51.78 67.14 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 114.215 1.191 . . . . 0.0 114.215 -174.913 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -123.29 23.27 9.14 Favored 'General case' 0 CA--C 1.496 -1.108 0 CA-C-O 122.032 0.92 . . . . 0.0 109.891 -172.411 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . 0.456 ' HA3' ' SG ' ' A' ' 205' ' ' CYS . . . -140.47 -178.15 16.76 Favored Glycine 0 C--N 1.281 -2.516 0 CA-C-N 114.071 -1.422 . . . . 0.0 109.906 178.716 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 47.6 pttt -143.91 162.52 35.91 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 -177.146 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.407 HG21 ' H ' ' A' ' 159' ' ' SER . 46.7 mt -92.25 135.98 25.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 -179.632 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.46 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 10.8 m -71.19 -23.14 22.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-O 121.872 0.844 . . . . 0.0 111.382 -175.281 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 159' ' ' SER . . . . . 0.407 ' H ' HG21 ' A' ' 157' ' ' ILE . 20.8 t -122.89 173.59 7.69 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -178.849 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 71.0 m -162.48 -47.14 0.04 OUTLIER 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.52 0.676 . . . . 0.0 109.97 178.235 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -150.19 78.67 1.34 Allowed 'General case' 0 N--CA 1.44 -0.964 0 CA-C-O 121.85 0.833 . . . . 0.0 109.589 179.479 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.51 -23.24 34.72 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.486 -179.133 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -111.03 149.69 40.83 Favored Pre-proline 0 C--N 1.311 -1.079 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.133 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.63 -3.92 14.54 Favored 'Trans proline' 0 N--CA 1.482 0.839 0 C-N-CA 123.023 2.482 . . . . 0.0 110.842 177.621 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . 0.442 ' C ' ' H ' ' A' ' 167' ' ' GLU . 17.7 t70 -89.06 -26.77 21.23 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 179.192 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 50.9 mtt180 71.69 -16.29 0.4 Allowed 'General case' 0 CA--C 1.497 -1.063 0 C-N-CA 127.426 2.29 . . . . 0.0 116.21 170.668 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . 0.442 ' H ' ' C ' ' A' ' 165' ' ' ASP . 22.9 mm-40 -77.48 154.83 32.16 Favored 'General case' 0 C--N 1.249 -3.777 0 CA-C-N 114.761 -1.108 . . . . 0.0 109.34 176.999 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . 0.461 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 95.5 m-85 -92.78 134.45 35.05 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 176.755 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 23.3 m80 -129.28 161.5 30.08 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -174.469 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . 0.411 ' HB2' HG22 ' A' ' 144' ' ' VAL . 87.1 t80 -51.9 107.74 0.22 Allowed 'General case' 0 N--CA 1.469 0.513 0 O-C-N 123.82 0.7 . . . . 0.0 110.675 174.54 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 139.05 -24.57 2.83 Favored Glycine 0 N--CA 1.433 -1.557 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -175.681 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -78.34 160.91 27.57 Favored 'General case' 0 N--CA 1.429 -1.523 0 CA-C-O 121.602 0.715 . . . . 0.0 112.897 -179.43 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . 0.414 ' HA ' ' O ' ' A' ' 190' ' ' MET . . . -148.28 118.46 7.28 Favored 'General case' 0 N--CA 1.423 -1.775 0 CA-C-N 114.376 -1.283 . . . . 0.0 109.027 179.793 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.475 HG22 ' CH2' ' A' ' 198' ' ' TRP . 46.2 t -86.18 107.41 16.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.13 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.46 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 78.9 ttt180 -99.64 140.57 33.65 Favored 'General case' 0 N--CA 1.42 -1.954 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 178.067 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -114.49 161.09 18.45 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 -176.468 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 7.7 p -140.9 128.06 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.812 0 CA-C-N 115.22 -0.9 . . . . 0.0 109.931 175.948 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 71.7 m -89.11 152.24 21.76 Favored 'General case' 0 C--N 1.276 -2.607 0 CA-C-N 114.915 -1.038 . . . . 0.0 110.138 -179.549 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -68.9 -179.92 1.62 Allowed 'General case' 0 C--O 1.239 0.532 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.714 178.663 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 8.8 p -47.02 -39.67 13.14 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 115.945 1.832 . . . . 0.0 115.945 -172.097 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -109.51 15.5 32.25 Favored Glycine 0 C--N 1.286 -2.212 0 C-N-CA 120.328 -0.939 . . . . 0.0 113.239 -176.626 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -116.12 157.97 23.94 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 117.974 0.887 . . . . 0.0 111.571 -178.24 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -126.93 158.05 37.82 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 106.557 -1.645 . . . . 0.0 106.557 175.763 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.419 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.5 tt -91.28 139.45 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.23 0 C-N-CA 119.167 -1.013 . . . . 0.0 110.806 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -50.04 -58.95 4.42 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 126.08 1.752 . . . . 0.0 113.106 -177.657 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -128.64 -103.88 1.15 Allowed Glycine 0 CA--C 1.493 -1.331 0 C-N-CA 120.247 -0.978 . . . . 0.0 111.276 -178.394 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -80.52 159.12 25.62 Favored 'General case' 0 CA--C 1.486 -1.497 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 177.815 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . 0.419 ' HA ' HD13 ' A' ' 184' ' ' ILE . 15.0 pt-20 -103.45 4.45 36.08 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.428 -0.909 . . . . 0.0 109.507 178.34 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -148.44 146.61 28.5 Favored 'General case' 0 N--CA 1.426 -1.654 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.018 -175.715 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.414 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 12.3 ptp -124.44 121.21 34.25 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.11 174.279 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 46.0 t-80 -98.77 145.41 26.97 Favored 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.069 -176.661 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 12.8 m -62.01 148.52 43.67 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 177.133 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 31.5 m -127.9 159.95 33.34 Favored 'General case' 0 N--CA 1.423 -1.813 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 173.074 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -69.97 -1.46 9.77 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -172.65 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -75.84 -15.91 60.16 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.039 0.447 . . . . 0.0 109.901 175.458 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 88.12 22.19 42.62 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -172.454 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -135.81 169.38 17.66 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -179.917 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . 0.475 ' CH2' HG22 ' A' ' 174' ' ' VAL . 78.1 m95 -87.13 151.42 23.22 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.818 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 39.6 t -71.1 -50.1 37.28 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 121.531 0.682 . . . . 0.0 109.186 177.739 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 25.4 mmtp -88.49 148.99 23.88 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-O 121.417 0.627 . . . . 0.0 111.623 -179.798 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -89.11 150.65 22.63 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.813 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 27.3 ttpp -58.73 112.95 5.69 Favored Pre-proline 0 C--O 1.237 0.4 0 N-CA-C 114.443 1.275 . . . . 0.0 114.443 -173.306 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -72.01 171.38 16.8 Favored 'Trans proline' 0 N--CA 1.451 -1.014 0 C-N-CA 123.395 2.73 . . . . 0.0 110.631 175.322 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.4 mttp -123.36 167.06 14.29 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -177.753 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.456 ' SG ' ' HA3' ' A' ' 155' ' ' GLY . 94.5 m -106.59 104.65 14.39 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 172.195 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 11.4 m . . . . . 0 C--N 1.296 -1.751 0 CA-C-N 114.782 -1.099 . . . . 0.0 112.327 -171.924 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo . . . . . 0 CA--C 1.536 0.611 0 CA-C-O 121.783 0.66 . . . . 0.0 111.082 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.5 m -82.5 -32.86 28.57 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.309 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.53 -85.86 0.4 Allowed Glycine 0 CA--C 1.458 -3.508 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 173.073 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.2 t60 179.42 130.43 0.23 Allowed Pre-proline 0 C--N 1.271 -2.818 0 N-CA-C 104.153 -2.536 . . . . 0.0 104.153 -176.056 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.4 -33.07 5.81 Favored 'Trans proline' 0 N--CA 1.474 0.363 0 C-N-CA 121.625 1.55 . . . . 0.0 112.744 -175.423 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 134.52 177.26 14.82 Favored Glycine 0 N--CA 1.419 -2.445 0 N-CA-C 107.021 -2.432 . . . . 0.0 107.021 -176.017 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -134.91 162.96 30.95 Favored 'General case' 0 C--N 1.287 -2.14 0 CA-C-N 118.36 1.08 . . . . 0.0 109.433 179.848 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.7 t -119.35 131.44 24.37 Favored Pre-proline 0 N--CA 1.416 -2.153 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.183 -178.516 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.02 -11.69 17.85 Favored 'Trans proline' 0 N--CA 1.459 -0.509 0 C-N-CA 122.563 2.176 . . . . 0.0 111.616 177.872 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -88.93 -2.89 58.81 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.216 -177.814 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.445 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 175.57 -128.02 1.34 Allowed Glycine 0 N--CA 1.414 -2.793 0 C-N-CA 118.961 -1.59 . . . . 0.0 113.63 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.1 p -138.56 170.5 15.89 Favored 'General case' 0 C--N 1.291 -1.96 0 CA-C-N 114.841 -0.68 . . . . 0.0 110.972 -174.641 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.2 p90 -140.74 145.65 36.71 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 171.023 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.7 m -120.32 161.23 21.49 Favored 'General case' 0 C--N 1.271 -2.843 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -176.894 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.5 mt -119.56 120.97 38.29 Favored 'General case' 0 C--N 1.28 -2.448 0 CA-C-O 121.028 0.442 . . . . 0.0 109.867 -177.443 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.468 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 24.0 p -109.99 129.02 55.73 Favored 'General case' 0 C--N 1.285 -2.218 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.52 -175.383 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 113.38 -54.91 0.54 Allowed Glycine 0 N--CA 1.432 -1.593 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.073 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -121.24 -12.63 5.67 Favored Glycine 0 C--N 1.305 -1.19 0 C-N-CA 119.965 -1.112 . . . . 0.0 113.335 -179.514 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 47.7 m-80 61.26 18.55 9.28 Favored 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 123.485 0.714 . . . . 0.0 112.22 -178.168 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.557 ' O ' HG13 ' A' ' 108' ' ' VAL . 18.7 m -151.32 -174.48 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.206 -1.21 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -175.806 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -99.71 46.05 0.98 Allowed 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 118.732 0.696 . . . . 0.0 110.619 -177.339 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.738 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.1 pt-20 -86.91 179.79 6.65 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.632 177.019 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 41.2 m-85 -76.12 137.28 40.01 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 122.039 -0.413 . . . . 0.0 111.301 177.089 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.98 -7.96 70.11 Favored Glycine 0 N--CA 1.441 -0.969 0 CA-C-N 115.603 -0.726 . . . . 0.0 113.048 178.003 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.738 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.9 p -87.14 146.8 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.881 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 -175.163 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.468 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.9 mtpt -110.25 125.84 53.53 Favored 'General case' 0 N--CA 1.419 -2.011 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.248 178.129 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -88.42 95.99 10.42 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 175.442 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 77.5 t -90.08 113.65 26.55 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.901 0 C-N-CA 123.988 0.915 . . . . 0.0 108.819 -177.451 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -88.48 134.6 33.8 Favored 'General case' 0 C--N 1.285 -2.228 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.992 -178.948 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.1 t -142.82 124.04 14.6 Favored 'General case' 0 N--CA 1.428 -1.561 0 CA-C-O 122.067 0.937 . . . . 0.0 109.399 179.51 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 78.0 m -75.35 166.46 23.57 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.949 -174.064 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.445 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 85.2 m-20 -85.46 -177.03 6.34 Favored 'General case' 0 C--O 1.216 -0.698 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.295 178.393 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -42.93 -54.44 4.21 Favored 'General case' 0 C--N 1.311 -1.072 0 C-N-CA 126.163 1.785 . . . . 0.0 114.527 -177.435 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -92.41 17.34 57.64 Favored Glycine 0 C--N 1.299 -1.495 0 C-N-CA 119.497 -1.335 . . . . 0.0 112.859 -175.111 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.598 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 77.8 m-85 -133.95 147.32 51.04 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.182 -177.304 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . 0.435 ' OE1' ' HB3' ' A' ' 142' ' ' GLU . 0.0 OUTLIER -136.3 160.07 39.84 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -178.849 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 10.4 tp -83.7 141.44 31.47 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 118.915 -1.114 . . . . 0.0 109.947 -176.309 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.05 122.91 43.21 Favored 'General case' 0 N--CA 1.411 -2.381 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 179.177 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.66 -160.42 13.7 Favored Glycine 0 C--N 1.293 -1.855 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.77 -176.568 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -105.9 -48.31 3.65 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.129 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.5 mm -73.4 129.51 36.16 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.132 -173.458 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -130.0 12.99 5.73 Favored 'General case' 0 C--O 1.213 -0.838 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 177.516 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.462 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 34.0 p90 -149.67 161.74 41.59 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.85 -176.48 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 44.3 mtp180 -127.46 131.78 50.13 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 172.069 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -108.06 131.98 54.03 Favored 'General case' 0 C--N 1.283 -2.301 0 C-N-CA 119.202 -0.999 . . . . 0.0 109.5 -178.405 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 21.6 t -81.4 99.27 8.62 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.829 -1.149 . . . . 0.0 109.155 176.533 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.423 ' OD2' HG21 ' A' ' 131' ' ' THR . 8.6 t70 -96.35 -167.13 1.52 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 178.447 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.423 HG21 ' OD2' ' A' ' 130' ' ' ASP . 9.0 t -59.37 -28.46 66.9 Favored 'General case' 0 C--N 1.31 -1.121 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -174.733 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -85.95 -23.65 26.85 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.549 0.69 . . . . 0.0 110.213 179.596 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 128.96 -153.96 20.01 Favored Glycine 0 N--CA 1.421 -2.362 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -175.646 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -64.87 113.38 3.79 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -179.878 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 65.0 p -73.09 172.48 10.97 Favored 'General case' 0 C--O 1.27 2.154 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 176.188 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 63.6 m-20 59.68 -156.74 0.34 Allowed 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 175.984 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -141.15 -177.51 5.15 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 173.092 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 57.0 mt -65.73 116.88 36.17 Favored Pre-proline 0 C--N 1.273 -2.728 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 174.806 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -68.61 160.83 47.77 Favored 'Trans proline' 0 C--O 1.246 0.91 0 C-N-CA 122.418 2.079 . . . . 0.0 112.308 -176.01 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 48.7 mm -90.67 131.52 37.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.364 -176.382 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.598 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 36.6 t -114.08 137.62 51.49 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 105.752 -1.944 . . . . 0.0 105.752 175.697 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.435 ' HB3' ' OE1' ' A' ' 119' ' ' GLN . 9.7 tp10 -119.1 157.59 27.56 Favored 'General case' 0 C--N 1.277 -2.557 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.473 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 24.0 t -79.84 138.54 19.72 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.073 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 -178.908 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 70.6 t -60.01 122.01 9.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 124.305 1.003 . . . . 0.0 108.399 179.331 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 59.9 mttm -120.33 156.06 32.07 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.899 -178.815 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 80.1 m -108.65 -171.54 1.87 Allowed 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 123.825 0.85 . . . . 0.0 110.677 -179.827 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . 0.474 HD12 ' HD2' ' A' ' 148' ' ' PRO . 1.5 tp -95.56 134.34 24.39 Favored Pre-proline 0 N--CA 1.421 -1.913 0 O-C-N 122.027 -0.421 . . . . 0.0 110.023 -177.181 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.474 ' HD2' HD12 ' A' ' 147' ' ' LEU . 12.7 Cg_endo -58.2 121.51 10.12 Favored 'Trans proline' 0 CA--C 1.535 0.543 0 C-N-CA 123.23 2.62 . . . . 0.0 111.563 177.333 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 28.7 t -85.94 143.65 11.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 -177.975 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 19.5 p -77.98 -83.12 0.08 Allowed 'General case' 0 N--CA 1.42 -1.974 0 CA-C-N 116.806 -0.179 . . . . 0.0 111.308 175.436 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.96 156.56 0.21 Allowed Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 125.143 1.377 . . . . 0.0 107.757 179.604 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -69.79 162.93 40.18 Favored 'Trans proline' 0 C--N 1.353 0.816 0 C-N-CA 121.723 1.615 . . . . 0.0 110.896 172.915 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -62.3 -50.6 71.02 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -174.926 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 55.4 m-80 -113.76 38.17 3.04 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 -177.96 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -154.06 -164.41 12.75 Favored Glycine 0 N--CA 1.425 -2.051 0 CA-C-N 115.026 -0.988 . . . . 0.0 111.189 178.353 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -156.0 173.24 17.09 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -178.601 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 49.7 mt -88.98 134.73 27.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 CA-C-O 121.148 0.499 . . . . 0.0 110.499 -179.251 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 55.1 t -73.98 -43.38 52.27 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 C-N-CA 124.149 0.98 . . . . 0.0 109.455 178.779 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 2.1 m -84.18 87.92 7.19 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -179.86 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 11.2 p -83.66 -31.22 26.26 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.352 0.596 . . . . 0.0 112.086 -176.95 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -139.97 94.46 2.76 Favored 'General case' 0 C--N 1.309 -1.192 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.306 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 162' ' ' MET . . . . . 0.432 ' HG2' ' HG2' ' A' ' 163' ' ' GLU . 1.6 pmm? -103.74 -35.91 8.05 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.476 -178.578 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.463 ' OE1' ' HB3' ' A' ' 165' ' ' ASP . 8.9 pt-20 -148.89 146.78 22.39 Favored Pre-proline 0 N--CA 1.441 -0.907 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.236 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -79.0 0.68 9.81 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 122.851 2.367 . . . . 0.0 112.92 -178.769 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . 0.463 ' HB3' ' OE1' ' A' ' 163' ' ' GLU . 28.7 t70 -94.33 -33.78 13.07 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -178.425 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 14.5 mmm180 57.3 18.12 4.11 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 125.952 1.701 . . . . 0.0 115.36 174.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -91.24 -9.79 43.95 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-O 121.23 0.538 . . . . 0.0 110.065 -179.449 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 68.97 93.21 0.08 Allowed 'General case' 0 CA--C 1.49 -1.355 0 C-N-CA 126.143 1.777 . . . . 0.0 111.681 177.558 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.482 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 20.9 p-80 -96.34 159.52 14.9 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.623 -179.135 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 50.3 t80 -50.78 123.29 8.73 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 125.311 1.444 . . . . 0.0 109.59 176.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.62 -10.93 21.39 Favored Glycine 0 N--CA 1.425 -2.092 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.621 -178.068 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.0 mm-40 -89.65 143.64 26.64 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-N 117.805 0.802 . . . . 0.0 111.195 179.585 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -111.86 126.44 55.09 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.468 -1.242 . . . . 0.0 107.826 177.848 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.507 HG11 ' CG ' ' A' ' 190' ' ' MET . 0.3 OUTLIER -117.76 118.5 58.57 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.246 0 C-N-CA 119.249 -0.981 . . . . 0.0 108.384 178.73 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 43.9 ttm180 -104.54 157.52 17.12 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 -179.275 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -129.12 154.35 46.79 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -176.031 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.5 p -135.82 152.13 30.47 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.158 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.581 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 74.8 m -105.48 146.29 29.74 Favored 'General case' 0 C--N 1.274 -2.716 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.871 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -65.88 172.93 3.23 Favored 'General case' 0 CA--C 1.503 -0.832 0 O-C-N 123.732 0.645 . . . . 0.0 110.473 -177.441 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 6.0 p -53.75 104.9 0.11 Allowed 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 124.317 1.047 . . . . 0.0 112.939 -177.764 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.18 -3.64 31.47 Favored Glycine 0 N--CA 1.433 -1.508 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.457 177.889 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -112.64 150.27 31.68 Favored 'General case' 0 N--CA 1.42 -1.946 0 O-C-N 122.162 -0.611 . . . . 0.0 110.397 179.89 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 65.0 pttt -123.36 160.3 27.06 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 1.7 tp -76.18 142.2 14.72 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -179.787 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -88.5 -69.1 0.72 Allowed 'General case' 0 C--N 1.287 -2.114 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -77.8 -128.22 0.42 Allowed Glycine 0 N--CA 1.437 -1.251 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.717 176.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . 0.421 ' O ' ' HB3' ' A' ' 203' ' ' PRO . 5.6 t70 -98.28 162.04 13.39 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.281 -1.378 . . . . 0.0 107.281 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -99.78 1.1 42.84 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 119.513 1.051 . . . . 0.0 112.23 -170.618 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -152.01 153.84 34.83 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 121.398 0.618 . . . . 0.0 112.475 -177.154 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.507 ' CG ' HG11 ' A' ' 174' ' ' VAL . 16.7 ptp -132.72 148.51 52.33 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.289 178.659 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 47.6 m80 -115.17 145.44 42.39 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.604 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 42.8 t -81.58 102.25 10.51 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 177.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 51.9 m -121.66 158.0 29.63 Favored 'General case' 0 N--CA 1.425 -1.688 0 N-CA-C 114.096 1.147 . . . . 0.0 114.096 -168.607 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 21.98 -76.87 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 129.483 3.113 . . . . 0.0 116.973 174.389 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -62.76 -21.2 65.66 Favored 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 125.014 1.325 . . . . 0.0 113.58 -172.059 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 101.73 20.72 12.38 Favored Glycine 0 N--CA 1.435 -1.42 0 C-N-CA 119.62 -1.276 . . . . 0.0 110.913 -175.819 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 21.9 p90 -146.67 173.18 12.58 Favored 'General case' 0 N--CA 1.426 -1.649 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 175.068 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.3 m95 -69.18 138.44 54.1 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 123.651 0.594 . . . . 0.0 111.62 -175.366 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 13.0 p -68.31 -33.4 74.26 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.656 178.841 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 59.5 mmtt -107.23 149.57 27.59 Favored 'General case' 0 N--CA 1.432 -1.352 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.617 -179.765 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -79.84 163.89 24.03 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 114.463 -1.244 . . . . 0.0 109.018 176.467 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 9.6 mtpm? -64.89 128.52 93.78 Favored Pre-proline 0 CA--C 1.502 -0.867 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.964 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . 0.421 ' HB3' ' O ' ' A' ' 187' ' ' ASP . 95.3 Cg_endo -78.78 166.95 22.97 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 C-N-CA 122.247 1.964 . . . . 0.0 111.975 179.55 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.2 tttp -122.44 156.74 33.42 Favored 'General case' 0 N--CA 1.414 -2.268 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 -179.493 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 92.3 m -118.07 116.27 26.53 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 176.796 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 27.4 m . . . . . 0 C--N 1.301 -1.542 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.546 -176.571 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo . . . . . 0 CA--C 1.542 0.915 0 CA-C-O 120.948 0.312 . . . . 0.0 112.113 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.8 m -80.33 -31.9 37.97 Favored 'General case' 0 CA--C 1.502 -0.898 0 CA-C-O 122.262 1.03 . . . . 0.0 108.338 177.787 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.42 -87.97 0.46 Allowed Glycine 1 N--CA 1.395 -4.064 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 173.444 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 26.7 t-80 -176.47 133.22 0.4 Allowed Pre-proline 0 C--N 1.262 -3.213 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 -175.273 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.4 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 85.7 Cg_endo -81.91 1.04 9.49 Favored 'Trans proline' 0 N--CA 1.475 0.422 0 C-N-CA 122.58 2.187 . . . . 0.0 113.464 -174.819 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 100.72 -169.24 21.06 Favored Glycine 0 C--N 1.291 -1.96 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 -175.394 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -151.06 178.37 9.26 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.521 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.9 t -142.99 139.09 16.43 Favored Pre-proline 0 N--CA 1.427 -1.596 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.813 -176.984 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.97 -11.87 21.55 Favored 'Trans proline' 0 CA--C 1.534 0.5 0 C-N-CA 122.635 2.223 . . . . 0.0 111.349 176.227 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -89.63 -4.15 57.93 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.228 -177.021 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.56 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 173.83 -123.73 0.99 Allowed Glycine 0 N--CA 1.419 -2.444 0 C-N-CA 119.823 -1.18 . . . . 0.0 112.371 179.766 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.1 t -165.22 -163.25 0.67 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.28 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.433 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 54.4 p90 -145.72 175.07 10.66 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 178.593 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.8 m -136.01 163.43 30.32 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 176.645 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 23.8 mt -118.94 120.89 38.61 Favored 'General case' 0 C--N 1.285 -2.22 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -178.885 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.401 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 26.1 p -114.13 128.75 56.52 Favored 'General case' 0 C--N 1.285 -2.21 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -175.411 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 97.36 19.67 24.93 Favored Glycine 0 C--N 1.299 -1.48 0 C-N-CA 119.849 -1.167 . . . . 0.0 111.149 -179.523 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.52 -32.16 0.15 Allowed Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 118.911 -1.614 . . . . 0.0 114.417 179.445 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 65.93 19.45 11.26 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 123.205 0.602 . . . . 0.0 111.174 -176.242 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.469 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.3 m -149.23 -177.86 0.47 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.084 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -175.552 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 38.1 m-85 -103.88 47.8 0.87 Allowed 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 118.726 0.694 . . . . 0.0 110.171 -179.772 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.706 ' O ' HG13 ' A' ' 108' ' ' VAL . 10.7 pt-20 -83.63 177.8 8.24 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.311 -1.313 . . . . 0.0 111.554 179.226 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 45.5 m-85 -77.67 130.42 36.8 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.645 174.064 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 91.23 15.72 55.09 Favored Glycine 0 N--CA 1.434 -1.491 0 C-N-CA 120.203 -0.999 . . . . 0.0 112.377 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.706 HG13 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -106.38 149.5 9.77 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 176.06 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.401 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.2 mtpt -113.95 125.69 54.31 Favored 'General case' 0 N--CA 1.418 -2.048 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.485 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -90.01 89.27 7.63 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.225 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 28.5 m -84.91 112.28 21.74 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.981 0 CA-C-O 122.164 0.983 . . . . 0.0 109.565 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . 0.433 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 33.8 m-85 -78.92 142.21 36.94 Favored 'General case' 0 C--N 1.269 -2.9 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.123 -179.569 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.9 t -138.84 122.58 17.57 Favored 'General case' 0 N--CA 1.411 -2.422 0 CA-C-N 115.135 -0.938 . . . . 0.0 108.822 -179.639 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 88.0 m -73.68 160.8 31.04 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 115.487 -0.778 . . . . 0.0 112.0 -178.383 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.56 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 81.2 m-20 -76.44 -176.53 3.72 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.293 179.703 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -52.46 -48.52 65.8 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 124.655 1.182 . . . . 0.0 113.491 -177.28 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.32 10.53 70.98 Favored Glycine 0 C--N 1.3 -1.437 0 C-N-CA 119.786 -1.197 . . . . 0.0 113.306 -177.971 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.53 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 93.6 m-85 -127.62 161.02 29.85 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 122.166 -0.608 . . . . 0.0 111.419 -175.753 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.49 150.43 43.75 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.026 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.21 133.03 39.01 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 -179.681 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.03 127.54 55.92 Favored 'General case' 0 N--CA 1.414 -2.241 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.143 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.2 -163.27 12.62 Favored Glycine 0 C--N 1.296 -1.666 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.811 -179.804 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -108.96 -30.05 8.29 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 178.632 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.7 mm -88.16 127.06 41.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.513 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -129.56 9.84 5.57 Favored 'General case' 0 C--O 1.202 -1.44 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.034 176.777 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 22.1 p90 -139.08 165.52 26.94 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.397 -171.916 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.508 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 52.2 mtp180 -128.57 126.82 41.11 Favored 'General case' 0 C--O 1.204 -1.311 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 171.395 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -98.17 133.11 43.05 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.542 -0.863 . . . . 0.0 109.947 179.187 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 36.2 t -89.86 110.62 21.54 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.31 174.555 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.45 ' CG ' ' H ' ' A' ' 131' ' ' THR . 36.1 t70 -113.44 -167.21 1.17 Allowed 'General case' 0 C--N 1.289 -2.033 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 175.485 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.45 ' H ' ' CG ' ' A' ' 130' ' ' ASP . 15.3 t -67.09 -20.53 65.81 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.319 1.057 . . . . 0.0 109.69 -179.318 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -70.22 -23.73 62.98 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 114.279 -1.328 . . . . 0.0 109.233 175.001 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 105.9 -154.87 16.93 Favored Glycine 0 N--CA 1.42 -2.39 0 N-CA-C 107.169 -2.373 . . . . 0.0 107.169 -173.313 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 96.1 m95 -65.33 99.18 0.38 Allowed 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 117.666 0.733 . . . . 0.0 109.83 172.776 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.6 p -58.64 -67.58 0.35 Allowed 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 124.74 1.216 . . . . 0.0 112.839 -173.009 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . 0.508 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 3.0 m-20 -70.37 167.13 18.81 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.33 178.868 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . 0.41 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 21.9 t0 -98.64 175.55 5.95 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.537 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.41 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 68.7 mt -63.92 121.83 73.52 Favored Pre-proline 0 C--N 1.273 -2.741 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 175.079 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -63.73 174.35 3.8 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 122.482 2.121 . . . . 0.0 112.791 -179.102 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 65.8 mt -98.9 140.73 17.81 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -175.307 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.53 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 42.4 t -128.92 119.5 24.48 Favored 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 -179.784 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -103.14 140.9 36.74 Favored 'General case' 0 C--N 1.279 -2.476 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 -175.901 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.413 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 10.8 p -70.9 138.74 21.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 173.932 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 92.7 t -59.61 114.66 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.73 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -176.371 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 92.4 mttt -113.73 144.55 42.76 Favored 'General case' 0 N--CA 1.426 -1.67 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.274 -177.787 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 82.9 m -112.03 160.95 17.0 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 114.732 -1.122 . . . . 0.0 109.165 179.778 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 59.7 mt -64.82 138.19 97.39 Favored Pre-proline 0 C--N 1.318 -0.781 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -179.183 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -63.48 127.47 19.97 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.821 2.347 . . . . 0.0 111.103 179.376 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.4 t -85.21 142.42 13.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -179.788 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.9 p -67.45 -82.98 0.03 OUTLIER 'General case' 0 N--CA 1.425 -1.704 0 O-C-N 123.604 0.565 . . . . 0.0 111.223 177.412 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 168.41 159.52 0.16 Allowed Pre-proline 0 CA--C 1.513 -0.474 0 C-N-CA 125.554 1.542 . . . . 0.0 106.99 179.716 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -82.88 169.11 13.46 Favored 'Trans proline' 0 N--CA 1.448 -1.196 0 C-N-CA 121.643 1.562 . . . . 0.0 111.352 173.688 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -60.54 -57.02 14.5 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -176.827 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -112.02 25.19 11.82 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.12 0.962 . . . . 0.0 109.798 -172.908 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -146.02 -172.03 16.01 Favored Glycine 0 C--N 1.284 -2.324 0 CA-C-N 114.421 -1.263 . . . . 0.0 110.984 179.04 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.0 pttm -149.79 169.12 21.83 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 178.504 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.546 HG12 ' CE2' ' A' ' 176' ' ' PHE . 62.8 mt -88.2 130.58 37.54 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.879 179.453 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.479 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 12.9 m -87.15 -29.04 5.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.324 0.583 . . . . 0.0 109.628 179.8 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 159' ' ' SER . . . . . 0.414 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 25.2 m -104.55 40.82 1.41 Allowed 'General case' 0 C--N 1.308 -1.233 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.631 -174.812 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 160' ' ' SER . . . . . 0.422 ' HA ' ' OH ' ' A' ' 168' ' ' TYR . 12.1 p -67.12 161.53 24.37 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.2 -178.749 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -46.69 107.35 0.1 Allowed 'General case' 0 C--O 1.24 0.561 0 O-C-N 124.177 0.923 . . . . 0.0 111.805 -179.794 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 34.0 mtm -60.78 -52.47 64.96 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 114.486 -1.233 . . . . 0.0 108.934 179.054 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -129.18 149.82 73.71 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 104.664 -2.347 . . . . 0.0 104.664 174.963 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.82 -6.15 17.76 Favored 'Trans proline' 0 N--CA 1.478 0.58 0 C-N-CA 122.31 2.007 . . . . 0.0 110.998 179.058 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -91.08 -37.05 13.66 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 -179.894 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 23.1 mmm180 -92.68 89.16 6.55 Favored 'General case' 0 N--CA 1.427 -1.614 0 CA-C-N 114.426 -1.261 . . . . 0.0 108.058 179.726 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -84.48 174.08 10.34 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 114.49 -1.232 . . . . 0.0 110.888 -172.57 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . 0.422 ' OH ' ' HA ' ' A' ' 160' ' ' SER . 72.1 m-85 -68.93 113.39 6.3 Favored 'General case' 0 CA--C 1.476 -1.896 0 CA-C-O 121.194 0.521 . . . . 0.0 109.876 -179.008 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 56.7 p-80 -130.44 167.93 17.81 Favored 'General case' 0 C--N 1.281 -2.395 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.038 -174.496 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 79.8 t80 -47.69 132.12 14.34 Favored 'General case' 0 CA--C 1.506 -0.73 0 O-C-N 124.418 1.074 . . . . 0.0 110.612 178.755 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 108.67 -26.11 17.11 Favored Glycine 0 N--CA 1.418 -2.55 0 C-N-CA 120.378 -0.915 . . . . 0.0 111.781 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -76.83 134.05 39.17 Favored 'General case' 0 N--CA 1.414 -2.247 0 CA-C-O 121.664 0.745 . . . . 0.0 110.524 -179.061 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -110.57 90.83 3.44 Favored 'General case' 0 C--N 1.269 -2.893 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 173.959 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.414 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 14.6 p -73.15 105.1 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.9 0 CA-C-O 121.706 0.765 . . . . 0.0 109.257 -176.127 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.506 ' HD2' ' OE2' ' A' ' 188' ' ' GLU . 12.4 ttp180 -97.11 152.73 18.49 Favored 'General case' 0 N--CA 1.411 -2.387 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.387 -175.503 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.546 ' CE2' HG12 ' A' ' 157' ' ' ILE . 81.7 m-85 -121.2 153.22 37.88 Favored 'General case' 0 N--CA 1.428 -1.563 0 C-N-CA 124.173 0.989 . . . . 0.0 109.151 -177.462 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.445 ' HB ' ' CG1' ' A' ' 158' ' ' VAL . 10.3 p -135.7 149.59 28.24 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . 0.421 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 76.6 m -90.06 141.07 29.04 Favored 'General case' 0 C--N 1.268 -2.959 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.464 178.314 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -70.91 -52.6 19.06 Favored 'General case' 0 CA--C 1.477 -1.855 0 CA-C-N 115.298 -0.864 . . . . 0.0 112.338 -175.347 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 180' ' ' SER . . . . . 0.431 ' HB3' ' CE2' ' A' ' 182' ' ' TYR . 34.3 t -116.01 -158.88 0.7 Allowed 'General case' 0 C--N 1.26 -3.287 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -177.183 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -71.77 51.03 1.18 Allowed Glycine 0 C--O 1.229 -0.203 0 O-C-N 123.473 0.483 . . . . 0.0 113.294 -177.975 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . 0.431 ' CE2' ' HB3' ' A' ' 180' ' ' SER . 90.5 m-85 -103.51 170.64 7.83 Favored 'General case' 0 C--N 1.292 -1.913 0 C-N-CA 123.137 0.575 . . . . 0.0 109.539 177.463 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . 0.451 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 39.4 pttt -126.5 150.92 48.46 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 176.374 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.5 tp -65.31 142.68 16.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 CA-C-O 121.427 0.632 . . . . 0.0 110.025 176.096 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -67.23 -58.41 4.89 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.915 -178.362 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -120.96 -111.03 2.22 Favored Glycine 0 N--CA 1.42 -2.396 0 N-CA-C 110.589 -1.005 . . . . 0.0 110.589 -178.941 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -88.91 144.9 25.88 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.225 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . 0.506 ' OE2' ' HD2' ' A' ' 175' ' ' ARG . 12.8 pt-20 -87.62 1.27 54.13 Favored 'General case' 0 C--O 1.205 -1.282 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.986 -176.045 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -145.16 151.18 38.05 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 121.191 0.52 . . . . 0.0 111.312 -179.186 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.408 ' CG ' ' HE1' ' A' ' 176' ' ' PHE . 0.0 OUTLIER -123.4 140.82 52.62 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 175.966 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 26.3 m80 -100.42 140.39 34.74 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.835 -0.346 . . . . 0.0 110.313 176.899 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 52.6 t -86.56 104.41 15.98 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 174.301 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 18.0 m -74.94 156.88 35.86 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-N 115.225 -0.898 . . . . 0.0 111.095 -177.524 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -68.63 1.84 2.89 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.794 1.238 . . . . 0.0 114.163 -174.371 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . 0.417 ' HB3' ' CE2' ' A' ' 197' ' ' PHE . 36.9 t70 -102.1 -17.37 16.06 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 121.33 0.586 . . . . 0.0 109.69 175.609 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 101.34 53.75 0.99 Allowed Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.935 179.912 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . 0.417 ' CE2' ' HB3' ' A' ' 195' ' ' ASP . 52.1 p90 -154.76 156.95 37.25 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.918 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 78.8 m95 -83.96 130.5 34.89 Favored 'General case' 0 N--CA 1.431 -1.394 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 175.39 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 7.7 m -63.8 -29.21 70.44 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.53 -179.81 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . 0.433 ' HD2' ' H ' ' A' ' 201' ' ' GLU . 4.0 mmmt -117.89 152.79 34.69 Favored 'General case' 0 N--CA 1.411 -2.395 0 O-C-N 121.943 -0.473 . . . . 0.0 110.882 -179.516 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.433 ' H ' ' HD2' ' A' ' 200' ' ' LYS . 12.8 pt-20 -71.28 165.63 23.28 Favored 'General case' 0 C--O 1.252 1.205 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 174.875 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . 0.403 ' HB3' ' HE2' ' A' ' 202' ' ' LYS . 41.6 mtpt -61.32 125.3 83.83 Favored Pre-proline 0 N--CA 1.447 -0.602 0 C-N-CA 120.341 -0.544 . . . . 0.0 110.136 174.919 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -88.84 175.04 3.74 Favored 'Trans proline' 0 N--CA 1.419 -2.854 0 C-N-CA 121.791 1.661 . . . . 0.0 110.001 172.932 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.6 mttp -137.91 177.22 8.04 Favored 'General case' 0 C--N 1.284 -2.276 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 -177.073 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.451 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 68.1 m -118.76 104.27 10.43 Favored 'General case' 0 C--N 1.283 -2.324 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 171.776 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.9 m . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 114.306 -1.316 . . . . 0.0 111.337 -172.27 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo . . . . . 0 CA--C 1.536 0.595 0 CA-C-O 120.926 0.303 . . . . 0.0 112.269 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . 0.406 ' HB3' ' CD1' ' A' ' 134' ' ' TRP . 4.5 m -93.16 -24.56 18.19 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.242 0.544 . . . . 0.0 111.558 175.003 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.94 -93.55 0.59 Allowed Glycine 0 CA--C 1.46 -3.345 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 173.196 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 -170.23 132.77 1.02 Allowed Pre-proline 0 C--N 1.262 -3.201 0 N-CA-C 104.02 -2.585 . . . . 0.0 104.02 -175.478 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.478 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 87.9 Cg_endo -81.32 -19.81 7.58 Favored 'Trans proline' 0 C--N 1.332 -0.341 0 C-N-CA 121.637 1.558 . . . . 0.0 113.553 -173.189 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 130.1 -165.39 22.47 Favored Glycine 0 N--CA 1.426 -2.013 0 N-CA-C 110.186 -1.166 . . . . 0.0 110.186 -177.358 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -151.04 151.34 31.89 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 -178.659 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.1 t -131.07 127.5 22.0 Favored Pre-proline 0 C--N 1.303 -1.456 0 C-N-CA 120.338 -0.545 . . . . 0.0 110.553 179.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.46 -18.37 26.08 Favored 'Trans proline' 0 C--O 1.237 0.445 0 C-N-CA 122.523 2.149 . . . . 0.0 111.554 178.843 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.492 ' CB ' ' HB2' ' A' ' 141' ' ' CYS . 59.7 m-85 -78.92 -17.26 55.83 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.192 -177.461 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.462 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -168.97 -126.76 0.87 Allowed Glycine 0 CA--C 1.477 -2.284 0 C-N-CA 120.212 -0.994 . . . . 0.0 111.167 -178.933 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.1 t -160.07 -169.87 2.65 Favored 'General case' 0 C--N 1.284 -2.243 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.651 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.421 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 37.8 p90 -147.11 165.46 29.89 Favored 'General case' 0 N--CA 1.432 -1.331 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 177.582 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.7 m -132.81 161.75 33.32 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 177.879 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 26.6 mt -109.93 137.54 47.57 Favored 'General case' 0 C--N 1.271 -2.837 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.47 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.521 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 11.1 p -134.11 141.6 47.2 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -173.979 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 100.33 -42.37 1.97 Allowed Glycine 0 C--N 1.303 -1.304 0 N-CA-C 108.148 -1.981 . . . . 0.0 108.148 -173.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.449 ' HA3' ' OE2' ' A' ' 105' ' ' GLU . . . -139.63 -143.09 4.33 Favored Glycine 0 N--CA 1.406 -3.358 0 N-CA-C 108.029 -2.028 . . . . 0.0 108.029 176.085 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -151.61 16.22 0.69 Allowed 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.41 1.1 . . . . 0.0 109.829 -178.51 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.543 ' O ' HG13 ' A' ' 108' ' ' VAL . 28.7 m -147.5 -170.57 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 -175.511 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.478 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 30.5 m-85 -96.17 39.11 1.16 Allowed 'General case' 0 C--N 1.307 -1.255 0 CA-C-O 121.99 0.9 . . . . 0.0 110.022 -177.832 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.7 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.2 pt-20 -71.83 178.03 3.89 Favored 'General case' 0 C--O 1.202 -1.44 0 C-N-CA 127.197 2.199 . . . . 0.0 111.888 179.009 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . 0.532 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 27.6 m-85 -79.32 135.9 36.86 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-O 121.008 0.432 . . . . 0.0 110.971 176.49 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.24 3.24 82.34 Favored Glycine 0 N--CA 1.442 -0.91 0 C-N-CA 121.001 -0.618 . . . . 0.0 112.349 178.804 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.7 HG12 ' O ' ' A' ' 105' ' ' GLU . 8.5 p -92.75 142.81 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.549 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.521 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -107.52 126.82 53.0 Favored 'General case' 0 C--N 1.28 -2.437 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 177.682 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -89.32 87.98 7.32 Favored 'General case' 0 C--N 1.28 -2.436 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 174.896 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.442 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 30.0 m -84.97 116.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.383 0 CA-C-O 121.989 0.899 . . . . 0.0 109.403 -179.423 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . 0.421 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 33.9 m-85 -85.73 142.59 28.89 Favored 'General case' 0 C--N 1.27 -2.877 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.42 179.754 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -138.0 124.61 20.9 Favored 'General case' 0 N--CA 1.405 -2.725 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -178.92 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.7 m -74.08 155.61 38.3 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 115.3 -0.863 . . . . 0.0 112.262 -175.498 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.462 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 72.2 m-20 -68.09 173.81 4.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.175 178.482 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -50.75 -48.21 59.17 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 123.78 0.832 . . . . 0.0 112.547 -177.922 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.477 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -89.8 30.88 5.53 Favored Glycine 0 N--CA 1.438 -1.222 0 C-N-CA 120.778 -0.725 . . . . 0.0 113.05 -178.417 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -146.65 157.4 43.7 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 122.177 -0.602 . . . . 0.0 109.555 -176.424 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.5 150.7 47.74 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 122.688 0.395 . . . . 0.0 110.334 177.076 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.99 117.21 15.51 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -175.336 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -103.13 126.13 50.16 Favored 'General case' 0 N--CA 1.407 -2.593 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -178.876 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 120.33 176.54 15.77 Favored Glycine 0 C--N 1.29 -1.98 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.706 -177.551 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -93.77 -24.77 17.68 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.906 0.86 . . . . 0.0 109.02 -178.384 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.428 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.2 mm -104.03 129.22 56.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 114.851 -1.068 . . . . 0.0 109.213 -176.538 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -119.0 -2.49 10.8 Favored 'General case' 0 C--O 1.201 -1.493 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 177.611 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 39.8 p90 -138.46 162.18 35.13 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 120.945 0.402 . . . . 0.0 110.526 -169.374 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 61.1 mtp180 -123.53 135.24 53.91 Favored 'General case' 0 C--N 1.282 -2.328 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 170.989 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -110.45 130.58 55.53 Favored 'General case' 0 C--N 1.284 -2.253 0 C-N-CA 119.046 -1.061 . . . . 0.0 110.215 -178.517 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . 0.532 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 36.9 t -75.99 98.96 4.41 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.328 0.585 . . . . 0.0 109.918 177.878 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.446 ' OD2' HG22 ' A' ' 131' ' ' THR . 20.3 t70 -100.14 -175.43 2.94 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 178.172 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.446 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -69.26 -19.49 63.92 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-O 121.997 0.904 . . . . 0.0 109.237 179.441 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -83.12 -12.79 56.69 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.304 -1.316 . . . . 0.0 109.326 179.831 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 110.37 -164.19 12.29 Favored Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -175.942 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.406 ' CD1' ' HB3' ' A' ' 85' ' ' CYS . 98.5 m95 -64.26 114.79 4.47 Favored 'General case' 0 C--O 1.248 0.978 0 CA-C-N 117.922 0.861 . . . . 0.0 109.88 175.363 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 68.6 p -71.29 164.87 24.86 Favored 'General case' 0 N--CA 1.417 -2.108 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 177.702 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 55.8 m-20 65.53 -158.87 0.28 Allowed 'General case' 0 C--O 1.245 0.826 0 O-C-N 123.843 0.714 . . . . 0.0 109.276 173.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -136.48 176.28 8.85 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 175.866 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.1 mt -64.29 120.44 64.81 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 124.271 0.982 . . . . 0.0 108.368 175.338 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . 0.428 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 45.6 Cg_endo -67.68 176.52 4.99 Favored 'Trans proline' 0 C--O 1.248 1.024 0 C-N-CA 123.034 2.489 . . . . 0.0 112.583 -179.256 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.1 mm -111.71 137.0 46.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 CA-C-O 121.108 0.48 . . . . 0.0 110.318 -173.234 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.492 ' HB2' ' CB ' ' A' ' 93' ' ' PHE . 99.3 m -113.52 111.12 21.38 Favored 'General case' 0 C--N 1.279 -2.47 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 172.83 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -93.67 151.63 19.53 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 179.211 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 8.9 p -74.09 141.26 16.37 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.553 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . 0.477 HG22 ' C ' ' A' ' 117' ' ' GLY . 15.6 m -67.09 101.14 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.776 0 CA-C-O 121.967 0.889 . . . . 0.0 110.024 177.843 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -85.18 123.51 30.77 Favored 'General case' 0 N--CA 1.407 -2.599 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.314 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.491 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 62.6 m -83.2 122.28 28.2 Favored 'General case' 0 C--N 1.273 -2.758 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 178.02 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 80.6 mt -53.36 131.69 52.94 Favored Pre-proline 0 C--N 1.313 -0.985 0 N-CA-C 113.629 0.974 . . . . 0.0 113.629 -175.693 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -56.44 121.03 9.31 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 123.33 2.687 . . . . 0.0 110.989 -178.575 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.5 p -89.28 149.48 4.01 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.973 -175.878 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.4 p -81.73 -173.45 4.44 Favored 'General case' 0 N--CA 1.422 -1.837 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 175.245 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -123.37 155.63 64.98 Favored Pre-proline 0 C--N 1.285 -2.238 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -172.802 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -77.35 169.72 20.73 Favored 'Trans proline' 0 CA--C 1.543 0.97 0 C-N-CA 121.92 1.746 . . . . 0.0 112.491 178.277 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -64.31 -57.5 9.21 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -178.816 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 -97.87 20.09 12.7 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.846 0.831 . . . . 0.0 110.269 -174.145 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -142.79 -173.27 14.41 Favored Glycine 0 N--CA 1.412 -2.903 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.985 179.878 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 19.8 pttp -156.76 178.31 10.49 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -179.187 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 59.5 mt -101.09 138.35 25.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 CA-C-N 117.83 0.286 . . . . 0.0 111.066 -177.33 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.444 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.7 m -84.69 -33.64 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 177.426 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 6.1 m -95.78 48.62 1.13 Allowed 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.943 -174.584 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 25.5 m -70.29 94.44 0.93 Allowed 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.69 0.281 . . . . 0.0 110.264 -178.492 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 57.39 -166.02 0.15 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 123.996 0.919 . . . . 0.0 109.98 -175.219 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 63.2 mtm -135.94 -61.24 0.71 Allowed 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 106.179 -1.785 . . . . 0.0 106.179 173.233 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -129.82 151.23 77.82 Favored Pre-proline 0 C--N 1.291 -1.945 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 171.718 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -61.08 -15.23 38.05 Favored 'Trans proline' 0 N--CA 1.482 0.83 0 C-N-CA 122.948 2.432 . . . . 0.0 113.353 -177.455 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -104.92 -29.2 10.64 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.25 0.548 . . . . 0.0 110.661 179.565 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 30.3 mmm180 -93.39 99.48 11.98 Favored 'General case' 0 N--CA 1.429 -1.483 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.735 -175.844 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -76.11 -177.9 4.18 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.176 -179.513 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -67.69 130.98 44.68 Favored 'General case' 0 CA--C 1.502 -0.902 0 CA-C-O 120.984 0.421 . . . . 0.0 110.088 179.285 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -125.49 165.05 19.17 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -177.3 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . 0.462 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 92.4 t80 -51.57 134.86 29.16 Favored 'General case' 0 C--O 1.239 0.526 0 O-C-N 123.885 0.741 . . . . 0.0 109.11 170.586 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 109.94 -10.05 31.89 Favored Glycine 0 N--CA 1.424 -2.103 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.732 -179.112 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 -99.55 159.29 15.14 Favored 'General case' 0 N--CA 1.433 -1.291 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.916 -178.842 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' A' ' 190' ' ' MET . . . -138.73 123.98 19.21 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 175.688 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.532 HG23 ' CH2' ' A' ' 198' ' ' TRP . 85.0 t -87.68 109.71 19.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.047 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.444 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 41.2 ttm180 -96.71 142.57 28.58 Favored 'General case' 0 N--CA 1.416 -2.162 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 177.781 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -110.19 159.59 17.24 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 -177.294 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.435 HG21 ' CG1' ' A' ' 158' ' ' VAL . 0.1 OUTLIER -130.76 139.79 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.467 -2.247 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.675 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . 0.483 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 77.4 m -84.79 129.52 34.81 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 173.501 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -53.28 -51.63 61.69 Favored 'General case' 0 CA--C 1.48 -1.713 0 C-N-CA 124.76 1.224 . . . . 0.0 112.584 -175.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 13.3 t -123.63 -154.58 0.61 Allowed 'General case' 0 N--CA 1.402 -2.837 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 -177.052 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -74.22 51.11 2.06 Favored Glycine 0 N--CA 1.443 -0.838 0 O-C-N 123.588 0.555 . . . . 0.0 113.78 -176.468 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . 0.483 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 98.4 m-85 -100.89 168.39 9.66 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 176.114 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 50.6 pttt -121.41 146.05 47.29 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.794 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.465 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.8 tt -76.86 141.8 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.766 0 C-N-CA 119.691 -0.804 . . . . 0.0 110.276 176.403 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -53.75 -61.13 2.5 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 125.086 1.354 . . . . 0.0 113.228 -176.227 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -123.89 -97.81 1.27 Allowed Glycine 0 CA--C 1.496 -1.147 0 C-N-CA 120.33 -0.938 . . . . 0.0 112.814 -178.654 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -85.07 159.97 20.08 Favored 'General case' 0 CA--C 1.48 -1.728 0 N-CA-C 106.876 -1.527 . . . . 0.0 106.876 176.75 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . 0.465 ' HA ' HD13 ' A' ' 184' ' ' ILE . 14.5 pt-20 -102.47 3.86 38.08 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 118.114 -1.434 . . . . 0.0 109.468 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 8.7 pt-20 -151.45 147.37 26.78 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-N 115.547 -0.751 . . . . 0.0 112.386 -176.216 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.47 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 13.9 ptp -113.79 128.25 56.34 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.649 175.446 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 34.1 t-80 -110.56 146.56 35.85 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 116.746 -0.206 . . . . 0.0 110.473 -174.646 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 88.6 m -75.06 155.04 37.63 Favored 'General case' 0 C--O 1.241 0.642 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 178.436 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 60.6 m -126.17 171.46 10.86 Favored 'General case' 0 C--O 1.256 1.395 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 169.387 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -78.4 91.56 4.49 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.261 1.029 . . . . 0.0 112.496 -172.347 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 9.5 t70 174.22 -38.18 0.01 OUTLIER 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 113.15 -1.841 . . . . 0.0 106.293 176.508 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . 0.491 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 119.65 18.69 4.33 Favored Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.196 -179.534 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -109.65 158.13 18.38 Favored 'General case' 0 C--O 1.251 1.168 0 O-C-N 122.226 -0.573 . . . . 0.0 109.969 176.418 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . 0.532 ' CH2' HG23 ' A' ' 174' ' ' VAL . 87.6 m95 -87.31 144.69 26.67 Favored 'General case' 0 N--CA 1.423 -1.815 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 176.18 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.2 m -92.94 7.59 43.33 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-O 121.879 0.847 . . . . 0.0 110.926 -178.176 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . 0.468 ' HG3' ' N ' ' A' ' 201' ' ' GLU . 0.8 OUTLIER -139.39 153.28 47.61 Favored 'General case' 0 N--CA 1.417 -2.102 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 177.096 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . 0.468 ' N ' ' HG3' ' A' ' 200' ' ' LYS . 0.2 OUTLIER -105.28 171.93 7.06 Favored 'General case' 0 C--N 1.279 -2.461 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 178.9 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . 0.402 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 45.8 mtpt -63.38 117.61 35.74 Favored Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 114.154 1.168 . . . . 0.0 114.154 -174.865 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -82.33 171.31 12.58 Favored 'Trans proline' 0 N--CA 1.445 -1.369 0 C-N-CA 122.793 2.329 . . . . 0.0 108.953 172.246 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . 0.43 ' O ' ' HA ' ' A' ' 184' ' ' ILE . 38.8 mtpt -122.38 174.55 6.95 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.966 -0.694 . . . . 0.0 109.432 179.681 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 57.3 m -115.39 107.56 15.37 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 173.19 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m . . . . . 0 C--N 1.281 -2.413 0 CA-C-N 114.371 -1.286 . . . . 0.0 109.736 -173.638 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo . . . . . 0 N--CA 1.477 0.548 0 CA-C-O 121.078 0.366 . . . . 0.0 112.766 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 65.1 m -73.32 -27.15 61.36 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.547 0.689 . . . . 0.0 110.677 178.027 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.19 13.12 40.19 Favored Glycine 0 C--N 1.3 -1.417 0 CA-C-N 115.206 -0.907 . . . . 0.0 114.832 172.724 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.7 t60 68.77 125.37 0.03 OUTLIER Pre-proline 0 N--CA 1.489 1.484 0 C-N-CA 123.841 0.856 . . . . 0.0 108.931 -179.234 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.418 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 92.7 Cg_endo -75.97 7.77 3.09 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 123.059 2.506 . . . . 0.0 114.862 -171.998 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 97.94 -166.0 22.25 Favored Glycine 0 C--N 1.277 -2.715 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -175.514 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -143.37 140.21 30.38 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 -179.036 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.3 t -102.64 129.53 25.73 Favored Pre-proline 0 C--N 1.299 -1.624 0 CA-C-O 121.234 0.54 . . . . 0.0 110.829 -178.366 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.25 -11.55 25.0 Favored 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 122.544 2.163 . . . . 0.0 111.474 177.599 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -87.25 -3.02 59.03 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.518 -178.285 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 167.69 -120.85 0.93 Allowed Glycine 0 N--CA 1.43 -1.717 0 C-N-CA 120.271 -0.966 . . . . 0.0 111.797 179.235 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.4 t -151.49 -172.86 4.33 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 123.71 0.3 . . . . 0.0 110.361 179.447 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.6 p90 -146.13 156.42 43.42 Favored 'General case' 0 N--CA 1.436 -1.168 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 176.65 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 5.5 m -121.92 166.52 14.29 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 178.041 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.441 HD11 ' CE1' ' A' ' 104' ' ' PHE . 14.8 mt -120.14 128.83 53.78 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.897 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.431 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 33.7 p -115.91 135.72 53.72 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 -178.262 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 114.53 -65.04 0.29 Allowed Glycine 0 N--CA 1.429 -1.781 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -179.243 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -119.69 -5.93 10.72 Favored Glycine 0 C--N 1.309 -0.938 0 C-N-CA 119.98 -1.105 . . . . 0.0 113.143 -178.991 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 59.79 19.62 8.44 Favored 'General case' 0 N--CA 1.495 1.809 0 C-N-CA 123.04 0.536 . . . . 0.0 112.373 -178.079 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.506 ' O ' HG12 ' A' ' 108' ' ' VAL . 23.0 m -146.67 -171.12 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.203 -1.379 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -176.028 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.441 ' CE1' HD11 ' A' ' 98' ' ' LEU . 54.0 m-85 -106.42 39.41 1.83 Allowed 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 118.565 0.62 . . . . 0.0 110.635 -175.756 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.736 ' O ' HG11 ' A' ' 108' ' ' VAL . 11.5 pt-20 -85.43 -176.61 6.18 Favored 'General case' 0 C--O 1.202 -1.443 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.52 179.165 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 -75.63 137.29 40.64 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.935 -0.478 . . . . 0.0 111.143 177.702 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.35 4.93 73.23 Favored Glycine 0 N--CA 1.433 -1.536 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.962 178.132 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.736 HG11 ' O ' ' A' ' 105' ' ' GLU . 13.9 p -95.02 146.22 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 C-N-CA 119.854 -0.738 . . . . 0.0 109.179 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.431 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 56.3 mtpt -110.17 123.75 50.32 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.591 179.198 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.508 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.3 93.63 9.13 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 176.469 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 76.7 t -86.03 109.62 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.772 0 C-N-CA 123.972 0.909 . . . . 0.0 109.208 -177.803 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -82.99 139.22 33.42 Favored 'General case' 0 C--N 1.286 -2.17 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.773 -179.566 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 11.1 t -136.83 127.78 27.57 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.738 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 82.3 m -81.31 160.18 24.25 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.822 -174.593 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -72.46 177.21 4.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.9 175.926 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -56.57 -47.02 80.39 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -176.14 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -78.01 11.1 23.32 Favored Glycine 0 CA--C 1.522 0.495 0 CA-C-N 116.186 -0.461 . . . . 0.0 114.236 -178.876 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.598 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 82.5 m-85 -133.45 156.73 47.19 Favored 'General case' 0 C--N 1.311 -1.094 0 O-C-N 122.368 -0.489 . . . . 0.0 110.713 -179.195 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -143.44 147.97 35.4 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.006 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 7.2 tp -76.95 144.03 39.08 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-O 120.978 0.418 . . . . 0.0 110.834 -173.158 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.82 125.38 46.36 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -179.778 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 108.12 -176.28 20.34 Favored Glycine 0 C--N 1.291 -1.919 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -174.532 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -101.07 -24.95 14.21 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.363 0.602 . . . . 0.0 110.288 -179.726 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.2 mm -80.96 127.25 39.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -178.578 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -134.42 11.38 3.79 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 -178.561 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.508 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 32.8 p90 -149.01 167.71 25.08 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 -172.135 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.498 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 46.7 mtp180 -129.2 119.37 23.93 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 171.769 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -91.23 128.68 37.15 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.755 -0.778 . . . . 0.0 110.149 178.687 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 35.2 t -87.07 107.13 18.3 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.338 -0.945 . . . . 0.0 109.89 175.126 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.439 ' OD1' HG22 ' A' ' 131' ' ' THR . 7.2 t70 -100.61 -168.73 1.61 Allowed 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 176.342 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.439 HG22 ' OD1' ' A' ' 130' ' ' ASP . 11.1 t -69.84 -18.15 63.43 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 122.445 1.117 . . . . 0.0 109.176 178.279 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -80.67 -7.0 59.18 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 114.294 -1.321 . . . . 0.0 109.327 177.036 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 97.34 -158.57 21.08 Favored Glycine 0 N--CA 1.429 -1.77 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -176.316 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . 0.416 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 90.0 m95 -65.32 108.48 1.94 Allowed 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 175.963 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 30.0 p -64.05 -55.2 23.93 Favored 'General case' 0 C--N 1.317 -0.84 0 C-N-CA 123.705 0.802 . . . . 0.0 111.581 -176.251 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . 0.498 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.3 m120 -78.64 167.22 21.56 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 114.857 -1.065 . . . . 0.0 109.04 -179.708 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -99.86 179.12 4.62 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 175.162 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.7 mt -65.63 118.98 56.45 Favored Pre-proline 0 C--N 1.325 -0.494 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 174.113 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.7 146.64 84.5 Favored 'Trans proline' 0 C--O 1.25 1.101 0 C-N-CA 122.322 2.015 . . . . 0.0 112.802 -176.292 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 66.0 mt -72.4 130.35 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.58 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.0 -179.783 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.598 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 45.3 t -121.48 142.42 50.07 Favored 'General case' 0 C--N 1.274 -2.678 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 176.354 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 6.1 tp10 -121.43 152.97 38.48 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -174.73 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.453 HG23 ' NE2' ' A' ' 169' ' ' HIS . 8.1 p -73.74 141.73 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.5 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.019 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 74.7 t -60.95 119.82 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.882 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 52.8 mtmt -125.42 138.43 54.02 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.477 -177.504 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 2.1 p -110.75 160.61 16.56 Favored 'General case' 0 C--N 1.287 -2.112 0 CA-C-N 115.298 -0.865 . . . . 0.0 112.18 -179.186 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . 0.403 HD13 ' HD2' ' A' ' 148' ' ' PRO . 0.3 OUTLIER -77.97 135.6 62.87 Favored Pre-proline 0 N--CA 1.426 -1.65 0 C-N-CA 124.573 1.149 . . . . 0.0 111.302 -173.533 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.403 ' HD2' HD13 ' A' ' 147' ' ' LEU . 12.1 Cg_endo -55.97 126.87 23.84 Favored 'Trans proline' 0 C--O 1.244 0.784 0 C-N-CA 123.812 3.008 . . . . 0.0 112.661 179.304 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 10.8 p -91.21 150.31 3.8 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.128 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 19.9 p -71.53 -88.34 0.02 OUTLIER 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 113.505 0.928 . . . . 0.0 113.505 -177.324 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 171.91 164.3 0.25 Allowed Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 179.738 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . 0.431 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 73.7 Cg_endo -78.45 166.02 24.61 Favored 'Trans proline' 0 N--CA 1.454 -0.849 0 C-N-CA 121.688 1.592 . . . . 0.0 110.419 171.624 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -64.94 -61.53 2.11 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -179.754 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -91.34 35.56 0.93 Allowed 'General case' 0 C--O 1.247 0.963 0 O-C-N 121.773 -0.579 . . . . 0.0 111.24 179.709 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -156.85 -161.78 11.02 Favored Glycine 0 N--CA 1.425 -2.053 0 C-N-CA 120.145 -1.026 . . . . 0.0 112.384 178.263 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 59.5 pttt -159.07 -178.48 7.26 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -178.394 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 58.2 mt -96.62 141.3 15.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 117.577 0.171 . . . . 0.0 111.159 -178.604 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.443 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.3 m -88.77 -31.98 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.931 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 176.317 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.8 m -92.58 88.98 6.52 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.027 -176.07 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.0 m -55.51 136.83 49.64 Favored 'General case' 0 C--N 1.309 -1.152 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.585 179.695 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . 0.439 ' C ' ' H ' ' A' ' 163' ' ' GLU . . . -65.98 171.35 4.56 Favored 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 116.013 -0.539 . . . . 0.0 112.408 -175.91 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.92 11.14 2.83 Favored 'General case' 0 C--O 1.207 -1.155 0 C-N-CA 123.381 0.672 . . . . 0.0 110.831 178.801 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.439 ' H ' ' C ' ' A' ' 161' ' ' ALA 0.337 49.4 mt-10 34.26 -77.23 0.0 OUTLIER Pre-proline 0 N--CA 1.487 1.423 0 C-N-CA 129.253 3.021 . . . . 0.0 119.07 173.094 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -59.4 -19.5 51.59 Favored 'Trans proline' 0 C--N 1.38 2.23 0 CA-C-N 122.34 1.872 . . . . 0.0 111.361 174.227 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . 0.449 ' C ' ' HG3' ' A' ' 166' ' ' ARG . 6.6 m-20 -106.31 -38.35 6.26 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 175.864 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.449 ' HG3' ' C ' ' A' ' 165' ' ' ASP 0.358 7.9 ppt_? 45.31 7.84 0.0 OUTLIER 'General case' 0 C--N 1.358 0.954 0 N-CA-C 118.041 2.608 . . . . 0.0 118.041 -172.911 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -103.19 135.44 44.84 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 107.931 -1.136 . . . . 0.0 107.931 175.719 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . 0.438 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 73.2 m-85 -87.48 139.11 30.88 Favored 'General case' 0 C--N 1.287 -2.149 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.446 -173.288 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.453 ' NE2' HG23 ' A' ' 143' ' ' VAL . 54.9 t-80 -86.32 146.23 26.58 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.023 -0.99 . . . . 0.0 108.687 179.817 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 83.6 t80 -54.64 129.73 37.66 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.714 176.32 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 112.91 -22.17 16.85 Favored Glycine 0 N--CA 1.432 -1.602 0 C-N-CA 120.155 -1.021 . . . . 0.0 111.994 -178.006 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -70.35 150.88 45.85 Favored 'General case' 0 C--O 1.251 1.149 0 CA-C-O 120.87 0.367 . . . . 0.0 110.276 178.359 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -134.65 103.1 5.52 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.604 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 95.7 t -76.79 108.92 10.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.617 -178.025 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.443 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 29.5 ttp180 -101.49 142.2 33.22 Favored 'General case' 0 N--CA 1.407 -2.612 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.459 177.813 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . 0.431 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 62.8 m-85 -113.26 153.32 28.6 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.664 -174.809 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -121.29 152.54 24.75 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.275 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.996 179.296 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 67.9 m -99.51 138.87 35.99 Favored 'General case' 0 N--CA 1.403 -2.786 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 172.396 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -55.41 -52.41 63.67 Favored 'General case' 0 CA--C 1.486 -1.49 0 N-CA-C 114.192 1.182 . . . . 0.0 114.192 -175.131 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 58.9 m -150.33 -100.32 0.07 Allowed 'General case' 0 C--N 1.286 -2.153 0 C-N-CA 120.144 -0.622 . . . . 0.0 112.042 -177.005 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -87.5 44.68 3.29 Favored Glycine 0 CA--C 1.494 -1.254 0 CA-C-O 121.264 0.369 . . . . 0.0 112.343 -177.654 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -123.9 158.59 31.58 Favored 'General case' 0 N--CA 1.415 -2.2 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.531 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . 0.433 ' O ' ' HD2' ' A' ' 183' ' ' LYS . 1.2 pptp? -132.01 143.13 49.85 Favored 'General case' 0 C--N 1.288 -2.066 0 O-C-N 123.878 0.736 . . . . 0.0 109.178 179.118 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . 0.424 HD11 ' HA ' ' A' ' 188' ' ' GLU . 4.2 tt -71.57 142.47 15.4 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.26 0 CA-C-O 121.489 0.661 . . . . 0.0 111.626 -178.299 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -76.59 -57.08 4.06 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.735 -175.845 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -93.05 -126.42 4.16 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 120.277 -0.963 . . . . 0.0 111.954 -177.776 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -93.28 158.83 15.55 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 176.677 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . 0.424 ' HA ' HD11 ' A' ' 184' ' ' ILE . 14.5 pt-20 -95.1 -7.81 38.33 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 118.915 -1.114 . . . . 0.0 110.976 -174.333 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -138.91 135.79 34.81 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.163 0.506 . . . . 0.0 112.339 -176.497 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 12.8 ptp -116.12 124.05 49.38 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.398 176.301 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 52.0 t-80 -97.95 135.99 38.87 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.702 -176.234 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 16.4 t -71.15 118.61 14.15 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.34 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.5 m -97.56 165.33 12.04 Favored 'General case' 0 N--CA 1.437 -1.112 0 O-C-N 123.606 0.567 . . . . 0.0 110.445 -175.756 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -65.51 -6.76 11.6 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 124.514 1.126 . . . . 0.0 112.316 -177.573 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -74.25 -22.2 59.43 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.565 175.532 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 92.44 14.51 55.53 Favored Glycine 0 N--CA 1.435 -1.418 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -174.521 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -136.6 176.81 8.37 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.587 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 88.1 m95 -84.78 152.28 23.78 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.92 -177.521 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 21.0 p -80.23 -14.58 58.31 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.508 179.835 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 64.8 mmtt -124.36 165.98 16.75 Favored 'General case' 0 CA--C 1.477 -1.846 0 CA-C-O 122.141 0.972 . . . . 0.0 113.6 -173.957 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -91.47 166.44 12.86 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 113.053 -1.885 . . . . 0.0 109.337 176.322 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 6.1 mmmm -65.96 109.78 3.68 Favored Pre-proline 0 C--N 1.318 -0.787 0 O-C-N 124.053 0.846 . . . . 0.0 112.939 178.854 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -92.04 156.85 3.28 Favored 'Trans proline' 0 N--CA 1.424 -2.612 0 C-N-CA 122.42 2.08 . . . . 0.0 110.412 177.687 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . 0.403 ' HA ' ' HB3' ' A' ' 152' ' ' PRO . 19.1 ptpt -135.68 155.81 49.83 Favored 'General case' 0 C--N 1.287 -2.126 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.005 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 97.5 m -93.29 118.52 31.37 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 177.569 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.1 m . . . . . 0 C--N 1.291 -1.951 0 CA-C-N 114.007 -1.451 . . . . 0.0 107.326 -178.267 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.452 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 41.0 Cg_endo . . . . . 0 CA--C 1.534 0.505 0 CA-C-O 121.181 0.409 . . . . 0.0 111.642 . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . 0.547 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 3.2 m -94.36 -17.9 22.11 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 122.1 0.952 . . . . 0.0 110.211 174.176 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.73 -87.72 0.54 Allowed Glycine 2 N--CA 1.391 -4.356 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 172.364 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.4 t-80 -171.85 138.24 1.02 Allowed Pre-proline 0 C--N 1.247 -3.854 0 N-CA-C 105.735 -1.95 . . . . 0.0 105.735 -172.739 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.49 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 91.9 Cg_endo -87.45 2.06 6.87 Favored 'Trans proline' 0 C--N 1.322 -0.837 0 C-N-CA 121.946 1.764 . . . . 0.0 112.764 -177.76 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.07 -166.37 13.1 Favored Glycine 0 N--CA 1.428 -1.875 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 -179.708 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -159.27 124.12 4.08 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 177.659 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.8 t -110.56 137.32 20.69 Favored Pre-proline 0 C--N 1.296 -1.735 0 CA-C-O 120.895 0.379 . . . . 0.0 111.749 -178.585 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -83.07 -10.11 10.39 Favored 'Trans proline' 0 CA--C 1.544 1.0 0 C-N-CA 122.742 2.295 . . . . 0.0 112.062 174.063 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -88.81 6.76 37.42 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.414 0.626 . . . . 0.0 111.143 -178.624 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.412 ' HA2' ' ND2' ' A' ' 115' ' ' ASN . . . 161.95 -123.86 1.24 Allowed Glycine 0 N--CA 1.415 -2.751 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.607 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.6 t -164.29 -159.72 0.5 Allowed 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 -178.592 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.6 p90 -152.88 165.53 35.17 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 176.987 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -127.83 159.52 34.61 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 177.906 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.1 mt -117.18 132.18 56.7 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -178.54 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 16.5 p -125.53 129.77 50.39 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -176.388 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.57 27.74 34.68 Favored Glycine 0 C--N 1.313 -0.703 0 C-N-CA 120.353 -0.927 . . . . 0.0 111.653 -179.447 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 178.37 -45.81 0.09 OUTLIER Glycine 0 N--CA 1.433 -1.542 0 C-N-CA 119.69 -1.243 . . . . 0.0 112.8 -179.158 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 70.44 8.42 6.6 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 124.195 0.998 . . . . 0.0 109.965 -178.304 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.559 ' O ' HG13 ' A' ' 108' ' ' VAL . 25.2 m -148.82 -175.74 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.125 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 -177.864 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.49 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 23.5 m-85 -98.9 38.08 1.43 Allowed 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 118.995 0.816 . . . . 0.0 110.782 -176.296 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.747 ' O ' HG12 ' A' ' 108' ' ' VAL . 15.2 pt-20 -79.86 175.54 10.54 Favored 'General case' 0 C--O 1.195 -1.765 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.815 -179.344 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . 0.522 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 43.0 m-85 -74.73 126.24 30.45 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 122.144 -0.347 . . . . 0.0 111.536 179.404 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 102.21 -1.22 50.66 Favored Glycine 0 N--CA 1.439 -1.16 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.618 179.713 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.747 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -92.45 147.55 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.053 0 C-N-CA 120.068 -0.653 . . . . 0.0 109.626 -179.447 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -114.19 123.51 49.75 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 177.8 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.81 94.85 9.88 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 177.86 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 76.8 t -84.16 108.36 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.921 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -179.439 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . 0.53 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 37.6 t80 -74.82 140.99 44.32 Favored 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 123.563 0.745 . . . . 0.0 109.37 -177.012 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 3.3 t -144.3 111.49 5.9 Favored 'General case' 0 N--CA 1.426 -1.632 0 CA-C-O 121.919 0.866 . . . . 0.0 110.492 -179.637 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.514 ' SG ' ' HE1' ' A' ' 112' ' ' TYR . 74.7 m -71.46 162.17 29.86 Favored 'General case' 0 C--O 1.255 1.365 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.803 178.501 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.412 ' ND2' ' HA2' ' A' ' 94' ' ' GLY . 37.6 m-20 -74.99 -177.37 3.31 Favored 'General case' 0 C--O 1.211 -0.942 0 CA-C-N 115.817 -0.628 . . . . 0.0 109.905 175.582 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -66.86 -35.05 79.14 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -174.947 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.415 ' HA2' ' CD2' ' A' ' 170' ' ' PHE . . . -73.98 -6.19 72.64 Favored Glycine 0 C--N 1.311 -0.829 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.741 178.948 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.541 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 87.8 m-85 -129.88 167.91 17.43 Favored 'General case' 0 N--CA 1.441 -0.903 0 O-C-N 122.427 -0.455 . . . . 0.0 110.189 -176.615 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -146.27 157.55 43.81 Favored 'General case' 0 C--N 1.289 -2.033 0 CA-C-O 120.908 0.385 . . . . 0.0 110.682 -178.325 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -78.93 125.78 29.83 Favored 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 178.236 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.563 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -115.45 134.26 55.26 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 178.2 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.03 -178.07 20.6 Favored Glycine 0 C--N 1.289 -2.036 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -178.501 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -96.46 -40.53 9.03 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 -178.699 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.579 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 46.8 mm -77.26 124.06 34.99 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.696 -178.271 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -131.54 9.27 4.66 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 -176.615 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.47 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 18.5 p90 -143.88 166.99 23.38 Favored 'General case' 0 N--CA 1.425 -1.689 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -174.978 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . 0.435 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 63.3 mtp180 -131.95 122.58 25.82 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 171.345 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -91.84 124.8 36.24 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 119.889 -0.724 . . . . 0.0 111.166 178.386 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . 0.522 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 36.0 t -80.0 105.03 10.98 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 175.2 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.437 ' OD2' HG21 ' A' ' 131' ' ' THR . 6.9 t70 -118.9 -169.92 1.82 Allowed 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -178.448 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.437 HG21 ' OD2' ' A' ' 130' ' ' ASP . 12.4 t -57.75 -26.01 61.25 Favored 'General case' 0 CA--C 1.563 1.45 0 C-N-CA 123.803 0.841 . . . . 0.0 112.266 -174.19 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -84.36 -24.86 29.53 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.882 0.848 . . . . 0.0 110.585 -179.731 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.547 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 125.52 -152.55 17.92 Favored Glycine 0 N--CA 1.419 -2.484 0 N-CA-C 106.811 -2.515 . . . . 0.0 106.811 -171.641 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -70.48 114.75 8.9 Favored 'General case' 0 N--CA 1.433 -1.321 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 175.281 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.3 p -64.94 -54.77 25.42 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.762 0.791 . . . . 0.0 111.456 -176.606 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . 0.435 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.8 m120 -78.96 167.77 20.65 Favored 'General case' 0 C--N 1.296 -1.758 0 CA-C-N 114.703 -1.135 . . . . 0.0 108.619 -178.716 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -98.96 -179.91 4.42 Favored 'General case' 0 C--N 1.29 -2.018 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 175.004 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.1 mt -65.17 121.17 72.9 Favored Pre-proline 0 C--N 1.309 -1.175 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 177.526 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . 0.579 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 23.2 Cg_exo -57.67 167.29 4.09 Favored 'Trans proline' 0 C--O 1.245 0.853 0 C-N-CA 122.709 2.273 . . . . 0.0 112.179 177.909 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.563 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 3.6 mp -94.27 132.25 38.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 -171.019 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.541 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 8.5 t -112.62 119.39 37.97 Favored 'General case' 0 N--CA 1.423 -1.792 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 176.233 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -108.96 156.02 20.19 Favored 'General case' 0 C--N 1.274 -2.717 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 178.566 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.645 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 15.0 t -80.18 149.81 5.09 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.315 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 177.348 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 57.1 t -67.66 115.65 6.09 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.622 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.568 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.645 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 39.8 mtpt -123.23 157.67 32.58 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.799 -173.745 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 p -134.12 155.51 49.95 Favored 'General case' 0 C--N 1.286 -2.167 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.443 -179.228 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -55.69 147.09 42.77 Favored Pre-proline 0 N--CA 1.443 -0.807 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -177.086 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -71.77 129.9 16.16 Favored 'Trans proline' 0 N--CA 1.444 -1.43 0 C-N-CA 122.841 2.361 . . . . 0.0 111.914 -178.59 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 46.9 t -95.75 129.19 46.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.595 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.5 p -74.04 -73.93 0.21 Allowed 'General case' 0 N--CA 1.428 -1.551 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 178.215 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 175.82 156.68 0.39 Allowed Pre-proline 0 C--N 1.328 -0.347 0 C-N-CA 125.034 1.334 . . . . 0.0 107.526 178.613 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -66.76 167.04 20.37 Favored 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.532 1.488 . . . . 0.0 109.605 170.852 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . 0.556 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.0 OUTLIER -62.52 -45.16 94.26 Favored 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -175.181 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . 0.556 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 42.7 m-80 -116.51 26.92 9.54 Favored 'General case' 0 CA--C 1.504 -0.813 0 CA-C-O 121.552 0.692 . . . . 0.0 109.689 179.881 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -142.09 -171.7 13.18 Favored Glycine 0 N--CA 1.423 -2.211 0 C-N-CA 120.233 -0.984 . . . . 0.0 111.814 179.834 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 44.2 pttt -153.26 171.1 19.06 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -177.39 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 53.2 mt -96.02 139.34 19.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 120.606 0.241 . . . . 0.0 111.372 -176.151 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.523 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 5.0 m -99.03 -28.32 3.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 CA-C-O 121.269 0.556 . . . . 0.0 110.09 178.305 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 159' ' ' SER . . . . . 0.441 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 46.3 m -110.19 112.64 24.74 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.374 -172.041 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 66.8 m -152.19 112.14 4.02 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 175.729 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -70.6 95.71 1.12 Allowed 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 175.004 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 162' ' ' MET . . . . . 0.461 ' HA ' ' HE3' ' A' ' 162' ' ' MET . 4.8 mmt -99.37 28.82 4.3 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.694 0.759 . . . . 0.0 110.004 -174.019 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 57.5 mm-40 -57.27 167.48 1.2 Allowed Pre-proline 0 C--N 1.307 -1.274 0 CA-C-N 113.492 -1.685 . . . . 0.0 108.693 174.752 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -55.42 -12.34 5.78 Favored 'Trans proline' 0 N--CA 1.5 1.906 0 C-N-CA 123.216 2.611 . . . . 0.0 114.177 178.502 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . 0.42 ' C ' ' HG3' ' A' ' 166' ' ' ARG . 5.4 t70 -94.73 -48.47 6.04 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 123.921 0.888 . . . . 0.0 109.182 -179.623 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . 0.42 ' HG3' ' C ' ' A' ' 165' ' ' ASP 0.28 3.0 ppt_? 39.39 32.75 0.09 Allowed 'General case' 0 C--O 1.239 0.532 0 N-CA-C 117.653 2.464 . . . . 0.0 117.653 -178.985 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -92.38 152.29 19.82 Favored 'General case' 0 N--CA 1.426 -1.661 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 173.893 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -80.67 130.44 35.1 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 176.888 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -135.08 160.41 38.44 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -178.737 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . 0.415 ' CD2' ' HA2' ' A' ' 117' ' ' GLY . 0.9 OUTLIER -61.55 114.67 3.38 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 172.259 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 135.3 -21.16 3.68 Favored Glycine 0 N--CA 1.427 -1.919 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 -176.198 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 25.7 tp60 -76.81 124.04 27.11 Favored 'General case' 0 N--CA 1.401 -2.89 0 C-N-CA 122.883 0.473 . . . . 0.0 109.986 178.271 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -112.07 118.07 34.38 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 171.262 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . 0.441 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 72.0 t -98.41 113.76 34.02 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -177.712 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.523 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 72.2 ttt180 -104.02 149.48 25.13 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 -179.678 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -122.45 162.74 21.12 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 121.579 0.704 . . . . 0.0 111.346 -174.455 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.42 149.33 33.56 Favored 'Isoleucine or valine' 0 CA--C 1.475 -1.942 0 CA-C-N 113.998 -1.455 . . . . 0.0 109.644 174.097 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 73.1 m -111.72 128.38 56.07 Favored 'General case' 0 N--CA 1.406 -2.674 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 176.062 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -50.45 159.74 0.47 Allowed 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 114.62 -1.173 . . . . 0.0 111.713 177.291 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 48.1 t -47.88 113.32 0.7 Allowed 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.42 -175.891 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.55 -17.3 30.95 Favored Glycine 0 N--CA 1.429 -1.796 0 C-N-CA 120.593 -0.813 . . . . 0.0 113.574 178.237 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -99.63 159.57 14.94 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 117.939 0.87 . . . . 0.0 110.965 -177.803 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 16.1 pttm -124.55 150.22 46.12 Favored 'General case' 0 N--CA 1.42 -1.958 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 175.615 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -74.93 133.58 31.21 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.468 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 174.807 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -77.47 -54.71 6.11 Favored 'General case' 0 C--N 1.282 -2.353 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -176.875 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -88.1 -134.65 4.7 Favored Glycine 0 C--N 1.301 -1.372 0 C-N-CA 120.958 -0.639 . . . . 0.0 111.836 177.558 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -87.36 158.7 18.97 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 178.83 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -96.37 6.17 49.34 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.067 -176.154 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -147.38 146.22 29.55 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 121.058 0.456 . . . . 0.0 111.981 -177.109 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 12.9 ptp -126.05 132.06 52.03 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.55 176.465 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 24.0 t-80 -105.84 136.09 46.11 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -177.876 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 8.6 t -74.22 124.55 26.6 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 177.338 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 27.1 t -97.18 171.55 8.38 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 122.91 0.484 . . . . 0.0 110.732 -176.361 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -68.14 -11.41 59.11 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 125.027 1.331 . . . . 0.0 114.439 -173.05 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . 0.502 ' HB3' ' CD1' ' A' ' 197' ' ' PHE . 29.3 t70 -94.23 -3.35 50.88 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 122.415 1.102 . . . . 0.0 109.959 177.68 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 82.81 49.81 4.93 Favored Glycine 0 N--CA 1.434 -1.497 0 C-N-CA 120.443 -0.884 . . . . 0.0 111.442 179.894 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . 0.502 ' CD1' ' HB3' ' A' ' 195' ' ' ASP . 3.1 p90 -151.77 158.97 44.05 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 178.322 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 87.4 m95 -76.38 135.22 39.49 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 176.551 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.9 p -61.1 -28.32 69.01 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.736 0.779 . . . . 0.0 111.291 -177.295 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 40.0 mmtt -113.71 162.83 15.79 Favored 'General case' 0 N--CA 1.418 -2.042 0 CA-C-N 114.729 -1.123 . . . . 0.0 111.062 -178.946 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -75.38 172.28 12.76 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 105.845 -1.909 . . . . 0.0 105.845 172.483 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . 0.478 ' HZ1' ' HB3' ' A' ' 202' ' ' LYS . 3.1 ttpm? -85.2 116.4 65.32 Favored Pre-proline 0 N--CA 1.421 -1.922 0 C-N-CA 117.321 -1.751 . . . . 0.0 107.773 179.18 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -67.08 166.42 23.1 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 122.774 2.316 . . . . 0.0 112.885 -174.733 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . 0.536 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 87.0 tttt -123.2 153.19 40.42 Favored 'General case' 0 C--N 1.286 -2.155 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.627 -173.627 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 99.9 m -109.82 112.85 25.14 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 177.009 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--N 1.304 -1.381 0 CA-C-N 115.173 -0.921 . . . . 0.0 108.871 -177.127 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo . . . . . 0 CA--C 1.536 0.611 0 CA-C-O 121.783 0.659 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.6 m -90.28 -32.89 16.34 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.001 178.86 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 109.68 -78.02 0.23 Allowed Glycine 0 CA--C 1.457 -3.538 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.333 168.833 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.0 t60 179.93 128.49 0.24 Allowed Pre-proline 0 C--N 1.274 -2.705 0 N-CA-C 105.08 -2.193 . . . . 0.0 105.08 -176.811 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -75.98 -0.99 10.88 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 C-N-CA 123.647 2.898 . . . . 0.0 114.448 -172.236 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.66 179.64 16.93 Favored Glycine 0 N--CA 1.41 -3.093 0 N-CA-C 107.362 -2.295 . . . . 0.0 107.362 -173.495 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -150.16 160.26 43.8 Favored 'General case' 0 C--N 1.275 -2.641 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 -177.584 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.0 t -142.18 136.38 14.89 Favored Pre-proline 0 C--N 1.297 -1.676 0 C-N-CA 120.118 -0.633 . . . . 0.0 111.459 -176.778 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -79.67 -8.94 14.72 Favored 'Trans proline' 0 CA--C 1.533 0.432 0 C-N-CA 123.127 2.551 . . . . 0.0 112.022 176.631 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -93.23 4.28 54.26 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 121.315 0.579 . . . . 0.0 111.202 -176.858 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.613 ' HA2' ' OD1' ' A' ' 115' ' ' ASN . . . 170.19 -131.49 2.26 Favored Glycine 0 N--CA 1.401 -3.636 0 C-N-CA 120.278 -0.963 . . . . 0.0 110.921 -179.548 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.9 t -162.14 -166.64 1.45 Allowed 'General case' 0 C--N 1.277 -2.572 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -178.951 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -148.14 163.17 37.76 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 178.191 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -123.12 160.08 27.19 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 178.858 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -119.7 117.15 27.49 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.865 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.513 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 30.8 p -107.03 130.9 54.59 Favored 'General case' 0 C--N 1.279 -2.496 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.441 -174.04 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 112.86 -67.44 0.24 Allowed Glycine 0 N--CA 1.424 -2.123 0 N-CA-C 110.871 -0.891 . . . . 0.0 110.871 -178.689 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -114.58 -8.84 15.57 Favored Glycine 0 C--N 1.314 -0.66 0 C-N-CA 120.109 -1.043 . . . . 0.0 113.335 -176.097 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 47.9 m-80 61.1 18.63 9.2 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 123.253 0.621 . . . . 0.0 112.371 -178.334 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.497 ' O ' HG12 ' A' ' 108' ' ' VAL . 20.6 m -148.47 -176.73 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 -175.76 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -98.8 43.28 1.06 Allowed 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.13 0.491 . . . . 0.0 110.4 -177.237 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.668 ' O ' HG11 ' A' ' 108' ' ' VAL . 17.8 pt-20 -82.63 -175.95 6.02 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.772 -1.104 . . . . 0.0 111.549 177.394 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -80.71 140.26 35.68 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.393 175.285 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.12 -4.89 84.68 Favored Glycine 0 N--CA 1.443 -0.887 0 CA-C-N 115.77 -0.65 . . . . 0.0 113.298 177.691 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.668 HG11 ' O ' ' A' ' 105' ' ' GLU . 15.0 p -88.02 148.21 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -178.237 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.513 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 58.4 mtpt -109.87 128.93 55.65 Favored 'General case' 0 N--CA 1.414 -2.267 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 177.096 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.474 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -91.27 90.69 7.86 Favored 'General case' 0 C--N 1.281 -2.397 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 175.423 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 26.5 m -90.74 110.52 22.33 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-O 122.645 1.212 . . . . 0.0 109.461 -177.361 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 27.5 m-85 -76.9 144.55 38.84 Favored 'General case' 0 C--N 1.272 -2.768 0 CA-C-N 115.074 -0.966 . . . . 0.0 112.324 -178.243 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.2 t -139.7 116.45 10.86 Favored 'General case' 0 N--CA 1.421 -1.912 0 CA-C-N 114.799 -1.091 . . . . 0.0 108.731 -179.28 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 91.4 m -70.82 161.28 31.23 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -179.307 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.613 ' OD1' ' HA2' ' A' ' 94' ' ' GLY . 4.9 m-20 -74.89 -176.73 3.01 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.003 -0.999 . . . . 0.0 110.955 177.552 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -56.03 -49.92 72.36 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 123.68 0.792 . . . . 0.0 112.746 -177.599 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -89.44 19.01 42.5 Favored Glycine 0 N--CA 1.438 -1.217 0 C-N-CA 120.804 -0.712 . . . . 0.0 113.539 -177.802 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.607 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 87.2 m-85 -137.5 159.21 42.59 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 117.287 0.544 . . . . 0.0 110.488 -179.982 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . 0.527 ' OE1' ' HB3' ' A' ' 142' ' ' GLU . 0.0 OUTLIER -145.35 159.17 43.45 Favored 'General case' 0 N--CA 1.425 -1.714 0 C-N-CA 121.087 -0.245 . . . . 0.0 110.348 179.129 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.92 122.71 27.58 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 -176.902 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -107.9 127.62 53.9 Favored 'General case' 0 N--CA 1.414 -2.233 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 179.853 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 113.48 179.41 19.24 Favored Glycine 0 C--N 1.291 -1.93 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -178.182 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -94.49 -30.19 14.55 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.852 0.834 . . . . 0.0 108.77 -177.793 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.2 mm -87.14 122.8 39.44 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.56 0 CA-C-N 114.922 -1.035 . . . . 0.0 109.101 -179.331 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -124.4 1.24 8.36 Favored 'General case' 0 C--O 1.203 -1.38 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 178.811 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 40.4 p90 -139.34 164.74 29.05 Favored 'General case' 0 C--N 1.288 -2.087 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -170.432 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 43.1 mtp180 -127.87 133.63 49.35 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 171.706 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -103.98 128.14 51.53 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 -178.485 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 13.7 t -82.85 105.22 13.69 Favored 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 117.749 -1.58 . . . . 0.0 110.332 177.18 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.458 ' OD1' HG22 ' A' ' 131' ' ' THR . 9.1 t70 -97.84 -168.68 1.71 Allowed 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 177.483 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.458 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.3 t -66.83 -22.57 66.0 Favored 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 118.161 0.437 . . . . 0.0 111.468 -175.123 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -88.95 -9.29 52.03 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.681 0.753 . . . . 0.0 110.03 178.67 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 114.72 -160.8 13.0 Favored Glycine 0 N--CA 1.428 -1.838 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -176.808 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -64.22 113.57 3.66 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 122.543 0.337 . . . . 0.0 111.819 -179.044 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 66.3 p -73.61 176.03 6.56 Favored 'General case' 0 C--O 1.269 2.124 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.408 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 35.1 m-20 60.68 -149.08 0.43 Allowed 'General case' 0 C--O 1.244 0.787 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 179.281 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -144.2 -173.11 3.92 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 171.343 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 73.5 mt -66.01 119.29 60.18 Favored Pre-proline 0 C--N 1.272 -2.798 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 174.877 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -62.15 163.19 20.61 Favored 'Trans proline' 0 C--O 1.253 1.266 0 C-N-CA 122.686 2.257 . . . . 0.0 112.011 -178.918 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.7 mm -93.83 123.72 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 CA-C-O 121.505 0.669 . . . . 0.0 109.939 -173.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.606 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 22.0 t -107.51 110.1 21.94 Favored 'General case' 0 C--N 1.263 -3.187 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 176.607 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.527 ' HB3' ' OE1' ' A' ' 119' ' ' GLN . 10.5 tp10 -101.2 150.77 22.62 Favored 'General case' 0 N--CA 1.409 -2.478 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -175.898 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.607 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 8.6 t -75.63 137.01 23.69 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.385 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.129 -177.696 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 42.9 t -67.96 112.15 2.88 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.933 0 N-CA-C 106.538 -1.652 . . . . 0.0 106.538 174.888 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . 0.426 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 35.3 mtmm -129.86 161.57 30.51 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-N 115.5 -0.773 . . . . 0.0 108.951 -175.609 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -129.62 164.5 23.75 Favored 'General case' 0 C--N 1.271 -2.831 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.896 -178.138 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 85.4 mt -70.63 142.38 88.67 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 113.931 1.085 . . . . 0.0 113.931 -175.67 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_endo -63.39 119.66 6.8 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 123.05 2.5 . . . . 0.0 110.178 175.811 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.401 HG22 ' SD ' ' A' ' 190' ' ' MET . 3.7 t -80.29 151.84 4.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.249 -174.398 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 150' ' ' THR . . . . . 0.429 ' O ' HD11 ' A' ' 157' ' ' ILE . 27.9 p -87.93 -159.08 0.5 Allowed 'General case' 0 N--CA 1.414 -2.24 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 170.971 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -128.9 151.59 77.69 Favored Pre-proline 0 C--N 1.283 -2.306 0 O-C-N 121.142 -0.973 . . . . 0.0 109.53 -172.277 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . 0.428 ' HB3' ' O ' ' A' ' 203' ' ' PRO . 24.0 Cg_endo -66.86 160.7 45.56 Favored 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.055 1.836 . . . . 0.0 112.419 178.072 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -48.88 -45.79 41.64 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 126.0 1.72 . . . . 0.0 114.389 -175.516 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.5 m-80 -126.84 27.15 6.06 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-O 122.077 0.941 . . . . 0.0 109.49 -178.477 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . 0.406 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -132.15 -169.41 12.3 Favored Glycine 0 N--CA 1.42 -2.382 0 CA-C-N 114.714 -1.13 . . . . 0.0 111.066 179.572 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . 0.401 ' HG3' HG23 ' A' ' 177' ' ' VAL . 45.3 pttt -157.94 171.78 19.65 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -177.746 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.429 HD11 ' O ' ' A' ' 150' ' ' THR . 58.6 mt -97.2 131.84 43.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 C-N-CA 122.022 0.129 . . . . 0.0 110.743 -177.613 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.473 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.5 m -75.19 -38.33 41.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.321 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.0 m -86.54 35.31 0.66 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 124.87 1.268 . . . . 0.0 109.134 -176.501 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.0 t -67.17 167.94 11.21 Favored 'General case' 0 N--CA 1.436 -1.139 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.529 -175.822 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 67.32 96.22 0.06 Allowed 'General case' 0 CA--C 1.507 -0.7 0 CA-C-O 122.319 1.057 . . . . 0.0 110.921 -175.961 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 162' ' ' MET . . . . . 0.428 ' HE3' ' HB3' ' A' ' 162' ' ' MET . 22.8 ttp -108.31 107.89 18.66 Favored 'General case' 0 N--CA 1.403 -2.821 0 N-CA-C 104.49 -2.411 . . . . 0.0 104.49 179.559 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -82.1 154.88 69.99 Favored Pre-proline 0 C--N 1.252 -3.631 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.074 -170.772 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -56.94 -21.08 39.35 Favored 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.22 2.613 . . . . 0.0 114.073 -178.581 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -98.53 -38.09 9.31 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.565 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 19.1 mmm180 -100.19 71.79 1.61 Allowed 'General case' 0 N--CA 1.415 -2.194 0 CA-C-N 114.937 -1.028 . . . . 0.0 111.353 -175.707 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -85.36 170.31 12.87 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 175.089 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 62.0 m-85 -68.64 104.73 2.05 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.668 0.747 . . . . 0.0 111.557 -177.251 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -105.86 164.24 12.1 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 179.023 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 90.7 t80 -52.14 128.16 23.92 Favored 'General case' 0 C--N 1.317 -0.807 0 C-N-CA 123.123 0.569 . . . . 0.0 109.827 174.516 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.46 -33.95 5.15 Favored Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.382 -179.129 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -70.12 151.62 45.25 Favored 'General case' 0 C--O 1.259 1.557 0 CA-C-O 121.244 0.545 . . . . 0.0 109.825 179.863 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -135.09 131.16 36.59 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-N 115.344 -0.843 . . . . 0.0 109.467 179.339 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 95.3 t -100.12 114.68 39.4 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -178.594 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.538 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 43.2 ttm180 -101.49 142.99 32.05 Favored 'General case' 0 N--CA 1.419 -1.981 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 177.366 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -111.99 160.52 17.38 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 123.138 0.575 . . . . 0.0 110.876 -176.613 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.452 HG21 ' CG1' ' A' ' 158' ' ' VAL . 0.1 OUTLIER -131.52 143.29 40.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.933 178.962 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 93.4 m -102.17 132.1 48.28 Favored 'General case' 0 C--N 1.276 -2.603 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 174.168 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 59.0 m-80 -61.09 163.12 6.38 Favored 'General case' 0 CA--C 1.491 -1.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.569 -178.715 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 10.9 m -46.89 106.67 0.09 Allowed 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 125.51 1.524 . . . . 0.0 112.569 -175.723 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 115.79 -16.52 16.16 Favored Glycine 0 N--CA 1.435 -1.396 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.323 178.99 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -103.8 155.07 18.89 Favored 'General case' 0 CA--C 1.495 -1.138 0 CA-C-N 117.269 0.535 . . . . 0.0 111.609 -177.664 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -125.16 147.34 49.08 Favored 'General case' 0 N--CA 1.423 -1.785 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 177.981 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 9.1 tt -79.96 136.64 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.934 0 CA-C-O 121.802 0.811 . . . . 0.0 111.287 -177.296 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -81.87 -52.14 7.39 Favored 'General case' 0 C--N 1.292 -1.916 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.736 -177.707 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -86.4 -152.75 21.54 Favored Glycine 0 N--CA 1.433 -1.553 0 CA-C-N 114.97 -1.014 . . . . 0.0 111.042 178.487 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . 0.442 ' OD1' ' HD2' ' A' ' 200' ' ' LYS . 1.6 p-10 -92.7 163.11 13.88 Favored 'General case' 0 C--N 1.289 -2.024 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 177.955 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . 0.538 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 0.8 OUTLIER -99.87 3.74 44.75 Favored 'General case' 0 C--N 1.286 -2.181 0 C-N-CA 118.509 -1.277 . . . . 0.0 113.165 -171.683 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -144.39 121.81 11.67 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -173.986 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 190' ' ' MET . . . . . 0.401 ' SD ' HG22 ' A' ' 149' ' ' VAL . 15.0 ptp -105.46 131.19 53.19 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.403 177.955 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 25.1 t-80 -106.16 135.42 47.65 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.446 -176.952 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 7.3 t -72.74 112.48 8.83 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.043 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 193' ' ' SER . . . . . 0.422 ' OG ' ' HB3' ' A' ' 199' ' ' SER . 17.5 m -94.56 172.2 8.33 Favored 'General case' 0 N--CA 1.442 -0.856 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.289 -173.467 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -43.02 -43.1 4.11 Favored 'General case' 0 N--CA 1.495 1.775 0 C-N-CA 127.02 2.128 . . . . 0.0 114.538 -171.713 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -92.26 12.73 21.43 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 113.675 0.991 . . . . 0.0 113.675 -174.798 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 78.97 46.95 7.98 Favored Glycine 0 CA--C 1.496 -1.128 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.8 176.052 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -145.0 160.29 41.6 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.633 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -82.23 132.03 35.23 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 177.389 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 199' ' ' SER . . . . . 0.422 ' HB3' ' OG ' ' A' ' 193' ' ' SER . 23.8 p -66.06 -22.49 66.43 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.551 0.691 . . . . 0.0 111.11 -178.945 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . 0.442 ' HD2' ' OD1' ' A' ' 187' ' ' ASP . 26.5 mmtp -120.75 151.0 40.11 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.534 -177.829 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 73.0 mm-40 -89.42 166.53 13.66 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.211 176.928 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . 0.403 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 39.6 mtpt -63.95 119.04 51.63 Favored Pre-proline 0 C--N 1.319 -0.73 0 O-C-N 123.464 0.477 . . . . 0.0 111.057 179.513 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . 0.428 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 95.4 Cg_endo -77.39 168.1 23.43 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 122.642 2.228 . . . . 0.0 112.056 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 37.1 ttpt -119.9 150.86 39.79 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.86 -176.653 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 83.8 m -110.93 118.72 36.87 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 177.388 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 30.4 m . . . . . 0 C--N 1.3 -1.555 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.574 -175.325 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo . . . . . 0 CA--C 1.537 0.666 0 CA-C-O 121.603 0.585 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.7 m -82.83 -32.89 27.33 Favored 'General case' 0 CA--C 1.504 -0.814 0 CA-C-O 122.005 0.907 . . . . 0.0 108.612 179.024 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.75 -87.85 0.43 Allowed Glycine 0 N--CA 1.396 -3.967 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.366 174.415 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.0 t-80 -175.02 135.39 0.52 Allowed Pre-proline 0 C--N 1.264 -3.135 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 -173.711 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.524 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 66.9 Cg_endo -93.69 -5.18 2.76 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.497 2.131 . . . . 0.0 113.031 -178.139 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 106.73 175.93 23.08 Favored Glycine 0 CA--C 1.485 -1.826 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 178.787 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -151.43 152.88 33.66 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 177.319 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.415 HG22 ' CZ ' ' A' ' 112' ' ' TYR . 9.6 t -125.18 141.12 37.72 Favored Pre-proline 0 C--N 1.29 -1.994 0 O-C-N 123.385 0.428 . . . . 0.0 112.043 -175.218 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -79.84 -12.69 13.36 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 122.913 2.409 . . . . 0.0 111.405 173.511 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -85.98 2.26 46.93 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 121.744 0.783 . . . . 0.0 110.861 -178.7 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.6 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.48 -126.56 1.21 Allowed Glycine 0 N--CA 1.402 -3.571 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 -178.737 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.8 t -164.5 -166.23 1.06 Allowed 'General case' 0 C--N 1.27 -2.878 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.847 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -153.01 158.05 41.44 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 177.691 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.8 m -127.17 158.98 35.65 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 179.991 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 22.0 mt -116.55 127.49 54.56 Favored 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 -179.736 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.498 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 21.2 p -117.61 125.82 51.45 Favored 'General case' 0 C--N 1.29 -1.991 0 CA-C-O 121.311 0.577 . . . . 0.0 111.063 -175.728 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 121.55 -58.18 0.59 Allowed Glycine 0 N--CA 1.432 -1.602 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.306 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -130.82 -3.02 4.64 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.632 -0.794 . . . . 0.0 113.678 -177.868 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 2.3 t30 54.13 29.29 10.15 Favored 'General case' 0 CA--C 1.559 1.315 0 C-N-CA 125.776 1.631 . . . . 0.0 112.016 -178.922 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.531 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.7 m -149.74 -174.77 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.209 -1.043 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 179.699 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.524 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 20.6 m-85 -100.8 44.48 1.01 Allowed 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 118.767 0.712 . . . . 0.0 110.359 -178.174 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.741 ' O ' HG13 ' A' ' 108' ' ' VAL . 9.7 pt-20 -85.06 177.59 7.86 Favored 'General case' 0 C--O 1.211 -0.967 0 CA-C-N 114.639 -1.164 . . . . 0.0 111.89 178.413 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -76.58 133.13 39.76 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.219 177.372 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.02 5.06 64.4 Favored Glycine 0 N--CA 1.438 -1.232 0 CA-C-N 115.791 -0.64 . . . . 0.0 112.679 179.85 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.741 HG13 ' O ' ' A' ' 105' ' ' GLU . 11.0 p -97.44 147.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 -179.92 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 109' ' ' LYS . . . . . 0.498 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -109.64 130.64 55.5 Favored 'General case' 0 N--CA 1.42 -1.938 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 177.249 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . 0.529 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -94.49 95.71 9.0 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 175.034 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 78.7 t -89.3 112.9 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.859 0 C-N-CA 123.768 0.827 . . . . 0.0 108.8 -178.327 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 112' ' ' TYR . . . . . 0.501 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 9.6 t80 -81.9 138.39 35.03 Favored 'General case' 0 C--N 1.276 -2.597 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -177.785 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -138.55 120.56 15.56 Favored 'General case' 0 N--CA 1.424 -1.739 0 CA-C-O 121.785 0.802 . . . . 0.0 109.309 177.64 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 114' ' ' CYS . . . . . 0.453 ' SG ' ' HE1' ' A' ' 112' ' ' TYR . 75.8 m -73.94 160.28 31.58 Favored 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.597 -179.244 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.6 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 82.2 m-20 -78.32 177.12 8.69 Favored 'General case' 0 C--O 1.212 -0.884 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.111 176.706 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . 0.467 ' HG3' ' OD2' ' A' ' 194' ' ' ASP . 39.9 tt0 -44.81 -46.62 10.73 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 124.956 1.303 . . . . 0.0 114.308 -177.305 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.91 5.33 82.96 Favored Glycine 0 C--N 1.311 -0.858 0 C-N-CA 120.309 -0.948 . . . . 0.0 114.048 -176.663 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.498 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.3 m-85 -130.61 164.28 25.29 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 -176.506 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -148.1 155.77 41.84 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-O 120.988 0.423 . . . . 0.0 110.242 179.495 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -77.38 130.91 37.72 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 179.351 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.577 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -119.45 130.41 55.24 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.83 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.17 -175.07 21.82 Favored Glycine 0 C--N 1.295 -1.717 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.521 -179.597 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -91.8 -29.04 16.98 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 121.53 0.681 . . . . 0.0 109.646 -178.331 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 124' ' ' ILE . . . . . 0.582 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 46.9 mm -82.95 114.51 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.553 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.869 -177.778 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 -130.42 7.67 4.95 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.896 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 126' ' ' TYR . . . . . 0.529 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 17.8 p90 -151.57 156.43 40.46 Favored 'General case' 0 N--CA 1.425 -1.689 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.415 -173.446 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 52.1 mtp180 -121.34 125.29 46.65 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 105.14 -2.17 . . . . 0.0 105.14 171.538 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -101.73 126.88 48.67 Favored 'General case' 0 C--N 1.275 -2.65 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.074 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . 0.46 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 25.5 t -86.03 100.81 12.41 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 118.498 -1.281 . . . . 0.0 110.075 176.166 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.425 ' OD1' HG23 ' A' ' 131' ' ' THR . 9.2 t70 -98.71 -165.28 1.22 Allowed 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 105.456 -2.053 . . . . 0.0 105.456 175.602 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.425 HG23 ' OD1' ' A' ' 130' ' ' ASP . 10.2 t -63.5 -22.95 67.18 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 119.131 0.878 . . . . 0.0 112.143 -177.02 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -80.23 -13.57 59.11 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.652 0.739 . . . . 0.0 110.692 176.357 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.46 ' HA2' ' SG ' ' A' ' 129' ' ' CYS . . . 105.49 -148.51 16.52 Favored Glycine 0 N--CA 1.421 -2.339 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -175.375 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 85.0 m95 -69.13 109.55 4.09 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 176.908 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 28.9 p -61.14 -68.8 0.28 Allowed 'General case' 0 N--CA 1.438 -1.039 0 O-C-N 123.792 0.682 . . . . 0.0 111.48 -178.126 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 74.4 m-20 -75.62 177.13 7.02 Favored 'General case' 0 CA--C 1.489 -1.368 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.513 178.035 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -108.13 -168.91 1.43 Allowed 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 178.511 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.2 mt -60.87 117.98 30.76 Favored Pre-proline 0 C--N 1.295 -1.775 0 O-C-N 123.986 0.804 . . . . 0.0 109.33 177.272 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 139' ' ' PRO . . . . . 0.582 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 53.3 Cg_exo -52.77 165.99 0.99 Allowed 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.867 3.045 . . . . 0.0 113.916 178.644 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 140' ' ' ILE . . . . . 0.577 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 3.6 mp -90.73 130.7 39.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.172 -174.801 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 141' ' ' CYS . . . . . 0.498 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 25.4 t -123.6 114.93 20.68 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.318 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -110.41 149.79 29.76 Favored 'General case' 0 N--CA 1.405 -2.711 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 -177.961 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 9.6 p -73.69 143.53 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.898 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.572 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 89.3 t -68.69 123.05 21.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 177.155 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -109.3 140.14 43.36 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.149 -176.421 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 57.5 m -102.13 144.66 30.41 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.9 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 147' ' ' LEU . . . . . 0.4 HD23 ' HD2' ' A' ' 148' ' ' PRO . 1.4 tt -49.59 130.03 19.4 Favored Pre-proline 0 N--CA 1.432 -1.36 0 C-N-CA 125.275 1.43 . . . . 0.0 110.748 179.491 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.581 ' HA ' ' CD2' ' A' ' 168' ' ' TYR . 12.4 Cg_endo -57.74 110.59 0.65 Allowed 'Trans proline' 0 N--CA 1.454 -0.813 0 C-N-CA 123.557 2.838 . . . . 0.0 113.35 -178.522 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 13.6 p -83.81 142.72 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 CA-C-N 115.176 -0.92 . . . . 0.0 108.865 177.397 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 10.2 p -105.22 -156.4 0.57 Allowed 'General case' 0 C--N 1.288 -2.069 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.37 176.172 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -100.85 151.25 37.56 Favored Pre-proline 0 C--N 1.298 -1.649 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -170.636 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -75.62 170.24 20.64 Favored 'Trans proline' 0 N--CA 1.436 -1.906 0 C-N-CA 121.442 1.428 . . . . 0.0 110.914 175.25 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -50.41 -55.24 16.62 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 114.306 1.224 . . . . 0.0 114.306 -175.992 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 154' ' ' ASN . . . . . 0.438 ' HB2' ' O ' ' A' ' 205' ' ' CYS . 57.4 m-80 -113.95 27.04 9.82 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.19 0.519 . . . . 0.0 110.725 -177.544 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.7 -173.1 15.71 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 120.081 -1.057 . . . . 0.0 111.726 179.768 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 50.3 pttt -153.33 172.67 16.68 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -178.14 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 62.5 mt -86.04 132.1 32.91 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 CA-C-O 121.169 0.509 . . . . 0.0 111.058 -176.46 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.442 ' CG2' ' HB ' ' A' ' 177' ' ' VAL . 47.9 t -76.52 -40.31 33.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 C-N-CA 123.974 0.91 . . . . 0.0 108.907 177.172 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.0 m -84.08 32.28 0.49 Allowed 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.446 179.933 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 17.6 t -79.55 82.0 5.73 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-O 121.999 0.904 . . . . 0.0 112.568 -172.393 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -115.7 72.76 0.81 Allowed 'General case' 0 N--CA 1.411 -2.375 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 169.973 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.76 82.84 8.15 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-O 122.293 1.044 . . . . 0.0 110.204 -176.682 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 57.1 mm-40 -122.21 155.0 62.14 Favored Pre-proline 0 C--N 1.282 -2.336 0 CA-C-N 113.376 -1.738 . . . . 0.0 108.035 -176.608 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -57.22 -25.19 63.3 Favored 'Trans proline' 0 CA--C 1.545 1.033 0 C-N-CA 123.115 2.544 . . . . 0.0 113.529 -179.211 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -92.19 -34.26 14.37 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.907 0.86 . . . . 0.0 109.82 -179.177 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 6.2 mmp_? -81.7 81.38 7.77 Favored 'General case' 0 N--CA 1.422 -1.841 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.082 -177.824 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -103.46 165.54 10.97 Favored 'General case' 0 C--N 1.294 -1.84 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 176.203 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 168' ' ' TYR . . . . . 0.581 ' CD2' ' HA ' ' A' ' 148' ' ' PRO . 98.0 m-85 -78.71 103.41 8.63 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-O 121.661 0.743 . . . . 0.0 112.087 -174.594 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 27.7 m80 -98.38 155.47 17.21 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 114.506 -1.224 . . . . 0.0 107.966 -179.463 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -56.77 131.5 49.45 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 172.012 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 113.43 -15.03 22.64 Favored Glycine 0 N--CA 1.414 -2.768 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.234 -177.682 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 172' ' ' GLN . . . . . 0.402 ' O ' ' HA ' ' A' ' 191' ' ' HIS . 15.5 mm100 -74.58 134.38 42.13 Favored 'General case' 0 N--CA 1.423 -1.788 0 C-N-CA 120.223 -0.591 . . . . 0.0 111.976 179.55 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -115.15 94.34 4.69 Favored 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 173.562 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 66.2 t -81.61 109.02 15.36 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 CA-C-N 115.243 -0.889 . . . . 0.0 108.963 -176.121 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 175' ' ' ARG . . . . . 0.427 ' HD2' ' OE1' ' A' ' 188' ' ' GLU . 14.5 ttp180 -97.1 156.27 16.45 Favored 'General case' 0 N--CA 1.411 -2.387 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 179.055 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -127.09 156.35 41.85 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 124.038 0.935 . . . . 0.0 109.399 -175.006 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.442 ' HB ' ' CG2' ' A' ' 158' ' ' VAL . 12.2 p -133.56 141.07 45.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.461 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 80.5 m -102.54 153.63 19.89 Favored 'General case' 0 C--N 1.265 -3.105 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.961 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -64.62 163.46 13.68 Favored 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 119.972 -0.691 . . . . 0.0 110.153 176.73 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 15.8 m -43.54 -32.74 0.98 Allowed 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 116.37 1.989 . . . . 0.0 116.37 -170.724 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -113.36 21.09 17.87 Favored Glycine 0 C--N 1.293 -1.847 0 C-N-CA 120.1 -1.047 . . . . 0.0 113.375 -179.048 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -122.32 151.06 41.53 Favored 'General case' 0 N--CA 1.432 -1.335 0 O-C-N 122.129 -0.63 . . . . 0.0 111.356 179.28 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -124.15 143.59 50.4 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.158 -178.93 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.4 tt -74.87 140.55 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.928 0 CA-C-O 121.476 0.655 . . . . 0.0 111.288 -176.695 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -67.01 -64.57 0.83 Allowed 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.318 -177.261 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -103.41 -123.59 5.3 Favored Glycine 0 N--CA 1.436 -1.32 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.283 -179.558 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 187' ' ' ASP . . . . . 0.51 ' HB2' ' HG3' ' A' ' 200' ' ' LYS . 5.5 m-20 -91.63 153.4 19.73 Favored 'General case' 0 CA--C 1.491 -1.291 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -177.495 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 188' ' ' GLU . . . . . 0.427 ' OE1' ' HD2' ' A' ' 175' ' ' ARG . 14.2 pt-20 -91.65 -4.04 55.67 Favored 'General case' 0 C--O 1.205 -1.286 0 C-N-CA 119.944 -0.702 . . . . 0.0 111.174 -172.027 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -134.34 132.31 39.35 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 -177.72 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 14.4 ptp -112.68 123.54 50.53 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.271 174.881 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 191' ' ' HIS . . . . . 0.402 ' HA ' ' O ' ' A' ' 172' ' ' GLN . 16.4 t-80 -110.36 139.01 45.99 Favored 'General case' 0 C--N 1.279 -2.498 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.954 -177.317 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 22.0 m -62.64 130.14 43.69 Favored 'General case' 0 C--N 1.32 -0.705 0 O-C-N 123.657 0.598 . . . . 0.0 111.668 175.207 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 37.5 t -101.78 166.92 10.41 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.137 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 194' ' ' ASP . . . . . 0.467 ' OD2' ' HG3' ' A' ' 116' ' ' GLU . 6.3 t70 -52.41 -33.22 42.82 Favored 'General case' 0 N--CA 1.511 2.613 0 C-N-CA 124.236 1.014 . . . . 0.0 110.332 178.925 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -56.94 -26.21 59.14 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 113.75 -1.568 . . . . 0.0 111.742 179.807 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 89.59 15.53 58.2 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -174.97 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -125.27 170.54 11.19 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.064 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -85.39 142.49 29.24 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 123.678 0.611 . . . . 0.0 110.944 -177.699 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 30.7 t -60.64 -50.29 74.11 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.725 176.593 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 200' ' ' LYS . . . . . 0.51 ' HG3' ' HB2' ' A' ' 187' ' ' ASP . 12.9 mmmm -104.61 156.14 18.23 Favored 'General case' 0 CA--C 1.485 -1.548 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 174.227 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -89.06 171.73 9.63 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 170.546 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 34.9 ttmt -61.9 122.25 70.67 Favored Pre-proline 0 C--O 1.243 0.724 0 CA-C-N 118.985 0.811 . . . . 0.0 110.492 -176.246 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.04 -173.49 1.9 Allowed 'Trans proline' 0 N--CA 1.437 -1.833 0 C-N-CA 122.039 1.826 . . . . 0.0 111.067 179.122 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 66.0 mttm -126.58 160.88 29.39 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.118 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 205' ' ' CYS . . . . . 0.438 ' O ' ' HB2' ' A' ' 154' ' ' ASN . 97.4 m -116.62 105.19 12.17 Favored 'General case' 0 C--N 1.27 -2.887 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 170.852 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 23.7 m . . . . . 0 C--N 1.286 -2.176 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.033 -173.547 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.428 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 30.6 Cg_endo . . . . . 0 CA--C 1.542 0.907 0 CA-C-O 121.436 0.515 . . . . 0.0 111.761 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.1 m -85.03 -37.68 20.09 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 177.758 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.08 -92.41 0.48 Allowed Glycine 0 N--CA 1.41 -3.095 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 173.662 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.9 t60 -177.24 123.73 0.28 Allowed Pre-proline 0 C--N 1.26 -3.314 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 -177.309 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.427 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 34.8 Cg_endo -66.72 -49.91 1.42 Allowed 'Trans proline' 0 C--O 1.209 -0.933 0 C-N-CA 121.33 1.353 . . . . 0.0 110.722 -177.179 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 150.32 169.18 16.08 Favored Glycine 0 N--CA 1.401 -3.642 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 -177.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -136.03 139.93 43.46 Favored 'General case' 0 C--N 1.264 -3.113 0 CA-C-N 117.31 0.555 . . . . 0.0 109.688 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.5 t -99.9 128.97 29.58 Favored Pre-proline 0 N--CA 1.409 -2.525 0 CA-C-N 115.111 -0.949 . . . . 0.0 111.304 -172.443 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -69.04 -24.01 33.44 Favored 'Trans proline' 0 C--O 1.24 0.591 0 C-N-CA 122.884 2.389 . . . . 0.0 110.214 175.704 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -75.06 -28.28 60.31 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 114.014 -1.448 . . . . 0.0 110.763 -176.659 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.437 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -151.0 -133.21 2.03 Favored Glycine 0 N--CA 1.409 -3.159 0 C-N-CA 119.071 -1.538 . . . . 0.0 112.783 -177.819 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.0 p -144.1 170.67 15.51 Favored 'General case' 0 C--N 1.275 -2.64 0 CA-C-N 113.885 -1.157 . . . . 0.0 108.896 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.458 ' HA ' ' HA ' ' A' ' 112' ' ' TYR . 17.8 p90 -140.69 153.55 46.0 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 172.302 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -127.26 160.12 32.27 Favored 'General case' 0 C--N 1.274 -2.705 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -116.72 118.63 33.07 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 121.293 0.568 . . . . 0.0 109.874 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 26.2 p -111.88 133.64 53.95 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.755 -174.678 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 111.98 -53.13 0.6 Allowed Glycine 0 N--CA 1.434 -1.478 0 C-N-CA 120.865 -0.683 . . . . 0.0 111.557 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -131.31 -7.21 3.23 Favored Glycine 0 N--CA 1.441 -0.999 0 C-N-CA 120.196 -1.002 . . . . 0.0 113.109 -179.008 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 48.4 m-80 61.17 17.4 8.08 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.523 ' O ' HG11 ' A' ' 108' ' ' VAL . 19.7 m -149.01 -170.07 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.205 -1.286 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -177.938 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -103.47 45.57 0.95 Allowed 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 118.422 0.556 . . . . 0.0 110.083 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.71 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.9 pt-20 -86.08 176.28 8.09 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 114.957 -1.019 . . . . 0.0 111.58 177.832 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' TYR . . . . . 0.44 ' CE1' ' HA ' ' A' ' 131' ' ' THR . 46.0 m-85 -72.91 133.23 44.29 Favored 'General case' 0 C--N 1.293 -1.859 0 O-C-N 121.976 -0.453 . . . . 0.0 111.273 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.36 -8.7 69.42 Favored Glycine 0 N--CA 1.434 -1.453 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.232 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.71 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.2 p -80.67 147.69 6.19 Favored 'Isoleucine or valine' 0 C--O 1.238 0.481 0 CA-C-N 117.553 0.676 . . . . 0.0 109.946 -176.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 16.8 mtpp -112.38 119.08 37.03 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.556 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -87.91 96.49 10.5 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.424 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.509 HG12 ' HB3' ' A' ' 126' ' ' TYR . 18.8 m -94.81 115.82 34.59 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.327 0 CA-C-O 122.036 0.922 . . . . 0.0 109.979 -177.02 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' TYR . . . . . 0.458 ' HA ' ' HA ' ' A' ' 96' ' ' PHE . 33.3 m-85 -83.07 144.43 29.9 Favored 'General case' 0 C--N 1.265 -3.072 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.524 -178.777 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.4 t -143.64 127.79 17.6 Favored 'General case' 0 N--CA 1.427 -1.621 0 CA-C-N 115.275 -0.875 . . . . 0.0 108.803 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 81.4 m -73.71 163.39 28.04 Favored 'General case' 0 C--N 1.292 -1.891 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.317 -176.635 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.437 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 95.4 m-20 -95.25 -179.15 4.69 Favored 'General case' 0 CA--C 1.476 -1.887 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.72 -178.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -69.09 93.96 0.63 Allowed 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 124.573 1.171 . . . . 0.0 109.753 177.409 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 133.66 2.13 3.64 Favored Glycine 0 C--N 1.259 -3.698 0 CA-C-N 112.961 -1.927 . . . . 0.0 111.781 177.862 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.429 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 87.8 m-85 -133.49 158.7 42.44 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -177.485 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -142.11 158.06 44.18 Favored 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 -177.649 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 13.9 tp -83.07 146.27 28.8 Favored 'General case' 0 N--CA 1.413 -2.282 0 C-N-CA 119.491 -0.884 . . . . 0.0 109.169 -177.842 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.09 121.64 38.33 Favored 'General case' 0 N--CA 1.405 -2.709 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.359 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 100.4 174.93 29.96 Favored Glycine 0 C--N 1.292 -1.897 0 N-CA-C 110.914 -0.875 . . . . 0.0 110.914 -174.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -88.05 -37.89 15.9 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.255 0.55 . . . . 0.0 110.112 -177.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.3 mm -66.7 124.47 21.96 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.758 -177.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -127.13 -4.34 6.23 Favored 'General case' 0 C--O 1.204 -1.317 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.509 ' HB3' HG12 ' A' ' 111' ' ' VAL . 11.9 p90 -137.23 161.83 35.14 Favored 'General case' 0 C--N 1.293 -1.888 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.496 -170.472 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 49.9 mtp180 -125.28 136.11 53.19 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 106.112 -1.81 . . . . 0.0 106.112 171.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -115.32 130.94 57.05 Favored 'General case' 0 C--N 1.273 -2.719 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 33.0 t -86.49 112.26 21.35 Favored 'General case' 0 C--N 1.293 -1.869 0 C-N-CA 119.109 -1.036 . . . . 0.0 110.83 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.454 ' OD2' HG22 ' A' ' 131' ' ' THR . 14.9 t70 -103.24 -171.26 1.91 Allowed 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 175.339 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.454 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -71.16 -17.78 62.53 Favored 'General case' 0 C--N 1.291 -1.946 0 CA-C-O 121.874 0.845 . . . . 0.0 110.309 -175.027 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -87.9 -8.77 55.34 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.691 179.367 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 112.78 -164.32 12.07 Favored Glycine 0 N--CA 1.427 -1.936 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -177.061 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.427 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 97.8 m95 -60.97 123.34 17.32 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 117.255 0.527 . . . . 0.0 110.579 176.037 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.6 p -64.46 -71.77 0.17 Allowed 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 123.554 0.742 . . . . 0.0 111.99 -178.589 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -81.58 177.66 8.8 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.175 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -106.12 177.84 4.74 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.282 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 65.0 mt -61.38 121.11 61.21 Favored Pre-proline 0 C--O 1.245 0.861 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 176.346 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.13 166.89 23.48 Favored 'Trans proline' 0 C--O 1.26 1.625 0 C-N-CA 122.424 2.083 . . . . 0.0 111.637 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 55.7 mt -90.06 127.02 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.03 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -177.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.429 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 53.6 t -121.07 115.62 23.46 Favored 'General case' 0 C--N 1.269 -2.916 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 174.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.18 151.95 23.43 Favored 'General case' 0 C--N 1.282 -2.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 109.864 -177.236 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.5 p -68.88 137.52 24.18 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.105 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.682 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 41.5 t -63.95 125.91 21.58 Favored 'Isoleucine or valine' 0 C--O 1.247 0.951 0 CA-C-O 121.111 0.482 . . . . 0.0 109.74 178.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -119.13 133.55 55.72 Favored 'General case' 0 N--CA 1.418 -2.074 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -179.428 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 72.8 m -99.63 141.18 32.77 Favored 'General case' 0 C--N 1.261 -3.267 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.283 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.0 mm? -58.63 138.5 86.12 Favored Pre-proline 0 N--CA 1.427 -1.579 0 N-CA-C 114.209 1.188 . . . . 0.0 114.209 -175.499 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 23.5 Cg_exo -58.25 107.4 0.32 Allowed 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 123.346 2.698 . . . . 0.0 111.117 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 5.9 p -69.26 140.58 18.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 20.5 p -71.9 -71.81 0.26 Allowed 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 111.405 0.15 . . . . 0.0 111.405 -178.346 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.38 162.3 0.21 Allowed Pre-proline 0 C--O 1.248 1.005 0 C-N-CA 125.748 1.619 . . . . 0.0 106.712 177.393 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' PRO . . . . . 0.403 ' HB3' ' O ' ' A' ' 203' ' ' PRO . 51.3 Cg_endo -74.3 170.88 19.19 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 121.512 1.475 . . . . 0.0 109.469 169.742 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -60.67 -48.92 79.62 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 114.055 1.132 . . . . 0.0 114.055 -173.678 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 32.2 m120 -117.31 32.39 6.19 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.505 0.669 . . . . 0.0 109.668 -177.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.06 -176.59 18.22 Favored Glycine 0 C--N 1.303 -1.269 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.477 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.4 ptmt -145.21 173.27 12.09 Favored 'General case' 0 N--CA 1.434 -1.231 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -178.355 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 69.0 mt -88.22 138.49 19.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 CA-C-O 121.3 0.572 . . . . 0.0 110.957 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.6 t -89.29 -39.71 12.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 C-N-CA 124.426 1.09 . . . . 0.0 109.402 176.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 9.9 m . . . . . 0 C--N 1.313 -1.02 0 C-N-CA 123.512 0.725 . . . . 0.0 111.09 -178.128 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 . . . . . 0 N--CA 1.424 -1.768 0 CA-C-O 121.53 0.681 . . . . 0.0 111.198 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 47.2 m170 -84.32 164.07 19.21 Favored 'General case' 0 C--O 1.248 1.019 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.115 -179.199 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 72.4 t80 -52.63 134.64 35.68 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 123.697 0.799 . . . . 0.0 110.765 173.842 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 102.01 -23.34 34.92 Favored Glycine 0 C--N 1.314 -0.674 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.305 179.02 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -72.85 133.97 44.67 Favored 'General case' 0 N--CA 1.434 -1.229 0 CA-C-O 121.085 0.469 . . . . 0.0 111.991 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.421 ' HB2' ' NE2' ' A' ' 191' ' ' HIS . . . -106.28 115.73 30.72 Favored 'General case' 0 N--CA 1.421 -1.889 0 CA-C-N 114.733 -1.122 . . . . 0.0 109.142 178.403 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 48.3 t -91.27 108.75 20.25 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 175.775 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.485 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 20.4 ttp180 -99.4 153.79 18.72 Favored 'General case' 0 N--CA 1.403 -2.82 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 177.715 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 83.4 m-85 -127.24 158.9 35.93 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 123.24 0.616 . . . . 0.0 109.533 -174.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.9 p -140.57 140.32 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.579 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.094 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 178' ' ' CYS . . . . . 0.406 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 77.1 m -89.62 149.61 22.74 Favored 'General case' 0 C--N 1.278 -2.54 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.186 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 81.8 m-20 -76.15 179.4 5.72 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.307 -178.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 25.2 p -53.72 111.26 0.7 Allowed 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 124.027 0.931 . . . . 0.0 112.511 -176.224 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 97.38 2.31 58.98 Favored Glycine 0 N--CA 1.433 -1.544 0 CA-C-N 115.846 -0.615 . . . . 0.0 113.847 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 182' ' ' TYR . . . . . 0.406 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 90.2 m-85 -111.6 149.09 31.97 Favored 'General case' 0 CA--C 1.484 -1.573 0 CA-C-N 117.971 0.886 . . . . 0.0 110.704 -179.432 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -122.38 145.86 47.88 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -178.678 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.6 tt -76.3 137.01 23.5 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 CA-C-O 122.049 0.928 . . . . 0.0 111.798 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -84.33 -48.66 9.48 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.171 -176.382 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -91.09 -136.2 6.75 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.315 177.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 187' ' ' ASP . . . . . 0.465 ' OD1' ' HG3' ' A' ' 189' ' ' GLU . 12.2 t70 -102.58 163.68 12.09 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 178.443 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.485 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 15.8 pt-20 -91.15 -13.85 32.22 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 118.887 0.767 . . . . 0.0 112.668 -174.509 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 189' ' ' GLU . . . . . 0.465 ' HG3' ' OD1' ' A' ' 187' ' ' ASP . 0.0 OUTLIER -120.03 144.92 47.28 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 112.84 0.682 . . . . 0.0 112.84 -176.724 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 37.0 ttm -135.97 124.33 23.35 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 124.864 1.266 . . . . 0.0 109.075 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 191' ' ' HIS . . . . . 0.421 ' NE2' ' HB2' ' A' ' 173' ' ' ALA . 30.7 m80 -97.86 155.44 17.06 Favored 'General case' 0 C--N 1.276 -2.618 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 40.6 t -94.94 116.88 29.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 173.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 8.4 p -100.23 170.21 8.61 Favored 'General case' 0 N--CA 1.437 -1.122 0 O-C-N 123.354 0.409 . . . . 0.0 111.174 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -60.01 -21.26 61.08 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 123.607 0.763 . . . . 0.0 112.064 -175.044 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 13.7 m-20 -64.51 -17.54 63.99 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.741 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 80.94 20.48 65.24 Favored Glycine 0 CA--C 1.488 -1.656 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -130.48 153.44 48.79 Favored 'General case' 0 N--CA 1.407 -2.597 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 -174.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 78.2 m95 -76.84 131.47 38.65 Favored 'General case' 0 C--N 1.291 -1.971 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.34 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.5 m -69.06 -38.33 79.01 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 115.639 -0.709 . . . . 0.0 112.289 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -103.73 156.95 17.41 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 20.0 pm0 -78.83 157.91 28.27 Favored 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 177.485 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -68.05 116.62 40.71 Favored Pre-proline 0 C--O 1.246 0.908 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 175.231 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 203' ' ' PRO . . . . . 0.403 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 98.3 Cg_endo -76.98 161.5 32.86 Favored 'Trans proline' 0 N--CA 1.433 -2.088 0 C-N-CA 122.218 1.945 . . . . 0.0 110.998 -178.813 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -104.52 161.83 13.77 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 120.226 -0.589 . . . . 0.0 109.6 178.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 88.9 m -122.19 108.55 13.43 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 172.08 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.1 m . . . . . 0 C--N 1.291 -1.957 0 O-C-N 124.405 1.066 . . . . 0.0 108.818 -173.788 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.451 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 19.1 Cg_endo . . . . . 0 CA--C 1.537 0.657 0 CA-C-O 120.859 0.274 . . . . 0.0 112.205 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 50.0 m -71.67 -43.98 65.07 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.756 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 97.07 112.44 2.94 Favored Glycine 0 C--O 1.187 -2.791 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 -179.245 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -34.36 119.52 0.54 Allowed Pre-proline 0 C--N 1.296 -1.734 0 C-N-CA 127.235 2.214 . . . . 0.0 112.129 -173.512 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -60.67 -43.32 32.99 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.283 2.655 . . . . 0.0 113.305 -172.413 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 139.73 -174.98 22.06 Favored Glycine 0 N--CA 1.421 -2.336 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -133.78 156.66 47.6 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-N 117.403 0.602 . . . . 0.0 109.691 -178.031 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.1 t -115.3 126.63 27.59 Favored Pre-proline 0 C--N 1.305 -1.368 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.282 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -66.97 -18.8 52.29 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.555 2.17 . . . . 0.0 112.556 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -87.7 -15.05 38.21 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.37 -175.393 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.497 ' HA2' ' ND2' ' A' ' 115' ' ' ASN . . . -163.62 -133.43 1.48 Allowed Glycine 0 N--CA 1.409 -3.136 0 C-N-CA 118.635 -1.745 . . . . 0.0 113.004 -177.413 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.1 p -144.2 179.59 7.13 Favored 'General case' 0 C--N 1.284 -2.249 0 CA-C-N 114.439 -0.881 . . . . 0.0 109.264 -176.634 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -141.5 157.65 44.86 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 172.644 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.4 m -127.56 162.53 26.24 Favored 'General case' 0 C--N 1.278 -2.524 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.0 mt -118.43 117.03 27.94 Favored 'General case' 0 C--N 1.277 -2.579 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.502 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 19.5 p -109.16 127.63 54.35 Favored 'General case' 0 C--N 1.282 -2.364 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.245 -172.557 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 113.97 -37.92 3.38 Favored Glycine 0 N--CA 1.433 -1.567 0 C-N-CA 120.406 -0.902 . . . . 0.0 111.975 179.212 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -144.28 -7.14 0.5 Allowed Glycine 0 C--N 1.315 -0.588 0 C-N-CA 119.715 -1.231 . . . . 0.0 113.756 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 92.6 m-20 61.14 15.11 6.01 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.495 ' O ' HG11 ' A' ' 108' ' ' VAL . 24.0 m -146.52 -169.42 0.24 Allowed 'Isoleucine or valine' 0 C--O 1.209 -1.027 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -176.641 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -106.46 40.29 1.65 Allowed 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 118.29 0.496 . . . . 0.0 110.227 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.715 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.1 pt-20 -83.04 176.48 9.21 Favored 'General case' 0 C--O 1.205 -1.24 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.046 178.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' TYR . . . . . 0.451 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 35.5 m-85 -72.88 133.26 44.33 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.218 177.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.51 5.05 63.6 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.34 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.715 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -94.97 147.16 5.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.171 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.502 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 51.8 mtpt -110.76 118.47 36.25 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 178.701 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -83.28 92.48 7.51 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.301 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.507 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 35.0 m -89.1 117.71 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.824 0 CA-C-O 122.151 0.977 . . . . 0.0 109.903 -178.521 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 31.5 m-85 -85.88 139.48 31.21 Favored 'General case' 0 C--N 1.263 -3.182 0 CA-C-N 115.129 -0.941 . . . . 0.0 108.896 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.2 t -138.96 124.6 19.54 Favored 'General case' 0 N--CA 1.407 -2.603 0 CA-C-O 121.999 0.904 . . . . 0.0 109.671 -178.629 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 74.3 m -71.74 161.79 30.44 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-N 115.0 -1.0 . . . . 0.0 112.455 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.497 ' ND2' ' HA2' ' A' ' 94' ' ' GLY . 81.3 m-20 -86.31 -176.59 5.95 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.479 179.098 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -46.87 -50.94 17.81 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 126.513 1.925 . . . . 0.0 114.008 -177.817 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -91.19 28.36 8.17 Favored Glycine 0 C--N 1.305 -1.158 0 C-N-CA 119.736 -1.221 . . . . 0.0 113.179 -177.726 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.455 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 98.8 m-85 -149.37 167.51 25.94 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -173.627 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.88 156.87 38.37 Favored 'General case' 0 N--CA 1.435 -1.195 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.81 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.529 ' HG ' ' HB2' ' A' ' 125' ' ' ASN . 0.5 OUTLIER -85.99 128.39 34.84 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -175.182 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -102.1 130.1 48.62 Favored 'General case' 0 N--CA 1.422 -1.864 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 -175.741 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.74 -159.7 13.83 Favored Glycine 0 C--N 1.297 -1.63 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.296 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -106.03 -41.63 5.33 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 121.835 0.826 . . . . 0.0 109.267 -178.277 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 51.1 mm -85.17 122.92 38.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 CA-C-N 114.772 -1.104 . . . . 0.0 110.069 -176.331 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.529 ' HB2' ' HG ' ' A' ' 120' ' ' LEU . 3.9 p-10 -127.59 7.12 6.27 Favored 'General case' 0 C--O 1.202 -1.41 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 176.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.507 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 15.4 p90 -134.25 168.21 19.3 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -171.784 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.514 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 36.3 mtp180 -130.67 119.89 23.1 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 170.399 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -92.32 126.76 37.54 Favored 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.846 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 49.3 t -84.7 108.04 17.21 Favored 'General case' 0 N--CA 1.434 -1.266 0 C-N-CA 119.142 -1.023 . . . . 0.0 109.249 174.457 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -101.76 -171.22 1.94 Allowed 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 105.354 -2.091 . . . . 0.0 105.354 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 15.3 t -64.37 -15.34 60.26 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.841 0.829 . . . . 0.0 110.593 -178.511 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -97.88 -2.17 41.35 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.255 -178.686 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 103.48 -159.44 16.93 Favored Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -177.836 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.442 ' CH2' HG13 ' A' ' 108' ' ' VAL . 86.9 m95 -68.64 108.47 3.37 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 177.892 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 41.7 p -67.71 -57.51 6.23 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 115.439 -0.8 . . . . 0.0 112.655 -175.432 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' ASN . . . . . 0.514 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 6.4 m120 -71.83 171.22 12.07 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.957 -178.518 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 25.2 m-20 -100.74 176.61 5.24 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 176.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 88.6 mt -66.35 119.07 59.39 Favored Pre-proline 0 C--O 1.237 0.407 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 173.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.402 ' HB2' HD11 ' A' ' 120' ' ' LEU . 29.7 Cg_endo -64.46 164.7 22.48 Favored 'Trans proline' 0 N--CA 1.451 -0.993 0 C-N-CA 122.601 2.2 . . . . 0.0 112.986 -177.722 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 50.0 mm -96.49 124.47 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.766 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.903 -175.461 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.455 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 48.9 t -105.66 136.12 45.83 Favored 'General case' 0 C--N 1.27 -2.882 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 177.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -124.91 141.8 51.88 Favored 'General case' 0 N--CA 1.413 -2.28 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -177.236 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 6.2 p -68.34 139.19 21.09 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 O-C-N 123.874 0.734 . . . . 0.0 109.573 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.646 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 21.1 m -65.83 129.44 30.14 Favored 'Isoleucine or valine' 0 C--O 1.251 1.168 0 C-N-CA 120.48 -0.488 . . . . 0.0 110.094 178.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 89.4 mttt -114.79 166.6 11.58 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -178.134 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 82.0 m -129.43 -174.22 3.23 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-O 121.135 0.493 . . . . 0.0 111.457 -175.081 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 31.1 mt -77.72 137.0 62.76 Favored Pre-proline 0 N--CA 1.439 -0.991 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.315 177.305 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -70.86 112.51 3.29 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 C-N-CA 122.279 1.986 . . . . 0.0 109.683 175.671 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 27.8 t -82.81 136.61 22.51 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 -179.203 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.6 p -76.93 -73.71 0.28 Allowed 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 123.104 0.252 . . . . 0.0 111.518 179.371 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 167.9 160.19 0.15 Allowed Pre-proline 0 C--O 1.239 0.548 0 C-N-CA 126.128 1.771 . . . . 0.0 106.95 -179.368 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -77.49 170.05 19.99 Favored 'Trans proline' 0 CA--C 1.542 0.883 0 C-N-CA 121.586 1.524 . . . . 0.0 110.26 170.298 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -63.14 -52.6 61.87 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 -176.126 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 31.1 m120 -106.48 33.45 3.87 Favored 'General case' 0 CA--C 1.499 -1.011 0 CA-C-O 121.363 0.601 . . . . 0.0 109.981 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -151.59 -167.35 14.85 Favored Glycine 0 N--CA 1.42 -2.406 0 C-N-CA 120.133 -1.032 . . . . 0.0 112.062 178.79 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' LYS . . . . . 0.518 ' HG3' HG23 ' A' ' 177' ' ' VAL . 59.6 pttt -154.55 176.19 12.7 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -179.435 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 159' ' ' SER . 49.3 mt -98.31 145.05 10.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -179.303 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.677 HG12 HG22 ' A' ' 177' ' ' VAL . 2.5 m -89.12 -31.39 5.42 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.081 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 159' ' ' SER . . . . . 0.425 ' N ' HG22 ' A' ' 157' ' ' ILE . 6.7 m . . . . . 0 C--N 1.313 -1.02 0 C-N-CA 124.603 1.161 . . . . 0.0 110.951 -175.325 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 . . . . . 0 N--CA 1.463 0.184 0 CA-C-O 121.623 0.725 . . . . 0.0 112.181 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.411 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 35.9 m80 -141.61 162.44 35.48 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -177.086 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.646 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 91.6 t80 -48.25 139.43 8.58 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-O 121.194 0.521 . . . . 0.0 112.104 175.342 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 87.37 -15.22 55.31 Favored Glycine 0 N--CA 1.423 -2.217 0 CA-C-O 119.204 -0.776 . . . . 0.0 113.867 175.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 29.2 mm-40 -65.0 135.76 56.01 Favored 'General case' 0 CA--C 1.496 -1.127 0 CA-C-N 118.233 1.017 . . . . 0.0 111.157 -178.353 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -104.71 113.96 27.87 Favored 'General case' 0 C--N 1.287 -2.148 0 CA-C-N 114.518 -1.219 . . . . 0.0 108.325 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 98.0 t -105.5 102.28 13.62 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.115 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.472 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 40.9 ttm180 -97.06 146.97 24.5 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.437 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -116.06 156.54 26.19 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.14 0.495 . . . . 0.0 110.217 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.677 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -127.76 135.18 63.75 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.131 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.146 177.583 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 77.7 m -93.91 139.25 31.13 Favored 'General case' 0 C--N 1.262 -3.231 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 173.744 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -56.02 157.55 4.47 Favored 'General case' 0 C--N 1.294 -1.829 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.208 176.707 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.8 m -52.25 111.12 0.57 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 124.319 1.012 . . . . 0.0 112.07 -174.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 106.6 1.71 37.35 Favored Glycine 0 N--CA 1.426 -1.984 0 C-N-CA 120.317 -0.944 . . . . 0.0 112.863 177.744 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -113.41 158.81 20.17 Favored 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 117.994 0.897 . . . . 0.0 110.169 176.59 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 15.6 pttm -120.62 153.38 36.91 Favored 'General case' 0 N--CA 1.428 -1.573 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.403 HD13 ' HA ' ' A' ' 188' ' ' GLU . 2.1 tt -84.67 131.06 34.93 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.911 0 C-N-CA 119.28 -0.968 . . . . 0.0 109.728 176.701 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -82.43 -48.33 11.22 Favored 'General case' 0 C--N 1.286 -2.165 0 CA-C-N 114.717 -1.129 . . . . 0.0 109.747 -175.265 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -83.89 -151.66 12.62 Favored Glycine 0 C--N 1.304 -1.213 0 CA-C-N 114.847 -1.07 . . . . 0.0 110.528 176.605 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -80.62 164.56 22.78 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.403 ' HA ' HD13 ' A' ' 184' ' ' ILE . 16.2 pt-20 -89.32 -3.27 58.55 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.91 -172.085 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -157.89 162.48 38.32 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.57 -176.257 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 17.8 ptp -137.06 153.67 50.53 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 114.81 -1.086 . . . . 0.0 108.16 176.103 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 22.0 m80 -125.64 151.66 46.22 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.652 0.263 . . . . 0.0 110.676 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 18.9 m -76.21 112.6 12.86 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 171.062 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 23.3 t -82.24 171.05 14.71 Favored 'General case' 0 N--CA 1.422 -1.85 0 O-C-N 124.383 1.052 . . . . 0.0 110.038 -176.574 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -50.54 -34.92 27.32 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 125.448 1.499 . . . . 0.0 112.198 -178.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -69.48 -14.24 62.77 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.155 -0.93 . . . . 0.0 113.367 -177.579 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 83.7 29.25 32.81 Favored Glycine 0 C--O 1.225 -0.466 0 C-N-CA 120.439 -0.886 . . . . 0.0 110.893 -174.577 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -138.33 172.64 12.6 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 70.6 m95 -80.16 136.28 36.48 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 120.816 0.341 . . . . 0.0 111.252 -179.342 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 25.7 p -73.88 -22.57 59.68 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.197 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.593 ' HE2' ' HA ' ' A' ' 200' ' ' LYS . 3.9 mmpt? -122.62 166.49 14.78 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.483 0.658 . . . . 0.0 111.572 -179.404 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -89.71 164.68 14.59 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 179.255 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 43.7 mtpt -66.63 122.76 83.54 Favored Pre-proline 0 C--N 1.309 -1.155 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.038 174.877 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -77.58 163.38 29.47 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 C-N-CA 122.03 1.82 . . . . 0.0 111.155 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 53.7 tttp -120.22 152.09 38.23 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -178.101 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 88.8 m -114.81 114.81 26.05 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 176.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 19.5 m . . . . . 0 C--N 1.3 -1.582 0 O-C-N 124.277 0.985 . . . . 0.0 109.175 -175.447 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo . . . . . 0 CA--C 1.538 0.689 0 CA-C-O 122.001 0.751 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 37.2 m -88.33 -36.49 16.61 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 177.204 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 120.53 -91.36 0.49 Allowed Glycine 0 CA--C 1.458 -3.484 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 172.359 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.2 t-80 -176.11 127.6 0.35 Allowed Pre-proline 0 C--N 1.266 -3.05 0 N-CA-C 104.77 -2.308 . . . . 0.0 104.77 -176.157 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.463 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 61.5 Cg_endo -74.1 -17.5 21.96 Favored 'Trans proline' 0 C--N 1.329 -0.478 0 C-N-CA 122.44 2.093 . . . . 0.0 113.977 -175.301 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 131.0 -173.78 20.16 Favored Glycine 0 N--CA 1.427 -1.909 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 -176.432 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -147.39 144.13 28.47 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.7 t -122.32 130.08 24.83 Favored Pre-proline 0 C--N 1.305 -1.352 0 CA-C-O 121.194 0.521 . . . . 0.0 111.279 -178.12 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.74 -12.21 24.23 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.689 2.259 . . . . 0.0 111.676 178.074 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -95.04 14.36 22.11 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.717 -176.372 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 160.22 -122.33 1.12 Allowed Glycine 0 N--CA 1.421 -2.366 0 N-CA-C 111.084 -0.807 . . . . 0.0 111.084 178.607 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 t -172.31 -168.23 0.52 Allowed 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -177.551 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -147.56 170.2 17.97 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.7 m -138.46 156.83 47.19 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.492 HD11 ' CE1' ' A' ' 104' ' ' PHE . 14.6 mt -106.65 133.41 51.37 Favored 'General case' 0 C--N 1.276 -2.601 0 CA-C-O 121.213 0.53 . . . . 0.0 110.375 -176.731 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.458 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 23.8 p -121.23 116.68 25.36 Favored 'General case' 0 C--N 1.294 -1.813 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.59 -176.382 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.56 -58.93 0.7 Allowed Glycine 0 N--CA 1.434 -1.47 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -179.51 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.426 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -127.23 -4.51 5.9 Favored Glycine 0 N--CA 1.437 -1.247 0 C-N-CA 120.159 -1.019 . . . . 0.0 112.479 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 63.05 12.91 6.31 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 123.706 0.803 . . . . 0.0 112.517 -177.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.525 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.6 m -145.12 -171.86 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 -176.633 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.492 ' CE1' HD11 ' A' ' 98' ' ' LEU . 27.1 m-85 -101.01 44.45 1.01 Allowed 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 118.648 0.658 . . . . 0.0 110.074 -176.03 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.697 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.6 pt-20 -84.68 179.28 7.4 Favored 'General case' 0 C--O 1.209 -1.035 0 CA-C-N 114.639 -1.164 . . . . 0.0 112.101 178.11 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -78.57 132.2 37.06 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.359 0.6 . . . . 0.0 111.345 178.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 101.06 -8.67 57.64 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 115.067 -0.97 . . . . 0.0 112.475 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.697 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -86.29 143.7 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 CA-C-O 121.418 0.628 . . . . 0.0 110.726 -174.586 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.458 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 19.6 mtpp -110.05 119.57 39.72 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.634 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.476 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -85.57 95.08 9.21 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 177.615 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 55.3 t -90.33 114.93 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.58 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 -177.61 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -83.94 138.92 32.9 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.94 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.3 t -134.07 116.73 15.8 Favored 'General case' 0 N--CA 1.42 -1.957 0 CA-C-N 115.032 -0.986 . . . . 0.0 108.672 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 21.0 m -72.88 160.06 32.74 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.49 -175.193 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -68.63 -179.72 1.47 Allowed 'General case' 0 C--N 1.315 -0.911 0 C-N-CA 122.95 0.5 . . . . 0.0 111.392 -177.584 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -59.43 -50.96 71.94 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 123.828 0.851 . . . . 0.0 111.212 -177.423 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -87.56 31.16 4.63 Favored Glycine 0 C--N 1.309 -0.924 0 C-N-CA 120.984 -0.627 . . . . 0.0 113.094 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -145.76 161.44 39.92 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -177.072 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -142.22 173.67 11.31 Favored 'General case' 0 C--N 1.271 -2.845 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 -179.357 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 11.9 tp -92.4 149.92 21.12 Favored 'General case' 0 C--N 1.273 -2.753 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.525 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -132.65 130.91 40.76 Favored 'General case' 0 N--CA 1.415 -2.204 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 177.9 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 116.49 -153.41 17.44 Favored Glycine 0 N--CA 1.433 -1.547 0 C-N-CA 120.646 -0.788 . . . . 0.0 111.526 179.08 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -112.3 -41.69 3.86 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 121.82 0.819 . . . . 0.0 110.068 -178.554 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.43 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.5 mm -85.97 144.34 9.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.782 -173.735 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 22.4 p-10 -135.24 4.32 3.18 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-O 120.79 0.328 . . . . 0.0 110.595 175.484 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.476 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 5.4 p90 -145.95 165.98 27.38 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.232 -172.381 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.463 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 44.8 mtp180 -128.56 125.67 38.74 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.409 -1.7 . . . . 0.0 106.409 171.777 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 109' ' ' LYS . 55.9 tt0 -103.71 136.04 44.15 Favored 'General case' 0 C--N 1.286 -2.19 0 C-N-CA 118.352 -1.339 . . . . 0.0 110.378 179.411 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' CYS . . . . . 0.427 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 21.2 t -87.33 106.93 18.27 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.237 175.336 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -102.62 -166.76 1.31 Allowed 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 104.621 -2.363 . . . . 0.0 104.621 175.286 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 10.6 t -61.21 -29.83 70.05 Favored 'General case' 0 C--N 1.295 -1.769 0 CA-C-N 118.93 0.786 . . . . 0.0 112.81 -175.032 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -78.76 -16.53 57.08 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 121.743 0.782 . . . . 0.0 110.798 177.273 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.427 ' HA2' ' SG ' ' A' ' 129' ' ' CYS . . . 116.02 -148.16 18.9 Favored Glycine 0 N--CA 1.416 -2.676 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 -175.237 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 86.7 m95 -66.92 109.66 3.03 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 117.092 0.446 . . . . 0.0 109.858 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.1 p -64.82 -69.58 0.28 Allowed 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 124.219 1.008 . . . . 0.0 112.037 -176.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' ASN . . . . . 0.41 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 3.7 m-20 -75.79 167.94 20.94 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 114.012 -1.449 . . . . 0.0 108.94 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -104.23 178.13 4.65 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 123.629 0.58 . . . . 0.0 110.393 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 64.6 mt -64.31 126.19 89.91 Favored Pre-proline 0 C--N 1.314 -0.941 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.625 -178.565 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.43 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 48.2 Cg_endo -70.36 170.77 16.5 Favored 'Trans proline' 0 C--O 1.251 1.172 0 C-N-CA 122.654 2.236 . . . . 0.0 112.404 178.362 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.525 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 56.1 mt -97.6 127.43 49.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.742 -178.232 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 61.2 m -106.82 123.83 48.72 Favored 'General case' 0 C--N 1.273 -2.737 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 169.558 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -111.8 151.4 29.06 Favored 'General case' 0 C--N 1.276 -2.618 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.17 142.49 15.48 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.829 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.594 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.4 m -68.52 113.69 4.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 119.93 -0.708 . . . . 0.0 109.462 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 87.8 mttt -105.46 133.99 49.31 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.189 -177.13 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.3 m -97.32 149.97 21.48 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' LEU . . . . . 0.411 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.2 mm? -59.44 143.83 85.13 Favored Pre-proline 0 N--CA 1.42 -1.937 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 177.922 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 35.0 Cg_exo -56.94 114.37 1.89 Allowed 'Trans proline' 0 C--O 1.252 1.204 0 C-N-CA 123.479 2.786 . . . . 0.0 111.429 179.121 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.4 p -89.0 137.64 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.723 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.713 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' THR . . . . . 0.413 ' O ' HD11 ' A' ' 157' ' ' ILE . 15.3 p -94.12 -158.74 0.65 Allowed 'General case' 0 N--CA 1.414 -2.262 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.065 177.271 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.448 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . -122.44 160.21 49.23 Favored Pre-proline 0 C--N 1.291 -1.944 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 -173.872 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -71.3 -170.21 0.48 Allowed 'Trans proline' 0 CA--C 1.555 1.545 0 C-N-CA 121.171 1.247 . . . . 0.0 110.61 176.355 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.27 -46.5 17.66 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 112.557 0.577 . . . . 0.0 112.557 -171.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 28.9 m120 -110.52 14.59 22.45 Favored 'General case' 0 CA--C 1.502 -0.901 0 CA-C-O 121.435 0.636 . . . . 0.0 110.586 -179.565 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -127.96 -176.2 14.36 Favored Glycine 0 N--CA 1.423 -2.212 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' LYS . . . . . 0.461 ' HG3' HG23 ' A' ' 177' ' ' VAL . 45.6 pttt -151.56 -178.83 6.92 Favored 'General case' 0 C--N 1.292 -1.913 0 C-N-CA 123.451 0.7 . . . . 0.0 109.229 -175.759 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.419 HG22 ' N ' ' A' ' 159' ' ' SER . 56.1 mt -103.3 135.04 42.71 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 CA-C-N 118.018 0.372 . . . . 0.0 111.193 -176.1 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.52 HG12 HG22 ' A' ' 177' ' ' VAL . 2.7 m -79.0 -32.17 15.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.03 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 159' ' ' SER . . . . . 0.419 ' N ' HG22 ' A' ' 157' ' ' ILE . 5.0 m . . . . . 0 C--N 1.32 -0.708 0 C-N-CA 124.588 1.155 . . . . 0.0 110.013 -176.304 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 64.5 m-85 . . . . . 0 N--CA 1.429 -1.501 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 45.6 m170 -120.77 163.78 17.6 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -176.57 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.594 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 93.7 t80 -46.83 126.55 8.84 Favored 'General case' 0 C--O 1.237 0.416 0 O-C-N 124.284 0.99 . . . . 0.0 109.964 172.491 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 115.75 -34.63 4.67 Favored Glycine 0 N--CA 1.424 -2.152 0 C-N-CA 120.097 -1.049 . . . . 0.0 111.656 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -67.41 134.33 51.24 Favored 'General case' 0 C--O 1.25 1.097 0 CA-C-O 121.519 0.676 . . . . 0.0 112.669 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -124.87 107.32 10.76 Favored 'General case' 0 N--CA 1.431 -1.419 0 CA-C-N 114.284 -1.325 . . . . 0.0 107.934 179.431 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 64.9 t -92.64 116.92 34.87 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.088 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.938 -176.803 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.481 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 39.8 ttm180 -106.44 147.8 28.89 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 176.572 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -111.99 160.32 17.58 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 123.589 0.755 . . . . 0.0 110.228 -177.081 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.52 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -132.65 155.66 41.54 Favored 'Isoleucine or valine' 0 CA--C 1.469 -2.163 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.531 178.411 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 10.0 m -111.89 145.19 39.95 Favored 'General case' 0 N--CA 1.396 -3.162 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.24 172.496 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -64.28 171.99 2.76 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.993 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.9 m -48.2 -25.73 1.62 Allowed 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 116.677 2.103 . . . . 0.0 116.677 -169.666 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -112.51 8.9 26.29 Favored Glycine 0 C--N 1.298 -1.533 0 C-N-CA 120.2 -1.0 . . . . 0.0 113.568 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -126.84 178.87 5.68 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 117.3 0.55 . . . . 0.0 111.793 -176.431 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 15.0 pttp -150.68 165.13 34.36 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.7 tp -71.86 151.92 8.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.232 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -80.17 -73.12 0.37 Allowed 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.196 176.859 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -102.35 -100.18 2.51 Favored Glycine 0 CA--C 1.5 -0.887 0 C-N-CA 120.156 -1.021 . . . . 0.0 112.001 -177.563 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -86.43 154.28 21.27 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 177.3 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -108.68 3.6 22.94 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.991 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -153.05 158.71 42.36 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -174.362 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.3 ptp -135.8 156.08 49.36 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 124.695 1.198 . . . . 0.0 108.787 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.1 t-80 -137.5 142.25 41.49 Favored 'General case' 0 C--N 1.31 -1.124 0 O-C-N 122.305 -0.247 . . . . 0.0 110.659 -176.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 30.1 m -80.31 123.38 27.94 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 123.691 0.619 . . . . 0.0 111.398 174.767 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 67.6 m -111.62 -175.93 2.82 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 175.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.02 -17.61 53.19 Favored 'General case' 0 N--CA 1.504 2.229 0 C-N-CA 122.84 0.456 . . . . 0.0 111.843 -173.758 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -55.97 -35.56 66.87 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 124.441 1.096 . . . . 0.0 111.053 177.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 87.09 17.07 59.88 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 -173.274 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -137.07 165.74 25.33 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.0 m95 -77.16 140.64 40.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 O-C-N 123.755 0.659 . . . . 0.0 109.279 178.182 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.3 m -81.16 -6.0 58.35 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.504 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 17.2 tppt? -136.9 161.63 35.49 Favored 'General case' 0 N--CA 1.427 -1.611 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -104.25 178.08 4.66 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 117.554 0.161 . . . . 0.0 110.771 -177.577 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? -64.11 117.36 35.57 Favored Pre-proline 0 C--O 1.243 0.723 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 177.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -76.96 -169.06 0.66 Allowed 'Trans proline' 0 N--CA 1.446 -1.265 0 C-N-CA 122.107 1.872 . . . . 0.0 110.651 176.132 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 204' ' ' LYS . . . . . 0.429 ' HG2' ' N ' ' A' ' 205' ' ' CYS . 46.5 tttm -131.14 160.26 35.25 Favored 'General case' 0 N--CA 1.42 -1.972 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -177.111 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.429 ' N ' ' HG2' ' A' ' 204' ' ' LYS . 9.4 t -110.88 129.68 55.8 Favored 'General case' 0 N--CA 1.423 -1.789 0 N-CA-C 105.697 -1.964 . . . . 0.0 105.697 176.261 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 11.0 m . . . . . 0 C--N 1.301 -1.535 0 CA-C-O 118.491 -0.766 . . . . 0.0 111.578 -174.657 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo . . . . . 0 N--CA 1.483 0.907 0 CA-C-O 121.581 0.576 . . . . 0.0 112.658 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 59.6 m -71.63 -24.71 61.92 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.787 -178.314 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 96.43 14.72 43.43 Favored Glycine 0 C--N 1.302 -1.359 0 CA-C-N 115.444 -0.798 . . . . 0.0 114.808 171.407 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 9.4 t60 69.23 115.39 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.764 0 C-N-CA 123.96 0.904 . . . . 0.0 109.835 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.402 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 42.7 Cg_endo -67.48 -42.25 7.51 Favored 'Trans proline' 0 C--O 1.221 -0.358 0 C-N-CA 122.141 1.894 . . . . 0.0 112.644 -174.434 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 136.07 174.64 13.45 Favored Glycine 0 N--CA 1.422 -2.286 0 N-CA-C 107.592 -2.203 . . . . 0.0 107.592 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 48.1 t0 -134.32 169.02 17.83 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 -177.31 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.0 t -131.56 126.43 21.09 Favored Pre-proline 0 C--N 1.285 -2.197 0 CA-C-N 117.897 0.317 . . . . 0.0 110.927 -177.228 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -69.72 -11.39 30.8 Favored 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 122.888 2.392 . . . . 0.0 111.477 177.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -91.84 4.12 53.59 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.06 -178.425 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.596 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.9 -131.36 1.95 Allowed Glycine 0 N--CA 1.401 -3.691 0 C-N-CA 119.637 -1.268 . . . . 0.0 112.475 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.7 p -153.83 -179.17 7.58 Favored 'General case' 0 C--N 1.287 -2.113 0 C-N-CA 124.4 1.08 . . . . 0.0 109.708 -177.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -145.68 160.34 41.84 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 172.118 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.3 m -125.4 159.93 30.64 Favored 'General case' 0 C--N 1.283 -2.3 0 N-CA-C 107.111 -1.441 . . . . 0.0 107.111 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 16.7 mt -116.97 115.82 26.19 Favored 'General case' 0 C--N 1.273 -2.733 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.527 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 31.9 p -106.76 133.04 52.04 Favored 'General case' 0 C--N 1.271 -2.843 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.257 -173.719 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 108.04 -67.67 0.23 Allowed Glycine 0 N--CA 1.429 -1.828 0 N-CA-C 110.611 -0.995 . . . . 0.0 110.611 -179.159 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.425 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -106.58 -14.83 18.74 Favored Glycine 0 C--N 1.309 -0.926 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.784 -176.708 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 59.81 19.09 7.94 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.206 1.002 . . . . 0.0 112.787 -178.025 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.457 ' O ' HG11 ' A' ' 108' ' ' VAL . 27.8 m -150.24 -172.19 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 -177.506 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -100.47 41.37 1.18 Allowed 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 118.642 0.655 . . . . 0.0 111.164 -176.651 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.706 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.9 pt-20 -85.64 179.94 7.0 Favored 'General case' 0 C--O 1.207 -1.145 0 C-N-CA 123.971 0.908 . . . . 0.0 112.577 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -75.13 132.7 41.39 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.808 -0.557 . . . . 0.0 111.128 176.85 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.06 -5.42 63.38 Favored Glycine 0 N--CA 1.438 -1.206 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.681 178.064 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.706 HG12 ' O ' ' A' ' 105' ' ' GLU . 13.7 p -85.27 145.66 7.63 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.527 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 19.0 mtpp -111.55 113.96 26.71 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.604 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -81.4 94.23 6.76 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 177.255 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.465 HG12 ' CB ' ' A' ' 126' ' ' TYR . 33.0 m -92.19 120.11 40.83 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.193 0 CA-C-O 121.969 0.89 . . . . 0.0 108.897 -177.825 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -87.79 138.58 31.34 Favored 'General case' 0 C--N 1.262 -3.199 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.794 -177.554 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.0 t -137.36 110.23 7.65 Favored 'General case' 0 N--CA 1.407 -2.61 0 CA-C-O 122.381 1.086 . . . . 0.0 109.214 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.454 ' HA ' ' HA3' ' A' ' 94' ' ' GLY . 15.8 m -67.87 159.24 30.84 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.473 -1.239 . . . . 0.0 110.465 -177.145 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.596 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 92.0 m-20 -77.26 -179.11 5.46 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 120.746 0.308 . . . . 0.0 111.322 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -46.58 -52.51 13.37 Favored 'General case' 0 C--N 1.31 -1.138 0 C-N-CA 126.266 1.826 . . . . 0.0 114.428 -177.401 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -82.19 6.25 68.5 Favored Glycine 0 C--N 1.315 -0.589 0 C-N-CA 120.543 -0.837 . . . . 0.0 113.178 -176.431 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -128.19 166.96 17.53 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -176.585 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -145.35 165.73 27.62 Favored 'General case' 0 C--N 1.283 -2.312 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 176.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.07 123.68 29.73 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -178.827 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -106.85 126.31 52.14 Favored 'General case' 0 N--CA 1.416 -2.151 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 178.113 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 110.9 174.6 20.21 Favored Glycine 0 C--N 1.299 -1.486 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -176.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -85.6 -44.02 12.99 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 -178.114 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.7 mm -72.08 125.15 30.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 CA-C-N 114.175 -1.375 . . . . 0.0 110.39 -177.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -125.4 5.06 7.67 Favored 'General case' 0 C--O 1.202 -1.398 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 175.123 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.465 ' CB ' HG12 ' A' ' 111' ' ' VAL . 15.7 p90 -143.27 163.06 34.02 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.288 -171.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 50.9 mtp180 -126.96 130.51 50.22 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 174.23 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -106.14 130.25 54.06 Favored 'General case' 0 C--N 1.29 -2.0 0 C-N-CA 119.707 -0.797 . . . . 0.0 108.978 -179.483 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 26.5 t -84.31 108.51 17.2 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.466 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.426 ' OD1' HG22 ' A' ' 131' ' ' THR . 6.5 t70 -107.98 -167.22 1.22 Allowed 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.38 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.426 HG22 ' OD1' ' A' ' 130' ' ' ASP . 12.4 t -74.53 -12.61 60.52 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-O 121.861 0.838 . . . . 0.0 109.646 -178.91 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -86.46 -8.93 57.2 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.96 175.282 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 100.95 -153.56 19.14 Favored Glycine 0 N--CA 1.427 -1.963 0 N-CA-C 108.63 -1.788 . . . . 0.0 108.63 -175.614 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.402 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 95.2 m95 -67.33 111.25 3.92 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 117.565 0.683 . . . . 0.0 110.003 175.776 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 33.3 p -54.25 -58.88 5.72 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 124.877 1.271 . . . . 0.0 112.551 -176.843 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -92.98 -175.62 3.93 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.449 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -117.19 177.96 4.53 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.381 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.2 mt -57.39 118.79 27.29 Favored Pre-proline 0 C--N 1.286 -2.189 0 C-N-CA 125.65 1.58 . . . . 0.0 109.343 177.078 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -73.24 -177.58 3.07 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.901 2.4 . . . . 0.0 111.914 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 67.1 mt -105.32 133.18 50.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-O 120.903 0.382 . . . . 0.0 111.716 -172.065 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 90.6 m -111.4 91.15 3.55 Favored 'General case' 0 C--N 1.297 -1.682 0 CA-C-O 121.693 0.758 . . . . 0.0 109.039 174.361 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -86.85 148.54 25.33 Favored 'General case' 0 N--CA 1.424 -1.77 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -177.219 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.8 p -70.07 137.51 23.9 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 177.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 95.4 t -64.62 126.01 22.61 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -115.44 143.98 44.5 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.033 -176.026 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -120.75 159.59 25.09 Favored 'General case' 0 C--N 1.281 -2.41 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.147 177.62 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -68.46 147.08 98.11 Favored Pre-proline 0 N--CA 1.421 -1.899 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -175.126 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -71.93 116.42 4.7 Favored 'Trans proline' 0 N--CA 1.442 -1.522 0 C-N-CA 122.701 2.268 . . . . 0.0 110.546 178.099 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.445 HG21 ' SD ' ' A' ' 190' ' ' MET . 60.1 t -74.81 144.46 12.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.319 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.4 p -66.57 -84.85 0.02 OUTLIER 'General case' 0 N--CA 1.438 -1.026 0 O-C-N 123.379 0.424 . . . . 0.0 111.629 177.795 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 168.01 162.58 0.15 Allowed Pre-proline 0 CA--C 1.513 -0.46 0 C-N-CA 126.106 1.763 . . . . 0.0 106.463 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -76.54 168.3 23.98 Favored 'Trans proline' 0 N--CA 1.446 -1.313 0 C-N-CA 121.324 1.349 . . . . 0.0 110.001 171.267 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -60.02 -50.9 71.92 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 113.862 1.06 . . . . 0.0 113.862 -176.58 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 55.0 m-80 -110.67 32.61 5.09 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.563 0.696 . . . . 0.0 109.791 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -149.15 -176.79 22.73 Favored Glycine 0 N--CA 1.425 -2.081 0 C-N-CA 120.219 -0.991 . . . . 0.0 111.384 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -144.45 169.37 18.07 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -178.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.528 HG12 ' CD2' ' A' ' 176' ' ' PHE . 51.6 mt -98.47 137.45 25.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.478 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.8 m -84.5 -28.02 6.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 CA-C-O 121.986 0.898 . . . . 0.0 108.701 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 159' ' ' SER . . . . . 0.517 ' H ' HG22 ' A' ' 157' ' ' ILE . 12.9 m . . . . . 0 C--N 1.312 -1.038 0 CA-C-N 114.704 -1.135 . . . . 0.0 112.496 -176.303 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 69.7 m-85 . . . . . 0 N--CA 1.429 -1.491 0 CA-C-O 121.682 0.753 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 46.8 m170 -115.29 163.51 15.58 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.744 -176.175 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -51.93 127.46 21.25 Favored 'General case' 0 C--O 1.245 0.843 0 O-C-N 124.134 0.896 . . . . 0.0 108.983 172.734 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 108.23 -22.81 26.4 Favored Glycine 0 N--CA 1.435 -1.422 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.306 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 30.1 mm-40 -71.67 144.67 49.28 Favored 'General case' 0 C--O 1.256 1.398 0 CA-C-N 117.185 0.492 . . . . 0.0 110.314 178.666 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -123.03 104.99 9.57 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.253 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.547 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 54.4 t -79.85 106.62 11.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.832 -178.023 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.478 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 25.9 ttp85 -98.62 143.45 29.0 Favored 'General case' 0 N--CA 1.41 -2.452 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.736 179.138 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.528 ' CD2' HG12 ' A' ' 157' ' ' ILE . 64.0 m-85 -112.85 165.75 12.02 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -178.107 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.7 p -146.73 138.25 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.291 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.113 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.5 m -92.67 148.28 22.19 Favored 'General case' 0 C--N 1.265 -3.101 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.391 -178.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -69.64 162.41 27.71 Favored 'General case' 0 CA--C 1.497 -1.063 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.664 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 16.3 m -52.08 109.44 0.38 Allowed 'General case' 0 C--N 1.303 -1.439 0 O-C-N 124.404 1.065 . . . . 0.0 112.368 -175.391 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.58 -9.17 30.36 Favored Glycine 0 N--CA 1.435 -1.385 0 CA-C-N 115.715 -0.675 . . . . 0.0 113.073 178.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -108.81 153.12 23.94 Favored 'General case' 0 CA--C 1.497 -1.059 0 CA-C-N 117.886 0.843 . . . . 0.0 110.886 -178.484 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 16.9 pttp -115.71 159.54 21.25 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 7.0 tp -74.36 146.19 10.23 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 176.309 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -91.46 -61.21 1.7 Allowed 'General case' 0 C--N 1.27 -2.876 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -90.99 -130.48 4.68 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 177.167 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -87.8 153.14 21.58 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 176.141 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -92.55 8.19 39.95 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 120.365 -0.534 . . . . 0.0 110.465 -177.088 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 189' ' ' GLU . . . . . 0.547 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 2.0 pt-20 -155.94 143.76 19.64 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 121.123 0.487 . . . . 0.0 111.925 -179.505 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.445 ' SD ' HG21 ' A' ' 149' ' ' VAL . 13.9 ptp -125.65 138.28 53.9 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.01 -0.995 . . . . 0.0 109.336 176.835 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 50.1 t-80 -100.56 138.77 37.17 Favored 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 123.089 0.556 . . . . 0.0 110.045 -176.498 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 23.6 t -82.76 107.08 15.12 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 174.547 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 50.7 m -100.21 -178.59 3.87 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 114.046 1.128 . . . . 0.0 114.046 -171.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -49.17 -34.97 15.7 Favored 'General case' 0 N--CA 1.51 2.541 0 C-N-CA 125.908 1.683 . . . . 0.0 113.179 -174.153 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -81.8 -7.67 59.62 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 113.456 0.909 . . . . 0.0 113.456 -176.446 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 83.42 10.19 82.39 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.15 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -112.96 169.76 8.69 Favored 'General case' 0 N--CA 1.427 -1.599 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 177.545 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.3 m95 -83.66 134.99 34.76 Favored 'General case' 0 N--CA 1.417 -2.087 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.24 178.682 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 35.9 p -63.38 -32.26 73.64 Favored 'General case' 0 C--O 1.249 1.063 0 CA-C-O 121.523 0.677 . . . . 0.0 112.229 -177.575 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 26.3 mmtp -116.49 157.08 25.76 Favored 'General case' 0 CA--C 1.483 -1.601 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.352 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 201' ' ' GLU . . . . . 0.438 ' CD ' ' H ' ' A' ' 201' ' ' GLU . 0.3 OUTLIER -86.43 172.13 10.61 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.684 179.813 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 7.6 mmmm -55.13 119.9 26.13 Favored Pre-proline 0 C--N 1.321 -0.634 0 O-C-N 123.697 0.623 . . . . 0.0 111.786 178.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -86.5 -173.44 1.21 Allowed 'Trans proline' 0 N--CA 1.424 -2.589 0 C-N-CA 122.061 1.841 . . . . 0.0 109.987 178.774 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 24.5 ttmm -148.08 164.41 33.93 Favored 'General case' 0 C--N 1.278 -2.506 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -176.406 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.549 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 98.4 m -126.06 116.04 20.79 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 174.69 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--N 1.3 -1.574 0 O-C-N 124.416 1.072 . . . . 0.0 109.747 -175.392 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo . . . . . 0 N--CA 1.477 0.528 0 CA-C-O 121.313 0.464 . . . . 0.0 112.159 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.6 m -84.25 -29.97 26.05 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.37 -98.1 0.74 Allowed Glycine 0 N--CA 1.398 -3.891 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.919 171.837 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -177.08 110.75 0.23 Allowed Pre-proline 0 C--N 1.258 -3.407 0 N-CA-C 105.759 -1.941 . . . . 0.0 105.759 -176.075 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.451 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 45.0 Cg_endo -64.76 -30.82 59.04 Favored 'Trans proline' 0 N--CA 1.474 0.334 0 C-N-CA 122.92 2.414 . . . . 0.0 112.963 -171.848 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.95 -174.39 19.13 Favored Glycine 0 N--CA 1.419 -2.483 0 N-CA-C 108.481 -1.848 . . . . 0.0 108.481 -176.513 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -142.57 164.64 29.56 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 107.815 -1.179 . . . . 0.0 107.815 -176.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.4 t -125.05 127.31 25.1 Favored Pre-proline 0 C--N 1.295 -1.769 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 -178.478 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -68.64 -22.38 37.91 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.483 2.122 . . . . 0.0 110.667 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -81.24 -1.64 45.72 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.219 -1.355 . . . . 0.0 111.984 -175.477 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.43 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 177.38 -130.66 1.66 Allowed Glycine 0 N--CA 1.414 -2.791 0 C-N-CA 119.695 -1.241 . . . . 0.0 111.84 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 24.4 p -146.59 179.16 7.75 Favored 'General case' 0 C--N 1.285 -2.225 0 O-C-N 124.119 0.541 . . . . 0.0 110.096 -178.563 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -143.07 155.28 44.58 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 171.501 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.5 m -121.24 163.65 18.2 Favored 'General case' 0 C--N 1.279 -2.482 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.584 ' HA ' ' O ' ' A' ' 109' ' ' LYS . 32.0 mt -120.82 124.0 43.97 Favored 'General case' 0 C--N 1.277 -2.561 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.236 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.65 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 34.1 p -115.93 125.56 52.73 Favored 'General case' 0 C--N 1.285 -2.235 0 O-C-N 123.625 0.578 . . . . 0.0 110.793 -175.635 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 99.95 11.76 42.13 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.828 178.553 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -178.91 -28.76 0.05 OUTLIER Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 119.371 -1.395 . . . . 0.0 113.813 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 69.6 10.88 7.81 Favored 'General case' 0 N--CA 1.5 2.073 0 CA-C-O 122.674 1.226 . . . . 0.0 110.599 -177.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.438 ' O ' HG11 ' A' ' 108' ' ' VAL . 35.9 m -143.72 -169.79 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 114.684 -1.144 . . . . 0.0 107.937 -174.225 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 36.4 m-85 -110.87 43.9 1.36 Allowed 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.489 0.662 . . . . 0.0 110.567 -175.47 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.721 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.1 pt-20 -86.23 -176.58 5.97 Favored 'General case' 0 C--O 1.207 -1.165 0 CA-C-N 114.445 -1.252 . . . . 0.0 112.474 177.388 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.2 m-85 -78.82 131.99 36.69 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 122.021 -0.425 . . . . 0.0 111.467 178.313 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.48 5.33 61.82 Favored Glycine 0 N--CA 1.438 -1.214 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.659 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.721 HG12 ' O ' ' A' ' 105' ' ' GLU . 9.9 p -101.75 148.66 7.23 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.65 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 89.2 mttt -108.83 138.89 44.44 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 176.042 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -97.14 86.55 3.97 Favored 'General case' 0 C--N 1.264 -3.12 0 N-CA-C 105.515 -2.031 . . . . 0.0 105.515 169.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.484 HG12 ' CB ' ' A' ' 126' ' ' TYR . 21.2 m -85.61 118.17 31.85 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 -177.066 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -88.04 141.04 28.88 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.725 -0.609 . . . . 0.0 111.22 -175.837 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -139.36 114.36 9.49 Favored 'General case' 0 N--CA 1.412 -2.352 0 CA-C-O 122.129 0.966 . . . . 0.0 108.777 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 10.5 m -73.43 159.6 33.0 Favored 'General case' 0 C--N 1.289 -2.064 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.976 -175.648 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.43 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 68.6 m-20 -69.18 179.1 2.05 Favored 'General case' 0 C--O 1.216 -0.683 0 C-N-CA 123.023 0.529 . . . . 0.0 111.299 178.441 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -55.73 -46.57 77.74 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.556 0.742 . . . . 0.0 112.072 -178.199 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -81.92 7.8 61.88 Favored Glycine 0 C--N 1.308 -1.014 0 CA-C-N 115.839 -0.619 . . . . 0.0 113.95 -177.803 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -129.98 152.3 49.6 Favored 'General case' 0 N--CA 1.426 -1.63 0 CA-C-O 121.495 0.664 . . . . 0.0 110.072 -178.234 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -126.44 158.43 36.04 Favored 'General case' 0 C--N 1.271 -2.824 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.3 tt -89.56 129.47 36.02 Favored 'General case' 0 C--N 1.272 -2.8 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.552 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.64 128.18 55.98 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -175.682 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 116.06 173.48 17.21 Favored Glycine 0 C--N 1.294 -1.751 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 -176.025 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -87.73 -35.72 17.76 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -179.326 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 47.4 mm -85.73 137.04 21.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.288 -176.044 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -123.93 2.46 8.72 Favored 'General case' 0 C--O 1.21 -0.998 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.307 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.484 ' CB ' HG12 ' A' ' 111' ' ' VAL . 50.0 p90 -145.47 169.44 18.35 Favored 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -170.523 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.452 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 54.9 mtp180 -126.17 115.52 19.91 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 170.682 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -91.91 124.22 35.87 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 119.749 -0.781 . . . . 0.0 109.426 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.8 t -83.93 104.03 13.68 Favored 'General case' 0 CA--C 1.498 -1.056 0 C-N-CA 118.819 -1.152 . . . . 0.0 108.858 176.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.45 ' OD1' HG22 ' A' ' 131' ' ' THR . 7.9 t70 -99.53 -171.07 2.0 Allowed 'General case' 0 C--N 1.288 -2.103 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 178.634 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.45 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.3 t -61.42 -14.77 30.77 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 124.408 1.083 . . . . 0.0 112.508 -174.346 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -98.52 -15.34 19.59 Favored 'General case' 0 C--N 1.315 -0.913 0 O-C-N 121.757 -0.59 . . . . 0.0 110.637 178.6 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 124.18 -161.09 18.7 Favored Glycine 0 C--N 1.305 -1.188 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 -177.142 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.451 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 89.3 m95 -64.91 101.3 0.48 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.889 0.345 . . . . 0.0 110.173 176.77 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.5 p -58.31 -57.19 14.0 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 124.105 0.962 . . . . 0.0 112.254 -176.145 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' ASN . . . . . 0.452 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 3.5 m120 -81.36 177.53 8.92 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.19 -0.914 . . . . 0.0 109.321 -177.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -111.11 179.6 4.0 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 176.873 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 84.4 mt -72.53 117.95 63.46 Favored Pre-proline 0 C--N 1.317 -0.843 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -66.35 157.79 58.44 Favored 'Trans proline' 0 C--O 1.253 1.267 0 C-N-CA 122.513 2.142 . . . . 0.0 110.624 178.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 62.4 mt -92.24 129.48 42.79 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-O 120.877 0.37 . . . . 0.0 110.722 -173.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 84.5 m -99.41 105.4 17.34 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 171.307 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -92.94 150.14 20.77 Favored 'General case' 0 N--CA 1.407 -2.601 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 -179.188 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 5.8 p -74.4 131.02 35.65 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.645 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.832 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 84.7 t -52.7 132.05 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 O-C-N 123.906 0.754 . . . . 0.0 110.89 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.429 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 85.0 mttt -106.32 153.91 21.52 Favored 'General case' 0 N--CA 1.433 -1.295 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.016 -176.733 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.9 m -124.03 165.06 18.12 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.639 -178.73 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' LEU . . . . . 0.553 HD23 ' HD2' ' A' ' 148' ' ' PRO . 0.5 OUTLIER -62.58 130.85 93.85 Favored Pre-proline 0 N--CA 1.426 -1.64 0 C-N-CA 125.154 1.382 . . . . 0.0 110.777 178.099 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.553 ' HD2' HD23 ' A' ' 147' ' ' LEU . 24.1 Cg_endo -65.91 110.26 1.67 Allowed 'Trans proline' 0 C--N 1.314 -1.244 0 C-N-CA 123.174 2.582 . . . . 0.0 111.635 175.843 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 7.8 p -86.59 143.94 10.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 38.9 p -82.49 -83.48 0.13 Allowed 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -177.55 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.3 161.74 0.46 Allowed Pre-proline 0 C--N 1.326 -0.429 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 -179.485 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' PRO . . . . . 0.481 ' HD3' ' CD2' ' A' ' 176' ' ' PHE . 43.5 Cg_endo -73.51 -169.39 0.53 Allowed 'Trans proline' 0 CA--C 1.546 1.125 0 C-N-CA 121.654 1.569 . . . . 0.0 111.27 172.638 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' GLU . . . . . 0.512 ' H ' ' CD ' ' A' ' 153' ' ' GLU . 0.2 OUTLIER -88.44 -37.2 16.02 Favored 'General case' 0 C--N 1.287 -2.131 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -174.899 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 154' ' ' ASN . . . . . 0.45 ' OD1' ' HG2' ' A' ' 153' ' ' GLU . 25.7 m120 -120.86 22.82 10.98 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 122.074 0.94 . . . . 0.0 109.827 179.345 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 155' ' ' GLY . . . . . 0.411 ' HA3' ' SG ' ' A' ' 205' ' ' CYS . . . -146.49 178.97 23.81 Favored Glycine 0 N--CA 1.425 -2.041 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.431 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 156' ' ' LYS . . . . . 0.448 ' HG3' HG23 ' A' ' 177' ' ' VAL . 21.9 pttm -145.62 -176.66 5.22 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -178.093 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.444 HG22 ' N ' ' A' ' 159' ' ' SER . 64.4 mt -95.56 141.2 15.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 C-N-CA 122.505 0.322 . . . . 0.0 110.703 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.573 HG12 HG22 ' A' ' 177' ' ' VAL . 2.3 m -79.91 -35.39 16.11 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.461 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 177.568 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 159' ' ' SER . . . . . 0.444 ' N ' HG22 ' A' ' 157' ' ' ILE . 5.3 m . . . . . 0 CA--C 1.55 0.946 0 C-N-CA 125.429 1.492 . . . . 0.0 111.375 -174.435 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 168' ' ' TYR . . . . . 0.429 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 82.6 m-85 . . . . . 0 CA--C 1.494 -1.202 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 12.1 m-70 -117.83 161.06 20.35 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.691 -175.351 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 42.5 t80 -55.72 125.27 20.5 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 174.371 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 109.86 -14.13 31.87 Favored Glycine 0 N--CA 1.42 -2.398 0 C-N-CA 120.047 -1.073 . . . . 0.0 111.492 -177.101 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 87.1 mm-40 -86.71 139.38 30.81 Favored 'General case' 0 N--CA 1.433 -1.305 0 C-N-CA 119.533 -0.867 . . . . 0.0 109.822 176.738 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -120.59 116.14 24.77 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.616 178.531 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 88.1 t -90.29 106.04 16.88 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.647 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.517 ' HB3' HG22 ' A' ' 158' ' ' VAL . 46.1 ttm180 -104.65 142.47 34.61 Favored 'General case' 0 N--CA 1.405 -2.689 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.481 ' CD2' ' HD3' ' A' ' 152' ' ' PRO . 88.5 m-85 -108.81 157.44 18.58 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 121.431 0.634 . . . . 0.0 110.922 -175.852 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.573 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -130.69 133.12 63.82 Favored 'Isoleucine or valine' 0 CA--C 1.471 -2.078 0 CA-C-N 114.908 -1.042 . . . . 0.0 108.507 178.626 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 93.4 m -95.33 128.34 42.1 Favored 'General case' 0 C--N 1.259 -3.337 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 177.195 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 77.1 m-20 -60.09 160.09 8.62 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 114.95 -1.023 . . . . 0.0 111.419 -178.195 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 14.9 m -37.38 102.82 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 126.484 1.914 . . . . 0.0 114.91 -174.146 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 111.66 -18.39 24.78 Favored Glycine 0 N--CA 1.441 -0.982 0 C-N-CA 120.998 -0.62 . . . . 0.0 113.066 177.365 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 182' ' ' TYR . . . . . 0.423 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 93.8 m-85 -96.12 156.0 16.52 Favored 'General case' 0 N--CA 1.434 -1.233 0 CA-C-N 117.094 0.447 . . . . 0.0 111.394 -177.352 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -123.18 155.15 37.64 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.3 tp -72.42 142.84 14.7 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.2 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -71.83 -71.24 0.28 Allowed 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.852 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -100.02 -105.86 2.73 Favored Glycine 0 N--CA 1.431 -1.665 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -99.34 163.28 12.6 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -105.88 0.8 26.24 Favored 'General case' 0 CA--C 1.499 -1.008 0 C-N-CA 119.351 -0.94 . . . . 0.0 111.249 -173.261 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -148.12 152.63 37.65 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 114.085 1.142 . . . . 0.0 114.085 -175.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.5 ptp -131.15 138.23 49.37 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.233 -1.349 . . . . 0.0 108.496 177.448 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 45.6 t-80 -123.42 137.42 54.81 Favored 'General case' 0 C--N 1.292 -1.902 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.448 -176.294 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 16.2 m -61.93 113.81 3.01 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.994 176.104 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 14.9 m -102.76 174.15 6.01 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.054 178.344 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -48.74 140.79 8.04 Favored 'General case' 0 N--CA 1.488 1.433 0 C-N-CA 123.833 0.853 . . . . 0.0 112.352 178.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 26.2 t70 76.47 -6.45 2.0 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 125.944 1.698 . . . . 0.0 111.937 178.128 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 93.04 50.94 2.35 Favored Glycine 0 N--CA 1.434 -1.499 0 C-N-CA 120.529 -0.844 . . . . 0.0 112.087 177.505 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -116.7 141.61 47.98 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 176.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 67.1 m95 -79.78 132.06 36.06 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 171.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.1 p -65.85 -20.34 66.2 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.245 0.545 . . . . 0.0 112.172 -179.276 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.543 ' HA ' ' HE3' ' A' ' 200' ' ' LYS . 0.0 OUTLIER -134.17 171.1 14.7 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.597 178.43 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -108.57 170.25 8.14 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.492 -178.383 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 5.5 tppp? -56.06 114.87 8.34 Favored Pre-proline 0 C--O 1.233 0.237 0 O-C-N 124.047 0.842 . . . . 0.0 110.814 -178.254 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -80.76 -167.78 0.55 Allowed 'Trans proline' 0 N--CA 1.434 -2.0 0 C-N-CA 122.145 1.897 . . . . 0.0 110.625 176.753 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 5.0 ttmp? -146.38 160.31 42.23 Favored 'General case' 0 C--N 1.28 -2.422 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -174.775 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.423 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 87.0 m -117.41 105.93 12.66 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-O 121.518 0.675 . . . . 0.0 110.693 177.617 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.2 m . . . . . 0 N--CA 1.433 -1.314 0 CA-C-N 115.003 -0.998 . . . . 0.0 110.079 -176.2 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 CA--C 1.53 0.325 0 CA-C-O 121.565 0.569 . . . . 0.0 111.322 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 36.2 m -89.1 -42.16 11.87 Favored 'General case' 0 N--CA 1.426 -1.633 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.645 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 121.4 -86.0 0.39 Allowed Glycine 0 CA--C 1.472 -2.603 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 172.536 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -179.59 127.13 0.24 Allowed Pre-proline 0 C--N 1.274 -2.691 0 N-CA-C 104.078 -2.564 . . . . 0.0 104.078 -177.55 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.414 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 95.2 Cg_endo -77.58 4.85 5.64 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 C-N-CA 123.355 2.703 . . . . 0.0 115.584 -170.225 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.75 -168.86 12.91 Favored Glycine 0 C--N 1.287 -2.167 0 N-CA-C 107.688 -2.165 . . . . 0.0 107.688 -174.248 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -151.12 -175.42 5.15 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 118.439 1.119 . . . . 0.0 108.846 -176.801 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 t -155.33 125.85 3.41 Favored Pre-proline 0 N--CA 1.424 -1.739 0 CA-C-O 121.065 0.46 . . . . 0.0 111.395 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -78.73 -5.95 14.99 Favored 'Trans proline' 0 C--O 1.239 0.556 0 C-N-CA 123.088 2.526 . . . . 0.0 112.069 178.461 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.535 ' HB2' ' HB2' ' A' ' 141' ' ' CYS . 27.0 m-85 -99.46 1.28 43.96 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.325 -177.649 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.461 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.86 -136.59 3.52 Favored Glycine 0 N--CA 1.405 -3.385 0 C-N-CA 118.817 -1.659 . . . . 0.0 113.043 -178.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.9 p -146.37 -176.85 5.33 Favored 'General case' 0 C--N 1.283 -2.311 0 CA-C-N 114.655 -0.773 . . . . 0.0 110.795 -174.041 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 44.6 p90 -146.58 161.53 40.31 Favored 'General case' 0 N--CA 1.431 -1.422 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 171.732 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.7 m -131.81 154.51 49.04 Favored 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 179.546 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.507 ' HB2' ' HA ' ' A' ' 102' ' ' ASN . 16.1 mt -110.07 127.68 54.99 Favored 'General case' 0 C--N 1.272 -2.78 0 CA-C-O 120.995 0.426 . . . . 0.0 110.064 -177.039 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.491 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 24.1 p -120.45 132.94 55.45 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.136 -177.613 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.44 19.34 32.86 Favored Glycine 0 C--N 1.307 -1.065 0 C-N-CA 120.599 -0.81 . . . . 0.0 111.809 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 167.92 -27.04 0.14 Allowed Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.612 178.094 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ASN . . . . . 0.507 ' HA ' ' HB2' ' A' ' 98' ' ' LEU . 7.5 t30 61.28 20.07 10.71 Favored 'General case' 0 CA--C 1.56 1.338 0 CA-C-O 122.699 1.238 . . . . 0.0 110.519 -178.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.546 ' O ' HG11 ' A' ' 108' ' ' VAL . 31.1 m -144.55 -170.57 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.207 -1.164 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 -179.035 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -106.53 45.19 0.99 Allowed 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 118.394 0.543 . . . . 0.0 110.392 -178.157 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.717 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.4 pt-20 -90.43 -177.97 5.21 Favored 'General case' 0 C--O 1.207 -1.143 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.769 177.483 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 46.9 m-85 -77.61 133.24 38.48 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.859 -0.526 . . . . 0.0 111.456 178.526 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.84 0.12 64.33 Favored Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.895 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.717 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.7 p -94.22 145.71 7.61 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.491 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 15.1 mtpp -109.94 124.39 51.31 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.65 91.13 8.63 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 176.094 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 62.5 t -88.63 112.24 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.962 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -177.144 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -81.39 134.9 35.62 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-O 121.19 0.519 . . . . 0.0 111.681 -178.627 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.1 t -132.55 104.91 6.92 Favored 'General case' 0 N--CA 1.421 -1.916 0 CA-C-O 122.157 0.979 . . . . 0.0 109.16 -178.512 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 13.4 m -66.83 157.98 31.62 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.62 -1.173 . . . . 0.0 110.826 -178.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.461 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 95.4 m-20 -75.55 178.44 5.99 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.748 -0.206 . . . . 0.0 111.548 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -45.7 -54.63 7.54 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.945 1.298 . . . . 0.0 113.324 -177.569 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.497 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -85.16 25.94 5.85 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 120.3 -0.953 . . . . 0.0 113.626 -176.357 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.67 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 81.1 m-85 -145.98 154.89 42.4 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 117.321 0.56 . . . . 0.0 110.092 -176.593 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.03 161.84 33.3 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 176.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.28 115.4 21.33 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 -178.384 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -98.31 129.74 45.0 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 179.461 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 121.35 166.74 13.03 Favored Glycine 0 C--N 1.29 -1.99 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -177.722 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.0 mt-10 -88.99 -21.3 23.57 Favored 'General case' 0 C--N 1.295 -1.799 0 CA-C-O 121.955 0.883 . . . . 0.0 109.306 -177.794 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.481 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.5 mm -107.76 131.21 58.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.804 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.815 -178.443 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -123.57 11.5 9.21 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -177.496 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.471 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 15.5 p90 -152.03 161.42 42.67 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -175.24 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.414 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 62.9 mtp180 -126.43 129.02 47.9 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 172.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -105.87 132.19 52.27 Favored 'General case' 0 C--N 1.279 -2.492 0 C-N-CA 119.101 -1.039 . . . . 0.0 109.461 -178.334 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.1 t -82.11 101.8 10.64 Favored 'General case' 0 C--N 1.293 -1.876 0 C-N-CA 118.219 -1.392 . . . . 0.0 109.927 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.555 ' OD2' HG22 ' A' ' 131' ' ' THR . 13.3 t70 -101.83 -171.35 1.96 Allowed 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.555 HG22 ' OD2' ' A' ' 130' ' ' ASP . 8.8 t -54.93 -31.99 60.84 Favored 'General case' 0 CA--C 1.56 1.331 0 C-N-CA 124.182 0.993 . . . . 0.0 112.805 -175.47 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -85.72 -15.36 42.45 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.908 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 122.98 -159.89 17.55 Favored Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -176.866 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.0 m95 -62.23 112.17 2.28 Favored 'General case' 0 C--O 1.248 0.983 0 CA-C-N 117.173 0.486 . . . . 0.0 110.39 177.051 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 68.4 p -71.08 162.82 28.78 Favored 'General case' 0 C--O 1.266 1.932 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 65.6 -171.16 0.19 Allowed 'General case' 0 CA--C 1.509 -0.629 0 O-C-N 124.209 0.943 . . . . 0.0 111.451 174.334 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -108.51 171.79 7.21 Favored 'General case' 0 C--N 1.295 -1.804 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.566 177.37 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 66.2 mt -67.68 118.5 58.05 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 171.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.481 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 35.0 Cg_endo -66.2 159.06 51.58 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 122.056 1.837 . . . . 0.0 111.114 178.257 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 74.5 mt -109.39 134.59 50.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 C-N-CA 120.68 -0.408 . . . . 0.0 109.953 -171.303 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.535 ' HB2' ' HB2' ' A' ' 93' ' ' PHE . 94.9 m -102.96 110.73 22.76 Favored 'General case' 0 C--N 1.277 -2.57 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 175.144 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.86 152.17 20.04 Favored 'General case' 0 CA--C 1.462 -2.41 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.843 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.67 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 2.8 t -69.12 142.2 16.42 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.044 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.546 -177.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.689 HG23 ' HB2' ' A' ' 170' ' ' PHE . 10.4 m -66.82 122.52 18.01 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 178.072 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.465 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 49.7 mtmt -121.81 127.18 50.28 Favored 'General case' 0 N--CA 1.408 -2.565 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.923 -172.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 60.8 m -84.2 153.68 23.5 Favored 'General case' 0 C--N 1.28 -2.436 0 CA-C-N 113.981 -1.463 . . . . 0.0 108.504 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' LEU . . . . . 0.402 ' HB2' ' HD2' ' A' ' 148' ' ' PRO . 3.6 pp -67.52 160.72 70.74 Favored Pre-proline 0 CA--C 1.553 1.075 0 O-C-N 123.236 0.335 . . . . 0.0 110.229 -178.075 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.433 ' HA ' ' CE2' ' A' ' 168' ' ' TYR . 39.4 Cg_endo -74.28 123.21 8.08 Favored 'Trans proline' 0 N--CA 1.446 -1.297 0 C-N-CA 122.499 2.133 . . . . 0.0 112.348 -175.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.648 HG12 ' O ' ' A' ' 150' ' ' THR . 62.0 t -75.07 137.68 22.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.977 -178.554 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' THR . . . . . 0.648 ' O ' HG12 ' A' ' 149' ' ' VAL . 25.4 p -95.95 -158.01 0.62 Allowed 'General case' 0 N--CA 1.417 -2.105 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 172.183 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -127.38 151.39 74.73 Favored Pre-proline 0 C--N 1.274 -2.682 0 O-C-N 120.406 -1.434 . . . . 0.0 110.352 -171.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -68.76 161.44 45.42 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.615 1.543 . . . . 0.0 112.259 177.23 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -60.04 -43.64 95.22 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 -174.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 57.6 m-80 -117.49 29.36 7.91 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -148.31 -167.21 13.4 Favored Glycine 0 N--CA 1.435 -1.42 0 C-N-CA 119.989 -1.101 . . . . 0.0 112.081 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -154.85 177.14 11.62 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.434 HD11 ' O ' ' A' ' 150' ' ' THR . 58.9 mt -88.75 129.7 39.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 CA-C-O 120.833 0.349 . . . . 0.0 110.713 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.414 ' CG2' ' HB ' ' A' ' 177' ' ' VAL . 34.9 t -64.34 -35.61 74.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.555 0 C-N-CA 123.902 0.881 . . . . 0.0 109.947 178.562 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 37.3 t . . . . . 0 N--CA 1.43 -1.472 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 173.75 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 168' ' ' TYR . . . . . 0.465 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 99.6 m-85 . . . . . 0 CA--C 1.501 -0.922 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -97.4 160.23 14.45 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -177.337 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.689 ' HB2' HG23 ' A' ' 144' ' ' VAL . 53.6 t80 -54.83 111.66 0.87 Allowed 'General case' 0 C--O 1.241 0.62 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 171.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 137.55 -12.82 3.73 Favored Glycine 0 N--CA 1.425 -2.064 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -173.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 81.9 mm-40 -82.98 143.97 30.29 Favored 'General case' 0 C--O 1.248 1.009 0 CA-C-O 121.436 0.636 . . . . 0.0 112.116 177.238 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -134.88 111.1 9.59 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 172.374 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 76.7 t -97.75 111.53 27.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 CA-C-O 120.983 0.42 . . . . 0.0 110.083 -177.182 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 79.6 ttt180 -95.33 153.84 17.49 Favored 'General case' 0 N--CA 1.426 -1.644 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.05 178.426 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -125.49 153.56 43.37 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 124.264 1.026 . . . . 0.0 109.458 -175.398 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.414 ' HB ' ' CG2' ' A' ' 158' ' ' VAL . 14.7 p -135.59 143.02 37.78 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 72.6 m -96.17 146.57 24.57 Favored 'General case' 0 C--N 1.272 -2.802 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.508 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -87.71 168.38 13.03 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.762 -176.491 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 32.4 t 50.06 -113.2 0.63 Allowed 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 124.058 0.943 . . . . 0.0 113.357 178.394 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -118.87 23.83 8.61 Favored Glycine 0 N--CA 1.417 -2.577 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -79.87 158.12 26.81 Favored 'General case' 0 C--O 1.249 1.046 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.117 -176.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 20.9 ptmt -121.14 160.56 23.48 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 115.503 -0.771 . . . . 0.0 109.476 -178.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.427 HD11 ' CG ' ' A' ' 203' ' ' PRO . 3.6 tp -79.29 145.91 8.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.449 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -69.61 -66.96 0.52 Allowed 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.617 178.484 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -115.69 -98.54 2.15 Favored Glycine 0 N--CA 1.433 -1.548 0 C-N-CA 120.442 -0.885 . . . . 0.0 111.364 -179.358 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -98.84 145.38 27.03 Favored 'General case' 0 CA--C 1.483 -1.604 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -178.842 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.429 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 12.0 pt-20 -102.97 12.08 36.54 Favored 'General case' 0 C--N 1.287 -2.138 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.915 -175.766 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -149.05 132.51 16.65 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 121.555 0.693 . . . . 0.0 112.552 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.7 ptp -114.21 125.33 53.81 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.282 176.372 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 27.3 t-80 -103.85 148.33 26.26 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 -178.429 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 5.0 m -75.02 140.88 43.89 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 177.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 50.7 m -96.71 154.95 16.99 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 171.723 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -73.77 -2.67 24.42 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.754 0.788 . . . . 0.0 110.882 -177.786 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -81.29 -10.43 59.58 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.827 178.847 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 94.48 26.51 13.41 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.769 -0.729 . . . . 0.0 113.514 178.524 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 19.5 p90 -147.78 173.44 12.8 Favored 'General case' 0 C--N 1.309 -1.155 0 O-C-N 122.263 -0.551 . . . . 0.0 110.376 177.424 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -83.05 145.15 29.45 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 123.433 0.458 . . . . 0.0 110.486 -179.058 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 6.7 m -82.91 -0.52 48.82 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.847 0.356 . . . . 0.0 111.336 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 15.7 tppt? -140.14 153.5 46.69 Favored 'General case' 0 N--CA 1.424 -1.731 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -177.415 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -87.87 155.04 20.06 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.68 175.483 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 202' ' ' LYS . . . . . 0.453 ' HB3' ' HE2' ' A' ' 202' ' ' LYS . 38.9 mtpt -59.95 126.67 84.08 Favored Pre-proline 0 N--CA 1.434 -1.261 0 O-C-N 123.731 0.645 . . . . 0.0 110.042 174.669 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 203' ' ' PRO . . . . . 0.427 ' CG ' HD11 ' A' ' 184' ' ' ILE . 90.9 Cg_endo -82.93 -167.95 0.53 Allowed 'Trans proline' 0 N--CA 1.436 -1.901 0 C-N-CA 122.514 2.143 . . . . 0.0 110.66 177.313 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -132.25 170.47 15.0 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.478 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 89.2 m -120.42 112.67 19.28 Favored 'General case' 0 C--N 1.274 -2.689 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 172.868 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 28.2 m . . . . . 0 C--N 1.281 -2.375 0 CA-C-N 114.105 -1.407 . . . . 0.0 109.206 -172.216 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.461 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 32.7 Cg_endo . . . . . 0 CA--C 1.546 1.11 0 CA-C-O 120.902 0.293 . . . . 0.0 112.201 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' CYS . . . . . 0.619 ' HB3' ' NE1' ' A' ' 134' ' ' TRP . 0.9 OUTLIER -87.7 -16.79 33.31 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.37 0.605 . . . . 0.0 110.133 175.132 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 102.72 -93.8 1.09 Allowed Glycine 1 N--CA 1.391 -4.357 0 N-CA-C 108.748 -1.741 . . . . 0.0 108.748 174.781 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -170.38 132.06 0.96 Allowed Pre-proline 0 C--N 1.253 -3.628 0 N-CA-C 105.571 -2.011 . . . . 0.0 105.571 -175.785 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -73.27 -28.72 12.19 Favored 'Trans proline' 0 N--CA 1.477 0.512 0 C-N-CA 122.152 1.901 . . . . 0.0 113.481 -173.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 133.41 150.28 6.29 Favored Glycine 0 N--CA 1.425 -2.036 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -178.049 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -111.89 125.89 54.52 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -178.661 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.6 t -89.5 125.59 60.98 Favored Pre-proline 0 C--N 1.3 -1.557 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 178.798 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -70.1 -10.42 28.25 Favored 'Trans proline' 0 C--O 1.221 -0.371 0 C-N-CA 122.833 2.355 . . . . 0.0 111.911 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -92.44 -2.55 56.21 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.398 0.618 . . . . 0.0 110.616 -178.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.509 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -178.71 -119.5 0.61 Allowed Glycine 0 N--CA 1.422 -2.294 0 C-N-CA 119.948 -1.12 . . . . 0.0 111.952 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.2 t -170.25 -162.55 0.3 Allowed 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.434 ' CB ' ' HA ' ' A' ' 112' ' ' TYR . 52.5 p90 -148.37 170.93 16.88 Favored 'General case' 0 C--N 1.311 -1.106 0 O-C-N 121.61 -0.681 . . . . 0.0 110.844 178.564 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -123.47 163.31 21.14 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 177.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.2 mt -121.99 129.42 52.46 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.41 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 32.6 p -122.84 124.63 43.71 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -176.135 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 92.99 30.18 9.68 Favored Glycine 0 C--N 1.298 -1.548 0 C-N-CA 120.325 -0.941 . . . . 0.0 111.185 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 167.25 -33.16 0.21 Allowed Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 119.464 -1.35 . . . . 0.0 113.417 176.692 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 65.46 14.79 9.68 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 123.577 0.751 . . . . 0.0 112.995 -177.702 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.519 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.4 m -151.7 -168.89 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.213 -0.85 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -177.43 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -106.52 38.14 2.14 Favored 'General case' 0 C--O 1.252 1.217 0 CA-C-N 118.737 0.699 . . . . 0.0 110.445 -175.628 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.673 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.1 pt-20 -78.49 178.74 7.52 Favored 'General case' 0 C--O 1.2 -1.521 0 CA-C-N 114.22 -1.354 . . . . 0.0 111.003 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' TYR . . . . . 0.678 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 23.7 m-85 -79.63 134.04 36.43 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-O 120.958 0.408 . . . . 0.0 111.276 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.49 4.55 60.74 Favored Glycine 0 N--CA 1.44 -1.056 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.638 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.673 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.5 p -99.44 145.11 11.06 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 C-N-CA 120.425 -0.51 . . . . 0.0 109.876 -179.308 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.41 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 58.7 mtpt -108.1 125.09 51.18 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.609 176.661 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.82 94.06 9.65 Favored 'General case' 0 C--N 1.289 -2.055 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.334 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.459 HG12 ' HB3' ' A' ' 126' ' ' TYR . 32.8 m -94.07 116.12 34.55 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.188 0 CA-C-O 122.599 1.19 . . . . 0.0 108.434 -178.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' TYR . . . . . 0.434 ' HA ' ' CB ' ' A' ' 96' ' ' PHE . 13.4 m-85 -78.74 141.75 37.6 Favored 'General case' 0 C--N 1.267 -2.985 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.667 -174.094 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.7 t -133.57 106.99 7.73 Favored 'General case' 0 N--CA 1.411 -2.386 0 CA-C-N 115.114 -0.948 . . . . 0.0 108.772 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 95.4 m -63.67 160.45 16.92 Favored 'General case' 0 C--N 1.296 -1.737 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.261 177.168 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.509 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 78.9 m-20 -74.35 -177.87 3.23 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.656 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -58.56 -45.29 89.3 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 123.58 0.752 . . . . 0.0 112.719 -174.651 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.36 24.13 6.63 Favored Glycine 0 C--O 1.212 -1.249 0 C-N-CA 120.747 -0.739 . . . . 0.0 113.302 179.732 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -147.82 169.93 18.71 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.99 -0.712 . . . . 0.0 109.952 -173.14 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -152.13 162.98 40.29 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.548 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -78.45 140.84 38.61 Favored 'General case' 0 C--N 1.288 -2.069 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.524 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.4 OUTLIER -119.24 126.52 51.71 Favored 'General case' 0 N--CA 1.409 -2.488 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.244 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.52 -170.24 14.27 Favored Glycine 0 C--N 1.289 -2.061 0 C-N-CA 120.69 -0.766 . . . . 0.0 111.607 -178.747 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -98.66 -38.81 8.97 Favored 'General case' 0 C--N 1.309 -1.195 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 -177.139 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.5 mm -78.62 120.48 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.716 0 CA-C-N 114.668 -1.151 . . . . 0.0 109.098 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -123.36 6.33 9.04 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.488 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 25.8 p90 -143.29 165.4 27.57 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -171.265 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 34.4 mtp180 -129.09 143.19 50.78 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 169.126 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -113.6 130.21 56.42 Favored 'General case' 0 C--N 1.287 -2.135 0 C-N-CA 119.426 -0.909 . . . . 0.0 109.895 -178.645 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' CYS . . . . . 0.678 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 37.8 t -80.35 90.39 5.58 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 176.142 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.482 ' OD2' HG22 ' A' ' 131' ' ' THR . 16.9 t70 -97.21 -170.62 2.05 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 179.017 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.482 HG22 ' OD2' ' A' ' 130' ' ' ASP . 15.1 t -59.03 -32.36 69.67 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 123.485 0.714 . . . . 0.0 112.875 -172.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -75.86 -34.09 60.03 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 121.488 0.661 . . . . 0.0 110.393 178.012 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.478 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 140.0 -153.91 23.57 Favored Glycine 0 N--CA 1.417 -2.602 0 N-CA-C 107.81 -2.116 . . . . 0.0 107.81 -174.599 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.619 ' NE1' ' HB3' ' A' ' 85' ' ' CYS . 98.3 m95 -65.86 116.61 7.21 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 117.655 0.728 . . . . 0.0 111.326 176.707 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 54.4 p -74.74 171.13 14.49 Favored 'General case' 0 C--O 1.269 2.119 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.036 176.478 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 87.0 m-20 59.05 -158.3 0.31 Allowed 'General case' 0 CA--C 1.515 -0.391 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -136.58 -179.48 5.71 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 172.044 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.9 mt -57.5 121.21 46.67 Favored Pre-proline 0 C--N 1.273 -2.721 0 C-N-CA 123.945 0.898 . . . . 0.0 108.595 175.402 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -63.49 169.68 9.35 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 122.663 2.242 . . . . 0.0 112.386 -179.231 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.524 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 52.8 mt -95.83 139.89 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.856 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -173.608 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 38.3 t -126.59 136.57 52.71 Favored 'General case' 0 C--N 1.276 -2.628 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.684 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -130.64 154.55 47.78 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -178.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 4.2 p -70.64 147.96 11.07 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.614 HG23 ' HB2' ' A' ' 170' ' ' PHE . 2.3 m -67.57 107.58 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.521 176.412 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -89.9 137.16 32.57 Favored 'General case' 0 N--CA 1.436 -1.168 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.72 -178.088 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.8 m -102.89 138.14 40.17 Favored 'General case' 0 C--N 1.282 -2.328 0 N-CA-C 106.111 -1.811 . . . . 0.0 106.111 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' LEU . . . . . 0.457 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.0 mm? -63.0 148.22 92.89 Favored Pre-proline 0 N--CA 1.433 -1.275 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -177.685 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 26.8 Cg_exo -61.2 121.84 10.25 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 122.911 2.408 . . . . 0.0 110.571 175.692 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.6 p -93.22 151.82 3.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.2 p -88.68 -177.16 5.49 Favored 'General case' 0 N--CA 1.431 -1.385 0 C-N-CA 120.9 -0.32 . . . . 0.0 110.291 175.028 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -108.79 158.94 32.77 Favored Pre-proline 0 C--N 1.294 -1.832 0 C-N-CA 122.415 0.286 . . . . 0.0 111.412 -171.711 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.78 157.39 61.43 Favored 'Trans proline' 0 C--N 1.362 1.247 0 C-N-CA 122.779 2.32 . . . . 0.0 111.292 175.252 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -59.02 -57.25 13.91 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 113.737 1.014 . . . . 0.0 113.737 -175.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 -102.5 36.56 2.13 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -178.474 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -150.91 -154.56 6.56 Favored Glycine 0 N--CA 1.413 -2.851 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.399 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' LYS . . . . . 0.671 ' HG3' HG23 ' A' ' 177' ' ' VAL . 17.5 ptmt -163.84 -177.55 5.18 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 123.658 0.783 . . . . 0.0 109.002 -178.799 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 55.2 mt -100.22 135.8 34.43 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.502 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.6 m -82.5 -33.71 11.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.539 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 7.2 m . . . . . 0 N--CA 1.425 -1.696 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.356 -173.771 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 . . . . . 0 N--CA 1.424 -1.738 0 CA-C-O 121.58 0.705 . . . . 0.0 109.269 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 30.5 m170 -114.36 160.1 19.5 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.614 ' HB2' HG23 ' A' ' 144' ' ' VAL . 0.6 OUTLIER -53.99 120.85 6.93 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 174.141 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 122.17 -23.92 7.13 Favored Glycine 0 N--CA 1.428 -1.86 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -177.645 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 15.6 mm100 -70.53 145.32 50.92 Favored 'General case' 0 C--O 1.256 1.423 0 CA-C-O 121.656 0.741 . . . . 0.0 110.783 178.509 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -116.01 112.59 22.02 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 173.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 8.4 p -95.64 112.91 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.316 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.502 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 79.5 ttt180 -110.61 143.68 40.67 Favored 'General case' 0 C--N 1.28 -2.417 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.005 -175.229 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -114.18 159.65 19.87 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.053 -174.115 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.671 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.0 OUTLIER -129.8 154.06 39.75 Favored 'Isoleucine or valine' 0 CA--C 1.469 -2.148 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.746 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 82.7 m -115.22 140.07 49.4 Favored 'General case' 0 N--CA 1.395 -3.19 0 CA-C-N 114.158 -1.383 . . . . 0.0 108.787 174.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -67.97 161.64 26.12 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.286 177.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 17.3 t -55.12 117.39 3.44 Favored 'General case' 0 C--N 1.311 -1.09 0 O-C-N 124.167 0.917 . . . . 0.0 111.287 -173.448 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 113.41 -20.98 17.93 Favored Glycine 0 N--CA 1.429 -1.802 0 CA-C-N 115.066 -0.97 . . . . 0.0 111.743 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 182' ' ' TYR . . . . . 0.438 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 96.8 m-85 -104.2 157.36 17.18 Favored 'General case' 0 N--CA 1.432 -1.358 0 O-C-N 122.397 -0.472 . . . . 0.0 111.572 -177.703 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -124.17 154.35 40.21 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.9 tp -69.25 148.59 11.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 176.321 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -55.91 -59.77 4.42 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 123.842 0.857 . . . . 0.0 110.758 177.475 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -134.16 -83.6 0.2 Allowed Glycine 0 N--CA 1.437 -1.283 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.238 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 187' ' ' ASP . . . . . 0.455 ' OD2' ' HD2' ' A' ' 200' ' ' LYS . 74.2 m-20 -102.56 134.94 45.09 Favored 'General case' 0 CA--C 1.499 -0.985 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -85.33 -1.76 57.33 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.536 -178.455 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 189' ' ' GLU . . . . . 0.526 ' O ' ' HG3' ' A' ' 200' ' ' LYS . 0.0 OUTLIER -134.42 143.08 47.36 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-O 121.253 0.549 . . . . 0.0 111.157 -175.878 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.457 ' HG3' ' H ' ' A' ' 200' ' ' LYS . 31.8 ttm -126.14 115.26 19.52 Favored 'General case' 0 N--CA 1.416 -2.167 0 C-N-CA 125.039 1.335 . . . . 0.0 108.07 178.232 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 8.1 m80 -94.62 154.9 17.13 Favored 'General case' 0 C--N 1.267 -3.013 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.045 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 45.0 t -98.76 142.42 30.33 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 13.7 p -119.52 -174.51 2.75 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -173.895 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -56.56 -22.21 31.86 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 125.317 1.447 . . . . 0.0 111.806 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -64.57 -21.01 66.58 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.338 -178.595 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 81.67 14.87 77.07 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -174.049 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -141.04 177.83 7.79 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.428 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -81.16 147.06 30.21 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.14 -176.339 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 26.6 m -82.3 -29.62 31.0 Favored 'General case' 0 N--CA 1.422 -1.831 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.117 177.129 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.526 ' HG3' ' O ' ' A' ' 189' ' ' GLU . 6.4 mmpt? -98.47 166.12 11.51 Favored 'General case' 0 N--CA 1.441 -0.881 0 C-N-CA 117.974 -1.491 . . . . 0.0 112.913 177.037 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -96.74 163.84 12.83 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 104.365 -2.457 . . . . 0.0 104.365 171.121 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 202' ' ' LYS . . . . . 0.458 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 4.9 mtpm? -66.69 125.59 90.89 Favored Pre-proline 0 C--N 1.304 -1.388 0 C-N-CA 119.862 -0.735 . . . . 0.0 112.406 178.366 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 203' ' ' PRO . . . . . 0.458 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 7.3 Cg_endo -89.46 -174.08 0.86 Allowed 'Trans proline' 0 N--CA 1.42 -2.838 0 C-N-CA 121.746 1.631 . . . . 0.0 109.767 171.293 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 20.5 pttm -149.67 175.94 11.11 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.707 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.438 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 73.6 m -113.26 113.9 25.96 Favored 'General case' 0 C--N 1.283 -2.287 0 O-C-N 123.683 0.615 . . . . 0.0 109.524 -178.437 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.5 m . . . . . 0 N--CA 1.422 -1.832 0 CA-C-N 113.765 -1.561 . . . . 0.0 109.005 -174.104 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo . . . . . 0 CA--C 1.533 0.47 0 CA-C-O 121.444 0.518 . . . . 0.0 111.728 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 33.9 m -79.37 -33.31 43.0 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.21 -92.72 0.55 Allowed Glycine 1 N--CA 1.394 -4.159 0 CA-C-N 114.104 -1.407 . . . . 0.0 109.717 172.748 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 54.3 t-80 -174.8 133.54 0.5 Allowed Pre-proline 0 C--N 1.255 -3.543 0 N-CA-C 103.85 -2.648 . . . . 0.0 103.85 -175.479 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.476 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 86.9 Cg_endo -80.61 3.0 8.09 Favored 'Trans proline' 0 C--N 1.328 -0.502 0 C-N-CA 122.643 2.228 . . . . 0.0 113.899 -173.831 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.3 -166.08 17.26 Favored Glycine 0 C--N 1.287 -2.163 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 -175.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -145.1 151.25 38.2 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -177.12 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 t -120.98 130.33 24.9 Favored Pre-proline 0 N--CA 1.429 -1.503 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -78.83 -7.59 15.55 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.59 2.194 . . . . 0.0 111.908 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -96.64 19.0 13.05 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.482 -179.168 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 155.97 -119.07 0.89 Allowed Glycine 0 N--CA 1.42 -2.378 0 C-N-CA 119.941 -1.124 . . . . 0.0 111.995 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.7 t -168.6 -169.85 1.12 Allowed 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -176.121 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.408 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 45.4 p90 -143.48 163.28 33.56 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 177.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.1 m -124.61 162.83 23.27 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 106.349 -1.723 . . . . 0.0 106.349 178.299 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 15.4 mt -123.37 125.2 44.55 Favored 'General case' 0 C--N 1.279 -2.493 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.424 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 44.1 p -119.68 134.09 55.37 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 -176.184 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.31 25.72 42.62 Favored Glycine 0 C--N 1.312 -0.775 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.19 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 172.87 -35.71 0.13 Allowed Glycine 0 CA--C 1.486 -1.768 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 61.18 18.97 9.61 Favored 'General case' 0 CA--C 1.521 -0.144 0 C-N-CA 124.394 1.077 . . . . 0.0 112.2 178.701 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.54 ' O ' HG11 ' A' ' 108' ' ' VAL . 31.1 m -154.12 -167.3 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.208 -1.103 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 -178.624 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 21.3 m-85 -105.42 42.71 1.2 Allowed 'General case' 0 C--N 1.311 -1.109 0 CA-C-N 119.392 0.996 . . . . 0.0 110.139 -176.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.704 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.1 pt-20 -86.23 179.14 6.97 Favored 'General case' 0 C--O 1.205 -1.251 0 CA-C-N 114.564 -1.198 . . . . 0.0 111.733 178.166 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.1 m-85 -74.9 136.18 41.47 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 122.017 -0.427 . . . . 0.0 111.391 177.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.09 6.93 70.9 Favored Glycine 0 C--N 1.31 -0.88 0 CA-C-N 115.914 -0.585 . . . . 0.0 113.034 177.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.704 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.8 p -97.9 145.64 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.062 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.424 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 59.4 mtpt -110.25 122.84 48.61 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 177.641 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.475 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -85.5 85.37 7.43 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.369 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.489 HG12 ' HB3' ' A' ' 126' ' ' TYR . 31.8 m -83.39 107.0 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.027 0 CA-C-O 122.812 1.291 . . . . 0.0 109.558 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' TYR . . . . . 0.408 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 31.8 m-85 -73.17 134.84 44.54 Favored 'General case' 0 C--N 1.276 -2.606 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.964 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.6 t -129.81 114.55 16.07 Favored 'General case' 0 N--CA 1.408 -2.529 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 87.2 m -66.66 161.68 22.81 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 115.596 -0.729 . . . . 0.0 112.518 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 5.0 t-20 -68.85 -173.54 0.49 Allowed 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.136 -177.386 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -58.38 -52.17 66.73 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 123.109 0.564 . . . . 0.0 111.902 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.04 12.56 63.81 Favored Glycine 0 N--CA 1.437 -1.297 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.99 -177.484 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.512 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.6 m-85 -129.44 159.09 37.33 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 117.157 0.478 . . . . 0.0 110.72 -177.639 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -140.79 152.84 45.52 Favored 'General case' 0 C--N 1.288 -2.102 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -179.248 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.479 ' HG ' ' HB2' ' A' ' 125' ' ' ASN . 0.5 OUTLIER -78.29 126.36 30.68 Favored 'General case' 0 C--N 1.281 -2.401 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 179.17 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.434 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.3 OUTLIER -108.01 130.61 55.05 Favored 'General case' 0 N--CA 1.418 -2.044 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -178.791 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 114.69 -169.41 12.86 Favored Glycine 0 C--N 1.292 -1.91 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.078 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -103.82 -31.77 9.64 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-O 121.52 0.676 . . . . 0.0 109.763 -179.108 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.428 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.9 mm -89.16 120.59 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.562 -178.835 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.479 ' HB2' ' HG ' ' A' ' 120' ' ' LEU . 3.7 p-10 -125.6 9.59 7.75 Favored 'General case' 0 C--O 1.203 -1.368 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.489 ' HB3' HG12 ' A' ' 111' ' ' VAL . 22.4 p90 -140.67 168.39 19.91 Favored 'General case' 0 C--N 1.282 -2.347 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -170.359 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.488 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 48.7 mtp180 -132.5 117.9 18.59 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 169.34 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -91.89 128.33 37.69 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 118.881 -1.128 . . . . 0.0 109.969 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 47.8 t -84.62 109.74 18.21 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.183 -1.007 . . . . 0.0 109.652 175.226 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.429 ' OD2' HG22 ' A' ' 131' ' ' THR . 9.9 t70 -111.71 -164.35 0.91 Allowed 'General case' 0 C--N 1.287 -2.126 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.63 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.429 HG22 ' OD2' ' A' ' 130' ' ' ASP . 12.0 t -63.4 -21.35 66.24 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -174.567 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -82.32 -22.77 35.46 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-O 121.87 0.843 . . . . 0.0 109.551 177.717 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 118.55 -145.25 18.28 Favored Glycine 0 N--CA 1.419 -2.44 0 N-CA-C 107.227 -2.349 . . . . 0.0 107.227 -171.284 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -69.92 111.42 5.63 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 108.984 -0.746 . . . . 0.0 108.984 177.08 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 37.8 p -66.65 -57.23 7.62 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-O 121.394 0.616 . . . . 0.0 111.499 -177.059 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' ASN . . . . . 0.488 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 4.9 m120 -75.94 169.96 17.17 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.733 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 22.0 m-20 -106.51 -178.2 3.58 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.8 mt -64.89 123.71 84.46 Favored Pre-proline 0 C--N 1.318 -0.791 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 177.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.428 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 35.5 Cg_endo -67.97 174.06 8.38 Favored 'Trans proline' 0 C--O 1.242 0.7 0 C-N-CA 122.867 2.378 . . . . 0.0 112.971 -179.103 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.434 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 63.1 mt -96.13 139.08 19.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 -176.475 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.512 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 33.9 t -128.21 125.21 38.53 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.767 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 13.7 tp10 -120.02 155.57 32.62 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -174.352 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 8.6 p -75.41 134.51 29.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.178 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.433 ' O ' ' HB2' ' A' ' 169' ' ' HIS . 83.0 t -60.21 123.91 13.6 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.711 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.171 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 51.2 mttm -106.12 158.39 16.85 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 120.944 0.402 . . . . 0.0 110.457 -175.856 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 60.6 m -117.46 161.6 19.32 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 2.2 pp -72.47 155.38 91.24 Favored Pre-proline 0 C--N 1.307 -1.259 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.287 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -78.23 126.02 7.47 Favored 'Trans proline' 0 N--CA 1.439 -1.683 0 C-N-CA 122.294 1.996 . . . . 0.0 113.152 -175.764 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.494 HG12 ' O ' ' A' ' 150' ' ' THR . 54.3 t -69.46 135.67 27.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-N 114.041 -1.436 . . . . 0.0 110.349 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' THR . . . . . 0.494 ' O ' HG12 ' A' ' 149' ' ' VAL . 11.5 p -93.7 170.85 9.27 Favored 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 171.518 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -93.46 156.75 39.54 Favored Pre-proline 0 C--N 1.267 -2.995 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -174.373 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -74.35 152.96 44.88 Favored 'Trans proline' 0 N--CA 1.428 -2.371 0 C-N-CA 120.761 0.974 . . . . 0.0 110.905 172.284 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -54.66 -44.34 73.17 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 114.72 1.378 . . . . 0.0 114.72 -172.072 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.8 m-80 -122.71 31.41 6.08 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 122.154 0.978 . . . . 0.0 108.746 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -139.57 -161.79 8.86 Favored Glycine 0 N--CA 1.428 -1.888 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 40.6 pttt -157.64 163.14 38.55 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 -178.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 49.3 mt -89.36 132.33 34.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-O 121.005 0.431 . . . . 0.0 110.029 -177.768 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.7 t -74.85 -48.22 34.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-O 122.182 0.991 . . . . 0.0 108.393 177.18 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' SER . . . . . 0.493 ' CB ' ' HA ' ' A' ' 174' ' ' VAL . 6.3 m . . . . . 0 C--N 1.289 -2.039 0 CA-C-N 114.553 -1.203 . . . . 0.0 111.388 -175.611 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 . . . . . 0 N--CA 1.406 -2.647 0 N-CA-C 105.874 -1.899 . . . . 0.0 105.874 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 2.1 p-80 -145.46 168.72 19.87 Favored 'General case' 0 C--N 1.279 -2.47 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.675 -176.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -51.76 121.04 5.9 Favored 'General case' 0 C--O 1.242 0.695 0 O-C-N 124.31 1.006 . . . . 0.0 110.307 -176.015 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 123.49 -17.46 7.85 Favored Glycine 0 N--CA 1.427 -1.952 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.202 -175.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 25.3 mm-40 -78.67 135.34 37.17 Favored 'General case' 0 C--O 1.255 1.371 0 CA-C-O 121.716 0.77 . . . . 0.0 112.254 178.581 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -125.7 109.8 13.01 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 105.582 -2.007 . . . . 0.0 105.582 173.351 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.493 ' HA ' ' CB ' ' A' ' 159' ' ' SER . 53.6 t -107.4 122.61 61.85 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.687 -173.14 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.422 ' HG3' ' O ' ' A' ' 188' ' ' GLU . 24.0 ttp180 -111.66 161.51 16.17 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.322 177.163 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -130.73 162.47 29.39 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 124.397 1.079 . . . . 0.0 110.296 -174.145 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.79 143.9 35.1 Favored 'Isoleucine or valine' 0 CA--C 1.471 -2.093 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.45 176.692 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 76.7 m -105.68 131.52 52.95 Favored 'General case' 0 N--CA 1.395 -3.216 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 173.265 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -54.1 164.36 0.65 Allowed 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.309 177.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 26.7 t -33.71 -47.88 0.26 Allowed 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 116.771 2.137 . . . . 0.0 116.771 -168.239 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -104.28 15.36 50.63 Favored Glycine 0 C--N 1.288 -2.136 0 C-N-CA 120.056 -1.069 . . . . 0.0 115.025 -173.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -120.09 162.14 19.79 Favored 'General case' 0 CA--C 1.497 -1.065 0 CA-C-N 118.344 1.072 . . . . 0.0 112.424 -176.791 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.447 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 25.5 pttm -123.28 154.2 39.16 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.474 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 2.8 tp -72.47 145.09 12.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.613 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -82.16 -71.16 0.5 Allowed 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 120.962 -0.295 . . . . 0.0 110.481 179.187 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.0 -89.58 0.63 Allowed Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.948 -177.675 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -136.36 159.99 40.1 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 -177.809 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.422 ' O ' ' HG3' ' A' ' 175' ' ' ARG . 1.0 OUTLIER -103.37 3.26 34.99 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 118.999 -1.08 . . . . 0.0 112.707 -171.979 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 189' ' ' GLU . . . . . 0.578 ' O ' ' HG3' ' A' ' 200' ' ' LYS . 4.3 pt-20 -149.75 143.57 25.5 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 113.572 0.953 . . . . 0.0 113.572 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.459 ' HB3' ' HB2' ' A' ' 200' ' ' LYS . 12.8 ptp -133.37 144.14 49.4 Favored 'General case' 0 C--N 1.315 -0.898 0 C-N-CA 124.146 0.978 . . . . 0.0 111.275 -176.74 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 49.4 t-80 -125.69 141.05 52.21 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.506 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 13.2 m -65.32 129.55 40.13 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 177.01 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 193' ' ' SER . . . . . 0.41 ' OG ' ' HB3' ' A' ' 199' ' ' SER . 14.5 m -104.45 167.26 9.86 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.931 177.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -48.18 -37.23 15.22 Favored 'General case' 0 N--CA 1.496 1.874 0 C-N-CA 125.529 1.532 . . . . 0.0 113.535 -176.375 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -68.74 -16.01 63.68 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -176.408 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 196' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 99.33 27.79 7.95 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.195 -1.002 . . . . 0.0 113.248 178.287 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -150.21 179.2 8.3 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 122.391 -0.476 . . . . 0.0 110.356 176.618 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -84.84 135.77 33.95 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 123.924 0.765 . . . . 0.0 110.881 -176.414 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 199' ' ' SER . . . . . 0.41 ' HB3' ' OG ' ' A' ' 193' ' ' SER . 9.5 p -73.26 -24.24 60.42 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.682 0.753 . . . . 0.0 111.136 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.578 ' HG3' ' O ' ' A' ' 189' ' ' GLU . 28.2 mmtp -94.9 179.88 5.08 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 115.026 -0.988 . . . . 0.0 112.909 -177.526 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -100.75 148.87 24.41 Favored 'General case' 0 C--N 1.292 -1.925 0 CA-C-N 113.557 -1.656 . . . . 0.0 110.735 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 202' ' ' LYS . . . . . 0.61 ' HE2' ' HD2' ' A' ' 203' ' ' PRO . 0.1 OUTLIER -75.03 107.98 4.76 Favored Pre-proline 0 C--N 1.323 -0.563 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 175.123 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 203' ' ' PRO . . . . . 0.61 ' HD2' ' HE2' ' A' ' 202' ' ' LYS . 71.8 Cg_endo -88.81 174.25 4.0 Favored 'Trans proline' 0 N--CA 1.435 -1.915 0 C-N-CA 122.743 2.296 . . . . 0.0 114.898 -172.121 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -124.36 174.27 7.85 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -176.497 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 91.1 m -128.77 101.38 6.09 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 174.236 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 21.1 m . . . . . 0 C--N 1.294 -1.832 0 CA-C-N 114.226 -1.352 . . . . 0.0 108.679 -173.176 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo . . . . . 0 CA--C 1.542 0.908 0 CA-C-O 121.056 0.357 . . . . 0.0 112.008 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 61.7 m -82.67 -29.92 29.64 Favored 'General case' 0 CA--C 1.507 -0.675 0 CA-C-O 122.418 1.104 . . . . 0.0 108.228 177.022 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 113.2 -91.45 0.58 Allowed Glycine 0 N--CA 1.4 -3.737 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 173.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 46.1 t-80 -175.1 135.26 0.51 Allowed Pre-proline 0 C--N 1.257 -3.453 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 -176.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.574 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 94.0 Cg_endo -80.9 2.04 8.86 Favored 'Trans proline' 0 C--N 1.324 -0.754 0 C-N-CA 122.364 2.043 . . . . 0.0 113.156 -175.714 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 94.42 176.07 38.81 Favored Glycine 0 C--N 1.287 -2.14 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -173.093 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -144.46 159.28 43.01 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 117.444 0.622 . . . . 0.0 109.453 -176.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.7 t -120.18 131.3 24.47 Favored Pre-proline 0 C--N 1.298 -1.645 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.25 -177.256 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -71.7 -19.12 28.1 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.337 2.025 . . . . 0.0 110.561 176.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -86.58 16.0 5.06 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.755 -1.112 . . . . 0.0 110.481 -174.859 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 164.78 -131.94 2.55 Favored Glycine 1 N--CA 1.396 -4.001 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.591 178.339 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.3 p -154.77 175.52 13.61 Favored 'General case' 0 C--N 1.288 -2.104 0 C-N-CA 124.182 0.993 . . . . 0.0 109.896 -173.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -144.95 154.07 42.2 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 171.462 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.8 m -126.13 162.14 26.04 Favored 'General case' 0 C--N 1.275 -2.648 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 17.6 mt -112.47 135.95 52.56 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 18.8 p -129.03 126.93 40.54 Favored 'General case' 0 C--N 1.281 -2.386 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.893 -178.022 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.47 29.23 14.55 Favored Glycine 0 C--N 1.302 -1.319 0 C-N-CA 120.407 -0.902 . . . . 0.0 111.978 179.628 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 172.12 -36.58 0.15 Allowed Glycine 0 N--CA 1.431 -1.699 0 C-N-CA 119.964 -1.112 . . . . 0.0 112.7 178.695 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 70.73 1.94 3.93 Favored 'General case' 0 N--CA 1.511 2.582 0 CA-C-O 122.206 1.003 . . . . 0.0 110.728 -178.154 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.46 ' O ' HG11 ' A' ' 108' ' ' VAL . 34.3 m -143.94 -171.24 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -173.439 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -105.45 45.41 0.97 Allowed 'General case' 0 C--N 1.304 -1.401 0 CA-C-O 121.269 0.557 . . . . 0.0 110.216 -176.599 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.693 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.7 pt-20 -83.01 177.65 8.52 Favored 'General case' 0 C--O 1.213 -0.857 0 CA-C-N 114.585 -1.189 . . . . 0.0 111.607 177.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 43.6 m-85 -77.42 130.92 37.68 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-O 120.941 0.401 . . . . 0.0 110.801 176.625 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.87 2.37 58.39 Favored Glycine 0 N--CA 1.437 -1.238 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.555 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.693 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.7 p -94.77 145.89 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.285 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 19.7 mtpp -111.94 120.77 43.03 Favored 'General case' 0 C--N 1.286 -2.157 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -86.86 92.8 9.11 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 77.2 t -86.39 118.41 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.611 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -178.524 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -85.99 145.58 27.04 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.289 -178.707 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.9 t -144.34 110.66 5.52 Favored 'General case' 0 N--CA 1.407 -2.61 0 CA-C-O 122.208 1.004 . . . . 0.0 108.446 -179.408 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 41.7 m -71.22 158.81 35.75 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.813 -173.313 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.513 ' HB3' ' HD2' ' A' ' 118' ' ' TYR . 4.2 t-20 -60.24 171.9 0.94 Allowed 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 125.128 1.371 . . . . 0.0 111.33 -177.416 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -59.44 -41.87 90.6 Favored 'General case' 0 C--N 1.297 -1.685 0 C-N-CA 124.568 1.147 . . . . 0.0 110.017 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.433 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -86.63 19.82 26.66 Favored Glycine 0 CA--C 1.529 0.932 0 CA-C-N 115.368 -0.833 . . . . 0.0 113.739 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.583 ' HE1' HG22 ' A' ' 143' ' ' VAL . 97.9 m-85 -147.11 173.85 12.11 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 5.6 pt20 -143.68 165.44 27.64 Favored 'General case' 0 C--N 1.281 -2.403 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.601 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.3 tt -94.51 137.88 33.1 Favored 'General case' 0 C--N 1.28 -2.447 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -178.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -124.74 135.15 52.75 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 -177.815 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.66 159.5 15.39 Favored Glycine 0 N--CA 1.438 -1.191 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -78.99 -27.33 43.32 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.719 0.771 . . . . 0.0 109.085 -177.77 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.426 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 47.2 mm -89.76 132.78 33.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 114.814 -1.085 . . . . 0.0 108.311 -177.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -133.07 12.94 4.28 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -177.789 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' TYR . . . . . . . . . . . . . 2.8 p90 -152.65 169.21 23.26 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 -173.45 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.574 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 54.1 mtp180 -131.84 120.1 22.13 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 169.115 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -94.53 138.35 32.53 Favored 'General case' 0 C--N 1.287 -2.128 0 C-N-CA 118.893 -1.123 . . . . 0.0 110.565 177.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.0 t -89.69 104.35 16.92 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 118.881 -1.128 . . . . 0.0 109.61 174.115 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.444 ' OD2' HG22 ' A' ' 131' ' ' THR . 12.1 t70 -97.08 -172.22 2.39 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 176.601 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.444 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -67.25 -11.44 57.47 Favored 'General case' 0 C--N 1.293 -1.855 0 C-N-CA 123.259 0.623 . . . . 0.0 112.274 -174.643 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -94.6 -12.5 27.35 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.82 0.819 . . . . 0.0 109.412 176.558 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.15 -159.25 13.86 Favored Glycine 0 N--CA 1.431 -1.685 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -175.576 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.0 m95 -63.65 105.23 0.76 Allowed 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 120.894 0.378 . . . . 0.0 111.259 178.088 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 24.9 p -61.32 -64.89 0.8 Allowed 'General case' 0 C--O 1.241 0.652 0 C-N-CA 124.955 1.302 . . . . 0.0 112.87 -175.293 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' ASN . . . . . 0.486 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.3 m120 -71.18 173.42 7.7 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.211 -177.099 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -106.55 176.43 5.17 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 175.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 77.5 mt -69.2 125.98 92.38 Favored Pre-proline 0 C--N 1.311 -1.085 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.447 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.426 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 55.0 Cg_endo -70.68 168.69 22.04 Favored 'Trans proline' 0 C--O 1.249 1.073 0 C-N-CA 122.719 2.279 . . . . 0.0 111.145 177.092 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.6 mm -97.93 129.53 47.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 120.436 -0.506 . . . . 0.0 111.245 -173.886 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 99.5 m -101.93 103.34 13.98 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 171.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -95.09 152.39 18.38 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 -179.002 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.583 HG22 ' HE1' ' A' ' 118' ' ' TYR . 3.2 t -76.69 145.51 10.2 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.514 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 -175.822 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 170' ' ' PHE . 5.9 m -73.71 108.39 5.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 174.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -104.75 127.2 52.45 Favored 'General case' 0 N--CA 1.412 -2.352 0 CA-C-N 114.45 -1.25 . . . . 0.0 111.095 -174.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.56 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 3.4 m -85.44 148.5 25.96 Favored 'General case' 0 C--N 1.282 -2.356 0 CA-C-N 113.738 -1.574 . . . . 0.0 110.078 -173.444 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 59.4 mt -56.36 132.46 76.19 Favored Pre-proline 0 C--N 1.319 -0.75 0 N-CA-C 112.677 0.621 . . . . 0.0 112.677 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_endo -62.49 111.4 1.3 Allowed 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 123.499 2.799 . . . . 0.0 112.391 -178.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.3 t -79.05 139.16 18.81 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.5 p -79.02 -75.9 0.22 Allowed 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 123.868 0.73 . . . . 0.0 111.51 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 166.42 159.62 0.11 Allowed Pre-proline 0 C--O 1.24 0.59 0 C-N-CA 126.248 1.819 . . . . 0.0 107.054 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -73.73 171.81 17.07 Favored 'Trans proline' 0 CA--C 1.535 0.569 0 C-N-CA 121.519 1.479 . . . . 0.0 109.572 169.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -69.67 -62.57 1.33 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -177.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.5 m-80 -95.82 38.43 1.17 Allowed 'General case' 0 C--N 1.313 -1.01 0 O-C-N 121.562 -0.711 . . . . 0.0 110.488 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -155.1 -168.57 18.5 Favored Glycine 0 N--CA 1.426 -1.973 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.964 178.189 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -153.0 174.79 13.71 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 -178.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.408 HG12 ' CD1' ' A' ' 176' ' ' PHE . 52.5 mt -91.58 139.62 17.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -178.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.456 HG21 ' HB3' ' A' ' 175' ' ' ARG . 4.7 m -77.46 -37.17 24.55 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.576 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 178.503 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 28.6 t . . . . . 0 N--CA 1.435 -1.199 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -178.88 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 . . . . . 0 N--CA 1.434 -1.228 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -121.61 155.81 34.3 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 -175.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.515 ' HB2' HG23 ' A' ' 144' ' ' VAL . 81.7 t80 -49.68 121.09 4.78 Favored 'General case' 0 C--O 1.244 0.798 0 O-C-N 123.686 0.616 . . . . 0.0 110.56 175.81 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 132.28 -29.65 3.29 Favored Glycine 0 N--CA 1.42 -2.41 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 -177.766 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.8 mm-40 -63.24 128.85 37.73 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 179.022 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -118.06 82.66 1.87 Allowed 'General case' 0 N--CA 1.423 -1.813 0 N-CA-C 104.32 -2.474 . . . . 0.0 104.32 170.715 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.469 HG13 ' HG3' ' A' ' 190' ' ' MET . 14.9 p -77.63 111.56 14.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.004 -169.553 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.456 ' HB3' HG21 ' A' ' 158' ' ' VAL . 40.1 ttm180 -97.74 148.29 23.5 Favored 'General case' 0 N--CA 1.416 -2.159 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.716 -177.907 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.473 ' HZ ' ' SD ' ' A' ' 190' ' ' MET . 51.2 m-85 -115.46 150.98 35.61 Favored 'General case' 0 N--CA 1.42 -1.967 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 -179.38 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.413 ' HB ' HG12 ' A' ' 158' ' ' VAL . 13.7 p -126.49 141.05 47.08 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.749 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 178.273 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.4 m -99.64 163.59 12.43 Favored 'General case' 0 C--N 1.262 -3.207 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.001 -178.666 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -66.52 172.63 3.95 Favored 'General case' 0 CA--C 1.497 -1.066 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.204 179.227 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 21.8 m -42.99 -31.95 0.59 Allowed 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 116.335 1.976 . . . . 0.0 116.335 -172.033 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -126.42 24.02 5.64 Favored Glycine 0 C--N 1.289 -2.069 0 C-N-CA 119.376 -1.393 . . . . 0.0 113.377 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -118.42 151.94 36.83 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.815 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 50.9 pttt -115.27 157.03 24.33 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 -179.68 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.577 HD13 ' HA ' ' A' ' 188' ' ' GLU . 5.0 tt -86.1 143.59 11.17 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.506 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.224 175.403 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -77.56 -68.16 0.65 Allowed 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -173.799 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -80.63 -109.61 0.3 Allowed Glycine 0 C--O 1.245 0.798 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.976 -177.476 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -95.93 175.8 6.36 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 176.466 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.577 ' HA ' HD13 ' A' ' 184' ' ' ILE . 10.3 pt-20 -104.28 -19.09 14.22 Favored 'General case' 0 C--N 1.28 -2.435 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -177.316 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 189' ' ' GLU . . . . . 0.451 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 5.3 pt-20 -141.45 150.21 41.98 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.053 -176.184 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.473 ' SD ' ' HZ ' ' A' ' 176' ' ' PHE . 0.1 OUTLIER -117.39 125.72 51.46 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.174 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -97.26 132.7 42.76 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 176.137 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 192' ' ' CYS . . . . . 0.469 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 48.7 t -80.39 136.8 36.44 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.114 179.422 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 193' ' ' SER . . . . . 0.446 ' HB2' ' OD1' ' A' ' 195' ' ' ASP . 11.1 m -98.99 173.54 6.79 Favored 'General case' 0 N--CA 1.423 -1.792 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.643 179.427 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -67.41 -8.85 36.23 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 124.157 0.983 . . . . 0.0 112.47 -176.213 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 195' ' ' ASP . . . . . 0.446 ' OD1' ' HB2' ' A' ' 193' ' ' SER . 11.8 p-10 -94.25 4.99 53.13 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 122.223 -0.298 . . . . 0.0 111.406 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 196' ' ' GLY . . . . . 0.56 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 79.49 11.63 84.64 Favored Glycine 0 CA--C 1.526 0.73 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.486 178.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -117.92 150.76 38.68 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 122.345 -0.503 . . . . 0.0 110.3 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 198' ' ' TRP . . . . . 0.469 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 82.3 m95 -78.9 135.59 37.03 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.037 177.671 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 26.4 t -74.43 -16.91 60.86 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-O 121.19 0.519 . . . . 0.0 110.547 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.413 ' HB2' ' HA ' ' A' ' 190' ' ' MET . 24.5 mmtp -108.82 158.14 17.93 Favored 'General case' 0 CA--C 1.5 -0.978 0 O-C-N 122.123 -0.361 . . . . 0.0 110.551 178.762 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -97.58 170.44 9.02 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 123.477 0.486 . . . . 0.0 110.66 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 7.6 mmmm -69.06 115.8 35.43 Favored Pre-proline 0 CA--C 1.516 -0.354 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -178.125 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 203' ' ' PRO . . . . . 0.451 ' HG2' HD11 ' A' ' 184' ' ' ILE . 78.0 Cg_endo -88.15 168.28 6.52 Favored 'Trans proline' 0 N--CA 1.446 -1.313 0 C-N-CA 122.862 2.375 . . . . 0.0 112.159 -179.355 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -115.73 165.93 12.51 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 86.6 m -114.71 109.83 18.81 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 172.779 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 30.8 m . . . . . 0 C--O 1.254 1.302 0 O-C-N 124.332 1.02 . . . . 0.0 109.444 -173.858 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo . . . . . 0 CA--C 1.535 0.543 0 CA-C-O 121.74 0.642 . . . . 0.0 110.866 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.0 m -86.65 -35.6 19.26 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 117.46 -88.53 0.46 Allowed Glycine 0 N--CA 1.404 -3.49 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 174.451 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.5 t-80 -176.67 135.9 0.42 Allowed Pre-proline 0 C--N 1.255 -3.509 0 N-CA-C 104.458 -2.423 . . . . 0.0 104.458 -175.601 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.436 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 91.7 Cg_endo -82.15 -0.29 10.18 Favored 'Trans proline' 0 C--N 1.329 -0.494 0 C-N-CA 121.993 1.795 . . . . 0.0 112.791 -176.197 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.33 -155.82 15.9 Favored Glycine 0 N--CA 1.42 -2.387 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -177.304 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -156.02 157.41 36.1 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 178.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.5 t -122.91 127.51 25.69 Favored Pre-proline 0 C--N 1.293 -1.875 0 CA-C-N 118.226 0.467 . . . . 0.0 110.822 -177.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -65.47 -16.01 52.16 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.772 2.315 . . . . 0.0 111.64 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -86.7 -9.37 56.11 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.335 -178.452 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 173.14 -125.29 1.13 Allowed Glycine 0 N--CA 1.433 -1.549 0 C-N-CA 118.755 -1.688 . . . . 0.0 113.907 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.8 t -148.88 -169.76 3.45 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -176.046 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -151.81 162.4 41.09 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 177.59 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -126.02 162.51 25.11 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.4 mt -113.93 138.74 49.92 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.411 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 26.5 p -132.68 137.64 47.02 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -178.123 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.2 24.25 52.32 Favored Glycine 0 C--N 1.309 -0.921 0 N-CA-C 108.556 -1.818 . . . . 0.0 108.556 -173.501 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 145.6 154.3 6.12 Favored Glycine 1 N--CA 1.39 -4.398 0 N-CA-C 107.334 -2.306 . . . . 0.0 107.334 -177.405 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -108.6 29.07 7.75 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 177.115 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.418 ' O ' HG21 ' A' ' 108' ' ' VAL . 35.6 m -144.31 -175.17 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 CA-C-N 114.686 -1.143 . . . . 0.0 109.068 -173.418 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -108.4 47.13 0.92 Allowed 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 121.464 0.649 . . . . 0.0 109.543 -177.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.689 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.2 pt-20 -82.41 178.13 8.39 Favored 'General case' 0 C--O 1.213 -0.828 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.248 178.293 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -76.44 132.77 39.83 Favored 'General case' 0 C--N 1.289 -2.05 0 O-C-N 122.059 -0.401 . . . . 0.0 110.149 175.723 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.35 5.06 63.86 Favored Glycine 0 N--CA 1.431 -1.644 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.633 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.689 HG12 ' O ' ' A' ' 105' ' ' GLU . 10.4 p -96.69 144.4 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.411 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 20.5 mtpp -112.38 118.08 34.22 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -179.407 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -82.83 92.1 7.2 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 177.726 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 75.9 t -82.73 111.68 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.618 0 C-N-CA 123.942 0.897 . . . . 0.0 109.44 -178.632 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -80.6 144.12 32.62 Favored 'General case' 0 C--N 1.293 -1.858 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.672 -179.225 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.1 t -145.87 112.43 5.9 Favored 'General case' 0 N--CA 1.418 -2.041 0 CA-C-N 115.048 -0.978 . . . . 0.0 108.677 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 83.0 m -70.46 163.24 27.19 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.127 -178.366 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 -68.38 174.36 4.12 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.514 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -59.96 -39.09 84.43 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 112.781 0.659 . . . . 0.0 112.781 -174.238 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -85.61 9.96 66.28 Favored Glycine 0 C--N 1.3 -1.43 0 C-N-CA 121.275 -0.488 . . . . 0.0 113.668 179.278 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -131.44 163.12 28.63 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -146.16 134.86 22.27 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.396 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 9.5 tt -70.3 138.46 51.53 Favored 'General case' 0 C--N 1.293 -1.873 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.621 -177.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.45 140.75 49.02 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.018 -172.322 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 108.37 -172.81 17.28 Favored Glycine 0 C--N 1.303 -1.252 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.272 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 30.0 mm-40 -99.68 -19.63 16.7 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 117.084 0.442 . . . . 0.0 111.18 -177.478 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.9 mm -98.59 135.99 31.32 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -178.23 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -130.52 13.3 5.47 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.355 178.523 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 11.4 p90 -145.34 169.96 17.25 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -174.166 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.496 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 46.6 mtp180 -131.01 120.83 24.04 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 169.33 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -95.04 136.61 35.15 Favored 'General case' 0 C--N 1.28 -2.418 0 C-N-CA 119.228 -0.989 . . . . 0.0 110.223 178.384 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 27.1 t -92.61 109.19 20.6 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.923 -1.111 . . . . 0.0 109.473 173.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -110.3 -167.52 1.2 Allowed 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 105.004 -2.221 . . . . 0.0 105.004 175.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 14.8 t -67.03 -13.8 62.27 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 119.056 0.844 . . . . 0.0 111.409 -177.394 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -79.21 -15.68 57.67 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 121.745 0.784 . . . . 0.0 109.646 174.828 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 104.19 -154.62 17.64 Favored Glycine 0 N--CA 1.431 -1.69 0 N-CA-C 107.181 -2.368 . . . . 0.0 107.181 -173.814 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.9 m95 -64.36 106.72 1.17 Allowed 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 118.12 0.96 . . . . 0.0 108.535 172.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.0 p -63.52 -66.01 0.6 Allowed 'General case' 0 C--O 1.253 1.269 0 C-N-CA 124.001 0.92 . . . . 0.0 111.647 -174.344 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' ASN . . . . . 0.496 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.6 m120 -67.09 167.88 11.16 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-N 114.84 -1.073 . . . . 0.0 109.036 -179.31 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -100.7 -178.97 3.94 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 176.37 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 82.1 mt -72.13 120.69 81.73 Favored Pre-proline 0 C--N 1.313 -1.0 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 175.88 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.29 137.81 53.1 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 122.062 1.842 . . . . 0.0 110.911 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 69.7 mt -63.88 141.55 18.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.989 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.739 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 46.2 t -131.39 140.61 49.7 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -123.72 157.33 34.19 Favored 'General case' 0 N--CA 1.408 -2.551 0 CA-C-O 121.102 0.477 . . . . 0.0 110.324 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 5.7 p -75.1 137.9 22.06 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.511 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 97.5 t -58.55 117.52 1.82 Allowed 'Isoleucine or valine' 0 C--O 1.251 1.154 0 O-C-N 123.566 0.541 . . . . 0.0 110.18 -178.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 53.9 mttp -93.09 142.44 27.29 Favored 'General case' 0 N--CA 1.425 -1.704 0 CA-C-N 115.254 -0.885 . . . . 0.0 108.78 179.272 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.0 m -109.25 151.35 26.66 Favored 'General case' 0 C--N 1.278 -2.532 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -179.074 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 64.9 mt -56.17 137.45 74.22 Favored Pre-proline 0 C--N 1.319 -0.722 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.424 ' HA ' ' CD2' ' A' ' 168' ' ' TYR . 34.8 Cg_endo -66.71 94.87 0.33 Allowed 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 123.317 2.678 . . . . 0.0 111.6 179.202 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 9.5 p -69.41 142.78 15.61 Favored 'Isoleucine or valine' 0 C--O 1.25 1.119 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.01 -177.729 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 11.6 p -97.59 -166.25 1.36 Allowed 'General case' 0 N--CA 1.42 -1.961 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.882 177.45 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -119.61 156.35 53.64 Favored Pre-proline 0 C--N 1.297 -1.716 0 O-C-N 122.119 -0.363 . . . . 0.0 110.714 -171.04 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.4 175.36 6.03 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 122.224 1.949 . . . . 0.0 111.446 174.442 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' GLU . . . . . 0.498 ' CD ' ' H ' ' A' ' 153' ' ' GLU . 0.0 OUTLIER -82.72 -43.57 16.66 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 120.999 0.428 . . . . 0.0 111.068 -174.801 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 154' ' ' ASN . . . . . 0.432 ' HB2' ' HB2' ' A' ' 205' ' ' CYS . 27.7 m120 -98.86 18.86 16.07 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.348 0.594 . . . . 0.0 110.488 -179.676 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -147.31 -166.34 12.41 Favored Glycine 0 N--CA 1.424 -2.118 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.664 -178.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 62.5 pttt -154.68 -179.42 7.98 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -177.822 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 50.0 mt -100.95 132.07 47.4 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.207 0 CA-C-N 117.745 0.248 . . . . 0.0 110.859 -177.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.573 HG12 HG22 ' A' ' 177' ' ' VAL . 2.3 m -78.02 -29.19 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.793 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 15.4 m . . . . . 0 C--N 1.311 -1.101 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.954 -177.063 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 168' ' ' TYR . . . . . 0.424 ' CD2' ' HA ' ' A' ' 148' ' ' PRO . 79.7 m-85 . . . . . 0 N--CA 1.429 -1.513 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -130.95 164.62 24.92 Favored 'General case' 0 C--N 1.291 -1.953 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -178.161 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 92.5 t80 -58.07 111.61 1.24 Allowed 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 173.144 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 134.19 -23.76 3.65 Favored Glycine 0 N--CA 1.426 -1.981 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -174.405 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 81.0 mm-40 -78.53 140.51 38.54 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-O 121.339 0.59 . . . . 0.0 111.339 177.787 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -131.17 109.62 10.57 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 176.41 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 97.6 t -94.14 118.29 39.75 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.206 0 CA-C-N 115.472 -0.786 . . . . 0.0 110.578 -173.688 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.471 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 41.7 ttm180 -105.46 144.86 31.65 Favored 'General case' 0 N--CA 1.426 -1.654 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.604 176.174 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -114.24 159.27 20.33 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 123.586 0.754 . . . . 0.0 109.948 -176.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.573 HG22 HG12 ' A' ' 158' ' ' VAL . 0.0 OUTLIER -132.03 145.04 35.45 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.284 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.951 178.49 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 84.2 m -109.81 136.45 49.1 Favored 'General case' 0 C--N 1.268 -2.954 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.569 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 55.5 m-80 -60.51 164.76 4.2 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.082 178.299 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 24.1 m -48.05 108.19 0.16 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 124.799 1.312 . . . . 0.0 113.282 -175.256 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.78 -9.6 29.92 Favored Glycine 0 N--CA 1.421 -2.331 0 C-N-CA 120.543 -0.836 . . . . 0.0 112.737 177.136 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -109.36 155.49 21.16 Favored 'General case' 0 N--CA 1.423 -1.819 0 CA-C-N 117.219 0.51 . . . . 0.0 110.282 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.536 ' HE2' ' O ' ' A' ' 184' ' ' ILE . 18.7 ptmt -130.26 163.23 27.21 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.536 ' O ' ' HE2' ' A' ' 183' ' ' LYS . 3.7 tp -74.32 148.17 8.37 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.046 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -85.65 -74.29 0.41 Allowed 'General case' 0 C--N 1.289 -2.048 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.042 178.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -79.48 -97.88 0.28 Allowed Glycine 0 N--CA 1.442 -0.937 0 C-N-CA 121.043 -0.598 . . . . 0.0 112.443 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -118.19 150.92 38.6 Favored 'General case' 0 CA--C 1.484 -1.566 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.349 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -95.15 -1.92 50.91 Favored 'General case' 0 CA--C 1.499 -1.007 0 C-N-CA 120.155 -0.618 . . . . 0.0 111.049 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 189' ' ' GLU . . . . . 0.481 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.5 pt-20 -146.35 146.72 30.77 Favored 'General case' 0 C--N 1.294 -1.844 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.437 -178.086 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.0 ptp -131.98 131.43 42.56 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.117 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 42.4 t-80 -102.83 138.52 39.61 Favored 'General case' 0 C--N 1.29 -1.989 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 177.457 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 192' ' ' CYS . . . . . 0.419 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 42.7 t -81.95 135.41 35.39 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.711 177.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.0 m -99.21 165.07 11.88 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 178.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -75.43 4.52 7.22 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.219 0.533 . . . . 0.0 111.621 -176.381 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -68.45 -32.51 72.58 Favored 'General case' 0 CA--C 1.507 -0.706 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.286 172.226 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 109.4 8.82 26.41 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 111.079 -0.808 . . . . 0.0 111.079 -175.562 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -142.06 173.23 11.7 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-O 120.691 0.282 . . . . 0.0 110.651 177.524 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 198' ' ' TRP . . . . . 0.419 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 66.2 m95 -82.95 148.25 27.73 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.056 -175.296 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 20.3 m -67.51 -25.27 65.76 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.654 0.74 . . . . 0.0 110.754 178.377 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.406 ' HA ' ' HD3' ' A' ' 200' ' ' LYS . 26.4 mmtp -124.63 148.88 47.65 Favored 'General case' 0 CA--C 1.487 -1.456 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.947 179.064 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -82.05 161.51 22.9 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 175.358 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 202' ' ' LYS . . . . . 0.413 ' HE2' ' HB2' ' A' ' 202' ' ' LYS . 10.5 ptmm? -63.51 137.95 97.23 Favored Pre-proline 0 N--CA 1.431 -1.396 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.6 -178.359 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 203' ' ' PRO . . . . . 0.419 ' CG ' HD11 ' A' ' 184' ' ' ILE . 63.7 Cg_endo -86.89 -169.98 0.58 Allowed 'Trans proline' 0 N--CA 1.434 -1.985 0 C-N-CA 122.815 2.343 . . . . 0.0 113.919 -175.267 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 204' ' ' LYS . . . . . 0.49 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 61.2 tttp -134.42 158.61 43.44 Favored 'General case' 0 N--CA 1.424 -1.753 0 CA-C-N 113.948 -1.478 . . . . 0.0 107.669 -176.519 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.432 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 89.3 m -116.08 115.58 26.34 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 174.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.563 -175.51 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.49 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 33.0 Cg_endo . . . . . 0 CA--C 1.538 0.723 0 CA-C-O 121.107 0.378 . . . . 0.0 112.012 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.0 m -84.86 -32.62 23.12 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 121.891 0.853 . . . . 0.0 109.347 177.526 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.91 -92.05 0.53 Allowed Glycine 0 N--CA 1.405 -3.408 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 175.337 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.2 t-80 -174.44 139.45 0.69 Allowed Pre-proline 0 C--N 1.265 -3.089 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 -176.371 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.458 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 88.1 Cg_endo -85.91 -0.1 8.48 Favored 'Trans proline' 0 N--CA 1.473 0.274 0 C-N-CA 122.093 1.862 . . . . 0.0 112.947 -175.222 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.446 ' HA3' HD11 ' A' ' 138' ' ' ILE . . . 109.59 -172.64 16.19 Favored Glycine 0 C--N 1.296 -1.692 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -176.06 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -146.96 163.61 35.64 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.8 t -141.32 139.19 18.55 Favored Pre-proline 0 C--N 1.3 -1.556 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.528 -176.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -77.4 -12.7 16.99 Favored 'Trans proline' 0 CA--C 1.529 0.267 0 C-N-CA 122.696 2.264 . . . . 0.0 111.288 176.588 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -88.48 2.46 52.79 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.771 -175.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 159.59 -133.66 3.42 Favored Glycine 0 N--CA 1.41 -3.093 0 C-N-CA 120.213 -0.994 . . . . 0.0 111.859 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 14.1 p -148.85 -172.89 4.21 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -173.577 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -144.11 167.15 23.08 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 173.18 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -131.59 157.76 42.78 Favored 'General case' 0 C--N 1.279 -2.457 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 178.207 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 22.7 mt -110.9 138.84 46.79 Favored 'General case' 0 C--N 1.265 -3.099 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.286 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.2 p -129.96 131.02 45.79 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.342 -178.094 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.18 16.19 45.0 Favored Glycine 0 CA--C 1.501 -0.797 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -175.046 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 147.77 160.46 8.95 Favored Glycine 1 N--CA 1.376 -5.305 0 N-CA-C 106.212 -2.755 . . . . 0.0 106.212 -175.752 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -114.09 35.77 4.0 Favored 'General case' 0 C--N 1.25 -3.739 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 -179.579 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.445 ' O ' HG11 ' A' ' 108' ' ' VAL . 16.7 m -144.96 -173.82 0.49 Allowed 'Isoleucine or valine' 0 C--O 1.204 -1.291 0 CA-C-N 114.371 -1.286 . . . . 0.0 109.623 -175.126 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.458 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 29.5 m-85 -110.02 46.6 1.01 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 121.392 0.615 . . . . 0.0 109.554 -178.015 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.704 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.0 pt-20 -86.91 178.74 6.87 Favored 'General case' 0 C--O 1.212 -0.892 0 CA-C-N 114.909 -1.041 . . . . 0.0 111.427 178.209 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -75.54 132.26 40.6 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.223 177.44 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 90.69 10.49 63.19 Favored Glycine 0 N--CA 1.438 -1.194 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.969 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.704 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.5 p -102.29 148.07 8.2 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 176.67 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 52.4 mtpt -117.12 123.22 46.22 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 120.907 0.384 . . . . 0.0 110.532 -179.092 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.39 91.62 8.57 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.17 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.8 t -85.16 110.97 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.31 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -78.17 143.24 37.4 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 112.462 0.542 . . . . 0.0 112.462 -177.569 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.8 t -142.98 112.94 7.06 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 121.712 0.768 . . . . 0.0 109.461 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 89.8 m -65.81 162.17 19.41 Favored 'General case' 0 C--N 1.311 -1.09 0 N-CA-C 114.329 1.233 . . . . 0.0 114.329 -178.075 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -68.71 -179.97 1.57 Allowed 'General case' 0 N--CA 1.433 -1.293 0 C-N-CA 125.612 1.565 . . . . 0.0 109.892 178.358 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -59.95 -52.65 64.48 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 124.099 0.959 . . . . 0.0 111.145 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -86.81 33.1 3.81 Favored Glycine 0 C--N 1.308 -1.007 0 C-N-CA 120.426 -0.892 . . . . 0.0 113.791 -176.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.525 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 86.3 m-85 -150.54 170.43 19.13 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 123.725 0.81 . . . . 0.0 110.024 -177.142 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 5.3 pt20 -150.34 156.89 42.37 Favored 'General case' 0 N--CA 1.427 -1.617 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 176.659 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 8.2 tt -87.42 136.68 32.84 Favored 'General case' 0 C--N 1.27 -2.881 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.51 130.34 56.37 Favored 'General case' 0 N--CA 1.428 -1.54 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -176.578 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 120.97 172.14 14.45 Favored Glycine 0 N--CA 1.43 -1.733 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 -178.551 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 57.2 mm-40 -88.57 -25.43 22.5 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-O 121.256 0.55 . . . . 0.0 109.942 178.473 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.7 mm -87.44 127.78 40.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-N 114.604 -1.18 . . . . 0.0 108.528 -179.589 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -133.52 14.98 4.07 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.042 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.403 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 30.3 p90 -153.65 159.84 42.2 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-O 121.031 0.443 . . . . 0.0 110.558 -175.549 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -122.7 134.65 54.46 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 171.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -112.56 126.49 55.4 Favored 'General case' 0 C--N 1.278 -2.524 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -176.556 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 28.8 t -82.63 99.53 9.62 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 117.738 -1.585 . . . . 0.0 110.675 177.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.476 ' OD2' HG22 ' A' ' 131' ' ' THR . 14.1 t70 -95.87 -168.35 1.75 Allowed 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 175.112 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.476 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -64.65 -23.58 67.3 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -172.707 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -78.76 -28.13 44.76 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.778 0.799 . . . . 0.0 109.787 176.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 130.65 -154.35 20.66 Favored Glycine 0 N--CA 1.422 -2.257 0 N-CA-C 108.614 -1.795 . . . . 0.0 108.614 -175.07 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.402 ' CH2' HG13 ' A' ' 108' ' ' VAL . 97.5 m95 -65.06 112.47 3.37 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 117.112 0.456 . . . . 0.0 111.411 178.127 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 76.5 p -73.47 159.94 32.46 Favored 'General case' 0 C--O 1.271 2.227 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 175.874 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 89.3 m-20 63.4 -163.15 0.27 Allowed 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' ASP . . . . . 0.458 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 17.1 t70 -141.25 -173.24 3.69 Favored 'General case' 0 C--N 1.283 -2.291 0 N-CA-C 106.114 -1.809 . . . . 0.0 106.114 173.488 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.458 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 67.1 mt -66.32 120.53 70.89 Favored Pre-proline 0 C--N 1.266 -3.027 0 C-N-CA 124.643 1.177 . . . . 0.0 108.727 179.753 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -68.31 139.25 45.16 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 122.238 1.958 . . . . 0.0 111.126 -179.627 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 73.6 mt -62.49 125.89 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 CA-C-O 121.742 0.782 . . . . 0.0 110.732 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.525 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 43.1 t -102.48 123.95 47.16 Favored 'General case' 0 N--CA 1.406 -2.652 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 176.6 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -105.09 154.47 20.11 Favored 'General case' 0 N--CA 1.413 -2.291 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 -174.613 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 15.0 p -80.39 143.37 12.5 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.768 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.285 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.57 HG23 ' HB2' ' A' ' 170' ' ' PHE . 6.4 m -65.3 130.86 30.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 176.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.451 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 96.2 mttt -120.03 141.62 49.56 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.291 -174.741 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.4 m -108.92 160.06 16.3 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 124.199 0.937 . . . . 0.0 108.568 177.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' LEU . . . . . 0.414 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.0 mm? -76.63 149.69 81.22 Favored Pre-proline 0 N--CA 1.418 -2.074 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 2.9 Cg_exo -68.19 114.76 3.53 Favored 'Trans proline' 0 N--CA 1.442 -1.503 0 C-N-CA 122.679 2.253 . . . . 0.0 110.242 175.65 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.43 HG21 ' SD ' ' A' ' 190' ' ' MET . 41.5 t -71.36 147.19 11.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.142 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.27 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 22.8 p -71.57 -80.4 0.06 Allowed 'General case' 0 N--CA 1.435 -1.221 0 O-C-N 123.117 0.26 . . . . 0.0 111.353 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.6 161.02 0.48 Allowed Pre-proline 0 C--O 1.24 0.587 0 C-N-CA 125.607 1.563 . . . . 0.0 107.612 177.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -78.84 -158.03 0.08 OUTLIER 'Trans proline' 0 CA--C 1.547 1.17 0 C-N-CA 121.555 1.503 . . . . 0.0 111.048 171.817 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' GLU . . . . . 0.463 ' H ' ' CD ' ' A' ' 153' ' ' GLU . 0.0 OUTLIER -99.91 -52.16 3.51 Favored 'General case' 0 C--N 1.31 -1.148 0 O-C-N 121.861 -0.524 . . . . 0.0 112.271 -175.668 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -107.19 25.58 11.23 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.605 0.716 . . . . 0.0 110.141 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -151.13 -176.78 24.33 Favored Glycine 0 N--CA 1.417 -2.633 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.339 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 16.5 pttm -145.82 168.93 19.6 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 -179.334 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.449 HG12 ' CD2' ' A' ' 176' ' ' PHE . 52.1 mt -91.6 141.84 13.9 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.463 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.5 m -90.98 -30.65 4.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 178.319 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 10.4 m . . . . . 0 C--N 1.311 -1.073 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.472 -174.075 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 168' ' ' TYR . . . . . 0.451 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 79.6 m-85 . . . . . 0 N--CA 1.432 -1.327 0 CA-C-O 121.506 0.669 . . . . 0.0 109.897 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 20.0 m170 -106.36 160.44 15.38 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 114.538 -1.21 . . . . 0.0 108.249 -175.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.57 ' HB2' HG23 ' A' ' 144' ' ' VAL . 65.0 t80 -50.02 123.99 9.25 Favored 'General case' 0 N--CA 1.47 0.539 0 O-C-N 123.287 0.367 . . . . 0.0 110.107 172.179 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 102.43 -0.83 49.87 Favored Glycine 0 N--CA 1.428 -1.839 0 C-N-CA 119.497 -1.335 . . . . 0.0 112.919 178.758 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 30.3 mm-40 -88.13 145.02 26.15 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 175.66 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -113.47 117.77 32.64 Favored 'General case' 0 C--N 1.281 -2.409 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.511 -179.613 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 54.5 t -98.71 101.24 11.87 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 176.305 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.463 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 16.2 ttm180 -93.45 145.98 24.1 Favored 'General case' 0 N--CA 1.415 -2.219 0 CA-C-N 114.906 -1.043 . . . . 0.0 110.54 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.449 ' CD2' HG12 ' A' ' 157' ' ' ILE . 68.6 m-85 -114.89 156.15 25.52 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 14.6 p -137.01 139.84 43.76 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.212 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.6 m -95.5 138.75 32.73 Favored 'General case' 0 C--N 1.269 -2.934 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.237 -176.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 179' ' ' ASN . . . . . 0.468 ' O ' ' HD2' ' A' ' 182' ' ' TYR . 58.9 m-20 -82.72 165.42 19.95 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 -179.349 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.7 t 49.07 -142.55 0.55 Allowed 'General case' 0 CA--C 1.548 0.867 0 O-C-N 124.057 0.848 . . . . 0.0 110.805 178.265 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -93.49 32.44 5.76 Favored Glycine 0 N--CA 1.428 -1.865 0 C-N-CA 121.19 -0.529 . . . . 0.0 111.876 178.454 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 182' ' ' TYR . . . . . 0.468 ' HD2' ' O ' ' A' ' 179' ' ' ASN . 96.9 m-85 -84.23 160.49 20.78 Favored 'General case' 0 N--CA 1.443 -0.802 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.378 -179.216 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -126.54 155.03 43.03 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 2.6 tp -71.82 144.77 12.91 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 178.747 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -85.71 -65.85 0.96 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.363 179.092 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -86.26 -113.88 0.87 Allowed Glycine 0 N--CA 1.439 -1.162 0 N-CA-C 111.817 -0.513 . . . . 0.0 111.817 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -100.05 157.47 16.53 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.827 -1.545 . . . . 0.0 106.827 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -93.51 -8.7 40.7 Favored 'General case' 0 N--CA 1.433 -1.283 0 C-N-CA 119.305 -0.958 . . . . 0.0 109.401 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 189' ' ' GLU . . . . . 0.43 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 2.9 pt-20 -146.23 130.41 17.48 Favored 'General case' 0 N--CA 1.43 -1.442 0 CA-C-O 121.932 0.872 . . . . 0.0 112.835 178.698 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.43 ' SD ' HG21 ' A' ' 149' ' ' VAL . 12.8 ptp -102.01 143.16 32.21 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.514 177.182 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -113.66 150.11 33.69 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 2.4 m -74.04 123.18 23.87 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 123.685 0.615 . . . . 0.0 110.795 173.759 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 193' ' ' SER . . . . . 0.423 ' HB2' ' OG ' ' A' ' 199' ' ' SER . 34.4 t -83.94 167.52 16.88 Favored 'General case' 0 N--CA 1.423 -1.795 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 176.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -71.81 -5.16 32.21 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 123.534 0.734 . . . . 0.0 111.351 -177.141 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -84.82 -18.87 33.6 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.412 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 88.81 27.46 24.04 Favored Glycine 0 N--CA 1.451 -0.309 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 -173.669 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -131.94 161.55 32.82 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 179.409 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -77.87 131.06 37.35 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 176.464 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 199' ' ' SER . . . . . 0.423 ' OG ' ' HB2' ' A' ' 193' ' ' SER . 15.0 m -68.04 -39.45 83.05 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-O 121.548 0.69 . . . . 0.0 110.064 -179.353 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 21.5 mmtp -96.33 150.27 20.76 Favored 'General case' 0 C--N 1.307 -1.247 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.75 177.789 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 22.9 mm-40 -86.3 166.23 15.81 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 176.874 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 28.3 ttmt -67.47 121.85 80.68 Favored Pre-proline 0 C--N 1.324 -0.519 0 C-N-CA 119.51 -0.876 . . . . 0.0 109.47 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.5 -174.86 2.44 Favored 'Trans proline' 0 N--CA 1.437 -1.834 0 C-N-CA 121.996 1.797 . . . . 0.0 111.759 179.183 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 204' ' ' LYS . . . . . 0.424 ' HG2' ' OE1' ' A' ' 153' ' ' GLU . 48.2 mttm -127.9 162.58 26.39 Favored 'General case' 0 C--N 1.287 -2.124 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.295 179.217 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 77.5 m -113.32 106.28 14.42 Favored 'General case' 0 C--N 1.281 -2.408 0 O-C-N 124.057 0.848 . . . . 0.0 109.137 170.433 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.5 m . . . . . 0 N--CA 1.431 -1.415 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.313 -173.759 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.447 ' HG2' ' HA ' ' A' ' 105' ' ' GLU . 33.9 Cg_endo . . . . . 0 CA--C 1.536 0.608 0 CA-C-O 121.113 0.38 . . . . 0.0 111.934 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.8 m -86.49 -33.69 20.27 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 176.085 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.74 -96.66 0.67 Allowed Glycine 0 N--CA 1.402 -3.593 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 173.035 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 56.0 t-80 -173.1 121.03 0.41 Allowed Pre-proline 0 C--N 1.263 -3.169 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -175.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.08 -30.79 13.05 Favored 'Trans proline' 0 C--O 1.219 -0.436 0 C-N-CA 121.909 1.74 . . . . 0.0 113.369 -171.666 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.22 176.13 14.34 Favored Glycine 0 CA--C 1.483 -1.936 0 N-CA-C 108.347 -1.901 . . . . 0.0 108.347 -176.468 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -134.7 -175.49 3.91 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -177.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 2.1 t -141.47 133.5 13.78 Favored Pre-proline 0 C--N 1.303 -1.43 0 CA-C-O 121.234 0.54 . . . . 0.0 112.131 -178.115 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -71.83 -18.1 28.53 Favored 'Trans proline' 0 C--O 1.238 0.513 0 C-N-CA 122.554 2.169 . . . . 0.0 111.389 175.809 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -86.72 -3.42 59.04 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.072 -176.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.474 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.89 -123.47 0.94 Allowed Glycine 0 N--CA 1.424 -2.157 0 C-N-CA 120.033 -1.079 . . . . 0.0 112.04 179.234 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 11.7 t -157.93 -166.48 1.98 Allowed 'General case' 0 C--N 1.285 -2.205 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -149.77 162.15 40.83 Favored 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 177.755 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 7.0 m -128.34 161.41 29.47 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 -178.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 25.4 mt -117.11 128.6 55.29 Favored 'General case' 0 C--N 1.266 -3.042 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.439 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 32.0 p -123.76 135.17 53.67 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -175.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 105.95 -45.33 1.32 Allowed Glycine 0 C--N 1.305 -1.19 0 N-CA-C 111.69 -0.564 . . . . 0.0 111.69 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.464 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -131.9 -16.59 1.41 Allowed Glycine 0 C--O 1.219 -0.784 0 C-N-CA 120.263 -0.97 . . . . 0.0 113.524 -177.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 64.5 12.97 7.84 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 123.657 0.783 . . . . 0.0 113.014 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.516 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.4 m -145.95 -169.4 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 -177.201 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -105.14 45.54 0.96 Allowed 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 118.692 0.678 . . . . 0.0 110.461 -178.232 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.721 ' O ' HG12 ' A' ' 108' ' ' VAL . 9.3 pt-20 -89.68 -176.18 4.9 Favored 'General case' 0 C--O 1.208 -1.094 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.884 178.231 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -79.08 138.63 38.04 Favored 'General case' 0 C--N 1.31 -1.132 0 O-C-N 121.648 -0.657 . . . . 0.0 111.119 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 85.59 4.31 85.6 Favored Glycine 0 N--CA 1.439 -1.155 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.992 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.721 HG12 ' O ' ' A' ' 105' ' ' GLU . 15.0 p -93.39 143.67 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.943 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 177.552 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.439 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 54.9 mtpt -108.08 118.38 36.6 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.368 178.669 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -83.08 91.87 7.29 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 175.575 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.421 HG12 ' CB ' ' A' ' 126' ' ' TYR . 32.3 m -91.83 117.58 35.44 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.405 0 CA-C-O 122.19 0.995 . . . . 0.0 108.735 -178.042 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 36.4 m-85 -84.42 146.71 27.51 Favored 'General case' 0 C--N 1.264 -3.143 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.918 -176.606 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.1 t -144.06 118.54 9.7 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-O 122.102 0.954 . . . . 0.0 108.919 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 3.8 m -75.12 160.93 29.87 Favored 'General case' 0 C--N 1.284 -2.25 0 CA-C-N 115.29 -0.868 . . . . 0.0 108.966 -176.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.474 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 75.4 m-20 -73.15 171.03 13.72 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 177.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -48.06 -49.37 31.72 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.553 1.141 . . . . 0.0 113.525 -176.663 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.548 ' HA2' ' CD2' ' A' ' 170' ' ' PHE . . . -80.61 8.46 54.8 Favored Glycine 0 C--N 1.309 -0.95 0 CA-C-N 116.025 -0.534 . . . . 0.0 113.37 -176.635 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.63 ' CE1' HG22 ' A' ' 143' ' ' VAL . 94.0 m-85 -130.71 150.61 51.81 Favored 'General case' 0 N--CA 1.434 -1.249 0 CA-C-O 121.501 0.667 . . . . 0.0 110.397 -178.478 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -119.08 163.5 16.92 Favored 'General case' 0 C--N 1.276 -2.614 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.47 HD11 ' HB2' ' A' ' 139' ' ' PRO . 13.4 tp -83.48 141.53 31.59 Favored 'General case' 0 C--N 1.282 -2.361 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 177.273 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.452 HD22 ' HA ' ' A' ' 121' ' ' LEU . 0.3 OUTLIER -112.72 116.94 30.92 Favored 'General case' 0 N--CA 1.408 -2.57 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.149 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.6 -169.33 13.14 Favored Glycine 0 C--N 1.276 -2.777 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.02 -174.8 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -100.53 -48.93 4.37 Favored 'General case' 0 C--N 1.287 -2.111 0 CA-C-N 114.926 -0.637 . . . . 0.0 109.304 -174.779 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.6 mm -68.0 126.67 28.27 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 CA-C-N 114.589 -1.187 . . . . 0.0 109.874 -176.085 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -122.91 3.13 9.42 Favored 'General case' 0 C--O 1.198 -1.654 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.219 176.346 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.421 ' CB ' HG12 ' A' ' 111' ' ' VAL . 20.9 p90 -138.28 161.85 35.84 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.068 -173.441 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 58.1 mtp180 -126.5 131.18 51.68 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 170.552 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -107.62 132.18 53.58 Favored 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 -177.443 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 43.1 t -81.02 104.5 11.57 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 118.02 -1.472 . . . . 0.0 110.303 176.367 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.516 ' OD1' HG22 ' A' ' 131' ' ' THR . 15.0 t70 -97.23 -169.43 1.85 Allowed 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.575 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.516 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.0 t -68.73 -17.02 63.98 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.631 0.729 . . . . 0.0 110.921 -175.614 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -87.9 -24.01 23.77 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.694 177.011 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 122.65 -154.03 16.95 Favored Glycine 0 N--CA 1.416 -2.646 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -174.335 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.431 ' CH2' HG13 ' A' ' 108' ' ' VAL . 93.9 m95 -63.34 115.1 4.27 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 55.4 p -76.66 168.87 19.32 Favored 'General case' 0 C--O 1.261 1.689 0 N-CA-C 109.287 -0.635 . . . . 0.0 109.287 176.531 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 61.53 -170.75 0.16 Allowed 'General case' 0 C--O 1.242 0.672 0 O-C-N 123.94 0.775 . . . . 0.0 111.918 177.438 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.64 171.29 7.61 Favored 'General case' 0 CA--C 1.469 -2.163 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 175.339 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.6 mt -67.57 113.4 14.0 Favored Pre-proline 0 C--N 1.297 -1.708 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 170.294 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.47 ' HB2' HD11 ' A' ' 120' ' ' LEU . 45.2 Cg_endo -66.46 131.69 27.06 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 122.052 1.835 . . . . 0.0 111.711 -176.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 69.3 mt -80.58 131.58 33.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.887 -176.902 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 74.3 m -103.52 149.56 24.74 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 174.191 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -125.49 168.37 13.73 Favored 'General case' 0 C--N 1.287 -2.117 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 174.226 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.63 HG22 ' CE1' ' A' ' 118' ' ' TYR . 99.6 t -67.65 143.3 15.51 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 177.028 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.446 ' HB ' ' HB2' ' A' ' 170' ' ' PHE . 72.6 t -61.5 130.7 25.99 Favored 'Isoleucine or valine' 0 C--O 1.242 0.668 0 N-CA-C 107.877 -1.156 . . . . 0.0 107.877 174.509 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.44 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 84.0 mttt -120.28 152.19 38.14 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 -175.264 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 59.0 m -118.42 160.04 22.4 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 64.4 mt -69.72 144.73 94.06 Favored Pre-proline 0 C--O 1.24 0.603 0 N-CA-C 112.282 0.475 . . . . 0.0 112.282 178.597 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -64.68 131.48 29.59 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 123.197 2.598 . . . . 0.0 112.449 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 44.2 t -90.94 136.82 23.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 179.245 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 15.3 p -73.55 -85.93 0.03 OUTLIER 'General case' 0 C--N 1.314 -0.965 0 CA-C-O 120.636 0.255 . . . . 0.0 111.55 178.565 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 177.0 150.24 0.35 Allowed Pre-proline 0 C--O 1.242 0.672 0 C-N-CA 125.627 1.571 . . . . 0.0 107.493 177.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' PRO . . . . . 0.413 ' HB3' ' O ' ' A' ' 203' ' ' PRO . 59.0 Cg_endo -77.88 171.16 17.75 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.008 1.805 . . . . 0.0 111.263 174.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -65.06 -59.96 3.55 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 114.645 1.35 . . . . 0.0 114.645 -174.733 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -107.52 29.88 6.78 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-O 121.845 0.831 . . . . 0.0 110.161 -178.198 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.88 178.14 22.89 Favored Glycine 0 N--CA 1.419 -2.438 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.72 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 57.5 pttt -145.79 166.14 26.79 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.178 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.429 HG23 HG13 ' A' ' 174' ' ' VAL . 56.9 mt -83.69 134.13 27.62 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 CA-C-O 121.348 0.594 . . . . 0.0 111.005 -178.455 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.5 t -68.81 -43.1 82.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.131 -0.94 . . . . 0.0 109.595 178.044 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 35.0 t . . . . . 0 N--CA 1.443 -0.781 0 CA-C-O 121.676 0.75 . . . . 0.0 109.464 176.392 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 . . . . . 0 C--O 1.24 0.575 0 CA-C-O 121.777 0.798 . . . . 0.0 112.79 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.498 ' HB3' HG11 ' A' ' 143' ' ' VAL . 38.0 m80 -95.43 152.02 18.78 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 114.399 -1.273 . . . . 0.0 112.057 -178.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.548 ' CD2' ' HA2' ' A' ' 117' ' ' GLY . 0.9 OUTLIER -62.56 106.04 0.72 Allowed 'General case' 0 C--O 1.239 0.535 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 172.731 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 138.35 -12.53 3.52 Favored Glycine 0 N--CA 1.428 -1.884 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -174.681 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 31.7 mm-40 -99.34 160.74 14.06 Favored 'General case' 0 C--O 1.259 1.57 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 177.131 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -140.78 135.24 31.28 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 178.799 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.497 HG23 ' CH2' ' A' ' 198' ' ' TRP . 92.7 t -99.34 106.03 18.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.631 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.404 ' HA ' ' HA ' ' A' ' 189' ' ' GLU . 56.3 ttt180 -97.95 158.17 15.69 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 178.24 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -130.45 153.49 48.72 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -172.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.2 p -134.97 143.19 38.07 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 81.9 m -99.03 145.3 27.23 Favored 'General case' 0 C--N 1.283 -2.296 0 CA-C-N 115.607 -0.724 . . . . 0.0 112.218 -175.49 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -69.79 159.49 33.48 Favored 'General case' 0 N--CA 1.434 -1.257 0 CA-C-N 115.383 -0.826 . . . . 0.0 108.885 175.089 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 38.4 m -58.44 112.3 1.53 Allowed 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.805 -175.096 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 114.72 -13.43 20.3 Favored Glycine 0 N--CA 1.438 -1.218 0 CA-C-N 115.145 -0.934 . . . . 0.0 111.761 -178.878 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -107.83 160.96 15.33 Favored 'General case' 0 N--CA 1.433 -1.305 0 CA-C-O 120.876 0.369 . . . . 0.0 111.733 -177.635 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.533 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 22.3 pttm -131.24 152.75 50.2 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 178.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.569 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.4 tt -80.61 136.05 24.05 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.285 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.332 175.738 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -75.0 -54.95 6.29 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.078 -176.502 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -91.38 -144.61 13.22 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.519 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -77.92 157.9 29.6 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.569 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.4 pt-20 -89.91 -5.63 56.58 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.557 -174.538 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 189' ' ' GLU . . . . . 0.436 ' HG2' ' HG3' ' A' ' 188' ' ' GLU . 3.6 pt-20 -147.77 142.28 26.47 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.17 0.51 . . . . 0.0 111.977 -175.465 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.472 ' CG ' ' HB ' ' A' ' 174' ' ' VAL . 14.3 ptp -120.29 134.79 55.19 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.105 -0.952 . . . . 0.0 108.537 175.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 21.9 t-80 -112.36 147.01 37.29 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 110.56 -0.163 . . . . 0.0 110.56 -175.257 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 192' ' ' CYS . . . . . 0.404 ' HB3' ' HA ' ' A' ' 170' ' ' PHE . 1.5 m -70.68 120.01 15.66 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 116.663 -0.244 . . . . 0.0 110.542 173.82 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.1 m -98.7 163.95 12.43 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.836 178.104 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -47.17 -32.66 4.55 Favored 'General case' 0 N--CA 1.498 1.926 0 C-N-CA 126.533 1.933 . . . . 0.0 114.078 -178.759 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -73.1 -17.08 61.44 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 94.99 28.35 10.08 Favored Glycine 0 C--N 1.307 -1.069 0 C-N-CA 119.917 -1.135 . . . . 0.0 112.093 -178.397 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 2.5 p90 -140.62 172.05 13.25 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 176.45 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 198' ' ' TRP . . . . . 0.497 ' CH2' HG23 ' A' ' 174' ' ' VAL . 87.5 m95 -82.22 143.3 31.47 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 123.717 0.636 . . . . 0.0 111.129 -178.505 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 5.0 m -69.13 -6.46 28.72 Favored 'General case' 0 CA--C 1.549 0.937 0 C-N-CA 124.109 0.964 . . . . 0.0 111.245 178.197 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.459 ' HB2' ' HB3' ' A' ' 190' ' ' MET . 25.9 mmmt -140.52 150.99 44.41 Favored 'General case' 0 CA--C 1.482 -1.666 0 C-N-CA 123.863 0.865 . . . . 0.0 109.467 -178.315 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -89.65 157.62 17.94 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 104.561 -2.385 . . . . 0.0 104.561 169.401 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 25.9 ttpp -60.85 114.44 10.4 Favored Pre-proline 0 C--O 1.243 0.759 0 N-CA-C 114.479 1.289 . . . . 0.0 114.479 -172.062 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 203' ' ' PRO . . . . . 0.436 ' HG2' HD11 ' A' ' 184' ' ' ILE . 90.3 Cg_endo -78.89 165.58 24.21 Favored 'Trans proline' 0 N--CA 1.435 -1.936 0 C-N-CA 123.113 2.542 . . . . 0.0 109.786 176.09 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.9 pttt -139.08 162.76 34.15 Favored 'General case' 0 C--N 1.285 -2.209 0 C-N-CA 120.005 -0.678 . . . . 0.0 111.543 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.533 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 73.6 m -96.29 121.4 38.04 Favored 'General case' 0 N--CA 1.406 -2.628 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.052 179.378 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 13.4 m . . . . . 0 C--N 1.295 -1.775 0 C-N-CA 125.384 1.474 . . . . 0.0 108.181 -177.02 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo . . . . . 0 CA--C 1.538 0.703 0 CA-C-O 121.201 0.417 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 34.2 m -75.54 -37.18 60.21 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.674 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 120.41 -95.86 0.6 Allowed Glycine 0 N--CA 1.4 -3.742 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 173.608 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 64.9 t-80 -173.26 123.67 0.43 Allowed Pre-proline 0 C--N 1.253 -3.596 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 -175.281 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.496 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 81.3 Cg_endo -76.02 -3.52 13.96 Favored 'Trans proline' 0 C--O 1.213 -0.75 0 C-N-CA 122.766 2.31 . . . . 0.0 113.841 -171.519 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 112.97 -175.58 16.78 Favored Glycine 0 C--N 1.285 -2.295 0 N-CA-C 108.296 -1.921 . . . . 0.0 108.296 -176.522 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -152.92 118.52 5.31 Favored 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -176.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.1 t -91.22 133.85 30.91 Favored Pre-proline 0 C--N 1.304 -1.389 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -173.124 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -77.65 -13.73 16.17 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 122.725 2.283 . . . . 0.0 111.453 173.816 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -81.01 -10.32 59.72 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.934 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.535 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -178.41 -133.74 1.96 Allowed Glycine 0 N--CA 1.407 -3.299 0 C-N-CA 119.583 -1.294 . . . . 0.0 112.494 -178.746 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 21.0 p -143.39 -177.5 5.41 Favored 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -177.268 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 37.7 p90 -149.92 157.24 42.97 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 173.148 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.5 m -131.81 152.21 51.14 Favored 'General case' 0 C--N 1.289 -2.065 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.446 HD11 ' CE1' ' A' ' 104' ' ' PHE . 16.2 mt -106.12 131.49 53.32 Favored 'General case' 0 C--N 1.273 -2.731 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 20.5 p -123.01 137.92 54.82 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.0 -175.875 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 101.99 -56.96 0.66 Allowed Glycine 0 N--CA 1.436 -1.318 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -177.686 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.485 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -110.04 -30.5 3.4 Favored Glycine 0 C--O 1.21 -1.383 0 C-N-CA 120.991 -0.623 . . . . 0.0 113.121 -178.216 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 42.0 m-80 70.6 11.4 7.28 Favored 'General case' 0 N--CA 1.506 2.329 0 C-N-CA 123.879 0.872 . . . . 0.0 110.96 -177.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.503 ' O ' HG11 ' A' ' 108' ' ' VAL . 24.3 m -148.8 -175.14 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.76 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 -179.385 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.446 ' CE1' HD11 ' A' ' 98' ' ' LEU . 24.4 m-85 -99.17 42.42 1.1 Allowed 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 119.25 0.932 . . . . 0.0 111.049 -176.151 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.718 ' O ' HG12 ' A' ' 108' ' ' VAL . 9.6 pt-20 -83.01 -179.67 7.51 Favored 'General case' 0 C--O 1.208 -1.128 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.877 177.812 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -75.61 132.96 40.98 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.743 -0.598 . . . . 0.0 111.827 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.52 3.87 66.4 Favored Glycine 0 N--CA 1.435 -1.383 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.842 177.583 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.718 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.9 p -90.28 143.7 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 C-N-CA 119.993 -0.683 . . . . 0.0 109.223 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.7 mtpt -107.81 119.36 39.24 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 178.47 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.44 93.3 9.1 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 177.869 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 79.4 t -85.37 113.94 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.506 0 C-N-CA 123.478 0.711 . . . . 0.0 109.231 -178.007 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -87.16 134.75 33.49 Favored 'General case' 0 C--N 1.282 -2.335 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.843 179.205 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -132.01 130.12 40.99 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 10.1 m -82.34 154.43 25.28 Favored 'General case' 0 C--N 1.278 -2.535 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.659 -173.117 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.535 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 86.5 m-20 -71.26 177.24 3.98 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-N 116.765 -0.198 . . . . 0.0 111.47 179.445 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' GLU . . . . . 0.412 ' O ' ' HB2' ' A' ' 194' ' ' ASP . 45.6 tt0 -52.41 -54.59 30.1 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 123.845 0.858 . . . . 0.0 112.021 -174.759 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.94 34.69 3.17 Favored Glycine 0 C--N 1.308 -0.992 0 C-N-CA 120.787 -0.72 . . . . 0.0 113.171 -179.14 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -147.09 156.4 42.97 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.103 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -133.91 169.1 17.59 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.301 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.446 HD11 ' HB2' ' A' ' 139' ' ' PRO . 15.4 tp -92.2 142.66 27.24 Favored 'General case' 0 C--N 1.28 -2.42 0 C-N-CA 119.574 -0.851 . . . . 0.0 109.006 177.622 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -124.58 122.49 37.72 Favored 'General case' 0 N--CA 1.414 -2.239 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 177.077 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.5 171.6 15.63 Favored Glycine 0 C--N 1.286 -2.201 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.691 -176.608 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -95.91 -25.9 15.81 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.396 0.617 . . . . 0.0 109.808 -176.209 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.6 mm -90.2 137.36 21.69 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 23.0 p-10 -135.69 8.02 3.29 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 120.715 0.293 . . . . 0.0 110.639 179.556 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.5 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 28.8 p90 -146.29 171.35 15.11 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.067 -173.57 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.573 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 33.3 mtp180 -129.05 119.76 24.78 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 173.275 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -90.6 128.42 36.59 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.198 -1.001 . . . . 0.0 109.395 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 42.3 t -84.64 113.05 20.99 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.859 -1.136 . . . . 0.0 110.554 175.458 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -103.48 -172.33 2.09 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.873 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 10.8 t -64.19 -25.76 68.22 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.489 0.551 . . . . 0.0 112.489 -174.715 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -84.96 -23.94 28.54 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.13 0.491 . . . . 0.0 111.186 178.454 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 138.09 -158.01 24.59 Favored Glycine 0 N--CA 1.435 -1.381 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -177.776 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.413 ' CH2' HG13 ' A' ' 108' ' ' VAL . 93.4 m95 -68.57 113.04 5.74 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 178.441 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.2 p -64.49 -65.25 0.7 Allowed 'General case' 0 C--O 1.243 0.724 0 C-N-CA 123.049 0.54 . . . . 0.0 111.607 -176.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' ASN . . . . . 0.573 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 4.1 m120 -72.38 167.82 19.72 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 137' ' ' ASP . . . . . 0.401 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 10.4 t70 -104.66 -171.65 1.96 Allowed 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 176.329 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.401 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 78.8 mt -72.92 121.6 85.48 Favored Pre-proline 0 C--N 1.274 -2.686 0 C-N-CA 124.497 1.119 . . . . 0.0 108.256 179.674 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.446 ' HB2' HD11 ' A' ' 120' ' ' LEU . 53.0 Cg_endo -69.69 160.7 48.73 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 122.027 1.818 . . . . 0.0 110.763 177.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.1 mm -95.91 124.64 48.66 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 CA-C-O 121.523 0.677 . . . . 0.0 110.95 -175.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 68.2 m -100.22 120.27 39.64 Favored 'General case' 0 C--N 1.271 -2.806 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 171.174 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 16.4 tp10 -102.36 146.1 28.54 Favored 'General case' 0 C--N 1.272 -2.777 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 -178.683 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.15 136.79 25.58 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.882 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.398 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.503 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.1 m -59.77 128.44 20.71 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 CA-C-O 121.22 0.533 . . . . 0.0 110.378 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 59.8 mttm -112.68 145.92 39.59 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.56 -174.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.2 m -118.33 137.95 52.74 Favored 'General case' 0 C--N 1.277 -2.551 0 N-CA-C 106.157 -1.794 . . . . 0.0 106.157 -179.34 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 78.3 mt -62.32 143.42 95.63 Favored Pre-proline 0 C--N 1.313 -1.008 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -176.619 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -66.04 122.81 10.44 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.039 2.493 . . . . 0.0 110.408 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 51.7 t -76.33 149.25 6.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.941 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 6.3 p -68.95 -84.46 0.03 OUTLIER 'General case' 0 N--CA 1.439 -0.999 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.922 176.347 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 166.0 159.81 0.1 OUTLIER Pre-proline 0 CA--C 1.501 -0.94 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 177.102 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -72.28 156.11 55.36 Favored 'Trans proline' 0 N--CA 1.431 -2.167 0 CA-C-N 119.801 0.965 . . . . 0.0 109.89 171.094 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -64.92 -33.25 75.58 Favored 'General case' 0 C--N 1.28 -2.43 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -173.136 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -125.59 25.44 6.98 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-O 122.626 1.203 . . . . 0.0 109.045 -174.863 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.89 -155.8 6.59 Favored Glycine 0 N--CA 1.415 -2.738 0 CA-C-N 113.519 -1.673 . . . . 0.0 110.432 178.646 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' LYS . . . . . 0.514 ' HG3' HG23 ' A' ' 177' ' ' VAL . 24.1 pttm -157.79 174.41 15.34 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 41.7 mt -94.45 133.64 34.72 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.422 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.455 ' CG2' HG22 ' A' ' 177' ' ' VAL . 58.2 t -73.53 -48.45 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 177.737 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.9 m . . . . . 0 N--CA 1.429 -1.504 0 CA-C-N 115.019 -0.991 . . . . 0.0 109.021 -179.857 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 . . . . . 0 N--CA 1.408 -2.538 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 27.7 m170 -128.71 175.67 8.41 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -175.679 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.503 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 70.8 t80 -53.93 135.42 42.44 Favored 'General case' 0 C--N 1.306 -1.302 0 O-C-N 124.185 0.928 . . . . 0.0 110.052 172.777 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 101.3 -27.3 21.17 Favored Glycine 0 N--CA 1.43 -1.752 0 C-N-CA 120.126 -1.035 . . . . 0.0 112.306 178.851 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -68.14 147.21 52.62 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 117.28 0.54 . . . . 0.0 111.177 -178.704 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -128.44 116.13 19.26 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-N 114.457 -1.247 . . . . 0.0 107.794 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 69.5 t -100.18 110.31 26.97 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.928 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.237 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 64.1 ttt180 -97.07 155.64 16.71 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -178.777 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -128.27 161.87 28.34 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 123.669 0.787 . . . . 0.0 109.714 -174.635 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.514 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.1 OUTLIER -134.52 150.71 30.79 Favored 'Isoleucine or valine' 0 CA--C 1.474 -1.949 0 O-C-N 124.04 0.838 . . . . 0.0 109.111 178.659 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.2 m -110.83 137.5 48.41 Favored 'General case' 0 N--CA 1.395 -3.21 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 175.58 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -65.9 177.05 1.41 Allowed 'General case' 0 C--N 1.287 -2.136 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.853 -177.877 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.0 m -39.6 -36.11 0.37 Allowed 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 127.351 2.26 . . . . 0.0 116.823 -172.569 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -118.18 21.43 10.13 Favored Glycine 0 C--N 1.29 -2.005 0 C-N-CA 119.553 -1.308 . . . . 0.0 113.604 -178.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 182' ' ' TYR . . . . . 0.414 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 98.8 m-85 -126.92 156.36 41.59 Favored 'General case' 0 N--CA 1.436 -1.167 0 CA-C-N 117.754 0.777 . . . . 0.0 112.975 -177.17 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.453 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 25.0 pttm -124.96 153.07 43.31 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 179.105 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.3 tp -72.93 146.91 10.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.472 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -83.04 -62.23 1.65 Allowed 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -103.15 -115.72 4.1 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -85.61 154.37 21.75 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -98.11 2.53 48.72 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 -178.277 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -155.79 149.61 25.24 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -176.91 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.0 ptp -126.82 126.14 42.87 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 114.945 -1.025 . . . . 0.0 111.331 179.154 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -95.76 148.28 22.74 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 177.096 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 192' ' ' CYS . . . . . 0.469 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 34.5 t -95.31 135.8 36.47 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 119.803 -0.759 . . . . 0.0 111.238 178.682 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 19.5 m -84.94 162.28 19.49 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 124.281 1.033 . . . . 0.0 109.294 177.685 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 194' ' ' ASP . . . . . 0.44 ' O ' HG11 ' A' ' 144' ' ' VAL . 4.5 p-10 -72.84 -7.72 52.14 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.247 0.546 . . . . 0.0 112.29 -174.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 195' ' ' ASP . . . . . 0.439 ' HB2' ' CD2' ' A' ' 197' ' ' PHE . 2.8 m-20 -77.81 -12.59 59.99 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 174.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 89.74 39.98 6.07 Favored Glycine 0 N--CA 1.438 -1.188 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.795 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 197' ' ' PHE . . . . . 0.439 ' CD2' ' HB2' ' A' ' 195' ' ' ASP . 42.1 p90 -144.69 156.78 44.26 Favored 'General case' 0 C--N 1.318 -0.771 0 O-C-N 122.121 -0.634 . . . . 0.0 109.506 177.558 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 198' ' ' TRP . . . . . 0.469 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 81.9 m95 -76.12 128.85 35.83 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.4 m -63.07 -33.65 75.9 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.264 0.554 . . . . 0.0 110.078 -178.853 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.449 ' HD3' ' HA ' ' A' ' 200' ' ' LYS . 28.0 mmtp -108.68 148.35 30.56 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.85 177.803 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -87.42 178.17 6.9 Favored 'General case' 0 C--N 1.289 -2.059 0 CA-C-N 114.835 -1.075 . . . . 0.0 110.683 -178.433 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 8.7 mmmm -59.84 120.34 49.05 Favored Pre-proline 0 N--CA 1.442 -0.855 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.283 177.165 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -90.49 178.89 1.97 Allowed 'Trans proline' 0 N--CA 1.427 -2.386 0 C-N-CA 122.467 2.111 . . . . 0.0 110.179 176.115 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -128.98 165.84 20.35 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.453 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 88.9 m -122.25 104.59 9.55 Favored 'General case' 0 N--CA 1.415 -2.205 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 172.108 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--N 1.297 -1.695 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.049 -174.728 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo . . . . . 0 CA--C 1.535 0.545 0 CA-C-O 121.404 0.502 . . . . 0.0 111.396 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 39.6 m -85.22 -33.85 22.15 Favored 'General case' 0 C--N 1.315 -0.921 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 177.337 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.72 -94.07 0.58 Allowed Glycine 0 N--CA 1.398 -3.848 0 CA-C-N 114.467 -1.242 . . . . 0.0 110.005 171.495 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 11.2 t60 -175.07 123.9 0.36 Allowed Pre-proline 0 C--N 1.252 -3.649 0 N-CA-C 104.422 -2.436 . . . . 0.0 104.422 -174.657 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.431 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 74.4 Cg_endo -79.0 -23.61 7.67 Favored 'Trans proline' 0 C--N 1.329 -0.473 0 C-N-CA 122.031 1.821 . . . . 0.0 112.906 -175.193 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.1 176.77 20.45 Favored Glycine 0 CA--C 1.475 -2.459 0 N-CA-C 108.263 -1.935 . . . . 0.0 108.263 -175.159 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.1 t0 -136.87 155.15 50.16 Favored 'General case' 0 C--N 1.275 -2.663 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -176.337 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.4 t -99.57 127.2 34.84 Favored Pre-proline 0 C--N 1.294 -1.805 0 CA-C-O 120.836 0.35 . . . . 0.0 110.302 -176.796 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.9 -13.67 39.09 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.695 2.263 . . . . 0.0 112.3 -178.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.4 ' CD2' ' HB2' ' A' ' 141' ' ' CYS . 31.6 m-85 -94.62 1.48 55.6 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.72 -177.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.492 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 179.98 -129.94 1.42 Allowed Glycine 0 N--CA 1.416 -2.657 0 C-N-CA 119.234 -1.46 . . . . 0.0 112.482 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 22.0 p -149.13 -176.38 5.34 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 124.216 0.598 . . . . 0.0 110.0 -177.007 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -144.71 164.33 31.33 Favored 'General case' 0 C--N 1.313 -1.022 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 172.043 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.2 m -129.29 160.48 32.87 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 179.237 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.7 mt -117.51 125.01 50.13 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.121 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.467 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 21.7 p -117.86 137.87 52.49 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.442 -175.462 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 102.25 -47.72 1.13 Allowed Glycine 0 C--N 1.299 -1.497 0 N-CA-C 111.126 -0.789 . . . . 0.0 111.126 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.448 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -122.85 -21.17 2.68 Favored Glycine 0 N--CA 1.438 -1.168 0 C-N-CA 120.37 -0.919 . . . . 0.0 113.361 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 64.25 14.72 8.89 Favored 'General case' 0 N--CA 1.5 2.048 0 C-N-CA 123.357 0.663 . . . . 0.0 112.666 -178.541 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.514 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.0 m -152.1 -172.89 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -178.232 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -99.9 43.87 1.04 Allowed 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 119.368 0.986 . . . . 0.0 111.061 -177.677 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.723 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.0 pt-20 -84.64 178.21 7.77 Favored 'General case' 0 C--O 1.205 -1.268 0 CA-C-N 114.681 -1.145 . . . . 0.0 111.983 178.225 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -71.91 135.83 46.66 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 122.076 -0.39 . . . . 0.0 110.798 177.021 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.63 -7.65 71.14 Favored Glycine 0 N--CA 1.435 -1.378 0 C-N-CA 120.148 -1.025 . . . . 0.0 113.418 178.283 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.723 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -85.31 143.48 11.52 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 119.709 -0.797 . . . . 0.0 110.581 -176.274 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.467 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.8 mtpt -108.82 117.0 33.05 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.49 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -83.3 92.41 7.5 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.482 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 89.5 t -87.33 114.23 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.587 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -176.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -86.33 139.32 31.09 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-O 121.409 0.623 . . . . 0.0 111.013 -177.874 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -133.66 109.13 8.98 Favored 'General case' 0 N--CA 1.407 -2.587 0 CA-C-O 122.334 1.064 . . . . 0.0 109.387 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 12.8 m -67.57 153.17 44.31 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.423 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.492 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 86.8 m-20 -68.71 178.77 1.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.869 0.366 . . . . 0.0 111.558 -179.012 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -57.38 -37.21 72.3 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -176.166 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -86.61 18.16 35.67 Favored Glycine 0 C--N 1.304 -1.237 0 C-N-CA 120.68 -0.771 . . . . 0.0 113.322 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -145.79 166.34 26.19 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -175.59 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -140.55 163.9 31.61 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.579 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -87.18 120.37 28.39 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 179.357 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.6 129.89 47.8 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 -178.154 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.8 -176.51 22.18 Favored Glycine 0 C--N 1.301 -1.366 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -91.46 -38.58 12.47 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.316 0.579 . . . . 0.0 110.0 -179.052 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.5 mm -78.08 120.62 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -176.26 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -129.16 8.05 5.53 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -177.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.49 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 22.8 p90 -151.19 169.68 21.3 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 -174.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.581 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 57.8 mtp180 -129.14 122.57 30.11 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 173.472 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -94.65 127.29 40.51 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 119.557 -0.857 . . . . 0.0 110.316 178.775 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 47.4 t -83.27 113.1 20.46 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.087 175.029 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.526 ' OD1' HG22 ' A' ' 131' ' ' THR . 8.4 t70 -110.3 -164.33 0.92 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.526 HG22 ' OD1' ' A' ' 130' ' ' ASP . 5.9 t -52.65 -33.45 46.98 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 -172.84 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -102.26 -10.39 19.59 Favored 'General case' 0 C--N 1.316 -0.875 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.83 -177.349 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 133.32 -153.96 21.01 Favored Glycine 0 N--CA 1.421 -2.346 0 N-CA-C 110.781 -0.927 . . . . 0.0 110.781 -178.062 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.409 ' CH2' HG13 ' A' ' 108' ' ' VAL . 86.2 m95 -67.65 119.93 13.21 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 122.527 0.331 . . . . 0.0 110.228 -178.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.0 p -71.58 -63.76 1.06 Allowed 'General case' 0 C--O 1.251 1.17 0 CA-C-O 121.544 0.687 . . . . 0.0 111.1 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' ASN . . . . . 0.581 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.8 m120 -69.99 164.36 24.1 Favored 'General case' 0 CA--C 1.489 -1.383 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.828 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 137' ' ' ASP . . . . . 0.403 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 12.1 t70 -103.35 -171.84 2.01 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 176.042 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.403 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 64.1 mt -69.48 120.68 78.7 Favored Pre-proline 0 C--N 1.28 -2.427 0 C-N-CA 124.439 1.096 . . . . 0.0 109.625 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -69.77 172.76 12.06 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.558 2.172 . . . . 0.0 112.485 178.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 49.1 mm -109.36 130.5 62.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.051 -173.245 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.4 ' HB2' ' CD2' ' A' ' 93' ' ' PHE . 89.1 m -109.06 114.34 28.0 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 174.354 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -103.09 157.23 17.14 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 176.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 13.6 p -70.62 145.43 12.79 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.069 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.617 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.4 m -72.35 136.28 25.99 Favored 'Isoleucine or valine' 0 C--O 1.248 1.015 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 175.841 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 64.4 mmtt -105.8 151.82 24.0 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -174.735 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 39.6 m -114.91 145.77 41.85 Favored 'General case' 0 C--N 1.28 -2.43 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 176.84 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.75 145.89 91.44 Favored Pre-proline 0 N--CA 1.418 -2.05 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -179.454 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -69.95 125.1 11.66 Favored 'Trans proline' 0 N--CA 1.444 -1.431 0 C-N-CA 122.885 2.39 . . . . 0.0 111.532 -178.546 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.8 t -97.98 137.82 24.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 13.5 p -76.74 -81.7 0.08 Allowed 'General case' 0 C--N 1.314 -0.962 0 O-C-N 123.126 0.267 . . . . 0.0 110.96 177.028 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.07 156.22 0.24 Allowed Pre-proline 0 C--O 1.24 0.566 0 C-N-CA 125.403 1.481 . . . . 0.0 107.895 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' PRO . . . . . 0.479 ' HG2' ' HA3' ' A' ' 155' ' ' GLY . 37.1 Cg_endo -71.02 162.1 43.84 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 121.966 1.777 . . . . 0.0 110.17 172.475 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -55.51 -44.99 77.15 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -174.733 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 154' ' ' ASN . . . . . 0.413 ' HB2' ' HB2' ' A' ' 205' ' ' CYS . 25.1 m120 -116.45 28.0 8.85 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.242 0.544 . . . . 0.0 109.73 -177.333 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 155' ' ' GLY . . . . . 0.479 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -143.32 -174.6 15.72 Favored Glycine 0 N--CA 1.439 -1.162 0 C-N-CA 120.181 -1.009 . . . . 0.0 112.661 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 31.7 pttt -152.9 161.02 43.06 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 123.193 0.597 . . . . 0.0 109.638 -176.362 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.463 HG23 HG13 ' A' ' 174' ' ' VAL . 58.2 mt -82.44 134.11 27.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 O-C-N 123.27 0.356 . . . . 0.0 110.773 -179.052 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.501 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.7 m -85.69 -32.14 6.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 CA-C-O 121.216 0.531 . . . . 0.0 110.585 -178.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 8.8 t . . . . . 0 N--CA 1.44 -0.957 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.431 -172.273 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 168' ' ' TYR . . . . . 0.461 ' HB3' ' HB2' ' A' ' 146' ' ' CYS . 97.5 m-85 . . . . . 0 N--CA 1.421 -1.893 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 21.3 m80 -130.31 166.44 20.38 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -175.187 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.617 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 76.7 t80 -54.36 124.2 15.25 Favored 'General case' 0 C--O 1.247 0.945 0 C-N-CA 120.651 -0.42 . . . . 0.0 109.909 174.288 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 124.59 -26.43 5.71 Favored Glycine 0 N--CA 1.423 -2.218 0 C-N-CA 120.441 -0.885 . . . . 0.0 111.391 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 16.0 mm100 -59.08 131.56 51.39 Favored 'General case' 0 C--O 1.248 1.013 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -179.23 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -119.33 96.1 5.07 Favored 'General case' 0 N--CA 1.424 -1.735 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.463 HG13 HG23 ' A' ' 157' ' ' ILE . 73.4 t -88.89 101.6 12.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.25 -176.102 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.501 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 40.5 ttm180 -91.85 146.35 23.82 Favored 'General case' 0 N--CA 1.417 -2.084 0 CA-C-N 114.557 -1.201 . . . . 0.0 109.422 176.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -116.5 150.44 37.9 Favored 'General case' 0 N--CA 1.416 -2.135 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.396 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.6 p -129.84 142.45 43.83 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 177.836 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 178' ' ' CYS . . . . . 0.413 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 70.3 m -94.1 148.41 22.2 Favored 'General case' 0 C--N 1.264 -3.114 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.344 -177.238 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -62.33 158.15 18.06 Favored 'General case' 0 CA--C 1.495 -1.166 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.578 178.49 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.2 m -42.11 103.92 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.22 0 O-C-N 125.173 1.545 . . . . 0.0 113.891 -174.589 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.02 -10.56 31.78 Favored Glycine 0 N--CA 1.432 -1.625 0 C-N-CA 120.469 -0.872 . . . . 0.0 113.731 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 182' ' ' TYR . . . . . 0.413 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 77.4 m-85 -97.63 160.38 14.35 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 117.809 0.805 . . . . 0.0 111.611 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.21 148.46 52.46 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.44 HD13 ' HA ' ' A' ' 188' ' ' GLU . 2.4 tt -79.77 144.99 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.148 0 CA-C-O 121.428 0.632 . . . . 0.0 110.817 -175.492 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -81.6 -65.27 1.03 Allowed 'General case' 0 C--N 1.294 -1.822 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.915 -176.534 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -78.52 -110.21 0.2 Allowed Glycine 0 C--N 1.309 -0.932 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.978 -178.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -106.59 179.46 4.26 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.329 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.44 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.7 pt-20 -100.16 -11.9 20.06 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 118.974 0.806 . . . . 0.0 110.518 -174.288 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -152.61 164.38 37.79 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -173.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.2 ptp -133.79 136.89 44.8 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.079 176.176 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 44.6 t-80 -112.69 147.81 36.01 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 116.63 -0.259 . . . . 0.0 110.496 -178.104 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 61.1 m -75.08 121.2 21.67 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 123.067 0.547 . . . . 0.0 112.097 175.317 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 48.8 m -88.54 -175.23 4.88 Favored 'General case' 0 C--N 1.31 -1.136 0 C-N-CA 123.394 0.678 . . . . 0.0 110.205 174.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -51.81 -34.89 42.16 Favored 'General case' 0 N--CA 1.5 2.04 0 C-N-CA 125.073 1.349 . . . . 0.0 113.05 -178.504 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -78.06 -4.02 45.13 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 123.347 0.659 . . . . 0.0 112.608 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 196' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 69.25 28.42 72.71 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 108.051 -2.019 . . . . 0.0 108.051 -168.191 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -105.72 148.22 27.68 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-N 114.177 -1.012 . . . . 0.0 108.447 -176.16 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 83.6 m95 -81.97 123.67 29.08 Favored 'General case' 0 C--N 1.292 -1.906 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 10.9 m -62.4 -29.01 70.18 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 122.989 0.516 . . . . 0.0 111.837 -178.548 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -118.93 155.75 30.76 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 107.078 -1.452 . . . . 0.0 107.078 -178.103 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -95.3 164.06 13.0 Favored 'General case' 0 C--N 1.288 -2.105 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 176.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 54.6 mtpt -54.42 115.87 9.48 Favored Pre-proline 0 C--N 1.319 -0.76 0 O-C-N 123.815 0.697 . . . . 0.0 112.586 -176.423 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 203' ' ' PRO . . . . . 0.475 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 5.7 Cg_exo -78.06 162.56 28.86 Favored 'Trans proline' 0 N--CA 1.432 -2.093 0 C-N-CA 121.813 1.675 . . . . 0.0 111.231 177.456 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 50.7 tttp -109.0 157.94 18.19 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 -177.674 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.413 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 95.0 m -114.33 120.96 42.16 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 175.167 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.9 m . . . . . 0 C--N 1.307 -1.271 0 O-C-N 124.284 0.99 . . . . 0.0 109.318 -177.223 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.511 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 19.3 Cg_endo . . . . . 0 CA--C 1.532 0.412 0 CA-C-O 120.648 0.186 . . . . 0.0 112.308 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' CYS . . . . . 0.455 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 26.8 m -83.85 -26.55 29.38 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-O 121.465 0.65 . . . . 0.0 110.245 176.323 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.8 -86.65 0.44 Allowed Glycine 0 CA--C 1.452 -3.888 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 170.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.2 t60 -175.03 131.41 0.44 Allowed Pre-proline 0 C--N 1.26 -3.32 0 N-CA-C 104.81 -2.292 . . . . 0.0 104.81 -174.349 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -82.0 6.42 5.7 Favored 'Trans proline' 0 N--CA 1.484 0.963 0 C-N-CA 122.627 2.218 . . . . 0.0 114.641 -172.014 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 108.89 -167.19 12.91 Favored Glycine 0 C--N 1.289 -2.046 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -176.75 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -154.97 155.47 34.27 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 1.7 t -129.51 129.54 23.21 Favored Pre-proline 0 C--N 1.297 -1.675 0 CA-C-O 120.757 0.313 . . . . 0.0 110.561 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.49 -10.05 18.79 Favored 'Trans proline' 0 C--O 1.223 -0.258 0 C-N-CA 122.523 2.148 . . . . 0.0 111.451 -179.588 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.483 ' HB2' ' HB2' ' A' ' 141' ' ' CYS . 28.4 m-85 -96.78 -52.11 4.03 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 122.213 1.006 . . . . 0.0 108.656 -179.478 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -106.49 -155.17 20.82 Favored Glycine 0 N--CA 1.401 -3.642 0 C-N-CA 119.78 -1.2 . . . . 0.0 112.502 -176.181 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.8 p -146.48 177.38 9.09 Favored 'General case' 0 C--N 1.261 -3.281 0 C-N-CA 125.226 1.411 . . . . 0.0 107.304 178.189 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.412 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 44.3 p90 -142.47 164.44 30.12 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.79 174.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -129.12 159.16 36.88 Favored 'General case' 0 C--N 1.284 -2.277 0 N-CA-C 106.641 -1.614 . . . . 0.0 106.641 -179.682 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.3 mt -118.25 119.09 33.63 Favored 'General case' 0 C--N 1.274 -2.713 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 177.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.497 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 37.3 p -116.49 136.85 52.64 Favored 'General case' 0 C--N 1.273 -2.759 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.551 -174.676 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.0 17.99 56.8 Favored Glycine 0 N--CA 1.429 -1.792 0 C-N-CA 119.593 -1.289 . . . . 0.0 111.107 -178.84 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 173.72 -31.85 0.1 Allowed Glycine 0 N--CA 1.436 -1.36 0 C-N-CA 119.229 -1.462 . . . . 0.0 113.596 -179.206 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 6.6 t30 66.28 9.73 6.61 Favored 'General case' 0 CA--C 1.556 1.175 0 CA-C-O 122.09 0.948 . . . . 0.0 111.728 -178.835 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.506 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.3 m -142.75 -168.92 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.459 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 -177.46 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -108.51 36.54 2.79 Favored 'General case' 0 C--O 1.25 1.092 0 CA-C-N 119.29 0.95 . . . . 0.0 110.796 -176.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.722 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.3 pt-20 -79.0 177.68 8.61 Favored 'General case' 0 C--O 1.195 -1.765 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.159 179.107 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' TYR . . . . . 0.462 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 48.2 m-85 -72.98 130.76 41.08 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 120.858 0.361 . . . . 0.0 111.641 178.771 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.42 -0.55 63.61 Favored Glycine 0 N--CA 1.437 -1.248 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.997 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.722 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.4 p -90.28 145.67 7.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.497 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 16.4 mtpp -109.75 127.18 54.45 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.745 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -88.76 85.19 6.72 Favored 'General case' 0 C--N 1.284 -2.272 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 175.467 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.484 HG12 ' CB ' ' A' ' 126' ' ' TYR . 29.4 m -87.07 114.64 26.52 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 CA-C-O 122.568 1.175 . . . . 0.0 109.461 -179.108 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' TYR . . . . . 0.412 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 31.4 m-85 -77.99 144.86 36.37 Favored 'General case' 0 C--N 1.27 -2.853 0 CA-C-N 115.098 -0.955 . . . . 0.0 110.833 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.2 t -142.02 118.08 10.64 Favored 'General case' 0 N--CA 1.413 -2.29 0 N-CA-C 107.108 -1.442 . . . . 0.0 107.108 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 38.0 m -75.34 158.51 32.69 Favored 'General case' 0 C--N 1.279 -2.479 0 O-C-N 121.992 -0.443 . . . . 0.0 110.651 -175.459 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -77.65 -179.09 5.68 Favored 'General case' 0 CA--C 1.495 -1.151 0 C-N-CA 119.993 -0.683 . . . . 0.0 111.05 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -52.12 -52.73 49.71 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 124.099 0.874 . . . . 0.0 112.323 -176.306 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.481 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -83.94 25.29 5.41 Favored Glycine 0 C--N 1.304 -1.219 0 C-N-CA 120.625 -0.798 . . . . 0.0 113.831 -178.29 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.656 ' HE1' HG22 ' A' ' 143' ' ' VAL . 87.6 m-85 -144.31 152.01 40.16 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 122.268 -0.548 . . . . 0.0 110.08 -176.665 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -126.78 162.05 26.76 Favored 'General case' 0 C--N 1.276 -2.613 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 -179.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 3.1 tt -93.06 128.24 38.88 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.07 -178.64 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -111.5 126.03 54.53 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 -177.364 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 113.52 164.79 15.76 Favored Glycine 0 C--N 1.286 -2.228 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -175.9 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 13.6 mm-40 -91.97 -31.48 15.6 Favored 'General case' 0 C--N 1.3 -1.543 0 CA-C-O 121.987 0.899 . . . . 0.0 109.382 -177.798 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.522 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.0 mm -82.57 127.47 39.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 178.328 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.42 2.8 9.69 Favored 'General case' 0 C--O 1.204 -1.339 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -177.221 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.484 ' CB ' HG12 ' A' ' 111' ' ' VAL . 10.8 p90 -143.54 164.08 31.36 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 120.506 -0.478 . . . . 0.0 109.817 -170.323 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -131.12 132.27 44.7 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 171.544 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -106.0 133.23 51.05 Favored 'General case' 0 C--N 1.284 -2.257 0 C-N-CA 118.533 -1.267 . . . . 0.0 110.773 -178.339 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' CYS . . . . . 0.462 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 39.7 t -75.72 96.88 3.7 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.29 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.439 ' OD1' HG22 ' A' ' 131' ' ' THR . 8.0 t70 -94.26 -175.05 3.54 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 178.314 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.454 ' HA ' ' CE1' ' A' ' 106' ' ' TYR . 13.9 t -68.28 -23.4 64.75 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-O 121.898 0.856 . . . . 0.0 109.889 -176.56 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -77.59 -39.06 46.87 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.613 177.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.455 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 145.21 -159.47 27.89 Favored Glycine 0 N--CA 1.421 -2.355 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -174.645 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 98.1 m95 -67.98 122.48 18.31 Favored 'General case' 0 C--N 1.309 -1.193 0 CA-C-N 117.639 0.719 . . . . 0.0 110.517 178.582 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 76.2 p -76.63 170.76 15.83 Favored 'General case' 0 C--O 1.265 1.885 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.132 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 74.4 m-20 61.91 -165.34 0.23 Allowed 'General case' 0 C--O 1.246 0.894 0 O-C-N 123.951 0.782 . . . . 0.0 111.474 174.689 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -122.53 168.83 11.66 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 80.6 mt -67.54 119.63 67.14 Favored Pre-proline 0 C--N 1.307 -1.252 0 O-C-N 123.247 0.342 . . . . 0.0 110.089 176.456 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.522 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 33.9 Cg_endo -65.99 150.09 85.69 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 122.733 2.288 . . . . 0.0 110.527 177.317 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 61.8 mt -96.46 130.27 45.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-O 121.106 0.479 . . . . 0.0 111.034 -174.024 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.483 ' HB2' ' HB2' ' A' ' 93' ' ' PHE . 93.1 m -99.38 107.69 20.01 Favored 'General case' 0 C--N 1.284 -2.273 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 172.08 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -91.96 154.41 18.83 Favored 'General case' 0 N--CA 1.412 -2.362 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 177.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.656 HG22 ' HE1' ' A' ' 118' ' ' TYR . 4.5 t -80.02 141.36 15.39 Favored 'Isoleucine or valine' 0 C--N 1.256 -3.494 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -175.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.555 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 15.9 m -68.4 100.12 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-O 121.85 0.833 . . . . 0.0 109.987 -178.837 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.448 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 94.9 mttt -100.69 136.56 40.36 Favored 'General case' 0 N--CA 1.421 -1.879 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.053 -174.841 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 60.6 m -98.96 167.87 10.46 Favored 'General case' 0 C--N 1.291 -1.955 0 CA-C-N 114.321 -1.309 . . . . 0.0 109.056 -177.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 2.2 pp -79.73 154.92 75.96 Favored Pre-proline 0 N--CA 1.427 -1.612 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 178.239 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -79.64 118.82 3.92 Favored 'Trans proline' 0 N--CA 1.441 -1.564 0 C-N-CA 122.46 2.106 . . . . 0.0 111.719 -177.051 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.0 t -67.65 144.61 14.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.733 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.1 p -77.17 -83.54 0.07 Allowed 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 119.644 -0.217 . . . . 0.0 111.496 176.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 173.51 162.69 0.3 Allowed Pre-proline 0 N--CA 1.473 0.715 0 C-N-CA 125.171 1.388 . . . . 0.0 108.361 178.162 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' PRO . . . . . 0.46 ' HB3' ' HA ' ' A' ' 204' ' ' LYS . 72.6 Cg_endo -84.04 166.46 12.9 Favored 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 122.361 2.041 . . . . 0.0 110.997 170.878 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -72.11 -62.56 1.39 Allowed 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 114.099 1.148 . . . . 0.0 114.099 -176.333 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 154' ' ' ASN . . . . . 0.422 ' HB2' ' O ' ' A' ' 205' ' ' CYS . 43.7 m-80 -97.24 31.35 2.49 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 121.943 0.878 . . . . 0.0 110.075 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -150.87 -169.99 17.36 Favored Glycine 0 N--CA 1.422 -2.274 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.59 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' LYS . . . . . 0.458 ' HG3' HG23 ' A' ' 177' ' ' VAL . 21.9 pttm -151.84 171.62 17.47 Favored 'General case' 0 C--N 1.289 -2.034 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.249 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 54.3 mt -90.87 135.09 27.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-O 120.951 0.405 . . . . 0.0 111.415 -178.788 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.474 ' CG2' HG22 ' A' ' 177' ' ' VAL . 57.0 t -70.83 -50.03 46.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 C-N-CA 124.214 1.006 . . . . 0.0 108.468 177.065 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 1.7 m . . . . . 0 C--N 1.303 -1.432 0 C-N-CA 124.558 1.143 . . . . 0.0 111.018 -176.513 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 168' ' ' TYR . . . . . 0.448 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 74.4 m-85 . . . . . 0 C--O 1.2 -1.516 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.486 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 44.6 p-80 -153.21 171.44 18.51 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-O 118.675 -0.678 . . . . 0.0 109.19 -172.641 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.555 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 62.0 t80 -50.77 133.2 26.39 Favored 'General case' 0 C--O 1.239 0.528 0 O-C-N 123.732 0.645 . . . . 0.0 110.512 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 106.06 -26.99 18.91 Favored Glycine 0 N--CA 1.434 -1.48 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -177.369 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 172' ' ' GLN . . . . . 0.406 ' HG3' ' H ' ' A' ' 169' ' ' HIS . 19.7 mm-40 -76.12 140.43 41.8 Favored 'General case' 0 CA--C 1.503 -0.838 0 CA-C-O 121.629 0.728 . . . . 0.0 110.413 178.727 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.426 ' HB2' ' CD2' ' A' ' 191' ' ' HIS . . . -129.62 119.91 24.37 Favored 'General case' 0 C--N 1.279 -2.495 0 CA-C-N 114.139 -1.391 . . . . 0.0 107.315 176.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.495 HG23 ' CH2' ' A' ' 198' ' ' TRP . 68.1 t -93.65 108.38 20.45 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.992 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 176.021 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.451 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 76.2 ttt180 -103.24 156.29 17.82 Favored 'General case' 0 N--CA 1.409 -2.479 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -127.96 153.15 47.04 Favored 'General case' 0 C--N 1.291 -1.972 0 C-N-CA 123.179 0.591 . . . . 0.0 110.158 -170.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.474 HG22 ' CG2' ' A' ' 158' ' ' VAL . 0.1 OUTLIER -127.91 141.15 47.22 Favored 'Isoleucine or valine' 0 CA--C 1.467 -2.212 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.262 179.04 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 72.1 m -95.96 132.75 40.96 Favored 'General case' 0 N--CA 1.389 -3.487 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.08 176.238 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 -67.12 170.03 7.59 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 113.985 -1.462 . . . . 0.0 109.711 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.3 m -49.84 109.47 0.29 Allowed 'General case' 0 C--N 1.297 -1.7 0 O-C-N 124.394 1.059 . . . . 0.0 113.463 -174.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 97.16 18.21 29.68 Favored Glycine 0 N--CA 1.433 -1.527 0 CA-C-N 115.234 -0.894 . . . . 0.0 114.633 174.735 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -128.53 164.9 21.8 Favored 'General case' 0 C--O 1.241 0.645 0 CA-C-N 118.457 1.128 . . . . 0.0 112.572 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.503 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 56.7 pttt -122.12 154.84 36.86 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 106.741 -1.578 . . . . 0.0 106.741 178.77 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 5.4 tp -72.67 145.9 11.5 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 174.453 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -70.4 -69.73 0.34 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 120.983 0.421 . . . . 0.0 110.108 -177.066 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -109.65 -82.76 1.39 Allowed Glycine 0 N--CA 1.431 -1.66 0 C-N-CA 120.24 -0.981 . . . . 0.0 111.851 178.824 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -113.99 151.81 31.85 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -177.586 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.451 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 8.9 pt-20 -109.82 9.71 24.64 Favored 'General case' 0 C--N 1.3 -1.587 0 CA-C-N 118.448 0.567 . . . . 0.0 110.708 -179.333 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -148.73 130.35 14.96 Favored 'General case' 0 C--N 1.295 -1.788 0 CA-C-O 122.012 0.911 . . . . 0.0 113.315 -178.822 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.424 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 16.5 ptp -121.46 144.72 48.53 Favored 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.21 178.003 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 191' ' ' HIS . . . . . 0.426 ' CD2' ' HB2' ' A' ' 173' ' ' ALA . 34.5 m80 -117.25 147.77 42.24 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 120.469 0.176 . . . . 0.0 111.032 -179.411 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 4.9 m -76.17 115.92 16.37 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.475 172.61 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 193' ' ' SER . . . . . 0.516 ' HB2' ' OD1' ' A' ' 195' ' ' ASP . 13.0 m -85.55 177.19 7.83 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.458 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -76.85 3.43 12.0 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 121.348 0.595 . . . . 0.0 112.272 -176.254 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 195' ' ' ASP . . . . . 0.516 ' OD1' ' HB2' ' A' ' 193' ' ' SER . 43.4 p-10 -92.61 -15.68 26.56 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 123.267 0.627 . . . . 0.0 109.755 177.077 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 90.93 19.47 43.14 Favored Glycine 0 N--CA 1.432 -1.603 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.586 -178.746 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -128.47 168.94 14.92 Favored 'General case' 0 C--N 1.314 -0.96 0 O-C-N 122.152 -0.617 . . . . 0.0 111.458 178.838 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 198' ' ' TRP . . . . . 0.495 ' CH2' HG23 ' A' ' 174' ' ' VAL . 85.9 m95 -82.46 131.03 35.22 Favored 'General case' 0 N--CA 1.436 -1.172 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.646 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 31.0 p -62.53 -29.66 70.72 Favored 'General case' 0 C--N 1.312 -1.025 0 C-N-CA 124.579 1.152 . . . . 0.0 113.108 -177.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 3.1 tppp? -126.17 158.18 36.25 Favored 'General case' 0 N--CA 1.432 -1.329 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -81.12 174.24 11.78 Favored 'General case' 0 C--N 1.312 -1.041 0 O-C-N 123.318 0.386 . . . . 0.0 110.033 -178.466 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 202' ' ' LYS . . . . . 0.418 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 37.5 mtpt -70.0 121.35 82.61 Favored Pre-proline 0 N--CA 1.438 -1.064 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.301 176.851 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -89.08 -162.36 0.13 Allowed 'Trans proline' 0 N--CA 1.431 -2.153 0 C-N-CA 122.388 2.059 . . . . 0.0 109.44 173.642 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 204' ' ' LYS . . . . . 0.46 ' HA ' ' HB3' ' A' ' 152' ' ' PRO . 18.0 ptpt -166.39 174.09 9.36 Favored 'General case' 0 N--CA 1.416 -2.141 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.504 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 80.7 m -114.03 128.89 56.58 Favored 'General case' 0 C--N 1.276 -2.607 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 177.727 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.8 m . . . . . 0 C--N 1.28 -2.432 0 O-C-N 124.49 1.118 . . . . 0.0 108.542 -172.642 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 39.7 Cg_endo . . . . . 0 CA--C 1.54 0.804 0 CA-C-O 121.245 0.435 . . . . 0.0 111.977 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 61.3 m -90.07 -32.5 16.68 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 122.148 0.975 . . . . 0.0 108.654 176.168 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 111.82 -83.84 0.34 Allowed Glycine 0 CA--C 1.455 -3.715 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 171.043 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 63.3 t-80 -179.83 130.83 0.25 Allowed Pre-proline 0 C--N 1.267 -2.979 0 N-CA-C 104.928 -2.249 . . . . 0.0 104.928 -175.848 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.416 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 88.1 Cg_endo -84.12 1.48 8.74 Favored 'Trans proline' 0 N--CA 1.485 1.008 0 C-N-CA 122.677 2.251 . . . . 0.0 113.915 -172.797 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 94.19 179.75 38.25 Favored Glycine 0 N--CA 1.429 -1.831 0 N-CA-C 108.492 -1.843 . . . . 0.0 108.492 -173.112 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -140.7 -179.66 6.17 Favored 'General case' 0 C--N 1.29 -2.005 0 CA-C-N 117.628 0.714 . . . . 0.0 109.767 -178.178 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.0 t -126.53 138.47 32.49 Favored Pre-proline 0 C--N 1.307 -1.245 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -77.34 -20.89 12.2 Favored 'Trans proline' 0 CA--C 1.534 0.514 0 C-N-CA 122.537 2.158 . . . . 0.0 112.255 -179.097 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.402 ' O ' ' HB2' ' A' ' 115' ' ' ASN . 59.0 m-85 -80.82 -50.4 9.87 Favored 'General case' 0 CA--C 1.5 -0.967 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.477 -176.287 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -122.49 -136.45 4.89 Favored Glycine 0 N--CA 1.421 -2.338 0 C-N-CA 120.558 -0.829 . . . . 0.0 111.115 -178.626 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.7 p -148.21 -172.51 4.09 Favored 'General case' 0 C--N 1.294 -1.813 0 C-N-CA 123.594 0.758 . . . . 0.0 109.073 -178.521 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 38.5 p90 -145.01 163.76 33.23 Favored 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 120.381 -0.528 . . . . 0.0 109.984 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.6 m -135.75 158.91 43.22 Favored 'General case' 0 C--N 1.288 -2.084 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 178.578 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.423 HD11 ' CE1' ' A' ' 104' ' ' PHE . 18.1 mt -110.18 122.05 46.71 Favored 'General case' 0 C--N 1.28 -2.414 0 CA-C-O 120.94 0.4 . . . . 0.0 110.384 -178.029 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 19.2 p -114.43 136.27 53.19 Favored 'General case' 0 C--N 1.286 -2.162 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.924 -176.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 95.78 11.74 54.52 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 120.035 -1.078 . . . . 0.0 112.174 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 171.59 -23.96 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 119.274 -1.441 . . . . 0.0 113.818 -178.841 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 65.4 17.3 10.92 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 179.191 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.498 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.3 m -148.97 -176.23 0.41 Allowed 'Isoleucine or valine' 0 C--O 1.205 -1.242 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -175.726 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.423 ' CE1' HD11 ' A' ' 98' ' ' LEU . 41.2 m-85 -102.84 47.32 0.89 Allowed 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 118.299 0.5 . . . . 0.0 110.401 -179.452 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.712 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.8 pt-20 -88.44 179.54 6.29 Favored 'General case' 0 C--O 1.207 -1.147 0 CA-C-N 115.477 -0.783 . . . . 0.0 111.092 177.467 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -79.36 135.76 36.8 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.075 176.843 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.52 1.3 62.27 Favored Glycine 0 N--CA 1.434 -1.449 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.832 -179.262 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.712 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.5 p -97.54 150.67 4.53 Favored 'Isoleucine or valine' 0 C--O 1.246 0.908 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 14.6 mtpp -113.82 127.87 56.18 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -179.698 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -90.34 93.05 9.17 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 175.773 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 44.0 t -88.19 114.95 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.662 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.063 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.1 m-85 -85.15 133.48 34.2 Favored 'General case' 0 C--N 1.284 -2.246 0 CA-C-N 115.496 -0.775 . . . . 0.0 109.632 179.582 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.8 t -125.82 127.43 46.08 Favored 'General case' 0 N--CA 1.409 -2.508 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -177.85 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 79.6 m -75.32 159.99 30.83 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.402 ' HB2' ' O ' ' A' ' 93' ' ' PHE . 6.7 t-20 -69.53 -175.84 0.9 Allowed 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 114.053 -1.431 . . . . 0.0 109.487 178.148 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -67.1 -44.38 80.11 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 120.998 0.427 . . . . 0.0 111.081 -179.555 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.21 8.12 68.8 Favored Glycine 0 C--N 1.31 -0.878 0 CA-C-N 115.965 -0.561 . . . . 0.0 113.14 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.664 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 70.7 m-85 -127.95 160.64 31.26 Favored 'General case' 0 C--N 1.311 -1.073 0 O-C-N 122.534 -0.392 . . . . 0.0 110.955 178.798 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.33 144.26 30.62 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -178.769 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -75.6 126.95 32.01 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -174.657 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -110.79 130.92 55.44 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 -177.391 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.02 174.81 20.18 Favored Glycine 0 C--N 1.301 -1.408 0 N-CA-C 111.528 -0.629 . . . . 0.0 111.528 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -83.31 -36.22 24.62 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.416 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 49.5 mm -87.97 125.0 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.862 0 CA-C-N 113.977 -1.465 . . . . 0.0 109.247 -175.833 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -127.54 3.96 6.19 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.369 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.414 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 17.9 p90 -144.05 165.11 28.7 Favored 'General case' 0 N--CA 1.422 -1.848 0 C-N-CA 119.901 -0.72 . . . . 0.0 110.757 -171.745 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.416 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 45.9 mtp180 -126.19 132.79 51.71 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 173.093 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -108.76 134.15 51.86 Favored 'General case' 0 C--N 1.277 -2.586 0 C-N-CA 119.464 -0.895 . . . . 0.0 108.864 -177.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 17.5 t -85.74 99.96 11.69 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 118.292 -1.363 . . . . 0.0 109.403 177.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.448 ' OD2' HG22 ' A' ' 131' ' ' THR . 8.5 t70 -104.32 -167.84 1.41 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 177.123 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.448 HG22 ' OD2' ' A' ' 130' ' ' ASP . 9.6 t -65.14 -15.87 62.88 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 119.048 0.84 . . . . 0.0 111.633 -177.072 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -81.79 -13.49 57.64 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.697 0.76 . . . . 0.0 109.839 176.104 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 102.49 -157.46 18.24 Favored Glycine 0 N--CA 1.428 -1.847 0 N-CA-C 107.522 -2.231 . . . . 0.0 107.522 -174.445 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.411 ' CD2' ' HB3' ' A' ' 88' ' ' PRO . 94.6 m95 -62.28 106.64 0.77 Allowed 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 117.714 0.757 . . . . 0.0 110.405 173.766 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 62.3 p -71.8 171.48 11.57 Favored 'General case' 0 C--O 1.269 2.086 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.192 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 1.8 m-20 62.87 -158.57 0.32 Allowed 'General case' 0 C--O 1.245 0.83 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.029 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 29.0 t0 -141.11 173.03 11.87 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 173.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 70.1 mt -59.36 121.71 58.46 Favored Pre-proline 0 C--N 1.269 -2.915 0 C-N-CA 125.14 1.376 . . . . 0.0 108.352 175.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.416 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 38.2 Cg_endo -64.78 178.32 1.85 Allowed 'Trans proline' 0 C--O 1.251 1.17 0 C-N-CA 123.097 2.531 . . . . 0.0 113.614 -176.628 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 63.5 mt -98.37 129.52 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.066 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.69 -176.094 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.614 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 33.6 t -114.69 107.12 15.04 Favored 'General case' 0 C--N 1.273 -2.735 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 178.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -99.35 152.1 20.33 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-O 121.625 0.726 . . . . 0.0 110.933 -176.105 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.664 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 3.3 t -73.1 136.52 25.32 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.049 0 CA-C-N 113.902 -1.499 . . . . 0.0 108.609 -179.703 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.87 125.02 20.9 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.097 0 O-C-N 124.957 1.411 . . . . 0.0 108.064 177.052 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.522 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 45.6 mttp -122.9 162.62 21.88 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.382 -174.863 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 57.0 m -124.58 168.34 13.26 Favored 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 114.309 -1.314 . . . . 0.0 107.734 175.036 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 71.5 mt -74.73 143.59 78.76 Favored Pre-proline 0 C--N 1.307 -1.244 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -179.387 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.444 ' HA ' ' CE2' ' A' ' 168' ' ' TYR . 17.5 Cg_endo -62.73 122.36 10.65 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.945 2.43 . . . . 0.0 110.761 178.283 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 48.0 t -91.81 142.02 13.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.005 -175.87 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 21.0 p -79.95 -82.67 0.11 Allowed 'General case' 0 N--CA 1.43 -1.47 0 CA-C-N 116.727 -0.215 . . . . 0.0 110.907 176.79 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.49 165.7 0.45 Allowed Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 124.051 0.94 . . . . 0.0 108.724 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' PRO . . . . . 0.521 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 55.6 Cg_endo -76.57 160.93 34.63 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.024 1.816 . . . . 0.0 109.742 167.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -53.3 -50.77 64.21 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 114.287 1.218 . . . . 0.0 114.287 -175.055 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -113.3 38.06 2.99 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.342 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -154.78 -167.43 16.56 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.918 -1.134 . . . . 0.0 112.53 177.633 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -153.04 170.24 20.95 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 -177.347 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.457 HG22 ' H ' ' A' ' 159' ' ' SER . 73.3 mt -86.02 137.67 20.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 177.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.52 HG21 ' HB3' ' A' ' 175' ' ' ARG . 14.5 m -69.11 -32.68 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-O 121.597 0.713 . . . . 0.0 110.872 -177.766 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 159' ' ' SER . . . . . 0.457 ' H ' HG22 ' A' ' 157' ' ' ILE . 24.3 t . . . . . 0 N--CA 1.424 -1.741 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -178.099 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 168' ' ' TYR . . . . . 0.489 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 67.4 m-85 . . . . . 0 CA--C 1.506 -0.736 0 CA-C-O 120.861 0.363 . . . . 0.0 110.628 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 28.1 m80 -98.02 161.45 13.72 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.534 -173.765 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -58.0 135.69 56.99 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.868 172.525 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 103.5 -18.26 48.39 Favored Glycine 0 N--CA 1.429 -1.803 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.62 -179.292 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.9 tp60 -76.96 128.83 35.24 Favored 'General case' 0 N--CA 1.398 -3.037 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -110.6 131.14 55.31 Favored 'General case' 0 N--CA 1.418 -2.027 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 172.468 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 55.5 t -107.87 99.56 8.88 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.32 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.52 ' HB3' HG21 ' A' ' 158' ' ' VAL . 41.7 ttm180 -89.76 144.09 26.26 Favored 'General case' 0 N--CA 1.42 -1.928 0 CA-C-N 115.043 -0.981 . . . . 0.0 109.025 178.124 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.521 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 78.1 m-85 -113.93 160.42 18.82 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -178.171 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.9 p -139.53 150.45 22.52 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.057 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 63.9 m -109.7 157.64 18.9 Favored 'General case' 0 C--N 1.287 -2.123 0 O-C-N 123.39 0.431 . . . . 0.0 111.602 -175.692 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -78.41 170.7 16.21 Favored 'General case' 0 N--CA 1.439 -1.018 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.534 179.284 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 23.1 t -49.64 105.93 0.1 Allowed 'General case' 0 C--N 1.313 -1.013 0 C-N-CA 124.88 1.272 . . . . 0.0 112.918 -175.261 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 111.74 -15.08 26.75 Favored Glycine 0 N--CA 1.43 -1.719 0 CA-C-N 115.285 -0.87 . . . . 0.0 113.252 175.328 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 182' ' ' TYR . . . . . 0.462 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 93.5 m-85 -103.84 159.84 15.3 Favored 'General case' 0 N--CA 1.433 -1.323 0 CA-C-N 117.783 0.791 . . . . 0.0 111.353 -176.858 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 53.4 pttt -135.04 155.7 50.3 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 175.792 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.479 HD13 ' HA ' ' A' ' 188' ' ' GLU . 12.5 tt -81.95 141.98 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.57 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.568 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -66.16 -79.02 0.05 OUTLIER 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 114.283 1.216 . . . . 0.0 114.283 -171.631 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -83.64 -92.87 0.67 Allowed Glycine 0 CA--C 1.496 -1.135 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.183 -175.756 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -94.32 173.71 7.5 Favored 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.479 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.7 pt-20 -122.82 4.83 9.43 Favored 'General case' 0 N--CA 1.438 -1.029 0 C-N-CA 120.613 -0.435 . . . . 0.0 110.205 178.074 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 189' ' ' GLU . . . . . 0.471 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 7.1 pt-20 -163.46 120.02 1.77 Allowed 'General case' 0 N--CA 1.432 -1.345 0 CA-C-O 121.943 0.877 . . . . 0.0 112.144 -175.013 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 12.8 ptp -100.53 132.12 46.08 Favored 'General case' 0 C--N 1.281 -2.41 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.501 177.648 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 23.8 t-80 -107.24 143.46 35.43 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.918 -177.89 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 2.5 m -70.21 116.79 10.97 Favored 'General case' 0 CA--C 1.5 -0.946 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.944 172.546 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 2.6 m -83.39 151.73 25.37 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.632 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -67.75 -8.92 39.53 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 121.17 0.51 . . . . 0.0 112.362 -175.079 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 195' ' ' ASP . . . . . 0.421 ' HB3' ' CE1' ' A' ' 197' ' ' PHE . 26.0 t70 -82.87 -16.81 46.11 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-O 121.279 0.562 . . . . 0.0 110.638 177.464 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 99.78 38.62 3.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.669 -0.777 . . . . 0.0 113.724 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 197' ' ' PHE . . . . . 0.421 ' CE1' ' HB3' ' A' ' 195' ' ' ASP . 44.7 p90 -149.08 156.18 41.83 Favored 'General case' 0 C--O 1.249 1.04 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.707 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 83.4 m95 -72.79 128.33 35.2 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 175.713 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.0 m -51.74 -36.65 47.89 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.047 0.539 . . . . 0.0 111.621 -178.666 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 28.3 mmtp -116.24 163.79 15.47 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.463 177.408 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -88.18 162.57 16.62 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.652 178.822 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 202' ' ' LYS . . . . . 0.442 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 0.2 OUTLIER -57.55 105.09 0.48 Allowed Pre-proline 0 CA--C 1.57 1.731 0 C-N-CA 125.667 1.587 . . . . 0.0 112.758 -176.548 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 203' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 5.3 Cg_endo -89.0 170.89 4.88 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 124.005 3.136 . . . . 0.0 113.671 -176.708 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 20.1 pttm -135.06 162.21 33.13 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.046 -176.462 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.462 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 83.2 m -100.72 119.43 38.59 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 124.264 0.978 . . . . 0.0 108.537 177.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 25.5 m . . . . . 0 C--N 1.287 -2.128 0 O-C-N 124.441 1.088 . . . . 0.0 109.776 -174.188 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 18.4 Cg_endo . . . . . 0 CA--C 1.543 0.938 0 CA-C-O 121.4 0.5 . . . . 0.0 111.882 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' CYS . . . . . 0.484 ' HB3' ' NE1' ' A' ' 134' ' ' TRP . 23.6 m -89.42 -27.3 20.49 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.035 0.445 . . . . 0.0 111.606 176.303 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.62 -83.14 0.32 Allowed Glycine 0 CA--C 1.456 -3.652 0 C-N-CA 120.292 -0.956 . . . . 0.0 111.249 170.405 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -175.66 129.21 0.39 Allowed Pre-proline 0 C--N 1.269 -2.934 0 N-CA-C 106.498 -1.667 . . . . 0.0 106.498 -176.002 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -82.81 7.97 4.86 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 123.231 2.62 . . . . 0.0 114.476 -171.828 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 120.69 164.92 12.59 Favored Glycine 0 C--N 1.292 -1.881 0 N-CA-C 108.316 -1.914 . . . . 0.0 108.316 -175.477 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -145.82 111.93 5.7 Favored 'General case' 0 C--N 1.293 -1.859 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -177.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 8.2 t -98.92 140.65 21.89 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -172.583 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -85.38 -9.02 8.42 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.853 2.369 . . . . 0.0 111.548 173.851 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -94.81 16.41 15.95 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.251 0.548 . . . . 0.0 110.593 -176.149 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 156.43 -121.95 1.14 Allowed Glycine 0 N--CA 1.41 -3.072 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 t -171.85 -160.33 0.16 Allowed 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.652 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -149.94 164.82 34.43 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.364 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.8 m -125.33 160.76 28.55 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 178.268 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.0 mt -119.71 131.82 55.49 Favored 'General case' 0 C--N 1.277 -2.578 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -179.023 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 38.9 p -126.21 131.28 52.0 Favored 'General case' 0 C--N 1.286 -2.178 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -177.787 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 87.71 24.98 33.88 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.503 -0.856 . . . . 0.0 111.68 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 176.1 -37.8 0.1 OUTLIER Glycine 0 N--CA 1.434 -1.447 0 C-N-CA 119.93 -1.129 . . . . 0.0 112.799 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 67.39 11.36 8.34 Favored 'General case' 0 N--CA 1.498 1.925 0 C-N-CA 124.354 1.062 . . . . 0.0 109.694 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.504 ' O ' HG11 ' A' ' 108' ' ' VAL . 25.1 m -150.56 -168.38 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.085 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 -177.539 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 24.4 m-85 -104.75 38.25 1.95 Allowed 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 118.347 0.521 . . . . 0.0 110.788 -175.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.702 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.2 pt-20 -79.19 173.81 12.2 Favored 'General case' 0 C--O 1.195 -1.763 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.782 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' TYR . . . . . 0.492 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 41.8 m-85 -72.44 133.14 44.71 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.975 178.668 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.34 -0.1 71.09 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 115.739 -0.664 . . . . 0.0 113.064 178.293 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.702 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.5 p -89.45 148.77 4.31 Favored 'Isoleucine or valine' 0 C--O 1.243 0.763 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.753 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -112.16 131.52 55.42 Favored 'General case' 0 C--N 1.283 -2.295 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.362 177.657 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.494 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -94.96 94.93 8.3 Favored 'General case' 0 C--N 1.285 -2.213 0 CA-C-N 115.382 -0.826 . . . . 0.0 108.791 176.411 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 91.8 t -86.54 106.84 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.812 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' TYR . . . . . 0.499 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 18.4 t80 -74.14 138.19 43.7 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 123.495 0.718 . . . . 0.0 109.19 -177.559 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.2 t -142.07 114.68 8.48 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.097 0.951 . . . . 0.0 110.09 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 73.6 m -71.35 163.19 28.16 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 115.374 -0.83 . . . . 0.0 112.193 -179.382 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -73.42 -175.04 1.82 Allowed 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.862 178.836 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -62.13 -45.93 91.25 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-O 121.228 0.537 . . . . 0.0 111.748 -177.324 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -79.82 4.32 66.0 Favored Glycine 0 C--N 1.313 -0.716 0 CA-C-N 115.879 -0.601 . . . . 0.0 114.285 -179.093 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.408 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.1 m-85 -129.77 166.25 20.27 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 -177.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 7.8 pt20 -150.49 160.87 43.47 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -77.59 133.94 38.34 Favored 'General case' 0 N--CA 1.424 -1.774 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.511 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -120.89 132.12 54.78 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 177.683 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 112.1 -170.14 13.44 Favored Glycine 0 N--CA 1.43 -1.76 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -178.746 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -100.77 -37.34 8.75 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.532 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 49.3 mm -80.97 125.53 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.071 0 CA-C-N 114.865 -1.061 . . . . 0.0 110.284 -177.848 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.407 ' HA ' ' HB3' ' A' ' 139' ' ' PRO . 10.4 p30 -132.03 11.05 4.64 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.499 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.494 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 24.3 p90 -142.88 161.09 39.02 Favored 'General case' 0 C--N 1.312 -1.058 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -178.364 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 54.8 mtp180 -129.88 138.02 50.72 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 172.196 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -109.07 128.56 55.09 Favored 'General case' 0 C--N 1.281 -2.403 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.552 -178.651 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' CYS . . . . . 0.492 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 38.9 t -76.84 96.06 4.21 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.033 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.414 ' OD2' HG22 ' A' ' 131' ' ' THR . 11.2 t70 -103.12 -171.6 1.97 Allowed 'General case' 0 N--CA 1.426 -1.65 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 179.181 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.414 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.8 t -69.48 -20.35 63.74 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.054 0.454 . . . . 0.0 111.873 -173.05 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -82.02 -25.37 34.72 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 121.516 0.674 . . . . 0.0 109.5 175.171 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 130.11 -154.37 20.52 Favored Glycine 0 N--CA 1.422 -2.254 0 N-CA-C 108.291 -1.923 . . . . 0.0 108.291 -174.377 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.484 ' NE1' ' HB3' ' A' ' 85' ' ' CYS . 98.5 m95 -68.93 118.7 12.18 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 117.519 0.66 . . . . 0.0 110.977 178.572 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 75.7 p -70.42 166.16 20.97 Favored 'General case' 0 C--O 1.277 2.552 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 175.621 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 60.81 -162.94 0.26 Allowed 'General case' 0 C--O 1.246 0.896 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -129.72 -176.02 3.78 Favored 'General case' 0 C--N 1.283 -2.298 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 173.39 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 75.1 mt -63.42 117.8 37.76 Favored Pre-proline 0 C--N 1.278 -2.519 0 C-N-CA 124.219 1.008 . . . . 0.0 108.289 176.686 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.532 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 24.0 Cg_exo -55.7 158.36 13.67 Favored 'Trans proline' 0 C--O 1.251 1.172 0 C-N-CA 122.346 2.031 . . . . 0.0 111.904 178.903 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.511 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 46.6 mm -87.76 134.24 28.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 C-N-CA 120.192 -0.603 . . . . 0.0 109.885 -172.048 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.408 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 12.3 t -118.75 112.11 19.34 Favored 'General case' 0 C--N 1.28 -2.445 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.638 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -108.86 155.66 20.56 Favored 'General case' 0 C--N 1.278 -2.542 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -178.575 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.6 p -75.8 140.01 18.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 176.781 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.499 ' HB ' ' HB2' ' A' ' 170' ' ' PHE . 71.3 t -60.21 130.78 24.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 179.341 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -118.6 136.88 53.63 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -178.416 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 77.1 m -97.21 160.58 14.25 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.052 -177.638 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' LEU . . . . . 0.543 HD12 ' HD2' ' A' ' 148' ' ' PRO . 15.0 tp -71.75 125.91 91.58 Favored Pre-proline 0 N--CA 1.384 -3.725 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -178.0 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.543 ' HD2' HD12 ' A' ' 147' ' ' LEU . 14.2 Cg_endo -58.34 131.29 42.06 Favored 'Trans proline' 0 C--O 1.24 0.585 0 C-N-CA 123.839 3.026 . . . . 0.0 113.025 -176.091 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.7 t -93.51 139.59 17.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.0 p -74.98 -76.89 0.13 Allowed 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 111.657 0.243 . . . . 0.0 111.657 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.56 158.38 0.21 Allowed Pre-proline 0 CA--C 1.508 -0.665 0 N-CA-C 106.703 -1.592 . . . . 0.0 106.703 178.109 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -77.56 167.46 24.21 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 121.388 1.392 . . . . 0.0 109.33 171.597 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' GLU . . . . . 0.507 ' OE1' ' HG3' ' A' ' 204' ' ' LYS . 0.1 OUTLIER -74.68 -46.83 35.32 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -173.109 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 154' ' ' ASN . . . . . 0.456 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 55.2 m-80 -106.45 23.76 13.66 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.766 0.793 . . . . 0.0 110.748 -177.682 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -145.07 -157.43 7.23 Favored Glycine 0 N--CA 1.421 -2.337 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.826 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 21.4 pttp -157.78 169.58 24.3 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 43.3 mt -95.94 124.87 48.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 CA-C-O 121.4 0.619 . . . . 0.0 111.199 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.4 ' CG2' HG22 ' A' ' 177' ' ' VAL . 80.7 t -67.64 -46.29 83.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 C-N-CA 124.486 1.114 . . . . 0.0 109.661 179.385 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 14.9 m . . . . . 0 C--N 1.311 -1.093 0 N-CA-C 114.017 1.117 . . . . 0.0 114.017 -173.977 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 . . . . . 0 N--CA 1.441 -0.894 0 CA-C-O 121.983 0.897 . . . . 0.0 110.58 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 51.4 m170 -88.1 155.73 19.64 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.268 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.499 ' HB2' ' HB ' ' A' ' 144' ' ' VAL . 52.9 t80 -54.35 113.51 1.3 Allowed 'General case' 0 CA--C 1.509 -0.602 0 CA-C-O 121.484 0.659 . . . . 0.0 110.15 176.904 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 171' ' ' GLY . . . . . 0.417 ' H ' ' HB2' ' A' ' 192' ' ' CYS . . . 132.44 -25.33 3.83 Favored Glycine 0 N--CA 1.407 -3.243 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 -177.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.7 mm-40 -68.41 137.63 54.68 Favored 'General case' 0 C--O 1.256 1.402 0 CA-C-O 121.845 0.831 . . . . 0.0 111.747 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -112.94 117.76 32.97 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 175.088 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.523 ' HB ' ' HG2' ' A' ' 190' ' ' MET . 53.3 t -99.47 105.32 17.28 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 CA-C-O 121.336 0.589 . . . . 0.0 110.089 -178.183 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.421 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 27.3 ttm180 -94.92 152.8 18.05 Favored 'General case' 0 N--CA 1.414 -2.237 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.694 178.13 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -125.04 157.63 35.73 Favored 'General case' 0 C--N 1.284 -2.249 0 C-N-CA 124.491 1.116 . . . . 0.0 108.869 -175.312 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.4 HG22 ' CG2' ' A' ' 158' ' ' VAL . 0.0 OUTLIER -131.37 151.44 35.62 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.958 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.912 175.636 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 7.7 m -118.06 135.2 54.33 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 114.136 -1.393 . . . . 0.0 108.154 173.779 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -62.63 161.39 12.3 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 124.233 0.958 . . . . 0.0 110.421 178.386 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 7.5 t -62.37 109.76 1.45 Allowed 'General case' 0 C--N 1.299 -1.597 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.323 -174.209 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 122.97 -19.93 7.72 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -177.402 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 182' ' ' TYR . . . . . 0.595 ' HB3' ' SG ' ' A' ' 205' ' ' CYS . 82.6 m-85 -107.69 160.86 15.38 Favored 'General case' 0 N--CA 1.429 -1.495 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.83 146.9 33.39 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.566 HD13 ' HA ' ' A' ' 188' ' ' GLU . 9.5 tt -80.72 140.02 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.808 0 CA-C-O 121.8 0.81 . . . . 0.0 111.513 -176.446 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -83.02 -51.02 7.93 Favored 'General case' 0 C--N 1.294 -1.829 0 CA-C-N 115.164 -0.925 . . . . 0.0 109.26 -176.112 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.58 -158.91 25.18 Favored Glycine 0 C--N 1.298 -1.573 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 173.584 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -79.74 160.36 26.26 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 122.283 -0.539 . . . . 0.0 110.108 177.485 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.566 ' HA ' HD13 ' A' ' 184' ' ' ILE . 10.5 pt-20 -91.17 9.33 31.55 Favored 'General case' 0 C--O 1.205 -1.241 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.362 -176.167 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 189' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.2 pt-20 -155.37 138.82 15.87 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.225 0.536 . . . . 0.0 111.431 -178.767 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.523 ' HG2' ' HB ' ' A' ' 174' ' ' VAL . 6.2 ptm -127.37 144.78 51.0 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 178.401 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 52.5 t-80 -126.48 142.33 51.57 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.593 -0.692 . . . . 0.0 110.742 -175.537 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 192' ' ' CYS . . . . . 0.417 ' HB2' ' H ' ' A' ' 171' ' ' GLY . 6.4 m -59.32 125.21 22.7 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 176.219 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 12.1 m -104.02 165.43 11.05 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.111 179.441 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -54.06 -30.59 48.73 Favored 'General case' 0 N--CA 1.498 1.943 0 C-N-CA 123.975 0.91 . . . . 0.0 111.901 179.481 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -54.98 -30.03 58.28 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 124.906 1.282 . . . . 0.0 111.39 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 196' ' ' GLY . . . . . 0.512 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 98.06 11.73 48.4 Favored Glycine 0 CA--C 1.497 -1.057 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -174.123 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -130.54 -170.88 2.42 Favored 'General case' 0 N--CA 1.429 -1.475 0 CA-C-N 114.526 -0.837 . . . . 0.0 109.281 -178.583 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 198' ' ' TRP . . . . . 0.412 ' CE3' ' HG3' ' A' ' 190' ' ' MET . 85.7 m95 -96.25 154.14 17.42 Favored 'General case' 0 N--CA 1.426 -1.658 0 CA-C-O 121.094 0.473 . . . . 0.0 111.335 -175.27 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 13.7 p -75.14 -17.78 60.35 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.626 176.66 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.45 ' HD3' ' HA ' ' A' ' 200' ' ' LYS . 23.9 mmtp -128.62 159.03 36.84 Favored 'General case' 0 CA--C 1.492 -1.254 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.176 179.118 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -87.15 -175.86 5.47 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 3.8 tppp? -72.49 115.14 36.39 Favored Pre-proline 0 C--O 1.249 1.053 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 173.636 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.73 177.5 8.74 Favored 'Trans proline' 0 N--CA 1.43 -2.231 0 C-N-CA 121.755 1.636 . . . . 0.0 110.645 177.519 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 204' ' ' LYS . . . . . 0.507 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 23.7 ttmm -128.56 152.75 47.94 Favored 'General case' 0 C--N 1.275 -2.654 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.45 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.595 ' SG ' ' HB3' ' A' ' 182' ' ' TYR . 18.2 t -111.42 117.83 34.14 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 179.209 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--N 1.305 -1.342 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.33 -174.39 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 28.9 Cg_endo . . . . . 0 CA--C 1.543 0.931 0 CA-C-O 121.988 0.745 . . . . 0.0 111.786 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 63.8 m -81.64 -27.97 33.86 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-O 122.066 0.936 . . . . 0.0 109.144 177.134 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.95 -91.37 0.56 Allowed Glycine 0 N--CA 1.4 -3.712 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 173.213 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -179.4 125.5 0.24 Allowed Pre-proline 0 C--N 1.256 -3.47 0 N-CA-C 103.906 -2.627 . . . . 0.0 103.906 -176.113 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.547 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 72.3 Cg_endo -76.82 5.09 5.13 Favored 'Trans proline' 0 N--CA 1.488 1.204 0 C-N-CA 122.649 2.233 . . . . 0.0 113.343 -173.905 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 97.98 -160.38 20.84 Favored Glycine 0 N--CA 1.419 -2.453 0 N-CA-C 106.725 -2.55 . . . . 0.0 106.725 -173.488 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -155.31 -168.66 2.91 Favored 'General case' 0 C--N 1.281 -2.389 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.6 t -143.42 120.32 6.72 Favored Pre-proline 0 C--N 1.289 -2.055 0 CA-C-N 118.867 0.758 . . . . 0.0 110.596 -178.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.86 -0.08 9.83 Favored 'Trans proline' 0 CA--C 1.53 0.315 0 C-N-CA 122.831 2.354 . . . . 0.0 111.047 178.52 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -107.25 13.74 26.88 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.379 178.859 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 164.77 -128.38 1.79 Allowed Glycine 0 N--CA 1.422 -2.262 0 C-N-CA 119.516 -1.326 . . . . 0.0 112.684 179.036 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.3 p -151.52 173.54 14.48 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 123.322 0.649 . . . . 0.0 110.303 -174.097 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -140.62 161.48 37.65 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 169.281 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.9 m -127.0 159.99 32.46 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.438 HD11 ' CE1' ' A' ' 104' ' ' PHE . 20.8 mt -117.03 122.89 45.5 Favored 'General case' 0 C--N 1.28 -2.414 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 -179.167 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 29.8 p -115.55 122.08 44.59 Favored 'General case' 0 C--N 1.286 -2.162 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.557 -176.518 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.91 -54.98 0.77 Allowed Glycine 0 N--CA 1.421 -2.339 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -178.69 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -141.81 3.86 2.09 Favored Glycine 0 N--CA 1.437 -1.28 0 C-N-CA 120.14 -1.029 . . . . 0.0 113.316 -178.004 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 59.99 18.51 7.65 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.512 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.4 m -147.48 -173.86 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 -174.032 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.438 ' CE1' HD11 ' A' ' 98' ' ' LEU . 26.9 m-85 -102.89 45.9 0.94 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 118.447 0.567 . . . . 0.0 109.665 -179.412 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.664 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.0 pt-20 -86.57 -175.03 5.29 Favored 'General case' 0 C--O 1.211 -0.924 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.211 178.124 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -80.36 137.14 36.52 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.86 -0.525 . . . . 0.0 111.455 179.424 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 88.65 -0.97 83.39 Favored Glycine 0 N--CA 1.439 -1.129 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.849 178.723 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.664 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.4 p -90.08 147.53 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -176.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.4 mtpt -111.37 125.89 54.34 Favored 'General case' 0 N--CA 1.413 -2.281 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.706 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.402 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -89.57 93.25 9.42 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 174.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 54.1 t -88.2 116.43 30.08 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.454 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -179.315 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -87.52 141.59 28.51 Favored 'General case' 0 C--N 1.282 -2.341 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.109 -177.807 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.3 t -139.04 110.53 7.03 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-O 122.265 1.031 . . . . 0.0 108.488 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 33.2 m -68.75 163.03 24.96 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.114 -174.705 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -65.97 177.22 1.4 Allowed 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 124.31 1.044 . . . . 0.0 110.439 -178.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -58.92 -46.77 87.13 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 123.98 0.912 . . . . 0.0 112.086 -178.357 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.15 24.47 6.16 Favored Glycine 0 CA--C 1.524 0.609 0 C-N-CA 121.325 -0.464 . . . . 0.0 113.342 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -146.38 164.94 30.84 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 -177.134 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.4 pt20 -145.45 170.0 17.24 Favored 'General case' 0 C--N 1.275 -2.653 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 176.426 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.5 124.18 31.78 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 179.267 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.73 128.42 55.27 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 106.212 -1.773 . . . . 0.0 106.212 178.046 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 110.81 167.94 19.13 Favored Glycine 0 C--N 1.292 -1.886 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.605 -177.6 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -87.15 -26.57 23.53 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-O 121.816 0.817 . . . . 0.0 109.855 -175.443 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.425 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.9 mm -91.17 129.7 41.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.989 -1.005 . . . . 0.0 108.526 179.478 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 24.2 p-10 -130.81 9.62 4.98 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 120.845 0.355 . . . . 0.0 110.46 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.402 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 36.3 p90 -150.7 164.25 36.58 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.703 -173.778 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.547 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 45.3 mtp180 -123.66 134.47 53.74 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 173.313 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -110.13 134.03 52.6 Favored 'General case' 0 C--N 1.29 -1.987 0 C-N-CA 119.524 -0.87 . . . . 0.0 108.72 179.549 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.6 t -85.98 109.06 18.51 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.076 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -102.78 -169.36 1.65 Allowed 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 177.422 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 15.0 t -66.19 -15.39 63.11 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 123.119 0.567 . . . . 0.0 112.074 -175.903 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -99.09 -7.0 27.37 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-O 121.446 0.641 . . . . 0.0 109.979 177.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 114.25 -163.12 12.2 Favored Glycine 0 N--CA 1.439 -1.133 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 90.9 m95 -62.67 109.0 1.27 Allowed 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 116.681 0.24 . . . . 0.0 110.842 177.826 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 30.6 p -59.11 -73.56 0.08 Allowed 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 125.265 1.426 . . . . 0.0 113.076 -176.488 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -73.57 177.88 5.06 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.857 -177.498 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -100.97 175.6 5.55 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.951 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 87.1 mt -70.16 125.4 91.97 Favored Pre-proline 0 C--N 1.309 -1.165 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.024 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.425 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 36.5 Cg_endo -65.76 172.1 8.75 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 122.716 2.277 . . . . 0.0 112.73 179.241 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 46.2 mm -101.77 124.94 55.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-O 121.231 0.539 . . . . 0.0 111.562 -173.268 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 94.7 m -97.71 99.29 10.64 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 174.335 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -92.19 146.08 24.0 Favored 'General case' 0 N--CA 1.416 -2.13 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.68 130.3 35.21 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.579 HG23 ' HB2' ' A' ' 170' ' ' PHE . 12.1 m -59.22 141.01 16.68 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 CA-C-O 121.138 0.494 . . . . 0.0 112.001 -176.575 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 83.4 mttt -121.12 136.94 54.88 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.081 -175.013 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 89.1 m -103.67 152.25 22.01 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 172.799 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 1.8 pp -60.39 154.05 56.09 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-O 120.868 0.366 . . . . 0.0 110.867 -177.815 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -78.12 102.95 1.62 Allowed 'Trans proline' 0 N--CA 1.441 -1.578 0 C-N-CA 122.504 2.136 . . . . 0.0 112.506 -176.782 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 7.7 p -73.36 134.28 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.301 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.534 177.465 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.1 p -75.62 -75.31 0.18 Allowed 'General case' 0 N--CA 1.439 -0.988 0 CA-C-N 116.162 -0.472 . . . . 0.0 112.217 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.408 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . 171.81 159.96 0.24 Allowed Pre-proline 0 C--O 1.239 0.51 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 -177.784 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' PRO . . . . . 0.464 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 56.5 Cg_endo -75.57 161.06 37.64 Favored 'Trans proline' 0 N--CA 1.443 -1.459 0 C-N-CA 121.263 1.309 . . . . 0.0 109.55 171.791 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -57.89 -41.5 82.69 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 114.414 1.265 . . . . 0.0 114.414 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 56.0 m-80 -113.33 23.47 13.21 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.581 0.705 . . . . 0.0 110.041 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 155' ' ' GLY . . . . . 0.44 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -139.48 -163.3 9.46 Favored Glycine 0 N--CA 1.433 -1.536 0 C-N-CA 119.93 -1.129 . . . . 0.0 112.017 -178.896 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 156' ' ' LYS . . . . . 0.408 ' HA ' ' HB1' ' A' ' 151' ' ' ALA . 19.7 pttp -160.62 177.18 10.75 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -179.761 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.431 HG12 ' CE1' ' A' ' 176' ' ' PHE . 38.4 mt -95.47 140.42 17.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 123.278 0.361 . . . . 0.0 111.806 -175.545 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.47 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.8 m -92.13 -36.1 7.48 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 175.617 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.4 m . . . . . 0 N--CA 1.436 -1.162 0 CA-C-N 115.66 -0.7 . . . . 0.0 109.832 -177.055 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 . . . . . 0 N--CA 1.433 -1.28 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -96.2 167.62 11.09 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.48 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.579 ' HB2' HG23 ' A' ' 144' ' ' VAL . 91.0 t80 -50.04 133.62 22.65 Favored 'General case' 0 N--CA 1.468 0.466 0 O-C-N 123.622 0.576 . . . . 0.0 111.019 178.184 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 111.69 -32.71 6.21 Favored Glycine 0 N--CA 1.427 -1.932 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -69.66 114.9 8.3 Favored 'General case' 0 N--CA 1.416 -2.173 0 CA-C-O 122.287 1.041 . . . . 0.0 112.303 178.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -101.95 103.44 14.08 Favored 'General case' 0 N--CA 1.416 -2.128 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 174.35 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.562 HG13 ' HG3' ' A' ' 190' ' ' MET . 6.8 p -86.04 108.34 17.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.274 0 CA-C-O 121.579 0.704 . . . . 0.0 110.263 -175.227 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.47 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 43.2 ttp180 -100.12 147.29 25.83 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.476 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.464 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 74.2 m-85 -111.93 167.8 10.09 Favored 'General case' 0 C--N 1.293 -1.857 0 CA-C-O 121.784 0.802 . . . . 0.0 111.408 -177.333 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -136.99 151.65 27.52 Favored 'Isoleucine or valine' 0 CA--C 1.455 -2.678 0 CA-C-N 114.152 -1.385 . . . . 0.0 108.766 177.265 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.8 m -112.41 122.36 47.49 Favored 'General case' 0 N--CA 1.392 -3.348 0 O-C-N 124.474 1.109 . . . . 0.0 108.068 177.618 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 48.3 m-80 -53.92 168.73 0.19 Allowed 'General case' 0 C--N 1.307 -1.263 0 O-C-N 124.761 1.288 . . . . 0.0 112.301 -179.12 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 16.8 m -49.86 104.66 0.07 Allowed 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 125.273 1.429 . . . . 0.0 112.259 -175.673 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.01 3.16 31.75 Favored Glycine 0 N--CA 1.435 -1.409 0 C-N-CA 120.837 -0.697 . . . . 0.0 113.261 178.438 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -124.67 158.58 32.82 Favored 'General case' 0 CA--C 1.484 -1.564 0 CA-C-N 117.341 0.57 . . . . 0.0 110.725 178.61 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.516 ' HG2' ' OXT' ' A' ' 206' ' ' VAL . 25.2 pttm -133.39 162.23 32.4 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 106.757 -1.571 . . . . 0.0 106.757 179.239 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.4 tp -76.4 149.16 6.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -81.35 -59.12 2.74 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.987 179.584 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -115.96 -110.32 2.7 Favored Glycine 0 C--N 1.304 -1.205 0 C-N-CA 120.464 -0.874 . . . . 0.0 111.965 179.29 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 187' ' ' ASP . . . . . 0.537 ' CG ' ' HD3' ' A' ' 200' ' ' LYS . 1.5 p-10 -77.36 150.02 35.18 Favored 'General case' 0 C--O 1.193 -1.873 0 C-N-CA 124.161 0.984 . . . . 0.0 108.939 177.444 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -107.21 5.68 27.94 Favored 'General case' 0 C--N 1.296 -1.751 0 C-N-CA 121.009 -0.276 . . . . 0.0 110.871 -178.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -152.1 152.22 32.07 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 113.57 0.952 . . . . 0.0 113.57 -172.381 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.562 ' HG3' HG13 ' A' ' 174' ' ' VAL . 0.0 OUTLIER -128.57 137.46 51.73 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.876 -1.056 . . . . 0.0 108.306 177.454 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 40.3 t-80 -105.49 130.02 53.65 Favored 'General case' 0 C--N 1.291 -1.953 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.124 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 51.3 t -70.74 113.93 8.31 Favored 'General case' 0 C--O 1.243 0.734 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 175.394 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 25.1 m -85.85 163.49 18.08 Favored 'General case' 0 N--CA 1.437 -1.086 0 C-N-CA 123.217 0.607 . . . . 0.0 111.689 -176.38 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -67.57 -10.87 55.91 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 -173.711 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 195' ' ' ASP . . . . . 0.407 ' HB2' ' CE2' ' A' ' 197' ' ' PHE . 19.4 m-20 -91.79 -0.99 57.56 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.402 0.62 . . . . 0.0 110.109 177.484 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 81.38 42.28 9.41 Favored Glycine 0 N--CA 1.436 -1.362 0 C-N-CA 120.993 -0.622 . . . . 0.0 113.282 179.337 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 197' ' ' PHE . . . . . 0.407 ' CE2' ' HB2' ' A' ' 195' ' ' ASP . 45.5 p90 -149.65 166.71 28.5 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 175.249 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.5 m95 -83.82 125.86 32.38 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 123.146 0.279 . . . . 0.0 110.484 -178.712 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 35.9 t -57.62 -38.98 75.88 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.597 177.068 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.537 ' HD3' ' CG ' ' A' ' 187' ' ' ASP . 1.8 mmpt? -101.91 178.6 4.57 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 115.718 -0.673 . . . . 0.0 111.039 177.5 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -113.69 178.78 4.16 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 179.4 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 51.5 mtpt -79.2 114.51 45.38 Favored Pre-proline 0 C--N 1.295 -1.802 0 C-N-CA 120.771 -0.372 . . . . 0.0 111.593 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.49 -171.73 1.19 Allowed 'Trans proline' 0 N--CA 1.437 -1.812 0 C-N-CA 122.001 1.801 . . . . 0.0 110.898 176.354 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 204' ' ' LYS . . . . . 0.446 ' HG2' HG13 ' A' ' 206' ' ' VAL . 34.0 ttpt -141.66 153.48 44.74 Favored 'General case' 0 N--CA 1.405 -2.722 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.738 -175.845 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.435 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 81.1 m -104.81 121.54 43.86 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 174.648 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.516 ' OXT' ' HG2' ' A' ' 183' ' ' LYS . 25.0 m . . . . . 0 C--N 1.305 -1.365 0 O-C-N 124.191 0.932 . . . . 0.0 110.101 -175.387 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo . . . . . 0 CA--C 1.54 0.812 0 CA-C-O 121.423 0.51 . . . . 0.0 111.764 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 39.3 m -82.27 -36.23 27.28 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 122.264 1.031 . . . . 0.0 108.235 177.224 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.48 -92.62 0.48 Allowed Glycine 0 N--CA 1.406 -3.327 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 174.375 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 46.6 t-80 -177.42 129.55 0.32 Allowed Pre-proline 0 C--N 1.261 -3.248 0 N-CA-C 103.991 -2.596 . . . . 0.0 103.991 -176.255 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.534 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 90.5 Cg_endo -80.24 2.55 8.38 Favored 'Trans proline' 0 C--N 1.327 -0.582 0 C-N-CA 122.446 2.098 . . . . 0.0 113.387 -173.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.48 -178.49 41.39 Favored Glycine 0 N--CA 1.422 -2.287 0 N-CA-C 109.037 -1.625 . . . . 0.0 109.037 -175.468 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -139.83 159.68 41.61 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 117.477 0.639 . . . . 0.0 110.177 -177.691 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 5.7 t -108.52 139.6 20.97 Favored Pre-proline 0 C--N 1.299 -1.59 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.632 -178.464 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 91' ' ' THR . 6.3 Cg_exo -82.41 -14.32 9.37 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.546 2.164 . . . . 0.0 111.155 178.396 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -86.79 -1.22 57.59 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.642 -175.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 172.17 -131.89 2.26 Favored Glycine 0 N--CA 1.408 -3.226 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 -178.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 35.8 p -145.62 -175.62 4.8 Favored 'General case' 0 C--N 1.289 -2.036 0 O-C-N 123.864 0.391 . . . . 0.0 110.012 -177.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -138.21 166.56 23.87 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 173.223 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -134.79 161.46 35.12 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.126 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.481 HD11 ' CE1' ' A' ' 104' ' ' PHE . 13.2 mt -119.14 124.16 46.16 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 -178.171 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.443 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 29.5 p -108.98 144.2 37.27 Favored 'General case' 0 C--N 1.284 -2.242 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -177.727 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 102.64 -70.36 0.32 Allowed Glycine 0 N--CA 1.432 -1.598 0 C-N-CA 120.01 -1.09 . . . . 0.0 110.671 -178.19 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.488 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -110.47 -18.61 8.44 Favored Glycine 0 C--N 1.307 -1.08 0 C-N-CA 120.283 -0.96 . . . . 0.0 112.187 -178.313 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 64.04 22.62 12.99 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 123.336 0.655 . . . . 0.0 111.163 -178.563 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.513 ' O ' HG21 ' A' ' 108' ' ' VAL . 18.4 m -151.1 -171.75 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.198 -1.623 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -178.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.481 ' CE1' HD11 ' A' ' 98' ' ' LEU . 22.1 m-85 -101.9 43.99 1.04 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 119.095 0.862 . . . . 0.0 110.568 -177.025 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.669 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.7 pt-20 -84.11 -179.66 7.28 Favored 'General case' 0 C--O 1.206 -1.222 0 CA-C-N 114.476 -1.238 . . . . 0.0 111.663 178.357 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 40.2 m-85 -76.7 135.55 39.08 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 122.029 -0.419 . . . . 0.0 110.881 176.817 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.62 9.3 75.42 Favored Glycine 0 N--CA 1.44 -1.057 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.704 178.779 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.669 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.9 p -95.6 148.8 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.484 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.443 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.7 mtpt -115.17 121.96 44.59 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.458 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -88.01 93.82 9.6 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.265 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 91.5 t -90.53 114.43 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.93 0 C-N-CA 124.414 1.086 . . . . 0.0 108.431 -177.252 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -84.76 139.44 31.96 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.511 -177.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.9 t -136.16 112.24 9.68 Favored 'General case' 0 N--CA 1.423 -1.796 0 CA-C-O 122.156 0.979 . . . . 0.0 109.943 -179.152 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 84.8 m -69.43 156.21 39.21 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.47 -0.786 . . . . 0.0 111.998 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 -67.7 172.93 4.69 Favored 'General case' 0 C--O 1.218 -0.573 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.069 176.126 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -53.33 -47.8 69.03 Favored 'General case' 0 C--N 1.313 -1.007 0 C-N-CA 124.022 0.929 . . . . 0.0 113.115 -174.132 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -85.02 15.35 44.17 Favored Glycine 0 C--N 1.307 -1.039 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.784 -179.569 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -130.34 162.27 29.43 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -144.77 145.34 31.62 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.5 tt -79.94 140.91 36.47 Favored 'General case' 0 C--N 1.279 -2.471 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.263 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.97 133.07 56.33 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -173.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 103.73 -169.41 18.08 Favored Glycine 0 C--N 1.306 -1.121 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.46 179.283 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -94.19 -47.45 6.64 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -178.651 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.0 mm -69.05 122.95 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 CA-C-N 114.464 -1.244 . . . . 0.0 109.626 -176.331 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -128.53 6.24 5.69 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.397 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 25.0 p90 -150.56 162.39 40.72 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 120.433 -0.507 . . . . 0.0 110.23 -173.857 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.534 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 39.9 mtp180 -121.78 132.97 54.89 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 106.226 -1.768 . . . . 0.0 106.226 173.235 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -108.7 128.9 55.27 Favored 'General case' 0 C--N 1.289 -2.035 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.7 t -85.35 107.33 17.3 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.087 -1.045 . . . . 0.0 109.642 177.116 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.418 ' CG ' ' H ' ' A' ' 131' ' ' THR . 34.1 t0 -103.86 -170.6 1.8 Allowed 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 178.27 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.418 ' H ' ' CG ' ' A' ' 130' ' ' ASP . 11.1 t -54.81 -29.49 54.71 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 124.56 1.144 . . . . 0.0 113.204 -177.033 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -81.82 -30.16 32.31 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 121.4 0.619 . . . . 0.0 110.382 176.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 132.86 -151.78 20.11 Favored Glycine 0 N--CA 1.42 -2.409 0 N-CA-C 108.744 -1.743 . . . . 0.0 108.744 -174.364 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 92.3 m95 -65.46 113.16 3.94 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 117.386 0.593 . . . . 0.0 109.778 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 22.3 p -64.65 -70.88 0.2 Allowed 'General case' 0 C--O 1.247 0.922 0 CA-C-O 121.6 0.714 . . . . 0.0 111.738 -178.326 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 -71.82 173.87 7.67 Favored 'General case' 0 CA--C 1.484 -1.559 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.959 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -110.01 -174.62 2.53 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -177.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.2 mt -66.58 118.56 55.25 Favored Pre-proline 0 C--O 1.244 0.814 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.405 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.61 155.93 63.96 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.788 2.325 . . . . 0.0 111.706 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 67.5 mt -84.81 136.15 23.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.032 -177.657 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 43.7 t -126.06 138.75 53.73 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 176.486 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.56 157.32 40.49 Favored 'General case' 0 N--CA 1.414 -2.243 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -178.498 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 11.5 p -75.09 136.34 25.3 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.88 178.365 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.96 130.53 25.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 C-N-CA 123.303 0.641 . . . . 0.0 109.303 178.432 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.555 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 44.0 mttp -131.46 159.11 39.02 Favored 'General case' 0 CA--C 1.499 -1.007 0 CA-C-O 121.564 0.697 . . . . 0.0 112.64 -177.429 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 39.5 m -123.28 149.53 44.68 Favored 'General case' 0 N--CA 1.42 -1.974 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 176.312 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 80.5 mt -65.38 148.76 97.81 Favored Pre-proline 0 C--N 1.309 -1.154 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -61.6 122.34 10.89 Favored 'Trans proline' 0 N--CA 1.459 -0.524 0 C-N-CA 123.199 2.599 . . . . 0.0 110.479 178.167 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 150' ' ' THR . 21.0 t -83.73 145.78 7.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -175.705 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 150' ' ' THR . . . . . 0.539 ' O ' HG12 ' A' ' 149' ' ' VAL . 15.6 p -88.13 -164.93 1.19 Allowed 'General case' 0 N--CA 1.411 -2.425 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 171.53 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.532 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . -113.09 156.37 42.97 Favored Pre-proline 0 C--N 1.266 -3.057 0 O-C-N 121.511 -0.743 . . . . 0.0 110.392 -172.494 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' PRO . . . . . 0.415 ' HD3' ' CD2' ' A' ' 176' ' ' PHE . 28.9 Cg_endo -65.26 158.51 51.95 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 122.252 1.968 . . . . 0.0 110.276 173.896 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' GLU . . . . . 0.416 ' HG2' ' HB2' ' A' ' 204' ' ' LYS . 10.2 pt-20 -53.78 -36.43 62.4 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 114.463 1.282 . . . . 0.0 114.463 -174.554 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 154' ' ' ASN . . . . . 0.43 ' HB2' ' HB2' ' A' ' 205' ' ' CYS . 20.3 m120 -127.7 36.1 4.4 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.789 0.804 . . . . 0.0 109.043 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 177' ' ' VAL . . . -152.7 -160.76 9.82 Favored Glycine 0 N--CA 1.429 -1.802 0 C-N-CA 119.628 -1.272 . . . . 0.0 113.231 178.103 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 156' ' ' LYS . . . . . 0.532 ' HA ' ' HB1' ' A' ' 151' ' ' ALA . 20.2 pttm -159.12 176.61 12.04 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 123.936 0.894 . . . . 0.0 109.863 -177.889 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 59.8 mt -94.52 142.1 13.96 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 122.24 0.216 . . . . 0.0 110.705 -178.656 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.541 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 12.2 m -99.83 -23.57 4.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 CA-C-O 121.722 0.772 . . . . 0.0 110.479 179.055 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 159' ' ' SER . . . . . 0.502 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 33.4 m . . . . . 0 C--N 1.298 -1.659 0 N-CA-C 114.742 1.386 . . . . 0.0 114.742 -168.496 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 . . . . . 0 N--CA 1.426 -1.648 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.555 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 21.4 p-80 -96.5 171.1 8.77 Favored 'General case' 0 C--N 1.291 -1.968 0 C-N-CA 120.137 -0.625 . . . . 0.0 111.082 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -51.51 125.6 15.02 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 123.872 0.733 . . . . 0.0 110.948 179.803 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.48 -10.23 21.89 Favored Glycine 0 N--CA 1.424 -2.111 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -177.61 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.2 mm-40 -85.26 136.96 33.28 Favored 'General case' 0 N--CA 1.438 -1.072 0 CA-C-O 121.537 0.684 . . . . 0.0 112.041 -179.636 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -115.11 120.38 39.59 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 176.715 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.502 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 83.3 t -108.1 110.98 33.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.641 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 72.7 ttt180 -106.37 147.72 28.91 Favored 'General case' 0 N--CA 1.425 -1.696 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.415 ' CD2' ' HD3' ' A' ' 152' ' ' PRO . 60.9 m-85 -119.41 165.97 13.66 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.025 0.441 . . . . 0.0 111.134 -175.142 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.467 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.0 OUTLIER -130.28 156.65 42.52 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.715 0 CA-C-N 115.069 -0.969 . . . . 0.0 109.745 175.21 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.7 m -111.81 142.98 43.5 Favored 'General case' 0 C--N 1.278 -2.531 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 171.441 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -44.74 -80.68 0.01 OUTLIER 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 114.331 1.234 . . . . 0.0 114.331 -177.173 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 64.6 m -149.24 -42.05 0.14 Allowed 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 114.018 1.118 . . . . 0.0 114.018 -178.364 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -102.29 2.22 50.53 Favored Glycine 0 C--N 1.291 -1.928 0 C-N-CA 120.152 -1.023 . . . . 0.0 114.742 -174.403 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -110.35 175.73 5.32 Favored 'General case' 0 CA--C 1.487 -1.445 0 CA-C-N 117.643 0.721 . . . . 0.0 111.122 -176.33 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 37.6 pttt -136.63 152.56 50.57 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 173.427 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.497 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.9 tt -70.97 143.2 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.473 0 CA-C-O 121.821 0.82 . . . . 0.0 112.71 -176.706 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -39.78 -59.63 1.13 Allowed 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 127.862 2.465 . . . . 0.0 113.061 179.046 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -145.24 -89.58 0.1 OUTLIER Glycine 0 CA--C 1.48 -2.122 0 C-N-CA 120.107 -1.044 . . . . 0.0 111.293 -177.642 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 187' ' ' ASP . . . . . 0.472 ' HB3' ' HG3' ' A' ' 200' ' ' LYS . 6.9 t0 -95.03 158.42 15.47 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.349 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.641 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 13.4 pt-20 -111.28 -9.48 14.29 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 121.084 -0.246 . . . . 0.0 110.772 -177.443 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 189' ' ' GLU . . . . . 0.463 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.9 pt-20 -131.49 124.67 30.62 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-O 121.816 0.817 . . . . 0.0 112.869 -178.096 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 17.4 ptp -109.65 151.01 27.41 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.811 178.412 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 63.4 m80 -127.37 156.73 41.57 Favored 'General case' 0 CA--C 1.498 -1.043 0 C-N-CA 122.403 0.281 . . . . 0.0 110.66 -178.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 5.1 m -81.75 117.14 21.82 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.066 176.287 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 37.2 m -82.1 152.54 26.5 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.398 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -72.1 78.51 0.94 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 122.852 1.31 . . . . 0.0 112.257 -176.532 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -175.36 -47.16 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.627 0 CA-C-N 112.986 -1.915 . . . . 0.0 106.186 -179.175 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 121.28 66.34 0.25 Allowed Glycine 0 N--CA 1.427 -1.901 0 CA-C-N 114.547 -1.206 . . . . 0.0 112.21 -178.75 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -167.29 161.94 14.59 Favored 'General case' 0 C--O 1.248 0.979 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 176.58 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.9 m95 -85.15 139.46 31.68 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 124.005 0.816 . . . . 0.0 110.846 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.7 p -71.51 -18.64 62.27 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.252 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.584 ' HE3' ' O ' ' A' ' 201' ' ' GLU . 0.0 OUTLIER -123.94 153.49 41.13 Favored 'General case' 0 N--CA 1.426 -1.626 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 -179.879 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 201' ' ' GLU . . . . . 0.584 ' O ' ' HE3' ' A' ' 200' ' ' LYS . 3.2 mp0 -77.55 168.4 20.05 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 106.532 -1.655 . . . . 0.0 106.532 177.261 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 202' ' ' LYS . . . . . 0.401 ' HB3' ' HE2' ' A' ' 202' ' ' LYS . 0.8 OUTLIER -68.89 114.91 26.14 Favored Pre-proline 0 C--N 1.311 -1.084 0 C-N-CA 119.915 -0.714 . . . . 0.0 109.722 176.566 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_endo -82.79 166.94 14.93 Favored 'Trans proline' 0 N--CA 1.431 -2.173 0 C-N-CA 121.95 1.766 . . . . 0.0 111.645 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 204' ' ' LYS . . . . . 0.416 ' HB2' ' HG2' ' A' ' 153' ' ' GLU . 9.8 ptpp? -131.08 179.06 6.22 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.16 -177.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.43 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 87.6 m -115.32 114.18 24.81 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 178.497 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.9 m . . . . . 0 C--N 1.302 -1.471 0 CA-C-N 114.796 -1.093 . . . . 0.0 109.692 -174.096 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.442 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 39.9 Cg_endo . . . . . 0 CA--C 1.538 0.711 0 CA-C-O 122.19 0.829 . . . . 0.0 110.772 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.9 m -92.41 -33.09 14.69 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.696 -1.138 . . . . 0.0 108.295 175.661 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.04 -91.79 0.58 Allowed Glycine 0 N--CA 1.402 -3.618 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 174.317 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.5 t-80 -174.7 132.61 0.49 Allowed Pre-proline 0 C--N 1.268 -2.973 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 -176.058 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.415 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 98.1 Cg_endo -81.97 5.75 6.12 Favored 'Trans proline' 0 N--CA 1.475 0.439 0 C-N-CA 122.363 2.042 . . . . 0.0 113.405 -172.492 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 113.58 -173.77 15.25 Favored Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -177.44 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -151.68 160.51 43.59 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 178.22 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.445 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 5.5 t -140.05 144.59 38.64 Favored Pre-proline 0 C--N 1.294 -1.809 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.723 -174.654 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 91' ' ' THR . 2.7 Cg_endo -83.09 -16.77 7.13 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 122.692 2.261 . . . . 0.0 110.611 174.12 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 40.4 m-85 -87.53 2.37 50.91 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.772 -175.018 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.523 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 164.4 -127.1 1.6 Allowed Glycine 0 N--CA 1.415 -2.726 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.756 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.2 t -161.08 -161.97 0.87 Allowed 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -178.181 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -155.02 159.43 40.31 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 177.45 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 16.2 m -121.34 163.35 18.78 Favored 'General case' 0 C--N 1.278 -2.527 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.456 HD11 ' CE1' ' A' ' 104' ' ' PHE . 20.6 mt -121.64 129.24 52.66 Favored 'General case' 0 C--N 1.284 -2.259 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -178.377 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.2 p -124.79 130.22 51.97 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.879 -176.071 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.33 20.97 28.4 Favored Glycine 0 C--N 1.303 -1.278 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.373 -178.63 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.94 -31.74 0.14 Allowed Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 119.907 -1.139 . . . . 0.0 113.128 177.809 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 6.7 m120 67.8 10.27 7.67 Favored 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 123.267 0.627 . . . . 0.0 112.461 -177.1 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.532 ' O ' HG11 ' A' ' 108' ' ' VAL . 27.3 m -143.34 -171.67 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.501 -0.909 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 -176.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.456 ' CE1' HD11 ' A' ' 98' ' ' LEU . 23.4 m-85 -104.71 46.36 0.92 Allowed 'General case' 0 C--N 1.311 -1.083 0 CA-C-O 121.092 0.473 . . . . 0.0 110.162 -177.509 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.726 ' O ' HG12 ' A' ' 108' ' ' VAL . 14.9 pt-20 -87.88 175.74 7.67 Favored 'General case' 0 C--O 1.212 -0.884 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.408 178.016 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' TYR . . . . . 0.442 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 42.4 m-85 -74.69 131.57 40.98 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-O 121.088 0.47 . . . . 0.0 111.441 178.661 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 96.72 -1.13 61.42 Favored Glycine 0 N--CA 1.437 -1.239 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.112 178.413 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.726 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.7 p -90.29 146.57 6.03 Favored 'Isoleucine or valine' 0 C--O 1.243 0.749 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.438 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.3 mtpt -109.5 122.97 48.59 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.543 178.737 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.495 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.46 93.17 9.07 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 176.877 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 75.7 t -86.46 108.03 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.745 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' TYR . . . . . 0.513 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 66.4 t80 -78.3 140.55 38.82 Favored 'General case' 0 C--N 1.268 -2.942 0 CA-C-N 114.121 -1.4 . . . . 0.0 109.952 -174.59 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -143.48 132.38 22.78 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-O 121.9 0.857 . . . . 0.0 109.858 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 57.0 m -85.69 159.64 19.75 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.817 -176.198 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.523 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 54.9 m-20 -65.85 176.97 1.41 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.726 178.523 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -56.12 -49.3 74.27 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 123.522 0.729 . . . . 0.0 112.396 -175.791 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.21 33.34 4.09 Favored Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.256 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 84.5 m-85 -146.56 158.21 43.86 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 124.224 1.01 . . . . 0.0 109.043 -178.33 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -136.1 169.75 17.12 Favored 'General case' 0 C--N 1.279 -2.457 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 177.129 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 10.5 tp -86.97 153.72 21.35 Favored 'General case' 0 C--N 1.287 -2.121 0 C-N-CA 119.259 -0.977 . . . . 0.0 108.397 178.266 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.05 125.31 31.11 Favored 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 176.218 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.68 175.8 20.04 Favored Glycine 0 C--N 1.292 -1.876 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -176.186 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -94.73 -28.9 15.06 Favored 'General case' 0 CA--C 1.5 -0.943 0 CA-C-O 121.26 0.553 . . . . 0.0 111.0 -177.327 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.584 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 48.8 mm -81.1 129.78 36.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.178 -178.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -133.21 9.15 4.06 Favored 'General case' 0 C--O 1.213 -0.851 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 178.158 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.495 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 22.6 p90 -147.54 158.75 44.13 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.19 0.519 . . . . 0.0 110.425 -176.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 59.7 mtp180 -125.12 132.11 53.16 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 172.259 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -107.3 130.82 54.72 Favored 'General case' 0 C--N 1.275 -2.65 0 C-N-CA 119.408 -0.917 . . . . 0.0 109.715 -177.692 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 35.8 t -82.52 101.57 10.81 Favored 'General case' 0 N--CA 1.428 -1.536 0 C-N-CA 118.098 -1.441 . . . . 0.0 110.454 177.839 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.41 ' OD1' HG22 ' A' ' 131' ' ' THR . 6.4 t70 -98.79 -169.56 1.8 Allowed 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 105.496 -2.038 . . . . 0.0 105.496 175.505 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.41 HG22 ' OD1' ' A' ' 130' ' ' ASP . 13.2 t -65.33 -24.36 67.24 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 118.362 0.528 . . . . 0.0 110.965 -176.869 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -70.51 -24.18 62.78 Favored 'General case' 0 C--O 1.249 1.03 0 CA-C-O 122.105 0.955 . . . . 0.0 110.558 175.243 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.62 -148.11 18.91 Favored Glycine 0 N--CA 1.411 -2.985 0 N-CA-C 107.577 -2.209 . . . . 0.0 107.577 -172.819 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.454 ' CH2' HG13 ' A' ' 108' ' ' VAL . 97.4 m95 -71.12 112.78 7.54 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 117.235 0.518 . . . . 0.0 110.822 177.722 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 65.0 p -70.5 168.12 16.9 Favored 'General case' 0 C--O 1.269 2.116 0 N-CA-C 109.001 -0.741 . . . . 0.0 109.001 176.686 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 63.44 -163.1 0.27 Allowed 'General case' 0 C--O 1.242 0.674 0 O-C-N 124.07 0.856 . . . . 0.0 108.992 177.163 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -126.31 178.73 5.65 Favored 'General case' 0 C--N 1.279 -2.478 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 173.743 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 57.0 mt -67.2 119.77 67.21 Favored Pre-proline 0 C--N 1.298 -1.638 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 175.264 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.584 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 1.5 Cg_endo -58.18 165.09 7.6 Favored 'Trans proline' 0 C--O 1.24 0.606 0 C-N-CA 122.451 2.101 . . . . 0.0 111.834 177.762 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 61.8 mt -102.18 135.8 37.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.236 -172.785 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.432 ' SG ' ' CE2' ' A' ' 112' ' ' TYR . 90.2 m -103.28 148.47 25.79 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 171.699 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -128.5 151.76 49.05 Favored 'General case' 0 C--N 1.266 -3.052 0 N-CA-C 105.261 -2.125 . . . . 0.0 105.261 174.429 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.554 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 7.3 p -71.45 147.35 10.97 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.607 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.131 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.61 HG23 ' HB2' ' A' ' 170' ' ' PHE . 11.6 m -67.18 121.92 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.911 0 C-N-CA 118.478 -1.289 . . . . 0.0 109.243 176.132 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.554 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 52.3 mtmt -115.97 142.91 46.17 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.307 -0.861 . . . . 0.0 111.312 -172.208 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 19.0 m -110.35 142.82 41.48 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 178.079 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' LEU . . . . . 0.483 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.1 mm? -60.95 144.42 90.51 Favored Pre-proline 0 N--CA 1.426 -1.661 0 N-CA-C 113.653 0.983 . . . . 0.0 113.653 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 31.4 Cg_exo -57.61 142.47 95.66 Favored 'Trans proline' 0 C--O 1.246 0.878 0 C-N-CA 123.493 2.796 . . . . 0.0 111.857 177.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.2 t -110.67 149.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 16.9 p -80.72 -83.57 0.11 Allowed 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 122.131 0.172 . . . . 0.0 111.093 178.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.35 153.51 0.23 Allowed Pre-proline 0 C--O 1.237 0.44 0 C-N-CA 125.883 1.673 . . . . 0.0 106.729 179.515 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.14 160.94 46.04 Favored 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 121.548 1.498 . . . . 0.0 111.574 175.118 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -65.4 -32.68 74.44 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 114.582 1.326 . . . . 0.0 114.582 -173.862 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 31.6 m120 -126.26 32.79 5.14 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 121.777 0.799 . . . . 0.0 108.901 -179.226 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -156.59 -168.09 18.81 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.413 178.968 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 24.0 pttm -150.02 171.66 16.49 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 117.178 0.489 . . . . 0.0 109.705 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 53.5 mt -94.92 129.22 45.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.498 HG22 ' O ' ' A' ' 175' ' ' ARG . 10.5 m -82.09 -24.71 9.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-O 121.369 0.604 . . . . 0.0 110.569 -177.328 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 6.5 m . . . . . 0 N--CA 1.443 -0.801 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.409 -177.466 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 . . . . . 0 N--CA 1.434 -1.247 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 -119.26 157.55 27.82 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 119.325 -0.369 . . . . 0.0 110.407 -172.143 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.61 ' HB2' HG23 ' A' ' 144' ' ' VAL . 85.7 t80 -35.15 127.75 0.54 Allowed 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 176.876 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 103.41 -30.31 10.58 Favored Glycine 0 N--CA 1.427 -1.943 0 CA-C-N 114.783 -1.099 . . . . 0.0 112.82 177.64 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -72.3 145.28 47.95 Favored 'General case' 0 N--CA 1.402 -2.827 0 CA-C-N 117.266 0.533 . . . . 0.0 110.248 -177.635 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -122.39 122.54 39.25 Favored 'General case' 0 N--CA 1.414 -2.241 0 CA-C-N 115.205 -0.907 . . . . 0.0 108.835 178.506 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 54.9 t -93.71 105.01 16.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.254 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 174.705 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.498 ' O ' HG22 ' A' ' 158' ' ' VAL . 19.3 ttp180 -103.37 146.64 28.18 Favored 'General case' 0 N--CA 1.402 -2.847 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -178.498 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -117.13 166.76 11.85 Favored 'General case' 0 C--N 1.279 -2.485 0 CA-C-O 121.102 0.477 . . . . 0.0 109.945 -174.182 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.0 p -145.43 139.8 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.21 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 174.859 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 178' ' ' CYS . . . . . 0.411 ' SG ' ' HB ' ' A' ' 184' ' ' ILE . 77.5 m -101.72 157.2 17.01 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -65.71 163.4 16.59 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 177.836 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 15.3 t -46.83 -33.45 4.48 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -169.453 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -108.52 18.04 32.97 Favored Glycine 0 C--N 1.289 -2.04 0 C-N-CA 120.427 -0.892 . . . . 0.0 114.203 -177.48 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -119.29 158.86 25.21 Favored 'General case' 0 CA--C 1.486 -1.519 0 CA-C-N 118.28 1.04 . . . . 0.0 110.795 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 14.8 pttm -120.14 150.97 39.76 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.316 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.424 HD13 ' HA ' ' A' ' 188' ' ' GLU . 8.3 tt -84.32 136.31 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.313 0 C-N-CA 119.279 -0.969 . . . . 0.0 108.902 174.485 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -86.65 -45.65 10.81 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.967 -1.015 . . . . 0.0 109.226 -174.894 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -78.46 -157.57 10.59 Favored Glycine 0 C--N 1.302 -1.33 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 173.355 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 187' ' ' ASP . . . . . 0.451 ' HB3' ' HG3' ' A' ' 200' ' ' LYS . 17.1 t70 -82.04 169.34 16.82 Favored 'General case' 0 C--N 1.314 -0.977 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.132 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.424 ' HA ' HD13 ' A' ' 184' ' ' ILE . 13.1 pt-20 -81.44 -13.57 58.07 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-N 118.778 0.717 . . . . 0.0 110.865 -173.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -147.47 170.77 16.7 Favored 'General case' 0 N--CA 1.423 -1.779 0 CA-C-O 121.513 0.673 . . . . 0.0 111.431 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.0 ptp -141.8 125.66 17.09 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.911 175.372 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 1.9 m80 -98.54 147.27 24.95 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.526 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 192' ' ' CYS . . . . . 0.409 ' HB3' ' HA ' ' A' ' 170' ' ' PHE . 1.7 m -73.62 110.78 8.18 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.834 171.272 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 28.8 m -83.61 160.02 21.48 Favored 'General case' 0 N--CA 1.428 -1.574 0 O-C-N 123.925 0.766 . . . . 0.0 109.342 -179.269 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -70.37 1.56 4.84 Favored 'General case' 0 N--CA 1.486 1.34 0 CA-C-O 121.261 0.553 . . . . 0.0 112.423 -176.826 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -84.6 -17.53 38.44 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.376 174.373 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 90.1 23.3 32.71 Favored Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.288 -0.958 . . . . 0.0 110.865 -174.273 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -131.01 164.5 25.26 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 58.0 m95 -79.59 143.37 34.8 Favored 'General case' 0 N--CA 1.426 -1.642 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 174.638 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.1 m -63.77 -20.77 66.02 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-O 121.153 0.502 . . . . 0.0 111.104 177.446 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.451 ' HG3' ' HB3' ' A' ' 187' ' ' ASP . 30.5 mmmt -133.74 158.78 42.44 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.058 -177.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 25.3 mm-40 -79.63 168.0 19.95 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 114.554 -1.203 . . . . 0.0 108.392 171.742 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 17.2 tptm -55.43 117.26 14.21 Favored Pre-proline 0 N--CA 1.439 -0.989 0 O-C-N 123.863 0.727 . . . . 0.0 110.02 176.355 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -87.5 158.4 7.94 Favored 'Trans proline' 0 N--CA 1.423 -2.639 0 C-N-CA 122.066 1.844 . . . . 0.0 111.663 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 204' ' ' LYS . . . . . 0.418 ' HG2' HG13 ' A' ' 206' ' ' VAL . 37.9 ttpt -122.42 149.08 44.32 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.709 -175.678 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.408 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 92.7 m -108.38 115.67 30.54 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 176.244 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 206' ' ' VAL . . . . . 0.418 HG13 ' HG2' ' A' ' 204' ' ' LYS . 9.4 m . . . . . 0 C--N 1.29 -1.981 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.126 -175.177 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo . . . . . 0 CA--C 1.534 0.477 0 CA-C-O 121.796 0.665 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 59.5 m -88.23 -36.99 16.44 Favored 'General case' 0 N--CA 1.435 -1.204 0 CA-C-N 114.813 -1.085 . . . . 0.0 109.29 175.79 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 115.98 -87.72 0.44 Allowed Glycine 0 CA--C 1.463 -3.206 0 N-CA-C 110.081 -1.207 . . . . 0.0 110.081 174.34 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.7 t-80 -177.72 127.77 0.29 Allowed Pre-proline 0 C--N 1.269 -2.922 0 N-CA-C 104.901 -2.259 . . . . 0.0 104.901 -175.642 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -79.99 12.26 2.52 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 123.043 2.495 . . . . 0.0 114.342 -171.909 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 106.03 -169.63 15.98 Favored Glycine 0 N--CA 1.424 -2.126 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -176.305 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -160.27 139.59 10.88 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 177.717 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.3 t -110.87 131.74 21.98 Favored Pre-proline 0 C--N 1.303 -1.449 0 C-N-CA 120.631 -0.428 . . . . 0.0 111.758 -175.85 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -70.02 -18.3 35.85 Favored 'Trans proline' 0 C--N 1.351 0.681 0 C-N-CA 122.826 2.351 . . . . 0.0 111.695 176.596 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -83.57 -2.5 56.18 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.329 -176.721 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.503 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.09 -124.49 1.04 Allowed Glycine 0 N--CA 1.414 -2.817 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.328 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 14.8 t -164.8 -165.27 0.89 Allowed 'General case' 0 C--N 1.285 -2.228 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.55 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.7 p90 -146.18 165.65 28.54 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.896 -0.503 . . . . 0.0 109.758 178.203 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -126.12 162.44 25.34 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.962 -1.495 . . . . 0.0 106.962 176.64 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 16.5 mt -114.88 132.91 56.37 Favored 'General case' 0 C--N 1.278 -2.51 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.314 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 19.9 p -128.9 128.48 43.9 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 -177.161 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 93.41 30.13 9.49 Favored Glycine 0 C--N 1.292 -1.863 0 C-N-CA 119.994 -1.098 . . . . 0.0 111.253 -178.302 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 164.17 -35.51 0.29 Allowed Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.705 -1.236 . . . . 0.0 111.974 177.396 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 68.85 14.25 8.91 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.547 0.739 . . . . 0.0 112.338 179.96 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.506 ' O ' HG11 ' A' ' 108' ' ' VAL . 29.3 m -147.74 -168.92 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.211 -0.951 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 -178.616 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -106.34 42.78 1.22 Allowed 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 119.118 0.872 . . . . 0.0 110.238 -178.115 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.719 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.8 pt-20 -79.27 173.91 12.11 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 114.641 -1.163 . . . . 0.0 111.588 178.262 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -75.98 127.59 33.3 Favored 'General case' 0 C--N 1.295 -1.762 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.059 176.201 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 104.17 -7.58 48.04 Favored Glycine 0 N--CA 1.435 -1.414 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.489 179.694 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.719 HG12 ' O ' ' A' ' 105' ' ' GLU . 13.9 p -87.76 148.9 4.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -178.32 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -112.03 123.72 50.86 Favored 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.574 179.181 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.445 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.85 96.99 10.4 Favored 'General case' 0 C--N 1.291 -1.939 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 176.523 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.426 HG12 ' HB3' ' A' ' 126' ' ' TYR . 22.6 m -95.24 111.18 25.32 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.511 0 CA-C-O 122.564 1.174 . . . . 0.0 109.457 -179.168 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -78.92 148.96 32.5 Favored 'General case' 0 C--N 1.26 -3.32 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.813 -177.62 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.9 t -145.35 130.94 18.85 Favored 'General case' 0 N--CA 1.422 -1.839 0 CA-C-N 115.012 -0.995 . . . . 0.0 108.895 177.295 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 20.5 m -82.47 160.61 22.63 Favored 'General case' 0 C--N 1.284 -2.277 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.314 -175.732 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.503 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 71.1 m-20 -73.19 -178.06 2.75 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.952 178.812 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -53.31 -53.09 56.02 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 125.02 1.328 . . . . 0.0 113.375 -175.43 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.403 ' O ' HG23 ' A' ' 143' ' ' VAL . . . -88.25 31.81 4.64 Favored Glycine 0 C--N 1.305 -1.18 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.414 -177.542 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -146.1 153.65 40.94 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -175.044 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -133.13 171.88 13.4 Favored 'General case' 0 C--N 1.272 -2.776 0 N-CA-C 105.923 -1.881 . . . . 0.0 105.923 175.663 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.449 HD11 ' HB2' ' A' ' 139' ' ' PRO . 13.1 tp -87.47 149.87 24.13 Favored 'General case' 0 C--N 1.282 -2.357 0 C-N-CA 119.135 -1.026 . . . . 0.0 108.563 179.216 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -122.51 121.83 37.48 Favored 'General case' 0 N--CA 1.408 -2.539 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 176.81 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.92 171.52 23.44 Favored Glycine 0 C--N 1.284 -2.33 0 C-N-CA 120.796 -0.716 . . . . 0.0 111.943 -175.434 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -86.27 -34.72 20.3 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.65 0.738 . . . . 0.0 109.495 -176.927 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.3 mm -77.97 126.67 38.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-N 114.988 -1.006 . . . . 0.0 109.814 -175.925 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -127.57 1.93 6.19 Favored 'General case' 0 C--O 1.201 -1.454 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 176.899 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.445 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 18.2 p90 -136.51 162.43 33.12 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.42 -171.64 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 63.3 mtp180 -130.78 131.12 44.51 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 170.341 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -103.9 132.31 50.28 Favored 'General case' 0 C--N 1.292 -1.899 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.698 179.509 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 23.9 t -82.22 97.78 8.42 Favored 'General case' 0 N--CA 1.425 -1.681 0 C-N-CA 118.238 -1.385 . . . . 0.0 109.257 175.741 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -94.83 -173.41 2.98 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 106.673 -1.602 . . . . 0.0 106.673 178.163 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 14.1 t -67.01 -14.39 62.85 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.69 0.757 . . . . 0.0 111.277 -175.192 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -86.73 -28.64 22.94 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.017 177.953 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 132.13 -163.85 23.86 Favored Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 -175.405 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.469 ' CH2' HG13 ' A' ' 108' ' ' VAL . 98.5 m95 -63.62 113.55 3.4 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 117.85 0.825 . . . . 0.0 110.858 175.714 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 51.9 p -70.67 166.84 19.93 Favored 'General case' 0 C--O 1.267 2.006 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 177.542 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 62.24 -163.39 0.26 Allowed 'General case' 0 C--O 1.251 1.145 0 O-C-N 123.921 0.763 . . . . 0.0 109.383 178.061 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 37.6 t0 -131.59 177.88 7.17 Favored 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 174.419 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 71.7 mt -62.68 114.98 13.84 Favored Pre-proline 0 C--N 1.27 -2.873 0 C-N-CA 124.774 1.229 . . . . 0.0 108.036 175.193 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.449 ' HB2' HD11 ' A' ' 120' ' ' LEU . 29.1 Cg_endo -65.07 151.31 86.13 Favored 'Trans proline' 0 N--CA 1.447 -1.264 0 C-N-CA 122.479 2.119 . . . . 0.0 112.062 -177.929 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 48.2 mt -87.16 134.37 27.77 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.118 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.512 -174.165 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 93.5 m -107.82 148.13 29.95 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 171.165 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -129.8 144.85 51.51 Favored 'General case' 0 C--N 1.284 -2.266 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -179.824 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 117' ' ' GLY . 4.8 p -73.26 129.43 36.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.846 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.637 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 27.6 m -54.19 130.02 15.71 Favored 'Isoleucine or valine' 0 C--O 1.243 0.741 0 O-C-N 123.848 0.717 . . . . 0.0 112.209 -174.827 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.435 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 94.8 mttt -112.54 170.08 8.43 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.533 -175.985 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.0 p -150.41 158.82 44.58 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.052 176.33 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 147' ' ' LEU . . . . . 0.475 HD23 ' HD2' ' A' ' 148' ' ' PRO . 1.4 tt -55.48 131.6 70.76 Favored Pre-proline 0 N--CA 1.429 -1.515 0 C-N-CA 125.59 1.556 . . . . 0.0 111.992 -178.258 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.475 ' HD2' HD23 ' A' ' 147' ' ' LEU . 37.8 Cg_endo -69.08 100.6 0.74 Allowed 'Trans proline' 0 N--CA 1.445 -1.334 0 C-N-CA 122.846 2.364 . . . . 0.0 111.806 176.963 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 10.2 p -64.07 140.05 20.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.935 0 CA-C-N 115.428 -0.805 . . . . 0.0 108.948 176.607 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 15.6 p -73.12 -82.38 0.05 Allowed 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -174.529 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 175.45 162.62 0.41 Allowed Pre-proline 0 CA--C 1.517 -0.311 0 C-N-CA 124.771 1.228 . . . . 0.0 107.843 179.403 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -74.05 -178.16 3.69 Favored 'Trans proline' 0 N--CA 1.446 -1.301 0 C-N-CA 121.353 1.369 . . . . 0.0 110.254 170.57 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 153' ' ' GLU . . . . . 0.542 ' OE2' ' HG3' ' A' ' 204' ' ' LYS . 0.0 OUTLIER -93.15 -41.07 10.13 Favored 'General case' 0 C--N 1.289 -2.04 0 O-C-N 122.051 -0.406 . . . . 0.0 111.413 -176.394 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 154' ' ' ASN . . . . . 0.436 ' OD1' ' HG2' ' A' ' 153' ' ' GLU . 23.3 m120 -107.59 21.12 17.92 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.529 0.68 . . . . 0.0 110.259 179.736 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -148.54 -172.68 18.65 Favored Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.677 -178.274 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 58.8 pttt -145.98 164.38 32.25 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -176.621 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.436 HG22 ' H ' ' A' ' 159' ' ' SER . 63.5 mt -88.51 136.01 24.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 177.866 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 175' ' ' ARG . 11.5 m -84.73 -25.82 6.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.128 0.489 . . . . 0.0 110.81 -178.004 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 159' ' ' SER . . . . . 0.436 ' H ' HG22 ' A' ' 157' ' ' ILE . 21.4 t . . . . . 0 N--CA 1.432 -1.338 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.761 -174.98 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 168' ' ' TYR . . . . . 0.435 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 95.1 m-85 . . . . . 0 N--CA 1.443 -0.812 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.444 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 77.1 m-70 -136.31 169.61 17.37 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.642 -173.747 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.637 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 91.7 t80 -50.11 128.94 20.16 Favored 'General case' 0 C--O 1.24 0.573 0 O-C-N 124.2 0.937 . . . . 0.0 110.571 173.468 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 101.14 -14.08 58.52 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 119.972 -1.108 . . . . 0.0 112.751 175.95 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 17.0 mm-40 -77.19 143.45 39.02 Favored 'General case' 0 C--O 1.251 1.143 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.154 178.272 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -124.86 101.19 6.96 Favored 'General case' 0 C--N 1.285 -2.228 0 CA-C-N 114.767 -1.106 . . . . 0.0 108.859 -179.697 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.409 ' HB ' ' HG3' ' A' ' 190' ' ' MET . 69.2 t -81.38 96.62 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.648 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.252 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.6 ' O ' HG22 ' A' ' 158' ' ' VAL . 26.4 ttp180 -96.81 142.99 28.15 Favored 'General case' 0 N--CA 1.4 -2.936 0 CA-C-N 114.55 -1.204 . . . . 0.0 108.052 177.191 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -113.07 162.14 16.27 Favored 'General case' 0 C--N 1.278 -2.502 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -176.243 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 14.5 p -143.86 137.15 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.346 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 175.761 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 178' ' ' CYS . . . . . 0.432 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 80.8 m -92.7 152.37 19.56 Favored 'General case' 0 C--N 1.257 -3.438 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.586 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 51.2 m-80 -70.6 166.16 21.26 Favored 'General case' 0 CA--C 1.493 -1.22 0 C-N-CA 120.368 -0.533 . . . . 0.0 110.176 179.546 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 12.6 t -53.61 110.31 0.56 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 124.274 0.984 . . . . 0.0 111.163 -176.082 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 116.44 -13.88 15.59 Favored Glycine 0 N--CA 1.435 -1.383 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.706 179.307 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 182' ' ' TYR . . . . . 0.432 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 96.4 m-85 -110.7 163.25 13.94 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 117.482 0.641 . . . . 0.0 110.876 -179.007 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 18.1 ptmt -135.39 157.26 47.34 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.692 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.414 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.8 tt -84.98 137.53 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.766 0 CA-C-O 121.609 0.718 . . . . 0.0 111.127 -179.367 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -72.2 -53.48 12.51 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.091 -177.455 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -93.9 -134.8 7.38 Favored Glycine 0 C--N 1.296 -1.674 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.087 -177.781 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -81.35 169.66 16.96 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 178.462 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.414 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.8 pt-20 -100.63 -15.76 17.65 Favored 'General case' 0 C--N 1.289 -2.048 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -176.338 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -144.19 138.32 28.01 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 -175.394 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.409 ' HG3' ' HB ' ' A' ' 174' ' ' VAL . 13.8 ptp -117.45 130.2 56.31 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.713 174.883 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -102.49 137.19 41.06 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.965 -177.031 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 192' ' ' CYS . . . . . 0.476 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 19.6 t -88.1 107.99 19.03 Favored 'General case' 0 C--O 1.253 1.274 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 174.515 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 21.7 m -102.81 -176.64 3.15 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 112.964 0.727 . . . . 0.0 112.964 -171.148 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -44.37 -39.32 4.56 Favored 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 126.148 1.779 . . . . 0.0 113.491 -176.973 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -63.54 -17.28 62.63 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.862 -177.047 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 78.57 32.91 40.23 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -174.092 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -144.11 171.92 13.62 Favored 'General case' 0 C--O 1.249 1.034 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 -179.544 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 198' ' ' TRP . . . . . 0.476 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 81.9 m95 -87.32 137.6 32.2 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 175.778 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 44.7 m -83.35 -3.31 57.38 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.168 0.509 . . . . 0.0 111.941 179.881 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 20.2 mmtp -128.54 162.15 27.91 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.581 179.471 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -95.65 166.09 12.0 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.935 179.86 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 202' ' ' LYS . . . . . 0.449 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 9.8 tptm -65.34 116.97 35.71 Favored Pre-proline 0 CA--C 1.547 0.834 0 C-N-CA 123.337 0.655 . . . . 0.0 111.299 179.168 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 203' ' ' PRO . . . . . 0.449 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 6.7 Cg_endo -90.54 177.87 2.17 Favored 'Trans proline' 0 CA--C 1.547 1.148 0 C-N-CA 122.658 2.238 . . . . 0.0 112.85 177.198 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 204' ' ' LYS . . . . . 0.542 ' HG3' ' OE2' ' A' ' 153' ' ' GLU . 22.1 ttmm -131.25 157.11 44.13 Favored 'General case' 0 C--N 1.318 -0.804 0 C-N-CA 124.319 1.048 . . . . 0.0 109.531 -177.238 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.429 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 87.8 m -104.06 119.22 38.47 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 173.857 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.296 -1.758 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.754 -174.693 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.4 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 31.7 Cg_endo . . . . . 0 CA--C 1.531 0.373 0 CA-C-O 121.665 0.611 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.9 m -88.43 -32.96 18.04 Favored 'General case' 0 N--CA 1.436 -1.125 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 176.332 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.99 -85.72 0.4 Allowed Glycine 0 CA--C 1.453 -3.839 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 171.58 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.2 t-80 -173.75 133.75 0.6 Allowed Pre-proline 0 C--N 1.266 -3.037 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 -174.328 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.507 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 89.9 Cg_endo -87.24 -5.07 7.63 Favored 'Trans proline' 0 C--O 1.242 0.686 0 C-N-CA 122.252 1.968 . . . . 0.0 112.94 -176.364 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.499 ' HA3' HD11 ' A' ' 138' ' ' ILE . . . 126.38 -161.72 20.67 Favored Glycine 0 N--CA 1.42 -2.379 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 -178.375 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -158.48 150.52 21.53 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 177.86 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.9 t -131.53 127.04 21.43 Favored Pre-proline 0 C--N 1.301 -1.519 0 C-N-CA 119.746 -0.781 . . . . 0.0 111.994 -177.382 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -71.37 -16.6 31.06 Favored 'Trans proline' 0 CA--C 1.534 0.522 0 C-N-CA 122.541 2.161 . . . . 0.0 111.502 177.075 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 71.5 m-85 -83.45 -6.6 59.51 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.988 -177.458 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.44 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 171.89 -129.94 1.84 Allowed Glycine 0 N--CA 1.414 -2.79 0 C-N-CA 118.838 -1.648 . . . . 0.0 113.48 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.5 p -141.21 178.6 7.28 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 114.989 -0.606 . . . . 0.0 111.288 -174.804 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.466 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 36.5 p90 -148.66 155.23 40.77 Favored 'General case' 0 N--CA 1.431 -1.383 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 171.327 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -123.98 153.15 41.69 Favored 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 -178.316 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -110.74 126.67 54.82 Favored 'General case' 0 C--N 1.271 -2.814 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -179.774 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.424 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 17.2 p -121.26 134.14 55.17 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.265 -176.508 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 108.14 -45.92 1.24 Allowed Glycine 0 C--N 1.311 -0.811 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.989 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.441 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -128.3 -18.21 1.88 Allowed Glycine 0 C--N 1.311 -0.842 0 C-N-CA 120.382 -0.913 . . . . 0.0 113.009 -179.901 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 63.27 16.55 9.54 Favored 'General case' 0 N--CA 1.494 1.731 0 C-N-CA 124.388 1.075 . . . . 0.0 110.868 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.513 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.6 m -148.41 -171.86 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.211 -0.965 0 N-CA-C 106.967 -1.494 . . . . 0.0 106.967 -178.912 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.507 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 32.6 m-85 -101.47 44.66 1.0 Allowed 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 118.794 0.725 . . . . 0.0 110.648 -177.486 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.69 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.2 pt-20 -86.51 -175.73 5.57 Favored 'General case' 0 C--O 1.207 -1.143 0 CA-C-N 114.837 -1.074 . . . . 0.0 111.468 177.638 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 106' ' ' TYR . . . . . 0.4 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 43.5 m-85 -81.05 139.65 35.59 Favored 'General case' 0 C--N 1.308 -1.226 0 O-C-N 121.686 -0.634 . . . . 0.0 111.085 178.786 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.44 4.29 80.55 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.655 -0.702 . . . . 0.0 112.529 179.122 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.69 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -94.25 142.92 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 C-N-CA 119.763 -0.775 . . . . 0.0 109.123 -179.628 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.424 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -107.67 121.23 44.26 Favored 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.708 178.441 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -86.81 89.67 8.04 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 175.575 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 94.6 t -85.71 115.13 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.638 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -177.647 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 112' ' ' TYR . . . . . 0.466 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 43.2 m-85 -86.63 145.77 26.59 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 116.605 -0.271 . . . . 0.0 111.116 -177.061 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.1 t -145.44 116.74 7.95 Favored 'General case' 0 N--CA 1.427 -1.602 0 CA-C-O 122.404 1.097 . . . . 0.0 109.471 178.11 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 28.4 m -72.89 164.95 25.86 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 114.901 -1.045 . . . . 0.0 111.191 -174.887 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.44 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 81.0 m-20 -75.31 171.71 13.73 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.505 177.143 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -58.49 -39.4 79.9 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 113.269 0.84 . . . . 0.0 113.269 -174.331 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.425 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -75.39 12.41 7.55 Favored Glycine 0 CA--C 1.526 0.752 0 C-N-CA 120.838 -0.696 . . . . 0.0 113.063 179.733 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.67 ' HE1' HG22 ' A' ' 143' ' ' VAL . 83.5 m-85 -147.09 170.09 17.9 Favored 'General case' 0 N--CA 1.427 -1.582 0 C-N-CA 124.56 1.144 . . . . 0.0 108.95 -177.51 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -140.58 173.5 11.43 Favored 'General case' 0 C--N 1.266 -3.058 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 175.699 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.9 tt -99.92 137.5 38.29 Favored 'General case' 0 C--N 1.27 -2.851 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -179.713 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.447 ' HB2' ' HB2' ' A' ' 142' ' ' GLU . 0.2 OUTLIER -127.52 135.83 50.89 Favored 'General case' 0 N--CA 1.423 -1.818 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -176.978 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 130.02 179.29 15.92 Favored Glycine 0 N--CA 1.421 -2.311 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 178.397 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 61.7 mm-40 -95.88 -17.05 21.4 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 122.282 1.039 . . . . 0.0 109.078 177.102 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.6 mm -101.5 142.84 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.588 0 CA-C-N 114.184 -1.371 . . . . 0.0 108.233 179.032 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -141.14 9.61 2.11 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-O 121.278 0.561 . . . . 0.0 109.517 177.795 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 126' ' ' TYR . . . . . . . . . . . . . 32.8 p90 -157.55 159.57 37.28 Favored 'General case' 0 N--CA 1.427 -1.602 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.747 -172.981 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 56.4 mtp180 -121.16 129.85 53.44 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 172.507 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -105.43 130.61 53.48 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -178.512 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.6 t -83.1 105.35 14.01 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 117.625 -1.63 . . . . 0.0 110.206 176.643 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.423 ' OD2' HG22 ' A' ' 131' ' ' THR . 22.5 t70 -94.38 -178.59 4.63 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 178.297 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.423 HG22 ' OD2' ' A' ' 130' ' ' ASP . 11.0 t -63.28 -22.49 66.91 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 121.728 0.775 . . . . 0.0 110.38 -177.729 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -76.59 -37.12 56.99 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.769 177.735 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 139.28 -159.49 25.69 Favored Glycine 0 N--CA 1.434 -1.462 0 N-CA-C 107.982 -2.047 . . . . 0.0 107.982 -173.938 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -66.38 122.99 18.77 Favored 'General case' 0 C--O 1.248 0.979 0 CA-C-N 118.258 1.029 . . . . 0.0 110.539 177.653 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 67.7 p -80.89 163.32 23.47 Favored 'General case' 0 N--CA 1.416 -2.167 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 175.814 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 61.74 -165.21 0.23 Allowed 'General case' 0 C--N 1.323 -0.582 0 O-C-N 124.017 0.823 . . . . 0.0 110.579 175.21 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -129.57 -179.92 5.45 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 175.678 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.499 HD11 ' HA3' ' A' ' 89' ' ' GLY . 62.3 mt -66.6 122.24 81.06 Favored Pre-proline 0 C--N 1.298 -1.648 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 173.245 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.55 158.15 54.59 Favored 'Trans proline' 0 C--O 1.243 0.742 0 C-N-CA 122.67 2.247 . . . . 0.0 111.416 179.275 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 68.0 mt -84.95 131.65 33.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 CA-C-O 121.03 0.443 . . . . 0.0 111.016 -174.051 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 91.4 m -98.45 102.01 13.62 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 173.263 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.447 ' HB2' ' HB2' ' A' ' 121' ' ' LEU . 1.0 OUTLIER -87.88 154.5 20.47 Favored 'General case' 0 CA--C 1.461 -2.443 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.147 178.693 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.67 HG22 ' HE1' ' A' ' 118' ' ' TYR . 4.3 t -80.7 137.34 21.58 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.367 0 CA-C-N 114.82 -1.082 . . . . 0.0 108.661 -177.197 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.6 HG23 ' HB2' ' A' ' 170' ' ' PHE . 3.7 m -69.83 98.34 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.153 177.407 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.454 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 49.2 mttm -88.07 131.81 34.53 Favored 'General case' 0 N--CA 1.417 -2.094 0 CA-C-N 113.754 -1.566 . . . . 0.0 109.387 -176.945 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.43 ' O ' ' HB2' ' A' ' 168' ' ' TYR . 61.6 m -94.16 127.43 39.99 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 107.17 -1.419 . . . . 0.0 107.17 177.026 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -50.24 138.94 19.69 Favored Pre-proline 0 N--CA 1.438 -1.071 0 N-CA-C 114.655 1.354 . . . . 0.0 114.655 -176.264 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -69.7 123.38 10.07 Favored 'Trans proline' 0 N--CA 1.444 -1.425 0 C-N-CA 122.926 2.417 . . . . 0.0 112.304 -175.522 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 21.2 t -91.84 130.75 40.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.4 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.3 m -74.93 -67.96 0.59 Allowed 'General case' 0 N--CA 1.414 -2.268 0 C-N-CA 122.764 0.425 . . . . 0.0 111.16 -177.866 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.96 150.12 0.22 Allowed Pre-proline 0 CA--C 1.509 -0.599 0 C-N-CA 124.686 1.194 . . . . 0.0 108.079 -178.934 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -77.07 174.7 12.41 Favored 'Trans proline' 0 N--CA 1.446 -1.315 0 C-N-CA 121.836 1.691 . . . . 0.0 110.811 173.947 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -61.58 -51.78 67.14 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 114.215 1.191 . . . . 0.0 114.215 -174.913 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -123.29 23.27 9.14 Favored 'General case' 0 CA--C 1.496 -1.108 0 CA-C-O 122.032 0.92 . . . . 0.0 109.891 -172.411 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 155' ' ' GLY . . . . . 0.472 ' HA3' ' SG ' ' A' ' 205' ' ' CYS . . . -140.47 -178.15 16.76 Favored Glycine 0 C--N 1.281 -2.516 0 CA-C-N 114.071 -1.422 . . . . 0.0 109.906 178.716 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 47.6 pttt -143.91 162.52 35.91 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 -177.146 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.559 HG22 ' H ' ' A' ' 159' ' ' SER . 46.7 mt -92.25 135.98 25.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 -179.632 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' A' ' 175' ' ' ARG . 10.8 m -71.19 -23.14 22.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-O 121.872 0.844 . . . . 0.0 111.382 -175.281 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 159' ' ' SER . . . . . 0.559 ' H ' HG22 ' A' ' 157' ' ' ILE . 20.8 t . . . . . 0 C--N 1.296 -1.724 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -178.849 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 168' ' ' TYR . . . . . 0.454 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 95.5 m-85 . . . . . 0 N--CA 1.444 -0.74 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 23.3 m80 -129.28 161.5 30.08 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -174.469 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.6 ' HB2' HG23 ' A' ' 144' ' ' VAL . 87.1 t80 -51.9 107.74 0.22 Allowed 'General case' 0 N--CA 1.469 0.513 0 O-C-N 123.82 0.7 . . . . 0.0 110.675 174.54 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 139.05 -24.57 2.83 Favored Glycine 0 N--CA 1.433 -1.557 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -175.681 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -78.34 160.91 27.57 Favored 'General case' 0 N--CA 1.429 -1.523 0 CA-C-O 121.602 0.715 . . . . 0.0 112.897 -179.43 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.424 ' HA ' ' O ' ' A' ' 190' ' ' MET . . . -148.28 118.46 7.28 Favored 'General case' 0 N--CA 1.423 -1.775 0 CA-C-N 114.376 -1.283 . . . . 0.0 109.027 179.793 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.482 HG23 ' CH2' ' A' ' 198' ' ' TRP . 46.2 t -86.18 107.41 16.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.13 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.537 ' HB3' HG21 ' A' ' 158' ' ' VAL . 78.9 ttt180 -99.64 140.57 33.65 Favored 'General case' 0 N--CA 1.42 -1.954 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 178.067 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -114.49 161.09 18.45 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 -176.468 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 7.7 p -140.9 128.06 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.812 0 CA-C-N 115.22 -0.9 . . . . 0.0 109.931 175.948 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 178' ' ' CYS . . . . . 0.454 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 71.7 m -89.11 152.24 21.76 Favored 'General case' 0 C--N 1.276 -2.607 0 CA-C-N 114.915 -1.038 . . . . 0.0 110.138 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -68.9 -179.92 1.62 Allowed 'General case' 0 C--O 1.239 0.532 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.714 178.663 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 8.8 p -47.02 -39.67 13.14 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 115.945 1.832 . . . . 0.0 115.945 -172.097 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -109.51 15.5 32.25 Favored Glycine 0 C--N 1.286 -2.212 0 C-N-CA 120.328 -0.939 . . . . 0.0 113.239 -176.626 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 182' ' ' TYR . . . . . 0.454 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 96.5 m-85 -116.12 157.97 23.94 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 117.974 0.887 . . . . 0.0 111.571 -178.24 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -126.93 158.05 37.82 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 106.557 -1.645 . . . . 0.0 106.557 175.763 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.674 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.5 tt -91.28 139.45 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.23 0 C-N-CA 119.167 -1.013 . . . . 0.0 110.806 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -50.04 -58.95 4.42 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 126.08 1.752 . . . . 0.0 113.106 -177.657 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -128.64 -103.88 1.15 Allowed Glycine 0 CA--C 1.493 -1.331 0 C-N-CA 120.247 -0.978 . . . . 0.0 111.276 -178.394 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -80.52 159.12 25.62 Favored 'General case' 0 CA--C 1.486 -1.497 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 177.815 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.674 ' HA ' HD13 ' A' ' 184' ' ' ILE . 15.0 pt-20 -103.45 4.45 36.08 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.428 -0.909 . . . . 0.0 109.507 178.34 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -148.44 146.61 28.5 Favored 'General case' 0 N--CA 1.426 -1.654 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.018 -175.715 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.424 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 12.3 ptp -124.44 121.21 34.25 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.11 174.279 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 46.0 t-80 -98.77 145.41 26.97 Favored 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.069 -176.661 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 12.8 m -62.01 148.52 43.67 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 177.133 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 31.5 m -127.9 159.95 33.34 Favored 'General case' 0 N--CA 1.423 -1.813 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 173.074 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -69.97 -1.46 9.77 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -172.65 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -75.84 -15.91 60.16 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.039 0.447 . . . . 0.0 109.901 175.458 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 88.12 22.19 42.62 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -172.454 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -135.81 169.38 17.66 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -179.917 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 198' ' ' TRP . . . . . 0.482 ' CH2' HG23 ' A' ' 174' ' ' VAL . 78.1 m95 -87.13 151.42 23.22 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.818 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 39.6 t -71.1 -50.1 37.28 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 121.531 0.682 . . . . 0.0 109.186 177.739 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.409 ' HD3' ' HA ' ' A' ' 200' ' ' LYS . 25.4 mmtp -88.49 148.99 23.88 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-O 121.417 0.627 . . . . 0.0 111.623 -179.798 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -89.11 150.65 22.63 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.813 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 202' ' ' LYS . . . . . 0.433 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 27.3 ttpp -58.73 112.95 5.69 Favored Pre-proline 0 C--O 1.237 0.4 0 N-CA-C 114.443 1.275 . . . . 0.0 114.443 -173.306 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 203' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 18.0 Cg_exo -72.01 171.38 16.8 Favored 'Trans proline' 0 N--CA 1.451 -1.014 0 C-N-CA 123.395 2.73 . . . . 0.0 110.631 175.322 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.4 mttp -123.36 167.06 14.29 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -177.753 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.472 ' SG ' ' HA3' ' A' ' 155' ' ' GLY . 94.5 m -106.59 104.65 14.39 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 172.195 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 11.4 m . . . . . 0 C--N 1.296 -1.751 0 CA-C-N 114.782 -1.099 . . . . 0.0 112.327 -171.924 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo . . . . . 0 CA--C 1.536 0.611 0 CA-C-O 121.783 0.66 . . . . 0.0 111.082 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.5 m -82.5 -32.86 28.57 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.309 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.53 -85.86 0.4 Allowed Glycine 0 CA--C 1.458 -3.508 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 173.073 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 179.42 130.43 0.23 Allowed Pre-proline 0 C--N 1.271 -2.818 0 N-CA-C 104.153 -2.536 . . . . 0.0 104.153 -176.056 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.4 -33.07 5.81 Favored 'Trans proline' 0 N--CA 1.474 0.363 0 C-N-CA 121.625 1.55 . . . . 0.0 112.744 -175.423 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 134.52 177.26 14.82 Favored Glycine 0 N--CA 1.419 -2.445 0 N-CA-C 107.021 -2.432 . . . . 0.0 107.021 -176.017 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -134.91 162.96 30.95 Favored 'General case' 0 C--N 1.287 -2.14 0 CA-C-N 118.36 1.08 . . . . 0.0 109.433 179.848 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.7 t -119.35 131.44 24.37 Favored Pre-proline 0 N--CA 1.416 -2.153 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.183 -178.516 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.02 -11.69 17.85 Favored 'Trans proline' 0 N--CA 1.459 -0.509 0 C-N-CA 122.563 2.176 . . . . 0.0 111.616 177.872 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -88.93 -2.89 58.81 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.216 -177.814 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.462 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 175.57 -128.02 1.34 Allowed Glycine 0 N--CA 1.414 -2.793 0 C-N-CA 118.961 -1.59 . . . . 0.0 113.63 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.1 p -138.56 170.5 15.89 Favored 'General case' 0 C--N 1.291 -1.96 0 CA-C-N 114.841 -0.68 . . . . 0.0 110.972 -174.641 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.2 p90 -140.74 145.65 36.71 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 171.023 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.7 m -120.32 161.23 21.49 Favored 'General case' 0 C--N 1.271 -2.843 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -176.894 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.5 mt -119.56 120.97 38.29 Favored 'General case' 0 C--N 1.28 -2.448 0 CA-C-O 121.028 0.442 . . . . 0.0 109.867 -177.443 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.48 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 24.0 p -109.99 129.02 55.73 Favored 'General case' 0 C--N 1.285 -2.218 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.52 -175.383 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 113.38 -54.91 0.54 Allowed Glycine 0 N--CA 1.432 -1.593 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.073 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.429 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -121.24 -12.63 5.67 Favored Glycine 0 C--N 1.305 -1.19 0 C-N-CA 119.965 -1.112 . . . . 0.0 113.335 -179.514 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 47.7 m-80 61.26 18.55 9.28 Favored 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 123.485 0.714 . . . . 0.0 112.22 -178.168 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.54 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.7 m -151.32 -174.48 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.206 -1.21 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -175.806 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -99.71 46.05 0.98 Allowed 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 118.732 0.696 . . . . 0.0 110.619 -177.339 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.691 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.1 pt-20 -86.91 179.79 6.65 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.632 177.019 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 41.2 m-85 -76.12 137.28 40.01 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 122.039 -0.413 . . . . 0.0 111.301 177.089 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.98 -7.96 70.11 Favored Glycine 0 N--CA 1.441 -0.969 0 CA-C-N 115.603 -0.726 . . . . 0.0 113.048 178.003 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.691 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.9 p -87.14 146.8 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.881 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 -175.163 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.48 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.9 mtpt -110.25 125.84 53.53 Favored 'General case' 0 N--CA 1.419 -2.011 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.248 178.129 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -88.42 95.99 10.42 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 175.442 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 77.5 t -90.08 113.65 26.55 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.901 0 C-N-CA 123.988 0.915 . . . . 0.0 108.819 -177.451 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -88.48 134.6 33.8 Favored 'General case' 0 C--N 1.285 -2.228 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.992 -178.948 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.1 t -142.82 124.04 14.6 Favored 'General case' 0 N--CA 1.428 -1.561 0 CA-C-O 122.067 0.937 . . . . 0.0 109.399 179.51 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.404 ' HB3' ' HB2' ' A' ' 118' ' ' TYR . 78.0 m -75.35 166.46 23.57 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.949 -174.064 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.462 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 85.2 m-20 -85.46 -177.03 6.34 Favored 'General case' 0 C--O 1.216 -0.698 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.295 178.393 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -42.93 -54.44 4.21 Favored 'General case' 0 C--N 1.311 -1.072 0 C-N-CA 126.163 1.785 . . . . 0.0 114.527 -177.435 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -92.41 17.34 57.64 Favored Glycine 0 C--N 1.299 -1.495 0 C-N-CA 119.497 -1.335 . . . . 0.0 112.859 -175.111 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.717 ' HE1' HG22 ' A' ' 143' ' ' VAL . 77.8 m-85 -133.95 147.32 51.04 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.182 -177.304 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 119' ' ' GLN . . . . . 0.438 ' OE1' ' HB3' ' A' ' 142' ' ' GLU . 0.0 OUTLIER -136.3 160.07 39.84 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -178.849 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 120' ' ' LEU . . . . . 0.452 HD22 ' HB3' ' A' ' 125' ' ' ASN . 10.4 tp -83.7 141.44 31.47 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 118.915 -1.114 . . . . 0.0 109.947 -176.309 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.05 122.91 43.21 Favored 'General case' 0 N--CA 1.411 -2.381 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 179.177 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.66 -160.42 13.7 Favored Glycine 0 C--N 1.293 -1.855 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.77 -176.568 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -105.9 -48.31 3.65 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.129 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.5 mm -73.4 129.51 36.16 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.132 -173.458 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.452 ' HB3' HD22 ' A' ' 120' ' ' LEU . 6.4 p30 -130.0 12.99 5.73 Favored 'General case' 0 C--O 1.213 -0.838 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 177.516 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.47 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 34.0 p90 -149.67 161.74 41.59 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.85 -176.48 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 44.3 mtp180 -127.46 131.78 50.13 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 172.069 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -108.06 131.98 54.03 Favored 'General case' 0 C--N 1.283 -2.301 0 C-N-CA 119.202 -0.999 . . . . 0.0 109.5 -178.405 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 21.6 t -81.4 99.27 8.62 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.829 -1.149 . . . . 0.0 109.155 176.533 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.425 ' OD2' HG22 ' A' ' 131' ' ' THR . 8.6 t70 -96.35 -167.13 1.52 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 178.447 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.425 HG22 ' OD2' ' A' ' 130' ' ' ASP . 9.0 t -59.37 -28.46 66.9 Favored 'General case' 0 C--N 1.31 -1.121 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -174.733 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -85.95 -23.65 26.85 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.549 0.69 . . . . 0.0 110.213 179.596 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 128.96 -153.96 20.01 Favored Glycine 0 N--CA 1.421 -2.362 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -175.646 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -64.87 113.38 3.79 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -179.878 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 65.0 p -73.09 172.48 10.97 Favored 'General case' 0 C--O 1.27 2.154 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 176.188 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 63.6 m-20 59.68 -156.74 0.34 Allowed 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 175.984 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -141.15 -177.51 5.15 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 173.092 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 57.0 mt -65.73 116.88 36.17 Favored Pre-proline 0 C--N 1.273 -2.728 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 174.806 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.413 ' HB2' HD11 ' A' ' 120' ' ' LEU . 49.2 Cg_endo -68.61 160.83 47.77 Favored 'Trans proline' 0 C--O 1.246 0.91 0 C-N-CA 122.418 2.079 . . . . 0.0 112.308 -176.01 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 48.7 mm -90.67 131.52 37.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.364 -176.382 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.613 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 36.6 t -114.08 137.62 51.49 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 105.752 -1.944 . . . . 0.0 105.752 175.697 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.438 ' HB3' ' OE1' ' A' ' 119' ' ' GLN . 9.7 tp10 -119.1 157.59 27.56 Favored 'General case' 0 C--N 1.277 -2.557 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.717 HG22 ' HE1' ' A' ' 118' ' ' TYR . 24.0 t -79.84 138.54 19.72 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.073 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 -178.908 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 70.6 t -60.01 122.01 9.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 124.305 1.003 . . . . 0.0 108.399 179.331 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.507 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 59.9 mttm -120.33 156.06 32.07 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.899 -178.815 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 80.1 m -108.65 -171.54 1.87 Allowed 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 123.825 0.85 . . . . 0.0 110.677 -179.827 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 147' ' ' LEU . . . . . 0.588 HD12 ' HD2' ' A' ' 148' ' ' PRO . 1.5 tp -95.56 134.34 24.39 Favored Pre-proline 0 N--CA 1.421 -1.913 0 O-C-N 122.027 -0.421 . . . . 0.0 110.023 -177.181 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.588 ' HD2' HD12 ' A' ' 147' ' ' LEU . 12.7 Cg_endo -58.2 121.51 10.12 Favored 'Trans proline' 0 CA--C 1.535 0.543 0 C-N-CA 123.23 2.62 . . . . 0.0 111.563 177.333 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 28.7 t -85.94 143.65 11.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 -177.975 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 19.5 p -77.98 -83.12 0.08 Allowed 'General case' 0 N--CA 1.42 -1.974 0 CA-C-N 116.806 -0.179 . . . . 0.0 111.308 175.436 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.96 156.56 0.21 Allowed Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 125.143 1.377 . . . . 0.0 107.757 179.604 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -69.79 162.93 40.18 Favored 'Trans proline' 0 C--N 1.353 0.816 0 C-N-CA 121.723 1.615 . . . . 0.0 110.896 172.915 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -62.3 -50.6 71.02 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -174.926 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 27.2 m120 -113.76 38.17 3.04 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 -177.96 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -154.06 -164.41 12.75 Favored Glycine 0 N--CA 1.425 -2.051 0 CA-C-N 115.026 -0.988 . . . . 0.0 111.189 178.353 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -156.0 173.24 17.09 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -178.601 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 49.7 mt -88.98 134.73 27.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 CA-C-O 121.148 0.499 . . . . 0.0 110.499 -179.251 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 55.1 t -73.98 -43.38 52.27 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 C-N-CA 124.149 0.98 . . . . 0.0 109.455 178.779 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 2.1 m . . . . . 0 C--N 1.29 -1.994 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -179.86 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 . . . . . 0 CA--C 1.49 -1.355 0 CA-C-O 121.074 0.464 . . . . 0.0 111.681 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.507 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 20.9 p-80 -96.34 159.52 14.9 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.623 -179.135 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 50.3 t80 -50.78 123.29 8.73 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 125.311 1.444 . . . . 0.0 109.59 176.978 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.62 -10.93 21.39 Favored Glycine 0 N--CA 1.425 -2.092 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.621 -178.068 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.0 mm-40 -89.65 143.64 26.64 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-N 117.805 0.802 . . . . 0.0 111.195 179.585 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -111.86 126.44 55.09 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.468 -1.242 . . . . 0.0 107.826 177.848 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.574 HG12 ' CG ' ' A' ' 190' ' ' MET . 0.3 OUTLIER -117.76 118.5 58.57 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.246 0 C-N-CA 119.249 -0.981 . . . . 0.0 108.384 178.73 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 43.9 ttm180 -104.54 157.52 17.12 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 -179.275 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -129.12 154.35 46.79 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -176.031 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.5 p -135.82 152.13 30.47 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.158 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.581 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 74.8 m -105.48 146.29 29.74 Favored 'General case' 0 C--N 1.274 -2.716 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.871 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -65.88 172.93 3.23 Favored 'General case' 0 CA--C 1.503 -0.832 0 O-C-N 123.732 0.645 . . . . 0.0 110.473 -177.441 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 6.0 p -53.75 104.9 0.11 Allowed 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 124.317 1.047 . . . . 0.0 112.939 -177.764 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.18 -3.64 31.47 Favored Glycine 0 N--CA 1.433 -1.508 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.457 177.889 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -112.64 150.27 31.68 Favored 'General case' 0 N--CA 1.42 -1.946 0 O-C-N 122.162 -0.611 . . . . 0.0 110.397 179.89 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 65.0 pttt -123.36 160.3 27.06 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.412 HD11 ' HB2' ' A' ' 203' ' ' PRO . 1.7 tp -76.18 142.2 14.72 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -179.787 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -88.5 -69.1 0.72 Allowed 'General case' 0 C--N 1.287 -2.114 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -77.8 -128.22 0.42 Allowed Glycine 0 N--CA 1.437 -1.251 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.717 176.964 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 187' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 203' ' ' PRO . 5.6 t70 -98.28 162.04 13.39 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.281 -1.378 . . . . 0.0 107.281 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -99.78 1.1 42.84 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 119.513 1.051 . . . . 0.0 112.23 -170.618 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -152.01 153.84 34.83 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 121.398 0.618 . . . . 0.0 112.475 -177.154 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.574 ' CG ' HG12 ' A' ' 174' ' ' VAL . 16.7 ptp -132.72 148.51 52.33 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.289 178.659 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 47.6 m80 -115.17 145.44 42.39 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.604 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 42.8 t -81.58 102.25 10.51 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 177.988 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 51.9 m -121.66 158.0 29.63 Favored 'General case' 0 N--CA 1.425 -1.688 0 N-CA-C 114.096 1.147 . . . . 0.0 114.096 -168.607 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 21.98 -76.87 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 129.483 3.113 . . . . 0.0 116.973 174.389 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -62.76 -21.2 65.66 Favored 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 125.014 1.325 . . . . 0.0 113.58 -172.059 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 101.73 20.72 12.38 Favored Glycine 0 N--CA 1.435 -1.42 0 C-N-CA 119.62 -1.276 . . . . 0.0 110.913 -175.819 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 21.9 p90 -146.67 173.18 12.58 Favored 'General case' 0 N--CA 1.426 -1.649 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 175.068 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.3 m95 -69.18 138.44 54.1 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 123.651 0.594 . . . . 0.0 111.62 -175.366 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 13.0 p -68.31 -33.4 74.26 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.656 178.841 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 59.5 mmtt -107.23 149.57 27.59 Favored 'General case' 0 N--CA 1.432 -1.352 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.617 -179.765 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -79.84 163.89 24.03 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 114.463 -1.244 . . . . 0.0 109.018 176.467 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 9.6 mtpm? -64.89 128.52 93.78 Favored Pre-proline 0 CA--C 1.502 -0.867 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.964 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 203' ' ' PRO . . . . . 0.443 ' HB3' ' O ' ' A' ' 187' ' ' ASP . 95.3 Cg_endo -78.78 166.95 22.97 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 C-N-CA 122.247 1.964 . . . . 0.0 111.975 179.55 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.2 tttp -122.44 156.74 33.42 Favored 'General case' 0 N--CA 1.414 -2.268 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 -179.493 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 92.3 m -118.07 116.27 26.53 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 176.796 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 27.4 m . . . . . 0 C--N 1.301 -1.542 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.546 -176.571 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo . . . . . 0 CA--C 1.542 0.915 0 CA-C-O 120.948 0.312 . . . . 0.0 112.113 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.8 m -80.33 -31.9 37.97 Favored 'General case' 0 CA--C 1.502 -0.898 0 CA-C-O 122.262 1.03 . . . . 0.0 108.338 177.787 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.42 -87.97 0.46 Allowed Glycine 1 N--CA 1.395 -4.064 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 173.444 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 10.4 t60 -176.47 133.22 0.4 Allowed Pre-proline 0 C--N 1.262 -3.213 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 -175.273 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.484 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 85.7 Cg_endo -81.91 1.04 9.49 Favored 'Trans proline' 0 N--CA 1.475 0.422 0 C-N-CA 122.58 2.187 . . . . 0.0 113.464 -174.819 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 100.72 -169.24 21.06 Favored Glycine 0 C--N 1.291 -1.96 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 -175.394 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -151.06 178.37 9.26 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.521 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.9 t -142.99 139.09 16.43 Favored Pre-proline 0 N--CA 1.427 -1.596 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.813 -176.984 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.97 -11.87 21.55 Favored 'Trans proline' 0 CA--C 1.534 0.5 0 C-N-CA 122.635 2.223 . . . . 0.0 111.349 176.227 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -89.63 -4.15 57.93 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.228 -177.021 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.572 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 173.83 -123.73 0.99 Allowed Glycine 0 N--CA 1.419 -2.444 0 C-N-CA 119.823 -1.18 . . . . 0.0 112.371 179.766 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.1 t -165.22 -163.25 0.67 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.28 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.445 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 54.4 p90 -145.72 175.07 10.66 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 178.593 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.8 m -136.01 163.43 30.32 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 176.645 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 23.8 mt -118.94 120.89 38.61 Favored 'General case' 0 C--N 1.285 -2.22 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -178.885 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.413 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 26.1 p -114.13 128.75 56.52 Favored 'General case' 0 C--N 1.285 -2.21 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -175.411 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 97.36 19.67 24.93 Favored Glycine 0 C--N 1.299 -1.48 0 C-N-CA 119.849 -1.167 . . . . 0.0 111.149 -179.523 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.52 -32.16 0.15 Allowed Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 118.911 -1.614 . . . . 0.0 114.417 179.445 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 65.93 19.45 11.26 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 123.205 0.602 . . . . 0.0 111.174 -176.242 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.465 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.3 m -149.23 -177.86 0.47 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.084 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -175.552 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 38.1 m-85 -103.88 47.8 0.87 Allowed 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 118.726 0.694 . . . . 0.0 110.171 -179.772 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.678 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.7 pt-20 -83.63 177.8 8.24 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.311 -1.313 . . . . 0.0 111.554 179.226 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 45.5 m-85 -77.67 130.42 36.8 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.645 174.064 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 91.23 15.72 55.09 Favored Glycine 0 N--CA 1.434 -1.491 0 C-N-CA 120.203 -0.999 . . . . 0.0 112.377 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.678 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -106.38 149.5 9.77 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 176.06 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.413 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.2 mtpt -113.95 125.69 54.31 Favored 'General case' 0 N--CA 1.418 -2.048 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.485 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -90.01 89.27 7.63 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.225 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.472 HG12 ' HB3' ' A' ' 126' ' ' TYR . 28.5 m -84.91 112.28 21.74 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.981 0 CA-C-O 122.164 0.983 . . . . 0.0 109.565 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 112' ' ' TYR . . . . . 0.445 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 33.8 m-85 -78.92 142.21 36.94 Favored 'General case' 0 C--N 1.269 -2.9 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.123 -179.569 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.9 t -138.84 122.58 17.57 Favored 'General case' 0 N--CA 1.411 -2.422 0 CA-C-N 115.135 -0.938 . . . . 0.0 108.822 -179.639 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 88.0 m -73.68 160.8 31.04 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 115.487 -0.778 . . . . 0.0 112.0 -178.383 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.572 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 81.2 m-20 -76.44 -176.53 3.72 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.293 179.703 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -52.46 -48.52 65.8 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 124.655 1.182 . . . . 0.0 113.491 -177.28 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.32 10.53 70.98 Favored Glycine 0 C--N 1.3 -1.437 0 C-N-CA 119.786 -1.197 . . . . 0.0 113.306 -177.971 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.538 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 93.6 m-85 -127.62 161.02 29.85 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 122.166 -0.608 . . . . 0.0 111.419 -175.753 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -140.49 150.43 43.75 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.026 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.21 133.03 39.01 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 -179.681 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.03 127.54 55.92 Favored 'General case' 0 N--CA 1.414 -2.241 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.143 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.2 -163.27 12.62 Favored Glycine 0 C--N 1.296 -1.666 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.811 -179.804 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -108.96 -30.05 8.29 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 178.632 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.7 mm -88.16 127.06 41.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.513 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -129.56 9.84 5.57 Favored 'General case' 0 C--O 1.202 -1.44 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.034 176.777 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.472 ' HB3' HG12 ' A' ' 111' ' ' VAL . 22.1 p90 -139.08 165.52 26.94 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.397 -171.916 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.542 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 52.2 mtp180 -128.57 126.82 41.11 Favored 'General case' 0 C--O 1.204 -1.311 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 171.395 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -98.17 133.11 43.05 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.542 -0.863 . . . . 0.0 109.947 179.187 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 36.2 t -89.86 110.62 21.54 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.31 174.555 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.42 ' CG ' ' H ' ' A' ' 131' ' ' THR . 36.1 t70 -113.44 -167.21 1.17 Allowed 'General case' 0 C--N 1.289 -2.033 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 175.485 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.42 ' H ' ' CG ' ' A' ' 130' ' ' ASP . 15.3 t -67.09 -20.53 65.81 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.319 1.057 . . . . 0.0 109.69 -179.318 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -70.22 -23.73 62.98 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 114.279 -1.328 . . . . 0.0 109.233 175.001 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 105.9 -154.87 16.93 Favored Glycine 0 N--CA 1.42 -2.39 0 N-CA-C 107.169 -2.373 . . . . 0.0 107.169 -173.313 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 96.1 m95 -65.33 99.18 0.38 Allowed 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 117.666 0.733 . . . . 0.0 109.83 172.776 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.6 p -58.64 -67.58 0.35 Allowed 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 124.74 1.216 . . . . 0.0 112.839 -173.009 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 136' ' ' ASN . . . . . 0.542 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 3.0 m-20 -70.37 167.13 18.81 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.33 178.868 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -98.64 175.55 5.95 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.537 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 68.7 mt -63.92 121.83 73.52 Favored Pre-proline 0 C--N 1.273 -2.741 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 175.079 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -63.73 174.35 3.8 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 122.482 2.121 . . . . 0.0 112.791 -179.102 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 65.8 mt -98.9 140.73 17.81 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -175.307 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.538 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 42.4 t -128.92 119.5 24.48 Favored 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 -179.784 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -103.14 140.9 36.74 Favored 'General case' 0 C--N 1.279 -2.476 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 -175.901 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.418 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 10.8 p -70.9 138.74 21.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 173.932 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 92.7 t -59.61 114.66 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.73 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -176.371 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 92.4 mttt -113.73 144.55 42.76 Favored 'General case' 0 N--CA 1.426 -1.67 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.274 -177.787 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 82.9 m -112.03 160.95 17.0 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 114.732 -1.122 . . . . 0.0 109.165 179.778 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 59.7 mt -64.82 138.19 97.39 Favored Pre-proline 0 C--N 1.318 -0.781 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -179.183 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -63.48 127.47 19.97 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.821 2.347 . . . . 0.0 111.103 179.376 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.4 t -85.21 142.42 13.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -179.788 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.9 p -67.45 -82.98 0.03 OUTLIER 'General case' 0 N--CA 1.425 -1.704 0 O-C-N 123.604 0.565 . . . . 0.0 111.223 177.412 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 168.41 159.52 0.16 Allowed Pre-proline 0 CA--C 1.513 -0.474 0 C-N-CA 125.554 1.542 . . . . 0.0 106.99 179.716 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -82.88 169.11 13.46 Favored 'Trans proline' 0 N--CA 1.448 -1.196 0 C-N-CA 121.643 1.562 . . . . 0.0 111.352 173.688 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -60.54 -57.02 14.5 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -176.827 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -112.02 25.19 11.82 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.12 0.962 . . . . 0.0 109.798 -172.908 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -146.02 -172.03 16.01 Favored Glycine 0 C--N 1.284 -2.324 0 CA-C-N 114.421 -1.263 . . . . 0.0 110.984 179.04 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.0 pttm -149.79 169.12 21.83 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 178.504 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.561 HG12 ' CE2' ' A' ' 176' ' ' PHE . 62.8 mt -88.2 130.58 37.54 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.879 179.453 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.492 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 12.9 m -87.15 -29.04 5.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.324 0.583 . . . . 0.0 109.628 179.8 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 159' ' ' SER . . . . . 0.528 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 25.2 m . . . . . 0 C--N 1.308 -1.233 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.631 -174.812 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 . . . . . 0 CA--C 1.476 -1.896 0 CA-C-O 121.194 0.521 . . . . 0.0 109.876 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 56.7 p-80 -130.44 167.93 17.81 Favored 'General case' 0 C--N 1.281 -2.395 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.038 -174.496 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 79.8 t80 -47.69 132.12 14.34 Favored 'General case' 0 CA--C 1.506 -0.73 0 O-C-N 124.418 1.074 . . . . 0.0 110.612 178.755 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 108.67 -26.11 17.11 Favored Glycine 0 N--CA 1.418 -2.55 0 C-N-CA 120.378 -0.915 . . . . 0.0 111.781 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -76.83 134.05 39.17 Favored 'General case' 0 N--CA 1.414 -2.247 0 CA-C-O 121.664 0.745 . . . . 0.0 110.524 -179.061 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -110.57 90.83 3.44 Favored 'General case' 0 C--N 1.269 -2.893 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 173.959 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.528 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 14.6 p -73.15 105.1 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.9 0 CA-C-O 121.706 0.765 . . . . 0.0 109.257 -176.127 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.514 ' HD2' ' OE2' ' A' ' 188' ' ' GLU . 12.4 ttp180 -97.11 152.73 18.49 Favored 'General case' 0 N--CA 1.411 -2.387 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.387 -175.503 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.561 ' CE2' HG12 ' A' ' 157' ' ' ILE . 81.7 m-85 -121.2 153.22 37.88 Favored 'General case' 0 N--CA 1.428 -1.563 0 C-N-CA 124.173 0.989 . . . . 0.0 109.151 -177.462 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.448 ' HB ' ' CG1' ' A' ' 158' ' ' VAL . 10.3 p -135.7 149.59 28.24 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 178' ' ' CYS . . . . . 0.438 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 76.6 m -90.06 141.07 29.04 Favored 'General case' 0 C--N 1.268 -2.959 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.464 178.314 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -70.91 -52.6 19.06 Favored 'General case' 0 CA--C 1.477 -1.855 0 CA-C-N 115.298 -0.864 . . . . 0.0 112.338 -175.347 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 180' ' ' SER . . . . . 0.445 ' HB3' ' CE2' ' A' ' 182' ' ' TYR . 34.3 t -116.01 -158.88 0.7 Allowed 'General case' 0 C--N 1.26 -3.287 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -177.183 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -71.77 51.03 1.18 Allowed Glycine 0 C--O 1.229 -0.203 0 O-C-N 123.473 0.483 . . . . 0.0 113.294 -177.975 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 182' ' ' TYR . . . . . 0.445 ' CE2' ' HB3' ' A' ' 180' ' ' SER . 90.5 m-85 -103.51 170.64 7.83 Favored 'General case' 0 C--N 1.292 -1.913 0 C-N-CA 123.137 0.575 . . . . 0.0 109.539 177.463 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.458 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 39.4 pttt -126.5 150.92 48.46 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 176.374 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.5 tp -65.31 142.68 16.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 CA-C-O 121.427 0.632 . . . . 0.0 110.025 176.096 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -67.23 -58.41 4.89 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.915 -178.362 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -120.96 -111.03 2.22 Favored Glycine 0 N--CA 1.42 -2.396 0 N-CA-C 110.589 -1.005 . . . . 0.0 110.589 -178.941 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -88.91 144.9 25.88 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.225 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.514 ' OE2' ' HD2' ' A' ' 175' ' ' ARG . 12.8 pt-20 -87.62 1.27 54.13 Favored 'General case' 0 C--O 1.205 -1.282 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.986 -176.045 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -145.16 151.18 38.05 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 121.191 0.52 . . . . 0.0 111.312 -179.186 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.492 ' HG3' HG13 ' A' ' 174' ' ' VAL . 0.0 OUTLIER -123.4 140.82 52.62 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 175.966 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 26.3 m80 -100.42 140.39 34.74 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.835 -0.346 . . . . 0.0 110.313 176.899 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 52.6 t -86.56 104.41 15.98 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 174.301 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 18.0 m -74.94 156.88 35.86 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-N 115.225 -0.898 . . . . 0.0 111.095 -177.524 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -68.63 1.84 2.89 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.794 1.238 . . . . 0.0 114.163 -174.371 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 195' ' ' ASP . . . . . 0.444 ' HB3' ' CE2' ' A' ' 197' ' ' PHE . 36.9 t70 -102.1 -17.37 16.06 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 121.33 0.586 . . . . 0.0 109.69 175.609 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 101.34 53.75 0.99 Allowed Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.935 179.912 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 197' ' ' PHE . . . . . 0.444 ' CE2' ' HB3' ' A' ' 195' ' ' ASP . 52.1 p90 -154.76 156.95 37.25 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.918 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 78.8 m95 -83.96 130.5 34.89 Favored 'General case' 0 N--CA 1.431 -1.394 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 175.39 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 7.7 m -63.8 -29.21 70.44 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.53 -179.81 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 4.0 mmmt -117.89 152.79 34.69 Favored 'General case' 0 N--CA 1.411 -2.395 0 O-C-N 121.943 -0.473 . . . . 0.0 110.882 -179.516 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -71.28 165.63 23.28 Favored 'General case' 0 C--O 1.252 1.205 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 174.875 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 202' ' ' LYS . . . . . 0.453 ' HB3' ' HE2' ' A' ' 202' ' ' LYS . 41.6 mtpt -61.32 125.3 83.83 Favored Pre-proline 0 N--CA 1.447 -0.602 0 C-N-CA 120.341 -0.544 . . . . 0.0 110.136 174.919 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -88.84 175.04 3.74 Favored 'Trans proline' 0 N--CA 1.419 -2.854 0 C-N-CA 121.791 1.661 . . . . 0.0 110.001 172.932 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.6 mttp -137.91 177.22 8.04 Favored 'General case' 0 C--N 1.284 -2.276 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 -177.073 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.458 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 68.1 m -118.76 104.27 10.43 Favored 'General case' 0 C--N 1.283 -2.324 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 171.776 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.9 m . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 114.306 -1.316 . . . . 0.0 111.337 -172.27 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.414 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 17.7 Cg_endo . . . . . 0 CA--C 1.536 0.595 0 CA-C-O 120.926 0.303 . . . . 0.0 112.269 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 85' ' ' CYS . . . . . 0.418 ' HB3' ' CD1' ' A' ' 134' ' ' TRP . 4.5 m -93.16 -24.56 18.19 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.242 0.544 . . . . 0.0 111.558 175.003 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.94 -93.55 0.59 Allowed Glycine 0 CA--C 1.46 -3.345 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 173.196 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 10.5 t60 -170.23 132.77 1.02 Allowed Pre-proline 0 C--N 1.262 -3.201 0 N-CA-C 104.02 -2.585 . . . . 0.0 104.02 -175.478 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.504 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 87.9 Cg_endo -81.32 -19.81 7.58 Favored 'Trans proline' 0 C--N 1.332 -0.341 0 C-N-CA 121.637 1.558 . . . . 0.0 113.553 -173.189 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 130.1 -165.39 22.47 Favored Glycine 0 N--CA 1.426 -2.013 0 N-CA-C 110.186 -1.166 . . . . 0.0 110.186 -177.358 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -151.04 151.34 31.89 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 -178.659 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.1 t -131.07 127.5 22.0 Favored Pre-proline 0 C--N 1.303 -1.456 0 C-N-CA 120.338 -0.545 . . . . 0.0 110.553 179.897 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.46 -18.37 26.08 Favored 'Trans proline' 0 C--O 1.237 0.445 0 C-N-CA 122.523 2.149 . . . . 0.0 111.554 178.843 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.531 ' CB ' ' HB2' ' A' ' 141' ' ' CYS . 59.7 m-85 -78.92 -17.26 55.83 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.192 -177.461 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.472 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -168.97 -126.76 0.87 Allowed Glycine 0 CA--C 1.477 -2.284 0 C-N-CA 120.212 -0.994 . . . . 0.0 111.167 -178.933 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.1 t -160.07 -169.87 2.65 Favored 'General case' 0 C--N 1.284 -2.243 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.651 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.431 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 37.8 p90 -147.11 165.46 29.89 Favored 'General case' 0 N--CA 1.432 -1.331 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 177.582 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.7 m -132.81 161.75 33.32 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 177.879 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 26.6 mt -109.93 137.54 47.57 Favored 'General case' 0 C--N 1.271 -2.837 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.47 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.536 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 11.1 p -134.11 141.6 47.2 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -173.979 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 100.33 -42.37 1.97 Allowed Glycine 0 C--N 1.303 -1.304 0 N-CA-C 108.148 -1.981 . . . . 0.0 108.148 -173.988 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.459 ' HA3' ' OE2' ' A' ' 105' ' ' GLU . . . -139.63 -143.09 4.33 Favored Glycine 0 N--CA 1.406 -3.358 0 N-CA-C 108.029 -2.028 . . . . 0.0 108.029 176.085 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -151.61 16.22 0.69 Allowed 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.41 1.1 . . . . 0.0 109.829 -178.51 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.531 ' O ' HG11 ' A' ' 108' ' ' VAL . 28.7 m -147.5 -170.57 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 -175.511 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.504 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 30.5 m-85 -96.17 39.11 1.16 Allowed 'General case' 0 C--N 1.307 -1.255 0 CA-C-O 121.99 0.9 . . . . 0.0 110.022 -177.832 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.661 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.2 pt-20 -71.83 178.03 3.89 Favored 'General case' 0 C--O 1.202 -1.44 0 C-N-CA 127.197 2.199 . . . . 0.0 111.888 179.009 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 106' ' ' TYR . . . . . 0.546 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 27.6 m-85 -79.32 135.9 36.86 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-O 121.008 0.432 . . . . 0.0 110.971 176.49 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.24 3.24 82.34 Favored Glycine 0 N--CA 1.442 -0.91 0 C-N-CA 121.001 -0.618 . . . . 0.0 112.349 178.804 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.661 HG12 ' O ' ' A' ' 105' ' ' GLU . 8.5 p -92.75 142.81 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.549 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.536 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -107.52 126.82 53.0 Favored 'General case' 0 C--N 1.28 -2.437 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 177.682 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -89.32 87.98 7.32 Favored 'General case' 0 C--N 1.28 -2.436 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 174.896 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.508 HG12 ' HB3' ' A' ' 126' ' ' TYR . 30.0 m -84.97 116.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.383 0 CA-C-O 121.989 0.899 . . . . 0.0 109.403 -179.423 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 112' ' ' TYR . . . . . 0.431 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 33.9 m-85 -85.73 142.59 28.89 Favored 'General case' 0 C--N 1.27 -2.877 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.42 179.754 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -138.0 124.61 20.9 Favored 'General case' 0 N--CA 1.405 -2.725 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -178.92 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.7 m -74.08 155.61 38.3 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 115.3 -0.863 . . . . 0.0 112.262 -175.498 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.472 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 72.2 m-20 -68.09 173.81 4.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.175 178.482 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -50.75 -48.21 59.17 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 123.78 0.832 . . . . 0.0 112.547 -177.922 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.465 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -89.8 30.88 5.53 Favored Glycine 0 N--CA 1.438 -1.222 0 C-N-CA 120.778 -0.725 . . . . 0.0 113.05 -178.417 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -146.65 157.4 43.7 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 122.177 -0.602 . . . . 0.0 109.555 -176.424 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.5 150.7 47.74 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 122.688 0.395 . . . . 0.0 110.334 177.076 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.99 117.21 15.51 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -175.336 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -103.13 126.13 50.16 Favored 'General case' 0 N--CA 1.407 -2.593 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -178.876 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 120.33 176.54 15.77 Favored Glycine 0 C--N 1.29 -1.98 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.706 -177.551 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -93.77 -24.77 17.68 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.906 0.86 . . . . 0.0 109.02 -178.384 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.458 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.2 mm -104.03 129.22 56.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 114.851 -1.068 . . . . 0.0 109.213 -176.538 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -119.0 -2.49 10.8 Favored 'General case' 0 C--O 1.201 -1.493 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 177.611 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.508 ' HB3' HG12 ' A' ' 111' ' ' VAL . 39.8 p90 -138.46 162.18 35.13 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 120.945 0.402 . . . . 0.0 110.526 -169.374 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 61.1 mtp180 -123.53 135.24 53.91 Favored 'General case' 0 C--N 1.282 -2.328 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 170.989 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -110.45 130.58 55.53 Favored 'General case' 0 C--N 1.284 -2.253 0 C-N-CA 119.046 -1.061 . . . . 0.0 110.215 -178.517 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 129' ' ' CYS . . . . . 0.546 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 36.9 t -75.99 98.96 4.41 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.328 0.585 . . . . 0.0 109.918 177.878 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.44 ' OD2' HG22 ' A' ' 131' ' ' THR . 20.3 t70 -100.14 -175.43 2.94 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 178.172 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.44 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -69.26 -19.49 63.92 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-O 121.997 0.904 . . . . 0.0 109.237 179.441 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -83.12 -12.79 56.69 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.304 -1.316 . . . . 0.0 109.326 179.831 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 110.37 -164.19 12.29 Favored Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -175.942 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.418 ' CD1' ' HB3' ' A' ' 85' ' ' CYS . 98.5 m95 -64.26 114.79 4.47 Favored 'General case' 0 C--O 1.248 0.978 0 CA-C-N 117.922 0.861 . . . . 0.0 109.88 175.363 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 68.6 p -71.29 164.87 24.86 Favored 'General case' 0 N--CA 1.417 -2.108 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 177.702 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 55.8 m-20 65.53 -158.87 0.28 Allowed 'General case' 0 C--O 1.245 0.826 0 O-C-N 123.843 0.714 . . . . 0.0 109.276 173.995 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -136.48 176.28 8.85 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 175.866 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.1 mt -64.29 120.44 64.81 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 124.271 0.982 . . . . 0.0 108.368 175.338 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.458 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 45.6 Cg_endo -67.68 176.52 4.99 Favored 'Trans proline' 0 C--O 1.248 1.024 0 C-N-CA 123.034 2.489 . . . . 0.0 112.583 -179.256 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.1 mm -111.71 137.0 46.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 CA-C-O 121.108 0.48 . . . . 0.0 110.318 -173.234 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.531 ' HB2' ' CB ' ' A' ' 93' ' ' PHE . 99.3 m -113.52 111.12 21.38 Favored 'General case' 0 C--N 1.279 -2.47 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 172.83 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -93.67 151.63 19.53 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 179.211 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 8.9 p -74.09 141.26 16.37 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.553 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.897 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 144' ' ' VAL . . . . . 0.506 HG23 ' HB2' ' A' ' 170' ' ' PHE . 15.6 m -67.09 101.14 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.776 0 CA-C-O 121.967 0.889 . . . . 0.0 110.024 177.843 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -85.18 123.51 30.77 Favored 'General case' 0 N--CA 1.407 -2.599 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.314 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.518 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 62.6 m -83.2 122.28 28.2 Favored 'General case' 0 C--N 1.273 -2.758 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 178.02 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 80.6 mt -53.36 131.69 52.94 Favored Pre-proline 0 C--N 1.313 -0.985 0 N-CA-C 113.629 0.974 . . . . 0.0 113.629 -175.693 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -56.44 121.03 9.31 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 123.33 2.687 . . . . 0.0 110.989 -178.575 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.5 p -89.28 149.48 4.01 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.973 -175.878 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.4 p -81.73 -173.45 4.44 Favored 'General case' 0 N--CA 1.422 -1.837 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 175.245 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -123.37 155.63 64.98 Favored Pre-proline 0 C--N 1.285 -2.238 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -172.802 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -77.35 169.72 20.73 Favored 'Trans proline' 0 CA--C 1.543 0.97 0 C-N-CA 121.92 1.746 . . . . 0.0 112.491 178.277 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -64.31 -57.5 9.21 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -178.816 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 -97.87 20.09 12.7 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.846 0.831 . . . . 0.0 110.269 -174.145 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -142.79 -173.27 14.41 Favored Glycine 0 N--CA 1.412 -2.903 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.985 179.878 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 156' ' ' LYS . . . . . 0.401 ' HG3' HG23 ' A' ' 177' ' ' VAL . 19.8 pttp -156.76 178.31 10.49 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -179.187 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 59.5 mt -101.09 138.35 25.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 CA-C-N 117.83 0.286 . . . . 0.0 111.066 -177.33 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.625 HG12 HG22 ' A' ' 177' ' ' VAL . 2.7 m -84.69 -33.64 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 177.426 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 6.1 m . . . . . 0 N--CA 1.444 -0.742 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.943 -174.584 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 . . . . . 0 CA--C 1.502 -0.902 0 CA-C-O 120.984 0.421 . . . . 0.0 110.088 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 21.5 m-70 -125.49 165.05 19.17 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -177.3 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.506 ' HB2' HG23 ' A' ' 144' ' ' VAL . 92.4 t80 -51.57 134.86 29.16 Favored 'General case' 0 C--O 1.239 0.526 0 O-C-N 123.885 0.741 . . . . 0.0 109.11 170.586 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 109.94 -10.05 31.89 Favored Glycine 0 N--CA 1.424 -2.103 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.732 -179.112 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 84.1 mm-40 -99.55 159.29 15.14 Favored 'General case' 0 N--CA 1.433 -1.291 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.916 -178.842 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 190' ' ' MET . . . -138.73 123.98 19.21 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 175.688 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.547 HG23 ' CH2' ' A' ' 198' ' ' TRP . 85.0 t -87.68 109.71 19.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.047 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.481 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 41.2 ttm180 -96.71 142.57 28.58 Favored 'General case' 0 N--CA 1.416 -2.162 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 177.781 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -110.19 159.59 17.24 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 -177.294 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.625 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -130.76 139.79 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.467 -2.247 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.675 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 178' ' ' CYS . . . . . 0.521 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 77.4 m -84.79 129.52 34.81 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 173.501 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -53.28 -51.63 61.69 Favored 'General case' 0 CA--C 1.48 -1.713 0 C-N-CA 124.76 1.224 . . . . 0.0 112.584 -175.997 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 13.3 t -123.63 -154.58 0.61 Allowed 'General case' 0 N--CA 1.402 -2.837 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 -177.052 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -74.22 51.11 2.06 Favored Glycine 0 N--CA 1.443 -0.838 0 O-C-N 123.588 0.555 . . . . 0.0 113.78 -176.468 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 182' ' ' TYR . . . . . 0.521 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 98.4 m-85 -100.89 168.39 9.66 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 176.114 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 50.6 pttt -121.41 146.05 47.29 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.794 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.759 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.8 tt -76.86 141.8 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.766 0 C-N-CA 119.691 -0.804 . . . . 0.0 110.276 176.403 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -53.75 -61.13 2.5 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 125.086 1.354 . . . . 0.0 113.228 -176.227 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -123.89 -97.81 1.27 Allowed Glycine 0 CA--C 1.496 -1.147 0 C-N-CA 120.33 -0.938 . . . . 0.0 112.814 -178.654 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -85.07 159.97 20.08 Favored 'General case' 0 CA--C 1.48 -1.728 0 N-CA-C 106.876 -1.527 . . . . 0.0 106.876 176.75 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.759 ' HA ' HD13 ' A' ' 184' ' ' ILE . 14.5 pt-20 -102.47 3.86 38.08 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 118.114 -1.434 . . . . 0.0 109.468 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 189' ' ' GLU . . . . . 0.476 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 8.7 pt-20 -151.45 147.37 26.78 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-N 115.547 -0.751 . . . . 0.0 112.386 -176.216 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.486 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 13.9 ptp -113.79 128.25 56.34 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.649 175.446 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -110.56 146.56 35.85 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 116.746 -0.206 . . . . 0.0 110.473 -174.646 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 88.6 m -75.06 155.04 37.63 Favored 'General case' 0 C--O 1.241 0.642 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 178.436 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 60.6 m -126.17 171.46 10.86 Favored 'General case' 0 C--O 1.256 1.395 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 169.387 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -78.4 91.56 4.49 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.261 1.029 . . . . 0.0 112.496 -172.347 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 9.5 t70 174.22 -38.18 0.01 OUTLIER 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 113.15 -1.841 . . . . 0.0 106.293 176.508 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 196' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 119.65 18.69 4.33 Favored Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.196 -179.534 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -109.65 158.13 18.38 Favored 'General case' 0 C--O 1.251 1.168 0 O-C-N 122.226 -0.573 . . . . 0.0 109.969 176.418 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 198' ' ' TRP . . . . . 0.547 ' CH2' HG23 ' A' ' 174' ' ' VAL . 87.6 m95 -87.31 144.69 26.67 Favored 'General case' 0 N--CA 1.423 -1.815 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 176.18 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.2 m -92.94 7.59 43.33 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-O 121.879 0.847 . . . . 0.0 110.926 -178.176 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.468 ' HB3' ' CB ' ' A' ' 190' ' ' MET . 0.8 OUTLIER -139.39 153.28 47.61 Favored 'General case' 0 N--CA 1.417 -2.102 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 177.096 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 201' ' ' GLU . . . . . 0.485 ' CD ' ' H ' ' A' ' 201' ' ' GLU . 0.2 OUTLIER -105.28 171.93 7.06 Favored 'General case' 0 C--N 1.279 -2.461 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 178.9 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 202' ' ' LYS . . . . . 0.454 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 45.8 mtpt -63.38 117.61 35.74 Favored Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 114.154 1.168 . . . . 0.0 114.154 -174.865 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 203' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 5.4 Cg_exo -82.33 171.31 12.58 Favored 'Trans proline' 0 N--CA 1.445 -1.369 0 C-N-CA 122.793 2.329 . . . . 0.0 108.953 172.246 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 204' ' ' LYS . . . . . 0.463 ' O ' ' HA ' ' A' ' 184' ' ' ILE . 38.8 mtpt -122.38 174.55 6.95 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.966 -0.694 . . . . 0.0 109.432 179.681 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 57.3 m -115.39 107.56 15.37 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 173.19 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m . . . . . 0 C--N 1.281 -2.413 0 CA-C-N 114.371 -1.286 . . . . 0.0 109.736 -173.638 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo . . . . . 0 N--CA 1.477 0.548 0 CA-C-O 121.078 0.366 . . . . 0.0 112.766 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 65.1 m -73.32 -27.15 61.36 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.547 0.689 . . . . 0.0 110.677 178.027 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.19 13.12 40.19 Favored Glycine 0 C--N 1.3 -1.417 0 CA-C-N 115.206 -0.907 . . . . 0.0 114.832 172.724 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.0 t-80 68.77 125.37 0.03 OUTLIER Pre-proline 0 N--CA 1.489 1.484 0 C-N-CA 123.841 0.856 . . . . 0.0 108.931 -179.234 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.519 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 92.7 Cg_endo -75.97 7.77 3.09 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 123.059 2.506 . . . . 0.0 114.862 -171.998 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 97.94 -166.0 22.25 Favored Glycine 0 C--N 1.277 -2.715 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -175.514 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -143.37 140.21 30.38 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 -179.036 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.3 t -102.64 129.53 25.73 Favored Pre-proline 0 C--N 1.299 -1.624 0 CA-C-O 121.234 0.54 . . . . 0.0 110.829 -178.366 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.25 -11.55 25.0 Favored 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 122.544 2.163 . . . . 0.0 111.474 177.599 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -87.25 -3.02 59.03 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.518 -178.285 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.402 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 167.69 -120.85 0.93 Allowed Glycine 0 N--CA 1.43 -1.717 0 C-N-CA 120.271 -0.966 . . . . 0.0 111.797 179.235 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.4 t -151.49 -172.86 4.33 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 123.71 0.3 . . . . 0.0 110.361 179.447 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.6 p90 -146.13 156.42 43.42 Favored 'General case' 0 N--CA 1.436 -1.168 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 176.65 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 5.5 m -121.92 166.52 14.29 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 178.041 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.451 HD11 ' CE1' ' A' ' 104' ' ' PHE . 14.8 mt -120.14 128.83 53.78 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.897 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.441 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 33.7 p -115.91 135.72 53.72 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 -178.262 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 114.53 -65.04 0.29 Allowed Glycine 0 N--CA 1.429 -1.781 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -179.243 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -119.69 -5.93 10.72 Favored Glycine 0 C--N 1.309 -0.938 0 C-N-CA 119.98 -1.105 . . . . 0.0 113.143 -178.991 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 59.79 19.62 8.44 Favored 'General case' 0 N--CA 1.495 1.809 0 C-N-CA 123.04 0.536 . . . . 0.0 112.373 -178.079 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.502 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.0 m -146.67 -171.12 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.203 -1.379 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -176.028 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.451 ' CE1' HD11 ' A' ' 98' ' ' LEU . 54.0 m-85 -106.42 39.41 1.83 Allowed 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 118.565 0.62 . . . . 0.0 110.635 -175.756 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.708 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.5 pt-20 -85.43 -176.61 6.18 Favored 'General case' 0 C--O 1.202 -1.443 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.52 179.165 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 -75.63 137.29 40.64 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.935 -0.478 . . . . 0.0 111.143 177.702 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.35 4.93 73.23 Favored Glycine 0 N--CA 1.433 -1.536 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.962 178.132 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.708 HG12 ' O ' ' A' ' 105' ' ' GLU . 13.9 p -95.02 146.22 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 C-N-CA 119.854 -0.738 . . . . 0.0 109.179 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.441 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 56.3 mtpt -110.17 123.75 50.32 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.591 179.198 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.524 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.3 93.63 9.13 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 176.469 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 76.7 t -86.03 109.62 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.772 0 C-N-CA 123.972 0.909 . . . . 0.0 109.208 -177.803 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -82.99 139.22 33.42 Favored 'General case' 0 C--N 1.286 -2.17 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.773 -179.566 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 11.1 t -136.83 127.78 27.57 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.738 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 82.3 m -81.31 160.18 24.25 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.822 -174.593 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.402 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 74.7 m-20 -72.46 177.21 4.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.9 175.926 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -56.57 -47.02 80.39 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -176.14 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -78.01 11.1 23.32 Favored Glycine 0 CA--C 1.522 0.495 0 CA-C-N 116.186 -0.461 . . . . 0.0 114.236 -178.876 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.612 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 82.5 m-85 -133.45 156.73 47.19 Favored 'General case' 0 C--N 1.311 -1.094 0 O-C-N 122.368 -0.489 . . . . 0.0 110.713 -179.195 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -143.44 147.97 35.4 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.006 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 7.2 tp -76.95 144.03 39.08 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-O 120.978 0.418 . . . . 0.0 110.834 -173.158 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.82 125.38 46.36 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -179.778 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 108.12 -176.28 20.34 Favored Glycine 0 C--N 1.291 -1.919 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -174.532 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -101.07 -24.95 14.21 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.363 0.602 . . . . 0.0 110.288 -179.726 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.2 mm -80.96 127.25 39.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -178.578 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -134.42 11.38 3.79 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 -178.561 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.524 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 32.8 p90 -149.01 167.71 25.08 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 -172.135 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.583 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 46.7 mtp180 -129.2 119.37 23.93 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 171.769 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -91.23 128.68 37.15 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.755 -0.778 . . . . 0.0 110.149 178.687 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 35.2 t -87.07 107.13 18.3 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.338 -0.945 . . . . 0.0 109.89 175.126 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.441 ' OD1' HG22 ' A' ' 131' ' ' THR . 7.2 t70 -100.61 -168.73 1.61 Allowed 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 176.342 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.441 HG22 ' OD1' ' A' ' 130' ' ' ASP . 11.1 t -69.84 -18.15 63.43 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 122.445 1.117 . . . . 0.0 109.176 178.279 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -80.67 -7.0 59.18 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 114.294 -1.321 . . . . 0.0 109.327 177.036 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 97.34 -158.57 21.08 Favored Glycine 0 N--CA 1.429 -1.77 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -176.316 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.405 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 90.0 m95 -65.32 108.48 1.94 Allowed 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 175.963 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 30.0 p -64.05 -55.2 23.93 Favored 'General case' 0 C--N 1.317 -0.84 0 C-N-CA 123.705 0.802 . . . . 0.0 111.581 -176.251 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 136' ' ' ASN . . . . . 0.583 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.3 m120 -78.64 167.22 21.56 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 114.857 -1.065 . . . . 0.0 109.04 -179.708 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -99.86 179.12 4.62 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 175.162 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.7 mt -65.63 118.98 56.45 Favored Pre-proline 0 C--N 1.325 -0.494 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 174.113 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.7 146.64 84.5 Favored 'Trans proline' 0 C--O 1.25 1.101 0 C-N-CA 122.322 2.015 . . . . 0.0 112.802 -176.292 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 66.0 mt -72.4 130.35 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.58 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.0 -179.783 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.612 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 45.3 t -121.48 142.42 50.07 Favored 'General case' 0 C--N 1.274 -2.678 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 176.354 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 6.1 tp10 -121.43 152.97 38.48 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -174.73 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.468 HG21 ' NE2' ' A' ' 169' ' ' HIS . 8.1 p -73.74 141.73 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.5 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.019 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 74.7 t -60.95 119.82 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.882 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 52.8 mtmt -125.42 138.43 54.02 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.477 -177.504 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 2.1 p -110.75 160.61 16.56 Favored 'General case' 0 C--N 1.287 -2.112 0 CA-C-N 115.298 -0.865 . . . . 0.0 112.18 -179.186 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 147' ' ' LEU . . . . . 0.483 HD12 ' HD2' ' A' ' 148' ' ' PRO . 0.3 OUTLIER -77.97 135.6 62.87 Favored Pre-proline 0 N--CA 1.426 -1.65 0 C-N-CA 124.573 1.149 . . . . 0.0 111.302 -173.533 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.483 ' HD2' HD12 ' A' ' 147' ' ' LEU . 12.1 Cg_endo -55.97 126.87 23.84 Favored 'Trans proline' 0 C--O 1.244 0.784 0 C-N-CA 123.812 3.008 . . . . 0.0 112.661 179.304 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 10.8 p -91.21 150.31 3.8 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.128 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 19.9 p -71.53 -88.34 0.02 OUTLIER 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 113.505 0.928 . . . . 0.0 113.505 -177.324 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 171.91 164.3 0.25 Allowed Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 179.738 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 152' ' ' PRO . . . . . 0.46 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 73.7 Cg_endo -78.45 166.02 24.61 Favored 'Trans proline' 0 N--CA 1.454 -0.849 0 C-N-CA 121.688 1.592 . . . . 0.0 110.419 171.624 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -64.94 -61.53 2.11 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -179.754 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -91.34 35.56 0.93 Allowed 'General case' 0 C--O 1.247 0.963 0 O-C-N 121.773 -0.579 . . . . 0.0 111.24 179.709 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -156.85 -161.78 11.02 Favored Glycine 0 N--CA 1.425 -2.053 0 C-N-CA 120.145 -1.026 . . . . 0.0 112.384 178.263 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 59.5 pttt -159.07 -178.48 7.26 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -178.394 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 58.2 mt -96.62 141.3 15.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 117.577 0.171 . . . . 0.0 111.159 -178.604 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.55 HG12 HG22 ' A' ' 177' ' ' VAL . 3.3 m -88.77 -31.98 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.931 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 176.317 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.8 m . . . . . 0 N--CA 1.442 -0.849 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.027 -176.07 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 168' ' ' TYR . . . . . 0.456 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 73.2 m-85 . . . . . 0 C--O 1.218 -0.593 0 N-CA-C 112.446 0.536 . . . . 0.0 112.446 . . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.468 ' NE2' HG21 ' A' ' 143' ' ' VAL . 54.9 t-80 -86.32 146.23 26.58 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.023 -0.99 . . . . 0.0 108.687 179.817 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 83.6 t80 -54.64 129.73 37.66 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.714 176.32 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 112.91 -22.17 16.85 Favored Glycine 0 N--CA 1.432 -1.602 0 C-N-CA 120.155 -1.021 . . . . 0.0 111.994 -178.006 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 86.2 mm-40 -70.35 150.88 45.85 Favored 'General case' 0 C--O 1.251 1.149 0 CA-C-O 120.87 0.367 . . . . 0.0 110.276 178.359 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -134.65 103.1 5.52 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.604 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 95.7 t -76.79 108.92 10.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.617 -178.025 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.465 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 29.5 ttp180 -101.49 142.2 33.22 Favored 'General case' 0 N--CA 1.407 -2.612 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.459 177.813 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 176' ' ' PHE . . . . . 0.46 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 62.8 m-85 -113.26 153.32 28.6 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.664 -174.809 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.55 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -121.29 152.54 24.75 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.275 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.996 179.296 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 67.9 m -99.51 138.87 35.99 Favored 'General case' 0 N--CA 1.403 -2.786 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 172.396 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -55.41 -52.41 63.67 Favored 'General case' 0 CA--C 1.486 -1.49 0 N-CA-C 114.192 1.182 . . . . 0.0 114.192 -175.131 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 58.9 m -150.33 -100.32 0.07 Allowed 'General case' 0 C--N 1.286 -2.153 0 C-N-CA 120.144 -0.622 . . . . 0.0 112.042 -177.005 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -87.5 44.68 3.29 Favored Glycine 0 CA--C 1.494 -1.254 0 CA-C-O 121.264 0.369 . . . . 0.0 112.343 -177.654 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -123.9 158.59 31.58 Favored 'General case' 0 N--CA 1.415 -2.2 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.531 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.446 ' O ' ' HD2' ' A' ' 183' ' ' LYS . 1.2 pptp? -132.01 143.13 49.85 Favored 'General case' 0 C--N 1.288 -2.066 0 O-C-N 123.878 0.736 . . . . 0.0 109.178 179.118 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.554 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.2 tt -71.57 142.47 15.4 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.26 0 CA-C-O 121.489 0.661 . . . . 0.0 111.626 -178.299 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -76.59 -57.08 4.06 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.735 -175.845 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -93.05 -126.42 4.16 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 120.277 -0.963 . . . . 0.0 111.954 -177.776 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -93.28 158.83 15.55 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 176.677 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.554 ' HA ' HD13 ' A' ' 184' ' ' ILE . 14.5 pt-20 -95.1 -7.81 38.33 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 118.915 -1.114 . . . . 0.0 110.976 -174.333 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -138.91 135.79 34.81 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.163 0.506 . . . . 0.0 112.339 -176.497 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.435 ' HB3' ' HB2' ' A' ' 200' ' ' LYS . 12.8 ptp -116.12 124.05 49.38 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.398 176.301 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 52.0 t-80 -97.95 135.99 38.87 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.702 -176.234 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 16.4 t -71.15 118.61 14.15 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.34 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.5 m -97.56 165.33 12.04 Favored 'General case' 0 N--CA 1.437 -1.112 0 O-C-N 123.606 0.567 . . . . 0.0 110.445 -175.756 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -65.51 -6.76 11.6 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 124.514 1.126 . . . . 0.0 112.316 -177.573 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -74.25 -22.2 59.43 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.565 175.532 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 92.44 14.51 55.53 Favored Glycine 0 N--CA 1.435 -1.418 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -174.521 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -136.6 176.81 8.37 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.587 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 88.1 m95 -84.78 152.28 23.78 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.92 -177.521 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 21.0 p -80.23 -14.58 58.31 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.508 179.835 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.435 ' HB2' ' HB3' ' A' ' 190' ' ' MET . 64.8 mmtt -124.36 165.98 16.75 Favored 'General case' 0 CA--C 1.477 -1.846 0 CA-C-O 122.141 0.972 . . . . 0.0 113.6 -173.957 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -91.47 166.44 12.86 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 113.053 -1.885 . . . . 0.0 109.337 176.322 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 6.1 mmmm -65.96 109.78 3.68 Favored Pre-proline 0 C--N 1.318 -0.787 0 O-C-N 124.053 0.846 . . . . 0.0 112.939 178.854 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -92.04 156.85 3.28 Favored 'Trans proline' 0 N--CA 1.424 -2.612 0 C-N-CA 122.42 2.08 . . . . 0.0 110.412 177.687 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 204' ' ' LYS . . . . . 0.443 ' HA ' ' HB3' ' A' ' 152' ' ' PRO . 19.1 ptpt -135.68 155.81 49.83 Favored 'General case' 0 C--N 1.287 -2.126 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.005 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 97.5 m -93.29 118.52 31.37 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 177.569 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.1 m . . . . . 0 C--N 1.291 -1.951 0 CA-C-N 114.007 -1.451 . . . . 0.0 107.326 -178.267 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.486 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 41.0 Cg_endo . . . . . 0 CA--C 1.534 0.505 0 CA-C-O 121.181 0.409 . . . . 0.0 111.642 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 85' ' ' CYS . . . . . 0.549 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 3.2 m -94.36 -17.9 22.11 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 122.1 0.952 . . . . 0.0 110.211 174.176 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.73 -87.72 0.54 Allowed Glycine 2 N--CA 1.391 -4.356 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 172.364 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -171.85 138.24 1.02 Allowed Pre-proline 0 C--N 1.247 -3.854 0 N-CA-C 105.735 -1.95 . . . . 0.0 105.735 -172.739 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.517 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 91.9 Cg_endo -87.45 2.06 6.87 Favored 'Trans proline' 0 C--N 1.322 -0.837 0 C-N-CA 121.946 1.764 . . . . 0.0 112.764 -177.76 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.07 -166.37 13.1 Favored Glycine 0 N--CA 1.428 -1.875 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 -179.708 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -159.27 124.12 4.08 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 177.659 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.8 t -110.56 137.32 20.69 Favored Pre-proline 0 C--N 1.296 -1.735 0 CA-C-O 120.895 0.379 . . . . 0.0 111.749 -178.585 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -83.07 -10.11 10.39 Favored 'Trans proline' 0 CA--C 1.544 1.0 0 C-N-CA 122.742 2.295 . . . . 0.0 112.062 174.063 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -88.81 6.76 37.42 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.414 0.626 . . . . 0.0 111.143 -178.624 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.419 ' HA2' ' ND2' ' A' ' 115' ' ' ASN . . . 161.95 -123.86 1.24 Allowed Glycine 0 N--CA 1.415 -2.751 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.607 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.6 t -164.29 -159.72 0.5 Allowed 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 -178.592 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.6 p90 -152.88 165.53 35.17 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 176.987 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -127.83 159.52 34.61 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 177.906 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.1 mt -117.18 132.18 56.7 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -178.54 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 16.5 p -125.53 129.77 50.39 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -176.388 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.57 27.74 34.68 Favored Glycine 0 C--N 1.313 -0.703 0 C-N-CA 120.353 -0.927 . . . . 0.0 111.653 -179.447 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 178.37 -45.81 0.09 OUTLIER Glycine 0 N--CA 1.433 -1.542 0 C-N-CA 119.69 -1.243 . . . . 0.0 112.8 -179.158 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 63.8 t30 70.44 8.42 6.6 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 124.195 0.998 . . . . 0.0 109.965 -178.304 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.553 ' O ' HG11 ' A' ' 108' ' ' VAL . 25.2 m -148.82 -175.74 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.125 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 -177.864 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.517 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 23.5 m-85 -98.9 38.08 1.43 Allowed 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 118.995 0.816 . . . . 0.0 110.782 -176.296 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.72 ' O ' HG12 ' A' ' 108' ' ' VAL . 15.2 pt-20 -79.86 175.54 10.54 Favored 'General case' 0 C--O 1.195 -1.765 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.815 -179.344 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 106' ' ' TYR . . . . . 0.534 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 43.0 m-85 -74.73 126.24 30.45 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 122.144 -0.347 . . . . 0.0 111.536 179.404 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 102.21 -1.22 50.66 Favored Glycine 0 N--CA 1.439 -1.16 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.618 179.713 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.72 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -92.45 147.55 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.053 0 C-N-CA 120.068 -0.653 . . . . 0.0 109.626 -179.447 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -114.19 123.51 49.75 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 177.8 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.474 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.81 94.85 9.88 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 177.86 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 76.8 t -84.16 108.36 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.921 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -179.439 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 112' ' ' TYR . . . . . 0.51 ' HE1' ' SG ' ' A' ' 114' ' ' CYS . 37.6 t80 -74.82 140.99 44.32 Favored 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 123.563 0.745 . . . . 0.0 109.37 -177.012 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 3.3 t -144.3 111.49 5.9 Favored 'General case' 0 N--CA 1.426 -1.632 0 CA-C-O 121.919 0.866 . . . . 0.0 110.492 -179.637 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.51 ' SG ' ' HE1' ' A' ' 112' ' ' TYR . 74.7 m -71.46 162.17 29.86 Favored 'General case' 0 C--O 1.255 1.365 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.803 178.501 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.419 ' ND2' ' HA2' ' A' ' 94' ' ' GLY . 37.6 m-20 -74.99 -177.37 3.31 Favored 'General case' 0 C--O 1.211 -0.942 0 CA-C-N 115.817 -0.628 . . . . 0.0 109.905 175.582 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -66.86 -35.05 79.14 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -174.947 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.426 ' HA2' ' CD2' ' A' ' 170' ' ' PHE . . . -73.98 -6.19 72.64 Favored Glycine 0 C--N 1.311 -0.829 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.741 178.948 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.61 ' HE1' HG22 ' A' ' 143' ' ' VAL . 87.8 m-85 -129.88 167.91 17.43 Favored 'General case' 0 N--CA 1.441 -0.903 0 O-C-N 122.427 -0.455 . . . . 0.0 110.189 -176.615 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -146.27 157.55 43.81 Favored 'General case' 0 C--N 1.289 -2.033 0 CA-C-O 120.908 0.385 . . . . 0.0 110.682 -178.325 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -78.93 125.78 29.83 Favored 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 178.236 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.589 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -115.45 134.26 55.26 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 178.2 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.03 -178.07 20.6 Favored Glycine 0 C--N 1.289 -2.036 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -178.501 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -96.46 -40.53 9.03 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 -178.699 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.582 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 46.8 mm -77.26 124.06 34.99 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.696 -178.271 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -131.54 9.27 4.66 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 -176.615 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 18.5 p90 -143.88 166.99 23.38 Favored 'General case' 0 N--CA 1.425 -1.689 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -174.978 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.5 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 63.3 mtp180 -131.95 122.58 25.82 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 171.345 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -91.84 124.8 36.24 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 119.889 -0.724 . . . . 0.0 111.166 178.386 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 129' ' ' CYS . . . . . 0.534 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 36.0 t -80.0 105.03 10.98 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 175.2 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.437 ' OD2' HG22 ' A' ' 131' ' ' THR . 6.9 t70 -118.9 -169.92 1.82 Allowed 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -178.448 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.437 HG22 ' OD2' ' A' ' 130' ' ' ASP . 12.4 t -57.75 -26.01 61.25 Favored 'General case' 0 CA--C 1.563 1.45 0 C-N-CA 123.803 0.841 . . . . 0.0 112.266 -174.19 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -84.36 -24.86 29.53 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.882 0.848 . . . . 0.0 110.585 -179.731 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.549 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 125.52 -152.55 17.92 Favored Glycine 0 N--CA 1.419 -2.484 0 N-CA-C 106.811 -2.515 . . . . 0.0 106.811 -171.641 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -70.48 114.75 8.9 Favored 'General case' 0 N--CA 1.433 -1.321 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 175.281 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.3 p -64.94 -54.77 25.42 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.762 0.791 . . . . 0.0 111.456 -176.606 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 136' ' ' ASN . . . . . 0.5 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.8 m120 -78.96 167.77 20.65 Favored 'General case' 0 C--N 1.296 -1.758 0 CA-C-N 114.703 -1.135 . . . . 0.0 108.619 -178.716 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -98.96 -179.91 4.42 Favored 'General case' 0 C--N 1.29 -2.018 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 175.004 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.1 mt -65.17 121.17 72.9 Favored Pre-proline 0 C--N 1.309 -1.175 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 177.526 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.582 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 23.2 Cg_exo -57.67 167.29 4.09 Favored 'Trans proline' 0 C--O 1.245 0.853 0 C-N-CA 122.709 2.273 . . . . 0.0 112.179 177.909 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.589 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 3.6 mp -94.27 132.25 38.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 -171.019 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 8.5 t -112.62 119.39 37.97 Favored 'General case' 0 N--CA 1.423 -1.792 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 176.233 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -108.96 156.02 20.19 Favored 'General case' 0 C--N 1.274 -2.717 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 178.566 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.659 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 15.0 t -80.18 149.81 5.09 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.315 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 177.348 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 57.1 t -67.66 115.65 6.09 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.622 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.568 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.659 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 39.8 mtpt -123.23 157.67 32.58 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.799 -173.745 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 p -134.12 155.51 49.95 Favored 'General case' 0 C--N 1.286 -2.167 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.443 -179.228 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -55.69 147.09 42.77 Favored Pre-proline 0 N--CA 1.443 -0.807 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -177.086 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -71.77 129.9 16.16 Favored 'Trans proline' 0 N--CA 1.444 -1.43 0 C-N-CA 122.841 2.361 . . . . 0.0 111.914 -178.59 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 46.9 t -95.75 129.19 46.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.595 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.5 p -74.04 -73.93 0.21 Allowed 'General case' 0 N--CA 1.428 -1.551 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 178.215 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 175.82 156.68 0.39 Allowed Pre-proline 0 C--N 1.328 -0.347 0 C-N-CA 125.034 1.334 . . . . 0.0 107.526 178.613 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 152' ' ' PRO . . . . . 0.425 ' HG2' ' HA3' ' A' ' 155' ' ' GLY . 10.9 Cg_endo -66.76 167.04 20.37 Favored 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.532 1.488 . . . . 0.0 109.605 170.852 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 153' ' ' GLU . . . . . 0.536 ' OE1' ' HG3' ' A' ' 204' ' ' LYS . 0.0 OUTLIER -62.52 -45.16 94.26 Favored 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -175.181 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 154' ' ' ASN . . . . . 0.424 ' OD1' ' HG2' ' A' ' 153' ' ' GLU . 24.7 m120 -116.51 26.92 9.54 Favored 'General case' 0 CA--C 1.504 -0.813 0 CA-C-O 121.552 0.692 . . . . 0.0 109.689 179.881 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 155' ' ' GLY . . . . . 0.425 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -142.09 -171.7 13.18 Favored Glycine 0 N--CA 1.423 -2.211 0 C-N-CA 120.233 -0.984 . . . . 0.0 111.814 179.834 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 156' ' ' LYS . . . . . 0.415 ' HG3' HG23 ' A' ' 177' ' ' VAL . 44.2 pttt -153.26 171.1 19.06 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -177.39 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 53.2 mt -96.02 139.34 19.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 120.606 0.241 . . . . 0.0 111.372 -176.151 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.543 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 5.0 m -99.03 -28.32 3.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 CA-C-O 121.269 0.556 . . . . 0.0 110.09 178.305 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 159' ' ' SER . . . . . 0.556 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 46.3 m . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.374 -172.041 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 . . . . . 0 N--CA 1.437 -1.089 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -135.08 160.41 38.44 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -178.737 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 170' ' ' PHE . . . . . 0.426 ' CD2' ' HA2' ' A' ' 117' ' ' GLY . 0.9 OUTLIER -61.55 114.67 3.38 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 172.259 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 135.3 -21.16 3.68 Favored Glycine 0 N--CA 1.427 -1.919 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 -176.198 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 25.7 tp60 -76.81 124.04 27.11 Favored 'General case' 0 N--CA 1.401 -2.89 0 C-N-CA 122.883 0.473 . . . . 0.0 109.986 178.271 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -112.07 118.07 34.38 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 171.262 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.556 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 72.0 t -98.41 113.76 34.02 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -177.712 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.543 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 72.2 ttt180 -104.02 149.48 25.13 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 -179.678 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -122.45 162.74 21.12 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 121.579 0.704 . . . . 0.0 111.346 -174.455 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.415 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.0 OUTLIER -129.42 149.33 33.56 Favored 'Isoleucine or valine' 0 CA--C 1.475 -1.942 0 CA-C-N 113.998 -1.455 . . . . 0.0 109.644 174.097 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 178' ' ' CYS . . . . . 0.418 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 73.1 m -111.72 128.38 56.07 Favored 'General case' 0 N--CA 1.406 -2.674 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 176.062 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -50.45 159.74 0.47 Allowed 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 114.62 -1.173 . . . . 0.0 111.713 177.291 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 48.1 t -47.88 113.32 0.7 Allowed 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.42 -175.891 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.55 -17.3 30.95 Favored Glycine 0 N--CA 1.429 -1.796 0 C-N-CA 120.593 -0.813 . . . . 0.0 113.574 178.237 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 182' ' ' TYR . . . . . 0.418 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 95.7 m-85 -99.63 159.57 14.94 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 117.939 0.87 . . . . 0.0 110.965 -177.803 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 16.1 pttm -124.55 150.22 46.12 Favored 'General case' 0 N--CA 1.42 -1.958 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 175.615 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -74.93 133.58 31.21 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.468 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 174.807 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -77.47 -54.71 6.11 Favored 'General case' 0 C--N 1.282 -2.353 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -176.875 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -88.1 -134.65 4.7 Favored Glycine 0 C--N 1.301 -1.372 0 C-N-CA 120.958 -0.639 . . . . 0.0 111.836 177.558 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -87.36 158.7 18.97 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 178.83 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -96.37 6.17 49.34 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.067 -176.154 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -147.38 146.22 29.55 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 121.058 0.456 . . . . 0.0 111.981 -177.109 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.413 ' CE ' ' HA ' ' A' ' 202' ' ' LYS . 12.9 ptp -126.05 132.06 52.03 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.55 176.465 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 24.0 t-80 -105.84 136.09 46.11 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -177.876 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 8.6 t -74.22 124.55 26.6 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 177.338 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 27.1 t -97.18 171.55 8.38 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 122.91 0.484 . . . . 0.0 110.732 -176.361 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -68.14 -11.41 59.11 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 125.027 1.331 . . . . 0.0 114.439 -173.05 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 195' ' ' ASP . . . . . 0.514 ' HB3' ' CD1' ' A' ' 197' ' ' PHE . 29.3 t70 -94.23 -3.35 50.88 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 122.415 1.102 . . . . 0.0 109.959 177.68 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 82.81 49.81 4.93 Favored Glycine 0 N--CA 1.434 -1.497 0 C-N-CA 120.443 -0.884 . . . . 0.0 111.442 179.894 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 197' ' ' PHE . . . . . 0.514 ' CD1' ' HB3' ' A' ' 195' ' ' ASP . 3.1 p90 -151.77 158.97 44.05 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 178.322 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 87.4 m95 -76.38 135.22 39.49 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 176.551 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.9 p -61.1 -28.32 69.01 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.736 0.779 . . . . 0.0 111.291 -177.295 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 40.0 mmtt -113.71 162.83 15.79 Favored 'General case' 0 N--CA 1.418 -2.042 0 CA-C-N 114.729 -1.123 . . . . 0.0 111.062 -178.946 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -75.38 172.28 12.76 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 105.845 -1.909 . . . . 0.0 105.845 172.483 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 202' ' ' LYS . . . . . 0.413 ' HA ' ' CE ' ' A' ' 190' ' ' MET . 3.1 ttpm? -85.2 116.4 65.32 Favored Pre-proline 0 N--CA 1.421 -1.922 0 C-N-CA 117.321 -1.751 . . . . 0.0 107.773 179.18 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -67.08 166.42 23.1 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 122.774 2.316 . . . . 0.0 112.885 -174.733 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 204' ' ' LYS . . . . . 0.536 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 87.0 tttt -123.2 153.19 40.42 Favored 'General case' 0 C--N 1.286 -2.155 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.627 -173.627 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 99.9 m -109.82 112.85 25.14 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 177.009 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--N 1.304 -1.381 0 CA-C-N 115.173 -0.921 . . . . 0.0 108.871 -177.127 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo . . . . . 0 CA--C 1.536 0.611 0 CA-C-O 121.783 0.659 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.6 m -90.28 -32.89 16.34 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.001 178.86 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 109.68 -78.02 0.23 Allowed Glycine 0 CA--C 1.457 -3.538 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.333 168.833 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.0 t60 179.93 128.49 0.24 Allowed Pre-proline 0 C--N 1.274 -2.705 0 N-CA-C 105.08 -2.193 . . . . 0.0 105.08 -176.811 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.416 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 72.3 Cg_endo -75.98 -0.99 10.88 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 C-N-CA 123.647 2.898 . . . . 0.0 114.448 -172.236 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.66 179.64 16.93 Favored Glycine 0 N--CA 1.41 -3.093 0 N-CA-C 107.362 -2.295 . . . . 0.0 107.362 -173.495 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -150.16 160.26 43.8 Favored 'General case' 0 C--N 1.275 -2.641 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 -177.584 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.0 t -142.18 136.38 14.89 Favored Pre-proline 0 C--N 1.297 -1.676 0 C-N-CA 120.118 -0.633 . . . . 0.0 111.459 -176.778 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -79.67 -8.94 14.72 Favored 'Trans proline' 0 CA--C 1.533 0.432 0 C-N-CA 123.127 2.551 . . . . 0.0 112.022 176.631 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -93.23 4.28 54.26 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 121.315 0.579 . . . . 0.0 111.202 -176.858 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.627 ' HA2' ' OD1' ' A' ' 115' ' ' ASN . . . 170.19 -131.49 2.26 Favored Glycine 0 N--CA 1.401 -3.636 0 C-N-CA 120.278 -0.963 . . . . 0.0 110.921 -179.548 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.9 t -162.14 -166.64 1.45 Allowed 'General case' 0 C--N 1.277 -2.572 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -178.951 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.429 ' HA ' ' HA ' ' A' ' 112' ' ' TYR . 48.7 p90 -148.14 163.17 37.76 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 178.191 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -123.12 160.08 27.19 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 178.858 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -119.7 117.15 27.49 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.865 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.524 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 30.8 p -107.03 130.9 54.59 Favored 'General case' 0 C--N 1.279 -2.496 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.441 -174.04 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 112.86 -67.44 0.24 Allowed Glycine 0 N--CA 1.424 -2.123 0 N-CA-C 110.871 -0.891 . . . . 0.0 110.871 -178.689 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -114.58 -8.84 15.57 Favored Glycine 0 C--N 1.314 -0.66 0 C-N-CA 120.109 -1.043 . . . . 0.0 113.335 -176.097 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 47.9 m-80 61.1 18.63 9.2 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 123.253 0.621 . . . . 0.0 112.371 -178.334 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.498 ' O ' HG11 ' A' ' 108' ' ' VAL . 20.6 m -148.47 -176.73 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 -175.76 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -98.8 43.28 1.06 Allowed 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.13 0.491 . . . . 0.0 110.4 -177.237 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.653 ' O ' HG12 ' A' ' 108' ' ' VAL . 17.8 pt-20 -82.63 -175.95 6.02 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.772 -1.104 . . . . 0.0 111.549 177.394 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -80.71 140.26 35.68 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.393 175.285 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.12 -4.89 84.68 Favored Glycine 0 N--CA 1.443 -0.887 0 CA-C-N 115.77 -0.65 . . . . 0.0 113.298 177.691 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.653 HG12 ' O ' ' A' ' 105' ' ' GLU . 15.0 p -88.02 148.21 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -178.237 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.524 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 58.4 mtpt -109.87 128.93 55.65 Favored 'General case' 0 N--CA 1.414 -2.267 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 177.096 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -91.27 90.69 7.86 Favored 'General case' 0 C--N 1.281 -2.397 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 175.423 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.46 HG12 ' HB3' ' A' ' 126' ' ' TYR . 26.5 m -90.74 110.52 22.33 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-O 122.645 1.212 . . . . 0.0 109.461 -177.361 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 112' ' ' TYR . . . . . 0.429 ' HA ' ' HA ' ' A' ' 96' ' ' PHE . 27.5 m-85 -76.9 144.55 38.84 Favored 'General case' 0 C--N 1.272 -2.768 0 CA-C-N 115.074 -0.966 . . . . 0.0 112.324 -178.243 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.2 t -139.7 116.45 10.86 Favored 'General case' 0 N--CA 1.421 -1.912 0 CA-C-N 114.799 -1.091 . . . . 0.0 108.731 -179.28 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 91.4 m -70.82 161.28 31.23 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -179.307 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.627 ' OD1' ' HA2' ' A' ' 94' ' ' GLY . 4.9 m-20 -74.89 -176.73 3.01 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.003 -0.999 . . . . 0.0 110.955 177.552 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -56.03 -49.92 72.36 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 123.68 0.792 . . . . 0.0 112.746 -177.599 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -89.44 19.01 42.5 Favored Glycine 0 N--CA 1.438 -1.217 0 C-N-CA 120.804 -0.712 . . . . 0.0 113.539 -177.802 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.69 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 87.2 m-85 -137.5 159.21 42.59 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 117.287 0.544 . . . . 0.0 110.488 -179.982 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 119' ' ' GLN . . . . . 0.534 ' OE1' ' HB3' ' A' ' 142' ' ' GLU . 0.0 OUTLIER -145.35 159.17 43.45 Favored 'General case' 0 N--CA 1.425 -1.714 0 C-N-CA 121.087 -0.245 . . . . 0.0 110.348 179.129 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.92 122.71 27.58 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 -176.902 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -107.9 127.62 53.9 Favored 'General case' 0 N--CA 1.414 -2.233 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 179.853 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 113.48 179.41 19.24 Favored Glycine 0 C--N 1.291 -1.93 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -178.182 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -94.49 -30.19 14.55 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.852 0.834 . . . . 0.0 108.77 -177.793 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.2 mm -87.14 122.8 39.44 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.56 0 CA-C-N 114.922 -1.035 . . . . 0.0 109.101 -179.331 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -124.4 1.24 8.36 Favored 'General case' 0 C--O 1.203 -1.38 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 178.811 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.502 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 40.4 p90 -139.34 164.74 29.05 Favored 'General case' 0 C--N 1.288 -2.087 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -170.432 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 127' ' ' ARG . . . . . 0.416 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 43.1 mtp180 -127.87 133.63 49.35 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 171.706 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -103.98 128.14 51.53 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 -178.485 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 13.7 t -82.85 105.22 13.69 Favored 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 117.749 -1.58 . . . . 0.0 110.332 177.18 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.462 ' OD1' HG22 ' A' ' 131' ' ' THR . 9.1 t70 -97.84 -168.68 1.71 Allowed 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 177.483 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.462 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.3 t -66.83 -22.57 66.0 Favored 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 118.161 0.437 . . . . 0.0 111.468 -175.123 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -88.95 -9.29 52.03 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.681 0.753 . . . . 0.0 110.03 178.67 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 114.72 -160.8 13.0 Favored Glycine 0 N--CA 1.428 -1.838 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -176.808 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 134' ' ' TRP . . . . . 0.416 ' CH2' HG13 ' A' ' 108' ' ' VAL . 96.9 m95 -64.22 113.57 3.66 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 122.543 0.337 . . . . 0.0 111.819 -179.044 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 66.3 p -73.61 176.03 6.56 Favored 'General case' 0 C--O 1.269 2.124 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.408 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 35.1 m-20 60.68 -149.08 0.43 Allowed 'General case' 0 C--O 1.244 0.787 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 179.281 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -144.2 -173.11 3.92 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 171.343 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 73.5 mt -66.01 119.29 60.18 Favored Pre-proline 0 C--N 1.272 -2.798 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 174.877 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -62.15 163.19 20.61 Favored 'Trans proline' 0 C--O 1.253 1.266 0 C-N-CA 122.686 2.257 . . . . 0.0 112.011 -178.918 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.7 mm -93.83 123.72 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 CA-C-O 121.505 0.669 . . . . 0.0 109.939 -173.976 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.631 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 22.0 t -107.51 110.1 21.94 Favored 'General case' 0 C--N 1.263 -3.187 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 176.607 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.534 ' HB3' ' OE1' ' A' ' 119' ' ' GLN . 10.5 tp10 -101.2 150.77 22.62 Favored 'General case' 0 N--CA 1.409 -2.478 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -175.898 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.69 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 8.6 t -75.63 137.01 23.69 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.385 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.129 -177.696 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 42.9 t -67.96 112.15 2.88 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.933 0 N-CA-C 106.538 -1.652 . . . . 0.0 106.538 174.888 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 145' ' ' LYS . . . . . 0.432 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 35.3 mtmm -129.86 161.57 30.51 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-N 115.5 -0.773 . . . . 0.0 108.951 -175.609 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -129.62 164.5 23.75 Favored 'General case' 0 C--N 1.271 -2.831 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.896 -178.138 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 85.4 mt -70.63 142.38 88.67 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 113.931 1.085 . . . . 0.0 113.931 -175.67 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_endo -63.39 119.66 6.8 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 123.05 2.5 . . . . 0.0 110.178 175.811 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.7 t -80.29 151.84 4.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.249 -174.398 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 150' ' ' THR . . . . . 0.425 ' O ' HD11 ' A' ' 157' ' ' ILE . 27.9 p -87.93 -159.08 0.5 Allowed 'General case' 0 N--CA 1.414 -2.24 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 170.971 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -128.9 151.59 77.69 Favored Pre-proline 0 C--N 1.283 -2.306 0 O-C-N 121.142 -0.973 . . . . 0.0 109.53 -172.277 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 152' ' ' PRO . . . . . 0.453 ' HG2' ' HA3' ' A' ' 155' ' ' GLY . 24.0 Cg_endo -66.86 160.7 45.56 Favored 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.055 1.836 . . . . 0.0 112.419 178.072 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -48.88 -45.79 41.64 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 126.0 1.72 . . . . 0.0 114.389 -175.516 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.5 m-80 -126.84 27.15 6.06 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-O 122.077 0.941 . . . . 0.0 109.49 -178.477 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 155' ' ' GLY . . . . . 0.453 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -132.15 -169.41 12.3 Favored Glycine 0 N--CA 1.42 -2.382 0 CA-C-N 114.714 -1.13 . . . . 0.0 111.066 179.572 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 156' ' ' LYS . . . . . 0.481 ' HG3' HG23 ' A' ' 177' ' ' VAL . 45.3 pttt -157.94 171.78 19.65 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -177.746 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.425 HD11 ' O ' ' A' ' 150' ' ' THR . 58.6 mt -97.2 131.84 43.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 C-N-CA 122.022 0.129 . . . . 0.0 110.743 -177.613 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.581 HG12 HG22 ' A' ' 177' ' ' VAL . 3.5 m -75.19 -38.33 41.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.321 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 CA--C 1.537 0.468 0 C-N-CA 124.87 1.268 . . . . 0.0 109.134 -176.501 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 62.0 m-85 . . . . . 0 N--CA 1.448 -0.553 0 CA-C-O 121.668 0.747 . . . . 0.0 111.557 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -105.86 164.24 12.1 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 179.023 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 90.7 t80 -52.14 128.16 23.92 Favored 'General case' 0 C--N 1.317 -0.807 0 C-N-CA 123.123 0.569 . . . . 0.0 109.827 174.516 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.46 -33.95 5.15 Favored Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.382 -179.129 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 87.1 mm-40 -70.12 151.62 45.25 Favored 'General case' 0 C--O 1.259 1.557 0 CA-C-O 121.244 0.545 . . . . 0.0 109.825 179.863 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -135.09 131.16 36.59 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-N 115.344 -0.843 . . . . 0.0 109.467 179.339 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 95.3 t -100.12 114.68 39.4 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -178.594 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.575 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 43.2 ttm180 -101.49 142.99 32.05 Favored 'General case' 0 N--CA 1.419 -1.981 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 177.366 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -111.99 160.52 17.38 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 123.138 0.575 . . . . 0.0 110.876 -176.613 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.581 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -131.52 143.29 40.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.933 178.962 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 93.4 m -102.17 132.1 48.28 Favored 'General case' 0 C--N 1.276 -2.603 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 174.168 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 59.0 m-80 -61.09 163.12 6.38 Favored 'General case' 0 CA--C 1.491 -1.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.569 -178.715 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 10.9 m -46.89 106.67 0.09 Allowed 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 125.51 1.524 . . . . 0.0 112.569 -175.723 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 115.79 -16.52 16.16 Favored Glycine 0 N--CA 1.435 -1.396 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.323 178.99 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 182' ' ' TYR . . . . . 0.431 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 90.1 m-85 -103.8 155.07 18.89 Favored 'General case' 0 CA--C 1.495 -1.138 0 CA-C-N 117.269 0.535 . . . . 0.0 111.609 -177.664 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -125.16 147.34 49.08 Favored 'General case' 0 N--CA 1.423 -1.785 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 177.981 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 9.1 tt -79.96 136.64 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.934 0 CA-C-O 121.802 0.811 . . . . 0.0 111.287 -177.296 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -81.87 -52.14 7.39 Favored 'General case' 0 C--N 1.292 -1.916 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.736 -177.707 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -86.4 -152.75 21.54 Favored Glycine 0 N--CA 1.433 -1.553 0 CA-C-N 114.97 -1.014 . . . . 0.0 111.042 178.487 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 187' ' ' ASP . . . . . 0.421 ' OD1' ' HD2' ' A' ' 200' ' ' LYS . 1.6 p-10 -92.7 163.11 13.88 Favored 'General case' 0 C--N 1.289 -2.024 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 177.955 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.575 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 0.8 OUTLIER -99.87 3.74 44.75 Favored 'General case' 0 C--N 1.286 -2.181 0 C-N-CA 118.509 -1.277 . . . . 0.0 113.165 -171.683 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -144.39 121.81 11.67 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -173.986 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 190' ' ' MET . . . . . 0.434 ' HB3' ' HB2' ' A' ' 200' ' ' LYS . 15.0 ptp -105.46 131.19 53.19 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.403 177.955 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 25.1 t-80 -106.16 135.42 47.65 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.446 -176.952 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 7.3 t -72.74 112.48 8.83 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.043 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 193' ' ' SER . . . . . 0.424 ' OG ' ' HB3' ' A' ' 199' ' ' SER . 17.5 m -94.56 172.2 8.33 Favored 'General case' 0 N--CA 1.442 -0.856 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.289 -173.467 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -43.02 -43.1 4.11 Favored 'General case' 0 N--CA 1.495 1.775 0 C-N-CA 127.02 2.128 . . . . 0.0 114.538 -171.713 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -92.26 12.73 21.43 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 113.675 0.991 . . . . 0.0 113.675 -174.798 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 78.97 46.95 7.98 Favored Glycine 0 CA--C 1.496 -1.128 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.8 176.052 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -145.0 160.29 41.6 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.633 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -82.23 132.03 35.23 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 177.389 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 199' ' ' SER . . . . . 0.424 ' HB3' ' OG ' ' A' ' 193' ' ' SER . 23.8 p -66.06 -22.49 66.43 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.551 0.691 . . . . 0.0 111.11 -178.945 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.434 ' HB2' ' HB3' ' A' ' 190' ' ' MET . 26.5 mmtp -120.75 151.0 40.11 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.534 -177.829 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 73.0 mm-40 -89.42 166.53 13.66 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.211 176.928 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 202' ' ' LYS . . . . . 0.449 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 39.6 mtpt -63.95 119.04 51.63 Favored Pre-proline 0 C--N 1.319 -0.73 0 O-C-N 123.464 0.477 . . . . 0.0 111.057 179.513 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 203' ' ' PRO . . . . . 0.441 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 95.4 Cg_endo -77.39 168.1 23.43 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 122.642 2.228 . . . . 0.0 112.056 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 37.1 ttpt -119.9 150.86 39.79 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.86 -176.653 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.431 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 83.8 m -110.93 118.72 36.87 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 177.388 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 30.4 m . . . . . 0 C--N 1.3 -1.555 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.574 -175.325 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo . . . . . 0 CA--C 1.537 0.666 0 CA-C-O 121.603 0.585 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.7 m -82.83 -32.89 27.33 Favored 'General case' 0 CA--C 1.504 -0.814 0 CA-C-O 122.005 0.907 . . . . 0.0 108.612 179.024 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.75 -87.85 0.43 Allowed Glycine 0 N--CA 1.396 -3.967 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.366 174.415 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.0 t-80 -175.02 135.39 0.52 Allowed Pre-proline 0 C--N 1.264 -3.135 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 -173.711 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.545 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 66.9 Cg_endo -93.69 -5.18 2.76 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.497 2.131 . . . . 0.0 113.031 -178.139 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 106.73 175.93 23.08 Favored Glycine 0 CA--C 1.485 -1.826 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 178.787 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -151.43 152.88 33.66 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 177.319 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.423 HG21 ' CZ ' ' A' ' 112' ' ' TYR . 9.6 t -125.18 141.12 37.72 Favored Pre-proline 0 C--N 1.29 -1.994 0 O-C-N 123.385 0.428 . . . . 0.0 112.043 -175.218 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -79.84 -12.69 13.36 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 122.913 2.409 . . . . 0.0 111.405 173.511 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -85.98 2.26 46.93 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 121.744 0.783 . . . . 0.0 110.861 -178.7 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.609 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.48 -126.56 1.21 Allowed Glycine 0 N--CA 1.402 -3.571 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 -178.737 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.8 t -164.5 -166.23 1.06 Allowed 'General case' 0 C--N 1.27 -2.878 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.847 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -153.01 158.05 41.44 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 177.691 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.8 m -127.17 158.98 35.65 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 179.991 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.412 ' HB2' ' HA ' ' A' ' 102' ' ' ASN . 22.0 mt -116.55 127.49 54.56 Favored 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 -179.736 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.509 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 21.2 p -117.61 125.82 51.45 Favored 'General case' 0 C--N 1.29 -1.991 0 CA-C-O 121.311 0.577 . . . . 0.0 111.063 -175.728 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 121.55 -58.18 0.59 Allowed Glycine 0 N--CA 1.432 -1.602 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.306 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -130.82 -3.02 4.64 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.632 -0.794 . . . . 0.0 113.678 -177.868 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 102' ' ' ASN . . . . . 0.412 ' HA ' ' HB2' ' A' ' 98' ' ' LEU . 2.3 t30 54.13 29.29 10.15 Favored 'General case' 0 CA--C 1.559 1.315 0 C-N-CA 125.776 1.631 . . . . 0.0 112.016 -178.922 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.532 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.7 m -149.74 -174.77 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.209 -1.043 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 179.699 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.545 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 20.6 m-85 -100.8 44.48 1.01 Allowed 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 118.767 0.712 . . . . 0.0 110.359 -178.174 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 105' ' ' GLU . . . . . 0.684 ' O ' HG12 ' A' ' 108' ' ' VAL . 9.7 pt-20 -85.06 177.59 7.86 Favored 'General case' 0 C--O 1.211 -0.967 0 CA-C-N 114.639 -1.164 . . . . 0.0 111.89 178.413 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -76.58 133.13 39.76 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.219 177.372 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.02 5.06 64.4 Favored Glycine 0 N--CA 1.438 -1.232 0 CA-C-N 115.791 -0.64 . . . . 0.0 112.679 179.85 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.684 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.0 p -97.44 147.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 -179.92 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 109' ' ' LYS . . . . . 0.509 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -109.64 130.64 55.5 Favored 'General case' 0 N--CA 1.42 -1.938 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 177.249 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 110' ' ' ALA . . . . . 0.527 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -94.49 95.71 9.0 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 175.034 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 78.7 t -89.3 112.9 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.859 0 C-N-CA 123.768 0.827 . . . . 0.0 108.8 -178.327 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 112' ' ' TYR . . . . . 0.489 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 9.6 t80 -81.9 138.39 35.03 Favored 'General case' 0 C--N 1.276 -2.597 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -177.785 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -138.55 120.56 15.56 Favored 'General case' 0 N--CA 1.424 -1.739 0 CA-C-O 121.785 0.802 . . . . 0.0 109.309 177.64 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 114' ' ' CYS . . . . . 0.447 ' SG ' ' HE1' ' A' ' 112' ' ' TYR . 75.8 m -73.94 160.28 31.58 Favored 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.597 -179.244 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.609 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 82.2 m-20 -78.32 177.12 8.69 Favored 'General case' 0 C--O 1.212 -0.884 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.111 176.706 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 116' ' ' GLU . . . . . 0.476 ' HG3' ' OD2' ' A' ' 194' ' ' ASP . 39.9 tt0 -44.81 -46.62 10.73 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 124.956 1.303 . . . . 0.0 114.308 -177.305 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.91 5.33 82.96 Favored Glycine 0 C--N 1.311 -0.858 0 C-N-CA 120.309 -0.948 . . . . 0.0 114.048 -176.663 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 118' ' ' TYR . . . . . 0.499 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.3 m-85 -130.61 164.28 25.29 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 -176.506 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -148.1 155.77 41.84 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-O 120.988 0.423 . . . . 0.0 110.242 179.495 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -77.38 130.91 37.72 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 179.351 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 121' ' ' LEU . . . . . 0.588 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -119.45 130.41 55.24 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.83 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.17 -175.07 21.82 Favored Glycine 0 C--N 1.295 -1.717 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.521 -179.597 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -91.8 -29.04 16.98 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 121.53 0.681 . . . . 0.0 109.646 -178.331 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 124' ' ' ILE . . . . . 0.569 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 46.9 mm -82.95 114.51 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.553 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.869 -177.778 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -130.42 7.67 4.95 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.896 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 126' ' ' TYR . . . . . 0.527 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 17.8 p90 -151.57 156.43 40.46 Favored 'General case' 0 N--CA 1.425 -1.689 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.415 -173.446 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 52.1 mtp180 -121.34 125.29 46.65 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 105.14 -2.17 . . . . 0.0 105.14 171.538 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -101.73 126.88 48.67 Favored 'General case' 0 C--N 1.275 -2.65 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.074 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 129' ' ' CYS . . . . . 0.459 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 25.5 t -86.03 100.81 12.41 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 118.498 -1.281 . . . . 0.0 110.075 176.166 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.424 ' OD1' HG22 ' A' ' 131' ' ' THR . 9.2 t70 -98.71 -165.28 1.22 Allowed 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 105.456 -2.053 . . . . 0.0 105.456 175.602 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.424 HG22 ' OD1' ' A' ' 130' ' ' ASP . 10.2 t -63.5 -22.95 67.18 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 119.131 0.878 . . . . 0.0 112.143 -177.02 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -80.23 -13.57 59.11 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.652 0.739 . . . . 0.0 110.692 176.357 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.459 ' HA2' ' SG ' ' A' ' 129' ' ' CYS . . . 105.49 -148.51 16.52 Favored Glycine 0 N--CA 1.421 -2.339 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -175.375 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 85.0 m95 -69.13 109.55 4.09 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 176.908 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 28.9 p -61.14 -68.8 0.28 Allowed 'General case' 0 N--CA 1.438 -1.039 0 O-C-N 123.792 0.682 . . . . 0.0 111.48 -178.126 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 74.4 m-20 -75.62 177.13 7.02 Favored 'General case' 0 CA--C 1.489 -1.368 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.513 178.035 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -108.13 -168.91 1.43 Allowed 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 178.511 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.2 mt -60.87 117.98 30.76 Favored Pre-proline 0 C--N 1.295 -1.775 0 O-C-N 123.986 0.804 . . . . 0.0 109.33 177.272 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 139' ' ' PRO . . . . . 0.569 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 53.3 Cg_exo -52.77 165.99 0.99 Allowed 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.867 3.045 . . . . 0.0 113.916 178.644 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 140' ' ' ILE . . . . . 0.588 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 3.6 mp -90.73 130.7 39.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.172 -174.801 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 141' ' ' CYS . . . . . 0.499 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 25.4 t -123.6 114.93 20.68 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.318 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -110.41 149.79 29.76 Favored 'General case' 0 N--CA 1.405 -2.711 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 -177.961 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 9.6 p -73.69 143.53 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.898 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.572 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 89.3 t -68.69 123.05 21.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 177.155 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -109.3 140.14 43.36 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.149 -176.421 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 57.5 m -102.13 144.66 30.41 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.9 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 147' ' ' LEU . . . . . 0.4 HD23 ' HD2' ' A' ' 148' ' ' PRO . 1.4 tt -49.59 130.03 19.4 Favored Pre-proline 0 N--CA 1.432 -1.36 0 C-N-CA 125.275 1.43 . . . . 0.0 110.748 179.491 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.563 ' HA ' ' CD2' ' A' ' 168' ' ' TYR . 12.4 Cg_endo -57.74 110.59 0.65 Allowed 'Trans proline' 0 N--CA 1.454 -0.813 0 C-N-CA 123.557 2.838 . . . . 0.0 113.35 -178.522 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 13.6 p -83.81 142.72 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 CA-C-N 115.176 -0.92 . . . . 0.0 108.865 177.397 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 10.2 p -105.22 -156.4 0.57 Allowed 'General case' 0 C--N 1.288 -2.069 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.37 176.172 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 151' ' ' ALA . . . . . 0.457 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . -100.85 151.25 37.56 Favored Pre-proline 0 C--N 1.298 -1.649 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -170.636 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -75.62 170.24 20.64 Favored 'Trans proline' 0 N--CA 1.436 -1.906 0 C-N-CA 121.442 1.428 . . . . 0.0 110.914 175.25 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -50.41 -55.24 16.62 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 114.306 1.224 . . . . 0.0 114.306 -175.992 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 154' ' ' ASN . . . . . 0.436 ' HB2' ' O ' ' A' ' 205' ' ' CYS . 57.4 m-80 -113.95 27.04 9.82 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.19 0.519 . . . . 0.0 110.725 -177.544 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.7 -173.1 15.71 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 120.081 -1.057 . . . . 0.0 111.726 179.768 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 156' ' ' LYS . . . . . 0.457 ' HA ' ' HB1' ' A' ' 151' ' ' ALA . 50.3 pttt -153.33 172.67 16.68 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -178.14 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 62.5 mt -86.04 132.1 32.91 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 CA-C-O 121.169 0.509 . . . . 0.0 111.058 -176.46 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.447 ' CG2' ' HB ' ' A' ' 177' ' ' VAL . 47.9 t -76.52 -40.31 33.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 C-N-CA 123.974 0.91 . . . . 0.0 108.907 177.172 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 C--N 1.301 -1.519 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.446 179.933 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 168' ' ' TYR . . . . . 0.563 ' CD2' ' HA ' ' A' ' 148' ' ' PRO . 98.0 m-85 . . . . . 0 CA--C 1.508 -0.658 0 CA-C-O 121.661 0.743 . . . . 0.0 112.087 . . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 80.1 m-70 -98.38 155.47 17.21 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 114.506 -1.224 . . . . 0.0 107.966 -179.463 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -56.77 131.5 49.45 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 172.012 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 171' ' ' GLY . . . . . 0.438 ' H ' ' HB2' ' A' ' 192' ' ' CYS . . . 113.43 -15.03 22.64 Favored Glycine 0 N--CA 1.414 -2.768 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.234 -177.682 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 172' ' ' GLN . . . . . 0.426 ' O ' ' HA ' ' A' ' 191' ' ' HIS . 15.5 mm100 -74.58 134.38 42.13 Favored 'General case' 0 N--CA 1.423 -1.788 0 C-N-CA 120.223 -0.591 . . . . 0.0 111.976 179.55 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -115.15 94.34 4.69 Favored 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 173.562 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 66.2 t -81.61 109.02 15.36 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 CA-C-N 115.243 -0.889 . . . . 0.0 108.963 -176.121 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 175' ' ' ARG . . . . . 0.45 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 14.5 ttp180 -97.1 156.27 16.45 Favored 'General case' 0 N--CA 1.411 -2.387 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 179.055 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -127.09 156.35 41.85 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 124.038 0.935 . . . . 0.0 109.399 -175.006 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.447 ' HB ' ' CG2' ' A' ' 158' ' ' VAL . 12.2 p -133.56 141.07 45.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.461 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 80.5 m -102.54 153.63 19.89 Favored 'General case' 0 C--N 1.265 -3.105 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.961 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -64.62 163.46 13.68 Favored 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 119.972 -0.691 . . . . 0.0 110.153 176.73 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 15.8 m -43.54 -32.74 0.98 Allowed 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 116.37 1.989 . . . . 0.0 116.37 -170.724 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -113.36 21.09 17.87 Favored Glycine 0 C--N 1.293 -1.847 0 C-N-CA 120.1 -1.047 . . . . 0.0 113.375 -179.048 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -122.32 151.06 41.53 Favored 'General case' 0 N--CA 1.432 -1.335 0 O-C-N 122.129 -0.63 . . . . 0.0 111.356 179.28 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -124.15 143.59 50.4 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.158 -178.93 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 184' ' ' ILE . . . . . 0.527 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.4 tt -74.87 140.55 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.928 0 CA-C-O 121.476 0.655 . . . . 0.0 111.288 -176.695 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -67.01 -64.57 0.83 Allowed 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.318 -177.261 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -103.41 -123.59 5.3 Favored Glycine 0 N--CA 1.436 -1.32 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.283 -179.558 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 187' ' ' ASP . . . . . 0.583 ' HB2' ' HG3' ' A' ' 200' ' ' LYS . 5.5 m-20 -91.63 153.4 19.73 Favored 'General case' 0 CA--C 1.491 -1.291 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -177.495 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 188' ' ' GLU . . . . . 0.527 ' HA ' HD13 ' A' ' 184' ' ' ILE . 14.2 pt-20 -91.65 -4.04 55.67 Favored 'General case' 0 C--O 1.205 -1.286 0 C-N-CA 119.944 -0.702 . . . . 0.0 111.174 -172.027 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -134.34 132.31 39.35 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 -177.72 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 14.4 ptp -112.68 123.54 50.53 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.271 174.881 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 191' ' ' HIS . . . . . 0.426 ' HA ' ' O ' ' A' ' 172' ' ' GLN . 16.4 t-80 -110.36 139.01 45.99 Favored 'General case' 0 C--N 1.279 -2.498 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.954 -177.317 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 192' ' ' CYS . . . . . 0.438 ' HB2' ' H ' ' A' ' 171' ' ' GLY . 22.0 m -62.64 130.14 43.69 Favored 'General case' 0 C--N 1.32 -0.705 0 O-C-N 123.657 0.598 . . . . 0.0 111.668 175.207 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 37.5 t -101.78 166.92 10.41 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.137 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 194' ' ' ASP . . . . . 0.476 ' OD2' ' HG3' ' A' ' 116' ' ' GLU . 6.3 t70 -52.41 -33.22 42.82 Favored 'General case' 0 N--CA 1.511 2.613 0 C-N-CA 124.236 1.014 . . . . 0.0 110.332 178.925 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -56.94 -26.21 59.14 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 113.75 -1.568 . . . . 0.0 111.742 179.807 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 89.59 15.53 58.2 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -174.97 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -125.27 170.54 11.19 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.064 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -85.39 142.49 29.24 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 123.678 0.611 . . . . 0.0 110.944 -177.699 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 30.7 t -60.64 -50.29 74.11 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.725 176.593 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 200' ' ' LYS . . . . . 0.583 ' HG3' ' HB2' ' A' ' 187' ' ' ASP . 12.9 mmmm -104.61 156.14 18.23 Favored 'General case' 0 CA--C 1.485 -1.548 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 174.227 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -89.06 171.73 9.63 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 170.546 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 34.9 ttmt -61.9 122.25 70.67 Favored Pre-proline 0 C--O 1.243 0.724 0 CA-C-N 118.985 0.811 . . . . 0.0 110.492 -176.246 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.04 -173.49 1.9 Allowed 'Trans proline' 0 N--CA 1.437 -1.833 0 C-N-CA 122.039 1.826 . . . . 0.0 111.067 179.122 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 66.0 mttm -126.58 160.88 29.39 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.118 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 205' ' ' CYS . . . . . 0.436 ' O ' ' HB2' ' A' ' 154' ' ' ASN . 97.4 m -116.62 105.19 12.17 Favored 'General case' 0 C--N 1.27 -2.887 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 170.852 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 23.7 m . . . . . 0 C--N 1.286 -2.176 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.033 -173.547 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.428 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 30.6 Cg_endo . . . . . 0 CA--C 1.542 0.907 0 CA-C-O 121.436 0.515 . . . . 0.0 111.761 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.1 m -85.03 -37.68 20.09 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 177.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.08 -92.41 0.48 Allowed Glycine 0 N--CA 1.41 -3.095 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 173.662 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.9 t60 -177.24 123.73 0.28 Allowed Pre-proline 0 C--N 1.26 -3.314 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 -177.309 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.427 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 34.8 Cg_endo -66.72 -49.91 1.42 Allowed 'Trans proline' 0 C--O 1.209 -0.933 0 C-N-CA 121.33 1.353 . . . . 0.0 110.722 -177.179 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 150.32 169.18 16.08 Favored Glycine 0 N--CA 1.401 -3.642 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 -177.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -136.03 139.93 43.46 Favored 'General case' 0 C--N 1.264 -3.113 0 CA-C-N 117.31 0.555 . . . . 0.0 109.688 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.5 t -99.9 128.97 29.58 Favored Pre-proline 0 N--CA 1.409 -2.525 0 CA-C-N 115.111 -0.949 . . . . 0.0 111.304 -172.443 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -69.04 -24.01 33.44 Favored 'Trans proline' 0 C--O 1.24 0.591 0 C-N-CA 122.884 2.389 . . . . 0.0 110.214 175.704 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -75.06 -28.28 60.31 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 114.014 -1.448 . . . . 0.0 110.763 -176.659 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.437 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -151.0 -133.21 2.03 Favored Glycine 0 N--CA 1.409 -3.159 0 C-N-CA 119.071 -1.538 . . . . 0.0 112.783 -177.819 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.0 p -144.1 170.67 15.51 Favored 'General case' 0 C--N 1.275 -2.64 0 CA-C-N 113.885 -1.157 . . . . 0.0 108.896 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.458 ' HA ' ' HA ' ' A' ' 112' ' ' TYR . 17.8 p90 -140.69 153.55 46.0 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 172.302 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -127.26 160.12 32.27 Favored 'General case' 0 C--N 1.274 -2.705 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -116.72 118.63 33.07 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 121.293 0.568 . . . . 0.0 109.874 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 26.2 p -111.88 133.64 53.95 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.755 -174.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 111.98 -53.13 0.6 Allowed Glycine 0 N--CA 1.434 -1.478 0 C-N-CA 120.865 -0.683 . . . . 0.0 111.557 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -131.31 -7.21 3.23 Favored Glycine 0 N--CA 1.441 -0.999 0 C-N-CA 120.196 -1.002 . . . . 0.0 113.109 -179.008 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 48.4 m-80 61.17 17.4 8.08 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.523 ' O ' HG11 ' A' ' 108' ' ' VAL . 19.7 m -149.01 -170.07 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.205 -1.286 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -177.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -103.47 45.57 0.95 Allowed 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 118.422 0.556 . . . . 0.0 110.083 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.71 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.9 pt-20 -86.08 176.28 8.09 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 114.957 -1.019 . . . . 0.0 111.58 177.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' TYR . . . . . 0.44 ' CE1' ' HA ' ' A' ' 131' ' ' THR . 46.0 m-85 -72.91 133.23 44.29 Favored 'General case' 0 C--N 1.293 -1.859 0 O-C-N 121.976 -0.453 . . . . 0.0 111.273 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.36 -8.7 69.42 Favored Glycine 0 N--CA 1.434 -1.453 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.232 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.71 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.2 p -80.67 147.69 6.19 Favored 'Isoleucine or valine' 0 C--O 1.238 0.481 0 CA-C-N 117.553 0.676 . . . . 0.0 109.946 -176.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 16.8 mtpp -112.38 119.08 37.03 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.556 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -87.91 96.49 10.5 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.424 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.509 HG12 ' HB3' ' A' ' 126' ' ' TYR . 18.8 m -94.81 115.82 34.59 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.327 0 CA-C-O 122.036 0.922 . . . . 0.0 109.979 -177.02 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' TYR . . . . . 0.458 ' HA ' ' HA ' ' A' ' 96' ' ' PHE . 33.3 m-85 -83.07 144.43 29.9 Favored 'General case' 0 C--N 1.265 -3.072 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.524 -178.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.4 t -143.64 127.79 17.6 Favored 'General case' 0 N--CA 1.427 -1.621 0 CA-C-N 115.275 -0.875 . . . . 0.0 108.803 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 81.4 m -73.71 163.39 28.04 Favored 'General case' 0 C--N 1.292 -1.891 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.317 -176.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.437 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 95.4 m-20 -95.25 -179.15 4.69 Favored 'General case' 0 CA--C 1.476 -1.887 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.72 -178.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -69.09 93.96 0.63 Allowed 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 124.573 1.171 . . . . 0.0 109.753 177.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 133.66 2.13 3.64 Favored Glycine 0 C--N 1.259 -3.698 0 CA-C-N 112.961 -1.927 . . . . 0.0 111.781 177.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.429 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 87.8 m-85 -133.49 158.7 42.44 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -177.485 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -142.11 158.06 44.18 Favored 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 -177.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 13.9 tp -83.07 146.27 28.8 Favored 'General case' 0 N--CA 1.413 -2.282 0 C-N-CA 119.491 -0.884 . . . . 0.0 109.169 -177.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.09 121.64 38.33 Favored 'General case' 0 N--CA 1.405 -2.709 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.359 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 100.4 174.93 29.96 Favored Glycine 0 C--N 1.292 -1.897 0 N-CA-C 110.914 -0.875 . . . . 0.0 110.914 -174.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -88.05 -37.89 15.9 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.255 0.55 . . . . 0.0 110.112 -177.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.3 mm -66.7 124.47 21.96 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.758 -177.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -127.13 -4.34 6.23 Favored 'General case' 0 C--O 1.204 -1.317 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.509 ' HB3' HG12 ' A' ' 111' ' ' VAL . 11.9 p90 -137.23 161.83 35.14 Favored 'General case' 0 C--N 1.293 -1.888 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.496 -170.472 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 49.9 mtp180 -125.28 136.11 53.19 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 106.112 -1.81 . . . . 0.0 106.112 171.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -115.32 130.94 57.05 Favored 'General case' 0 C--N 1.273 -2.719 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 33.0 t -86.49 112.26 21.35 Favored 'General case' 0 C--N 1.293 -1.869 0 C-N-CA 119.109 -1.036 . . . . 0.0 110.83 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.454 ' OD2' HG22 ' A' ' 131' ' ' THR . 14.9 t70 -103.24 -171.26 1.91 Allowed 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 175.339 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.454 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -71.16 -17.78 62.53 Favored 'General case' 0 C--N 1.291 -1.946 0 CA-C-O 121.874 0.845 . . . . 0.0 110.309 -175.027 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -87.9 -8.77 55.34 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.691 179.367 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 112.78 -164.32 12.07 Favored Glycine 0 N--CA 1.427 -1.936 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -177.061 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.427 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 97.8 m95 -60.97 123.34 17.32 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 117.255 0.527 . . . . 0.0 110.579 176.037 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.6 p -64.46 -71.77 0.17 Allowed 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 123.554 0.742 . . . . 0.0 111.99 -178.589 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -81.58 177.66 8.8 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.175 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -106.12 177.84 4.74 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.282 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 65.0 mt -61.38 121.11 61.21 Favored Pre-proline 0 C--O 1.245 0.861 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 176.346 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.13 166.89 23.48 Favored 'Trans proline' 0 C--O 1.26 1.625 0 C-N-CA 122.424 2.083 . . . . 0.0 111.637 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 55.7 mt -90.06 127.02 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.03 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -177.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.429 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 53.6 t -121.07 115.62 23.46 Favored 'General case' 0 C--N 1.269 -2.916 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 174.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.18 151.95 23.43 Favored 'General case' 0 C--N 1.282 -2.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 109.864 -177.236 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.5 p -68.88 137.52 24.18 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.105 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.682 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 41.5 t -63.95 125.91 21.58 Favored 'Isoleucine or valine' 0 C--O 1.247 0.951 0 CA-C-O 121.111 0.482 . . . . 0.0 109.74 178.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -119.13 133.55 55.72 Favored 'General case' 0 N--CA 1.418 -2.074 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -179.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 72.8 m -99.63 141.18 32.77 Favored 'General case' 0 C--N 1.261 -3.267 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.283 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.0 mm? -58.63 138.5 86.12 Favored Pre-proline 0 N--CA 1.427 -1.579 0 N-CA-C 114.209 1.188 . . . . 0.0 114.209 -175.499 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 23.5 Cg_exo -58.25 107.4 0.32 Allowed 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 123.346 2.698 . . . . 0.0 111.117 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 5.9 p -69.26 140.58 18.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 20.5 p -71.9 -71.81 0.26 Allowed 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 111.405 0.15 . . . . 0.0 111.405 -178.346 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.38 162.3 0.21 Allowed Pre-proline 0 C--O 1.248 1.005 0 C-N-CA 125.748 1.619 . . . . 0.0 106.712 177.393 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' PRO . . . . . 0.403 ' HB3' ' O ' ' A' ' 203' ' ' PRO . 51.3 Cg_endo -74.3 170.88 19.19 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 121.512 1.475 . . . . 0.0 109.469 169.742 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -60.67 -48.92 79.62 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 114.055 1.132 . . . . 0.0 114.055 -173.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 32.2 m120 -117.31 32.39 6.19 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.505 0.669 . . . . 0.0 109.668 -177.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.06 -176.59 18.22 Favored Glycine 0 C--N 1.303 -1.269 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.477 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.4 ptmt -145.21 173.27 12.09 Favored 'General case' 0 N--CA 1.434 -1.231 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -178.355 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 69.0 mt -88.22 138.49 19.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 CA-C-O 121.3 0.572 . . . . 0.0 110.957 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.6 t -89.29 -39.71 12.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 C-N-CA 124.426 1.09 . . . . 0.0 109.402 176.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 9.9 m -85.46 45.61 1.21 Allowed 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 123.512 0.725 . . . . 0.0 111.09 -178.128 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 25.4 m -77.45 -30.17 53.17 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-O 121.019 0.438 . . . . 0.0 111.185 -178.333 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -123.12 156.25 35.36 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.28 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 22.3 ptp 174.53 -33.69 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.804 1.241 . . . . 0.0 107.7 -177.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.489 ' HB2' ' H ' ' A' ' 166' ' ' ARG . 49.0 mt-10 -146.18 160.15 43.6 Favored Pre-proline 0 C--N 1.311 -1.104 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 178.068 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -82.8 -6.95 11.48 Favored 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 122.199 1.933 . . . . 0.0 110.178 172.271 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -96.33 -49.39 5.21 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.172 -1.377 . . . . 0.0 108.817 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.489 ' H ' ' HB2' ' A' ' 163' ' ' GLU 0.383 7.5 ppt_? 35.52 75.67 0.06 Allowed 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 119.064 2.987 . . . . 0.0 119.064 178.022 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -95.49 148.67 22.23 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 104.228 -2.508 . . . . 0.0 104.228 167.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -87.33 91.7 8.82 Favored 'General case' 0 C--N 1.276 -2.606 0 C-N-CA 119.119 -1.032 . . . . 0.0 111.198 178.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 47.2 m170 -84.32 164.07 19.21 Favored 'General case' 0 C--O 1.248 1.019 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.115 -179.199 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 72.4 t80 -52.63 134.64 35.68 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 123.697 0.799 . . . . 0.0 110.765 173.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 102.01 -23.34 34.92 Favored Glycine 0 C--N 1.314 -0.674 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.305 179.02 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -72.85 133.97 44.67 Favored 'General case' 0 N--CA 1.434 -1.229 0 CA-C-O 121.085 0.469 . . . . 0.0 111.991 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.421 ' HB2' ' NE2' ' A' ' 191' ' ' HIS . . . -106.28 115.73 30.72 Favored 'General case' 0 N--CA 1.421 -1.889 0 CA-C-N 114.733 -1.122 . . . . 0.0 109.142 178.403 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 48.3 t -91.27 108.75 20.25 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 175.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.485 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 20.4 ttp180 -99.4 153.79 18.72 Favored 'General case' 0 N--CA 1.403 -2.82 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 177.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 83.4 m-85 -127.24 158.9 35.93 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 123.24 0.616 . . . . 0.0 109.533 -174.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.9 p -140.57 140.32 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.579 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.094 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' CYS . . . . . 0.406 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 77.1 m -89.62 149.61 22.74 Favored 'General case' 0 C--N 1.278 -2.54 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.186 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 81.8 m-20 -76.15 179.4 5.72 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.307 -178.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 25.2 p -53.72 111.26 0.7 Allowed 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 124.027 0.931 . . . . 0.0 112.511 -176.224 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 97.38 2.31 58.98 Favored Glycine 0 N--CA 1.433 -1.544 0 CA-C-N 115.846 -0.615 . . . . 0.0 113.847 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 182' ' ' TYR . . . . . 0.406 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 90.2 m-85 -111.6 149.09 31.97 Favored 'General case' 0 CA--C 1.484 -1.573 0 CA-C-N 117.971 0.886 . . . . 0.0 110.704 -179.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -122.38 145.86 47.88 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -178.678 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.6 tt -76.3 137.01 23.5 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 CA-C-O 122.049 0.928 . . . . 0.0 111.798 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -84.33 -48.66 9.48 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.171 -176.382 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -91.09 -136.2 6.75 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.315 177.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 187' ' ' ASP . . . . . 0.465 ' OD1' ' HG3' ' A' ' 189' ' ' GLU . 12.2 t70 -102.58 163.68 12.09 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 178.443 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.485 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 15.8 pt-20 -91.15 -13.85 32.22 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 118.887 0.767 . . . . 0.0 112.668 -174.509 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.465 ' HG3' ' OD1' ' A' ' 187' ' ' ASP . 0.0 OUTLIER -120.03 144.92 47.28 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 112.84 0.682 . . . . 0.0 112.84 -176.724 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 37.0 ttm -135.97 124.33 23.35 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 124.864 1.266 . . . . 0.0 109.075 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 191' ' ' HIS . . . . . 0.421 ' NE2' ' HB2' ' A' ' 173' ' ' ALA . 30.7 m80 -97.86 155.44 17.06 Favored 'General case' 0 C--N 1.276 -2.618 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 40.6 t -94.94 116.88 29.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 173.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 8.4 p -100.23 170.21 8.61 Favored 'General case' 0 N--CA 1.437 -1.122 0 O-C-N 123.354 0.409 . . . . 0.0 111.174 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -60.01 -21.26 61.08 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 123.607 0.763 . . . . 0.0 112.064 -175.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 13.7 m-20 -64.51 -17.54 63.99 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.741 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 80.94 20.48 65.24 Favored Glycine 0 CA--C 1.488 -1.656 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -130.48 153.44 48.79 Favored 'General case' 0 N--CA 1.407 -2.597 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 -174.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 78.2 m95 -76.84 131.47 38.65 Favored 'General case' 0 C--N 1.291 -1.971 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.34 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.5 m -69.06 -38.33 79.01 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 115.639 -0.709 . . . . 0.0 112.289 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -103.73 156.95 17.41 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 20.0 pm0 -78.83 157.91 28.27 Favored 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 177.485 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -68.05 116.62 40.71 Favored Pre-proline 0 C--O 1.246 0.908 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 175.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.403 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 98.3 Cg_endo -76.98 161.5 32.86 Favored 'Trans proline' 0 N--CA 1.433 -2.088 0 C-N-CA 122.218 1.945 . . . . 0.0 110.998 -178.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -104.52 161.83 13.77 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 120.226 -0.589 . . . . 0.0 109.6 178.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 88.9 m -122.19 108.55 13.43 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 172.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.1 m . . . . . 0 C--N 1.291 -1.957 0 O-C-N 124.405 1.066 . . . . 0.0 108.818 -173.788 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.451 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 19.1 Cg_endo . . . . . 0 CA--C 1.537 0.657 0 CA-C-O 120.859 0.274 . . . . 0.0 112.205 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 50.0 m -71.67 -43.98 65.07 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.756 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 97.07 112.44 2.94 Favored Glycine 0 C--O 1.187 -2.791 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 -179.245 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -34.36 119.52 0.54 Allowed Pre-proline 0 C--N 1.296 -1.734 0 C-N-CA 127.235 2.214 . . . . 0.0 112.129 -173.512 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -60.67 -43.32 32.99 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.283 2.655 . . . . 0.0 113.305 -172.413 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 139.73 -174.98 22.06 Favored Glycine 0 N--CA 1.421 -2.336 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -133.78 156.66 47.6 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-N 117.403 0.602 . . . . 0.0 109.691 -178.031 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.1 t -115.3 126.63 27.59 Favored Pre-proline 0 C--N 1.305 -1.368 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.282 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -66.97 -18.8 52.29 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.555 2.17 . . . . 0.0 112.556 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -87.7 -15.05 38.21 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.37 -175.393 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.497 ' HA2' ' ND2' ' A' ' 115' ' ' ASN . . . -163.62 -133.43 1.48 Allowed Glycine 0 N--CA 1.409 -3.136 0 C-N-CA 118.635 -1.745 . . . . 0.0 113.004 -177.413 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.1 p -144.2 179.59 7.13 Favored 'General case' 0 C--N 1.284 -2.249 0 CA-C-N 114.439 -0.881 . . . . 0.0 109.264 -176.634 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -141.5 157.65 44.86 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 172.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.4 m -127.56 162.53 26.24 Favored 'General case' 0 C--N 1.278 -2.524 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.0 mt -118.43 117.03 27.94 Favored 'General case' 0 C--N 1.277 -2.579 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.502 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 19.5 p -109.16 127.63 54.35 Favored 'General case' 0 C--N 1.282 -2.364 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.245 -172.557 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 113.97 -37.92 3.38 Favored Glycine 0 N--CA 1.433 -1.567 0 C-N-CA 120.406 -0.902 . . . . 0.0 111.975 179.212 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -144.28 -7.14 0.5 Allowed Glycine 0 C--N 1.315 -0.588 0 C-N-CA 119.715 -1.231 . . . . 0.0 113.756 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 92.6 m-20 61.14 15.11 6.01 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.495 ' O ' HG11 ' A' ' 108' ' ' VAL . 24.0 m -146.52 -169.42 0.24 Allowed 'Isoleucine or valine' 0 C--O 1.209 -1.027 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -176.641 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -106.46 40.29 1.65 Allowed 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 118.29 0.496 . . . . 0.0 110.227 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.715 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.1 pt-20 -83.04 176.48 9.21 Favored 'General case' 0 C--O 1.205 -1.24 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.046 178.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' TYR . . . . . 0.451 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 35.5 m-85 -72.88 133.26 44.33 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.218 177.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.51 5.05 63.6 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.34 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.715 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -94.97 147.16 5.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.171 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.502 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 51.8 mtpt -110.76 118.47 36.25 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 178.701 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -83.28 92.48 7.51 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.301 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.507 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 35.0 m -89.1 117.71 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.824 0 CA-C-O 122.151 0.977 . . . . 0.0 109.903 -178.521 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 31.5 m-85 -85.88 139.48 31.21 Favored 'General case' 0 C--N 1.263 -3.182 0 CA-C-N 115.129 -0.941 . . . . 0.0 108.896 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.2 t -138.96 124.6 19.54 Favored 'General case' 0 N--CA 1.407 -2.603 0 CA-C-O 121.999 0.904 . . . . 0.0 109.671 -178.629 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 74.3 m -71.74 161.79 30.44 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-N 115.0 -1.0 . . . . 0.0 112.455 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.497 ' ND2' ' HA2' ' A' ' 94' ' ' GLY . 81.3 m-20 -86.31 -176.59 5.95 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.479 179.098 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -46.87 -50.94 17.81 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 126.513 1.925 . . . . 0.0 114.008 -177.817 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -91.19 28.36 8.17 Favored Glycine 0 C--N 1.305 -1.158 0 C-N-CA 119.736 -1.221 . . . . 0.0 113.179 -177.726 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.455 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 98.8 m-85 -149.37 167.51 25.94 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -173.627 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -153.88 156.87 38.37 Favored 'General case' 0 N--CA 1.435 -1.195 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.81 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.529 ' HG ' ' HB2' ' A' ' 125' ' ' ASN . 0.5 OUTLIER -85.99 128.39 34.84 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -175.182 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -102.1 130.1 48.62 Favored 'General case' 0 N--CA 1.422 -1.864 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 -175.741 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.74 -159.7 13.83 Favored Glycine 0 C--N 1.297 -1.63 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.296 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -106.03 -41.63 5.33 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 121.835 0.826 . . . . 0.0 109.267 -178.277 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 51.1 mm -85.17 122.92 38.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 CA-C-N 114.772 -1.104 . . . . 0.0 110.069 -176.331 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.529 ' HB2' ' HG ' ' A' ' 120' ' ' LEU . 3.9 p-10 -127.59 7.12 6.27 Favored 'General case' 0 C--O 1.202 -1.41 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 176.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.507 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 15.4 p90 -134.25 168.21 19.3 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -171.784 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.514 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 36.3 mtp180 -130.67 119.89 23.1 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 170.399 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -92.32 126.76 37.54 Favored 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.846 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 49.3 t -84.7 108.04 17.21 Favored 'General case' 0 N--CA 1.434 -1.266 0 C-N-CA 119.142 -1.023 . . . . 0.0 109.249 174.457 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -101.76 -171.22 1.94 Allowed 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 105.354 -2.091 . . . . 0.0 105.354 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 15.3 t -64.37 -15.34 60.26 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.841 0.829 . . . . 0.0 110.593 -178.511 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -97.88 -2.17 41.35 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.255 -178.686 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 103.48 -159.44 16.93 Favored Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -177.836 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.442 ' CH2' HG13 ' A' ' 108' ' ' VAL . 86.9 m95 -68.64 108.47 3.37 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 177.892 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 41.7 p -67.71 -57.51 6.23 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 115.439 -0.8 . . . . 0.0 112.655 -175.432 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' ASN . . . . . 0.514 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 6.4 m120 -71.83 171.22 12.07 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.957 -178.518 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 25.2 m-20 -100.74 176.61 5.24 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 176.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 88.6 mt -66.35 119.07 59.39 Favored Pre-proline 0 C--O 1.237 0.407 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 173.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.402 ' HB2' HD11 ' A' ' 120' ' ' LEU . 29.7 Cg_endo -64.46 164.7 22.48 Favored 'Trans proline' 0 N--CA 1.451 -0.993 0 C-N-CA 122.601 2.2 . . . . 0.0 112.986 -177.722 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 50.0 mm -96.49 124.47 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.766 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.903 -175.461 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.455 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 48.9 t -105.66 136.12 45.83 Favored 'General case' 0 C--N 1.27 -2.882 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 177.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -124.91 141.8 51.88 Favored 'General case' 0 N--CA 1.413 -2.28 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -177.236 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 6.2 p -68.34 139.19 21.09 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 O-C-N 123.874 0.734 . . . . 0.0 109.573 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.646 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 21.1 m -65.83 129.44 30.14 Favored 'Isoleucine or valine' 0 C--O 1.251 1.168 0 C-N-CA 120.48 -0.488 . . . . 0.0 110.094 178.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 89.4 mttt -114.79 166.6 11.58 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -178.134 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 82.0 m -129.43 -174.22 3.23 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-O 121.135 0.493 . . . . 0.0 111.457 -175.081 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 31.1 mt -77.72 137.0 62.76 Favored Pre-proline 0 N--CA 1.439 -0.991 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.315 177.305 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -70.86 112.51 3.29 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 C-N-CA 122.279 1.986 . . . . 0.0 109.683 175.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 27.8 t -82.81 136.61 22.51 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 -179.203 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.6 p -76.93 -73.71 0.28 Allowed 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 123.104 0.252 . . . . 0.0 111.518 179.371 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 167.9 160.19 0.15 Allowed Pre-proline 0 C--O 1.239 0.548 0 C-N-CA 126.128 1.771 . . . . 0.0 106.95 -179.368 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -77.49 170.05 19.99 Favored 'Trans proline' 0 CA--C 1.542 0.883 0 C-N-CA 121.586 1.524 . . . . 0.0 110.26 170.298 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -63.14 -52.6 61.87 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 -176.126 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 31.1 m120 -106.48 33.45 3.87 Favored 'General case' 0 CA--C 1.499 -1.011 0 CA-C-O 121.363 0.601 . . . . 0.0 109.981 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -151.59 -167.35 14.85 Favored Glycine 0 N--CA 1.42 -2.406 0 C-N-CA 120.133 -1.032 . . . . 0.0 112.062 178.79 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' LYS . . . . . 0.518 ' HG3' HG23 ' A' ' 177' ' ' VAL . 59.6 pttt -154.55 176.19 12.7 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -179.435 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 159' ' ' SER . 49.3 mt -98.31 145.05 10.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -179.303 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.677 HG12 HG22 ' A' ' 177' ' ' VAL . 2.5 m -89.12 -31.39 5.42 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.081 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.425 ' N ' HG22 ' A' ' 157' ' ' ILE . 6.7 m -93.95 45.3 1.14 Allowed 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 124.603 1.161 . . . . 0.0 110.951 -175.325 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.4 m -82.18 4.98 21.27 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -176.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -136.07 134.01 37.96 Favored 'General case' 0 N--CA 1.434 -1.267 0 CA-C-O 120.773 0.32 . . . . 0.0 110.518 179.35 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 21.4 ptp -176.59 -42.11 0.01 OUTLIER 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 126.29 1.836 . . . . 0.0 106.084 178.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -136.63 148.64 64.44 Favored Pre-proline 0 N--CA 1.437 -1.11 0 N-CA-C 103.958 -2.608 . . . . 0.0 103.958 166.419 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.81 -8.1 22.74 Favored 'Trans proline' 0 CA--C 1.542 0.917 0 C-N-CA 122.082 1.855 . . . . 0.0 110.977 175.497 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -103.34 -19.73 14.34 Favored 'General case' 0 CA--C 1.469 -2.137 0 CA-C-N 114.309 -1.314 . . . . 0.0 108.789 -179.19 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.482 ' HD2' ' O ' ' A' ' 166' ' ' ARG 0.289 0.0 OUTLIER 37.17 75.36 0.07 Allowed 'General case' 0 N--CA 1.434 -1.268 0 C-N-CA 125.362 1.465 . . . . 0.0 114.026 -175.207 . . . . . . . . 4 4 . 1 . 002 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -91.31 -23.39 20.13 Favored 'General case' 0 C--N 1.298 -1.671 0 CA-C-N 113.66 -1.609 . . . . 0.0 110.712 -178.533 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 72.2 152.33 0.12 Allowed 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 113.255 -1.793 . . . . 0.0 112.181 177.257 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.411 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 35.9 m80 -141.61 162.44 35.48 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -177.086 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.646 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 91.6 t80 -48.25 139.43 8.58 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-O 121.194 0.521 . . . . 0.0 112.104 175.342 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 87.37 -15.22 55.31 Favored Glycine 0 N--CA 1.423 -2.217 0 CA-C-O 119.204 -0.776 . . . . 0.0 113.867 175.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 29.2 mm-40 -65.0 135.76 56.01 Favored 'General case' 0 CA--C 1.496 -1.127 0 CA-C-N 118.233 1.017 . . . . 0.0 111.157 -178.353 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -104.71 113.96 27.87 Favored 'General case' 0 C--N 1.287 -2.148 0 CA-C-N 114.518 -1.219 . . . . 0.0 108.325 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 98.0 t -105.5 102.28 13.62 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.115 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.472 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 40.9 ttm180 -97.06 146.97 24.5 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.437 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -116.06 156.54 26.19 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.14 0.495 . . . . 0.0 110.217 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.677 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -127.76 135.18 63.75 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.131 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.146 177.583 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 77.7 m -93.91 139.25 31.13 Favored 'General case' 0 C--N 1.262 -3.231 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 173.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -56.02 157.55 4.47 Favored 'General case' 0 C--N 1.294 -1.829 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.208 176.707 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.8 m -52.25 111.12 0.57 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 124.319 1.012 . . . . 0.0 112.07 -174.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 106.6 1.71 37.35 Favored Glycine 0 N--CA 1.426 -1.984 0 C-N-CA 120.317 -0.944 . . . . 0.0 112.863 177.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -113.41 158.81 20.17 Favored 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 117.994 0.897 . . . . 0.0 110.169 176.59 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 15.6 pttm -120.62 153.38 36.91 Favored 'General case' 0 N--CA 1.428 -1.573 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.403 HD13 ' HA ' ' A' ' 188' ' ' GLU . 2.1 tt -84.67 131.06 34.93 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.911 0 C-N-CA 119.28 -0.968 . . . . 0.0 109.728 176.701 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -82.43 -48.33 11.22 Favored 'General case' 0 C--N 1.286 -2.165 0 CA-C-N 114.717 -1.129 . . . . 0.0 109.747 -175.265 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -83.89 -151.66 12.62 Favored Glycine 0 C--N 1.304 -1.213 0 CA-C-N 114.847 -1.07 . . . . 0.0 110.528 176.605 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -80.62 164.56 22.78 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.403 ' HA ' HD13 ' A' ' 184' ' ' ILE . 16.2 pt-20 -89.32 -3.27 58.55 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.91 -172.085 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -157.89 162.48 38.32 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.57 -176.257 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 17.8 ptp -137.06 153.67 50.53 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 114.81 -1.086 . . . . 0.0 108.16 176.103 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 22.0 m80 -125.64 151.66 46.22 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.652 0.263 . . . . 0.0 110.676 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 18.9 m -76.21 112.6 12.86 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 171.062 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 23.3 t -82.24 171.05 14.71 Favored 'General case' 0 N--CA 1.422 -1.85 0 O-C-N 124.383 1.052 . . . . 0.0 110.038 -176.574 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -50.54 -34.92 27.32 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 125.448 1.499 . . . . 0.0 112.198 -178.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -69.48 -14.24 62.77 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.155 -0.93 . . . . 0.0 113.367 -177.579 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 83.7 29.25 32.81 Favored Glycine 0 C--O 1.225 -0.466 0 C-N-CA 120.439 -0.886 . . . . 0.0 110.893 -174.577 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -138.33 172.64 12.6 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 70.6 m95 -80.16 136.28 36.48 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 120.816 0.341 . . . . 0.0 111.252 -179.342 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 25.7 p -73.88 -22.57 59.68 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.197 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.593 ' HE2' ' HA ' ' A' ' 200' ' ' LYS . 3.9 mmpt? -122.62 166.49 14.78 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.483 0.658 . . . . 0.0 111.572 -179.404 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -89.71 164.68 14.59 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 179.255 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 43.7 mtpt -66.63 122.76 83.54 Favored Pre-proline 0 C--N 1.309 -1.155 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.038 174.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -77.58 163.38 29.47 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 C-N-CA 122.03 1.82 . . . . 0.0 111.155 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 53.7 tttp -120.22 152.09 38.23 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -178.101 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 88.8 m -114.81 114.81 26.05 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 176.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 19.5 m . . . . . 0 C--N 1.3 -1.582 0 O-C-N 124.277 0.985 . . . . 0.0 109.175 -175.447 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo . . . . . 0 CA--C 1.538 0.689 0 CA-C-O 122.001 0.751 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 37.2 m -88.33 -36.49 16.61 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 177.204 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 120.53 -91.36 0.49 Allowed Glycine 0 CA--C 1.458 -3.484 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 172.359 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.2 t-80 -176.11 127.6 0.35 Allowed Pre-proline 0 C--N 1.266 -3.05 0 N-CA-C 104.77 -2.308 . . . . 0.0 104.77 -176.157 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.463 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 61.5 Cg_endo -74.1 -17.5 21.96 Favored 'Trans proline' 0 C--N 1.329 -0.478 0 C-N-CA 122.44 2.093 . . . . 0.0 113.977 -175.301 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 131.0 -173.78 20.16 Favored Glycine 0 N--CA 1.427 -1.909 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 -176.432 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -147.39 144.13 28.47 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.7 t -122.32 130.08 24.83 Favored Pre-proline 0 C--N 1.305 -1.352 0 CA-C-O 121.194 0.521 . . . . 0.0 111.279 -178.12 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.74 -12.21 24.23 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.689 2.259 . . . . 0.0 111.676 178.074 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -95.04 14.36 22.11 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.717 -176.372 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 160.22 -122.33 1.12 Allowed Glycine 0 N--CA 1.421 -2.366 0 N-CA-C 111.084 -0.807 . . . . 0.0 111.084 178.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 t -172.31 -168.23 0.52 Allowed 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -177.551 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -147.56 170.2 17.97 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.7 m -138.46 156.83 47.19 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.492 HD11 ' CE1' ' A' ' 104' ' ' PHE . 14.6 mt -106.65 133.41 51.37 Favored 'General case' 0 C--N 1.276 -2.601 0 CA-C-O 121.213 0.53 . . . . 0.0 110.375 -176.731 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.458 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 23.8 p -121.23 116.68 25.36 Favored 'General case' 0 C--N 1.294 -1.813 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.59 -176.382 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.56 -58.93 0.7 Allowed Glycine 0 N--CA 1.434 -1.47 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -179.51 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.426 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -127.23 -4.51 5.9 Favored Glycine 0 N--CA 1.437 -1.247 0 C-N-CA 120.159 -1.019 . . . . 0.0 112.479 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 63.05 12.91 6.31 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 123.706 0.803 . . . . 0.0 112.517 -177.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.525 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.6 m -145.12 -171.86 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 -176.633 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.492 ' CE1' HD11 ' A' ' 98' ' ' LEU . 27.1 m-85 -101.01 44.45 1.01 Allowed 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 118.648 0.658 . . . . 0.0 110.074 -176.03 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.697 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.6 pt-20 -84.68 179.28 7.4 Favored 'General case' 0 C--O 1.209 -1.035 0 CA-C-N 114.639 -1.164 . . . . 0.0 112.101 178.11 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -78.57 132.2 37.06 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.359 0.6 . . . . 0.0 111.345 178.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 101.06 -8.67 57.64 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 115.067 -0.97 . . . . 0.0 112.475 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.697 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -86.29 143.7 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 CA-C-O 121.418 0.628 . . . . 0.0 110.726 -174.586 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.458 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 19.6 mtpp -110.05 119.57 39.72 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.634 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.476 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -85.57 95.08 9.21 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 177.615 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 55.3 t -90.33 114.93 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.58 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 -177.61 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -83.94 138.92 32.9 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.94 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.3 t -134.07 116.73 15.8 Favored 'General case' 0 N--CA 1.42 -1.957 0 CA-C-N 115.032 -0.986 . . . . 0.0 108.672 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 21.0 m -72.88 160.06 32.74 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.49 -175.193 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -68.63 -179.72 1.47 Allowed 'General case' 0 C--N 1.315 -0.911 0 C-N-CA 122.95 0.5 . . . . 0.0 111.392 -177.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -59.43 -50.96 71.94 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 123.828 0.851 . . . . 0.0 111.212 -177.423 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -87.56 31.16 4.63 Favored Glycine 0 C--N 1.309 -0.924 0 C-N-CA 120.984 -0.627 . . . . 0.0 113.094 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -145.76 161.44 39.92 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -177.072 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -142.22 173.67 11.31 Favored 'General case' 0 C--N 1.271 -2.845 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 -179.357 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 11.9 tp -92.4 149.92 21.12 Favored 'General case' 0 C--N 1.273 -2.753 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.525 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -132.65 130.91 40.76 Favored 'General case' 0 N--CA 1.415 -2.204 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 177.9 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 116.49 -153.41 17.44 Favored Glycine 0 N--CA 1.433 -1.547 0 C-N-CA 120.646 -0.788 . . . . 0.0 111.526 179.08 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -112.3 -41.69 3.86 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 121.82 0.819 . . . . 0.0 110.068 -178.554 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.43 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.5 mm -85.97 144.34 9.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.782 -173.735 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 22.4 p-10 -135.24 4.32 3.18 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-O 120.79 0.328 . . . . 0.0 110.595 175.484 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.476 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 5.4 p90 -145.95 165.98 27.38 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.232 -172.381 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.463 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 44.8 mtp180 -128.56 125.67 38.74 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.409 -1.7 . . . . 0.0 106.409 171.777 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 109' ' ' LYS . 55.9 tt0 -103.71 136.04 44.15 Favored 'General case' 0 C--N 1.286 -2.19 0 C-N-CA 118.352 -1.339 . . . . 0.0 110.378 179.411 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' CYS . . . . . 0.427 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 21.2 t -87.33 106.93 18.27 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.237 175.336 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -102.62 -166.76 1.31 Allowed 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 104.621 -2.363 . . . . 0.0 104.621 175.286 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 10.6 t -61.21 -29.83 70.05 Favored 'General case' 0 C--N 1.295 -1.769 0 CA-C-N 118.93 0.786 . . . . 0.0 112.81 -175.032 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -78.76 -16.53 57.08 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 121.743 0.782 . . . . 0.0 110.798 177.273 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.427 ' HA2' ' SG ' ' A' ' 129' ' ' CYS . . . 116.02 -148.16 18.9 Favored Glycine 0 N--CA 1.416 -2.676 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 -175.237 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 86.7 m95 -66.92 109.66 3.03 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 117.092 0.446 . . . . 0.0 109.858 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.1 p -64.82 -69.58 0.28 Allowed 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 124.219 1.008 . . . . 0.0 112.037 -176.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' ASN . . . . . 0.41 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 3.7 m-20 -75.79 167.94 20.94 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 114.012 -1.449 . . . . 0.0 108.94 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -104.23 178.13 4.65 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 123.629 0.58 . . . . 0.0 110.393 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 64.6 mt -64.31 126.19 89.91 Favored Pre-proline 0 C--N 1.314 -0.941 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.625 -178.565 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.43 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 48.2 Cg_endo -70.36 170.77 16.5 Favored 'Trans proline' 0 C--O 1.251 1.172 0 C-N-CA 122.654 2.236 . . . . 0.0 112.404 178.362 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.525 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 56.1 mt -97.6 127.43 49.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.742 -178.232 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 61.2 m -106.82 123.83 48.72 Favored 'General case' 0 C--N 1.273 -2.737 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 169.558 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -111.8 151.4 29.06 Favored 'General case' 0 C--N 1.276 -2.618 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.17 142.49 15.48 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.594 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.4 m -68.52 113.69 4.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 119.93 -0.708 . . . . 0.0 109.462 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 87.8 mttt -105.46 133.99 49.31 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.189 -177.13 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.3 m -97.32 149.97 21.48 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' LEU . . . . . 0.411 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.2 mm? -59.44 143.83 85.13 Favored Pre-proline 0 N--CA 1.42 -1.937 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 177.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 35.0 Cg_exo -56.94 114.37 1.89 Allowed 'Trans proline' 0 C--O 1.252 1.204 0 C-N-CA 123.479 2.786 . . . . 0.0 111.429 179.121 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.4 p -89.0 137.64 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.723 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.713 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' THR . . . . . 0.413 ' O ' HD11 ' A' ' 157' ' ' ILE . 15.3 p -94.12 -158.74 0.65 Allowed 'General case' 0 N--CA 1.414 -2.262 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.065 177.271 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.448 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . -122.44 160.21 49.23 Favored Pre-proline 0 C--N 1.291 -1.944 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 -173.872 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -71.3 -170.21 0.48 Allowed 'Trans proline' 0 CA--C 1.555 1.545 0 C-N-CA 121.171 1.247 . . . . 0.0 110.61 176.355 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.27 -46.5 17.66 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 112.557 0.577 . . . . 0.0 112.557 -171.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 28.9 m120 -110.52 14.59 22.45 Favored 'General case' 0 CA--C 1.502 -0.901 0 CA-C-O 121.435 0.636 . . . . 0.0 110.586 -179.565 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -127.96 -176.2 14.36 Favored Glycine 0 N--CA 1.423 -2.212 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' LYS . . . . . 0.461 ' HG3' HG23 ' A' ' 177' ' ' VAL . 45.6 pttt -151.56 -178.83 6.92 Favored 'General case' 0 C--N 1.292 -1.913 0 C-N-CA 123.451 0.7 . . . . 0.0 109.229 -175.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.419 HG22 ' N ' ' A' ' 159' ' ' SER . 56.1 mt -103.3 135.04 42.71 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 CA-C-N 118.018 0.372 . . . . 0.0 111.193 -176.1 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.52 HG12 HG22 ' A' ' 177' ' ' VAL . 2.7 m -79.0 -32.17 15.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.03 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.419 ' N ' HG22 ' A' ' 157' ' ' ILE . 5.0 m -95.62 42.68 1.09 Allowed 'General case' 0 C--N 1.32 -0.708 0 C-N-CA 124.588 1.155 . . . . 0.0 110.013 -176.304 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 59.0 m -75.4 88.5 2.61 Favored 'General case' 0 C--N 1.323 -0.543 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -176.236 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -158.18 72.13 0.61 Allowed 'General case' 0 CA--C 1.496 -1.11 0 CA-C-O 122.09 0.948 . . . . 0.0 110.829 174.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 20.9 ttp -97.65 111.1 23.52 Favored 'General case' 0 C--N 1.27 -2.867 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 172.053 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.485 ' HB2' ' HG3' ' A' ' 166' ' ' ARG . 47.5 mt-10 -123.81 161.16 48.03 Favored Pre-proline 0 C--N 1.279 -2.464 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -174.536 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -73.55 10.31 1.31 Allowed 'Trans proline' 0 C--O 1.242 0.686 0 C-N-CA 122.851 2.367 . . . . 0.0 113.475 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -126.13 -61.76 1.2 Allowed 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 178.092 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.485 ' HG3' ' HB2' ' A' ' 163' ' ' GLU . 0.1 OUTLIER -91.22 99.52 12.5 Favored 'General case' 0 N--CA 1.416 -2.141 0 CA-C-O 122.825 1.298 . . . . 0.0 109.613 175.923 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -96.77 -176.89 3.72 Favored 'General case' 0 C--N 1.283 -2.321 0 CA-C-N 113.725 -1.579 . . . . 0.0 107.795 -177.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 64.5 m-85 -77.52 105.86 8.92 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 45.6 m170 -120.77 163.78 17.6 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -176.57 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.594 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 93.7 t80 -46.83 126.55 8.84 Favored 'General case' 0 C--O 1.237 0.416 0 O-C-N 124.284 0.99 . . . . 0.0 109.964 172.491 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 115.75 -34.63 4.67 Favored Glycine 0 N--CA 1.424 -2.152 0 C-N-CA 120.097 -1.049 . . . . 0.0 111.656 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -67.41 134.33 51.24 Favored 'General case' 0 C--O 1.25 1.097 0 CA-C-O 121.519 0.676 . . . . 0.0 112.669 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -124.87 107.32 10.76 Favored 'General case' 0 N--CA 1.431 -1.419 0 CA-C-N 114.284 -1.325 . . . . 0.0 107.934 179.431 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 64.9 t -92.64 116.92 34.87 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.088 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.938 -176.803 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.481 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 39.8 ttm180 -106.44 147.8 28.89 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 176.572 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -111.99 160.32 17.58 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 123.589 0.755 . . . . 0.0 110.228 -177.081 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.52 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -132.65 155.66 41.54 Favored 'Isoleucine or valine' 0 CA--C 1.469 -2.163 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.531 178.411 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 10.0 m -111.89 145.19 39.95 Favored 'General case' 0 N--CA 1.396 -3.162 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.24 172.496 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -64.28 171.99 2.76 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.993 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.9 m -48.2 -25.73 1.62 Allowed 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 116.677 2.103 . . . . 0.0 116.677 -169.666 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -112.51 8.9 26.29 Favored Glycine 0 C--N 1.298 -1.533 0 C-N-CA 120.2 -1.0 . . . . 0.0 113.568 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -126.84 178.87 5.68 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 117.3 0.55 . . . . 0.0 111.793 -176.431 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 15.0 pttp -150.68 165.13 34.36 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.7 tp -71.86 151.92 8.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.232 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -80.17 -73.12 0.37 Allowed 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.196 176.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -102.35 -100.18 2.51 Favored Glycine 0 CA--C 1.5 -0.887 0 C-N-CA 120.156 -1.021 . . . . 0.0 112.001 -177.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -86.43 154.28 21.27 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 177.3 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -108.68 3.6 22.94 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.991 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -153.05 158.71 42.36 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -174.362 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.3 ptp -135.8 156.08 49.36 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 124.695 1.198 . . . . 0.0 108.787 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.1 t-80 -137.5 142.25 41.49 Favored 'General case' 0 C--N 1.31 -1.124 0 O-C-N 122.305 -0.247 . . . . 0.0 110.659 -176.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 30.1 m -80.31 123.38 27.94 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 123.691 0.619 . . . . 0.0 111.398 174.767 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 67.6 m -111.62 -175.93 2.82 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 175.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.02 -17.61 53.19 Favored 'General case' 0 N--CA 1.504 2.229 0 C-N-CA 122.84 0.456 . . . . 0.0 111.843 -173.758 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -55.97 -35.56 66.87 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 124.441 1.096 . . . . 0.0 111.053 177.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 87.09 17.07 59.88 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 -173.274 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -137.07 165.74 25.33 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.0 m95 -77.16 140.64 40.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 O-C-N 123.755 0.659 . . . . 0.0 109.279 178.182 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.3 m -81.16 -6.0 58.35 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.504 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 17.2 tppt? -136.9 161.63 35.49 Favored 'General case' 0 N--CA 1.427 -1.611 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -104.25 178.08 4.66 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 117.554 0.161 . . . . 0.0 110.771 -177.577 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? -64.11 117.36 35.57 Favored Pre-proline 0 C--O 1.243 0.723 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 177.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -76.96 -169.06 0.66 Allowed 'Trans proline' 0 N--CA 1.446 -1.265 0 C-N-CA 122.107 1.872 . . . . 0.0 110.651 176.132 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 204' ' ' LYS . . . . . 0.429 ' HG2' ' N ' ' A' ' 205' ' ' CYS . 46.5 tttm -131.14 160.26 35.25 Favored 'General case' 0 N--CA 1.42 -1.972 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -177.111 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.429 ' N ' ' HG2' ' A' ' 204' ' ' LYS . 9.4 t -110.88 129.68 55.8 Favored 'General case' 0 N--CA 1.423 -1.789 0 N-CA-C 105.697 -1.964 . . . . 0.0 105.697 176.261 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 11.0 m . . . . . 0 C--N 1.301 -1.535 0 CA-C-O 118.491 -0.766 . . . . 0.0 111.578 -174.657 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo . . . . . 0 N--CA 1.483 0.907 0 CA-C-O 121.581 0.576 . . . . 0.0 112.658 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 59.6 m -71.63 -24.71 61.92 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.787 -178.314 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 96.43 14.72 43.43 Favored Glycine 0 C--N 1.302 -1.359 0 CA-C-N 115.444 -0.798 . . . . 0.0 114.808 171.407 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 9.4 t60 69.23 115.39 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.764 0 C-N-CA 123.96 0.904 . . . . 0.0 109.835 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.402 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 42.7 Cg_endo -67.48 -42.25 7.51 Favored 'Trans proline' 0 C--O 1.221 -0.358 0 C-N-CA 122.141 1.894 . . . . 0.0 112.644 -174.434 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 136.07 174.64 13.45 Favored Glycine 0 N--CA 1.422 -2.286 0 N-CA-C 107.592 -2.203 . . . . 0.0 107.592 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 48.1 t0 -134.32 169.02 17.83 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 -177.31 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.0 t -131.56 126.43 21.09 Favored Pre-proline 0 C--N 1.285 -2.197 0 CA-C-N 117.897 0.317 . . . . 0.0 110.927 -177.228 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -69.72 -11.39 30.8 Favored 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 122.888 2.392 . . . . 0.0 111.477 177.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -91.84 4.12 53.59 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.06 -178.425 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.596 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.9 -131.36 1.95 Allowed Glycine 0 N--CA 1.401 -3.691 0 C-N-CA 119.637 -1.268 . . . . 0.0 112.475 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.7 p -153.83 -179.17 7.58 Favored 'General case' 0 C--N 1.287 -2.113 0 C-N-CA 124.4 1.08 . . . . 0.0 109.708 -177.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -145.68 160.34 41.84 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 172.118 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.3 m -125.4 159.93 30.64 Favored 'General case' 0 C--N 1.283 -2.3 0 N-CA-C 107.111 -1.441 . . . . 0.0 107.111 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 16.7 mt -116.97 115.82 26.19 Favored 'General case' 0 C--N 1.273 -2.733 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.527 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 31.9 p -106.76 133.04 52.04 Favored 'General case' 0 C--N 1.271 -2.843 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.257 -173.719 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 108.04 -67.67 0.23 Allowed Glycine 0 N--CA 1.429 -1.828 0 N-CA-C 110.611 -0.995 . . . . 0.0 110.611 -179.159 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.425 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -106.58 -14.83 18.74 Favored Glycine 0 C--N 1.309 -0.926 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.784 -176.708 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 59.81 19.09 7.94 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.206 1.002 . . . . 0.0 112.787 -178.025 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.457 ' O ' HG11 ' A' ' 108' ' ' VAL . 27.8 m -150.24 -172.19 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 -177.506 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -100.47 41.37 1.18 Allowed 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 118.642 0.655 . . . . 0.0 111.164 -176.651 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.706 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.9 pt-20 -85.64 179.94 7.0 Favored 'General case' 0 C--O 1.207 -1.145 0 C-N-CA 123.971 0.908 . . . . 0.0 112.577 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -75.13 132.7 41.39 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.808 -0.557 . . . . 0.0 111.128 176.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.06 -5.42 63.38 Favored Glycine 0 N--CA 1.438 -1.206 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.681 178.064 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.706 HG12 ' O ' ' A' ' 105' ' ' GLU . 13.7 p -85.27 145.66 7.63 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.527 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 19.0 mtpp -111.55 113.96 26.71 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.604 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -81.4 94.23 6.76 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 177.255 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.465 HG12 ' CB ' ' A' ' 126' ' ' TYR . 33.0 m -92.19 120.11 40.83 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.193 0 CA-C-O 121.969 0.89 . . . . 0.0 108.897 -177.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -87.79 138.58 31.34 Favored 'General case' 0 C--N 1.262 -3.199 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.794 -177.554 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.0 t -137.36 110.23 7.65 Favored 'General case' 0 N--CA 1.407 -2.61 0 CA-C-O 122.381 1.086 . . . . 0.0 109.214 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.454 ' HA ' ' HA3' ' A' ' 94' ' ' GLY . 15.8 m -67.87 159.24 30.84 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.473 -1.239 . . . . 0.0 110.465 -177.145 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.596 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 92.0 m-20 -77.26 -179.11 5.46 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 120.746 0.308 . . . . 0.0 111.322 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -46.58 -52.51 13.37 Favored 'General case' 0 C--N 1.31 -1.138 0 C-N-CA 126.266 1.826 . . . . 0.0 114.428 -177.401 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -82.19 6.25 68.5 Favored Glycine 0 C--N 1.315 -0.589 0 C-N-CA 120.543 -0.837 . . . . 0.0 113.178 -176.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -128.19 166.96 17.53 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -176.585 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -145.35 165.73 27.62 Favored 'General case' 0 C--N 1.283 -2.312 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 176.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.07 123.68 29.73 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -178.827 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -106.85 126.31 52.14 Favored 'General case' 0 N--CA 1.416 -2.151 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 178.113 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 110.9 174.6 20.21 Favored Glycine 0 C--N 1.299 -1.486 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -176.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -85.6 -44.02 12.99 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 -178.114 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.7 mm -72.08 125.15 30.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 CA-C-N 114.175 -1.375 . . . . 0.0 110.39 -177.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -125.4 5.06 7.67 Favored 'General case' 0 C--O 1.202 -1.398 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 175.123 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.465 ' CB ' HG12 ' A' ' 111' ' ' VAL . 15.7 p90 -143.27 163.06 34.02 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.288 -171.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 50.9 mtp180 -126.96 130.51 50.22 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 174.23 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -106.14 130.25 54.06 Favored 'General case' 0 C--N 1.29 -2.0 0 C-N-CA 119.707 -0.797 . . . . 0.0 108.978 -179.483 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 26.5 t -84.31 108.51 17.2 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.466 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.426 ' OD1' HG22 ' A' ' 131' ' ' THR . 6.5 t70 -107.98 -167.22 1.22 Allowed 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.38 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.426 HG22 ' OD1' ' A' ' 130' ' ' ASP . 12.4 t -74.53 -12.61 60.52 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-O 121.861 0.838 . . . . 0.0 109.646 -178.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -86.46 -8.93 57.2 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.96 175.282 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 100.95 -153.56 19.14 Favored Glycine 0 N--CA 1.427 -1.963 0 N-CA-C 108.63 -1.788 . . . . 0.0 108.63 -175.614 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.402 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 95.2 m95 -67.33 111.25 3.92 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 117.565 0.683 . . . . 0.0 110.003 175.776 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 33.3 p -54.25 -58.88 5.72 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 124.877 1.271 . . . . 0.0 112.551 -176.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -92.98 -175.62 3.93 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.449 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -117.19 177.96 4.53 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.381 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.2 mt -57.39 118.79 27.29 Favored Pre-proline 0 C--N 1.286 -2.189 0 C-N-CA 125.65 1.58 . . . . 0.0 109.343 177.078 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -73.24 -177.58 3.07 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.901 2.4 . . . . 0.0 111.914 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 67.1 mt -105.32 133.18 50.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-O 120.903 0.382 . . . . 0.0 111.716 -172.065 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 90.6 m -111.4 91.15 3.55 Favored 'General case' 0 C--N 1.297 -1.682 0 CA-C-O 121.693 0.758 . . . . 0.0 109.039 174.361 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -86.85 148.54 25.33 Favored 'General case' 0 N--CA 1.424 -1.77 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -177.219 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.8 p -70.07 137.51 23.9 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 177.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 95.4 t -64.62 126.01 22.61 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -115.44 143.98 44.5 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.033 -176.026 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -120.75 159.59 25.09 Favored 'General case' 0 C--N 1.281 -2.41 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.147 177.62 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -68.46 147.08 98.11 Favored Pre-proline 0 N--CA 1.421 -1.899 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -175.126 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -71.93 116.42 4.7 Favored 'Trans proline' 0 N--CA 1.442 -1.522 0 C-N-CA 122.701 2.268 . . . . 0.0 110.546 178.099 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.445 HG21 ' SD ' ' A' ' 190' ' ' MET . 60.1 t -74.81 144.46 12.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.319 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.4 p -66.57 -84.85 0.02 OUTLIER 'General case' 0 N--CA 1.438 -1.026 0 O-C-N 123.379 0.424 . . . . 0.0 111.629 177.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 168.01 162.58 0.15 Allowed Pre-proline 0 CA--C 1.513 -0.46 0 C-N-CA 126.106 1.763 . . . . 0.0 106.463 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -76.54 168.3 23.98 Favored 'Trans proline' 0 N--CA 1.446 -1.313 0 C-N-CA 121.324 1.349 . . . . 0.0 110.001 171.267 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -60.02 -50.9 71.92 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 113.862 1.06 . . . . 0.0 113.862 -176.58 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 55.0 m-80 -110.67 32.61 5.09 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.563 0.696 . . . . 0.0 109.791 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -149.15 -176.79 22.73 Favored Glycine 0 N--CA 1.425 -2.081 0 C-N-CA 120.219 -0.991 . . . . 0.0 111.384 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -144.45 169.37 18.07 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -178.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.528 HG12 ' CD2' ' A' ' 176' ' ' PHE . 51.6 mt -98.47 137.45 25.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.478 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.8 m -84.5 -28.02 6.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 CA-C-O 121.986 0.898 . . . . 0.0 108.701 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.517 ' H ' HG22 ' A' ' 157' ' ' ILE . 12.9 m -91.34 14.95 13.11 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 114.704 -1.135 . . . . 0.0 112.496 -176.303 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 160' ' ' SER . . . . . 0.436 ' OG ' ' HB ' ' A' ' 157' ' ' ILE . 70.6 m -89.31 -78.09 0.36 Allowed 'General case' 0 C--N 1.313 -0.997 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.48 178.104 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -80.89 89.68 5.87 Favored 'General case' 0 N--CA 1.434 -1.243 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.383 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 53.4 mtm -118.68 -49.44 2.44 Favored 'General case' 0 C--N 1.283 -2.283 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 174.672 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 69.6 mm-40 -157.94 147.45 15.07 Favored Pre-proline 0 C--N 1.316 -0.886 0 N-CA-C 105.176 -2.157 . . . . 0.0 105.176 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -79.63 -11.54 14.1 Favored 'Trans proline' 0 CA--C 1.545 1.072 0 C-N-CA 122.298 1.999 . . . . 0.0 113.419 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 29.8 m-20 -96.27 -16.32 21.44 Favored 'General case' 0 CA--C 1.496 -1.119 0 CA-C-O 120.969 0.414 . . . . 0.0 110.602 -177.141 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 29.2 mmm180 -77.53 107.55 10.06 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.776 -176.311 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' GLU . . . . . 0.469 ' HB2' ' NE2' ' A' ' 169' ' ' HIS . 32.6 mt-10 -87.24 164.52 16.28 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.118 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 69.7 m-85 -83.33 110.05 17.79 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.682 0.753 . . . . 0.0 109.563 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.469 ' NE2' ' HB2' ' A' ' 167' ' ' GLU . 46.8 m170 -115.29 163.51 15.58 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.744 -176.175 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -51.93 127.46 21.25 Favored 'General case' 0 C--O 1.245 0.843 0 O-C-N 124.134 0.896 . . . . 0.0 108.983 172.734 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 108.23 -22.81 26.4 Favored Glycine 0 N--CA 1.435 -1.422 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.306 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 30.1 mm-40 -71.67 144.67 49.28 Favored 'General case' 0 C--O 1.256 1.398 0 CA-C-N 117.185 0.492 . . . . 0.0 110.314 178.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -123.03 104.99 9.57 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.253 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.547 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 54.4 t -79.85 106.62 11.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.832 -178.023 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.478 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 25.9 ttp85 -98.62 143.45 29.0 Favored 'General case' 0 N--CA 1.41 -2.452 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.736 179.138 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.528 ' CD2' HG12 ' A' ' 157' ' ' ILE . 64.0 m-85 -112.85 165.75 12.02 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -178.107 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.7 p -146.73 138.25 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.291 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.113 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.5 m -92.67 148.28 22.19 Favored 'General case' 0 C--N 1.265 -3.101 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.391 -178.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -69.64 162.41 27.71 Favored 'General case' 0 CA--C 1.497 -1.063 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.664 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 16.3 m -52.08 109.44 0.38 Allowed 'General case' 0 C--N 1.303 -1.439 0 O-C-N 124.404 1.065 . . . . 0.0 112.368 -175.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.58 -9.17 30.36 Favored Glycine 0 N--CA 1.435 -1.385 0 CA-C-N 115.715 -0.675 . . . . 0.0 113.073 178.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -108.81 153.12 23.94 Favored 'General case' 0 CA--C 1.497 -1.059 0 CA-C-N 117.886 0.843 . . . . 0.0 110.886 -178.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 16.9 pttp -115.71 159.54 21.25 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 7.0 tp -74.36 146.19 10.23 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 176.309 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -91.46 -61.21 1.7 Allowed 'General case' 0 C--N 1.27 -2.876 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -90.99 -130.48 4.68 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 177.167 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -87.8 153.14 21.58 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 176.141 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -92.55 8.19 39.95 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 120.365 -0.534 . . . . 0.0 110.465 -177.088 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.547 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 2.0 pt-20 -155.94 143.76 19.64 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 121.123 0.487 . . . . 0.0 111.925 -179.505 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.445 ' SD ' HG21 ' A' ' 149' ' ' VAL . 13.9 ptp -125.65 138.28 53.9 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.01 -0.995 . . . . 0.0 109.336 176.835 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 50.1 t-80 -100.56 138.77 37.17 Favored 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 123.089 0.556 . . . . 0.0 110.045 -176.498 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 23.6 t -82.76 107.08 15.12 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 174.547 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 50.7 m -100.21 -178.59 3.87 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 114.046 1.128 . . . . 0.0 114.046 -171.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -49.17 -34.97 15.7 Favored 'General case' 0 N--CA 1.51 2.541 0 C-N-CA 125.908 1.683 . . . . 0.0 113.179 -174.153 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -81.8 -7.67 59.62 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 113.456 0.909 . . . . 0.0 113.456 -176.446 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 83.42 10.19 82.39 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.15 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -112.96 169.76 8.69 Favored 'General case' 0 N--CA 1.427 -1.599 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 177.545 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.3 m95 -83.66 134.99 34.76 Favored 'General case' 0 N--CA 1.417 -2.087 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.24 178.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 35.9 p -63.38 -32.26 73.64 Favored 'General case' 0 C--O 1.249 1.063 0 CA-C-O 121.523 0.677 . . . . 0.0 112.229 -177.575 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 26.3 mmtp -116.49 157.08 25.76 Favored 'General case' 0 CA--C 1.483 -1.601 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.352 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.438 ' CD ' ' H ' ' A' ' 201' ' ' GLU . 0.3 OUTLIER -86.43 172.13 10.61 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.684 179.813 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 7.6 mmmm -55.13 119.9 26.13 Favored Pre-proline 0 C--N 1.321 -0.634 0 O-C-N 123.697 0.623 . . . . 0.0 111.786 178.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -86.5 -173.44 1.21 Allowed 'Trans proline' 0 N--CA 1.424 -2.589 0 C-N-CA 122.061 1.841 . . . . 0.0 109.987 178.774 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 24.5 ttmm -148.08 164.41 33.93 Favored 'General case' 0 C--N 1.278 -2.506 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -176.406 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.549 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 98.4 m -126.06 116.04 20.79 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 174.69 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--N 1.3 -1.574 0 O-C-N 124.416 1.072 . . . . 0.0 109.747 -175.392 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo . . . . . 0 N--CA 1.477 0.528 0 CA-C-O 121.313 0.464 . . . . 0.0 112.159 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.6 m -84.25 -29.97 26.05 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.37 -98.1 0.74 Allowed Glycine 0 N--CA 1.398 -3.891 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.919 171.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -177.08 110.75 0.23 Allowed Pre-proline 0 C--N 1.258 -3.407 0 N-CA-C 105.759 -1.941 . . . . 0.0 105.759 -176.075 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.451 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 45.0 Cg_endo -64.76 -30.82 59.04 Favored 'Trans proline' 0 N--CA 1.474 0.334 0 C-N-CA 122.92 2.414 . . . . 0.0 112.963 -171.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.95 -174.39 19.13 Favored Glycine 0 N--CA 1.419 -2.483 0 N-CA-C 108.481 -1.848 . . . . 0.0 108.481 -176.513 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -142.57 164.64 29.56 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 107.815 -1.179 . . . . 0.0 107.815 -176.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.4 t -125.05 127.31 25.1 Favored Pre-proline 0 C--N 1.295 -1.769 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 -178.478 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -68.64 -22.38 37.91 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.483 2.122 . . . . 0.0 110.667 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -81.24 -1.64 45.72 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.219 -1.355 . . . . 0.0 111.984 -175.477 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.43 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 177.38 -130.66 1.66 Allowed Glycine 0 N--CA 1.414 -2.791 0 C-N-CA 119.695 -1.241 . . . . 0.0 111.84 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 24.4 p -146.59 179.16 7.75 Favored 'General case' 0 C--N 1.285 -2.225 0 O-C-N 124.119 0.541 . . . . 0.0 110.096 -178.563 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -143.07 155.28 44.58 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 171.501 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.5 m -121.24 163.65 18.2 Favored 'General case' 0 C--N 1.279 -2.482 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.584 ' HA ' ' O ' ' A' ' 109' ' ' LYS . 32.0 mt -120.82 124.0 43.97 Favored 'General case' 0 C--N 1.277 -2.561 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.236 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.65 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 34.1 p -115.93 125.56 52.73 Favored 'General case' 0 C--N 1.285 -2.235 0 O-C-N 123.625 0.578 . . . . 0.0 110.793 -175.635 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 99.95 11.76 42.13 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.828 178.553 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -178.91 -28.76 0.05 OUTLIER Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 119.371 -1.395 . . . . 0.0 113.813 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 69.6 10.88 7.81 Favored 'General case' 0 N--CA 1.5 2.073 0 CA-C-O 122.674 1.226 . . . . 0.0 110.599 -177.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.438 ' O ' HG11 ' A' ' 108' ' ' VAL . 35.9 m -143.72 -169.79 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 114.684 -1.144 . . . . 0.0 107.937 -174.225 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 36.4 m-85 -110.87 43.9 1.36 Allowed 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.489 0.662 . . . . 0.0 110.567 -175.47 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.721 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.1 pt-20 -86.23 -176.58 5.97 Favored 'General case' 0 C--O 1.207 -1.165 0 CA-C-N 114.445 -1.252 . . . . 0.0 112.474 177.388 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.2 m-85 -78.82 131.99 36.69 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 122.021 -0.425 . . . . 0.0 111.467 178.313 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.48 5.33 61.82 Favored Glycine 0 N--CA 1.438 -1.214 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.659 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.721 HG12 ' O ' ' A' ' 105' ' ' GLU . 9.9 p -101.75 148.66 7.23 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.65 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 89.2 mttt -108.83 138.89 44.44 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 176.042 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -97.14 86.55 3.97 Favored 'General case' 0 C--N 1.264 -3.12 0 N-CA-C 105.515 -2.031 . . . . 0.0 105.515 169.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.484 HG12 ' CB ' ' A' ' 126' ' ' TYR . 21.2 m -85.61 118.17 31.85 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 -177.066 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -88.04 141.04 28.88 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.725 -0.609 . . . . 0.0 111.22 -175.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -139.36 114.36 9.49 Favored 'General case' 0 N--CA 1.412 -2.352 0 CA-C-O 122.129 0.966 . . . . 0.0 108.777 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 10.5 m -73.43 159.6 33.0 Favored 'General case' 0 C--N 1.289 -2.064 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.976 -175.648 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.43 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 68.6 m-20 -69.18 179.1 2.05 Favored 'General case' 0 C--O 1.216 -0.683 0 C-N-CA 123.023 0.529 . . . . 0.0 111.299 178.441 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -55.73 -46.57 77.74 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.556 0.742 . . . . 0.0 112.072 -178.199 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -81.92 7.8 61.88 Favored Glycine 0 C--N 1.308 -1.014 0 CA-C-N 115.839 -0.619 . . . . 0.0 113.95 -177.803 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -129.98 152.3 49.6 Favored 'General case' 0 N--CA 1.426 -1.63 0 CA-C-O 121.495 0.664 . . . . 0.0 110.072 -178.234 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -126.44 158.43 36.04 Favored 'General case' 0 C--N 1.271 -2.824 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.3 tt -89.56 129.47 36.02 Favored 'General case' 0 C--N 1.272 -2.8 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.552 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.64 128.18 55.98 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -175.682 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 116.06 173.48 17.21 Favored Glycine 0 C--N 1.294 -1.751 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 -176.025 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -87.73 -35.72 17.76 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -179.326 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 47.4 mm -85.73 137.04 21.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.288 -176.044 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -123.93 2.46 8.72 Favored 'General case' 0 C--O 1.21 -0.998 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.307 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.484 ' CB ' HG12 ' A' ' 111' ' ' VAL . 50.0 p90 -145.47 169.44 18.35 Favored 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -170.523 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.452 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 54.9 mtp180 -126.17 115.52 19.91 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 170.682 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -91.91 124.22 35.87 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 119.749 -0.781 . . . . 0.0 109.426 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.8 t -83.93 104.03 13.68 Favored 'General case' 0 CA--C 1.498 -1.056 0 C-N-CA 118.819 -1.152 . . . . 0.0 108.858 176.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.45 ' OD1' HG22 ' A' ' 131' ' ' THR . 7.9 t70 -99.53 -171.07 2.0 Allowed 'General case' 0 C--N 1.288 -2.103 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 178.634 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.45 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.3 t -61.42 -14.77 30.77 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 124.408 1.083 . . . . 0.0 112.508 -174.346 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -98.52 -15.34 19.59 Favored 'General case' 0 C--N 1.315 -0.913 0 O-C-N 121.757 -0.59 . . . . 0.0 110.637 178.6 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 124.18 -161.09 18.7 Favored Glycine 0 C--N 1.305 -1.188 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 -177.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.451 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 89.3 m95 -64.91 101.3 0.48 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.889 0.345 . . . . 0.0 110.173 176.77 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.5 p -58.31 -57.19 14.0 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 124.105 0.962 . . . . 0.0 112.254 -176.145 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' ASN . . . . . 0.452 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 3.5 m120 -81.36 177.53 8.92 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.19 -0.914 . . . . 0.0 109.321 -177.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -111.11 179.6 4.0 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 176.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 84.4 mt -72.53 117.95 63.46 Favored Pre-proline 0 C--N 1.317 -0.843 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -66.35 157.79 58.44 Favored 'Trans proline' 0 C--O 1.253 1.267 0 C-N-CA 122.513 2.142 . . . . 0.0 110.624 178.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 62.4 mt -92.24 129.48 42.79 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-O 120.877 0.37 . . . . 0.0 110.722 -173.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 84.5 m -99.41 105.4 17.34 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 171.307 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -92.94 150.14 20.77 Favored 'General case' 0 N--CA 1.407 -2.601 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 -179.188 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 5.8 p -74.4 131.02 35.65 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.645 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 84.7 t -52.7 132.05 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 O-C-N 123.906 0.754 . . . . 0.0 110.89 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.429 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 85.0 mttt -106.32 153.91 21.52 Favored 'General case' 0 N--CA 1.433 -1.295 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.016 -176.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.9 m -124.03 165.06 18.12 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.639 -178.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' LEU . . . . . 0.553 HD23 ' HD2' ' A' ' 148' ' ' PRO . 0.5 OUTLIER -62.58 130.85 93.85 Favored Pre-proline 0 N--CA 1.426 -1.64 0 C-N-CA 125.154 1.382 . . . . 0.0 110.777 178.099 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.553 ' HD2' HD23 ' A' ' 147' ' ' LEU . 24.1 Cg_endo -65.91 110.26 1.67 Allowed 'Trans proline' 0 C--N 1.314 -1.244 0 C-N-CA 123.174 2.582 . . . . 0.0 111.635 175.843 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 7.8 p -86.59 143.94 10.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 38.9 p -82.49 -83.48 0.13 Allowed 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -177.55 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.3 161.74 0.46 Allowed Pre-proline 0 C--N 1.326 -0.429 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 -179.485 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' PRO . . . . . 0.481 ' HD3' ' CD2' ' A' ' 176' ' ' PHE . 43.5 Cg_endo -73.51 -169.39 0.53 Allowed 'Trans proline' 0 CA--C 1.546 1.125 0 C-N-CA 121.654 1.569 . . . . 0.0 111.27 172.638 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' GLU . . . . . 0.512 ' H ' ' CD ' ' A' ' 153' ' ' GLU . 0.2 OUTLIER -88.44 -37.2 16.02 Favored 'General case' 0 C--N 1.287 -2.131 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -174.899 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 154' ' ' ASN . . . . . 0.45 ' OD1' ' HG2' ' A' ' 153' ' ' GLU . 25.7 m120 -120.86 22.82 10.98 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 122.074 0.94 . . . . 0.0 109.827 179.345 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 155' ' ' GLY . . . . . 0.411 ' HA3' ' SG ' ' A' ' 205' ' ' CYS . . . -146.49 178.97 23.81 Favored Glycine 0 N--CA 1.425 -2.041 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.431 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 156' ' ' LYS . . . . . 0.448 ' HG3' HG23 ' A' ' 177' ' ' VAL . 21.9 pttm -145.62 -176.66 5.22 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -178.093 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.444 HG22 ' N ' ' A' ' 159' ' ' SER . 64.4 mt -95.56 141.2 15.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 C-N-CA 122.505 0.322 . . . . 0.0 110.703 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.573 HG12 HG22 ' A' ' 177' ' ' VAL . 2.3 m -79.91 -35.39 16.11 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.461 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 177.568 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.444 ' N ' HG22 ' A' ' 157' ' ' ILE . 5.3 m -79.74 31.98 0.25 Allowed 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 125.429 1.492 . . . . 0.0 111.375 -174.435 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 19.7 m -82.41 76.13 9.29 Favored 'General case' 0 N--CA 1.435 -1.206 0 CA-C-O 121.688 0.756 . . . . 0.0 112.363 -176.576 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -133.21 87.89 2.44 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 105.9 -1.889 . . . . 0.0 105.9 173.082 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -97.94 94.55 6.94 Favored 'General case' 0 N--CA 1.408 -2.566 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.494 -170.568 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.642 ' HB2' ' HG2' ' A' ' 166' ' ' ARG . 42.7 mt-10 -99.73 153.47 37.75 Favored Pre-proline 0 C--N 1.27 -2.877 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 173.056 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -73.6 -6.0 17.99 Favored 'Trans proline' 0 N--CA 1.476 0.493 0 C-N-CA 122.307 2.005 . . . . 0.0 111.164 178.265 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -97.05 -30.82 12.83 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.642 ' HG2' ' HB2' ' A' ' 163' ' ' GLU . 28.8 mmt180 -93.6 89.03 6.08 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.782 -1.099 . . . . 0.0 109.298 -177.461 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' GLU . . . . . 0.485 ' HB2' ' NE2' ' A' ' 169' ' ' HIS . 27.2 mt-10 -88.4 171.61 10.0 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 174.364 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 168' ' ' TYR . . . . . 0.429 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 82.6 m-85 -72.0 106.09 4.15 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.489 -0.884 . . . . 0.0 108.711 175.159 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.485 ' NE2' ' HB2' ' A' ' 167' ' ' GLU . 49.7 m170 -117.83 161.06 20.35 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.691 -175.351 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 42.5 t80 -55.72 125.27 20.5 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 174.371 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 109.86 -14.13 31.87 Favored Glycine 0 N--CA 1.42 -2.398 0 C-N-CA 120.047 -1.073 . . . . 0.0 111.492 -177.101 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 87.1 mm-40 -86.71 139.38 30.81 Favored 'General case' 0 N--CA 1.433 -1.305 0 C-N-CA 119.533 -0.867 . . . . 0.0 109.822 176.738 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -120.59 116.14 24.77 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.616 178.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 88.1 t -90.29 106.04 16.88 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.517 ' HB3' HG22 ' A' ' 158' ' ' VAL . 46.1 ttm180 -104.65 142.47 34.61 Favored 'General case' 0 N--CA 1.405 -2.689 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.481 ' CD2' ' HD3' ' A' ' 152' ' ' PRO . 88.5 m-85 -108.81 157.44 18.58 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 121.431 0.634 . . . . 0.0 110.922 -175.852 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.573 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -130.69 133.12 63.82 Favored 'Isoleucine or valine' 0 CA--C 1.471 -2.078 0 CA-C-N 114.908 -1.042 . . . . 0.0 108.507 178.626 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 93.4 m -95.33 128.34 42.1 Favored 'General case' 0 C--N 1.259 -3.337 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 177.195 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 77.1 m-20 -60.09 160.09 8.62 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 114.95 -1.023 . . . . 0.0 111.419 -178.195 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 14.9 m -37.38 102.82 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 126.484 1.914 . . . . 0.0 114.91 -174.146 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 111.66 -18.39 24.78 Favored Glycine 0 N--CA 1.441 -0.982 0 C-N-CA 120.998 -0.62 . . . . 0.0 113.066 177.365 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 182' ' ' TYR . . . . . 0.423 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 93.8 m-85 -96.12 156.0 16.52 Favored 'General case' 0 N--CA 1.434 -1.233 0 CA-C-N 117.094 0.447 . . . . 0.0 111.394 -177.352 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -123.18 155.15 37.64 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.3 tp -72.42 142.84 14.7 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.2 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -71.83 -71.24 0.28 Allowed 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.852 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -100.02 -105.86 2.73 Favored Glycine 0 N--CA 1.431 -1.665 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -99.34 163.28 12.6 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -105.88 0.8 26.24 Favored 'General case' 0 CA--C 1.499 -1.008 0 C-N-CA 119.351 -0.94 . . . . 0.0 111.249 -173.261 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -148.12 152.63 37.65 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 114.085 1.142 . . . . 0.0 114.085 -175.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.5 ptp -131.15 138.23 49.37 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.233 -1.349 . . . . 0.0 108.496 177.448 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 45.6 t-80 -123.42 137.42 54.81 Favored 'General case' 0 C--N 1.292 -1.902 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.448 -176.294 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 16.2 m -61.93 113.81 3.01 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.994 176.104 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 14.9 m -102.76 174.15 6.01 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.054 178.344 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -48.74 140.79 8.04 Favored 'General case' 0 N--CA 1.488 1.433 0 C-N-CA 123.833 0.853 . . . . 0.0 112.352 178.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 26.2 t70 76.47 -6.45 2.0 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 125.944 1.698 . . . . 0.0 111.937 178.128 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 93.04 50.94 2.35 Favored Glycine 0 N--CA 1.434 -1.499 0 C-N-CA 120.529 -0.844 . . . . 0.0 112.087 177.505 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -116.7 141.61 47.98 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 176.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 67.1 m95 -79.78 132.06 36.06 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 171.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.1 p -65.85 -20.34 66.2 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.245 0.545 . . . . 0.0 112.172 -179.276 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.543 ' HA ' ' HE3' ' A' ' 200' ' ' LYS . 0.0 OUTLIER -134.17 171.1 14.7 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.597 178.43 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -108.57 170.25 8.14 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.492 -178.383 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 5.5 tppp? -56.06 114.87 8.34 Favored Pre-proline 0 C--O 1.233 0.237 0 O-C-N 124.047 0.842 . . . . 0.0 110.814 -178.254 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -80.76 -167.78 0.55 Allowed 'Trans proline' 0 N--CA 1.434 -2.0 0 C-N-CA 122.145 1.897 . . . . 0.0 110.625 176.753 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 5.0 ttmp? -146.38 160.31 42.23 Favored 'General case' 0 C--N 1.28 -2.422 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -174.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.423 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 87.0 m -117.41 105.93 12.66 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-O 121.518 0.675 . . . . 0.0 110.693 177.617 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.2 m . . . . . 0 N--CA 1.433 -1.314 0 CA-C-N 115.003 -0.998 . . . . 0.0 110.079 -176.2 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 CA--C 1.53 0.325 0 CA-C-O 121.565 0.569 . . . . 0.0 111.322 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 36.2 m -89.1 -42.16 11.87 Favored 'General case' 0 N--CA 1.426 -1.633 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.645 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 121.4 -86.0 0.39 Allowed Glycine 0 CA--C 1.472 -2.603 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 172.536 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -179.59 127.13 0.24 Allowed Pre-proline 0 C--N 1.274 -2.691 0 N-CA-C 104.078 -2.564 . . . . 0.0 104.078 -177.55 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.414 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 95.2 Cg_endo -77.58 4.85 5.64 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 C-N-CA 123.355 2.703 . . . . 0.0 115.584 -170.225 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.75 -168.86 12.91 Favored Glycine 0 C--N 1.287 -2.167 0 N-CA-C 107.688 -2.165 . . . . 0.0 107.688 -174.248 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -151.12 -175.42 5.15 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 118.439 1.119 . . . . 0.0 108.846 -176.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 t -155.33 125.85 3.41 Favored Pre-proline 0 N--CA 1.424 -1.739 0 CA-C-O 121.065 0.46 . . . . 0.0 111.395 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -78.73 -5.95 14.99 Favored 'Trans proline' 0 C--O 1.239 0.556 0 C-N-CA 123.088 2.526 . . . . 0.0 112.069 178.461 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.535 ' HB2' ' HB2' ' A' ' 141' ' ' CYS . 27.0 m-85 -99.46 1.28 43.96 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.325 -177.649 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.461 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.86 -136.59 3.52 Favored Glycine 0 N--CA 1.405 -3.385 0 C-N-CA 118.817 -1.659 . . . . 0.0 113.043 -178.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.9 p -146.37 -176.85 5.33 Favored 'General case' 0 C--N 1.283 -2.311 0 CA-C-N 114.655 -0.773 . . . . 0.0 110.795 -174.041 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 44.6 p90 -146.58 161.53 40.31 Favored 'General case' 0 N--CA 1.431 -1.422 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 171.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.7 m -131.81 154.51 49.04 Favored 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 179.546 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.507 ' HB2' ' HA ' ' A' ' 102' ' ' ASN . 16.1 mt -110.07 127.68 54.99 Favored 'General case' 0 C--N 1.272 -2.78 0 CA-C-O 120.995 0.426 . . . . 0.0 110.064 -177.039 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.491 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 24.1 p -120.45 132.94 55.45 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.136 -177.613 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.44 19.34 32.86 Favored Glycine 0 C--N 1.307 -1.065 0 C-N-CA 120.599 -0.81 . . . . 0.0 111.809 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 167.92 -27.04 0.14 Allowed Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.612 178.094 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ASN . . . . . 0.507 ' HA ' ' HB2' ' A' ' 98' ' ' LEU . 7.5 t30 61.28 20.07 10.71 Favored 'General case' 0 CA--C 1.56 1.338 0 CA-C-O 122.699 1.238 . . . . 0.0 110.519 -178.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.546 ' O ' HG11 ' A' ' 108' ' ' VAL . 31.1 m -144.55 -170.57 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.207 -1.164 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 -179.035 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -106.53 45.19 0.99 Allowed 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 118.394 0.543 . . . . 0.0 110.392 -178.157 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.717 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.4 pt-20 -90.43 -177.97 5.21 Favored 'General case' 0 C--O 1.207 -1.143 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.769 177.483 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 46.9 m-85 -77.61 133.24 38.48 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.859 -0.526 . . . . 0.0 111.456 178.526 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.84 0.12 64.33 Favored Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.895 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.717 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.7 p -94.22 145.71 7.61 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.491 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 15.1 mtpp -109.94 124.39 51.31 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.65 91.13 8.63 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 176.094 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 62.5 t -88.63 112.24 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.962 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -177.144 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -81.39 134.9 35.62 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-O 121.19 0.519 . . . . 0.0 111.681 -178.627 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.1 t -132.55 104.91 6.92 Favored 'General case' 0 N--CA 1.421 -1.916 0 CA-C-O 122.157 0.979 . . . . 0.0 109.16 -178.512 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 13.4 m -66.83 157.98 31.62 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.62 -1.173 . . . . 0.0 110.826 -178.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.461 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 95.4 m-20 -75.55 178.44 5.99 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.748 -0.206 . . . . 0.0 111.548 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -45.7 -54.63 7.54 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.945 1.298 . . . . 0.0 113.324 -177.569 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.497 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -85.16 25.94 5.85 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 120.3 -0.953 . . . . 0.0 113.626 -176.357 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.67 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 81.1 m-85 -145.98 154.89 42.4 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 117.321 0.56 . . . . 0.0 110.092 -176.593 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.03 161.84 33.3 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 176.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.28 115.4 21.33 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 -178.384 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -98.31 129.74 45.0 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 179.461 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 121.35 166.74 13.03 Favored Glycine 0 C--N 1.29 -1.99 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -177.722 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.0 mt-10 -88.99 -21.3 23.57 Favored 'General case' 0 C--N 1.295 -1.799 0 CA-C-O 121.955 0.883 . . . . 0.0 109.306 -177.794 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.481 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.5 mm -107.76 131.21 58.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.804 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.815 -178.443 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -123.57 11.5 9.21 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -177.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.471 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 15.5 p90 -152.03 161.42 42.67 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -175.24 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.414 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 62.9 mtp180 -126.43 129.02 47.9 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 172.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -105.87 132.19 52.27 Favored 'General case' 0 C--N 1.279 -2.492 0 C-N-CA 119.101 -1.039 . . . . 0.0 109.461 -178.334 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.1 t -82.11 101.8 10.64 Favored 'General case' 0 C--N 1.293 -1.876 0 C-N-CA 118.219 -1.392 . . . . 0.0 109.927 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.555 ' OD2' HG22 ' A' ' 131' ' ' THR . 13.3 t70 -101.83 -171.35 1.96 Allowed 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.555 HG22 ' OD2' ' A' ' 130' ' ' ASP . 8.8 t -54.93 -31.99 60.84 Favored 'General case' 0 CA--C 1.56 1.331 0 C-N-CA 124.182 0.993 . . . . 0.0 112.805 -175.47 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -85.72 -15.36 42.45 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.908 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 122.98 -159.89 17.55 Favored Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -176.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.0 m95 -62.23 112.17 2.28 Favored 'General case' 0 C--O 1.248 0.983 0 CA-C-N 117.173 0.486 . . . . 0.0 110.39 177.051 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 68.4 p -71.08 162.82 28.78 Favored 'General case' 0 C--O 1.266 1.932 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 65.6 -171.16 0.19 Allowed 'General case' 0 CA--C 1.509 -0.629 0 O-C-N 124.209 0.943 . . . . 0.0 111.451 174.334 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -108.51 171.79 7.21 Favored 'General case' 0 C--N 1.295 -1.804 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.566 177.37 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 66.2 mt -67.68 118.5 58.05 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 171.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.481 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 35.0 Cg_endo -66.2 159.06 51.58 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 122.056 1.837 . . . . 0.0 111.114 178.257 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 74.5 mt -109.39 134.59 50.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 C-N-CA 120.68 -0.408 . . . . 0.0 109.953 -171.303 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.535 ' HB2' ' HB2' ' A' ' 93' ' ' PHE . 94.9 m -102.96 110.73 22.76 Favored 'General case' 0 C--N 1.277 -2.57 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 175.144 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.86 152.17 20.04 Favored 'General case' 0 CA--C 1.462 -2.41 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.67 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 2.8 t -69.12 142.2 16.42 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.044 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.546 -177.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.689 HG23 ' HB2' ' A' ' 170' ' ' PHE . 10.4 m -66.82 122.52 18.01 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 178.072 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.465 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 49.7 mtmt -121.81 127.18 50.28 Favored 'General case' 0 N--CA 1.408 -2.565 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.923 -172.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 60.8 m -84.2 153.68 23.5 Favored 'General case' 0 C--N 1.28 -2.436 0 CA-C-N 113.981 -1.463 . . . . 0.0 108.504 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' LEU . . . . . 0.402 ' HB2' ' HD2' ' A' ' 148' ' ' PRO . 3.6 pp -67.52 160.72 70.74 Favored Pre-proline 0 CA--C 1.553 1.075 0 O-C-N 123.236 0.335 . . . . 0.0 110.229 -178.075 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.433 ' HA ' ' CE2' ' A' ' 168' ' ' TYR . 39.4 Cg_endo -74.28 123.21 8.08 Favored 'Trans proline' 0 N--CA 1.446 -1.297 0 C-N-CA 122.499 2.133 . . . . 0.0 112.348 -175.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.648 HG12 ' O ' ' A' ' 150' ' ' THR . 62.0 t -75.07 137.68 22.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.977 -178.554 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' THR . . . . . 0.648 ' O ' HG12 ' A' ' 149' ' ' VAL . 25.4 p -95.95 -158.01 0.62 Allowed 'General case' 0 N--CA 1.417 -2.105 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 172.183 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -127.38 151.39 74.73 Favored Pre-proline 0 C--N 1.274 -2.682 0 O-C-N 120.406 -1.434 . . . . 0.0 110.352 -171.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -68.76 161.44 45.42 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.615 1.543 . . . . 0.0 112.259 177.23 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -60.04 -43.64 95.22 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 -174.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 57.6 m-80 -117.49 29.36 7.91 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -148.31 -167.21 13.4 Favored Glycine 0 N--CA 1.435 -1.42 0 C-N-CA 119.989 -1.101 . . . . 0.0 112.081 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -154.85 177.14 11.62 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.434 HD11 ' O ' ' A' ' 150' ' ' THR . 58.9 mt -88.75 129.7 39.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 CA-C-O 120.833 0.349 . . . . 0.0 110.713 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.414 ' CG2' ' HB ' ' A' ' 177' ' ' VAL . 34.9 t -64.34 -35.61 74.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.555 0 C-N-CA 123.902 0.881 . . . . 0.0 109.947 178.562 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 37.3 t -79.89 65.93 5.21 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 173.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 20.7 m -69.8 -27.19 64.69 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.72 179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -71.56 98.79 1.93 Allowed 'General case' 0 N--CA 1.432 -1.368 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 171.061 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 36.0 tpp -154.21 89.54 1.29 Allowed 'General case' 0 N--CA 1.416 -2.136 0 CA-C-N 115.124 -0.944 . . . . 0.0 108.997 -173.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.488 ' HG2' ' HG3' ' A' ' 166' ' ' ARG . 0.6 OUTLIER -84.57 134.31 42.6 Favored Pre-proline 0 C--N 1.278 -2.503 0 CA-C-N 114.11 -1.405 . . . . 0.0 109.315 176.745 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.72 20.66 0.38 Allowed 'Trans proline' 0 N--CA 1.486 1.085 0 C-N-CA 123.962 3.108 . . . . 0.0 114.494 -171.576 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 29.8 m-20 -106.48 -23.09 12.6 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-O 121.172 0.51 . . . . 0.0 110.186 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.496 ' HD3' ' O ' ' A' ' 166' ' ' ARG . 0.0 OUTLIER -99.89 114.12 27.13 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-O 121.743 0.782 . . . . 0.0 111.952 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 37.8 mt-10 -74.78 156.63 36.33 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.288 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' TYR . . . . . 0.465 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 99.6 m-85 -78.15 101.64 7.14 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -97.4 160.23 14.45 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -177.337 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.689 ' HB2' HG23 ' A' ' 144' ' ' VAL . 53.6 t80 -54.83 111.66 0.87 Allowed 'General case' 0 C--O 1.241 0.62 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 171.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 137.55 -12.82 3.73 Favored Glycine 0 N--CA 1.425 -2.064 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -173.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -82.98 143.97 30.29 Favored 'General case' 0 C--O 1.248 1.009 0 CA-C-O 121.436 0.636 . . . . 0.0 112.116 177.238 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -134.88 111.1 9.59 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 172.374 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 76.7 t -97.75 111.53 27.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 CA-C-O 120.983 0.42 . . . . 0.0 110.083 -177.182 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 79.6 ttt180 -95.33 153.84 17.49 Favored 'General case' 0 N--CA 1.426 -1.644 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.05 178.426 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -125.49 153.56 43.37 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 124.264 1.026 . . . . 0.0 109.458 -175.398 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.414 ' HB ' ' CG2' ' A' ' 158' ' ' VAL . 14.7 p -135.59 143.02 37.78 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 72.6 m -96.17 146.57 24.57 Favored 'General case' 0 C--N 1.272 -2.802 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.508 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -87.71 168.38 13.03 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.762 -176.491 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 32.4 t 50.06 -113.2 0.63 Allowed 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 124.058 0.943 . . . . 0.0 113.357 178.394 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -118.87 23.83 8.61 Favored Glycine 0 N--CA 1.417 -2.577 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -79.87 158.12 26.81 Favored 'General case' 0 C--O 1.249 1.046 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.117 -176.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 20.9 ptmt -121.14 160.56 23.48 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 115.503 -0.771 . . . . 0.0 109.476 -178.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.427 HD11 ' CG ' ' A' ' 203' ' ' PRO . 3.6 tp -79.29 145.91 8.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.449 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -69.61 -66.96 0.52 Allowed 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.617 178.484 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -115.69 -98.54 2.15 Favored Glycine 0 N--CA 1.433 -1.548 0 C-N-CA 120.442 -0.885 . . . . 0.0 111.364 -179.358 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -98.84 145.38 27.03 Favored 'General case' 0 CA--C 1.483 -1.604 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -178.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.429 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 12.0 pt-20 -102.97 12.08 36.54 Favored 'General case' 0 C--N 1.287 -2.138 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.915 -175.766 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -149.05 132.51 16.65 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 121.555 0.693 . . . . 0.0 112.552 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.7 ptp -114.21 125.33 53.81 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.282 176.372 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 27.3 t-80 -103.85 148.33 26.26 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 -178.429 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 5.0 m -75.02 140.88 43.89 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 177.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 50.7 m -96.71 154.95 16.99 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 171.723 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -73.77 -2.67 24.42 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.754 0.788 . . . . 0.0 110.882 -177.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -81.29 -10.43 59.58 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.827 178.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 94.48 26.51 13.41 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.769 -0.729 . . . . 0.0 113.514 178.524 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 19.5 p90 -147.78 173.44 12.8 Favored 'General case' 0 C--N 1.309 -1.155 0 O-C-N 122.263 -0.551 . . . . 0.0 110.376 177.424 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -83.05 145.15 29.45 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 123.433 0.458 . . . . 0.0 110.486 -179.058 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 6.7 m -82.91 -0.52 48.82 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.847 0.356 . . . . 0.0 111.336 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 15.7 tppt? -140.14 153.5 46.69 Favored 'General case' 0 N--CA 1.424 -1.731 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -177.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -87.87 155.04 20.06 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.68 175.483 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 202' ' ' LYS . . . . . 0.453 ' HB3' ' HE2' ' A' ' 202' ' ' LYS . 38.9 mtpt -59.95 126.67 84.08 Favored Pre-proline 0 N--CA 1.434 -1.261 0 O-C-N 123.731 0.645 . . . . 0.0 110.042 174.669 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.427 ' CG ' HD11 ' A' ' 184' ' ' ILE . 90.9 Cg_endo -82.93 -167.95 0.53 Allowed 'Trans proline' 0 N--CA 1.436 -1.901 0 C-N-CA 122.514 2.143 . . . . 0.0 110.66 177.313 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -132.25 170.47 15.0 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.478 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 89.2 m -120.42 112.67 19.28 Favored 'General case' 0 C--N 1.274 -2.689 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 172.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 28.2 m . . . . . 0 C--N 1.281 -2.375 0 CA-C-N 114.105 -1.407 . . . . 0.0 109.206 -172.216 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.461 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 32.7 Cg_endo . . . . . 0 CA--C 1.546 1.11 0 CA-C-O 120.902 0.293 . . . . 0.0 112.201 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' CYS . . . . . 0.619 ' HB3' ' NE1' ' A' ' 134' ' ' TRP . 0.9 OUTLIER -87.7 -16.79 33.31 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.37 0.605 . . . . 0.0 110.133 175.132 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 102.72 -93.8 1.09 Allowed Glycine 1 N--CA 1.391 -4.357 0 N-CA-C 108.748 -1.741 . . . . 0.0 108.748 174.781 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -170.38 132.06 0.96 Allowed Pre-proline 0 C--N 1.253 -3.628 0 N-CA-C 105.571 -2.011 . . . . 0.0 105.571 -175.785 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -73.27 -28.72 12.19 Favored 'Trans proline' 0 N--CA 1.477 0.512 0 C-N-CA 122.152 1.901 . . . . 0.0 113.481 -173.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 133.41 150.28 6.29 Favored Glycine 0 N--CA 1.425 -2.036 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -178.049 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -111.89 125.89 54.52 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -178.661 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.6 t -89.5 125.59 60.98 Favored Pre-proline 0 C--N 1.3 -1.557 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 178.798 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -70.1 -10.42 28.25 Favored 'Trans proline' 0 C--O 1.221 -0.371 0 C-N-CA 122.833 2.355 . . . . 0.0 111.911 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -92.44 -2.55 56.21 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.398 0.618 . . . . 0.0 110.616 -178.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.509 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -178.71 -119.5 0.61 Allowed Glycine 0 N--CA 1.422 -2.294 0 C-N-CA 119.948 -1.12 . . . . 0.0 111.952 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.2 t -170.25 -162.55 0.3 Allowed 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.434 ' CB ' ' HA ' ' A' ' 112' ' ' TYR . 52.5 p90 -148.37 170.93 16.88 Favored 'General case' 0 C--N 1.311 -1.106 0 O-C-N 121.61 -0.681 . . . . 0.0 110.844 178.564 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -123.47 163.31 21.14 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 177.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.2 mt -121.99 129.42 52.46 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.41 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 32.6 p -122.84 124.63 43.71 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -176.135 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 92.99 30.18 9.68 Favored Glycine 0 C--N 1.298 -1.548 0 C-N-CA 120.325 -0.941 . . . . 0.0 111.185 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 167.25 -33.16 0.21 Allowed Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 119.464 -1.35 . . . . 0.0 113.417 176.692 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 65.46 14.79 9.68 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 123.577 0.751 . . . . 0.0 112.995 -177.702 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.519 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.4 m -151.7 -168.89 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.213 -0.85 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -177.43 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -106.52 38.14 2.14 Favored 'General case' 0 C--O 1.252 1.217 0 CA-C-N 118.737 0.699 . . . . 0.0 110.445 -175.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.673 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.1 pt-20 -78.49 178.74 7.52 Favored 'General case' 0 C--O 1.2 -1.521 0 CA-C-N 114.22 -1.354 . . . . 0.0 111.003 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' TYR . . . . . 0.678 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 23.7 m-85 -79.63 134.04 36.43 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-O 120.958 0.408 . . . . 0.0 111.276 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.49 4.55 60.74 Favored Glycine 0 N--CA 1.44 -1.056 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.638 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.673 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.5 p -99.44 145.11 11.06 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 C-N-CA 120.425 -0.51 . . . . 0.0 109.876 -179.308 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.41 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 58.7 mtpt -108.1 125.09 51.18 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.609 176.661 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.82 94.06 9.65 Favored 'General case' 0 C--N 1.289 -2.055 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.334 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.459 HG12 ' HB3' ' A' ' 126' ' ' TYR . 32.8 m -94.07 116.12 34.55 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.188 0 CA-C-O 122.599 1.19 . . . . 0.0 108.434 -178.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' TYR . . . . . 0.434 ' HA ' ' CB ' ' A' ' 96' ' ' PHE . 13.4 m-85 -78.74 141.75 37.6 Favored 'General case' 0 C--N 1.267 -2.985 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.667 -174.094 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.7 t -133.57 106.99 7.73 Favored 'General case' 0 N--CA 1.411 -2.386 0 CA-C-N 115.114 -0.948 . . . . 0.0 108.772 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 95.4 m -63.67 160.45 16.92 Favored 'General case' 0 C--N 1.296 -1.737 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.261 177.168 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.509 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 78.9 m-20 -74.35 -177.87 3.23 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.656 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -58.56 -45.29 89.3 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 123.58 0.752 . . . . 0.0 112.719 -174.651 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.36 24.13 6.63 Favored Glycine 0 C--O 1.212 -1.249 0 C-N-CA 120.747 -0.739 . . . . 0.0 113.302 179.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -147.82 169.93 18.71 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.99 -0.712 . . . . 0.0 109.952 -173.14 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -152.13 162.98 40.29 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.548 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -78.45 140.84 38.61 Favored 'General case' 0 C--N 1.288 -2.069 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.524 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.4 OUTLIER -119.24 126.52 51.71 Favored 'General case' 0 N--CA 1.409 -2.488 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.244 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.52 -170.24 14.27 Favored Glycine 0 C--N 1.289 -2.061 0 C-N-CA 120.69 -0.766 . . . . 0.0 111.607 -178.747 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -98.66 -38.81 8.97 Favored 'General case' 0 C--N 1.309 -1.195 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 -177.139 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.5 mm -78.62 120.48 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.716 0 CA-C-N 114.668 -1.151 . . . . 0.0 109.098 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -123.36 6.33 9.04 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.488 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 25.8 p90 -143.29 165.4 27.57 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -171.265 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 34.4 mtp180 -129.09 143.19 50.78 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 169.126 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -113.6 130.21 56.42 Favored 'General case' 0 C--N 1.287 -2.135 0 C-N-CA 119.426 -0.909 . . . . 0.0 109.895 -178.645 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' CYS . . . . . 0.678 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 37.8 t -80.35 90.39 5.58 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 176.142 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.482 ' OD2' HG22 ' A' ' 131' ' ' THR . 16.9 t70 -97.21 -170.62 2.05 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 179.017 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.482 HG22 ' OD2' ' A' ' 130' ' ' ASP . 15.1 t -59.03 -32.36 69.67 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 123.485 0.714 . . . . 0.0 112.875 -172.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -75.86 -34.09 60.03 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 121.488 0.661 . . . . 0.0 110.393 178.012 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.478 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 140.0 -153.91 23.57 Favored Glycine 0 N--CA 1.417 -2.602 0 N-CA-C 107.81 -2.116 . . . . 0.0 107.81 -174.599 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.619 ' NE1' ' HB3' ' A' ' 85' ' ' CYS . 98.3 m95 -65.86 116.61 7.21 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 117.655 0.728 . . . . 0.0 111.326 176.707 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 54.4 p -74.74 171.13 14.49 Favored 'General case' 0 C--O 1.269 2.119 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.036 176.478 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 87.0 m-20 59.05 -158.3 0.31 Allowed 'General case' 0 CA--C 1.515 -0.391 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -136.58 -179.48 5.71 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 172.044 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.9 mt -57.5 121.21 46.67 Favored Pre-proline 0 C--N 1.273 -2.721 0 C-N-CA 123.945 0.898 . . . . 0.0 108.595 175.402 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -63.49 169.68 9.35 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 122.663 2.242 . . . . 0.0 112.386 -179.231 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.524 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 52.8 mt -95.83 139.89 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.856 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -173.608 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 38.3 t -126.59 136.57 52.71 Favored 'General case' 0 C--N 1.276 -2.628 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.684 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -130.64 154.55 47.78 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -178.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 4.2 p -70.64 147.96 11.07 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.614 HG23 ' HB2' ' A' ' 170' ' ' PHE . 2.3 m -67.57 107.58 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.521 176.412 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -89.9 137.16 32.57 Favored 'General case' 0 N--CA 1.436 -1.168 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.72 -178.088 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.8 m -102.89 138.14 40.17 Favored 'General case' 0 C--N 1.282 -2.328 0 N-CA-C 106.111 -1.811 . . . . 0.0 106.111 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' LEU . . . . . 0.457 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.0 mm? -63.0 148.22 92.89 Favored Pre-proline 0 N--CA 1.433 -1.275 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -177.685 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 26.8 Cg_exo -61.2 121.84 10.25 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 122.911 2.408 . . . . 0.0 110.571 175.692 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.6 p -93.22 151.82 3.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.2 p -88.68 -177.16 5.49 Favored 'General case' 0 N--CA 1.431 -1.385 0 C-N-CA 120.9 -0.32 . . . . 0.0 110.291 175.028 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -108.79 158.94 32.77 Favored Pre-proline 0 C--N 1.294 -1.832 0 C-N-CA 122.415 0.286 . . . . 0.0 111.412 -171.711 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.78 157.39 61.43 Favored 'Trans proline' 0 C--N 1.362 1.247 0 C-N-CA 122.779 2.32 . . . . 0.0 111.292 175.252 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -59.02 -57.25 13.91 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 113.737 1.014 . . . . 0.0 113.737 -175.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 -102.5 36.56 2.13 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -178.474 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -150.91 -154.56 6.56 Favored Glycine 0 N--CA 1.413 -2.851 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.399 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' LYS . . . . . 0.671 ' HG3' HG23 ' A' ' 177' ' ' VAL . 17.5 ptmt -163.84 -177.55 5.18 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 123.658 0.783 . . . . 0.0 109.002 -178.799 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 55.2 mt -100.22 135.8 34.43 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.502 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.6 m -82.5 -33.71 11.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.539 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 7.2 m -82.7 79.21 9.17 Favored 'General case' 0 N--CA 1.425 -1.696 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.356 -173.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 15.9 m -77.09 75.29 3.66 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.751 178.34 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -125.77 94.36 4.1 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 114.628 -1.169 . . . . 0.0 109.37 -179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 38.0 tpp -157.3 86.85 0.96 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 176.016 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.445 ' CG ' ' HB2' ' A' ' 166' ' ' ARG . 8.5 pt-20 -150.66 165.52 17.21 Favored Pre-proline 0 C--N 1.288 -2.071 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.396 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 164' ' ' PRO . . . . . 0.439 ' HD2' ' HB2' ' A' ' 163' ' ' GLU . 3.0 Cg_endo -44.44 -28.73 2.75 Favored 'Trans proline' 0 N--CA 1.485 0.978 0 C-N-CA 124.67 3.58 . . . . 0.0 116.127 -177.805 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -108.47 -44.83 4.0 Favored 'General case' 0 C--N 1.311 -1.084 0 C-N-CA 119.219 -0.992 . . . . 0.0 110.396 -177.298 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.445 ' HB2' ' CG ' ' A' ' 163' ' ' GLU . 4.7 mmp_? -87.42 95.38 9.99 Favored 'General case' 0 N--CA 1.427 -1.597 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.237 -177.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 167' ' ' GLU . . . . . 0.462 ' HB2' ' NE2' ' A' ' 169' ' ' HIS . 27.7 mt-10 -110.97 -177.78 3.3 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 105.469 -2.048 . . . . 0.0 105.469 174.53 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -86.15 105.33 16.48 Favored 'General case' 0 C--N 1.295 -1.791 0 CA-C-O 121.58 0.705 . . . . 0.0 109.269 175.833 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.462 ' NE2' ' HB2' ' A' ' 167' ' ' GLU . 30.5 m170 -114.36 160.1 19.5 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -178.886 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.614 ' HB2' HG23 ' A' ' 144' ' ' VAL . 0.6 OUTLIER -53.99 120.85 6.93 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 174.141 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 122.17 -23.92 7.13 Favored Glycine 0 N--CA 1.428 -1.86 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -177.645 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 15.6 mm100 -70.53 145.32 50.92 Favored 'General case' 0 C--O 1.256 1.423 0 CA-C-O 121.656 0.741 . . . . 0.0 110.783 178.509 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -116.01 112.59 22.02 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 173.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 8.4 p -95.64 112.91 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.316 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.502 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 79.5 ttt180 -110.61 143.68 40.67 Favored 'General case' 0 C--N 1.28 -2.417 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.005 -175.229 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -114.18 159.65 19.87 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.053 -174.115 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.671 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.0 OUTLIER -129.8 154.06 39.75 Favored 'Isoleucine or valine' 0 CA--C 1.469 -2.148 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.746 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 82.7 m -115.22 140.07 49.4 Favored 'General case' 0 N--CA 1.395 -3.19 0 CA-C-N 114.158 -1.383 . . . . 0.0 108.787 174.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -67.97 161.64 26.12 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.286 177.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 17.3 t -55.12 117.39 3.44 Favored 'General case' 0 C--N 1.311 -1.09 0 O-C-N 124.167 0.917 . . . . 0.0 111.287 -173.448 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 113.41 -20.98 17.93 Favored Glycine 0 N--CA 1.429 -1.802 0 CA-C-N 115.066 -0.97 . . . . 0.0 111.743 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 182' ' ' TYR . . . . . 0.438 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 96.8 m-85 -104.2 157.36 17.18 Favored 'General case' 0 N--CA 1.432 -1.358 0 O-C-N 122.397 -0.472 . . . . 0.0 111.572 -177.703 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -124.17 154.35 40.21 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.9 tp -69.25 148.59 11.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 176.321 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -55.91 -59.77 4.42 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 123.842 0.857 . . . . 0.0 110.758 177.475 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -134.16 -83.6 0.2 Allowed Glycine 0 N--CA 1.437 -1.283 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.238 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 187' ' ' ASP . . . . . 0.455 ' OD2' ' HD2' ' A' ' 200' ' ' LYS . 74.2 m-20 -102.56 134.94 45.09 Favored 'General case' 0 CA--C 1.499 -0.985 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -85.33 -1.76 57.33 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.536 -178.455 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.526 ' O ' ' HG3' ' A' ' 200' ' ' LYS . 0.0 OUTLIER -134.42 143.08 47.36 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-O 121.253 0.549 . . . . 0.0 111.157 -175.878 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.457 ' HG3' ' H ' ' A' ' 200' ' ' LYS . 31.8 ttm -126.14 115.26 19.52 Favored 'General case' 0 N--CA 1.416 -2.167 0 C-N-CA 125.039 1.335 . . . . 0.0 108.07 178.232 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 8.1 m80 -94.62 154.9 17.13 Favored 'General case' 0 C--N 1.267 -3.013 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.045 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 45.0 t -98.76 142.42 30.33 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 13.7 p -119.52 -174.51 2.75 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -173.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -56.56 -22.21 31.86 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 125.317 1.447 . . . . 0.0 111.806 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -64.57 -21.01 66.58 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.338 -178.595 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 81.67 14.87 77.07 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -174.049 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -141.04 177.83 7.79 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.428 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -81.16 147.06 30.21 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.14 -176.339 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 26.6 m -82.3 -29.62 31.0 Favored 'General case' 0 N--CA 1.422 -1.831 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.117 177.129 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.526 ' HG3' ' O ' ' A' ' 189' ' ' GLU . 6.4 mmpt? -98.47 166.12 11.51 Favored 'General case' 0 N--CA 1.441 -0.881 0 C-N-CA 117.974 -1.491 . . . . 0.0 112.913 177.037 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -96.74 163.84 12.83 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 104.365 -2.457 . . . . 0.0 104.365 171.121 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 202' ' ' LYS . . . . . 0.458 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 4.9 mtpm? -66.69 125.59 90.89 Favored Pre-proline 0 C--N 1.304 -1.388 0 C-N-CA 119.862 -0.735 . . . . 0.0 112.406 178.366 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.458 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 7.3 Cg_endo -89.46 -174.08 0.86 Allowed 'Trans proline' 0 N--CA 1.42 -2.838 0 C-N-CA 121.746 1.631 . . . . 0.0 109.767 171.293 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 20.5 pttm -149.67 175.94 11.11 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.707 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.438 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 73.6 m -113.26 113.9 25.96 Favored 'General case' 0 C--N 1.283 -2.287 0 O-C-N 123.683 0.615 . . . . 0.0 109.524 -178.437 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.5 m . . . . . 0 N--CA 1.422 -1.832 0 CA-C-N 113.765 -1.561 . . . . 0.0 109.005 -174.104 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo . . . . . 0 CA--C 1.533 0.47 0 CA-C-O 121.444 0.518 . . . . 0.0 111.728 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 33.9 m -79.37 -33.31 43.0 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.21 -92.72 0.55 Allowed Glycine 1 N--CA 1.394 -4.159 0 CA-C-N 114.104 -1.407 . . . . 0.0 109.717 172.748 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 54.3 t-80 -174.8 133.54 0.5 Allowed Pre-proline 0 C--N 1.255 -3.543 0 N-CA-C 103.85 -2.648 . . . . 0.0 103.85 -175.479 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.476 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 86.9 Cg_endo -80.61 3.0 8.09 Favored 'Trans proline' 0 C--N 1.328 -0.502 0 C-N-CA 122.643 2.228 . . . . 0.0 113.899 -173.831 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.3 -166.08 17.26 Favored Glycine 0 C--N 1.287 -2.163 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 -175.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -145.1 151.25 38.2 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -177.12 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 t -120.98 130.33 24.9 Favored Pre-proline 0 N--CA 1.429 -1.503 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -78.83 -7.59 15.55 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.59 2.194 . . . . 0.0 111.908 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -96.64 19.0 13.05 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.482 -179.168 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 155.97 -119.07 0.89 Allowed Glycine 0 N--CA 1.42 -2.378 0 C-N-CA 119.941 -1.124 . . . . 0.0 111.995 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.7 t -168.6 -169.85 1.12 Allowed 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -176.121 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.408 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 45.4 p90 -143.48 163.28 33.56 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 177.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.1 m -124.61 162.83 23.27 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 106.349 -1.723 . . . . 0.0 106.349 178.299 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 15.4 mt -123.37 125.2 44.55 Favored 'General case' 0 C--N 1.279 -2.493 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.424 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 44.1 p -119.68 134.09 55.37 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 -176.184 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.31 25.72 42.62 Favored Glycine 0 C--N 1.312 -0.775 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.19 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 172.87 -35.71 0.13 Allowed Glycine 0 CA--C 1.486 -1.768 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 61.18 18.97 9.61 Favored 'General case' 0 CA--C 1.521 -0.144 0 C-N-CA 124.394 1.077 . . . . 0.0 112.2 178.701 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.54 ' O ' HG11 ' A' ' 108' ' ' VAL . 31.1 m -154.12 -167.3 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.208 -1.103 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 -178.624 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 21.3 m-85 -105.42 42.71 1.2 Allowed 'General case' 0 C--N 1.311 -1.109 0 CA-C-N 119.392 0.996 . . . . 0.0 110.139 -176.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.704 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.1 pt-20 -86.23 179.14 6.97 Favored 'General case' 0 C--O 1.205 -1.251 0 CA-C-N 114.564 -1.198 . . . . 0.0 111.733 178.166 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.1 m-85 -74.9 136.18 41.47 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 122.017 -0.427 . . . . 0.0 111.391 177.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.09 6.93 70.9 Favored Glycine 0 C--N 1.31 -0.88 0 CA-C-N 115.914 -0.585 . . . . 0.0 113.034 177.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.704 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.8 p -97.9 145.64 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.062 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.424 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 59.4 mtpt -110.25 122.84 48.61 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 177.641 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.475 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -85.5 85.37 7.43 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.369 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.489 HG12 ' HB3' ' A' ' 126' ' ' TYR . 31.8 m -83.39 107.0 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.027 0 CA-C-O 122.812 1.291 . . . . 0.0 109.558 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' TYR . . . . . 0.408 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 31.8 m-85 -73.17 134.84 44.54 Favored 'General case' 0 C--N 1.276 -2.606 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.964 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.6 t -129.81 114.55 16.07 Favored 'General case' 0 N--CA 1.408 -2.529 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 87.2 m -66.66 161.68 22.81 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 115.596 -0.729 . . . . 0.0 112.518 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 5.0 t-20 -68.85 -173.54 0.49 Allowed 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.136 -177.386 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -58.38 -52.17 66.73 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 123.109 0.564 . . . . 0.0 111.902 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.04 12.56 63.81 Favored Glycine 0 N--CA 1.437 -1.297 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.99 -177.484 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.512 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.6 m-85 -129.44 159.09 37.33 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 117.157 0.478 . . . . 0.0 110.72 -177.639 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -140.79 152.84 45.52 Favored 'General case' 0 C--N 1.288 -2.102 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -179.248 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.479 ' HG ' ' HB2' ' A' ' 125' ' ' ASN . 0.5 OUTLIER -78.29 126.36 30.68 Favored 'General case' 0 C--N 1.281 -2.401 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 179.17 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.434 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.3 OUTLIER -108.01 130.61 55.05 Favored 'General case' 0 N--CA 1.418 -2.044 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -178.791 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 114.69 -169.41 12.86 Favored Glycine 0 C--N 1.292 -1.91 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.078 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -103.82 -31.77 9.64 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-O 121.52 0.676 . . . . 0.0 109.763 -179.108 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.428 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.9 mm -89.16 120.59 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.562 -178.835 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.479 ' HB2' ' HG ' ' A' ' 120' ' ' LEU . 3.7 p-10 -125.6 9.59 7.75 Favored 'General case' 0 C--O 1.203 -1.368 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.489 ' HB3' HG12 ' A' ' 111' ' ' VAL . 22.4 p90 -140.67 168.39 19.91 Favored 'General case' 0 C--N 1.282 -2.347 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -170.359 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.488 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 48.7 mtp180 -132.5 117.9 18.59 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 169.34 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -91.89 128.33 37.69 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 118.881 -1.128 . . . . 0.0 109.969 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 47.8 t -84.62 109.74 18.21 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.183 -1.007 . . . . 0.0 109.652 175.226 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.429 ' OD2' HG22 ' A' ' 131' ' ' THR . 9.9 t70 -111.71 -164.35 0.91 Allowed 'General case' 0 C--N 1.287 -2.126 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.63 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.429 HG22 ' OD2' ' A' ' 130' ' ' ASP . 12.0 t -63.4 -21.35 66.24 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -174.567 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -82.32 -22.77 35.46 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-O 121.87 0.843 . . . . 0.0 109.551 177.717 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 118.55 -145.25 18.28 Favored Glycine 0 N--CA 1.419 -2.44 0 N-CA-C 107.227 -2.349 . . . . 0.0 107.227 -171.284 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -69.92 111.42 5.63 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 108.984 -0.746 . . . . 0.0 108.984 177.08 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 37.8 p -66.65 -57.23 7.62 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-O 121.394 0.616 . . . . 0.0 111.499 -177.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' ASN . . . . . 0.488 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 4.9 m120 -75.94 169.96 17.17 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.733 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 22.0 m-20 -106.51 -178.2 3.58 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.8 mt -64.89 123.71 84.46 Favored Pre-proline 0 C--N 1.318 -0.791 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 177.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.428 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 35.5 Cg_endo -67.97 174.06 8.38 Favored 'Trans proline' 0 C--O 1.242 0.7 0 C-N-CA 122.867 2.378 . . . . 0.0 112.971 -179.103 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.434 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 63.1 mt -96.13 139.08 19.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 -176.475 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.512 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 33.9 t -128.21 125.21 38.53 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.767 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 13.7 tp10 -120.02 155.57 32.62 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -174.352 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 8.6 p -75.41 134.51 29.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.178 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.433 ' O ' ' HB2' ' A' ' 169' ' ' HIS . 83.0 t -60.21 123.91 13.6 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.711 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.171 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 51.2 mttm -106.12 158.39 16.85 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 120.944 0.402 . . . . 0.0 110.457 -175.856 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 60.6 m -117.46 161.6 19.32 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 2.2 pp -72.47 155.38 91.24 Favored Pre-proline 0 C--N 1.307 -1.259 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.287 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -78.23 126.02 7.47 Favored 'Trans proline' 0 N--CA 1.439 -1.683 0 C-N-CA 122.294 1.996 . . . . 0.0 113.152 -175.764 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.494 HG12 ' O ' ' A' ' 150' ' ' THR . 54.3 t -69.46 135.67 27.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-N 114.041 -1.436 . . . . 0.0 110.349 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' THR . . . . . 0.494 ' O ' HG12 ' A' ' 149' ' ' VAL . 11.5 p -93.7 170.85 9.27 Favored 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 171.518 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -93.46 156.75 39.54 Favored Pre-proline 0 C--N 1.267 -2.995 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -174.373 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -74.35 152.96 44.88 Favored 'Trans proline' 0 N--CA 1.428 -2.371 0 C-N-CA 120.761 0.974 . . . . 0.0 110.905 172.284 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -54.66 -44.34 73.17 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 114.72 1.378 . . . . 0.0 114.72 -172.072 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.8 m-80 -122.71 31.41 6.08 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 122.154 0.978 . . . . 0.0 108.746 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -139.57 -161.79 8.86 Favored Glycine 0 N--CA 1.428 -1.888 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 40.6 pttt -157.64 163.14 38.55 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 -178.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 49.3 mt -89.36 132.33 34.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-O 121.005 0.431 . . . . 0.0 110.029 -177.768 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.7 t -74.85 -48.22 34.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-O 122.182 0.991 . . . . 0.0 108.393 177.18 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.493 ' CB ' ' HA ' ' A' ' 174' ' ' VAL . 6.3 m -94.73 43.06 1.09 Allowed 'General case' 0 C--N 1.289 -2.039 0 CA-C-N 114.553 -1.203 . . . . 0.0 111.388 -175.611 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 32.0 t -68.5 102.29 1.42 Allowed 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.723 -0.217 . . . . 0.0 111.076 -177.618 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 43.06 78.81 0.05 OUTLIER 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.438 1.495 . . . . 0.0 113.923 177.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 17.0 ptp -85.36 -19.1 31.94 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.468 0.651 . . . . 0.0 110.261 -177.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -77.13 148.81 78.8 Favored Pre-proline 0 C--N 1.313 -0.991 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.588 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.6 -4.18 14.89 Favored 'Trans proline' 0 N--CA 1.479 0.665 0 C-N-CA 123.21 2.606 . . . . 0.0 111.156 178.194 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' ASP . . . . . 0.417 ' C ' ' H ' ' A' ' 167' ' ' GLU . 4.0 m-20 -93.59 -29.41 15.49 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 105.122 -2.177 . . . . 0.0 105.122 178.808 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 69.32 -2.14 1.96 Allowed 'General case' 0 CA--C 1.501 -0.91 0 C-N-CA 127.287 2.235 . . . . 0.0 113.414 -177.379 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' GLU . . . . . 0.417 ' H ' ' C ' ' A' ' 165' ' ' ASP . 45.4 mt-10 -70.44 145.33 51.08 Favored 'General case' 0 C--N 1.274 -2.693 0 CA-C-N 113.53 -1.668 . . . . 0.0 107.326 172.629 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -90.74 126.32 35.96 Favored 'General case' 0 C--N 1.27 -2.881 0 N-CA-C 105.874 -1.899 . . . . 0.0 105.874 168.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 2.1 p-80 -145.46 168.72 19.87 Favored 'General case' 0 C--N 1.279 -2.47 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.675 -176.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -51.76 121.04 5.9 Favored 'General case' 0 C--O 1.242 0.695 0 O-C-N 124.31 1.006 . . . . 0.0 110.307 -176.015 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 123.49 -17.46 7.85 Favored Glycine 0 N--CA 1.427 -1.952 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.202 -175.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 25.3 mm-40 -78.67 135.34 37.17 Favored 'General case' 0 C--O 1.255 1.371 0 CA-C-O 121.716 0.77 . . . . 0.0 112.254 178.581 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -125.7 109.8 13.01 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 105.582 -2.007 . . . . 0.0 105.582 173.351 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.493 ' HA ' ' CB ' ' A' ' 159' ' ' SER . 53.6 t -107.4 122.61 61.85 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.687 -173.14 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.422 ' HG3' ' O ' ' A' ' 188' ' ' GLU . 24.0 ttp180 -111.66 161.51 16.17 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.322 177.163 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -130.73 162.47 29.39 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 124.397 1.079 . . . . 0.0 110.296 -174.145 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.79 143.9 35.1 Favored 'Isoleucine or valine' 0 CA--C 1.471 -2.093 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.45 176.692 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 76.7 m -105.68 131.52 52.95 Favored 'General case' 0 N--CA 1.395 -3.216 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 173.265 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -54.1 164.36 0.65 Allowed 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.309 177.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 26.7 t -33.71 -47.88 0.26 Allowed 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 116.771 2.137 . . . . 0.0 116.771 -168.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -104.28 15.36 50.63 Favored Glycine 0 C--N 1.288 -2.136 0 C-N-CA 120.056 -1.069 . . . . 0.0 115.025 -173.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -120.09 162.14 19.79 Favored 'General case' 0 CA--C 1.497 -1.065 0 CA-C-N 118.344 1.072 . . . . 0.0 112.424 -176.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.447 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 25.5 pttm -123.28 154.2 39.16 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.474 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 2.8 tp -72.47 145.09 12.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.613 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -82.16 -71.16 0.5 Allowed 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 120.962 -0.295 . . . . 0.0 110.481 179.187 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.0 -89.58 0.63 Allowed Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.948 -177.675 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -136.36 159.99 40.1 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 -177.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.422 ' O ' ' HG3' ' A' ' 175' ' ' ARG . 1.0 OUTLIER -103.37 3.26 34.99 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 118.999 -1.08 . . . . 0.0 112.707 -171.979 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.578 ' O ' ' HG3' ' A' ' 200' ' ' LYS . 4.3 pt-20 -149.75 143.57 25.5 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 113.572 0.953 . . . . 0.0 113.572 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.459 ' HB3' ' HB2' ' A' ' 200' ' ' LYS . 12.8 ptp -133.37 144.14 49.4 Favored 'General case' 0 C--N 1.315 -0.898 0 C-N-CA 124.146 0.978 . . . . 0.0 111.275 -176.74 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 49.4 t-80 -125.69 141.05 52.21 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.506 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 13.2 m -65.32 129.55 40.13 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 177.01 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 193' ' ' SER . . . . . 0.41 ' OG ' ' HB3' ' A' ' 199' ' ' SER . 14.5 m -104.45 167.26 9.86 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.931 177.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -48.18 -37.23 15.22 Favored 'General case' 0 N--CA 1.496 1.874 0 C-N-CA 125.529 1.532 . . . . 0.0 113.535 -176.375 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -68.74 -16.01 63.68 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -176.408 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 196' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 99.33 27.79 7.95 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.195 -1.002 . . . . 0.0 113.248 178.287 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -150.21 179.2 8.3 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 122.391 -0.476 . . . . 0.0 110.356 176.618 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -84.84 135.77 33.95 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 123.924 0.765 . . . . 0.0 110.881 -176.414 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 199' ' ' SER . . . . . 0.41 ' HB3' ' OG ' ' A' ' 193' ' ' SER . 9.5 p -73.26 -24.24 60.42 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.682 0.753 . . . . 0.0 111.136 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.578 ' HG3' ' O ' ' A' ' 189' ' ' GLU . 28.2 mmtp -94.9 179.88 5.08 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 115.026 -0.988 . . . . 0.0 112.909 -177.526 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -100.75 148.87 24.41 Favored 'General case' 0 C--N 1.292 -1.925 0 CA-C-N 113.557 -1.656 . . . . 0.0 110.735 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 202' ' ' LYS . . . . . 0.61 ' HE2' ' HD2' ' A' ' 203' ' ' PRO . 0.1 OUTLIER -75.03 107.98 4.76 Favored Pre-proline 0 C--N 1.323 -0.563 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 175.123 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.61 ' HD2' ' HE2' ' A' ' 202' ' ' LYS . 71.8 Cg_endo -88.81 174.25 4.0 Favored 'Trans proline' 0 N--CA 1.435 -1.915 0 C-N-CA 122.743 2.296 . . . . 0.0 114.898 -172.121 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -124.36 174.27 7.85 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -176.497 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 91.1 m -128.77 101.38 6.09 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 174.236 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 21.1 m . . . . . 0 C--N 1.294 -1.832 0 CA-C-N 114.226 -1.352 . . . . 0.0 108.679 -173.176 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo . . . . . 0 CA--C 1.542 0.908 0 CA-C-O 121.056 0.357 . . . . 0.0 112.008 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 61.7 m -82.67 -29.92 29.64 Favored 'General case' 0 CA--C 1.507 -0.675 0 CA-C-O 122.418 1.104 . . . . 0.0 108.228 177.022 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 113.2 -91.45 0.58 Allowed Glycine 0 N--CA 1.4 -3.737 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 173.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 46.1 t-80 -175.1 135.26 0.51 Allowed Pre-proline 0 C--N 1.257 -3.453 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 -176.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.574 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 94.0 Cg_endo -80.9 2.04 8.86 Favored 'Trans proline' 0 C--N 1.324 -0.754 0 C-N-CA 122.364 2.043 . . . . 0.0 113.156 -175.714 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 94.42 176.07 38.81 Favored Glycine 0 C--N 1.287 -2.14 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -173.093 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -144.46 159.28 43.01 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 117.444 0.622 . . . . 0.0 109.453 -176.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.7 t -120.18 131.3 24.47 Favored Pre-proline 0 C--N 1.298 -1.645 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.25 -177.256 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -71.7 -19.12 28.1 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.337 2.025 . . . . 0.0 110.561 176.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -86.58 16.0 5.06 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.755 -1.112 . . . . 0.0 110.481 -174.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 164.78 -131.94 2.55 Favored Glycine 1 N--CA 1.396 -4.001 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.591 178.339 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.3 p -154.77 175.52 13.61 Favored 'General case' 0 C--N 1.288 -2.104 0 C-N-CA 124.182 0.993 . . . . 0.0 109.896 -173.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -144.95 154.07 42.2 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 171.462 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.8 m -126.13 162.14 26.04 Favored 'General case' 0 C--N 1.275 -2.648 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 17.6 mt -112.47 135.95 52.56 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 18.8 p -129.03 126.93 40.54 Favored 'General case' 0 C--N 1.281 -2.386 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.893 -178.022 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.47 29.23 14.55 Favored Glycine 0 C--N 1.302 -1.319 0 C-N-CA 120.407 -0.902 . . . . 0.0 111.978 179.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 172.12 -36.58 0.15 Allowed Glycine 0 N--CA 1.431 -1.699 0 C-N-CA 119.964 -1.112 . . . . 0.0 112.7 178.695 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 70.73 1.94 3.93 Favored 'General case' 0 N--CA 1.511 2.582 0 CA-C-O 122.206 1.003 . . . . 0.0 110.728 -178.154 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.46 ' O ' HG11 ' A' ' 108' ' ' VAL . 34.3 m -143.94 -171.24 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -173.439 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -105.45 45.41 0.97 Allowed 'General case' 0 C--N 1.304 -1.401 0 CA-C-O 121.269 0.557 . . . . 0.0 110.216 -176.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.693 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.7 pt-20 -83.01 177.65 8.52 Favored 'General case' 0 C--O 1.213 -0.857 0 CA-C-N 114.585 -1.189 . . . . 0.0 111.607 177.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 43.6 m-85 -77.42 130.92 37.68 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-O 120.941 0.401 . . . . 0.0 110.801 176.625 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.87 2.37 58.39 Favored Glycine 0 N--CA 1.437 -1.238 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.555 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.693 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.7 p -94.77 145.89 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.285 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 19.7 mtpp -111.94 120.77 43.03 Favored 'General case' 0 C--N 1.286 -2.157 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -86.86 92.8 9.11 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 77.2 t -86.39 118.41 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.611 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -178.524 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -85.99 145.58 27.04 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.289 -178.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.9 t -144.34 110.66 5.52 Favored 'General case' 0 N--CA 1.407 -2.61 0 CA-C-O 122.208 1.004 . . . . 0.0 108.446 -179.408 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 41.7 m -71.22 158.81 35.75 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.813 -173.313 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.513 ' HB3' ' HD2' ' A' ' 118' ' ' TYR . 4.2 t-20 -60.24 171.9 0.94 Allowed 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 125.128 1.371 . . . . 0.0 111.33 -177.416 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -59.44 -41.87 90.6 Favored 'General case' 0 C--N 1.297 -1.685 0 C-N-CA 124.568 1.147 . . . . 0.0 110.017 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.433 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -86.63 19.82 26.66 Favored Glycine 0 CA--C 1.529 0.932 0 CA-C-N 115.368 -0.833 . . . . 0.0 113.739 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.583 ' HE1' HG22 ' A' ' 143' ' ' VAL . 97.9 m-85 -147.11 173.85 12.11 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 5.6 pt20 -143.68 165.44 27.64 Favored 'General case' 0 C--N 1.281 -2.403 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.3 tt -94.51 137.88 33.1 Favored 'General case' 0 C--N 1.28 -2.447 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -178.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -124.74 135.15 52.75 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 -177.815 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.66 159.5 15.39 Favored Glycine 0 N--CA 1.438 -1.191 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -78.99 -27.33 43.32 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.719 0.771 . . . . 0.0 109.085 -177.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.426 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 47.2 mm -89.76 132.78 33.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 114.814 -1.085 . . . . 0.0 108.311 -177.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -133.07 12.94 4.28 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -177.789 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' TYR . . . . . . . . . . . . . 2.8 p90 -152.65 169.21 23.26 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 -173.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.574 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 54.1 mtp180 -131.84 120.1 22.13 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 169.115 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -94.53 138.35 32.53 Favored 'General case' 0 C--N 1.287 -2.128 0 C-N-CA 118.893 -1.123 . . . . 0.0 110.565 177.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.0 t -89.69 104.35 16.92 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 118.881 -1.128 . . . . 0.0 109.61 174.115 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.444 ' OD2' HG22 ' A' ' 131' ' ' THR . 12.1 t70 -97.08 -172.22 2.39 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 176.601 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.444 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -67.25 -11.44 57.47 Favored 'General case' 0 C--N 1.293 -1.855 0 C-N-CA 123.259 0.623 . . . . 0.0 112.274 -174.643 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -94.6 -12.5 27.35 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.82 0.819 . . . . 0.0 109.412 176.558 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.15 -159.25 13.86 Favored Glycine 0 N--CA 1.431 -1.685 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -175.576 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.0 m95 -63.65 105.23 0.76 Allowed 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 120.894 0.378 . . . . 0.0 111.259 178.088 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 24.9 p -61.32 -64.89 0.8 Allowed 'General case' 0 C--O 1.241 0.652 0 C-N-CA 124.955 1.302 . . . . 0.0 112.87 -175.293 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' ASN . . . . . 0.486 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.3 m120 -71.18 173.42 7.7 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.211 -177.099 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -106.55 176.43 5.17 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 175.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 77.5 mt -69.2 125.98 92.38 Favored Pre-proline 0 C--N 1.311 -1.085 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.447 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.426 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 55.0 Cg_endo -70.68 168.69 22.04 Favored 'Trans proline' 0 C--O 1.249 1.073 0 C-N-CA 122.719 2.279 . . . . 0.0 111.145 177.092 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.6 mm -97.93 129.53 47.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 120.436 -0.506 . . . . 0.0 111.245 -173.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 99.5 m -101.93 103.34 13.98 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 171.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -95.09 152.39 18.38 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 -179.002 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.583 HG22 ' HE1' ' A' ' 118' ' ' TYR . 3.2 t -76.69 145.51 10.2 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.514 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 -175.822 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 170' ' ' PHE . 5.9 m -73.71 108.39 5.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 174.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -104.75 127.2 52.45 Favored 'General case' 0 N--CA 1.412 -2.352 0 CA-C-N 114.45 -1.25 . . . . 0.0 111.095 -174.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.56 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 3.4 m -85.44 148.5 25.96 Favored 'General case' 0 C--N 1.282 -2.356 0 CA-C-N 113.738 -1.574 . . . . 0.0 110.078 -173.444 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 59.4 mt -56.36 132.46 76.19 Favored Pre-proline 0 C--N 1.319 -0.75 0 N-CA-C 112.677 0.621 . . . . 0.0 112.677 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_endo -62.49 111.4 1.3 Allowed 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 123.499 2.799 . . . . 0.0 112.391 -178.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.3 t -79.05 139.16 18.81 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.5 p -79.02 -75.9 0.22 Allowed 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 123.868 0.73 . . . . 0.0 111.51 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 166.42 159.62 0.11 Allowed Pre-proline 0 C--O 1.24 0.59 0 C-N-CA 126.248 1.819 . . . . 0.0 107.054 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -73.73 171.81 17.07 Favored 'Trans proline' 0 CA--C 1.535 0.569 0 C-N-CA 121.519 1.479 . . . . 0.0 109.572 169.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -69.67 -62.57 1.33 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -177.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.5 m-80 -95.82 38.43 1.17 Allowed 'General case' 0 C--N 1.313 -1.01 0 O-C-N 121.562 -0.711 . . . . 0.0 110.488 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -155.1 -168.57 18.5 Favored Glycine 0 N--CA 1.426 -1.973 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.964 178.189 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -153.0 174.79 13.71 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 -178.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.408 HG12 ' CD1' ' A' ' 176' ' ' PHE . 52.5 mt -91.58 139.62 17.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -178.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.456 HG21 ' HB3' ' A' ' 175' ' ' ARG . 4.7 m -77.46 -37.17 24.55 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.576 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 178.503 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 28.6 t -115.95 79.64 1.33 Allowed 'General case' 0 N--CA 1.435 -1.199 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 32.3 m -77.98 74.2 4.54 Favored 'General case' 0 N--CA 1.43 -1.43 0 CA-C-O 121.751 0.786 . . . . 0.0 109.388 179.168 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -74.84 5.63 4.84 Favored 'General case' 0 C--O 1.211 -0.957 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.403 -175.36 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.687 ' O ' ' HA ' ' A' ' 166' ' ' ARG . 19.0 ptp -67.1 -15.27 63.61 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 124.356 1.062 . . . . 0.0 111.439 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.517 ' H ' ' HD2' ' A' ' 164' ' ' PRO . 24.4 mm-40 -125.46 -55.1 0.03 OUTLIER Pre-proline 0 N--CA 1.48 1.027 0 N-CA-C 115.687 1.736 . . . . 0.0 115.687 -178.576 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' PRO . . . . . 0.517 ' HD2' ' H ' ' A' ' 163' ' ' GLU . 11.6 Cg_endo -57.57 -27.15 75.6 Favored 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 121.431 1.42 . . . . 0.0 111.536 177.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 23.0 t0 -127.76 -9.43 5.55 Favored 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -179.55 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.687 ' HA ' ' O ' ' A' ' 162' ' ' MET 0.253 72.8 mtt-85 62.83 -42.13 0.18 Allowed 'General case' 0 C--N 1.37 1.495 0 N-CA-C 117.543 2.423 . . . . 0.0 117.543 -179.328 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 -116.84 145.04 43.82 Favored 'General case' 1 C--N 1.22 -5.024 0 CA-C-N 114.84 -1.073 . . . . 0.0 108.999 -174.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -88.9 129.35 35.62 Favored 'General case' 0 C--N 1.295 -1.761 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 176.073 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 55.2 m80 -121.61 155.81 34.3 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 -175.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.515 ' HB2' HG23 ' A' ' 144' ' ' VAL . 81.7 t80 -49.68 121.09 4.78 Favored 'General case' 0 C--O 1.244 0.798 0 O-C-N 123.686 0.616 . . . . 0.0 110.56 175.81 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 132.28 -29.65 3.29 Favored Glycine 0 N--CA 1.42 -2.41 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 -177.766 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.8 mm-40 -63.24 128.85 37.73 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 179.022 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -118.06 82.66 1.87 Allowed 'General case' 0 N--CA 1.423 -1.813 0 N-CA-C 104.32 -2.474 . . . . 0.0 104.32 170.715 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.469 HG13 ' HG3' ' A' ' 190' ' ' MET . 14.9 p -77.63 111.56 14.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.004 -169.553 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.456 ' HB3' HG21 ' A' ' 158' ' ' VAL . 40.1 ttm180 -97.74 148.29 23.5 Favored 'General case' 0 N--CA 1.416 -2.159 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.716 -177.907 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.473 ' HZ ' ' SD ' ' A' ' 190' ' ' MET . 51.2 m-85 -115.46 150.98 35.61 Favored 'General case' 0 N--CA 1.42 -1.967 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 -179.38 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.413 ' HB ' HG12 ' A' ' 158' ' ' VAL . 13.7 p -126.49 141.05 47.08 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.749 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 178.273 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.4 m -99.64 163.59 12.43 Favored 'General case' 0 C--N 1.262 -3.207 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.001 -178.666 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -66.52 172.63 3.95 Favored 'General case' 0 CA--C 1.497 -1.066 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.204 179.227 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 21.8 m -42.99 -31.95 0.59 Allowed 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 116.335 1.976 . . . . 0.0 116.335 -172.033 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -126.42 24.02 5.64 Favored Glycine 0 C--N 1.289 -2.069 0 C-N-CA 119.376 -1.393 . . . . 0.0 113.377 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -118.42 151.94 36.83 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.815 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 50.9 pttt -115.27 157.03 24.33 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 -179.68 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.577 HD13 ' HA ' ' A' ' 188' ' ' GLU . 5.0 tt -86.1 143.59 11.17 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.506 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.224 175.403 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -77.56 -68.16 0.65 Allowed 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -173.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -80.63 -109.61 0.3 Allowed Glycine 0 C--O 1.245 0.798 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.976 -177.476 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -95.93 175.8 6.36 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 176.466 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.577 ' HA ' HD13 ' A' ' 184' ' ' ILE . 10.3 pt-20 -104.28 -19.09 14.22 Favored 'General case' 0 C--N 1.28 -2.435 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -177.316 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.451 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 5.3 pt-20 -141.45 150.21 41.98 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.053 -176.184 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.473 ' SD ' ' HZ ' ' A' ' 176' ' ' PHE . 0.1 OUTLIER -117.39 125.72 51.46 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.174 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -97.26 132.7 42.76 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 176.137 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 192' ' ' CYS . . . . . 0.469 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 48.7 t -80.39 136.8 36.44 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.114 179.422 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 193' ' ' SER . . . . . 0.446 ' HB2' ' OD1' ' A' ' 195' ' ' ASP . 11.1 m -98.99 173.54 6.79 Favored 'General case' 0 N--CA 1.423 -1.792 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.643 179.427 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -67.41 -8.85 36.23 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 124.157 0.983 . . . . 0.0 112.47 -176.213 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 195' ' ' ASP . . . . . 0.446 ' OD1' ' HB2' ' A' ' 193' ' ' SER . 11.8 p-10 -94.25 4.99 53.13 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 122.223 -0.298 . . . . 0.0 111.406 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 196' ' ' GLY . . . . . 0.56 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 79.49 11.63 84.64 Favored Glycine 0 CA--C 1.526 0.73 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.486 178.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -117.92 150.76 38.68 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 122.345 -0.503 . . . . 0.0 110.3 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 198' ' ' TRP . . . . . 0.469 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 82.3 m95 -78.9 135.59 37.03 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.037 177.671 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 26.4 t -74.43 -16.91 60.86 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-O 121.19 0.519 . . . . 0.0 110.547 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.413 ' HB2' ' HA ' ' A' ' 190' ' ' MET . 24.5 mmtp -108.82 158.14 17.93 Favored 'General case' 0 CA--C 1.5 -0.978 0 O-C-N 122.123 -0.361 . . . . 0.0 110.551 178.762 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -97.58 170.44 9.02 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 123.477 0.486 . . . . 0.0 110.66 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 7.6 mmmm -69.06 115.8 35.43 Favored Pre-proline 0 CA--C 1.516 -0.354 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -178.125 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.451 ' HG2' HD11 ' A' ' 184' ' ' ILE . 78.0 Cg_endo -88.15 168.28 6.52 Favored 'Trans proline' 0 N--CA 1.446 -1.313 0 C-N-CA 122.862 2.375 . . . . 0.0 112.159 -179.355 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -115.73 165.93 12.51 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 86.6 m -114.71 109.83 18.81 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 172.779 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 30.8 m . . . . . 0 C--O 1.254 1.302 0 O-C-N 124.332 1.02 . . . . 0.0 109.444 -173.858 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo . . . . . 0 CA--C 1.535 0.543 0 CA-C-O 121.74 0.642 . . . . 0.0 110.866 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.0 m -86.65 -35.6 19.26 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 117.46 -88.53 0.46 Allowed Glycine 0 N--CA 1.404 -3.49 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 174.451 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.5 t-80 -176.67 135.9 0.42 Allowed Pre-proline 0 C--N 1.255 -3.509 0 N-CA-C 104.458 -2.423 . . . . 0.0 104.458 -175.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.436 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 91.7 Cg_endo -82.15 -0.29 10.18 Favored 'Trans proline' 0 C--N 1.329 -0.494 0 C-N-CA 121.993 1.795 . . . . 0.0 112.791 -176.197 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.33 -155.82 15.9 Favored Glycine 0 N--CA 1.42 -2.387 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -177.304 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -156.02 157.41 36.1 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 178.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.5 t -122.91 127.51 25.69 Favored Pre-proline 0 C--N 1.293 -1.875 0 CA-C-N 118.226 0.467 . . . . 0.0 110.822 -177.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -65.47 -16.01 52.16 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.772 2.315 . . . . 0.0 111.64 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -86.7 -9.37 56.11 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.335 -178.452 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 173.14 -125.29 1.13 Allowed Glycine 0 N--CA 1.433 -1.549 0 C-N-CA 118.755 -1.688 . . . . 0.0 113.907 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.8 t -148.88 -169.76 3.45 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -176.046 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -151.81 162.4 41.09 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 177.59 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -126.02 162.51 25.11 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.4 mt -113.93 138.74 49.92 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.411 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 26.5 p -132.68 137.64 47.02 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -178.123 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.2 24.25 52.32 Favored Glycine 0 C--N 1.309 -0.921 0 N-CA-C 108.556 -1.818 . . . . 0.0 108.556 -173.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 145.6 154.3 6.12 Favored Glycine 1 N--CA 1.39 -4.398 0 N-CA-C 107.334 -2.306 . . . . 0.0 107.334 -177.405 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -108.6 29.07 7.75 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 177.115 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.418 ' O ' HG21 ' A' ' 108' ' ' VAL . 35.6 m -144.31 -175.17 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 CA-C-N 114.686 -1.143 . . . . 0.0 109.068 -173.418 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -108.4 47.13 0.92 Allowed 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 121.464 0.649 . . . . 0.0 109.543 -177.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.689 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.2 pt-20 -82.41 178.13 8.39 Favored 'General case' 0 C--O 1.213 -0.828 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.248 178.293 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -76.44 132.77 39.83 Favored 'General case' 0 C--N 1.289 -2.05 0 O-C-N 122.059 -0.401 . . . . 0.0 110.149 175.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.35 5.06 63.86 Favored Glycine 0 N--CA 1.431 -1.644 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.633 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.689 HG12 ' O ' ' A' ' 105' ' ' GLU . 10.4 p -96.69 144.4 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.411 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 20.5 mtpp -112.38 118.08 34.22 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -179.407 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -82.83 92.1 7.2 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 177.726 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 75.9 t -82.73 111.68 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.618 0 C-N-CA 123.942 0.897 . . . . 0.0 109.44 -178.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -80.6 144.12 32.62 Favored 'General case' 0 C--N 1.293 -1.858 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.672 -179.225 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.1 t -145.87 112.43 5.9 Favored 'General case' 0 N--CA 1.418 -2.041 0 CA-C-N 115.048 -0.978 . . . . 0.0 108.677 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 83.0 m -70.46 163.24 27.19 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.127 -178.366 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 -68.38 174.36 4.12 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.514 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -59.96 -39.09 84.43 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 112.781 0.659 . . . . 0.0 112.781 -174.238 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -85.61 9.96 66.28 Favored Glycine 0 C--N 1.3 -1.43 0 C-N-CA 121.275 -0.488 . . . . 0.0 113.668 179.278 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -131.44 163.12 28.63 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -146.16 134.86 22.27 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.396 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 9.5 tt -70.3 138.46 51.53 Favored 'General case' 0 C--N 1.293 -1.873 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.621 -177.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.45 140.75 49.02 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.018 -172.322 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 108.37 -172.81 17.28 Favored Glycine 0 C--N 1.303 -1.252 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.272 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 30.0 mm-40 -99.68 -19.63 16.7 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 117.084 0.442 . . . . 0.0 111.18 -177.478 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.9 mm -98.59 135.99 31.32 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -178.23 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -130.52 13.3 5.47 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.355 178.523 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 11.4 p90 -145.34 169.96 17.25 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -174.166 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.496 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 46.6 mtp180 -131.01 120.83 24.04 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 169.33 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -95.04 136.61 35.15 Favored 'General case' 0 C--N 1.28 -2.418 0 C-N-CA 119.228 -0.989 . . . . 0.0 110.223 178.384 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 27.1 t -92.61 109.19 20.6 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.923 -1.111 . . . . 0.0 109.473 173.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -110.3 -167.52 1.2 Allowed 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 105.004 -2.221 . . . . 0.0 105.004 175.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 14.8 t -67.03 -13.8 62.27 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 119.056 0.844 . . . . 0.0 111.409 -177.394 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -79.21 -15.68 57.67 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 121.745 0.784 . . . . 0.0 109.646 174.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 104.19 -154.62 17.64 Favored Glycine 0 N--CA 1.431 -1.69 0 N-CA-C 107.181 -2.368 . . . . 0.0 107.181 -173.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.9 m95 -64.36 106.72 1.17 Allowed 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 118.12 0.96 . . . . 0.0 108.535 172.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.0 p -63.52 -66.01 0.6 Allowed 'General case' 0 C--O 1.253 1.269 0 C-N-CA 124.001 0.92 . . . . 0.0 111.647 -174.344 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' ASN . . . . . 0.496 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.6 m120 -67.09 167.88 11.16 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-N 114.84 -1.073 . . . . 0.0 109.036 -179.31 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -100.7 -178.97 3.94 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 176.37 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 82.1 mt -72.13 120.69 81.73 Favored Pre-proline 0 C--N 1.313 -1.0 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 175.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.29 137.81 53.1 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 122.062 1.842 . . . . 0.0 110.911 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 69.7 mt -63.88 141.55 18.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.989 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.739 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 46.2 t -131.39 140.61 49.7 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -123.72 157.33 34.19 Favored 'General case' 0 N--CA 1.408 -2.551 0 CA-C-O 121.102 0.477 . . . . 0.0 110.324 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 5.7 p -75.1 137.9 22.06 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.511 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 97.5 t -58.55 117.52 1.82 Allowed 'Isoleucine or valine' 0 C--O 1.251 1.154 0 O-C-N 123.566 0.541 . . . . 0.0 110.18 -178.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 53.9 mttp -93.09 142.44 27.29 Favored 'General case' 0 N--CA 1.425 -1.704 0 CA-C-N 115.254 -0.885 . . . . 0.0 108.78 179.272 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.0 m -109.25 151.35 26.66 Favored 'General case' 0 C--N 1.278 -2.532 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -179.074 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 64.9 mt -56.17 137.45 74.22 Favored Pre-proline 0 C--N 1.319 -0.722 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.424 ' HA ' ' CD2' ' A' ' 168' ' ' TYR . 34.8 Cg_endo -66.71 94.87 0.33 Allowed 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 123.317 2.678 . . . . 0.0 111.6 179.202 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 9.5 p -69.41 142.78 15.61 Favored 'Isoleucine or valine' 0 C--O 1.25 1.119 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.01 -177.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 11.6 p -97.59 -166.25 1.36 Allowed 'General case' 0 N--CA 1.42 -1.961 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.882 177.45 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -119.61 156.35 53.64 Favored Pre-proline 0 C--N 1.297 -1.716 0 O-C-N 122.119 -0.363 . . . . 0.0 110.714 -171.04 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.4 175.36 6.03 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 122.224 1.949 . . . . 0.0 111.446 174.442 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' GLU . . . . . 0.498 ' H ' ' CD ' ' A' ' 153' ' ' GLU . 0.0 OUTLIER -82.72 -43.57 16.66 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 120.999 0.428 . . . . 0.0 111.068 -174.801 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 154' ' ' ASN . . . . . 0.432 ' HB2' ' HB2' ' A' ' 205' ' ' CYS . 27.7 m120 -98.86 18.86 16.07 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.348 0.594 . . . . 0.0 110.488 -179.676 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -147.31 -166.34 12.41 Favored Glycine 0 N--CA 1.424 -2.118 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.664 -178.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 62.5 pttt -154.68 -179.42 7.98 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -177.822 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 50.0 mt -100.95 132.07 47.4 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.207 0 CA-C-N 117.745 0.248 . . . . 0.0 110.859 -177.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.573 HG12 HG22 ' A' ' 177' ' ' VAL . 2.3 m -78.02 -29.19 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.793 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 15.4 m -98.77 40.37 1.2 Allowed 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.954 -177.063 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 15.4 t -67.39 -27.29 66.97 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -102.16 97.76 8.02 Favored 'General case' 0 N--CA 1.422 -1.839 0 N-CA-C 105.982 -1.858 . . . . 0.0 105.982 170.054 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.422 ' SD ' ' HA ' ' A' ' 166' ' ' ARG . 0.0 OUTLIER -71.07 -60.13 2.4 Favored 'General case' 0 CA--C 1.498 -1.054 0 CA-C-O 121.794 0.807 . . . . 0.0 110.007 -172.747 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.432 ' HB2' ' HD2' ' A' ' 164' ' ' PRO . 10.0 pt-20 -161.09 165.75 16.5 Favored Pre-proline 0 C--N 1.314 -0.942 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 -175.388 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 164' ' ' PRO . . . . . 0.432 ' HD2' ' HB2' ' A' ' 163' ' ' GLU . 34.8 Cg_endo -65.41 1.88 1.84 Allowed 'Trans proline' 0 N--CA 1.49 1.322 0 C-N-CA 123.056 2.504 . . . . 0.0 114.091 178.651 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -108.05 -9.4 15.63 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-O 122.645 1.212 . . . . 0.0 108.063 178.146 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.422 ' HA ' ' SD ' ' A' ' 162' ' ' MET . 18.4 mmm180 57.61 30.37 18.7 Favored 'General case' 0 C--O 1.245 0.836 0 N-CA-C 117.287 2.328 . . . . 0.0 117.287 167.164 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 167' ' ' GLU . . . . . 0.528 ' HB2' ' CE1' ' A' ' 169' ' ' HIS . 60.1 mt-10 -126.26 170.33 11.98 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 171.087 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 168' ' ' TYR . . . . . 0.424 ' CD2' ' HA ' ' A' ' 148' ' ' PRO . 79.7 m-85 -93.84 123.34 37.13 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 174.601 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.528 ' CE1' ' HB2' ' A' ' 167' ' ' GLU . 37.4 m80 -130.95 164.62 24.92 Favored 'General case' 0 C--N 1.291 -1.953 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -178.161 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 92.5 t80 -58.07 111.61 1.24 Allowed 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 173.144 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 134.19 -23.76 3.65 Favored Glycine 0 N--CA 1.426 -1.981 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -174.405 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 81.0 mm-40 -78.53 140.51 38.54 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-O 121.339 0.59 . . . . 0.0 111.339 177.787 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -131.17 109.62 10.57 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 176.41 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 97.6 t -94.14 118.29 39.75 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.206 0 CA-C-N 115.472 -0.786 . . . . 0.0 110.578 -173.688 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.471 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 41.7 ttm180 -105.46 144.86 31.65 Favored 'General case' 0 N--CA 1.426 -1.654 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.604 176.174 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -114.24 159.27 20.33 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 123.586 0.754 . . . . 0.0 109.948 -176.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.573 HG22 HG12 ' A' ' 158' ' ' VAL . 0.0 OUTLIER -132.03 145.04 35.45 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.284 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.951 178.49 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 84.2 m -109.81 136.45 49.1 Favored 'General case' 0 C--N 1.268 -2.954 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.569 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 55.5 m-80 -60.51 164.76 4.2 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.082 178.299 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 24.1 m -48.05 108.19 0.16 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 124.799 1.312 . . . . 0.0 113.282 -175.256 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.78 -9.6 29.92 Favored Glycine 0 N--CA 1.421 -2.331 0 C-N-CA 120.543 -0.836 . . . . 0.0 112.737 177.136 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -109.36 155.49 21.16 Favored 'General case' 0 N--CA 1.423 -1.819 0 CA-C-N 117.219 0.51 . . . . 0.0 110.282 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.536 ' HE2' ' O ' ' A' ' 184' ' ' ILE . 18.7 ptmt -130.26 163.23 27.21 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.536 ' O ' ' HE2' ' A' ' 183' ' ' LYS . 3.7 tp -74.32 148.17 8.37 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.046 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -85.65 -74.29 0.41 Allowed 'General case' 0 C--N 1.289 -2.048 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.042 178.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -79.48 -97.88 0.28 Allowed Glycine 0 N--CA 1.442 -0.937 0 C-N-CA 121.043 -0.598 . . . . 0.0 112.443 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -118.19 150.92 38.6 Favored 'General case' 0 CA--C 1.484 -1.566 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.349 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -95.15 -1.92 50.91 Favored 'General case' 0 CA--C 1.499 -1.007 0 C-N-CA 120.155 -0.618 . . . . 0.0 111.049 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.481 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.5 pt-20 -146.35 146.72 30.77 Favored 'General case' 0 C--N 1.294 -1.844 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.437 -178.086 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.0 ptp -131.98 131.43 42.56 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.117 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 42.4 t-80 -102.83 138.52 39.61 Favored 'General case' 0 C--N 1.29 -1.989 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 177.457 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 192' ' ' CYS . . . . . 0.419 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 42.7 t -81.95 135.41 35.39 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.711 177.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.0 m -99.21 165.07 11.88 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 178.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -75.43 4.52 7.22 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.219 0.533 . . . . 0.0 111.621 -176.381 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -68.45 -32.51 72.58 Favored 'General case' 0 CA--C 1.507 -0.706 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.286 172.226 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 109.4 8.82 26.41 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 111.079 -0.808 . . . . 0.0 111.079 -175.562 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -142.06 173.23 11.7 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-O 120.691 0.282 . . . . 0.0 110.651 177.524 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 198' ' ' TRP . . . . . 0.419 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 66.2 m95 -82.95 148.25 27.73 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.056 -175.296 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 20.3 m -67.51 -25.27 65.76 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.654 0.74 . . . . 0.0 110.754 178.377 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.406 ' HA ' ' HD3' ' A' ' 200' ' ' LYS . 26.4 mmtp -124.63 148.88 47.65 Favored 'General case' 0 CA--C 1.487 -1.456 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.947 179.064 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -82.05 161.51 22.9 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 175.358 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 202' ' ' LYS . . . . . 0.413 ' HB2' ' HE2' ' A' ' 202' ' ' LYS . 10.5 ptmm? -63.51 137.95 97.23 Favored Pre-proline 0 N--CA 1.431 -1.396 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.6 -178.359 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.419 ' CG ' HD11 ' A' ' 184' ' ' ILE . 63.7 Cg_endo -86.89 -169.98 0.58 Allowed 'Trans proline' 0 N--CA 1.434 -1.985 0 C-N-CA 122.815 2.343 . . . . 0.0 113.919 -175.267 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 204' ' ' LYS . . . . . 0.49 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 61.2 tttp -134.42 158.61 43.44 Favored 'General case' 0 N--CA 1.424 -1.753 0 CA-C-N 113.948 -1.478 . . . . 0.0 107.669 -176.519 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.432 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 89.3 m -116.08 115.58 26.34 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 174.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.563 -175.51 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.49 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 33.0 Cg_endo . . . . . 0 CA--C 1.538 0.723 0 CA-C-O 121.107 0.378 . . . . 0.0 112.012 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.0 m -84.86 -32.62 23.12 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 121.891 0.853 . . . . 0.0 109.347 177.526 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.91 -92.05 0.53 Allowed Glycine 0 N--CA 1.405 -3.408 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 175.337 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.2 t-80 -174.44 139.45 0.69 Allowed Pre-proline 0 C--N 1.265 -3.089 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 -176.371 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.458 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 88.1 Cg_endo -85.91 -0.1 8.48 Favored 'Trans proline' 0 N--CA 1.473 0.274 0 C-N-CA 122.093 1.862 . . . . 0.0 112.947 -175.222 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.446 ' HA3' HD11 ' A' ' 138' ' ' ILE . . . 109.59 -172.64 16.19 Favored Glycine 0 C--N 1.296 -1.692 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -176.06 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -146.96 163.61 35.64 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.8 t -141.32 139.19 18.55 Favored Pre-proline 0 C--N 1.3 -1.556 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.528 -176.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -77.4 -12.7 16.99 Favored 'Trans proline' 0 CA--C 1.529 0.267 0 C-N-CA 122.696 2.264 . . . . 0.0 111.288 176.588 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -88.48 2.46 52.79 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.771 -175.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 159.59 -133.66 3.42 Favored Glycine 0 N--CA 1.41 -3.093 0 C-N-CA 120.213 -0.994 . . . . 0.0 111.859 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 14.1 p -148.85 -172.89 4.21 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -173.577 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -144.11 167.15 23.08 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 173.18 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -131.59 157.76 42.78 Favored 'General case' 0 C--N 1.279 -2.457 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 178.207 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 22.7 mt -110.9 138.84 46.79 Favored 'General case' 0 C--N 1.265 -3.099 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.286 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.2 p -129.96 131.02 45.79 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.342 -178.094 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.18 16.19 45.0 Favored Glycine 0 CA--C 1.501 -0.797 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -175.046 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 147.77 160.46 8.95 Favored Glycine 1 N--CA 1.376 -5.305 0 N-CA-C 106.212 -2.755 . . . . 0.0 106.212 -175.752 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -114.09 35.77 4.0 Favored 'General case' 0 C--N 1.25 -3.739 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 -179.579 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.445 ' O ' HG11 ' A' ' 108' ' ' VAL . 16.7 m -144.96 -173.82 0.49 Allowed 'Isoleucine or valine' 0 C--O 1.204 -1.291 0 CA-C-N 114.371 -1.286 . . . . 0.0 109.623 -175.126 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.458 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 29.5 m-85 -110.02 46.6 1.01 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 121.392 0.615 . . . . 0.0 109.554 -178.015 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.704 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.0 pt-20 -86.91 178.74 6.87 Favored 'General case' 0 C--O 1.212 -0.892 0 CA-C-N 114.909 -1.041 . . . . 0.0 111.427 178.209 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -75.54 132.26 40.6 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.223 177.44 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 90.69 10.49 63.19 Favored Glycine 0 N--CA 1.438 -1.194 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.969 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.704 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.5 p -102.29 148.07 8.2 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 176.67 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 52.4 mtpt -117.12 123.22 46.22 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 120.907 0.384 . . . . 0.0 110.532 -179.092 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.39 91.62 8.57 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.17 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.8 t -85.16 110.97 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.31 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -78.17 143.24 37.4 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 112.462 0.542 . . . . 0.0 112.462 -177.569 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.8 t -142.98 112.94 7.06 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 121.712 0.768 . . . . 0.0 109.461 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 89.8 m -65.81 162.17 19.41 Favored 'General case' 0 C--N 1.311 -1.09 0 N-CA-C 114.329 1.233 . . . . 0.0 114.329 -178.075 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -68.71 -179.97 1.57 Allowed 'General case' 0 N--CA 1.433 -1.293 0 C-N-CA 125.612 1.565 . . . . 0.0 109.892 178.358 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -59.95 -52.65 64.48 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 124.099 0.959 . . . . 0.0 111.145 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -86.81 33.1 3.81 Favored Glycine 0 C--N 1.308 -1.007 0 C-N-CA 120.426 -0.892 . . . . 0.0 113.791 -176.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.525 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 86.3 m-85 -150.54 170.43 19.13 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 123.725 0.81 . . . . 0.0 110.024 -177.142 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 5.3 pt20 -150.34 156.89 42.37 Favored 'General case' 0 N--CA 1.427 -1.617 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 176.659 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 8.2 tt -87.42 136.68 32.84 Favored 'General case' 0 C--N 1.27 -2.881 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.51 130.34 56.37 Favored 'General case' 0 N--CA 1.428 -1.54 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -176.578 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 120.97 172.14 14.45 Favored Glycine 0 N--CA 1.43 -1.733 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 -178.551 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 57.2 mm-40 -88.57 -25.43 22.5 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-O 121.256 0.55 . . . . 0.0 109.942 178.473 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.7 mm -87.44 127.78 40.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-N 114.604 -1.18 . . . . 0.0 108.528 -179.589 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -133.52 14.98 4.07 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.042 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.403 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 30.3 p90 -153.65 159.84 42.2 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-O 121.031 0.443 . . . . 0.0 110.558 -175.549 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -122.7 134.65 54.46 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 171.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -112.56 126.49 55.4 Favored 'General case' 0 C--N 1.278 -2.524 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -176.556 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 28.8 t -82.63 99.53 9.62 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 117.738 -1.585 . . . . 0.0 110.675 177.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.476 ' OD2' HG22 ' A' ' 131' ' ' THR . 14.1 t70 -95.87 -168.35 1.75 Allowed 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 175.112 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.476 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -64.65 -23.58 67.3 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -172.707 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -78.76 -28.13 44.76 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.778 0.799 . . . . 0.0 109.787 176.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 130.65 -154.35 20.66 Favored Glycine 0 N--CA 1.422 -2.257 0 N-CA-C 108.614 -1.795 . . . . 0.0 108.614 -175.07 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.402 ' CH2' HG13 ' A' ' 108' ' ' VAL . 97.5 m95 -65.06 112.47 3.37 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 117.112 0.456 . . . . 0.0 111.411 178.127 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 76.5 p -73.47 159.94 32.46 Favored 'General case' 0 C--O 1.271 2.227 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 175.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 89.3 m-20 63.4 -163.15 0.27 Allowed 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' ASP . . . . . 0.458 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 17.1 t70 -141.25 -173.24 3.69 Favored 'General case' 0 C--N 1.283 -2.291 0 N-CA-C 106.114 -1.809 . . . . 0.0 106.114 173.488 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.458 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 67.1 mt -66.32 120.53 70.89 Favored Pre-proline 0 C--N 1.266 -3.027 0 C-N-CA 124.643 1.177 . . . . 0.0 108.727 179.753 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -68.31 139.25 45.16 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 122.238 1.958 . . . . 0.0 111.126 -179.627 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 73.6 mt -62.49 125.89 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 CA-C-O 121.742 0.782 . . . . 0.0 110.732 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.525 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 43.1 t -102.48 123.95 47.16 Favored 'General case' 0 N--CA 1.406 -2.652 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 176.6 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -105.09 154.47 20.11 Favored 'General case' 0 N--CA 1.413 -2.291 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 -174.613 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 15.0 p -80.39 143.37 12.5 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.768 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.285 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.57 HG23 ' HB2' ' A' ' 170' ' ' PHE . 6.4 m -65.3 130.86 30.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 176.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.451 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 96.2 mttt -120.03 141.62 49.56 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.291 -174.741 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.4 m -108.92 160.06 16.3 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 124.199 0.937 . . . . 0.0 108.568 177.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' LEU . . . . . 0.414 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.0 mm? -76.63 149.69 81.22 Favored Pre-proline 0 N--CA 1.418 -2.074 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 2.9 Cg_exo -68.19 114.76 3.53 Favored 'Trans proline' 0 N--CA 1.442 -1.503 0 C-N-CA 122.679 2.253 . . . . 0.0 110.242 175.65 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.43 HG21 ' SD ' ' A' ' 190' ' ' MET . 41.5 t -71.36 147.19 11.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.142 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.27 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 22.8 p -71.57 -80.4 0.06 Allowed 'General case' 0 N--CA 1.435 -1.221 0 O-C-N 123.117 0.26 . . . . 0.0 111.353 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.6 161.02 0.48 Allowed Pre-proline 0 C--O 1.24 0.587 0 C-N-CA 125.607 1.563 . . . . 0.0 107.612 177.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -78.84 -158.03 0.08 OUTLIER 'Trans proline' 0 CA--C 1.547 1.17 0 C-N-CA 121.555 1.503 . . . . 0.0 111.048 171.817 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' GLU . . . . . 0.463 ' H ' ' CD ' ' A' ' 153' ' ' GLU . 0.0 OUTLIER -99.91 -52.16 3.51 Favored 'General case' 0 C--N 1.31 -1.148 0 O-C-N 121.861 -0.524 . . . . 0.0 112.271 -175.668 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -107.19 25.58 11.23 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.605 0.716 . . . . 0.0 110.141 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -151.13 -176.78 24.33 Favored Glycine 0 N--CA 1.417 -2.633 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.339 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 16.5 pttm -145.82 168.93 19.6 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 -179.334 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.465 ' HB ' ' OG ' ' A' ' 160' ' ' SER . 52.1 mt -91.6 141.84 13.9 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.463 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.5 m -90.98 -30.65 4.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 178.319 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.418 ' HA ' ' SD ' ' A' ' 162' ' ' MET . 10.4 m -98.85 36.79 1.61 Allowed 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.472 -174.075 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 160' ' ' SER . . . . . 0.465 ' OG ' ' HB ' ' A' ' 157' ' ' ILE . 29.6 m -77.64 69.91 3.94 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 117.741 0.246 . . . . 0.0 111.179 -179.649 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 46.24 79.67 0.05 Allowed 'General case' 0 C--O 1.234 0.289 0 C-N-CA 124.807 1.243 . . . . 0.0 112.278 -177.597 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.418 ' SD ' ' HA ' ' A' ' 159' ' ' SER . 4.0 mpp? -56.9 -43.65 81.57 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-O 121.617 0.723 . . . . 0.0 109.665 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.479 ' HG3' ' HG2' ' A' ' 166' ' ' ARG . 9.0 pt-20 -118.71 138.65 26.16 Favored Pre-proline 0 C--N 1.298 -1.666 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 176.668 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -77.58 16.0 1.15 Allowed 'Trans proline' 0 N--CA 1.48 0.706 0 C-N-CA 123.039 2.493 . . . . 0.0 113.444 -175.277 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -105.09 -32.7 8.58 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 121.416 0.627 . . . . 0.0 109.905 -176.751 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.479 ' HG2' ' HG3' ' A' ' 163' ' ' GLU . 12.5 ptp180 -96.7 118.98 34.32 Favored 'General case' 0 N--CA 1.391 -3.391 0 C-N-CA 118.659 -1.216 . . . . 0.0 112.986 -174.131 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 30.4 mm-40 -82.64 168.88 16.85 Favored 'General case' 0 C--N 1.276 -2.625 0 CA-C-N 113.552 -1.658 . . . . 0.0 108.534 171.267 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 168' ' ' TYR . . . . . 0.451 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 79.6 m-85 -75.58 104.96 6.37 Favored 'General case' 0 C--N 1.293 -1.868 0 CA-C-O 121.506 0.669 . . . . 0.0 109.897 -179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 20.0 m170 -106.36 160.44 15.38 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 114.538 -1.21 . . . . 0.0 108.249 -175.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.57 ' HB2' HG23 ' A' ' 144' ' ' VAL . 65.0 t80 -50.02 123.99 9.25 Favored 'General case' 0 N--CA 1.47 0.539 0 O-C-N 123.287 0.367 . . . . 0.0 110.107 172.179 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 102.43 -0.83 49.87 Favored Glycine 0 N--CA 1.428 -1.839 0 C-N-CA 119.497 -1.335 . . . . 0.0 112.919 178.758 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 30.3 mm-40 -88.13 145.02 26.15 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 175.66 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -113.47 117.77 32.64 Favored 'General case' 0 C--N 1.281 -2.409 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.511 -179.613 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 54.5 t -98.71 101.24 11.87 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 176.305 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.463 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 16.2 ttm180 -93.45 145.98 24.1 Favored 'General case' 0 N--CA 1.415 -2.219 0 CA-C-N 114.906 -1.043 . . . . 0.0 110.54 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.449 ' CD2' HG12 ' A' ' 157' ' ' ILE . 68.6 m-85 -114.89 156.15 25.52 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 14.6 p -137.01 139.84 43.76 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.212 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.6 m -95.5 138.75 32.73 Favored 'General case' 0 C--N 1.269 -2.934 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.237 -176.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 179' ' ' ASN . . . . . 0.468 ' O ' ' HD2' ' A' ' 182' ' ' TYR . 58.9 m-20 -82.72 165.42 19.95 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 -179.349 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.7 t 49.07 -142.55 0.55 Allowed 'General case' 0 CA--C 1.548 0.867 0 O-C-N 124.057 0.848 . . . . 0.0 110.805 178.265 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -93.49 32.44 5.76 Favored Glycine 0 N--CA 1.428 -1.865 0 C-N-CA 121.19 -0.529 . . . . 0.0 111.876 178.454 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 182' ' ' TYR . . . . . 0.468 ' HD2' ' O ' ' A' ' 179' ' ' ASN . 96.9 m-85 -84.23 160.49 20.78 Favored 'General case' 0 N--CA 1.443 -0.802 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.378 -179.216 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -126.54 155.03 43.03 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 2.6 tp -71.82 144.77 12.91 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 178.747 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -85.71 -65.85 0.96 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.363 179.092 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -86.26 -113.88 0.87 Allowed Glycine 0 N--CA 1.439 -1.162 0 N-CA-C 111.817 -0.513 . . . . 0.0 111.817 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -100.05 157.47 16.53 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.827 -1.545 . . . . 0.0 106.827 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -93.51 -8.7 40.7 Favored 'General case' 0 N--CA 1.433 -1.283 0 C-N-CA 119.305 -0.958 . . . . 0.0 109.401 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.43 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 2.9 pt-20 -146.23 130.41 17.48 Favored 'General case' 0 N--CA 1.43 -1.442 0 CA-C-O 121.932 0.872 . . . . 0.0 112.835 178.698 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.43 ' SD ' HG21 ' A' ' 149' ' ' VAL . 12.8 ptp -102.01 143.16 32.21 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.514 177.182 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -113.66 150.11 33.69 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 2.4 m -74.04 123.18 23.87 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 123.685 0.615 . . . . 0.0 110.795 173.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 193' ' ' SER . . . . . 0.423 ' HB2' ' OG ' ' A' ' 199' ' ' SER . 34.4 t -83.94 167.52 16.88 Favored 'General case' 0 N--CA 1.423 -1.795 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 176.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -71.81 -5.16 32.21 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 123.534 0.734 . . . . 0.0 111.351 -177.141 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -84.82 -18.87 33.6 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.412 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 88.81 27.46 24.04 Favored Glycine 0 N--CA 1.451 -0.309 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 -173.669 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -131.94 161.55 32.82 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 179.409 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -77.87 131.06 37.35 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 176.464 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 199' ' ' SER . . . . . 0.423 ' OG ' ' HB2' ' A' ' 193' ' ' SER . 15.0 m -68.04 -39.45 83.05 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-O 121.548 0.69 . . . . 0.0 110.064 -179.353 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 21.5 mmtp -96.33 150.27 20.76 Favored 'General case' 0 C--N 1.307 -1.247 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.75 177.789 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 22.9 mm-40 -86.3 166.23 15.81 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 176.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 28.3 ttmt -67.47 121.85 80.68 Favored Pre-proline 0 C--N 1.324 -0.519 0 C-N-CA 119.51 -0.876 . . . . 0.0 109.47 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.5 -174.86 2.44 Favored 'Trans proline' 0 N--CA 1.437 -1.834 0 C-N-CA 121.996 1.797 . . . . 0.0 111.759 179.183 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 204' ' ' LYS . . . . . 0.424 ' HG2' ' OE1' ' A' ' 153' ' ' GLU . 48.2 mttm -127.9 162.58 26.39 Favored 'General case' 0 C--N 1.287 -2.124 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.295 179.217 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 77.5 m -113.32 106.28 14.42 Favored 'General case' 0 C--N 1.281 -2.408 0 O-C-N 124.057 0.848 . . . . 0.0 109.137 170.433 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.5 m . . . . . 0 N--CA 1.431 -1.415 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.313 -173.759 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.447 ' HG2' ' HA ' ' A' ' 105' ' ' GLU . 33.9 Cg_endo . . . . . 0 CA--C 1.536 0.608 0 CA-C-O 121.113 0.38 . . . . 0.0 111.934 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.8 m -86.49 -33.69 20.27 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 176.085 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.74 -96.66 0.67 Allowed Glycine 0 N--CA 1.402 -3.593 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 173.035 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 56.0 t-80 -173.1 121.03 0.41 Allowed Pre-proline 0 C--N 1.263 -3.169 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -175.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.08 -30.79 13.05 Favored 'Trans proline' 0 C--O 1.219 -0.436 0 C-N-CA 121.909 1.74 . . . . 0.0 113.369 -171.666 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.22 176.13 14.34 Favored Glycine 0 CA--C 1.483 -1.936 0 N-CA-C 108.347 -1.901 . . . . 0.0 108.347 -176.468 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -134.7 -175.49 3.91 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -177.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 2.1 t -141.47 133.5 13.78 Favored Pre-proline 0 C--N 1.303 -1.43 0 CA-C-O 121.234 0.54 . . . . 0.0 112.131 -178.115 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -71.83 -18.1 28.53 Favored 'Trans proline' 0 C--O 1.238 0.513 0 C-N-CA 122.554 2.169 . . . . 0.0 111.389 175.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -86.72 -3.42 59.04 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.072 -176.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.474 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.89 -123.47 0.94 Allowed Glycine 0 N--CA 1.424 -2.157 0 C-N-CA 120.033 -1.079 . . . . 0.0 112.04 179.234 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 11.7 t -157.93 -166.48 1.98 Allowed 'General case' 0 C--N 1.285 -2.205 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -149.77 162.15 40.83 Favored 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 177.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 7.0 m -128.34 161.41 29.47 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 -178.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 25.4 mt -117.11 128.6 55.29 Favored 'General case' 0 C--N 1.266 -3.042 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.439 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 32.0 p -123.76 135.17 53.67 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -175.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 105.95 -45.33 1.32 Allowed Glycine 0 C--N 1.305 -1.19 0 N-CA-C 111.69 -0.564 . . . . 0.0 111.69 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.464 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -131.9 -16.59 1.41 Allowed Glycine 0 C--O 1.219 -0.784 0 C-N-CA 120.263 -0.97 . . . . 0.0 113.524 -177.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 64.5 12.97 7.84 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 123.657 0.783 . . . . 0.0 113.014 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.516 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.4 m -145.95 -169.4 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 -177.201 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -105.14 45.54 0.96 Allowed 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 118.692 0.678 . . . . 0.0 110.461 -178.232 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.721 ' O ' HG12 ' A' ' 108' ' ' VAL . 9.3 pt-20 -89.68 -176.18 4.9 Favored 'General case' 0 C--O 1.208 -1.094 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.884 178.231 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -79.08 138.63 38.04 Favored 'General case' 0 C--N 1.31 -1.132 0 O-C-N 121.648 -0.657 . . . . 0.0 111.119 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 85.59 4.31 85.6 Favored Glycine 0 N--CA 1.439 -1.155 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.992 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.721 HG12 ' O ' ' A' ' 105' ' ' GLU . 15.0 p -93.39 143.67 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.943 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 177.552 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.439 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 54.9 mtpt -108.08 118.38 36.6 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.368 178.669 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -83.08 91.87 7.29 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 175.575 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.421 HG12 ' CB ' ' A' ' 126' ' ' TYR . 32.3 m -91.83 117.58 35.44 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.405 0 CA-C-O 122.19 0.995 . . . . 0.0 108.735 -178.042 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 36.4 m-85 -84.42 146.71 27.51 Favored 'General case' 0 C--N 1.264 -3.143 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.918 -176.606 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.1 t -144.06 118.54 9.7 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-O 122.102 0.954 . . . . 0.0 108.919 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 3.8 m -75.12 160.93 29.87 Favored 'General case' 0 C--N 1.284 -2.25 0 CA-C-N 115.29 -0.868 . . . . 0.0 108.966 -176.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.474 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 75.4 m-20 -73.15 171.03 13.72 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 177.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -48.06 -49.37 31.72 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.553 1.141 . . . . 0.0 113.525 -176.663 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.548 ' HA2' ' CD2' ' A' ' 170' ' ' PHE . . . -80.61 8.46 54.8 Favored Glycine 0 C--N 1.309 -0.95 0 CA-C-N 116.025 -0.534 . . . . 0.0 113.37 -176.635 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.63 ' CE1' HG22 ' A' ' 143' ' ' VAL . 94.0 m-85 -130.71 150.61 51.81 Favored 'General case' 0 N--CA 1.434 -1.249 0 CA-C-O 121.501 0.667 . . . . 0.0 110.397 -178.478 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -119.08 163.5 16.92 Favored 'General case' 0 C--N 1.276 -2.614 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.47 HD11 ' HB2' ' A' ' 139' ' ' PRO . 13.4 tp -83.48 141.53 31.59 Favored 'General case' 0 C--N 1.282 -2.361 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 177.273 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.452 HD22 ' HA ' ' A' ' 121' ' ' LEU . 0.3 OUTLIER -112.72 116.94 30.92 Favored 'General case' 0 N--CA 1.408 -2.57 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.149 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.6 -169.33 13.14 Favored Glycine 0 C--N 1.276 -2.777 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.02 -174.8 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -100.53 -48.93 4.37 Favored 'General case' 0 C--N 1.287 -2.111 0 CA-C-N 114.926 -0.637 . . . . 0.0 109.304 -174.779 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.6 mm -68.0 126.67 28.27 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 CA-C-N 114.589 -1.187 . . . . 0.0 109.874 -176.085 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -122.91 3.13 9.42 Favored 'General case' 0 C--O 1.198 -1.654 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.219 176.346 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.421 ' CB ' HG12 ' A' ' 111' ' ' VAL . 20.9 p90 -138.28 161.85 35.84 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.068 -173.441 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 58.1 mtp180 -126.5 131.18 51.68 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 170.552 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -107.62 132.18 53.58 Favored 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 -177.443 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 43.1 t -81.02 104.5 11.57 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 118.02 -1.472 . . . . 0.0 110.303 176.367 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.516 ' OD1' HG22 ' A' ' 131' ' ' THR . 15.0 t70 -97.23 -169.43 1.85 Allowed 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.575 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.516 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.0 t -68.73 -17.02 63.98 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.631 0.729 . . . . 0.0 110.921 -175.614 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -87.9 -24.01 23.77 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.694 177.011 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 122.65 -154.03 16.95 Favored Glycine 0 N--CA 1.416 -2.646 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -174.335 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.431 ' CH2' HG13 ' A' ' 108' ' ' VAL . 93.9 m95 -63.34 115.1 4.27 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 55.4 p -76.66 168.87 19.32 Favored 'General case' 0 C--O 1.261 1.689 0 N-CA-C 109.287 -0.635 . . . . 0.0 109.287 176.531 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 61.53 -170.75 0.16 Allowed 'General case' 0 C--O 1.242 0.672 0 O-C-N 123.94 0.775 . . . . 0.0 111.918 177.438 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.64 171.29 7.61 Favored 'General case' 0 CA--C 1.469 -2.163 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 175.339 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.6 mt -67.57 113.4 14.0 Favored Pre-proline 0 C--N 1.297 -1.708 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 170.294 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.47 ' HB2' HD11 ' A' ' 120' ' ' LEU . 45.2 Cg_endo -66.46 131.69 27.06 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 122.052 1.835 . . . . 0.0 111.711 -176.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 69.3 mt -80.58 131.58 33.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.887 -176.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 74.3 m -103.52 149.56 24.74 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 174.191 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -125.49 168.37 13.73 Favored 'General case' 0 C--N 1.287 -2.117 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 174.226 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.63 HG22 ' CE1' ' A' ' 118' ' ' TYR . 99.6 t -67.65 143.3 15.51 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 177.028 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.446 ' HB ' ' HB2' ' A' ' 170' ' ' PHE . 72.6 t -61.5 130.7 25.99 Favored 'Isoleucine or valine' 0 C--O 1.242 0.668 0 N-CA-C 107.877 -1.156 . . . . 0.0 107.877 174.509 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.44 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 84.0 mttt -120.28 152.19 38.14 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 -175.264 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 59.0 m -118.42 160.04 22.4 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 64.4 mt -69.72 144.73 94.06 Favored Pre-proline 0 C--O 1.24 0.603 0 N-CA-C 112.282 0.475 . . . . 0.0 112.282 178.597 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -64.68 131.48 29.59 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 123.197 2.598 . . . . 0.0 112.449 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 44.2 t -90.94 136.82 23.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 179.245 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 15.3 p -73.55 -85.93 0.03 OUTLIER 'General case' 0 C--N 1.314 -0.965 0 CA-C-O 120.636 0.255 . . . . 0.0 111.55 178.565 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 177.0 150.24 0.35 Allowed Pre-proline 0 C--O 1.242 0.672 0 C-N-CA 125.627 1.571 . . . . 0.0 107.493 177.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' PRO . . . . . 0.413 ' HB3' ' O ' ' A' ' 203' ' ' PRO . 59.0 Cg_endo -77.88 171.16 17.75 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.008 1.805 . . . . 0.0 111.263 174.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -65.06 -59.96 3.55 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 114.645 1.35 . . . . 0.0 114.645 -174.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -107.52 29.88 6.78 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-O 121.845 0.831 . . . . 0.0 110.161 -178.198 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.88 178.14 22.89 Favored Glycine 0 N--CA 1.419 -2.438 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.72 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 57.5 pttt -145.79 166.14 26.79 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.178 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.429 HG23 HG13 ' A' ' 174' ' ' VAL . 56.9 mt -83.69 134.13 27.62 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 CA-C-O 121.348 0.594 . . . . 0.0 111.005 -178.455 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.5 t -68.81 -43.1 82.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.131 -0.94 . . . . 0.0 109.595 178.044 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 35.0 t -79.67 82.7 5.74 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 121.676 0.75 . . . . 0.0 109.464 176.392 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 45.3 m -94.81 149.07 21.63 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.106 178.59 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 68.44 86.12 0.13 Allowed 'General case' 0 CA--C 1.501 -0.924 0 CA-C-O 122.637 1.208 . . . . 0.0 112.418 -177.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.504 ' O ' ' HA ' ' A' ' 166' ' ' ARG . 57.2 mmm -95.37 86.64 4.56 Favored 'General case' 0 N--CA 1.406 -2.666 0 CA-C-N 114.422 -1.263 . . . . 0.0 109.47 -179.079 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.599 ' H ' ' HD2' ' A' ' 164' ' ' PRO . 8.2 mm-40 -142.68 -41.5 0.01 OUTLIER Pre-proline 0 C--N 1.289 -2.057 0 CA-C-N 113.642 -1.617 . . . . 0.0 111.966 -178.255 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 164' ' ' PRO . . . . . 0.599 ' HD2' ' H ' ' A' ' 163' ' ' GLU . 7.4 Cg_endo -56.52 -22.76 44.47 Favored 'Trans proline' 0 C--N 1.373 1.828 0 CA-C-N 120.403 1.179 . . . . 0.0 111.02 166.681 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -125.66 -20.48 4.68 Favored 'General case' 0 C--O 1.213 -0.832 0 CA-C-N 116.024 -0.534 . . . . 0.0 109.777 178.599 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.504 ' HA ' ' O ' ' A' ' 162' ' ' MET . 24.2 mtp180 58.97 -81.57 0.02 OUTLIER 'General case' 0 C--N 1.362 1.129 0 N-CA-C 114.821 1.415 . . . . 0.0 114.821 -178.252 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -97.19 133.38 41.91 Favored 'General case' 1 C--N 1.243 -4.056 0 C-N-CA 126.403 1.881 . . . . 0.0 109.235 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -61.32 110.03 1.3 Allowed 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.777 0.798 . . . . 0.0 112.79 -175.526 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.498 ' HB3' HG11 ' A' ' 143' ' ' VAL . 38.0 m80 -95.43 152.02 18.78 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 114.399 -1.273 . . . . 0.0 112.057 -178.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.548 ' CD2' ' HA2' ' A' ' 117' ' ' GLY . 0.9 OUTLIER -62.56 106.04 0.72 Allowed 'General case' 0 C--O 1.239 0.535 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 172.731 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 138.35 -12.53 3.52 Favored Glycine 0 N--CA 1.428 -1.884 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -174.681 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 31.7 mm-40 -99.34 160.74 14.06 Favored 'General case' 0 C--O 1.259 1.57 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 177.131 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -140.78 135.24 31.28 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 178.799 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.497 HG23 ' CH2' ' A' ' 198' ' ' TRP . 92.7 t -99.34 106.03 18.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.631 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.404 ' HA ' ' HA ' ' A' ' 189' ' ' GLU . 56.3 ttt180 -97.95 158.17 15.69 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 178.24 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -130.45 153.49 48.72 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -172.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.2 p -134.97 143.19 38.07 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 81.9 m -99.03 145.3 27.23 Favored 'General case' 0 C--N 1.283 -2.296 0 CA-C-N 115.607 -0.724 . . . . 0.0 112.218 -175.49 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -69.79 159.49 33.48 Favored 'General case' 0 N--CA 1.434 -1.257 0 CA-C-N 115.383 -0.826 . . . . 0.0 108.885 175.089 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 38.4 m -58.44 112.3 1.53 Allowed 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.805 -175.096 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 114.72 -13.43 20.3 Favored Glycine 0 N--CA 1.438 -1.218 0 CA-C-N 115.145 -0.934 . . . . 0.0 111.761 -178.878 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -107.83 160.96 15.33 Favored 'General case' 0 N--CA 1.433 -1.305 0 CA-C-O 120.876 0.369 . . . . 0.0 111.733 -177.635 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.533 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 22.3 pttm -131.24 152.75 50.2 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 178.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.569 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.4 tt -80.61 136.05 24.05 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.285 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.332 175.738 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -75.0 -54.95 6.29 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.078 -176.502 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -91.38 -144.61 13.22 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.519 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -77.92 157.9 29.6 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.569 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.4 pt-20 -89.91 -5.63 56.58 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.557 -174.538 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.436 ' HG2' ' HG3' ' A' ' 188' ' ' GLU . 3.6 pt-20 -147.77 142.28 26.47 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.17 0.51 . . . . 0.0 111.977 -175.465 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.472 ' CG ' ' HB ' ' A' ' 174' ' ' VAL . 14.3 ptp -120.29 134.79 55.19 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.105 -0.952 . . . . 0.0 108.537 175.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 21.9 t-80 -112.36 147.01 37.29 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 110.56 -0.163 . . . . 0.0 110.56 -175.257 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 192' ' ' CYS . . . . . 0.404 ' HB3' ' HA ' ' A' ' 170' ' ' PHE . 1.5 m -70.68 120.01 15.66 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 116.663 -0.244 . . . . 0.0 110.542 173.82 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.1 m -98.7 163.95 12.43 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.836 178.104 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -47.17 -32.66 4.55 Favored 'General case' 0 N--CA 1.498 1.926 0 C-N-CA 126.533 1.933 . . . . 0.0 114.078 -178.759 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -73.1 -17.08 61.44 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 94.99 28.35 10.08 Favored Glycine 0 C--N 1.307 -1.069 0 C-N-CA 119.917 -1.135 . . . . 0.0 112.093 -178.397 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 2.5 p90 -140.62 172.05 13.25 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 176.45 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 198' ' ' TRP . . . . . 0.497 ' CH2' HG23 ' A' ' 174' ' ' VAL . 87.5 m95 -82.22 143.3 31.47 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 123.717 0.636 . . . . 0.0 111.129 -178.505 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 5.0 m -69.13 -6.46 28.72 Favored 'General case' 0 CA--C 1.549 0.937 0 C-N-CA 124.109 0.964 . . . . 0.0 111.245 178.197 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.459 ' HB2' ' HB3' ' A' ' 190' ' ' MET . 25.9 mmmt -140.52 150.99 44.41 Favored 'General case' 0 CA--C 1.482 -1.666 0 C-N-CA 123.863 0.865 . . . . 0.0 109.467 -178.315 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -89.65 157.62 17.94 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 104.561 -2.385 . . . . 0.0 104.561 169.401 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 25.9 ttpp -60.85 114.44 10.4 Favored Pre-proline 0 C--O 1.243 0.759 0 N-CA-C 114.479 1.289 . . . . 0.0 114.479 -172.062 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.436 ' HG2' HD11 ' A' ' 184' ' ' ILE . 90.3 Cg_endo -78.89 165.58 24.21 Favored 'Trans proline' 0 N--CA 1.435 -1.936 0 C-N-CA 123.113 2.542 . . . . 0.0 109.786 176.09 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.9 pttt -139.08 162.76 34.15 Favored 'General case' 0 C--N 1.285 -2.209 0 C-N-CA 120.005 -0.678 . . . . 0.0 111.543 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.533 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 73.6 m -96.29 121.4 38.04 Favored 'General case' 0 N--CA 1.406 -2.628 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.052 179.378 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 13.4 m . . . . . 0 C--N 1.295 -1.775 0 C-N-CA 125.384 1.474 . . . . 0.0 108.181 -177.02 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo . . . . . 0 CA--C 1.538 0.703 0 CA-C-O 121.201 0.417 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 34.2 m -75.54 -37.18 60.21 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.674 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 120.41 -95.86 0.6 Allowed Glycine 0 N--CA 1.4 -3.742 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 173.608 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 64.9 t-80 -173.26 123.67 0.43 Allowed Pre-proline 0 C--N 1.253 -3.596 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 -175.281 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.496 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 81.3 Cg_endo -76.02 -3.52 13.96 Favored 'Trans proline' 0 C--O 1.213 -0.75 0 C-N-CA 122.766 2.31 . . . . 0.0 113.841 -171.519 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 112.97 -175.58 16.78 Favored Glycine 0 C--N 1.285 -2.295 0 N-CA-C 108.296 -1.921 . . . . 0.0 108.296 -176.522 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -152.92 118.52 5.31 Favored 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -176.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.1 t -91.22 133.85 30.91 Favored Pre-proline 0 C--N 1.304 -1.389 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -173.124 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -77.65 -13.73 16.17 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 122.725 2.283 . . . . 0.0 111.453 173.816 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -81.01 -10.32 59.72 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.934 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.535 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -178.41 -133.74 1.96 Allowed Glycine 0 N--CA 1.407 -3.299 0 C-N-CA 119.583 -1.294 . . . . 0.0 112.494 -178.746 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 21.0 p -143.39 -177.5 5.41 Favored 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -177.268 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 37.7 p90 -149.92 157.24 42.97 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 173.148 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.5 m -131.81 152.21 51.14 Favored 'General case' 0 C--N 1.289 -2.065 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.446 HD11 ' CE1' ' A' ' 104' ' ' PHE . 16.2 mt -106.12 131.49 53.32 Favored 'General case' 0 C--N 1.273 -2.731 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 20.5 p -123.01 137.92 54.82 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.0 -175.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 101.99 -56.96 0.66 Allowed Glycine 0 N--CA 1.436 -1.318 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -177.686 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.485 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -110.04 -30.5 3.4 Favored Glycine 0 C--O 1.21 -1.383 0 C-N-CA 120.991 -0.623 . . . . 0.0 113.121 -178.216 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 42.0 m-80 70.6 11.4 7.28 Favored 'General case' 0 N--CA 1.506 2.329 0 C-N-CA 123.879 0.872 . . . . 0.0 110.96 -177.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.503 ' O ' HG11 ' A' ' 108' ' ' VAL . 24.3 m -148.8 -175.14 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.76 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 -179.385 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.446 ' CE1' HD11 ' A' ' 98' ' ' LEU . 24.4 m-85 -99.17 42.42 1.1 Allowed 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 119.25 0.932 . . . . 0.0 111.049 -176.151 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.718 ' O ' HG12 ' A' ' 108' ' ' VAL . 9.6 pt-20 -83.01 -179.67 7.51 Favored 'General case' 0 C--O 1.208 -1.128 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.877 177.812 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -75.61 132.96 40.98 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.743 -0.598 . . . . 0.0 111.827 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.52 3.87 66.4 Favored Glycine 0 N--CA 1.435 -1.383 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.842 177.583 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.718 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.9 p -90.28 143.7 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 C-N-CA 119.993 -0.683 . . . . 0.0 109.223 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.7 mtpt -107.81 119.36 39.24 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 178.47 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.44 93.3 9.1 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 177.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 79.4 t -85.37 113.94 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.506 0 C-N-CA 123.478 0.711 . . . . 0.0 109.231 -178.007 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -87.16 134.75 33.49 Favored 'General case' 0 C--N 1.282 -2.335 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.843 179.205 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -132.01 130.12 40.99 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 10.1 m -82.34 154.43 25.28 Favored 'General case' 0 C--N 1.278 -2.535 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.659 -173.117 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.535 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 86.5 m-20 -71.26 177.24 3.98 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-N 116.765 -0.198 . . . . 0.0 111.47 179.445 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLU . . . . . 0.412 ' O ' ' HB2' ' A' ' 194' ' ' ASP . 45.6 tt0 -52.41 -54.59 30.1 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 123.845 0.858 . . . . 0.0 112.021 -174.759 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.94 34.69 3.17 Favored Glycine 0 C--N 1.308 -0.992 0 C-N-CA 120.787 -0.72 . . . . 0.0 113.171 -179.14 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -147.09 156.4 42.97 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.103 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -133.91 169.1 17.59 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.301 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.446 HD11 ' HB2' ' A' ' 139' ' ' PRO . 15.4 tp -92.2 142.66 27.24 Favored 'General case' 0 C--N 1.28 -2.42 0 C-N-CA 119.574 -0.851 . . . . 0.0 109.006 177.622 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -124.58 122.49 37.72 Favored 'General case' 0 N--CA 1.414 -2.239 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 177.077 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.5 171.6 15.63 Favored Glycine 0 C--N 1.286 -2.201 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.691 -176.608 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -95.91 -25.9 15.81 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.396 0.617 . . . . 0.0 109.808 -176.209 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.6 mm -90.2 137.36 21.69 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 23.0 p-10 -135.69 8.02 3.29 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 120.715 0.293 . . . . 0.0 110.639 179.556 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.5 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 28.8 p90 -146.29 171.35 15.11 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.067 -173.57 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.573 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 33.3 mtp180 -129.05 119.76 24.78 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 173.275 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -90.6 128.42 36.59 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.198 -1.001 . . . . 0.0 109.395 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 42.3 t -84.64 113.05 20.99 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.859 -1.136 . . . . 0.0 110.554 175.458 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -103.48 -172.33 2.09 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 10.8 t -64.19 -25.76 68.22 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.489 0.551 . . . . 0.0 112.489 -174.715 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -84.96 -23.94 28.54 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.13 0.491 . . . . 0.0 111.186 178.454 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 138.09 -158.01 24.59 Favored Glycine 0 N--CA 1.435 -1.381 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -177.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.413 ' CH2' HG13 ' A' ' 108' ' ' VAL . 93.4 m95 -68.57 113.04 5.74 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 178.441 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.2 p -64.49 -65.25 0.7 Allowed 'General case' 0 C--O 1.243 0.724 0 C-N-CA 123.049 0.54 . . . . 0.0 111.607 -176.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' ASN . . . . . 0.573 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 4.1 m120 -72.38 167.82 19.72 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' ASP . . . . . 0.401 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 10.4 t70 -104.66 -171.65 1.96 Allowed 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 176.329 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.401 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 78.8 mt -72.92 121.6 85.48 Favored Pre-proline 0 C--N 1.274 -2.686 0 C-N-CA 124.497 1.119 . . . . 0.0 108.256 179.674 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.446 ' HB2' HD11 ' A' ' 120' ' ' LEU . 53.0 Cg_endo -69.69 160.7 48.73 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 122.027 1.818 . . . . 0.0 110.763 177.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.1 mm -95.91 124.64 48.66 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 CA-C-O 121.523 0.677 . . . . 0.0 110.95 -175.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 68.2 m -100.22 120.27 39.64 Favored 'General case' 0 C--N 1.271 -2.806 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 171.174 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 16.4 tp10 -102.36 146.1 28.54 Favored 'General case' 0 C--N 1.272 -2.777 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 -178.683 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.15 136.79 25.58 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.882 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.398 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.503 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.1 m -59.77 128.44 20.71 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 CA-C-O 121.22 0.533 . . . . 0.0 110.378 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 59.8 mttm -112.68 145.92 39.59 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.56 -174.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.2 m -118.33 137.95 52.74 Favored 'General case' 0 C--N 1.277 -2.551 0 N-CA-C 106.157 -1.794 . . . . 0.0 106.157 -179.34 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 78.3 mt -62.32 143.42 95.63 Favored Pre-proline 0 C--N 1.313 -1.008 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -176.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -66.04 122.81 10.44 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.039 2.493 . . . . 0.0 110.408 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 51.7 t -76.33 149.25 6.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.941 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 6.3 p -68.95 -84.46 0.03 OUTLIER 'General case' 0 N--CA 1.439 -0.999 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.922 176.347 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 166.0 159.81 0.1 OUTLIER Pre-proline 0 CA--C 1.501 -0.94 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 177.102 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -72.28 156.11 55.36 Favored 'Trans proline' 0 N--CA 1.431 -2.167 0 CA-C-N 119.801 0.965 . . . . 0.0 109.89 171.094 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -64.92 -33.25 75.58 Favored 'General case' 0 C--N 1.28 -2.43 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -173.136 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -125.59 25.44 6.98 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-O 122.626 1.203 . . . . 0.0 109.045 -174.863 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.89 -155.8 6.59 Favored Glycine 0 N--CA 1.415 -2.738 0 CA-C-N 113.519 -1.673 . . . . 0.0 110.432 178.646 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' LYS . . . . . 0.514 ' HG3' HG23 ' A' ' 177' ' ' VAL . 24.1 pttm -157.79 174.41 15.34 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 41.7 mt -94.45 133.64 34.72 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.422 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.455 ' CG2' HG22 ' A' ' 177' ' ' VAL . 58.2 t -73.53 -48.45 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 177.737 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.9 m -79.62 85.4 5.35 Favored 'General case' 0 N--CA 1.429 -1.504 0 CA-C-N 115.019 -0.991 . . . . 0.0 109.021 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 37.0 t -121.71 -34.91 3.31 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.328 -175.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -113.25 91.17 3.55 Favored 'General case' 0 C--N 1.315 -0.92 0 O-C-N 121.924 -0.485 . . . . 0.0 110.919 -179.498 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 3.5 mpp? -112.87 -40.36 4.02 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.525 0.678 . . . . 0.0 109.994 178.102 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.409 ' HB2' ' H ' ' A' ' 166' ' ' ARG . 46.5 mt-10 -156.88 168.09 13.18 Favored Pre-proline 0 C--N 1.306 -1.317 0 N-CA-C 104.907 -2.257 . . . . 0.0 104.907 -178.147 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -75.98 -22.73 12.89 Favored 'Trans proline' 0 CA--C 1.545 1.044 0 C-N-CA 121.262 1.308 . . . . 0.0 110.78 169.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -94.77 -55.87 2.97 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -178.095 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.481 ' HD2' ' O ' ' A' ' 166' ' ' ARG 0.297 0.6 OUTLIER 37.85 75.36 0.07 Allowed 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 179.058 . . . . . . . . 4 4 . 1 . 013 nuclear build full ' A' A ' 167' ' ' GLU . . . . . 0.515 ' HB2' ' NE2' ' A' ' 169' ' ' HIS . 48.3 mt-10 -80.73 140.2 35.7 Favored 'General case' 0 N--CA 1.423 -1.782 0 N-CA-C 105.851 -1.907 . . . . 0.0 105.851 172.384 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -83.49 126.52 32.86 Favored 'General case' 0 C--N 1.271 -2.835 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.515 ' NE2' ' HB2' ' A' ' 167' ' ' GLU . 27.7 m170 -128.71 175.67 8.41 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -175.679 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.503 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 70.8 t80 -53.93 135.42 42.44 Favored 'General case' 0 C--N 1.306 -1.302 0 O-C-N 124.185 0.928 . . . . 0.0 110.052 172.777 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 101.3 -27.3 21.17 Favored Glycine 0 N--CA 1.43 -1.752 0 C-N-CA 120.126 -1.035 . . . . 0.0 112.306 178.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -68.14 147.21 52.62 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 117.28 0.54 . . . . 0.0 111.177 -178.704 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -128.44 116.13 19.26 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-N 114.457 -1.247 . . . . 0.0 107.794 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 69.5 t -100.18 110.31 26.97 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.928 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.237 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 64.1 ttt180 -97.07 155.64 16.71 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -178.777 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -128.27 161.87 28.34 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 123.669 0.787 . . . . 0.0 109.714 -174.635 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.514 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.1 OUTLIER -134.52 150.71 30.79 Favored 'Isoleucine or valine' 0 CA--C 1.474 -1.949 0 O-C-N 124.04 0.838 . . . . 0.0 109.111 178.659 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.2 m -110.83 137.5 48.41 Favored 'General case' 0 N--CA 1.395 -3.21 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 175.58 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -65.9 177.05 1.41 Allowed 'General case' 0 C--N 1.287 -2.136 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.853 -177.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.0 m -39.6 -36.11 0.37 Allowed 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 127.351 2.26 . . . . 0.0 116.823 -172.569 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -118.18 21.43 10.13 Favored Glycine 0 C--N 1.29 -2.005 0 C-N-CA 119.553 -1.308 . . . . 0.0 113.604 -178.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 182' ' ' TYR . . . . . 0.414 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 98.8 m-85 -126.92 156.36 41.59 Favored 'General case' 0 N--CA 1.436 -1.167 0 CA-C-N 117.754 0.777 . . . . 0.0 112.975 -177.17 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.453 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 25.0 pttm -124.96 153.07 43.31 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 179.105 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.3 tp -72.93 146.91 10.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.472 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -83.04 -62.23 1.65 Allowed 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -103.15 -115.72 4.1 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -85.61 154.37 21.75 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -98.11 2.53 48.72 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 -178.277 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -155.79 149.61 25.24 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -176.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.0 ptp -126.82 126.14 42.87 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 114.945 -1.025 . . . . 0.0 111.331 179.154 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -95.76 148.28 22.74 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 177.096 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 192' ' ' CYS . . . . . 0.469 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 34.5 t -95.31 135.8 36.47 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 119.803 -0.759 . . . . 0.0 111.238 178.682 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 19.5 m -84.94 162.28 19.49 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 124.281 1.033 . . . . 0.0 109.294 177.685 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 194' ' ' ASP . . . . . 0.44 ' O ' HG11 ' A' ' 144' ' ' VAL . 4.5 p-10 -72.84 -7.72 52.14 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.247 0.546 . . . . 0.0 112.29 -174.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 195' ' ' ASP . . . . . 0.439 ' HB2' ' CD2' ' A' ' 197' ' ' PHE . 2.8 m-20 -77.81 -12.59 59.99 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 174.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 89.74 39.98 6.07 Favored Glycine 0 N--CA 1.438 -1.188 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.795 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 197' ' ' PHE . . . . . 0.439 ' CD2' ' HB2' ' A' ' 195' ' ' ASP . 42.1 p90 -144.69 156.78 44.26 Favored 'General case' 0 C--N 1.318 -0.771 0 O-C-N 122.121 -0.634 . . . . 0.0 109.506 177.558 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 198' ' ' TRP . . . . . 0.469 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 81.9 m95 -76.12 128.85 35.83 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.4 m -63.07 -33.65 75.9 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.264 0.554 . . . . 0.0 110.078 -178.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.449 ' HD3' ' HA ' ' A' ' 200' ' ' LYS . 28.0 mmtp -108.68 148.35 30.56 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.85 177.803 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -87.42 178.17 6.9 Favored 'General case' 0 C--N 1.289 -2.059 0 CA-C-N 114.835 -1.075 . . . . 0.0 110.683 -178.433 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 8.7 mmmm -59.84 120.34 49.05 Favored Pre-proline 0 N--CA 1.442 -0.855 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.283 177.165 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -90.49 178.89 1.97 Allowed 'Trans proline' 0 N--CA 1.427 -2.386 0 C-N-CA 122.467 2.111 . . . . 0.0 110.179 176.115 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -128.98 165.84 20.35 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.453 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 88.9 m -122.25 104.59 9.55 Favored 'General case' 0 N--CA 1.415 -2.205 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 172.108 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--N 1.297 -1.695 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.049 -174.728 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo . . . . . 0 CA--C 1.535 0.545 0 CA-C-O 121.404 0.502 . . . . 0.0 111.396 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 39.6 m -85.22 -33.85 22.15 Favored 'General case' 0 C--N 1.315 -0.921 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 177.337 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.72 -94.07 0.58 Allowed Glycine 0 N--CA 1.398 -3.848 0 CA-C-N 114.467 -1.242 . . . . 0.0 110.005 171.495 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 11.2 t60 -175.07 123.9 0.36 Allowed Pre-proline 0 C--N 1.252 -3.649 0 N-CA-C 104.422 -2.436 . . . . 0.0 104.422 -174.657 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.431 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 74.4 Cg_endo -79.0 -23.61 7.67 Favored 'Trans proline' 0 C--N 1.329 -0.473 0 C-N-CA 122.031 1.821 . . . . 0.0 112.906 -175.193 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.1 176.77 20.45 Favored Glycine 0 CA--C 1.475 -2.459 0 N-CA-C 108.263 -1.935 . . . . 0.0 108.263 -175.159 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.1 t0 -136.87 155.15 50.16 Favored 'General case' 0 C--N 1.275 -2.663 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -176.337 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.4 t -99.57 127.2 34.84 Favored Pre-proline 0 C--N 1.294 -1.805 0 CA-C-O 120.836 0.35 . . . . 0.0 110.302 -176.796 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.9 -13.67 39.09 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.695 2.263 . . . . 0.0 112.3 -178.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.4 ' CD2' ' HB2' ' A' ' 141' ' ' CYS . 31.6 m-85 -94.62 1.48 55.6 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.72 -177.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.492 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 179.98 -129.94 1.42 Allowed Glycine 0 N--CA 1.416 -2.657 0 C-N-CA 119.234 -1.46 . . . . 0.0 112.482 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 22.0 p -149.13 -176.38 5.34 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 124.216 0.598 . . . . 0.0 110.0 -177.007 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -144.71 164.33 31.33 Favored 'General case' 0 C--N 1.313 -1.022 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 172.043 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.2 m -129.29 160.48 32.87 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 179.237 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.7 mt -117.51 125.01 50.13 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.121 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.467 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 21.7 p -117.86 137.87 52.49 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.442 -175.462 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 102.25 -47.72 1.13 Allowed Glycine 0 C--N 1.299 -1.497 0 N-CA-C 111.126 -0.789 . . . . 0.0 111.126 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.448 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -122.85 -21.17 2.68 Favored Glycine 0 N--CA 1.438 -1.168 0 C-N-CA 120.37 -0.919 . . . . 0.0 113.361 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 64.25 14.72 8.89 Favored 'General case' 0 N--CA 1.5 2.048 0 C-N-CA 123.357 0.663 . . . . 0.0 112.666 -178.541 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.514 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.0 m -152.1 -172.89 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -178.232 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -99.9 43.87 1.04 Allowed 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 119.368 0.986 . . . . 0.0 111.061 -177.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.723 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.0 pt-20 -84.64 178.21 7.77 Favored 'General case' 0 C--O 1.205 -1.268 0 CA-C-N 114.681 -1.145 . . . . 0.0 111.983 178.225 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -71.91 135.83 46.66 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 122.076 -0.39 . . . . 0.0 110.798 177.021 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.63 -7.65 71.14 Favored Glycine 0 N--CA 1.435 -1.378 0 C-N-CA 120.148 -1.025 . . . . 0.0 113.418 178.283 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.723 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -85.31 143.48 11.52 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 119.709 -0.797 . . . . 0.0 110.581 -176.274 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.467 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.8 mtpt -108.82 117.0 33.05 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.49 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -83.3 92.41 7.5 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.482 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 89.5 t -87.33 114.23 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.587 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -176.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -86.33 139.32 31.09 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-O 121.409 0.623 . . . . 0.0 111.013 -177.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -133.66 109.13 8.98 Favored 'General case' 0 N--CA 1.407 -2.587 0 CA-C-O 122.334 1.064 . . . . 0.0 109.387 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 12.8 m -67.57 153.17 44.31 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.423 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.492 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 86.8 m-20 -68.71 178.77 1.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.869 0.366 . . . . 0.0 111.558 -179.012 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -57.38 -37.21 72.3 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -176.166 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -86.61 18.16 35.67 Favored Glycine 0 C--N 1.304 -1.237 0 C-N-CA 120.68 -0.771 . . . . 0.0 113.322 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -145.79 166.34 26.19 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -175.59 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -140.55 163.9 31.61 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.579 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -87.18 120.37 28.39 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 179.357 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.6 129.89 47.8 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 -178.154 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.8 -176.51 22.18 Favored Glycine 0 C--N 1.301 -1.366 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -91.46 -38.58 12.47 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.316 0.579 . . . . 0.0 110.0 -179.052 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.5 mm -78.08 120.62 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -176.26 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -129.16 8.05 5.53 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -177.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.49 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 22.8 p90 -151.19 169.68 21.3 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 -174.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.581 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 57.8 mtp180 -129.14 122.57 30.11 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 173.472 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -94.65 127.29 40.51 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 119.557 -0.857 . . . . 0.0 110.316 178.775 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 47.4 t -83.27 113.1 20.46 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.087 175.029 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.526 ' OD1' HG22 ' A' ' 131' ' ' THR . 8.4 t70 -110.3 -164.33 0.92 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.526 HG22 ' OD1' ' A' ' 130' ' ' ASP . 5.9 t -52.65 -33.45 46.98 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 -172.84 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -102.26 -10.39 19.59 Favored 'General case' 0 C--N 1.316 -0.875 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.83 -177.349 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 133.32 -153.96 21.01 Favored Glycine 0 N--CA 1.421 -2.346 0 N-CA-C 110.781 -0.927 . . . . 0.0 110.781 -178.062 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.409 ' CH2' HG13 ' A' ' 108' ' ' VAL . 86.2 m95 -67.65 119.93 13.21 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 122.527 0.331 . . . . 0.0 110.228 -178.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.0 p -71.58 -63.76 1.06 Allowed 'General case' 0 C--O 1.251 1.17 0 CA-C-O 121.544 0.687 . . . . 0.0 111.1 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' ASN . . . . . 0.581 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.8 m120 -69.99 164.36 24.1 Favored 'General case' 0 CA--C 1.489 -1.383 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.828 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' ASP . . . . . 0.403 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 12.1 t70 -103.35 -171.84 2.01 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 176.042 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.403 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 64.1 mt -69.48 120.68 78.7 Favored Pre-proline 0 C--N 1.28 -2.427 0 C-N-CA 124.439 1.096 . . . . 0.0 109.625 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -69.77 172.76 12.06 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.558 2.172 . . . . 0.0 112.485 178.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 49.1 mm -109.36 130.5 62.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.051 -173.245 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.4 ' HB2' ' CD2' ' A' ' 93' ' ' PHE . 89.1 m -109.06 114.34 28.0 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 174.354 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -103.09 157.23 17.14 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 176.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 13.6 p -70.62 145.43 12.79 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.069 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.617 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.4 m -72.35 136.28 25.99 Favored 'Isoleucine or valine' 0 C--O 1.248 1.015 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 175.841 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 64.4 mmtt -105.8 151.82 24.0 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -174.735 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 39.6 m -114.91 145.77 41.85 Favored 'General case' 0 C--N 1.28 -2.43 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 176.84 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.75 145.89 91.44 Favored Pre-proline 0 N--CA 1.418 -2.05 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -179.454 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -69.95 125.1 11.66 Favored 'Trans proline' 0 N--CA 1.444 -1.431 0 C-N-CA 122.885 2.39 . . . . 0.0 111.532 -178.546 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.8 t -97.98 137.82 24.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 13.5 p -76.74 -81.7 0.08 Allowed 'General case' 0 C--N 1.314 -0.962 0 O-C-N 123.126 0.267 . . . . 0.0 110.96 177.028 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.07 156.22 0.24 Allowed Pre-proline 0 C--O 1.24 0.566 0 C-N-CA 125.403 1.481 . . . . 0.0 107.895 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' PRO . . . . . 0.479 ' HG2' ' HA3' ' A' ' 155' ' ' GLY . 37.1 Cg_endo -71.02 162.1 43.84 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 121.966 1.777 . . . . 0.0 110.17 172.475 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -55.51 -44.99 77.15 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -174.733 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 154' ' ' ASN . . . . . 0.413 ' HB2' ' HB2' ' A' ' 205' ' ' CYS . 25.1 m120 -116.45 28.0 8.85 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.242 0.544 . . . . 0.0 109.73 -177.333 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 155' ' ' GLY . . . . . 0.479 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -143.32 -174.6 15.72 Favored Glycine 0 N--CA 1.439 -1.162 0 C-N-CA 120.181 -1.009 . . . . 0.0 112.661 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 31.7 pttt -152.9 161.02 43.06 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 123.193 0.597 . . . . 0.0 109.638 -176.362 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.463 HG23 HG13 ' A' ' 174' ' ' VAL . 58.2 mt -82.44 134.11 27.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 O-C-N 123.27 0.356 . . . . 0.0 110.773 -179.052 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.501 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.7 m -85.69 -32.14 6.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 CA-C-O 121.216 0.531 . . . . 0.0 110.585 -178.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 8.8 t -83.98 102.14 12.23 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.431 -172.273 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 45.2 m 65.09 -174.9 0.18 Allowed 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 123.98 0.912 . . . . 0.0 110.948 -176.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -108.19 167.6 9.89 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.272 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 34.5 tpp -80.75 90.41 5.82 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-O 122.045 0.926 . . . . 0.0 110.214 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.433 ' C ' ' H ' ' A' ' 165' ' ' ASP . 34.4 mt-10 -128.13 152.0 77.0 Favored Pre-proline 0 C--N 1.298 -1.637 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 -178.705 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -77.72 13.76 1.6 Allowed 'Trans proline' 0 N--CA 1.479 0.64 0 C-N-CA 122.993 2.462 . . . . 0.0 110.378 177.213 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' ASP . . . . . 0.436 ' OD2' ' HD2' ' A' ' 166' ' ' ARG . 10.2 t70 -98.67 -39.04 8.87 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 114.364 -1.289 . . . . 0.0 108.877 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.436 ' HD2' ' OD2' ' A' ' 165' ' ' ASP . 18.6 mmm180 -78.19 103.03 7.88 Favored 'General case' 0 N--CA 1.42 -1.967 0 CA-C-N 114.932 -1.031 . . . . 0.0 111.195 -176.172 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -83.91 160.99 20.98 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 173.233 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 168' ' ' TYR . . . . . 0.461 ' HB3' ' HB2' ' A' ' 146' ' ' CYS . 97.5 m-85 -109.4 130.3 55.5 Favored 'General case' 0 C--N 1.284 -2.271 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 173.504 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 21.3 m80 -130.31 166.44 20.38 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -175.187 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.617 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 76.7 t80 -54.36 124.2 15.25 Favored 'General case' 0 C--O 1.247 0.945 0 C-N-CA 120.651 -0.42 . . . . 0.0 109.909 174.288 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 124.59 -26.43 5.71 Favored Glycine 0 N--CA 1.423 -2.218 0 C-N-CA 120.441 -0.885 . . . . 0.0 111.391 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 16.0 mm100 -59.08 131.56 51.39 Favored 'General case' 0 C--O 1.248 1.013 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -179.23 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -119.33 96.1 5.07 Favored 'General case' 0 N--CA 1.424 -1.735 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.463 HG13 HG23 ' A' ' 157' ' ' ILE . 73.4 t -88.89 101.6 12.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.25 -176.102 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.501 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 40.5 ttm180 -91.85 146.35 23.82 Favored 'General case' 0 N--CA 1.417 -2.084 0 CA-C-N 114.557 -1.201 . . . . 0.0 109.422 176.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -116.5 150.44 37.9 Favored 'General case' 0 N--CA 1.416 -2.135 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.396 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.6 p -129.84 142.45 43.83 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 177.836 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 178' ' ' CYS . . . . . 0.413 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 70.3 m -94.1 148.41 22.2 Favored 'General case' 0 C--N 1.264 -3.114 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.344 -177.238 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -62.33 158.15 18.06 Favored 'General case' 0 CA--C 1.495 -1.166 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.578 178.49 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.2 m -42.11 103.92 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.22 0 O-C-N 125.173 1.545 . . . . 0.0 113.891 -174.589 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.02 -10.56 31.78 Favored Glycine 0 N--CA 1.432 -1.625 0 C-N-CA 120.469 -0.872 . . . . 0.0 113.731 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 182' ' ' TYR . . . . . 0.413 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 77.4 m-85 -97.63 160.38 14.35 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 117.809 0.805 . . . . 0.0 111.611 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.21 148.46 52.46 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.44 HD13 ' HA ' ' A' ' 188' ' ' GLU . 2.4 tt -79.77 144.99 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.148 0 CA-C-O 121.428 0.632 . . . . 0.0 110.817 -175.492 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -81.6 -65.27 1.03 Allowed 'General case' 0 C--N 1.294 -1.822 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.915 -176.534 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -78.52 -110.21 0.2 Allowed Glycine 0 C--N 1.309 -0.932 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.978 -178.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -106.59 179.46 4.26 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.329 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.44 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.7 pt-20 -100.16 -11.9 20.06 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 118.974 0.806 . . . . 0.0 110.518 -174.288 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -152.61 164.38 37.79 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -173.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.2 ptp -133.79 136.89 44.8 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.079 176.176 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 44.6 t-80 -112.69 147.81 36.01 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 116.63 -0.259 . . . . 0.0 110.496 -178.104 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 61.1 m -75.08 121.2 21.67 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 123.067 0.547 . . . . 0.0 112.097 175.317 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 48.8 m -88.54 -175.23 4.88 Favored 'General case' 0 C--N 1.31 -1.136 0 C-N-CA 123.394 0.678 . . . . 0.0 110.205 174.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -51.81 -34.89 42.16 Favored 'General case' 0 N--CA 1.5 2.04 0 C-N-CA 125.073 1.349 . . . . 0.0 113.05 -178.504 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -78.06 -4.02 45.13 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 123.347 0.659 . . . . 0.0 112.608 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 196' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 69.25 28.42 72.71 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 108.051 -2.019 . . . . 0.0 108.051 -168.191 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -105.72 148.22 27.68 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-N 114.177 -1.012 . . . . 0.0 108.447 -176.16 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 83.6 m95 -81.97 123.67 29.08 Favored 'General case' 0 C--N 1.292 -1.906 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 10.9 m -62.4 -29.01 70.18 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 122.989 0.516 . . . . 0.0 111.837 -178.548 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -118.93 155.75 30.76 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 107.078 -1.452 . . . . 0.0 107.078 -178.103 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -95.3 164.06 13.0 Favored 'General case' 0 C--N 1.288 -2.105 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 176.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 54.6 mtpt -54.42 115.87 9.48 Favored Pre-proline 0 C--N 1.319 -0.76 0 O-C-N 123.815 0.697 . . . . 0.0 112.586 -176.423 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.475 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 5.7 Cg_exo -78.06 162.56 28.86 Favored 'Trans proline' 0 N--CA 1.432 -2.093 0 C-N-CA 121.813 1.675 . . . . 0.0 111.231 177.456 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 50.7 tttp -109.0 157.94 18.19 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 -177.674 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.413 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 95.0 m -114.33 120.96 42.16 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 175.167 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.9 m . . . . . 0 C--N 1.307 -1.271 0 O-C-N 124.284 0.99 . . . . 0.0 109.318 -177.223 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.511 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 19.3 Cg_endo . . . . . 0 CA--C 1.532 0.412 0 CA-C-O 120.648 0.186 . . . . 0.0 112.308 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' CYS . . . . . 0.455 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 26.8 m -83.85 -26.55 29.38 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-O 121.465 0.65 . . . . 0.0 110.245 176.323 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.8 -86.65 0.44 Allowed Glycine 0 CA--C 1.452 -3.888 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 170.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.2 t60 -175.03 131.41 0.44 Allowed Pre-proline 0 C--N 1.26 -3.32 0 N-CA-C 104.81 -2.292 . . . . 0.0 104.81 -174.349 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -82.0 6.42 5.7 Favored 'Trans proline' 0 N--CA 1.484 0.963 0 C-N-CA 122.627 2.218 . . . . 0.0 114.641 -172.014 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 108.89 -167.19 12.91 Favored Glycine 0 C--N 1.289 -2.046 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -176.75 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -154.97 155.47 34.27 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 1.7 t -129.51 129.54 23.21 Favored Pre-proline 0 C--N 1.297 -1.675 0 CA-C-O 120.757 0.313 . . . . 0.0 110.561 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.49 -10.05 18.79 Favored 'Trans proline' 0 C--O 1.223 -0.258 0 C-N-CA 122.523 2.148 . . . . 0.0 111.451 -179.588 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.483 ' HB2' ' HB2' ' A' ' 141' ' ' CYS . 28.4 m-85 -96.78 -52.11 4.03 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 122.213 1.006 . . . . 0.0 108.656 -179.478 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -106.49 -155.17 20.82 Favored Glycine 0 N--CA 1.401 -3.642 0 C-N-CA 119.78 -1.2 . . . . 0.0 112.502 -176.181 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.8 p -146.48 177.38 9.09 Favored 'General case' 0 C--N 1.261 -3.281 0 C-N-CA 125.226 1.411 . . . . 0.0 107.304 178.189 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.412 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 44.3 p90 -142.47 164.44 30.12 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.79 174.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -129.12 159.16 36.88 Favored 'General case' 0 C--N 1.284 -2.277 0 N-CA-C 106.641 -1.614 . . . . 0.0 106.641 -179.682 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.3 mt -118.25 119.09 33.63 Favored 'General case' 0 C--N 1.274 -2.713 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 177.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.497 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 37.3 p -116.49 136.85 52.64 Favored 'General case' 0 C--N 1.273 -2.759 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.551 -174.676 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.0 17.99 56.8 Favored Glycine 0 N--CA 1.429 -1.792 0 C-N-CA 119.593 -1.289 . . . . 0.0 111.107 -178.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 173.72 -31.85 0.1 Allowed Glycine 0 N--CA 1.436 -1.36 0 C-N-CA 119.229 -1.462 . . . . 0.0 113.596 -179.206 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 6.6 t30 66.28 9.73 6.61 Favored 'General case' 0 CA--C 1.556 1.175 0 CA-C-O 122.09 0.948 . . . . 0.0 111.728 -178.835 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.506 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.3 m -142.75 -168.92 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.459 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 -177.46 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -108.51 36.54 2.79 Favored 'General case' 0 C--O 1.25 1.092 0 CA-C-N 119.29 0.95 . . . . 0.0 110.796 -176.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.722 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.3 pt-20 -79.0 177.68 8.61 Favored 'General case' 0 C--O 1.195 -1.765 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.159 179.107 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' TYR . . . . . 0.462 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 48.2 m-85 -72.98 130.76 41.08 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 120.858 0.361 . . . . 0.0 111.641 178.771 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.42 -0.55 63.61 Favored Glycine 0 N--CA 1.437 -1.248 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.997 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.722 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.4 p -90.28 145.67 7.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.497 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 16.4 mtpp -109.75 127.18 54.45 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.745 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -88.76 85.19 6.72 Favored 'General case' 0 C--N 1.284 -2.272 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 175.467 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.484 HG12 ' CB ' ' A' ' 126' ' ' TYR . 29.4 m -87.07 114.64 26.52 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 CA-C-O 122.568 1.175 . . . . 0.0 109.461 -179.108 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' TYR . . . . . 0.412 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 31.4 m-85 -77.99 144.86 36.37 Favored 'General case' 0 C--N 1.27 -2.853 0 CA-C-N 115.098 -0.955 . . . . 0.0 110.833 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.2 t -142.02 118.08 10.64 Favored 'General case' 0 N--CA 1.413 -2.29 0 N-CA-C 107.108 -1.442 . . . . 0.0 107.108 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 38.0 m -75.34 158.51 32.69 Favored 'General case' 0 C--N 1.279 -2.479 0 O-C-N 121.992 -0.443 . . . . 0.0 110.651 -175.459 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -77.65 -179.09 5.68 Favored 'General case' 0 CA--C 1.495 -1.151 0 C-N-CA 119.993 -0.683 . . . . 0.0 111.05 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -52.12 -52.73 49.71 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 124.099 0.874 . . . . 0.0 112.323 -176.306 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.481 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -83.94 25.29 5.41 Favored Glycine 0 C--N 1.304 -1.219 0 C-N-CA 120.625 -0.798 . . . . 0.0 113.831 -178.29 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.656 ' HE1' HG22 ' A' ' 143' ' ' VAL . 87.6 m-85 -144.31 152.01 40.16 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 122.268 -0.548 . . . . 0.0 110.08 -176.665 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -126.78 162.05 26.76 Favored 'General case' 0 C--N 1.276 -2.613 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 -179.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 3.1 tt -93.06 128.24 38.88 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.07 -178.64 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -111.5 126.03 54.53 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 -177.364 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 113.52 164.79 15.76 Favored Glycine 0 C--N 1.286 -2.228 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -175.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 13.6 mm-40 -91.97 -31.48 15.6 Favored 'General case' 0 C--N 1.3 -1.543 0 CA-C-O 121.987 0.899 . . . . 0.0 109.382 -177.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.522 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.0 mm -82.57 127.47 39.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 178.328 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.42 2.8 9.69 Favored 'General case' 0 C--O 1.204 -1.339 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -177.221 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.484 ' CB ' HG12 ' A' ' 111' ' ' VAL . 10.8 p90 -143.54 164.08 31.36 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 120.506 -0.478 . . . . 0.0 109.817 -170.323 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -131.12 132.27 44.7 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 171.544 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -106.0 133.23 51.05 Favored 'General case' 0 C--N 1.284 -2.257 0 C-N-CA 118.533 -1.267 . . . . 0.0 110.773 -178.339 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' CYS . . . . . 0.462 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 39.7 t -75.72 96.88 3.7 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.29 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.439 ' OD1' HG22 ' A' ' 131' ' ' THR . 8.0 t70 -94.26 -175.05 3.54 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 178.314 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.454 ' HA ' ' CE1' ' A' ' 106' ' ' TYR . 13.9 t -68.28 -23.4 64.75 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-O 121.898 0.856 . . . . 0.0 109.889 -176.56 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -77.59 -39.06 46.87 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.613 177.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.455 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 145.21 -159.47 27.89 Favored Glycine 0 N--CA 1.421 -2.355 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -174.645 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 98.1 m95 -67.98 122.48 18.31 Favored 'General case' 0 C--N 1.309 -1.193 0 CA-C-N 117.639 0.719 . . . . 0.0 110.517 178.582 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 76.2 p -76.63 170.76 15.83 Favored 'General case' 0 C--O 1.265 1.885 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.132 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 74.4 m-20 61.91 -165.34 0.23 Allowed 'General case' 0 C--O 1.246 0.894 0 O-C-N 123.951 0.782 . . . . 0.0 111.474 174.689 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -122.53 168.83 11.66 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 80.6 mt -67.54 119.63 67.14 Favored Pre-proline 0 C--N 1.307 -1.252 0 O-C-N 123.247 0.342 . . . . 0.0 110.089 176.456 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.522 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 33.9 Cg_endo -65.99 150.09 85.69 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 122.733 2.288 . . . . 0.0 110.527 177.317 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 61.8 mt -96.46 130.27 45.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-O 121.106 0.479 . . . . 0.0 111.034 -174.024 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.483 ' HB2' ' HB2' ' A' ' 93' ' ' PHE . 93.1 m -99.38 107.69 20.01 Favored 'General case' 0 C--N 1.284 -2.273 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 172.08 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -91.96 154.41 18.83 Favored 'General case' 0 N--CA 1.412 -2.362 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 177.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.656 HG22 ' HE1' ' A' ' 118' ' ' TYR . 4.5 t -80.02 141.36 15.39 Favored 'Isoleucine or valine' 0 C--N 1.256 -3.494 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -175.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.555 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 15.9 m -68.4 100.12 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-O 121.85 0.833 . . . . 0.0 109.987 -178.837 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.448 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 94.9 mttt -100.69 136.56 40.36 Favored 'General case' 0 N--CA 1.421 -1.879 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.053 -174.841 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 60.6 m -98.96 167.87 10.46 Favored 'General case' 0 C--N 1.291 -1.955 0 CA-C-N 114.321 -1.309 . . . . 0.0 109.056 -177.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 2.2 pp -79.73 154.92 75.96 Favored Pre-proline 0 N--CA 1.427 -1.612 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 178.239 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -79.64 118.82 3.92 Favored 'Trans proline' 0 N--CA 1.441 -1.564 0 C-N-CA 122.46 2.106 . . . . 0.0 111.719 -177.051 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.0 t -67.65 144.61 14.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.733 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.1 p -77.17 -83.54 0.07 Allowed 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 119.644 -0.217 . . . . 0.0 111.496 176.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 173.51 162.69 0.3 Allowed Pre-proline 0 N--CA 1.473 0.715 0 C-N-CA 125.171 1.388 . . . . 0.0 108.361 178.162 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' PRO . . . . . 0.46 ' HB3' ' HA ' ' A' ' 204' ' ' LYS . 72.6 Cg_endo -84.04 166.46 12.9 Favored 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 122.361 2.041 . . . . 0.0 110.997 170.878 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -72.11 -62.56 1.39 Allowed 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 114.099 1.148 . . . . 0.0 114.099 -176.333 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 154' ' ' ASN . . . . . 0.422 ' HB2' ' O ' ' A' ' 205' ' ' CYS . 43.7 m-80 -97.24 31.35 2.49 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 121.943 0.878 . . . . 0.0 110.075 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -150.87 -169.99 17.36 Favored Glycine 0 N--CA 1.422 -2.274 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.59 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' LYS . . . . . 0.458 ' HG3' HG23 ' A' ' 177' ' ' VAL . 21.9 pttm -151.84 171.62 17.47 Favored 'General case' 0 C--N 1.289 -2.034 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.249 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 54.3 mt -90.87 135.09 27.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-O 120.951 0.405 . . . . 0.0 111.415 -178.788 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.474 ' CG2' HG22 ' A' ' 177' ' ' VAL . 57.0 t -70.83 -50.03 46.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 C-N-CA 124.214 1.006 . . . . 0.0 108.468 177.065 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 1.7 m -82.52 27.86 0.49 Allowed 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 124.558 1.143 . . . . 0.0 111.018 -176.513 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 7.2 p -68.5 -69.49 0.32 Allowed 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -174.11 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -94.59 77.83 3.78 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.923 0.868 . . . . 0.0 113.216 -174.222 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.522 ' O ' ' HG2' ' A' ' 163' ' ' GLU . 62.6 mtm -90.09 -55.51 3.58 Favored 'General case' 0 C--N 1.293 -1.887 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 170.448 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.522 ' HG2' ' O ' ' A' ' 162' ' ' MET . 10.5 mm-40 -175.36 145.66 0.86 Allowed Pre-proline 0 CA--C 1.503 -0.855 0 C-N-CA 129.412 3.085 . . . . 0.0 104.935 175.316 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -84.29 -7.3 10.01 Favored 'Trans proline' 0 C--N 1.316 -1.137 0 C-N-CA 122.436 2.091 . . . . 0.0 111.787 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -97.62 -19.47 18.28 Favored 'General case' 0 CA--C 1.47 -2.117 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.261 -176.034 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -81.72 126.94 32.4 Favored 'General case' 0 N--CA 1.398 -3.036 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.204 -179.635 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -86.91 143.55 27.36 Favored 'General case' 0 C--N 1.272 -2.791 0 CA-C-N 114.783 -1.099 . . . . 0.0 109.279 -179.213 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 168' ' ' TYR . . . . . 0.448 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 74.4 m-85 -67.83 136.91 54.86 Favored 'General case' 0 C--O 1.2 -1.516 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.486 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 44.6 p-80 -153.21 171.44 18.51 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-O 118.675 -0.678 . . . . 0.0 109.19 -172.641 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.555 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 62.0 t80 -50.77 133.2 26.39 Favored 'General case' 0 C--O 1.239 0.528 0 O-C-N 123.732 0.645 . . . . 0.0 110.512 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 106.06 -26.99 18.91 Favored Glycine 0 N--CA 1.434 -1.48 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -177.369 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 172' ' ' GLN . . . . . 0.407 ' HA ' HE21 ' A' ' 172' ' ' GLN . 0.0 OUTLIER -76.12 140.43 41.8 Favored 'General case' 0 CA--C 1.503 -0.838 0 CA-C-O 121.629 0.728 . . . . 0.0 110.413 178.727 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.426 ' HB2' ' CD2' ' A' ' 191' ' ' HIS . . . -129.62 119.91 24.37 Favored 'General case' 0 C--N 1.279 -2.495 0 CA-C-N 114.139 -1.391 . . . . 0.0 107.315 176.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.495 HG23 ' CH2' ' A' ' 198' ' ' TRP . 68.1 t -93.65 108.38 20.45 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.992 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 176.021 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.451 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 76.2 ttt180 -103.24 156.29 17.82 Favored 'General case' 0 N--CA 1.409 -2.479 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -127.96 153.15 47.04 Favored 'General case' 0 C--N 1.291 -1.972 0 C-N-CA 123.179 0.591 . . . . 0.0 110.158 -170.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.474 HG22 ' CG2' ' A' ' 158' ' ' VAL . 0.1 OUTLIER -127.91 141.15 47.22 Favored 'Isoleucine or valine' 0 CA--C 1.467 -2.212 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.262 179.04 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 72.1 m -95.96 132.75 40.96 Favored 'General case' 0 N--CA 1.389 -3.487 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.08 176.238 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 -67.12 170.03 7.59 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 113.985 -1.462 . . . . 0.0 109.711 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.3 m -49.84 109.47 0.29 Allowed 'General case' 0 C--N 1.297 -1.7 0 O-C-N 124.394 1.059 . . . . 0.0 113.463 -174.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 97.16 18.21 29.68 Favored Glycine 0 N--CA 1.433 -1.527 0 CA-C-N 115.234 -0.894 . . . . 0.0 114.633 174.735 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -128.53 164.9 21.8 Favored 'General case' 0 C--O 1.241 0.645 0 CA-C-N 118.457 1.128 . . . . 0.0 112.572 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.503 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 56.7 pttt -122.12 154.84 36.86 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 106.741 -1.578 . . . . 0.0 106.741 178.77 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 5.4 tp -72.67 145.9 11.5 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 174.453 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -70.4 -69.73 0.34 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 120.983 0.421 . . . . 0.0 110.108 -177.066 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -109.65 -82.76 1.39 Allowed Glycine 0 N--CA 1.431 -1.66 0 C-N-CA 120.24 -0.981 . . . . 0.0 111.851 178.824 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -113.99 151.81 31.85 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -177.586 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.451 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 8.9 pt-20 -109.82 9.71 24.64 Favored 'General case' 0 C--N 1.3 -1.587 0 CA-C-N 118.448 0.567 . . . . 0.0 110.708 -179.333 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -148.73 130.35 14.96 Favored 'General case' 0 C--N 1.295 -1.788 0 CA-C-O 122.012 0.911 . . . . 0.0 113.315 -178.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.424 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 16.5 ptp -121.46 144.72 48.53 Favored 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.21 178.003 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 191' ' ' HIS . . . . . 0.426 ' CD2' ' HB2' ' A' ' 173' ' ' ALA . 34.5 m80 -117.25 147.77 42.24 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 120.469 0.176 . . . . 0.0 111.032 -179.411 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 4.9 m -76.17 115.92 16.37 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.475 172.61 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 193' ' ' SER . . . . . 0.516 ' HB2' ' OD1' ' A' ' 195' ' ' ASP . 13.0 m -85.55 177.19 7.83 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.458 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -76.85 3.43 12.0 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 121.348 0.595 . . . . 0.0 112.272 -176.254 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 195' ' ' ASP . . . . . 0.516 ' OD1' ' HB2' ' A' ' 193' ' ' SER . 43.4 p-10 -92.61 -15.68 26.56 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 123.267 0.627 . . . . 0.0 109.755 177.077 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 90.93 19.47 43.14 Favored Glycine 0 N--CA 1.432 -1.603 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.586 -178.746 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -128.47 168.94 14.92 Favored 'General case' 0 C--N 1.314 -0.96 0 O-C-N 122.152 -0.617 . . . . 0.0 111.458 178.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 198' ' ' TRP . . . . . 0.495 ' CH2' HG23 ' A' ' 174' ' ' VAL . 85.9 m95 -82.46 131.03 35.22 Favored 'General case' 0 N--CA 1.436 -1.172 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.646 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 31.0 p -62.53 -29.66 70.72 Favored 'General case' 0 C--N 1.312 -1.025 0 C-N-CA 124.579 1.152 . . . . 0.0 113.108 -177.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 3.1 tppp? -126.17 158.18 36.25 Favored 'General case' 0 N--CA 1.432 -1.329 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -81.12 174.24 11.78 Favored 'General case' 0 C--N 1.312 -1.041 0 O-C-N 123.318 0.386 . . . . 0.0 110.033 -178.466 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 202' ' ' LYS . . . . . 0.418 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 37.5 mtpt -70.0 121.35 82.61 Favored Pre-proline 0 N--CA 1.438 -1.064 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.301 176.851 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -89.08 -162.36 0.13 Allowed 'Trans proline' 0 N--CA 1.431 -2.153 0 C-N-CA 122.388 2.059 . . . . 0.0 109.44 173.642 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 204' ' ' LYS . . . . . 0.46 ' HA ' ' HB3' ' A' ' 152' ' ' PRO . 18.0 ptpt -166.39 174.09 9.36 Favored 'General case' 0 N--CA 1.416 -2.141 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.504 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 80.7 m -114.03 128.89 56.58 Favored 'General case' 0 C--N 1.276 -2.607 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 177.727 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.8 m . . . . . 0 C--N 1.28 -2.432 0 O-C-N 124.49 1.118 . . . . 0.0 108.542 -172.642 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 39.7 Cg_endo . . . . . 0 CA--C 1.54 0.804 0 CA-C-O 121.245 0.435 . . . . 0.0 111.977 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 61.3 m -90.07 -32.5 16.68 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 122.148 0.975 . . . . 0.0 108.654 176.168 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 111.82 -83.84 0.34 Allowed Glycine 0 CA--C 1.455 -3.715 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 171.043 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 63.3 t-80 -179.83 130.83 0.25 Allowed Pre-proline 0 C--N 1.267 -2.979 0 N-CA-C 104.928 -2.249 . . . . 0.0 104.928 -175.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.416 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 88.1 Cg_endo -84.12 1.48 8.74 Favored 'Trans proline' 0 N--CA 1.485 1.008 0 C-N-CA 122.677 2.251 . . . . 0.0 113.915 -172.797 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 94.19 179.75 38.25 Favored Glycine 0 N--CA 1.429 -1.831 0 N-CA-C 108.492 -1.843 . . . . 0.0 108.492 -173.112 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -140.7 -179.66 6.17 Favored 'General case' 0 C--N 1.29 -2.005 0 CA-C-N 117.628 0.714 . . . . 0.0 109.767 -178.178 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.0 t -126.53 138.47 32.49 Favored Pre-proline 0 C--N 1.307 -1.245 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -77.34 -20.89 12.2 Favored 'Trans proline' 0 CA--C 1.534 0.514 0 C-N-CA 122.537 2.158 . . . . 0.0 112.255 -179.097 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.402 ' O ' ' HB2' ' A' ' 115' ' ' ASN . 59.0 m-85 -80.82 -50.4 9.87 Favored 'General case' 0 CA--C 1.5 -0.967 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.477 -176.287 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -122.49 -136.45 4.89 Favored Glycine 0 N--CA 1.421 -2.338 0 C-N-CA 120.558 -0.829 . . . . 0.0 111.115 -178.626 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.7 p -148.21 -172.51 4.09 Favored 'General case' 0 C--N 1.294 -1.813 0 C-N-CA 123.594 0.758 . . . . 0.0 109.073 -178.521 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 38.5 p90 -145.01 163.76 33.23 Favored 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 120.381 -0.528 . . . . 0.0 109.984 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.6 m -135.75 158.91 43.22 Favored 'General case' 0 C--N 1.288 -2.084 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 178.578 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.423 HD11 ' CE1' ' A' ' 104' ' ' PHE . 18.1 mt -110.18 122.05 46.71 Favored 'General case' 0 C--N 1.28 -2.414 0 CA-C-O 120.94 0.4 . . . . 0.0 110.384 -178.029 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 19.2 p -114.43 136.27 53.19 Favored 'General case' 0 C--N 1.286 -2.162 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.924 -176.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 95.78 11.74 54.52 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 120.035 -1.078 . . . . 0.0 112.174 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 171.59 -23.96 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 119.274 -1.441 . . . . 0.0 113.818 -178.841 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 65.4 17.3 10.92 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 179.191 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.498 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.3 m -148.97 -176.23 0.41 Allowed 'Isoleucine or valine' 0 C--O 1.205 -1.242 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -175.726 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.423 ' CE1' HD11 ' A' ' 98' ' ' LEU . 41.2 m-85 -102.84 47.32 0.89 Allowed 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 118.299 0.5 . . . . 0.0 110.401 -179.452 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.712 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.8 pt-20 -88.44 179.54 6.29 Favored 'General case' 0 C--O 1.207 -1.147 0 CA-C-N 115.477 -0.783 . . . . 0.0 111.092 177.467 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -79.36 135.76 36.8 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.075 176.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.52 1.3 62.27 Favored Glycine 0 N--CA 1.434 -1.449 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.832 -179.262 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.712 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.5 p -97.54 150.67 4.53 Favored 'Isoleucine or valine' 0 C--O 1.246 0.908 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 14.6 mtpp -113.82 127.87 56.18 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -179.698 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -90.34 93.05 9.17 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 175.773 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 44.0 t -88.19 114.95 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.662 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.063 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.1 m-85 -85.15 133.48 34.2 Favored 'General case' 0 C--N 1.284 -2.246 0 CA-C-N 115.496 -0.775 . . . . 0.0 109.632 179.582 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.8 t -125.82 127.43 46.08 Favored 'General case' 0 N--CA 1.409 -2.508 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -177.85 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 79.6 m -75.32 159.99 30.83 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.402 ' HB2' ' O ' ' A' ' 93' ' ' PHE . 6.7 t-20 -69.53 -175.84 0.9 Allowed 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 114.053 -1.431 . . . . 0.0 109.487 178.148 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -67.1 -44.38 80.11 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 120.998 0.427 . . . . 0.0 111.081 -179.555 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.21 8.12 68.8 Favored Glycine 0 C--N 1.31 -0.878 0 CA-C-N 115.965 -0.561 . . . . 0.0 113.14 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.664 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 70.7 m-85 -127.95 160.64 31.26 Favored 'General case' 0 C--N 1.311 -1.073 0 O-C-N 122.534 -0.392 . . . . 0.0 110.955 178.798 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.33 144.26 30.62 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -178.769 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -75.6 126.95 32.01 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -174.657 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -110.79 130.92 55.44 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 -177.391 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.02 174.81 20.18 Favored Glycine 0 C--N 1.301 -1.408 0 N-CA-C 111.528 -0.629 . . . . 0.0 111.528 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -83.31 -36.22 24.62 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.416 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 49.5 mm -87.97 125.0 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.862 0 CA-C-N 113.977 -1.465 . . . . 0.0 109.247 -175.833 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -127.54 3.96 6.19 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.369 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.414 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 17.9 p90 -144.05 165.11 28.7 Favored 'General case' 0 N--CA 1.422 -1.848 0 C-N-CA 119.901 -0.72 . . . . 0.0 110.757 -171.745 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.416 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 45.9 mtp180 -126.19 132.79 51.71 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 173.093 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -108.76 134.15 51.86 Favored 'General case' 0 C--N 1.277 -2.586 0 C-N-CA 119.464 -0.895 . . . . 0.0 108.864 -177.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 17.5 t -85.74 99.96 11.69 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 118.292 -1.363 . . . . 0.0 109.403 177.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.448 ' OD2' HG22 ' A' ' 131' ' ' THR . 8.5 t70 -104.32 -167.84 1.41 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 177.123 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.448 HG22 ' OD2' ' A' ' 130' ' ' ASP . 9.6 t -65.14 -15.87 62.88 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 119.048 0.84 . . . . 0.0 111.633 -177.072 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -81.79 -13.49 57.64 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.697 0.76 . . . . 0.0 109.839 176.104 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 102.49 -157.46 18.24 Favored Glycine 0 N--CA 1.428 -1.847 0 N-CA-C 107.522 -2.231 . . . . 0.0 107.522 -174.445 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.411 ' CD2' ' HB3' ' A' ' 88' ' ' PRO . 94.6 m95 -62.28 106.64 0.77 Allowed 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 117.714 0.757 . . . . 0.0 110.405 173.766 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 62.3 p -71.8 171.48 11.57 Favored 'General case' 0 C--O 1.269 2.086 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.192 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 1.8 m-20 62.87 -158.57 0.32 Allowed 'General case' 0 C--O 1.245 0.83 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.029 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 29.0 t0 -141.11 173.03 11.87 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 173.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 70.1 mt -59.36 121.71 58.46 Favored Pre-proline 0 C--N 1.269 -2.915 0 C-N-CA 125.14 1.376 . . . . 0.0 108.352 175.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.416 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 38.2 Cg_endo -64.78 178.32 1.85 Allowed 'Trans proline' 0 C--O 1.251 1.17 0 C-N-CA 123.097 2.531 . . . . 0.0 113.614 -176.628 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 63.5 mt -98.37 129.52 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.066 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.69 -176.094 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.614 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 33.6 t -114.69 107.12 15.04 Favored 'General case' 0 C--N 1.273 -2.735 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 178.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -99.35 152.1 20.33 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-O 121.625 0.726 . . . . 0.0 110.933 -176.105 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.664 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 3.3 t -73.1 136.52 25.32 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.049 0 CA-C-N 113.902 -1.499 . . . . 0.0 108.609 -179.703 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.87 125.02 20.9 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.097 0 O-C-N 124.957 1.411 . . . . 0.0 108.064 177.052 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.522 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 45.6 mttp -122.9 162.62 21.88 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.382 -174.863 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 57.0 m -124.58 168.34 13.26 Favored 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 114.309 -1.314 . . . . 0.0 107.734 175.036 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 71.5 mt -74.73 143.59 78.76 Favored Pre-proline 0 C--N 1.307 -1.244 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -179.387 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.444 ' HA ' ' CE2' ' A' ' 168' ' ' TYR . 17.5 Cg_endo -62.73 122.36 10.65 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.945 2.43 . . . . 0.0 110.761 178.283 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 48.0 t -91.81 142.02 13.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.005 -175.87 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 21.0 p -79.95 -82.67 0.11 Allowed 'General case' 0 N--CA 1.43 -1.47 0 CA-C-N 116.727 -0.215 . . . . 0.0 110.907 176.79 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.49 165.7 0.45 Allowed Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 124.051 0.94 . . . . 0.0 108.724 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' PRO . . . . . 0.521 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 55.6 Cg_endo -76.57 160.93 34.63 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.024 1.816 . . . . 0.0 109.742 167.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -53.3 -50.77 64.21 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 114.287 1.218 . . . . 0.0 114.287 -175.055 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -113.3 38.06 2.99 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.342 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -154.78 -167.43 16.56 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.918 -1.134 . . . . 0.0 112.53 177.633 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -153.04 170.24 20.95 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 -177.347 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.457 HG22 ' H ' ' A' ' 159' ' ' SER . 73.3 mt -86.02 137.67 20.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 177.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.52 HG21 ' HB3' ' A' ' 175' ' ' ARG . 14.5 m -69.11 -32.68 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-O 121.597 0.713 . . . . 0.0 110.872 -177.766 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.457 ' H ' HG22 ' A' ' 157' ' ' ILE . 24.3 t -113.25 -163.32 0.85 Allowed 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -178.099 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 28.9 p -151.69 -67.39 0.17 Allowed 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 121.022 -0.271 . . . . 0.0 111.076 177.212 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 60.58 23.75 13.48 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.526 1.131 . . . . 0.0 110.589 -178.492 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.477 ' CE ' ' HA ' ' A' ' 162' ' ' MET . 0.0 OUTLIER -99.53 87.52 3.61 Favored 'General case' 0 N--CA 1.428 -1.553 0 CA-C-O 121.697 0.76 . . . . 0.0 110.783 -174.709 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.406 ' HB2' ' CG ' ' A' ' 166' ' ' ARG . 48.9 mt-10 -129.33 159.39 69.43 Favored Pre-proline 0 C--N 1.294 -1.825 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 177.022 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -53.53 -34.93 74.67 Favored 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 122.81 2.34 . . . . 0.0 113.905 178.651 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -92.11 -23.58 19.4 Favored 'General case' 0 N--CA 1.476 0.843 0 CA-C-O 122.164 0.983 . . . . 0.0 109.768 -178.728 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.406 ' CG ' ' HB2' ' A' ' 163' ' ' GLU . 34.6 mmt180 -94.82 93.35 7.43 Favored 'General case' 0 N--CA 1.417 -2.11 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.989 -175.524 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -89.11 163.34 15.51 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.201 -1.778 . . . . 0.0 106.201 169.446 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' TYR . . . . . 0.489 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 67.4 m-85 -64.97 109.83 2.25 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 119.098 0.863 . . . . 0.0 110.628 179.453 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 28.1 m80 -98.02 161.45 13.72 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.534 -173.765 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -58.0 135.69 56.99 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.868 172.525 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 103.5 -18.26 48.39 Favored Glycine 0 N--CA 1.429 -1.803 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.62 -179.292 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.9 tp60 -76.96 128.83 35.24 Favored 'General case' 0 N--CA 1.398 -3.037 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -110.6 131.14 55.31 Favored 'General case' 0 N--CA 1.418 -2.027 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 172.468 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 55.5 t -107.87 99.56 8.88 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.32 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.52 ' HB3' HG21 ' A' ' 158' ' ' VAL . 41.7 ttm180 -89.76 144.09 26.26 Favored 'General case' 0 N--CA 1.42 -1.928 0 CA-C-N 115.043 -0.981 . . . . 0.0 109.025 178.124 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.521 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 78.1 m-85 -113.93 160.42 18.82 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -178.171 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.9 p -139.53 150.45 22.52 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.057 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 63.9 m -109.7 157.64 18.9 Favored 'General case' 0 C--N 1.287 -2.123 0 O-C-N 123.39 0.431 . . . . 0.0 111.602 -175.692 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -78.41 170.7 16.21 Favored 'General case' 0 N--CA 1.439 -1.018 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.534 179.284 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 23.1 t -49.64 105.93 0.1 Allowed 'General case' 0 C--N 1.313 -1.013 0 C-N-CA 124.88 1.272 . . . . 0.0 112.918 -175.261 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 111.74 -15.08 26.75 Favored Glycine 0 N--CA 1.43 -1.719 0 CA-C-N 115.285 -0.87 . . . . 0.0 113.252 175.328 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 182' ' ' TYR . . . . . 0.462 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 93.5 m-85 -103.84 159.84 15.3 Favored 'General case' 0 N--CA 1.433 -1.323 0 CA-C-N 117.783 0.791 . . . . 0.0 111.353 -176.858 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 53.4 pttt -135.04 155.7 50.3 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 175.792 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.479 HD13 ' HA ' ' A' ' 188' ' ' GLU . 12.5 tt -81.95 141.98 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.57 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.568 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -66.16 -79.02 0.05 OUTLIER 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 114.283 1.216 . . . . 0.0 114.283 -171.631 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -83.64 -92.87 0.67 Allowed Glycine 0 CA--C 1.496 -1.135 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.183 -175.756 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -94.32 173.71 7.5 Favored 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.479 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.7 pt-20 -122.82 4.83 9.43 Favored 'General case' 0 N--CA 1.438 -1.029 0 C-N-CA 120.613 -0.435 . . . . 0.0 110.205 178.074 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.471 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 7.1 pt-20 -163.46 120.02 1.77 Allowed 'General case' 0 N--CA 1.432 -1.345 0 CA-C-O 121.943 0.877 . . . . 0.0 112.144 -175.013 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 12.8 ptp -100.53 132.12 46.08 Favored 'General case' 0 C--N 1.281 -2.41 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.501 177.648 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 23.8 t-80 -107.24 143.46 35.43 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.918 -177.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 2.5 m -70.21 116.79 10.97 Favored 'General case' 0 CA--C 1.5 -0.946 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.944 172.546 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 2.6 m -83.39 151.73 25.37 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.632 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -67.75 -8.92 39.53 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 121.17 0.51 . . . . 0.0 112.362 -175.079 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 195' ' ' ASP . . . . . 0.421 ' HB3' ' CE1' ' A' ' 197' ' ' PHE . 26.0 t70 -82.87 -16.81 46.11 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-O 121.279 0.562 . . . . 0.0 110.638 177.464 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 99.78 38.62 3.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.669 -0.777 . . . . 0.0 113.724 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 197' ' ' PHE . . . . . 0.421 ' CE1' ' HB3' ' A' ' 195' ' ' ASP . 44.7 p90 -149.08 156.18 41.83 Favored 'General case' 0 C--O 1.249 1.04 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.707 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 83.4 m95 -72.79 128.33 35.2 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 175.713 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.0 m -51.74 -36.65 47.89 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.047 0.539 . . . . 0.0 111.621 -178.666 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 28.3 mmtp -116.24 163.79 15.47 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.463 177.408 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -88.18 162.57 16.62 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.652 178.822 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 202' ' ' LYS . . . . . 0.442 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 0.2 OUTLIER -57.55 105.09 0.48 Allowed Pre-proline 0 CA--C 1.57 1.731 0 C-N-CA 125.667 1.587 . . . . 0.0 112.758 -176.548 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 5.3 Cg_endo -89.0 170.89 4.88 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 124.005 3.136 . . . . 0.0 113.671 -176.708 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 20.1 pttm -135.06 162.21 33.13 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.046 -176.462 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.462 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 83.2 m -100.72 119.43 38.59 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 124.264 0.978 . . . . 0.0 108.537 177.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 25.5 m . . . . . 0 C--N 1.287 -2.128 0 O-C-N 124.441 1.088 . . . . 0.0 109.776 -174.188 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 18.4 Cg_endo . . . . . 0 CA--C 1.543 0.938 0 CA-C-O 121.4 0.5 . . . . 0.0 111.882 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' CYS . . . . . 0.484 ' HB3' ' NE1' ' A' ' 134' ' ' TRP . 23.6 m -89.42 -27.3 20.49 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.035 0.445 . . . . 0.0 111.606 176.303 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.62 -83.14 0.32 Allowed Glycine 0 CA--C 1.456 -3.652 0 C-N-CA 120.292 -0.956 . . . . 0.0 111.249 170.405 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -175.66 129.21 0.39 Allowed Pre-proline 0 C--N 1.269 -2.934 0 N-CA-C 106.498 -1.667 . . . . 0.0 106.498 -176.002 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -82.81 7.97 4.86 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 123.231 2.62 . . . . 0.0 114.476 -171.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 120.69 164.92 12.59 Favored Glycine 0 C--N 1.292 -1.881 0 N-CA-C 108.316 -1.914 . . . . 0.0 108.316 -175.477 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -145.82 111.93 5.7 Favored 'General case' 0 C--N 1.293 -1.859 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -177.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 8.2 t -98.92 140.65 21.89 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -172.583 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -85.38 -9.02 8.42 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.853 2.369 . . . . 0.0 111.548 173.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -94.81 16.41 15.95 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.251 0.548 . . . . 0.0 110.593 -176.149 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 156.43 -121.95 1.14 Allowed Glycine 0 N--CA 1.41 -3.072 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 t -171.85 -160.33 0.16 Allowed 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.652 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -149.94 164.82 34.43 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.364 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.8 m -125.33 160.76 28.55 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 178.268 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.0 mt -119.71 131.82 55.49 Favored 'General case' 0 C--N 1.277 -2.578 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -179.023 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 38.9 p -126.21 131.28 52.0 Favored 'General case' 0 C--N 1.286 -2.178 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -177.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 87.71 24.98 33.88 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.503 -0.856 . . . . 0.0 111.68 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 176.1 -37.8 0.1 OUTLIER Glycine 0 N--CA 1.434 -1.447 0 C-N-CA 119.93 -1.129 . . . . 0.0 112.799 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 67.39 11.36 8.34 Favored 'General case' 0 N--CA 1.498 1.925 0 C-N-CA 124.354 1.062 . . . . 0.0 109.694 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.504 ' O ' HG11 ' A' ' 108' ' ' VAL . 25.1 m -150.56 -168.38 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.085 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 -177.539 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 24.4 m-85 -104.75 38.25 1.95 Allowed 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 118.347 0.521 . . . . 0.0 110.788 -175.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.702 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.2 pt-20 -79.19 173.81 12.2 Favored 'General case' 0 C--O 1.195 -1.763 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.782 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' TYR . . . . . 0.492 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 41.8 m-85 -72.44 133.14 44.71 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.975 178.668 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.34 -0.1 71.09 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 115.739 -0.664 . . . . 0.0 113.064 178.293 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.702 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.5 p -89.45 148.77 4.31 Favored 'Isoleucine or valine' 0 C--O 1.243 0.763 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.753 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -112.16 131.52 55.42 Favored 'General case' 0 C--N 1.283 -2.295 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.362 177.657 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.494 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -94.96 94.93 8.3 Favored 'General case' 0 C--N 1.285 -2.213 0 CA-C-N 115.382 -0.826 . . . . 0.0 108.791 176.411 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 91.8 t -86.54 106.84 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.812 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' TYR . . . . . 0.499 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 18.4 t80 -74.14 138.19 43.7 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 123.495 0.718 . . . . 0.0 109.19 -177.559 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.2 t -142.07 114.68 8.48 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.097 0.951 . . . . 0.0 110.09 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 73.6 m -71.35 163.19 28.16 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 115.374 -0.83 . . . . 0.0 112.193 -179.382 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -73.42 -175.04 1.82 Allowed 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.862 178.836 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -62.13 -45.93 91.25 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-O 121.228 0.537 . . . . 0.0 111.748 -177.324 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -79.82 4.32 66.0 Favored Glycine 0 C--N 1.313 -0.716 0 CA-C-N 115.879 -0.601 . . . . 0.0 114.285 -179.093 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.408 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.1 m-85 -129.77 166.25 20.27 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 -177.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 7.8 pt20 -150.49 160.87 43.47 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -77.59 133.94 38.34 Favored 'General case' 0 N--CA 1.424 -1.774 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.511 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -120.89 132.12 54.78 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 177.683 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 112.1 -170.14 13.44 Favored Glycine 0 N--CA 1.43 -1.76 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -178.746 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -100.77 -37.34 8.75 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.532 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 49.3 mm -80.97 125.53 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.071 0 CA-C-N 114.865 -1.061 . . . . 0.0 110.284 -177.848 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.407 ' HA ' ' HB3' ' A' ' 139' ' ' PRO . 10.4 p30 -132.03 11.05 4.64 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.499 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.494 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 24.3 p90 -142.88 161.09 39.02 Favored 'General case' 0 C--N 1.312 -1.058 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -178.364 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 54.8 mtp180 -129.88 138.02 50.72 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 172.196 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -109.07 128.56 55.09 Favored 'General case' 0 C--N 1.281 -2.403 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.552 -178.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' CYS . . . . . 0.492 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 38.9 t -76.84 96.06 4.21 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.033 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.414 ' OD2' HG22 ' A' ' 131' ' ' THR . 11.2 t70 -103.12 -171.6 1.97 Allowed 'General case' 0 N--CA 1.426 -1.65 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 179.181 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.414 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.8 t -69.48 -20.35 63.74 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.054 0.454 . . . . 0.0 111.873 -173.05 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -82.02 -25.37 34.72 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 121.516 0.674 . . . . 0.0 109.5 175.171 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 130.11 -154.37 20.52 Favored Glycine 0 N--CA 1.422 -2.254 0 N-CA-C 108.291 -1.923 . . . . 0.0 108.291 -174.377 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.484 ' NE1' ' HB3' ' A' ' 85' ' ' CYS . 98.5 m95 -68.93 118.7 12.18 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 117.519 0.66 . . . . 0.0 110.977 178.572 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 75.7 p -70.42 166.16 20.97 Favored 'General case' 0 C--O 1.277 2.552 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 175.621 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 60.81 -162.94 0.26 Allowed 'General case' 0 C--O 1.246 0.896 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -129.72 -176.02 3.78 Favored 'General case' 0 C--N 1.283 -2.298 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 173.39 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 75.1 mt -63.42 117.8 37.76 Favored Pre-proline 0 C--N 1.278 -2.519 0 C-N-CA 124.219 1.008 . . . . 0.0 108.289 176.686 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.532 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 24.0 Cg_exo -55.7 158.36 13.67 Favored 'Trans proline' 0 C--O 1.251 1.172 0 C-N-CA 122.346 2.031 . . . . 0.0 111.904 178.903 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.511 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 46.6 mm -87.76 134.24 28.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 C-N-CA 120.192 -0.603 . . . . 0.0 109.885 -172.048 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.408 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 12.3 t -118.75 112.11 19.34 Favored 'General case' 0 C--N 1.28 -2.445 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.638 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -108.86 155.66 20.56 Favored 'General case' 0 C--N 1.278 -2.542 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -178.575 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.6 p -75.8 140.01 18.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 176.781 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.499 ' HB ' ' HB2' ' A' ' 170' ' ' PHE . 71.3 t -60.21 130.78 24.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 179.341 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -118.6 136.88 53.63 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -178.416 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 77.1 m -97.21 160.58 14.25 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.052 -177.638 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' LEU . . . . . 0.543 HD12 ' HD2' ' A' ' 148' ' ' PRO . 15.0 tp -71.75 125.91 91.58 Favored Pre-proline 0 N--CA 1.384 -3.725 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -178.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.543 ' HD2' HD12 ' A' ' 147' ' ' LEU . 14.2 Cg_endo -58.34 131.29 42.06 Favored 'Trans proline' 0 C--O 1.24 0.585 0 C-N-CA 123.839 3.026 . . . . 0.0 113.025 -176.091 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.7 t -93.51 139.59 17.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.0 p -74.98 -76.89 0.13 Allowed 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 111.657 0.243 . . . . 0.0 111.657 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.56 158.38 0.21 Allowed Pre-proline 0 CA--C 1.508 -0.665 0 N-CA-C 106.703 -1.592 . . . . 0.0 106.703 178.109 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -77.56 167.46 24.21 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 121.388 1.392 . . . . 0.0 109.33 171.597 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' GLU . . . . . 0.507 ' OE1' ' HG3' ' A' ' 204' ' ' LYS . 0.1 OUTLIER -74.68 -46.83 35.32 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -173.109 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 154' ' ' ASN . . . . . 0.456 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 55.2 m-80 -106.45 23.76 13.66 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.766 0.793 . . . . 0.0 110.748 -177.682 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -145.07 -157.43 7.23 Favored Glycine 0 N--CA 1.421 -2.337 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.826 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 21.4 pttp -157.78 169.58 24.3 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 43.3 mt -95.94 124.87 48.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 CA-C-O 121.4 0.619 . . . . 0.0 111.199 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.4 ' CG2' HG22 ' A' ' 177' ' ' VAL . 80.7 t -67.64 -46.29 83.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 C-N-CA 124.486 1.114 . . . . 0.0 109.661 179.385 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 14.9 m -78.51 4.33 13.6 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 114.017 1.117 . . . . 0.0 114.017 -173.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 69.1 m -91.88 -27.2 18.09 Favored 'General case' 0 C--N 1.291 -1.961 0 C-N-CA 120.156 -0.618 . . . . 0.0 110.088 176.165 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -88.81 79.61 7.37 Favored 'General case' 0 N--CA 1.435 -1.188 0 CA-C-O 121.738 0.78 . . . . 0.0 111.125 -178.604 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.444 ' H ' ' H ' ' A' ' 163' ' ' GLU . 57.9 mtm -157.92 -31.32 0.08 Allowed 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 126.107 1.763 . . . . 0.0 107.042 178.492 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.444 ' H ' ' H ' ' A' ' 162' ' ' MET . 10.3 pt-20 -166.3 145.7 4.98 Favored Pre-proline 0 N--CA 1.441 -0.881 0 CA-C-N 114.168 -1.378 . . . . 0.0 107.95 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -81.61 -8.98 12.4 Favored 'Trans proline' 0 C--N 1.323 -0.777 0 C-N-CA 121.877 1.718 . . . . 0.0 112.485 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -80.88 -63.61 1.37 Allowed 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 -172.523 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . 0.322 4.7 ppt_? 23.65 83.18 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 117.809 2.522 . . . . 0.0 117.809 176.853 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -76.11 -12.24 60.08 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 115.281 -0.872 . . . . 0.0 111.263 178.153 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 68.08 85.08 0.14 Allowed 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 125.778 1.631 . . . . 0.0 110.58 -176.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 51.4 m170 -88.1 155.73 19.64 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.268 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.499 ' HB2' ' HB ' ' A' ' 144' ' ' VAL . 52.9 t80 -54.35 113.51 1.3 Allowed 'General case' 0 CA--C 1.509 -0.602 0 CA-C-O 121.484 0.659 . . . . 0.0 110.15 176.904 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 171' ' ' GLY . . . . . 0.417 ' H ' ' HB2' ' A' ' 192' ' ' CYS . . . 132.44 -25.33 3.83 Favored Glycine 0 N--CA 1.407 -3.243 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 -177.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.7 mm-40 -68.41 137.63 54.68 Favored 'General case' 0 C--O 1.256 1.402 0 CA-C-O 121.845 0.831 . . . . 0.0 111.747 -178.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -112.94 117.76 32.97 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 175.088 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.523 ' HB ' ' HG2' ' A' ' 190' ' ' MET . 53.3 t -99.47 105.32 17.28 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 CA-C-O 121.336 0.589 . . . . 0.0 110.089 -178.183 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.421 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 27.3 ttm180 -94.92 152.8 18.05 Favored 'General case' 0 N--CA 1.414 -2.237 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.694 178.13 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -125.04 157.63 35.73 Favored 'General case' 0 C--N 1.284 -2.249 0 C-N-CA 124.491 1.116 . . . . 0.0 108.869 -175.312 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.4 HG22 ' CG2' ' A' ' 158' ' ' VAL . 0.0 OUTLIER -131.37 151.44 35.62 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.958 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.912 175.636 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 7.7 m -118.06 135.2 54.33 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 114.136 -1.393 . . . . 0.0 108.154 173.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -62.63 161.39 12.3 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 124.233 0.958 . . . . 0.0 110.421 178.386 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 7.5 t -62.37 109.76 1.45 Allowed 'General case' 0 C--N 1.299 -1.597 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.323 -174.209 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 122.97 -19.93 7.72 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -177.402 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 182' ' ' TYR . . . . . 0.595 ' HB3' ' SG ' ' A' ' 205' ' ' CYS . 82.6 m-85 -107.69 160.86 15.38 Favored 'General case' 0 N--CA 1.429 -1.495 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.83 146.9 33.39 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.566 HD13 ' HA ' ' A' ' 188' ' ' GLU . 9.5 tt -80.72 140.02 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.808 0 CA-C-O 121.8 0.81 . . . . 0.0 111.513 -176.446 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -83.02 -51.02 7.93 Favored 'General case' 0 C--N 1.294 -1.829 0 CA-C-N 115.164 -0.925 . . . . 0.0 109.26 -176.112 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.58 -158.91 25.18 Favored Glycine 0 C--N 1.298 -1.573 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 173.584 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -79.74 160.36 26.26 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 122.283 -0.539 . . . . 0.0 110.108 177.485 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.566 ' HA ' HD13 ' A' ' 184' ' ' ILE . 10.5 pt-20 -91.17 9.33 31.55 Favored 'General case' 0 C--O 1.205 -1.241 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.362 -176.167 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.2 pt-20 -155.37 138.82 15.87 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.225 0.536 . . . . 0.0 111.431 -178.767 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.523 ' HG2' ' HB ' ' A' ' 174' ' ' VAL . 6.2 ptm -127.37 144.78 51.0 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 178.401 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 52.5 t-80 -126.48 142.33 51.57 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.593 -0.692 . . . . 0.0 110.742 -175.537 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 192' ' ' CYS . . . . . 0.417 ' HB2' ' H ' ' A' ' 171' ' ' GLY . 6.4 m -59.32 125.21 22.7 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 176.219 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 12.1 m -104.02 165.43 11.05 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.111 179.441 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -54.06 -30.59 48.73 Favored 'General case' 0 N--CA 1.498 1.943 0 C-N-CA 123.975 0.91 . . . . 0.0 111.901 179.481 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -54.98 -30.03 58.28 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 124.906 1.282 . . . . 0.0 111.39 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 196' ' ' GLY . . . . . 0.512 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 98.06 11.73 48.4 Favored Glycine 0 CA--C 1.497 -1.057 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -174.123 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -130.54 -170.88 2.42 Favored 'General case' 0 N--CA 1.429 -1.475 0 CA-C-N 114.526 -0.837 . . . . 0.0 109.281 -178.583 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 198' ' ' TRP . . . . . 0.412 ' CE3' ' HG3' ' A' ' 190' ' ' MET . 85.7 m95 -96.25 154.14 17.42 Favored 'General case' 0 N--CA 1.426 -1.658 0 CA-C-O 121.094 0.473 . . . . 0.0 111.335 -175.27 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 13.7 p -75.14 -17.78 60.35 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.626 176.66 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.45 ' HD3' ' HA ' ' A' ' 200' ' ' LYS . 23.9 mmtp -128.62 159.03 36.84 Favored 'General case' 0 CA--C 1.492 -1.254 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.176 179.118 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -87.15 -175.86 5.47 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 3.8 tppp? -72.49 115.14 36.39 Favored Pre-proline 0 C--O 1.249 1.053 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 173.636 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.73 177.5 8.74 Favored 'Trans proline' 0 N--CA 1.43 -2.231 0 C-N-CA 121.755 1.636 . . . . 0.0 110.645 177.519 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 204' ' ' LYS . . . . . 0.507 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 23.7 ttmm -128.56 152.75 47.94 Favored 'General case' 0 C--N 1.275 -2.654 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.45 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.595 ' SG ' ' HB3' ' A' ' 182' ' ' TYR . 18.2 t -111.42 117.83 34.14 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 179.209 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--N 1.305 -1.342 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.33 -174.39 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 28.9 Cg_endo . . . . . 0 CA--C 1.543 0.931 0 CA-C-O 121.988 0.745 . . . . 0.0 111.786 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 63.8 m -81.64 -27.97 33.86 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-O 122.066 0.936 . . . . 0.0 109.144 177.134 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.95 -91.37 0.56 Allowed Glycine 0 N--CA 1.4 -3.712 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 173.213 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -179.4 125.5 0.24 Allowed Pre-proline 0 C--N 1.256 -3.47 0 N-CA-C 103.906 -2.627 . . . . 0.0 103.906 -176.113 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.547 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 72.3 Cg_endo -76.82 5.09 5.13 Favored 'Trans proline' 0 N--CA 1.488 1.204 0 C-N-CA 122.649 2.233 . . . . 0.0 113.343 -173.905 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 97.98 -160.38 20.84 Favored Glycine 0 N--CA 1.419 -2.453 0 N-CA-C 106.725 -2.55 . . . . 0.0 106.725 -173.488 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -155.31 -168.66 2.91 Favored 'General case' 0 C--N 1.281 -2.389 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.6 t -143.42 120.32 6.72 Favored Pre-proline 0 C--N 1.289 -2.055 0 CA-C-N 118.867 0.758 . . . . 0.0 110.596 -178.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.86 -0.08 9.83 Favored 'Trans proline' 0 CA--C 1.53 0.315 0 C-N-CA 122.831 2.354 . . . . 0.0 111.047 178.52 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -107.25 13.74 26.88 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.379 178.859 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 164.77 -128.38 1.79 Allowed Glycine 0 N--CA 1.422 -2.262 0 C-N-CA 119.516 -1.326 . . . . 0.0 112.684 179.036 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.3 p -151.52 173.54 14.48 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 123.322 0.649 . . . . 0.0 110.303 -174.097 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -140.62 161.48 37.65 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 169.281 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.9 m -127.0 159.99 32.46 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.438 HD11 ' CE1' ' A' ' 104' ' ' PHE . 20.8 mt -117.03 122.89 45.5 Favored 'General case' 0 C--N 1.28 -2.414 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 -179.167 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 29.8 p -115.55 122.08 44.59 Favored 'General case' 0 C--N 1.286 -2.162 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.557 -176.518 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.91 -54.98 0.77 Allowed Glycine 0 N--CA 1.421 -2.339 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -178.69 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -141.81 3.86 2.09 Favored Glycine 0 N--CA 1.437 -1.28 0 C-N-CA 120.14 -1.029 . . . . 0.0 113.316 -178.004 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 59.99 18.51 7.65 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.512 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.4 m -147.48 -173.86 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 -174.032 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.438 ' CE1' HD11 ' A' ' 98' ' ' LEU . 26.9 m-85 -102.89 45.9 0.94 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 118.447 0.567 . . . . 0.0 109.665 -179.412 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.664 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.0 pt-20 -86.57 -175.03 5.29 Favored 'General case' 0 C--O 1.211 -0.924 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.211 178.124 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -80.36 137.14 36.52 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.86 -0.525 . . . . 0.0 111.455 179.424 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 88.65 -0.97 83.39 Favored Glycine 0 N--CA 1.439 -1.129 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.849 178.723 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.664 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.4 p -90.08 147.53 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -176.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.4 mtpt -111.37 125.89 54.34 Favored 'General case' 0 N--CA 1.413 -2.281 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.706 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.402 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -89.57 93.25 9.42 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 174.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 54.1 t -88.2 116.43 30.08 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.454 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -179.315 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -87.52 141.59 28.51 Favored 'General case' 0 C--N 1.282 -2.341 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.109 -177.807 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.3 t -139.04 110.53 7.03 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-O 122.265 1.031 . . . . 0.0 108.488 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 33.2 m -68.75 163.03 24.96 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.114 -174.705 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -65.97 177.22 1.4 Allowed 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 124.31 1.044 . . . . 0.0 110.439 -178.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -58.92 -46.77 87.13 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 123.98 0.912 . . . . 0.0 112.086 -178.357 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.15 24.47 6.16 Favored Glycine 0 CA--C 1.524 0.609 0 C-N-CA 121.325 -0.464 . . . . 0.0 113.342 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -146.38 164.94 30.84 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 -177.134 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.4 pt20 -145.45 170.0 17.24 Favored 'General case' 0 C--N 1.275 -2.653 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 176.426 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.5 124.18 31.78 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 179.267 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.73 128.42 55.27 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 106.212 -1.773 . . . . 0.0 106.212 178.046 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 110.81 167.94 19.13 Favored Glycine 0 C--N 1.292 -1.886 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.605 -177.6 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -87.15 -26.57 23.53 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-O 121.816 0.817 . . . . 0.0 109.855 -175.443 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.425 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.9 mm -91.17 129.7 41.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.989 -1.005 . . . . 0.0 108.526 179.478 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 24.2 p-10 -130.81 9.62 4.98 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 120.845 0.355 . . . . 0.0 110.46 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.402 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 36.3 p90 -150.7 164.25 36.58 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.703 -173.778 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.547 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 45.3 mtp180 -123.66 134.47 53.74 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 173.313 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -110.13 134.03 52.6 Favored 'General case' 0 C--N 1.29 -1.987 0 C-N-CA 119.524 -0.87 . . . . 0.0 108.72 179.549 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.6 t -85.98 109.06 18.51 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.076 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -102.78 -169.36 1.65 Allowed 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 177.422 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 15.0 t -66.19 -15.39 63.11 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 123.119 0.567 . . . . 0.0 112.074 -175.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -99.09 -7.0 27.37 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-O 121.446 0.641 . . . . 0.0 109.979 177.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 114.25 -163.12 12.2 Favored Glycine 0 N--CA 1.439 -1.133 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 90.9 m95 -62.67 109.0 1.27 Allowed 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 116.681 0.24 . . . . 0.0 110.842 177.826 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 30.6 p -59.11 -73.56 0.08 Allowed 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 125.265 1.426 . . . . 0.0 113.076 -176.488 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -73.57 177.88 5.06 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.857 -177.498 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -100.97 175.6 5.55 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.951 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 87.1 mt -70.16 125.4 91.97 Favored Pre-proline 0 C--N 1.309 -1.165 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.024 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.425 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 36.5 Cg_endo -65.76 172.1 8.75 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 122.716 2.277 . . . . 0.0 112.73 179.241 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 46.2 mm -101.77 124.94 55.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-O 121.231 0.539 . . . . 0.0 111.562 -173.268 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 94.7 m -97.71 99.29 10.64 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 174.335 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -92.19 146.08 24.0 Favored 'General case' 0 N--CA 1.416 -2.13 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.68 130.3 35.21 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.579 HG23 ' HB2' ' A' ' 170' ' ' PHE . 12.1 m -59.22 141.01 16.68 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 CA-C-O 121.138 0.494 . . . . 0.0 112.001 -176.575 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 83.4 mttt -121.12 136.94 54.88 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.081 -175.013 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 89.1 m -103.67 152.25 22.01 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 172.799 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 1.8 pp -60.39 154.05 56.09 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-O 120.868 0.366 . . . . 0.0 110.867 -177.815 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -78.12 102.95 1.62 Allowed 'Trans proline' 0 N--CA 1.441 -1.578 0 C-N-CA 122.504 2.136 . . . . 0.0 112.506 -176.782 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 7.7 p -73.36 134.28 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.301 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.534 177.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.1 p -75.62 -75.31 0.18 Allowed 'General case' 0 N--CA 1.439 -0.988 0 CA-C-N 116.162 -0.472 . . . . 0.0 112.217 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.408 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . 171.81 159.96 0.24 Allowed Pre-proline 0 C--O 1.239 0.51 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 -177.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' PRO . . . . . 0.464 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 56.5 Cg_endo -75.57 161.06 37.64 Favored 'Trans proline' 0 N--CA 1.443 -1.459 0 C-N-CA 121.263 1.309 . . . . 0.0 109.55 171.791 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -57.89 -41.5 82.69 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 114.414 1.265 . . . . 0.0 114.414 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 56.0 m-80 -113.33 23.47 13.21 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.581 0.705 . . . . 0.0 110.041 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 155' ' ' GLY . . . . . 0.44 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -139.48 -163.3 9.46 Favored Glycine 0 N--CA 1.433 -1.536 0 C-N-CA 119.93 -1.129 . . . . 0.0 112.017 -178.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 156' ' ' LYS . . . . . 0.408 ' HA ' ' HB1' ' A' ' 151' ' ' ALA . 19.7 pttp -160.62 177.18 10.75 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -179.761 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.431 HG12 ' CE1' ' A' ' 176' ' ' PHE . 38.4 mt -95.47 140.42 17.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 123.278 0.361 . . . . 0.0 111.806 -175.545 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.47 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.8 m -92.13 -36.1 7.48 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 175.617 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.4 m -89.71 66.42 7.12 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 115.66 -0.7 . . . . 0.0 109.832 -177.055 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 45.6 m -82.99 89.87 6.94 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.305 1.05 . . . . 0.0 110.636 -177.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 161' ' ' ALA . . . . . 0.551 ' HA ' ' HG2' ' A' ' 164' ' ' PRO . . . -108.88 27.73 9.18 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.647 -177.652 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.562 ' HE2' ' HA ' ' A' ' 162' ' ' MET . 0.0 OUTLIER -67.01 -2.08 4.93 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 123.784 0.833 . . . . 0.0 112.968 -173.179 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.56 ' H ' ' HD2' ' A' ' 164' ' ' PRO . 48.2 mt-10 -140.54 -50.24 0.02 OUTLIER Pre-proline 0 C--N 1.305 -1.357 0 C-N-CA 124.02 0.928 . . . . 0.0 113.095 178.707 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 164' ' ' PRO . . . . . 0.56 ' HD2' ' H ' ' A' ' 163' ' ' GLU . 10.3 Cg_endo -55.74 -25.84 53.45 Favored 'Trans proline' 0 C--N 1.375 1.932 0 CA-C-N 121.011 1.397 . . . . 0.0 112.144 174.137 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -124.54 -9.22 7.41 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 176.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 51.3 mtt180 65.3 -45.67 0.36 Allowed 'General case' 0 C--N 1.363 1.162 0 C-N-CA 126.602 1.961 . . . . 0.0 115.965 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -121.65 -167.16 1.48 Allowed 'General case' 1 C--N 1.22 -5.063 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 -179.002 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -113.39 102.02 9.93 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 172.209 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -96.2 167.62 11.09 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.48 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.579 ' HB2' HG23 ' A' ' 144' ' ' VAL . 91.0 t80 -50.04 133.62 22.65 Favored 'General case' 0 N--CA 1.468 0.466 0 O-C-N 123.622 0.576 . . . . 0.0 111.019 178.184 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 111.69 -32.71 6.21 Favored Glycine 0 N--CA 1.427 -1.932 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -69.66 114.9 8.3 Favored 'General case' 0 N--CA 1.416 -2.173 0 CA-C-O 122.287 1.041 . . . . 0.0 112.303 178.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -101.95 103.44 14.08 Favored 'General case' 0 N--CA 1.416 -2.128 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 174.35 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.562 HG13 ' HG3' ' A' ' 190' ' ' MET . 6.8 p -86.04 108.34 17.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.274 0 CA-C-O 121.579 0.704 . . . . 0.0 110.263 -175.227 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.47 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 43.2 ttp180 -100.12 147.29 25.83 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.476 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.464 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 74.2 m-85 -111.93 167.8 10.09 Favored 'General case' 0 C--N 1.293 -1.857 0 CA-C-O 121.784 0.802 . . . . 0.0 111.408 -177.333 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -136.99 151.65 27.52 Favored 'Isoleucine or valine' 0 CA--C 1.455 -2.678 0 CA-C-N 114.152 -1.385 . . . . 0.0 108.766 177.265 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.8 m -112.41 122.36 47.49 Favored 'General case' 0 N--CA 1.392 -3.348 0 O-C-N 124.474 1.109 . . . . 0.0 108.068 177.618 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 48.3 m-80 -53.92 168.73 0.19 Allowed 'General case' 0 C--N 1.307 -1.263 0 O-C-N 124.761 1.288 . . . . 0.0 112.301 -179.12 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 16.8 m -49.86 104.66 0.07 Allowed 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 125.273 1.429 . . . . 0.0 112.259 -175.673 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.01 3.16 31.75 Favored Glycine 0 N--CA 1.435 -1.409 0 C-N-CA 120.837 -0.697 . . . . 0.0 113.261 178.438 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -124.67 158.58 32.82 Favored 'General case' 0 CA--C 1.484 -1.564 0 CA-C-N 117.341 0.57 . . . . 0.0 110.725 178.61 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.516 ' HG2' ' OXT' ' A' ' 206' ' ' VAL . 25.2 pttm -133.39 162.23 32.4 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 106.757 -1.571 . . . . 0.0 106.757 179.239 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.4 tp -76.4 149.16 6.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -81.35 -59.12 2.74 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.987 179.584 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -115.96 -110.32 2.7 Favored Glycine 0 C--N 1.304 -1.205 0 C-N-CA 120.464 -0.874 . . . . 0.0 111.965 179.29 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 187' ' ' ASP . . . . . 0.537 ' CG ' ' HD3' ' A' ' 200' ' ' LYS . 1.5 p-10 -77.36 150.02 35.18 Favored 'General case' 0 C--O 1.193 -1.873 0 C-N-CA 124.161 0.984 . . . . 0.0 108.939 177.444 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -107.21 5.68 27.94 Favored 'General case' 0 C--N 1.296 -1.751 0 C-N-CA 121.009 -0.276 . . . . 0.0 110.871 -178.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -152.1 152.22 32.07 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 113.57 0.952 . . . . 0.0 113.57 -172.381 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.562 ' HG3' HG13 ' A' ' 174' ' ' VAL . 0.0 OUTLIER -128.57 137.46 51.73 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.876 -1.056 . . . . 0.0 108.306 177.454 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 40.3 t-80 -105.49 130.02 53.65 Favored 'General case' 0 C--N 1.291 -1.953 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.124 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 51.3 t -70.74 113.93 8.31 Favored 'General case' 0 C--O 1.243 0.734 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 175.394 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 25.1 m -85.85 163.49 18.08 Favored 'General case' 0 N--CA 1.437 -1.086 0 C-N-CA 123.217 0.607 . . . . 0.0 111.689 -176.38 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -67.57 -10.87 55.91 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 -173.711 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 195' ' ' ASP . . . . . 0.407 ' HB2' ' CE2' ' A' ' 197' ' ' PHE . 19.4 m-20 -91.79 -0.99 57.56 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.402 0.62 . . . . 0.0 110.109 177.484 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 81.38 42.28 9.41 Favored Glycine 0 N--CA 1.436 -1.362 0 C-N-CA 120.993 -0.622 . . . . 0.0 113.282 179.337 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 197' ' ' PHE . . . . . 0.407 ' CE2' ' HB2' ' A' ' 195' ' ' ASP . 45.5 p90 -149.65 166.71 28.5 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 175.249 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.5 m95 -83.82 125.86 32.38 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 123.146 0.279 . . . . 0.0 110.484 -178.712 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 35.9 t -57.62 -38.98 75.88 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.597 177.068 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.537 ' HD3' ' CG ' ' A' ' 187' ' ' ASP . 1.8 mmpt? -101.91 178.6 4.57 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 115.718 -0.673 . . . . 0.0 111.039 177.5 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -113.69 178.78 4.16 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 179.4 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 51.5 mtpt -79.2 114.51 45.38 Favored Pre-proline 0 C--N 1.295 -1.802 0 C-N-CA 120.771 -0.372 . . . . 0.0 111.593 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.49 -171.73 1.19 Allowed 'Trans proline' 0 N--CA 1.437 -1.812 0 C-N-CA 122.001 1.801 . . . . 0.0 110.898 176.354 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 204' ' ' LYS . . . . . 0.446 ' HG2' HG13 ' A' ' 206' ' ' VAL . 34.0 ttpt -141.66 153.48 44.74 Favored 'General case' 0 N--CA 1.405 -2.722 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.738 -175.845 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.435 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 81.1 m -104.81 121.54 43.86 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 174.648 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.516 ' OXT' ' HG2' ' A' ' 183' ' ' LYS . 25.0 m . . . . . 0 C--N 1.305 -1.365 0 O-C-N 124.191 0.932 . . . . 0.0 110.101 -175.387 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo . . . . . 0 CA--C 1.54 0.812 0 CA-C-O 121.423 0.51 . . . . 0.0 111.764 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 39.3 m -82.27 -36.23 27.28 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 122.264 1.031 . . . . 0.0 108.235 177.224 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.48 -92.62 0.48 Allowed Glycine 0 N--CA 1.406 -3.327 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 174.375 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 46.6 t-80 -177.42 129.55 0.32 Allowed Pre-proline 0 C--N 1.261 -3.248 0 N-CA-C 103.991 -2.596 . . . . 0.0 103.991 -176.255 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.534 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 90.5 Cg_endo -80.24 2.55 8.38 Favored 'Trans proline' 0 C--N 1.327 -0.582 0 C-N-CA 122.446 2.098 . . . . 0.0 113.387 -173.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.48 -178.49 41.39 Favored Glycine 0 N--CA 1.422 -2.287 0 N-CA-C 109.037 -1.625 . . . . 0.0 109.037 -175.468 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -139.83 159.68 41.61 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 117.477 0.639 . . . . 0.0 110.177 -177.691 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 5.7 t -108.52 139.6 20.97 Favored Pre-proline 0 C--N 1.299 -1.59 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.632 -178.464 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 91' ' ' THR . 6.3 Cg_exo -82.41 -14.32 9.37 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.546 2.164 . . . . 0.0 111.155 178.396 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -86.79 -1.22 57.59 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.642 -175.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 172.17 -131.89 2.26 Favored Glycine 0 N--CA 1.408 -3.226 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 -178.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 35.8 p -145.62 -175.62 4.8 Favored 'General case' 0 C--N 1.289 -2.036 0 O-C-N 123.864 0.391 . . . . 0.0 110.012 -177.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -138.21 166.56 23.87 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 173.223 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -134.79 161.46 35.12 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.126 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.481 HD11 ' CE1' ' A' ' 104' ' ' PHE . 13.2 mt -119.14 124.16 46.16 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 -178.171 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.443 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 29.5 p -108.98 144.2 37.27 Favored 'General case' 0 C--N 1.284 -2.242 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -177.727 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 102.64 -70.36 0.32 Allowed Glycine 0 N--CA 1.432 -1.598 0 C-N-CA 120.01 -1.09 . . . . 0.0 110.671 -178.19 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.488 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -110.47 -18.61 8.44 Favored Glycine 0 C--N 1.307 -1.08 0 C-N-CA 120.283 -0.96 . . . . 0.0 112.187 -178.313 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 64.04 22.62 12.99 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 123.336 0.655 . . . . 0.0 111.163 -178.563 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.513 ' O ' HG21 ' A' ' 108' ' ' VAL . 18.4 m -151.1 -171.75 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.198 -1.623 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -178.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.481 ' CE1' HD11 ' A' ' 98' ' ' LEU . 22.1 m-85 -101.9 43.99 1.04 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 119.095 0.862 . . . . 0.0 110.568 -177.025 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.669 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.7 pt-20 -84.11 -179.66 7.28 Favored 'General case' 0 C--O 1.206 -1.222 0 CA-C-N 114.476 -1.238 . . . . 0.0 111.663 178.357 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 40.2 m-85 -76.7 135.55 39.08 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 122.029 -0.419 . . . . 0.0 110.881 176.817 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.62 9.3 75.42 Favored Glycine 0 N--CA 1.44 -1.057 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.704 178.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.669 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.9 p -95.6 148.8 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.484 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.443 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.7 mtpt -115.17 121.96 44.59 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.458 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -88.01 93.82 9.6 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.265 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 91.5 t -90.53 114.43 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.93 0 C-N-CA 124.414 1.086 . . . . 0.0 108.431 -177.252 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -84.76 139.44 31.96 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.511 -177.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.9 t -136.16 112.24 9.68 Favored 'General case' 0 N--CA 1.423 -1.796 0 CA-C-O 122.156 0.979 . . . . 0.0 109.943 -179.152 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 84.8 m -69.43 156.21 39.21 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.47 -0.786 . . . . 0.0 111.998 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 -67.7 172.93 4.69 Favored 'General case' 0 C--O 1.218 -0.573 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.069 176.126 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -53.33 -47.8 69.03 Favored 'General case' 0 C--N 1.313 -1.007 0 C-N-CA 124.022 0.929 . . . . 0.0 113.115 -174.132 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -85.02 15.35 44.17 Favored Glycine 0 C--N 1.307 -1.039 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.784 -179.569 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -130.34 162.27 29.43 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -144.77 145.34 31.62 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.5 tt -79.94 140.91 36.47 Favored 'General case' 0 C--N 1.279 -2.471 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.263 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.97 133.07 56.33 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -173.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 103.73 -169.41 18.08 Favored Glycine 0 C--N 1.306 -1.121 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.46 179.283 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -94.19 -47.45 6.64 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -178.651 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.0 mm -69.05 122.95 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 CA-C-N 114.464 -1.244 . . . . 0.0 109.626 -176.331 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -128.53 6.24 5.69 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.397 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 25.0 p90 -150.56 162.39 40.72 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 120.433 -0.507 . . . . 0.0 110.23 -173.857 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.534 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 39.9 mtp180 -121.78 132.97 54.89 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 106.226 -1.768 . . . . 0.0 106.226 173.235 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -108.7 128.9 55.27 Favored 'General case' 0 C--N 1.289 -2.035 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.7 t -85.35 107.33 17.3 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.087 -1.045 . . . . 0.0 109.642 177.116 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.418 ' CG ' ' H ' ' A' ' 131' ' ' THR . 34.1 t0 -103.86 -170.6 1.8 Allowed 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 178.27 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.418 ' H ' ' CG ' ' A' ' 130' ' ' ASP . 11.1 t -54.81 -29.49 54.71 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 124.56 1.144 . . . . 0.0 113.204 -177.033 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -81.82 -30.16 32.31 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 121.4 0.619 . . . . 0.0 110.382 176.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 132.86 -151.78 20.11 Favored Glycine 0 N--CA 1.42 -2.409 0 N-CA-C 108.744 -1.743 . . . . 0.0 108.744 -174.364 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 92.3 m95 -65.46 113.16 3.94 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 117.386 0.593 . . . . 0.0 109.778 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 22.3 p -64.65 -70.88 0.2 Allowed 'General case' 0 C--O 1.247 0.922 0 CA-C-O 121.6 0.714 . . . . 0.0 111.738 -178.326 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 -71.82 173.87 7.67 Favored 'General case' 0 CA--C 1.484 -1.559 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.959 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -110.01 -174.62 2.53 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -177.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.2 mt -66.58 118.56 55.25 Favored Pre-proline 0 C--O 1.244 0.814 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.405 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.61 155.93 63.96 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.788 2.325 . . . . 0.0 111.706 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 67.5 mt -84.81 136.15 23.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.032 -177.657 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 43.7 t -126.06 138.75 53.73 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 176.486 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.56 157.32 40.49 Favored 'General case' 0 N--CA 1.414 -2.243 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -178.498 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 11.5 p -75.09 136.34 25.3 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.88 178.365 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.96 130.53 25.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 C-N-CA 123.303 0.641 . . . . 0.0 109.303 178.432 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.555 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 44.0 mttp -131.46 159.11 39.02 Favored 'General case' 0 CA--C 1.499 -1.007 0 CA-C-O 121.564 0.697 . . . . 0.0 112.64 -177.429 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 39.5 m -123.28 149.53 44.68 Favored 'General case' 0 N--CA 1.42 -1.974 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 176.312 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 80.5 mt -65.38 148.76 97.81 Favored Pre-proline 0 C--N 1.309 -1.154 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -61.6 122.34 10.89 Favored 'Trans proline' 0 N--CA 1.459 -0.524 0 C-N-CA 123.199 2.599 . . . . 0.0 110.479 178.167 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 150' ' ' THR . 21.0 t -83.73 145.78 7.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -175.705 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 150' ' ' THR . . . . . 0.539 ' O ' HG12 ' A' ' 149' ' ' VAL . 15.6 p -88.13 -164.93 1.19 Allowed 'General case' 0 N--CA 1.411 -2.425 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 171.53 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.532 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . -113.09 156.37 42.97 Favored Pre-proline 0 C--N 1.266 -3.057 0 O-C-N 121.511 -0.743 . . . . 0.0 110.392 -172.494 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' PRO . . . . . 0.415 ' HD3' ' CD2' ' A' ' 176' ' ' PHE . 28.9 Cg_endo -65.26 158.51 51.95 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 122.252 1.968 . . . . 0.0 110.276 173.896 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' GLU . . . . . 0.416 ' HG2' ' HB2' ' A' ' 204' ' ' LYS . 10.2 pt-20 -53.78 -36.43 62.4 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 114.463 1.282 . . . . 0.0 114.463 -174.554 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' ASN . . . . . 0.43 ' HB2' ' HB2' ' A' ' 205' ' ' CYS . 20.3 m120 -127.7 36.1 4.4 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.789 0.804 . . . . 0.0 109.043 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 177' ' ' VAL . . . -152.7 -160.76 9.82 Favored Glycine 0 N--CA 1.429 -1.802 0 C-N-CA 119.628 -1.272 . . . . 0.0 113.231 178.103 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 156' ' ' LYS . . . . . 0.532 ' HA ' ' HB1' ' A' ' 151' ' ' ALA . 20.2 pttm -159.12 176.61 12.04 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 123.936 0.894 . . . . 0.0 109.863 -177.889 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 59.8 mt -94.52 142.1 13.96 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 122.24 0.216 . . . . 0.0 110.705 -178.656 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.541 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 12.2 m -99.83 -23.57 4.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 CA-C-O 121.722 0.772 . . . . 0.0 110.479 179.055 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.502 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 33.4 m -108.18 133.61 52.2 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 114.742 1.386 . . . . 0.0 114.742 -168.496 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 160' ' ' SER . . . . . 0.71 ' HA ' ' SD ' ' A' ' 162' ' ' MET . 58.2 m 55.13 34.79 23.36 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.953 1.464 . . . . 0.0 114.953 166.64 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -106.38 22.5 15.67 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.605 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.71 ' SD ' ' HA ' ' A' ' 160' ' ' SER . 3.7 mpp? -57.94 -43.68 86.51 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.503 -178.484 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.403 ' HB2' ' CG ' ' A' ' 166' ' ' ARG . 24.0 mm-40 -123.55 145.61 47.55 Favored Pre-proline 0 C--N 1.311 -1.084 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -82.67 -12.33 10.01 Favored 'Trans proline' 0 CA--C 1.547 1.154 0 C-N-CA 122.423 2.082 . . . . 0.0 113.188 -179.147 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -104.08 -10.29 18.12 Favored 'General case' 0 CA--C 1.487 -1.446 0 CA-C-O 121.138 0.494 . . . . 0.0 110.939 -174.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.403 ' CG ' ' HB2' ' A' ' 163' ' ' GLU . 0.1 OUTLIER -84.52 124.87 31.86 Favored 'General case' 0 N--CA 1.419 -1.993 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 -177.334 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -79.07 -173.98 3.85 Favored 'General case' 0 C--N 1.283 -2.308 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.306 179.229 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 168' ' ' TYR . . . . . 0.419 ' HE1' ' HB2' ' A' ' 160' ' ' SER . 98.4 m-85 -120.47 107.25 12.66 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.81 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.555 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 21.4 p-80 -96.5 171.1 8.77 Favored 'General case' 0 C--N 1.291 -1.968 0 C-N-CA 120.137 -0.625 . . . . 0.0 111.082 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -51.51 125.6 15.02 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 123.872 0.733 . . . . 0.0 110.948 179.803 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.48 -10.23 21.89 Favored Glycine 0 N--CA 1.424 -2.111 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -177.61 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.2 mm-40 -85.26 136.96 33.28 Favored 'General case' 0 N--CA 1.438 -1.072 0 CA-C-O 121.537 0.684 . . . . 0.0 112.041 -179.636 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -115.11 120.38 39.59 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 176.715 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.502 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 83.3 t -108.1 110.98 33.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.641 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 72.7 ttt180 -106.37 147.72 28.91 Favored 'General case' 0 N--CA 1.425 -1.696 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.415 ' CD2' ' HD3' ' A' ' 152' ' ' PRO . 60.9 m-85 -119.41 165.97 13.66 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.025 0.441 . . . . 0.0 111.134 -175.142 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.467 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.0 OUTLIER -130.28 156.65 42.52 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.715 0 CA-C-N 115.069 -0.969 . . . . 0.0 109.745 175.21 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.7 m -111.81 142.98 43.5 Favored 'General case' 0 C--N 1.278 -2.531 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 171.441 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -44.74 -80.68 0.01 OUTLIER 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 114.331 1.234 . . . . 0.0 114.331 -177.173 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 64.6 m -149.24 -42.05 0.14 Allowed 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 114.018 1.118 . . . . 0.0 114.018 -178.364 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -102.29 2.22 50.53 Favored Glycine 0 C--N 1.291 -1.928 0 C-N-CA 120.152 -1.023 . . . . 0.0 114.742 -174.403 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -110.35 175.73 5.32 Favored 'General case' 0 CA--C 1.487 -1.445 0 CA-C-N 117.643 0.721 . . . . 0.0 111.122 -176.33 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 37.6 pttt -136.63 152.56 50.57 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 173.427 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.497 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.9 tt -70.97 143.2 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.473 0 CA-C-O 121.821 0.82 . . . . 0.0 112.71 -176.706 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -39.78 -59.63 1.13 Allowed 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 127.862 2.465 . . . . 0.0 113.061 179.046 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -145.24 -89.58 0.1 OUTLIER Glycine 0 CA--C 1.48 -2.122 0 C-N-CA 120.107 -1.044 . . . . 0.0 111.293 -177.642 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 187' ' ' ASP . . . . . 0.472 ' HB3' ' HG3' ' A' ' 200' ' ' LYS . 6.9 t0 -95.03 158.42 15.47 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.349 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.641 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 13.4 pt-20 -111.28 -9.48 14.29 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 121.084 -0.246 . . . . 0.0 110.772 -177.443 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.463 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.9 pt-20 -131.49 124.67 30.62 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-O 121.816 0.817 . . . . 0.0 112.869 -178.096 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 17.4 ptp -109.65 151.01 27.41 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.811 178.412 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 63.4 m80 -127.37 156.73 41.57 Favored 'General case' 0 CA--C 1.498 -1.043 0 C-N-CA 122.403 0.281 . . . . 0.0 110.66 -178.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 5.1 m -81.75 117.14 21.82 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.066 176.287 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 37.2 m -82.1 152.54 26.5 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.398 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -72.1 78.51 0.94 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 122.852 1.31 . . . . 0.0 112.257 -176.532 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -175.36 -47.16 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.627 0 CA-C-N 112.986 -1.915 . . . . 0.0 106.186 -179.175 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 121.28 66.34 0.25 Allowed Glycine 0 N--CA 1.427 -1.901 0 CA-C-N 114.547 -1.206 . . . . 0.0 112.21 -178.75 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -167.29 161.94 14.59 Favored 'General case' 0 C--O 1.248 0.979 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 176.58 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.9 m95 -85.15 139.46 31.68 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 124.005 0.816 . . . . 0.0 110.846 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.7 p -71.51 -18.64 62.27 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.252 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.584 ' HE3' ' O ' ' A' ' 201' ' ' GLU . 0.0 OUTLIER -123.94 153.49 41.13 Favored 'General case' 0 N--CA 1.426 -1.626 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 -179.879 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.584 ' O ' ' HE3' ' A' ' 200' ' ' LYS . 3.2 mp0 -77.55 168.4 20.05 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 106.532 -1.655 . . . . 0.0 106.532 177.261 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 202' ' ' LYS . . . . . 0.401 ' HB3' ' HE2' ' A' ' 202' ' ' LYS . 0.8 OUTLIER -68.89 114.91 26.14 Favored Pre-proline 0 C--N 1.311 -1.084 0 C-N-CA 119.915 -0.714 . . . . 0.0 109.722 176.566 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_endo -82.79 166.94 14.93 Favored 'Trans proline' 0 N--CA 1.431 -2.173 0 C-N-CA 121.95 1.766 . . . . 0.0 111.645 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 204' ' ' LYS . . . . . 0.416 ' HB2' ' HG2' ' A' ' 153' ' ' GLU . 9.8 ptpp? -131.08 179.06 6.22 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.16 -177.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.43 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 87.6 m -115.32 114.18 24.81 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 178.497 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.9 m . . . . . 0 C--N 1.302 -1.471 0 CA-C-N 114.796 -1.093 . . . . 0.0 109.692 -174.096 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.442 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 39.9 Cg_endo . . . . . 0 CA--C 1.538 0.711 0 CA-C-O 122.19 0.829 . . . . 0.0 110.772 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.9 m -92.41 -33.09 14.69 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.696 -1.138 . . . . 0.0 108.295 175.661 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.04 -91.79 0.58 Allowed Glycine 0 N--CA 1.402 -3.618 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 174.317 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.5 t-80 -174.7 132.61 0.49 Allowed Pre-proline 0 C--N 1.268 -2.973 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 -176.058 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.415 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 98.1 Cg_endo -81.97 5.75 6.12 Favored 'Trans proline' 0 N--CA 1.475 0.439 0 C-N-CA 122.363 2.042 . . . . 0.0 113.405 -172.492 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 113.58 -173.77 15.25 Favored Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -177.44 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -151.68 160.51 43.59 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 178.22 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.445 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 5.5 t -140.05 144.59 38.64 Favored Pre-proline 0 C--N 1.294 -1.809 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.723 -174.654 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 91' ' ' THR . 2.7 Cg_endo -83.09 -16.77 7.13 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 122.692 2.261 . . . . 0.0 110.611 174.12 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 40.4 m-85 -87.53 2.37 50.91 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.772 -175.018 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.523 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 164.4 -127.1 1.6 Allowed Glycine 0 N--CA 1.415 -2.726 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.756 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.2 t -161.08 -161.97 0.87 Allowed 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -178.181 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -155.02 159.43 40.31 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 177.45 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 16.2 m -121.34 163.35 18.78 Favored 'General case' 0 C--N 1.278 -2.527 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.456 HD11 ' CE1' ' A' ' 104' ' ' PHE . 20.6 mt -121.64 129.24 52.66 Favored 'General case' 0 C--N 1.284 -2.259 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -178.377 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.2 p -124.79 130.22 51.97 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.879 -176.071 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.33 20.97 28.4 Favored Glycine 0 C--N 1.303 -1.278 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.373 -178.63 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.94 -31.74 0.14 Allowed Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 119.907 -1.139 . . . . 0.0 113.128 177.809 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 6.7 m120 67.8 10.27 7.67 Favored 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 123.267 0.627 . . . . 0.0 112.461 -177.1 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.532 ' O ' HG11 ' A' ' 108' ' ' VAL . 27.3 m -143.34 -171.67 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.501 -0.909 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 -176.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.456 ' CE1' HD11 ' A' ' 98' ' ' LEU . 23.4 m-85 -104.71 46.36 0.92 Allowed 'General case' 0 C--N 1.311 -1.083 0 CA-C-O 121.092 0.473 . . . . 0.0 110.162 -177.509 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.726 ' O ' HG12 ' A' ' 108' ' ' VAL . 14.9 pt-20 -87.88 175.74 7.67 Favored 'General case' 0 C--O 1.212 -0.884 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.408 178.016 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' TYR . . . . . 0.442 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 42.4 m-85 -74.69 131.57 40.98 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-O 121.088 0.47 . . . . 0.0 111.441 178.661 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 96.72 -1.13 61.42 Favored Glycine 0 N--CA 1.437 -1.239 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.112 178.413 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.726 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.7 p -90.29 146.57 6.03 Favored 'Isoleucine or valine' 0 C--O 1.243 0.749 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.438 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.3 mtpt -109.5 122.97 48.59 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.543 178.737 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.495 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.46 93.17 9.07 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 176.877 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 75.7 t -86.46 108.03 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.745 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' TYR . . . . . 0.513 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 66.4 t80 -78.3 140.55 38.82 Favored 'General case' 0 C--N 1.268 -2.942 0 CA-C-N 114.121 -1.4 . . . . 0.0 109.952 -174.59 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -143.48 132.38 22.78 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-O 121.9 0.857 . . . . 0.0 109.858 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 57.0 m -85.69 159.64 19.75 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.817 -176.198 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.523 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 54.9 m-20 -65.85 176.97 1.41 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.726 178.523 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -56.12 -49.3 74.27 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 123.522 0.729 . . . . 0.0 112.396 -175.791 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.21 33.34 4.09 Favored Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.256 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 84.5 m-85 -146.56 158.21 43.86 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 124.224 1.01 . . . . 0.0 109.043 -178.33 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -136.1 169.75 17.12 Favored 'General case' 0 C--N 1.279 -2.457 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 177.129 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 10.5 tp -86.97 153.72 21.35 Favored 'General case' 0 C--N 1.287 -2.121 0 C-N-CA 119.259 -0.977 . . . . 0.0 108.397 178.266 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.05 125.31 31.11 Favored 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 176.218 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.68 175.8 20.04 Favored Glycine 0 C--N 1.292 -1.876 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -176.186 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -94.73 -28.9 15.06 Favored 'General case' 0 CA--C 1.5 -0.943 0 CA-C-O 121.26 0.553 . . . . 0.0 111.0 -177.327 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.584 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 48.8 mm -81.1 129.78 36.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.178 -178.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -133.21 9.15 4.06 Favored 'General case' 0 C--O 1.213 -0.851 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 178.158 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.495 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 22.6 p90 -147.54 158.75 44.13 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.19 0.519 . . . . 0.0 110.425 -176.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 59.7 mtp180 -125.12 132.11 53.16 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 172.259 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -107.3 130.82 54.72 Favored 'General case' 0 C--N 1.275 -2.65 0 C-N-CA 119.408 -0.917 . . . . 0.0 109.715 -177.692 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 35.8 t -82.52 101.57 10.81 Favored 'General case' 0 N--CA 1.428 -1.536 0 C-N-CA 118.098 -1.441 . . . . 0.0 110.454 177.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.41 ' OD1' HG22 ' A' ' 131' ' ' THR . 6.4 t70 -98.79 -169.56 1.8 Allowed 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 105.496 -2.038 . . . . 0.0 105.496 175.505 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.41 HG22 ' OD1' ' A' ' 130' ' ' ASP . 13.2 t -65.33 -24.36 67.24 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 118.362 0.528 . . . . 0.0 110.965 -176.869 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -70.51 -24.18 62.78 Favored 'General case' 0 C--O 1.249 1.03 0 CA-C-O 122.105 0.955 . . . . 0.0 110.558 175.243 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.62 -148.11 18.91 Favored Glycine 0 N--CA 1.411 -2.985 0 N-CA-C 107.577 -2.209 . . . . 0.0 107.577 -172.819 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.454 ' CH2' HG13 ' A' ' 108' ' ' VAL . 97.4 m95 -71.12 112.78 7.54 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 117.235 0.518 . . . . 0.0 110.822 177.722 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 65.0 p -70.5 168.12 16.9 Favored 'General case' 0 C--O 1.269 2.116 0 N-CA-C 109.001 -0.741 . . . . 0.0 109.001 176.686 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 63.44 -163.1 0.27 Allowed 'General case' 0 C--O 1.242 0.674 0 O-C-N 124.07 0.856 . . . . 0.0 108.992 177.163 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -126.31 178.73 5.65 Favored 'General case' 0 C--N 1.279 -2.478 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 173.743 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 57.0 mt -67.2 119.77 67.21 Favored Pre-proline 0 C--N 1.298 -1.638 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 175.264 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.584 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 1.5 Cg_endo -58.18 165.09 7.6 Favored 'Trans proline' 0 C--O 1.24 0.606 0 C-N-CA 122.451 2.101 . . . . 0.0 111.834 177.762 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 61.8 mt -102.18 135.8 37.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.236 -172.785 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.432 ' SG ' ' CE2' ' A' ' 112' ' ' TYR . 90.2 m -103.28 148.47 25.79 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 171.699 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -128.5 151.76 49.05 Favored 'General case' 0 C--N 1.266 -3.052 0 N-CA-C 105.261 -2.125 . . . . 0.0 105.261 174.429 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.554 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 7.3 p -71.45 147.35 10.97 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.607 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.131 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.61 HG23 ' HB2' ' A' ' 170' ' ' PHE . 11.6 m -67.18 121.92 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.911 0 C-N-CA 118.478 -1.289 . . . . 0.0 109.243 176.132 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.554 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 52.3 mtmt -115.97 142.91 46.17 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.307 -0.861 . . . . 0.0 111.312 -172.208 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 19.0 m -110.35 142.82 41.48 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 178.079 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' LEU . . . . . 0.483 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.1 mm? -60.95 144.42 90.51 Favored Pre-proline 0 N--CA 1.426 -1.661 0 N-CA-C 113.653 0.983 . . . . 0.0 113.653 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 31.4 Cg_exo -57.61 142.47 95.66 Favored 'Trans proline' 0 C--O 1.246 0.878 0 C-N-CA 123.493 2.796 . . . . 0.0 111.857 177.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.2 t -110.67 149.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 16.9 p -80.72 -83.57 0.11 Allowed 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 122.131 0.172 . . . . 0.0 111.093 178.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.35 153.51 0.23 Allowed Pre-proline 0 C--O 1.237 0.44 0 C-N-CA 125.883 1.673 . . . . 0.0 106.729 179.515 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.14 160.94 46.04 Favored 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 121.548 1.498 . . . . 0.0 111.574 175.118 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -65.4 -32.68 74.44 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 114.582 1.326 . . . . 0.0 114.582 -173.862 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 31.6 m120 -126.26 32.79 5.14 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 121.777 0.799 . . . . 0.0 108.901 -179.226 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -156.59 -168.09 18.81 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.413 178.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 24.0 pttm -150.02 171.66 16.49 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 117.178 0.489 . . . . 0.0 109.705 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 53.5 mt -94.92 129.22 45.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.498 HG22 ' O ' ' A' ' 175' ' ' ARG . 10.5 m -82.09 -24.71 9.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-O 121.369 0.604 . . . . 0.0 110.569 -177.328 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 6.5 m -82.83 -6.83 59.62 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.409 -177.466 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 15.5 p 55.07 160.93 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 126.378 1.871 . . . . 0.0 115.119 -178.239 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -87.29 117.67 26.2 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 176.471 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 65.8 mtm -65.29 -76.57 0.07 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.328 0.585 . . . . 0.0 110.197 -177.006 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -144.14 150.12 47.71 Favored Pre-proline 0 C--N 1.298 -1.654 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 178.665 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -63.86 -18.5 64.17 Favored 'Trans proline' 0 CA--C 1.547 1.141 0 C-N-CA 122.794 2.329 . . . . 0.0 113.684 -179.53 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -96.01 -25.14 16.04 Favored 'General case' 0 CA--C 1.501 -0.939 0 CA-C-O 121.085 0.469 . . . . 0.0 110.152 179.342 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 5.0 mmp_? -84.16 113.35 21.01 Favored 'General case' 0 N--CA 1.421 -1.921 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.698 -176.384 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -82.23 168.81 17.26 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.149 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -88.13 140.32 29.61 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 177.183 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.481 ' CD2' ' HG2' ' A' ' 145' ' ' LYS . 39.0 m170 -119.26 157.55 27.82 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 119.325 -0.369 . . . . 0.0 110.407 -172.143 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.61 ' HB2' HG23 ' A' ' 144' ' ' VAL . 85.7 t80 -35.15 127.75 0.54 Allowed 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 176.876 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 103.41 -30.31 10.58 Favored Glycine 0 N--CA 1.427 -1.943 0 CA-C-N 114.783 -1.099 . . . . 0.0 112.82 177.64 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -72.3 145.28 47.95 Favored 'General case' 0 N--CA 1.402 -2.827 0 CA-C-N 117.266 0.533 . . . . 0.0 110.248 -177.635 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -122.39 122.54 39.25 Favored 'General case' 0 N--CA 1.414 -2.241 0 CA-C-N 115.205 -0.907 . . . . 0.0 108.835 178.506 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 54.9 t -93.71 105.01 16.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.254 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 174.705 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.498 ' O ' HG22 ' A' ' 158' ' ' VAL . 19.3 ttp180 -103.37 146.64 28.18 Favored 'General case' 0 N--CA 1.402 -2.847 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -178.498 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -117.13 166.76 11.85 Favored 'General case' 0 C--N 1.279 -2.485 0 CA-C-O 121.102 0.477 . . . . 0.0 109.945 -174.182 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.0 p -145.43 139.8 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.21 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 174.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' CYS . . . . . 0.411 ' SG ' ' HB ' ' A' ' 184' ' ' ILE . 77.5 m -101.72 157.2 17.01 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -65.71 163.4 16.59 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 177.836 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 15.3 t -46.83 -33.45 4.48 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -169.453 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -108.52 18.04 32.97 Favored Glycine 0 C--N 1.289 -2.04 0 C-N-CA 120.427 -0.892 . . . . 0.0 114.203 -177.48 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -119.29 158.86 25.21 Favored 'General case' 0 CA--C 1.486 -1.519 0 CA-C-N 118.28 1.04 . . . . 0.0 110.795 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 14.8 pttm -120.14 150.97 39.76 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.316 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.424 HD13 ' HA ' ' A' ' 188' ' ' GLU . 8.3 tt -84.32 136.31 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.313 0 C-N-CA 119.279 -0.969 . . . . 0.0 108.902 174.485 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -86.65 -45.65 10.81 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.967 -1.015 . . . . 0.0 109.226 -174.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -78.46 -157.57 10.59 Favored Glycine 0 C--N 1.302 -1.33 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 173.355 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 187' ' ' ASP . . . . . 0.451 ' HB3' ' HG3' ' A' ' 200' ' ' LYS . 17.1 t70 -82.04 169.34 16.82 Favored 'General case' 0 C--N 1.314 -0.977 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.132 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.424 ' HA ' HD13 ' A' ' 184' ' ' ILE . 13.1 pt-20 -81.44 -13.57 58.07 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-N 118.778 0.717 . . . . 0.0 110.865 -173.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -147.47 170.77 16.7 Favored 'General case' 0 N--CA 1.423 -1.779 0 CA-C-O 121.513 0.673 . . . . 0.0 111.431 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.0 ptp -141.8 125.66 17.09 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.911 175.372 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 1.9 m80 -98.54 147.27 24.95 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.526 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 192' ' ' CYS . . . . . 0.409 ' HB3' ' HA ' ' A' ' 170' ' ' PHE . 1.7 m -73.62 110.78 8.18 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.834 171.272 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 28.8 m -83.61 160.02 21.48 Favored 'General case' 0 N--CA 1.428 -1.574 0 O-C-N 123.925 0.766 . . . . 0.0 109.342 -179.269 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -70.37 1.56 4.84 Favored 'General case' 0 N--CA 1.486 1.34 0 CA-C-O 121.261 0.553 . . . . 0.0 112.423 -176.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -84.6 -17.53 38.44 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.376 174.373 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 90.1 23.3 32.71 Favored Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.288 -0.958 . . . . 0.0 110.865 -174.273 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -131.01 164.5 25.26 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 58.0 m95 -79.59 143.37 34.8 Favored 'General case' 0 N--CA 1.426 -1.642 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 174.638 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.1 m -63.77 -20.77 66.02 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-O 121.153 0.502 . . . . 0.0 111.104 177.446 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.451 ' HG3' ' HB3' ' A' ' 187' ' ' ASP . 30.5 mmmt -133.74 158.78 42.44 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.058 -177.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 25.3 mm-40 -79.63 168.0 19.95 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 114.554 -1.203 . . . . 0.0 108.392 171.742 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 17.2 tptm -55.43 117.26 14.21 Favored Pre-proline 0 N--CA 1.439 -0.989 0 O-C-N 123.863 0.727 . . . . 0.0 110.02 176.355 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -87.5 158.4 7.94 Favored 'Trans proline' 0 N--CA 1.423 -2.639 0 C-N-CA 122.066 1.844 . . . . 0.0 111.663 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 204' ' ' LYS . . . . . 0.418 ' HG2' HG13 ' A' ' 206' ' ' VAL . 37.9 ttpt -122.42 149.08 44.32 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.709 -175.678 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.408 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 92.7 m -108.38 115.67 30.54 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 176.244 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 206' ' ' VAL . . . . . 0.418 HG13 ' HG2' ' A' ' 204' ' ' LYS . 9.4 m . . . . . 0 C--N 1.29 -1.981 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.126 -175.177 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo . . . . . 0 CA--C 1.534 0.477 0 CA-C-O 121.796 0.665 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 59.5 m -88.23 -36.99 16.44 Favored 'General case' 0 N--CA 1.435 -1.204 0 CA-C-N 114.813 -1.085 . . . . 0.0 109.29 175.79 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 115.98 -87.72 0.44 Allowed Glycine 0 CA--C 1.463 -3.206 0 N-CA-C 110.081 -1.207 . . . . 0.0 110.081 174.34 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.7 t-80 -177.72 127.77 0.29 Allowed Pre-proline 0 C--N 1.269 -2.922 0 N-CA-C 104.901 -2.259 . . . . 0.0 104.901 -175.642 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -79.99 12.26 2.52 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 123.043 2.495 . . . . 0.0 114.342 -171.909 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 106.03 -169.63 15.98 Favored Glycine 0 N--CA 1.424 -2.126 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -176.305 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -160.27 139.59 10.88 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 177.717 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.3 t -110.87 131.74 21.98 Favored Pre-proline 0 C--N 1.303 -1.449 0 C-N-CA 120.631 -0.428 . . . . 0.0 111.758 -175.85 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -70.02 -18.3 35.85 Favored 'Trans proline' 0 C--N 1.351 0.681 0 C-N-CA 122.826 2.351 . . . . 0.0 111.695 176.596 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -83.57 -2.5 56.18 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.329 -176.721 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.503 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.09 -124.49 1.04 Allowed Glycine 0 N--CA 1.414 -2.817 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.328 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 14.8 t -164.8 -165.27 0.89 Allowed 'General case' 0 C--N 1.285 -2.228 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.55 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.7 p90 -146.18 165.65 28.54 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.896 -0.503 . . . . 0.0 109.758 178.203 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -126.12 162.44 25.34 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.962 -1.495 . . . . 0.0 106.962 176.64 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 16.5 mt -114.88 132.91 56.37 Favored 'General case' 0 C--N 1.278 -2.51 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.314 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 19.9 p -128.9 128.48 43.9 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 -177.161 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 93.41 30.13 9.49 Favored Glycine 0 C--N 1.292 -1.863 0 C-N-CA 119.994 -1.098 . . . . 0.0 111.253 -178.302 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 164.17 -35.51 0.29 Allowed Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.705 -1.236 . . . . 0.0 111.974 177.396 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 68.85 14.25 8.91 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.547 0.739 . . . . 0.0 112.338 179.96 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.506 ' O ' HG11 ' A' ' 108' ' ' VAL . 29.3 m -147.74 -168.92 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.211 -0.951 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 -178.616 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -106.34 42.78 1.22 Allowed 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 119.118 0.872 . . . . 0.0 110.238 -178.115 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.719 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.8 pt-20 -79.27 173.91 12.11 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 114.641 -1.163 . . . . 0.0 111.588 178.262 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -75.98 127.59 33.3 Favored 'General case' 0 C--N 1.295 -1.762 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.059 176.201 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 104.17 -7.58 48.04 Favored Glycine 0 N--CA 1.435 -1.414 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.489 179.694 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.719 HG12 ' O ' ' A' ' 105' ' ' GLU . 13.9 p -87.76 148.9 4.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -178.32 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -112.03 123.72 50.86 Favored 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.574 179.181 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.445 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.85 96.99 10.4 Favored 'General case' 0 C--N 1.291 -1.939 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 176.523 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.426 HG12 ' HB3' ' A' ' 126' ' ' TYR . 22.6 m -95.24 111.18 25.32 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.511 0 CA-C-O 122.564 1.174 . . . . 0.0 109.457 -179.168 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -78.92 148.96 32.5 Favored 'General case' 0 C--N 1.26 -3.32 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.813 -177.62 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.9 t -145.35 130.94 18.85 Favored 'General case' 0 N--CA 1.422 -1.839 0 CA-C-N 115.012 -0.995 . . . . 0.0 108.895 177.295 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 20.5 m -82.47 160.61 22.63 Favored 'General case' 0 C--N 1.284 -2.277 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.314 -175.732 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.503 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 71.1 m-20 -73.19 -178.06 2.75 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.952 178.812 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -53.31 -53.09 56.02 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 125.02 1.328 . . . . 0.0 113.375 -175.43 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.403 ' O ' HG23 ' A' ' 143' ' ' VAL . . . -88.25 31.81 4.64 Favored Glycine 0 C--N 1.305 -1.18 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.414 -177.542 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -146.1 153.65 40.94 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -175.044 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -133.13 171.88 13.4 Favored 'General case' 0 C--N 1.272 -2.776 0 N-CA-C 105.923 -1.881 . . . . 0.0 105.923 175.663 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.449 HD11 ' HB2' ' A' ' 139' ' ' PRO . 13.1 tp -87.47 149.87 24.13 Favored 'General case' 0 C--N 1.282 -2.357 0 C-N-CA 119.135 -1.026 . . . . 0.0 108.563 179.216 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -122.51 121.83 37.48 Favored 'General case' 0 N--CA 1.408 -2.539 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 176.81 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.92 171.52 23.44 Favored Glycine 0 C--N 1.284 -2.33 0 C-N-CA 120.796 -0.716 . . . . 0.0 111.943 -175.434 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -86.27 -34.72 20.3 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.65 0.738 . . . . 0.0 109.495 -176.927 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.3 mm -77.97 126.67 38.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-N 114.988 -1.006 . . . . 0.0 109.814 -175.925 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -127.57 1.93 6.19 Favored 'General case' 0 C--O 1.201 -1.454 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 176.899 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.445 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 18.2 p90 -136.51 162.43 33.12 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.42 -171.64 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 63.3 mtp180 -130.78 131.12 44.51 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 170.341 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -103.9 132.31 50.28 Favored 'General case' 0 C--N 1.292 -1.899 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.698 179.509 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 23.9 t -82.22 97.78 8.42 Favored 'General case' 0 N--CA 1.425 -1.681 0 C-N-CA 118.238 -1.385 . . . . 0.0 109.257 175.741 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -94.83 -173.41 2.98 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 106.673 -1.602 . . . . 0.0 106.673 178.163 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 14.1 t -67.01 -14.39 62.85 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.69 0.757 . . . . 0.0 111.277 -175.192 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -86.73 -28.64 22.94 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.017 177.953 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 132.13 -163.85 23.86 Favored Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 -175.405 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.469 ' CH2' HG13 ' A' ' 108' ' ' VAL . 98.5 m95 -63.62 113.55 3.4 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 117.85 0.825 . . . . 0.0 110.858 175.714 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 51.9 p -70.67 166.84 19.93 Favored 'General case' 0 C--O 1.267 2.006 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 177.542 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 62.24 -163.39 0.26 Allowed 'General case' 0 C--O 1.251 1.145 0 O-C-N 123.921 0.763 . . . . 0.0 109.383 178.061 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 37.6 t0 -131.59 177.88 7.17 Favored 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 174.419 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 71.7 mt -62.68 114.98 13.84 Favored Pre-proline 0 C--N 1.27 -2.873 0 C-N-CA 124.774 1.229 . . . . 0.0 108.036 175.193 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.449 ' HB2' HD11 ' A' ' 120' ' ' LEU . 29.1 Cg_endo -65.07 151.31 86.13 Favored 'Trans proline' 0 N--CA 1.447 -1.264 0 C-N-CA 122.479 2.119 . . . . 0.0 112.062 -177.929 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 48.2 mt -87.16 134.37 27.77 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.118 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.512 -174.165 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 93.5 m -107.82 148.13 29.95 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 171.165 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -129.8 144.85 51.51 Favored 'General case' 0 C--N 1.284 -2.266 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -179.824 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 117' ' ' GLY . 4.8 p -73.26 129.43 36.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.846 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.637 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 27.6 m -54.19 130.02 15.71 Favored 'Isoleucine or valine' 0 C--O 1.243 0.741 0 O-C-N 123.848 0.717 . . . . 0.0 112.209 -174.827 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.435 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 94.8 mttt -112.54 170.08 8.43 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.533 -175.985 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.0 p -150.41 158.82 44.58 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.052 176.33 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 147' ' ' LEU . . . . . 0.475 HD23 ' HD2' ' A' ' 148' ' ' PRO . 1.4 tt -55.48 131.6 70.76 Favored Pre-proline 0 N--CA 1.429 -1.515 0 C-N-CA 125.59 1.556 . . . . 0.0 111.992 -178.258 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.475 ' HD2' HD23 ' A' ' 147' ' ' LEU . 37.8 Cg_endo -69.08 100.6 0.74 Allowed 'Trans proline' 0 N--CA 1.445 -1.334 0 C-N-CA 122.846 2.364 . . . . 0.0 111.806 176.963 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 10.2 p -64.07 140.05 20.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.935 0 CA-C-N 115.428 -0.805 . . . . 0.0 108.948 176.607 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 15.6 p -73.12 -82.38 0.05 Allowed 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -174.529 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 175.45 162.62 0.41 Allowed Pre-proline 0 CA--C 1.517 -0.311 0 C-N-CA 124.771 1.228 . . . . 0.0 107.843 179.403 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -74.05 -178.16 3.69 Favored 'Trans proline' 0 N--CA 1.446 -1.301 0 C-N-CA 121.353 1.369 . . . . 0.0 110.254 170.57 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 153' ' ' GLU . . . . . 0.542 ' OE2' ' HG3' ' A' ' 204' ' ' LYS . 0.0 OUTLIER -93.15 -41.07 10.13 Favored 'General case' 0 C--N 1.289 -2.04 0 O-C-N 122.051 -0.406 . . . . 0.0 111.413 -176.394 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 154' ' ' ASN . . . . . 0.436 ' OD1' ' HG2' ' A' ' 153' ' ' GLU . 23.3 m120 -107.59 21.12 17.92 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.529 0.68 . . . . 0.0 110.259 179.736 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -148.54 -172.68 18.65 Favored Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.677 -178.274 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 58.8 pttt -145.98 164.38 32.25 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -176.621 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.436 HG22 ' H ' ' A' ' 159' ' ' SER . 63.5 mt -88.51 136.01 24.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 177.866 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 175' ' ' ARG . 11.5 m -84.73 -25.82 6.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.128 0.489 . . . . 0.0 110.81 -178.004 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.436 ' H ' HG22 ' A' ' 157' ' ' ILE . 21.4 t -128.58 92.4 3.41 Favored 'General case' 0 N--CA 1.432 -1.338 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.761 -174.98 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 32.2 t -148.78 97.54 2.73 Favored 'General case' 0 N--CA 1.426 -1.632 0 CA-C-O 121.108 0.48 . . . . 0.0 109.972 -178.627 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -100.09 90.88 4.53 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 176.364 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.434 ' CE ' ' HA ' ' A' ' 162' ' ' MET . 0.5 OUTLIER -84.22 84.3 7.67 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.815 0.817 . . . . 0.0 109.732 -177.825 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.464 ' HB2' ' HB2' ' A' ' 166' ' ' ARG . 45.8 mm-40 -109.1 163.42 17.04 Favored Pre-proline 0 C--N 1.296 -1.754 0 CA-C-N 114.311 -1.313 . . . . 0.0 108.67 -178.058 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.86 -12.61 19.86 Favored 'Trans proline' 0 C--O 1.221 -0.338 0 C-N-CA 121.954 1.77 . . . . 0.0 110.83 174.67 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -103.51 -38.74 7.03 Favored 'General case' 0 CA--C 1.494 -1.194 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.663 -178.145 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.464 ' HB2' ' HB2' ' A' ' 163' ' ' GLU . 9.9 mmt180 -98.43 100.33 11.58 Favored 'General case' 0 N--CA 1.416 -2.142 0 CA-C-N 115.195 -0.911 . . . . 0.0 113.45 -174.202 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.68 179.7 5.42 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 105.361 -2.088 . . . . 0.0 105.361 167.313 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 168' ' ' TYR . . . . . 0.435 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 95.1 m-85 -77.24 138.46 39.43 Favored 'General case' 0 C--N 1.296 -1.759 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.139 178.575 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.444 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 77.1 m-70 -136.31 169.61 17.37 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.642 -173.747 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.637 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 91.7 t80 -50.11 128.94 20.16 Favored 'General case' 0 C--O 1.24 0.573 0 O-C-N 124.2 0.937 . . . . 0.0 110.571 173.468 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 101.14 -14.08 58.52 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 119.972 -1.108 . . . . 0.0 112.751 175.95 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 17.0 mm-40 -77.19 143.45 39.02 Favored 'General case' 0 C--O 1.251 1.143 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.154 178.272 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -124.86 101.19 6.96 Favored 'General case' 0 C--N 1.285 -2.228 0 CA-C-N 114.767 -1.106 . . . . 0.0 108.859 -179.697 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.409 ' HB ' ' HG3' ' A' ' 190' ' ' MET . 69.2 t -81.38 96.62 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.648 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.252 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.6 ' O ' HG22 ' A' ' 158' ' ' VAL . 26.4 ttp180 -96.81 142.99 28.15 Favored 'General case' 0 N--CA 1.4 -2.936 0 CA-C-N 114.55 -1.204 . . . . 0.0 108.052 177.191 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -113.07 162.14 16.27 Favored 'General case' 0 C--N 1.278 -2.502 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -176.243 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 14.5 p -143.86 137.15 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.346 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 175.761 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 178' ' ' CYS . . . . . 0.432 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 80.8 m -92.7 152.37 19.56 Favored 'General case' 0 C--N 1.257 -3.438 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.586 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 51.2 m-80 -70.6 166.16 21.26 Favored 'General case' 0 CA--C 1.493 -1.22 0 C-N-CA 120.368 -0.533 . . . . 0.0 110.176 179.546 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 12.6 t -53.61 110.31 0.56 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 124.274 0.984 . . . . 0.0 111.163 -176.082 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 116.44 -13.88 15.59 Favored Glycine 0 N--CA 1.435 -1.383 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.706 179.307 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 182' ' ' TYR . . . . . 0.432 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 96.4 m-85 -110.7 163.25 13.94 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 117.482 0.641 . . . . 0.0 110.876 -179.007 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 18.1 ptmt -135.39 157.26 47.34 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.692 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.414 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.8 tt -84.98 137.53 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.766 0 CA-C-O 121.609 0.718 . . . . 0.0 111.127 -179.367 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -72.2 -53.48 12.51 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.091 -177.455 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -93.9 -134.8 7.38 Favored Glycine 0 C--N 1.296 -1.674 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.087 -177.781 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -81.35 169.66 16.96 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 178.462 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.414 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.8 pt-20 -100.63 -15.76 17.65 Favored 'General case' 0 C--N 1.289 -2.048 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -176.338 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -144.19 138.32 28.01 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 -175.394 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.409 ' HG3' ' HB ' ' A' ' 174' ' ' VAL . 13.8 ptp -117.45 130.2 56.31 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.713 174.883 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -102.49 137.19 41.06 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.965 -177.031 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 192' ' ' CYS . . . . . 0.476 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 19.6 t -88.1 107.99 19.03 Favored 'General case' 0 C--O 1.253 1.274 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 174.515 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 21.7 m -102.81 -176.64 3.15 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 112.964 0.727 . . . . 0.0 112.964 -171.148 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -44.37 -39.32 4.56 Favored 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 126.148 1.779 . . . . 0.0 113.491 -176.973 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -63.54 -17.28 62.63 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.862 -177.047 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 78.57 32.91 40.23 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -174.092 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -144.11 171.92 13.62 Favored 'General case' 0 C--O 1.249 1.034 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 -179.544 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 198' ' ' TRP . . . . . 0.476 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 81.9 m95 -87.32 137.6 32.2 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 175.778 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 44.7 m -83.35 -3.31 57.38 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.168 0.509 . . . . 0.0 111.941 179.881 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 20.2 mmtp -128.54 162.15 27.91 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.581 179.471 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -95.65 166.09 12.0 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.935 179.86 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 202' ' ' LYS . . . . . 0.449 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 9.8 tptm -65.34 116.97 35.71 Favored Pre-proline 0 CA--C 1.547 0.834 0 C-N-CA 123.337 0.655 . . . . 0.0 111.299 179.168 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.449 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 6.7 Cg_endo -90.54 177.87 2.17 Favored 'Trans proline' 0 CA--C 1.547 1.148 0 C-N-CA 122.658 2.238 . . . . 0.0 112.85 177.198 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 204' ' ' LYS . . . . . 0.542 ' HG3' ' OE2' ' A' ' 153' ' ' GLU . 22.1 ttmm -131.25 157.11 44.13 Favored 'General case' 0 C--N 1.318 -0.804 0 C-N-CA 124.319 1.048 . . . . 0.0 109.531 -177.238 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.429 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 87.8 m -104.06 119.22 38.47 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 173.857 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.296 -1.758 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.754 -174.693 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.4 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 31.7 Cg_endo . . . . . 0 CA--C 1.531 0.373 0 CA-C-O 121.665 0.611 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.9 m -88.43 -32.96 18.04 Favored 'General case' 0 N--CA 1.436 -1.125 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 176.332 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.99 -85.72 0.4 Allowed Glycine 0 CA--C 1.453 -3.839 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 171.58 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.2 t-80 -173.75 133.75 0.6 Allowed Pre-proline 0 C--N 1.266 -3.037 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 -174.328 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.507 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 89.9 Cg_endo -87.24 -5.07 7.63 Favored 'Trans proline' 0 C--O 1.242 0.686 0 C-N-CA 122.252 1.968 . . . . 0.0 112.94 -176.364 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.499 ' HA3' HD11 ' A' ' 138' ' ' ILE . . . 126.38 -161.72 20.67 Favored Glycine 0 N--CA 1.42 -2.379 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 -178.375 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -158.48 150.52 21.53 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 177.86 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.9 t -131.53 127.04 21.43 Favored Pre-proline 0 C--N 1.301 -1.519 0 C-N-CA 119.746 -0.781 . . . . 0.0 111.994 -177.382 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -71.37 -16.6 31.06 Favored 'Trans proline' 0 CA--C 1.534 0.522 0 C-N-CA 122.541 2.161 . . . . 0.0 111.502 177.075 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 71.5 m-85 -83.45 -6.6 59.51 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.988 -177.458 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.44 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 171.89 -129.94 1.84 Allowed Glycine 0 N--CA 1.414 -2.79 0 C-N-CA 118.838 -1.648 . . . . 0.0 113.48 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.5 p -141.21 178.6 7.28 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 114.989 -0.606 . . . . 0.0 111.288 -174.804 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.466 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 36.5 p90 -148.66 155.23 40.77 Favored 'General case' 0 N--CA 1.431 -1.383 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 171.327 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -123.98 153.15 41.69 Favored 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 -178.316 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -110.74 126.67 54.82 Favored 'General case' 0 C--N 1.271 -2.814 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -179.774 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.424 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 17.2 p -121.26 134.14 55.17 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.265 -176.508 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 108.14 -45.92 1.24 Allowed Glycine 0 C--N 1.311 -0.811 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.989 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.441 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -128.3 -18.21 1.88 Allowed Glycine 0 C--N 1.311 -0.842 0 C-N-CA 120.382 -0.913 . . . . 0.0 113.009 -179.901 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 63.27 16.55 9.54 Favored 'General case' 0 N--CA 1.494 1.731 0 C-N-CA 124.388 1.075 . . . . 0.0 110.868 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.513 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.6 m -148.41 -171.86 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.211 -0.965 0 N-CA-C 106.967 -1.494 . . . . 0.0 106.967 -178.912 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.507 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 32.6 m-85 -101.47 44.66 1.0 Allowed 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 118.794 0.725 . . . . 0.0 110.648 -177.486 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.69 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.2 pt-20 -86.51 -175.73 5.57 Favored 'General case' 0 C--O 1.207 -1.143 0 CA-C-N 114.837 -1.074 . . . . 0.0 111.468 177.638 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 106' ' ' TYR . . . . . 0.4 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 43.5 m-85 -81.05 139.65 35.59 Favored 'General case' 0 C--N 1.308 -1.226 0 O-C-N 121.686 -0.634 . . . . 0.0 111.085 178.786 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.44 4.29 80.55 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.655 -0.702 . . . . 0.0 112.529 179.122 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.69 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -94.25 142.92 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 C-N-CA 119.763 -0.775 . . . . 0.0 109.123 -179.628 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.424 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -107.67 121.23 44.26 Favored 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.708 178.441 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -86.81 89.67 8.04 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 175.575 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 94.6 t -85.71 115.13 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.638 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -177.647 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 112' ' ' TYR . . . . . 0.466 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 43.2 m-85 -86.63 145.77 26.59 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 116.605 -0.271 . . . . 0.0 111.116 -177.061 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.1 t -145.44 116.74 7.95 Favored 'General case' 0 N--CA 1.427 -1.602 0 CA-C-O 122.404 1.097 . . . . 0.0 109.471 178.11 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 28.4 m -72.89 164.95 25.86 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 114.901 -1.045 . . . . 0.0 111.191 -174.887 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.44 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 81.0 m-20 -75.31 171.71 13.73 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.505 177.143 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -58.49 -39.4 79.9 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 113.269 0.84 . . . . 0.0 113.269 -174.331 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.425 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -75.39 12.41 7.55 Favored Glycine 0 CA--C 1.526 0.752 0 C-N-CA 120.838 -0.696 . . . . 0.0 113.063 179.733 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.67 ' HE1' HG22 ' A' ' 143' ' ' VAL . 83.5 m-85 -147.09 170.09 17.9 Favored 'General case' 0 N--CA 1.427 -1.582 0 C-N-CA 124.56 1.144 . . . . 0.0 108.95 -177.51 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.2 pt20 -140.58 173.5 11.43 Favored 'General case' 0 C--N 1.266 -3.058 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 175.699 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.9 tt -99.92 137.5 38.29 Favored 'General case' 0 C--N 1.27 -2.851 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -179.713 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.447 ' HB2' ' HB2' ' A' ' 142' ' ' GLU . 0.2 OUTLIER -127.52 135.83 50.89 Favored 'General case' 0 N--CA 1.423 -1.818 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -176.978 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 130.02 179.29 15.92 Favored Glycine 0 N--CA 1.421 -2.311 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 178.397 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 61.7 mm-40 -95.88 -17.05 21.4 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 122.282 1.039 . . . . 0.0 109.078 177.102 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.6 mm -101.5 142.84 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.588 0 CA-C-N 114.184 -1.371 . . . . 0.0 108.233 179.032 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -141.14 9.61 2.11 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-O 121.278 0.561 . . . . 0.0 109.517 177.795 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 126' ' ' TYR . . . . . . . . . . . . . 32.8 p90 -157.55 159.57 37.28 Favored 'General case' 0 N--CA 1.427 -1.602 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.747 -172.981 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 56.4 mtp180 -121.16 129.85 53.44 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 172.507 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -105.43 130.61 53.48 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -178.512 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.6 t -83.1 105.35 14.01 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 117.625 -1.63 . . . . 0.0 110.206 176.643 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.423 ' OD2' HG22 ' A' ' 131' ' ' THR . 22.5 t70 -94.38 -178.59 4.63 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 178.297 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.423 HG22 ' OD2' ' A' ' 130' ' ' ASP . 11.0 t -63.28 -22.49 66.91 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 121.728 0.775 . . . . 0.0 110.38 -177.729 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -76.59 -37.12 56.99 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.769 177.735 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 139.28 -159.49 25.69 Favored Glycine 0 N--CA 1.434 -1.462 0 N-CA-C 107.982 -2.047 . . . . 0.0 107.982 -173.938 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -66.38 122.99 18.77 Favored 'General case' 0 C--O 1.248 0.979 0 CA-C-N 118.258 1.029 . . . . 0.0 110.539 177.653 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 67.7 p -80.89 163.32 23.47 Favored 'General case' 0 N--CA 1.416 -2.167 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 175.814 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 61.74 -165.21 0.23 Allowed 'General case' 0 C--N 1.323 -0.582 0 O-C-N 124.017 0.823 . . . . 0.0 110.579 175.21 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -129.57 -179.92 5.45 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 175.678 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.499 HD11 ' HA3' ' A' ' 89' ' ' GLY . 62.3 mt -66.6 122.24 81.06 Favored Pre-proline 0 C--N 1.298 -1.648 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 173.245 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.55 158.15 54.59 Favored 'Trans proline' 0 C--O 1.243 0.742 0 C-N-CA 122.67 2.247 . . . . 0.0 111.416 179.275 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 68.0 mt -84.95 131.65 33.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 CA-C-O 121.03 0.443 . . . . 0.0 111.016 -174.051 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 91.4 m -98.45 102.01 13.62 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 173.263 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.447 ' HB2' ' HB2' ' A' ' 121' ' ' LEU . 1.0 OUTLIER -87.88 154.5 20.47 Favored 'General case' 0 CA--C 1.461 -2.443 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.147 178.693 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.67 HG22 ' HE1' ' A' ' 118' ' ' TYR . 4.3 t -80.7 137.34 21.58 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.367 0 CA-C-N 114.82 -1.082 . . . . 0.0 108.661 -177.197 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.6 HG23 ' HB2' ' A' ' 170' ' ' PHE . 3.7 m -69.83 98.34 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.153 177.407 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.454 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 49.2 mttm -88.07 131.81 34.53 Favored 'General case' 0 N--CA 1.417 -2.094 0 CA-C-N 113.754 -1.566 . . . . 0.0 109.387 -176.945 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.43 ' O ' ' HB2' ' A' ' 168' ' ' TYR . 61.6 m -94.16 127.43 39.99 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 107.17 -1.419 . . . . 0.0 107.17 177.026 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -50.24 138.94 19.69 Favored Pre-proline 0 N--CA 1.438 -1.071 0 N-CA-C 114.655 1.354 . . . . 0.0 114.655 -176.264 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -69.7 123.38 10.07 Favored 'Trans proline' 0 N--CA 1.444 -1.425 0 C-N-CA 122.926 2.417 . . . . 0.0 112.304 -175.522 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 21.2 t -91.84 130.75 40.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.4 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.3 m -74.93 -67.96 0.59 Allowed 'General case' 0 N--CA 1.414 -2.268 0 C-N-CA 122.764 0.425 . . . . 0.0 111.16 -177.866 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.96 150.12 0.22 Allowed Pre-proline 0 CA--C 1.509 -0.599 0 C-N-CA 124.686 1.194 . . . . 0.0 108.079 -178.934 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -77.07 174.7 12.41 Favored 'Trans proline' 0 N--CA 1.446 -1.315 0 C-N-CA 121.836 1.691 . . . . 0.0 110.811 173.947 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -61.58 -51.78 67.14 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 114.215 1.191 . . . . 0.0 114.215 -174.913 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -123.29 23.27 9.14 Favored 'General case' 0 CA--C 1.496 -1.108 0 CA-C-O 122.032 0.92 . . . . 0.0 109.891 -172.411 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 155' ' ' GLY . . . . . 0.472 ' HA3' ' SG ' ' A' ' 205' ' ' CYS . . . -140.47 -178.15 16.76 Favored Glycine 0 C--N 1.281 -2.516 0 CA-C-N 114.071 -1.422 . . . . 0.0 109.906 178.716 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 47.6 pttt -143.91 162.52 35.91 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 -177.146 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.559 HG22 ' H ' ' A' ' 159' ' ' SER . 46.7 mt -92.25 135.98 25.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 -179.632 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' A' ' 175' ' ' ARG . 10.8 m -71.19 -23.14 22.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-O 121.872 0.844 . . . . 0.0 111.382 -175.281 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.559 ' H ' HG22 ' A' ' 157' ' ' ILE . 20.8 t -122.89 173.59 7.69 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -178.849 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 71.0 m -162.48 -47.14 0.04 OUTLIER 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.52 0.676 . . . . 0.0 109.97 178.235 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -150.19 78.67 1.34 Allowed 'General case' 0 N--CA 1.44 -0.964 0 CA-C-O 121.85 0.833 . . . . 0.0 109.589 179.479 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.51 -23.24 34.72 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.486 -179.133 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -111.03 149.69 40.83 Favored Pre-proline 0 C--N 1.311 -1.079 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.133 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.63 -3.92 14.54 Favored 'Trans proline' 0 N--CA 1.482 0.839 0 C-N-CA 123.023 2.482 . . . . 0.0 110.842 177.621 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -89.06 -26.77 21.23 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 179.192 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 50.9 mtt180 71.69 -16.29 0.4 Allowed 'General case' 0 CA--C 1.497 -1.063 0 C-N-CA 127.426 2.29 . . . . 0.0 116.21 170.668 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 22.9 mm-40 -77.48 154.83 32.16 Favored 'General case' 0 C--N 1.249 -3.777 0 CA-C-N 114.761 -1.108 . . . . 0.0 109.34 176.999 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 168' ' ' TYR . . . . . 0.454 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 95.5 m-85 -92.78 134.45 35.05 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 176.755 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 23.3 m80 -129.28 161.5 30.08 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -174.469 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.6 ' HB2' HG23 ' A' ' 144' ' ' VAL . 87.1 t80 -51.9 107.74 0.22 Allowed 'General case' 0 N--CA 1.469 0.513 0 O-C-N 123.82 0.7 . . . . 0.0 110.675 174.54 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 139.05 -24.57 2.83 Favored Glycine 0 N--CA 1.433 -1.557 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -175.681 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -78.34 160.91 27.57 Favored 'General case' 0 N--CA 1.429 -1.523 0 CA-C-O 121.602 0.715 . . . . 0.0 112.897 -179.43 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.424 ' HA ' ' O ' ' A' ' 190' ' ' MET . . . -148.28 118.46 7.28 Favored 'General case' 0 N--CA 1.423 -1.775 0 CA-C-N 114.376 -1.283 . . . . 0.0 109.027 179.793 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.482 HG23 ' CH2' ' A' ' 198' ' ' TRP . 46.2 t -86.18 107.41 16.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.13 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.537 ' HB3' HG21 ' A' ' 158' ' ' VAL . 78.9 ttt180 -99.64 140.57 33.65 Favored 'General case' 0 N--CA 1.42 -1.954 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 178.067 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -114.49 161.09 18.45 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 -176.468 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 7.7 p -140.9 128.06 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.812 0 CA-C-N 115.22 -0.9 . . . . 0.0 109.931 175.948 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 178' ' ' CYS . . . . . 0.454 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 71.7 m -89.11 152.24 21.76 Favored 'General case' 0 C--N 1.276 -2.607 0 CA-C-N 114.915 -1.038 . . . . 0.0 110.138 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -68.9 -179.92 1.62 Allowed 'General case' 0 C--O 1.239 0.532 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.714 178.663 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 8.8 p -47.02 -39.67 13.14 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 115.945 1.832 . . . . 0.0 115.945 -172.097 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -109.51 15.5 32.25 Favored Glycine 0 C--N 1.286 -2.212 0 C-N-CA 120.328 -0.939 . . . . 0.0 113.239 -176.626 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 182' ' ' TYR . . . . . 0.454 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 96.5 m-85 -116.12 157.97 23.94 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 117.974 0.887 . . . . 0.0 111.571 -178.24 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -126.93 158.05 37.82 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 106.557 -1.645 . . . . 0.0 106.557 175.763 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.674 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.5 tt -91.28 139.45 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.23 0 C-N-CA 119.167 -1.013 . . . . 0.0 110.806 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -50.04 -58.95 4.42 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 126.08 1.752 . . . . 0.0 113.106 -177.657 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -128.64 -103.88 1.15 Allowed Glycine 0 CA--C 1.493 -1.331 0 C-N-CA 120.247 -0.978 . . . . 0.0 111.276 -178.394 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -80.52 159.12 25.62 Favored 'General case' 0 CA--C 1.486 -1.497 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 177.815 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.674 ' HA ' HD13 ' A' ' 184' ' ' ILE . 15.0 pt-20 -103.45 4.45 36.08 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.428 -0.909 . . . . 0.0 109.507 178.34 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -148.44 146.61 28.5 Favored 'General case' 0 N--CA 1.426 -1.654 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.018 -175.715 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.424 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 12.3 ptp -124.44 121.21 34.25 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.11 174.279 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 46.0 t-80 -98.77 145.41 26.97 Favored 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.069 -176.661 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 12.8 m -62.01 148.52 43.67 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 177.133 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 31.5 m -127.9 159.95 33.34 Favored 'General case' 0 N--CA 1.423 -1.813 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 173.074 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -69.97 -1.46 9.77 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -172.65 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -75.84 -15.91 60.16 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.039 0.447 . . . . 0.0 109.901 175.458 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 88.12 22.19 42.62 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -172.454 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -135.81 169.38 17.66 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -179.917 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 198' ' ' TRP . . . . . 0.482 ' CH2' HG23 ' A' ' 174' ' ' VAL . 78.1 m95 -87.13 151.42 23.22 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.818 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 39.6 t -71.1 -50.1 37.28 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 121.531 0.682 . . . . 0.0 109.186 177.739 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.409 ' HD3' ' HA ' ' A' ' 200' ' ' LYS . 25.4 mmtp -88.49 148.99 23.88 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-O 121.417 0.627 . . . . 0.0 111.623 -179.798 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -89.11 150.65 22.63 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.813 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 202' ' ' LYS . . . . . 0.433 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 27.3 ttpp -58.73 112.95 5.69 Favored Pre-proline 0 C--O 1.237 0.4 0 N-CA-C 114.443 1.275 . . . . 0.0 114.443 -173.306 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 18.0 Cg_exo -72.01 171.38 16.8 Favored 'Trans proline' 0 N--CA 1.451 -1.014 0 C-N-CA 123.395 2.73 . . . . 0.0 110.631 175.322 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.4 mttp -123.36 167.06 14.29 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -177.753 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.472 ' SG ' ' HA3' ' A' ' 155' ' ' GLY . 94.5 m -106.59 104.65 14.39 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 172.195 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 11.4 m . . . . . 0 C--N 1.296 -1.751 0 CA-C-N 114.782 -1.099 . . . . 0.0 112.327 -171.924 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo . . . . . 0 CA--C 1.536 0.611 0 CA-C-O 121.783 0.66 . . . . 0.0 111.082 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.5 m -82.5 -32.86 28.57 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.309 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.53 -85.86 0.4 Allowed Glycine 0 CA--C 1.458 -3.508 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 173.073 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 179.42 130.43 0.23 Allowed Pre-proline 0 C--N 1.271 -2.818 0 N-CA-C 104.153 -2.536 . . . . 0.0 104.153 -176.056 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.4 -33.07 5.81 Favored 'Trans proline' 0 N--CA 1.474 0.363 0 C-N-CA 121.625 1.55 . . . . 0.0 112.744 -175.423 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 134.52 177.26 14.82 Favored Glycine 0 N--CA 1.419 -2.445 0 N-CA-C 107.021 -2.432 . . . . 0.0 107.021 -176.017 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -134.91 162.96 30.95 Favored 'General case' 0 C--N 1.287 -2.14 0 CA-C-N 118.36 1.08 . . . . 0.0 109.433 179.848 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.7 t -119.35 131.44 24.37 Favored Pre-proline 0 N--CA 1.416 -2.153 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.183 -178.516 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.02 -11.69 17.85 Favored 'Trans proline' 0 N--CA 1.459 -0.509 0 C-N-CA 122.563 2.176 . . . . 0.0 111.616 177.872 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -88.93 -2.89 58.81 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.216 -177.814 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.462 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 175.57 -128.02 1.34 Allowed Glycine 0 N--CA 1.414 -2.793 0 C-N-CA 118.961 -1.59 . . . . 0.0 113.63 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.1 p -138.56 170.5 15.89 Favored 'General case' 0 C--N 1.291 -1.96 0 CA-C-N 114.841 -0.68 . . . . 0.0 110.972 -174.641 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.2 p90 -140.74 145.65 36.71 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 171.023 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.7 m -120.32 161.23 21.49 Favored 'General case' 0 C--N 1.271 -2.843 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -176.894 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.5 mt -119.56 120.97 38.29 Favored 'General case' 0 C--N 1.28 -2.448 0 CA-C-O 121.028 0.442 . . . . 0.0 109.867 -177.443 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.48 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 24.0 p -109.99 129.02 55.73 Favored 'General case' 0 C--N 1.285 -2.218 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.52 -175.383 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 113.38 -54.91 0.54 Allowed Glycine 0 N--CA 1.432 -1.593 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.073 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.429 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -121.24 -12.63 5.67 Favored Glycine 0 C--N 1.305 -1.19 0 C-N-CA 119.965 -1.112 . . . . 0.0 113.335 -179.514 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 47.7 m-80 61.26 18.55 9.28 Favored 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 123.485 0.714 . . . . 0.0 112.22 -178.168 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.54 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.7 m -151.32 -174.48 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.206 -1.21 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -175.806 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -99.71 46.05 0.98 Allowed 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 118.732 0.696 . . . . 0.0 110.619 -177.339 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.691 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.1 pt-20 -86.91 179.79 6.65 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.632 177.019 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 41.2 m-85 -76.12 137.28 40.01 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 122.039 -0.413 . . . . 0.0 111.301 177.089 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.98 -7.96 70.11 Favored Glycine 0 N--CA 1.441 -0.969 0 CA-C-N 115.603 -0.726 . . . . 0.0 113.048 178.003 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.691 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.9 p -87.14 146.8 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.881 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 -175.163 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.48 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.9 mtpt -110.25 125.84 53.53 Favored 'General case' 0 N--CA 1.419 -2.011 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.248 178.129 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -88.42 95.99 10.42 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 175.442 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 77.5 t -90.08 113.65 26.55 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.901 0 C-N-CA 123.988 0.915 . . . . 0.0 108.819 -177.451 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -88.48 134.6 33.8 Favored 'General case' 0 C--N 1.285 -2.228 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.992 -178.948 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.1 t -142.82 124.04 14.6 Favored 'General case' 0 N--CA 1.428 -1.561 0 CA-C-O 122.067 0.937 . . . . 0.0 109.399 179.51 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.404 ' HB3' ' HB2' ' A' ' 118' ' ' TYR . 78.0 m -75.35 166.46 23.57 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.949 -174.064 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.462 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 85.2 m-20 -85.46 -177.03 6.34 Favored 'General case' 0 C--O 1.216 -0.698 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.295 178.393 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -42.93 -54.44 4.21 Favored 'General case' 0 C--N 1.311 -1.072 0 C-N-CA 126.163 1.785 . . . . 0.0 114.527 -177.435 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -92.41 17.34 57.64 Favored Glycine 0 C--N 1.299 -1.495 0 C-N-CA 119.497 -1.335 . . . . 0.0 112.859 -175.111 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.717 ' HE1' HG22 ' A' ' 143' ' ' VAL . 77.8 m-85 -133.95 147.32 51.04 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.182 -177.304 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 119' ' ' GLN . . . . . 0.438 ' OE1' ' HB3' ' A' ' 142' ' ' GLU . 0.0 OUTLIER -136.3 160.07 39.84 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -178.849 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 120' ' ' LEU . . . . . 0.452 HD22 ' HB3' ' A' ' 125' ' ' ASN . 10.4 tp -83.7 141.44 31.47 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 118.915 -1.114 . . . . 0.0 109.947 -176.309 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.05 122.91 43.21 Favored 'General case' 0 N--CA 1.411 -2.381 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 179.177 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.66 -160.42 13.7 Favored Glycine 0 C--N 1.293 -1.855 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.77 -176.568 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -105.9 -48.31 3.65 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.129 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.5 mm -73.4 129.51 36.16 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.132 -173.458 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.452 ' HB3' HD22 ' A' ' 120' ' ' LEU . 6.4 p30 -130.0 12.99 5.73 Favored 'General case' 0 C--O 1.213 -0.838 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 177.516 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.47 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 34.0 p90 -149.67 161.74 41.59 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.85 -176.48 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 44.3 mtp180 -127.46 131.78 50.13 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 172.069 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -108.06 131.98 54.03 Favored 'General case' 0 C--N 1.283 -2.301 0 C-N-CA 119.202 -0.999 . . . . 0.0 109.5 -178.405 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 21.6 t -81.4 99.27 8.62 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.829 -1.149 . . . . 0.0 109.155 176.533 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.425 ' OD2' HG22 ' A' ' 131' ' ' THR . 8.6 t70 -96.35 -167.13 1.52 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 178.447 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.425 HG22 ' OD2' ' A' ' 130' ' ' ASP . 9.0 t -59.37 -28.46 66.9 Favored 'General case' 0 C--N 1.31 -1.121 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -174.733 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -85.95 -23.65 26.85 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.549 0.69 . . . . 0.0 110.213 179.596 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 128.96 -153.96 20.01 Favored Glycine 0 N--CA 1.421 -2.362 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -175.646 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -64.87 113.38 3.79 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -179.878 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 65.0 p -73.09 172.48 10.97 Favored 'General case' 0 C--O 1.27 2.154 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 176.188 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 63.6 m-20 59.68 -156.74 0.34 Allowed 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 175.984 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -141.15 -177.51 5.15 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 173.092 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 57.0 mt -65.73 116.88 36.17 Favored Pre-proline 0 C--N 1.273 -2.728 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 174.806 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.413 ' HB2' HD11 ' A' ' 120' ' ' LEU . 49.2 Cg_endo -68.61 160.83 47.77 Favored 'Trans proline' 0 C--O 1.246 0.91 0 C-N-CA 122.418 2.079 . . . . 0.0 112.308 -176.01 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 48.7 mm -90.67 131.52 37.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.364 -176.382 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.613 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 36.6 t -114.08 137.62 51.49 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 105.752 -1.944 . . . . 0.0 105.752 175.697 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.438 ' HB3' ' OE1' ' A' ' 119' ' ' GLN . 9.7 tp10 -119.1 157.59 27.56 Favored 'General case' 0 C--N 1.277 -2.557 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.717 HG22 ' HE1' ' A' ' 118' ' ' TYR . 24.0 t -79.84 138.54 19.72 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.073 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 -178.908 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 70.6 t -60.01 122.01 9.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 124.305 1.003 . . . . 0.0 108.399 179.331 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.507 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 59.9 mttm -120.33 156.06 32.07 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.899 -178.815 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 80.1 m -108.65 -171.54 1.87 Allowed 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 123.825 0.85 . . . . 0.0 110.677 -179.827 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 147' ' ' LEU . . . . . 0.588 HD12 ' HD2' ' A' ' 148' ' ' PRO . 1.5 tp -95.56 134.34 24.39 Favored Pre-proline 0 N--CA 1.421 -1.913 0 O-C-N 122.027 -0.421 . . . . 0.0 110.023 -177.181 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.588 ' HD2' HD12 ' A' ' 147' ' ' LEU . 12.7 Cg_endo -58.2 121.51 10.12 Favored 'Trans proline' 0 CA--C 1.535 0.543 0 C-N-CA 123.23 2.62 . . . . 0.0 111.563 177.333 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 28.7 t -85.94 143.65 11.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 -177.975 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 19.5 p -77.98 -83.12 0.08 Allowed 'General case' 0 N--CA 1.42 -1.974 0 CA-C-N 116.806 -0.179 . . . . 0.0 111.308 175.436 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.96 156.56 0.21 Allowed Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 125.143 1.377 . . . . 0.0 107.757 179.604 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -69.79 162.93 40.18 Favored 'Trans proline' 0 C--N 1.353 0.816 0 C-N-CA 121.723 1.615 . . . . 0.0 110.896 172.915 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -62.3 -50.6 71.02 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -174.926 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 27.2 m120 -113.76 38.17 3.04 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 -177.96 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -154.06 -164.41 12.75 Favored Glycine 0 N--CA 1.425 -2.051 0 CA-C-N 115.026 -0.988 . . . . 0.0 111.189 178.353 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -156.0 173.24 17.09 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -178.601 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 49.7 mt -88.98 134.73 27.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 CA-C-O 121.148 0.499 . . . . 0.0 110.499 -179.251 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 55.1 t -73.98 -43.38 52.27 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 C-N-CA 124.149 0.98 . . . . 0.0 109.455 178.779 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 2.1 m -84.18 87.92 7.19 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -179.86 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 11.2 p -83.66 -31.22 26.26 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.352 0.596 . . . . 0.0 112.086 -176.95 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -139.97 94.46 2.76 Favored 'General case' 0 C--N 1.309 -1.192 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.306 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 162' ' ' MET . . . . . 0.465 ' HG2' ' HG2' ' A' ' 163' ' ' GLU . 1.6 pmm? -103.74 -35.91 8.05 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.476 -178.578 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.479 ' HG3' ' H ' ' A' ' 166' ' ' ARG . 8.9 pt-20 -148.89 146.78 22.39 Favored Pre-proline 0 N--CA 1.441 -0.907 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.236 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -79.0 0.68 9.81 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 122.851 2.367 . . . . 0.0 112.92 -178.769 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 165' ' ' ASP . . . . . 0.478 ' HB3' ' OE1' ' A' ' 163' ' ' GLU . 28.7 t70 -94.33 -33.78 13.07 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -178.425 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 166' ' ' ARG . . . . . 0.479 ' H ' ' HG3' ' A' ' 163' ' ' GLU . 14.5 mmm180 57.3 18.12 4.11 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 125.952 1.701 . . . . 0.0 115.36 174.978 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -91.24 -9.79 43.95 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-O 121.23 0.538 . . . . 0.0 110.065 -179.449 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 68.97 93.21 0.08 Allowed 'General case' 0 CA--C 1.49 -1.355 0 C-N-CA 126.143 1.777 . . . . 0.0 111.681 177.558 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.507 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 20.9 p-80 -96.34 159.52 14.9 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.623 -179.135 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 50.3 t80 -50.78 123.29 8.73 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 125.311 1.444 . . . . 0.0 109.59 176.978 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.62 -10.93 21.39 Favored Glycine 0 N--CA 1.425 -2.092 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.621 -178.068 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.0 mm-40 -89.65 143.64 26.64 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-N 117.805 0.802 . . . . 0.0 111.195 179.585 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -111.86 126.44 55.09 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.468 -1.242 . . . . 0.0 107.826 177.848 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.574 HG12 ' CG ' ' A' ' 190' ' ' MET . 0.3 OUTLIER -117.76 118.5 58.57 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.246 0 C-N-CA 119.249 -0.981 . . . . 0.0 108.384 178.73 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 43.9 ttm180 -104.54 157.52 17.12 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 -179.275 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -129.12 154.35 46.79 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -176.031 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.5 p -135.82 152.13 30.47 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.158 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.581 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 74.8 m -105.48 146.29 29.74 Favored 'General case' 0 C--N 1.274 -2.716 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.871 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -65.88 172.93 3.23 Favored 'General case' 0 CA--C 1.503 -0.832 0 O-C-N 123.732 0.645 . . . . 0.0 110.473 -177.441 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 6.0 p -53.75 104.9 0.11 Allowed 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 124.317 1.047 . . . . 0.0 112.939 -177.764 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.18 -3.64 31.47 Favored Glycine 0 N--CA 1.433 -1.508 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.457 177.889 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -112.64 150.27 31.68 Favored 'General case' 0 N--CA 1.42 -1.946 0 O-C-N 122.162 -0.611 . . . . 0.0 110.397 179.89 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 65.0 pttt -123.36 160.3 27.06 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.412 HD11 ' HB2' ' A' ' 203' ' ' PRO . 1.7 tp -76.18 142.2 14.72 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -179.787 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -88.5 -69.1 0.72 Allowed 'General case' 0 C--N 1.287 -2.114 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -77.8 -128.22 0.42 Allowed Glycine 0 N--CA 1.437 -1.251 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.717 176.964 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 187' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 203' ' ' PRO . 5.6 t70 -98.28 162.04 13.39 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.281 -1.378 . . . . 0.0 107.281 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -99.78 1.1 42.84 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 119.513 1.051 . . . . 0.0 112.23 -170.618 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -152.01 153.84 34.83 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 121.398 0.618 . . . . 0.0 112.475 -177.154 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.574 ' CG ' HG12 ' A' ' 174' ' ' VAL . 16.7 ptp -132.72 148.51 52.33 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.289 178.659 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 47.6 m80 -115.17 145.44 42.39 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.604 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 42.8 t -81.58 102.25 10.51 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 177.988 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 51.9 m -121.66 158.0 29.63 Favored 'General case' 0 N--CA 1.425 -1.688 0 N-CA-C 114.096 1.147 . . . . 0.0 114.096 -168.607 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 21.98 -76.87 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 129.483 3.113 . . . . 0.0 116.973 174.389 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -62.76 -21.2 65.66 Favored 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 125.014 1.325 . . . . 0.0 113.58 -172.059 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 101.73 20.72 12.38 Favored Glycine 0 N--CA 1.435 -1.42 0 C-N-CA 119.62 -1.276 . . . . 0.0 110.913 -175.819 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 21.9 p90 -146.67 173.18 12.58 Favored 'General case' 0 N--CA 1.426 -1.649 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 175.068 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.3 m95 -69.18 138.44 54.1 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 123.651 0.594 . . . . 0.0 111.62 -175.366 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 13.0 p -68.31 -33.4 74.26 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.656 178.841 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 59.5 mmtt -107.23 149.57 27.59 Favored 'General case' 0 N--CA 1.432 -1.352 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.617 -179.765 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -79.84 163.89 24.03 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 114.463 -1.244 . . . . 0.0 109.018 176.467 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 9.6 mtpm? -64.89 128.52 93.78 Favored Pre-proline 0 CA--C 1.502 -0.867 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.964 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.443 ' HB3' ' O ' ' A' ' 187' ' ' ASP . 95.3 Cg_endo -78.78 166.95 22.97 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 C-N-CA 122.247 1.964 . . . . 0.0 111.975 179.55 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.2 tttp -122.44 156.74 33.42 Favored 'General case' 0 N--CA 1.414 -2.268 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 -179.493 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 92.3 m -118.07 116.27 26.53 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 176.796 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 27.4 m . . . . . 0 C--N 1.301 -1.542 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.546 -176.571 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo . . . . . 0 CA--C 1.542 0.915 0 CA-C-O 120.948 0.312 . . . . 0.0 112.113 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.8 m -80.33 -31.9 37.97 Favored 'General case' 0 CA--C 1.502 -0.898 0 CA-C-O 122.262 1.03 . . . . 0.0 108.338 177.787 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.42 -87.97 0.46 Allowed Glycine 1 N--CA 1.395 -4.064 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 173.444 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 10.4 t60 -176.47 133.22 0.4 Allowed Pre-proline 0 C--N 1.262 -3.213 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 -175.273 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.484 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 85.7 Cg_endo -81.91 1.04 9.49 Favored 'Trans proline' 0 N--CA 1.475 0.422 0 C-N-CA 122.58 2.187 . . . . 0.0 113.464 -174.819 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 100.72 -169.24 21.06 Favored Glycine 0 C--N 1.291 -1.96 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 -175.394 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -151.06 178.37 9.26 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.521 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.9 t -142.99 139.09 16.43 Favored Pre-proline 0 N--CA 1.427 -1.596 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.813 -176.984 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.97 -11.87 21.55 Favored 'Trans proline' 0 CA--C 1.534 0.5 0 C-N-CA 122.635 2.223 . . . . 0.0 111.349 176.227 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -89.63 -4.15 57.93 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.228 -177.021 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.572 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 173.83 -123.73 0.99 Allowed Glycine 0 N--CA 1.419 -2.444 0 C-N-CA 119.823 -1.18 . . . . 0.0 112.371 179.766 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.1 t -165.22 -163.25 0.67 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.28 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.445 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 54.4 p90 -145.72 175.07 10.66 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 178.593 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.8 m -136.01 163.43 30.32 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 176.645 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 23.8 mt -118.94 120.89 38.61 Favored 'General case' 0 C--N 1.285 -2.22 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -178.885 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.413 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 26.1 p -114.13 128.75 56.52 Favored 'General case' 0 C--N 1.285 -2.21 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -175.411 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 97.36 19.67 24.93 Favored Glycine 0 C--N 1.299 -1.48 0 C-N-CA 119.849 -1.167 . . . . 0.0 111.149 -179.523 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.52 -32.16 0.15 Allowed Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 118.911 -1.614 . . . . 0.0 114.417 179.445 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 65.93 19.45 11.26 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 123.205 0.602 . . . . 0.0 111.174 -176.242 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.465 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.3 m -149.23 -177.86 0.47 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.084 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -175.552 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 38.1 m-85 -103.88 47.8 0.87 Allowed 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 118.726 0.694 . . . . 0.0 110.171 -179.772 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.678 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.7 pt-20 -83.63 177.8 8.24 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.311 -1.313 . . . . 0.0 111.554 179.226 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 45.5 m-85 -77.67 130.42 36.8 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.645 174.064 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 91.23 15.72 55.09 Favored Glycine 0 N--CA 1.434 -1.491 0 C-N-CA 120.203 -0.999 . . . . 0.0 112.377 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.678 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -106.38 149.5 9.77 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 176.06 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.413 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.2 mtpt -113.95 125.69 54.31 Favored 'General case' 0 N--CA 1.418 -2.048 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.485 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -90.01 89.27 7.63 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.225 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.472 HG12 ' HB3' ' A' ' 126' ' ' TYR . 28.5 m -84.91 112.28 21.74 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.981 0 CA-C-O 122.164 0.983 . . . . 0.0 109.565 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 112' ' ' TYR . . . . . 0.445 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 33.8 m-85 -78.92 142.21 36.94 Favored 'General case' 0 C--N 1.269 -2.9 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.123 -179.569 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.9 t -138.84 122.58 17.57 Favored 'General case' 0 N--CA 1.411 -2.422 0 CA-C-N 115.135 -0.938 . . . . 0.0 108.822 -179.639 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 88.0 m -73.68 160.8 31.04 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 115.487 -0.778 . . . . 0.0 112.0 -178.383 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.572 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 81.2 m-20 -76.44 -176.53 3.72 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.293 179.703 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -52.46 -48.52 65.8 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 124.655 1.182 . . . . 0.0 113.491 -177.28 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.32 10.53 70.98 Favored Glycine 0 C--N 1.3 -1.437 0 C-N-CA 119.786 -1.197 . . . . 0.0 113.306 -177.971 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.538 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 93.6 m-85 -127.62 161.02 29.85 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 122.166 -0.608 . . . . 0.0 111.419 -175.753 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -140.49 150.43 43.75 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.026 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.21 133.03 39.01 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 -179.681 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.03 127.54 55.92 Favored 'General case' 0 N--CA 1.414 -2.241 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.143 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.2 -163.27 12.62 Favored Glycine 0 C--N 1.296 -1.666 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.811 -179.804 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -108.96 -30.05 8.29 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 178.632 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.7 mm -88.16 127.06 41.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.513 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -129.56 9.84 5.57 Favored 'General case' 0 C--O 1.202 -1.44 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.034 176.777 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.472 ' HB3' HG12 ' A' ' 111' ' ' VAL . 22.1 p90 -139.08 165.52 26.94 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.397 -171.916 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.542 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 52.2 mtp180 -128.57 126.82 41.11 Favored 'General case' 0 C--O 1.204 -1.311 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 171.395 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -98.17 133.11 43.05 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.542 -0.863 . . . . 0.0 109.947 179.187 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 36.2 t -89.86 110.62 21.54 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.31 174.555 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.42 ' CG ' ' H ' ' A' ' 131' ' ' THR . 36.1 t70 -113.44 -167.21 1.17 Allowed 'General case' 0 C--N 1.289 -2.033 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 175.485 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.42 ' H ' ' CG ' ' A' ' 130' ' ' ASP . 15.3 t -67.09 -20.53 65.81 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.319 1.057 . . . . 0.0 109.69 -179.318 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -70.22 -23.73 62.98 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 114.279 -1.328 . . . . 0.0 109.233 175.001 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 105.9 -154.87 16.93 Favored Glycine 0 N--CA 1.42 -2.39 0 N-CA-C 107.169 -2.373 . . . . 0.0 107.169 -173.313 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 96.1 m95 -65.33 99.18 0.38 Allowed 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 117.666 0.733 . . . . 0.0 109.83 172.776 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.6 p -58.64 -67.58 0.35 Allowed 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 124.74 1.216 . . . . 0.0 112.839 -173.009 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 136' ' ' ASN . . . . . 0.542 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 3.0 m-20 -70.37 167.13 18.81 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.33 178.868 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -98.64 175.55 5.95 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.537 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 68.7 mt -63.92 121.83 73.52 Favored Pre-proline 0 C--N 1.273 -2.741 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 175.079 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -63.73 174.35 3.8 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 122.482 2.121 . . . . 0.0 112.791 -179.102 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 65.8 mt -98.9 140.73 17.81 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -175.307 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.538 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 42.4 t -128.92 119.5 24.48 Favored 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 -179.784 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -103.14 140.9 36.74 Favored 'General case' 0 C--N 1.279 -2.476 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 -175.901 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.418 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 10.8 p -70.9 138.74 21.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 173.932 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 92.7 t -59.61 114.66 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.73 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -176.371 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 92.4 mttt -113.73 144.55 42.76 Favored 'General case' 0 N--CA 1.426 -1.67 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.274 -177.787 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 82.9 m -112.03 160.95 17.0 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 114.732 -1.122 . . . . 0.0 109.165 179.778 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 59.7 mt -64.82 138.19 97.39 Favored Pre-proline 0 C--N 1.318 -0.781 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -179.183 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -63.48 127.47 19.97 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.821 2.347 . . . . 0.0 111.103 179.376 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.4 t -85.21 142.42 13.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -179.788 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.9 p -67.45 -82.98 0.03 OUTLIER 'General case' 0 N--CA 1.425 -1.704 0 O-C-N 123.604 0.565 . . . . 0.0 111.223 177.412 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 168.41 159.52 0.16 Allowed Pre-proline 0 CA--C 1.513 -0.474 0 C-N-CA 125.554 1.542 . . . . 0.0 106.99 179.716 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -82.88 169.11 13.46 Favored 'Trans proline' 0 N--CA 1.448 -1.196 0 C-N-CA 121.643 1.562 . . . . 0.0 111.352 173.688 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -60.54 -57.02 14.5 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -176.827 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -112.02 25.19 11.82 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.12 0.962 . . . . 0.0 109.798 -172.908 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -146.02 -172.03 16.01 Favored Glycine 0 C--N 1.284 -2.324 0 CA-C-N 114.421 -1.263 . . . . 0.0 110.984 179.04 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.0 pttm -149.79 169.12 21.83 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 178.504 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.561 HG12 ' CE2' ' A' ' 176' ' ' PHE . 62.8 mt -88.2 130.58 37.54 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.879 179.453 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.492 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 12.9 m -87.15 -29.04 5.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.324 0.583 . . . . 0.0 109.628 179.8 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.528 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 25.2 m -104.55 40.82 1.41 Allowed 'General case' 0 C--N 1.308 -1.233 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.631 -174.812 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 160' ' ' SER . . . . . 0.45 ' HA ' ' OH ' ' A' ' 168' ' ' TYR . 12.1 p -67.12 161.53 24.37 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.2 -178.749 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -46.69 107.35 0.1 Allowed 'General case' 0 C--O 1.24 0.561 0 O-C-N 124.177 0.923 . . . . 0.0 111.805 -179.794 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 34.0 mtm -60.78 -52.47 64.96 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 114.486 -1.233 . . . . 0.0 108.934 179.054 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -129.18 149.82 73.71 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 104.664 -2.347 . . . . 0.0 104.664 174.963 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.82 -6.15 17.76 Favored 'Trans proline' 0 N--CA 1.478 0.58 0 C-N-CA 122.31 2.007 . . . . 0.0 110.998 179.058 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -91.08 -37.05 13.66 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 -179.894 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 23.1 mmm180 -92.68 89.16 6.55 Favored 'General case' 0 N--CA 1.427 -1.614 0 CA-C-N 114.426 -1.261 . . . . 0.0 108.058 179.726 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -84.48 174.08 10.34 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 114.49 -1.232 . . . . 0.0 110.888 -172.57 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 168' ' ' TYR . . . . . 0.45 ' OH ' ' HA ' ' A' ' 160' ' ' SER . 72.1 m-85 -68.93 113.39 6.3 Favored 'General case' 0 CA--C 1.476 -1.896 0 CA-C-O 121.194 0.521 . . . . 0.0 109.876 -179.008 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 56.7 p-80 -130.44 167.93 17.81 Favored 'General case' 0 C--N 1.281 -2.395 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.038 -174.496 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 79.8 t80 -47.69 132.12 14.34 Favored 'General case' 0 CA--C 1.506 -0.73 0 O-C-N 124.418 1.074 . . . . 0.0 110.612 178.755 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 108.67 -26.11 17.11 Favored Glycine 0 N--CA 1.418 -2.55 0 C-N-CA 120.378 -0.915 . . . . 0.0 111.781 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -76.83 134.05 39.17 Favored 'General case' 0 N--CA 1.414 -2.247 0 CA-C-O 121.664 0.745 . . . . 0.0 110.524 -179.061 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -110.57 90.83 3.44 Favored 'General case' 0 C--N 1.269 -2.893 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 173.959 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.528 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 14.6 p -73.15 105.1 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.9 0 CA-C-O 121.706 0.765 . . . . 0.0 109.257 -176.127 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.514 ' HD2' ' OE2' ' A' ' 188' ' ' GLU . 12.4 ttp180 -97.11 152.73 18.49 Favored 'General case' 0 N--CA 1.411 -2.387 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.387 -175.503 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.561 ' CE2' HG12 ' A' ' 157' ' ' ILE . 81.7 m-85 -121.2 153.22 37.88 Favored 'General case' 0 N--CA 1.428 -1.563 0 C-N-CA 124.173 0.989 . . . . 0.0 109.151 -177.462 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.448 ' HB ' ' CG1' ' A' ' 158' ' ' VAL . 10.3 p -135.7 149.59 28.24 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 178' ' ' CYS . . . . . 0.438 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 76.6 m -90.06 141.07 29.04 Favored 'General case' 0 C--N 1.268 -2.959 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.464 178.314 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -70.91 -52.6 19.06 Favored 'General case' 0 CA--C 1.477 -1.855 0 CA-C-N 115.298 -0.864 . . . . 0.0 112.338 -175.347 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 180' ' ' SER . . . . . 0.445 ' HB3' ' CE2' ' A' ' 182' ' ' TYR . 34.3 t -116.01 -158.88 0.7 Allowed 'General case' 0 C--N 1.26 -3.287 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -177.183 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -71.77 51.03 1.18 Allowed Glycine 0 C--O 1.229 -0.203 0 O-C-N 123.473 0.483 . . . . 0.0 113.294 -177.975 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 182' ' ' TYR . . . . . 0.445 ' CE2' ' HB3' ' A' ' 180' ' ' SER . 90.5 m-85 -103.51 170.64 7.83 Favored 'General case' 0 C--N 1.292 -1.913 0 C-N-CA 123.137 0.575 . . . . 0.0 109.539 177.463 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.458 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 39.4 pttt -126.5 150.92 48.46 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 176.374 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.5 tp -65.31 142.68 16.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 CA-C-O 121.427 0.632 . . . . 0.0 110.025 176.096 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -67.23 -58.41 4.89 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.915 -178.362 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -120.96 -111.03 2.22 Favored Glycine 0 N--CA 1.42 -2.396 0 N-CA-C 110.589 -1.005 . . . . 0.0 110.589 -178.941 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -88.91 144.9 25.88 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.225 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.514 ' OE2' ' HD2' ' A' ' 175' ' ' ARG . 12.8 pt-20 -87.62 1.27 54.13 Favored 'General case' 0 C--O 1.205 -1.282 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.986 -176.045 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -145.16 151.18 38.05 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 121.191 0.52 . . . . 0.0 111.312 -179.186 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.492 ' HG3' HG13 ' A' ' 174' ' ' VAL . 0.0 OUTLIER -123.4 140.82 52.62 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 175.966 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 26.3 m80 -100.42 140.39 34.74 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.835 -0.346 . . . . 0.0 110.313 176.899 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 52.6 t -86.56 104.41 15.98 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 174.301 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 18.0 m -74.94 156.88 35.86 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-N 115.225 -0.898 . . . . 0.0 111.095 -177.524 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -68.63 1.84 2.89 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.794 1.238 . . . . 0.0 114.163 -174.371 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 195' ' ' ASP . . . . . 0.444 ' HB3' ' CE2' ' A' ' 197' ' ' PHE . 36.9 t70 -102.1 -17.37 16.06 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 121.33 0.586 . . . . 0.0 109.69 175.609 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 101.34 53.75 0.99 Allowed Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.935 179.912 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 197' ' ' PHE . . . . . 0.444 ' CE2' ' HB3' ' A' ' 195' ' ' ASP . 52.1 p90 -154.76 156.95 37.25 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.918 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 78.8 m95 -83.96 130.5 34.89 Favored 'General case' 0 N--CA 1.431 -1.394 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 175.39 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 7.7 m -63.8 -29.21 70.44 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.53 -179.81 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 4.0 mmmt -117.89 152.79 34.69 Favored 'General case' 0 N--CA 1.411 -2.395 0 O-C-N 121.943 -0.473 . . . . 0.0 110.882 -179.516 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -71.28 165.63 23.28 Favored 'General case' 0 C--O 1.252 1.205 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 174.875 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 202' ' ' LYS . . . . . 0.453 ' HB3' ' HE2' ' A' ' 202' ' ' LYS . 41.6 mtpt -61.32 125.3 83.83 Favored Pre-proline 0 N--CA 1.447 -0.602 0 C-N-CA 120.341 -0.544 . . . . 0.0 110.136 174.919 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -88.84 175.04 3.74 Favored 'Trans proline' 0 N--CA 1.419 -2.854 0 C-N-CA 121.791 1.661 . . . . 0.0 110.001 172.932 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.6 mttp -137.91 177.22 8.04 Favored 'General case' 0 C--N 1.284 -2.276 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 -177.073 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.458 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 68.1 m -118.76 104.27 10.43 Favored 'General case' 0 C--N 1.283 -2.324 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 171.776 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.9 m . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 114.306 -1.316 . . . . 0.0 111.337 -172.27 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.414 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 17.7 Cg_endo . . . . . 0 CA--C 1.536 0.595 0 CA-C-O 120.926 0.303 . . . . 0.0 112.269 . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 85' ' ' CYS . . . . . 0.418 ' HB3' ' CD1' ' A' ' 134' ' ' TRP . 4.5 m -93.16 -24.56 18.19 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.242 0.544 . . . . 0.0 111.558 175.003 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.94 -93.55 0.59 Allowed Glycine 0 CA--C 1.46 -3.345 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 173.196 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 10.5 t60 -170.23 132.77 1.02 Allowed Pre-proline 0 C--N 1.262 -3.201 0 N-CA-C 104.02 -2.585 . . . . 0.0 104.02 -175.478 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.504 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 87.9 Cg_endo -81.32 -19.81 7.58 Favored 'Trans proline' 0 C--N 1.332 -0.341 0 C-N-CA 121.637 1.558 . . . . 0.0 113.553 -173.189 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 130.1 -165.39 22.47 Favored Glycine 0 N--CA 1.426 -2.013 0 N-CA-C 110.186 -1.166 . . . . 0.0 110.186 -177.358 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -151.04 151.34 31.89 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 -178.659 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.1 t -131.07 127.5 22.0 Favored Pre-proline 0 C--N 1.303 -1.456 0 C-N-CA 120.338 -0.545 . . . . 0.0 110.553 179.897 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.46 -18.37 26.08 Favored 'Trans proline' 0 C--O 1.237 0.445 0 C-N-CA 122.523 2.149 . . . . 0.0 111.554 178.843 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.531 ' CB ' ' HB2' ' A' ' 141' ' ' CYS . 59.7 m-85 -78.92 -17.26 55.83 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.192 -177.461 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.472 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -168.97 -126.76 0.87 Allowed Glycine 0 CA--C 1.477 -2.284 0 C-N-CA 120.212 -0.994 . . . . 0.0 111.167 -178.933 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.1 t -160.07 -169.87 2.65 Favored 'General case' 0 C--N 1.284 -2.243 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.651 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.431 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 37.8 p90 -147.11 165.46 29.89 Favored 'General case' 0 N--CA 1.432 -1.331 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 177.582 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.7 m -132.81 161.75 33.32 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 177.879 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 26.6 mt -109.93 137.54 47.57 Favored 'General case' 0 C--N 1.271 -2.837 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.47 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.536 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 11.1 p -134.11 141.6 47.2 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -173.979 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 100.33 -42.37 1.97 Allowed Glycine 0 C--N 1.303 -1.304 0 N-CA-C 108.148 -1.981 . . . . 0.0 108.148 -173.988 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.459 ' HA3' ' OE2' ' A' ' 105' ' ' GLU . . . -139.63 -143.09 4.33 Favored Glycine 0 N--CA 1.406 -3.358 0 N-CA-C 108.029 -2.028 . . . . 0.0 108.029 176.085 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -151.61 16.22 0.69 Allowed 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.41 1.1 . . . . 0.0 109.829 -178.51 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.531 ' O ' HG11 ' A' ' 108' ' ' VAL . 28.7 m -147.5 -170.57 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 -175.511 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.504 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 30.5 m-85 -96.17 39.11 1.16 Allowed 'General case' 0 C--N 1.307 -1.255 0 CA-C-O 121.99 0.9 . . . . 0.0 110.022 -177.832 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.661 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.2 pt-20 -71.83 178.03 3.89 Favored 'General case' 0 C--O 1.202 -1.44 0 C-N-CA 127.197 2.199 . . . . 0.0 111.888 179.009 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 106' ' ' TYR . . . . . 0.546 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 27.6 m-85 -79.32 135.9 36.86 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-O 121.008 0.432 . . . . 0.0 110.971 176.49 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.24 3.24 82.34 Favored Glycine 0 N--CA 1.442 -0.91 0 C-N-CA 121.001 -0.618 . . . . 0.0 112.349 178.804 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.661 HG12 ' O ' ' A' ' 105' ' ' GLU . 8.5 p -92.75 142.81 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.549 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.536 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -107.52 126.82 53.0 Favored 'General case' 0 C--N 1.28 -2.437 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 177.682 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -89.32 87.98 7.32 Favored 'General case' 0 C--N 1.28 -2.436 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 174.896 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.508 HG12 ' HB3' ' A' ' 126' ' ' TYR . 30.0 m -84.97 116.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.383 0 CA-C-O 121.989 0.899 . . . . 0.0 109.403 -179.423 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 112' ' ' TYR . . . . . 0.431 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 33.9 m-85 -85.73 142.59 28.89 Favored 'General case' 0 C--N 1.27 -2.877 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.42 179.754 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -138.0 124.61 20.9 Favored 'General case' 0 N--CA 1.405 -2.725 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -178.92 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.7 m -74.08 155.61 38.3 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 115.3 -0.863 . . . . 0.0 112.262 -175.498 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.472 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 72.2 m-20 -68.09 173.81 4.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.175 178.482 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -50.75 -48.21 59.17 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 123.78 0.832 . . . . 0.0 112.547 -177.922 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.465 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -89.8 30.88 5.53 Favored Glycine 0 N--CA 1.438 -1.222 0 C-N-CA 120.778 -0.725 . . . . 0.0 113.05 -178.417 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -146.65 157.4 43.7 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 122.177 -0.602 . . . . 0.0 109.555 -176.424 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.5 150.7 47.74 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 122.688 0.395 . . . . 0.0 110.334 177.076 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.99 117.21 15.51 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -175.336 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -103.13 126.13 50.16 Favored 'General case' 0 N--CA 1.407 -2.593 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -178.876 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 120.33 176.54 15.77 Favored Glycine 0 C--N 1.29 -1.98 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.706 -177.551 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -93.77 -24.77 17.68 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.906 0.86 . . . . 0.0 109.02 -178.384 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.458 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.2 mm -104.03 129.22 56.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 114.851 -1.068 . . . . 0.0 109.213 -176.538 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -119.0 -2.49 10.8 Favored 'General case' 0 C--O 1.201 -1.493 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 177.611 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.508 ' HB3' HG12 ' A' ' 111' ' ' VAL . 39.8 p90 -138.46 162.18 35.13 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 120.945 0.402 . . . . 0.0 110.526 -169.374 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 61.1 mtp180 -123.53 135.24 53.91 Favored 'General case' 0 C--N 1.282 -2.328 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 170.989 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -110.45 130.58 55.53 Favored 'General case' 0 C--N 1.284 -2.253 0 C-N-CA 119.046 -1.061 . . . . 0.0 110.215 -178.517 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 129' ' ' CYS . . . . . 0.546 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 36.9 t -75.99 98.96 4.41 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.328 0.585 . . . . 0.0 109.918 177.878 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.44 ' OD2' HG22 ' A' ' 131' ' ' THR . 20.3 t70 -100.14 -175.43 2.94 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 178.172 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.44 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -69.26 -19.49 63.92 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-O 121.997 0.904 . . . . 0.0 109.237 179.441 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -83.12 -12.79 56.69 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.304 -1.316 . . . . 0.0 109.326 179.831 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 110.37 -164.19 12.29 Favored Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -175.942 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.418 ' CD1' ' HB3' ' A' ' 85' ' ' CYS . 98.5 m95 -64.26 114.79 4.47 Favored 'General case' 0 C--O 1.248 0.978 0 CA-C-N 117.922 0.861 . . . . 0.0 109.88 175.363 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 68.6 p -71.29 164.87 24.86 Favored 'General case' 0 N--CA 1.417 -2.108 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 177.702 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 55.8 m-20 65.53 -158.87 0.28 Allowed 'General case' 0 C--O 1.245 0.826 0 O-C-N 123.843 0.714 . . . . 0.0 109.276 173.995 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -136.48 176.28 8.85 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 175.866 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.1 mt -64.29 120.44 64.81 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 124.271 0.982 . . . . 0.0 108.368 175.338 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.458 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 45.6 Cg_endo -67.68 176.52 4.99 Favored 'Trans proline' 0 C--O 1.248 1.024 0 C-N-CA 123.034 2.489 . . . . 0.0 112.583 -179.256 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.1 mm -111.71 137.0 46.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 CA-C-O 121.108 0.48 . . . . 0.0 110.318 -173.234 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.531 ' HB2' ' CB ' ' A' ' 93' ' ' PHE . 99.3 m -113.52 111.12 21.38 Favored 'General case' 0 C--N 1.279 -2.47 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 172.83 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -93.67 151.63 19.53 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 179.211 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 8.9 p -74.09 141.26 16.37 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.553 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.897 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 144' ' ' VAL . . . . . 0.506 HG23 ' HB2' ' A' ' 170' ' ' PHE . 15.6 m -67.09 101.14 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.776 0 CA-C-O 121.967 0.889 . . . . 0.0 110.024 177.843 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -85.18 123.51 30.77 Favored 'General case' 0 N--CA 1.407 -2.599 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.314 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.518 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 62.6 m -83.2 122.28 28.2 Favored 'General case' 0 C--N 1.273 -2.758 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 178.02 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 80.6 mt -53.36 131.69 52.94 Favored Pre-proline 0 C--N 1.313 -0.985 0 N-CA-C 113.629 0.974 . . . . 0.0 113.629 -175.693 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -56.44 121.03 9.31 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 123.33 2.687 . . . . 0.0 110.989 -178.575 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.5 p -89.28 149.48 4.01 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.973 -175.878 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.4 p -81.73 -173.45 4.44 Favored 'General case' 0 N--CA 1.422 -1.837 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 175.245 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -123.37 155.63 64.98 Favored Pre-proline 0 C--N 1.285 -2.238 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -172.802 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -77.35 169.72 20.73 Favored 'Trans proline' 0 CA--C 1.543 0.97 0 C-N-CA 121.92 1.746 . . . . 0.0 112.491 178.277 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -64.31 -57.5 9.21 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -178.816 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 -97.87 20.09 12.7 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.846 0.831 . . . . 0.0 110.269 -174.145 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -142.79 -173.27 14.41 Favored Glycine 0 N--CA 1.412 -2.903 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.985 179.878 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 156' ' ' LYS . . . . . 0.401 ' HG3' HG23 ' A' ' 177' ' ' VAL . 19.8 pttp -156.76 178.31 10.49 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -179.187 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 59.5 mt -101.09 138.35 25.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 CA-C-N 117.83 0.286 . . . . 0.0 111.066 -177.33 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.625 HG12 HG22 ' A' ' 177' ' ' VAL . 2.7 m -84.69 -33.64 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 177.426 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 6.1 m -95.78 48.62 1.13 Allowed 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.943 -174.584 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 25.5 m -70.29 94.44 0.93 Allowed 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.69 0.281 . . . . 0.0 110.264 -178.492 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 57.39 -166.02 0.15 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 123.996 0.919 . . . . 0.0 109.98 -175.219 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 63.2 mtm -135.94 -61.24 0.71 Allowed 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 106.179 -1.785 . . . . 0.0 106.179 173.233 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -129.82 151.23 77.82 Favored Pre-proline 0 C--N 1.291 -1.945 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 171.718 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -61.08 -15.23 38.05 Favored 'Trans proline' 0 N--CA 1.482 0.83 0 C-N-CA 122.948 2.432 . . . . 0.0 113.353 -177.455 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -104.92 -29.2 10.64 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.25 0.548 . . . . 0.0 110.661 179.565 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 30.3 mmm180 -93.39 99.48 11.98 Favored 'General case' 0 N--CA 1.429 -1.483 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.735 -175.844 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -76.11 -177.9 4.18 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.176 -179.513 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -67.69 130.98 44.68 Favored 'General case' 0 CA--C 1.502 -0.902 0 CA-C-O 120.984 0.421 . . . . 0.0 110.088 179.285 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 21.5 m-70 -125.49 165.05 19.17 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -177.3 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.506 ' HB2' HG23 ' A' ' 144' ' ' VAL . 92.4 t80 -51.57 134.86 29.16 Favored 'General case' 0 C--O 1.239 0.526 0 O-C-N 123.885 0.741 . . . . 0.0 109.11 170.586 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 109.94 -10.05 31.89 Favored Glycine 0 N--CA 1.424 -2.103 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.732 -179.112 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 84.1 mm-40 -99.55 159.29 15.14 Favored 'General case' 0 N--CA 1.433 -1.291 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.916 -178.842 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 190' ' ' MET . . . -138.73 123.98 19.21 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 175.688 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.547 HG23 ' CH2' ' A' ' 198' ' ' TRP . 85.0 t -87.68 109.71 19.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.047 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.481 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 41.2 ttm180 -96.71 142.57 28.58 Favored 'General case' 0 N--CA 1.416 -2.162 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 177.781 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -110.19 159.59 17.24 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 -177.294 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.625 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -130.76 139.79 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.467 -2.247 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.675 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 178' ' ' CYS . . . . . 0.521 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 77.4 m -84.79 129.52 34.81 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 173.501 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -53.28 -51.63 61.69 Favored 'General case' 0 CA--C 1.48 -1.713 0 C-N-CA 124.76 1.224 . . . . 0.0 112.584 -175.997 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 13.3 t -123.63 -154.58 0.61 Allowed 'General case' 0 N--CA 1.402 -2.837 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 -177.052 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -74.22 51.11 2.06 Favored Glycine 0 N--CA 1.443 -0.838 0 O-C-N 123.588 0.555 . . . . 0.0 113.78 -176.468 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 182' ' ' TYR . . . . . 0.521 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 98.4 m-85 -100.89 168.39 9.66 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 176.114 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 50.6 pttt -121.41 146.05 47.29 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.794 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.759 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.8 tt -76.86 141.8 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.766 0 C-N-CA 119.691 -0.804 . . . . 0.0 110.276 176.403 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -53.75 -61.13 2.5 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 125.086 1.354 . . . . 0.0 113.228 -176.227 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -123.89 -97.81 1.27 Allowed Glycine 0 CA--C 1.496 -1.147 0 C-N-CA 120.33 -0.938 . . . . 0.0 112.814 -178.654 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -85.07 159.97 20.08 Favored 'General case' 0 CA--C 1.48 -1.728 0 N-CA-C 106.876 -1.527 . . . . 0.0 106.876 176.75 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.759 ' HA ' HD13 ' A' ' 184' ' ' ILE . 14.5 pt-20 -102.47 3.86 38.08 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 118.114 -1.434 . . . . 0.0 109.468 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 189' ' ' GLU . . . . . 0.476 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 8.7 pt-20 -151.45 147.37 26.78 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-N 115.547 -0.751 . . . . 0.0 112.386 -176.216 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.486 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 13.9 ptp -113.79 128.25 56.34 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.649 175.446 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -110.56 146.56 35.85 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 116.746 -0.206 . . . . 0.0 110.473 -174.646 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 88.6 m -75.06 155.04 37.63 Favored 'General case' 0 C--O 1.241 0.642 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 178.436 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 60.6 m -126.17 171.46 10.86 Favored 'General case' 0 C--O 1.256 1.395 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 169.387 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -78.4 91.56 4.49 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.261 1.029 . . . . 0.0 112.496 -172.347 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 9.5 t70 174.22 -38.18 0.01 OUTLIER 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 113.15 -1.841 . . . . 0.0 106.293 176.508 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 196' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 119.65 18.69 4.33 Favored Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.196 -179.534 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -109.65 158.13 18.38 Favored 'General case' 0 C--O 1.251 1.168 0 O-C-N 122.226 -0.573 . . . . 0.0 109.969 176.418 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 198' ' ' TRP . . . . . 0.547 ' CH2' HG23 ' A' ' 174' ' ' VAL . 87.6 m95 -87.31 144.69 26.67 Favored 'General case' 0 N--CA 1.423 -1.815 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 176.18 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.2 m -92.94 7.59 43.33 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-O 121.879 0.847 . . . . 0.0 110.926 -178.176 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.468 ' HB3' ' CB ' ' A' ' 190' ' ' MET . 0.8 OUTLIER -139.39 153.28 47.61 Favored 'General case' 0 N--CA 1.417 -2.102 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 177.096 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 201' ' ' GLU . . . . . 0.485 ' CD ' ' H ' ' A' ' 201' ' ' GLU . 0.2 OUTLIER -105.28 171.93 7.06 Favored 'General case' 0 C--N 1.279 -2.461 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 178.9 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 202' ' ' LYS . . . . . 0.454 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 45.8 mtpt -63.38 117.61 35.74 Favored Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 114.154 1.168 . . . . 0.0 114.154 -174.865 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 5.4 Cg_exo -82.33 171.31 12.58 Favored 'Trans proline' 0 N--CA 1.445 -1.369 0 C-N-CA 122.793 2.329 . . . . 0.0 108.953 172.246 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 204' ' ' LYS . . . . . 0.463 ' O ' ' HA ' ' A' ' 184' ' ' ILE . 38.8 mtpt -122.38 174.55 6.95 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.966 -0.694 . . . . 0.0 109.432 179.681 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 57.3 m -115.39 107.56 15.37 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 173.19 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m . . . . . 0 C--N 1.281 -2.413 0 CA-C-N 114.371 -1.286 . . . . 0.0 109.736 -173.638 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo . . . . . 0 N--CA 1.477 0.548 0 CA-C-O 121.078 0.366 . . . . 0.0 112.766 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 65.1 m -73.32 -27.15 61.36 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.547 0.689 . . . . 0.0 110.677 178.027 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.19 13.12 40.19 Favored Glycine 0 C--N 1.3 -1.417 0 CA-C-N 115.206 -0.907 . . . . 0.0 114.832 172.724 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 34.0 t-80 68.77 125.37 0.03 OUTLIER Pre-proline 0 N--CA 1.489 1.484 0 C-N-CA 123.841 0.856 . . . . 0.0 108.931 -179.234 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.519 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 92.7 Cg_endo -75.97 7.77 3.09 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 123.059 2.506 . . . . 0.0 114.862 -171.998 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 97.94 -166.0 22.25 Favored Glycine 0 C--N 1.277 -2.715 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -175.514 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -143.37 140.21 30.38 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 -179.036 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.3 t -102.64 129.53 25.73 Favored Pre-proline 0 C--N 1.299 -1.624 0 CA-C-O 121.234 0.54 . . . . 0.0 110.829 -178.366 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.25 -11.55 25.0 Favored 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 122.544 2.163 . . . . 0.0 111.474 177.599 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -87.25 -3.02 59.03 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.518 -178.285 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.402 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 167.69 -120.85 0.93 Allowed Glycine 0 N--CA 1.43 -1.717 0 C-N-CA 120.271 -0.966 . . . . 0.0 111.797 179.235 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.4 t -151.49 -172.86 4.33 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 123.71 0.3 . . . . 0.0 110.361 179.447 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.6 p90 -146.13 156.42 43.42 Favored 'General case' 0 N--CA 1.436 -1.168 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 176.65 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 5.5 m -121.92 166.52 14.29 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 178.041 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.451 HD11 ' CE1' ' A' ' 104' ' ' PHE . 14.8 mt -120.14 128.83 53.78 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.897 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.441 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 33.7 p -115.91 135.72 53.72 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 -178.262 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 114.53 -65.04 0.29 Allowed Glycine 0 N--CA 1.429 -1.781 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -179.243 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -119.69 -5.93 10.72 Favored Glycine 0 C--N 1.309 -0.938 0 C-N-CA 119.98 -1.105 . . . . 0.0 113.143 -178.991 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 59.79 19.62 8.44 Favored 'General case' 0 N--CA 1.495 1.809 0 C-N-CA 123.04 0.536 . . . . 0.0 112.373 -178.079 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.502 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.0 m -146.67 -171.12 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.203 -1.379 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -176.028 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.451 ' CE1' HD11 ' A' ' 98' ' ' LEU . 54.0 m-85 -106.42 39.41 1.83 Allowed 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 118.565 0.62 . . . . 0.0 110.635 -175.756 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.708 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.5 pt-20 -85.43 -176.61 6.18 Favored 'General case' 0 C--O 1.202 -1.443 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.52 179.165 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 -75.63 137.29 40.64 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.935 -0.478 . . . . 0.0 111.143 177.702 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.35 4.93 73.23 Favored Glycine 0 N--CA 1.433 -1.536 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.962 178.132 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.708 HG12 ' O ' ' A' ' 105' ' ' GLU . 13.9 p -95.02 146.22 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 C-N-CA 119.854 -0.738 . . . . 0.0 109.179 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.441 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 56.3 mtpt -110.17 123.75 50.32 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.591 179.198 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.524 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.3 93.63 9.13 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 176.469 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 76.7 t -86.03 109.62 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.772 0 C-N-CA 123.972 0.909 . . . . 0.0 109.208 -177.803 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -82.99 139.22 33.42 Favored 'General case' 0 C--N 1.286 -2.17 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.773 -179.566 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 11.1 t -136.83 127.78 27.57 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.738 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 82.3 m -81.31 160.18 24.25 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.822 -174.593 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.402 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 74.7 m-20 -72.46 177.21 4.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.9 175.926 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -56.57 -47.02 80.39 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -176.14 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -78.01 11.1 23.32 Favored Glycine 0 CA--C 1.522 0.495 0 CA-C-N 116.186 -0.461 . . . . 0.0 114.236 -178.876 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.612 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 82.5 m-85 -133.45 156.73 47.19 Favored 'General case' 0 C--N 1.311 -1.094 0 O-C-N 122.368 -0.489 . . . . 0.0 110.713 -179.195 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -143.44 147.97 35.4 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.006 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 7.2 tp -76.95 144.03 39.08 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-O 120.978 0.418 . . . . 0.0 110.834 -173.158 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.82 125.38 46.36 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -179.778 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 108.12 -176.28 20.34 Favored Glycine 0 C--N 1.291 -1.919 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -174.532 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -101.07 -24.95 14.21 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.363 0.602 . . . . 0.0 110.288 -179.726 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.2 mm -80.96 127.25 39.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -178.578 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -134.42 11.38 3.79 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 -178.561 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.524 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 32.8 p90 -149.01 167.71 25.08 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 -172.135 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.583 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 46.7 mtp180 -129.2 119.37 23.93 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 171.769 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -91.23 128.68 37.15 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.755 -0.778 . . . . 0.0 110.149 178.687 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 35.2 t -87.07 107.13 18.3 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.338 -0.945 . . . . 0.0 109.89 175.126 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.441 ' OD1' HG22 ' A' ' 131' ' ' THR . 7.2 t70 -100.61 -168.73 1.61 Allowed 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 176.342 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.441 HG22 ' OD1' ' A' ' 130' ' ' ASP . 11.1 t -69.84 -18.15 63.43 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 122.445 1.117 . . . . 0.0 109.176 178.279 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -80.67 -7.0 59.18 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 114.294 -1.321 . . . . 0.0 109.327 177.036 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 97.34 -158.57 21.08 Favored Glycine 0 N--CA 1.429 -1.77 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -176.316 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.405 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 90.0 m95 -65.32 108.48 1.94 Allowed 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 175.963 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 30.0 p -64.05 -55.2 23.93 Favored 'General case' 0 C--N 1.317 -0.84 0 C-N-CA 123.705 0.802 . . . . 0.0 111.581 -176.251 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 136' ' ' ASN . . . . . 0.583 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.3 m120 -78.64 167.22 21.56 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 114.857 -1.065 . . . . 0.0 109.04 -179.708 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -99.86 179.12 4.62 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 175.162 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.7 mt -65.63 118.98 56.45 Favored Pre-proline 0 C--N 1.325 -0.494 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 174.113 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.7 146.64 84.5 Favored 'Trans proline' 0 C--O 1.25 1.101 0 C-N-CA 122.322 2.015 . . . . 0.0 112.802 -176.292 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 66.0 mt -72.4 130.35 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.58 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.0 -179.783 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.612 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 45.3 t -121.48 142.42 50.07 Favored 'General case' 0 C--N 1.274 -2.678 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 176.354 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 6.1 tp10 -121.43 152.97 38.48 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -174.73 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.468 HG21 ' NE2' ' A' ' 169' ' ' HIS . 8.1 p -73.74 141.73 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.5 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.019 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 74.7 t -60.95 119.82 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.882 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 52.8 mtmt -125.42 138.43 54.02 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.477 -177.504 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 2.1 p -110.75 160.61 16.56 Favored 'General case' 0 C--N 1.287 -2.112 0 CA-C-N 115.298 -0.865 . . . . 0.0 112.18 -179.186 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 147' ' ' LEU . . . . . 0.483 HD12 ' HD2' ' A' ' 148' ' ' PRO . 0.3 OUTLIER -77.97 135.6 62.87 Favored Pre-proline 0 N--CA 1.426 -1.65 0 C-N-CA 124.573 1.149 . . . . 0.0 111.302 -173.533 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.483 ' HD2' HD12 ' A' ' 147' ' ' LEU . 12.1 Cg_endo -55.97 126.87 23.84 Favored 'Trans proline' 0 C--O 1.244 0.784 0 C-N-CA 123.812 3.008 . . . . 0.0 112.661 179.304 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 10.8 p -91.21 150.31 3.8 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.128 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 19.9 p -71.53 -88.34 0.02 OUTLIER 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 113.505 0.928 . . . . 0.0 113.505 -177.324 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 171.91 164.3 0.25 Allowed Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 179.738 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 152' ' ' PRO . . . . . 0.46 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 73.7 Cg_endo -78.45 166.02 24.61 Favored 'Trans proline' 0 N--CA 1.454 -0.849 0 C-N-CA 121.688 1.592 . . . . 0.0 110.419 171.624 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -64.94 -61.53 2.11 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -179.754 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -91.34 35.56 0.93 Allowed 'General case' 0 C--O 1.247 0.963 0 O-C-N 121.773 -0.579 . . . . 0.0 111.24 179.709 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -156.85 -161.78 11.02 Favored Glycine 0 N--CA 1.425 -2.053 0 C-N-CA 120.145 -1.026 . . . . 0.0 112.384 178.263 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 59.5 pttt -159.07 -178.48 7.26 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -178.394 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 58.2 mt -96.62 141.3 15.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 117.577 0.171 . . . . 0.0 111.159 -178.604 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.55 HG12 HG22 ' A' ' 177' ' ' VAL . 3.3 m -88.77 -31.98 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.931 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 176.317 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.8 m -92.58 88.98 6.52 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.027 -176.07 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.0 m -55.51 136.83 49.64 Favored 'General case' 0 C--N 1.309 -1.152 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.585 179.695 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -65.98 171.35 4.56 Favored 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 116.013 -0.539 . . . . 0.0 112.408 -175.91 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.92 11.14 2.83 Favored 'General case' 0 C--O 1.207 -1.155 0 C-N-CA 123.381 0.672 . . . . 0.0 110.831 178.801 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . 0.337 49.4 mt-10 34.26 -77.23 0.0 OUTLIER Pre-proline 0 N--CA 1.487 1.423 0 C-N-CA 129.253 3.021 . . . . 0.0 119.07 173.094 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -59.4 -19.5 51.59 Favored 'Trans proline' 0 C--N 1.38 2.23 0 CA-C-N 122.34 1.872 . . . . 0.0 111.361 174.227 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -106.31 -38.35 6.26 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 175.864 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . 0.358 7.9 ppt_? 45.31 7.84 0.0 OUTLIER 'General case' 0 C--N 1.358 0.954 0 N-CA-C 118.041 2.608 . . . . 0.0 118.041 -172.911 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -103.19 135.44 44.84 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 107.931 -1.136 . . . . 0.0 107.931 175.719 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 168' ' ' TYR . . . . . 0.456 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 73.2 m-85 -87.48 139.11 30.88 Favored 'General case' 0 C--N 1.287 -2.149 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.446 -173.288 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.468 ' NE2' HG21 ' A' ' 143' ' ' VAL . 54.9 t-80 -86.32 146.23 26.58 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.023 -0.99 . . . . 0.0 108.687 179.817 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 83.6 t80 -54.64 129.73 37.66 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.714 176.32 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 112.91 -22.17 16.85 Favored Glycine 0 N--CA 1.432 -1.602 0 C-N-CA 120.155 -1.021 . . . . 0.0 111.994 -178.006 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 86.2 mm-40 -70.35 150.88 45.85 Favored 'General case' 0 C--O 1.251 1.149 0 CA-C-O 120.87 0.367 . . . . 0.0 110.276 178.359 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -134.65 103.1 5.52 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.604 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 95.7 t -76.79 108.92 10.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.617 -178.025 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.465 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 29.5 ttp180 -101.49 142.2 33.22 Favored 'General case' 0 N--CA 1.407 -2.612 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.459 177.813 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 176' ' ' PHE . . . . . 0.46 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 62.8 m-85 -113.26 153.32 28.6 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.664 -174.809 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.55 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -121.29 152.54 24.75 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.275 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.996 179.296 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 67.9 m -99.51 138.87 35.99 Favored 'General case' 0 N--CA 1.403 -2.786 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 172.396 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -55.41 -52.41 63.67 Favored 'General case' 0 CA--C 1.486 -1.49 0 N-CA-C 114.192 1.182 . . . . 0.0 114.192 -175.131 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 58.9 m -150.33 -100.32 0.07 Allowed 'General case' 0 C--N 1.286 -2.153 0 C-N-CA 120.144 -0.622 . . . . 0.0 112.042 -177.005 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -87.5 44.68 3.29 Favored Glycine 0 CA--C 1.494 -1.254 0 CA-C-O 121.264 0.369 . . . . 0.0 112.343 -177.654 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -123.9 158.59 31.58 Favored 'General case' 0 N--CA 1.415 -2.2 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.531 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.446 ' O ' ' HD2' ' A' ' 183' ' ' LYS . 1.2 pptp? -132.01 143.13 49.85 Favored 'General case' 0 C--N 1.288 -2.066 0 O-C-N 123.878 0.736 . . . . 0.0 109.178 179.118 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.554 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.2 tt -71.57 142.47 15.4 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.26 0 CA-C-O 121.489 0.661 . . . . 0.0 111.626 -178.299 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -76.59 -57.08 4.06 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.735 -175.845 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -93.05 -126.42 4.16 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 120.277 -0.963 . . . . 0.0 111.954 -177.776 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -93.28 158.83 15.55 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 176.677 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.554 ' HA ' HD13 ' A' ' 184' ' ' ILE . 14.5 pt-20 -95.1 -7.81 38.33 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 118.915 -1.114 . . . . 0.0 110.976 -174.333 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -138.91 135.79 34.81 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.163 0.506 . . . . 0.0 112.339 -176.497 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.435 ' HB3' ' HB2' ' A' ' 200' ' ' LYS . 12.8 ptp -116.12 124.05 49.38 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.398 176.301 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 52.0 t-80 -97.95 135.99 38.87 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.702 -176.234 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 16.4 t -71.15 118.61 14.15 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.34 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.5 m -97.56 165.33 12.04 Favored 'General case' 0 N--CA 1.437 -1.112 0 O-C-N 123.606 0.567 . . . . 0.0 110.445 -175.756 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -65.51 -6.76 11.6 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 124.514 1.126 . . . . 0.0 112.316 -177.573 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -74.25 -22.2 59.43 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.565 175.532 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 92.44 14.51 55.53 Favored Glycine 0 N--CA 1.435 -1.418 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -174.521 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -136.6 176.81 8.37 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.587 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 88.1 m95 -84.78 152.28 23.78 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.92 -177.521 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 21.0 p -80.23 -14.58 58.31 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.508 179.835 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.435 ' HB2' ' HB3' ' A' ' 190' ' ' MET . 64.8 mmtt -124.36 165.98 16.75 Favored 'General case' 0 CA--C 1.477 -1.846 0 CA-C-O 122.141 0.972 . . . . 0.0 113.6 -173.957 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -91.47 166.44 12.86 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 113.053 -1.885 . . . . 0.0 109.337 176.322 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 6.1 mmmm -65.96 109.78 3.68 Favored Pre-proline 0 C--N 1.318 -0.787 0 O-C-N 124.053 0.846 . . . . 0.0 112.939 178.854 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -92.04 156.85 3.28 Favored 'Trans proline' 0 N--CA 1.424 -2.612 0 C-N-CA 122.42 2.08 . . . . 0.0 110.412 177.687 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 204' ' ' LYS . . . . . 0.443 ' HA ' ' HB3' ' A' ' 152' ' ' PRO . 19.1 ptpt -135.68 155.81 49.83 Favored 'General case' 0 C--N 1.287 -2.126 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.005 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 97.5 m -93.29 118.52 31.37 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 177.569 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.1 m . . . . . 0 C--N 1.291 -1.951 0 CA-C-N 114.007 -1.451 . . . . 0.0 107.326 -178.267 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.486 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 41.0 Cg_endo . . . . . 0 CA--C 1.534 0.505 0 CA-C-O 121.181 0.409 . . . . 0.0 111.642 . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 85' ' ' CYS . . . . . 0.549 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 3.2 m -94.36 -17.9 22.11 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 122.1 0.952 . . . . 0.0 110.211 174.176 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.73 -87.72 0.54 Allowed Glycine 2 N--CA 1.391 -4.356 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 172.364 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -171.85 138.24 1.02 Allowed Pre-proline 0 C--N 1.247 -3.854 0 N-CA-C 105.735 -1.95 . . . . 0.0 105.735 -172.739 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.517 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 91.9 Cg_endo -87.45 2.06 6.87 Favored 'Trans proline' 0 C--N 1.322 -0.837 0 C-N-CA 121.946 1.764 . . . . 0.0 112.764 -177.76 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.07 -166.37 13.1 Favored Glycine 0 N--CA 1.428 -1.875 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 -179.708 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -159.27 124.12 4.08 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 177.659 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.8 t -110.56 137.32 20.69 Favored Pre-proline 0 C--N 1.296 -1.735 0 CA-C-O 120.895 0.379 . . . . 0.0 111.749 -178.585 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -83.07 -10.11 10.39 Favored 'Trans proline' 0 CA--C 1.544 1.0 0 C-N-CA 122.742 2.295 . . . . 0.0 112.062 174.063 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -88.81 6.76 37.42 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.414 0.626 . . . . 0.0 111.143 -178.624 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.419 ' HA2' ' ND2' ' A' ' 115' ' ' ASN . . . 161.95 -123.86 1.24 Allowed Glycine 0 N--CA 1.415 -2.751 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.607 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.6 t -164.29 -159.72 0.5 Allowed 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 -178.592 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.6 p90 -152.88 165.53 35.17 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 176.987 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -127.83 159.52 34.61 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 177.906 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.1 mt -117.18 132.18 56.7 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -178.54 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 16.5 p -125.53 129.77 50.39 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -176.388 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.57 27.74 34.68 Favored Glycine 0 C--N 1.313 -0.703 0 C-N-CA 120.353 -0.927 . . . . 0.0 111.653 -179.447 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 178.37 -45.81 0.09 OUTLIER Glycine 0 N--CA 1.433 -1.542 0 C-N-CA 119.69 -1.243 . . . . 0.0 112.8 -179.158 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 63.8 t30 70.44 8.42 6.6 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 124.195 0.998 . . . . 0.0 109.965 -178.304 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.553 ' O ' HG11 ' A' ' 108' ' ' VAL . 25.2 m -148.82 -175.74 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.125 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 -177.864 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.517 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 23.5 m-85 -98.9 38.08 1.43 Allowed 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 118.995 0.816 . . . . 0.0 110.782 -176.296 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.72 ' O ' HG12 ' A' ' 108' ' ' VAL . 15.2 pt-20 -79.86 175.54 10.54 Favored 'General case' 0 C--O 1.195 -1.765 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.815 -179.344 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 106' ' ' TYR . . . . . 0.534 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 43.0 m-85 -74.73 126.24 30.45 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 122.144 -0.347 . . . . 0.0 111.536 179.404 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 102.21 -1.22 50.66 Favored Glycine 0 N--CA 1.439 -1.16 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.618 179.713 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.72 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -92.45 147.55 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.053 0 C-N-CA 120.068 -0.653 . . . . 0.0 109.626 -179.447 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -114.19 123.51 49.75 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 177.8 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.474 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.81 94.85 9.88 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 177.86 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 76.8 t -84.16 108.36 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.921 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -179.439 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 112' ' ' TYR . . . . . 0.51 ' HE1' ' SG ' ' A' ' 114' ' ' CYS . 37.6 t80 -74.82 140.99 44.32 Favored 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 123.563 0.745 . . . . 0.0 109.37 -177.012 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 3.3 t -144.3 111.49 5.9 Favored 'General case' 0 N--CA 1.426 -1.632 0 CA-C-O 121.919 0.866 . . . . 0.0 110.492 -179.637 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.51 ' SG ' ' HE1' ' A' ' 112' ' ' TYR . 74.7 m -71.46 162.17 29.86 Favored 'General case' 0 C--O 1.255 1.365 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.803 178.501 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.419 ' ND2' ' HA2' ' A' ' 94' ' ' GLY . 37.6 m-20 -74.99 -177.37 3.31 Favored 'General case' 0 C--O 1.211 -0.942 0 CA-C-N 115.817 -0.628 . . . . 0.0 109.905 175.582 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -66.86 -35.05 79.14 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -174.947 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.426 ' HA2' ' CD2' ' A' ' 170' ' ' PHE . . . -73.98 -6.19 72.64 Favored Glycine 0 C--N 1.311 -0.829 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.741 178.948 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.61 ' HE1' HG22 ' A' ' 143' ' ' VAL . 87.8 m-85 -129.88 167.91 17.43 Favored 'General case' 0 N--CA 1.441 -0.903 0 O-C-N 122.427 -0.455 . . . . 0.0 110.189 -176.615 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 6.5 pt20 -146.27 157.55 43.81 Favored 'General case' 0 C--N 1.289 -2.033 0 CA-C-O 120.908 0.385 . . . . 0.0 110.682 -178.325 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -78.93 125.78 29.83 Favored 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 178.236 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.589 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -115.45 134.26 55.26 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 178.2 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.03 -178.07 20.6 Favored Glycine 0 C--N 1.289 -2.036 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -178.501 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -96.46 -40.53 9.03 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 -178.699 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.582 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 46.8 mm -77.26 124.06 34.99 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.696 -178.271 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -131.54 9.27 4.66 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 -176.615 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 18.5 p90 -143.88 166.99 23.38 Favored 'General case' 0 N--CA 1.425 -1.689 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -174.978 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.5 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 63.3 mtp180 -131.95 122.58 25.82 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 171.345 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -91.84 124.8 36.24 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 119.889 -0.724 . . . . 0.0 111.166 178.386 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 129' ' ' CYS . . . . . 0.534 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 36.0 t -80.0 105.03 10.98 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 175.2 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.437 ' OD2' HG22 ' A' ' 131' ' ' THR . 6.9 t70 -118.9 -169.92 1.82 Allowed 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -178.448 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.437 HG22 ' OD2' ' A' ' 130' ' ' ASP . 12.4 t -57.75 -26.01 61.25 Favored 'General case' 0 CA--C 1.563 1.45 0 C-N-CA 123.803 0.841 . . . . 0.0 112.266 -174.19 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -84.36 -24.86 29.53 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.882 0.848 . . . . 0.0 110.585 -179.731 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.549 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 125.52 -152.55 17.92 Favored Glycine 0 N--CA 1.419 -2.484 0 N-CA-C 106.811 -2.515 . . . . 0.0 106.811 -171.641 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -70.48 114.75 8.9 Favored 'General case' 0 N--CA 1.433 -1.321 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 175.281 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.3 p -64.94 -54.77 25.42 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.762 0.791 . . . . 0.0 111.456 -176.606 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 136' ' ' ASN . . . . . 0.5 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.8 m120 -78.96 167.77 20.65 Favored 'General case' 0 C--N 1.296 -1.758 0 CA-C-N 114.703 -1.135 . . . . 0.0 108.619 -178.716 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -98.96 -179.91 4.42 Favored 'General case' 0 C--N 1.29 -2.018 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 175.004 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.1 mt -65.17 121.17 72.9 Favored Pre-proline 0 C--N 1.309 -1.175 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 177.526 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.582 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 23.2 Cg_exo -57.67 167.29 4.09 Favored 'Trans proline' 0 C--O 1.245 0.853 0 C-N-CA 122.709 2.273 . . . . 0.0 112.179 177.909 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.589 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 3.6 mp -94.27 132.25 38.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 -171.019 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 8.5 t -112.62 119.39 37.97 Favored 'General case' 0 N--CA 1.423 -1.792 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 176.233 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -108.96 156.02 20.19 Favored 'General case' 0 C--N 1.274 -2.717 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 178.566 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.659 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 15.0 t -80.18 149.81 5.09 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.315 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 177.348 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 57.1 t -67.66 115.65 6.09 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.622 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.568 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.659 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 39.8 mtpt -123.23 157.67 32.58 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.799 -173.745 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 p -134.12 155.51 49.95 Favored 'General case' 0 C--N 1.286 -2.167 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.443 -179.228 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -55.69 147.09 42.77 Favored Pre-proline 0 N--CA 1.443 -0.807 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -177.086 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -71.77 129.9 16.16 Favored 'Trans proline' 0 N--CA 1.444 -1.43 0 C-N-CA 122.841 2.361 . . . . 0.0 111.914 -178.59 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 46.9 t -95.75 129.19 46.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.595 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.5 p -74.04 -73.93 0.21 Allowed 'General case' 0 N--CA 1.428 -1.551 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 178.215 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 175.82 156.68 0.39 Allowed Pre-proline 0 C--N 1.328 -0.347 0 C-N-CA 125.034 1.334 . . . . 0.0 107.526 178.613 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 152' ' ' PRO . . . . . 0.425 ' HG2' ' HA3' ' A' ' 155' ' ' GLY . 10.9 Cg_endo -66.76 167.04 20.37 Favored 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.532 1.488 . . . . 0.0 109.605 170.852 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 153' ' ' GLU . . . . . 0.536 ' OE1' ' HG3' ' A' ' 204' ' ' LYS . 0.0 OUTLIER -62.52 -45.16 94.26 Favored 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -175.181 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 154' ' ' ASN . . . . . 0.424 ' OD1' ' HG2' ' A' ' 153' ' ' GLU . 24.7 m120 -116.51 26.92 9.54 Favored 'General case' 0 CA--C 1.504 -0.813 0 CA-C-O 121.552 0.692 . . . . 0.0 109.689 179.881 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 155' ' ' GLY . . . . . 0.425 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -142.09 -171.7 13.18 Favored Glycine 0 N--CA 1.423 -2.211 0 C-N-CA 120.233 -0.984 . . . . 0.0 111.814 179.834 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 156' ' ' LYS . . . . . 0.415 ' HG3' HG23 ' A' ' 177' ' ' VAL . 44.2 pttt -153.26 171.1 19.06 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -177.39 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 53.2 mt -96.02 139.34 19.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 120.606 0.241 . . . . 0.0 111.372 -176.151 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.543 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 5.0 m -99.03 -28.32 3.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 CA-C-O 121.269 0.556 . . . . 0.0 110.09 178.305 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 159' ' ' SER . . . . . 0.556 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 46.3 m -110.19 112.64 24.74 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.374 -172.041 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 66.8 m -152.19 112.14 4.02 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 175.729 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -70.6 95.71 1.12 Allowed 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 175.004 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 4.8 mmt -99.37 28.82 4.3 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.694 0.759 . . . . 0.0 110.004 -174.019 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.422 ' HB3' ' HD2' ' A' ' 164' ' ' PRO . 57.5 mm-40 -57.27 167.48 1.2 Allowed Pre-proline 0 C--N 1.307 -1.274 0 CA-C-N 113.492 -1.685 . . . . 0.0 108.693 174.752 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 164' ' ' PRO . . . . . 0.422 ' HD2' ' HB3' ' A' ' 163' ' ' GLU . 12.1 Cg_endo -55.42 -12.34 5.78 Favored 'Trans proline' 0 N--CA 1.5 1.906 0 C-N-CA 123.216 2.611 . . . . 0.0 114.177 178.502 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -94.73 -48.47 6.04 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 123.921 0.888 . . . . 0.0 109.182 -179.623 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . 0.28 3.0 ppt_? 39.39 32.75 0.09 Allowed 'General case' 0 C--O 1.239 0.532 0 N-CA-C 117.653 2.464 . . . . 0.0 117.653 -178.985 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -92.38 152.29 19.82 Favored 'General case' 0 N--CA 1.426 -1.661 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 173.893 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -80.67 130.44 35.1 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 176.888 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 82.4 m-70 -135.08 160.41 38.44 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -178.737 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 170' ' ' PHE . . . . . 0.426 ' CD2' ' HA2' ' A' ' 117' ' ' GLY . 0.9 OUTLIER -61.55 114.67 3.38 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 172.259 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 135.3 -21.16 3.68 Favored Glycine 0 N--CA 1.427 -1.919 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 -176.198 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 25.7 tp60 -76.81 124.04 27.11 Favored 'General case' 0 N--CA 1.401 -2.89 0 C-N-CA 122.883 0.473 . . . . 0.0 109.986 178.271 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -112.07 118.07 34.38 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 171.262 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.556 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 72.0 t -98.41 113.76 34.02 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -177.712 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.543 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 72.2 ttt180 -104.02 149.48 25.13 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 -179.678 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -122.45 162.74 21.12 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 121.579 0.704 . . . . 0.0 111.346 -174.455 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.415 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.0 OUTLIER -129.42 149.33 33.56 Favored 'Isoleucine or valine' 0 CA--C 1.475 -1.942 0 CA-C-N 113.998 -1.455 . . . . 0.0 109.644 174.097 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 178' ' ' CYS . . . . . 0.418 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 73.1 m -111.72 128.38 56.07 Favored 'General case' 0 N--CA 1.406 -2.674 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 176.062 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -50.45 159.74 0.47 Allowed 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 114.62 -1.173 . . . . 0.0 111.713 177.291 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 48.1 t -47.88 113.32 0.7 Allowed 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.42 -175.891 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.55 -17.3 30.95 Favored Glycine 0 N--CA 1.429 -1.796 0 C-N-CA 120.593 -0.813 . . . . 0.0 113.574 178.237 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 182' ' ' TYR . . . . . 0.418 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 95.7 m-85 -99.63 159.57 14.94 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 117.939 0.87 . . . . 0.0 110.965 -177.803 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 16.1 pttm -124.55 150.22 46.12 Favored 'General case' 0 N--CA 1.42 -1.958 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 175.615 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -74.93 133.58 31.21 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.468 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 174.807 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -77.47 -54.71 6.11 Favored 'General case' 0 C--N 1.282 -2.353 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -176.875 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -88.1 -134.65 4.7 Favored Glycine 0 C--N 1.301 -1.372 0 C-N-CA 120.958 -0.639 . . . . 0.0 111.836 177.558 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -87.36 158.7 18.97 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 178.83 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -96.37 6.17 49.34 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.067 -176.154 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -147.38 146.22 29.55 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 121.058 0.456 . . . . 0.0 111.981 -177.109 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.413 ' CE ' ' HA ' ' A' ' 202' ' ' LYS . 12.9 ptp -126.05 132.06 52.03 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.55 176.465 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 24.0 t-80 -105.84 136.09 46.11 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -177.876 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 8.6 t -74.22 124.55 26.6 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 177.338 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 27.1 t -97.18 171.55 8.38 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 122.91 0.484 . . . . 0.0 110.732 -176.361 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -68.14 -11.41 59.11 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 125.027 1.331 . . . . 0.0 114.439 -173.05 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 195' ' ' ASP . . . . . 0.514 ' HB3' ' CD1' ' A' ' 197' ' ' PHE . 29.3 t70 -94.23 -3.35 50.88 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 122.415 1.102 . . . . 0.0 109.959 177.68 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 82.81 49.81 4.93 Favored Glycine 0 N--CA 1.434 -1.497 0 C-N-CA 120.443 -0.884 . . . . 0.0 111.442 179.894 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 197' ' ' PHE . . . . . 0.514 ' CD1' ' HB3' ' A' ' 195' ' ' ASP . 3.1 p90 -151.77 158.97 44.05 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 178.322 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 87.4 m95 -76.38 135.22 39.49 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 176.551 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.9 p -61.1 -28.32 69.01 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.736 0.779 . . . . 0.0 111.291 -177.295 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 40.0 mmtt -113.71 162.83 15.79 Favored 'General case' 0 N--CA 1.418 -2.042 0 CA-C-N 114.729 -1.123 . . . . 0.0 111.062 -178.946 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -75.38 172.28 12.76 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 105.845 -1.909 . . . . 0.0 105.845 172.483 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 202' ' ' LYS . . . . . 0.413 ' HA ' ' CE ' ' A' ' 190' ' ' MET . 3.1 ttpm? -85.2 116.4 65.32 Favored Pre-proline 0 N--CA 1.421 -1.922 0 C-N-CA 117.321 -1.751 . . . . 0.0 107.773 179.18 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -67.08 166.42 23.1 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 122.774 2.316 . . . . 0.0 112.885 -174.733 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 204' ' ' LYS . . . . . 0.536 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 87.0 tttt -123.2 153.19 40.42 Favored 'General case' 0 C--N 1.286 -2.155 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.627 -173.627 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 99.9 m -109.82 112.85 25.14 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 177.009 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--N 1.304 -1.381 0 CA-C-N 115.173 -0.921 . . . . 0.0 108.871 -177.127 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo . . . . . 0 CA--C 1.536 0.611 0 CA-C-O 121.783 0.659 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.6 m -90.28 -32.89 16.34 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.001 178.86 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 109.68 -78.02 0.23 Allowed Glycine 0 CA--C 1.457 -3.538 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.333 168.833 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.0 t60 179.93 128.49 0.24 Allowed Pre-proline 0 C--N 1.274 -2.705 0 N-CA-C 105.08 -2.193 . . . . 0.0 105.08 -176.811 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.416 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 72.3 Cg_endo -75.98 -0.99 10.88 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 C-N-CA 123.647 2.898 . . . . 0.0 114.448 -172.236 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.66 179.64 16.93 Favored Glycine 0 N--CA 1.41 -3.093 0 N-CA-C 107.362 -2.295 . . . . 0.0 107.362 -173.495 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -150.16 160.26 43.8 Favored 'General case' 0 C--N 1.275 -2.641 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 -177.584 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.0 t -142.18 136.38 14.89 Favored Pre-proline 0 C--N 1.297 -1.676 0 C-N-CA 120.118 -0.633 . . . . 0.0 111.459 -176.778 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -79.67 -8.94 14.72 Favored 'Trans proline' 0 CA--C 1.533 0.432 0 C-N-CA 123.127 2.551 . . . . 0.0 112.022 176.631 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -93.23 4.28 54.26 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 121.315 0.579 . . . . 0.0 111.202 -176.858 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.627 ' HA2' ' OD1' ' A' ' 115' ' ' ASN . . . 170.19 -131.49 2.26 Favored Glycine 0 N--CA 1.401 -3.636 0 C-N-CA 120.278 -0.963 . . . . 0.0 110.921 -179.548 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.9 t -162.14 -166.64 1.45 Allowed 'General case' 0 C--N 1.277 -2.572 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -178.951 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.429 ' HA ' ' HA ' ' A' ' 112' ' ' TYR . 48.7 p90 -148.14 163.17 37.76 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 178.191 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -123.12 160.08 27.19 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 178.858 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -119.7 117.15 27.49 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.865 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.524 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 30.8 p -107.03 130.9 54.59 Favored 'General case' 0 C--N 1.279 -2.496 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.441 -174.04 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 112.86 -67.44 0.24 Allowed Glycine 0 N--CA 1.424 -2.123 0 N-CA-C 110.871 -0.891 . . . . 0.0 110.871 -178.689 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -114.58 -8.84 15.57 Favored Glycine 0 C--N 1.314 -0.66 0 C-N-CA 120.109 -1.043 . . . . 0.0 113.335 -176.097 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 47.9 m-80 61.1 18.63 9.2 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 123.253 0.621 . . . . 0.0 112.371 -178.334 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.498 ' O ' HG11 ' A' ' 108' ' ' VAL . 20.6 m -148.47 -176.73 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 -175.76 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -98.8 43.28 1.06 Allowed 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.13 0.491 . . . . 0.0 110.4 -177.237 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.653 ' O ' HG12 ' A' ' 108' ' ' VAL . 17.8 pt-20 -82.63 -175.95 6.02 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.772 -1.104 . . . . 0.0 111.549 177.394 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -80.71 140.26 35.68 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.393 175.285 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.12 -4.89 84.68 Favored Glycine 0 N--CA 1.443 -0.887 0 CA-C-N 115.77 -0.65 . . . . 0.0 113.298 177.691 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.653 HG12 ' O ' ' A' ' 105' ' ' GLU . 15.0 p -88.02 148.21 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -178.237 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.524 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 58.4 mtpt -109.87 128.93 55.65 Favored 'General case' 0 N--CA 1.414 -2.267 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 177.096 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -91.27 90.69 7.86 Favored 'General case' 0 C--N 1.281 -2.397 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 175.423 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.46 HG12 ' HB3' ' A' ' 126' ' ' TYR . 26.5 m -90.74 110.52 22.33 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-O 122.645 1.212 . . . . 0.0 109.461 -177.361 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 112' ' ' TYR . . . . . 0.429 ' HA ' ' HA ' ' A' ' 96' ' ' PHE . 27.5 m-85 -76.9 144.55 38.84 Favored 'General case' 0 C--N 1.272 -2.768 0 CA-C-N 115.074 -0.966 . . . . 0.0 112.324 -178.243 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.2 t -139.7 116.45 10.86 Favored 'General case' 0 N--CA 1.421 -1.912 0 CA-C-N 114.799 -1.091 . . . . 0.0 108.731 -179.28 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 91.4 m -70.82 161.28 31.23 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -179.307 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.627 ' OD1' ' HA2' ' A' ' 94' ' ' GLY . 4.9 m-20 -74.89 -176.73 3.01 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.003 -0.999 . . . . 0.0 110.955 177.552 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -56.03 -49.92 72.36 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 123.68 0.792 . . . . 0.0 112.746 -177.599 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -89.44 19.01 42.5 Favored Glycine 0 N--CA 1.438 -1.217 0 C-N-CA 120.804 -0.712 . . . . 0.0 113.539 -177.802 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.69 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 87.2 m-85 -137.5 159.21 42.59 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 117.287 0.544 . . . . 0.0 110.488 -179.982 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 119' ' ' GLN . . . . . 0.534 ' OE1' ' HB3' ' A' ' 142' ' ' GLU . 0.0 OUTLIER -145.35 159.17 43.45 Favored 'General case' 0 N--CA 1.425 -1.714 0 C-N-CA 121.087 -0.245 . . . . 0.0 110.348 179.129 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.92 122.71 27.58 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 -176.902 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -107.9 127.62 53.9 Favored 'General case' 0 N--CA 1.414 -2.233 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 179.853 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 113.48 179.41 19.24 Favored Glycine 0 C--N 1.291 -1.93 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -178.182 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -94.49 -30.19 14.55 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.852 0.834 . . . . 0.0 108.77 -177.793 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.2 mm -87.14 122.8 39.44 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.56 0 CA-C-N 114.922 -1.035 . . . . 0.0 109.101 -179.331 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -124.4 1.24 8.36 Favored 'General case' 0 C--O 1.203 -1.38 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 178.811 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.502 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 40.4 p90 -139.34 164.74 29.05 Favored 'General case' 0 C--N 1.288 -2.087 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -170.432 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 127' ' ' ARG . . . . . 0.416 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 43.1 mtp180 -127.87 133.63 49.35 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 171.706 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -103.98 128.14 51.53 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 -178.485 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 13.7 t -82.85 105.22 13.69 Favored 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 117.749 -1.58 . . . . 0.0 110.332 177.18 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.462 ' OD1' HG22 ' A' ' 131' ' ' THR . 9.1 t70 -97.84 -168.68 1.71 Allowed 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 177.483 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.462 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.3 t -66.83 -22.57 66.0 Favored 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 118.161 0.437 . . . . 0.0 111.468 -175.123 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -88.95 -9.29 52.03 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.681 0.753 . . . . 0.0 110.03 178.67 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 114.72 -160.8 13.0 Favored Glycine 0 N--CA 1.428 -1.838 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -176.808 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 134' ' ' TRP . . . . . 0.416 ' CH2' HG13 ' A' ' 108' ' ' VAL . 96.9 m95 -64.22 113.57 3.66 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 122.543 0.337 . . . . 0.0 111.819 -179.044 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 66.3 p -73.61 176.03 6.56 Favored 'General case' 0 C--O 1.269 2.124 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.408 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 35.1 m-20 60.68 -149.08 0.43 Allowed 'General case' 0 C--O 1.244 0.787 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 179.281 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -144.2 -173.11 3.92 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 171.343 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 73.5 mt -66.01 119.29 60.18 Favored Pre-proline 0 C--N 1.272 -2.798 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 174.877 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -62.15 163.19 20.61 Favored 'Trans proline' 0 C--O 1.253 1.266 0 C-N-CA 122.686 2.257 . . . . 0.0 112.011 -178.918 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.7 mm -93.83 123.72 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 CA-C-O 121.505 0.669 . . . . 0.0 109.939 -173.976 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.631 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 22.0 t -107.51 110.1 21.94 Favored 'General case' 0 C--N 1.263 -3.187 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 176.607 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.534 ' HB3' ' OE1' ' A' ' 119' ' ' GLN . 10.5 tp10 -101.2 150.77 22.62 Favored 'General case' 0 N--CA 1.409 -2.478 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -175.898 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.69 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 8.6 t -75.63 137.01 23.69 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.385 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.129 -177.696 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 42.9 t -67.96 112.15 2.88 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.933 0 N-CA-C 106.538 -1.652 . . . . 0.0 106.538 174.888 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 145' ' ' LYS . . . . . 0.432 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 35.3 mtmm -129.86 161.57 30.51 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-N 115.5 -0.773 . . . . 0.0 108.951 -175.609 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -129.62 164.5 23.75 Favored 'General case' 0 C--N 1.271 -2.831 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.896 -178.138 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 85.4 mt -70.63 142.38 88.67 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 113.931 1.085 . . . . 0.0 113.931 -175.67 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_endo -63.39 119.66 6.8 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 123.05 2.5 . . . . 0.0 110.178 175.811 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.7 t -80.29 151.84 4.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.249 -174.398 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 150' ' ' THR . . . . . 0.425 ' O ' HD11 ' A' ' 157' ' ' ILE . 27.9 p -87.93 -159.08 0.5 Allowed 'General case' 0 N--CA 1.414 -2.24 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 170.971 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -128.9 151.59 77.69 Favored Pre-proline 0 C--N 1.283 -2.306 0 O-C-N 121.142 -0.973 . . . . 0.0 109.53 -172.277 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 152' ' ' PRO . . . . . 0.453 ' HG2' ' HA3' ' A' ' 155' ' ' GLY . 24.0 Cg_endo -66.86 160.7 45.56 Favored 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.055 1.836 . . . . 0.0 112.419 178.072 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -48.88 -45.79 41.64 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 126.0 1.72 . . . . 0.0 114.389 -175.516 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.5 m-80 -126.84 27.15 6.06 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-O 122.077 0.941 . . . . 0.0 109.49 -178.477 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 155' ' ' GLY . . . . . 0.453 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -132.15 -169.41 12.3 Favored Glycine 0 N--CA 1.42 -2.382 0 CA-C-N 114.714 -1.13 . . . . 0.0 111.066 179.572 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 156' ' ' LYS . . . . . 0.481 ' HG3' HG23 ' A' ' 177' ' ' VAL . 45.3 pttt -157.94 171.78 19.65 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -177.746 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.425 HD11 ' O ' ' A' ' 150' ' ' THR . 58.6 mt -97.2 131.84 43.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 C-N-CA 122.022 0.129 . . . . 0.0 110.743 -177.613 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.581 HG12 HG22 ' A' ' 177' ' ' VAL . 3.5 m -75.19 -38.33 41.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.321 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.0 m -86.54 35.31 0.66 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 124.87 1.268 . . . . 0.0 109.134 -176.501 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.0 t -67.17 167.94 11.21 Favored 'General case' 0 N--CA 1.436 -1.139 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.529 -175.822 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 67.32 96.22 0.06 Allowed 'General case' 0 CA--C 1.507 -0.7 0 CA-C-O 122.319 1.057 . . . . 0.0 110.921 -175.961 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 22.8 ttp -108.31 107.89 18.66 Favored 'General case' 0 N--CA 1.403 -2.821 0 N-CA-C 104.49 -2.411 . . . . 0.0 104.49 179.559 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -82.1 154.88 69.99 Favored Pre-proline 0 C--N 1.252 -3.631 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.074 -170.772 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -56.94 -21.08 39.35 Favored 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.22 2.613 . . . . 0.0 114.073 -178.581 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -98.53 -38.09 9.31 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.565 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 19.1 mmm180 -100.19 71.79 1.61 Allowed 'General case' 0 N--CA 1.415 -2.194 0 CA-C-N 114.937 -1.028 . . . . 0.0 111.353 -175.707 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -85.36 170.31 12.87 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 175.089 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 62.0 m-85 -68.64 104.73 2.05 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.668 0.747 . . . . 0.0 111.557 -177.251 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -105.86 164.24 12.1 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 179.023 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 90.7 t80 -52.14 128.16 23.92 Favored 'General case' 0 C--N 1.317 -0.807 0 C-N-CA 123.123 0.569 . . . . 0.0 109.827 174.516 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.46 -33.95 5.15 Favored Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.382 -179.129 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 87.1 mm-40 -70.12 151.62 45.25 Favored 'General case' 0 C--O 1.259 1.557 0 CA-C-O 121.244 0.545 . . . . 0.0 109.825 179.863 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -135.09 131.16 36.59 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-N 115.344 -0.843 . . . . 0.0 109.467 179.339 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 95.3 t -100.12 114.68 39.4 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -178.594 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.575 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 43.2 ttm180 -101.49 142.99 32.05 Favored 'General case' 0 N--CA 1.419 -1.981 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 177.366 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -111.99 160.52 17.38 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 123.138 0.575 . . . . 0.0 110.876 -176.613 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.581 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -131.52 143.29 40.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.933 178.962 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 93.4 m -102.17 132.1 48.28 Favored 'General case' 0 C--N 1.276 -2.603 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 174.168 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 59.0 m-80 -61.09 163.12 6.38 Favored 'General case' 0 CA--C 1.491 -1.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.569 -178.715 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 10.9 m -46.89 106.67 0.09 Allowed 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 125.51 1.524 . . . . 0.0 112.569 -175.723 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 115.79 -16.52 16.16 Favored Glycine 0 N--CA 1.435 -1.396 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.323 178.99 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 182' ' ' TYR . . . . . 0.431 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 90.1 m-85 -103.8 155.07 18.89 Favored 'General case' 0 CA--C 1.495 -1.138 0 CA-C-N 117.269 0.535 . . . . 0.0 111.609 -177.664 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -125.16 147.34 49.08 Favored 'General case' 0 N--CA 1.423 -1.785 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 177.981 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 9.1 tt -79.96 136.64 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.934 0 CA-C-O 121.802 0.811 . . . . 0.0 111.287 -177.296 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -81.87 -52.14 7.39 Favored 'General case' 0 C--N 1.292 -1.916 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.736 -177.707 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -86.4 -152.75 21.54 Favored Glycine 0 N--CA 1.433 -1.553 0 CA-C-N 114.97 -1.014 . . . . 0.0 111.042 178.487 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 187' ' ' ASP . . . . . 0.421 ' OD1' ' HD2' ' A' ' 200' ' ' LYS . 1.6 p-10 -92.7 163.11 13.88 Favored 'General case' 0 C--N 1.289 -2.024 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 177.955 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.575 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 0.8 OUTLIER -99.87 3.74 44.75 Favored 'General case' 0 C--N 1.286 -2.181 0 C-N-CA 118.509 -1.277 . . . . 0.0 113.165 -171.683 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -144.39 121.81 11.67 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -173.986 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 190' ' ' MET . . . . . 0.434 ' HB3' ' HB2' ' A' ' 200' ' ' LYS . 15.0 ptp -105.46 131.19 53.19 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.403 177.955 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 25.1 t-80 -106.16 135.42 47.65 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.446 -176.952 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 7.3 t -72.74 112.48 8.83 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.043 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 193' ' ' SER . . . . . 0.424 ' OG ' ' HB3' ' A' ' 199' ' ' SER . 17.5 m -94.56 172.2 8.33 Favored 'General case' 0 N--CA 1.442 -0.856 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.289 -173.467 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -43.02 -43.1 4.11 Favored 'General case' 0 N--CA 1.495 1.775 0 C-N-CA 127.02 2.128 . . . . 0.0 114.538 -171.713 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -92.26 12.73 21.43 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 113.675 0.991 . . . . 0.0 113.675 -174.798 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 78.97 46.95 7.98 Favored Glycine 0 CA--C 1.496 -1.128 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.8 176.052 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -145.0 160.29 41.6 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.633 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -82.23 132.03 35.23 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 177.389 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 199' ' ' SER . . . . . 0.424 ' HB3' ' OG ' ' A' ' 193' ' ' SER . 23.8 p -66.06 -22.49 66.43 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.551 0.691 . . . . 0.0 111.11 -178.945 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.434 ' HB2' ' HB3' ' A' ' 190' ' ' MET . 26.5 mmtp -120.75 151.0 40.11 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.534 -177.829 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 73.0 mm-40 -89.42 166.53 13.66 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.211 176.928 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 202' ' ' LYS . . . . . 0.449 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 39.6 mtpt -63.95 119.04 51.63 Favored Pre-proline 0 C--N 1.319 -0.73 0 O-C-N 123.464 0.477 . . . . 0.0 111.057 179.513 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 203' ' ' PRO . . . . . 0.441 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 95.4 Cg_endo -77.39 168.1 23.43 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 122.642 2.228 . . . . 0.0 112.056 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 37.1 ttpt -119.9 150.86 39.79 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.86 -176.653 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.431 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 83.8 m -110.93 118.72 36.87 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 177.388 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 30.4 m . . . . . 0 C--N 1.3 -1.555 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.574 -175.325 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo . . . . . 0 CA--C 1.537 0.666 0 CA-C-O 121.603 0.585 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.7 m -82.83 -32.89 27.33 Favored 'General case' 0 CA--C 1.504 -0.814 0 CA-C-O 122.005 0.907 . . . . 0.0 108.612 179.024 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.75 -87.85 0.43 Allowed Glycine 0 N--CA 1.396 -3.967 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.366 174.415 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.0 t-80 -175.02 135.39 0.52 Allowed Pre-proline 0 C--N 1.264 -3.135 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 -173.711 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.545 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 66.9 Cg_endo -93.69 -5.18 2.76 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.497 2.131 . . . . 0.0 113.031 -178.139 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 106.73 175.93 23.08 Favored Glycine 0 CA--C 1.485 -1.826 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 178.787 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -151.43 152.88 33.66 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 177.319 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.423 HG21 ' CZ ' ' A' ' 112' ' ' TYR . 9.6 t -125.18 141.12 37.72 Favored Pre-proline 0 C--N 1.29 -1.994 0 O-C-N 123.385 0.428 . . . . 0.0 112.043 -175.218 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -79.84 -12.69 13.36 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 122.913 2.409 . . . . 0.0 111.405 173.511 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -85.98 2.26 46.93 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 121.744 0.783 . . . . 0.0 110.861 -178.7 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.609 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.48 -126.56 1.21 Allowed Glycine 0 N--CA 1.402 -3.571 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 -178.737 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.8 t -164.5 -166.23 1.06 Allowed 'General case' 0 C--N 1.27 -2.878 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.847 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -153.01 158.05 41.44 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 177.691 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.8 m -127.17 158.98 35.65 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 179.991 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.412 ' HB2' ' HA ' ' A' ' 102' ' ' ASN . 22.0 mt -116.55 127.49 54.56 Favored 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 -179.736 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.509 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 21.2 p -117.61 125.82 51.45 Favored 'General case' 0 C--N 1.29 -1.991 0 CA-C-O 121.311 0.577 . . . . 0.0 111.063 -175.728 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 121.55 -58.18 0.59 Allowed Glycine 0 N--CA 1.432 -1.602 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.306 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -130.82 -3.02 4.64 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.632 -0.794 . . . . 0.0 113.678 -177.868 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 102' ' ' ASN . . . . . 0.412 ' HA ' ' HB2' ' A' ' 98' ' ' LEU . 2.3 t30 54.13 29.29 10.15 Favored 'General case' 0 CA--C 1.559 1.315 0 C-N-CA 125.776 1.631 . . . . 0.0 112.016 -178.922 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.532 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.7 m -149.74 -174.77 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.209 -1.043 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 179.699 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.545 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 20.6 m-85 -100.8 44.48 1.01 Allowed 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 118.767 0.712 . . . . 0.0 110.359 -178.174 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.684 ' O ' HG12 ' A' ' 108' ' ' VAL . 9.7 pt-20 -85.06 177.59 7.86 Favored 'General case' 0 C--O 1.211 -0.967 0 CA-C-N 114.639 -1.164 . . . . 0.0 111.89 178.413 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -76.58 133.13 39.76 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.219 177.372 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.02 5.06 64.4 Favored Glycine 0 N--CA 1.438 -1.232 0 CA-C-N 115.791 -0.64 . . . . 0.0 112.679 179.85 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.684 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.0 p -97.44 147.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 -179.92 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 109' ' ' LYS . . . . . 0.509 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -109.64 130.64 55.5 Favored 'General case' 0 N--CA 1.42 -1.938 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 177.249 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.527 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -94.49 95.71 9.0 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 175.034 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 78.7 t -89.3 112.9 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.859 0 C-N-CA 123.768 0.827 . . . . 0.0 108.8 -178.327 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 112' ' ' TYR . . . . . 0.489 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 9.6 t80 -81.9 138.39 35.03 Favored 'General case' 0 C--N 1.276 -2.597 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -177.785 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -138.55 120.56 15.56 Favored 'General case' 0 N--CA 1.424 -1.739 0 CA-C-O 121.785 0.802 . . . . 0.0 109.309 177.64 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 114' ' ' CYS . . . . . 0.447 ' SG ' ' HE1' ' A' ' 112' ' ' TYR . 75.8 m -73.94 160.28 31.58 Favored 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.597 -179.244 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.609 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 82.2 m-20 -78.32 177.12 8.69 Favored 'General case' 0 C--O 1.212 -0.884 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.111 176.706 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 116' ' ' GLU . . . . . 0.476 ' HG3' ' OD2' ' A' ' 194' ' ' ASP . 39.9 tt0 -44.81 -46.62 10.73 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 124.956 1.303 . . . . 0.0 114.308 -177.305 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.91 5.33 82.96 Favored Glycine 0 C--N 1.311 -0.858 0 C-N-CA 120.309 -0.948 . . . . 0.0 114.048 -176.663 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.499 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.3 m-85 -130.61 164.28 25.29 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 -176.506 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -148.1 155.77 41.84 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-O 120.988 0.423 . . . . 0.0 110.242 179.495 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -77.38 130.91 37.72 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 179.351 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.588 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -119.45 130.41 55.24 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.83 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.17 -175.07 21.82 Favored Glycine 0 C--N 1.295 -1.717 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.521 -179.597 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -91.8 -29.04 16.98 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 121.53 0.681 . . . . 0.0 109.646 -178.331 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 124' ' ' ILE . . . . . 0.569 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 46.9 mm -82.95 114.51 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.553 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.869 -177.778 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -130.42 7.67 4.95 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.896 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 126' ' ' TYR . . . . . 0.527 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 17.8 p90 -151.57 156.43 40.46 Favored 'General case' 0 N--CA 1.425 -1.689 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.415 -173.446 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 52.1 mtp180 -121.34 125.29 46.65 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 105.14 -2.17 . . . . 0.0 105.14 171.538 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -101.73 126.88 48.67 Favored 'General case' 0 C--N 1.275 -2.65 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.074 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 129' ' ' CYS . . . . . 0.459 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 25.5 t -86.03 100.81 12.41 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 118.498 -1.281 . . . . 0.0 110.075 176.166 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.424 ' OD1' HG22 ' A' ' 131' ' ' THR . 9.2 t70 -98.71 -165.28 1.22 Allowed 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 105.456 -2.053 . . . . 0.0 105.456 175.602 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.424 HG22 ' OD1' ' A' ' 130' ' ' ASP . 10.2 t -63.5 -22.95 67.18 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 119.131 0.878 . . . . 0.0 112.143 -177.02 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -80.23 -13.57 59.11 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.652 0.739 . . . . 0.0 110.692 176.357 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.459 ' HA2' ' SG ' ' A' ' 129' ' ' CYS . . . 105.49 -148.51 16.52 Favored Glycine 0 N--CA 1.421 -2.339 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -175.375 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 85.0 m95 -69.13 109.55 4.09 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 176.908 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 28.9 p -61.14 -68.8 0.28 Allowed 'General case' 0 N--CA 1.438 -1.039 0 O-C-N 123.792 0.682 . . . . 0.0 111.48 -178.126 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 74.4 m-20 -75.62 177.13 7.02 Favored 'General case' 0 CA--C 1.489 -1.368 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.513 178.035 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -108.13 -168.91 1.43 Allowed 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 178.511 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.2 mt -60.87 117.98 30.76 Favored Pre-proline 0 C--N 1.295 -1.775 0 O-C-N 123.986 0.804 . . . . 0.0 109.33 177.272 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 139' ' ' PRO . . . . . 0.569 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 53.3 Cg_exo -52.77 165.99 0.99 Allowed 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.867 3.045 . . . . 0.0 113.916 178.644 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 140' ' ' ILE . . . . . 0.588 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 3.6 mp -90.73 130.7 39.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.172 -174.801 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 141' ' ' CYS . . . . . 0.499 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 25.4 t -123.6 114.93 20.68 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.318 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -110.41 149.79 29.76 Favored 'General case' 0 N--CA 1.405 -2.711 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 -177.961 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 9.6 p -73.69 143.53 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.898 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.572 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 89.3 t -68.69 123.05 21.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 177.155 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -109.3 140.14 43.36 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.149 -176.421 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 57.5 m -102.13 144.66 30.41 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.9 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 147' ' ' LEU . . . . . 0.4 HD23 ' HD2' ' A' ' 148' ' ' PRO . 1.4 tt -49.59 130.03 19.4 Favored Pre-proline 0 N--CA 1.432 -1.36 0 C-N-CA 125.275 1.43 . . . . 0.0 110.748 179.491 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.563 ' HA ' ' CD2' ' A' ' 168' ' ' TYR . 12.4 Cg_endo -57.74 110.59 0.65 Allowed 'Trans proline' 0 N--CA 1.454 -0.813 0 C-N-CA 123.557 2.838 . . . . 0.0 113.35 -178.522 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 13.6 p -83.81 142.72 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 CA-C-N 115.176 -0.92 . . . . 0.0 108.865 177.397 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 10.2 p -105.22 -156.4 0.57 Allowed 'General case' 0 C--N 1.288 -2.069 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.37 176.172 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 151' ' ' ALA . . . . . 0.457 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . -100.85 151.25 37.56 Favored Pre-proline 0 C--N 1.298 -1.649 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -170.636 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -75.62 170.24 20.64 Favored 'Trans proline' 0 N--CA 1.436 -1.906 0 C-N-CA 121.442 1.428 . . . . 0.0 110.914 175.25 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -50.41 -55.24 16.62 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 114.306 1.224 . . . . 0.0 114.306 -175.992 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 154' ' ' ASN . . . . . 0.436 ' HB2' ' O ' ' A' ' 205' ' ' CYS . 57.4 m-80 -113.95 27.04 9.82 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.19 0.519 . . . . 0.0 110.725 -177.544 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.7 -173.1 15.71 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 120.081 -1.057 . . . . 0.0 111.726 179.768 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 156' ' ' LYS . . . . . 0.457 ' HA ' ' HB1' ' A' ' 151' ' ' ALA . 50.3 pttt -153.33 172.67 16.68 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -178.14 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 62.5 mt -86.04 132.1 32.91 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 CA-C-O 121.169 0.509 . . . . 0.0 111.058 -176.46 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.447 ' CG2' ' HB ' ' A' ' 177' ' ' VAL . 47.9 t -76.52 -40.31 33.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 C-N-CA 123.974 0.91 . . . . 0.0 108.907 177.172 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.0 m -84.08 32.28 0.49 Allowed 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.446 179.933 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 17.6 t -79.55 82.0 5.73 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-O 121.999 0.904 . . . . 0.0 112.568 -172.393 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -115.7 72.76 0.81 Allowed 'General case' 0 N--CA 1.411 -2.375 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 169.973 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.76 82.84 8.15 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-O 122.293 1.044 . . . . 0.0 110.204 -176.682 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 57.1 mm-40 -122.21 155.0 62.14 Favored Pre-proline 0 C--N 1.282 -2.336 0 CA-C-N 113.376 -1.738 . . . . 0.0 108.035 -176.608 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -57.22 -25.19 63.3 Favored 'Trans proline' 0 CA--C 1.545 1.033 0 C-N-CA 123.115 2.544 . . . . 0.0 113.529 -179.211 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -92.19 -34.26 14.37 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.907 0.86 . . . . 0.0 109.82 -179.177 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 6.2 mmp_? -81.7 81.38 7.77 Favored 'General case' 0 N--CA 1.422 -1.841 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.082 -177.824 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -103.46 165.54 10.97 Favored 'General case' 0 C--N 1.294 -1.84 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 176.203 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 168' ' ' TYR . . . . . 0.563 ' CD2' ' HA ' ' A' ' 148' ' ' PRO . 98.0 m-85 -78.71 103.41 8.63 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-O 121.661 0.743 . . . . 0.0 112.087 -174.594 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 27.7 m80 -98.38 155.47 17.21 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 114.506 -1.224 . . . . 0.0 107.966 -179.463 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -56.77 131.5 49.45 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 172.012 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 171' ' ' GLY . . . . . 0.438 ' H ' ' HB2' ' A' ' 192' ' ' CYS . . . 113.43 -15.03 22.64 Favored Glycine 0 N--CA 1.414 -2.768 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.234 -177.682 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 172' ' ' GLN . . . . . 0.426 ' O ' ' HA ' ' A' ' 191' ' ' HIS . 15.5 mm100 -74.58 134.38 42.13 Favored 'General case' 0 N--CA 1.423 -1.788 0 C-N-CA 120.223 -0.591 . . . . 0.0 111.976 179.55 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -115.15 94.34 4.69 Favored 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 173.562 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 66.2 t -81.61 109.02 15.36 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 CA-C-N 115.243 -0.889 . . . . 0.0 108.963 -176.121 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 175' ' ' ARG . . . . . 0.45 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 14.5 ttp180 -97.1 156.27 16.45 Favored 'General case' 0 N--CA 1.411 -2.387 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 179.055 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -127.09 156.35 41.85 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 124.038 0.935 . . . . 0.0 109.399 -175.006 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.447 ' HB ' ' CG2' ' A' ' 158' ' ' VAL . 12.2 p -133.56 141.07 45.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.461 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 80.5 m -102.54 153.63 19.89 Favored 'General case' 0 C--N 1.265 -3.105 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.961 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -64.62 163.46 13.68 Favored 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 119.972 -0.691 . . . . 0.0 110.153 176.73 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 15.8 m -43.54 -32.74 0.98 Allowed 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 116.37 1.989 . . . . 0.0 116.37 -170.724 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -113.36 21.09 17.87 Favored Glycine 0 C--N 1.293 -1.847 0 C-N-CA 120.1 -1.047 . . . . 0.0 113.375 -179.048 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -122.32 151.06 41.53 Favored 'General case' 0 N--CA 1.432 -1.335 0 O-C-N 122.129 -0.63 . . . . 0.0 111.356 179.28 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -124.15 143.59 50.4 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.158 -178.93 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 184' ' ' ILE . . . . . 0.527 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.4 tt -74.87 140.55 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.928 0 CA-C-O 121.476 0.655 . . . . 0.0 111.288 -176.695 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -67.01 -64.57 0.83 Allowed 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.318 -177.261 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -103.41 -123.59 5.3 Favored Glycine 0 N--CA 1.436 -1.32 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.283 -179.558 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 187' ' ' ASP . . . . . 0.583 ' HB2' ' HG3' ' A' ' 200' ' ' LYS . 5.5 m-20 -91.63 153.4 19.73 Favored 'General case' 0 CA--C 1.491 -1.291 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -177.495 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 188' ' ' GLU . . . . . 0.527 ' HA ' HD13 ' A' ' 184' ' ' ILE . 14.2 pt-20 -91.65 -4.04 55.67 Favored 'General case' 0 C--O 1.205 -1.286 0 C-N-CA 119.944 -0.702 . . . . 0.0 111.174 -172.027 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -134.34 132.31 39.35 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 -177.72 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 14.4 ptp -112.68 123.54 50.53 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.271 174.881 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 191' ' ' HIS . . . . . 0.426 ' HA ' ' O ' ' A' ' 172' ' ' GLN . 16.4 t-80 -110.36 139.01 45.99 Favored 'General case' 0 C--N 1.279 -2.498 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.954 -177.317 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 192' ' ' CYS . . . . . 0.438 ' HB2' ' H ' ' A' ' 171' ' ' GLY . 22.0 m -62.64 130.14 43.69 Favored 'General case' 0 C--N 1.32 -0.705 0 O-C-N 123.657 0.598 . . . . 0.0 111.668 175.207 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 37.5 t -101.78 166.92 10.41 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.137 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 194' ' ' ASP . . . . . 0.476 ' OD2' ' HG3' ' A' ' 116' ' ' GLU . 6.3 t70 -52.41 -33.22 42.82 Favored 'General case' 0 N--CA 1.511 2.613 0 C-N-CA 124.236 1.014 . . . . 0.0 110.332 178.925 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -56.94 -26.21 59.14 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 113.75 -1.568 . . . . 0.0 111.742 179.807 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 89.59 15.53 58.2 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -174.97 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -125.27 170.54 11.19 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.064 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -85.39 142.49 29.24 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 123.678 0.611 . . . . 0.0 110.944 -177.699 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 30.7 t -60.64 -50.29 74.11 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.725 176.593 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 200' ' ' LYS . . . . . 0.583 ' HG3' ' HB2' ' A' ' 187' ' ' ASP . 12.9 mmmm -104.61 156.14 18.23 Favored 'General case' 0 CA--C 1.485 -1.548 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 174.227 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -89.06 171.73 9.63 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 170.546 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 34.9 ttmt -61.9 122.25 70.67 Favored Pre-proline 0 C--O 1.243 0.724 0 CA-C-N 118.985 0.811 . . . . 0.0 110.492 -176.246 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.04 -173.49 1.9 Allowed 'Trans proline' 0 N--CA 1.437 -1.833 0 C-N-CA 122.039 1.826 . . . . 0.0 111.067 179.122 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 66.0 mttm -126.58 160.88 29.39 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.118 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 205' ' ' CYS . . . . . 0.436 ' O ' ' HB2' ' A' ' 154' ' ' ASN . 97.4 m -116.62 105.19 12.17 Favored 'General case' 0 C--N 1.27 -2.887 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 170.852 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 23.7 m . . . . . 0 C--N 1.286 -2.176 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.033 -173.547 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.428 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 30.6 Cg_endo . . . . . 0 CA--C 1.542 0.907 0 CA-C-O 121.436 0.515 . . . . 0.0 111.761 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.1 m -85.03 -37.68 20.09 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 177.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.08 -92.41 0.48 Allowed Glycine 0 N--CA 1.41 -3.095 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 173.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.9 t60 -177.24 123.73 0.28 Allowed Pre-proline 0 C--N 1.26 -3.314 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 -177.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.427 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 34.8 Cg_endo -66.72 -49.91 1.42 Allowed 'Trans proline' 0 C--O 1.209 -0.933 0 C-N-CA 121.33 1.353 . . . . 0.0 110.722 -177.179 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 150.32 169.18 16.08 Favored Glycine 0 N--CA 1.401 -3.642 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 -177.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -136.03 139.93 43.46 Favored 'General case' 0 C--N 1.264 -3.113 0 CA-C-N 117.31 0.555 . . . . 0.0 109.688 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.5 t -99.9 128.97 29.58 Favored Pre-proline 0 N--CA 1.409 -2.525 0 CA-C-N 115.111 -0.949 . . . . 0.0 111.304 -172.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -69.04 -24.01 33.44 Favored 'Trans proline' 0 C--O 1.24 0.591 0 C-N-CA 122.884 2.389 . . . . 0.0 110.214 175.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -75.06 -28.28 60.31 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 114.014 -1.448 . . . . 0.0 110.763 -176.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.437 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -151.0 -133.21 2.03 Favored Glycine 0 N--CA 1.409 -3.159 0 C-N-CA 119.071 -1.538 . . . . 0.0 112.783 -177.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.0 p -144.1 170.67 15.51 Favored 'General case' 0 C--N 1.275 -2.64 0 CA-C-N 113.885 -1.157 . . . . 0.0 108.896 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.458 ' HA ' ' HA ' ' A' ' 112' ' ' TYR . 17.8 p90 -140.69 153.55 46.0 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 172.302 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -127.26 160.12 32.27 Favored 'General case' 0 C--N 1.274 -2.705 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -116.72 118.63 33.07 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 121.293 0.568 . . . . 0.0 109.874 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 26.2 p -111.88 133.64 53.95 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.755 -174.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 111.98 -53.13 0.6 Allowed Glycine 0 N--CA 1.434 -1.478 0 C-N-CA 120.865 -0.683 . . . . 0.0 111.557 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -131.31 -7.21 3.23 Favored Glycine 0 N--CA 1.441 -0.999 0 C-N-CA 120.196 -1.002 . . . . 0.0 113.109 -179.008 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 48.4 m-80 61.17 17.4 8.08 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.523 ' O ' HG11 ' A' ' 108' ' ' VAL . 19.7 m -149.01 -170.07 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.205 -1.286 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -177.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -103.47 45.57 0.95 Allowed 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 118.422 0.556 . . . . 0.0 110.083 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.71 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.9 pt-20 -86.08 176.28 8.09 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 114.957 -1.019 . . . . 0.0 111.58 177.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . 0.44 ' CE1' ' HA ' ' A' ' 131' ' ' THR . 46.0 m-85 -72.91 133.23 44.29 Favored 'General case' 0 C--N 1.293 -1.859 0 O-C-N 121.976 -0.453 . . . . 0.0 111.273 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.36 -8.7 69.42 Favored Glycine 0 N--CA 1.434 -1.453 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.232 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.71 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.2 p -80.67 147.69 6.19 Favored 'Isoleucine or valine' 0 C--O 1.238 0.481 0 CA-C-N 117.553 0.676 . . . . 0.0 109.946 -176.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 16.8 mtpp -112.38 119.08 37.03 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -87.91 96.49 10.5 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.509 HG12 ' HB3' ' A' ' 126' ' ' TYR . 18.8 m -94.81 115.82 34.59 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.327 0 CA-C-O 122.036 0.922 . . . . 0.0 109.979 -177.02 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . 0.458 ' HA ' ' HA ' ' A' ' 96' ' ' PHE . 33.3 m-85 -83.07 144.43 29.9 Favored 'General case' 0 C--N 1.265 -3.072 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.524 -178.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.4 t -143.64 127.79 17.6 Favored 'General case' 0 N--CA 1.427 -1.621 0 CA-C-N 115.275 -0.875 . . . . 0.0 108.803 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 81.4 m -73.71 163.39 28.04 Favored 'General case' 0 C--N 1.292 -1.891 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.317 -176.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.437 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 95.4 m-20 -95.25 -179.15 4.69 Favored 'General case' 0 CA--C 1.476 -1.887 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.72 -178.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -69.09 93.96 0.63 Allowed 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 124.573 1.171 . . . . 0.0 109.753 177.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 133.66 2.13 3.64 Favored Glycine 0 C--N 1.259 -3.698 0 CA-C-N 112.961 -1.927 . . . . 0.0 111.781 177.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.429 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 87.8 m-85 -133.49 158.7 42.44 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -177.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -142.11 158.06 44.18 Favored 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 -177.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 13.9 tp -83.07 146.27 28.8 Favored 'General case' 0 N--CA 1.413 -2.282 0 C-N-CA 119.491 -0.884 . . . . 0.0 109.169 -177.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.09 121.64 38.33 Favored 'General case' 0 N--CA 1.405 -2.709 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.359 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 100.4 174.93 29.96 Favored Glycine 0 C--N 1.292 -1.897 0 N-CA-C 110.914 -0.875 . . . . 0.0 110.914 -174.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -88.05 -37.89 15.9 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.255 0.55 . . . . 0.0 110.112 -177.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.3 mm -66.7 124.47 21.96 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.758 -177.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -127.13 -4.34 6.23 Favored 'General case' 0 C--O 1.204 -1.317 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.509 ' HB3' HG12 ' A' ' 111' ' ' VAL . 11.9 p90 -137.23 161.83 35.14 Favored 'General case' 0 C--N 1.293 -1.888 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.496 -170.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 49.9 mtp180 -125.28 136.11 53.19 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 106.112 -1.81 . . . . 0.0 106.112 171.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -115.32 130.94 57.05 Favored 'General case' 0 C--N 1.273 -2.719 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 33.0 t -86.49 112.26 21.35 Favored 'General case' 0 C--N 1.293 -1.869 0 C-N-CA 119.109 -1.036 . . . . 0.0 110.83 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.454 ' OD2' HG22 ' A' ' 131' ' ' THR . 14.9 t70 -103.24 -171.26 1.91 Allowed 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 175.339 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.454 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -71.16 -17.78 62.53 Favored 'General case' 0 C--N 1.291 -1.946 0 CA-C-O 121.874 0.845 . . . . 0.0 110.309 -175.027 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -87.9 -8.77 55.34 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.691 179.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 112.78 -164.32 12.07 Favored Glycine 0 N--CA 1.427 -1.936 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -177.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.427 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 97.8 m95 -60.97 123.34 17.32 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 117.255 0.527 . . . . 0.0 110.579 176.037 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.6 p -64.46 -71.77 0.17 Allowed 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 123.554 0.742 . . . . 0.0 111.99 -178.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -81.58 177.66 8.8 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.175 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -106.12 177.84 4.74 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.282 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 65.0 mt -61.38 121.11 61.21 Favored Pre-proline 0 C--O 1.245 0.861 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 176.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.13 166.89 23.48 Favored 'Trans proline' 0 C--O 1.26 1.625 0 C-N-CA 122.424 2.083 . . . . 0.0 111.637 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 55.7 mt -90.06 127.02 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.03 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -177.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.429 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 53.6 t -121.07 115.62 23.46 Favored 'General case' 0 C--N 1.269 -2.916 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 174.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.18 151.95 23.43 Favored 'General case' 0 C--N 1.282 -2.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 109.864 -177.236 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.5 p -68.88 137.52 24.18 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.105 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 41.5 t -63.95 125.91 21.58 Favored 'Isoleucine or valine' 0 C--O 1.247 0.951 0 CA-C-O 121.111 0.482 . . . . 0.0 109.74 178.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -119.13 133.55 55.72 Favored 'General case' 0 N--CA 1.418 -2.074 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -179.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 72.8 m -99.63 141.18 32.77 Favored 'General case' 0 C--N 1.261 -3.267 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.0 mm? -58.63 138.5 86.12 Favored Pre-proline 0 N--CA 1.427 -1.579 0 N-CA-C 114.209 1.188 . . . . 0.0 114.209 -175.499 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 23.5 Cg_exo -58.25 107.4 0.32 Allowed 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 123.346 2.698 . . . . 0.0 111.117 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 5.9 p -69.26 140.58 18.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 20.5 p -71.9 -71.81 0.26 Allowed 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 111.405 0.15 . . . . 0.0 111.405 -178.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.38 162.3 0.21 Allowed Pre-proline 0 C--O 1.248 1.005 0 C-N-CA 125.748 1.619 . . . . 0.0 106.712 177.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . 0.403 ' HB3' ' O ' ' A' ' 203' ' ' PRO . 51.3 Cg_endo -74.3 170.88 19.19 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 121.512 1.475 . . . . 0.0 109.469 169.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . 0.491 ' HG3' ' ND2' ' A' ' 154' ' ' ASN . 11.4 pt-20 -60.67 -48.92 79.62 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 114.055 1.132 . . . . 0.0 114.055 -173.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . 0.491 ' ND2' ' HG3' ' A' ' 153' ' ' GLU . 60.2 m-80 -117.31 32.39 6.19 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.505 0.669 . . . . 0.0 109.668 -177.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.06 -176.59 18.22 Favored Glycine 0 C--N 1.303 -1.269 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.477 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.4 ptmt -145.21 173.27 12.09 Favored 'General case' 0 N--CA 1.434 -1.231 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -178.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 69.0 mt -88.22 138.49 19.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 CA-C-O 121.3 0.572 . . . . 0.0 110.957 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.6 t -89.29 -39.71 12.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 C-N-CA 124.426 1.09 . . . . 0.0 109.402 176.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 9.9 m . . . . . 0 C--N 1.313 -1.02 0 C-N-CA 123.512 0.725 . . . . 0.0 111.09 -178.128 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 . . . . . 0 N--CA 1.424 -1.768 0 CA-C-O 121.53 0.681 . . . . 0.0 111.198 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 47.2 m170 -84.32 164.07 19.21 Favored 'General case' 0 C--O 1.248 1.019 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.115 -179.199 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 72.4 t80 -52.63 134.64 35.68 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 123.697 0.799 . . . . 0.0 110.765 173.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 102.01 -23.34 34.92 Favored Glycine 0 C--N 1.314 -0.674 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.305 179.02 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -72.85 133.97 44.67 Favored 'General case' 0 N--CA 1.434 -1.229 0 CA-C-O 121.085 0.469 . . . . 0.0 111.991 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.421 ' HB2' ' NE2' ' A' ' 191' ' ' HIS . . . -106.28 115.73 30.72 Favored 'General case' 0 N--CA 1.421 -1.889 0 CA-C-N 114.733 -1.122 . . . . 0.0 109.142 178.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 48.3 t -91.27 108.75 20.25 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 175.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.485 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 20.4 ttp180 -99.4 153.79 18.72 Favored 'General case' 0 N--CA 1.403 -2.82 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 177.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 83.4 m-85 -127.24 158.9 35.93 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 123.24 0.616 . . . . 0.0 109.533 -174.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.9 p -140.57 140.32 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.579 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . 0.406 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 77.1 m -89.62 149.61 22.74 Favored 'General case' 0 C--N 1.278 -2.54 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.186 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 81.8 m-20 -76.15 179.4 5.72 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.307 -178.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 25.2 p -53.72 111.26 0.7 Allowed 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 124.027 0.931 . . . . 0.0 112.511 -176.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 97.38 2.31 58.98 Favored Glycine 0 N--CA 1.433 -1.544 0 CA-C-N 115.846 -0.615 . . . . 0.0 113.847 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . 0.406 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 90.2 m-85 -111.6 149.09 31.97 Favored 'General case' 0 CA--C 1.484 -1.573 0 CA-C-N 117.971 0.886 . . . . 0.0 110.704 -179.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -122.38 145.86 47.88 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -178.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.6 tt -76.3 137.01 23.5 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 CA-C-O 122.049 0.928 . . . . 0.0 111.798 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -84.33 -48.66 9.48 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.171 -176.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -91.09 -136.2 6.75 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.315 177.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . 0.465 ' OD1' ' HG3' ' A' ' 189' ' ' GLU . 12.2 t70 -102.58 163.68 12.09 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 178.443 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.485 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 15.8 pt-20 -91.15 -13.85 32.22 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 118.887 0.767 . . . . 0.0 112.668 -174.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . 0.465 ' HG3' ' OD1' ' A' ' 187' ' ' ASP . 0.0 OUTLIER -120.03 144.92 47.28 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 112.84 0.682 . . . . 0.0 112.84 -176.724 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 37.0 ttm -135.97 124.33 23.35 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 124.864 1.266 . . . . 0.0 109.075 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . 0.421 ' NE2' ' HB2' ' A' ' 173' ' ' ALA . 30.7 m80 -97.86 155.44 17.06 Favored 'General case' 0 C--N 1.276 -2.618 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 40.6 t -94.94 116.88 29.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 173.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 8.4 p -100.23 170.21 8.61 Favored 'General case' 0 N--CA 1.437 -1.122 0 O-C-N 123.354 0.409 . . . . 0.0 111.174 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -60.01 -21.26 61.08 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 123.607 0.763 . . . . 0.0 112.064 -175.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 13.7 m-20 -64.51 -17.54 63.99 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.741 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 80.94 20.48 65.24 Favored Glycine 0 CA--C 1.488 -1.656 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -130.48 153.44 48.79 Favored 'General case' 0 N--CA 1.407 -2.597 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 -174.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 78.2 m95 -76.84 131.47 38.65 Favored 'General case' 0 C--N 1.291 -1.971 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.34 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.5 m -69.06 -38.33 79.01 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 115.639 -0.709 . . . . 0.0 112.289 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -103.73 156.95 17.41 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 20.0 pm0 -78.83 157.91 28.27 Favored 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 177.485 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -68.05 116.62 40.71 Favored Pre-proline 0 C--O 1.246 0.908 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 175.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . 0.403 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 98.3 Cg_endo -76.98 161.5 32.86 Favored 'Trans proline' 0 N--CA 1.433 -2.088 0 C-N-CA 122.218 1.945 . . . . 0.0 110.998 -178.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -104.52 161.83 13.77 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 120.226 -0.589 . . . . 0.0 109.6 178.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 88.9 m -122.19 108.55 13.43 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 172.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.1 m . . . . . 0 C--N 1.291 -1.957 0 O-C-N 124.405 1.066 . . . . 0.0 108.818 -173.788 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.451 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 19.1 Cg_endo . . . . . 0 CA--C 1.537 0.657 0 CA-C-O 120.859 0.274 . . . . 0.0 112.205 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 50.0 m -71.67 -43.98 65.07 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.756 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 97.07 112.44 2.94 Favored Glycine 0 C--O 1.187 -2.791 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 -179.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -34.36 119.52 0.54 Allowed Pre-proline 0 C--N 1.296 -1.734 0 C-N-CA 127.235 2.214 . . . . 0.0 112.129 -173.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -60.67 -43.32 32.99 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.283 2.655 . . . . 0.0 113.305 -172.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 139.73 -174.98 22.06 Favored Glycine 0 N--CA 1.421 -2.336 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -133.78 156.66 47.6 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-N 117.403 0.602 . . . . 0.0 109.691 -178.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.1 t -115.3 126.63 27.59 Favored Pre-proline 0 C--N 1.305 -1.368 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.282 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -66.97 -18.8 52.29 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.555 2.17 . . . . 0.0 112.556 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -87.7 -15.05 38.21 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.37 -175.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.497 ' HA2' ' ND2' ' A' ' 115' ' ' ASN . . . -163.62 -133.43 1.48 Allowed Glycine 0 N--CA 1.409 -3.136 0 C-N-CA 118.635 -1.745 . . . . 0.0 113.004 -177.413 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.1 p -144.2 179.59 7.13 Favored 'General case' 0 C--N 1.284 -2.249 0 CA-C-N 114.439 -0.881 . . . . 0.0 109.264 -176.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -141.5 157.65 44.86 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 172.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.4 m -127.56 162.53 26.24 Favored 'General case' 0 C--N 1.278 -2.524 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.0 mt -118.43 117.03 27.94 Favored 'General case' 0 C--N 1.277 -2.579 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.502 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 19.5 p -109.16 127.63 54.35 Favored 'General case' 0 C--N 1.282 -2.364 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.245 -172.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 113.97 -37.92 3.38 Favored Glycine 0 N--CA 1.433 -1.567 0 C-N-CA 120.406 -0.902 . . . . 0.0 111.975 179.212 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -144.28 -7.14 0.5 Allowed Glycine 0 C--N 1.315 -0.588 0 C-N-CA 119.715 -1.231 . . . . 0.0 113.756 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 92.6 m-20 61.14 15.11 6.01 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.495 ' O ' HG11 ' A' ' 108' ' ' VAL . 24.0 m -146.52 -169.42 0.24 Allowed 'Isoleucine or valine' 0 C--O 1.209 -1.027 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -176.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -106.46 40.29 1.65 Allowed 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 118.29 0.496 . . . . 0.0 110.227 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.715 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.1 pt-20 -83.04 176.48 9.21 Favored 'General case' 0 C--O 1.205 -1.24 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.046 178.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . 0.451 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 35.5 m-85 -72.88 133.26 44.33 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.218 177.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.51 5.05 63.6 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.34 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.715 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -94.97 147.16 5.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.171 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.502 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 51.8 mtpt -110.76 118.47 36.25 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 178.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -83.28 92.48 7.51 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.301 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.507 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 35.0 m -89.1 117.71 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.824 0 CA-C-O 122.151 0.977 . . . . 0.0 109.903 -178.521 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 31.5 m-85 -85.88 139.48 31.21 Favored 'General case' 0 C--N 1.263 -3.182 0 CA-C-N 115.129 -0.941 . . . . 0.0 108.896 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.2 t -138.96 124.6 19.54 Favored 'General case' 0 N--CA 1.407 -2.603 0 CA-C-O 121.999 0.904 . . . . 0.0 109.671 -178.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 74.3 m -71.74 161.79 30.44 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-N 115.0 -1.0 . . . . 0.0 112.455 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.497 ' ND2' ' HA2' ' A' ' 94' ' ' GLY . 81.3 m-20 -86.31 -176.59 5.95 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.479 179.098 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -46.87 -50.94 17.81 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 126.513 1.925 . . . . 0.0 114.008 -177.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -91.19 28.36 8.17 Favored Glycine 0 C--N 1.305 -1.158 0 C-N-CA 119.736 -1.221 . . . . 0.0 113.179 -177.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.455 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 98.8 m-85 -149.37 167.51 25.94 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -173.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.488 HE22 HD23 ' A' ' 121' ' ' LEU . 1.0 OUTLIER -153.88 156.87 38.37 Favored 'General case' 0 N--CA 1.435 -1.195 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.81 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.529 ' HG ' ' HB2' ' A' ' 125' ' ' ASN . 0.5 OUTLIER -85.99 128.39 34.84 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -175.182 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.488 HD23 HE22 ' A' ' 119' ' ' GLN . 0.3 OUTLIER -102.1 130.1 48.62 Favored 'General case' 0 N--CA 1.422 -1.864 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 -175.741 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.74 -159.7 13.83 Favored Glycine 0 C--N 1.297 -1.63 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.296 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -106.03 -41.63 5.33 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 121.835 0.826 . . . . 0.0 109.267 -178.277 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 51.1 mm -85.17 122.92 38.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 CA-C-N 114.772 -1.104 . . . . 0.0 110.069 -176.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.529 ' HB2' ' HG ' ' A' ' 120' ' ' LEU . 3.9 p-10 -127.59 7.12 6.27 Favored 'General case' 0 C--O 1.202 -1.41 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 176.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.507 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 15.4 p90 -134.25 168.21 19.3 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -171.784 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.514 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 36.3 mtp180 -130.67 119.89 23.1 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 170.399 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -92.32 126.76 37.54 Favored 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.846 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 49.3 t -84.7 108.04 17.21 Favored 'General case' 0 N--CA 1.434 -1.266 0 C-N-CA 119.142 -1.023 . . . . 0.0 109.249 174.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -101.76 -171.22 1.94 Allowed 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 105.354 -2.091 . . . . 0.0 105.354 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 15.3 t -64.37 -15.34 60.26 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.841 0.829 . . . . 0.0 110.593 -178.511 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -97.88 -2.17 41.35 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.255 -178.686 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 103.48 -159.44 16.93 Favored Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -177.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.442 ' CH2' HG13 ' A' ' 108' ' ' VAL . 86.9 m95 -68.64 108.47 3.37 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 177.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 41.7 p -67.71 -57.51 6.23 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 115.439 -0.8 . . . . 0.0 112.655 -175.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . 0.514 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 6.4 m120 -71.83 171.22 12.07 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.957 -178.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 25.2 m-20 -100.74 176.61 5.24 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 176.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 88.6 mt -66.35 119.07 59.39 Favored Pre-proline 0 C--O 1.237 0.407 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 173.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.402 ' HB2' HD11 ' A' ' 120' ' ' LEU . 29.7 Cg_endo -64.46 164.7 22.48 Favored 'Trans proline' 0 N--CA 1.451 -0.993 0 C-N-CA 122.601 2.2 . . . . 0.0 112.986 -177.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 50.0 mm -96.49 124.47 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.766 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.903 -175.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.455 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 48.9 t -105.66 136.12 45.83 Favored 'General case' 0 C--N 1.27 -2.882 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 177.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -124.91 141.8 51.88 Favored 'General case' 0 N--CA 1.413 -2.28 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -177.236 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 6.2 p -68.34 139.19 21.09 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 O-C-N 123.874 0.734 . . . . 0.0 109.573 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.646 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 21.1 m -65.83 129.44 30.14 Favored 'Isoleucine or valine' 0 C--O 1.251 1.168 0 C-N-CA 120.48 -0.488 . . . . 0.0 110.094 178.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 89.4 mttt -114.79 166.6 11.58 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -178.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 82.0 m -129.43 -174.22 3.23 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-O 121.135 0.493 . . . . 0.0 111.457 -175.081 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 31.1 mt -77.72 137.0 62.76 Favored Pre-proline 0 N--CA 1.439 -0.991 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.315 177.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -70.86 112.51 3.29 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 C-N-CA 122.279 1.986 . . . . 0.0 109.683 175.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 27.8 t -82.81 136.61 22.51 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 -179.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.6 p -76.93 -73.71 0.28 Allowed 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 123.104 0.252 . . . . 0.0 111.518 179.371 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 167.9 160.19 0.15 Allowed Pre-proline 0 C--O 1.239 0.548 0 C-N-CA 126.128 1.771 . . . . 0.0 106.95 -179.368 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -77.49 170.05 19.99 Favored 'Trans proline' 0 CA--C 1.542 0.883 0 C-N-CA 121.586 1.524 . . . . 0.0 110.26 170.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -63.14 -52.6 61.87 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 -176.126 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -106.48 33.45 3.87 Favored 'General case' 0 CA--C 1.499 -1.011 0 CA-C-O 121.363 0.601 . . . . 0.0 109.981 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -151.59 -167.35 14.85 Favored Glycine 0 N--CA 1.42 -2.406 0 C-N-CA 120.133 -1.032 . . . . 0.0 112.062 178.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . 0.518 ' HG3' HG23 ' A' ' 177' ' ' VAL . 59.6 pttt -154.55 176.19 12.7 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -179.435 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 159' ' ' SER . 49.3 mt -98.31 145.05 10.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -179.303 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.677 HG12 HG22 ' A' ' 177' ' ' VAL . 2.5 m -89.12 -31.39 5.42 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.081 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . 0.425 ' N ' HG22 ' A' ' 157' ' ' ILE . 6.7 m . . . . . 0 C--N 1.313 -1.02 0 C-N-CA 124.603 1.161 . . . . 0.0 110.951 -175.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 . . . . . 0 N--CA 1.463 0.184 0 CA-C-O 121.623 0.725 . . . . 0.0 112.181 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.411 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 35.9 m80 -141.61 162.44 35.48 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -177.086 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.646 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 91.6 t80 -48.25 139.43 8.58 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-O 121.194 0.521 . . . . 0.0 112.104 175.342 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 87.37 -15.22 55.31 Favored Glycine 0 N--CA 1.423 -2.217 0 CA-C-O 119.204 -0.776 . . . . 0.0 113.867 175.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 29.2 mm-40 -65.0 135.76 56.01 Favored 'General case' 0 CA--C 1.496 -1.127 0 CA-C-N 118.233 1.017 . . . . 0.0 111.157 -178.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -104.71 113.96 27.87 Favored 'General case' 0 C--N 1.287 -2.148 0 CA-C-N 114.518 -1.219 . . . . 0.0 108.325 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 98.0 t -105.5 102.28 13.62 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.472 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 40.9 ttm180 -97.06 146.97 24.5 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.437 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -116.06 156.54 26.19 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.14 0.495 . . . . 0.0 110.217 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.677 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -127.76 135.18 63.75 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.131 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.146 177.583 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 77.7 m -93.91 139.25 31.13 Favored 'General case' 0 C--N 1.262 -3.231 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 173.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -56.02 157.55 4.47 Favored 'General case' 0 C--N 1.294 -1.829 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.208 176.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.8 m -52.25 111.12 0.57 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 124.319 1.012 . . . . 0.0 112.07 -174.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 106.6 1.71 37.35 Favored Glycine 0 N--CA 1.426 -1.984 0 C-N-CA 120.317 -0.944 . . . . 0.0 112.863 177.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -113.41 158.81 20.17 Favored 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 117.994 0.897 . . . . 0.0 110.169 176.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 15.6 pttm -120.62 153.38 36.91 Favored 'General case' 0 N--CA 1.428 -1.573 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.403 HD13 ' HA ' ' A' ' 188' ' ' GLU . 2.1 tt -84.67 131.06 34.93 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.911 0 C-N-CA 119.28 -0.968 . . . . 0.0 109.728 176.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -82.43 -48.33 11.22 Favored 'General case' 0 C--N 1.286 -2.165 0 CA-C-N 114.717 -1.129 . . . . 0.0 109.747 -175.265 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -83.89 -151.66 12.62 Favored Glycine 0 C--N 1.304 -1.213 0 CA-C-N 114.847 -1.07 . . . . 0.0 110.528 176.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -80.62 164.56 22.78 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.403 ' HA ' HD13 ' A' ' 184' ' ' ILE . 16.2 pt-20 -89.32 -3.27 58.55 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.91 -172.085 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -157.89 162.48 38.32 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.57 -176.257 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 17.8 ptp -137.06 153.67 50.53 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 114.81 -1.086 . . . . 0.0 108.16 176.103 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 22.0 m80 -125.64 151.66 46.22 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.652 0.263 . . . . 0.0 110.676 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 18.9 m -76.21 112.6 12.86 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 171.062 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 23.3 t -82.24 171.05 14.71 Favored 'General case' 0 N--CA 1.422 -1.85 0 O-C-N 124.383 1.052 . . . . 0.0 110.038 -176.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -50.54 -34.92 27.32 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 125.448 1.499 . . . . 0.0 112.198 -178.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -69.48 -14.24 62.77 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.155 -0.93 . . . . 0.0 113.367 -177.579 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 83.7 29.25 32.81 Favored Glycine 0 C--O 1.225 -0.466 0 C-N-CA 120.439 -0.886 . . . . 0.0 110.893 -174.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -138.33 172.64 12.6 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 70.6 m95 -80.16 136.28 36.48 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 120.816 0.341 . . . . 0.0 111.252 -179.342 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 25.7 p -73.88 -22.57 59.68 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.197 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.593 ' HE2' ' HA ' ' A' ' 200' ' ' LYS . 3.9 mmpt? -122.62 166.49 14.78 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.483 0.658 . . . . 0.0 111.572 -179.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -89.71 164.68 14.59 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 179.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 43.7 mtpt -66.63 122.76 83.54 Favored Pre-proline 0 C--N 1.309 -1.155 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.038 174.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -77.58 163.38 29.47 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 C-N-CA 122.03 1.82 . . . . 0.0 111.155 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 53.7 tttp -120.22 152.09 38.23 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -178.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 88.8 m -114.81 114.81 26.05 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 176.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 19.5 m . . . . . 0 C--N 1.3 -1.582 0 O-C-N 124.277 0.985 . . . . 0.0 109.175 -175.447 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo . . . . . 0 CA--C 1.538 0.689 0 CA-C-O 122.001 0.751 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 37.2 m -88.33 -36.49 16.61 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 177.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 120.53 -91.36 0.49 Allowed Glycine 0 CA--C 1.458 -3.484 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 172.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -176.11 127.6 0.35 Allowed Pre-proline 0 C--N 1.266 -3.05 0 N-CA-C 104.77 -2.308 . . . . 0.0 104.77 -176.157 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.463 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 61.5 Cg_endo -74.1 -17.5 21.96 Favored 'Trans proline' 0 C--N 1.329 -0.478 0 C-N-CA 122.44 2.093 . . . . 0.0 113.977 -175.301 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 131.0 -173.78 20.16 Favored Glycine 0 N--CA 1.427 -1.909 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 -176.432 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -147.39 144.13 28.47 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.7 t -122.32 130.08 24.83 Favored Pre-proline 0 C--N 1.305 -1.352 0 CA-C-O 121.194 0.521 . . . . 0.0 111.279 -178.12 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.74 -12.21 24.23 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.689 2.259 . . . . 0.0 111.676 178.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -95.04 14.36 22.11 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.717 -176.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 160.22 -122.33 1.12 Allowed Glycine 0 N--CA 1.421 -2.366 0 N-CA-C 111.084 -0.807 . . . . 0.0 111.084 178.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 t -172.31 -168.23 0.52 Allowed 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -177.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -147.56 170.2 17.97 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.7 m -138.46 156.83 47.19 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.492 HD11 ' CE1' ' A' ' 104' ' ' PHE . 14.6 mt -106.65 133.41 51.37 Favored 'General case' 0 C--N 1.276 -2.601 0 CA-C-O 121.213 0.53 . . . . 0.0 110.375 -176.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.458 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 23.8 p -121.23 116.68 25.36 Favored 'General case' 0 C--N 1.294 -1.813 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.59 -176.382 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.56 -58.93 0.7 Allowed Glycine 0 N--CA 1.434 -1.47 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -179.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.426 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -127.23 -4.51 5.9 Favored Glycine 0 N--CA 1.437 -1.247 0 C-N-CA 120.159 -1.019 . . . . 0.0 112.479 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 63.05 12.91 6.31 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 123.706 0.803 . . . . 0.0 112.517 -177.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.525 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.6 m -145.12 -171.86 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 -176.633 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.492 ' CE1' HD11 ' A' ' 98' ' ' LEU . 27.1 m-85 -101.01 44.45 1.01 Allowed 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 118.648 0.658 . . . . 0.0 110.074 -176.03 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.697 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.6 pt-20 -84.68 179.28 7.4 Favored 'General case' 0 C--O 1.209 -1.035 0 CA-C-N 114.639 -1.164 . . . . 0.0 112.101 178.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -78.57 132.2 37.06 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.359 0.6 . . . . 0.0 111.345 178.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 101.06 -8.67 57.64 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 115.067 -0.97 . . . . 0.0 112.475 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.697 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -86.29 143.7 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 CA-C-O 121.418 0.628 . . . . 0.0 110.726 -174.586 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.458 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 19.6 mtpp -110.05 119.57 39.72 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.476 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -85.57 95.08 9.21 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 177.615 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 55.3 t -90.33 114.93 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.58 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 -177.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -83.94 138.92 32.9 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.94 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.3 t -134.07 116.73 15.8 Favored 'General case' 0 N--CA 1.42 -1.957 0 CA-C-N 115.032 -0.986 . . . . 0.0 108.672 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 21.0 m -72.88 160.06 32.74 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.49 -175.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -68.63 -179.72 1.47 Allowed 'General case' 0 C--N 1.315 -0.911 0 C-N-CA 122.95 0.5 . . . . 0.0 111.392 -177.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -59.43 -50.96 71.94 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 123.828 0.851 . . . . 0.0 111.212 -177.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -87.56 31.16 4.63 Favored Glycine 0 C--N 1.309 -0.924 0 C-N-CA 120.984 -0.627 . . . . 0.0 113.094 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -145.76 161.44 39.92 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -177.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -142.22 173.67 11.31 Favored 'General case' 0 C--N 1.271 -2.845 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 -179.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 11.9 tp -92.4 149.92 21.12 Favored 'General case' 0 C--N 1.273 -2.753 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.525 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -132.65 130.91 40.76 Favored 'General case' 0 N--CA 1.415 -2.204 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 177.9 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 116.49 -153.41 17.44 Favored Glycine 0 N--CA 1.433 -1.547 0 C-N-CA 120.646 -0.788 . . . . 0.0 111.526 179.08 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -112.3 -41.69 3.86 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 121.82 0.819 . . . . 0.0 110.068 -178.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.43 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.5 mm -85.97 144.34 9.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.782 -173.735 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 22.4 p-10 -135.24 4.32 3.18 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-O 120.79 0.328 . . . . 0.0 110.595 175.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.476 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 5.4 p90 -145.95 165.98 27.38 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.232 -172.381 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.463 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 44.8 mtp180 -128.56 125.67 38.74 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.409 -1.7 . . . . 0.0 106.409 171.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 109' ' ' LYS . 55.9 tt0 -103.71 136.04 44.15 Favored 'General case' 0 C--N 1.286 -2.19 0 C-N-CA 118.352 -1.339 . . . . 0.0 110.378 179.411 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . 0.427 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 21.2 t -87.33 106.93 18.27 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.237 175.336 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -102.62 -166.76 1.31 Allowed 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 104.621 -2.363 . . . . 0.0 104.621 175.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 10.6 t -61.21 -29.83 70.05 Favored 'General case' 0 C--N 1.295 -1.769 0 CA-C-N 118.93 0.786 . . . . 0.0 112.81 -175.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -78.76 -16.53 57.08 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 121.743 0.782 . . . . 0.0 110.798 177.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.427 ' HA2' ' SG ' ' A' ' 129' ' ' CYS . . . 116.02 -148.16 18.9 Favored Glycine 0 N--CA 1.416 -2.676 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 -175.237 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 86.7 m95 -66.92 109.66 3.03 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 117.092 0.446 . . . . 0.0 109.858 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.1 p -64.82 -69.58 0.28 Allowed 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 124.219 1.008 . . . . 0.0 112.037 -176.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . 0.41 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 3.7 m-20 -75.79 167.94 20.94 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 114.012 -1.449 . . . . 0.0 108.94 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -104.23 178.13 4.65 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 123.629 0.58 . . . . 0.0 110.393 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 64.6 mt -64.31 126.19 89.91 Favored Pre-proline 0 C--N 1.314 -0.941 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.625 -178.565 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.43 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 48.2 Cg_endo -70.36 170.77 16.5 Favored 'Trans proline' 0 C--O 1.251 1.172 0 C-N-CA 122.654 2.236 . . . . 0.0 112.404 178.362 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.525 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 56.1 mt -97.6 127.43 49.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.742 -178.232 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 61.2 m -106.82 123.83 48.72 Favored 'General case' 0 C--N 1.273 -2.737 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 169.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -111.8 151.4 29.06 Favored 'General case' 0 C--N 1.276 -2.618 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.17 142.49 15.48 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.594 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.4 m -68.52 113.69 4.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 119.93 -0.708 . . . . 0.0 109.462 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 87.8 mttt -105.46 133.99 49.31 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.189 -177.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.3 m -97.32 149.97 21.48 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . 0.411 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.2 mm? -59.44 143.83 85.13 Favored Pre-proline 0 N--CA 1.42 -1.937 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 177.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 35.0 Cg_exo -56.94 114.37 1.89 Allowed 'Trans proline' 0 C--O 1.252 1.204 0 C-N-CA 123.479 2.786 . . . . 0.0 111.429 179.121 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.4 p -89.0 137.64 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.723 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.713 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . 0.413 ' O ' HD11 ' A' ' 157' ' ' ILE . 15.3 p -94.12 -158.74 0.65 Allowed 'General case' 0 N--CA 1.414 -2.262 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.065 177.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.448 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . -122.44 160.21 49.23 Favored Pre-proline 0 C--N 1.291 -1.944 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 -173.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -71.3 -170.21 0.48 Allowed 'Trans proline' 0 CA--C 1.555 1.545 0 C-N-CA 121.171 1.247 . . . . 0.0 110.61 176.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . 0.53 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.0 OUTLIER -79.27 -46.5 17.66 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 112.557 0.577 . . . . 0.0 112.557 -171.942 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . 0.53 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 57.5 m-80 -110.52 14.59 22.45 Favored 'General case' 0 CA--C 1.502 -0.901 0 CA-C-O 121.435 0.636 . . . . 0.0 110.586 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -127.96 -176.2 14.36 Favored Glycine 0 N--CA 1.423 -2.212 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . 0.461 ' HG3' HG23 ' A' ' 177' ' ' VAL . 45.6 pttt -151.56 -178.83 6.92 Favored 'General case' 0 C--N 1.292 -1.913 0 C-N-CA 123.451 0.7 . . . . 0.0 109.229 -175.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.419 HG22 ' N ' ' A' ' 159' ' ' SER . 56.1 mt -103.3 135.04 42.71 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 CA-C-N 118.018 0.372 . . . . 0.0 111.193 -176.1 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.52 HG12 HG22 ' A' ' 177' ' ' VAL . 2.7 m -79.0 -32.17 15.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.03 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . 0.419 ' N ' HG22 ' A' ' 157' ' ' ILE . 5.0 m . . . . . 0 C--N 1.32 -0.708 0 C-N-CA 124.588 1.155 . . . . 0.0 110.013 -176.304 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 64.5 m-85 . . . . . 0 N--CA 1.429 -1.501 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 45.6 m170 -120.77 163.78 17.6 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -176.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.594 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 93.7 t80 -46.83 126.55 8.84 Favored 'General case' 0 C--O 1.237 0.416 0 O-C-N 124.284 0.99 . . . . 0.0 109.964 172.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 115.75 -34.63 4.67 Favored Glycine 0 N--CA 1.424 -2.152 0 C-N-CA 120.097 -1.049 . . . . 0.0 111.656 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -67.41 134.33 51.24 Favored 'General case' 0 C--O 1.25 1.097 0 CA-C-O 121.519 0.676 . . . . 0.0 112.669 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -124.87 107.32 10.76 Favored 'General case' 0 N--CA 1.431 -1.419 0 CA-C-N 114.284 -1.325 . . . . 0.0 107.934 179.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 64.9 t -92.64 116.92 34.87 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.088 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.938 -176.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.481 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 39.8 ttm180 -106.44 147.8 28.89 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 176.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -111.99 160.32 17.58 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 123.589 0.755 . . . . 0.0 110.228 -177.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.52 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -132.65 155.66 41.54 Favored 'Isoleucine or valine' 0 CA--C 1.469 -2.163 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.531 178.411 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 10.0 m -111.89 145.19 39.95 Favored 'General case' 0 N--CA 1.396 -3.162 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.24 172.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -64.28 171.99 2.76 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.993 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.9 m -48.2 -25.73 1.62 Allowed 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 116.677 2.103 . . . . 0.0 116.677 -169.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -112.51 8.9 26.29 Favored Glycine 0 C--N 1.298 -1.533 0 C-N-CA 120.2 -1.0 . . . . 0.0 113.568 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -126.84 178.87 5.68 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 117.3 0.55 . . . . 0.0 111.793 -176.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 15.0 pttp -150.68 165.13 34.36 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.7 tp -71.86 151.92 8.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.232 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -80.17 -73.12 0.37 Allowed 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.196 176.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -102.35 -100.18 2.51 Favored Glycine 0 CA--C 1.5 -0.887 0 C-N-CA 120.156 -1.021 . . . . 0.0 112.001 -177.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -86.43 154.28 21.27 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 177.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -108.68 3.6 22.94 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.991 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -153.05 158.71 42.36 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -174.362 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.3 ptp -135.8 156.08 49.36 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 124.695 1.198 . . . . 0.0 108.787 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.1 t-80 -137.5 142.25 41.49 Favored 'General case' 0 C--N 1.31 -1.124 0 O-C-N 122.305 -0.247 . . . . 0.0 110.659 -176.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 30.1 m -80.31 123.38 27.94 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 123.691 0.619 . . . . 0.0 111.398 174.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 67.6 m -111.62 -175.93 2.82 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 175.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.02 -17.61 53.19 Favored 'General case' 0 N--CA 1.504 2.229 0 C-N-CA 122.84 0.456 . . . . 0.0 111.843 -173.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -55.97 -35.56 66.87 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 124.441 1.096 . . . . 0.0 111.053 177.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 87.09 17.07 59.88 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 -173.274 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -137.07 165.74 25.33 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.0 m95 -77.16 140.64 40.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 O-C-N 123.755 0.659 . . . . 0.0 109.279 178.182 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.3 m -81.16 -6.0 58.35 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.504 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 17.2 tppt? -136.9 161.63 35.49 Favored 'General case' 0 N--CA 1.427 -1.611 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -104.25 178.08 4.66 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 117.554 0.161 . . . . 0.0 110.771 -177.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? -64.11 117.36 35.57 Favored Pre-proline 0 C--O 1.243 0.723 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 177.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -76.96 -169.06 0.66 Allowed 'Trans proline' 0 N--CA 1.446 -1.265 0 C-N-CA 122.107 1.872 . . . . 0.0 110.651 176.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . 0.429 ' HG2' ' N ' ' A' ' 205' ' ' CYS . 46.5 tttm -131.14 160.26 35.25 Favored 'General case' 0 N--CA 1.42 -1.972 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -177.111 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.429 ' N ' ' HG2' ' A' ' 204' ' ' LYS . 9.4 t -110.88 129.68 55.8 Favored 'General case' 0 N--CA 1.423 -1.789 0 N-CA-C 105.697 -1.964 . . . . 0.0 105.697 176.261 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 11.0 m . . . . . 0 C--N 1.301 -1.535 0 CA-C-O 118.491 -0.766 . . . . 0.0 111.578 -174.657 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo . . . . . 0 N--CA 1.483 0.907 0 CA-C-O 121.581 0.576 . . . . 0.0 112.658 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 59.6 m -71.63 -24.71 61.92 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.787 -178.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 96.43 14.72 43.43 Favored Glycine 0 C--N 1.302 -1.359 0 CA-C-N 115.444 -0.798 . . . . 0.0 114.808 171.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 59.2 t-80 69.23 115.39 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.764 0 C-N-CA 123.96 0.904 . . . . 0.0 109.835 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.402 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 42.7 Cg_endo -67.48 -42.25 7.51 Favored 'Trans proline' 0 C--O 1.221 -0.358 0 C-N-CA 122.141 1.894 . . . . 0.0 112.644 -174.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 136.07 174.64 13.45 Favored Glycine 0 N--CA 1.422 -2.286 0 N-CA-C 107.592 -2.203 . . . . 0.0 107.592 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 48.1 t0 -134.32 169.02 17.83 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 -177.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.0 t -131.56 126.43 21.09 Favored Pre-proline 0 C--N 1.285 -2.197 0 CA-C-N 117.897 0.317 . . . . 0.0 110.927 -177.228 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -69.72 -11.39 30.8 Favored 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 122.888 2.392 . . . . 0.0 111.477 177.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -91.84 4.12 53.59 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.06 -178.425 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.596 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.9 -131.36 1.95 Allowed Glycine 0 N--CA 1.401 -3.691 0 C-N-CA 119.637 -1.268 . . . . 0.0 112.475 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.7 p -153.83 -179.17 7.58 Favored 'General case' 0 C--N 1.287 -2.113 0 C-N-CA 124.4 1.08 . . . . 0.0 109.708 -177.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -145.68 160.34 41.84 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 172.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.3 m -125.4 159.93 30.64 Favored 'General case' 0 C--N 1.283 -2.3 0 N-CA-C 107.111 -1.441 . . . . 0.0 107.111 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 16.7 mt -116.97 115.82 26.19 Favored 'General case' 0 C--N 1.273 -2.733 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.527 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 31.9 p -106.76 133.04 52.04 Favored 'General case' 0 C--N 1.271 -2.843 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.257 -173.719 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 108.04 -67.67 0.23 Allowed Glycine 0 N--CA 1.429 -1.828 0 N-CA-C 110.611 -0.995 . . . . 0.0 110.611 -179.159 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.425 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -106.58 -14.83 18.74 Favored Glycine 0 C--N 1.309 -0.926 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.784 -176.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 59.81 19.09 7.94 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.206 1.002 . . . . 0.0 112.787 -178.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.457 ' O ' HG11 ' A' ' 108' ' ' VAL . 27.8 m -150.24 -172.19 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 -177.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -100.47 41.37 1.18 Allowed 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 118.642 0.655 . . . . 0.0 111.164 -176.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.706 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.9 pt-20 -85.64 179.94 7.0 Favored 'General case' 0 C--O 1.207 -1.145 0 C-N-CA 123.971 0.908 . . . . 0.0 112.577 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -75.13 132.7 41.39 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.808 -0.557 . . . . 0.0 111.128 176.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.06 -5.42 63.38 Favored Glycine 0 N--CA 1.438 -1.206 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.681 178.064 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.706 HG12 ' O ' ' A' ' 105' ' ' GLU . 13.7 p -85.27 145.66 7.63 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.527 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 19.0 mtpp -111.55 113.96 26.71 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -81.4 94.23 6.76 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 177.255 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.465 HG12 ' CB ' ' A' ' 126' ' ' TYR . 33.0 m -92.19 120.11 40.83 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.193 0 CA-C-O 121.969 0.89 . . . . 0.0 108.897 -177.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -87.79 138.58 31.34 Favored 'General case' 0 C--N 1.262 -3.199 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.794 -177.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.0 t -137.36 110.23 7.65 Favored 'General case' 0 N--CA 1.407 -2.61 0 CA-C-O 122.381 1.086 . . . . 0.0 109.214 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.454 ' HA ' ' HA3' ' A' ' 94' ' ' GLY . 15.8 m -67.87 159.24 30.84 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.473 -1.239 . . . . 0.0 110.465 -177.145 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.596 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 92.0 m-20 -77.26 -179.11 5.46 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 120.746 0.308 . . . . 0.0 111.322 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -46.58 -52.51 13.37 Favored 'General case' 0 C--N 1.31 -1.138 0 C-N-CA 126.266 1.826 . . . . 0.0 114.428 -177.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -82.19 6.25 68.5 Favored Glycine 0 C--N 1.315 -0.589 0 C-N-CA 120.543 -0.837 . . . . 0.0 113.178 -176.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -128.19 166.96 17.53 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -176.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -145.35 165.73 27.62 Favored 'General case' 0 C--N 1.283 -2.312 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 176.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.07 123.68 29.73 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -178.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -106.85 126.31 52.14 Favored 'General case' 0 N--CA 1.416 -2.151 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 178.113 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 110.9 174.6 20.21 Favored Glycine 0 C--N 1.299 -1.486 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -176.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -85.6 -44.02 12.99 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 -178.114 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.7 mm -72.08 125.15 30.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 CA-C-N 114.175 -1.375 . . . . 0.0 110.39 -177.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -125.4 5.06 7.67 Favored 'General case' 0 C--O 1.202 -1.398 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 175.123 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.465 ' CB ' HG12 ' A' ' 111' ' ' VAL . 15.7 p90 -143.27 163.06 34.02 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.288 -171.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 50.9 mtp180 -126.96 130.51 50.22 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 174.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -106.14 130.25 54.06 Favored 'General case' 0 C--N 1.29 -2.0 0 C-N-CA 119.707 -0.797 . . . . 0.0 108.978 -179.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 26.5 t -84.31 108.51 17.2 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.466 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.426 ' OD1' HG22 ' A' ' 131' ' ' THR . 6.5 t70 -107.98 -167.22 1.22 Allowed 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.38 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.426 HG22 ' OD1' ' A' ' 130' ' ' ASP . 12.4 t -74.53 -12.61 60.52 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-O 121.861 0.838 . . . . 0.0 109.646 -178.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -86.46 -8.93 57.2 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.96 175.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 100.95 -153.56 19.14 Favored Glycine 0 N--CA 1.427 -1.963 0 N-CA-C 108.63 -1.788 . . . . 0.0 108.63 -175.614 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.402 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 95.2 m95 -67.33 111.25 3.92 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 117.565 0.683 . . . . 0.0 110.003 175.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 33.3 p -54.25 -58.88 5.72 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 124.877 1.271 . . . . 0.0 112.551 -176.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -92.98 -175.62 3.93 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.449 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -117.19 177.96 4.53 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.2 mt -57.39 118.79 27.29 Favored Pre-proline 0 C--N 1.286 -2.189 0 C-N-CA 125.65 1.58 . . . . 0.0 109.343 177.078 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -73.24 -177.58 3.07 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.901 2.4 . . . . 0.0 111.914 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 67.1 mt -105.32 133.18 50.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-O 120.903 0.382 . . . . 0.0 111.716 -172.065 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 90.6 m -111.4 91.15 3.55 Favored 'General case' 0 C--N 1.297 -1.682 0 CA-C-O 121.693 0.758 . . . . 0.0 109.039 174.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -86.85 148.54 25.33 Favored 'General case' 0 N--CA 1.424 -1.77 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -177.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.8 p -70.07 137.51 23.9 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 177.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 95.4 t -64.62 126.01 22.61 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -115.44 143.98 44.5 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.033 -176.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -120.75 159.59 25.09 Favored 'General case' 0 C--N 1.281 -2.41 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.147 177.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -68.46 147.08 98.11 Favored Pre-proline 0 N--CA 1.421 -1.899 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -175.126 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -71.93 116.42 4.7 Favored 'Trans proline' 0 N--CA 1.442 -1.522 0 C-N-CA 122.701 2.268 . . . . 0.0 110.546 178.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.445 HG21 ' SD ' ' A' ' 190' ' ' MET . 60.1 t -74.81 144.46 12.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.319 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.4 p -66.57 -84.85 0.02 OUTLIER 'General case' 0 N--CA 1.438 -1.026 0 O-C-N 123.379 0.424 . . . . 0.0 111.629 177.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 168.01 162.58 0.15 Allowed Pre-proline 0 CA--C 1.513 -0.46 0 C-N-CA 126.106 1.763 . . . . 0.0 106.463 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -76.54 168.3 23.98 Favored 'Trans proline' 0 N--CA 1.446 -1.313 0 C-N-CA 121.324 1.349 . . . . 0.0 110.001 171.267 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -60.02 -50.9 71.92 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 113.862 1.06 . . . . 0.0 113.862 -176.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 55.0 m-80 -110.67 32.61 5.09 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.563 0.696 . . . . 0.0 109.791 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -149.15 -176.79 22.73 Favored Glycine 0 N--CA 1.425 -2.081 0 C-N-CA 120.219 -0.991 . . . . 0.0 111.384 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -144.45 169.37 18.07 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -178.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.528 HG12 ' CD2' ' A' ' 176' ' ' PHE . 51.6 mt -98.47 137.45 25.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.478 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.8 m -84.5 -28.02 6.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 CA-C-O 121.986 0.898 . . . . 0.0 108.701 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . 0.517 ' H ' HG22 ' A' ' 157' ' ' ILE . 12.9 m . . . . . 0 C--N 1.312 -1.038 0 CA-C-N 114.704 -1.135 . . . . 0.0 112.496 -176.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 69.7 m-85 . . . . . 0 N--CA 1.429 -1.491 0 CA-C-O 121.682 0.753 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 46.8 m170 -115.29 163.51 15.58 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.744 -176.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -51.93 127.46 21.25 Favored 'General case' 0 C--O 1.245 0.843 0 O-C-N 124.134 0.896 . . . . 0.0 108.983 172.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 108.23 -22.81 26.4 Favored Glycine 0 N--CA 1.435 -1.422 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.306 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 30.1 mm-40 -71.67 144.67 49.28 Favored 'General case' 0 C--O 1.256 1.398 0 CA-C-N 117.185 0.492 . . . . 0.0 110.314 178.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -123.03 104.99 9.57 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.547 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 54.4 t -79.85 106.62 11.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.832 -178.023 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.478 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 25.9 ttp85 -98.62 143.45 29.0 Favored 'General case' 0 N--CA 1.41 -2.452 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.736 179.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.528 ' CD2' HG12 ' A' ' 157' ' ' ILE . 64.0 m-85 -112.85 165.75 12.02 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -178.107 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.7 p -146.73 138.25 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.291 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.5 m -92.67 148.28 22.19 Favored 'General case' 0 C--N 1.265 -3.101 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.391 -178.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -69.64 162.41 27.71 Favored 'General case' 0 CA--C 1.497 -1.063 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.664 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 16.3 m -52.08 109.44 0.38 Allowed 'General case' 0 C--N 1.303 -1.439 0 O-C-N 124.404 1.065 . . . . 0.0 112.368 -175.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.58 -9.17 30.36 Favored Glycine 0 N--CA 1.435 -1.385 0 CA-C-N 115.715 -0.675 . . . . 0.0 113.073 178.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -108.81 153.12 23.94 Favored 'General case' 0 CA--C 1.497 -1.059 0 CA-C-N 117.886 0.843 . . . . 0.0 110.886 -178.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 16.9 pttp -115.71 159.54 21.25 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 7.0 tp -74.36 146.19 10.23 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 176.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -91.46 -61.21 1.7 Allowed 'General case' 0 C--N 1.27 -2.876 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -90.99 -130.48 4.68 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 177.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -87.8 153.14 21.58 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 176.141 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -92.55 8.19 39.95 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 120.365 -0.534 . . . . 0.0 110.465 -177.088 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . 0.547 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 2.0 pt-20 -155.94 143.76 19.64 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 121.123 0.487 . . . . 0.0 111.925 -179.505 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.445 ' SD ' HG21 ' A' ' 149' ' ' VAL . 13.9 ptp -125.65 138.28 53.9 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.01 -0.995 . . . . 0.0 109.336 176.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 50.1 t-80 -100.56 138.77 37.17 Favored 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 123.089 0.556 . . . . 0.0 110.045 -176.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 23.6 t -82.76 107.08 15.12 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 174.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 50.7 m -100.21 -178.59 3.87 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 114.046 1.128 . . . . 0.0 114.046 -171.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -49.17 -34.97 15.7 Favored 'General case' 0 N--CA 1.51 2.541 0 C-N-CA 125.908 1.683 . . . . 0.0 113.179 -174.153 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -81.8 -7.67 59.62 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 113.456 0.909 . . . . 0.0 113.456 -176.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 83.42 10.19 82.39 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.15 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -112.96 169.76 8.69 Favored 'General case' 0 N--CA 1.427 -1.599 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 177.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.3 m95 -83.66 134.99 34.76 Favored 'General case' 0 N--CA 1.417 -2.087 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.24 178.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 35.9 p -63.38 -32.26 73.64 Favored 'General case' 0 C--O 1.249 1.063 0 CA-C-O 121.523 0.677 . . . . 0.0 112.229 -177.575 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 26.3 mmtp -116.49 157.08 25.76 Favored 'General case' 0 CA--C 1.483 -1.601 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.352 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . 0.438 ' H ' ' CD ' ' A' ' 201' ' ' GLU . 0.3 OUTLIER -86.43 172.13 10.61 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.684 179.813 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 7.6 mmmm -55.13 119.9 26.13 Favored Pre-proline 0 C--N 1.321 -0.634 0 O-C-N 123.697 0.623 . . . . 0.0 111.786 178.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -86.5 -173.44 1.21 Allowed 'Trans proline' 0 N--CA 1.424 -2.589 0 C-N-CA 122.061 1.841 . . . . 0.0 109.987 178.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 24.5 ttmm -148.08 164.41 33.93 Favored 'General case' 0 C--N 1.278 -2.506 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -176.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.549 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 98.4 m -126.06 116.04 20.79 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 174.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--N 1.3 -1.574 0 O-C-N 124.416 1.072 . . . . 0.0 109.747 -175.392 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo . . . . . 0 N--CA 1.477 0.528 0 CA-C-O 121.313 0.464 . . . . 0.0 112.159 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.6 m -84.25 -29.97 26.05 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.37 -98.1 0.74 Allowed Glycine 0 N--CA 1.398 -3.891 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.919 171.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -177.08 110.75 0.23 Allowed Pre-proline 0 C--N 1.258 -3.407 0 N-CA-C 105.759 -1.941 . . . . 0.0 105.759 -176.075 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.451 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 45.0 Cg_endo -64.76 -30.82 59.04 Favored 'Trans proline' 0 N--CA 1.474 0.334 0 C-N-CA 122.92 2.414 . . . . 0.0 112.963 -171.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.95 -174.39 19.13 Favored Glycine 0 N--CA 1.419 -2.483 0 N-CA-C 108.481 -1.848 . . . . 0.0 108.481 -176.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -142.57 164.64 29.56 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 107.815 -1.179 . . . . 0.0 107.815 -176.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.4 t -125.05 127.31 25.1 Favored Pre-proline 0 C--N 1.295 -1.769 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 -178.478 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -68.64 -22.38 37.91 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.483 2.122 . . . . 0.0 110.667 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -81.24 -1.64 45.72 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.219 -1.355 . . . . 0.0 111.984 -175.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.43 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 177.38 -130.66 1.66 Allowed Glycine 0 N--CA 1.414 -2.791 0 C-N-CA 119.695 -1.241 . . . . 0.0 111.84 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 24.4 p -146.59 179.16 7.75 Favored 'General case' 0 C--N 1.285 -2.225 0 O-C-N 124.119 0.541 . . . . 0.0 110.096 -178.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -143.07 155.28 44.58 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 171.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.5 m -121.24 163.65 18.2 Favored 'General case' 0 C--N 1.279 -2.482 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.584 ' HA ' ' O ' ' A' ' 109' ' ' LYS . 32.0 mt -120.82 124.0 43.97 Favored 'General case' 0 C--N 1.277 -2.561 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.236 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.65 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 34.1 p -115.93 125.56 52.73 Favored 'General case' 0 C--N 1.285 -2.235 0 O-C-N 123.625 0.578 . . . . 0.0 110.793 -175.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 99.95 11.76 42.13 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.828 178.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -178.91 -28.76 0.05 OUTLIER Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 119.371 -1.395 . . . . 0.0 113.813 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 69.6 10.88 7.81 Favored 'General case' 0 N--CA 1.5 2.073 0 CA-C-O 122.674 1.226 . . . . 0.0 110.599 -177.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.438 ' O ' HG11 ' A' ' 108' ' ' VAL . 35.9 m -143.72 -169.79 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 114.684 -1.144 . . . . 0.0 107.937 -174.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 36.4 m-85 -110.87 43.9 1.36 Allowed 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.489 0.662 . . . . 0.0 110.567 -175.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.721 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.1 pt-20 -86.23 -176.58 5.97 Favored 'General case' 0 C--O 1.207 -1.165 0 CA-C-N 114.445 -1.252 . . . . 0.0 112.474 177.388 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.2 m-85 -78.82 131.99 36.69 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 122.021 -0.425 . . . . 0.0 111.467 178.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.48 5.33 61.82 Favored Glycine 0 N--CA 1.438 -1.214 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.659 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.721 HG12 ' O ' ' A' ' 105' ' ' GLU . 9.9 p -101.75 148.66 7.23 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.65 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 89.2 mttt -108.83 138.89 44.44 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 176.042 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -97.14 86.55 3.97 Favored 'General case' 0 C--N 1.264 -3.12 0 N-CA-C 105.515 -2.031 . . . . 0.0 105.515 169.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.484 HG12 ' CB ' ' A' ' 126' ' ' TYR . 21.2 m -85.61 118.17 31.85 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 -177.066 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -88.04 141.04 28.88 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.725 -0.609 . . . . 0.0 111.22 -175.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -139.36 114.36 9.49 Favored 'General case' 0 N--CA 1.412 -2.352 0 CA-C-O 122.129 0.966 . . . . 0.0 108.777 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 10.5 m -73.43 159.6 33.0 Favored 'General case' 0 C--N 1.289 -2.064 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.976 -175.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.43 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 68.6 m-20 -69.18 179.1 2.05 Favored 'General case' 0 C--O 1.216 -0.683 0 C-N-CA 123.023 0.529 . . . . 0.0 111.299 178.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -55.73 -46.57 77.74 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.556 0.742 . . . . 0.0 112.072 -178.199 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -81.92 7.8 61.88 Favored Glycine 0 C--N 1.308 -1.014 0 CA-C-N 115.839 -0.619 . . . . 0.0 113.95 -177.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -129.98 152.3 49.6 Favored 'General case' 0 N--CA 1.426 -1.63 0 CA-C-O 121.495 0.664 . . . . 0.0 110.072 -178.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.44 158.43 36.04 Favored 'General case' 0 C--N 1.271 -2.824 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.3 tt -89.56 129.47 36.02 Favored 'General case' 0 C--N 1.272 -2.8 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.552 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.64 128.18 55.98 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -175.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 116.06 173.48 17.21 Favored Glycine 0 C--N 1.294 -1.751 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 -176.025 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -87.73 -35.72 17.76 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -179.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 47.4 mm -85.73 137.04 21.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.288 -176.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -123.93 2.46 8.72 Favored 'General case' 0 C--O 1.21 -0.998 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.307 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.484 ' CB ' HG12 ' A' ' 111' ' ' VAL . 50.0 p90 -145.47 169.44 18.35 Favored 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -170.523 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.452 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 54.9 mtp180 -126.17 115.52 19.91 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 170.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -91.91 124.22 35.87 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 119.749 -0.781 . . . . 0.0 109.426 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.8 t -83.93 104.03 13.68 Favored 'General case' 0 CA--C 1.498 -1.056 0 C-N-CA 118.819 -1.152 . . . . 0.0 108.858 176.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.45 ' OD1' HG22 ' A' ' 131' ' ' THR . 7.9 t70 -99.53 -171.07 2.0 Allowed 'General case' 0 C--N 1.288 -2.103 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 178.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.45 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.3 t -61.42 -14.77 30.77 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 124.408 1.083 . . . . 0.0 112.508 -174.346 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -98.52 -15.34 19.59 Favored 'General case' 0 C--N 1.315 -0.913 0 O-C-N 121.757 -0.59 . . . . 0.0 110.637 178.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 124.18 -161.09 18.7 Favored Glycine 0 C--N 1.305 -1.188 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 -177.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.451 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 89.3 m95 -64.91 101.3 0.48 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.889 0.345 . . . . 0.0 110.173 176.77 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.5 p -58.31 -57.19 14.0 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 124.105 0.962 . . . . 0.0 112.254 -176.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . 0.452 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 3.5 m120 -81.36 177.53 8.92 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.19 -0.914 . . . . 0.0 109.321 -177.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -111.11 179.6 4.0 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 176.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 84.4 mt -72.53 117.95 63.46 Favored Pre-proline 0 C--N 1.317 -0.843 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -66.35 157.79 58.44 Favored 'Trans proline' 0 C--O 1.253 1.267 0 C-N-CA 122.513 2.142 . . . . 0.0 110.624 178.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 62.4 mt -92.24 129.48 42.79 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-O 120.877 0.37 . . . . 0.0 110.722 -173.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 84.5 m -99.41 105.4 17.34 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 171.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -92.94 150.14 20.77 Favored 'General case' 0 N--CA 1.407 -2.601 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 -179.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 5.8 p -74.4 131.02 35.65 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.645 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 84.7 t -52.7 132.05 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 O-C-N 123.906 0.754 . . . . 0.0 110.89 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.429 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 85.0 mttt -106.32 153.91 21.52 Favored 'General case' 0 N--CA 1.433 -1.295 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.016 -176.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.9 m -124.03 165.06 18.12 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.639 -178.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . 0.553 HD23 ' HD2' ' A' ' 148' ' ' PRO . 0.5 OUTLIER -62.58 130.85 93.85 Favored Pre-proline 0 N--CA 1.426 -1.64 0 C-N-CA 125.154 1.382 . . . . 0.0 110.777 178.099 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.553 ' HD2' HD23 ' A' ' 147' ' ' LEU . 24.1 Cg_endo -65.91 110.26 1.67 Allowed 'Trans proline' 0 C--N 1.314 -1.244 0 C-N-CA 123.174 2.582 . . . . 0.0 111.635 175.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 7.8 p -86.59 143.94 10.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 38.9 p -82.49 -83.48 0.13 Allowed 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -177.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.3 161.74 0.46 Allowed Pre-proline 0 C--N 1.326 -0.429 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 -179.485 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . 0.481 ' HD3' ' CD2' ' A' ' 176' ' ' PHE . 43.5 Cg_endo -73.51 -169.39 0.53 Allowed 'Trans proline' 0 CA--C 1.546 1.125 0 C-N-CA 121.654 1.569 . . . . 0.0 111.27 172.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . 0.6 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.2 OUTLIER -88.44 -37.2 16.02 Favored 'General case' 0 C--N 1.287 -2.131 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -174.899 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . 0.6 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 49.8 m-80 -120.86 22.82 10.98 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 122.074 0.94 . . . . 0.0 109.827 179.345 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . 0.411 ' HA3' ' SG ' ' A' ' 205' ' ' CYS . . . -146.49 178.97 23.81 Favored Glycine 0 N--CA 1.425 -2.041 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.431 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . 0.448 ' HG3' HG23 ' A' ' 177' ' ' VAL . 21.9 pttm -145.62 -176.66 5.22 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -178.093 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.444 HG22 ' N ' ' A' ' 159' ' ' SER . 64.4 mt -95.56 141.2 15.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 C-N-CA 122.505 0.322 . . . . 0.0 110.703 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.573 HG12 HG22 ' A' ' 177' ' ' VAL . 2.3 m -79.91 -35.39 16.11 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.461 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 177.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . 0.444 ' N ' HG22 ' A' ' 157' ' ' ILE . 5.3 m . . . . . 0 CA--C 1.55 0.946 0 C-N-CA 125.429 1.492 . . . . 0.0 111.375 -174.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . 0.429 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 82.6 m-85 . . . . . 0 CA--C 1.494 -1.202 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 49.7 m170 -117.83 161.06 20.35 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.691 -175.351 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 42.5 t80 -55.72 125.27 20.5 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 174.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 109.86 -14.13 31.87 Favored Glycine 0 N--CA 1.42 -2.398 0 C-N-CA 120.047 -1.073 . . . . 0.0 111.492 -177.101 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 87.1 mm-40 -86.71 139.38 30.81 Favored 'General case' 0 N--CA 1.433 -1.305 0 C-N-CA 119.533 -0.867 . . . . 0.0 109.822 176.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -120.59 116.14 24.77 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.616 178.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 88.1 t -90.29 106.04 16.88 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.517 ' HB3' HG22 ' A' ' 158' ' ' VAL . 46.1 ttm180 -104.65 142.47 34.61 Favored 'General case' 0 N--CA 1.405 -2.689 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.481 ' CD2' ' HD3' ' A' ' 152' ' ' PRO . 88.5 m-85 -108.81 157.44 18.58 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 121.431 0.634 . . . . 0.0 110.922 -175.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.573 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -130.69 133.12 63.82 Favored 'Isoleucine or valine' 0 CA--C 1.471 -2.078 0 CA-C-N 114.908 -1.042 . . . . 0.0 108.507 178.626 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 93.4 m -95.33 128.34 42.1 Favored 'General case' 0 C--N 1.259 -3.337 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 177.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 77.1 m-20 -60.09 160.09 8.62 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 114.95 -1.023 . . . . 0.0 111.419 -178.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 14.9 m -37.38 102.82 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 126.484 1.914 . . . . 0.0 114.91 -174.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 111.66 -18.39 24.78 Favored Glycine 0 N--CA 1.441 -0.982 0 C-N-CA 120.998 -0.62 . . . . 0.0 113.066 177.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . 0.423 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 93.8 m-85 -96.12 156.0 16.52 Favored 'General case' 0 N--CA 1.434 -1.233 0 CA-C-N 117.094 0.447 . . . . 0.0 111.394 -177.352 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -123.18 155.15 37.64 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.3 tp -72.42 142.84 14.7 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.2 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -71.83 -71.24 0.28 Allowed 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.852 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -100.02 -105.86 2.73 Favored Glycine 0 N--CA 1.431 -1.665 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -99.34 163.28 12.6 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -105.88 0.8 26.24 Favored 'General case' 0 CA--C 1.499 -1.008 0 C-N-CA 119.351 -0.94 . . . . 0.0 111.249 -173.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -148.12 152.63 37.65 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 114.085 1.142 . . . . 0.0 114.085 -175.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.5 ptp -131.15 138.23 49.37 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.233 -1.349 . . . . 0.0 108.496 177.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 45.6 t-80 -123.42 137.42 54.81 Favored 'General case' 0 C--N 1.292 -1.902 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.448 -176.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 16.2 m -61.93 113.81 3.01 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.994 176.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 14.9 m -102.76 174.15 6.01 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.054 178.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -48.74 140.79 8.04 Favored 'General case' 0 N--CA 1.488 1.433 0 C-N-CA 123.833 0.853 . . . . 0.0 112.352 178.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 26.2 t70 76.47 -6.45 2.0 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 125.944 1.698 . . . . 0.0 111.937 178.128 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 93.04 50.94 2.35 Favored Glycine 0 N--CA 1.434 -1.499 0 C-N-CA 120.529 -0.844 . . . . 0.0 112.087 177.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -116.7 141.61 47.98 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 176.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 67.1 m95 -79.78 132.06 36.06 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 171.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.1 p -65.85 -20.34 66.2 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.245 0.545 . . . . 0.0 112.172 -179.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.543 ' HA ' ' HE3' ' A' ' 200' ' ' LYS . 0.0 OUTLIER -134.17 171.1 14.7 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.597 178.43 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -108.57 170.25 8.14 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.492 -178.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 5.5 tppp? -56.06 114.87 8.34 Favored Pre-proline 0 C--O 1.233 0.237 0 O-C-N 124.047 0.842 . . . . 0.0 110.814 -178.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -80.76 -167.78 0.55 Allowed 'Trans proline' 0 N--CA 1.434 -2.0 0 C-N-CA 122.145 1.897 . . . . 0.0 110.625 176.753 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 5.0 ttmp? -146.38 160.31 42.23 Favored 'General case' 0 C--N 1.28 -2.422 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -174.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.423 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 87.0 m -117.41 105.93 12.66 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-O 121.518 0.675 . . . . 0.0 110.693 177.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.2 m . . . . . 0 N--CA 1.433 -1.314 0 CA-C-N 115.003 -0.998 . . . . 0.0 110.079 -176.2 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 CA--C 1.53 0.325 0 CA-C-O 121.565 0.569 . . . . 0.0 111.322 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 36.2 m -89.1 -42.16 11.87 Favored 'General case' 0 N--CA 1.426 -1.633 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 121.4 -86.0 0.39 Allowed Glycine 0 CA--C 1.472 -2.603 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 172.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -179.59 127.13 0.24 Allowed Pre-proline 0 C--N 1.274 -2.691 0 N-CA-C 104.078 -2.564 . . . . 0.0 104.078 -177.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.414 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 95.2 Cg_endo -77.58 4.85 5.64 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 C-N-CA 123.355 2.703 . . . . 0.0 115.584 -170.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.75 -168.86 12.91 Favored Glycine 0 C--N 1.287 -2.167 0 N-CA-C 107.688 -2.165 . . . . 0.0 107.688 -174.248 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -151.12 -175.42 5.15 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 118.439 1.119 . . . . 0.0 108.846 -176.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 t -155.33 125.85 3.41 Favored Pre-proline 0 N--CA 1.424 -1.739 0 CA-C-O 121.065 0.46 . . . . 0.0 111.395 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -78.73 -5.95 14.99 Favored 'Trans proline' 0 C--O 1.239 0.556 0 C-N-CA 123.088 2.526 . . . . 0.0 112.069 178.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.535 ' HB2' ' HB2' ' A' ' 141' ' ' CYS . 27.0 m-85 -99.46 1.28 43.96 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.325 -177.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.461 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.86 -136.59 3.52 Favored Glycine 0 N--CA 1.405 -3.385 0 C-N-CA 118.817 -1.659 . . . . 0.0 113.043 -178.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.9 p -146.37 -176.85 5.33 Favored 'General case' 0 C--N 1.283 -2.311 0 CA-C-N 114.655 -0.773 . . . . 0.0 110.795 -174.041 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 44.6 p90 -146.58 161.53 40.31 Favored 'General case' 0 N--CA 1.431 -1.422 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 171.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.7 m -131.81 154.51 49.04 Favored 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 179.546 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.507 ' HB2' ' HA ' ' A' ' 102' ' ' ASN . 16.1 mt -110.07 127.68 54.99 Favored 'General case' 0 C--N 1.272 -2.78 0 CA-C-O 120.995 0.426 . . . . 0.0 110.064 -177.039 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.491 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 24.1 p -120.45 132.94 55.45 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.136 -177.613 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.44 19.34 32.86 Favored Glycine 0 C--N 1.307 -1.065 0 C-N-CA 120.599 -0.81 . . . . 0.0 111.809 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 167.92 -27.04 0.14 Allowed Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.612 178.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . 0.507 ' HA ' ' HB2' ' A' ' 98' ' ' LEU . 7.5 t30 61.28 20.07 10.71 Favored 'General case' 0 CA--C 1.56 1.338 0 CA-C-O 122.699 1.238 . . . . 0.0 110.519 -178.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.546 ' O ' HG11 ' A' ' 108' ' ' VAL . 31.1 m -144.55 -170.57 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.207 -1.164 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 -179.035 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -106.53 45.19 0.99 Allowed 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 118.394 0.543 . . . . 0.0 110.392 -178.157 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.717 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.4 pt-20 -90.43 -177.97 5.21 Favored 'General case' 0 C--O 1.207 -1.143 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.769 177.483 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 46.9 m-85 -77.61 133.24 38.48 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.859 -0.526 . . . . 0.0 111.456 178.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.84 0.12 64.33 Favored Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.895 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.717 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.7 p -94.22 145.71 7.61 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.491 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 15.1 mtpp -109.94 124.39 51.31 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.65 91.13 8.63 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 176.094 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 62.5 t -88.63 112.24 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.962 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -177.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -81.39 134.9 35.62 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-O 121.19 0.519 . . . . 0.0 111.681 -178.627 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.1 t -132.55 104.91 6.92 Favored 'General case' 0 N--CA 1.421 -1.916 0 CA-C-O 122.157 0.979 . . . . 0.0 109.16 -178.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 13.4 m -66.83 157.98 31.62 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.62 -1.173 . . . . 0.0 110.826 -178.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.461 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 95.4 m-20 -75.55 178.44 5.99 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.748 -0.206 . . . . 0.0 111.548 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -45.7 -54.63 7.54 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.945 1.298 . . . . 0.0 113.324 -177.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.497 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -85.16 25.94 5.85 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 120.3 -0.953 . . . . 0.0 113.626 -176.357 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.67 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 81.1 m-85 -145.98 154.89 42.4 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 117.321 0.56 . . . . 0.0 110.092 -176.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.03 161.84 33.3 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 176.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.28 115.4 21.33 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 -178.384 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -98.31 129.74 45.0 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 179.461 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 121.35 166.74 13.03 Favored Glycine 0 C--N 1.29 -1.99 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -177.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.0 mt-10 -88.99 -21.3 23.57 Favored 'General case' 0 C--N 1.295 -1.799 0 CA-C-O 121.955 0.883 . . . . 0.0 109.306 -177.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.481 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.5 mm -107.76 131.21 58.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.804 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.815 -178.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -123.57 11.5 9.21 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -177.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.471 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 15.5 p90 -152.03 161.42 42.67 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -175.24 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.414 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 62.9 mtp180 -126.43 129.02 47.9 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 172.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -105.87 132.19 52.27 Favored 'General case' 0 C--N 1.279 -2.492 0 C-N-CA 119.101 -1.039 . . . . 0.0 109.461 -178.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.1 t -82.11 101.8 10.64 Favored 'General case' 0 C--N 1.293 -1.876 0 C-N-CA 118.219 -1.392 . . . . 0.0 109.927 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.555 ' OD2' HG22 ' A' ' 131' ' ' THR . 13.3 t70 -101.83 -171.35 1.96 Allowed 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.555 HG22 ' OD2' ' A' ' 130' ' ' ASP . 8.8 t -54.93 -31.99 60.84 Favored 'General case' 0 CA--C 1.56 1.331 0 C-N-CA 124.182 0.993 . . . . 0.0 112.805 -175.47 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -85.72 -15.36 42.45 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.908 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 122.98 -159.89 17.55 Favored Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -176.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.0 m95 -62.23 112.17 2.28 Favored 'General case' 0 C--O 1.248 0.983 0 CA-C-N 117.173 0.486 . . . . 0.0 110.39 177.051 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 68.4 p -71.08 162.82 28.78 Favored 'General case' 0 C--O 1.266 1.932 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 65.6 -171.16 0.19 Allowed 'General case' 0 CA--C 1.509 -0.629 0 O-C-N 124.209 0.943 . . . . 0.0 111.451 174.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -108.51 171.79 7.21 Favored 'General case' 0 C--N 1.295 -1.804 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.566 177.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 66.2 mt -67.68 118.5 58.05 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 171.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.481 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 35.0 Cg_endo -66.2 159.06 51.58 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 122.056 1.837 . . . . 0.0 111.114 178.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 74.5 mt -109.39 134.59 50.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 C-N-CA 120.68 -0.408 . . . . 0.0 109.953 -171.303 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.535 ' HB2' ' HB2' ' A' ' 93' ' ' PHE . 94.9 m -102.96 110.73 22.76 Favored 'General case' 0 C--N 1.277 -2.57 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 175.144 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.86 152.17 20.04 Favored 'General case' 0 CA--C 1.462 -2.41 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.67 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 2.8 t -69.12 142.2 16.42 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.044 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.546 -177.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.689 HG23 ' HB2' ' A' ' 170' ' ' PHE . 10.4 m -66.82 122.52 18.01 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 178.072 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.465 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 49.7 mtmt -121.81 127.18 50.28 Favored 'General case' 0 N--CA 1.408 -2.565 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.923 -172.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 60.8 m -84.2 153.68 23.5 Favored 'General case' 0 C--N 1.28 -2.436 0 CA-C-N 113.981 -1.463 . . . . 0.0 108.504 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . 0.402 ' HB2' ' HD2' ' A' ' 148' ' ' PRO . 3.6 pp -67.52 160.72 70.74 Favored Pre-proline 0 CA--C 1.553 1.075 0 O-C-N 123.236 0.335 . . . . 0.0 110.229 -178.075 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.433 ' HA ' ' CE2' ' A' ' 168' ' ' TYR . 39.4 Cg_endo -74.28 123.21 8.08 Favored 'Trans proline' 0 N--CA 1.446 -1.297 0 C-N-CA 122.499 2.133 . . . . 0.0 112.348 -175.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.648 HG12 ' O ' ' A' ' 150' ' ' THR . 62.0 t -75.07 137.68 22.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.977 -178.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . 0.648 ' O ' HG12 ' A' ' 149' ' ' VAL . 25.4 p -95.95 -158.01 0.62 Allowed 'General case' 0 N--CA 1.417 -2.105 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 172.183 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -127.38 151.39 74.73 Favored Pre-proline 0 C--N 1.274 -2.682 0 O-C-N 120.406 -1.434 . . . . 0.0 110.352 -171.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -68.76 161.44 45.42 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.615 1.543 . . . . 0.0 112.259 177.23 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -60.04 -43.64 95.22 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 -174.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 57.6 m-80 -117.49 29.36 7.91 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -148.31 -167.21 13.4 Favored Glycine 0 N--CA 1.435 -1.42 0 C-N-CA 119.989 -1.101 . . . . 0.0 112.081 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -154.85 177.14 11.62 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.434 HD11 ' O ' ' A' ' 150' ' ' THR . 58.9 mt -88.75 129.7 39.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 CA-C-O 120.833 0.349 . . . . 0.0 110.713 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.414 ' CG2' ' HB ' ' A' ' 177' ' ' VAL . 34.9 t -64.34 -35.61 74.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.555 0 C-N-CA 123.902 0.881 . . . . 0.0 109.947 178.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 37.3 t . . . . . 0 N--CA 1.43 -1.472 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 173.75 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . 0.465 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 99.6 m-85 . . . . . 0 CA--C 1.501 -0.922 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -97.4 160.23 14.45 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -177.337 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.689 ' HB2' HG23 ' A' ' 144' ' ' VAL . 53.6 t80 -54.83 111.66 0.87 Allowed 'General case' 0 C--O 1.241 0.62 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 171.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 137.55 -12.82 3.73 Favored Glycine 0 N--CA 1.425 -2.064 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -173.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -82.98 143.97 30.29 Favored 'General case' 0 C--O 1.248 1.009 0 CA-C-O 121.436 0.636 . . . . 0.0 112.116 177.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -134.88 111.1 9.59 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 172.374 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 76.7 t -97.75 111.53 27.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 CA-C-O 120.983 0.42 . . . . 0.0 110.083 -177.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 79.6 ttt180 -95.33 153.84 17.49 Favored 'General case' 0 N--CA 1.426 -1.644 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.05 178.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -125.49 153.56 43.37 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 124.264 1.026 . . . . 0.0 109.458 -175.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.414 ' HB ' ' CG2' ' A' ' 158' ' ' VAL . 14.7 p -135.59 143.02 37.78 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 72.6 m -96.17 146.57 24.57 Favored 'General case' 0 C--N 1.272 -2.802 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.508 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -87.71 168.38 13.03 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.762 -176.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 32.4 t 50.06 -113.2 0.63 Allowed 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 124.058 0.943 . . . . 0.0 113.357 178.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -118.87 23.83 8.61 Favored Glycine 0 N--CA 1.417 -2.577 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -79.87 158.12 26.81 Favored 'General case' 0 C--O 1.249 1.046 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.117 -176.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 20.9 ptmt -121.14 160.56 23.48 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 115.503 -0.771 . . . . 0.0 109.476 -178.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.427 HD11 ' CG ' ' A' ' 203' ' ' PRO . 3.6 tp -79.29 145.91 8.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.449 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -69.61 -66.96 0.52 Allowed 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.617 178.484 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -115.69 -98.54 2.15 Favored Glycine 0 N--CA 1.433 -1.548 0 C-N-CA 120.442 -0.885 . . . . 0.0 111.364 -179.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -98.84 145.38 27.03 Favored 'General case' 0 CA--C 1.483 -1.604 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -178.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.429 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 12.0 pt-20 -102.97 12.08 36.54 Favored 'General case' 0 C--N 1.287 -2.138 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.915 -175.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -149.05 132.51 16.65 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 121.555 0.693 . . . . 0.0 112.552 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.7 ptp -114.21 125.33 53.81 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.282 176.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 27.3 t-80 -103.85 148.33 26.26 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 -178.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 5.0 m -75.02 140.88 43.89 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 177.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 50.7 m -96.71 154.95 16.99 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 171.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -73.77 -2.67 24.42 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.754 0.788 . . . . 0.0 110.882 -177.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -81.29 -10.43 59.58 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.827 178.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 94.48 26.51 13.41 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.769 -0.729 . . . . 0.0 113.514 178.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 19.5 p90 -147.78 173.44 12.8 Favored 'General case' 0 C--N 1.309 -1.155 0 O-C-N 122.263 -0.551 . . . . 0.0 110.376 177.424 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -83.05 145.15 29.45 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 123.433 0.458 . . . . 0.0 110.486 -179.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 6.7 m -82.91 -0.52 48.82 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.847 0.356 . . . . 0.0 111.336 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 15.7 tppt? -140.14 153.5 46.69 Favored 'General case' 0 N--CA 1.424 -1.731 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -177.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -87.87 155.04 20.06 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.68 175.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . 0.453 ' HB3' ' HE2' ' A' ' 202' ' ' LYS . 38.9 mtpt -59.95 126.67 84.08 Favored Pre-proline 0 N--CA 1.434 -1.261 0 O-C-N 123.731 0.645 . . . . 0.0 110.042 174.669 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . 0.427 ' CG ' HD11 ' A' ' 184' ' ' ILE . 90.9 Cg_endo -82.93 -167.95 0.53 Allowed 'Trans proline' 0 N--CA 1.436 -1.901 0 C-N-CA 122.514 2.143 . . . . 0.0 110.66 177.313 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -132.25 170.47 15.0 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.478 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 89.2 m -120.42 112.67 19.28 Favored 'General case' 0 C--N 1.274 -2.689 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 172.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 28.2 m . . . . . 0 C--N 1.281 -2.375 0 CA-C-N 114.105 -1.407 . . . . 0.0 109.206 -172.216 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.461 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 32.7 Cg_endo . . . . . 0 CA--C 1.546 1.11 0 CA-C-O 120.902 0.293 . . . . 0.0 112.201 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . 0.619 ' HB3' ' NE1' ' A' ' 134' ' ' TRP . 0.9 OUTLIER -87.7 -16.79 33.31 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.37 0.605 . . . . 0.0 110.133 175.132 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 102.72 -93.8 1.09 Allowed Glycine 1 N--CA 1.391 -4.357 0 N-CA-C 108.748 -1.741 . . . . 0.0 108.748 174.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -170.38 132.06 0.96 Allowed Pre-proline 0 C--N 1.253 -3.628 0 N-CA-C 105.571 -2.011 . . . . 0.0 105.571 -175.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -73.27 -28.72 12.19 Favored 'Trans proline' 0 N--CA 1.477 0.512 0 C-N-CA 122.152 1.901 . . . . 0.0 113.481 -173.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 133.41 150.28 6.29 Favored Glycine 0 N--CA 1.425 -2.036 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -178.049 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -111.89 125.89 54.52 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -178.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.6 t -89.5 125.59 60.98 Favored Pre-proline 0 C--N 1.3 -1.557 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 178.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -70.1 -10.42 28.25 Favored 'Trans proline' 0 C--O 1.221 -0.371 0 C-N-CA 122.833 2.355 . . . . 0.0 111.911 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -92.44 -2.55 56.21 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.398 0.618 . . . . 0.0 110.616 -178.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.509 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -178.71 -119.5 0.61 Allowed Glycine 0 N--CA 1.422 -2.294 0 C-N-CA 119.948 -1.12 . . . . 0.0 111.952 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.2 t -170.25 -162.55 0.3 Allowed 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.434 ' CB ' ' HA ' ' A' ' 112' ' ' TYR . 52.5 p90 -148.37 170.93 16.88 Favored 'General case' 0 C--N 1.311 -1.106 0 O-C-N 121.61 -0.681 . . . . 0.0 110.844 178.564 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -123.47 163.31 21.14 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 177.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.2 mt -121.99 129.42 52.46 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.41 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 32.6 p -122.84 124.63 43.71 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -176.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 92.99 30.18 9.68 Favored Glycine 0 C--N 1.298 -1.548 0 C-N-CA 120.325 -0.941 . . . . 0.0 111.185 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 167.25 -33.16 0.21 Allowed Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 119.464 -1.35 . . . . 0.0 113.417 176.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 65.46 14.79 9.68 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 123.577 0.751 . . . . 0.0 112.995 -177.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.519 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.4 m -151.7 -168.89 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.213 -0.85 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -177.43 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -106.52 38.14 2.14 Favored 'General case' 0 C--O 1.252 1.217 0 CA-C-N 118.737 0.699 . . . . 0.0 110.445 -175.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.673 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.1 pt-20 -78.49 178.74 7.52 Favored 'General case' 0 C--O 1.2 -1.521 0 CA-C-N 114.22 -1.354 . . . . 0.0 111.003 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . 0.678 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 23.7 m-85 -79.63 134.04 36.43 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-O 120.958 0.408 . . . . 0.0 111.276 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.49 4.55 60.74 Favored Glycine 0 N--CA 1.44 -1.056 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.638 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.673 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.5 p -99.44 145.11 11.06 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 C-N-CA 120.425 -0.51 . . . . 0.0 109.876 -179.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.41 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 58.7 mtpt -108.1 125.09 51.18 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.609 176.661 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.82 94.06 9.65 Favored 'General case' 0 C--N 1.289 -2.055 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.334 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.459 HG12 ' HB3' ' A' ' 126' ' ' TYR . 32.8 m -94.07 116.12 34.55 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.188 0 CA-C-O 122.599 1.19 . . . . 0.0 108.434 -178.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . 0.434 ' HA ' ' CB ' ' A' ' 96' ' ' PHE . 13.4 m-85 -78.74 141.75 37.6 Favored 'General case' 0 C--N 1.267 -2.985 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.667 -174.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.7 t -133.57 106.99 7.73 Favored 'General case' 0 N--CA 1.411 -2.386 0 CA-C-N 115.114 -0.948 . . . . 0.0 108.772 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 95.4 m -63.67 160.45 16.92 Favored 'General case' 0 C--N 1.296 -1.737 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.261 177.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.509 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 78.9 m-20 -74.35 -177.87 3.23 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.656 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -58.56 -45.29 89.3 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 123.58 0.752 . . . . 0.0 112.719 -174.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.36 24.13 6.63 Favored Glycine 0 C--O 1.212 -1.249 0 C-N-CA 120.747 -0.739 . . . . 0.0 113.302 179.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -147.82 169.93 18.71 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.99 -0.712 . . . . 0.0 109.952 -173.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -152.13 162.98 40.29 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -78.45 140.84 38.61 Favored 'General case' 0 C--N 1.288 -2.069 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.524 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.4 OUTLIER -119.24 126.52 51.71 Favored 'General case' 0 N--CA 1.409 -2.488 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.244 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.52 -170.24 14.27 Favored Glycine 0 C--N 1.289 -2.061 0 C-N-CA 120.69 -0.766 . . . . 0.0 111.607 -178.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -98.66 -38.81 8.97 Favored 'General case' 0 C--N 1.309 -1.195 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 -177.139 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.5 mm -78.62 120.48 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.716 0 CA-C-N 114.668 -1.151 . . . . 0.0 109.098 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -123.36 6.33 9.04 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.488 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 25.8 p90 -143.29 165.4 27.57 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -171.265 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 34.4 mtp180 -129.09 143.19 50.78 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 169.126 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -113.6 130.21 56.42 Favored 'General case' 0 C--N 1.287 -2.135 0 C-N-CA 119.426 -0.909 . . . . 0.0 109.895 -178.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . 0.678 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 37.8 t -80.35 90.39 5.58 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 176.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.482 ' OD2' HG22 ' A' ' 131' ' ' THR . 16.9 t70 -97.21 -170.62 2.05 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 179.017 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.482 HG22 ' OD2' ' A' ' 130' ' ' ASP . 15.1 t -59.03 -32.36 69.67 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 123.485 0.714 . . . . 0.0 112.875 -172.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -75.86 -34.09 60.03 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 121.488 0.661 . . . . 0.0 110.393 178.012 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.478 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 140.0 -153.91 23.57 Favored Glycine 0 N--CA 1.417 -2.602 0 N-CA-C 107.81 -2.116 . . . . 0.0 107.81 -174.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.619 ' NE1' ' HB3' ' A' ' 85' ' ' CYS . 98.3 m95 -65.86 116.61 7.21 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 117.655 0.728 . . . . 0.0 111.326 176.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 54.4 p -74.74 171.13 14.49 Favored 'General case' 0 C--O 1.269 2.119 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.036 176.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 87.0 m-20 59.05 -158.3 0.31 Allowed 'General case' 0 CA--C 1.515 -0.391 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -136.58 -179.48 5.71 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 172.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.9 mt -57.5 121.21 46.67 Favored Pre-proline 0 C--N 1.273 -2.721 0 C-N-CA 123.945 0.898 . . . . 0.0 108.595 175.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -63.49 169.68 9.35 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 122.663 2.242 . . . . 0.0 112.386 -179.231 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.524 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 52.8 mt -95.83 139.89 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.856 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -173.608 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 38.3 t -126.59 136.57 52.71 Favored 'General case' 0 C--N 1.276 -2.628 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -130.64 154.55 47.78 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -178.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 4.2 p -70.64 147.96 11.07 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.614 HG23 ' HB2' ' A' ' 170' ' ' PHE . 2.3 m -67.57 107.58 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.521 176.412 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -89.9 137.16 32.57 Favored 'General case' 0 N--CA 1.436 -1.168 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.72 -178.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.8 m -102.89 138.14 40.17 Favored 'General case' 0 C--N 1.282 -2.328 0 N-CA-C 106.111 -1.811 . . . . 0.0 106.111 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . 0.457 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.0 mm? -63.0 148.22 92.89 Favored Pre-proline 0 N--CA 1.433 -1.275 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -177.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 26.8 Cg_exo -61.2 121.84 10.25 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 122.911 2.408 . . . . 0.0 110.571 175.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.6 p -93.22 151.82 3.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.2 p -88.68 -177.16 5.49 Favored 'General case' 0 N--CA 1.431 -1.385 0 C-N-CA 120.9 -0.32 . . . . 0.0 110.291 175.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -108.79 158.94 32.77 Favored Pre-proline 0 C--N 1.294 -1.832 0 C-N-CA 122.415 0.286 . . . . 0.0 111.412 -171.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.78 157.39 61.43 Favored 'Trans proline' 0 C--N 1.362 1.247 0 C-N-CA 122.779 2.32 . . . . 0.0 111.292 175.252 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -59.02 -57.25 13.91 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 113.737 1.014 . . . . 0.0 113.737 -175.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 -102.5 36.56 2.13 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -178.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -150.91 -154.56 6.56 Favored Glycine 0 N--CA 1.413 -2.851 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.399 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . 0.671 ' HG3' HG23 ' A' ' 177' ' ' VAL . 17.5 ptmt -163.84 -177.55 5.18 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 123.658 0.783 . . . . 0.0 109.002 -178.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 55.2 mt -100.22 135.8 34.43 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.502 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.6 m -82.5 -33.71 11.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.539 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 7.2 m . . . . . 0 N--CA 1.425 -1.696 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.356 -173.771 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 . . . . . 0 N--CA 1.424 -1.738 0 CA-C-O 121.58 0.705 . . . . 0.0 109.269 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 30.5 m170 -114.36 160.1 19.5 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.614 ' HB2' HG23 ' A' ' 144' ' ' VAL . 0.6 OUTLIER -53.99 120.85 6.93 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 174.141 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 122.17 -23.92 7.13 Favored Glycine 0 N--CA 1.428 -1.86 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -177.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 15.6 mm100 -70.53 145.32 50.92 Favored 'General case' 0 C--O 1.256 1.423 0 CA-C-O 121.656 0.741 . . . . 0.0 110.783 178.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -116.01 112.59 22.02 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 173.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 8.4 p -95.64 112.91 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.316 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.502 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 79.5 ttt180 -110.61 143.68 40.67 Favored 'General case' 0 C--N 1.28 -2.417 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.005 -175.229 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -114.18 159.65 19.87 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.053 -174.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.671 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.0 OUTLIER -129.8 154.06 39.75 Favored 'Isoleucine or valine' 0 CA--C 1.469 -2.148 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.746 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 82.7 m -115.22 140.07 49.4 Favored 'General case' 0 N--CA 1.395 -3.19 0 CA-C-N 114.158 -1.383 . . . . 0.0 108.787 174.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -67.97 161.64 26.12 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.286 177.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 17.3 t -55.12 117.39 3.44 Favored 'General case' 0 C--N 1.311 -1.09 0 O-C-N 124.167 0.917 . . . . 0.0 111.287 -173.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 113.41 -20.98 17.93 Favored Glycine 0 N--CA 1.429 -1.802 0 CA-C-N 115.066 -0.97 . . . . 0.0 111.743 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . 0.438 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 96.8 m-85 -104.2 157.36 17.18 Favored 'General case' 0 N--CA 1.432 -1.358 0 O-C-N 122.397 -0.472 . . . . 0.0 111.572 -177.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -124.17 154.35 40.21 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.9 tp -69.25 148.59 11.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 176.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -55.91 -59.77 4.42 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 123.842 0.857 . . . . 0.0 110.758 177.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -134.16 -83.6 0.2 Allowed Glycine 0 N--CA 1.437 -1.283 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.238 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . 0.455 ' OD2' ' HD2' ' A' ' 200' ' ' LYS . 74.2 m-20 -102.56 134.94 45.09 Favored 'General case' 0 CA--C 1.499 -0.985 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -85.33 -1.76 57.33 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.536 -178.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . 0.526 ' O ' ' HG3' ' A' ' 200' ' ' LYS . 0.0 OUTLIER -134.42 143.08 47.36 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-O 121.253 0.549 . . . . 0.0 111.157 -175.878 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.457 ' HG3' ' H ' ' A' ' 200' ' ' LYS . 31.8 ttm -126.14 115.26 19.52 Favored 'General case' 0 N--CA 1.416 -2.167 0 C-N-CA 125.039 1.335 . . . . 0.0 108.07 178.232 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 8.1 m80 -94.62 154.9 17.13 Favored 'General case' 0 C--N 1.267 -3.013 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.045 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 45.0 t -98.76 142.42 30.33 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 13.7 p -119.52 -174.51 2.75 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -173.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -56.56 -22.21 31.86 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 125.317 1.447 . . . . 0.0 111.806 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -64.57 -21.01 66.58 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.338 -178.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 81.67 14.87 77.07 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -174.049 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -141.04 177.83 7.79 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.428 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -81.16 147.06 30.21 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.14 -176.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 26.6 m -82.3 -29.62 31.0 Favored 'General case' 0 N--CA 1.422 -1.831 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.117 177.129 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.526 ' HG3' ' O ' ' A' ' 189' ' ' GLU . 6.4 mmpt? -98.47 166.12 11.51 Favored 'General case' 0 N--CA 1.441 -0.881 0 C-N-CA 117.974 -1.491 . . . . 0.0 112.913 177.037 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -96.74 163.84 12.83 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 104.365 -2.457 . . . . 0.0 104.365 171.121 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . 0.458 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 4.9 mtpm? -66.69 125.59 90.89 Favored Pre-proline 0 C--N 1.304 -1.388 0 C-N-CA 119.862 -0.735 . . . . 0.0 112.406 178.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . 0.458 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 7.3 Cg_endo -89.46 -174.08 0.86 Allowed 'Trans proline' 0 N--CA 1.42 -2.838 0 C-N-CA 121.746 1.631 . . . . 0.0 109.767 171.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 20.5 pttm -149.67 175.94 11.11 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.438 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 73.6 m -113.26 113.9 25.96 Favored 'General case' 0 C--N 1.283 -2.287 0 O-C-N 123.683 0.615 . . . . 0.0 109.524 -178.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.5 m . . . . . 0 N--CA 1.422 -1.832 0 CA-C-N 113.765 -1.561 . . . . 0.0 109.005 -174.104 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo . . . . . 0 CA--C 1.533 0.47 0 CA-C-O 121.444 0.518 . . . . 0.0 111.728 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 33.9 m -79.37 -33.31 43.0 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.21 -92.72 0.55 Allowed Glycine 1 N--CA 1.394 -4.159 0 CA-C-N 114.104 -1.407 . . . . 0.0 109.717 172.748 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -174.8 133.54 0.5 Allowed Pre-proline 0 C--N 1.255 -3.543 0 N-CA-C 103.85 -2.648 . . . . 0.0 103.85 -175.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.476 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 86.9 Cg_endo -80.61 3.0 8.09 Favored 'Trans proline' 0 C--N 1.328 -0.502 0 C-N-CA 122.643 2.228 . . . . 0.0 113.899 -173.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.3 -166.08 17.26 Favored Glycine 0 C--N 1.287 -2.163 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 -175.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -145.1 151.25 38.2 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -177.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 t -120.98 130.33 24.9 Favored Pre-proline 0 N--CA 1.429 -1.503 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -78.83 -7.59 15.55 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.59 2.194 . . . . 0.0 111.908 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -96.64 19.0 13.05 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.482 -179.168 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 155.97 -119.07 0.89 Allowed Glycine 0 N--CA 1.42 -2.378 0 C-N-CA 119.941 -1.124 . . . . 0.0 111.995 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.7 t -168.6 -169.85 1.12 Allowed 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -176.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.408 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 45.4 p90 -143.48 163.28 33.56 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 177.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.1 m -124.61 162.83 23.27 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 106.349 -1.723 . . . . 0.0 106.349 178.299 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 15.4 mt -123.37 125.2 44.55 Favored 'General case' 0 C--N 1.279 -2.493 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.424 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 44.1 p -119.68 134.09 55.37 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 -176.184 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.31 25.72 42.62 Favored Glycine 0 C--N 1.312 -0.775 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.19 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 172.87 -35.71 0.13 Allowed Glycine 0 CA--C 1.486 -1.768 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 61.18 18.97 9.61 Favored 'General case' 0 CA--C 1.521 -0.144 0 C-N-CA 124.394 1.077 . . . . 0.0 112.2 178.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.54 ' O ' HG11 ' A' ' 108' ' ' VAL . 31.1 m -154.12 -167.3 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.208 -1.103 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 -178.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 21.3 m-85 -105.42 42.71 1.2 Allowed 'General case' 0 C--N 1.311 -1.109 0 CA-C-N 119.392 0.996 . . . . 0.0 110.139 -176.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.704 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.1 pt-20 -86.23 179.14 6.97 Favored 'General case' 0 C--O 1.205 -1.251 0 CA-C-N 114.564 -1.198 . . . . 0.0 111.733 178.166 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.1 m-85 -74.9 136.18 41.47 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 122.017 -0.427 . . . . 0.0 111.391 177.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.09 6.93 70.9 Favored Glycine 0 C--N 1.31 -0.88 0 CA-C-N 115.914 -0.585 . . . . 0.0 113.034 177.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.704 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.8 p -97.9 145.64 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.062 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.424 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 59.4 mtpt -110.25 122.84 48.61 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 177.641 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.475 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -85.5 85.37 7.43 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.489 HG12 ' HB3' ' A' ' 126' ' ' TYR . 31.8 m -83.39 107.0 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.027 0 CA-C-O 122.812 1.291 . . . . 0.0 109.558 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . 0.408 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 31.8 m-85 -73.17 134.84 44.54 Favored 'General case' 0 C--N 1.276 -2.606 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.964 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.6 t -129.81 114.55 16.07 Favored 'General case' 0 N--CA 1.408 -2.529 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 87.2 m -66.66 161.68 22.81 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 115.596 -0.729 . . . . 0.0 112.518 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 5.0 t-20 -68.85 -173.54 0.49 Allowed 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.136 -177.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -58.38 -52.17 66.73 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 123.109 0.564 . . . . 0.0 111.902 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.04 12.56 63.81 Favored Glycine 0 N--CA 1.437 -1.297 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.99 -177.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.512 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.6 m-85 -129.44 159.09 37.33 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 117.157 0.478 . . . . 0.0 110.72 -177.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.79 152.84 45.52 Favored 'General case' 0 C--N 1.288 -2.102 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.479 ' HG ' ' HB2' ' A' ' 125' ' ' ASN . 0.5 OUTLIER -78.29 126.36 30.68 Favored 'General case' 0 C--N 1.281 -2.401 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 179.17 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.434 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.3 OUTLIER -108.01 130.61 55.05 Favored 'General case' 0 N--CA 1.418 -2.044 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -178.791 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 114.69 -169.41 12.86 Favored Glycine 0 C--N 1.292 -1.91 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -103.82 -31.77 9.64 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-O 121.52 0.676 . . . . 0.0 109.763 -179.108 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.428 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.9 mm -89.16 120.59 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.562 -178.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.479 ' HB2' ' HG ' ' A' ' 120' ' ' LEU . 3.7 p-10 -125.6 9.59 7.75 Favored 'General case' 0 C--O 1.203 -1.368 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.489 ' HB3' HG12 ' A' ' 111' ' ' VAL . 22.4 p90 -140.67 168.39 19.91 Favored 'General case' 0 C--N 1.282 -2.347 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -170.359 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.488 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 48.7 mtp180 -132.5 117.9 18.59 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 169.34 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -91.89 128.33 37.69 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 118.881 -1.128 . . . . 0.0 109.969 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 47.8 t -84.62 109.74 18.21 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.183 -1.007 . . . . 0.0 109.652 175.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.429 ' OD2' HG22 ' A' ' 131' ' ' THR . 9.9 t70 -111.71 -164.35 0.91 Allowed 'General case' 0 C--N 1.287 -2.126 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.429 HG22 ' OD2' ' A' ' 130' ' ' ASP . 12.0 t -63.4 -21.35 66.24 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -174.567 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -82.32 -22.77 35.46 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-O 121.87 0.843 . . . . 0.0 109.551 177.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 118.55 -145.25 18.28 Favored Glycine 0 N--CA 1.419 -2.44 0 N-CA-C 107.227 -2.349 . . . . 0.0 107.227 -171.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -69.92 111.42 5.63 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 108.984 -0.746 . . . . 0.0 108.984 177.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 37.8 p -66.65 -57.23 7.62 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-O 121.394 0.616 . . . . 0.0 111.499 -177.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . 0.488 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 4.9 m120 -75.94 169.96 17.17 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.733 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 22.0 m-20 -106.51 -178.2 3.58 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.8 mt -64.89 123.71 84.46 Favored Pre-proline 0 C--N 1.318 -0.791 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 177.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.428 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 35.5 Cg_endo -67.97 174.06 8.38 Favored 'Trans proline' 0 C--O 1.242 0.7 0 C-N-CA 122.867 2.378 . . . . 0.0 112.971 -179.103 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.434 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 63.1 mt -96.13 139.08 19.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 -176.475 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.512 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 33.9 t -128.21 125.21 38.53 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 13.7 tp10 -120.02 155.57 32.62 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -174.352 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 8.6 p -75.41 134.51 29.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.178 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.433 ' O ' ' HB2' ' A' ' 169' ' ' HIS . 83.0 t -60.21 123.91 13.6 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.711 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.171 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 51.2 mttm -106.12 158.39 16.85 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 120.944 0.402 . . . . 0.0 110.457 -175.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 60.6 m -117.46 161.6 19.32 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 2.2 pp -72.47 155.38 91.24 Favored Pre-proline 0 C--N 1.307 -1.259 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -78.23 126.02 7.47 Favored 'Trans proline' 0 N--CA 1.439 -1.683 0 C-N-CA 122.294 1.996 . . . . 0.0 113.152 -175.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.494 HG12 ' O ' ' A' ' 150' ' ' THR . 54.3 t -69.46 135.67 27.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-N 114.041 -1.436 . . . . 0.0 110.349 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . 0.494 ' O ' HG12 ' A' ' 149' ' ' VAL . 11.5 p -93.7 170.85 9.27 Favored 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 171.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -93.46 156.75 39.54 Favored Pre-proline 0 C--N 1.267 -2.995 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -174.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -74.35 152.96 44.88 Favored 'Trans proline' 0 N--CA 1.428 -2.371 0 C-N-CA 120.761 0.974 . . . . 0.0 110.905 172.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -54.66 -44.34 73.17 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 114.72 1.378 . . . . 0.0 114.72 -172.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.8 m-80 -122.71 31.41 6.08 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 122.154 0.978 . . . . 0.0 108.746 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -139.57 -161.79 8.86 Favored Glycine 0 N--CA 1.428 -1.888 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 40.6 pttt -157.64 163.14 38.55 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 -178.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 49.3 mt -89.36 132.33 34.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-O 121.005 0.431 . . . . 0.0 110.029 -177.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.7 t -74.85 -48.22 34.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-O 122.182 0.991 . . . . 0.0 108.393 177.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . 0.493 ' CB ' ' HA ' ' A' ' 174' ' ' VAL . 6.3 m . . . . . 0 C--N 1.289 -2.039 0 CA-C-N 114.553 -1.203 . . . . 0.0 111.388 -175.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 . . . . . 0 N--CA 1.406 -2.647 0 N-CA-C 105.874 -1.899 . . . . 0.0 105.874 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 2.1 p-80 -145.46 168.72 19.87 Favored 'General case' 0 C--N 1.279 -2.47 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.675 -176.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -51.76 121.04 5.9 Favored 'General case' 0 C--O 1.242 0.695 0 O-C-N 124.31 1.006 . . . . 0.0 110.307 -176.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 123.49 -17.46 7.85 Favored Glycine 0 N--CA 1.427 -1.952 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.202 -175.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 25.3 mm-40 -78.67 135.34 37.17 Favored 'General case' 0 C--O 1.255 1.371 0 CA-C-O 121.716 0.77 . . . . 0.0 112.254 178.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -125.7 109.8 13.01 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 105.582 -2.007 . . . . 0.0 105.582 173.351 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.493 ' HA ' ' CB ' ' A' ' 159' ' ' SER . 53.6 t -107.4 122.61 61.85 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.687 -173.14 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.422 ' HG3' ' O ' ' A' ' 188' ' ' GLU . 24.0 ttp180 -111.66 161.51 16.17 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.322 177.163 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -130.73 162.47 29.39 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 124.397 1.079 . . . . 0.0 110.296 -174.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.79 143.9 35.1 Favored 'Isoleucine or valine' 0 CA--C 1.471 -2.093 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.45 176.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 76.7 m -105.68 131.52 52.95 Favored 'General case' 0 N--CA 1.395 -3.216 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 173.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -54.1 164.36 0.65 Allowed 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.309 177.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 26.7 t -33.71 -47.88 0.26 Allowed 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 116.771 2.137 . . . . 0.0 116.771 -168.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -104.28 15.36 50.63 Favored Glycine 0 C--N 1.288 -2.136 0 C-N-CA 120.056 -1.069 . . . . 0.0 115.025 -173.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -120.09 162.14 19.79 Favored 'General case' 0 CA--C 1.497 -1.065 0 CA-C-N 118.344 1.072 . . . . 0.0 112.424 -176.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.447 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 25.5 pttm -123.28 154.2 39.16 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.474 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 2.8 tp -72.47 145.09 12.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -82.16 -71.16 0.5 Allowed 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 120.962 -0.295 . . . . 0.0 110.481 179.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.0 -89.58 0.63 Allowed Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.948 -177.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -136.36 159.99 40.1 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 -177.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.422 ' O ' ' HG3' ' A' ' 175' ' ' ARG . 1.0 OUTLIER -103.37 3.26 34.99 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 118.999 -1.08 . . . . 0.0 112.707 -171.979 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . 0.578 ' O ' ' HG3' ' A' ' 200' ' ' LYS . 4.3 pt-20 -149.75 143.57 25.5 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 113.572 0.953 . . . . 0.0 113.572 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.459 ' HB3' ' HB2' ' A' ' 200' ' ' LYS . 12.8 ptp -133.37 144.14 49.4 Favored 'General case' 0 C--N 1.315 -0.898 0 C-N-CA 124.146 0.978 . . . . 0.0 111.275 -176.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 49.4 t-80 -125.69 141.05 52.21 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.506 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 13.2 m -65.32 129.55 40.13 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 177.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . 0.41 ' OG ' ' HB3' ' A' ' 199' ' ' SER . 14.5 m -104.45 167.26 9.86 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.931 177.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -48.18 -37.23 15.22 Favored 'General case' 0 N--CA 1.496 1.874 0 C-N-CA 125.529 1.532 . . . . 0.0 113.535 -176.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -68.74 -16.01 63.68 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -176.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 99.33 27.79 7.95 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.195 -1.002 . . . . 0.0 113.248 178.287 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -150.21 179.2 8.3 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 122.391 -0.476 . . . . 0.0 110.356 176.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -84.84 135.77 33.95 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 123.924 0.765 . . . . 0.0 110.881 -176.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . 0.41 ' HB3' ' OG ' ' A' ' 193' ' ' SER . 9.5 p -73.26 -24.24 60.42 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.682 0.753 . . . . 0.0 111.136 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.578 ' HG3' ' O ' ' A' ' 189' ' ' GLU . 28.2 mmtp -94.9 179.88 5.08 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 115.026 -0.988 . . . . 0.0 112.909 -177.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -100.75 148.87 24.41 Favored 'General case' 0 C--N 1.292 -1.925 0 CA-C-N 113.557 -1.656 . . . . 0.0 110.735 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . 0.61 ' HE2' ' HD2' ' A' ' 203' ' ' PRO . 0.1 OUTLIER -75.03 107.98 4.76 Favored Pre-proline 0 C--N 1.323 -0.563 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 175.123 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . 0.61 ' HD2' ' HE2' ' A' ' 202' ' ' LYS . 71.8 Cg_endo -88.81 174.25 4.0 Favored 'Trans proline' 0 N--CA 1.435 -1.915 0 C-N-CA 122.743 2.296 . . . . 0.0 114.898 -172.121 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -124.36 174.27 7.85 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -176.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 91.1 m -128.77 101.38 6.09 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 174.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 21.1 m . . . . . 0 C--N 1.294 -1.832 0 CA-C-N 114.226 -1.352 . . . . 0.0 108.679 -173.176 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo . . . . . 0 CA--C 1.542 0.908 0 CA-C-O 121.056 0.357 . . . . 0.0 112.008 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 61.7 m -82.67 -29.92 29.64 Favored 'General case' 0 CA--C 1.507 -0.675 0 CA-C-O 122.418 1.104 . . . . 0.0 108.228 177.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 113.2 -91.45 0.58 Allowed Glycine 0 N--CA 1.4 -3.737 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 173.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.8 t60 -175.1 135.26 0.51 Allowed Pre-proline 0 C--N 1.257 -3.453 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 -176.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.574 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 94.0 Cg_endo -80.9 2.04 8.86 Favored 'Trans proline' 0 C--N 1.324 -0.754 0 C-N-CA 122.364 2.043 . . . . 0.0 113.156 -175.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 94.42 176.07 38.81 Favored Glycine 0 C--N 1.287 -2.14 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -173.093 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -144.46 159.28 43.01 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 117.444 0.622 . . . . 0.0 109.453 -176.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.7 t -120.18 131.3 24.47 Favored Pre-proline 0 C--N 1.298 -1.645 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.25 -177.256 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -71.7 -19.12 28.1 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.337 2.025 . . . . 0.0 110.561 176.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -86.58 16.0 5.06 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.755 -1.112 . . . . 0.0 110.481 -174.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 164.78 -131.94 2.55 Favored Glycine 1 N--CA 1.396 -4.001 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.591 178.339 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.3 p -154.77 175.52 13.61 Favored 'General case' 0 C--N 1.288 -2.104 0 C-N-CA 124.182 0.993 . . . . 0.0 109.896 -173.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -144.95 154.07 42.2 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 171.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.8 m -126.13 162.14 26.04 Favored 'General case' 0 C--N 1.275 -2.648 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 17.6 mt -112.47 135.95 52.56 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 18.8 p -129.03 126.93 40.54 Favored 'General case' 0 C--N 1.281 -2.386 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.893 -178.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.47 29.23 14.55 Favored Glycine 0 C--N 1.302 -1.319 0 C-N-CA 120.407 -0.902 . . . . 0.0 111.978 179.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 172.12 -36.58 0.15 Allowed Glycine 0 N--CA 1.431 -1.699 0 C-N-CA 119.964 -1.112 . . . . 0.0 112.7 178.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 70.73 1.94 3.93 Favored 'General case' 0 N--CA 1.511 2.582 0 CA-C-O 122.206 1.003 . . . . 0.0 110.728 -178.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.46 ' O ' HG11 ' A' ' 108' ' ' VAL . 34.3 m -143.94 -171.24 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -173.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -105.45 45.41 0.97 Allowed 'General case' 0 C--N 1.304 -1.401 0 CA-C-O 121.269 0.557 . . . . 0.0 110.216 -176.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.693 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.7 pt-20 -83.01 177.65 8.52 Favored 'General case' 0 C--O 1.213 -0.857 0 CA-C-N 114.585 -1.189 . . . . 0.0 111.607 177.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 43.6 m-85 -77.42 130.92 37.68 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-O 120.941 0.401 . . . . 0.0 110.801 176.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.87 2.37 58.39 Favored Glycine 0 N--CA 1.437 -1.238 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.555 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.693 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.7 p -94.77 145.89 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.285 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 19.7 mtpp -111.94 120.77 43.03 Favored 'General case' 0 C--N 1.286 -2.157 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -86.86 92.8 9.11 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 77.2 t -86.39 118.41 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.611 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -178.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -85.99 145.58 27.04 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.289 -178.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.9 t -144.34 110.66 5.52 Favored 'General case' 0 N--CA 1.407 -2.61 0 CA-C-O 122.208 1.004 . . . . 0.0 108.446 -179.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 41.7 m -71.22 158.81 35.75 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.813 -173.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.513 ' HB3' ' HD2' ' A' ' 118' ' ' TYR . 4.2 t-20 -60.24 171.9 0.94 Allowed 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 125.128 1.371 . . . . 0.0 111.33 -177.416 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -59.44 -41.87 90.6 Favored 'General case' 0 C--N 1.297 -1.685 0 C-N-CA 124.568 1.147 . . . . 0.0 110.017 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.433 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -86.63 19.82 26.66 Favored Glycine 0 CA--C 1.529 0.932 0 CA-C-N 115.368 -0.833 . . . . 0.0 113.739 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.583 ' HE1' HG22 ' A' ' 143' ' ' VAL . 97.9 m-85 -147.11 173.85 12.11 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.414 HE21 ' HB2' ' A' ' 119' ' ' GLN . 0.0 OUTLIER -143.68 165.44 27.64 Favored 'General case' 0 C--N 1.281 -2.403 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.601 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.3 tt -94.51 137.88 33.1 Favored 'General case' 0 C--N 1.28 -2.447 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -178.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -124.74 135.15 52.75 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 -177.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.66 159.5 15.39 Favored Glycine 0 N--CA 1.438 -1.191 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -78.99 -27.33 43.32 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.719 0.771 . . . . 0.0 109.085 -177.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.426 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 47.2 mm -89.76 132.78 33.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 114.814 -1.085 . . . . 0.0 108.311 -177.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -133.07 12.94 4.28 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -177.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . . . . . . . . . 2.8 p90 -152.65 169.21 23.26 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 -173.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.574 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 54.1 mtp180 -131.84 120.1 22.13 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 169.115 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -94.53 138.35 32.53 Favored 'General case' 0 C--N 1.287 -2.128 0 C-N-CA 118.893 -1.123 . . . . 0.0 110.565 177.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.0 t -89.69 104.35 16.92 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 118.881 -1.128 . . . . 0.0 109.61 174.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.444 ' OD2' HG22 ' A' ' 131' ' ' THR . 12.1 t70 -97.08 -172.22 2.39 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 176.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.444 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -67.25 -11.44 57.47 Favored 'General case' 0 C--N 1.293 -1.855 0 C-N-CA 123.259 0.623 . . . . 0.0 112.274 -174.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -94.6 -12.5 27.35 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.82 0.819 . . . . 0.0 109.412 176.558 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.15 -159.25 13.86 Favored Glycine 0 N--CA 1.431 -1.685 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -175.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.0 m95 -63.65 105.23 0.76 Allowed 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 120.894 0.378 . . . . 0.0 111.259 178.088 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 24.9 p -61.32 -64.89 0.8 Allowed 'General case' 0 C--O 1.241 0.652 0 C-N-CA 124.955 1.302 . . . . 0.0 112.87 -175.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . 0.486 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.3 m120 -71.18 173.42 7.7 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.211 -177.099 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -106.55 176.43 5.17 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 175.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 77.5 mt -69.2 125.98 92.38 Favored Pre-proline 0 C--N 1.311 -1.085 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.426 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 55.0 Cg_endo -70.68 168.69 22.04 Favored 'Trans proline' 0 C--O 1.249 1.073 0 C-N-CA 122.719 2.279 . . . . 0.0 111.145 177.092 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.6 mm -97.93 129.53 47.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 120.436 -0.506 . . . . 0.0 111.245 -173.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 99.5 m -101.93 103.34 13.98 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 171.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -95.09 152.39 18.38 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 -179.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.583 HG22 ' HE1' ' A' ' 118' ' ' TYR . 3.2 t -76.69 145.51 10.2 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.514 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 -175.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 170' ' ' PHE . 5.9 m -73.71 108.39 5.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 174.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -104.75 127.2 52.45 Favored 'General case' 0 N--CA 1.412 -2.352 0 CA-C-N 114.45 -1.25 . . . . 0.0 111.095 -174.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.56 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 3.4 m -85.44 148.5 25.96 Favored 'General case' 0 C--N 1.282 -2.356 0 CA-C-N 113.738 -1.574 . . . . 0.0 110.078 -173.444 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 59.4 mt -56.36 132.46 76.19 Favored Pre-proline 0 C--N 1.319 -0.75 0 N-CA-C 112.677 0.621 . . . . 0.0 112.677 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_endo -62.49 111.4 1.3 Allowed 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 123.499 2.799 . . . . 0.0 112.391 -178.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.3 t -79.05 139.16 18.81 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.5 p -79.02 -75.9 0.22 Allowed 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 123.868 0.73 . . . . 0.0 111.51 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 166.42 159.62 0.11 Allowed Pre-proline 0 C--O 1.24 0.59 0 C-N-CA 126.248 1.819 . . . . 0.0 107.054 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -73.73 171.81 17.07 Favored 'Trans proline' 0 CA--C 1.535 0.569 0 C-N-CA 121.519 1.479 . . . . 0.0 109.572 169.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -69.67 -62.57 1.33 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -177.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.5 m-80 -95.82 38.43 1.17 Allowed 'General case' 0 C--N 1.313 -1.01 0 O-C-N 121.562 -0.711 . . . . 0.0 110.488 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -155.1 -168.57 18.5 Favored Glycine 0 N--CA 1.426 -1.973 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.964 178.189 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -153.0 174.79 13.71 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 -178.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.408 HG12 ' CD1' ' A' ' 176' ' ' PHE . 52.5 mt -91.58 139.62 17.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -178.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.456 HG21 ' HB3' ' A' ' 175' ' ' ARG . 4.7 m -77.46 -37.17 24.55 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.576 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 178.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 28.6 t . . . . . 0 N--CA 1.435 -1.199 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -178.88 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 . . . . . 0 N--CA 1.434 -1.228 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 55.2 m80 -121.61 155.81 34.3 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 -175.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.515 ' HB2' HG23 ' A' ' 144' ' ' VAL . 81.7 t80 -49.68 121.09 4.78 Favored 'General case' 0 C--O 1.244 0.798 0 O-C-N 123.686 0.616 . . . . 0.0 110.56 175.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 132.28 -29.65 3.29 Favored Glycine 0 N--CA 1.42 -2.41 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 -177.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.8 mm-40 -63.24 128.85 37.73 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 179.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -118.06 82.66 1.87 Allowed 'General case' 0 N--CA 1.423 -1.813 0 N-CA-C 104.32 -2.474 . . . . 0.0 104.32 170.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.469 HG13 ' HG3' ' A' ' 190' ' ' MET . 14.9 p -77.63 111.56 14.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.004 -169.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.456 ' HB3' HG21 ' A' ' 158' ' ' VAL . 40.1 ttm180 -97.74 148.29 23.5 Favored 'General case' 0 N--CA 1.416 -2.159 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.716 -177.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.473 ' HZ ' ' SD ' ' A' ' 190' ' ' MET . 51.2 m-85 -115.46 150.98 35.61 Favored 'General case' 0 N--CA 1.42 -1.967 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 -179.38 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.413 ' HB ' HG12 ' A' ' 158' ' ' VAL . 13.7 p -126.49 141.05 47.08 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.749 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 178.273 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.4 m -99.64 163.59 12.43 Favored 'General case' 0 C--N 1.262 -3.207 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.001 -178.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -66.52 172.63 3.95 Favored 'General case' 0 CA--C 1.497 -1.066 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.204 179.227 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 21.8 m -42.99 -31.95 0.59 Allowed 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 116.335 1.976 . . . . 0.0 116.335 -172.033 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -126.42 24.02 5.64 Favored Glycine 0 C--N 1.289 -2.069 0 C-N-CA 119.376 -1.393 . . . . 0.0 113.377 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -118.42 151.94 36.83 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.815 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 50.9 pttt -115.27 157.03 24.33 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 -179.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.577 HD13 ' HA ' ' A' ' 188' ' ' GLU . 5.0 tt -86.1 143.59 11.17 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.506 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.224 175.403 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -77.56 -68.16 0.65 Allowed 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -173.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -80.63 -109.61 0.3 Allowed Glycine 0 C--O 1.245 0.798 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.976 -177.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -95.93 175.8 6.36 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 176.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.577 ' HA ' HD13 ' A' ' 184' ' ' ILE . 10.3 pt-20 -104.28 -19.09 14.22 Favored 'General case' 0 C--N 1.28 -2.435 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -177.316 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . 0.451 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 5.3 pt-20 -141.45 150.21 41.98 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.053 -176.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.473 ' SD ' ' HZ ' ' A' ' 176' ' ' PHE . 0.1 OUTLIER -117.39 125.72 51.46 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.174 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -97.26 132.7 42.76 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 176.137 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . 0.469 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 48.7 t -80.39 136.8 36.44 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.114 179.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . 0.446 ' HB2' ' OD1' ' A' ' 195' ' ' ASP . 11.1 m -98.99 173.54 6.79 Favored 'General case' 0 N--CA 1.423 -1.792 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.643 179.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -67.41 -8.85 36.23 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 124.157 0.983 . . . . 0.0 112.47 -176.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . 0.446 ' OD1' ' HB2' ' A' ' 193' ' ' SER . 11.8 p-10 -94.25 4.99 53.13 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 122.223 -0.298 . . . . 0.0 111.406 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . 0.56 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 79.49 11.63 84.64 Favored Glycine 0 CA--C 1.526 0.73 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.486 178.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -117.92 150.76 38.68 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 122.345 -0.503 . . . . 0.0 110.3 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . 0.469 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 82.3 m95 -78.9 135.59 37.03 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.037 177.671 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 26.4 t -74.43 -16.91 60.86 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-O 121.19 0.519 . . . . 0.0 110.547 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.413 ' HB2' ' HA ' ' A' ' 190' ' ' MET . 24.5 mmtp -108.82 158.14 17.93 Favored 'General case' 0 CA--C 1.5 -0.978 0 O-C-N 122.123 -0.361 . . . . 0.0 110.551 178.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -97.58 170.44 9.02 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 123.477 0.486 . . . . 0.0 110.66 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 7.6 mmmm -69.06 115.8 35.43 Favored Pre-proline 0 CA--C 1.516 -0.354 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -178.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . 0.451 ' HG2' HD11 ' A' ' 184' ' ' ILE . 78.0 Cg_endo -88.15 168.28 6.52 Favored 'Trans proline' 0 N--CA 1.446 -1.313 0 C-N-CA 122.862 2.375 . . . . 0.0 112.159 -179.355 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -115.73 165.93 12.51 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 86.6 m -114.71 109.83 18.81 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 172.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 30.8 m . . . . . 0 C--O 1.254 1.302 0 O-C-N 124.332 1.02 . . . . 0.0 109.444 -173.858 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo . . . . . 0 CA--C 1.535 0.543 0 CA-C-O 121.74 0.642 . . . . 0.0 110.866 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.0 m -86.65 -35.6 19.26 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 117.46 -88.53 0.46 Allowed Glycine 0 N--CA 1.404 -3.49 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 174.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.5 t-80 -176.67 135.9 0.42 Allowed Pre-proline 0 C--N 1.255 -3.509 0 N-CA-C 104.458 -2.423 . . . . 0.0 104.458 -175.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.436 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 91.7 Cg_endo -82.15 -0.29 10.18 Favored 'Trans proline' 0 C--N 1.329 -0.494 0 C-N-CA 121.993 1.795 . . . . 0.0 112.791 -176.197 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.33 -155.82 15.9 Favored Glycine 0 N--CA 1.42 -2.387 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -177.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -156.02 157.41 36.1 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 178.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.5 t -122.91 127.51 25.69 Favored Pre-proline 0 C--N 1.293 -1.875 0 CA-C-N 118.226 0.467 . . . . 0.0 110.822 -177.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -65.47 -16.01 52.16 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.772 2.315 . . . . 0.0 111.64 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -86.7 -9.37 56.11 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.335 -178.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 173.14 -125.29 1.13 Allowed Glycine 0 N--CA 1.433 -1.549 0 C-N-CA 118.755 -1.688 . . . . 0.0 113.907 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.8 t -148.88 -169.76 3.45 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -176.046 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -151.81 162.4 41.09 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 177.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -126.02 162.51 25.11 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.4 mt -113.93 138.74 49.92 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.411 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 26.5 p -132.68 137.64 47.02 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -178.123 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.2 24.25 52.32 Favored Glycine 0 C--N 1.309 -0.921 0 N-CA-C 108.556 -1.818 . . . . 0.0 108.556 -173.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 145.6 154.3 6.12 Favored Glycine 1 N--CA 1.39 -4.398 0 N-CA-C 107.334 -2.306 . . . . 0.0 107.334 -177.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -108.6 29.07 7.75 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 177.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.418 ' O ' HG21 ' A' ' 108' ' ' VAL . 35.6 m -144.31 -175.17 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 CA-C-N 114.686 -1.143 . . . . 0.0 109.068 -173.418 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -108.4 47.13 0.92 Allowed 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 121.464 0.649 . . . . 0.0 109.543 -177.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.689 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.2 pt-20 -82.41 178.13 8.39 Favored 'General case' 0 C--O 1.213 -0.828 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.248 178.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -76.44 132.77 39.83 Favored 'General case' 0 C--N 1.289 -2.05 0 O-C-N 122.059 -0.401 . . . . 0.0 110.149 175.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.35 5.06 63.86 Favored Glycine 0 N--CA 1.431 -1.644 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.633 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.689 HG12 ' O ' ' A' ' 105' ' ' GLU . 10.4 p -96.69 144.4 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.411 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 20.5 mtpp -112.38 118.08 34.22 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -179.407 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -82.83 92.1 7.2 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 177.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.41 HG13 ' ND2' ' A' ' 125' ' ' ASN . 75.9 t -82.73 111.68 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.618 0 C-N-CA 123.942 0.897 . . . . 0.0 109.44 -178.632 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -80.6 144.12 32.62 Favored 'General case' 0 C--N 1.293 -1.858 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.672 -179.225 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.1 t -145.87 112.43 5.9 Favored 'General case' 0 N--CA 1.418 -2.041 0 CA-C-N 115.048 -0.978 . . . . 0.0 108.677 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 83.0 m -70.46 163.24 27.19 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.127 -178.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 -68.38 174.36 4.12 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.514 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -59.96 -39.09 84.43 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 112.781 0.659 . . . . 0.0 112.781 -174.238 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -85.61 9.96 66.28 Favored Glycine 0 C--N 1.3 -1.43 0 C-N-CA 121.275 -0.488 . . . . 0.0 113.668 179.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -131.44 163.12 28.63 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.16 134.86 22.27 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 9.5 tt -70.3 138.46 51.53 Favored 'General case' 0 C--N 1.293 -1.873 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.621 -177.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.45 140.75 49.02 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.018 -172.322 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 108.37 -172.81 17.28 Favored Glycine 0 C--N 1.303 -1.252 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.272 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 30.0 mm-40 -99.68 -19.63 16.7 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 117.084 0.442 . . . . 0.0 111.18 -177.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.9 mm -98.59 135.99 31.32 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -178.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.41 ' ND2' HG13 ' A' ' 111' ' ' VAL . 2.6 p-10 -130.52 13.3 5.47 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.355 178.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 11.4 p90 -145.34 169.96 17.25 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -174.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.496 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 46.6 mtp180 -131.01 120.83 24.04 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 169.33 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -95.04 136.61 35.15 Favored 'General case' 0 C--N 1.28 -2.418 0 C-N-CA 119.228 -0.989 . . . . 0.0 110.223 178.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 27.1 t -92.61 109.19 20.6 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.923 -1.111 . . . . 0.0 109.473 173.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -110.3 -167.52 1.2 Allowed 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 105.004 -2.221 . . . . 0.0 105.004 175.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 14.8 t -67.03 -13.8 62.27 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 119.056 0.844 . . . . 0.0 111.409 -177.394 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -79.21 -15.68 57.67 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 121.745 0.784 . . . . 0.0 109.646 174.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 104.19 -154.62 17.64 Favored Glycine 0 N--CA 1.431 -1.69 0 N-CA-C 107.181 -2.368 . . . . 0.0 107.181 -173.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.9 m95 -64.36 106.72 1.17 Allowed 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 118.12 0.96 . . . . 0.0 108.535 172.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.0 p -63.52 -66.01 0.6 Allowed 'General case' 0 C--O 1.253 1.269 0 C-N-CA 124.001 0.92 . . . . 0.0 111.647 -174.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . 0.496 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.6 m120 -67.09 167.88 11.16 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-N 114.84 -1.073 . . . . 0.0 109.036 -179.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -100.7 -178.97 3.94 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 176.37 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 82.1 mt -72.13 120.69 81.73 Favored Pre-proline 0 C--N 1.313 -1.0 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 175.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.29 137.81 53.1 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 122.062 1.842 . . . . 0.0 110.911 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 69.7 mt -63.88 141.55 18.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.989 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 46.2 t -131.39 140.61 49.7 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -123.72 157.33 34.19 Favored 'General case' 0 N--CA 1.408 -2.551 0 CA-C-O 121.102 0.477 . . . . 0.0 110.324 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 5.7 p -75.1 137.9 22.06 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 97.5 t -58.55 117.52 1.82 Allowed 'Isoleucine or valine' 0 C--O 1.251 1.154 0 O-C-N 123.566 0.541 . . . . 0.0 110.18 -178.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 53.9 mttp -93.09 142.44 27.29 Favored 'General case' 0 N--CA 1.425 -1.704 0 CA-C-N 115.254 -0.885 . . . . 0.0 108.78 179.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.0 m -109.25 151.35 26.66 Favored 'General case' 0 C--N 1.278 -2.532 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -179.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 64.9 mt -56.17 137.45 74.22 Favored Pre-proline 0 C--N 1.319 -0.722 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.424 ' HA ' ' CD2' ' A' ' 168' ' ' TYR . 34.8 Cg_endo -66.71 94.87 0.33 Allowed 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 123.317 2.678 . . . . 0.0 111.6 179.202 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 9.5 p -69.41 142.78 15.61 Favored 'Isoleucine or valine' 0 C--O 1.25 1.119 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.01 -177.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 11.6 p -97.59 -166.25 1.36 Allowed 'General case' 0 N--CA 1.42 -1.961 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.882 177.45 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -119.61 156.35 53.64 Favored Pre-proline 0 C--N 1.297 -1.716 0 O-C-N 122.119 -0.363 . . . . 0.0 110.714 -171.04 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.4 175.36 6.03 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 122.224 1.949 . . . . 0.0 111.446 174.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . 0.498 ' CD ' ' H ' ' A' ' 153' ' ' GLU . 0.0 OUTLIER -82.72 -43.57 16.66 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 120.999 0.428 . . . . 0.0 111.068 -174.801 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . 0.452 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 55.9 m-80 -98.86 18.86 16.07 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.348 0.594 . . . . 0.0 110.488 -179.676 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -147.31 -166.34 12.41 Favored Glycine 0 N--CA 1.424 -2.118 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.664 -178.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 62.5 pttt -154.68 -179.42 7.98 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -177.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 50.0 mt -100.95 132.07 47.4 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.207 0 CA-C-N 117.745 0.248 . . . . 0.0 110.859 -177.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.573 HG12 HG22 ' A' ' 177' ' ' VAL . 2.3 m -78.02 -29.19 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 15.4 m . . . . . 0 C--N 1.311 -1.101 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.954 -177.063 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . 0.424 ' CD2' ' HA ' ' A' ' 148' ' ' PRO . 79.7 m-85 . . . . . 0 N--CA 1.429 -1.513 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -130.95 164.62 24.92 Favored 'General case' 0 C--N 1.291 -1.953 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -178.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 92.5 t80 -58.07 111.61 1.24 Allowed 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 173.144 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 134.19 -23.76 3.65 Favored Glycine 0 N--CA 1.426 -1.981 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -174.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 81.0 mm-40 -78.53 140.51 38.54 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-O 121.339 0.59 . . . . 0.0 111.339 177.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -131.17 109.62 10.57 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 176.41 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 97.6 t -94.14 118.29 39.75 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.206 0 CA-C-N 115.472 -0.786 . . . . 0.0 110.578 -173.688 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.471 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 41.7 ttm180 -105.46 144.86 31.65 Favored 'General case' 0 N--CA 1.426 -1.654 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.604 176.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -114.24 159.27 20.33 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 123.586 0.754 . . . . 0.0 109.948 -176.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.573 HG22 HG12 ' A' ' 158' ' ' VAL . 0.0 OUTLIER -132.03 145.04 35.45 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.284 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.951 178.49 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 84.2 m -109.81 136.45 49.1 Favored 'General case' 0 C--N 1.268 -2.954 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 55.5 m-80 -60.51 164.76 4.2 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.082 178.299 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 24.1 m -48.05 108.19 0.16 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 124.799 1.312 . . . . 0.0 113.282 -175.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.78 -9.6 29.92 Favored Glycine 0 N--CA 1.421 -2.331 0 C-N-CA 120.543 -0.836 . . . . 0.0 112.737 177.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -109.36 155.49 21.16 Favored 'General case' 0 N--CA 1.423 -1.819 0 CA-C-N 117.219 0.51 . . . . 0.0 110.282 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.536 ' HE2' ' O ' ' A' ' 184' ' ' ILE . 18.7 ptmt -130.26 163.23 27.21 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.536 ' O ' ' HE2' ' A' ' 183' ' ' LYS . 3.7 tp -74.32 148.17 8.37 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.046 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -85.65 -74.29 0.41 Allowed 'General case' 0 C--N 1.289 -2.048 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.042 178.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -79.48 -97.88 0.28 Allowed Glycine 0 N--CA 1.442 -0.937 0 C-N-CA 121.043 -0.598 . . . . 0.0 112.443 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -118.19 150.92 38.6 Favored 'General case' 0 CA--C 1.484 -1.566 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.349 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -95.15 -1.92 50.91 Favored 'General case' 0 CA--C 1.499 -1.007 0 C-N-CA 120.155 -0.618 . . . . 0.0 111.049 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . 0.481 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.5 pt-20 -146.35 146.72 30.77 Favored 'General case' 0 C--N 1.294 -1.844 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.437 -178.086 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.0 ptp -131.98 131.43 42.56 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.117 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 42.4 t-80 -102.83 138.52 39.61 Favored 'General case' 0 C--N 1.29 -1.989 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 177.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . 0.419 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 42.7 t -81.95 135.41 35.39 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.711 177.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.0 m -99.21 165.07 11.88 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 178.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -75.43 4.52 7.22 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.219 0.533 . . . . 0.0 111.621 -176.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -68.45 -32.51 72.58 Favored 'General case' 0 CA--C 1.507 -0.706 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.286 172.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 109.4 8.82 26.41 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 111.079 -0.808 . . . . 0.0 111.079 -175.562 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -142.06 173.23 11.7 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-O 120.691 0.282 . . . . 0.0 110.651 177.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . 0.419 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 66.2 m95 -82.95 148.25 27.73 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.056 -175.296 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 20.3 m -67.51 -25.27 65.76 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.654 0.74 . . . . 0.0 110.754 178.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.406 ' HA ' ' HD3' ' A' ' 200' ' ' LYS . 26.4 mmtp -124.63 148.88 47.65 Favored 'General case' 0 CA--C 1.487 -1.456 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.947 179.064 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -82.05 161.51 22.9 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 175.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . 0.413 ' HB2' ' HE2' ' A' ' 202' ' ' LYS . 10.5 ptmm? -63.51 137.95 97.23 Favored Pre-proline 0 N--CA 1.431 -1.396 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.6 -178.359 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . 0.419 ' CG ' HD11 ' A' ' 184' ' ' ILE . 63.7 Cg_endo -86.89 -169.98 0.58 Allowed 'Trans proline' 0 N--CA 1.434 -1.985 0 C-N-CA 122.815 2.343 . . . . 0.0 113.919 -175.267 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . 0.49 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 61.2 tttp -134.42 158.61 43.44 Favored 'General case' 0 N--CA 1.424 -1.753 0 CA-C-N 113.948 -1.478 . . . . 0.0 107.669 -176.519 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.432 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 89.3 m -116.08 115.58 26.34 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 174.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.563 -175.51 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.49 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 33.0 Cg_endo . . . . . 0 CA--C 1.538 0.723 0 CA-C-O 121.107 0.378 . . . . 0.0 112.012 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.0 m -84.86 -32.62 23.12 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 121.891 0.853 . . . . 0.0 109.347 177.526 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.91 -92.05 0.53 Allowed Glycine 0 N--CA 1.405 -3.408 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 175.337 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.2 t-80 -174.44 139.45 0.69 Allowed Pre-proline 0 C--N 1.265 -3.089 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 -176.371 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.458 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 88.1 Cg_endo -85.91 -0.1 8.48 Favored 'Trans proline' 0 N--CA 1.473 0.274 0 C-N-CA 122.093 1.862 . . . . 0.0 112.947 -175.222 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.446 ' HA3' HD11 ' A' ' 138' ' ' ILE . . . 109.59 -172.64 16.19 Favored Glycine 0 C--N 1.296 -1.692 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -176.06 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -146.96 163.61 35.64 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.8 t -141.32 139.19 18.55 Favored Pre-proline 0 C--N 1.3 -1.556 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.528 -176.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -77.4 -12.7 16.99 Favored 'Trans proline' 0 CA--C 1.529 0.267 0 C-N-CA 122.696 2.264 . . . . 0.0 111.288 176.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -88.48 2.46 52.79 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.771 -175.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 159.59 -133.66 3.42 Favored Glycine 0 N--CA 1.41 -3.093 0 C-N-CA 120.213 -0.994 . . . . 0.0 111.859 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 14.1 p -148.85 -172.89 4.21 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -173.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -144.11 167.15 23.08 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 173.18 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -131.59 157.76 42.78 Favored 'General case' 0 C--N 1.279 -2.457 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 178.207 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 22.7 mt -110.9 138.84 46.79 Favored 'General case' 0 C--N 1.265 -3.099 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.286 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.2 p -129.96 131.02 45.79 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.342 -178.094 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.18 16.19 45.0 Favored Glycine 0 CA--C 1.501 -0.797 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -175.046 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 147.77 160.46 8.95 Favored Glycine 1 N--CA 1.376 -5.305 0 N-CA-C 106.212 -2.755 . . . . 0.0 106.212 -175.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -114.09 35.77 4.0 Favored 'General case' 0 C--N 1.25 -3.739 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 -179.579 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.445 ' O ' HG11 ' A' ' 108' ' ' VAL . 16.7 m -144.96 -173.82 0.49 Allowed 'Isoleucine or valine' 0 C--O 1.204 -1.291 0 CA-C-N 114.371 -1.286 . . . . 0.0 109.623 -175.126 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.458 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 29.5 m-85 -110.02 46.6 1.01 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 121.392 0.615 . . . . 0.0 109.554 -178.015 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.704 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.0 pt-20 -86.91 178.74 6.87 Favored 'General case' 0 C--O 1.212 -0.892 0 CA-C-N 114.909 -1.041 . . . . 0.0 111.427 178.209 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -75.54 132.26 40.6 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.223 177.44 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 90.69 10.49 63.19 Favored Glycine 0 N--CA 1.438 -1.194 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.969 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.704 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.5 p -102.29 148.07 8.2 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 176.67 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 52.4 mtpt -117.12 123.22 46.22 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 120.907 0.384 . . . . 0.0 110.532 -179.092 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.39 91.62 8.57 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.17 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.8 t -85.16 110.97 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.31 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -78.17 143.24 37.4 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 112.462 0.542 . . . . 0.0 112.462 -177.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.8 t -142.98 112.94 7.06 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 121.712 0.768 . . . . 0.0 109.461 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 89.8 m -65.81 162.17 19.41 Favored 'General case' 0 C--N 1.311 -1.09 0 N-CA-C 114.329 1.233 . . . . 0.0 114.329 -178.075 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -68.71 -179.97 1.57 Allowed 'General case' 0 N--CA 1.433 -1.293 0 C-N-CA 125.612 1.565 . . . . 0.0 109.892 178.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -59.95 -52.65 64.48 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 124.099 0.959 . . . . 0.0 111.145 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -86.81 33.1 3.81 Favored Glycine 0 C--N 1.308 -1.007 0 C-N-CA 120.426 -0.892 . . . . 0.0 113.791 -176.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.525 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 86.3 m-85 -150.54 170.43 19.13 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 123.725 0.81 . . . . 0.0 110.024 -177.142 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.406 HE21 ' HB2' ' A' ' 119' ' ' GLN . 0.0 OUTLIER -150.34 156.89 42.37 Favored 'General case' 0 N--CA 1.427 -1.617 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 176.659 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 8.2 tt -87.42 136.68 32.84 Favored 'General case' 0 C--N 1.27 -2.881 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.51 130.34 56.37 Favored 'General case' 0 N--CA 1.428 -1.54 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -176.578 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 120.97 172.14 14.45 Favored Glycine 0 N--CA 1.43 -1.733 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 -178.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 57.2 mm-40 -88.57 -25.43 22.5 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-O 121.256 0.55 . . . . 0.0 109.942 178.473 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.7 mm -87.44 127.78 40.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-N 114.604 -1.18 . . . . 0.0 108.528 -179.589 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -133.52 14.98 4.07 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.042 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.403 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 30.3 p90 -153.65 159.84 42.2 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-O 121.031 0.443 . . . . 0.0 110.558 -175.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -122.7 134.65 54.46 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 171.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -112.56 126.49 55.4 Favored 'General case' 0 C--N 1.278 -2.524 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -176.556 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 28.8 t -82.63 99.53 9.62 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 117.738 -1.585 . . . . 0.0 110.675 177.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.476 ' OD2' HG22 ' A' ' 131' ' ' THR . 14.1 t70 -95.87 -168.35 1.75 Allowed 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 175.112 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.476 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -64.65 -23.58 67.3 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -172.707 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -78.76 -28.13 44.76 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.778 0.799 . . . . 0.0 109.787 176.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 130.65 -154.35 20.66 Favored Glycine 0 N--CA 1.422 -2.257 0 N-CA-C 108.614 -1.795 . . . . 0.0 108.614 -175.07 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.402 ' CH2' HG13 ' A' ' 108' ' ' VAL . 97.5 m95 -65.06 112.47 3.37 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 117.112 0.456 . . . . 0.0 111.411 178.127 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 76.5 p -73.47 159.94 32.46 Favored 'General case' 0 C--O 1.271 2.227 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 175.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 89.3 m-20 63.4 -163.15 0.27 Allowed 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . 0.458 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 17.1 t70 -141.25 -173.24 3.69 Favored 'General case' 0 C--N 1.283 -2.291 0 N-CA-C 106.114 -1.809 . . . . 0.0 106.114 173.488 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.458 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 67.1 mt -66.32 120.53 70.89 Favored Pre-proline 0 C--N 1.266 -3.027 0 C-N-CA 124.643 1.177 . . . . 0.0 108.727 179.753 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -68.31 139.25 45.16 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 122.238 1.958 . . . . 0.0 111.126 -179.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 73.6 mt -62.49 125.89 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 CA-C-O 121.742 0.782 . . . . 0.0 110.732 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.525 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 43.1 t -102.48 123.95 47.16 Favored 'General case' 0 N--CA 1.406 -2.652 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 176.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -105.09 154.47 20.11 Favored 'General case' 0 N--CA 1.413 -2.291 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 -174.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 15.0 p -80.39 143.37 12.5 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.768 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.285 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.57 HG23 ' HB2' ' A' ' 170' ' ' PHE . 6.4 m -65.3 130.86 30.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 176.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.451 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 96.2 mttt -120.03 141.62 49.56 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.291 -174.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.4 m -108.92 160.06 16.3 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 124.199 0.937 . . . . 0.0 108.568 177.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . 0.414 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.0 mm? -76.63 149.69 81.22 Favored Pre-proline 0 N--CA 1.418 -2.074 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 2.9 Cg_exo -68.19 114.76 3.53 Favored 'Trans proline' 0 N--CA 1.442 -1.503 0 C-N-CA 122.679 2.253 . . . . 0.0 110.242 175.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.43 HG21 ' SD ' ' A' ' 190' ' ' MET . 41.5 t -71.36 147.19 11.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.142 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.27 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 22.8 p -71.57 -80.4 0.06 Allowed 'General case' 0 N--CA 1.435 -1.221 0 O-C-N 123.117 0.26 . . . . 0.0 111.353 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.6 161.02 0.48 Allowed Pre-proline 0 C--O 1.24 0.587 0 C-N-CA 125.607 1.563 . . . . 0.0 107.612 177.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -78.84 -158.03 0.08 OUTLIER 'Trans proline' 0 CA--C 1.547 1.17 0 C-N-CA 121.555 1.503 . . . . 0.0 111.048 171.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . 0.463 ' CD ' ' H ' ' A' ' 153' ' ' GLU . 0.0 OUTLIER -99.91 -52.16 3.51 Favored 'General case' 0 C--N 1.31 -1.148 0 O-C-N 121.861 -0.524 . . . . 0.0 112.271 -175.668 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 61.8 m-80 -107.19 25.58 11.23 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.605 0.716 . . . . 0.0 110.141 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -151.13 -176.78 24.33 Favored Glycine 0 N--CA 1.417 -2.633 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 16.5 pttm -145.82 168.93 19.6 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 -179.334 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.449 HG12 ' CD2' ' A' ' 176' ' ' PHE . 52.1 mt -91.6 141.84 13.9 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.463 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.5 m -90.98 -30.65 4.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 178.319 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 10.4 m . . . . . 0 C--N 1.311 -1.073 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.472 -174.075 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . 0.451 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 79.6 m-85 . . . . . 0 N--CA 1.432 -1.327 0 CA-C-O 121.506 0.669 . . . . 0.0 109.897 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 20.0 m170 -106.36 160.44 15.38 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 114.538 -1.21 . . . . 0.0 108.249 -175.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.57 ' HB2' HG23 ' A' ' 144' ' ' VAL . 65.0 t80 -50.02 123.99 9.25 Favored 'General case' 0 N--CA 1.47 0.539 0 O-C-N 123.287 0.367 . . . . 0.0 110.107 172.179 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 102.43 -0.83 49.87 Favored Glycine 0 N--CA 1.428 -1.839 0 C-N-CA 119.497 -1.335 . . . . 0.0 112.919 178.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 30.3 mm-40 -88.13 145.02 26.15 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 175.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -113.47 117.77 32.64 Favored 'General case' 0 C--N 1.281 -2.409 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.511 -179.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 54.5 t -98.71 101.24 11.87 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 176.305 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.463 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 16.2 ttm180 -93.45 145.98 24.1 Favored 'General case' 0 N--CA 1.415 -2.219 0 CA-C-N 114.906 -1.043 . . . . 0.0 110.54 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.449 ' CD2' HG12 ' A' ' 157' ' ' ILE . 68.6 m-85 -114.89 156.15 25.52 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 14.6 p -137.01 139.84 43.76 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.212 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.6 m -95.5 138.75 32.73 Favored 'General case' 0 C--N 1.269 -2.934 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.237 -176.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . 0.468 ' O ' ' HD2' ' A' ' 182' ' ' TYR . 58.9 m-20 -82.72 165.42 19.95 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 -179.349 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.7 t 49.07 -142.55 0.55 Allowed 'General case' 0 CA--C 1.548 0.867 0 O-C-N 124.057 0.848 . . . . 0.0 110.805 178.265 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -93.49 32.44 5.76 Favored Glycine 0 N--CA 1.428 -1.865 0 C-N-CA 121.19 -0.529 . . . . 0.0 111.876 178.454 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . 0.468 ' HD2' ' O ' ' A' ' 179' ' ' ASN . 96.9 m-85 -84.23 160.49 20.78 Favored 'General case' 0 N--CA 1.443 -0.802 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.378 -179.216 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -126.54 155.03 43.03 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 2.6 tp -71.82 144.77 12.91 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 178.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -85.71 -65.85 0.96 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.363 179.092 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -86.26 -113.88 0.87 Allowed Glycine 0 N--CA 1.439 -1.162 0 N-CA-C 111.817 -0.513 . . . . 0.0 111.817 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -100.05 157.47 16.53 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.827 -1.545 . . . . 0.0 106.827 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -93.51 -8.7 40.7 Favored 'General case' 0 N--CA 1.433 -1.283 0 C-N-CA 119.305 -0.958 . . . . 0.0 109.401 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . 0.43 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 2.9 pt-20 -146.23 130.41 17.48 Favored 'General case' 0 N--CA 1.43 -1.442 0 CA-C-O 121.932 0.872 . . . . 0.0 112.835 178.698 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.43 ' SD ' HG21 ' A' ' 149' ' ' VAL . 12.8 ptp -102.01 143.16 32.21 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.514 177.182 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -113.66 150.11 33.69 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 2.4 m -74.04 123.18 23.87 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 123.685 0.615 . . . . 0.0 110.795 173.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . 0.423 ' HB2' ' OG ' ' A' ' 199' ' ' SER . 34.4 t -83.94 167.52 16.88 Favored 'General case' 0 N--CA 1.423 -1.795 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 176.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -71.81 -5.16 32.21 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 123.534 0.734 . . . . 0.0 111.351 -177.141 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -84.82 -18.87 33.6 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.412 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 88.81 27.46 24.04 Favored Glycine 0 N--CA 1.451 -0.309 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 -173.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -131.94 161.55 32.82 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 179.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -77.87 131.06 37.35 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 176.464 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . 0.423 ' OG ' ' HB2' ' A' ' 193' ' ' SER . 15.0 m -68.04 -39.45 83.05 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-O 121.548 0.69 . . . . 0.0 110.064 -179.353 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 21.5 mmtp -96.33 150.27 20.76 Favored 'General case' 0 C--N 1.307 -1.247 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.75 177.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 22.9 mm-40 -86.3 166.23 15.81 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 176.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 28.3 ttmt -67.47 121.85 80.68 Favored Pre-proline 0 C--N 1.324 -0.519 0 C-N-CA 119.51 -0.876 . . . . 0.0 109.47 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.5 -174.86 2.44 Favored 'Trans proline' 0 N--CA 1.437 -1.834 0 C-N-CA 121.996 1.797 . . . . 0.0 111.759 179.183 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . 0.424 ' HG2' ' OE1' ' A' ' 153' ' ' GLU . 48.2 mttm -127.9 162.58 26.39 Favored 'General case' 0 C--N 1.287 -2.124 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.295 179.217 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 77.5 m -113.32 106.28 14.42 Favored 'General case' 0 C--N 1.281 -2.408 0 O-C-N 124.057 0.848 . . . . 0.0 109.137 170.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.5 m . . . . . 0 N--CA 1.431 -1.415 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.313 -173.759 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.447 ' HG2' ' HA ' ' A' ' 105' ' ' GLU . 33.9 Cg_endo . . . . . 0 CA--C 1.536 0.608 0 CA-C-O 121.113 0.38 . . . . 0.0 111.934 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.8 m -86.49 -33.69 20.27 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 176.085 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.74 -96.66 0.67 Allowed Glycine 0 N--CA 1.402 -3.593 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 173.035 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 56.0 t-80 -173.1 121.03 0.41 Allowed Pre-proline 0 C--N 1.263 -3.169 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -175.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.08 -30.79 13.05 Favored 'Trans proline' 0 C--O 1.219 -0.436 0 C-N-CA 121.909 1.74 . . . . 0.0 113.369 -171.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.22 176.13 14.34 Favored Glycine 0 CA--C 1.483 -1.936 0 N-CA-C 108.347 -1.901 . . . . 0.0 108.347 -176.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -134.7 -175.49 3.91 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -177.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 2.1 t -141.47 133.5 13.78 Favored Pre-proline 0 C--N 1.303 -1.43 0 CA-C-O 121.234 0.54 . . . . 0.0 112.131 -178.115 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -71.83 -18.1 28.53 Favored 'Trans proline' 0 C--O 1.238 0.513 0 C-N-CA 122.554 2.169 . . . . 0.0 111.389 175.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -86.72 -3.42 59.04 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.072 -176.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.474 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.89 -123.47 0.94 Allowed Glycine 0 N--CA 1.424 -2.157 0 C-N-CA 120.033 -1.079 . . . . 0.0 112.04 179.234 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 11.7 t -157.93 -166.48 1.98 Allowed 'General case' 0 C--N 1.285 -2.205 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -149.77 162.15 40.83 Favored 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 177.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 7.0 m -128.34 161.41 29.47 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 -178.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 25.4 mt -117.11 128.6 55.29 Favored 'General case' 0 C--N 1.266 -3.042 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.439 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 32.0 p -123.76 135.17 53.67 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -175.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 105.95 -45.33 1.32 Allowed Glycine 0 C--N 1.305 -1.19 0 N-CA-C 111.69 -0.564 . . . . 0.0 111.69 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.464 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -131.9 -16.59 1.41 Allowed Glycine 0 C--O 1.219 -0.784 0 C-N-CA 120.263 -0.97 . . . . 0.0 113.524 -177.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 64.5 12.97 7.84 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 123.657 0.783 . . . . 0.0 113.014 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.516 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.4 m -145.95 -169.4 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 -177.201 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -105.14 45.54 0.96 Allowed 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 118.692 0.678 . . . . 0.0 110.461 -178.232 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.721 ' O ' HG12 ' A' ' 108' ' ' VAL . 9.3 pt-20 -89.68 -176.18 4.9 Favored 'General case' 0 C--O 1.208 -1.094 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.884 178.231 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -79.08 138.63 38.04 Favored 'General case' 0 C--N 1.31 -1.132 0 O-C-N 121.648 -0.657 . . . . 0.0 111.119 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 85.59 4.31 85.6 Favored Glycine 0 N--CA 1.439 -1.155 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.992 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.721 HG12 ' O ' ' A' ' 105' ' ' GLU . 15.0 p -93.39 143.67 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.943 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 177.552 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.439 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 54.9 mtpt -108.08 118.38 36.6 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.368 178.669 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -83.08 91.87 7.29 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 175.575 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.421 HG12 ' CB ' ' A' ' 126' ' ' TYR . 32.3 m -91.83 117.58 35.44 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.405 0 CA-C-O 122.19 0.995 . . . . 0.0 108.735 -178.042 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 36.4 m-85 -84.42 146.71 27.51 Favored 'General case' 0 C--N 1.264 -3.143 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.918 -176.606 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.1 t -144.06 118.54 9.7 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-O 122.102 0.954 . . . . 0.0 108.919 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 3.8 m -75.12 160.93 29.87 Favored 'General case' 0 C--N 1.284 -2.25 0 CA-C-N 115.29 -0.868 . . . . 0.0 108.966 -176.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.474 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 75.4 m-20 -73.15 171.03 13.72 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 177.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -48.06 -49.37 31.72 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.553 1.141 . . . . 0.0 113.525 -176.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.548 ' HA2' ' CD2' ' A' ' 170' ' ' PHE . . . -80.61 8.46 54.8 Favored Glycine 0 C--N 1.309 -0.95 0 CA-C-N 116.025 -0.534 . . . . 0.0 113.37 -176.635 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.63 ' CE1' HG22 ' A' ' 143' ' ' VAL . 94.0 m-85 -130.71 150.61 51.81 Favored 'General case' 0 N--CA 1.434 -1.249 0 CA-C-O 121.501 0.667 . . . . 0.0 110.397 -178.478 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -119.08 163.5 16.92 Favored 'General case' 0 C--N 1.276 -2.614 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.47 HD11 ' HB2' ' A' ' 139' ' ' PRO . 13.4 tp -83.48 141.53 31.59 Favored 'General case' 0 C--N 1.282 -2.361 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 177.273 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.452 HD22 ' HA ' ' A' ' 121' ' ' LEU . 0.3 OUTLIER -112.72 116.94 30.92 Favored 'General case' 0 N--CA 1.408 -2.57 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.149 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.6 -169.33 13.14 Favored Glycine 0 C--N 1.276 -2.777 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.02 -174.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -100.53 -48.93 4.37 Favored 'General case' 0 C--N 1.287 -2.111 0 CA-C-N 114.926 -0.637 . . . . 0.0 109.304 -174.779 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.6 mm -68.0 126.67 28.27 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 CA-C-N 114.589 -1.187 . . . . 0.0 109.874 -176.085 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -122.91 3.13 9.42 Favored 'General case' 0 C--O 1.198 -1.654 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.219 176.346 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.421 ' CB ' HG12 ' A' ' 111' ' ' VAL . 20.9 p90 -138.28 161.85 35.84 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.068 -173.441 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 58.1 mtp180 -126.5 131.18 51.68 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 170.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -107.62 132.18 53.58 Favored 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 -177.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 43.1 t -81.02 104.5 11.57 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 118.02 -1.472 . . . . 0.0 110.303 176.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.516 ' OD1' HG22 ' A' ' 131' ' ' THR . 15.0 t70 -97.23 -169.43 1.85 Allowed 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.516 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.0 t -68.73 -17.02 63.98 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.631 0.729 . . . . 0.0 110.921 -175.614 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -87.9 -24.01 23.77 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.694 177.011 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 122.65 -154.03 16.95 Favored Glycine 0 N--CA 1.416 -2.646 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -174.335 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.431 ' CH2' HG13 ' A' ' 108' ' ' VAL . 93.9 m95 -63.34 115.1 4.27 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 55.4 p -76.66 168.87 19.32 Favored 'General case' 0 C--O 1.261 1.689 0 N-CA-C 109.287 -0.635 . . . . 0.0 109.287 176.531 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 61.53 -170.75 0.16 Allowed 'General case' 0 C--O 1.242 0.672 0 O-C-N 123.94 0.775 . . . . 0.0 111.918 177.438 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.64 171.29 7.61 Favored 'General case' 0 CA--C 1.469 -2.163 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 175.339 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.6 mt -67.57 113.4 14.0 Favored Pre-proline 0 C--N 1.297 -1.708 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 170.294 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.47 ' HB2' HD11 ' A' ' 120' ' ' LEU . 45.2 Cg_endo -66.46 131.69 27.06 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 122.052 1.835 . . . . 0.0 111.711 -176.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 69.3 mt -80.58 131.58 33.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.887 -176.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 74.3 m -103.52 149.56 24.74 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 174.191 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -125.49 168.37 13.73 Favored 'General case' 0 C--N 1.287 -2.117 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 174.226 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.63 HG22 ' CE1' ' A' ' 118' ' ' TYR . 99.6 t -67.65 143.3 15.51 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 177.028 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.446 ' HB ' ' HB2' ' A' ' 170' ' ' PHE . 72.6 t -61.5 130.7 25.99 Favored 'Isoleucine or valine' 0 C--O 1.242 0.668 0 N-CA-C 107.877 -1.156 . . . . 0.0 107.877 174.509 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.44 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 84.0 mttt -120.28 152.19 38.14 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 -175.264 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 59.0 m -118.42 160.04 22.4 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 64.4 mt -69.72 144.73 94.06 Favored Pre-proline 0 C--O 1.24 0.603 0 N-CA-C 112.282 0.475 . . . . 0.0 112.282 178.597 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -64.68 131.48 29.59 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 123.197 2.598 . . . . 0.0 112.449 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 44.2 t -90.94 136.82 23.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 179.245 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 15.3 p -73.55 -85.93 0.03 OUTLIER 'General case' 0 C--N 1.314 -0.965 0 CA-C-O 120.636 0.255 . . . . 0.0 111.55 178.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 177.0 150.24 0.35 Allowed Pre-proline 0 C--O 1.242 0.672 0 C-N-CA 125.627 1.571 . . . . 0.0 107.493 177.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . 0.413 ' HB3' ' O ' ' A' ' 203' ' ' PRO . 59.0 Cg_endo -77.88 171.16 17.75 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.008 1.805 . . . . 0.0 111.263 174.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -65.06 -59.96 3.55 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 114.645 1.35 . . . . 0.0 114.645 -174.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -107.52 29.88 6.78 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-O 121.845 0.831 . . . . 0.0 110.161 -178.198 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.88 178.14 22.89 Favored Glycine 0 N--CA 1.419 -2.438 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 57.5 pttt -145.79 166.14 26.79 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.178 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.429 HG23 HG13 ' A' ' 174' ' ' VAL . 56.9 mt -83.69 134.13 27.62 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 CA-C-O 121.348 0.594 . . . . 0.0 111.005 -178.455 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.5 t -68.81 -43.1 82.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.131 -0.94 . . . . 0.0 109.595 178.044 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 35.0 t . . . . . 0 N--CA 1.443 -0.781 0 CA-C-O 121.676 0.75 . . . . 0.0 109.464 176.392 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 . . . . . 0 C--O 1.24 0.575 0 CA-C-O 121.777 0.798 . . . . 0.0 112.79 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.498 ' HB3' HG11 ' A' ' 143' ' ' VAL . 38.0 m80 -95.43 152.02 18.78 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 114.399 -1.273 . . . . 0.0 112.057 -178.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.548 ' CD2' ' HA2' ' A' ' 117' ' ' GLY . 0.9 OUTLIER -62.56 106.04 0.72 Allowed 'General case' 0 C--O 1.239 0.535 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 172.731 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 138.35 -12.53 3.52 Favored Glycine 0 N--CA 1.428 -1.884 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -174.681 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 31.7 mm-40 -99.34 160.74 14.06 Favored 'General case' 0 C--O 1.259 1.57 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 177.131 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -140.78 135.24 31.28 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 178.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.497 HG23 ' CH2' ' A' ' 198' ' ' TRP . 92.7 t -99.34 106.03 18.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.404 ' HA ' ' HA ' ' A' ' 189' ' ' GLU . 56.3 ttt180 -97.95 158.17 15.69 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 178.24 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -130.45 153.49 48.72 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -172.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.2 p -134.97 143.19 38.07 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 81.9 m -99.03 145.3 27.23 Favored 'General case' 0 C--N 1.283 -2.296 0 CA-C-N 115.607 -0.724 . . . . 0.0 112.218 -175.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -69.79 159.49 33.48 Favored 'General case' 0 N--CA 1.434 -1.257 0 CA-C-N 115.383 -0.826 . . . . 0.0 108.885 175.089 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 38.4 m -58.44 112.3 1.53 Allowed 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.805 -175.096 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 114.72 -13.43 20.3 Favored Glycine 0 N--CA 1.438 -1.218 0 CA-C-N 115.145 -0.934 . . . . 0.0 111.761 -178.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -107.83 160.96 15.33 Favored 'General case' 0 N--CA 1.433 -1.305 0 CA-C-O 120.876 0.369 . . . . 0.0 111.733 -177.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.533 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 22.3 pttm -131.24 152.75 50.2 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 178.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.569 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.4 tt -80.61 136.05 24.05 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.285 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.332 175.738 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -75.0 -54.95 6.29 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.078 -176.502 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -91.38 -144.61 13.22 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.519 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -77.92 157.9 29.6 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.569 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.4 pt-20 -89.91 -5.63 56.58 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.557 -174.538 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . 0.436 ' HG2' ' HG3' ' A' ' 188' ' ' GLU . 3.6 pt-20 -147.77 142.28 26.47 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.17 0.51 . . . . 0.0 111.977 -175.465 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.472 ' CG ' ' HB ' ' A' ' 174' ' ' VAL . 14.3 ptp -120.29 134.79 55.19 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.105 -0.952 . . . . 0.0 108.537 175.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 21.9 t-80 -112.36 147.01 37.29 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 110.56 -0.163 . . . . 0.0 110.56 -175.257 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . 0.404 ' HB3' ' HA ' ' A' ' 170' ' ' PHE . 1.5 m -70.68 120.01 15.66 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 116.663 -0.244 . . . . 0.0 110.542 173.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.1 m -98.7 163.95 12.43 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.836 178.104 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -47.17 -32.66 4.55 Favored 'General case' 0 N--CA 1.498 1.926 0 C-N-CA 126.533 1.933 . . . . 0.0 114.078 -178.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -73.1 -17.08 61.44 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 94.99 28.35 10.08 Favored Glycine 0 C--N 1.307 -1.069 0 C-N-CA 119.917 -1.135 . . . . 0.0 112.093 -178.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 2.5 p90 -140.62 172.05 13.25 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 176.45 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . 0.497 ' CH2' HG23 ' A' ' 174' ' ' VAL . 87.5 m95 -82.22 143.3 31.47 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 123.717 0.636 . . . . 0.0 111.129 -178.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 5.0 m -69.13 -6.46 28.72 Favored 'General case' 0 CA--C 1.549 0.937 0 C-N-CA 124.109 0.964 . . . . 0.0 111.245 178.197 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.459 ' HB2' ' HB3' ' A' ' 190' ' ' MET . 25.9 mmmt -140.52 150.99 44.41 Favored 'General case' 0 CA--C 1.482 -1.666 0 C-N-CA 123.863 0.865 . . . . 0.0 109.467 -178.315 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -89.65 157.62 17.94 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 104.561 -2.385 . . . . 0.0 104.561 169.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 25.9 ttpp -60.85 114.44 10.4 Favored Pre-proline 0 C--O 1.243 0.759 0 N-CA-C 114.479 1.289 . . . . 0.0 114.479 -172.062 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . 0.436 ' HG2' HD11 ' A' ' 184' ' ' ILE . 90.3 Cg_endo -78.89 165.58 24.21 Favored 'Trans proline' 0 N--CA 1.435 -1.936 0 C-N-CA 123.113 2.542 . . . . 0.0 109.786 176.09 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.9 pttt -139.08 162.76 34.15 Favored 'General case' 0 C--N 1.285 -2.209 0 C-N-CA 120.005 -0.678 . . . . 0.0 111.543 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.533 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 73.6 m -96.29 121.4 38.04 Favored 'General case' 0 N--CA 1.406 -2.628 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.052 179.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 13.4 m . . . . . 0 C--N 1.295 -1.775 0 C-N-CA 125.384 1.474 . . . . 0.0 108.181 -177.02 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo . . . . . 0 CA--C 1.538 0.703 0 CA-C-O 121.201 0.417 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 34.2 m -75.54 -37.18 60.21 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.674 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 120.41 -95.86 0.6 Allowed Glycine 0 N--CA 1.4 -3.742 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 173.608 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.2 t60 -173.26 123.67 0.43 Allowed Pre-proline 0 C--N 1.253 -3.596 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 -175.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.496 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 81.3 Cg_endo -76.02 -3.52 13.96 Favored 'Trans proline' 0 C--O 1.213 -0.75 0 C-N-CA 122.766 2.31 . . . . 0.0 113.841 -171.519 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 112.97 -175.58 16.78 Favored Glycine 0 C--N 1.285 -2.295 0 N-CA-C 108.296 -1.921 . . . . 0.0 108.296 -176.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -152.92 118.52 5.31 Favored 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -176.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.1 t -91.22 133.85 30.91 Favored Pre-proline 0 C--N 1.304 -1.389 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -173.124 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -77.65 -13.73 16.17 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 122.725 2.283 . . . . 0.0 111.453 173.816 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -81.01 -10.32 59.72 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.934 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.535 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -178.41 -133.74 1.96 Allowed Glycine 0 N--CA 1.407 -3.299 0 C-N-CA 119.583 -1.294 . . . . 0.0 112.494 -178.746 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 21.0 p -143.39 -177.5 5.41 Favored 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -177.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 37.7 p90 -149.92 157.24 42.97 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 173.148 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.5 m -131.81 152.21 51.14 Favored 'General case' 0 C--N 1.289 -2.065 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.446 HD11 ' CE1' ' A' ' 104' ' ' PHE . 16.2 mt -106.12 131.49 53.32 Favored 'General case' 0 C--N 1.273 -2.731 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 20.5 p -123.01 137.92 54.82 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.0 -175.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 101.99 -56.96 0.66 Allowed Glycine 0 N--CA 1.436 -1.318 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -177.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.485 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -110.04 -30.5 3.4 Favored Glycine 0 C--O 1.21 -1.383 0 C-N-CA 120.991 -0.623 . . . . 0.0 113.121 -178.216 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 42.0 m-80 70.6 11.4 7.28 Favored 'General case' 0 N--CA 1.506 2.329 0 C-N-CA 123.879 0.872 . . . . 0.0 110.96 -177.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.503 ' O ' HG11 ' A' ' 108' ' ' VAL . 24.3 m -148.8 -175.14 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.76 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 -179.385 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.446 ' CE1' HD11 ' A' ' 98' ' ' LEU . 24.4 m-85 -99.17 42.42 1.1 Allowed 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 119.25 0.932 . . . . 0.0 111.049 -176.151 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.718 ' O ' HG12 ' A' ' 108' ' ' VAL . 9.6 pt-20 -83.01 -179.67 7.51 Favored 'General case' 0 C--O 1.208 -1.128 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.877 177.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -75.61 132.96 40.98 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.743 -0.598 . . . . 0.0 111.827 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.52 3.87 66.4 Favored Glycine 0 N--CA 1.435 -1.383 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.842 177.583 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.718 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.9 p -90.28 143.7 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 C-N-CA 119.993 -0.683 . . . . 0.0 109.223 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.7 mtpt -107.81 119.36 39.24 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 178.47 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.44 93.3 9.1 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 177.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 79.4 t -85.37 113.94 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.506 0 C-N-CA 123.478 0.711 . . . . 0.0 109.231 -178.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -87.16 134.75 33.49 Favored 'General case' 0 C--N 1.282 -2.335 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.843 179.205 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -132.01 130.12 40.99 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 10.1 m -82.34 154.43 25.28 Favored 'General case' 0 C--N 1.278 -2.535 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.659 -173.117 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.535 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 86.5 m-20 -71.26 177.24 3.98 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-N 116.765 -0.198 . . . . 0.0 111.47 179.445 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . 0.412 ' O ' ' HB2' ' A' ' 194' ' ' ASP . 45.6 tt0 -52.41 -54.59 30.1 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 123.845 0.858 . . . . 0.0 112.021 -174.759 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.94 34.69 3.17 Favored Glycine 0 C--N 1.308 -0.992 0 C-N-CA 120.787 -0.72 . . . . 0.0 113.171 -179.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -147.09 156.4 42.97 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.103 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -133.91 169.1 17.59 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.446 HD11 ' HB2' ' A' ' 139' ' ' PRO . 15.4 tp -92.2 142.66 27.24 Favored 'General case' 0 C--N 1.28 -2.42 0 C-N-CA 119.574 -0.851 . . . . 0.0 109.006 177.622 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -124.58 122.49 37.72 Favored 'General case' 0 N--CA 1.414 -2.239 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 177.077 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.5 171.6 15.63 Favored Glycine 0 C--N 1.286 -2.201 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.691 -176.608 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -95.91 -25.9 15.81 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.396 0.617 . . . . 0.0 109.808 -176.209 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.6 mm -90.2 137.36 21.69 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 23.0 p-10 -135.69 8.02 3.29 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 120.715 0.293 . . . . 0.0 110.639 179.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.5 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 28.8 p90 -146.29 171.35 15.11 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.067 -173.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.573 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 33.3 mtp180 -129.05 119.76 24.78 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 173.275 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -90.6 128.42 36.59 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.198 -1.001 . . . . 0.0 109.395 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 42.3 t -84.64 113.05 20.99 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.859 -1.136 . . . . 0.0 110.554 175.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -103.48 -172.33 2.09 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 10.8 t -64.19 -25.76 68.22 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.489 0.551 . . . . 0.0 112.489 -174.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -84.96 -23.94 28.54 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.13 0.491 . . . . 0.0 111.186 178.454 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 138.09 -158.01 24.59 Favored Glycine 0 N--CA 1.435 -1.381 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -177.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.413 ' CH2' HG13 ' A' ' 108' ' ' VAL . 93.4 m95 -68.57 113.04 5.74 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 178.441 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.2 p -64.49 -65.25 0.7 Allowed 'General case' 0 C--O 1.243 0.724 0 C-N-CA 123.049 0.54 . . . . 0.0 111.607 -176.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . 0.573 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 4.1 m120 -72.38 167.82 19.72 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . 0.401 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 10.4 t70 -104.66 -171.65 1.96 Allowed 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 176.329 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.401 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 78.8 mt -72.92 121.6 85.48 Favored Pre-proline 0 C--N 1.274 -2.686 0 C-N-CA 124.497 1.119 . . . . 0.0 108.256 179.674 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.446 ' HB2' HD11 ' A' ' 120' ' ' LEU . 53.0 Cg_endo -69.69 160.7 48.73 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 122.027 1.818 . . . . 0.0 110.763 177.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.1 mm -95.91 124.64 48.66 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 CA-C-O 121.523 0.677 . . . . 0.0 110.95 -175.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 68.2 m -100.22 120.27 39.64 Favored 'General case' 0 C--N 1.271 -2.806 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 171.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 16.4 tp10 -102.36 146.1 28.54 Favored 'General case' 0 C--N 1.272 -2.777 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 -178.683 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.15 136.79 25.58 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.882 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.503 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.1 m -59.77 128.44 20.71 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 CA-C-O 121.22 0.533 . . . . 0.0 110.378 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 59.8 mttm -112.68 145.92 39.59 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.56 -174.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.2 m -118.33 137.95 52.74 Favored 'General case' 0 C--N 1.277 -2.551 0 N-CA-C 106.157 -1.794 . . . . 0.0 106.157 -179.34 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 78.3 mt -62.32 143.42 95.63 Favored Pre-proline 0 C--N 1.313 -1.008 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -176.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -66.04 122.81 10.44 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.039 2.493 . . . . 0.0 110.408 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 51.7 t -76.33 149.25 6.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.941 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 6.3 p -68.95 -84.46 0.03 OUTLIER 'General case' 0 N--CA 1.439 -0.999 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.922 176.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 166.0 159.81 0.1 OUTLIER Pre-proline 0 CA--C 1.501 -0.94 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 177.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -72.28 156.11 55.36 Favored 'Trans proline' 0 N--CA 1.431 -2.167 0 CA-C-N 119.801 0.965 . . . . 0.0 109.89 171.094 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -64.92 -33.25 75.58 Favored 'General case' 0 C--N 1.28 -2.43 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -173.136 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -125.59 25.44 6.98 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-O 122.626 1.203 . . . . 0.0 109.045 -174.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.89 -155.8 6.59 Favored Glycine 0 N--CA 1.415 -2.738 0 CA-C-N 113.519 -1.673 . . . . 0.0 110.432 178.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . 0.514 ' HG3' HG23 ' A' ' 177' ' ' VAL . 24.1 pttm -157.79 174.41 15.34 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 41.7 mt -94.45 133.64 34.72 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.422 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.455 ' CG2' HG22 ' A' ' 177' ' ' VAL . 58.2 t -73.53 -48.45 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 177.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.9 m . . . . . 0 N--CA 1.429 -1.504 0 CA-C-N 115.019 -0.991 . . . . 0.0 109.021 -179.857 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 . . . . . 0 N--CA 1.408 -2.538 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 27.7 m170 -128.71 175.67 8.41 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -175.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.503 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 70.8 t80 -53.93 135.42 42.44 Favored 'General case' 0 C--N 1.306 -1.302 0 O-C-N 124.185 0.928 . . . . 0.0 110.052 172.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 101.3 -27.3 21.17 Favored Glycine 0 N--CA 1.43 -1.752 0 C-N-CA 120.126 -1.035 . . . . 0.0 112.306 178.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -68.14 147.21 52.62 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 117.28 0.54 . . . . 0.0 111.177 -178.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -128.44 116.13 19.26 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-N 114.457 -1.247 . . . . 0.0 107.794 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 69.5 t -100.18 110.31 26.97 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.928 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.237 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 64.1 ttt180 -97.07 155.64 16.71 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -178.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -128.27 161.87 28.34 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 123.669 0.787 . . . . 0.0 109.714 -174.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.514 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.1 OUTLIER -134.52 150.71 30.79 Favored 'Isoleucine or valine' 0 CA--C 1.474 -1.949 0 O-C-N 124.04 0.838 . . . . 0.0 109.111 178.659 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.2 m -110.83 137.5 48.41 Favored 'General case' 0 N--CA 1.395 -3.21 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 175.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -65.9 177.05 1.41 Allowed 'General case' 0 C--N 1.287 -2.136 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.853 -177.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.0 m -39.6 -36.11 0.37 Allowed 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 127.351 2.26 . . . . 0.0 116.823 -172.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -118.18 21.43 10.13 Favored Glycine 0 C--N 1.29 -2.005 0 C-N-CA 119.553 -1.308 . . . . 0.0 113.604 -178.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . 0.414 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 98.8 m-85 -126.92 156.36 41.59 Favored 'General case' 0 N--CA 1.436 -1.167 0 CA-C-N 117.754 0.777 . . . . 0.0 112.975 -177.17 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.453 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 25.0 pttm -124.96 153.07 43.31 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 179.105 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.3 tp -72.93 146.91 10.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.472 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -83.04 -62.23 1.65 Allowed 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -103.15 -115.72 4.1 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -85.61 154.37 21.75 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -98.11 2.53 48.72 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 -178.277 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -155.79 149.61 25.24 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -176.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.0 ptp -126.82 126.14 42.87 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 114.945 -1.025 . . . . 0.0 111.331 179.154 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -95.76 148.28 22.74 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 177.096 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . 0.469 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 34.5 t -95.31 135.8 36.47 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 119.803 -0.759 . . . . 0.0 111.238 178.682 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 19.5 m -84.94 162.28 19.49 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 124.281 1.033 . . . . 0.0 109.294 177.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . 0.44 ' O ' HG11 ' A' ' 144' ' ' VAL . 4.5 p-10 -72.84 -7.72 52.14 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.247 0.546 . . . . 0.0 112.29 -174.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . 0.439 ' HB2' ' CD2' ' A' ' 197' ' ' PHE . 2.8 m-20 -77.81 -12.59 59.99 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 174.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 89.74 39.98 6.07 Favored Glycine 0 N--CA 1.438 -1.188 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.795 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . 0.439 ' CD2' ' HB2' ' A' ' 195' ' ' ASP . 42.1 p90 -144.69 156.78 44.26 Favored 'General case' 0 C--N 1.318 -0.771 0 O-C-N 122.121 -0.634 . . . . 0.0 109.506 177.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . 0.469 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 81.9 m95 -76.12 128.85 35.83 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.4 m -63.07 -33.65 75.9 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.264 0.554 . . . . 0.0 110.078 -178.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.449 ' HD3' ' HA ' ' A' ' 200' ' ' LYS . 28.0 mmtp -108.68 148.35 30.56 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.85 177.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -87.42 178.17 6.9 Favored 'General case' 0 C--N 1.289 -2.059 0 CA-C-N 114.835 -1.075 . . . . 0.0 110.683 -178.433 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 8.7 mmmm -59.84 120.34 49.05 Favored Pre-proline 0 N--CA 1.442 -0.855 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.283 177.165 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -90.49 178.89 1.97 Allowed 'Trans proline' 0 N--CA 1.427 -2.386 0 C-N-CA 122.467 2.111 . . . . 0.0 110.179 176.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -128.98 165.84 20.35 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.453 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 88.9 m -122.25 104.59 9.55 Favored 'General case' 0 N--CA 1.415 -2.205 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 172.108 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--N 1.297 -1.695 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.049 -174.728 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo . . . . . 0 CA--C 1.535 0.545 0 CA-C-O 121.404 0.502 . . . . 0.0 111.396 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 39.6 m -85.22 -33.85 22.15 Favored 'General case' 0 C--N 1.315 -0.921 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 177.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.72 -94.07 0.58 Allowed Glycine 0 N--CA 1.398 -3.848 0 CA-C-N 114.467 -1.242 . . . . 0.0 110.005 171.495 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.0 t-80 -175.07 123.9 0.36 Allowed Pre-proline 0 C--N 1.252 -3.649 0 N-CA-C 104.422 -2.436 . . . . 0.0 104.422 -174.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.431 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 74.4 Cg_endo -79.0 -23.61 7.67 Favored 'Trans proline' 0 C--N 1.329 -0.473 0 C-N-CA 122.031 1.821 . . . . 0.0 112.906 -175.193 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.1 176.77 20.45 Favored Glycine 0 CA--C 1.475 -2.459 0 N-CA-C 108.263 -1.935 . . . . 0.0 108.263 -175.159 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.1 t0 -136.87 155.15 50.16 Favored 'General case' 0 C--N 1.275 -2.663 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -176.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.4 t -99.57 127.2 34.84 Favored Pre-proline 0 C--N 1.294 -1.805 0 CA-C-O 120.836 0.35 . . . . 0.0 110.302 -176.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.9 -13.67 39.09 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.695 2.263 . . . . 0.0 112.3 -178.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.4 ' CD2' ' HB2' ' A' ' 141' ' ' CYS . 31.6 m-85 -94.62 1.48 55.6 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.72 -177.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.492 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 179.98 -129.94 1.42 Allowed Glycine 0 N--CA 1.416 -2.657 0 C-N-CA 119.234 -1.46 . . . . 0.0 112.482 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 22.0 p -149.13 -176.38 5.34 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 124.216 0.598 . . . . 0.0 110.0 -177.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -144.71 164.33 31.33 Favored 'General case' 0 C--N 1.313 -1.022 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 172.043 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.2 m -129.29 160.48 32.87 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 179.237 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.7 mt -117.51 125.01 50.13 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.121 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.467 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 21.7 p -117.86 137.87 52.49 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.442 -175.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 102.25 -47.72 1.13 Allowed Glycine 0 C--N 1.299 -1.497 0 N-CA-C 111.126 -0.789 . . . . 0.0 111.126 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.448 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -122.85 -21.17 2.68 Favored Glycine 0 N--CA 1.438 -1.168 0 C-N-CA 120.37 -0.919 . . . . 0.0 113.361 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 64.25 14.72 8.89 Favored 'General case' 0 N--CA 1.5 2.048 0 C-N-CA 123.357 0.663 . . . . 0.0 112.666 -178.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.514 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.0 m -152.1 -172.89 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -178.232 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -99.9 43.87 1.04 Allowed 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 119.368 0.986 . . . . 0.0 111.061 -177.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.723 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.0 pt-20 -84.64 178.21 7.77 Favored 'General case' 0 C--O 1.205 -1.268 0 CA-C-N 114.681 -1.145 . . . . 0.0 111.983 178.225 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -71.91 135.83 46.66 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 122.076 -0.39 . . . . 0.0 110.798 177.021 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.63 -7.65 71.14 Favored Glycine 0 N--CA 1.435 -1.378 0 C-N-CA 120.148 -1.025 . . . . 0.0 113.418 178.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.723 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -85.31 143.48 11.52 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 119.709 -0.797 . . . . 0.0 110.581 -176.274 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.467 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.8 mtpt -108.82 117.0 33.05 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.49 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -83.3 92.41 7.5 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.482 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 89.5 t -87.33 114.23 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.587 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -176.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -86.33 139.32 31.09 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-O 121.409 0.623 . . . . 0.0 111.013 -177.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -133.66 109.13 8.98 Favored 'General case' 0 N--CA 1.407 -2.587 0 CA-C-O 122.334 1.064 . . . . 0.0 109.387 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 12.8 m -67.57 153.17 44.31 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.423 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.492 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 86.8 m-20 -68.71 178.77 1.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.869 0.366 . . . . 0.0 111.558 -179.012 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -57.38 -37.21 72.3 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -176.166 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -86.61 18.16 35.67 Favored Glycine 0 C--N 1.304 -1.237 0 C-N-CA 120.68 -0.771 . . . . 0.0 113.322 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -145.79 166.34 26.19 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -175.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.429 HE21 ' HB2' ' A' ' 119' ' ' GLN . 0.7 OUTLIER -140.55 163.9 31.61 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.579 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -87.18 120.37 28.39 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 179.357 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.6 129.89 47.8 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 -178.154 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.8 -176.51 22.18 Favored Glycine 0 C--N 1.301 -1.366 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -91.46 -38.58 12.47 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.316 0.579 . . . . 0.0 110.0 -179.052 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.5 mm -78.08 120.62 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -176.26 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -129.16 8.05 5.53 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -177.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.49 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 22.8 p90 -151.19 169.68 21.3 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 -174.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.581 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 57.8 mtp180 -129.14 122.57 30.11 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 173.472 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -94.65 127.29 40.51 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 119.557 -0.857 . . . . 0.0 110.316 178.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 47.4 t -83.27 113.1 20.46 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.087 175.029 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.526 ' OD1' HG22 ' A' ' 131' ' ' THR . 8.4 t70 -110.3 -164.33 0.92 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.526 HG22 ' OD1' ' A' ' 130' ' ' ASP . 5.9 t -52.65 -33.45 46.98 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 -172.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -102.26 -10.39 19.59 Favored 'General case' 0 C--N 1.316 -0.875 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.83 -177.349 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 133.32 -153.96 21.01 Favored Glycine 0 N--CA 1.421 -2.346 0 N-CA-C 110.781 -0.927 . . . . 0.0 110.781 -178.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.409 ' CH2' HG13 ' A' ' 108' ' ' VAL . 86.2 m95 -67.65 119.93 13.21 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 122.527 0.331 . . . . 0.0 110.228 -178.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.0 p -71.58 -63.76 1.06 Allowed 'General case' 0 C--O 1.251 1.17 0 CA-C-O 121.544 0.687 . . . . 0.0 111.1 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . 0.581 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.8 m120 -69.99 164.36 24.1 Favored 'General case' 0 CA--C 1.489 -1.383 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.828 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . 0.403 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 12.1 t70 -103.35 -171.84 2.01 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 176.042 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.403 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 64.1 mt -69.48 120.68 78.7 Favored Pre-proline 0 C--N 1.28 -2.427 0 C-N-CA 124.439 1.096 . . . . 0.0 109.625 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -69.77 172.76 12.06 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.558 2.172 . . . . 0.0 112.485 178.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 49.1 mm -109.36 130.5 62.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.051 -173.245 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.4 ' HB2' ' CD2' ' A' ' 93' ' ' PHE . 89.1 m -109.06 114.34 28.0 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 174.354 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -103.09 157.23 17.14 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 176.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 13.6 p -70.62 145.43 12.79 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.069 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.617 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.4 m -72.35 136.28 25.99 Favored 'Isoleucine or valine' 0 C--O 1.248 1.015 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 175.841 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 64.4 mmtt -105.8 151.82 24.0 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -174.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 39.6 m -114.91 145.77 41.85 Favored 'General case' 0 C--N 1.28 -2.43 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 176.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.75 145.89 91.44 Favored Pre-proline 0 N--CA 1.418 -2.05 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -179.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -69.95 125.1 11.66 Favored 'Trans proline' 0 N--CA 1.444 -1.431 0 C-N-CA 122.885 2.39 . . . . 0.0 111.532 -178.546 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.8 t -97.98 137.82 24.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 13.5 p -76.74 -81.7 0.08 Allowed 'General case' 0 C--N 1.314 -0.962 0 O-C-N 123.126 0.267 . . . . 0.0 110.96 177.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.07 156.22 0.24 Allowed Pre-proline 0 C--O 1.24 0.566 0 C-N-CA 125.403 1.481 . . . . 0.0 107.895 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . 0.479 ' HG2' ' HA3' ' A' ' 155' ' ' GLY . 37.1 Cg_endo -71.02 162.1 43.84 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 121.966 1.777 . . . . 0.0 110.17 172.475 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -55.51 -44.99 77.15 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -174.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . 0.413 ' HB2' ' HB2' ' A' ' 205' ' ' CYS . 56.0 m-80 -116.45 28.0 8.85 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.242 0.544 . . . . 0.0 109.73 -177.333 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . 0.479 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -143.32 -174.6 15.72 Favored Glycine 0 N--CA 1.439 -1.162 0 C-N-CA 120.181 -1.009 . . . . 0.0 112.661 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 31.7 pttt -152.9 161.02 43.06 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 123.193 0.597 . . . . 0.0 109.638 -176.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.463 HG23 HG13 ' A' ' 174' ' ' VAL . 58.2 mt -82.44 134.11 27.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 O-C-N 123.27 0.356 . . . . 0.0 110.773 -179.052 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.501 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.7 m -85.69 -32.14 6.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 CA-C-O 121.216 0.531 . . . . 0.0 110.585 -178.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 8.8 t . . . . . 0 N--CA 1.44 -0.957 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.431 -172.273 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . 0.461 ' HB3' ' HB2' ' A' ' 146' ' ' CYS . 97.5 m-85 . . . . . 0 N--CA 1.421 -1.893 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 21.3 m80 -130.31 166.44 20.38 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -175.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.617 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 76.7 t80 -54.36 124.2 15.25 Favored 'General case' 0 C--O 1.247 0.945 0 C-N-CA 120.651 -0.42 . . . . 0.0 109.909 174.288 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 124.59 -26.43 5.71 Favored Glycine 0 N--CA 1.423 -2.218 0 C-N-CA 120.441 -0.885 . . . . 0.0 111.391 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 16.0 mm100 -59.08 131.56 51.39 Favored 'General case' 0 C--O 1.248 1.013 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -179.23 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -119.33 96.1 5.07 Favored 'General case' 0 N--CA 1.424 -1.735 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.463 HG13 HG23 ' A' ' 157' ' ' ILE . 73.4 t -88.89 101.6 12.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.25 -176.102 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.501 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 40.5 ttm180 -91.85 146.35 23.82 Favored 'General case' 0 N--CA 1.417 -2.084 0 CA-C-N 114.557 -1.201 . . . . 0.0 109.422 176.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -116.5 150.44 37.9 Favored 'General case' 0 N--CA 1.416 -2.135 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.6 p -129.84 142.45 43.83 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 177.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . 0.413 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 70.3 m -94.1 148.41 22.2 Favored 'General case' 0 C--N 1.264 -3.114 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.344 -177.238 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -62.33 158.15 18.06 Favored 'General case' 0 CA--C 1.495 -1.166 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.578 178.49 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.2 m -42.11 103.92 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.22 0 O-C-N 125.173 1.545 . . . . 0.0 113.891 -174.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.02 -10.56 31.78 Favored Glycine 0 N--CA 1.432 -1.625 0 C-N-CA 120.469 -0.872 . . . . 0.0 113.731 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . 0.413 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 77.4 m-85 -97.63 160.38 14.35 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 117.809 0.805 . . . . 0.0 111.611 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.21 148.46 52.46 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.44 HD13 ' HA ' ' A' ' 188' ' ' GLU . 2.4 tt -79.77 144.99 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.148 0 CA-C-O 121.428 0.632 . . . . 0.0 110.817 -175.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -81.6 -65.27 1.03 Allowed 'General case' 0 C--N 1.294 -1.822 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.915 -176.534 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -78.52 -110.21 0.2 Allowed Glycine 0 C--N 1.309 -0.932 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.978 -178.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -106.59 179.46 4.26 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.44 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.7 pt-20 -100.16 -11.9 20.06 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 118.974 0.806 . . . . 0.0 110.518 -174.288 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -152.61 164.38 37.79 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -173.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.2 ptp -133.79 136.89 44.8 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.079 176.176 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 44.6 t-80 -112.69 147.81 36.01 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 116.63 -0.259 . . . . 0.0 110.496 -178.104 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 61.1 m -75.08 121.2 21.67 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 123.067 0.547 . . . . 0.0 112.097 175.317 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 48.8 m -88.54 -175.23 4.88 Favored 'General case' 0 C--N 1.31 -1.136 0 C-N-CA 123.394 0.678 . . . . 0.0 110.205 174.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -51.81 -34.89 42.16 Favored 'General case' 0 N--CA 1.5 2.04 0 C-N-CA 125.073 1.349 . . . . 0.0 113.05 -178.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -78.06 -4.02 45.13 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 123.347 0.659 . . . . 0.0 112.608 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 69.25 28.42 72.71 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 108.051 -2.019 . . . . 0.0 108.051 -168.191 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -105.72 148.22 27.68 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-N 114.177 -1.012 . . . . 0.0 108.447 -176.16 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 83.6 m95 -81.97 123.67 29.08 Favored 'General case' 0 C--N 1.292 -1.906 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 10.9 m -62.4 -29.01 70.18 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 122.989 0.516 . . . . 0.0 111.837 -178.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -118.93 155.75 30.76 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 107.078 -1.452 . . . . 0.0 107.078 -178.103 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -95.3 164.06 13.0 Favored 'General case' 0 C--N 1.288 -2.105 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 176.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 54.6 mtpt -54.42 115.87 9.48 Favored Pre-proline 0 C--N 1.319 -0.76 0 O-C-N 123.815 0.697 . . . . 0.0 112.586 -176.423 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . 0.475 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 5.7 Cg_exo -78.06 162.56 28.86 Favored 'Trans proline' 0 N--CA 1.432 -2.093 0 C-N-CA 121.813 1.675 . . . . 0.0 111.231 177.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 50.7 tttp -109.0 157.94 18.19 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 -177.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.413 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 95.0 m -114.33 120.96 42.16 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 175.167 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.9 m . . . . . 0 C--N 1.307 -1.271 0 O-C-N 124.284 0.99 . . . . 0.0 109.318 -177.223 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.511 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 19.3 Cg_endo . . . . . 0 CA--C 1.532 0.412 0 CA-C-O 120.648 0.186 . . . . 0.0 112.308 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . 0.455 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 26.8 m -83.85 -26.55 29.38 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-O 121.465 0.65 . . . . 0.0 110.245 176.323 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.8 -86.65 0.44 Allowed Glycine 0 CA--C 1.452 -3.888 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 170.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.2 t60 -175.03 131.41 0.44 Allowed Pre-proline 0 C--N 1.26 -3.32 0 N-CA-C 104.81 -2.292 . . . . 0.0 104.81 -174.349 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -82.0 6.42 5.7 Favored 'Trans proline' 0 N--CA 1.484 0.963 0 C-N-CA 122.627 2.218 . . . . 0.0 114.641 -172.014 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 108.89 -167.19 12.91 Favored Glycine 0 C--N 1.289 -2.046 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -176.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -154.97 155.47 34.27 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 1.7 t -129.51 129.54 23.21 Favored Pre-proline 0 C--N 1.297 -1.675 0 CA-C-O 120.757 0.313 . . . . 0.0 110.561 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.49 -10.05 18.79 Favored 'Trans proline' 0 C--O 1.223 -0.258 0 C-N-CA 122.523 2.148 . . . . 0.0 111.451 -179.588 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.483 ' HB2' ' HB2' ' A' ' 141' ' ' CYS . 28.4 m-85 -96.78 -52.11 4.03 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 122.213 1.006 . . . . 0.0 108.656 -179.478 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -106.49 -155.17 20.82 Favored Glycine 0 N--CA 1.401 -3.642 0 C-N-CA 119.78 -1.2 . . . . 0.0 112.502 -176.181 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.8 p -146.48 177.38 9.09 Favored 'General case' 0 C--N 1.261 -3.281 0 C-N-CA 125.226 1.411 . . . . 0.0 107.304 178.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.412 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 44.3 p90 -142.47 164.44 30.12 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.79 174.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -129.12 159.16 36.88 Favored 'General case' 0 C--N 1.284 -2.277 0 N-CA-C 106.641 -1.614 . . . . 0.0 106.641 -179.682 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.3 mt -118.25 119.09 33.63 Favored 'General case' 0 C--N 1.274 -2.713 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 177.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.497 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 37.3 p -116.49 136.85 52.64 Favored 'General case' 0 C--N 1.273 -2.759 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.551 -174.676 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.0 17.99 56.8 Favored Glycine 0 N--CA 1.429 -1.792 0 C-N-CA 119.593 -1.289 . . . . 0.0 111.107 -178.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 173.72 -31.85 0.1 Allowed Glycine 0 N--CA 1.436 -1.36 0 C-N-CA 119.229 -1.462 . . . . 0.0 113.596 -179.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 6.6 t30 66.28 9.73 6.61 Favored 'General case' 0 CA--C 1.556 1.175 0 CA-C-O 122.09 0.948 . . . . 0.0 111.728 -178.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.506 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.3 m -142.75 -168.92 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.459 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 -177.46 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -108.51 36.54 2.79 Favored 'General case' 0 C--O 1.25 1.092 0 CA-C-N 119.29 0.95 . . . . 0.0 110.796 -176.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.722 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.3 pt-20 -79.0 177.68 8.61 Favored 'General case' 0 C--O 1.195 -1.765 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.159 179.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . 0.462 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 48.2 m-85 -72.98 130.76 41.08 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 120.858 0.361 . . . . 0.0 111.641 178.771 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.42 -0.55 63.61 Favored Glycine 0 N--CA 1.437 -1.248 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.997 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.722 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.4 p -90.28 145.67 7.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.497 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 16.4 mtpp -109.75 127.18 54.45 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.745 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -88.76 85.19 6.72 Favored 'General case' 0 C--N 1.284 -2.272 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 175.467 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.484 HG12 ' CB ' ' A' ' 126' ' ' TYR . 29.4 m -87.07 114.64 26.52 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 CA-C-O 122.568 1.175 . . . . 0.0 109.461 -179.108 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . 0.412 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 31.4 m-85 -77.99 144.86 36.37 Favored 'General case' 0 C--N 1.27 -2.853 0 CA-C-N 115.098 -0.955 . . . . 0.0 110.833 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.2 t -142.02 118.08 10.64 Favored 'General case' 0 N--CA 1.413 -2.29 0 N-CA-C 107.108 -1.442 . . . . 0.0 107.108 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 38.0 m -75.34 158.51 32.69 Favored 'General case' 0 C--N 1.279 -2.479 0 O-C-N 121.992 -0.443 . . . . 0.0 110.651 -175.459 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -77.65 -179.09 5.68 Favored 'General case' 0 CA--C 1.495 -1.151 0 C-N-CA 119.993 -0.683 . . . . 0.0 111.05 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -52.12 -52.73 49.71 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 124.099 0.874 . . . . 0.0 112.323 -176.306 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.481 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -83.94 25.29 5.41 Favored Glycine 0 C--N 1.304 -1.219 0 C-N-CA 120.625 -0.798 . . . . 0.0 113.831 -178.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.656 ' HE1' HG22 ' A' ' 143' ' ' VAL . 87.6 m-85 -144.31 152.01 40.16 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 122.268 -0.548 . . . . 0.0 110.08 -176.665 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.42 HE21 ' HB2' ' A' ' 119' ' ' GLN . 0.0 OUTLIER -126.78 162.05 26.76 Favored 'General case' 0 C--N 1.276 -2.613 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 -179.386 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 3.1 tt -93.06 128.24 38.88 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.07 -178.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -111.5 126.03 54.53 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 -177.364 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 113.52 164.79 15.76 Favored Glycine 0 C--N 1.286 -2.228 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -175.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 13.6 mm-40 -91.97 -31.48 15.6 Favored 'General case' 0 C--N 1.3 -1.543 0 CA-C-O 121.987 0.899 . . . . 0.0 109.382 -177.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.522 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.0 mm -82.57 127.47 39.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 178.328 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.42 2.8 9.69 Favored 'General case' 0 C--O 1.204 -1.339 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -177.221 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.484 ' CB ' HG12 ' A' ' 111' ' ' VAL . 10.8 p90 -143.54 164.08 31.36 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 120.506 -0.478 . . . . 0.0 109.817 -170.323 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -131.12 132.27 44.7 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 171.544 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -106.0 133.23 51.05 Favored 'General case' 0 C--N 1.284 -2.257 0 C-N-CA 118.533 -1.267 . . . . 0.0 110.773 -178.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . 0.462 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 39.7 t -75.72 96.88 3.7 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.439 ' OD1' HG22 ' A' ' 131' ' ' THR . 8.0 t70 -94.26 -175.05 3.54 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 178.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.454 ' HA ' ' CE1' ' A' ' 106' ' ' TYR . 13.9 t -68.28 -23.4 64.75 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-O 121.898 0.856 . . . . 0.0 109.889 -176.56 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -77.59 -39.06 46.87 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.613 177.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.455 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 145.21 -159.47 27.89 Favored Glycine 0 N--CA 1.421 -2.355 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -174.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 98.1 m95 -67.98 122.48 18.31 Favored 'General case' 0 C--N 1.309 -1.193 0 CA-C-N 117.639 0.719 . . . . 0.0 110.517 178.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 76.2 p -76.63 170.76 15.83 Favored 'General case' 0 C--O 1.265 1.885 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 74.4 m-20 61.91 -165.34 0.23 Allowed 'General case' 0 C--O 1.246 0.894 0 O-C-N 123.951 0.782 . . . . 0.0 111.474 174.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -122.53 168.83 11.66 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 80.6 mt -67.54 119.63 67.14 Favored Pre-proline 0 C--N 1.307 -1.252 0 O-C-N 123.247 0.342 . . . . 0.0 110.089 176.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.522 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 33.9 Cg_endo -65.99 150.09 85.69 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 122.733 2.288 . . . . 0.0 110.527 177.317 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 61.8 mt -96.46 130.27 45.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-O 121.106 0.479 . . . . 0.0 111.034 -174.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.483 ' HB2' ' HB2' ' A' ' 93' ' ' PHE . 93.1 m -99.38 107.69 20.01 Favored 'General case' 0 C--N 1.284 -2.273 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 172.08 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -91.96 154.41 18.83 Favored 'General case' 0 N--CA 1.412 -2.362 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 177.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.656 HG22 ' HE1' ' A' ' 118' ' ' TYR . 4.5 t -80.02 141.36 15.39 Favored 'Isoleucine or valine' 0 C--N 1.256 -3.494 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -175.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.555 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 15.9 m -68.4 100.12 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-O 121.85 0.833 . . . . 0.0 109.987 -178.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.448 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 94.9 mttt -100.69 136.56 40.36 Favored 'General case' 0 N--CA 1.421 -1.879 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.053 -174.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 60.6 m -98.96 167.87 10.46 Favored 'General case' 0 C--N 1.291 -1.955 0 CA-C-N 114.321 -1.309 . . . . 0.0 109.056 -177.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 2.2 pp -79.73 154.92 75.96 Favored Pre-proline 0 N--CA 1.427 -1.612 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 178.239 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -79.64 118.82 3.92 Favored 'Trans proline' 0 N--CA 1.441 -1.564 0 C-N-CA 122.46 2.106 . . . . 0.0 111.719 -177.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.0 t -67.65 144.61 14.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.1 p -77.17 -83.54 0.07 Allowed 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 119.644 -0.217 . . . . 0.0 111.496 176.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 173.51 162.69 0.3 Allowed Pre-proline 0 N--CA 1.473 0.715 0 C-N-CA 125.171 1.388 . . . . 0.0 108.361 178.162 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . 0.46 ' HB3' ' HA ' ' A' ' 204' ' ' LYS . 72.6 Cg_endo -84.04 166.46 12.9 Favored 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 122.361 2.041 . . . . 0.0 110.997 170.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -72.11 -62.56 1.39 Allowed 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 114.099 1.148 . . . . 0.0 114.099 -176.333 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . 0.422 ' HB2' ' O ' ' A' ' 205' ' ' CYS . 43.7 m-80 -97.24 31.35 2.49 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 121.943 0.878 . . . . 0.0 110.075 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -150.87 -169.99 17.36 Favored Glycine 0 N--CA 1.422 -2.274 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.59 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . 0.458 ' HG3' HG23 ' A' ' 177' ' ' VAL . 21.9 pttm -151.84 171.62 17.47 Favored 'General case' 0 C--N 1.289 -2.034 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.249 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 54.3 mt -90.87 135.09 27.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-O 120.951 0.405 . . . . 0.0 111.415 -178.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.474 ' CG2' HG22 ' A' ' 177' ' ' VAL . 57.0 t -70.83 -50.03 46.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 C-N-CA 124.214 1.006 . . . . 0.0 108.468 177.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 1.7 m . . . . . 0 C--N 1.303 -1.432 0 C-N-CA 124.558 1.143 . . . . 0.0 111.018 -176.513 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . 0.448 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 74.4 m-85 . . . . . 0 C--O 1.2 -1.516 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.486 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 44.6 p-80 -153.21 171.44 18.51 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-O 118.675 -0.678 . . . . 0.0 109.19 -172.641 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.555 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 62.0 t80 -50.77 133.2 26.39 Favored 'General case' 0 C--O 1.239 0.528 0 O-C-N 123.732 0.645 . . . . 0.0 110.512 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 106.06 -26.99 18.91 Favored Glycine 0 N--CA 1.434 -1.48 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -177.369 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . 0.407 ' HA ' HE21 ' A' ' 172' ' ' GLN . 0.0 OUTLIER -76.12 140.43 41.8 Favored 'General case' 0 CA--C 1.503 -0.838 0 CA-C-O 121.629 0.728 . . . . 0.0 110.413 178.727 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.426 ' HB2' ' CD2' ' A' ' 191' ' ' HIS . . . -129.62 119.91 24.37 Favored 'General case' 0 C--N 1.279 -2.495 0 CA-C-N 114.139 -1.391 . . . . 0.0 107.315 176.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.495 HG23 ' CH2' ' A' ' 198' ' ' TRP . 68.1 t -93.65 108.38 20.45 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.992 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 176.021 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.451 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 76.2 ttt180 -103.24 156.29 17.82 Favored 'General case' 0 N--CA 1.409 -2.479 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -127.96 153.15 47.04 Favored 'General case' 0 C--N 1.291 -1.972 0 C-N-CA 123.179 0.591 . . . . 0.0 110.158 -170.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.474 HG22 ' CG2' ' A' ' 158' ' ' VAL . 0.1 OUTLIER -127.91 141.15 47.22 Favored 'Isoleucine or valine' 0 CA--C 1.467 -2.212 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.262 179.04 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 72.1 m -95.96 132.75 40.96 Favored 'General case' 0 N--CA 1.389 -3.487 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.08 176.238 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 -67.12 170.03 7.59 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 113.985 -1.462 . . . . 0.0 109.711 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.3 m -49.84 109.47 0.29 Allowed 'General case' 0 C--N 1.297 -1.7 0 O-C-N 124.394 1.059 . . . . 0.0 113.463 -174.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 97.16 18.21 29.68 Favored Glycine 0 N--CA 1.433 -1.527 0 CA-C-N 115.234 -0.894 . . . . 0.0 114.633 174.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -128.53 164.9 21.8 Favored 'General case' 0 C--O 1.241 0.645 0 CA-C-N 118.457 1.128 . . . . 0.0 112.572 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.503 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 56.7 pttt -122.12 154.84 36.86 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 106.741 -1.578 . . . . 0.0 106.741 178.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 5.4 tp -72.67 145.9 11.5 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 174.453 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -70.4 -69.73 0.34 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 120.983 0.421 . . . . 0.0 110.108 -177.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -109.65 -82.76 1.39 Allowed Glycine 0 N--CA 1.431 -1.66 0 C-N-CA 120.24 -0.981 . . . . 0.0 111.851 178.824 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -113.99 151.81 31.85 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -177.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.451 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 8.9 pt-20 -109.82 9.71 24.64 Favored 'General case' 0 C--N 1.3 -1.587 0 CA-C-N 118.448 0.567 . . . . 0.0 110.708 -179.333 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -148.73 130.35 14.96 Favored 'General case' 0 C--N 1.295 -1.788 0 CA-C-O 122.012 0.911 . . . . 0.0 113.315 -178.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.424 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 16.5 ptp -121.46 144.72 48.53 Favored 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.21 178.003 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . 0.426 ' CD2' ' HB2' ' A' ' 173' ' ' ALA . 34.5 m80 -117.25 147.77 42.24 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 120.469 0.176 . . . . 0.0 111.032 -179.411 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 4.9 m -76.17 115.92 16.37 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.475 172.61 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . 0.516 ' HB2' ' OD1' ' A' ' 195' ' ' ASP . 13.0 m -85.55 177.19 7.83 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.458 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -76.85 3.43 12.0 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 121.348 0.595 . . . . 0.0 112.272 -176.254 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . 0.516 ' OD1' ' HB2' ' A' ' 193' ' ' SER . 43.4 p-10 -92.61 -15.68 26.56 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 123.267 0.627 . . . . 0.0 109.755 177.077 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 90.93 19.47 43.14 Favored Glycine 0 N--CA 1.432 -1.603 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.586 -178.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -128.47 168.94 14.92 Favored 'General case' 0 C--N 1.314 -0.96 0 O-C-N 122.152 -0.617 . . . . 0.0 111.458 178.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . 0.495 ' CH2' HG23 ' A' ' 174' ' ' VAL . 85.9 m95 -82.46 131.03 35.22 Favored 'General case' 0 N--CA 1.436 -1.172 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.646 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 31.0 p -62.53 -29.66 70.72 Favored 'General case' 0 C--N 1.312 -1.025 0 C-N-CA 124.579 1.152 . . . . 0.0 113.108 -177.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 3.1 tppp? -126.17 158.18 36.25 Favored 'General case' 0 N--CA 1.432 -1.329 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -81.12 174.24 11.78 Favored 'General case' 0 C--N 1.312 -1.041 0 O-C-N 123.318 0.386 . . . . 0.0 110.033 -178.466 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . 0.418 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 37.5 mtpt -70.0 121.35 82.61 Favored Pre-proline 0 N--CA 1.438 -1.064 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.301 176.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -89.08 -162.36 0.13 Allowed 'Trans proline' 0 N--CA 1.431 -2.153 0 C-N-CA 122.388 2.059 . . . . 0.0 109.44 173.642 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . 0.46 ' HA ' ' HB3' ' A' ' 152' ' ' PRO . 18.0 ptpt -166.39 174.09 9.36 Favored 'General case' 0 N--CA 1.416 -2.141 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.504 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 80.7 m -114.03 128.89 56.58 Favored 'General case' 0 C--N 1.276 -2.607 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 177.727 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.8 m . . . . . 0 C--N 1.28 -2.432 0 O-C-N 124.49 1.118 . . . . 0.0 108.542 -172.642 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 39.7 Cg_endo . . . . . 0 CA--C 1.54 0.804 0 CA-C-O 121.245 0.435 . . . . 0.0 111.977 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 61.3 m -90.07 -32.5 16.68 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 122.148 0.975 . . . . 0.0 108.654 176.168 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 111.82 -83.84 0.34 Allowed Glycine 0 CA--C 1.455 -3.715 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 171.043 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 9.3 t60 -179.83 130.83 0.25 Allowed Pre-proline 0 C--N 1.267 -2.979 0 N-CA-C 104.928 -2.249 . . . . 0.0 104.928 -175.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.416 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 88.1 Cg_endo -84.12 1.48 8.74 Favored 'Trans proline' 0 N--CA 1.485 1.008 0 C-N-CA 122.677 2.251 . . . . 0.0 113.915 -172.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 94.19 179.75 38.25 Favored Glycine 0 N--CA 1.429 -1.831 0 N-CA-C 108.492 -1.843 . . . . 0.0 108.492 -173.112 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -140.7 -179.66 6.17 Favored 'General case' 0 C--N 1.29 -2.005 0 CA-C-N 117.628 0.714 . . . . 0.0 109.767 -178.178 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.0 t -126.53 138.47 32.49 Favored Pre-proline 0 C--N 1.307 -1.245 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -77.34 -20.89 12.2 Favored 'Trans proline' 0 CA--C 1.534 0.514 0 C-N-CA 122.537 2.158 . . . . 0.0 112.255 -179.097 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.402 ' O ' ' HB2' ' A' ' 115' ' ' ASN . 59.0 m-85 -80.82 -50.4 9.87 Favored 'General case' 0 CA--C 1.5 -0.967 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.477 -176.287 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -122.49 -136.45 4.89 Favored Glycine 0 N--CA 1.421 -2.338 0 C-N-CA 120.558 -0.829 . . . . 0.0 111.115 -178.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.7 p -148.21 -172.51 4.09 Favored 'General case' 0 C--N 1.294 -1.813 0 C-N-CA 123.594 0.758 . . . . 0.0 109.073 -178.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 38.5 p90 -145.01 163.76 33.23 Favored 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 120.381 -0.528 . . . . 0.0 109.984 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.6 m -135.75 158.91 43.22 Favored 'General case' 0 C--N 1.288 -2.084 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 178.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.423 HD11 ' CE1' ' A' ' 104' ' ' PHE . 18.1 mt -110.18 122.05 46.71 Favored 'General case' 0 C--N 1.28 -2.414 0 CA-C-O 120.94 0.4 . . . . 0.0 110.384 -178.029 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 19.2 p -114.43 136.27 53.19 Favored 'General case' 0 C--N 1.286 -2.162 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.924 -176.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 95.78 11.74 54.52 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 120.035 -1.078 . . . . 0.0 112.174 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 171.59 -23.96 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 119.274 -1.441 . . . . 0.0 113.818 -178.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 65.4 17.3 10.92 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 179.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.498 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.3 m -148.97 -176.23 0.41 Allowed 'Isoleucine or valine' 0 C--O 1.205 -1.242 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -175.726 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.423 ' CE1' HD11 ' A' ' 98' ' ' LEU . 41.2 m-85 -102.84 47.32 0.89 Allowed 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 118.299 0.5 . . . . 0.0 110.401 -179.452 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.712 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.8 pt-20 -88.44 179.54 6.29 Favored 'General case' 0 C--O 1.207 -1.147 0 CA-C-N 115.477 -0.783 . . . . 0.0 111.092 177.467 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -79.36 135.76 36.8 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.075 176.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.52 1.3 62.27 Favored Glycine 0 N--CA 1.434 -1.449 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.832 -179.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.712 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.5 p -97.54 150.67 4.53 Favored 'Isoleucine or valine' 0 C--O 1.246 0.908 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 14.6 mtpp -113.82 127.87 56.18 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -179.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -90.34 93.05 9.17 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 175.773 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 44.0 t -88.19 114.95 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.662 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.063 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.1 m-85 -85.15 133.48 34.2 Favored 'General case' 0 C--N 1.284 -2.246 0 CA-C-N 115.496 -0.775 . . . . 0.0 109.632 179.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.8 t -125.82 127.43 46.08 Favored 'General case' 0 N--CA 1.409 -2.508 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -177.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 79.6 m -75.32 159.99 30.83 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.402 ' HB2' ' O ' ' A' ' 93' ' ' PHE . 6.7 t-20 -69.53 -175.84 0.9 Allowed 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 114.053 -1.431 . . . . 0.0 109.487 178.148 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -67.1 -44.38 80.11 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 120.998 0.427 . . . . 0.0 111.081 -179.555 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.21 8.12 68.8 Favored Glycine 0 C--N 1.31 -0.878 0 CA-C-N 115.965 -0.561 . . . . 0.0 113.14 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.664 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 70.7 m-85 -127.95 160.64 31.26 Favored 'General case' 0 C--N 1.311 -1.073 0 O-C-N 122.534 -0.392 . . . . 0.0 110.955 178.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.33 144.26 30.62 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -178.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -75.6 126.95 32.01 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -174.657 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -110.79 130.92 55.44 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 -177.391 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.02 174.81 20.18 Favored Glycine 0 C--N 1.301 -1.408 0 N-CA-C 111.528 -0.629 . . . . 0.0 111.528 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -83.31 -36.22 24.62 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.416 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 49.5 mm -87.97 125.0 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.862 0 CA-C-N 113.977 -1.465 . . . . 0.0 109.247 -175.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -127.54 3.96 6.19 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.369 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.414 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 17.9 p90 -144.05 165.11 28.7 Favored 'General case' 0 N--CA 1.422 -1.848 0 C-N-CA 119.901 -0.72 . . . . 0.0 110.757 -171.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.416 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 45.9 mtp180 -126.19 132.79 51.71 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 173.093 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -108.76 134.15 51.86 Favored 'General case' 0 C--N 1.277 -2.586 0 C-N-CA 119.464 -0.895 . . . . 0.0 108.864 -177.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 17.5 t -85.74 99.96 11.69 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 118.292 -1.363 . . . . 0.0 109.403 177.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.448 ' OD2' HG22 ' A' ' 131' ' ' THR . 8.5 t70 -104.32 -167.84 1.41 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 177.123 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.448 HG22 ' OD2' ' A' ' 130' ' ' ASP . 9.6 t -65.14 -15.87 62.88 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 119.048 0.84 . . . . 0.0 111.633 -177.072 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -81.79 -13.49 57.64 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.697 0.76 . . . . 0.0 109.839 176.104 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 102.49 -157.46 18.24 Favored Glycine 0 N--CA 1.428 -1.847 0 N-CA-C 107.522 -2.231 . . . . 0.0 107.522 -174.445 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.411 ' CD2' ' HB3' ' A' ' 88' ' ' PRO . 94.6 m95 -62.28 106.64 0.77 Allowed 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 117.714 0.757 . . . . 0.0 110.405 173.766 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 62.3 p -71.8 171.48 11.57 Favored 'General case' 0 C--O 1.269 2.086 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.192 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 1.8 m-20 62.87 -158.57 0.32 Allowed 'General case' 0 C--O 1.245 0.83 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.029 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 29.0 t0 -141.11 173.03 11.87 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 173.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 70.1 mt -59.36 121.71 58.46 Favored Pre-proline 0 C--N 1.269 -2.915 0 C-N-CA 125.14 1.376 . . . . 0.0 108.352 175.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.416 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 38.2 Cg_endo -64.78 178.32 1.85 Allowed 'Trans proline' 0 C--O 1.251 1.17 0 C-N-CA 123.097 2.531 . . . . 0.0 113.614 -176.628 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 63.5 mt -98.37 129.52 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.066 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.69 -176.094 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.614 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 33.6 t -114.69 107.12 15.04 Favored 'General case' 0 C--N 1.273 -2.735 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 178.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -99.35 152.1 20.33 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-O 121.625 0.726 . . . . 0.0 110.933 -176.105 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.664 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 3.3 t -73.1 136.52 25.32 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.049 0 CA-C-N 113.902 -1.499 . . . . 0.0 108.609 -179.703 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.87 125.02 20.9 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.097 0 O-C-N 124.957 1.411 . . . . 0.0 108.064 177.052 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.522 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 45.6 mttp -122.9 162.62 21.88 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.382 -174.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 57.0 m -124.58 168.34 13.26 Favored 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 114.309 -1.314 . . . . 0.0 107.734 175.036 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 71.5 mt -74.73 143.59 78.76 Favored Pre-proline 0 C--N 1.307 -1.244 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -179.387 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.444 ' HA ' ' CE2' ' A' ' 168' ' ' TYR . 17.5 Cg_endo -62.73 122.36 10.65 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.945 2.43 . . . . 0.0 110.761 178.283 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 48.0 t -91.81 142.02 13.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.005 -175.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 21.0 p -79.95 -82.67 0.11 Allowed 'General case' 0 N--CA 1.43 -1.47 0 CA-C-N 116.727 -0.215 . . . . 0.0 110.907 176.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.49 165.7 0.45 Allowed Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 124.051 0.94 . . . . 0.0 108.724 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . 0.521 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 55.6 Cg_endo -76.57 160.93 34.63 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.024 1.816 . . . . 0.0 109.742 167.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -53.3 -50.77 64.21 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 114.287 1.218 . . . . 0.0 114.287 -175.055 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 55.6 m-80 -113.3 38.06 2.99 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -154.78 -167.43 16.56 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.918 -1.134 . . . . 0.0 112.53 177.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -153.04 170.24 20.95 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 -177.347 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.457 HG22 ' H ' ' A' ' 159' ' ' SER . 73.3 mt -86.02 137.67 20.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 177.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.52 HG21 ' HB3' ' A' ' 175' ' ' ARG . 14.5 m -69.11 -32.68 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-O 121.597 0.713 . . . . 0.0 110.872 -177.766 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . 0.457 ' H ' HG22 ' A' ' 157' ' ' ILE . 24.3 t . . . . . 0 N--CA 1.424 -1.741 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -178.099 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . 0.489 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 67.4 m-85 . . . . . 0 CA--C 1.506 -0.736 0 CA-C-O 120.861 0.363 . . . . 0.0 110.628 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 28.1 m80 -98.02 161.45 13.72 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.534 -173.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -58.0 135.69 56.99 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.868 172.525 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 103.5 -18.26 48.39 Favored Glycine 0 N--CA 1.429 -1.803 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.62 -179.292 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.9 tp60 -76.96 128.83 35.24 Favored 'General case' 0 N--CA 1.398 -3.037 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -110.6 131.14 55.31 Favored 'General case' 0 N--CA 1.418 -2.027 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 172.468 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 55.5 t -107.87 99.56 8.88 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.32 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.52 ' HB3' HG21 ' A' ' 158' ' ' VAL . 41.7 ttm180 -89.76 144.09 26.26 Favored 'General case' 0 N--CA 1.42 -1.928 0 CA-C-N 115.043 -0.981 . . . . 0.0 109.025 178.124 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.521 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 78.1 m-85 -113.93 160.42 18.82 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -178.171 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.9 p -139.53 150.45 22.52 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.057 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 63.9 m -109.7 157.64 18.9 Favored 'General case' 0 C--N 1.287 -2.123 0 O-C-N 123.39 0.431 . . . . 0.0 111.602 -175.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -78.41 170.7 16.21 Favored 'General case' 0 N--CA 1.439 -1.018 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.534 179.284 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 23.1 t -49.64 105.93 0.1 Allowed 'General case' 0 C--N 1.313 -1.013 0 C-N-CA 124.88 1.272 . . . . 0.0 112.918 -175.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 111.74 -15.08 26.75 Favored Glycine 0 N--CA 1.43 -1.719 0 CA-C-N 115.285 -0.87 . . . . 0.0 113.252 175.328 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . 0.462 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 93.5 m-85 -103.84 159.84 15.3 Favored 'General case' 0 N--CA 1.433 -1.323 0 CA-C-N 117.783 0.791 . . . . 0.0 111.353 -176.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 53.4 pttt -135.04 155.7 50.3 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 175.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.479 HD13 ' HA ' ' A' ' 188' ' ' GLU . 12.5 tt -81.95 141.98 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.57 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.568 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -66.16 -79.02 0.05 OUTLIER 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 114.283 1.216 . . . . 0.0 114.283 -171.631 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -83.64 -92.87 0.67 Allowed Glycine 0 CA--C 1.496 -1.135 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.183 -175.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -94.32 173.71 7.5 Favored 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.479 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.7 pt-20 -122.82 4.83 9.43 Favored 'General case' 0 N--CA 1.438 -1.029 0 C-N-CA 120.613 -0.435 . . . . 0.0 110.205 178.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . 0.471 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 7.1 pt-20 -163.46 120.02 1.77 Allowed 'General case' 0 N--CA 1.432 -1.345 0 CA-C-O 121.943 0.877 . . . . 0.0 112.144 -175.013 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 12.8 ptp -100.53 132.12 46.08 Favored 'General case' 0 C--N 1.281 -2.41 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.501 177.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 23.8 t-80 -107.24 143.46 35.43 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.918 -177.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 2.5 m -70.21 116.79 10.97 Favored 'General case' 0 CA--C 1.5 -0.946 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.944 172.546 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 2.6 m -83.39 151.73 25.37 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -67.75 -8.92 39.53 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 121.17 0.51 . . . . 0.0 112.362 -175.079 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . 0.421 ' HB3' ' CE1' ' A' ' 197' ' ' PHE . 26.0 t70 -82.87 -16.81 46.11 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-O 121.279 0.562 . . . . 0.0 110.638 177.464 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 99.78 38.62 3.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.669 -0.777 . . . . 0.0 113.724 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . 0.421 ' CE1' ' HB3' ' A' ' 195' ' ' ASP . 44.7 p90 -149.08 156.18 41.83 Favored 'General case' 0 C--O 1.249 1.04 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.707 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 83.4 m95 -72.79 128.33 35.2 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 175.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.0 m -51.74 -36.65 47.89 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.047 0.539 . . . . 0.0 111.621 -178.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 28.3 mmtp -116.24 163.79 15.47 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.463 177.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -88.18 162.57 16.62 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.652 178.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . 0.442 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 0.2 OUTLIER -57.55 105.09 0.48 Allowed Pre-proline 0 CA--C 1.57 1.731 0 C-N-CA 125.667 1.587 . . . . 0.0 112.758 -176.548 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 5.3 Cg_endo -89.0 170.89 4.88 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 124.005 3.136 . . . . 0.0 113.671 -176.708 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 20.1 pttm -135.06 162.21 33.13 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.046 -176.462 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.462 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 83.2 m -100.72 119.43 38.59 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 124.264 0.978 . . . . 0.0 108.537 177.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 25.5 m . . . . . 0 C--N 1.287 -2.128 0 O-C-N 124.441 1.088 . . . . 0.0 109.776 -174.188 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 18.4 Cg_endo . . . . . 0 CA--C 1.543 0.938 0 CA-C-O 121.4 0.5 . . . . 0.0 111.882 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . 0.484 ' HB3' ' NE1' ' A' ' 134' ' ' TRP . 23.6 m -89.42 -27.3 20.49 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.035 0.445 . . . . 0.0 111.606 176.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.62 -83.14 0.32 Allowed Glycine 0 CA--C 1.456 -3.652 0 C-N-CA 120.292 -0.956 . . . . 0.0 111.249 170.405 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -175.66 129.21 0.39 Allowed Pre-proline 0 C--N 1.269 -2.934 0 N-CA-C 106.498 -1.667 . . . . 0.0 106.498 -176.002 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -82.81 7.97 4.86 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 123.231 2.62 . . . . 0.0 114.476 -171.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 120.69 164.92 12.59 Favored Glycine 0 C--N 1.292 -1.881 0 N-CA-C 108.316 -1.914 . . . . 0.0 108.316 -175.477 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -145.82 111.93 5.7 Favored 'General case' 0 C--N 1.293 -1.859 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -177.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 8.2 t -98.92 140.65 21.89 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -172.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -85.38 -9.02 8.42 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.853 2.369 . . . . 0.0 111.548 173.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -94.81 16.41 15.95 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.251 0.548 . . . . 0.0 110.593 -176.149 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 156.43 -121.95 1.14 Allowed Glycine 0 N--CA 1.41 -3.072 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 t -171.85 -160.33 0.16 Allowed 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.652 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -149.94 164.82 34.43 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.364 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.8 m -125.33 160.76 28.55 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 178.268 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.0 mt -119.71 131.82 55.49 Favored 'General case' 0 C--N 1.277 -2.578 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -179.023 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 38.9 p -126.21 131.28 52.0 Favored 'General case' 0 C--N 1.286 -2.178 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -177.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 87.71 24.98 33.88 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.503 -0.856 . . . . 0.0 111.68 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 176.1 -37.8 0.1 OUTLIER Glycine 0 N--CA 1.434 -1.447 0 C-N-CA 119.93 -1.129 . . . . 0.0 112.799 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 67.39 11.36 8.34 Favored 'General case' 0 N--CA 1.498 1.925 0 C-N-CA 124.354 1.062 . . . . 0.0 109.694 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.504 ' O ' HG11 ' A' ' 108' ' ' VAL . 25.1 m -150.56 -168.38 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.085 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 -177.539 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 24.4 m-85 -104.75 38.25 1.95 Allowed 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 118.347 0.521 . . . . 0.0 110.788 -175.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.702 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.2 pt-20 -79.19 173.81 12.2 Favored 'General case' 0 C--O 1.195 -1.763 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.782 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . 0.492 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 41.8 m-85 -72.44 133.14 44.71 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.975 178.668 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.34 -0.1 71.09 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 115.739 -0.664 . . . . 0.0 113.064 178.293 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.702 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.5 p -89.45 148.77 4.31 Favored 'Isoleucine or valine' 0 C--O 1.243 0.763 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.753 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -112.16 131.52 55.42 Favored 'General case' 0 C--N 1.283 -2.295 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.362 177.657 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.494 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -94.96 94.93 8.3 Favored 'General case' 0 C--N 1.285 -2.213 0 CA-C-N 115.382 -0.826 . . . . 0.0 108.791 176.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 91.8 t -86.54 106.84 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.812 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . 0.499 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 18.4 t80 -74.14 138.19 43.7 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 123.495 0.718 . . . . 0.0 109.19 -177.559 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.2 t -142.07 114.68 8.48 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.097 0.951 . . . . 0.0 110.09 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 73.6 m -71.35 163.19 28.16 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 115.374 -0.83 . . . . 0.0 112.193 -179.382 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -73.42 -175.04 1.82 Allowed 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.862 178.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -62.13 -45.93 91.25 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-O 121.228 0.537 . . . . 0.0 111.748 -177.324 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -79.82 4.32 66.0 Favored Glycine 0 C--N 1.313 -0.716 0 CA-C-N 115.879 -0.601 . . . . 0.0 114.285 -179.093 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.408 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.1 m-85 -129.77 166.25 20.27 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 -177.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 7.8 pt20 -150.49 160.87 43.47 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -77.59 133.94 38.34 Favored 'General case' 0 N--CA 1.424 -1.774 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.511 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -120.89 132.12 54.78 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 177.683 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 112.1 -170.14 13.44 Favored Glycine 0 N--CA 1.43 -1.76 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -178.746 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -100.77 -37.34 8.75 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.532 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 49.3 mm -80.97 125.53 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.071 0 CA-C-N 114.865 -1.061 . . . . 0.0 110.284 -177.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.407 ' HA ' ' HB3' ' A' ' 139' ' ' PRO . 2.8 p-10 -132.03 11.05 4.64 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.499 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.494 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 24.3 p90 -142.88 161.09 39.02 Favored 'General case' 0 C--N 1.312 -1.058 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -178.364 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 54.8 mtp180 -129.88 138.02 50.72 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 172.196 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -109.07 128.56 55.09 Favored 'General case' 0 C--N 1.281 -2.403 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.552 -178.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . 0.492 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 38.9 t -76.84 96.06 4.21 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.033 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.414 ' OD2' HG22 ' A' ' 131' ' ' THR . 11.2 t70 -103.12 -171.6 1.97 Allowed 'General case' 0 N--CA 1.426 -1.65 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 179.181 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.414 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.8 t -69.48 -20.35 63.74 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.054 0.454 . . . . 0.0 111.873 -173.05 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -82.02 -25.37 34.72 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 121.516 0.674 . . . . 0.0 109.5 175.171 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 130.11 -154.37 20.52 Favored Glycine 0 N--CA 1.422 -2.254 0 N-CA-C 108.291 -1.923 . . . . 0.0 108.291 -174.377 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.484 ' NE1' ' HB3' ' A' ' 85' ' ' CYS . 98.5 m95 -68.93 118.7 12.18 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 117.519 0.66 . . . . 0.0 110.977 178.572 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 75.7 p -70.42 166.16 20.97 Favored 'General case' 0 C--O 1.277 2.552 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 175.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 60.81 -162.94 0.26 Allowed 'General case' 0 C--O 1.246 0.896 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -129.72 -176.02 3.78 Favored 'General case' 0 C--N 1.283 -2.298 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 173.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 75.1 mt -63.42 117.8 37.76 Favored Pre-proline 0 C--N 1.278 -2.519 0 C-N-CA 124.219 1.008 . . . . 0.0 108.289 176.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.532 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 24.0 Cg_exo -55.7 158.36 13.67 Favored 'Trans proline' 0 C--O 1.251 1.172 0 C-N-CA 122.346 2.031 . . . . 0.0 111.904 178.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.511 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 46.6 mm -87.76 134.24 28.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 C-N-CA 120.192 -0.603 . . . . 0.0 109.885 -172.048 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.408 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 12.3 t -118.75 112.11 19.34 Favored 'General case' 0 C--N 1.28 -2.445 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.638 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -108.86 155.66 20.56 Favored 'General case' 0 C--N 1.278 -2.542 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -178.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.6 p -75.8 140.01 18.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 176.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.499 ' HB ' ' HB2' ' A' ' 170' ' ' PHE . 71.3 t -60.21 130.78 24.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 179.341 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -118.6 136.88 53.63 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -178.416 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 77.1 m -97.21 160.58 14.25 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.052 -177.638 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . 0.543 HD12 ' HD2' ' A' ' 148' ' ' PRO . 15.0 tp -71.75 125.91 91.58 Favored Pre-proline 0 N--CA 1.384 -3.725 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -178.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.543 ' HD2' HD12 ' A' ' 147' ' ' LEU . 14.2 Cg_endo -58.34 131.29 42.06 Favored 'Trans proline' 0 C--O 1.24 0.585 0 C-N-CA 123.839 3.026 . . . . 0.0 113.025 -176.091 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.7 t -93.51 139.59 17.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.0 p -74.98 -76.89 0.13 Allowed 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 111.657 0.243 . . . . 0.0 111.657 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.56 158.38 0.21 Allowed Pre-proline 0 CA--C 1.508 -0.665 0 N-CA-C 106.703 -1.592 . . . . 0.0 106.703 178.109 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -77.56 167.46 24.21 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 121.388 1.392 . . . . 0.0 109.33 171.597 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . 0.507 ' OE1' ' HG3' ' A' ' 204' ' ' LYS . 0.1 OUTLIER -74.68 -46.83 35.32 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -173.109 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . 0.456 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 55.2 m-80 -106.45 23.76 13.66 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.766 0.793 . . . . 0.0 110.748 -177.682 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -145.07 -157.43 7.23 Favored Glycine 0 N--CA 1.421 -2.337 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.826 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 21.4 pttp -157.78 169.58 24.3 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 43.3 mt -95.94 124.87 48.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 CA-C-O 121.4 0.619 . . . . 0.0 111.199 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.4 ' CG2' HG22 ' A' ' 177' ' ' VAL . 80.7 t -67.64 -46.29 83.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 C-N-CA 124.486 1.114 . . . . 0.0 109.661 179.385 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 14.9 m . . . . . 0 C--N 1.311 -1.093 0 N-CA-C 114.017 1.117 . . . . 0.0 114.017 -173.977 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 . . . . . 0 N--CA 1.441 -0.894 0 CA-C-O 121.983 0.897 . . . . 0.0 110.58 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 51.4 m170 -88.1 155.73 19.64 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.268 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.499 ' HB2' ' HB ' ' A' ' 144' ' ' VAL . 52.9 t80 -54.35 113.51 1.3 Allowed 'General case' 0 CA--C 1.509 -0.602 0 CA-C-O 121.484 0.659 . . . . 0.0 110.15 176.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . 0.417 ' H ' ' HB2' ' A' ' 192' ' ' CYS . . . 132.44 -25.33 3.83 Favored Glycine 0 N--CA 1.407 -3.243 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 -177.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . 0.488 HE21 ' HA ' ' A' ' 172' ' ' GLN . 0.0 OUTLIER -68.41 137.63 54.68 Favored 'General case' 0 C--O 1.256 1.402 0 CA-C-O 121.845 0.831 . . . . 0.0 111.747 -178.776 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -112.94 117.76 32.97 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 175.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.523 ' HB ' ' HG2' ' A' ' 190' ' ' MET . 53.3 t -99.47 105.32 17.28 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 CA-C-O 121.336 0.589 . . . . 0.0 110.089 -178.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.421 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 27.3 ttm180 -94.92 152.8 18.05 Favored 'General case' 0 N--CA 1.414 -2.237 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.694 178.13 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -125.04 157.63 35.73 Favored 'General case' 0 C--N 1.284 -2.249 0 C-N-CA 124.491 1.116 . . . . 0.0 108.869 -175.312 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.4 HG22 ' CG2' ' A' ' 158' ' ' VAL . 0.0 OUTLIER -131.37 151.44 35.62 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.958 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.912 175.636 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 7.7 m -118.06 135.2 54.33 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 114.136 -1.393 . . . . 0.0 108.154 173.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -62.63 161.39 12.3 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 124.233 0.958 . . . . 0.0 110.421 178.386 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 7.5 t -62.37 109.76 1.45 Allowed 'General case' 0 C--N 1.299 -1.597 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.323 -174.209 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 122.97 -19.93 7.72 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -177.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . 0.595 ' HB3' ' SG ' ' A' ' 205' ' ' CYS . 82.6 m-85 -107.69 160.86 15.38 Favored 'General case' 0 N--CA 1.429 -1.495 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.83 146.9 33.39 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.566 HD13 ' HA ' ' A' ' 188' ' ' GLU . 9.5 tt -80.72 140.02 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.808 0 CA-C-O 121.8 0.81 . . . . 0.0 111.513 -176.446 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -83.02 -51.02 7.93 Favored 'General case' 0 C--N 1.294 -1.829 0 CA-C-N 115.164 -0.925 . . . . 0.0 109.26 -176.112 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.58 -158.91 25.18 Favored Glycine 0 C--N 1.298 -1.573 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 173.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -79.74 160.36 26.26 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 122.283 -0.539 . . . . 0.0 110.108 177.485 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.566 ' HA ' HD13 ' A' ' 184' ' ' ILE . 10.5 pt-20 -91.17 9.33 31.55 Favored 'General case' 0 C--O 1.205 -1.241 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.362 -176.167 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.2 pt-20 -155.37 138.82 15.87 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.225 0.536 . . . . 0.0 111.431 -178.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.523 ' HG2' ' HB ' ' A' ' 174' ' ' VAL . 6.2 ptm -127.37 144.78 51.0 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 178.401 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 52.5 t-80 -126.48 142.33 51.57 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.593 -0.692 . . . . 0.0 110.742 -175.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . 0.417 ' HB2' ' H ' ' A' ' 171' ' ' GLY . 6.4 m -59.32 125.21 22.7 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 176.219 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 12.1 m -104.02 165.43 11.05 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.111 179.441 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -54.06 -30.59 48.73 Favored 'General case' 0 N--CA 1.498 1.943 0 C-N-CA 123.975 0.91 . . . . 0.0 111.901 179.481 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -54.98 -30.03 58.28 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 124.906 1.282 . . . . 0.0 111.39 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . 0.512 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 98.06 11.73 48.4 Favored Glycine 0 CA--C 1.497 -1.057 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -174.123 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -130.54 -170.88 2.42 Favored 'General case' 0 N--CA 1.429 -1.475 0 CA-C-N 114.526 -0.837 . . . . 0.0 109.281 -178.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . 0.412 ' CE3' ' HG3' ' A' ' 190' ' ' MET . 85.7 m95 -96.25 154.14 17.42 Favored 'General case' 0 N--CA 1.426 -1.658 0 CA-C-O 121.094 0.473 . . . . 0.0 111.335 -175.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 13.7 p -75.14 -17.78 60.35 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.626 176.66 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.45 ' HD3' ' HA ' ' A' ' 200' ' ' LYS . 23.9 mmtp -128.62 159.03 36.84 Favored 'General case' 0 CA--C 1.492 -1.254 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.176 179.118 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -87.15 -175.86 5.47 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 3.8 tppp? -72.49 115.14 36.39 Favored Pre-proline 0 C--O 1.249 1.053 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 173.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.73 177.5 8.74 Favored 'Trans proline' 0 N--CA 1.43 -2.231 0 C-N-CA 121.755 1.636 . . . . 0.0 110.645 177.519 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . 0.507 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 23.7 ttmm -128.56 152.75 47.94 Favored 'General case' 0 C--N 1.275 -2.654 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.45 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.595 ' SG ' ' HB3' ' A' ' 182' ' ' TYR . 18.2 t -111.42 117.83 34.14 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 179.209 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--N 1.305 -1.342 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.33 -174.39 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 28.9 Cg_endo . . . . . 0 CA--C 1.543 0.931 0 CA-C-O 121.988 0.745 . . . . 0.0 111.786 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 63.8 m -81.64 -27.97 33.86 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-O 122.066 0.936 . . . . 0.0 109.144 177.134 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.95 -91.37 0.56 Allowed Glycine 0 N--CA 1.4 -3.712 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 173.213 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -179.4 125.5 0.24 Allowed Pre-proline 0 C--N 1.256 -3.47 0 N-CA-C 103.906 -2.627 . . . . 0.0 103.906 -176.113 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.547 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 72.3 Cg_endo -76.82 5.09 5.13 Favored 'Trans proline' 0 N--CA 1.488 1.204 0 C-N-CA 122.649 2.233 . . . . 0.0 113.343 -173.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 97.98 -160.38 20.84 Favored Glycine 0 N--CA 1.419 -2.453 0 N-CA-C 106.725 -2.55 . . . . 0.0 106.725 -173.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -155.31 -168.66 2.91 Favored 'General case' 0 C--N 1.281 -2.389 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.6 t -143.42 120.32 6.72 Favored Pre-proline 0 C--N 1.289 -2.055 0 CA-C-N 118.867 0.758 . . . . 0.0 110.596 -178.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.86 -0.08 9.83 Favored 'Trans proline' 0 CA--C 1.53 0.315 0 C-N-CA 122.831 2.354 . . . . 0.0 111.047 178.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -107.25 13.74 26.88 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.379 178.859 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 164.77 -128.38 1.79 Allowed Glycine 0 N--CA 1.422 -2.262 0 C-N-CA 119.516 -1.326 . . . . 0.0 112.684 179.036 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.3 p -151.52 173.54 14.48 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 123.322 0.649 . . . . 0.0 110.303 -174.097 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -140.62 161.48 37.65 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 169.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.9 m -127.0 159.99 32.46 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.438 HD11 ' CE1' ' A' ' 104' ' ' PHE . 20.8 mt -117.03 122.89 45.5 Favored 'General case' 0 C--N 1.28 -2.414 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 -179.167 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 29.8 p -115.55 122.08 44.59 Favored 'General case' 0 C--N 1.286 -2.162 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.557 -176.518 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.91 -54.98 0.77 Allowed Glycine 0 N--CA 1.421 -2.339 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -178.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -141.81 3.86 2.09 Favored Glycine 0 N--CA 1.437 -1.28 0 C-N-CA 120.14 -1.029 . . . . 0.0 113.316 -178.004 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 59.99 18.51 7.65 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.512 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.4 m -147.48 -173.86 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 -174.032 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.438 ' CE1' HD11 ' A' ' 98' ' ' LEU . 26.9 m-85 -102.89 45.9 0.94 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 118.447 0.567 . . . . 0.0 109.665 -179.412 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.664 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.0 pt-20 -86.57 -175.03 5.29 Favored 'General case' 0 C--O 1.211 -0.924 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.211 178.124 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -80.36 137.14 36.52 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.86 -0.525 . . . . 0.0 111.455 179.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 88.65 -0.97 83.39 Favored Glycine 0 N--CA 1.439 -1.129 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.849 178.723 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.664 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.4 p -90.08 147.53 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -176.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.4 mtpt -111.37 125.89 54.34 Favored 'General case' 0 N--CA 1.413 -2.281 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.706 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.402 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -89.57 93.25 9.42 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 174.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 54.1 t -88.2 116.43 30.08 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.454 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -179.315 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -87.52 141.59 28.51 Favored 'General case' 0 C--N 1.282 -2.341 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.109 -177.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.3 t -139.04 110.53 7.03 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-O 122.265 1.031 . . . . 0.0 108.488 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 33.2 m -68.75 163.03 24.96 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.114 -174.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -65.97 177.22 1.4 Allowed 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 124.31 1.044 . . . . 0.0 110.439 -178.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -58.92 -46.77 87.13 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 123.98 0.912 . . . . 0.0 112.086 -178.357 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.15 24.47 6.16 Favored Glycine 0 CA--C 1.524 0.609 0 C-N-CA 121.325 -0.464 . . . . 0.0 113.342 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -146.38 164.94 30.84 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 -177.134 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.4 pt20 -145.45 170.0 17.24 Favored 'General case' 0 C--N 1.275 -2.653 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 176.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.5 124.18 31.78 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 179.267 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.73 128.42 55.27 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 106.212 -1.773 . . . . 0.0 106.212 178.046 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 110.81 167.94 19.13 Favored Glycine 0 C--N 1.292 -1.886 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.605 -177.6 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -87.15 -26.57 23.53 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-O 121.816 0.817 . . . . 0.0 109.855 -175.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.425 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.9 mm -91.17 129.7 41.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.989 -1.005 . . . . 0.0 108.526 179.478 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 24.2 p-10 -130.81 9.62 4.98 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 120.845 0.355 . . . . 0.0 110.46 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.402 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 36.3 p90 -150.7 164.25 36.58 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.703 -173.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.547 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 45.3 mtp180 -123.66 134.47 53.74 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 173.313 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -110.13 134.03 52.6 Favored 'General case' 0 C--N 1.29 -1.987 0 C-N-CA 119.524 -0.87 . . . . 0.0 108.72 179.549 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.6 t -85.98 109.06 18.51 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.076 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -102.78 -169.36 1.65 Allowed 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 177.422 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 15.0 t -66.19 -15.39 63.11 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 123.119 0.567 . . . . 0.0 112.074 -175.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -99.09 -7.0 27.37 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-O 121.446 0.641 . . . . 0.0 109.979 177.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 114.25 -163.12 12.2 Favored Glycine 0 N--CA 1.439 -1.133 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 90.9 m95 -62.67 109.0 1.27 Allowed 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 116.681 0.24 . . . . 0.0 110.842 177.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 30.6 p -59.11 -73.56 0.08 Allowed 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 125.265 1.426 . . . . 0.0 113.076 -176.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -73.57 177.88 5.06 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.857 -177.498 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -100.97 175.6 5.55 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.951 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 87.1 mt -70.16 125.4 91.97 Favored Pre-proline 0 C--N 1.309 -1.165 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.425 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 36.5 Cg_endo -65.76 172.1 8.75 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 122.716 2.277 . . . . 0.0 112.73 179.241 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 46.2 mm -101.77 124.94 55.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-O 121.231 0.539 . . . . 0.0 111.562 -173.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 94.7 m -97.71 99.29 10.64 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 174.335 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -92.19 146.08 24.0 Favored 'General case' 0 N--CA 1.416 -2.13 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.68 130.3 35.21 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.579 HG23 ' HB2' ' A' ' 170' ' ' PHE . 12.1 m -59.22 141.01 16.68 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 CA-C-O 121.138 0.494 . . . . 0.0 112.001 -176.575 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 83.4 mttt -121.12 136.94 54.88 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.081 -175.013 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 89.1 m -103.67 152.25 22.01 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 172.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 1.8 pp -60.39 154.05 56.09 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-O 120.868 0.366 . . . . 0.0 110.867 -177.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -78.12 102.95 1.62 Allowed 'Trans proline' 0 N--CA 1.441 -1.578 0 C-N-CA 122.504 2.136 . . . . 0.0 112.506 -176.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 7.7 p -73.36 134.28 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.301 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.534 177.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.1 p -75.62 -75.31 0.18 Allowed 'General case' 0 N--CA 1.439 -0.988 0 CA-C-N 116.162 -0.472 . . . . 0.0 112.217 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.408 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . 171.81 159.96 0.24 Allowed Pre-proline 0 C--O 1.239 0.51 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 -177.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . 0.464 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 56.5 Cg_endo -75.57 161.06 37.64 Favored 'Trans proline' 0 N--CA 1.443 -1.459 0 C-N-CA 121.263 1.309 . . . . 0.0 109.55 171.791 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -57.89 -41.5 82.69 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 114.414 1.265 . . . . 0.0 114.414 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 56.0 m-80 -113.33 23.47 13.21 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.581 0.705 . . . . 0.0 110.041 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . 0.44 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -139.48 -163.3 9.46 Favored Glycine 0 N--CA 1.433 -1.536 0 C-N-CA 119.93 -1.129 . . . . 0.0 112.017 -178.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . 0.408 ' HA ' ' HB1' ' A' ' 151' ' ' ALA . 19.7 pttp -160.62 177.18 10.75 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -179.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.431 HG12 ' CE1' ' A' ' 176' ' ' PHE . 38.4 mt -95.47 140.42 17.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 123.278 0.361 . . . . 0.0 111.806 -175.545 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.47 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.8 m -92.13 -36.1 7.48 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 175.617 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.4 m . . . . . 0 N--CA 1.436 -1.162 0 CA-C-N 115.66 -0.7 . . . . 0.0 109.832 -177.055 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 . . . . . 0 N--CA 1.433 -1.28 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -96.2 167.62 11.09 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.48 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.579 ' HB2' HG23 ' A' ' 144' ' ' VAL . 91.0 t80 -50.04 133.62 22.65 Favored 'General case' 0 N--CA 1.468 0.466 0 O-C-N 123.622 0.576 . . . . 0.0 111.019 178.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 111.69 -32.71 6.21 Favored Glycine 0 N--CA 1.427 -1.932 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -69.66 114.9 8.3 Favored 'General case' 0 N--CA 1.416 -2.173 0 CA-C-O 122.287 1.041 . . . . 0.0 112.303 178.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -101.95 103.44 14.08 Favored 'General case' 0 N--CA 1.416 -2.128 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 174.35 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.562 HG13 ' HG3' ' A' ' 190' ' ' MET . 6.8 p -86.04 108.34 17.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.274 0 CA-C-O 121.579 0.704 . . . . 0.0 110.263 -175.227 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.47 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 43.2 ttp180 -100.12 147.29 25.83 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.476 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.464 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 74.2 m-85 -111.93 167.8 10.09 Favored 'General case' 0 C--N 1.293 -1.857 0 CA-C-O 121.784 0.802 . . . . 0.0 111.408 -177.333 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -136.99 151.65 27.52 Favored 'Isoleucine or valine' 0 CA--C 1.455 -2.678 0 CA-C-N 114.152 -1.385 . . . . 0.0 108.766 177.265 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.8 m -112.41 122.36 47.49 Favored 'General case' 0 N--CA 1.392 -3.348 0 O-C-N 124.474 1.109 . . . . 0.0 108.068 177.618 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 48.3 m-80 -53.92 168.73 0.19 Allowed 'General case' 0 C--N 1.307 -1.263 0 O-C-N 124.761 1.288 . . . . 0.0 112.301 -179.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 16.8 m -49.86 104.66 0.07 Allowed 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 125.273 1.429 . . . . 0.0 112.259 -175.673 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.01 3.16 31.75 Favored Glycine 0 N--CA 1.435 -1.409 0 C-N-CA 120.837 -0.697 . . . . 0.0 113.261 178.438 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -124.67 158.58 32.82 Favored 'General case' 0 CA--C 1.484 -1.564 0 CA-C-N 117.341 0.57 . . . . 0.0 110.725 178.61 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.516 ' HG2' ' OXT' ' A' ' 206' ' ' VAL . 25.2 pttm -133.39 162.23 32.4 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 106.757 -1.571 . . . . 0.0 106.757 179.239 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.4 tp -76.4 149.16 6.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -81.35 -59.12 2.74 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.987 179.584 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -115.96 -110.32 2.7 Favored Glycine 0 C--N 1.304 -1.205 0 C-N-CA 120.464 -0.874 . . . . 0.0 111.965 179.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . 0.537 ' CG ' ' HD3' ' A' ' 200' ' ' LYS . 1.5 p-10 -77.36 150.02 35.18 Favored 'General case' 0 C--O 1.193 -1.873 0 C-N-CA 124.161 0.984 . . . . 0.0 108.939 177.444 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -107.21 5.68 27.94 Favored 'General case' 0 C--N 1.296 -1.751 0 C-N-CA 121.009 -0.276 . . . . 0.0 110.871 -178.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -152.1 152.22 32.07 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 113.57 0.952 . . . . 0.0 113.57 -172.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.562 ' HG3' HG13 ' A' ' 174' ' ' VAL . 0.0 OUTLIER -128.57 137.46 51.73 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.876 -1.056 . . . . 0.0 108.306 177.454 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 40.3 t-80 -105.49 130.02 53.65 Favored 'General case' 0 C--N 1.291 -1.953 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.124 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 51.3 t -70.74 113.93 8.31 Favored 'General case' 0 C--O 1.243 0.734 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 175.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 25.1 m -85.85 163.49 18.08 Favored 'General case' 0 N--CA 1.437 -1.086 0 C-N-CA 123.217 0.607 . . . . 0.0 111.689 -176.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -67.57 -10.87 55.91 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 -173.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . 0.407 ' HB2' ' CE2' ' A' ' 197' ' ' PHE . 19.4 m-20 -91.79 -0.99 57.56 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.402 0.62 . . . . 0.0 110.109 177.484 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 81.38 42.28 9.41 Favored Glycine 0 N--CA 1.436 -1.362 0 C-N-CA 120.993 -0.622 . . . . 0.0 113.282 179.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . 0.407 ' CE2' ' HB2' ' A' ' 195' ' ' ASP . 45.5 p90 -149.65 166.71 28.5 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 175.249 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.5 m95 -83.82 125.86 32.38 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 123.146 0.279 . . . . 0.0 110.484 -178.712 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 35.9 t -57.62 -38.98 75.88 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.597 177.068 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.537 ' HD3' ' CG ' ' A' ' 187' ' ' ASP . 1.8 mmpt? -101.91 178.6 4.57 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 115.718 -0.673 . . . . 0.0 111.039 177.5 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -113.69 178.78 4.16 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 179.4 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 51.5 mtpt -79.2 114.51 45.38 Favored Pre-proline 0 C--N 1.295 -1.802 0 C-N-CA 120.771 -0.372 . . . . 0.0 111.593 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.49 -171.73 1.19 Allowed 'Trans proline' 0 N--CA 1.437 -1.812 0 C-N-CA 122.001 1.801 . . . . 0.0 110.898 176.354 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . 0.446 ' HG2' HG13 ' A' ' 206' ' ' VAL . 34.0 ttpt -141.66 153.48 44.74 Favored 'General case' 0 N--CA 1.405 -2.722 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.738 -175.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.435 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 81.1 m -104.81 121.54 43.86 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 174.648 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.516 ' OXT' ' HG2' ' A' ' 183' ' ' LYS . 25.0 m . . . . . 0 C--N 1.305 -1.365 0 O-C-N 124.191 0.932 . . . . 0.0 110.101 -175.387 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo . . . . . 0 CA--C 1.54 0.812 0 CA-C-O 121.423 0.51 . . . . 0.0 111.764 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 39.3 m -82.27 -36.23 27.28 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 122.264 1.031 . . . . 0.0 108.235 177.224 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.48 -92.62 0.48 Allowed Glycine 0 N--CA 1.406 -3.327 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 174.375 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.8 t60 -177.42 129.55 0.32 Allowed Pre-proline 0 C--N 1.261 -3.248 0 N-CA-C 103.991 -2.596 . . . . 0.0 103.991 -176.255 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.534 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 90.5 Cg_endo -80.24 2.55 8.38 Favored 'Trans proline' 0 C--N 1.327 -0.582 0 C-N-CA 122.446 2.098 . . . . 0.0 113.387 -173.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.48 -178.49 41.39 Favored Glycine 0 N--CA 1.422 -2.287 0 N-CA-C 109.037 -1.625 . . . . 0.0 109.037 -175.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -139.83 159.68 41.61 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 117.477 0.639 . . . . 0.0 110.177 -177.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 5.7 t -108.52 139.6 20.97 Favored Pre-proline 0 C--N 1.299 -1.59 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.632 -178.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 91' ' ' THR . 6.3 Cg_exo -82.41 -14.32 9.37 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.546 2.164 . . . . 0.0 111.155 178.396 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -86.79 -1.22 57.59 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.642 -175.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 172.17 -131.89 2.26 Favored Glycine 0 N--CA 1.408 -3.226 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 -178.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 35.8 p -145.62 -175.62 4.8 Favored 'General case' 0 C--N 1.289 -2.036 0 O-C-N 123.864 0.391 . . . . 0.0 110.012 -177.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -138.21 166.56 23.87 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 173.223 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -134.79 161.46 35.12 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.481 HD11 ' CE1' ' A' ' 104' ' ' PHE . 13.2 mt -119.14 124.16 46.16 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 -178.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.443 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 29.5 p -108.98 144.2 37.27 Favored 'General case' 0 C--N 1.284 -2.242 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -177.727 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 102.64 -70.36 0.32 Allowed Glycine 0 N--CA 1.432 -1.598 0 C-N-CA 120.01 -1.09 . . . . 0.0 110.671 -178.19 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.488 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -110.47 -18.61 8.44 Favored Glycine 0 C--N 1.307 -1.08 0 C-N-CA 120.283 -0.96 . . . . 0.0 112.187 -178.313 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 64.04 22.62 12.99 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 123.336 0.655 . . . . 0.0 111.163 -178.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.513 ' O ' HG21 ' A' ' 108' ' ' VAL . 18.4 m -151.1 -171.75 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.198 -1.623 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -178.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.481 ' CE1' HD11 ' A' ' 98' ' ' LEU . 22.1 m-85 -101.9 43.99 1.04 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 119.095 0.862 . . . . 0.0 110.568 -177.025 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.669 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.7 pt-20 -84.11 -179.66 7.28 Favored 'General case' 0 C--O 1.206 -1.222 0 CA-C-N 114.476 -1.238 . . . . 0.0 111.663 178.357 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 40.2 m-85 -76.7 135.55 39.08 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 122.029 -0.419 . . . . 0.0 110.881 176.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.62 9.3 75.42 Favored Glycine 0 N--CA 1.44 -1.057 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.704 178.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.669 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.9 p -95.6 148.8 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.484 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.443 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.7 mtpt -115.17 121.96 44.59 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.458 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -88.01 93.82 9.6 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.265 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 91.5 t -90.53 114.43 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.93 0 C-N-CA 124.414 1.086 . . . . 0.0 108.431 -177.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -84.76 139.44 31.96 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.511 -177.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.9 t -136.16 112.24 9.68 Favored 'General case' 0 N--CA 1.423 -1.796 0 CA-C-O 122.156 0.979 . . . . 0.0 109.943 -179.152 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 84.8 m -69.43 156.21 39.21 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.47 -0.786 . . . . 0.0 111.998 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 -67.7 172.93 4.69 Favored 'General case' 0 C--O 1.218 -0.573 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.069 176.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -53.33 -47.8 69.03 Favored 'General case' 0 C--N 1.313 -1.007 0 C-N-CA 124.022 0.929 . . . . 0.0 113.115 -174.132 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -85.02 15.35 44.17 Favored Glycine 0 C--N 1.307 -1.039 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.784 -179.569 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -130.34 162.27 29.43 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.77 145.34 31.62 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 -179.701 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.5 tt -79.94 140.91 36.47 Favored 'General case' 0 C--N 1.279 -2.471 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.263 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.97 133.07 56.33 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -173.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 103.73 -169.41 18.08 Favored Glycine 0 C--N 1.306 -1.121 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.46 179.283 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -94.19 -47.45 6.64 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -178.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.0 mm -69.05 122.95 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 CA-C-N 114.464 -1.244 . . . . 0.0 109.626 -176.331 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -128.53 6.24 5.69 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.397 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 25.0 p90 -150.56 162.39 40.72 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 120.433 -0.507 . . . . 0.0 110.23 -173.857 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.534 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 39.9 mtp180 -121.78 132.97 54.89 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 106.226 -1.768 . . . . 0.0 106.226 173.235 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -108.7 128.9 55.27 Favored 'General case' 0 C--N 1.289 -2.035 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.7 t -85.35 107.33 17.3 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.087 -1.045 . . . . 0.0 109.642 177.116 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.418 ' CG ' ' H ' ' A' ' 131' ' ' THR . 34.1 t0 -103.86 -170.6 1.8 Allowed 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 178.27 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.418 ' H ' ' CG ' ' A' ' 130' ' ' ASP . 11.1 t -54.81 -29.49 54.71 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 124.56 1.144 . . . . 0.0 113.204 -177.033 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -81.82 -30.16 32.31 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 121.4 0.619 . . . . 0.0 110.382 176.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 132.86 -151.78 20.11 Favored Glycine 0 N--CA 1.42 -2.409 0 N-CA-C 108.744 -1.743 . . . . 0.0 108.744 -174.364 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 92.3 m95 -65.46 113.16 3.94 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 117.386 0.593 . . . . 0.0 109.778 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 22.3 p -64.65 -70.88 0.2 Allowed 'General case' 0 C--O 1.247 0.922 0 CA-C-O 121.6 0.714 . . . . 0.0 111.738 -178.326 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 -71.82 173.87 7.67 Favored 'General case' 0 CA--C 1.484 -1.559 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.959 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -110.01 -174.62 2.53 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -177.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.2 mt -66.58 118.56 55.25 Favored Pre-proline 0 C--O 1.244 0.814 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.405 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.61 155.93 63.96 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.788 2.325 . . . . 0.0 111.706 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 67.5 mt -84.81 136.15 23.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.032 -177.657 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 43.7 t -126.06 138.75 53.73 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 176.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.56 157.32 40.49 Favored 'General case' 0 N--CA 1.414 -2.243 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -178.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 11.5 p -75.09 136.34 25.3 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.88 178.365 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.96 130.53 25.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 C-N-CA 123.303 0.641 . . . . 0.0 109.303 178.432 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.555 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 44.0 mttp -131.46 159.11 39.02 Favored 'General case' 0 CA--C 1.499 -1.007 0 CA-C-O 121.564 0.697 . . . . 0.0 112.64 -177.429 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 39.5 m -123.28 149.53 44.68 Favored 'General case' 0 N--CA 1.42 -1.974 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 176.312 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 80.5 mt -65.38 148.76 97.81 Favored Pre-proline 0 C--N 1.309 -1.154 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -61.6 122.34 10.89 Favored 'Trans proline' 0 N--CA 1.459 -0.524 0 C-N-CA 123.199 2.599 . . . . 0.0 110.479 178.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 150' ' ' THR . 21.0 t -83.73 145.78 7.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -175.705 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . 0.539 ' O ' HG12 ' A' ' 149' ' ' VAL . 15.6 p -88.13 -164.93 1.19 Allowed 'General case' 0 N--CA 1.411 -2.425 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 171.53 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.532 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . -113.09 156.37 42.97 Favored Pre-proline 0 C--N 1.266 -3.057 0 O-C-N 121.511 -0.743 . . . . 0.0 110.392 -172.494 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . 0.415 ' HD3' ' CD2' ' A' ' 176' ' ' PHE . 28.9 Cg_endo -65.26 158.51 51.95 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 122.252 1.968 . . . . 0.0 110.276 173.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . 0.427 ' HG3' HD22 ' A' ' 154' ' ' ASN . 10.2 pt-20 -53.78 -36.43 62.4 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 114.463 1.282 . . . . 0.0 114.463 -174.554 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . 0.43 ' HB2' ' HB2' ' A' ' 205' ' ' CYS . 48.4 m-80 -127.7 36.1 4.4 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.789 0.804 . . . . 0.0 109.043 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 177' ' ' VAL . . . -152.7 -160.76 9.82 Favored Glycine 0 N--CA 1.429 -1.802 0 C-N-CA 119.628 -1.272 . . . . 0.0 113.231 178.103 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . 0.532 ' HA ' ' HB1' ' A' ' 151' ' ' ALA . 20.2 pttm -159.12 176.61 12.04 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 123.936 0.894 . . . . 0.0 109.863 -177.889 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 59.8 mt -94.52 142.1 13.96 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 122.24 0.216 . . . . 0.0 110.705 -178.656 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.541 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 12.2 m -99.83 -23.57 4.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 CA-C-O 121.722 0.772 . . . . 0.0 110.479 179.055 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . 0.502 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 33.4 m . . . . . 0 C--N 1.298 -1.659 0 N-CA-C 114.742 1.386 . . . . 0.0 114.742 -168.496 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 . . . . . 0 N--CA 1.426 -1.648 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.555 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 21.4 p-80 -96.5 171.1 8.77 Favored 'General case' 0 C--N 1.291 -1.968 0 C-N-CA 120.137 -0.625 . . . . 0.0 111.082 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -51.51 125.6 15.02 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 123.872 0.733 . . . . 0.0 110.948 179.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.48 -10.23 21.89 Favored Glycine 0 N--CA 1.424 -2.111 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -177.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.2 mm-40 -85.26 136.96 33.28 Favored 'General case' 0 N--CA 1.438 -1.072 0 CA-C-O 121.537 0.684 . . . . 0.0 112.041 -179.636 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -115.11 120.38 39.59 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 176.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.502 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 83.3 t -108.1 110.98 33.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.641 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 72.7 ttt180 -106.37 147.72 28.91 Favored 'General case' 0 N--CA 1.425 -1.696 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.415 ' CD2' ' HD3' ' A' ' 152' ' ' PRO . 60.9 m-85 -119.41 165.97 13.66 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.025 0.441 . . . . 0.0 111.134 -175.142 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.467 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.0 OUTLIER -130.28 156.65 42.52 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.715 0 CA-C-N 115.069 -0.969 . . . . 0.0 109.745 175.21 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.7 m -111.81 142.98 43.5 Favored 'General case' 0 C--N 1.278 -2.531 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 171.441 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -44.74 -80.68 0.01 OUTLIER 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 114.331 1.234 . . . . 0.0 114.331 -177.173 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 64.6 m -149.24 -42.05 0.14 Allowed 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 114.018 1.118 . . . . 0.0 114.018 -178.364 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -102.29 2.22 50.53 Favored Glycine 0 C--N 1.291 -1.928 0 C-N-CA 120.152 -1.023 . . . . 0.0 114.742 -174.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -110.35 175.73 5.32 Favored 'General case' 0 CA--C 1.487 -1.445 0 CA-C-N 117.643 0.721 . . . . 0.0 111.122 -176.33 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 37.6 pttt -136.63 152.56 50.57 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 173.427 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.497 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.9 tt -70.97 143.2 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.473 0 CA-C-O 121.821 0.82 . . . . 0.0 112.71 -176.706 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -39.78 -59.63 1.13 Allowed 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 127.862 2.465 . . . . 0.0 113.061 179.046 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -145.24 -89.58 0.1 OUTLIER Glycine 0 CA--C 1.48 -2.122 0 C-N-CA 120.107 -1.044 . . . . 0.0 111.293 -177.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . 0.472 ' HB3' ' HG3' ' A' ' 200' ' ' LYS . 6.9 t0 -95.03 158.42 15.47 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.349 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.641 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 13.4 pt-20 -111.28 -9.48 14.29 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 121.084 -0.246 . . . . 0.0 110.772 -177.443 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . 0.463 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.9 pt-20 -131.49 124.67 30.62 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-O 121.816 0.817 . . . . 0.0 112.869 -178.096 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 17.4 ptp -109.65 151.01 27.41 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.811 178.412 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 63.4 m80 -127.37 156.73 41.57 Favored 'General case' 0 CA--C 1.498 -1.043 0 C-N-CA 122.403 0.281 . . . . 0.0 110.66 -178.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 5.1 m -81.75 117.14 21.82 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.066 176.287 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 37.2 m -82.1 152.54 26.5 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.398 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -72.1 78.51 0.94 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 122.852 1.31 . . . . 0.0 112.257 -176.532 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -175.36 -47.16 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.627 0 CA-C-N 112.986 -1.915 . . . . 0.0 106.186 -179.175 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 121.28 66.34 0.25 Allowed Glycine 0 N--CA 1.427 -1.901 0 CA-C-N 114.547 -1.206 . . . . 0.0 112.21 -178.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -167.29 161.94 14.59 Favored 'General case' 0 C--O 1.248 0.979 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 176.58 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.9 m95 -85.15 139.46 31.68 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 124.005 0.816 . . . . 0.0 110.846 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.7 p -71.51 -18.64 62.27 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.252 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.584 ' HE3' ' O ' ' A' ' 201' ' ' GLU . 0.0 OUTLIER -123.94 153.49 41.13 Favored 'General case' 0 N--CA 1.426 -1.626 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 -179.879 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . 0.584 ' O ' ' HE3' ' A' ' 200' ' ' LYS . 3.2 mp0 -77.55 168.4 20.05 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 106.532 -1.655 . . . . 0.0 106.532 177.261 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . 0.401 ' HB3' ' HE2' ' A' ' 202' ' ' LYS . 0.8 OUTLIER -68.89 114.91 26.14 Favored Pre-proline 0 C--N 1.311 -1.084 0 C-N-CA 119.915 -0.714 . . . . 0.0 109.722 176.566 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_endo -82.79 166.94 14.93 Favored 'Trans proline' 0 N--CA 1.431 -2.173 0 C-N-CA 121.95 1.766 . . . . 0.0 111.645 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . 0.416 ' HB2' ' HG2' ' A' ' 153' ' ' GLU . 9.8 ptpp? -131.08 179.06 6.22 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.16 -177.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.43 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 87.6 m -115.32 114.18 24.81 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 178.497 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.9 m . . . . . 0 C--N 1.302 -1.471 0 CA-C-N 114.796 -1.093 . . . . 0.0 109.692 -174.096 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.442 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 39.9 Cg_endo . . . . . 0 CA--C 1.538 0.711 0 CA-C-O 122.19 0.829 . . . . 0.0 110.772 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.9 m -92.41 -33.09 14.69 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.696 -1.138 . . . . 0.0 108.295 175.661 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.04 -91.79 0.58 Allowed Glycine 0 N--CA 1.402 -3.618 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 174.317 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.5 t-80 -174.7 132.61 0.49 Allowed Pre-proline 0 C--N 1.268 -2.973 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 -176.058 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.415 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 98.1 Cg_endo -81.97 5.75 6.12 Favored 'Trans proline' 0 N--CA 1.475 0.439 0 C-N-CA 122.363 2.042 . . . . 0.0 113.405 -172.492 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 113.58 -173.77 15.25 Favored Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -177.44 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -151.68 160.51 43.59 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 178.22 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.445 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 5.5 t -140.05 144.59 38.64 Favored Pre-proline 0 C--N 1.294 -1.809 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.723 -174.654 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 91' ' ' THR . 2.7 Cg_endo -83.09 -16.77 7.13 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 122.692 2.261 . . . . 0.0 110.611 174.12 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 40.4 m-85 -87.53 2.37 50.91 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.772 -175.018 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.523 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 164.4 -127.1 1.6 Allowed Glycine 0 N--CA 1.415 -2.726 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.756 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.2 t -161.08 -161.97 0.87 Allowed 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -178.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -155.02 159.43 40.31 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 177.45 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 16.2 m -121.34 163.35 18.78 Favored 'General case' 0 C--N 1.278 -2.527 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.456 HD11 ' CE1' ' A' ' 104' ' ' PHE . 20.6 mt -121.64 129.24 52.66 Favored 'General case' 0 C--N 1.284 -2.259 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -178.377 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.2 p -124.79 130.22 51.97 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.879 -176.071 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.33 20.97 28.4 Favored Glycine 0 C--N 1.303 -1.278 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.373 -178.63 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.94 -31.74 0.14 Allowed Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 119.907 -1.139 . . . . 0.0 113.128 177.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 6.7 m120 67.8 10.27 7.67 Favored 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 123.267 0.627 . . . . 0.0 112.461 -177.1 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.532 ' O ' HG11 ' A' ' 108' ' ' VAL . 27.3 m -143.34 -171.67 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.501 -0.909 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 -176.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.456 ' CE1' HD11 ' A' ' 98' ' ' LEU . 23.4 m-85 -104.71 46.36 0.92 Allowed 'General case' 0 C--N 1.311 -1.083 0 CA-C-O 121.092 0.473 . . . . 0.0 110.162 -177.509 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.726 ' O ' HG12 ' A' ' 108' ' ' VAL . 14.9 pt-20 -87.88 175.74 7.67 Favored 'General case' 0 C--O 1.212 -0.884 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.408 178.016 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . 0.442 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 42.4 m-85 -74.69 131.57 40.98 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-O 121.088 0.47 . . . . 0.0 111.441 178.661 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 96.72 -1.13 61.42 Favored Glycine 0 N--CA 1.437 -1.239 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.112 178.413 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.726 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.7 p -90.29 146.57 6.03 Favored 'Isoleucine or valine' 0 C--O 1.243 0.749 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.3 mtpt -109.5 122.97 48.59 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.543 178.737 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.495 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.46 93.17 9.07 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 176.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 75.7 t -86.46 108.03 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.745 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . 0.513 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 66.4 t80 -78.3 140.55 38.82 Favored 'General case' 0 C--N 1.268 -2.942 0 CA-C-N 114.121 -1.4 . . . . 0.0 109.952 -174.59 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -143.48 132.38 22.78 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-O 121.9 0.857 . . . . 0.0 109.858 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 57.0 m -85.69 159.64 19.75 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.817 -176.198 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.523 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 54.9 m-20 -65.85 176.97 1.41 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.726 178.523 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -56.12 -49.3 74.27 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 123.522 0.729 . . . . 0.0 112.396 -175.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.21 33.34 4.09 Favored Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.256 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 84.5 m-85 -146.56 158.21 43.86 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 124.224 1.01 . . . . 0.0 109.043 -178.33 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -136.1 169.75 17.12 Favored 'General case' 0 C--N 1.279 -2.457 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 177.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 10.5 tp -86.97 153.72 21.35 Favored 'General case' 0 C--N 1.287 -2.121 0 C-N-CA 119.259 -0.977 . . . . 0.0 108.397 178.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.05 125.31 31.11 Favored 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 176.218 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.68 175.8 20.04 Favored Glycine 0 C--N 1.292 -1.876 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -176.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -94.73 -28.9 15.06 Favored 'General case' 0 CA--C 1.5 -0.943 0 CA-C-O 121.26 0.553 . . . . 0.0 111.0 -177.327 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.584 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 48.8 mm -81.1 129.78 36.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.178 -178.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -133.21 9.15 4.06 Favored 'General case' 0 C--O 1.213 -0.851 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 178.158 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.495 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 22.6 p90 -147.54 158.75 44.13 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.19 0.519 . . . . 0.0 110.425 -176.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 59.7 mtp180 -125.12 132.11 53.16 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 172.259 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -107.3 130.82 54.72 Favored 'General case' 0 C--N 1.275 -2.65 0 C-N-CA 119.408 -0.917 . . . . 0.0 109.715 -177.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 35.8 t -82.52 101.57 10.81 Favored 'General case' 0 N--CA 1.428 -1.536 0 C-N-CA 118.098 -1.441 . . . . 0.0 110.454 177.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.41 ' OD1' HG22 ' A' ' 131' ' ' THR . 6.4 t70 -98.79 -169.56 1.8 Allowed 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 105.496 -2.038 . . . . 0.0 105.496 175.505 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.41 HG22 ' OD1' ' A' ' 130' ' ' ASP . 13.2 t -65.33 -24.36 67.24 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 118.362 0.528 . . . . 0.0 110.965 -176.869 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -70.51 -24.18 62.78 Favored 'General case' 0 C--O 1.249 1.03 0 CA-C-O 122.105 0.955 . . . . 0.0 110.558 175.243 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.62 -148.11 18.91 Favored Glycine 0 N--CA 1.411 -2.985 0 N-CA-C 107.577 -2.209 . . . . 0.0 107.577 -172.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.454 ' CH2' HG13 ' A' ' 108' ' ' VAL . 97.4 m95 -71.12 112.78 7.54 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 117.235 0.518 . . . . 0.0 110.822 177.722 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 65.0 p -70.5 168.12 16.9 Favored 'General case' 0 C--O 1.269 2.116 0 N-CA-C 109.001 -0.741 . . . . 0.0 109.001 176.686 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 63.44 -163.1 0.27 Allowed 'General case' 0 C--O 1.242 0.674 0 O-C-N 124.07 0.856 . . . . 0.0 108.992 177.163 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -126.31 178.73 5.65 Favored 'General case' 0 C--N 1.279 -2.478 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 173.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 57.0 mt -67.2 119.77 67.21 Favored Pre-proline 0 C--N 1.298 -1.638 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 175.264 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.584 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 1.5 Cg_endo -58.18 165.09 7.6 Favored 'Trans proline' 0 C--O 1.24 0.606 0 C-N-CA 122.451 2.101 . . . . 0.0 111.834 177.762 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 61.8 mt -102.18 135.8 37.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.236 -172.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.432 ' SG ' ' CE2' ' A' ' 112' ' ' TYR . 90.2 m -103.28 148.47 25.79 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 171.699 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -128.5 151.76 49.05 Favored 'General case' 0 C--N 1.266 -3.052 0 N-CA-C 105.261 -2.125 . . . . 0.0 105.261 174.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.554 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 7.3 p -71.45 147.35 10.97 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.607 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.131 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.61 HG23 ' HB2' ' A' ' 170' ' ' PHE . 11.6 m -67.18 121.92 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.911 0 C-N-CA 118.478 -1.289 . . . . 0.0 109.243 176.132 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.554 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 52.3 mtmt -115.97 142.91 46.17 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.307 -0.861 . . . . 0.0 111.312 -172.208 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 19.0 m -110.35 142.82 41.48 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 178.079 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . 0.483 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.1 mm? -60.95 144.42 90.51 Favored Pre-proline 0 N--CA 1.426 -1.661 0 N-CA-C 113.653 0.983 . . . . 0.0 113.653 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 31.4 Cg_exo -57.61 142.47 95.66 Favored 'Trans proline' 0 C--O 1.246 0.878 0 C-N-CA 123.493 2.796 . . . . 0.0 111.857 177.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.2 t -110.67 149.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 16.9 p -80.72 -83.57 0.11 Allowed 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 122.131 0.172 . . . . 0.0 111.093 178.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.35 153.51 0.23 Allowed Pre-proline 0 C--O 1.237 0.44 0 C-N-CA 125.883 1.673 . . . . 0.0 106.729 179.515 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.14 160.94 46.04 Favored 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 121.548 1.498 . . . . 0.0 111.574 175.118 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . 0.407 ' HG3' ' ND2' ' A' ' 154' ' ' ASN . 11.0 pt-20 -65.4 -32.68 74.44 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 114.582 1.326 . . . . 0.0 114.582 -173.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . 0.407 ' ND2' ' HG3' ' A' ' 153' ' ' GLU . 58.5 m-80 -126.26 32.79 5.14 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 121.777 0.799 . . . . 0.0 108.901 -179.226 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -156.59 -168.09 18.81 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.413 178.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 24.0 pttm -150.02 171.66 16.49 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 117.178 0.489 . . . . 0.0 109.705 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 53.5 mt -94.92 129.22 45.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.498 HG22 ' O ' ' A' ' 175' ' ' ARG . 10.5 m -82.09 -24.71 9.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-O 121.369 0.604 . . . . 0.0 110.569 -177.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 6.5 m . . . . . 0 N--CA 1.443 -0.801 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.409 -177.466 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 . . . . . 0 N--CA 1.434 -1.247 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.481 ' CD2' ' HG2' ' A' ' 145' ' ' LYS . 39.0 m170 -119.26 157.55 27.82 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 119.325 -0.369 . . . . 0.0 110.407 -172.143 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.61 ' HB2' HG23 ' A' ' 144' ' ' VAL . 85.7 t80 -35.15 127.75 0.54 Allowed 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 176.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 103.41 -30.31 10.58 Favored Glycine 0 N--CA 1.427 -1.943 0 CA-C-N 114.783 -1.099 . . . . 0.0 112.82 177.64 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -72.3 145.28 47.95 Favored 'General case' 0 N--CA 1.402 -2.827 0 CA-C-N 117.266 0.533 . . . . 0.0 110.248 -177.635 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -122.39 122.54 39.25 Favored 'General case' 0 N--CA 1.414 -2.241 0 CA-C-N 115.205 -0.907 . . . . 0.0 108.835 178.506 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 54.9 t -93.71 105.01 16.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.254 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 174.705 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.498 ' O ' HG22 ' A' ' 158' ' ' VAL . 19.3 ttp180 -103.37 146.64 28.18 Favored 'General case' 0 N--CA 1.402 -2.847 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -178.498 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -117.13 166.76 11.85 Favored 'General case' 0 C--N 1.279 -2.485 0 CA-C-O 121.102 0.477 . . . . 0.0 109.945 -174.182 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.0 p -145.43 139.8 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.21 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 174.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . 0.411 ' SG ' ' HB ' ' A' ' 184' ' ' ILE . 77.5 m -101.72 157.2 17.01 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -65.71 163.4 16.59 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 177.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 15.3 t -46.83 -33.45 4.48 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -169.453 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -108.52 18.04 32.97 Favored Glycine 0 C--N 1.289 -2.04 0 C-N-CA 120.427 -0.892 . . . . 0.0 114.203 -177.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -119.29 158.86 25.21 Favored 'General case' 0 CA--C 1.486 -1.519 0 CA-C-N 118.28 1.04 . . . . 0.0 110.795 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 14.8 pttm -120.14 150.97 39.76 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.316 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.424 HD13 ' HA ' ' A' ' 188' ' ' GLU . 8.3 tt -84.32 136.31 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.313 0 C-N-CA 119.279 -0.969 . . . . 0.0 108.902 174.485 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -86.65 -45.65 10.81 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.967 -1.015 . . . . 0.0 109.226 -174.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -78.46 -157.57 10.59 Favored Glycine 0 C--N 1.302 -1.33 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 173.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . 0.451 ' HB3' ' HG3' ' A' ' 200' ' ' LYS . 17.1 t70 -82.04 169.34 16.82 Favored 'General case' 0 C--N 1.314 -0.977 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.132 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.424 ' HA ' HD13 ' A' ' 184' ' ' ILE . 13.1 pt-20 -81.44 -13.57 58.07 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-N 118.778 0.717 . . . . 0.0 110.865 -173.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -147.47 170.77 16.7 Favored 'General case' 0 N--CA 1.423 -1.779 0 CA-C-O 121.513 0.673 . . . . 0.0 111.431 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.0 ptp -141.8 125.66 17.09 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.911 175.372 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 1.9 m80 -98.54 147.27 24.95 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.526 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . 0.409 ' HB3' ' HA ' ' A' ' 170' ' ' PHE . 1.7 m -73.62 110.78 8.18 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.834 171.272 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 28.8 m -83.61 160.02 21.48 Favored 'General case' 0 N--CA 1.428 -1.574 0 O-C-N 123.925 0.766 . . . . 0.0 109.342 -179.269 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -70.37 1.56 4.84 Favored 'General case' 0 N--CA 1.486 1.34 0 CA-C-O 121.261 0.553 . . . . 0.0 112.423 -176.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -84.6 -17.53 38.44 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.376 174.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 90.1 23.3 32.71 Favored Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.288 -0.958 . . . . 0.0 110.865 -174.273 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -131.01 164.5 25.26 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 58.0 m95 -79.59 143.37 34.8 Favored 'General case' 0 N--CA 1.426 -1.642 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 174.638 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.1 m -63.77 -20.77 66.02 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-O 121.153 0.502 . . . . 0.0 111.104 177.446 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.451 ' HG3' ' HB3' ' A' ' 187' ' ' ASP . 30.5 mmmt -133.74 158.78 42.44 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.058 -177.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 25.3 mm-40 -79.63 168.0 19.95 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 114.554 -1.203 . . . . 0.0 108.392 171.742 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 17.2 tptm -55.43 117.26 14.21 Favored Pre-proline 0 N--CA 1.439 -0.989 0 O-C-N 123.863 0.727 . . . . 0.0 110.02 176.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -87.5 158.4 7.94 Favored 'Trans proline' 0 N--CA 1.423 -2.639 0 C-N-CA 122.066 1.844 . . . . 0.0 111.663 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . 0.418 ' HG2' HG13 ' A' ' 206' ' ' VAL . 37.9 ttpt -122.42 149.08 44.32 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.709 -175.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.408 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 92.7 m -108.38 115.67 30.54 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 176.244 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . 0.418 HG13 ' HG2' ' A' ' 204' ' ' LYS . 9.4 m . . . . . 0 C--N 1.29 -1.981 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.126 -175.177 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo . . . . . 0 CA--C 1.534 0.477 0 CA-C-O 121.796 0.665 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 59.5 m -88.23 -36.99 16.44 Favored 'General case' 0 N--CA 1.435 -1.204 0 CA-C-N 114.813 -1.085 . . . . 0.0 109.29 175.79 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 115.98 -87.72 0.44 Allowed Glycine 0 CA--C 1.463 -3.206 0 N-CA-C 110.081 -1.207 . . . . 0.0 110.081 174.34 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 3.5 t60 -177.72 127.77 0.29 Allowed Pre-proline 0 C--N 1.269 -2.922 0 N-CA-C 104.901 -2.259 . . . . 0.0 104.901 -175.642 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -79.99 12.26 2.52 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 123.043 2.495 . . . . 0.0 114.342 -171.909 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 106.03 -169.63 15.98 Favored Glycine 0 N--CA 1.424 -2.126 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -176.305 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -160.27 139.59 10.88 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 177.717 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.3 t -110.87 131.74 21.98 Favored Pre-proline 0 C--N 1.303 -1.449 0 C-N-CA 120.631 -0.428 . . . . 0.0 111.758 -175.85 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -70.02 -18.3 35.85 Favored 'Trans proline' 0 C--N 1.351 0.681 0 C-N-CA 122.826 2.351 . . . . 0.0 111.695 176.596 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -83.57 -2.5 56.18 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.329 -176.721 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.503 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.09 -124.49 1.04 Allowed Glycine 0 N--CA 1.414 -2.817 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.328 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 14.8 t -164.8 -165.27 0.89 Allowed 'General case' 0 C--N 1.285 -2.228 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.55 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.7 p90 -146.18 165.65 28.54 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.896 -0.503 . . . . 0.0 109.758 178.203 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -126.12 162.44 25.34 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.962 -1.495 . . . . 0.0 106.962 176.64 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 16.5 mt -114.88 132.91 56.37 Favored 'General case' 0 C--N 1.278 -2.51 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.314 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 19.9 p -128.9 128.48 43.9 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 -177.161 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 93.41 30.13 9.49 Favored Glycine 0 C--N 1.292 -1.863 0 C-N-CA 119.994 -1.098 . . . . 0.0 111.253 -178.302 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 164.17 -35.51 0.29 Allowed Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.705 -1.236 . . . . 0.0 111.974 177.396 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 68.85 14.25 8.91 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.547 0.739 . . . . 0.0 112.338 179.96 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.506 ' O ' HG11 ' A' ' 108' ' ' VAL . 29.3 m -147.74 -168.92 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.211 -0.951 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 -178.616 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -106.34 42.78 1.22 Allowed 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 119.118 0.872 . . . . 0.0 110.238 -178.115 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.719 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.8 pt-20 -79.27 173.91 12.11 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 114.641 -1.163 . . . . 0.0 111.588 178.262 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -75.98 127.59 33.3 Favored 'General case' 0 C--N 1.295 -1.762 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.059 176.201 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 104.17 -7.58 48.04 Favored Glycine 0 N--CA 1.435 -1.414 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.489 179.694 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.719 HG12 ' O ' ' A' ' 105' ' ' GLU . 13.9 p -87.76 148.9 4.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -178.32 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -112.03 123.72 50.86 Favored 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.574 179.181 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.445 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.85 96.99 10.4 Favored 'General case' 0 C--N 1.291 -1.939 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 176.523 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.426 HG12 ' HB3' ' A' ' 126' ' ' TYR . 22.6 m -95.24 111.18 25.32 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.511 0 CA-C-O 122.564 1.174 . . . . 0.0 109.457 -179.168 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -78.92 148.96 32.5 Favored 'General case' 0 C--N 1.26 -3.32 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.813 -177.62 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.9 t -145.35 130.94 18.85 Favored 'General case' 0 N--CA 1.422 -1.839 0 CA-C-N 115.012 -0.995 . . . . 0.0 108.895 177.295 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 20.5 m -82.47 160.61 22.63 Favored 'General case' 0 C--N 1.284 -2.277 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.314 -175.732 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.503 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 71.1 m-20 -73.19 -178.06 2.75 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.952 178.812 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -53.31 -53.09 56.02 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 125.02 1.328 . . . . 0.0 113.375 -175.43 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.403 ' O ' HG23 ' A' ' 143' ' ' VAL . . . -88.25 31.81 4.64 Favored Glycine 0 C--N 1.305 -1.18 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.414 -177.542 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -146.1 153.65 40.94 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -175.044 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -133.13 171.88 13.4 Favored 'General case' 0 C--N 1.272 -2.776 0 N-CA-C 105.923 -1.881 . . . . 0.0 105.923 175.663 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.449 HD11 ' HB2' ' A' ' 139' ' ' PRO . 13.1 tp -87.47 149.87 24.13 Favored 'General case' 0 C--N 1.282 -2.357 0 C-N-CA 119.135 -1.026 . . . . 0.0 108.563 179.216 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -122.51 121.83 37.48 Favored 'General case' 0 N--CA 1.408 -2.539 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 176.81 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.92 171.52 23.44 Favored Glycine 0 C--N 1.284 -2.33 0 C-N-CA 120.796 -0.716 . . . . 0.0 111.943 -175.434 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -86.27 -34.72 20.3 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.65 0.738 . . . . 0.0 109.495 -176.927 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.3 mm -77.97 126.67 38.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-N 114.988 -1.006 . . . . 0.0 109.814 -175.925 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -127.57 1.93 6.19 Favored 'General case' 0 C--O 1.201 -1.454 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 176.899 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.445 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 18.2 p90 -136.51 162.43 33.12 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.42 -171.64 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 63.3 mtp180 -130.78 131.12 44.51 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 170.341 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -103.9 132.31 50.28 Favored 'General case' 0 C--N 1.292 -1.899 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.698 179.509 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 23.9 t -82.22 97.78 8.42 Favored 'General case' 0 N--CA 1.425 -1.681 0 C-N-CA 118.238 -1.385 . . . . 0.0 109.257 175.741 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -94.83 -173.41 2.98 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 106.673 -1.602 . . . . 0.0 106.673 178.163 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 14.1 t -67.01 -14.39 62.85 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.69 0.757 . . . . 0.0 111.277 -175.192 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -86.73 -28.64 22.94 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.017 177.953 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 132.13 -163.85 23.86 Favored Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 -175.405 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.469 ' CH2' HG13 ' A' ' 108' ' ' VAL . 98.5 m95 -63.62 113.55 3.4 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 117.85 0.825 . . . . 0.0 110.858 175.714 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 51.9 p -70.67 166.84 19.93 Favored 'General case' 0 C--O 1.267 2.006 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 177.542 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 62.24 -163.39 0.26 Allowed 'General case' 0 C--O 1.251 1.145 0 O-C-N 123.921 0.763 . . . . 0.0 109.383 178.061 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 37.6 t0 -131.59 177.88 7.17 Favored 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 174.419 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 71.7 mt -62.68 114.98 13.84 Favored Pre-proline 0 C--N 1.27 -2.873 0 C-N-CA 124.774 1.229 . . . . 0.0 108.036 175.193 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.449 ' HB2' HD11 ' A' ' 120' ' ' LEU . 29.1 Cg_endo -65.07 151.31 86.13 Favored 'Trans proline' 0 N--CA 1.447 -1.264 0 C-N-CA 122.479 2.119 . . . . 0.0 112.062 -177.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 48.2 mt -87.16 134.37 27.77 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.118 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.512 -174.165 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 93.5 m -107.82 148.13 29.95 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 171.165 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -129.8 144.85 51.51 Favored 'General case' 0 C--N 1.284 -2.266 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -179.824 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 117' ' ' GLY . 4.8 p -73.26 129.43 36.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.846 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.637 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 27.6 m -54.19 130.02 15.71 Favored 'Isoleucine or valine' 0 C--O 1.243 0.741 0 O-C-N 123.848 0.717 . . . . 0.0 112.209 -174.827 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.435 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 94.8 mttt -112.54 170.08 8.43 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.533 -175.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.0 p -150.41 158.82 44.58 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.052 176.33 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . 0.475 HD23 ' HD2' ' A' ' 148' ' ' PRO . 1.4 tt -55.48 131.6 70.76 Favored Pre-proline 0 N--CA 1.429 -1.515 0 C-N-CA 125.59 1.556 . . . . 0.0 111.992 -178.258 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.475 ' HD2' HD23 ' A' ' 147' ' ' LEU . 37.8 Cg_endo -69.08 100.6 0.74 Allowed 'Trans proline' 0 N--CA 1.445 -1.334 0 C-N-CA 122.846 2.364 . . . . 0.0 111.806 176.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 10.2 p -64.07 140.05 20.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.935 0 CA-C-N 115.428 -0.805 . . . . 0.0 108.948 176.607 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 15.6 p -73.12 -82.38 0.05 Allowed 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -174.529 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 175.45 162.62 0.41 Allowed Pre-proline 0 CA--C 1.517 -0.311 0 C-N-CA 124.771 1.228 . . . . 0.0 107.843 179.403 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -74.05 -178.16 3.69 Favored 'Trans proline' 0 N--CA 1.446 -1.301 0 C-N-CA 121.353 1.369 . . . . 0.0 110.254 170.57 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . 0.586 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.0 OUTLIER -93.15 -41.07 10.13 Favored 'General case' 0 C--N 1.289 -2.04 0 O-C-N 122.051 -0.406 . . . . 0.0 111.413 -176.394 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . 0.586 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 42.3 m-80 -107.59 21.12 17.92 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.529 0.68 . . . . 0.0 110.259 179.736 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -148.54 -172.68 18.65 Favored Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.677 -178.274 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 58.8 pttt -145.98 164.38 32.25 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -176.621 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.436 HG22 ' H ' ' A' ' 159' ' ' SER . 63.5 mt -88.51 136.01 24.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 177.866 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 175' ' ' ARG . 11.5 m -84.73 -25.82 6.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.128 0.489 . . . . 0.0 110.81 -178.004 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . 0.436 ' H ' HG22 ' A' ' 157' ' ' ILE . 21.4 t . . . . . 0 N--CA 1.432 -1.338 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.761 -174.98 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . 0.435 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 95.1 m-85 . . . . . 0 N--CA 1.443 -0.812 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.444 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 36.0 m80 -136.31 169.61 17.37 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.642 -173.747 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.637 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 91.7 t80 -50.11 128.94 20.16 Favored 'General case' 0 C--O 1.24 0.573 0 O-C-N 124.2 0.937 . . . . 0.0 110.571 173.468 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 101.14 -14.08 58.52 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 119.972 -1.108 . . . . 0.0 112.751 175.95 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . 0.58 HE21 ' HA ' ' A' ' 172' ' ' GLN . 0.0 OUTLIER -77.19 143.45 39.02 Favored 'General case' 0 C--O 1.251 1.143 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.154 178.272 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -124.86 101.19 6.96 Favored 'General case' 0 C--N 1.285 -2.228 0 CA-C-N 114.767 -1.106 . . . . 0.0 108.859 -179.697 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.409 ' HB ' ' HG3' ' A' ' 190' ' ' MET . 69.2 t -81.38 96.62 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.648 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.252 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.6 ' O ' HG22 ' A' ' 158' ' ' VAL . 26.4 ttp180 -96.81 142.99 28.15 Favored 'General case' 0 N--CA 1.4 -2.936 0 CA-C-N 114.55 -1.204 . . . . 0.0 108.052 177.191 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -113.07 162.14 16.27 Favored 'General case' 0 C--N 1.278 -2.502 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -176.243 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 14.5 p -143.86 137.15 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.346 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 175.761 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . 0.432 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 80.8 m -92.7 152.37 19.56 Favored 'General case' 0 C--N 1.257 -3.438 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.586 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 51.2 m-80 -70.6 166.16 21.26 Favored 'General case' 0 CA--C 1.493 -1.22 0 C-N-CA 120.368 -0.533 . . . . 0.0 110.176 179.546 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 12.6 t -53.61 110.31 0.56 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 124.274 0.984 . . . . 0.0 111.163 -176.082 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 116.44 -13.88 15.59 Favored Glycine 0 N--CA 1.435 -1.383 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.706 179.307 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . 0.432 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 96.4 m-85 -110.7 163.25 13.94 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 117.482 0.641 . . . . 0.0 110.876 -179.007 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 18.1 ptmt -135.39 157.26 47.34 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.692 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.414 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.8 tt -84.98 137.53 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.766 0 CA-C-O 121.609 0.718 . . . . 0.0 111.127 -179.367 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -72.2 -53.48 12.51 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.091 -177.455 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -93.9 -134.8 7.38 Favored Glycine 0 C--N 1.296 -1.674 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.087 -177.781 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -81.35 169.66 16.96 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 178.462 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.414 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.8 pt-20 -100.63 -15.76 17.65 Favored 'General case' 0 C--N 1.289 -2.048 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -176.338 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -144.19 138.32 28.01 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 -175.394 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.409 ' HG3' ' HB ' ' A' ' 174' ' ' VAL . 13.8 ptp -117.45 130.2 56.31 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.713 174.883 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -102.49 137.19 41.06 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.965 -177.031 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . 0.476 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 19.6 t -88.1 107.99 19.03 Favored 'General case' 0 C--O 1.253 1.274 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 174.515 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 21.7 m -102.81 -176.64 3.15 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 112.964 0.727 . . . . 0.0 112.964 -171.148 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -44.37 -39.32 4.56 Favored 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 126.148 1.779 . . . . 0.0 113.491 -176.973 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -63.54 -17.28 62.63 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.862 -177.047 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 78.57 32.91 40.23 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -174.092 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -144.11 171.92 13.62 Favored 'General case' 0 C--O 1.249 1.034 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 -179.544 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . 0.476 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 81.9 m95 -87.32 137.6 32.2 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 175.778 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 44.7 m -83.35 -3.31 57.38 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.168 0.509 . . . . 0.0 111.941 179.881 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 20.2 mmtp -128.54 162.15 27.91 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.581 179.471 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -95.65 166.09 12.0 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.935 179.86 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . 0.449 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 9.8 tptm -65.34 116.97 35.71 Favored Pre-proline 0 CA--C 1.547 0.834 0 C-N-CA 123.337 0.655 . . . . 0.0 111.299 179.168 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . 0.449 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 6.7 Cg_endo -90.54 177.87 2.17 Favored 'Trans proline' 0 CA--C 1.547 1.148 0 C-N-CA 122.658 2.238 . . . . 0.0 112.85 177.198 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . 0.542 ' HG3' ' OE2' ' A' ' 153' ' ' GLU . 22.1 ttmm -131.25 157.11 44.13 Favored 'General case' 0 C--N 1.318 -0.804 0 C-N-CA 124.319 1.048 . . . . 0.0 109.531 -177.238 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.429 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 87.8 m -104.06 119.22 38.47 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 173.857 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.296 -1.758 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.754 -174.693 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.4 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 31.7 Cg_endo . . . . . 0 CA--C 1.531 0.373 0 CA-C-O 121.665 0.611 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.9 m -88.43 -32.96 18.04 Favored 'General case' 0 N--CA 1.436 -1.125 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 176.332 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.99 -85.72 0.4 Allowed Glycine 0 CA--C 1.453 -3.839 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 171.58 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.2 t-80 -173.75 133.75 0.6 Allowed Pre-proline 0 C--N 1.266 -3.037 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 -174.328 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.507 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 89.9 Cg_endo -87.24 -5.07 7.63 Favored 'Trans proline' 0 C--O 1.242 0.686 0 C-N-CA 122.252 1.968 . . . . 0.0 112.94 -176.364 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.499 ' HA3' HD11 ' A' ' 138' ' ' ILE . . . 126.38 -161.72 20.67 Favored Glycine 0 N--CA 1.42 -2.379 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 -178.375 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -158.48 150.52 21.53 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 177.86 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.9 t -131.53 127.04 21.43 Favored Pre-proline 0 C--N 1.301 -1.519 0 C-N-CA 119.746 -0.781 . . . . 0.0 111.994 -177.382 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -71.37 -16.6 31.06 Favored 'Trans proline' 0 CA--C 1.534 0.522 0 C-N-CA 122.541 2.161 . . . . 0.0 111.502 177.075 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 71.5 m-85 -83.45 -6.6 59.51 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.988 -177.458 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.44 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 171.89 -129.94 1.84 Allowed Glycine 0 N--CA 1.414 -2.79 0 C-N-CA 118.838 -1.648 . . . . 0.0 113.48 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.5 p -141.21 178.6 7.28 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 114.989 -0.606 . . . . 0.0 111.288 -174.804 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.466 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 36.5 p90 -148.66 155.23 40.77 Favored 'General case' 0 N--CA 1.431 -1.383 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 171.327 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -123.98 153.15 41.69 Favored 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 -178.316 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -110.74 126.67 54.82 Favored 'General case' 0 C--N 1.271 -2.814 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -179.774 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.424 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 17.2 p -121.26 134.14 55.17 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.265 -176.508 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 108.14 -45.92 1.24 Allowed Glycine 0 C--N 1.311 -0.811 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.989 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.441 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -128.3 -18.21 1.88 Allowed Glycine 0 C--N 1.311 -0.842 0 C-N-CA 120.382 -0.913 . . . . 0.0 113.009 -179.901 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 63.27 16.55 9.54 Favored 'General case' 0 N--CA 1.494 1.731 0 C-N-CA 124.388 1.075 . . . . 0.0 110.868 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.513 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.6 m -148.41 -171.86 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.211 -0.965 0 N-CA-C 106.967 -1.494 . . . . 0.0 106.967 -178.912 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.507 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 32.6 m-85 -101.47 44.66 1.0 Allowed 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 118.794 0.725 . . . . 0.0 110.648 -177.486 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.69 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.2 pt-20 -86.51 -175.73 5.57 Favored 'General case' 0 C--O 1.207 -1.143 0 CA-C-N 114.837 -1.074 . . . . 0.0 111.468 177.638 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . 0.4 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 43.5 m-85 -81.05 139.65 35.59 Favored 'General case' 0 C--N 1.308 -1.226 0 O-C-N 121.686 -0.634 . . . . 0.0 111.085 178.786 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.44 4.29 80.55 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.655 -0.702 . . . . 0.0 112.529 179.122 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.69 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -94.25 142.92 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 C-N-CA 119.763 -0.775 . . . . 0.0 109.123 -179.628 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.424 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -107.67 121.23 44.26 Favored 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.708 178.441 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -86.81 89.67 8.04 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 175.575 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 94.6 t -85.71 115.13 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.638 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -177.647 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . 0.466 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 43.2 m-85 -86.63 145.77 26.59 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 116.605 -0.271 . . . . 0.0 111.116 -177.061 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.1 t -145.44 116.74 7.95 Favored 'General case' 0 N--CA 1.427 -1.602 0 CA-C-O 122.404 1.097 . . . . 0.0 109.471 178.11 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 28.4 m -72.89 164.95 25.86 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 114.901 -1.045 . . . . 0.0 111.191 -174.887 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.44 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 81.0 m-20 -75.31 171.71 13.73 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.505 177.143 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -58.49 -39.4 79.9 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 113.269 0.84 . . . . 0.0 113.269 -174.331 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.425 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -75.39 12.41 7.55 Favored Glycine 0 CA--C 1.526 0.752 0 C-N-CA 120.838 -0.696 . . . . 0.0 113.063 179.733 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.67 ' HE1' HG22 ' A' ' 143' ' ' VAL . 83.5 m-85 -147.09 170.09 17.9 Favored 'General case' 0 N--CA 1.427 -1.582 0 C-N-CA 124.56 1.144 . . . . 0.0 108.95 -177.51 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.443 HE21 ' HB2' ' A' ' 119' ' ' GLN . 0.7 OUTLIER -140.58 173.5 11.43 Favored 'General case' 0 C--N 1.266 -3.058 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 175.699 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.9 tt -99.92 137.5 38.29 Favored 'General case' 0 C--N 1.27 -2.851 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -179.713 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.447 ' HB2' ' HB2' ' A' ' 142' ' ' GLU . 0.2 OUTLIER -127.52 135.83 50.89 Favored 'General case' 0 N--CA 1.423 -1.818 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -176.978 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 130.02 179.29 15.92 Favored Glycine 0 N--CA 1.421 -2.311 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 178.397 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 61.7 mm-40 -95.88 -17.05 21.4 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 122.282 1.039 . . . . 0.0 109.078 177.102 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.6 mm -101.5 142.84 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.588 0 CA-C-N 114.184 -1.371 . . . . 0.0 108.233 179.032 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -141.14 9.61 2.11 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-O 121.278 0.561 . . . . 0.0 109.517 177.795 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . . . . . . . . . 32.8 p90 -157.55 159.57 37.28 Favored 'General case' 0 N--CA 1.427 -1.602 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.747 -172.981 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 56.4 mtp180 -121.16 129.85 53.44 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 172.507 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -105.43 130.61 53.48 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -178.512 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.6 t -83.1 105.35 14.01 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 117.625 -1.63 . . . . 0.0 110.206 176.643 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.423 ' OD2' HG22 ' A' ' 131' ' ' THR . 22.5 t70 -94.38 -178.59 4.63 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 178.297 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.423 HG22 ' OD2' ' A' ' 130' ' ' ASP . 11.0 t -63.28 -22.49 66.91 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 121.728 0.775 . . . . 0.0 110.38 -177.729 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -76.59 -37.12 56.99 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.769 177.735 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 139.28 -159.49 25.69 Favored Glycine 0 N--CA 1.434 -1.462 0 N-CA-C 107.982 -2.047 . . . . 0.0 107.982 -173.938 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -66.38 122.99 18.77 Favored 'General case' 0 C--O 1.248 0.979 0 CA-C-N 118.258 1.029 . . . . 0.0 110.539 177.653 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 67.7 p -80.89 163.32 23.47 Favored 'General case' 0 N--CA 1.416 -2.167 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 175.814 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 61.74 -165.21 0.23 Allowed 'General case' 0 C--N 1.323 -0.582 0 O-C-N 124.017 0.823 . . . . 0.0 110.579 175.21 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -129.57 -179.92 5.45 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 175.678 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.499 HD11 ' HA3' ' A' ' 89' ' ' GLY . 62.3 mt -66.6 122.24 81.06 Favored Pre-proline 0 C--N 1.298 -1.648 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 173.245 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.55 158.15 54.59 Favored 'Trans proline' 0 C--O 1.243 0.742 0 C-N-CA 122.67 2.247 . . . . 0.0 111.416 179.275 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 68.0 mt -84.95 131.65 33.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 CA-C-O 121.03 0.443 . . . . 0.0 111.016 -174.051 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 91.4 m -98.45 102.01 13.62 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 173.263 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.447 ' HB2' ' HB2' ' A' ' 121' ' ' LEU . 1.0 OUTLIER -87.88 154.5 20.47 Favored 'General case' 0 CA--C 1.461 -2.443 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.147 178.693 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.67 HG22 ' HE1' ' A' ' 118' ' ' TYR . 4.3 t -80.7 137.34 21.58 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.367 0 CA-C-N 114.82 -1.082 . . . . 0.0 108.661 -177.197 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.6 HG23 ' HB2' ' A' ' 170' ' ' PHE . 3.7 m -69.83 98.34 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.153 177.407 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.454 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 49.2 mttm -88.07 131.81 34.53 Favored 'General case' 0 N--CA 1.417 -2.094 0 CA-C-N 113.754 -1.566 . . . . 0.0 109.387 -176.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.43 ' O ' ' HB2' ' A' ' 168' ' ' TYR . 61.6 m -94.16 127.43 39.99 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 107.17 -1.419 . . . . 0.0 107.17 177.026 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -50.24 138.94 19.69 Favored Pre-proline 0 N--CA 1.438 -1.071 0 N-CA-C 114.655 1.354 . . . . 0.0 114.655 -176.264 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -69.7 123.38 10.07 Favored 'Trans proline' 0 N--CA 1.444 -1.425 0 C-N-CA 122.926 2.417 . . . . 0.0 112.304 -175.522 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 21.2 t -91.84 130.75 40.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.4 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.3 m -74.93 -67.96 0.59 Allowed 'General case' 0 N--CA 1.414 -2.268 0 C-N-CA 122.764 0.425 . . . . 0.0 111.16 -177.866 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.96 150.12 0.22 Allowed Pre-proline 0 CA--C 1.509 -0.599 0 C-N-CA 124.686 1.194 . . . . 0.0 108.079 -178.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -77.07 174.7 12.41 Favored 'Trans proline' 0 N--CA 1.446 -1.315 0 C-N-CA 121.836 1.691 . . . . 0.0 110.811 173.947 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -61.58 -51.78 67.14 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 114.215 1.191 . . . . 0.0 114.215 -174.913 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -123.29 23.27 9.14 Favored 'General case' 0 CA--C 1.496 -1.108 0 CA-C-O 122.032 0.92 . . . . 0.0 109.891 -172.411 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . 0.472 ' HA3' ' SG ' ' A' ' 205' ' ' CYS . . . -140.47 -178.15 16.76 Favored Glycine 0 C--N 1.281 -2.516 0 CA-C-N 114.071 -1.422 . . . . 0.0 109.906 178.716 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 47.6 pttt -143.91 162.52 35.91 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 -177.146 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.559 HG22 ' H ' ' A' ' 159' ' ' SER . 46.7 mt -92.25 135.98 25.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 -179.632 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' A' ' 175' ' ' ARG . 10.8 m -71.19 -23.14 22.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-O 121.872 0.844 . . . . 0.0 111.382 -175.281 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . 0.559 ' H ' HG22 ' A' ' 157' ' ' ILE . 20.8 t . . . . . 0 C--N 1.296 -1.724 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -178.849 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . 0.454 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 95.5 m-85 . . . . . 0 N--CA 1.444 -0.74 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 23.3 m80 -129.28 161.5 30.08 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -174.469 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.6 ' HB2' HG23 ' A' ' 144' ' ' VAL . 87.1 t80 -51.9 107.74 0.22 Allowed 'General case' 0 N--CA 1.469 0.513 0 O-C-N 123.82 0.7 . . . . 0.0 110.675 174.54 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 139.05 -24.57 2.83 Favored Glycine 0 N--CA 1.433 -1.557 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -175.681 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -78.34 160.91 27.57 Favored 'General case' 0 N--CA 1.429 -1.523 0 CA-C-O 121.602 0.715 . . . . 0.0 112.897 -179.43 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.424 ' HA ' ' O ' ' A' ' 190' ' ' MET . . . -148.28 118.46 7.28 Favored 'General case' 0 N--CA 1.423 -1.775 0 CA-C-N 114.376 -1.283 . . . . 0.0 109.027 179.793 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.482 HG23 ' CH2' ' A' ' 198' ' ' TRP . 46.2 t -86.18 107.41 16.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.13 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.537 ' HB3' HG21 ' A' ' 158' ' ' VAL . 78.9 ttt180 -99.64 140.57 33.65 Favored 'General case' 0 N--CA 1.42 -1.954 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 178.067 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -114.49 161.09 18.45 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 -176.468 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 7.7 p -140.9 128.06 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.812 0 CA-C-N 115.22 -0.9 . . . . 0.0 109.931 175.948 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . 0.454 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 71.7 m -89.11 152.24 21.76 Favored 'General case' 0 C--N 1.276 -2.607 0 CA-C-N 114.915 -1.038 . . . . 0.0 110.138 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -68.9 -179.92 1.62 Allowed 'General case' 0 C--O 1.239 0.532 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.714 178.663 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 8.8 p -47.02 -39.67 13.14 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 115.945 1.832 . . . . 0.0 115.945 -172.097 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -109.51 15.5 32.25 Favored Glycine 0 C--N 1.286 -2.212 0 C-N-CA 120.328 -0.939 . . . . 0.0 113.239 -176.626 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . 0.454 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 96.5 m-85 -116.12 157.97 23.94 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 117.974 0.887 . . . . 0.0 111.571 -178.24 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -126.93 158.05 37.82 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 106.557 -1.645 . . . . 0.0 106.557 175.763 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.674 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.5 tt -91.28 139.45 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.23 0 C-N-CA 119.167 -1.013 . . . . 0.0 110.806 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -50.04 -58.95 4.42 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 126.08 1.752 . . . . 0.0 113.106 -177.657 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -128.64 -103.88 1.15 Allowed Glycine 0 CA--C 1.493 -1.331 0 C-N-CA 120.247 -0.978 . . . . 0.0 111.276 -178.394 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -80.52 159.12 25.62 Favored 'General case' 0 CA--C 1.486 -1.497 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 177.815 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.674 ' HA ' HD13 ' A' ' 184' ' ' ILE . 15.0 pt-20 -103.45 4.45 36.08 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.428 -0.909 . . . . 0.0 109.507 178.34 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -148.44 146.61 28.5 Favored 'General case' 0 N--CA 1.426 -1.654 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.018 -175.715 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.424 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 12.3 ptp -124.44 121.21 34.25 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.11 174.279 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 46.0 t-80 -98.77 145.41 26.97 Favored 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.069 -176.661 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 12.8 m -62.01 148.52 43.67 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 177.133 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 31.5 m -127.9 159.95 33.34 Favored 'General case' 0 N--CA 1.423 -1.813 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 173.074 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -69.97 -1.46 9.77 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -172.65 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -75.84 -15.91 60.16 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.039 0.447 . . . . 0.0 109.901 175.458 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 88.12 22.19 42.62 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -172.454 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -135.81 169.38 17.66 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -179.917 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . 0.482 ' CH2' HG23 ' A' ' 174' ' ' VAL . 78.1 m95 -87.13 151.42 23.22 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.818 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 39.6 t -71.1 -50.1 37.28 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 121.531 0.682 . . . . 0.0 109.186 177.739 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.409 ' HD3' ' HA ' ' A' ' 200' ' ' LYS . 25.4 mmtp -88.49 148.99 23.88 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-O 121.417 0.627 . . . . 0.0 111.623 -179.798 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -89.11 150.65 22.63 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.813 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . 0.433 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 27.3 ttpp -58.73 112.95 5.69 Favored Pre-proline 0 C--O 1.237 0.4 0 N-CA-C 114.443 1.275 . . . . 0.0 114.443 -173.306 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 18.0 Cg_exo -72.01 171.38 16.8 Favored 'Trans proline' 0 N--CA 1.451 -1.014 0 C-N-CA 123.395 2.73 . . . . 0.0 110.631 175.322 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.4 mttp -123.36 167.06 14.29 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -177.753 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.472 ' SG ' ' HA3' ' A' ' 155' ' ' GLY . 94.5 m -106.59 104.65 14.39 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 172.195 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 11.4 m . . . . . 0 C--N 1.296 -1.751 0 CA-C-N 114.782 -1.099 . . . . 0.0 112.327 -171.924 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo . . . . . 0 CA--C 1.536 0.611 0 CA-C-O 121.783 0.66 . . . . 0.0 111.082 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.5 m -82.5 -32.86 28.57 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.309 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.53 -85.86 0.4 Allowed Glycine 0 CA--C 1.458 -3.508 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 173.073 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.2 t60 179.42 130.43 0.23 Allowed Pre-proline 0 C--N 1.271 -2.818 0 N-CA-C 104.153 -2.536 . . . . 0.0 104.153 -176.056 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.4 -33.07 5.81 Favored 'Trans proline' 0 N--CA 1.474 0.363 0 C-N-CA 121.625 1.55 . . . . 0.0 112.744 -175.423 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 134.52 177.26 14.82 Favored Glycine 0 N--CA 1.419 -2.445 0 N-CA-C 107.021 -2.432 . . . . 0.0 107.021 -176.017 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -134.91 162.96 30.95 Favored 'General case' 0 C--N 1.287 -2.14 0 CA-C-N 118.36 1.08 . . . . 0.0 109.433 179.848 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.7 t -119.35 131.44 24.37 Favored Pre-proline 0 N--CA 1.416 -2.153 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.183 -178.516 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.02 -11.69 17.85 Favored 'Trans proline' 0 N--CA 1.459 -0.509 0 C-N-CA 122.563 2.176 . . . . 0.0 111.616 177.872 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -88.93 -2.89 58.81 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.216 -177.814 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.462 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 175.57 -128.02 1.34 Allowed Glycine 0 N--CA 1.414 -2.793 0 C-N-CA 118.961 -1.59 . . . . 0.0 113.63 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.1 p -138.56 170.5 15.89 Favored 'General case' 0 C--N 1.291 -1.96 0 CA-C-N 114.841 -0.68 . . . . 0.0 110.972 -174.641 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.2 p90 -140.74 145.65 36.71 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 171.023 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.7 m -120.32 161.23 21.49 Favored 'General case' 0 C--N 1.271 -2.843 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -176.894 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.5 mt -119.56 120.97 38.29 Favored 'General case' 0 C--N 1.28 -2.448 0 CA-C-O 121.028 0.442 . . . . 0.0 109.867 -177.443 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.48 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 24.0 p -109.99 129.02 55.73 Favored 'General case' 0 C--N 1.285 -2.218 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.52 -175.383 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 113.38 -54.91 0.54 Allowed Glycine 0 N--CA 1.432 -1.593 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.073 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.429 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -121.24 -12.63 5.67 Favored Glycine 0 C--N 1.305 -1.19 0 C-N-CA 119.965 -1.112 . . . . 0.0 113.335 -179.514 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 47.7 m-80 61.26 18.55 9.28 Favored 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 123.485 0.714 . . . . 0.0 112.22 -178.168 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.54 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.7 m -151.32 -174.48 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.206 -1.21 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -175.806 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -99.71 46.05 0.98 Allowed 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 118.732 0.696 . . . . 0.0 110.619 -177.339 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.691 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.1 pt-20 -86.91 179.79 6.65 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.632 177.019 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 41.2 m-85 -76.12 137.28 40.01 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 122.039 -0.413 . . . . 0.0 111.301 177.089 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.98 -7.96 70.11 Favored Glycine 0 N--CA 1.441 -0.969 0 CA-C-N 115.603 -0.726 . . . . 0.0 113.048 178.003 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.691 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.9 p -87.14 146.8 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.881 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 -175.163 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.48 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.9 mtpt -110.25 125.84 53.53 Favored 'General case' 0 N--CA 1.419 -2.011 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.248 178.129 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -88.42 95.99 10.42 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 175.442 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 77.5 t -90.08 113.65 26.55 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.901 0 C-N-CA 123.988 0.915 . . . . 0.0 108.819 -177.451 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -88.48 134.6 33.8 Favored 'General case' 0 C--N 1.285 -2.228 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.992 -178.948 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.1 t -142.82 124.04 14.6 Favored 'General case' 0 N--CA 1.428 -1.561 0 CA-C-O 122.067 0.937 . . . . 0.0 109.399 179.51 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.404 ' HB3' ' HB2' ' A' ' 118' ' ' TYR . 78.0 m -75.35 166.46 23.57 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.949 -174.064 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.462 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 85.2 m-20 -85.46 -177.03 6.34 Favored 'General case' 0 C--O 1.216 -0.698 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.295 178.393 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -42.93 -54.44 4.21 Favored 'General case' 0 C--N 1.311 -1.072 0 C-N-CA 126.163 1.785 . . . . 0.0 114.527 -177.435 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -92.41 17.34 57.64 Favored Glycine 0 C--N 1.299 -1.495 0 C-N-CA 119.497 -1.335 . . . . 0.0 112.859 -175.111 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.717 ' HE1' HG22 ' A' ' 143' ' ' VAL . 77.8 m-85 -133.95 147.32 51.04 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.182 -177.304 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.438 ' OE1' ' HB3' ' A' ' 142' ' ' GLU . 0.0 OUTLIER -136.3 160.07 39.84 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -178.849 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . 0.452 HD22 ' HB3' ' A' ' 125' ' ' ASN . 10.4 tp -83.7 141.44 31.47 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 118.915 -1.114 . . . . 0.0 109.947 -176.309 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.05 122.91 43.21 Favored 'General case' 0 N--CA 1.411 -2.381 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 179.177 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.66 -160.42 13.7 Favored Glycine 0 C--N 1.293 -1.855 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.77 -176.568 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -105.9 -48.31 3.65 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.129 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.5 mm -73.4 129.51 36.16 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.132 -173.458 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.452 ' HB3' HD22 ' A' ' 120' ' ' LEU . 2.5 p-10 -130.0 12.99 5.73 Favored 'General case' 0 C--O 1.213 -0.838 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 177.516 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.47 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 34.0 p90 -149.67 161.74 41.59 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.85 -176.48 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 44.3 mtp180 -127.46 131.78 50.13 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 172.069 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -108.06 131.98 54.03 Favored 'General case' 0 C--N 1.283 -2.301 0 C-N-CA 119.202 -0.999 . . . . 0.0 109.5 -178.405 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 21.6 t -81.4 99.27 8.62 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.829 -1.149 . . . . 0.0 109.155 176.533 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.425 ' OD2' HG22 ' A' ' 131' ' ' THR . 8.6 t70 -96.35 -167.13 1.52 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 178.447 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.425 HG22 ' OD2' ' A' ' 130' ' ' ASP . 9.0 t -59.37 -28.46 66.9 Favored 'General case' 0 C--N 1.31 -1.121 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -174.733 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -85.95 -23.65 26.85 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.549 0.69 . . . . 0.0 110.213 179.596 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 128.96 -153.96 20.01 Favored Glycine 0 N--CA 1.421 -2.362 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -175.646 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -64.87 113.38 3.79 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -179.878 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 65.0 p -73.09 172.48 10.97 Favored 'General case' 0 C--O 1.27 2.154 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 176.188 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 63.6 m-20 59.68 -156.74 0.34 Allowed 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 175.984 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -141.15 -177.51 5.15 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 173.092 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 57.0 mt -65.73 116.88 36.17 Favored Pre-proline 0 C--N 1.273 -2.728 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 174.806 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.413 ' HB2' HD11 ' A' ' 120' ' ' LEU . 49.2 Cg_endo -68.61 160.83 47.77 Favored 'Trans proline' 0 C--O 1.246 0.91 0 C-N-CA 122.418 2.079 . . . . 0.0 112.308 -176.01 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 48.7 mm -90.67 131.52 37.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.364 -176.382 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.613 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 36.6 t -114.08 137.62 51.49 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 105.752 -1.944 . . . . 0.0 105.752 175.697 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.438 ' HB3' ' OE1' ' A' ' 119' ' ' GLN . 9.7 tp10 -119.1 157.59 27.56 Favored 'General case' 0 C--N 1.277 -2.557 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.717 HG22 ' HE1' ' A' ' 118' ' ' TYR . 24.0 t -79.84 138.54 19.72 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.073 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 -178.908 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 70.6 t -60.01 122.01 9.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 124.305 1.003 . . . . 0.0 108.399 179.331 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.507 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 59.9 mttm -120.33 156.06 32.07 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.899 -178.815 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 80.1 m -108.65 -171.54 1.87 Allowed 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 123.825 0.85 . . . . 0.0 110.677 -179.827 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . 0.588 HD12 ' HD2' ' A' ' 148' ' ' PRO . 1.5 tp -95.56 134.34 24.39 Favored Pre-proline 0 N--CA 1.421 -1.913 0 O-C-N 122.027 -0.421 . . . . 0.0 110.023 -177.181 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.588 ' HD2' HD12 ' A' ' 147' ' ' LEU . 12.7 Cg_endo -58.2 121.51 10.12 Favored 'Trans proline' 0 CA--C 1.535 0.543 0 C-N-CA 123.23 2.62 . . . . 0.0 111.563 177.333 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 28.7 t -85.94 143.65 11.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 -177.975 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 19.5 p -77.98 -83.12 0.08 Allowed 'General case' 0 N--CA 1.42 -1.974 0 CA-C-N 116.806 -0.179 . . . . 0.0 111.308 175.436 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.96 156.56 0.21 Allowed Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 125.143 1.377 . . . . 0.0 107.757 179.604 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -69.79 162.93 40.18 Favored 'Trans proline' 0 C--N 1.353 0.816 0 C-N-CA 121.723 1.615 . . . . 0.0 110.896 172.915 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . 0.43 ' HG3' HD22 ' A' ' 154' ' ' ASN . 11.0 pt-20 -62.3 -50.6 71.02 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -174.926 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . 0.43 HD22 ' HG3' ' A' ' 153' ' ' GLU . 55.4 m-80 -113.76 38.17 3.04 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 -177.96 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -154.06 -164.41 12.75 Favored Glycine 0 N--CA 1.425 -2.051 0 CA-C-N 115.026 -0.988 . . . . 0.0 111.189 178.353 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -156.0 173.24 17.09 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -178.601 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 49.7 mt -88.98 134.73 27.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 CA-C-O 121.148 0.499 . . . . 0.0 110.499 -179.251 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 55.1 t -73.98 -43.38 52.27 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 C-N-CA 124.149 0.98 . . . . 0.0 109.455 178.779 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 2.1 m . . . . . 0 C--N 1.29 -1.994 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -179.86 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 . . . . . 0 CA--C 1.49 -1.355 0 CA-C-O 121.074 0.464 . . . . 0.0 111.681 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.507 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 20.9 p-80 -96.34 159.52 14.9 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.623 -179.135 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 50.3 t80 -50.78 123.29 8.73 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 125.311 1.444 . . . . 0.0 109.59 176.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.62 -10.93 21.39 Favored Glycine 0 N--CA 1.425 -2.092 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.621 -178.068 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.0 mm-40 -89.65 143.64 26.64 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-N 117.805 0.802 . . . . 0.0 111.195 179.585 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -111.86 126.44 55.09 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.468 -1.242 . . . . 0.0 107.826 177.848 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.574 HG12 ' CG ' ' A' ' 190' ' ' MET . 0.3 OUTLIER -117.76 118.5 58.57 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.246 0 C-N-CA 119.249 -0.981 . . . . 0.0 108.384 178.73 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 43.9 ttm180 -104.54 157.52 17.12 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 -179.275 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -129.12 154.35 46.79 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -176.031 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.5 p -135.82 152.13 30.47 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.158 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.581 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 74.8 m -105.48 146.29 29.74 Favored 'General case' 0 C--N 1.274 -2.716 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.871 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -65.88 172.93 3.23 Favored 'General case' 0 CA--C 1.503 -0.832 0 O-C-N 123.732 0.645 . . . . 0.0 110.473 -177.441 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 6.0 p -53.75 104.9 0.11 Allowed 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 124.317 1.047 . . . . 0.0 112.939 -177.764 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.18 -3.64 31.47 Favored Glycine 0 N--CA 1.433 -1.508 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.457 177.889 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -112.64 150.27 31.68 Favored 'General case' 0 N--CA 1.42 -1.946 0 O-C-N 122.162 -0.611 . . . . 0.0 110.397 179.89 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 65.0 pttt -123.36 160.3 27.06 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.412 HD11 ' HB2' ' A' ' 203' ' ' PRO . 1.7 tp -76.18 142.2 14.72 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -179.787 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -88.5 -69.1 0.72 Allowed 'General case' 0 C--N 1.287 -2.114 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -77.8 -128.22 0.42 Allowed Glycine 0 N--CA 1.437 -1.251 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.717 176.964 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 203' ' ' PRO . 5.6 t70 -98.28 162.04 13.39 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.281 -1.378 . . . . 0.0 107.281 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -99.78 1.1 42.84 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 119.513 1.051 . . . . 0.0 112.23 -170.618 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -152.01 153.84 34.83 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 121.398 0.618 . . . . 0.0 112.475 -177.154 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.574 ' CG ' HG12 ' A' ' 174' ' ' VAL . 16.7 ptp -132.72 148.51 52.33 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.289 178.659 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 47.6 m80 -115.17 145.44 42.39 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.604 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 42.8 t -81.58 102.25 10.51 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 177.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 51.9 m -121.66 158.0 29.63 Favored 'General case' 0 N--CA 1.425 -1.688 0 N-CA-C 114.096 1.147 . . . . 0.0 114.096 -168.607 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 21.98 -76.87 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 129.483 3.113 . . . . 0.0 116.973 174.389 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -62.76 -21.2 65.66 Favored 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 125.014 1.325 . . . . 0.0 113.58 -172.059 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 101.73 20.72 12.38 Favored Glycine 0 N--CA 1.435 -1.42 0 C-N-CA 119.62 -1.276 . . . . 0.0 110.913 -175.819 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 21.9 p90 -146.67 173.18 12.58 Favored 'General case' 0 N--CA 1.426 -1.649 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 175.068 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.3 m95 -69.18 138.44 54.1 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 123.651 0.594 . . . . 0.0 111.62 -175.366 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 13.0 p -68.31 -33.4 74.26 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.656 178.841 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 59.5 mmtt -107.23 149.57 27.59 Favored 'General case' 0 N--CA 1.432 -1.352 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.617 -179.765 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -79.84 163.89 24.03 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 114.463 -1.244 . . . . 0.0 109.018 176.467 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 9.6 mtpm? -64.89 128.52 93.78 Favored Pre-proline 0 CA--C 1.502 -0.867 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.964 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . 0.443 ' HB3' ' O ' ' A' ' 187' ' ' ASP . 95.3 Cg_endo -78.78 166.95 22.97 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 C-N-CA 122.247 1.964 . . . . 0.0 111.975 179.55 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.2 tttp -122.44 156.74 33.42 Favored 'General case' 0 N--CA 1.414 -2.268 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 -179.493 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 92.3 m -118.07 116.27 26.53 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 176.796 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 27.4 m . . . . . 0 C--N 1.301 -1.542 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.546 -176.571 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo . . . . . 0 CA--C 1.542 0.915 0 CA-C-O 120.948 0.312 . . . . 0.0 112.113 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.8 m -80.33 -31.9 37.97 Favored 'General case' 0 CA--C 1.502 -0.898 0 CA-C-O 122.262 1.03 . . . . 0.0 108.338 177.787 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.42 -87.97 0.46 Allowed Glycine 1 N--CA 1.395 -4.064 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 173.444 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 26.7 t-80 -176.47 133.22 0.4 Allowed Pre-proline 0 C--N 1.262 -3.213 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 -175.273 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.484 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 85.7 Cg_endo -81.91 1.04 9.49 Favored 'Trans proline' 0 N--CA 1.475 0.422 0 C-N-CA 122.58 2.187 . . . . 0.0 113.464 -174.819 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 100.72 -169.24 21.06 Favored Glycine 0 C--N 1.291 -1.96 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 -175.394 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -151.06 178.37 9.26 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.521 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.9 t -142.99 139.09 16.43 Favored Pre-proline 0 N--CA 1.427 -1.596 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.813 -176.984 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.97 -11.87 21.55 Favored 'Trans proline' 0 CA--C 1.534 0.5 0 C-N-CA 122.635 2.223 . . . . 0.0 111.349 176.227 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -89.63 -4.15 57.93 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.228 -177.021 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.572 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 173.83 -123.73 0.99 Allowed Glycine 0 N--CA 1.419 -2.444 0 C-N-CA 119.823 -1.18 . . . . 0.0 112.371 179.766 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.1 t -165.22 -163.25 0.67 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.28 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.445 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 54.4 p90 -145.72 175.07 10.66 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 178.593 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.8 m -136.01 163.43 30.32 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 176.645 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 23.8 mt -118.94 120.89 38.61 Favored 'General case' 0 C--N 1.285 -2.22 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -178.885 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.413 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 26.1 p -114.13 128.75 56.52 Favored 'General case' 0 C--N 1.285 -2.21 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -175.411 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 97.36 19.67 24.93 Favored Glycine 0 C--N 1.299 -1.48 0 C-N-CA 119.849 -1.167 . . . . 0.0 111.149 -179.523 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.52 -32.16 0.15 Allowed Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 118.911 -1.614 . . . . 0.0 114.417 179.445 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 65.93 19.45 11.26 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 123.205 0.602 . . . . 0.0 111.174 -176.242 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.465 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.3 m -149.23 -177.86 0.47 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.084 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -175.552 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 38.1 m-85 -103.88 47.8 0.87 Allowed 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 118.726 0.694 . . . . 0.0 110.171 -179.772 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.678 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.7 pt-20 -83.63 177.8 8.24 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.311 -1.313 . . . . 0.0 111.554 179.226 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 45.5 m-85 -77.67 130.42 36.8 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.645 174.064 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 91.23 15.72 55.09 Favored Glycine 0 N--CA 1.434 -1.491 0 C-N-CA 120.203 -0.999 . . . . 0.0 112.377 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.678 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -106.38 149.5 9.77 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 176.06 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.413 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.2 mtpt -113.95 125.69 54.31 Favored 'General case' 0 N--CA 1.418 -2.048 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.485 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -90.01 89.27 7.63 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.225 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.472 HG12 ' HB3' ' A' ' 126' ' ' TYR . 28.5 m -84.91 112.28 21.74 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.981 0 CA-C-O 122.164 0.983 . . . . 0.0 109.565 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . 0.445 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 33.8 m-85 -78.92 142.21 36.94 Favored 'General case' 0 C--N 1.269 -2.9 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.123 -179.569 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.9 t -138.84 122.58 17.57 Favored 'General case' 0 N--CA 1.411 -2.422 0 CA-C-N 115.135 -0.938 . . . . 0.0 108.822 -179.639 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 88.0 m -73.68 160.8 31.04 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 115.487 -0.778 . . . . 0.0 112.0 -178.383 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.572 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 81.2 m-20 -76.44 -176.53 3.72 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.293 179.703 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -52.46 -48.52 65.8 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 124.655 1.182 . . . . 0.0 113.491 -177.28 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.32 10.53 70.98 Favored Glycine 0 C--N 1.3 -1.437 0 C-N-CA 119.786 -1.197 . . . . 0.0 113.306 -177.971 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.538 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 93.6 m-85 -127.62 161.02 29.85 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 122.166 -0.608 . . . . 0.0 111.419 -175.753 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.49 150.43 43.75 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.026 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.21 133.03 39.01 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 -179.681 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.03 127.54 55.92 Favored 'General case' 0 N--CA 1.414 -2.241 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.143 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.2 -163.27 12.62 Favored Glycine 0 C--N 1.296 -1.666 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.811 -179.804 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -108.96 -30.05 8.29 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 178.632 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.7 mm -88.16 127.06 41.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.513 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -129.56 9.84 5.57 Favored 'General case' 0 C--O 1.202 -1.44 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.034 176.777 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.472 ' HB3' HG12 ' A' ' 111' ' ' VAL . 22.1 p90 -139.08 165.52 26.94 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.397 -171.916 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.542 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 52.2 mtp180 -128.57 126.82 41.11 Favored 'General case' 0 C--O 1.204 -1.311 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 171.395 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -98.17 133.11 43.05 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.542 -0.863 . . . . 0.0 109.947 179.187 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 36.2 t -89.86 110.62 21.54 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.31 174.555 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.42 ' CG ' ' H ' ' A' ' 131' ' ' THR . 36.1 t70 -113.44 -167.21 1.17 Allowed 'General case' 0 C--N 1.289 -2.033 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 175.485 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.42 ' H ' ' CG ' ' A' ' 130' ' ' ASP . 15.3 t -67.09 -20.53 65.81 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.319 1.057 . . . . 0.0 109.69 -179.318 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -70.22 -23.73 62.98 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 114.279 -1.328 . . . . 0.0 109.233 175.001 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 105.9 -154.87 16.93 Favored Glycine 0 N--CA 1.42 -2.39 0 N-CA-C 107.169 -2.373 . . . . 0.0 107.169 -173.313 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 96.1 m95 -65.33 99.18 0.38 Allowed 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 117.666 0.733 . . . . 0.0 109.83 172.776 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.6 p -58.64 -67.58 0.35 Allowed 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 124.74 1.216 . . . . 0.0 112.839 -173.009 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . 0.542 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 3.0 m-20 -70.37 167.13 18.81 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.33 178.868 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -98.64 175.55 5.95 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.537 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 68.7 mt -63.92 121.83 73.52 Favored Pre-proline 0 C--N 1.273 -2.741 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 175.079 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -63.73 174.35 3.8 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 122.482 2.121 . . . . 0.0 112.791 -179.102 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 65.8 mt -98.9 140.73 17.81 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -175.307 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.538 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 42.4 t -128.92 119.5 24.48 Favored 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 -179.784 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -103.14 140.9 36.74 Favored 'General case' 0 C--N 1.279 -2.476 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 -175.901 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.418 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 10.8 p -70.9 138.74 21.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 173.932 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 92.7 t -59.61 114.66 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.73 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -176.371 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 92.4 mttt -113.73 144.55 42.76 Favored 'General case' 0 N--CA 1.426 -1.67 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.274 -177.787 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 82.9 m -112.03 160.95 17.0 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 114.732 -1.122 . . . . 0.0 109.165 179.778 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 59.7 mt -64.82 138.19 97.39 Favored Pre-proline 0 C--N 1.318 -0.781 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -179.183 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -63.48 127.47 19.97 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.821 2.347 . . . . 0.0 111.103 179.376 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.4 t -85.21 142.42 13.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -179.788 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.9 p -67.45 -82.98 0.03 OUTLIER 'General case' 0 N--CA 1.425 -1.704 0 O-C-N 123.604 0.565 . . . . 0.0 111.223 177.412 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 168.41 159.52 0.16 Allowed Pre-proline 0 CA--C 1.513 -0.474 0 C-N-CA 125.554 1.542 . . . . 0.0 106.99 179.716 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -82.88 169.11 13.46 Favored 'Trans proline' 0 N--CA 1.448 -1.196 0 C-N-CA 121.643 1.562 . . . . 0.0 111.352 173.688 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -60.54 -57.02 14.5 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -176.827 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -112.02 25.19 11.82 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.12 0.962 . . . . 0.0 109.798 -172.908 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -146.02 -172.03 16.01 Favored Glycine 0 C--N 1.284 -2.324 0 CA-C-N 114.421 -1.263 . . . . 0.0 110.984 179.04 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.0 pttm -149.79 169.12 21.83 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 178.504 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.561 HG12 ' CE2' ' A' ' 176' ' ' PHE . 62.8 mt -88.2 130.58 37.54 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.879 179.453 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.492 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 12.9 m -87.15 -29.04 5.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.324 0.583 . . . . 0.0 109.628 179.8 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . 0.528 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 25.2 m . . . . . 0 C--N 1.308 -1.233 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.631 -174.812 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 . . . . . 0 CA--C 1.476 -1.896 0 CA-C-O 121.194 0.521 . . . . 0.0 109.876 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 56.7 p-80 -130.44 167.93 17.81 Favored 'General case' 0 C--N 1.281 -2.395 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.038 -174.496 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 79.8 t80 -47.69 132.12 14.34 Favored 'General case' 0 CA--C 1.506 -0.73 0 O-C-N 124.418 1.074 . . . . 0.0 110.612 178.755 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 108.67 -26.11 17.11 Favored Glycine 0 N--CA 1.418 -2.55 0 C-N-CA 120.378 -0.915 . . . . 0.0 111.781 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -76.83 134.05 39.17 Favored 'General case' 0 N--CA 1.414 -2.247 0 CA-C-O 121.664 0.745 . . . . 0.0 110.524 -179.061 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -110.57 90.83 3.44 Favored 'General case' 0 C--N 1.269 -2.893 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 173.959 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.528 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 14.6 p -73.15 105.1 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.9 0 CA-C-O 121.706 0.765 . . . . 0.0 109.257 -176.127 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.514 ' HD2' ' OE2' ' A' ' 188' ' ' GLU . 12.4 ttp180 -97.11 152.73 18.49 Favored 'General case' 0 N--CA 1.411 -2.387 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.387 -175.503 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.561 ' CE2' HG12 ' A' ' 157' ' ' ILE . 81.7 m-85 -121.2 153.22 37.88 Favored 'General case' 0 N--CA 1.428 -1.563 0 C-N-CA 124.173 0.989 . . . . 0.0 109.151 -177.462 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.448 ' HB ' ' CG1' ' A' ' 158' ' ' VAL . 10.3 p -135.7 149.59 28.24 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . 0.438 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 76.6 m -90.06 141.07 29.04 Favored 'General case' 0 C--N 1.268 -2.959 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.464 178.314 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -70.91 -52.6 19.06 Favored 'General case' 0 CA--C 1.477 -1.855 0 CA-C-N 115.298 -0.864 . . . . 0.0 112.338 -175.347 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . 0.445 ' HB3' ' CE2' ' A' ' 182' ' ' TYR . 34.3 t -116.01 -158.88 0.7 Allowed 'General case' 0 C--N 1.26 -3.287 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -177.183 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -71.77 51.03 1.18 Allowed Glycine 0 C--O 1.229 -0.203 0 O-C-N 123.473 0.483 . . . . 0.0 113.294 -177.975 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . 0.445 ' CE2' ' HB3' ' A' ' 180' ' ' SER . 90.5 m-85 -103.51 170.64 7.83 Favored 'General case' 0 C--N 1.292 -1.913 0 C-N-CA 123.137 0.575 . . . . 0.0 109.539 177.463 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.458 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 39.4 pttt -126.5 150.92 48.46 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 176.374 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.5 tp -65.31 142.68 16.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 CA-C-O 121.427 0.632 . . . . 0.0 110.025 176.096 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -67.23 -58.41 4.89 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.915 -178.362 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -120.96 -111.03 2.22 Favored Glycine 0 N--CA 1.42 -2.396 0 N-CA-C 110.589 -1.005 . . . . 0.0 110.589 -178.941 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -88.91 144.9 25.88 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.225 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.514 ' OE2' ' HD2' ' A' ' 175' ' ' ARG . 12.8 pt-20 -87.62 1.27 54.13 Favored 'General case' 0 C--O 1.205 -1.282 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.986 -176.045 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -145.16 151.18 38.05 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 121.191 0.52 . . . . 0.0 111.312 -179.186 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.492 ' HG3' HG13 ' A' ' 174' ' ' VAL . 0.0 OUTLIER -123.4 140.82 52.62 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 175.966 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 26.3 m80 -100.42 140.39 34.74 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.835 -0.346 . . . . 0.0 110.313 176.899 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 52.6 t -86.56 104.41 15.98 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 174.301 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 18.0 m -74.94 156.88 35.86 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-N 115.225 -0.898 . . . . 0.0 111.095 -177.524 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -68.63 1.84 2.89 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.794 1.238 . . . . 0.0 114.163 -174.371 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . 0.444 ' HB3' ' CE2' ' A' ' 197' ' ' PHE . 36.9 t70 -102.1 -17.37 16.06 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 121.33 0.586 . . . . 0.0 109.69 175.609 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 101.34 53.75 0.99 Allowed Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.935 179.912 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . 0.444 ' CE2' ' HB3' ' A' ' 195' ' ' ASP . 52.1 p90 -154.76 156.95 37.25 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.918 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 78.8 m95 -83.96 130.5 34.89 Favored 'General case' 0 N--CA 1.431 -1.394 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 175.39 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 7.7 m -63.8 -29.21 70.44 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.53 -179.81 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 4.0 mmmt -117.89 152.79 34.69 Favored 'General case' 0 N--CA 1.411 -2.395 0 O-C-N 121.943 -0.473 . . . . 0.0 110.882 -179.516 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -71.28 165.63 23.28 Favored 'General case' 0 C--O 1.252 1.205 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 174.875 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . 0.453 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 41.6 mtpt -61.32 125.3 83.83 Favored Pre-proline 0 N--CA 1.447 -0.602 0 C-N-CA 120.341 -0.544 . . . . 0.0 110.136 174.919 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -88.84 175.04 3.74 Favored 'Trans proline' 0 N--CA 1.419 -2.854 0 C-N-CA 121.791 1.661 . . . . 0.0 110.001 172.932 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.6 mttp -137.91 177.22 8.04 Favored 'General case' 0 C--N 1.284 -2.276 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 -177.073 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.458 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 68.1 m -118.76 104.27 10.43 Favored 'General case' 0 C--N 1.283 -2.324 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 171.776 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.9 m . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 114.306 -1.316 . . . . 0.0 111.337 -172.27 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.414 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 17.7 Cg_endo . . . . . 0 CA--C 1.536 0.595 0 CA-C-O 120.926 0.303 . . . . 0.0 112.269 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . 0.418 ' HB3' ' CD1' ' A' ' 134' ' ' TRP . 4.5 m -93.16 -24.56 18.19 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.242 0.544 . . . . 0.0 111.558 175.003 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.94 -93.55 0.59 Allowed Glycine 0 CA--C 1.46 -3.345 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 173.196 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 -170.23 132.77 1.02 Allowed Pre-proline 0 C--N 1.262 -3.201 0 N-CA-C 104.02 -2.585 . . . . 0.0 104.02 -175.478 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.504 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 87.9 Cg_endo -81.32 -19.81 7.58 Favored 'Trans proline' 0 C--N 1.332 -0.341 0 C-N-CA 121.637 1.558 . . . . 0.0 113.553 -173.189 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 130.1 -165.39 22.47 Favored Glycine 0 N--CA 1.426 -2.013 0 N-CA-C 110.186 -1.166 . . . . 0.0 110.186 -177.358 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -151.04 151.34 31.89 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 -178.659 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.1 t -131.07 127.5 22.0 Favored Pre-proline 0 C--N 1.303 -1.456 0 C-N-CA 120.338 -0.545 . . . . 0.0 110.553 179.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.46 -18.37 26.08 Favored 'Trans proline' 0 C--O 1.237 0.445 0 C-N-CA 122.523 2.149 . . . . 0.0 111.554 178.843 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.531 ' CB ' ' HB2' ' A' ' 141' ' ' CYS . 59.7 m-85 -78.92 -17.26 55.83 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.192 -177.461 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.472 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -168.97 -126.76 0.87 Allowed Glycine 0 CA--C 1.477 -2.284 0 C-N-CA 120.212 -0.994 . . . . 0.0 111.167 -178.933 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.1 t -160.07 -169.87 2.65 Favored 'General case' 0 C--N 1.284 -2.243 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.651 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.431 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 37.8 p90 -147.11 165.46 29.89 Favored 'General case' 0 N--CA 1.432 -1.331 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 177.582 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.7 m -132.81 161.75 33.32 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 177.879 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 26.6 mt -109.93 137.54 47.57 Favored 'General case' 0 C--N 1.271 -2.837 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.47 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.536 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 11.1 p -134.11 141.6 47.2 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -173.979 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 100.33 -42.37 1.97 Allowed Glycine 0 C--N 1.303 -1.304 0 N-CA-C 108.148 -1.981 . . . . 0.0 108.148 -173.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.459 ' HA3' ' OE2' ' A' ' 105' ' ' GLU . . . -139.63 -143.09 4.33 Favored Glycine 0 N--CA 1.406 -3.358 0 N-CA-C 108.029 -2.028 . . . . 0.0 108.029 176.085 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -151.61 16.22 0.69 Allowed 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.41 1.1 . . . . 0.0 109.829 -178.51 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.531 ' O ' HG11 ' A' ' 108' ' ' VAL . 28.7 m -147.5 -170.57 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 -175.511 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.504 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 30.5 m-85 -96.17 39.11 1.16 Allowed 'General case' 0 C--N 1.307 -1.255 0 CA-C-O 121.99 0.9 . . . . 0.0 110.022 -177.832 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.661 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.2 pt-20 -71.83 178.03 3.89 Favored 'General case' 0 C--O 1.202 -1.44 0 C-N-CA 127.197 2.199 . . . . 0.0 111.888 179.009 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . 0.546 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 27.6 m-85 -79.32 135.9 36.86 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-O 121.008 0.432 . . . . 0.0 110.971 176.49 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.24 3.24 82.34 Favored Glycine 0 N--CA 1.442 -0.91 0 C-N-CA 121.001 -0.618 . . . . 0.0 112.349 178.804 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.661 HG12 ' O ' ' A' ' 105' ' ' GLU . 8.5 p -92.75 142.81 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.549 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.536 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -107.52 126.82 53.0 Favored 'General case' 0 C--N 1.28 -2.437 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 177.682 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -89.32 87.98 7.32 Favored 'General case' 0 C--N 1.28 -2.436 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 174.896 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.508 HG12 ' HB3' ' A' ' 126' ' ' TYR . 30.0 m -84.97 116.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.383 0 CA-C-O 121.989 0.899 . . . . 0.0 109.403 -179.423 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . 0.431 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 33.9 m-85 -85.73 142.59 28.89 Favored 'General case' 0 C--N 1.27 -2.877 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.42 179.754 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -138.0 124.61 20.9 Favored 'General case' 0 N--CA 1.405 -2.725 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -178.92 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.7 m -74.08 155.61 38.3 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 115.3 -0.863 . . . . 0.0 112.262 -175.498 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.472 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 72.2 m-20 -68.09 173.81 4.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.175 178.482 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -50.75 -48.21 59.17 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 123.78 0.832 . . . . 0.0 112.547 -177.922 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.465 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -89.8 30.88 5.53 Favored Glycine 0 N--CA 1.438 -1.222 0 C-N-CA 120.778 -0.725 . . . . 0.0 113.05 -178.417 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -146.65 157.4 43.7 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 122.177 -0.602 . . . . 0.0 109.555 -176.424 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.5 150.7 47.74 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 122.688 0.395 . . . . 0.0 110.334 177.076 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.99 117.21 15.51 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -175.336 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -103.13 126.13 50.16 Favored 'General case' 0 N--CA 1.407 -2.593 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -178.876 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 120.33 176.54 15.77 Favored Glycine 0 C--N 1.29 -1.98 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.706 -177.551 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -93.77 -24.77 17.68 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.906 0.86 . . . . 0.0 109.02 -178.384 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.458 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.2 mm -104.03 129.22 56.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 114.851 -1.068 . . . . 0.0 109.213 -176.538 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -119.0 -2.49 10.8 Favored 'General case' 0 C--O 1.201 -1.493 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 177.611 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.508 ' HB3' HG12 ' A' ' 111' ' ' VAL . 39.8 p90 -138.46 162.18 35.13 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 120.945 0.402 . . . . 0.0 110.526 -169.374 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 61.1 mtp180 -123.53 135.24 53.91 Favored 'General case' 0 C--N 1.282 -2.328 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 170.989 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -110.45 130.58 55.53 Favored 'General case' 0 C--N 1.284 -2.253 0 C-N-CA 119.046 -1.061 . . . . 0.0 110.215 -178.517 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . 0.546 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 36.9 t -75.99 98.96 4.41 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.328 0.585 . . . . 0.0 109.918 177.878 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.44 ' OD2' HG22 ' A' ' 131' ' ' THR . 20.3 t70 -100.14 -175.43 2.94 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 178.172 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.44 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -69.26 -19.49 63.92 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-O 121.997 0.904 . . . . 0.0 109.237 179.441 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -83.12 -12.79 56.69 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.304 -1.316 . . . . 0.0 109.326 179.831 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 110.37 -164.19 12.29 Favored Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -175.942 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.418 ' CD1' ' HB3' ' A' ' 85' ' ' CYS . 98.5 m95 -64.26 114.79 4.47 Favored 'General case' 0 C--O 1.248 0.978 0 CA-C-N 117.922 0.861 . . . . 0.0 109.88 175.363 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 68.6 p -71.29 164.87 24.86 Favored 'General case' 0 N--CA 1.417 -2.108 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 177.702 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 55.8 m-20 65.53 -158.87 0.28 Allowed 'General case' 0 C--O 1.245 0.826 0 O-C-N 123.843 0.714 . . . . 0.0 109.276 173.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -136.48 176.28 8.85 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 175.866 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.1 mt -64.29 120.44 64.81 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 124.271 0.982 . . . . 0.0 108.368 175.338 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.458 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 45.6 Cg_endo -67.68 176.52 4.99 Favored 'Trans proline' 0 C--O 1.248 1.024 0 C-N-CA 123.034 2.489 . . . . 0.0 112.583 -179.256 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.1 mm -111.71 137.0 46.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 CA-C-O 121.108 0.48 . . . . 0.0 110.318 -173.234 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.531 ' HB2' ' CB ' ' A' ' 93' ' ' PHE . 99.3 m -113.52 111.12 21.38 Favored 'General case' 0 C--N 1.279 -2.47 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 172.83 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -93.67 151.63 19.53 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 179.211 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 8.9 p -74.09 141.26 16.37 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.553 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . 0.506 HG23 ' HB2' ' A' ' 170' ' ' PHE . 15.6 m -67.09 101.14 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.776 0 CA-C-O 121.967 0.889 . . . . 0.0 110.024 177.843 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -85.18 123.51 30.77 Favored 'General case' 0 N--CA 1.407 -2.599 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.314 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.518 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 62.6 m -83.2 122.28 28.2 Favored 'General case' 0 C--N 1.273 -2.758 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 178.02 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 80.6 mt -53.36 131.69 52.94 Favored Pre-proline 0 C--N 1.313 -0.985 0 N-CA-C 113.629 0.974 . . . . 0.0 113.629 -175.693 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -56.44 121.03 9.31 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 123.33 2.687 . . . . 0.0 110.989 -178.575 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.5 p -89.28 149.48 4.01 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.973 -175.878 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.4 p -81.73 -173.45 4.44 Favored 'General case' 0 N--CA 1.422 -1.837 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 175.245 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -123.37 155.63 64.98 Favored Pre-proline 0 C--N 1.285 -2.238 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -172.802 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -77.35 169.72 20.73 Favored 'Trans proline' 0 CA--C 1.543 0.97 0 C-N-CA 121.92 1.746 . . . . 0.0 112.491 178.277 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -64.31 -57.5 9.21 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -178.816 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 -97.87 20.09 12.7 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.846 0.831 . . . . 0.0 110.269 -174.145 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -142.79 -173.27 14.41 Favored Glycine 0 N--CA 1.412 -2.903 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.985 179.878 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . 0.401 ' HG3' HG23 ' A' ' 177' ' ' VAL . 19.8 pttp -156.76 178.31 10.49 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -179.187 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 59.5 mt -101.09 138.35 25.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 CA-C-N 117.83 0.286 . . . . 0.0 111.066 -177.33 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.625 HG12 HG22 ' A' ' 177' ' ' VAL . 2.7 m -84.69 -33.64 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 177.426 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 6.1 m . . . . . 0 N--CA 1.444 -0.742 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.943 -174.584 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 . . . . . 0 CA--C 1.502 -0.902 0 CA-C-O 120.984 0.421 . . . . 0.0 110.088 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -125.49 165.05 19.17 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -177.3 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.506 ' HB2' HG23 ' A' ' 144' ' ' VAL . 92.4 t80 -51.57 134.86 29.16 Favored 'General case' 0 C--O 1.239 0.526 0 O-C-N 123.885 0.741 . . . . 0.0 109.11 170.586 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 109.94 -10.05 31.89 Favored Glycine 0 N--CA 1.424 -2.103 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.732 -179.112 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 -99.55 159.29 15.14 Favored 'General case' 0 N--CA 1.433 -1.291 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.916 -178.842 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 190' ' ' MET . . . -138.73 123.98 19.21 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 175.688 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.547 HG23 ' CH2' ' A' ' 198' ' ' TRP . 85.0 t -87.68 109.71 19.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.047 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.481 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 41.2 ttm180 -96.71 142.57 28.58 Favored 'General case' 0 N--CA 1.416 -2.162 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 177.781 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -110.19 159.59 17.24 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 -177.294 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.625 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -130.76 139.79 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.467 -2.247 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.675 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . 0.521 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 77.4 m -84.79 129.52 34.81 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 173.501 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -53.28 -51.63 61.69 Favored 'General case' 0 CA--C 1.48 -1.713 0 C-N-CA 124.76 1.224 . . . . 0.0 112.584 -175.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 13.3 t -123.63 -154.58 0.61 Allowed 'General case' 0 N--CA 1.402 -2.837 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 -177.052 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -74.22 51.11 2.06 Favored Glycine 0 N--CA 1.443 -0.838 0 O-C-N 123.588 0.555 . . . . 0.0 113.78 -176.468 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . 0.521 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 98.4 m-85 -100.89 168.39 9.66 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 176.114 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 50.6 pttt -121.41 146.05 47.29 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.794 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.759 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.8 tt -76.86 141.8 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.766 0 C-N-CA 119.691 -0.804 . . . . 0.0 110.276 176.403 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -53.75 -61.13 2.5 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 125.086 1.354 . . . . 0.0 113.228 -176.227 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -123.89 -97.81 1.27 Allowed Glycine 0 CA--C 1.496 -1.147 0 C-N-CA 120.33 -0.938 . . . . 0.0 112.814 -178.654 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -85.07 159.97 20.08 Favored 'General case' 0 CA--C 1.48 -1.728 0 N-CA-C 106.876 -1.527 . . . . 0.0 106.876 176.75 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.759 ' HA ' HD13 ' A' ' 184' ' ' ILE . 14.5 pt-20 -102.47 3.86 38.08 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 118.114 -1.434 . . . . 0.0 109.468 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . 0.476 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 8.7 pt-20 -151.45 147.37 26.78 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-N 115.547 -0.751 . . . . 0.0 112.386 -176.216 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.486 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 13.9 ptp -113.79 128.25 56.34 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.649 175.446 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 34.1 t-80 -110.56 146.56 35.85 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 116.746 -0.206 . . . . 0.0 110.473 -174.646 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 88.6 m -75.06 155.04 37.63 Favored 'General case' 0 C--O 1.241 0.642 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 178.436 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 60.6 m -126.17 171.46 10.86 Favored 'General case' 0 C--O 1.256 1.395 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 169.387 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -78.4 91.56 4.49 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.261 1.029 . . . . 0.0 112.496 -172.347 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 9.5 t70 174.22 -38.18 0.01 OUTLIER 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 113.15 -1.841 . . . . 0.0 106.293 176.508 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 119.65 18.69 4.33 Favored Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.196 -179.534 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -109.65 158.13 18.38 Favored 'General case' 0 C--O 1.251 1.168 0 O-C-N 122.226 -0.573 . . . . 0.0 109.969 176.418 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . 0.547 ' CH2' HG23 ' A' ' 174' ' ' VAL . 87.6 m95 -87.31 144.69 26.67 Favored 'General case' 0 N--CA 1.423 -1.815 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 176.18 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.2 m -92.94 7.59 43.33 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-O 121.879 0.847 . . . . 0.0 110.926 -178.176 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.468 ' HB3' ' CB ' ' A' ' 190' ' ' MET . 0.8 OUTLIER -139.39 153.28 47.61 Favored 'General case' 0 N--CA 1.417 -2.102 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 177.096 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . 0.485 ' H ' ' CD ' ' A' ' 201' ' ' GLU . 0.2 OUTLIER -105.28 171.93 7.06 Favored 'General case' 0 C--N 1.279 -2.461 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 178.9 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . 0.454 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 45.8 mtpt -63.38 117.61 35.74 Favored Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 114.154 1.168 . . . . 0.0 114.154 -174.865 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 5.4 Cg_exo -82.33 171.31 12.58 Favored 'Trans proline' 0 N--CA 1.445 -1.369 0 C-N-CA 122.793 2.329 . . . . 0.0 108.953 172.246 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . 0.463 ' O ' ' HA ' ' A' ' 184' ' ' ILE . 38.8 mtpt -122.38 174.55 6.95 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.966 -0.694 . . . . 0.0 109.432 179.681 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 57.3 m -115.39 107.56 15.37 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 173.19 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m . . . . . 0 C--N 1.281 -2.413 0 CA-C-N 114.371 -1.286 . . . . 0.0 109.736 -173.638 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo . . . . . 0 N--CA 1.477 0.548 0 CA-C-O 121.078 0.366 . . . . 0.0 112.766 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 65.1 m -73.32 -27.15 61.36 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.547 0.689 . . . . 0.0 110.677 178.027 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.19 13.12 40.19 Favored Glycine 0 C--N 1.3 -1.417 0 CA-C-N 115.206 -0.907 . . . . 0.0 114.832 172.724 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.7 t60 68.77 125.37 0.03 OUTLIER Pre-proline 0 N--CA 1.489 1.484 0 C-N-CA 123.841 0.856 . . . . 0.0 108.931 -179.234 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.519 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 92.7 Cg_endo -75.97 7.77 3.09 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 123.059 2.506 . . . . 0.0 114.862 -171.998 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 97.94 -166.0 22.25 Favored Glycine 0 C--N 1.277 -2.715 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -175.514 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -143.37 140.21 30.38 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 -179.036 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.3 t -102.64 129.53 25.73 Favored Pre-proline 0 C--N 1.299 -1.624 0 CA-C-O 121.234 0.54 . . . . 0.0 110.829 -178.366 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.25 -11.55 25.0 Favored 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 122.544 2.163 . . . . 0.0 111.474 177.599 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -87.25 -3.02 59.03 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.518 -178.285 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.402 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 167.69 -120.85 0.93 Allowed Glycine 0 N--CA 1.43 -1.717 0 C-N-CA 120.271 -0.966 . . . . 0.0 111.797 179.235 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.4 t -151.49 -172.86 4.33 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 123.71 0.3 . . . . 0.0 110.361 179.447 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.6 p90 -146.13 156.42 43.42 Favored 'General case' 0 N--CA 1.436 -1.168 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 176.65 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 5.5 m -121.92 166.52 14.29 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 178.041 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.451 HD11 ' CE1' ' A' ' 104' ' ' PHE . 14.8 mt -120.14 128.83 53.78 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.897 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.441 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 33.7 p -115.91 135.72 53.72 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 -178.262 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 114.53 -65.04 0.29 Allowed Glycine 0 N--CA 1.429 -1.781 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -179.243 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -119.69 -5.93 10.72 Favored Glycine 0 C--N 1.309 -0.938 0 C-N-CA 119.98 -1.105 . . . . 0.0 113.143 -178.991 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 59.79 19.62 8.44 Favored 'General case' 0 N--CA 1.495 1.809 0 C-N-CA 123.04 0.536 . . . . 0.0 112.373 -178.079 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.502 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.0 m -146.67 -171.12 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.203 -1.379 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -176.028 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.451 ' CE1' HD11 ' A' ' 98' ' ' LEU . 54.0 m-85 -106.42 39.41 1.83 Allowed 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 118.565 0.62 . . . . 0.0 110.635 -175.756 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.708 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.5 pt-20 -85.43 -176.61 6.18 Favored 'General case' 0 C--O 1.202 -1.443 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.52 179.165 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 -75.63 137.29 40.64 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.935 -0.478 . . . . 0.0 111.143 177.702 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.35 4.93 73.23 Favored Glycine 0 N--CA 1.433 -1.536 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.962 178.132 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.708 HG12 ' O ' ' A' ' 105' ' ' GLU . 13.9 p -95.02 146.22 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 C-N-CA 119.854 -0.738 . . . . 0.0 109.179 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.441 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 56.3 mtpt -110.17 123.75 50.32 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.591 179.198 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.524 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.3 93.63 9.13 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 176.469 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 76.7 t -86.03 109.62 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.772 0 C-N-CA 123.972 0.909 . . . . 0.0 109.208 -177.803 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -82.99 139.22 33.42 Favored 'General case' 0 C--N 1.286 -2.17 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.773 -179.566 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 11.1 t -136.83 127.78 27.57 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.738 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 82.3 m -81.31 160.18 24.25 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.822 -174.593 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.402 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 74.7 m-20 -72.46 177.21 4.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.9 175.926 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -56.57 -47.02 80.39 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -176.14 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -78.01 11.1 23.32 Favored Glycine 0 CA--C 1.522 0.495 0 CA-C-N 116.186 -0.461 . . . . 0.0 114.236 -178.876 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.612 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 82.5 m-85 -133.45 156.73 47.19 Favored 'General case' 0 C--N 1.311 -1.094 0 O-C-N 122.368 -0.489 . . . . 0.0 110.713 -179.195 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -143.44 147.97 35.4 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.006 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 7.2 tp -76.95 144.03 39.08 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-O 120.978 0.418 . . . . 0.0 110.834 -173.158 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.82 125.38 46.36 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -179.778 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 108.12 -176.28 20.34 Favored Glycine 0 C--N 1.291 -1.919 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -174.532 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -101.07 -24.95 14.21 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.363 0.602 . . . . 0.0 110.288 -179.726 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.2 mm -80.96 127.25 39.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -178.578 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -134.42 11.38 3.79 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 -178.561 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.524 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 32.8 p90 -149.01 167.71 25.08 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 -172.135 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.583 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 46.7 mtp180 -129.2 119.37 23.93 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 171.769 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -91.23 128.68 37.15 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.755 -0.778 . . . . 0.0 110.149 178.687 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 35.2 t -87.07 107.13 18.3 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.338 -0.945 . . . . 0.0 109.89 175.126 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.441 ' OD1' HG22 ' A' ' 131' ' ' THR . 7.2 t70 -100.61 -168.73 1.61 Allowed 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 176.342 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.441 HG22 ' OD1' ' A' ' 130' ' ' ASP . 11.1 t -69.84 -18.15 63.43 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 122.445 1.117 . . . . 0.0 109.176 178.279 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -80.67 -7.0 59.18 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 114.294 -1.321 . . . . 0.0 109.327 177.036 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 97.34 -158.57 21.08 Favored Glycine 0 N--CA 1.429 -1.77 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -176.316 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.405 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 90.0 m95 -65.32 108.48 1.94 Allowed 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 175.963 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 30.0 p -64.05 -55.2 23.93 Favored 'General case' 0 C--N 1.317 -0.84 0 C-N-CA 123.705 0.802 . . . . 0.0 111.581 -176.251 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . 0.583 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.3 m120 -78.64 167.22 21.56 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 114.857 -1.065 . . . . 0.0 109.04 -179.708 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -99.86 179.12 4.62 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 175.162 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.7 mt -65.63 118.98 56.45 Favored Pre-proline 0 C--N 1.325 -0.494 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 174.113 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.7 146.64 84.5 Favored 'Trans proline' 0 C--O 1.25 1.101 0 C-N-CA 122.322 2.015 . . . . 0.0 112.802 -176.292 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 66.0 mt -72.4 130.35 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.58 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.0 -179.783 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.612 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 45.3 t -121.48 142.42 50.07 Favored 'General case' 0 C--N 1.274 -2.678 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 176.354 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 6.1 tp10 -121.43 152.97 38.48 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -174.73 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.468 HG21 ' NE2' ' A' ' 169' ' ' HIS . 8.1 p -73.74 141.73 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.5 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.019 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 74.7 t -60.95 119.82 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.882 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 52.8 mtmt -125.42 138.43 54.02 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.477 -177.504 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 2.1 p -110.75 160.61 16.56 Favored 'General case' 0 C--N 1.287 -2.112 0 CA-C-N 115.298 -0.865 . . . . 0.0 112.18 -179.186 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . 0.483 HD12 ' HD2' ' A' ' 148' ' ' PRO . 0.3 OUTLIER -77.97 135.6 62.87 Favored Pre-proline 0 N--CA 1.426 -1.65 0 C-N-CA 124.573 1.149 . . . . 0.0 111.302 -173.533 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.483 ' HD2' HD12 ' A' ' 147' ' ' LEU . 12.1 Cg_endo -55.97 126.87 23.84 Favored 'Trans proline' 0 C--O 1.244 0.784 0 C-N-CA 123.812 3.008 . . . . 0.0 112.661 179.304 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 10.8 p -91.21 150.31 3.8 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.128 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 19.9 p -71.53 -88.34 0.02 OUTLIER 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 113.505 0.928 . . . . 0.0 113.505 -177.324 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 171.91 164.3 0.25 Allowed Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 179.738 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . 0.46 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 73.7 Cg_endo -78.45 166.02 24.61 Favored 'Trans proline' 0 N--CA 1.454 -0.849 0 C-N-CA 121.688 1.592 . . . . 0.0 110.419 171.624 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -64.94 -61.53 2.11 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -179.754 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -91.34 35.56 0.93 Allowed 'General case' 0 C--O 1.247 0.963 0 O-C-N 121.773 -0.579 . . . . 0.0 111.24 179.709 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -156.85 -161.78 11.02 Favored Glycine 0 N--CA 1.425 -2.053 0 C-N-CA 120.145 -1.026 . . . . 0.0 112.384 178.263 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 59.5 pttt -159.07 -178.48 7.26 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -178.394 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 58.2 mt -96.62 141.3 15.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 117.577 0.171 . . . . 0.0 111.159 -178.604 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.55 HG12 HG22 ' A' ' 177' ' ' VAL . 3.3 m -88.77 -31.98 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.931 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 176.317 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.8 m . . . . . 0 N--CA 1.442 -0.849 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.027 -176.07 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . 0.456 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 73.2 m-85 . . . . . 0 C--O 1.218 -0.593 0 N-CA-C 112.446 0.536 . . . . 0.0 112.446 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.468 ' NE2' HG21 ' A' ' 143' ' ' VAL . 54.9 t-80 -86.32 146.23 26.58 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.023 -0.99 . . . . 0.0 108.687 179.817 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 83.6 t80 -54.64 129.73 37.66 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.714 176.32 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 112.91 -22.17 16.85 Favored Glycine 0 N--CA 1.432 -1.602 0 C-N-CA 120.155 -1.021 . . . . 0.0 111.994 -178.006 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -70.35 150.88 45.85 Favored 'General case' 0 C--O 1.251 1.149 0 CA-C-O 120.87 0.367 . . . . 0.0 110.276 178.359 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -134.65 103.1 5.52 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.604 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 95.7 t -76.79 108.92 10.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.617 -178.025 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.465 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 29.5 ttp180 -101.49 142.2 33.22 Favored 'General case' 0 N--CA 1.407 -2.612 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.459 177.813 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . 0.46 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 62.8 m-85 -113.26 153.32 28.6 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.664 -174.809 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.55 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -121.29 152.54 24.75 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.275 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.996 179.296 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 67.9 m -99.51 138.87 35.99 Favored 'General case' 0 N--CA 1.403 -2.786 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 172.396 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -55.41 -52.41 63.67 Favored 'General case' 0 CA--C 1.486 -1.49 0 N-CA-C 114.192 1.182 . . . . 0.0 114.192 -175.131 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 58.9 m -150.33 -100.32 0.07 Allowed 'General case' 0 C--N 1.286 -2.153 0 C-N-CA 120.144 -0.622 . . . . 0.0 112.042 -177.005 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -87.5 44.68 3.29 Favored Glycine 0 CA--C 1.494 -1.254 0 CA-C-O 121.264 0.369 . . . . 0.0 112.343 -177.654 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -123.9 158.59 31.58 Favored 'General case' 0 N--CA 1.415 -2.2 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.531 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.446 ' O ' ' HD2' ' A' ' 183' ' ' LYS . 1.2 pptp? -132.01 143.13 49.85 Favored 'General case' 0 C--N 1.288 -2.066 0 O-C-N 123.878 0.736 . . . . 0.0 109.178 179.118 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.554 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.2 tt -71.57 142.47 15.4 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.26 0 CA-C-O 121.489 0.661 . . . . 0.0 111.626 -178.299 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -76.59 -57.08 4.06 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.735 -175.845 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -93.05 -126.42 4.16 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 120.277 -0.963 . . . . 0.0 111.954 -177.776 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -93.28 158.83 15.55 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 176.677 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.554 ' HA ' HD13 ' A' ' 184' ' ' ILE . 14.5 pt-20 -95.1 -7.81 38.33 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 118.915 -1.114 . . . . 0.0 110.976 -174.333 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -138.91 135.79 34.81 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.163 0.506 . . . . 0.0 112.339 -176.497 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.435 ' HB3' ' HB2' ' A' ' 200' ' ' LYS . 12.8 ptp -116.12 124.05 49.38 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.398 176.301 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 52.0 t-80 -97.95 135.99 38.87 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.702 -176.234 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 16.4 t -71.15 118.61 14.15 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.34 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.5 m -97.56 165.33 12.04 Favored 'General case' 0 N--CA 1.437 -1.112 0 O-C-N 123.606 0.567 . . . . 0.0 110.445 -175.756 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -65.51 -6.76 11.6 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 124.514 1.126 . . . . 0.0 112.316 -177.573 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -74.25 -22.2 59.43 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.565 175.532 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 92.44 14.51 55.53 Favored Glycine 0 N--CA 1.435 -1.418 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -174.521 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -136.6 176.81 8.37 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.587 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 88.1 m95 -84.78 152.28 23.78 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.92 -177.521 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 21.0 p -80.23 -14.58 58.31 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.508 179.835 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.435 ' HB2' ' HB3' ' A' ' 190' ' ' MET . 64.8 mmtt -124.36 165.98 16.75 Favored 'General case' 0 CA--C 1.477 -1.846 0 CA-C-O 122.141 0.972 . . . . 0.0 113.6 -173.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -91.47 166.44 12.86 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 113.053 -1.885 . . . . 0.0 109.337 176.322 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 6.1 mmmm -65.96 109.78 3.68 Favored Pre-proline 0 C--N 1.318 -0.787 0 O-C-N 124.053 0.846 . . . . 0.0 112.939 178.854 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -92.04 156.85 3.28 Favored 'Trans proline' 0 N--CA 1.424 -2.612 0 C-N-CA 122.42 2.08 . . . . 0.0 110.412 177.687 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . 0.443 ' HA ' ' HB3' ' A' ' 152' ' ' PRO . 19.1 ptpt -135.68 155.81 49.83 Favored 'General case' 0 C--N 1.287 -2.126 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.005 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 97.5 m -93.29 118.52 31.37 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 177.569 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.1 m . . . . . 0 C--N 1.291 -1.951 0 CA-C-N 114.007 -1.451 . . . . 0.0 107.326 -178.267 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.486 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 41.0 Cg_endo . . . . . 0 CA--C 1.534 0.505 0 CA-C-O 121.181 0.409 . . . . 0.0 111.642 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . 0.549 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 3.2 m -94.36 -17.9 22.11 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 122.1 0.952 . . . . 0.0 110.211 174.176 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.73 -87.72 0.54 Allowed Glycine 2 N--CA 1.391 -4.356 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 172.364 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.4 t-80 -171.85 138.24 1.02 Allowed Pre-proline 0 C--N 1.247 -3.854 0 N-CA-C 105.735 -1.95 . . . . 0.0 105.735 -172.739 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.517 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 91.9 Cg_endo -87.45 2.06 6.87 Favored 'Trans proline' 0 C--N 1.322 -0.837 0 C-N-CA 121.946 1.764 . . . . 0.0 112.764 -177.76 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.07 -166.37 13.1 Favored Glycine 0 N--CA 1.428 -1.875 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 -179.708 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -159.27 124.12 4.08 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 177.659 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.8 t -110.56 137.32 20.69 Favored Pre-proline 0 C--N 1.296 -1.735 0 CA-C-O 120.895 0.379 . . . . 0.0 111.749 -178.585 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -83.07 -10.11 10.39 Favored 'Trans proline' 0 CA--C 1.544 1.0 0 C-N-CA 122.742 2.295 . . . . 0.0 112.062 174.063 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -88.81 6.76 37.42 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.414 0.626 . . . . 0.0 111.143 -178.624 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.419 ' HA2' ' ND2' ' A' ' 115' ' ' ASN . . . 161.95 -123.86 1.24 Allowed Glycine 0 N--CA 1.415 -2.751 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.607 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.6 t -164.29 -159.72 0.5 Allowed 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 -178.592 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.6 p90 -152.88 165.53 35.17 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 176.987 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -127.83 159.52 34.61 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 177.906 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.1 mt -117.18 132.18 56.7 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -178.54 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 16.5 p -125.53 129.77 50.39 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -176.388 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.57 27.74 34.68 Favored Glycine 0 C--N 1.313 -0.703 0 C-N-CA 120.353 -0.927 . . . . 0.0 111.653 -179.447 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 178.37 -45.81 0.09 OUTLIER Glycine 0 N--CA 1.433 -1.542 0 C-N-CA 119.69 -1.243 . . . . 0.0 112.8 -179.158 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 70.44 8.42 6.6 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 124.195 0.998 . . . . 0.0 109.965 -178.304 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.553 ' O ' HG11 ' A' ' 108' ' ' VAL . 25.2 m -148.82 -175.74 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.125 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 -177.864 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.517 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 23.5 m-85 -98.9 38.08 1.43 Allowed 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 118.995 0.816 . . . . 0.0 110.782 -176.296 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.72 ' O ' HG12 ' A' ' 108' ' ' VAL . 15.2 pt-20 -79.86 175.54 10.54 Favored 'General case' 0 C--O 1.195 -1.765 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.815 -179.344 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . 0.534 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 43.0 m-85 -74.73 126.24 30.45 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 122.144 -0.347 . . . . 0.0 111.536 179.404 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 102.21 -1.22 50.66 Favored Glycine 0 N--CA 1.439 -1.16 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.618 179.713 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.72 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -92.45 147.55 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.053 0 C-N-CA 120.068 -0.653 . . . . 0.0 109.626 -179.447 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -114.19 123.51 49.75 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 177.8 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.474 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.81 94.85 9.88 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 177.86 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 76.8 t -84.16 108.36 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.921 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -179.439 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . 0.51 ' HE1' ' SG ' ' A' ' 114' ' ' CYS . 37.6 t80 -74.82 140.99 44.32 Favored 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 123.563 0.745 . . . . 0.0 109.37 -177.012 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 3.3 t -144.3 111.49 5.9 Favored 'General case' 0 N--CA 1.426 -1.632 0 CA-C-O 121.919 0.866 . . . . 0.0 110.492 -179.637 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.51 ' SG ' ' HE1' ' A' ' 112' ' ' TYR . 74.7 m -71.46 162.17 29.86 Favored 'General case' 0 C--O 1.255 1.365 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.803 178.501 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.419 ' ND2' ' HA2' ' A' ' 94' ' ' GLY . 37.6 m-20 -74.99 -177.37 3.31 Favored 'General case' 0 C--O 1.211 -0.942 0 CA-C-N 115.817 -0.628 . . . . 0.0 109.905 175.582 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -66.86 -35.05 79.14 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -174.947 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.426 ' HA2' ' CD2' ' A' ' 170' ' ' PHE . . . -73.98 -6.19 72.64 Favored Glycine 0 C--N 1.311 -0.829 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.741 178.948 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.61 ' HE1' HG22 ' A' ' 143' ' ' VAL . 87.8 m-85 -129.88 167.91 17.43 Favored 'General case' 0 N--CA 1.441 -0.903 0 O-C-N 122.427 -0.455 . . . . 0.0 110.189 -176.615 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.408 HE21 ' HB2' ' A' ' 119' ' ' GLN . 0.3 OUTLIER -146.27 157.55 43.81 Favored 'General case' 0 C--N 1.289 -2.033 0 CA-C-O 120.908 0.385 . . . . 0.0 110.682 -178.325 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -78.93 125.78 29.83 Favored 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 178.236 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.589 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -115.45 134.26 55.26 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 178.2 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.03 -178.07 20.6 Favored Glycine 0 C--N 1.289 -2.036 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -178.501 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -96.46 -40.53 9.03 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 -178.699 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.582 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 46.8 mm -77.26 124.06 34.99 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.696 -178.271 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -131.54 9.27 4.66 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 -176.615 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 18.5 p90 -143.88 166.99 23.38 Favored 'General case' 0 N--CA 1.425 -1.689 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -174.978 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.5 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 63.3 mtp180 -131.95 122.58 25.82 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 171.345 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -91.84 124.8 36.24 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 119.889 -0.724 . . . . 0.0 111.166 178.386 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . 0.534 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 36.0 t -80.0 105.03 10.98 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 175.2 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.437 ' OD2' HG22 ' A' ' 131' ' ' THR . 6.9 t70 -118.9 -169.92 1.82 Allowed 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -178.448 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.437 HG22 ' OD2' ' A' ' 130' ' ' ASP . 12.4 t -57.75 -26.01 61.25 Favored 'General case' 0 CA--C 1.563 1.45 0 C-N-CA 123.803 0.841 . . . . 0.0 112.266 -174.19 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -84.36 -24.86 29.53 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.882 0.848 . . . . 0.0 110.585 -179.731 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.549 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 125.52 -152.55 17.92 Favored Glycine 0 N--CA 1.419 -2.484 0 N-CA-C 106.811 -2.515 . . . . 0.0 106.811 -171.641 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -70.48 114.75 8.9 Favored 'General case' 0 N--CA 1.433 -1.321 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 175.281 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.3 p -64.94 -54.77 25.42 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.762 0.791 . . . . 0.0 111.456 -176.606 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . 0.5 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.8 m120 -78.96 167.77 20.65 Favored 'General case' 0 C--N 1.296 -1.758 0 CA-C-N 114.703 -1.135 . . . . 0.0 108.619 -178.716 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -98.96 -179.91 4.42 Favored 'General case' 0 C--N 1.29 -2.018 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 175.004 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.1 mt -65.17 121.17 72.9 Favored Pre-proline 0 C--N 1.309 -1.175 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 177.526 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.582 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 23.2 Cg_exo -57.67 167.29 4.09 Favored 'Trans proline' 0 C--O 1.245 0.853 0 C-N-CA 122.709 2.273 . . . . 0.0 112.179 177.909 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.589 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 3.6 mp -94.27 132.25 38.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 -171.019 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 8.5 t -112.62 119.39 37.97 Favored 'General case' 0 N--CA 1.423 -1.792 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 176.233 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -108.96 156.02 20.19 Favored 'General case' 0 C--N 1.274 -2.717 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 178.566 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.659 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 15.0 t -80.18 149.81 5.09 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.315 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 177.348 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 57.1 t -67.66 115.65 6.09 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.622 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.568 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.659 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 39.8 mtpt -123.23 157.67 32.58 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.799 -173.745 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 p -134.12 155.51 49.95 Favored 'General case' 0 C--N 1.286 -2.167 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.443 -179.228 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -55.69 147.09 42.77 Favored Pre-proline 0 N--CA 1.443 -0.807 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -177.086 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -71.77 129.9 16.16 Favored 'Trans proline' 0 N--CA 1.444 -1.43 0 C-N-CA 122.841 2.361 . . . . 0.0 111.914 -178.59 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 46.9 t -95.75 129.19 46.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.595 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.5 p -74.04 -73.93 0.21 Allowed 'General case' 0 N--CA 1.428 -1.551 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 178.215 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 175.82 156.68 0.39 Allowed Pre-proline 0 C--N 1.328 -0.347 0 C-N-CA 125.034 1.334 . . . . 0.0 107.526 178.613 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . 0.425 ' HG2' ' HA3' ' A' ' 155' ' ' GLY . 10.9 Cg_endo -66.76 167.04 20.37 Favored 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.532 1.488 . . . . 0.0 109.605 170.852 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . 0.568 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.0 OUTLIER -62.52 -45.16 94.26 Favored 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -175.181 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . 0.568 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 42.7 m-80 -116.51 26.92 9.54 Favored 'General case' 0 CA--C 1.504 -0.813 0 CA-C-O 121.552 0.692 . . . . 0.0 109.689 179.881 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . 0.425 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -142.09 -171.7 13.18 Favored Glycine 0 N--CA 1.423 -2.211 0 C-N-CA 120.233 -0.984 . . . . 0.0 111.814 179.834 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . 0.415 ' HG3' HG23 ' A' ' 177' ' ' VAL . 44.2 pttt -153.26 171.1 19.06 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -177.39 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 53.2 mt -96.02 139.34 19.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 120.606 0.241 . . . . 0.0 111.372 -176.151 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.543 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 5.0 m -99.03 -28.32 3.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 CA-C-O 121.269 0.556 . . . . 0.0 110.09 178.305 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . 0.556 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 46.3 m . . . . . 0 C--N 1.316 -0.866 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.374 -172.041 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 . . . . . 0 N--CA 1.437 -1.089 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -135.08 160.41 38.44 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -178.737 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . 0.426 ' CD2' ' HA2' ' A' ' 117' ' ' GLY . 0.9 OUTLIER -61.55 114.67 3.38 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 172.259 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 135.3 -21.16 3.68 Favored Glycine 0 N--CA 1.427 -1.919 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 -176.198 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 25.7 tp60 -76.81 124.04 27.11 Favored 'General case' 0 N--CA 1.401 -2.89 0 C-N-CA 122.883 0.473 . . . . 0.0 109.986 178.271 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -112.07 118.07 34.38 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 171.262 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.556 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 72.0 t -98.41 113.76 34.02 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -177.712 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.543 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 72.2 ttt180 -104.02 149.48 25.13 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 -179.678 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -122.45 162.74 21.12 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 121.579 0.704 . . . . 0.0 111.346 -174.455 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.415 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.0 OUTLIER -129.42 149.33 33.56 Favored 'Isoleucine or valine' 0 CA--C 1.475 -1.942 0 CA-C-N 113.998 -1.455 . . . . 0.0 109.644 174.097 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . 0.418 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 73.1 m -111.72 128.38 56.07 Favored 'General case' 0 N--CA 1.406 -2.674 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 176.062 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -50.45 159.74 0.47 Allowed 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 114.62 -1.173 . . . . 0.0 111.713 177.291 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 48.1 t -47.88 113.32 0.7 Allowed 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.42 -175.891 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.55 -17.3 30.95 Favored Glycine 0 N--CA 1.429 -1.796 0 C-N-CA 120.593 -0.813 . . . . 0.0 113.574 178.237 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . 0.418 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 95.7 m-85 -99.63 159.57 14.94 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 117.939 0.87 . . . . 0.0 110.965 -177.803 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 16.1 pttm -124.55 150.22 46.12 Favored 'General case' 0 N--CA 1.42 -1.958 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 175.615 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -74.93 133.58 31.21 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.468 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 174.807 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -77.47 -54.71 6.11 Favored 'General case' 0 C--N 1.282 -2.353 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -176.875 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -88.1 -134.65 4.7 Favored Glycine 0 C--N 1.301 -1.372 0 C-N-CA 120.958 -0.639 . . . . 0.0 111.836 177.558 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -87.36 158.7 18.97 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 178.83 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -96.37 6.17 49.34 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.067 -176.154 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -147.38 146.22 29.55 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 121.058 0.456 . . . . 0.0 111.981 -177.109 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.413 ' CE ' ' HA ' ' A' ' 202' ' ' LYS . 12.9 ptp -126.05 132.06 52.03 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.55 176.465 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 24.0 t-80 -105.84 136.09 46.11 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -177.876 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 8.6 t -74.22 124.55 26.6 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 177.338 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 27.1 t -97.18 171.55 8.38 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 122.91 0.484 . . . . 0.0 110.732 -176.361 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -68.14 -11.41 59.11 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 125.027 1.331 . . . . 0.0 114.439 -173.05 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . 0.514 ' HB3' ' CD1' ' A' ' 197' ' ' PHE . 29.3 t70 -94.23 -3.35 50.88 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 122.415 1.102 . . . . 0.0 109.959 177.68 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 82.81 49.81 4.93 Favored Glycine 0 N--CA 1.434 -1.497 0 C-N-CA 120.443 -0.884 . . . . 0.0 111.442 179.894 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . 0.514 ' CD1' ' HB3' ' A' ' 195' ' ' ASP . 3.1 p90 -151.77 158.97 44.05 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 178.322 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 87.4 m95 -76.38 135.22 39.49 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 176.551 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.9 p -61.1 -28.32 69.01 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.736 0.779 . . . . 0.0 111.291 -177.295 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 40.0 mmtt -113.71 162.83 15.79 Favored 'General case' 0 N--CA 1.418 -2.042 0 CA-C-N 114.729 -1.123 . . . . 0.0 111.062 -178.946 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -75.38 172.28 12.76 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 105.845 -1.909 . . . . 0.0 105.845 172.483 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . 0.413 ' HA ' ' CE ' ' A' ' 190' ' ' MET . 3.1 ttpm? -85.2 116.4 65.32 Favored Pre-proline 0 N--CA 1.421 -1.922 0 C-N-CA 117.321 -1.751 . . . . 0.0 107.773 179.18 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -67.08 166.42 23.1 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 122.774 2.316 . . . . 0.0 112.885 -174.733 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . 0.536 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 87.0 tttt -123.2 153.19 40.42 Favored 'General case' 0 C--N 1.286 -2.155 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.627 -173.627 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 99.9 m -109.82 112.85 25.14 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 177.009 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--N 1.304 -1.381 0 CA-C-N 115.173 -0.921 . . . . 0.0 108.871 -177.127 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo . . . . . 0 CA--C 1.536 0.611 0 CA-C-O 121.783 0.659 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.6 m -90.28 -32.89 16.34 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.001 178.86 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 109.68 -78.02 0.23 Allowed Glycine 0 CA--C 1.457 -3.538 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.333 168.833 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.0 t60 179.93 128.49 0.24 Allowed Pre-proline 0 C--N 1.274 -2.705 0 N-CA-C 105.08 -2.193 . . . . 0.0 105.08 -176.811 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.416 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 72.3 Cg_endo -75.98 -0.99 10.88 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 C-N-CA 123.647 2.898 . . . . 0.0 114.448 -172.236 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.66 179.64 16.93 Favored Glycine 0 N--CA 1.41 -3.093 0 N-CA-C 107.362 -2.295 . . . . 0.0 107.362 -173.495 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -150.16 160.26 43.8 Favored 'General case' 0 C--N 1.275 -2.641 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 -177.584 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.0 t -142.18 136.38 14.89 Favored Pre-proline 0 C--N 1.297 -1.676 0 C-N-CA 120.118 -0.633 . . . . 0.0 111.459 -176.778 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -79.67 -8.94 14.72 Favored 'Trans proline' 0 CA--C 1.533 0.432 0 C-N-CA 123.127 2.551 . . . . 0.0 112.022 176.631 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -93.23 4.28 54.26 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 121.315 0.579 . . . . 0.0 111.202 -176.858 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.627 ' HA2' ' OD1' ' A' ' 115' ' ' ASN . . . 170.19 -131.49 2.26 Favored Glycine 0 N--CA 1.401 -3.636 0 C-N-CA 120.278 -0.963 . . . . 0.0 110.921 -179.548 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.9 t -162.14 -166.64 1.45 Allowed 'General case' 0 C--N 1.277 -2.572 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -178.951 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.429 ' HA ' ' HA ' ' A' ' 112' ' ' TYR . 48.7 p90 -148.14 163.17 37.76 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 178.191 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -123.12 160.08 27.19 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 178.858 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -119.7 117.15 27.49 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.865 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.524 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 30.8 p -107.03 130.9 54.59 Favored 'General case' 0 C--N 1.279 -2.496 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.441 -174.04 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 112.86 -67.44 0.24 Allowed Glycine 0 N--CA 1.424 -2.123 0 N-CA-C 110.871 -0.891 . . . . 0.0 110.871 -178.689 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -114.58 -8.84 15.57 Favored Glycine 0 C--N 1.314 -0.66 0 C-N-CA 120.109 -1.043 . . . . 0.0 113.335 -176.097 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 47.9 m-80 61.1 18.63 9.2 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 123.253 0.621 . . . . 0.0 112.371 -178.334 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.498 ' O ' HG11 ' A' ' 108' ' ' VAL . 20.6 m -148.47 -176.73 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 -175.76 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -98.8 43.28 1.06 Allowed 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.13 0.491 . . . . 0.0 110.4 -177.237 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.653 ' O ' HG12 ' A' ' 108' ' ' VAL . 17.8 pt-20 -82.63 -175.95 6.02 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.772 -1.104 . . . . 0.0 111.549 177.394 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -80.71 140.26 35.68 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.393 175.285 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.12 -4.89 84.68 Favored Glycine 0 N--CA 1.443 -0.887 0 CA-C-N 115.77 -0.65 . . . . 0.0 113.298 177.691 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.653 HG12 ' O ' ' A' ' 105' ' ' GLU . 15.0 p -88.02 148.21 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -178.237 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.524 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 58.4 mtpt -109.87 128.93 55.65 Favored 'General case' 0 N--CA 1.414 -2.267 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 177.096 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -91.27 90.69 7.86 Favored 'General case' 0 C--N 1.281 -2.397 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 175.423 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.46 HG12 ' HB3' ' A' ' 126' ' ' TYR . 26.5 m -90.74 110.52 22.33 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-O 122.645 1.212 . . . . 0.0 109.461 -177.361 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . 0.429 ' HA ' ' HA ' ' A' ' 96' ' ' PHE . 27.5 m-85 -76.9 144.55 38.84 Favored 'General case' 0 C--N 1.272 -2.768 0 CA-C-N 115.074 -0.966 . . . . 0.0 112.324 -178.243 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.2 t -139.7 116.45 10.86 Favored 'General case' 0 N--CA 1.421 -1.912 0 CA-C-N 114.799 -1.091 . . . . 0.0 108.731 -179.28 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 91.4 m -70.82 161.28 31.23 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -179.307 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.627 ' OD1' ' HA2' ' A' ' 94' ' ' GLY . 4.9 m-20 -74.89 -176.73 3.01 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.003 -0.999 . . . . 0.0 110.955 177.552 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -56.03 -49.92 72.36 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 123.68 0.792 . . . . 0.0 112.746 -177.599 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -89.44 19.01 42.5 Favored Glycine 0 N--CA 1.438 -1.217 0 C-N-CA 120.804 -0.712 . . . . 0.0 113.539 -177.802 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.69 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 87.2 m-85 -137.5 159.21 42.59 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 117.287 0.544 . . . . 0.0 110.488 -179.982 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . 0.534 ' OE1' ' HB3' ' A' ' 142' ' ' GLU . 0.0 OUTLIER -145.35 159.17 43.45 Favored 'General case' 0 N--CA 1.425 -1.714 0 C-N-CA 121.087 -0.245 . . . . 0.0 110.348 179.129 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.92 122.71 27.58 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 -176.902 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -107.9 127.62 53.9 Favored 'General case' 0 N--CA 1.414 -2.233 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 179.853 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 113.48 179.41 19.24 Favored Glycine 0 C--N 1.291 -1.93 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -178.182 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -94.49 -30.19 14.55 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.852 0.834 . . . . 0.0 108.77 -177.793 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.2 mm -87.14 122.8 39.44 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.56 0 CA-C-N 114.922 -1.035 . . . . 0.0 109.101 -179.331 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -124.4 1.24 8.36 Favored 'General case' 0 C--O 1.203 -1.38 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 178.811 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.502 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 40.4 p90 -139.34 164.74 29.05 Favored 'General case' 0 C--N 1.288 -2.087 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -170.432 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . 0.416 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 43.1 mtp180 -127.87 133.63 49.35 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 171.706 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -103.98 128.14 51.53 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 -178.485 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 13.7 t -82.85 105.22 13.69 Favored 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 117.749 -1.58 . . . . 0.0 110.332 177.18 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.462 ' OD1' HG22 ' A' ' 131' ' ' THR . 9.1 t70 -97.84 -168.68 1.71 Allowed 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 177.483 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.462 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.3 t -66.83 -22.57 66.0 Favored 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 118.161 0.437 . . . . 0.0 111.468 -175.123 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -88.95 -9.29 52.03 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.681 0.753 . . . . 0.0 110.03 178.67 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 114.72 -160.8 13.0 Favored Glycine 0 N--CA 1.428 -1.838 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -176.808 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . 0.416 ' CH2' HG13 ' A' ' 108' ' ' VAL . 96.9 m95 -64.22 113.57 3.66 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 122.543 0.337 . . . . 0.0 111.819 -179.044 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 66.3 p -73.61 176.03 6.56 Favored 'General case' 0 C--O 1.269 2.124 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.408 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 35.1 m-20 60.68 -149.08 0.43 Allowed 'General case' 0 C--O 1.244 0.787 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 179.281 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -144.2 -173.11 3.92 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 171.343 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 73.5 mt -66.01 119.29 60.18 Favored Pre-proline 0 C--N 1.272 -2.798 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 174.877 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -62.15 163.19 20.61 Favored 'Trans proline' 0 C--O 1.253 1.266 0 C-N-CA 122.686 2.257 . . . . 0.0 112.011 -178.918 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.7 mm -93.83 123.72 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 CA-C-O 121.505 0.669 . . . . 0.0 109.939 -173.976 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.631 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 22.0 t -107.51 110.1 21.94 Favored 'General case' 0 C--N 1.263 -3.187 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 176.607 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.534 ' HB3' ' OE1' ' A' ' 119' ' ' GLN . 10.5 tp10 -101.2 150.77 22.62 Favored 'General case' 0 N--CA 1.409 -2.478 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -175.898 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.69 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 8.6 t -75.63 137.01 23.69 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.385 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.129 -177.696 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 42.9 t -67.96 112.15 2.88 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.933 0 N-CA-C 106.538 -1.652 . . . . 0.0 106.538 174.888 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . 0.432 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 35.3 mtmm -129.86 161.57 30.51 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-N 115.5 -0.773 . . . . 0.0 108.951 -175.609 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -129.62 164.5 23.75 Favored 'General case' 0 C--N 1.271 -2.831 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.896 -178.138 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 85.4 mt -70.63 142.38 88.67 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 113.931 1.085 . . . . 0.0 113.931 -175.67 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_endo -63.39 119.66 6.8 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 123.05 2.5 . . . . 0.0 110.178 175.811 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.7 t -80.29 151.84 4.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.249 -174.398 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . 0.425 ' O ' HD11 ' A' ' 157' ' ' ILE . 27.9 p -87.93 -159.08 0.5 Allowed 'General case' 0 N--CA 1.414 -2.24 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 170.971 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -128.9 151.59 77.69 Favored Pre-proline 0 C--N 1.283 -2.306 0 O-C-N 121.142 -0.973 . . . . 0.0 109.53 -172.277 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . 0.453 ' HG2' ' HA3' ' A' ' 155' ' ' GLY . 24.0 Cg_endo -66.86 160.7 45.56 Favored 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.055 1.836 . . . . 0.0 112.419 178.072 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -48.88 -45.79 41.64 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 126.0 1.72 . . . . 0.0 114.389 -175.516 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.5 m-80 -126.84 27.15 6.06 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-O 122.077 0.941 . . . . 0.0 109.49 -178.477 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . 0.453 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -132.15 -169.41 12.3 Favored Glycine 0 N--CA 1.42 -2.382 0 CA-C-N 114.714 -1.13 . . . . 0.0 111.066 179.572 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . 0.481 ' HG3' HG23 ' A' ' 177' ' ' VAL . 45.3 pttt -157.94 171.78 19.65 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -177.746 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.425 HD11 ' O ' ' A' ' 150' ' ' THR . 58.6 mt -97.2 131.84 43.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 C-N-CA 122.022 0.129 . . . . 0.0 110.743 -177.613 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.581 HG12 HG22 ' A' ' 177' ' ' VAL . 3.5 m -75.19 -38.33 41.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.321 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 CA--C 1.537 0.468 0 C-N-CA 124.87 1.268 . . . . 0.0 109.134 -176.501 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 62.0 m-85 . . . . . 0 N--CA 1.448 -0.553 0 CA-C-O 121.668 0.747 . . . . 0.0 111.557 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -105.86 164.24 12.1 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 179.023 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 90.7 t80 -52.14 128.16 23.92 Favored 'General case' 0 C--N 1.317 -0.807 0 C-N-CA 123.123 0.569 . . . . 0.0 109.827 174.516 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.46 -33.95 5.15 Favored Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.382 -179.129 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -70.12 151.62 45.25 Favored 'General case' 0 C--O 1.259 1.557 0 CA-C-O 121.244 0.545 . . . . 0.0 109.825 179.863 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -135.09 131.16 36.59 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-N 115.344 -0.843 . . . . 0.0 109.467 179.339 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 95.3 t -100.12 114.68 39.4 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -178.594 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.575 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 43.2 ttm180 -101.49 142.99 32.05 Favored 'General case' 0 N--CA 1.419 -1.981 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 177.366 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -111.99 160.52 17.38 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 123.138 0.575 . . . . 0.0 110.876 -176.613 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.581 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -131.52 143.29 40.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.933 178.962 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 93.4 m -102.17 132.1 48.28 Favored 'General case' 0 C--N 1.276 -2.603 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 174.168 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 59.0 m-80 -61.09 163.12 6.38 Favored 'General case' 0 CA--C 1.491 -1.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.569 -178.715 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 10.9 m -46.89 106.67 0.09 Allowed 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 125.51 1.524 . . . . 0.0 112.569 -175.723 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 115.79 -16.52 16.16 Favored Glycine 0 N--CA 1.435 -1.396 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.323 178.99 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . 0.431 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 90.1 m-85 -103.8 155.07 18.89 Favored 'General case' 0 CA--C 1.495 -1.138 0 CA-C-N 117.269 0.535 . . . . 0.0 111.609 -177.664 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -125.16 147.34 49.08 Favored 'General case' 0 N--CA 1.423 -1.785 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 177.981 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 9.1 tt -79.96 136.64 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.934 0 CA-C-O 121.802 0.811 . . . . 0.0 111.287 -177.296 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -81.87 -52.14 7.39 Favored 'General case' 0 C--N 1.292 -1.916 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.736 -177.707 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -86.4 -152.75 21.54 Favored Glycine 0 N--CA 1.433 -1.553 0 CA-C-N 114.97 -1.014 . . . . 0.0 111.042 178.487 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . 0.421 ' OD1' ' HD2' ' A' ' 200' ' ' LYS . 1.6 p-10 -92.7 163.11 13.88 Favored 'General case' 0 C--N 1.289 -2.024 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 177.955 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.575 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 0.8 OUTLIER -99.87 3.74 44.75 Favored 'General case' 0 C--N 1.286 -2.181 0 C-N-CA 118.509 -1.277 . . . . 0.0 113.165 -171.683 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -144.39 121.81 11.67 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -173.986 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . 0.434 ' HB3' ' HB2' ' A' ' 200' ' ' LYS . 15.0 ptp -105.46 131.19 53.19 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.403 177.955 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 25.1 t-80 -106.16 135.42 47.65 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.446 -176.952 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 7.3 t -72.74 112.48 8.83 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.043 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . 0.424 ' OG ' ' HB3' ' A' ' 199' ' ' SER . 17.5 m -94.56 172.2 8.33 Favored 'General case' 0 N--CA 1.442 -0.856 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.289 -173.467 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -43.02 -43.1 4.11 Favored 'General case' 0 N--CA 1.495 1.775 0 C-N-CA 127.02 2.128 . . . . 0.0 114.538 -171.713 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -92.26 12.73 21.43 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 113.675 0.991 . . . . 0.0 113.675 -174.798 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 78.97 46.95 7.98 Favored Glycine 0 CA--C 1.496 -1.128 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.8 176.052 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -145.0 160.29 41.6 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.633 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -82.23 132.03 35.23 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 177.389 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . 0.424 ' HB3' ' OG ' ' A' ' 193' ' ' SER . 23.8 p -66.06 -22.49 66.43 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.551 0.691 . . . . 0.0 111.11 -178.945 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.434 ' HB2' ' HB3' ' A' ' 190' ' ' MET . 26.5 mmtp -120.75 151.0 40.11 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.534 -177.829 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 73.0 mm-40 -89.42 166.53 13.66 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.211 176.928 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . 0.449 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 39.6 mtpt -63.95 119.04 51.63 Favored Pre-proline 0 C--N 1.319 -0.73 0 O-C-N 123.464 0.477 . . . . 0.0 111.057 179.513 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . 0.441 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 95.4 Cg_endo -77.39 168.1 23.43 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 122.642 2.228 . . . . 0.0 112.056 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 37.1 ttpt -119.9 150.86 39.79 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.86 -176.653 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.431 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 83.8 m -110.93 118.72 36.87 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 177.388 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 30.4 m . . . . . 0 C--N 1.3 -1.555 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.574 -175.325 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo . . . . . 0 CA--C 1.537 0.666 0 CA-C-O 121.603 0.585 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.7 m -82.83 -32.89 27.33 Favored 'General case' 0 CA--C 1.504 -0.814 0 CA-C-O 122.005 0.907 . . . . 0.0 108.612 179.024 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.75 -87.85 0.43 Allowed Glycine 0 N--CA 1.396 -3.967 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.366 174.415 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.0 t-80 -175.02 135.39 0.52 Allowed Pre-proline 0 C--N 1.264 -3.135 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 -173.711 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.545 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 66.9 Cg_endo -93.69 -5.18 2.76 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.497 2.131 . . . . 0.0 113.031 -178.139 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 106.73 175.93 23.08 Favored Glycine 0 CA--C 1.485 -1.826 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 178.787 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -151.43 152.88 33.66 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 177.319 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.423 HG21 ' CZ ' ' A' ' 112' ' ' TYR . 9.6 t -125.18 141.12 37.72 Favored Pre-proline 0 C--N 1.29 -1.994 0 O-C-N 123.385 0.428 . . . . 0.0 112.043 -175.218 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -79.84 -12.69 13.36 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 122.913 2.409 . . . . 0.0 111.405 173.511 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -85.98 2.26 46.93 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 121.744 0.783 . . . . 0.0 110.861 -178.7 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.609 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.48 -126.56 1.21 Allowed Glycine 0 N--CA 1.402 -3.571 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 -178.737 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.8 t -164.5 -166.23 1.06 Allowed 'General case' 0 C--N 1.27 -2.878 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.847 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -153.01 158.05 41.44 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 177.691 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.8 m -127.17 158.98 35.65 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 179.991 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.412 ' HB2' ' HA ' ' A' ' 102' ' ' ASN . 22.0 mt -116.55 127.49 54.56 Favored 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 -179.736 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.509 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 21.2 p -117.61 125.82 51.45 Favored 'General case' 0 C--N 1.29 -1.991 0 CA-C-O 121.311 0.577 . . . . 0.0 111.063 -175.728 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 121.55 -58.18 0.59 Allowed Glycine 0 N--CA 1.432 -1.602 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.306 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -130.82 -3.02 4.64 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.632 -0.794 . . . . 0.0 113.678 -177.868 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 102' ' ' ASN . . . . . 0.412 ' HA ' ' HB2' ' A' ' 98' ' ' LEU . 2.3 t30 54.13 29.29 10.15 Favored 'General case' 0 CA--C 1.559 1.315 0 C-N-CA 125.776 1.631 . . . . 0.0 112.016 -178.922 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.532 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.7 m -149.74 -174.77 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.209 -1.043 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 179.699 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.545 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 20.6 m-85 -100.8 44.48 1.01 Allowed 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 118.767 0.712 . . . . 0.0 110.359 -178.174 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 105' ' ' GLU . . . . . 0.684 ' O ' HG12 ' A' ' 108' ' ' VAL . 9.7 pt-20 -85.06 177.59 7.86 Favored 'General case' 0 C--O 1.211 -0.967 0 CA-C-N 114.639 -1.164 . . . . 0.0 111.89 178.413 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -76.58 133.13 39.76 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.219 177.372 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.02 5.06 64.4 Favored Glycine 0 N--CA 1.438 -1.232 0 CA-C-N 115.791 -0.64 . . . . 0.0 112.679 179.85 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.684 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.0 p -97.44 147.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 -179.92 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 109' ' ' LYS . . . . . 0.509 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -109.64 130.64 55.5 Favored 'General case' 0 N--CA 1.42 -1.938 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 177.249 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . 0.527 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -94.49 95.71 9.0 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 175.034 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 78.7 t -89.3 112.9 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.859 0 C-N-CA 123.768 0.827 . . . . 0.0 108.8 -178.327 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 112' ' ' TYR . . . . . 0.489 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 9.6 t80 -81.9 138.39 35.03 Favored 'General case' 0 C--N 1.276 -2.597 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -177.785 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -138.55 120.56 15.56 Favored 'General case' 0 N--CA 1.424 -1.739 0 CA-C-O 121.785 0.802 . . . . 0.0 109.309 177.64 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 114' ' ' CYS . . . . . 0.447 ' SG ' ' HE1' ' A' ' 112' ' ' TYR . 75.8 m -73.94 160.28 31.58 Favored 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.597 -179.244 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.609 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 82.2 m-20 -78.32 177.12 8.69 Favored 'General case' 0 C--O 1.212 -0.884 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.111 176.706 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . 0.476 ' HG3' ' OD2' ' A' ' 194' ' ' ASP . 39.9 tt0 -44.81 -46.62 10.73 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 124.956 1.303 . . . . 0.0 114.308 -177.305 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.91 5.33 82.96 Favored Glycine 0 C--N 1.311 -0.858 0 C-N-CA 120.309 -0.948 . . . . 0.0 114.048 -176.663 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 118' ' ' TYR . . . . . 0.499 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.3 m-85 -130.61 164.28 25.29 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 -176.506 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -148.1 155.77 41.84 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-O 120.988 0.423 . . . . 0.0 110.242 179.495 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -77.38 130.91 37.72 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 179.351 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 121' ' ' LEU . . . . . 0.588 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -119.45 130.41 55.24 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.83 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.17 -175.07 21.82 Favored Glycine 0 C--N 1.295 -1.717 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.521 -179.597 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -91.8 -29.04 16.98 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 121.53 0.681 . . . . 0.0 109.646 -178.331 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 124' ' ' ILE . . . . . 0.569 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 46.9 mm -82.95 114.51 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.553 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.869 -177.778 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 -130.42 7.67 4.95 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.896 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 126' ' ' TYR . . . . . 0.527 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 17.8 p90 -151.57 156.43 40.46 Favored 'General case' 0 N--CA 1.425 -1.689 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.415 -173.446 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 52.1 mtp180 -121.34 125.29 46.65 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 105.14 -2.17 . . . . 0.0 105.14 171.538 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -101.73 126.88 48.67 Favored 'General case' 0 C--N 1.275 -2.65 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.074 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . 0.459 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 25.5 t -86.03 100.81 12.41 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 118.498 -1.281 . . . . 0.0 110.075 176.166 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.424 ' OD1' HG22 ' A' ' 131' ' ' THR . 9.2 t70 -98.71 -165.28 1.22 Allowed 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 105.456 -2.053 . . . . 0.0 105.456 175.602 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.424 HG22 ' OD1' ' A' ' 130' ' ' ASP . 10.2 t -63.5 -22.95 67.18 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 119.131 0.878 . . . . 0.0 112.143 -177.02 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -80.23 -13.57 59.11 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.652 0.739 . . . . 0.0 110.692 176.357 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.459 ' HA2' ' SG ' ' A' ' 129' ' ' CYS . . . 105.49 -148.51 16.52 Favored Glycine 0 N--CA 1.421 -2.339 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -175.375 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 85.0 m95 -69.13 109.55 4.09 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 176.908 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 28.9 p -61.14 -68.8 0.28 Allowed 'General case' 0 N--CA 1.438 -1.039 0 O-C-N 123.792 0.682 . . . . 0.0 111.48 -178.126 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 74.4 m-20 -75.62 177.13 7.02 Favored 'General case' 0 CA--C 1.489 -1.368 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.513 178.035 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -108.13 -168.91 1.43 Allowed 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 178.511 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.2 mt -60.87 117.98 30.76 Favored Pre-proline 0 C--N 1.295 -1.775 0 O-C-N 123.986 0.804 . . . . 0.0 109.33 177.272 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 139' ' ' PRO . . . . . 0.569 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 53.3 Cg_exo -52.77 165.99 0.99 Allowed 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.867 3.045 . . . . 0.0 113.916 178.644 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 140' ' ' ILE . . . . . 0.588 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 3.6 mp -90.73 130.7 39.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.172 -174.801 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 141' ' ' CYS . . . . . 0.499 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 25.4 t -123.6 114.93 20.68 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.318 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -110.41 149.79 29.76 Favored 'General case' 0 N--CA 1.405 -2.711 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 -177.961 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 9.6 p -73.69 143.53 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.898 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.572 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 89.3 t -68.69 123.05 21.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 177.155 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -109.3 140.14 43.36 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.149 -176.421 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 57.5 m -102.13 144.66 30.41 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.9 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 147' ' ' LEU . . . . . 0.4 HD23 ' HD2' ' A' ' 148' ' ' PRO . 1.4 tt -49.59 130.03 19.4 Favored Pre-proline 0 N--CA 1.432 -1.36 0 C-N-CA 125.275 1.43 . . . . 0.0 110.748 179.491 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.563 ' HA ' ' CD2' ' A' ' 168' ' ' TYR . 12.4 Cg_endo -57.74 110.59 0.65 Allowed 'Trans proline' 0 N--CA 1.454 -0.813 0 C-N-CA 123.557 2.838 . . . . 0.0 113.35 -178.522 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 13.6 p -83.81 142.72 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 CA-C-N 115.176 -0.92 . . . . 0.0 108.865 177.397 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 10.2 p -105.22 -156.4 0.57 Allowed 'General case' 0 C--N 1.288 -2.069 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.37 176.172 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 151' ' ' ALA . . . . . 0.457 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . -100.85 151.25 37.56 Favored Pre-proline 0 C--N 1.298 -1.649 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -170.636 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -75.62 170.24 20.64 Favored 'Trans proline' 0 N--CA 1.436 -1.906 0 C-N-CA 121.442 1.428 . . . . 0.0 110.914 175.25 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -50.41 -55.24 16.62 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 114.306 1.224 . . . . 0.0 114.306 -175.992 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 154' ' ' ASN . . . . . 0.436 ' HB2' ' O ' ' A' ' 205' ' ' CYS . 57.4 m-80 -113.95 27.04 9.82 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.19 0.519 . . . . 0.0 110.725 -177.544 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.7 -173.1 15.71 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 120.081 -1.057 . . . . 0.0 111.726 179.768 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 156' ' ' LYS . . . . . 0.457 ' HA ' ' HB1' ' A' ' 151' ' ' ALA . 50.3 pttt -153.33 172.67 16.68 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -178.14 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 62.5 mt -86.04 132.1 32.91 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 CA-C-O 121.169 0.509 . . . . 0.0 111.058 -176.46 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.447 ' CG2' ' HB ' ' A' ' 177' ' ' VAL . 47.9 t -76.52 -40.31 33.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 C-N-CA 123.974 0.91 . . . . 0.0 108.907 177.172 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 C--N 1.301 -1.519 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.446 179.933 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 168' ' ' TYR . . . . . 0.563 ' CD2' ' HA ' ' A' ' 148' ' ' PRO . 98.0 m-85 . . . . . 0 CA--C 1.508 -0.658 0 CA-C-O 121.661 0.743 . . . . 0.0 112.087 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 27.7 m80 -98.38 155.47 17.21 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 114.506 -1.224 . . . . 0.0 107.966 -179.463 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -56.77 131.5 49.45 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 172.012 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . 0.438 ' H ' ' HB2' ' A' ' 192' ' ' CYS . . . 113.43 -15.03 22.64 Favored Glycine 0 N--CA 1.414 -2.768 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.234 -177.682 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 172' ' ' GLN . . . . . 0.426 ' O ' ' HA ' ' A' ' 191' ' ' HIS . 15.5 mm100 -74.58 134.38 42.13 Favored 'General case' 0 N--CA 1.423 -1.788 0 C-N-CA 120.223 -0.591 . . . . 0.0 111.976 179.55 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -115.15 94.34 4.69 Favored 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 173.562 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 66.2 t -81.61 109.02 15.36 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 CA-C-N 115.243 -0.889 . . . . 0.0 108.963 -176.121 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 175' ' ' ARG . . . . . 0.45 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 14.5 ttp180 -97.1 156.27 16.45 Favored 'General case' 0 N--CA 1.411 -2.387 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 179.055 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -127.09 156.35 41.85 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 124.038 0.935 . . . . 0.0 109.399 -175.006 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.447 ' HB ' ' CG2' ' A' ' 158' ' ' VAL . 12.2 p -133.56 141.07 45.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.461 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 80.5 m -102.54 153.63 19.89 Favored 'General case' 0 C--N 1.265 -3.105 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.961 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -64.62 163.46 13.68 Favored 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 119.972 -0.691 . . . . 0.0 110.153 176.73 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 15.8 m -43.54 -32.74 0.98 Allowed 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 116.37 1.989 . . . . 0.0 116.37 -170.724 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -113.36 21.09 17.87 Favored Glycine 0 C--N 1.293 -1.847 0 C-N-CA 120.1 -1.047 . . . . 0.0 113.375 -179.048 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -122.32 151.06 41.53 Favored 'General case' 0 N--CA 1.432 -1.335 0 O-C-N 122.129 -0.63 . . . . 0.0 111.356 179.28 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -124.15 143.59 50.4 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.158 -178.93 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 184' ' ' ILE . . . . . 0.527 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.4 tt -74.87 140.55 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.928 0 CA-C-O 121.476 0.655 . . . . 0.0 111.288 -176.695 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -67.01 -64.57 0.83 Allowed 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.318 -177.261 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -103.41 -123.59 5.3 Favored Glycine 0 N--CA 1.436 -1.32 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.283 -179.558 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 187' ' ' ASP . . . . . 0.583 ' HB2' ' HG3' ' A' ' 200' ' ' LYS . 5.5 m-20 -91.63 153.4 19.73 Favored 'General case' 0 CA--C 1.491 -1.291 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -177.495 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 188' ' ' GLU . . . . . 0.527 ' HA ' HD13 ' A' ' 184' ' ' ILE . 14.2 pt-20 -91.65 -4.04 55.67 Favored 'General case' 0 C--O 1.205 -1.286 0 C-N-CA 119.944 -0.702 . . . . 0.0 111.174 -172.027 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -134.34 132.31 39.35 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 -177.72 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 14.4 ptp -112.68 123.54 50.53 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.271 174.881 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 191' ' ' HIS . . . . . 0.426 ' HA ' ' O ' ' A' ' 172' ' ' GLN . 16.4 t-80 -110.36 139.01 45.99 Favored 'General case' 0 C--N 1.279 -2.498 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.954 -177.317 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 192' ' ' CYS . . . . . 0.438 ' HB2' ' H ' ' A' ' 171' ' ' GLY . 22.0 m -62.64 130.14 43.69 Favored 'General case' 0 C--N 1.32 -0.705 0 O-C-N 123.657 0.598 . . . . 0.0 111.668 175.207 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 37.5 t -101.78 166.92 10.41 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.137 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 194' ' ' ASP . . . . . 0.476 ' OD2' ' HG3' ' A' ' 116' ' ' GLU . 6.3 t70 -52.41 -33.22 42.82 Favored 'General case' 0 N--CA 1.511 2.613 0 C-N-CA 124.236 1.014 . . . . 0.0 110.332 178.925 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -56.94 -26.21 59.14 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 113.75 -1.568 . . . . 0.0 111.742 179.807 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 89.59 15.53 58.2 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -174.97 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -125.27 170.54 11.19 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.064 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -85.39 142.49 29.24 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 123.678 0.611 . . . . 0.0 110.944 -177.699 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 30.7 t -60.64 -50.29 74.11 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.725 176.593 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 200' ' ' LYS . . . . . 0.583 ' HG3' ' HB2' ' A' ' 187' ' ' ASP . 12.9 mmmm -104.61 156.14 18.23 Favored 'General case' 0 CA--C 1.485 -1.548 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 174.227 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -89.06 171.73 9.63 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 170.546 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 34.9 ttmt -61.9 122.25 70.67 Favored Pre-proline 0 C--O 1.243 0.724 0 CA-C-N 118.985 0.811 . . . . 0.0 110.492 -176.246 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.04 -173.49 1.9 Allowed 'Trans proline' 0 N--CA 1.437 -1.833 0 C-N-CA 122.039 1.826 . . . . 0.0 111.067 179.122 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 66.0 mttm -126.58 160.88 29.39 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.118 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 205' ' ' CYS . . . . . 0.436 ' O ' ' HB2' ' A' ' 154' ' ' ASN . 97.4 m -116.62 105.19 12.17 Favored 'General case' 0 C--N 1.27 -2.887 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 170.852 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 23.7 m . . . . . 0 C--N 1.286 -2.176 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.033 -173.547 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.428 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 30.6 Cg_endo . . . . . 0 CA--C 1.542 0.907 0 CA-C-O 121.436 0.515 . . . . 0.0 111.761 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.1 m -85.03 -37.68 20.09 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 177.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.08 -92.41 0.48 Allowed Glycine 0 N--CA 1.41 -3.095 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 173.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.9 t60 -177.24 123.73 0.28 Allowed Pre-proline 0 C--N 1.26 -3.314 0 N-CA-C 104.582 -2.377 . . . . 0.0 104.582 -177.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.427 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 34.8 Cg_endo -66.72 -49.91 1.42 Allowed 'Trans proline' 0 C--O 1.209 -0.933 0 C-N-CA 121.33 1.353 . . . . 0.0 110.722 -177.179 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 150.32 169.18 16.08 Favored Glycine 0 N--CA 1.401 -3.642 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 -177.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -136.03 139.93 43.46 Favored 'General case' 0 C--N 1.264 -3.113 0 CA-C-N 117.31 0.555 . . . . 0.0 109.688 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.5 t -99.9 128.97 29.58 Favored Pre-proline 0 N--CA 1.409 -2.525 0 CA-C-N 115.111 -0.949 . . . . 0.0 111.304 -172.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -69.04 -24.01 33.44 Favored 'Trans proline' 0 C--O 1.24 0.591 0 C-N-CA 122.884 2.389 . . . . 0.0 110.214 175.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 57.1 m-85 -75.06 -28.28 60.31 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 114.014 -1.448 . . . . 0.0 110.763 -176.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.437 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -151.0 -133.21 2.03 Favored Glycine 0 N--CA 1.409 -3.159 0 C-N-CA 119.071 -1.538 . . . . 0.0 112.783 -177.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.0 p -144.1 170.67 15.51 Favored 'General case' 0 C--N 1.275 -2.64 0 CA-C-N 113.885 -1.157 . . . . 0.0 108.896 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.458 ' HA ' ' HA ' ' A' ' 112' ' ' TYR . 17.8 p90 -140.69 153.55 46.0 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 172.302 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -127.26 160.12 32.27 Favored 'General case' 0 C--N 1.274 -2.705 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -116.72 118.63 33.07 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 121.293 0.568 . . . . 0.0 109.874 -178.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 26.2 p -111.88 133.64 53.95 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.755 -174.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 111.98 -53.13 0.6 Allowed Glycine 0 N--CA 1.434 -1.478 0 C-N-CA 120.865 -0.683 . . . . 0.0 111.557 179.273 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -131.31 -7.21 3.23 Favored Glycine 0 N--CA 1.441 -0.999 0 C-N-CA 120.196 -1.002 . . . . 0.0 113.109 -179.008 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 48.4 m-80 61.17 17.4 8.08 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 113.393 0.886 . . . . 0.0 113.393 179.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.523 ' O ' HG11 ' A' ' 108' ' ' VAL . 19.7 m -149.01 -170.07 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.205 -1.286 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -177.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -103.47 45.57 0.95 Allowed 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 118.422 0.556 . . . . 0.0 110.083 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.71 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.9 pt-20 -86.08 176.28 8.09 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 114.957 -1.019 . . . . 0.0 111.58 177.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . 0.44 ' CE1' ' HA ' ' A' ' 131' ' ' THR . 46.0 m-85 -72.91 133.23 44.29 Favored 'General case' 0 C--N 1.293 -1.859 0 O-C-N 121.976 -0.453 . . . . 0.0 111.273 178.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.36 -8.7 69.42 Favored Glycine 0 N--CA 1.434 -1.453 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.232 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.71 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.2 p -80.67 147.69 6.19 Favored 'Isoleucine or valine' 0 C--O 1.238 0.481 0 CA-C-N 117.553 0.676 . . . . 0.0 109.946 -176.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 16.8 mtpp -112.38 119.08 37.03 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -87.91 96.49 10.5 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.509 HG12 ' HB3' ' A' ' 126' ' ' TYR . 18.8 m -94.81 115.82 34.59 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.327 0 CA-C-O 122.036 0.922 . . . . 0.0 109.979 -177.02 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . 0.458 ' HA ' ' HA ' ' A' ' 96' ' ' PHE . 33.3 m-85 -83.07 144.43 29.9 Favored 'General case' 0 C--N 1.265 -3.072 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.524 -178.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.4 t -143.64 127.79 17.6 Favored 'General case' 0 N--CA 1.427 -1.621 0 CA-C-N 115.275 -0.875 . . . . 0.0 108.803 178.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 81.4 m -73.71 163.39 28.04 Favored 'General case' 0 C--N 1.292 -1.891 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.317 -176.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.437 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 95.4 m-20 -95.25 -179.15 4.69 Favored 'General case' 0 CA--C 1.476 -1.887 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.72 -178.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -69.09 93.96 0.63 Allowed 'General case' 0 N--CA 1.429 -1.522 0 O-C-N 124.573 1.171 . . . . 0.0 109.753 177.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 133.66 2.13 3.64 Favored Glycine 0 C--N 1.259 -3.698 0 CA-C-N 112.961 -1.927 . . . . 0.0 111.781 177.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.429 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 87.8 m-85 -133.49 158.7 42.44 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -177.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -142.11 158.06 44.18 Favored 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 -177.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 13.9 tp -83.07 146.27 28.8 Favored 'General case' 0 N--CA 1.413 -2.282 0 C-N-CA 119.491 -0.884 . . . . 0.0 109.169 -177.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.09 121.64 38.33 Favored 'General case' 0 N--CA 1.405 -2.709 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 178.359 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 100.4 174.93 29.96 Favored Glycine 0 C--N 1.292 -1.897 0 N-CA-C 110.914 -0.875 . . . . 0.0 110.914 -174.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -88.05 -37.89 15.9 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.255 0.55 . . . . 0.0 110.112 -177.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.3 mm -66.7 124.47 21.96 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.758 -177.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -127.13 -4.34 6.23 Favored 'General case' 0 C--O 1.204 -1.317 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.509 ' HB3' HG12 ' A' ' 111' ' ' VAL . 11.9 p90 -137.23 161.83 35.14 Favored 'General case' 0 C--N 1.293 -1.888 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.496 -170.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 49.9 mtp180 -125.28 136.11 53.19 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 106.112 -1.81 . . . . 0.0 106.112 171.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -115.32 130.94 57.05 Favored 'General case' 0 C--N 1.273 -2.719 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -177.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 33.0 t -86.49 112.26 21.35 Favored 'General case' 0 C--N 1.293 -1.869 0 C-N-CA 119.109 -1.036 . . . . 0.0 110.83 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.454 ' OD2' HG22 ' A' ' 131' ' ' THR . 14.9 t70 -103.24 -171.26 1.91 Allowed 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 175.339 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.454 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -71.16 -17.78 62.53 Favored 'General case' 0 C--N 1.291 -1.946 0 CA-C-O 121.874 0.845 . . . . 0.0 110.309 -175.027 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -87.9 -8.77 55.34 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.691 179.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 112.78 -164.32 12.07 Favored Glycine 0 N--CA 1.427 -1.936 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 -177.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.427 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 97.8 m95 -60.97 123.34 17.32 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 117.255 0.527 . . . . 0.0 110.579 176.037 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.6 p -64.46 -71.77 0.17 Allowed 'General case' 0 C--N 1.319 -0.747 0 C-N-CA 123.554 0.742 . . . . 0.0 111.99 -178.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -81.58 177.66 8.8 Favored 'General case' 0 C--N 1.308 -1.207 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.175 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -106.12 177.84 4.74 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.282 -179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 65.0 mt -61.38 121.11 61.21 Favored Pre-proline 0 C--O 1.245 0.861 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 176.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.13 166.89 23.48 Favored 'Trans proline' 0 C--O 1.26 1.625 0 C-N-CA 122.424 2.083 . . . . 0.0 111.637 179.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 55.7 mt -90.06 127.02 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.03 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -177.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.429 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 53.6 t -121.07 115.62 23.46 Favored 'General case' 0 C--N 1.269 -2.916 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 174.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -105.18 151.95 23.43 Favored 'General case' 0 C--N 1.282 -2.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 109.864 -177.236 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.5 p -68.88 137.52 24.18 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.105 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 41.5 t -63.95 125.91 21.58 Favored 'Isoleucine or valine' 0 C--O 1.247 0.951 0 CA-C-O 121.111 0.482 . . . . 0.0 109.74 178.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -119.13 133.55 55.72 Favored 'General case' 0 N--CA 1.418 -2.074 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 -179.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 72.8 m -99.63 141.18 32.77 Favored 'General case' 0 C--N 1.261 -3.267 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 176.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . 0.418 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.0 mm? -58.63 138.5 86.12 Favored Pre-proline 0 N--CA 1.427 -1.579 0 N-CA-C 114.209 1.188 . . . . 0.0 114.209 -175.499 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 23.5 Cg_exo -58.25 107.4 0.32 Allowed 'Trans proline' 0 N--CA 1.452 -0.927 0 C-N-CA 123.346 2.698 . . . . 0.0 111.117 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 5.9 p -69.26 140.58 18.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 20.5 p -71.9 -71.81 0.26 Allowed 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 111.405 0.15 . . . . 0.0 111.405 -178.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.38 162.3 0.21 Allowed Pre-proline 0 C--O 1.248 1.005 0 C-N-CA 125.748 1.619 . . . . 0.0 106.712 177.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . 0.403 ' HB3' ' O ' ' A' ' 203' ' ' PRO . 51.3 Cg_endo -74.3 170.88 19.19 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 121.512 1.475 . . . . 0.0 109.469 169.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . 0.491 ' HG3' ' ND2' ' A' ' 154' ' ' ASN . 11.4 pt-20 -60.67 -48.92 79.62 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 114.055 1.132 . . . . 0.0 114.055 -173.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . 0.491 ' ND2' ' HG3' ' A' ' 153' ' ' GLU . 60.2 m-80 -117.31 32.39 6.19 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.505 0.669 . . . . 0.0 109.668 -177.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.06 -176.59 18.22 Favored Glycine 0 C--N 1.303 -1.269 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.477 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.4 ptmt -145.21 173.27 12.09 Favored 'General case' 0 N--CA 1.434 -1.231 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -178.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 69.0 mt -88.22 138.49 19.05 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 CA-C-O 121.3 0.572 . . . . 0.0 110.957 -179.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.6 t -89.29 -39.71 12.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 C-N-CA 124.426 1.09 . . . . 0.0 109.402 176.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 9.9 m -85.46 45.61 1.21 Allowed 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 123.512 0.725 . . . . 0.0 111.09 -178.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 25.4 m -77.45 -30.17 53.17 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-O 121.019 0.438 . . . . 0.0 111.185 -178.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -123.12 156.25 35.36 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.28 -179.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 22.3 ptp 174.53 -33.69 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.044 0 C-N-CA 124.804 1.241 . . . . 0.0 107.7 -177.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.489 ' HB2' ' H ' ' A' ' 166' ' ' ARG . 49.0 mt-10 -146.18 160.15 43.6 Favored Pre-proline 0 C--N 1.311 -1.104 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 178.068 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -82.8 -6.95 11.48 Favored 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 122.199 1.933 . . . . 0.0 110.178 172.271 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -96.33 -49.39 5.21 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.172 -1.377 . . . . 0.0 108.817 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.489 ' H ' ' HB2' ' A' ' 163' ' ' GLU 0.383 7.5 ppt_? 35.52 75.67 0.06 Allowed 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 119.064 2.987 . . . . 0.0 119.064 178.022 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -95.49 148.67 22.23 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 104.228 -2.508 . . . . 0.0 104.228 167.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -87.33 91.7 8.82 Favored 'General case' 0 C--N 1.276 -2.606 0 C-N-CA 119.119 -1.032 . . . . 0.0 111.198 178.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 47.2 m170 -84.32 164.07 19.21 Favored 'General case' 0 C--O 1.248 1.019 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.115 -179.199 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 72.4 t80 -52.63 134.64 35.68 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 123.697 0.799 . . . . 0.0 110.765 173.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 102.01 -23.34 34.92 Favored Glycine 0 C--N 1.314 -0.674 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.305 179.02 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -72.85 133.97 44.67 Favored 'General case' 0 N--CA 1.434 -1.229 0 CA-C-O 121.085 0.469 . . . . 0.0 111.991 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.421 ' HB2' ' NE2' ' A' ' 191' ' ' HIS . . . -106.28 115.73 30.72 Favored 'General case' 0 N--CA 1.421 -1.889 0 CA-C-N 114.733 -1.122 . . . . 0.0 109.142 178.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 48.3 t -91.27 108.75 20.25 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 175.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.485 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 20.4 ttp180 -99.4 153.79 18.72 Favored 'General case' 0 N--CA 1.403 -2.82 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 177.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 83.4 m-85 -127.24 158.9 35.93 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 123.24 0.616 . . . . 0.0 109.533 -174.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.9 p -140.57 140.32 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.579 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . 0.406 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 77.1 m -89.62 149.61 22.74 Favored 'General case' 0 C--N 1.278 -2.54 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.186 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 81.8 m-20 -76.15 179.4 5.72 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.307 -178.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 25.2 p -53.72 111.26 0.7 Allowed 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 124.027 0.931 . . . . 0.0 112.511 -176.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 97.38 2.31 58.98 Favored Glycine 0 N--CA 1.433 -1.544 0 CA-C-N 115.846 -0.615 . . . . 0.0 113.847 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . 0.406 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 90.2 m-85 -111.6 149.09 31.97 Favored 'General case' 0 CA--C 1.484 -1.573 0 CA-C-N 117.971 0.886 . . . . 0.0 110.704 -179.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -122.38 145.86 47.88 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -178.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.6 tt -76.3 137.01 23.5 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 CA-C-O 122.049 0.928 . . . . 0.0 111.798 -177.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -84.33 -48.66 9.48 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.171 -176.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -91.09 -136.2 6.75 Favored Glycine 0 C--N 1.301 -1.382 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.315 177.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . 0.465 ' OD1' ' HG3' ' A' ' 189' ' ' GLU . 12.2 t70 -102.58 163.68 12.09 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 178.443 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.485 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 15.8 pt-20 -91.15 -13.85 32.22 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 118.887 0.767 . . . . 0.0 112.668 -174.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.465 ' HG3' ' OD1' ' A' ' 187' ' ' ASP . 0.0 OUTLIER -120.03 144.92 47.28 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 112.84 0.682 . . . . 0.0 112.84 -176.724 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 37.0 ttm -135.97 124.33 23.35 Favored 'General case' 0 N--CA 1.429 -1.489 0 C-N-CA 124.864 1.266 . . . . 0.0 109.075 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . 0.421 ' NE2' ' HB2' ' A' ' 173' ' ' ALA . 30.7 m80 -97.86 155.44 17.06 Favored 'General case' 0 C--N 1.276 -2.618 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 40.6 t -94.94 116.88 29.25 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 173.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 8.4 p -100.23 170.21 8.61 Favored 'General case' 0 N--CA 1.437 -1.122 0 O-C-N 123.354 0.409 . . . . 0.0 111.174 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -60.01 -21.26 61.08 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 123.607 0.763 . . . . 0.0 112.064 -175.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 13.7 m-20 -64.51 -17.54 63.99 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.741 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 80.94 20.48 65.24 Favored Glycine 0 CA--C 1.488 -1.656 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -177.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -130.48 153.44 48.79 Favored 'General case' 0 N--CA 1.407 -2.597 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 -174.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 78.2 m95 -76.84 131.47 38.65 Favored 'General case' 0 C--N 1.291 -1.971 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.34 -178.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.5 m -69.06 -38.33 79.01 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 115.639 -0.709 . . . . 0.0 112.289 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 1.6 tppp? -103.73 156.95 17.41 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 178.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 20.0 pm0 -78.83 157.91 28.27 Favored 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 177.485 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -68.05 116.62 40.71 Favored Pre-proline 0 C--O 1.246 0.908 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 175.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.403 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 98.3 Cg_endo -76.98 161.5 32.86 Favored 'Trans proline' 0 N--CA 1.433 -2.088 0 C-N-CA 122.218 1.945 . . . . 0.0 110.998 -178.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -104.52 161.83 13.77 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 120.226 -0.589 . . . . 0.0 109.6 178.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 88.9 m -122.19 108.55 13.43 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 172.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.1 m . . . . . 0 C--N 1.291 -1.957 0 O-C-N 124.405 1.066 . . . . 0.0 108.818 -173.788 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.451 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 19.1 Cg_endo . . . . . 0 CA--C 1.537 0.657 0 CA-C-O 120.859 0.274 . . . . 0.0 112.205 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 50.0 m -71.67 -43.98 65.07 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.756 -179.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 97.07 112.44 2.94 Favored Glycine 0 C--O 1.187 -2.791 0 N-CA-C 108.253 -1.939 . . . . 0.0 108.253 -179.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -34.36 119.52 0.54 Allowed Pre-proline 0 C--N 1.296 -1.734 0 C-N-CA 127.235 2.214 . . . . 0.0 112.129 -173.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -60.67 -43.32 32.99 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 123.283 2.655 . . . . 0.0 113.305 -172.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 139.73 -174.98 22.06 Favored Glycine 0 N--CA 1.421 -2.336 0 N-CA-C 108.428 -1.869 . . . . 0.0 108.428 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -133.78 156.66 47.6 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-N 117.403 0.602 . . . . 0.0 109.691 -178.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.1 t -115.3 126.63 27.59 Favored Pre-proline 0 C--N 1.305 -1.368 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.282 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -66.97 -18.8 52.29 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.555 2.17 . . . . 0.0 112.556 -179.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -87.7 -15.05 38.21 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.37 -175.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.497 ' HA2' ' ND2' ' A' ' 115' ' ' ASN . . . -163.62 -133.43 1.48 Allowed Glycine 0 N--CA 1.409 -3.136 0 C-N-CA 118.635 -1.745 . . . . 0.0 113.004 -177.413 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 18.1 p -144.2 179.59 7.13 Favored 'General case' 0 C--N 1.284 -2.249 0 CA-C-N 114.439 -0.881 . . . . 0.0 109.264 -176.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 32.0 p90 -141.5 157.65 44.86 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 172.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.4 m -127.56 162.53 26.24 Favored 'General case' 0 C--N 1.278 -2.524 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.0 mt -118.43 117.03 27.94 Favored 'General case' 0 C--N 1.277 -2.579 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.502 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 19.5 p -109.16 127.63 54.35 Favored 'General case' 0 C--N 1.282 -2.364 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.245 -172.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 113.97 -37.92 3.38 Favored Glycine 0 N--CA 1.433 -1.567 0 C-N-CA 120.406 -0.902 . . . . 0.0 111.975 179.212 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -144.28 -7.14 0.5 Allowed Glycine 0 C--N 1.315 -0.588 0 C-N-CA 119.715 -1.231 . . . . 0.0 113.756 -178.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 92.6 m-20 61.14 15.11 6.01 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 113.603 0.964 . . . . 0.0 113.603 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.495 ' O ' HG11 ' A' ' 108' ' ' VAL . 24.0 m -146.52 -169.42 0.24 Allowed 'Isoleucine or valine' 0 C--O 1.209 -1.027 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -176.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -106.46 40.29 1.65 Allowed 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 118.29 0.496 . . . . 0.0 110.227 -177.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.715 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.1 pt-20 -83.04 176.48 9.21 Favored 'General case' 0 C--O 1.205 -1.24 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.046 178.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . 0.451 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 35.5 m-85 -72.88 133.26 44.33 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 120.237 -0.585 . . . . 0.0 111.218 177.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.51 5.05 63.6 Favored Glycine 0 N--CA 1.43 -1.711 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.34 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.715 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -94.97 147.16 5.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.171 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.502 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 51.8 mtpt -110.76 118.47 36.25 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 178.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -83.28 92.48 7.51 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.301 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.507 ' HA ' ' HA ' ' A' ' 126' ' ' TYR . 35.0 m -89.1 117.71 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.824 0 CA-C-O 122.151 0.977 . . . . 0.0 109.903 -178.521 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 31.5 m-85 -85.88 139.48 31.21 Favored 'General case' 0 C--N 1.263 -3.182 0 CA-C-N 115.129 -0.941 . . . . 0.0 108.896 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.2 t -138.96 124.6 19.54 Favored 'General case' 0 N--CA 1.407 -2.603 0 CA-C-O 121.999 0.904 . . . . 0.0 109.671 -178.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 74.3 m -71.74 161.79 30.44 Favored 'General case' 0 C--N 1.289 -2.036 0 CA-C-N 115.0 -1.0 . . . . 0.0 112.455 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.497 ' ND2' ' HA2' ' A' ' 94' ' ' GLY . 81.3 m-20 -86.31 -176.59 5.95 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.479 179.098 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -46.87 -50.94 17.81 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 126.513 1.925 . . . . 0.0 114.008 -177.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -91.19 28.36 8.17 Favored Glycine 0 C--N 1.305 -1.158 0 C-N-CA 119.736 -1.221 . . . . 0.0 113.179 -177.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.455 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 98.8 m-85 -149.37 167.51 25.94 Favored 'General case' 0 C--N 1.31 -1.113 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -173.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.488 HE22 HD23 ' A' ' 121' ' ' LEU . 1.0 OUTLIER -153.88 156.87 38.37 Favored 'General case' 0 N--CA 1.435 -1.195 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 177.81 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.529 ' HG ' ' HB2' ' A' ' 125' ' ' ASN . 0.5 OUTLIER -85.99 128.39 34.84 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -175.182 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.488 HD23 HE22 ' A' ' 119' ' ' GLN . 0.3 OUTLIER -102.1 130.1 48.62 Favored 'General case' 0 N--CA 1.422 -1.864 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 -175.741 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.74 -159.7 13.83 Favored Glycine 0 C--N 1.297 -1.63 0 C-N-CA 120.368 -0.92 . . . . 0.0 112.296 179.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -106.03 -41.63 5.33 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 121.835 0.826 . . . . 0.0 109.267 -178.277 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 51.1 mm -85.17 122.92 38.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 CA-C-N 114.772 -1.104 . . . . 0.0 110.069 -176.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.529 ' HB2' ' HG ' ' A' ' 120' ' ' LEU . 3.9 p-10 -127.59 7.12 6.27 Favored 'General case' 0 C--O 1.202 -1.41 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 176.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.507 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 15.4 p90 -134.25 168.21 19.3 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -171.784 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.514 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 36.3 mtp180 -130.67 119.89 23.1 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 170.399 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -92.32 126.76 37.54 Favored 'General case' 0 C--N 1.293 -1.864 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.846 -179.261 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 49.3 t -84.7 108.04 17.21 Favored 'General case' 0 N--CA 1.434 -1.266 0 C-N-CA 119.142 -1.023 . . . . 0.0 109.249 174.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 8.4 t0 -101.76 -171.22 1.94 Allowed 'General case' 0 C--N 1.29 -1.992 0 N-CA-C 105.354 -2.091 . . . . 0.0 105.354 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 15.3 t -64.37 -15.34 60.26 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.841 0.829 . . . . 0.0 110.593 -178.511 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -97.88 -2.17 41.35 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.255 -178.686 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 103.48 -159.44 16.93 Favored Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -177.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.442 ' CH2' HG13 ' A' ' 108' ' ' VAL . 86.9 m95 -68.64 108.47 3.37 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 177.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 41.7 p -67.71 -57.51 6.23 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 115.439 -0.8 . . . . 0.0 112.655 -175.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.514 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 6.4 m120 -71.83 171.22 12.07 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.957 -178.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 25.2 m-20 -100.74 176.61 5.24 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 176.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 88.6 mt -66.35 119.07 59.39 Favored Pre-proline 0 C--O 1.237 0.407 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 173.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.402 ' HB2' HD11 ' A' ' 120' ' ' LEU . 29.7 Cg_endo -64.46 164.7 22.48 Favored 'Trans proline' 0 N--CA 1.451 -0.993 0 C-N-CA 122.601 2.2 . . . . 0.0 112.986 -177.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 50.0 mm -96.49 124.47 49.26 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.766 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.903 -175.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.455 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 48.9 t -105.66 136.12 45.83 Favored 'General case' 0 C--N 1.27 -2.882 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 177.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -124.91 141.8 51.88 Favored 'General case' 0 N--CA 1.413 -2.28 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -177.236 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 6.2 p -68.34 139.19 21.09 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.809 0 O-C-N 123.874 0.734 . . . . 0.0 109.573 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.646 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 21.1 m -65.83 129.44 30.14 Favored 'Isoleucine or valine' 0 C--O 1.251 1.168 0 C-N-CA 120.48 -0.488 . . . . 0.0 110.094 178.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 89.4 mttt -114.79 166.6 11.58 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -178.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 82.0 m -129.43 -174.22 3.23 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-O 121.135 0.493 . . . . 0.0 111.457 -175.081 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 31.1 mt -77.72 137.0 62.76 Favored Pre-proline 0 N--CA 1.439 -0.991 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.315 177.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -70.86 112.51 3.29 Favored 'Trans proline' 0 N--CA 1.442 -1.53 0 C-N-CA 122.279 1.986 . . . . 0.0 109.683 175.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 27.8 t -82.81 136.61 22.51 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 -179.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.6 p -76.93 -73.71 0.28 Allowed 'General case' 0 N--CA 1.431 -1.376 0 O-C-N 123.104 0.252 . . . . 0.0 111.518 179.371 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 167.9 160.19 0.15 Allowed Pre-proline 0 C--O 1.239 0.548 0 C-N-CA 126.128 1.771 . . . . 0.0 106.95 -179.368 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -77.49 170.05 19.99 Favored 'Trans proline' 0 CA--C 1.542 0.883 0 C-N-CA 121.586 1.524 . . . . 0.0 110.26 170.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -63.14 -52.6 61.87 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 -176.126 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -106.48 33.45 3.87 Favored 'General case' 0 CA--C 1.499 -1.011 0 CA-C-O 121.363 0.601 . . . . 0.0 109.981 -178.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -151.59 -167.35 14.85 Favored Glycine 0 N--CA 1.42 -2.406 0 C-N-CA 120.133 -1.032 . . . . 0.0 112.062 178.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . 0.518 ' HG3' HG23 ' A' ' 177' ' ' VAL . 59.6 pttt -154.55 176.19 12.7 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -179.435 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 159' ' ' SER . 49.3 mt -98.31 145.05 10.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -179.303 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.677 HG12 HG22 ' A' ' 177' ' ' VAL . 2.5 m -89.12 -31.39 5.42 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.081 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.425 ' N ' HG22 ' A' ' 157' ' ' ILE . 6.7 m -93.95 45.3 1.14 Allowed 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 124.603 1.161 . . . . 0.0 110.951 -175.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.4 m -82.18 4.98 21.27 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -176.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -136.07 134.01 37.96 Favored 'General case' 0 N--CA 1.434 -1.267 0 CA-C-O 120.773 0.32 . . . . 0.0 110.518 179.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 21.4 ptp -176.59 -42.11 0.01 OUTLIER 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 126.29 1.836 . . . . 0.0 106.084 178.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -136.63 148.64 64.44 Favored Pre-proline 0 N--CA 1.437 -1.11 0 N-CA-C 103.958 -2.608 . . . . 0.0 103.958 166.419 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.81 -8.1 22.74 Favored 'Trans proline' 0 CA--C 1.542 0.917 0 C-N-CA 122.082 1.855 . . . . 0.0 110.977 175.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -103.34 -19.73 14.34 Favored 'General case' 0 CA--C 1.469 -2.137 0 CA-C-N 114.309 -1.314 . . . . 0.0 108.789 -179.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.482 ' HD2' ' O ' ' A' ' 166' ' ' ARG 0.289 0.0 OUTLIER 37.17 75.36 0.07 Allowed 'General case' 0 N--CA 1.434 -1.268 0 C-N-CA 125.362 1.465 . . . . 0.0 114.026 -175.207 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -91.31 -23.39 20.13 Favored 'General case' 0 C--N 1.298 -1.671 0 CA-C-N 113.66 -1.609 . . . . 0.0 110.712 -178.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 72.2 152.33 0.12 Allowed 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 113.255 -1.793 . . . . 0.0 112.181 177.257 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.411 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 35.9 m80 -141.61 162.44 35.48 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -177.086 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.646 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 91.6 t80 -48.25 139.43 8.58 Favored 'General case' 0 N--CA 1.479 0.979 0 CA-C-O 121.194 0.521 . . . . 0.0 112.104 175.342 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 87.37 -15.22 55.31 Favored Glycine 0 N--CA 1.423 -2.217 0 CA-C-O 119.204 -0.776 . . . . 0.0 113.867 175.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 29.2 mm-40 -65.0 135.76 56.01 Favored 'General case' 0 CA--C 1.496 -1.127 0 CA-C-N 118.233 1.017 . . . . 0.0 111.157 -178.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -104.71 113.96 27.87 Favored 'General case' 0 C--N 1.287 -2.148 0 CA-C-N 114.518 -1.219 . . . . 0.0 108.325 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 98.0 t -105.5 102.28 13.62 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.472 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 40.9 ttm180 -97.06 146.97 24.5 Favored 'General case' 0 C--N 1.293 -1.849 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.437 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -116.06 156.54 26.19 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.14 0.495 . . . . 0.0 110.217 -176.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.677 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -127.76 135.18 63.75 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.131 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.146 177.583 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 77.7 m -93.91 139.25 31.13 Favored 'General case' 0 C--N 1.262 -3.231 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 173.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -56.02 157.55 4.47 Favored 'General case' 0 C--N 1.294 -1.829 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.208 176.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.8 m -52.25 111.12 0.57 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 124.319 1.012 . . . . 0.0 112.07 -174.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 106.6 1.71 37.35 Favored Glycine 0 N--CA 1.426 -1.984 0 C-N-CA 120.317 -0.944 . . . . 0.0 112.863 177.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -113.41 158.81 20.17 Favored 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 117.994 0.897 . . . . 0.0 110.169 176.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 15.6 pttm -120.62 153.38 36.91 Favored 'General case' 0 N--CA 1.428 -1.573 0 N-CA-C 106.63 -1.619 . . . . 0.0 106.63 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.403 HD13 ' HA ' ' A' ' 188' ' ' GLU . 2.1 tt -84.67 131.06 34.93 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.911 0 C-N-CA 119.28 -0.968 . . . . 0.0 109.728 176.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -82.43 -48.33 11.22 Favored 'General case' 0 C--N 1.286 -2.165 0 CA-C-N 114.717 -1.129 . . . . 0.0 109.747 -175.265 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -83.89 -151.66 12.62 Favored Glycine 0 C--N 1.304 -1.213 0 CA-C-N 114.847 -1.07 . . . . 0.0 110.528 176.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -80.62 164.56 22.78 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.403 ' HA ' HD13 ' A' ' 184' ' ' ILE . 16.2 pt-20 -89.32 -3.27 58.55 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.91 -172.085 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -157.89 162.48 38.32 Favored 'General case' 0 N--CA 1.422 -1.832 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.57 -176.257 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 17.8 ptp -137.06 153.67 50.53 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 114.81 -1.086 . . . . 0.0 108.16 176.103 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 22.0 m80 -125.64 151.66 46.22 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 120.652 0.263 . . . . 0.0 110.676 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 18.9 m -76.21 112.6 12.86 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 171.062 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 23.3 t -82.24 171.05 14.71 Favored 'General case' 0 N--CA 1.422 -1.85 0 O-C-N 124.383 1.052 . . . . 0.0 110.038 -176.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -50.54 -34.92 27.32 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 125.448 1.499 . . . . 0.0 112.198 -178.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -69.48 -14.24 62.77 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.155 -0.93 . . . . 0.0 113.367 -177.579 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 83.7 29.25 32.81 Favored Glycine 0 C--O 1.225 -0.466 0 C-N-CA 120.439 -0.886 . . . . 0.0 110.893 -174.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -138.33 172.64 12.6 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 70.6 m95 -80.16 136.28 36.48 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 120.816 0.341 . . . . 0.0 111.252 -179.342 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 25.7 p -73.88 -22.57 59.68 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.197 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.593 ' HE2' ' HA ' ' A' ' 200' ' ' LYS . 3.9 mmpt? -122.62 166.49 14.78 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.483 0.658 . . . . 0.0 111.572 -179.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -89.71 164.68 14.59 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 179.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 43.7 mtpt -66.63 122.76 83.54 Favored Pre-proline 0 C--N 1.309 -1.155 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.038 174.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -77.58 163.38 29.47 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 C-N-CA 122.03 1.82 . . . . 0.0 111.155 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 53.7 tttp -120.22 152.09 38.23 Favored 'General case' 0 C--N 1.282 -2.367 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -178.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 88.8 m -114.81 114.81 26.05 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 176.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 19.5 m . . . . . 0 C--N 1.3 -1.582 0 O-C-N 124.277 0.985 . . . . 0.0 109.175 -175.447 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo . . . . . 0 CA--C 1.538 0.689 0 CA-C-O 122.001 0.751 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 37.2 m -88.33 -36.49 16.61 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 177.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 120.53 -91.36 0.49 Allowed Glycine 0 CA--C 1.458 -3.484 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 172.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.5 t-160 -176.11 127.6 0.35 Allowed Pre-proline 0 C--N 1.266 -3.05 0 N-CA-C 104.77 -2.308 . . . . 0.0 104.77 -176.157 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.463 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 61.5 Cg_endo -74.1 -17.5 21.96 Favored 'Trans proline' 0 C--N 1.329 -0.478 0 C-N-CA 122.44 2.093 . . . . 0.0 113.977 -175.301 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 131.0 -173.78 20.16 Favored Glycine 0 N--CA 1.427 -1.909 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 -176.432 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -147.39 144.13 28.47 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.7 t -122.32 130.08 24.83 Favored Pre-proline 0 C--N 1.305 -1.352 0 CA-C-O 121.194 0.521 . . . . 0.0 111.279 -178.12 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -73.74 -12.21 24.23 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.689 2.259 . . . . 0.0 111.676 178.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -95.04 14.36 22.11 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.717 -176.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 160.22 -122.33 1.12 Allowed Glycine 0 N--CA 1.421 -2.366 0 N-CA-C 111.084 -0.807 . . . . 0.0 111.084 178.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 t -172.31 -168.23 0.52 Allowed 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -177.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -147.56 170.2 17.97 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.7 m -138.46 156.83 47.19 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.492 HD11 ' CE1' ' A' ' 104' ' ' PHE . 14.6 mt -106.65 133.41 51.37 Favored 'General case' 0 C--N 1.276 -2.601 0 CA-C-O 121.213 0.53 . . . . 0.0 110.375 -176.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.458 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 23.8 p -121.23 116.68 25.36 Favored 'General case' 0 C--N 1.294 -1.813 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.59 -176.382 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.56 -58.93 0.7 Allowed Glycine 0 N--CA 1.434 -1.47 0 N-CA-C 111.145 -0.782 . . . . 0.0 111.145 -179.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.426 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -127.23 -4.51 5.9 Favored Glycine 0 N--CA 1.437 -1.247 0 C-N-CA 120.159 -1.019 . . . . 0.0 112.479 179.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 63.05 12.91 6.31 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 123.706 0.803 . . . . 0.0 112.517 -177.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.525 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.6 m -145.12 -171.86 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 -176.633 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.492 ' CE1' HD11 ' A' ' 98' ' ' LEU . 27.1 m-85 -101.01 44.45 1.01 Allowed 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 118.648 0.658 . . . . 0.0 110.074 -176.03 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.697 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.6 pt-20 -84.68 179.28 7.4 Favored 'General case' 0 C--O 1.209 -1.035 0 CA-C-N 114.639 -1.164 . . . . 0.0 112.101 178.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -78.57 132.2 37.06 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.359 0.6 . . . . 0.0 111.345 178.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 101.06 -8.67 57.64 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 115.067 -0.97 . . . . 0.0 112.475 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.697 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -86.29 143.7 10.93 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 CA-C-O 121.418 0.628 . . . . 0.0 110.726 -174.586 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.458 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 19.6 mtpp -110.05 119.57 39.72 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.476 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -85.57 95.08 9.21 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 177.615 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 55.3 t -90.33 114.93 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.58 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 -177.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -83.94 138.92 32.9 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.94 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.3 t -134.07 116.73 15.8 Favored 'General case' 0 N--CA 1.42 -1.957 0 CA-C-N 115.032 -0.986 . . . . 0.0 108.672 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 21.0 m -72.88 160.06 32.74 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.49 -175.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -68.63 -179.72 1.47 Allowed 'General case' 0 C--N 1.315 -0.911 0 C-N-CA 122.95 0.5 . . . . 0.0 111.392 -177.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -59.43 -50.96 71.94 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 123.828 0.851 . . . . 0.0 111.212 -177.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -87.56 31.16 4.63 Favored Glycine 0 C--N 1.309 -0.924 0 C-N-CA 120.984 -0.627 . . . . 0.0 113.094 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -145.76 161.44 39.92 Favored 'General case' 0 N--CA 1.43 -1.473 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -177.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -142.22 173.67 11.31 Favored 'General case' 0 C--N 1.271 -2.845 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 -179.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 11.9 tp -92.4 149.92 21.12 Favored 'General case' 0 C--N 1.273 -2.753 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.525 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -132.65 130.91 40.76 Favored 'General case' 0 N--CA 1.415 -2.204 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 177.9 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 116.49 -153.41 17.44 Favored Glycine 0 N--CA 1.433 -1.547 0 C-N-CA 120.646 -0.788 . . . . 0.0 111.526 179.08 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -112.3 -41.69 3.86 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 121.82 0.819 . . . . 0.0 110.068 -178.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.43 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.5 mm -85.97 144.34 9.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.782 -173.735 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 22.4 p-10 -135.24 4.32 3.18 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-O 120.79 0.328 . . . . 0.0 110.595 175.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.476 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 5.4 p90 -145.95 165.98 27.38 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.232 -172.381 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.463 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 44.8 mtp180 -128.56 125.67 38.74 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.409 -1.7 . . . . 0.0 106.409 171.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 109' ' ' LYS . 55.9 tt0 -103.71 136.04 44.15 Favored 'General case' 0 C--N 1.286 -2.19 0 C-N-CA 118.352 -1.339 . . . . 0.0 110.378 179.411 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . 0.427 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 21.2 t -87.33 106.93 18.27 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 119.551 -0.86 . . . . 0.0 109.237 175.336 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -102.62 -166.76 1.31 Allowed 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 104.621 -2.363 . . . . 0.0 104.621 175.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 10.6 t -61.21 -29.83 70.05 Favored 'General case' 0 C--N 1.295 -1.769 0 CA-C-N 118.93 0.786 . . . . 0.0 112.81 -175.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -78.76 -16.53 57.08 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 121.743 0.782 . . . . 0.0 110.798 177.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.427 ' HA2' ' SG ' ' A' ' 129' ' ' CYS . . . 116.02 -148.16 18.9 Favored Glycine 0 N--CA 1.416 -2.676 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 -175.237 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 86.7 m95 -66.92 109.66 3.03 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 117.092 0.446 . . . . 0.0 109.858 178.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.1 p -64.82 -69.58 0.28 Allowed 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 124.219 1.008 . . . . 0.0 112.037 -176.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.41 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 3.7 m-20 -75.79 167.94 20.94 Favored 'General case' 0 C--N 1.294 -1.816 0 CA-C-N 114.012 -1.449 . . . . 0.0 108.94 -179.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -104.23 178.13 4.65 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 123.629 0.58 . . . . 0.0 110.393 179.063 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 64.6 mt -64.31 126.19 89.91 Favored Pre-proline 0 C--N 1.314 -0.941 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.625 -178.565 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.43 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 48.2 Cg_endo -70.36 170.77 16.5 Favored 'Trans proline' 0 C--O 1.251 1.172 0 C-N-CA 122.654 2.236 . . . . 0.0 112.404 178.362 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.525 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 56.1 mt -97.6 127.43 49.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.742 -178.232 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 61.2 m -106.82 123.83 48.72 Favored 'General case' 0 C--N 1.273 -2.737 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 169.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -111.8 151.4 29.06 Favored 'General case' 0 C--N 1.276 -2.618 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.17 142.49 15.48 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 178.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.594 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.4 m -68.52 113.69 4.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 119.93 -0.708 . . . . 0.0 109.462 177.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 87.8 mttt -105.46 133.99 49.31 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.189 -177.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.3 m -97.32 149.97 21.48 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . 0.411 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.2 mm? -59.44 143.83 85.13 Favored Pre-proline 0 N--CA 1.42 -1.937 0 N-CA-C 112.934 0.716 . . . . 0.0 112.934 177.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 35.0 Cg_exo -56.94 114.37 1.89 Allowed 'Trans proline' 0 C--O 1.252 1.204 0 C-N-CA 123.479 2.786 . . . . 0.0 111.429 179.121 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.4 p -89.0 137.64 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.723 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.713 179.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . 0.413 ' O ' HD11 ' A' ' 157' ' ' ILE . 15.3 p -94.12 -158.74 0.65 Allowed 'General case' 0 N--CA 1.414 -2.262 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.065 177.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.448 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . -122.44 160.21 49.23 Favored Pre-proline 0 C--N 1.291 -1.944 0 N-CA-C 106.445 -1.687 . . . . 0.0 106.445 -173.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -71.3 -170.21 0.48 Allowed 'Trans proline' 0 CA--C 1.555 1.545 0 C-N-CA 121.171 1.247 . . . . 0.0 110.61 176.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . 0.53 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.0 OUTLIER -79.27 -46.5 17.66 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 112.557 0.577 . . . . 0.0 112.557 -171.942 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . 0.53 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 57.5 m-80 -110.52 14.59 22.45 Favored 'General case' 0 CA--C 1.502 -0.901 0 CA-C-O 121.435 0.636 . . . . 0.0 110.586 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -127.96 -176.2 14.36 Favored Glycine 0 N--CA 1.423 -2.212 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . 0.461 ' HG3' HG23 ' A' ' 177' ' ' VAL . 45.6 pttt -151.56 -178.83 6.92 Favored 'General case' 0 C--N 1.292 -1.913 0 C-N-CA 123.451 0.7 . . . . 0.0 109.229 -175.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.419 HG22 ' N ' ' A' ' 159' ' ' SER . 56.1 mt -103.3 135.04 42.71 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.197 0 CA-C-N 118.018 0.372 . . . . 0.0 111.193 -176.1 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.52 HG12 HG22 ' A' ' 177' ' ' VAL . 2.7 m -79.0 -32.17 15.22 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.03 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.419 ' N ' HG22 ' A' ' 157' ' ' ILE . 5.0 m -95.62 42.68 1.09 Allowed 'General case' 0 C--N 1.32 -0.708 0 C-N-CA 124.588 1.155 . . . . 0.0 110.013 -176.304 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 59.0 m -75.4 88.5 2.61 Favored 'General case' 0 C--N 1.323 -0.543 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -176.236 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -158.18 72.13 0.61 Allowed 'General case' 0 CA--C 1.496 -1.11 0 CA-C-O 122.09 0.948 . . . . 0.0 110.829 174.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 20.9 ttp -97.65 111.1 23.52 Favored 'General case' 0 C--N 1.27 -2.867 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 172.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.485 ' HB2' ' HG3' ' A' ' 166' ' ' ARG . 47.5 mt-10 -123.81 161.16 48.03 Favored Pre-proline 0 C--N 1.279 -2.464 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -174.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -73.55 10.31 1.31 Allowed 'Trans proline' 0 C--O 1.242 0.686 0 C-N-CA 122.851 2.367 . . . . 0.0 113.475 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -126.13 -61.76 1.2 Allowed 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 178.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.485 ' HG3' ' HB2' ' A' ' 163' ' ' GLU . 0.1 OUTLIER -91.22 99.52 12.5 Favored 'General case' 0 N--CA 1.416 -2.141 0 CA-C-O 122.825 1.298 . . . . 0.0 109.613 175.923 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -96.77 -176.89 3.72 Favored 'General case' 0 C--N 1.283 -2.321 0 CA-C-N 113.725 -1.579 . . . . 0.0 107.795 -177.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 64.5 m-85 -77.52 105.86 8.92 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 45.6 m170 -120.77 163.78 17.6 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -176.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.594 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 93.7 t80 -46.83 126.55 8.84 Favored 'General case' 0 C--O 1.237 0.416 0 O-C-N 124.284 0.99 . . . . 0.0 109.964 172.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 115.75 -34.63 4.67 Favored Glycine 0 N--CA 1.424 -2.152 0 C-N-CA 120.097 -1.049 . . . . 0.0 111.656 -178.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -67.41 134.33 51.24 Favored 'General case' 0 C--O 1.25 1.097 0 CA-C-O 121.519 0.676 . . . . 0.0 112.669 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -124.87 107.32 10.76 Favored 'General case' 0 N--CA 1.431 -1.419 0 CA-C-N 114.284 -1.325 . . . . 0.0 107.934 179.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 64.9 t -92.64 116.92 34.87 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.088 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.938 -176.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.481 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 39.8 ttm180 -106.44 147.8 28.89 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 176.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -111.99 160.32 17.58 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 123.589 0.755 . . . . 0.0 110.228 -177.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.52 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -132.65 155.66 41.54 Favored 'Isoleucine or valine' 0 CA--C 1.469 -2.163 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.531 178.411 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 10.0 m -111.89 145.19 39.95 Favored 'General case' 0 N--CA 1.396 -3.162 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.24 172.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -64.28 171.99 2.76 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.993 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.9 m -48.2 -25.73 1.62 Allowed 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 116.677 2.103 . . . . 0.0 116.677 -169.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -112.51 8.9 26.29 Favored Glycine 0 C--N 1.298 -1.533 0 C-N-CA 120.2 -1.0 . . . . 0.0 113.568 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -126.84 178.87 5.68 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 117.3 0.55 . . . . 0.0 111.793 -176.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 15.0 pttp -150.68 165.13 34.36 Favored 'General case' 0 N--CA 1.442 -0.842 0 N-CA-C 106.838 -1.542 . . . . 0.0 106.838 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.7 tp -71.86 151.92 8.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.232 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -80.17 -73.12 0.37 Allowed 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.196 176.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -102.35 -100.18 2.51 Favored Glycine 0 CA--C 1.5 -0.887 0 C-N-CA 120.156 -1.021 . . . . 0.0 112.001 -177.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -86.43 154.28 21.27 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 177.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -108.68 3.6 22.94 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.991 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -153.05 158.71 42.36 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 114.123 1.157 . . . . 0.0 114.123 -174.362 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.3 ptp -135.8 156.08 49.36 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 124.695 1.198 . . . . 0.0 108.787 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.1 t-80 -137.5 142.25 41.49 Favored 'General case' 0 C--N 1.31 -1.124 0 O-C-N 122.305 -0.247 . . . . 0.0 110.659 -176.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 30.1 m -80.31 123.38 27.94 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 123.691 0.619 . . . . 0.0 111.398 174.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 67.6 m -111.62 -175.93 2.82 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 175.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.02 -17.61 53.19 Favored 'General case' 0 N--CA 1.504 2.229 0 C-N-CA 122.84 0.456 . . . . 0.0 111.843 -173.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -55.97 -35.56 66.87 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 124.441 1.096 . . . . 0.0 111.053 177.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 87.09 17.07 59.88 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 -173.274 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -137.07 165.74 25.33 Favored 'General case' 0 N--CA 1.422 -1.832 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.0 m95 -77.16 140.64 40.24 Favored 'General case' 0 N--CA 1.422 -1.832 0 O-C-N 123.755 0.659 . . . . 0.0 109.279 178.182 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.3 m -81.16 -6.0 58.35 Favored 'General case' 0 C--N 1.296 -1.752 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.504 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 17.2 tppt? -136.9 161.63 35.49 Favored 'General case' 0 N--CA 1.427 -1.611 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -104.25 178.08 4.66 Favored 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 117.554 0.161 . . . . 0.0 110.771 -177.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 5.4 tppp? -64.11 117.36 35.57 Favored Pre-proline 0 C--O 1.243 0.723 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 177.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -76.96 -169.06 0.66 Allowed 'Trans proline' 0 N--CA 1.446 -1.265 0 C-N-CA 122.107 1.872 . . . . 0.0 110.651 176.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . 0.429 ' HG2' ' N ' ' A' ' 205' ' ' CYS . 46.5 tttm -131.14 160.26 35.25 Favored 'General case' 0 N--CA 1.42 -1.972 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -177.111 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.429 ' N ' ' HG2' ' A' ' 204' ' ' LYS . 9.4 t -110.88 129.68 55.8 Favored 'General case' 0 N--CA 1.423 -1.789 0 N-CA-C 105.697 -1.964 . . . . 0.0 105.697 176.261 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 11.0 m . . . . . 0 C--N 1.301 -1.535 0 CA-C-O 118.491 -0.766 . . . . 0.0 111.578 -174.657 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo . . . . . 0 N--CA 1.483 0.907 0 CA-C-O 121.581 0.576 . . . . 0.0 112.658 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 59.6 m -71.63 -24.71 61.92 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.787 -178.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 96.43 14.72 43.43 Favored Glycine 0 C--N 1.302 -1.359 0 CA-C-N 115.444 -0.798 . . . . 0.0 114.808 171.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 59.2 t-80 69.23 115.39 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.764 0 C-N-CA 123.96 0.904 . . . . 0.0 109.835 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.402 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 42.7 Cg_endo -67.48 -42.25 7.51 Favored 'Trans proline' 0 C--O 1.221 -0.358 0 C-N-CA 122.141 1.894 . . . . 0.0 112.644 -174.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 136.07 174.64 13.45 Favored Glycine 0 N--CA 1.422 -2.286 0 N-CA-C 107.592 -2.203 . . . . 0.0 107.592 -177.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 48.1 t0 -134.32 169.02 17.83 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 -177.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.0 t -131.56 126.43 21.09 Favored Pre-proline 0 C--N 1.285 -2.197 0 CA-C-N 117.897 0.317 . . . . 0.0 110.927 -177.228 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -69.72 -11.39 30.8 Favored 'Trans proline' 0 N--CA 1.48 0.724 0 C-N-CA 122.888 2.392 . . . . 0.0 111.477 177.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -91.84 4.12 53.59 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.06 -178.425 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.596 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.9 -131.36 1.95 Allowed Glycine 0 N--CA 1.401 -3.691 0 C-N-CA 119.637 -1.268 . . . . 0.0 112.475 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.7 p -153.83 -179.17 7.58 Favored 'General case' 0 C--N 1.287 -2.113 0 C-N-CA 124.4 1.08 . . . . 0.0 109.708 -177.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 33.5 p90 -145.68 160.34 41.84 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 172.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.3 m -125.4 159.93 30.64 Favored 'General case' 0 C--N 1.283 -2.3 0 N-CA-C 107.111 -1.441 . . . . 0.0 107.111 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 16.7 mt -116.97 115.82 26.19 Favored 'General case' 0 C--N 1.273 -2.733 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.527 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 31.9 p -106.76 133.04 52.04 Favored 'General case' 0 C--N 1.271 -2.843 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.257 -173.719 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 108.04 -67.67 0.23 Allowed Glycine 0 N--CA 1.429 -1.828 0 N-CA-C 110.611 -0.995 . . . . 0.0 110.611 -179.159 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.425 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -106.58 -14.83 18.74 Favored Glycine 0 C--N 1.309 -0.926 0 C-N-CA 120.492 -0.861 . . . . 0.0 112.784 -176.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 59.81 19.09 7.94 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 124.206 1.002 . . . . 0.0 112.787 -178.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.457 ' O ' HG11 ' A' ' 108' ' ' VAL . 27.8 m -150.24 -172.19 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 -177.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -100.47 41.37 1.18 Allowed 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 118.642 0.655 . . . . 0.0 111.164 -176.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.706 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.9 pt-20 -85.64 179.94 7.0 Favored 'General case' 0 C--O 1.207 -1.145 0 C-N-CA 123.971 0.908 . . . . 0.0 112.577 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 43.5 m-85 -75.13 132.7 41.39 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.808 -0.557 . . . . 0.0 111.128 176.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.06 -5.42 63.38 Favored Glycine 0 N--CA 1.438 -1.206 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.681 178.064 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.706 HG12 ' O ' ' A' ' 105' ' ' GLU . 13.7 p -85.27 145.66 7.63 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.527 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 19.0 mtpp -111.55 113.96 26.71 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -81.4 94.23 6.76 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 177.255 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.465 HG12 ' CB ' ' A' ' 126' ' ' TYR . 33.0 m -92.19 120.11 40.83 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.193 0 CA-C-O 121.969 0.89 . . . . 0.0 108.897 -177.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -87.79 138.58 31.34 Favored 'General case' 0 C--N 1.262 -3.199 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.794 -177.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.0 t -137.36 110.23 7.65 Favored 'General case' 0 N--CA 1.407 -2.61 0 CA-C-O 122.381 1.086 . . . . 0.0 109.214 -179.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.454 ' HA ' ' HA3' ' A' ' 94' ' ' GLY . 15.8 m -67.87 159.24 30.84 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.473 -1.239 . . . . 0.0 110.465 -177.145 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.596 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 92.0 m-20 -77.26 -179.11 5.46 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 120.746 0.308 . . . . 0.0 111.322 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -46.58 -52.51 13.37 Favored 'General case' 0 C--N 1.31 -1.138 0 C-N-CA 126.266 1.826 . . . . 0.0 114.428 -177.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -82.19 6.25 68.5 Favored Glycine 0 C--N 1.315 -0.589 0 C-N-CA 120.543 -0.837 . . . . 0.0 113.178 -176.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 91.1 m-85 -128.19 166.96 17.53 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -176.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -145.35 165.73 27.62 Favored 'General case' 0 C--N 1.283 -2.312 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 176.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -83.07 123.68 29.73 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -178.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -106.85 126.31 52.14 Favored 'General case' 0 N--CA 1.416 -2.151 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 178.113 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 110.9 174.6 20.21 Favored Glycine 0 C--N 1.299 -1.486 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -176.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -85.6 -44.02 12.99 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 -178.114 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.7 mm -72.08 125.15 30.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.596 0 CA-C-N 114.175 -1.375 . . . . 0.0 110.39 -177.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -125.4 5.06 7.67 Favored 'General case' 0 C--O 1.202 -1.398 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 175.123 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.465 ' CB ' HG12 ' A' ' 111' ' ' VAL . 15.7 p90 -143.27 163.06 34.02 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.288 -171.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 50.9 mtp180 -126.96 130.51 50.22 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 174.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -106.14 130.25 54.06 Favored 'General case' 0 C--N 1.29 -2.0 0 C-N-CA 119.707 -0.797 . . . . 0.0 108.978 -179.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 26.5 t -84.31 108.51 17.2 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 119.668 -0.813 . . . . 0.0 110.466 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.426 ' OD1' HG22 ' A' ' 131' ' ' THR . 6.5 t70 -107.98 -167.22 1.22 Allowed 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.38 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.426 HG22 ' OD1' ' A' ' 130' ' ' ASP . 12.4 t -74.53 -12.61 60.52 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-O 121.861 0.838 . . . . 0.0 109.646 -178.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -86.46 -8.93 57.2 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.96 175.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 100.95 -153.56 19.14 Favored Glycine 0 N--CA 1.427 -1.963 0 N-CA-C 108.63 -1.788 . . . . 0.0 108.63 -175.614 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.402 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 95.2 m95 -67.33 111.25 3.92 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 117.565 0.683 . . . . 0.0 110.003 175.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 33.3 p -54.25 -58.88 5.72 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 124.877 1.271 . . . . 0.0 112.551 -176.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 87.2 m-20 -92.98 -175.62 3.93 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.449 179.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -117.19 177.96 4.53 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.2 mt -57.39 118.79 27.29 Favored Pre-proline 0 C--N 1.286 -2.189 0 C-N-CA 125.65 1.58 . . . . 0.0 109.343 177.078 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -73.24 -177.58 3.07 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.901 2.4 . . . . 0.0 111.914 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 67.1 mt -105.32 133.18 50.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-O 120.903 0.382 . . . . 0.0 111.716 -172.065 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 90.6 m -111.4 91.15 3.55 Favored 'General case' 0 C--N 1.297 -1.682 0 CA-C-O 121.693 0.758 . . . . 0.0 109.039 174.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -86.85 148.54 25.33 Favored 'General case' 0 N--CA 1.424 -1.77 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 -177.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.8 p -70.07 137.51 23.9 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 177.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 95.4 t -64.62 126.01 22.61 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -115.44 143.98 44.5 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.033 -176.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -120.75 159.59 25.09 Favored 'General case' 0 C--N 1.281 -2.41 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.147 177.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -68.46 147.08 98.11 Favored Pre-proline 0 N--CA 1.421 -1.899 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -175.126 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -71.93 116.42 4.7 Favored 'Trans proline' 0 N--CA 1.442 -1.522 0 C-N-CA 122.701 2.268 . . . . 0.0 110.546 178.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.445 HG21 ' SD ' ' A' ' 190' ' ' MET . 60.1 t -74.81 144.46 12.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.319 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.4 p -66.57 -84.85 0.02 OUTLIER 'General case' 0 N--CA 1.438 -1.026 0 O-C-N 123.379 0.424 . . . . 0.0 111.629 177.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 168.01 162.58 0.15 Allowed Pre-proline 0 CA--C 1.513 -0.46 0 C-N-CA 126.106 1.763 . . . . 0.0 106.463 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -76.54 168.3 23.98 Favored 'Trans proline' 0 N--CA 1.446 -1.313 0 C-N-CA 121.324 1.349 . . . . 0.0 110.001 171.267 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -60.02 -50.9 71.92 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 113.862 1.06 . . . . 0.0 113.862 -176.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 55.0 m-80 -110.67 32.61 5.09 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.563 0.696 . . . . 0.0 109.791 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -149.15 -176.79 22.73 Favored Glycine 0 N--CA 1.425 -2.081 0 C-N-CA 120.219 -0.991 . . . . 0.0 111.384 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.0 ptmt -144.45 169.37 18.07 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -178.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.528 HG12 ' CD2' ' A' ' 176' ' ' PHE . 51.6 mt -98.47 137.45 25.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.478 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.8 m -84.5 -28.02 6.92 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 CA-C-O 121.986 0.898 . . . . 0.0 108.701 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.517 ' H ' HG22 ' A' ' 157' ' ' ILE . 12.9 m -91.34 14.95 13.11 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 114.704 -1.135 . . . . 0.0 112.496 -176.303 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . 0.436 ' OG ' ' HB ' ' A' ' 157' ' ' ILE . 70.6 m -89.31 -78.09 0.36 Allowed 'General case' 0 C--N 1.313 -0.997 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.48 178.104 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -80.89 89.68 5.87 Favored 'General case' 0 N--CA 1.434 -1.243 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.383 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 53.4 mtm -118.68 -49.44 2.44 Favored 'General case' 0 C--N 1.283 -2.283 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 174.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 69.6 mm-40 -157.94 147.45 15.07 Favored Pre-proline 0 C--N 1.316 -0.886 0 N-CA-C 105.176 -2.157 . . . . 0.0 105.176 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -79.63 -11.54 14.1 Favored 'Trans proline' 0 CA--C 1.545 1.072 0 C-N-CA 122.298 1.999 . . . . 0.0 113.419 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 29.8 m-20 -96.27 -16.32 21.44 Favored 'General case' 0 CA--C 1.496 -1.119 0 CA-C-O 120.969 0.414 . . . . 0.0 110.602 -177.141 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 29.2 mmm180 -77.53 107.55 10.06 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.776 -176.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . 0.469 ' HB2' ' NE2' ' A' ' 169' ' ' HIS . 32.6 mt-10 -87.24 164.52 16.28 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 177.118 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 69.7 m-85 -83.33 110.05 17.79 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.682 0.753 . . . . 0.0 109.563 176.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.469 ' NE2' ' HB2' ' A' ' 167' ' ' GLU . 46.8 m170 -115.29 163.51 15.58 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.744 -176.175 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 52.4 t80 -51.93 127.46 21.25 Favored 'General case' 0 C--O 1.245 0.843 0 O-C-N 124.134 0.896 . . . . 0.0 108.983 172.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 108.23 -22.81 26.4 Favored Glycine 0 N--CA 1.435 -1.422 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.306 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 30.1 mm-40 -71.67 144.67 49.28 Favored 'General case' 0 C--O 1.256 1.398 0 CA-C-N 117.185 0.492 . . . . 0.0 110.314 178.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -123.03 104.99 9.57 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.547 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 54.4 t -79.85 106.62 11.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.832 -178.023 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.478 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 25.9 ttp85 -98.62 143.45 29.0 Favored 'General case' 0 N--CA 1.41 -2.452 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.736 179.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.528 ' CD2' HG12 ' A' ' 157' ' ' ILE . 64.0 m-85 -112.85 165.75 12.02 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -178.107 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.7 p -146.73 138.25 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.291 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.5 m -92.67 148.28 22.19 Favored 'General case' 0 C--N 1.265 -3.101 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.391 -178.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -69.64 162.41 27.71 Favored 'General case' 0 CA--C 1.497 -1.063 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.664 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 16.3 m -52.08 109.44 0.38 Allowed 'General case' 0 C--N 1.303 -1.439 0 O-C-N 124.404 1.065 . . . . 0.0 112.368 -175.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.58 -9.17 30.36 Favored Glycine 0 N--CA 1.435 -1.385 0 CA-C-N 115.715 -0.675 . . . . 0.0 113.073 178.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -108.81 153.12 23.94 Favored 'General case' 0 CA--C 1.497 -1.059 0 CA-C-N 117.886 0.843 . . . . 0.0 110.886 -178.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 16.9 pttp -115.71 159.54 21.25 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 7.0 tp -74.36 146.19 10.23 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 176.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -91.46 -61.21 1.7 Allowed 'General case' 0 C--N 1.27 -2.876 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -90.99 -130.48 4.68 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 177.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -87.8 153.14 21.58 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 176.141 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -92.55 8.19 39.95 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 120.365 -0.534 . . . . 0.0 110.465 -177.088 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.547 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 2.0 pt-20 -155.94 143.76 19.64 Favored 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 121.123 0.487 . . . . 0.0 111.925 -179.505 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.445 ' SD ' HG21 ' A' ' 149' ' ' VAL . 13.9 ptp -125.65 138.28 53.9 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.01 -0.995 . . . . 0.0 109.336 176.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 50.1 t-80 -100.56 138.77 37.17 Favored 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 123.089 0.556 . . . . 0.0 110.045 -176.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 23.6 t -82.76 107.08 15.12 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 174.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 50.7 m -100.21 -178.59 3.87 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 114.046 1.128 . . . . 0.0 114.046 -171.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -49.17 -34.97 15.7 Favored 'General case' 0 N--CA 1.51 2.541 0 C-N-CA 125.908 1.683 . . . . 0.0 113.179 -174.153 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -81.8 -7.67 59.62 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 113.456 0.909 . . . . 0.0 113.456 -176.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 83.42 10.19 82.39 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.15 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -112.96 169.76 8.69 Favored 'General case' 0 N--CA 1.427 -1.599 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 177.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.3 m95 -83.66 134.99 34.76 Favored 'General case' 0 N--CA 1.417 -2.087 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.24 178.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 35.9 p -63.38 -32.26 73.64 Favored 'General case' 0 C--O 1.249 1.063 0 CA-C-O 121.523 0.677 . . . . 0.0 112.229 -177.575 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 26.3 mmtp -116.49 157.08 25.76 Favored 'General case' 0 CA--C 1.483 -1.601 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.352 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.438 ' H ' ' CD ' ' A' ' 201' ' ' GLU . 0.3 OUTLIER -86.43 172.13 10.61 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.684 179.813 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 7.6 mmmm -55.13 119.9 26.13 Favored Pre-proline 0 C--N 1.321 -0.634 0 O-C-N 123.697 0.623 . . . . 0.0 111.786 178.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -86.5 -173.44 1.21 Allowed 'Trans proline' 0 N--CA 1.424 -2.589 0 C-N-CA 122.061 1.841 . . . . 0.0 109.987 178.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 24.5 ttmm -148.08 164.41 33.93 Favored 'General case' 0 C--N 1.278 -2.506 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 -176.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.549 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 98.4 m -126.06 116.04 20.79 Favored 'General case' 0 C--N 1.297 -1.713 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 174.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--N 1.3 -1.574 0 O-C-N 124.416 1.072 . . . . 0.0 109.747 -175.392 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo . . . . . 0 N--CA 1.477 0.528 0 CA-C-O 121.313 0.464 . . . . 0.0 112.159 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.6 m -84.25 -29.97 26.05 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 178.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.37 -98.1 0.74 Allowed Glycine 0 N--CA 1.398 -3.891 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.919 171.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -177.08 110.75 0.23 Allowed Pre-proline 0 C--N 1.258 -3.407 0 N-CA-C 105.759 -1.941 . . . . 0.0 105.759 -176.075 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.451 ' HD3' ' CZ2' ' A' ' 134' ' ' TRP . 45.0 Cg_endo -64.76 -30.82 59.04 Favored 'Trans proline' 0 N--CA 1.474 0.334 0 C-N-CA 122.92 2.414 . . . . 0.0 112.963 -171.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.95 -174.39 19.13 Favored Glycine 0 N--CA 1.419 -2.483 0 N-CA-C 108.481 -1.848 . . . . 0.0 108.481 -176.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -142.57 164.64 29.56 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 107.815 -1.179 . . . . 0.0 107.815 -176.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.4 t -125.05 127.31 25.1 Favored Pre-proline 0 C--N 1.295 -1.769 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 -178.478 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -68.64 -22.38 37.91 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.483 2.122 . . . . 0.0 110.667 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -81.24 -1.64 45.72 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.219 -1.355 . . . . 0.0 111.984 -175.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.43 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 177.38 -130.66 1.66 Allowed Glycine 0 N--CA 1.414 -2.791 0 C-N-CA 119.695 -1.241 . . . . 0.0 111.84 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 24.4 p -146.59 179.16 7.75 Favored 'General case' 0 C--N 1.285 -2.225 0 O-C-N 124.119 0.541 . . . . 0.0 110.096 -178.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -143.07 155.28 44.58 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 171.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.5 m -121.24 163.65 18.2 Favored 'General case' 0 C--N 1.279 -2.482 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.584 ' HA ' ' O ' ' A' ' 109' ' ' LYS . 32.0 mt -120.82 124.0 43.97 Favored 'General case' 0 C--N 1.277 -2.561 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.236 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.65 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 34.1 p -115.93 125.56 52.73 Favored 'General case' 0 C--N 1.285 -2.235 0 O-C-N 123.625 0.578 . . . . 0.0 110.793 -175.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 99.95 11.76 42.13 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.828 178.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -178.91 -28.76 0.05 OUTLIER Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 119.371 -1.395 . . . . 0.0 113.813 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 69.6 10.88 7.81 Favored 'General case' 0 N--CA 1.5 2.073 0 CA-C-O 122.674 1.226 . . . . 0.0 110.599 -177.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.438 ' O ' HG11 ' A' ' 108' ' ' VAL . 35.9 m -143.72 -169.79 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 114.684 -1.144 . . . . 0.0 107.937 -174.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 36.4 m-85 -110.87 43.9 1.36 Allowed 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.489 0.662 . . . . 0.0 110.567 -175.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.721 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.1 pt-20 -86.23 -176.58 5.97 Favored 'General case' 0 C--O 1.207 -1.165 0 CA-C-N 114.445 -1.252 . . . . 0.0 112.474 177.388 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.2 m-85 -78.82 131.99 36.69 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 122.021 -0.425 . . . . 0.0 111.467 178.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.48 5.33 61.82 Favored Glycine 0 N--CA 1.438 -1.214 0 CA-C-N 115.661 -0.7 . . . . 0.0 112.659 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.721 HG12 ' O ' ' A' ' 105' ' ' GLU . 9.9 p -101.75 148.66 7.23 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.342 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.65 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 89.2 mttt -108.83 138.89 44.44 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 176.042 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -97.14 86.55 3.97 Favored 'General case' 0 C--N 1.264 -3.12 0 N-CA-C 105.515 -2.031 . . . . 0.0 105.515 169.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.484 HG12 ' CB ' ' A' ' 126' ' ' TYR . 21.2 m -85.61 118.17 31.85 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 -177.066 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 32.4 m-85 -88.04 141.04 28.88 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.725 -0.609 . . . . 0.0 111.22 -175.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -139.36 114.36 9.49 Favored 'General case' 0 N--CA 1.412 -2.352 0 CA-C-O 122.129 0.966 . . . . 0.0 108.777 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 10.5 m -73.43 159.6 33.0 Favored 'General case' 0 C--N 1.289 -2.064 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.976 -175.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.43 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 68.6 m-20 -69.18 179.1 2.05 Favored 'General case' 0 C--O 1.216 -0.683 0 C-N-CA 123.023 0.529 . . . . 0.0 111.299 178.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -55.73 -46.57 77.74 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.556 0.742 . . . . 0.0 112.072 -178.199 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -81.92 7.8 61.88 Favored Glycine 0 C--N 1.308 -1.014 0 CA-C-N 115.839 -0.619 . . . . 0.0 113.95 -177.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -129.98 152.3 49.6 Favored 'General case' 0 N--CA 1.426 -1.63 0 CA-C-O 121.495 0.664 . . . . 0.0 110.072 -178.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.44 158.43 36.04 Favored 'General case' 0 C--N 1.271 -2.824 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.3 tt -89.56 129.47 36.02 Favored 'General case' 0 C--N 1.272 -2.8 0 C-N-CA 119.116 -1.034 . . . . 0.0 108.552 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.64 128.18 55.98 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -175.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 116.06 173.48 17.21 Favored Glycine 0 C--N 1.294 -1.751 0 N-CA-C 109.956 -1.258 . . . . 0.0 109.956 -176.025 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -87.73 -35.72 17.76 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -179.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 47.4 mm -85.73 137.04 21.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.288 -176.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -123.93 2.46 8.72 Favored 'General case' 0 C--O 1.21 -0.998 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.307 -179.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.484 ' CB ' HG12 ' A' ' 111' ' ' VAL . 50.0 p90 -145.47 169.44 18.35 Favored 'General case' 0 C--N 1.297 -1.686 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 -170.523 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.452 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 54.9 mtp180 -126.17 115.52 19.91 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 170.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -91.91 124.22 35.87 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 119.749 -0.781 . . . . 0.0 109.426 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.8 t -83.93 104.03 13.68 Favored 'General case' 0 CA--C 1.498 -1.056 0 C-N-CA 118.819 -1.152 . . . . 0.0 108.858 176.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.45 ' OD1' HG22 ' A' ' 131' ' ' THR . 7.9 t70 -99.53 -171.07 2.0 Allowed 'General case' 0 C--N 1.288 -2.103 0 N-CA-C 106.012 -1.847 . . . . 0.0 106.012 178.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.45 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.3 t -61.42 -14.77 30.77 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 124.408 1.083 . . . . 0.0 112.508 -174.346 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -98.52 -15.34 19.59 Favored 'General case' 0 C--N 1.315 -0.913 0 O-C-N 121.757 -0.59 . . . . 0.0 110.637 178.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 124.18 -161.09 18.7 Favored Glycine 0 C--N 1.305 -1.188 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 -177.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.451 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 89.3 m95 -64.91 101.3 0.48 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.889 0.345 . . . . 0.0 110.173 176.77 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.5 p -58.31 -57.19 14.0 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 124.105 0.962 . . . . 0.0 112.254 -176.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.452 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 3.5 m120 -81.36 177.53 8.92 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.19 -0.914 . . . . 0.0 109.321 -177.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -111.11 179.6 4.0 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 176.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 84.4 mt -72.53 117.95 63.46 Favored Pre-proline 0 C--N 1.317 -0.843 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -66.35 157.79 58.44 Favored 'Trans proline' 0 C--O 1.253 1.267 0 C-N-CA 122.513 2.142 . . . . 0.0 110.624 178.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 62.4 mt -92.24 129.48 42.79 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 CA-C-O 120.877 0.37 . . . . 0.0 110.722 -173.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 84.5 m -99.41 105.4 17.34 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 171.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -92.94 150.14 20.77 Favored 'General case' 0 N--CA 1.407 -2.601 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 -179.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 5.8 p -74.4 131.02 35.65 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.645 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 84.7 t -52.7 132.05 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 O-C-N 123.906 0.754 . . . . 0.0 110.89 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.429 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 85.0 mttt -106.32 153.91 21.52 Favored 'General case' 0 N--CA 1.433 -1.295 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.016 -176.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 58.9 m -124.03 165.06 18.12 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.639 -178.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . 0.553 HD23 ' HD2' ' A' ' 148' ' ' PRO . 0.5 OUTLIER -62.58 130.85 93.85 Favored Pre-proline 0 N--CA 1.426 -1.64 0 C-N-CA 125.154 1.382 . . . . 0.0 110.777 178.099 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.553 ' HD2' HD23 ' A' ' 147' ' ' LEU . 24.1 Cg_endo -65.91 110.26 1.67 Allowed 'Trans proline' 0 C--N 1.314 -1.244 0 C-N-CA 123.174 2.582 . . . . 0.0 111.635 175.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 7.8 p -86.59 143.94 10.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 38.9 p -82.49 -83.48 0.13 Allowed 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -177.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.3 161.74 0.46 Allowed Pre-proline 0 C--N 1.326 -0.429 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 -179.485 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . 0.481 ' HD3' ' CD2' ' A' ' 176' ' ' PHE . 43.5 Cg_endo -73.51 -169.39 0.53 Allowed 'Trans proline' 0 CA--C 1.546 1.125 0 C-N-CA 121.654 1.569 . . . . 0.0 111.27 172.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . 0.6 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.2 OUTLIER -88.44 -37.2 16.02 Favored 'General case' 0 C--N 1.287 -2.131 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -174.899 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . 0.6 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 49.8 m-80 -120.86 22.82 10.98 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 122.074 0.94 . . . . 0.0 109.827 179.345 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . 0.411 ' HA3' ' SG ' ' A' ' 205' ' ' CYS . . . -146.49 178.97 23.81 Favored Glycine 0 N--CA 1.425 -2.041 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.431 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . 0.448 ' HG3' HG23 ' A' ' 177' ' ' VAL . 21.9 pttm -145.62 -176.66 5.22 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -178.093 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.444 HG22 ' N ' ' A' ' 159' ' ' SER . 64.4 mt -95.56 141.2 15.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 C-N-CA 122.505 0.322 . . . . 0.0 110.703 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.573 HG12 HG22 ' A' ' 177' ' ' VAL . 2.3 m -79.91 -35.39 16.11 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.461 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 177.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.444 ' N ' HG22 ' A' ' 157' ' ' ILE . 5.3 m -79.74 31.98 0.25 Allowed 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 125.429 1.492 . . . . 0.0 111.375 -174.435 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 19.7 m -82.41 76.13 9.29 Favored 'General case' 0 N--CA 1.435 -1.206 0 CA-C-O 121.688 0.756 . . . . 0.0 112.363 -176.576 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -133.21 87.89 2.44 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 105.9 -1.889 . . . . 0.0 105.9 173.082 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -97.94 94.55 6.94 Favored 'General case' 0 N--CA 1.408 -2.566 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.494 -170.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.642 ' HB2' ' HG2' ' A' ' 166' ' ' ARG . 42.7 mt-10 -99.73 153.47 37.75 Favored Pre-proline 0 C--N 1.27 -2.877 0 N-CA-C 105.962 -1.866 . . . . 0.0 105.962 173.056 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -73.6 -6.0 17.99 Favored 'Trans proline' 0 N--CA 1.476 0.493 0 C-N-CA 122.307 2.005 . . . . 0.0 111.164 178.265 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -97.05 -30.82 12.83 Favored 'General case' 0 C--N 1.311 -1.075 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.642 ' HG2' ' HB2' ' A' ' 163' ' ' GLU . 28.8 mmt180 -93.6 89.03 6.08 Favored 'General case' 0 N--CA 1.43 -1.435 0 CA-C-N 114.782 -1.099 . . . . 0.0 109.298 -177.461 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . 0.485 ' HB2' ' NE2' ' A' ' 169' ' ' HIS . 27.2 mt-10 -88.4 171.61 10.0 Favored 'General case' 0 C--N 1.29 -1.988 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 174.364 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . 0.429 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 82.6 m-85 -72.0 106.09 4.15 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.489 -0.884 . . . . 0.0 108.711 175.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.485 ' NE2' ' HB2' ' A' ' 167' ' ' GLU . 49.7 m170 -117.83 161.06 20.35 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 114.928 -1.033 . . . . 0.0 109.691 -175.351 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 42.5 t80 -55.72 125.27 20.5 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 174.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 109.86 -14.13 31.87 Favored Glycine 0 N--CA 1.42 -2.398 0 C-N-CA 120.047 -1.073 . . . . 0.0 111.492 -177.101 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 87.1 mm-40 -86.71 139.38 30.81 Favored 'General case' 0 N--CA 1.433 -1.305 0 C-N-CA 119.533 -0.867 . . . . 0.0 109.822 176.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -120.59 116.14 24.77 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.616 178.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 88.1 t -90.29 106.04 16.88 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.059 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.517 ' HB3' HG22 ' A' ' 158' ' ' VAL . 46.1 ttm180 -104.65 142.47 34.61 Favored 'General case' 0 N--CA 1.405 -2.689 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.481 ' CD2' ' HD3' ' A' ' 152' ' ' PRO . 88.5 m-85 -108.81 157.44 18.58 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 121.431 0.634 . . . . 0.0 110.922 -175.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.573 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -130.69 133.12 63.82 Favored 'Isoleucine or valine' 0 CA--C 1.471 -2.078 0 CA-C-N 114.908 -1.042 . . . . 0.0 108.507 178.626 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 93.4 m -95.33 128.34 42.1 Favored 'General case' 0 C--N 1.259 -3.337 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 177.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 77.1 m-20 -60.09 160.09 8.62 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 114.95 -1.023 . . . . 0.0 111.419 -178.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 14.9 m -37.38 102.82 0.03 OUTLIER 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 126.484 1.914 . . . . 0.0 114.91 -174.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 111.66 -18.39 24.78 Favored Glycine 0 N--CA 1.441 -0.982 0 C-N-CA 120.998 -0.62 . . . . 0.0 113.066 177.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . 0.423 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 93.8 m-85 -96.12 156.0 16.52 Favored 'General case' 0 N--CA 1.434 -1.233 0 CA-C-N 117.094 0.447 . . . . 0.0 111.394 -177.352 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 25.8 pttm -123.18 155.15 37.64 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 179.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.3 tp -72.42 142.84 14.7 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.047 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.2 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -71.83 -71.24 0.28 Allowed 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.852 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -100.02 -105.86 2.73 Favored Glycine 0 N--CA 1.431 -1.665 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 179.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -99.34 163.28 12.6 Favored 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -105.88 0.8 26.24 Favored 'General case' 0 CA--C 1.499 -1.008 0 C-N-CA 119.351 -0.94 . . . . 0.0 111.249 -173.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -148.12 152.63 37.65 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 114.085 1.142 . . . . 0.0 114.085 -175.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.5 ptp -131.15 138.23 49.37 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.233 -1.349 . . . . 0.0 108.496 177.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 45.6 t-80 -123.42 137.42 54.81 Favored 'General case' 0 C--N 1.292 -1.902 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.448 -176.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 16.2 m -61.93 113.81 3.01 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.994 176.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 14.9 m -102.76 174.15 6.01 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.054 178.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -48.74 140.79 8.04 Favored 'General case' 0 N--CA 1.488 1.433 0 C-N-CA 123.833 0.853 . . . . 0.0 112.352 178.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 26.2 t70 76.47 -6.45 2.0 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 125.944 1.698 . . . . 0.0 111.937 178.128 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 93.04 50.94 2.35 Favored Glycine 0 N--CA 1.434 -1.499 0 C-N-CA 120.529 -0.844 . . . . 0.0 112.087 177.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 -116.7 141.61 47.98 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 176.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 67.1 m95 -79.78 132.06 36.06 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 171.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.1 p -65.85 -20.34 66.2 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.245 0.545 . . . . 0.0 112.172 -179.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.543 ' HA ' ' HE3' ' A' ' 200' ' ' LYS . 0.0 OUTLIER -134.17 171.1 14.7 Favored 'General case' 0 N--CA 1.432 -1.355 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.597 178.43 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -108.57 170.25 8.14 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.492 -178.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 5.5 tppp? -56.06 114.87 8.34 Favored Pre-proline 0 C--O 1.233 0.237 0 O-C-N 124.047 0.842 . . . . 0.0 110.814 -178.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -80.76 -167.78 0.55 Allowed 'Trans proline' 0 N--CA 1.434 -2.0 0 C-N-CA 122.145 1.897 . . . . 0.0 110.625 176.753 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 5.0 ttmp? -146.38 160.31 42.23 Favored 'General case' 0 C--N 1.28 -2.422 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -174.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.423 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 87.0 m -117.41 105.93 12.66 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-O 121.518 0.675 . . . . 0.0 110.693 177.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 17.2 m . . . . . 0 N--CA 1.433 -1.314 0 CA-C-N 115.003 -0.998 . . . . 0.0 110.079 -176.2 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo . . . . . 0 CA--C 1.53 0.325 0 CA-C-O 121.565 0.569 . . . . 0.0 111.322 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 36.2 m -89.1 -42.16 11.87 Favored 'General case' 0 N--CA 1.426 -1.633 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 121.4 -86.0 0.39 Allowed Glycine 0 CA--C 1.472 -2.603 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 172.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -179.59 127.13 0.24 Allowed Pre-proline 0 C--N 1.274 -2.691 0 N-CA-C 104.078 -2.564 . . . . 0.0 104.078 -177.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.414 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 95.2 Cg_endo -77.58 4.85 5.64 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 C-N-CA 123.355 2.703 . . . . 0.0 115.584 -170.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.75 -168.86 12.91 Favored Glycine 0 C--N 1.287 -2.167 0 N-CA-C 107.688 -2.165 . . . . 0.0 107.688 -174.248 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -151.12 -175.42 5.15 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 118.439 1.119 . . . . 0.0 108.846 -176.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 t -155.33 125.85 3.41 Favored Pre-proline 0 N--CA 1.424 -1.739 0 CA-C-O 121.065 0.46 . . . . 0.0 111.395 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -78.73 -5.95 14.99 Favored 'Trans proline' 0 C--O 1.239 0.556 0 C-N-CA 123.088 2.526 . . . . 0.0 112.069 178.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.535 ' HB2' ' HB2' ' A' ' 141' ' ' CYS . 27.0 m-85 -99.46 1.28 43.96 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.325 -177.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.461 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.86 -136.59 3.52 Favored Glycine 0 N--CA 1.405 -3.385 0 C-N-CA 118.817 -1.659 . . . . 0.0 113.043 -178.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.9 p -146.37 -176.85 5.33 Favored 'General case' 0 C--N 1.283 -2.311 0 CA-C-N 114.655 -0.773 . . . . 0.0 110.795 -174.041 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 44.6 p90 -146.58 161.53 40.31 Favored 'General case' 0 N--CA 1.431 -1.422 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 171.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.7 m -131.81 154.51 49.04 Favored 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 179.546 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.507 ' HB2' ' HA ' ' A' ' 102' ' ' ASN . 16.1 mt -110.07 127.68 54.99 Favored 'General case' 0 C--N 1.272 -2.78 0 CA-C-O 120.995 0.426 . . . . 0.0 110.064 -177.039 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.491 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 24.1 p -120.45 132.94 55.45 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.136 -177.613 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.44 19.34 32.86 Favored Glycine 0 C--N 1.307 -1.065 0 C-N-CA 120.599 -0.81 . . . . 0.0 111.809 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 167.92 -27.04 0.14 Allowed Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.612 178.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . 0.507 ' HA ' ' HB2' ' A' ' 98' ' ' LEU . 7.5 t30 61.28 20.07 10.71 Favored 'General case' 0 CA--C 1.56 1.338 0 CA-C-O 122.699 1.238 . . . . 0.0 110.519 -178.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.546 ' O ' HG11 ' A' ' 108' ' ' VAL . 31.1 m -144.55 -170.57 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.207 -1.164 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 -179.035 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -106.53 45.19 0.99 Allowed 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 118.394 0.543 . . . . 0.0 110.392 -178.157 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.717 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.4 pt-20 -90.43 -177.97 5.21 Favored 'General case' 0 C--O 1.207 -1.143 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.769 177.483 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 46.9 m-85 -77.61 133.24 38.48 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.859 -0.526 . . . . 0.0 111.456 178.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.84 0.12 64.33 Favored Glycine 0 N--CA 1.437 -1.256 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.895 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.717 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.7 p -94.22 145.71 7.61 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.491 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 15.1 mtpp -109.94 124.39 51.31 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.65 91.13 8.63 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 176.094 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 62.5 t -88.63 112.24 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.962 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -177.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -81.39 134.9 35.62 Favored 'General case' 0 C--N 1.284 -2.241 0 CA-C-O 121.19 0.519 . . . . 0.0 111.681 -178.627 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.1 t -132.55 104.91 6.92 Favored 'General case' 0 N--CA 1.421 -1.916 0 CA-C-O 122.157 0.979 . . . . 0.0 109.16 -178.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 13.4 m -66.83 157.98 31.62 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.62 -1.173 . . . . 0.0 110.826 -178.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.461 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 95.4 m-20 -75.55 178.44 5.99 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.748 -0.206 . . . . 0.0 111.548 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -45.7 -54.63 7.54 Favored 'General case' 0 N--CA 1.472 0.661 0 C-N-CA 124.945 1.298 . . . . 0.0 113.324 -177.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.497 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -85.16 25.94 5.85 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 120.3 -0.953 . . . . 0.0 113.626 -176.357 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.67 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 81.1 m-85 -145.98 154.89 42.4 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 117.321 0.56 . . . . 0.0 110.092 -176.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.03 161.84 33.3 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 176.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -82.28 115.4 21.33 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 -178.384 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -98.31 129.74 45.0 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 179.461 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 121.35 166.74 13.03 Favored Glycine 0 C--N 1.29 -1.99 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -177.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.0 mt-10 -88.99 -21.3 23.57 Favored 'General case' 0 C--N 1.295 -1.799 0 CA-C-O 121.955 0.883 . . . . 0.0 109.306 -177.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.481 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.5 mm -107.76 131.21 58.64 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.804 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.815 -178.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -123.57 11.5 9.21 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -177.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.471 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 15.5 p90 -152.03 161.42 42.67 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -175.24 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.414 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 62.9 mtp180 -126.43 129.02 47.9 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 172.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -105.87 132.19 52.27 Favored 'General case' 0 C--N 1.279 -2.492 0 C-N-CA 119.101 -1.039 . . . . 0.0 109.461 -178.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.1 t -82.11 101.8 10.64 Favored 'General case' 0 C--N 1.293 -1.876 0 C-N-CA 118.219 -1.392 . . . . 0.0 109.927 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.555 ' OD2' HG22 ' A' ' 131' ' ' THR . 13.3 t70 -101.83 -171.35 1.96 Allowed 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.555 HG22 ' OD2' ' A' ' 130' ' ' ASP . 8.8 t -54.93 -31.99 60.84 Favored 'General case' 0 CA--C 1.56 1.331 0 C-N-CA 124.182 0.993 . . . . 0.0 112.805 -175.47 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -85.72 -15.36 42.45 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.908 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 122.98 -159.89 17.55 Favored Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -176.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.0 m95 -62.23 112.17 2.28 Favored 'General case' 0 C--O 1.248 0.983 0 CA-C-N 117.173 0.486 . . . . 0.0 110.39 177.051 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 68.4 p -71.08 162.82 28.78 Favored 'General case' 0 C--O 1.266 1.932 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 178.086 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 65.6 -171.16 0.19 Allowed 'General case' 0 CA--C 1.509 -0.629 0 O-C-N 124.209 0.943 . . . . 0.0 111.451 174.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -108.51 171.79 7.21 Favored 'General case' 0 C--N 1.295 -1.804 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.566 177.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 66.2 mt -67.68 118.5 58.05 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 171.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.481 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 35.0 Cg_endo -66.2 159.06 51.58 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 122.056 1.837 . . . . 0.0 111.114 178.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 74.5 mt -109.39 134.59 50.95 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 C-N-CA 120.68 -0.408 . . . . 0.0 109.953 -171.303 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.535 ' HB2' ' HB2' ' A' ' 93' ' ' PHE . 94.9 m -102.96 110.73 22.76 Favored 'General case' 0 C--N 1.277 -2.57 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 175.144 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.86 152.17 20.04 Favored 'General case' 0 CA--C 1.462 -2.41 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 177.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.67 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 2.8 t -69.12 142.2 16.42 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.044 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.546 -177.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.689 HG23 ' HB2' ' A' ' 170' ' ' PHE . 10.4 m -66.82 122.52 18.01 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.795 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 178.072 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.465 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 49.7 mtmt -121.81 127.18 50.28 Favored 'General case' 0 N--CA 1.408 -2.565 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.923 -172.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 60.8 m -84.2 153.68 23.5 Favored 'General case' 0 C--N 1.28 -2.436 0 CA-C-N 113.981 -1.463 . . . . 0.0 108.504 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . 0.402 ' HB2' ' HD2' ' A' ' 148' ' ' PRO . 3.6 pp -67.52 160.72 70.74 Favored Pre-proline 0 CA--C 1.553 1.075 0 O-C-N 123.236 0.335 . . . . 0.0 110.229 -178.075 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.433 ' HA ' ' CE2' ' A' ' 168' ' ' TYR . 39.4 Cg_endo -74.28 123.21 8.08 Favored 'Trans proline' 0 N--CA 1.446 -1.297 0 C-N-CA 122.499 2.133 . . . . 0.0 112.348 -175.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.648 HG12 ' O ' ' A' ' 150' ' ' THR . 62.0 t -75.07 137.68 22.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-N 115.311 -0.859 . . . . 0.0 109.977 -178.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . 0.648 ' O ' HG12 ' A' ' 149' ' ' VAL . 25.4 p -95.95 -158.01 0.62 Allowed 'General case' 0 N--CA 1.417 -2.105 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 172.183 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -127.38 151.39 74.73 Favored Pre-proline 0 C--N 1.274 -2.682 0 O-C-N 120.406 -1.434 . . . . 0.0 110.352 -171.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -68.76 161.44 45.42 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.615 1.543 . . . . 0.0 112.259 177.23 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -60.04 -43.64 95.22 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 -174.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 57.6 m-80 -117.49 29.36 7.91 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -148.31 -167.21 13.4 Favored Glycine 0 N--CA 1.435 -1.42 0 C-N-CA 119.989 -1.101 . . . . 0.0 112.081 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -154.85 177.14 11.62 Favored 'General case' 0 N--CA 1.43 -1.469 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.434 HD11 ' O ' ' A' ' 150' ' ' THR . 58.9 mt -88.75 129.7 39.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 CA-C-O 120.833 0.349 . . . . 0.0 110.713 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.414 ' CG2' ' HB ' ' A' ' 177' ' ' VAL . 34.9 t -64.34 -35.61 74.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.555 0 C-N-CA 123.902 0.881 . . . . 0.0 109.947 178.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 37.3 t -79.89 65.93 5.21 Favored 'General case' 0 N--CA 1.43 -1.472 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 173.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 20.7 m -69.8 -27.19 64.69 Favored 'General case' 0 N--CA 1.43 -1.451 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.72 179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -71.56 98.79 1.93 Allowed 'General case' 0 N--CA 1.432 -1.368 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 171.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 36.0 tpp -154.21 89.54 1.29 Allowed 'General case' 0 N--CA 1.416 -2.136 0 CA-C-N 115.124 -0.944 . . . . 0.0 108.997 -173.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.488 ' HG2' ' HG3' ' A' ' 166' ' ' ARG . 0.6 OUTLIER -84.57 134.31 42.6 Favored Pre-proline 0 C--N 1.278 -2.503 0 CA-C-N 114.11 -1.405 . . . . 0.0 109.315 176.745 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -73.72 20.66 0.38 Allowed 'Trans proline' 0 N--CA 1.486 1.085 0 C-N-CA 123.962 3.108 . . . . 0.0 114.494 -171.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 29.8 m-20 -106.48 -23.09 12.6 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-O 121.172 0.51 . . . . 0.0 110.186 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.496 ' HD3' ' O ' ' A' ' 166' ' ' ARG . 0.0 OUTLIER -99.89 114.12 27.13 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-O 121.743 0.782 . . . . 0.0 111.952 -179.969 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 37.8 mt-10 -74.78 156.63 36.33 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.288 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . 0.465 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 99.6 m-85 -78.15 101.64 7.14 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -97.4 160.23 14.45 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -177.337 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.689 ' HB2' HG23 ' A' ' 144' ' ' VAL . 53.6 t80 -54.83 111.66 0.87 Allowed 'General case' 0 C--O 1.241 0.62 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 171.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 137.55 -12.82 3.73 Favored Glycine 0 N--CA 1.425 -2.064 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -173.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 12.9 mm100 -82.98 143.97 30.29 Favored 'General case' 0 C--O 1.248 1.009 0 CA-C-O 121.436 0.636 . . . . 0.0 112.116 177.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -134.88 111.1 9.59 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 106.875 -1.528 . . . . 0.0 106.875 172.374 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 76.7 t -97.75 111.53 27.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 CA-C-O 120.983 0.42 . . . . 0.0 110.083 -177.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 79.6 ttt180 -95.33 153.84 17.49 Favored 'General case' 0 N--CA 1.426 -1.644 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.05 178.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -125.49 153.56 43.37 Favored 'General case' 0 C--N 1.303 -1.448 0 C-N-CA 124.264 1.026 . . . . 0.0 109.458 -175.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.414 ' HB ' ' CG2' ' A' ' 158' ' ' VAL . 14.7 p -135.59 143.02 37.78 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 72.6 m -96.17 146.57 24.57 Favored 'General case' 0 C--N 1.272 -2.802 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.508 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 81.3 m-20 -87.71 168.38 13.03 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.762 -176.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 32.4 t 50.06 -113.2 0.63 Allowed 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 124.058 0.943 . . . . 0.0 113.357 178.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -118.87 23.83 8.61 Favored Glycine 0 N--CA 1.417 -2.577 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -79.87 158.12 26.81 Favored 'General case' 0 C--O 1.249 1.046 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.117 -176.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 20.9 ptmt -121.14 160.56 23.48 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 115.503 -0.771 . . . . 0.0 109.476 -178.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.427 HD11 ' CG ' ' A' ' 203' ' ' PRO . 3.6 tp -79.29 145.91 8.68 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.449 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 30.9 tt0 -69.61 -66.96 0.52 Allowed 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.617 178.484 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -115.69 -98.54 2.15 Favored Glycine 0 N--CA 1.433 -1.548 0 C-N-CA 120.442 -0.885 . . . . 0.0 111.364 -179.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -98.84 145.38 27.03 Favored 'General case' 0 CA--C 1.483 -1.604 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 -178.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.429 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 12.0 pt-20 -102.97 12.08 36.54 Favored 'General case' 0 C--N 1.287 -2.138 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.915 -175.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -149.05 132.51 16.65 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 121.555 0.693 . . . . 0.0 112.552 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.7 ptp -114.21 125.33 53.81 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.282 176.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 27.3 t-80 -103.85 148.33 26.26 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 -178.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 5.0 m -75.02 140.88 43.89 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 177.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 50.7 m -96.71 154.95 16.99 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 171.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -73.77 -2.67 24.42 Favored 'General case' 0 N--CA 1.491 1.593 0 CA-C-O 121.754 0.788 . . . . 0.0 110.882 -177.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -81.29 -10.43 59.58 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 114.919 -1.037 . . . . 0.0 109.827 178.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 94.48 26.51 13.41 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.769 -0.729 . . . . 0.0 113.514 178.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 19.5 p90 -147.78 173.44 12.8 Favored 'General case' 0 C--N 1.309 -1.155 0 O-C-N 122.263 -0.551 . . . . 0.0 110.376 177.424 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 92.9 m95 -83.05 145.15 29.45 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 123.433 0.458 . . . . 0.0 110.486 -179.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 6.7 m -82.91 -0.52 48.82 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.847 0.356 . . . . 0.0 111.336 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 15.7 tppt? -140.14 153.5 46.69 Favored 'General case' 0 N--CA 1.424 -1.731 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -177.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 21.2 mm-40 -87.87 155.04 20.06 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.68 175.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . 0.453 ' HB3' ' HE2' ' A' ' 202' ' ' LYS . 38.9 mtpt -59.95 126.67 84.08 Favored Pre-proline 0 N--CA 1.434 -1.261 0 O-C-N 123.731 0.645 . . . . 0.0 110.042 174.669 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.427 ' CG ' HD11 ' A' ' 184' ' ' ILE . 90.9 Cg_endo -82.93 -167.95 0.53 Allowed 'Trans proline' 0 N--CA 1.436 -1.901 0 C-N-CA 122.514 2.143 . . . . 0.0 110.66 177.313 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -132.25 170.47 15.0 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.478 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 89.2 m -120.42 112.67 19.28 Favored 'General case' 0 C--N 1.274 -2.689 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 172.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 28.2 m . . . . . 0 C--N 1.281 -2.375 0 CA-C-N 114.105 -1.407 . . . . 0.0 109.206 -172.216 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.461 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 32.7 Cg_endo . . . . . 0 CA--C 1.546 1.11 0 CA-C-O 120.902 0.293 . . . . 0.0 112.201 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . 0.619 ' HB3' ' NE1' ' A' ' 134' ' ' TRP . 0.9 OUTLIER -87.7 -16.79 33.31 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.37 0.605 . . . . 0.0 110.133 175.132 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 102.72 -93.8 1.09 Allowed Glycine 1 N--CA 1.391 -4.357 0 N-CA-C 108.748 -1.741 . . . . 0.0 108.748 174.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -170.38 132.06 0.96 Allowed Pre-proline 0 C--N 1.253 -3.628 0 N-CA-C 105.571 -2.011 . . . . 0.0 105.571 -175.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -73.27 -28.72 12.19 Favored 'Trans proline' 0 N--CA 1.477 0.512 0 C-N-CA 122.152 1.901 . . . . 0.0 113.481 -173.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 133.41 150.28 6.29 Favored Glycine 0 N--CA 1.425 -2.036 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -178.049 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -111.89 125.89 54.52 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -178.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.6 t -89.5 125.59 60.98 Favored Pre-proline 0 C--N 1.3 -1.557 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 178.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -70.1 -10.42 28.25 Favored 'Trans proline' 0 C--O 1.221 -0.371 0 C-N-CA 122.833 2.355 . . . . 0.0 111.911 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 43.5 m-85 -92.44 -2.55 56.21 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-O 121.398 0.618 . . . . 0.0 110.616 -178.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.509 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -178.71 -119.5 0.61 Allowed Glycine 0 N--CA 1.422 -2.294 0 C-N-CA 119.948 -1.12 . . . . 0.0 111.952 179.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.2 t -170.25 -162.55 0.3 Allowed 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.434 ' CB ' ' HA ' ' A' ' 112' ' ' TYR . 52.5 p90 -148.37 170.93 16.88 Favored 'General case' 0 C--N 1.311 -1.106 0 O-C-N 121.61 -0.681 . . . . 0.0 110.844 178.564 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -123.47 163.31 21.14 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 177.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.2 mt -121.99 129.42 52.46 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.41 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 32.6 p -122.84 124.63 43.71 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -176.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 92.99 30.18 9.68 Favored Glycine 0 C--N 1.298 -1.548 0 C-N-CA 120.325 -0.941 . . . . 0.0 111.185 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 167.25 -33.16 0.21 Allowed Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 119.464 -1.35 . . . . 0.0 113.417 176.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 65.46 14.79 9.68 Favored 'General case' 0 N--CA 1.489 1.507 0 C-N-CA 123.577 0.751 . . . . 0.0 112.995 -177.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.519 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.4 m -151.7 -168.89 0.11 Allowed 'Isoleucine or valine' 0 C--O 1.213 -0.85 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -177.43 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -106.52 38.14 2.14 Favored 'General case' 0 C--O 1.252 1.217 0 CA-C-N 118.737 0.699 . . . . 0.0 110.445 -175.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.673 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.1 pt-20 -78.49 178.74 7.52 Favored 'General case' 0 C--O 1.2 -1.521 0 CA-C-N 114.22 -1.354 . . . . 0.0 111.003 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . 0.678 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 23.7 m-85 -79.63 134.04 36.43 Favored 'General case' 0 C--N 1.29 -2.017 0 CA-C-O 120.958 0.408 . . . . 0.0 111.276 177.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.49 4.55 60.74 Favored Glycine 0 N--CA 1.44 -1.056 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.638 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.673 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.5 p -99.44 145.11 11.06 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 C-N-CA 120.425 -0.51 . . . . 0.0 109.876 -179.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.41 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 58.7 mtpt -108.1 125.09 51.18 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.609 176.661 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.82 94.06 9.65 Favored 'General case' 0 C--N 1.289 -2.055 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.334 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.459 HG12 ' HB3' ' A' ' 126' ' ' TYR . 32.8 m -94.07 116.12 34.55 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.188 0 CA-C-O 122.599 1.19 . . . . 0.0 108.434 -178.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . 0.434 ' HA ' ' CB ' ' A' ' 96' ' ' PHE . 13.4 m-85 -78.74 141.75 37.6 Favored 'General case' 0 C--N 1.267 -2.985 0 CA-C-N 115.085 -0.961 . . . . 0.0 112.667 -174.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.7 t -133.57 106.99 7.73 Favored 'General case' 0 N--CA 1.411 -2.386 0 CA-C-N 115.114 -0.948 . . . . 0.0 108.772 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 95.4 m -63.67 160.45 16.92 Favored 'General case' 0 C--N 1.296 -1.737 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.261 177.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.509 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 78.9 m-20 -74.35 -177.87 3.23 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.656 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -58.56 -45.29 89.3 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 123.58 0.752 . . . . 0.0 112.719 -174.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.36 24.13 6.63 Favored Glycine 0 C--O 1.212 -1.249 0 C-N-CA 120.747 -0.739 . . . . 0.0 113.302 179.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -147.82 169.93 18.71 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.99 -0.712 . . . . 0.0 109.952 -173.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -152.13 162.98 40.29 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 178.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -78.45 140.84 38.61 Favored 'General case' 0 C--N 1.288 -2.069 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.524 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.4 OUTLIER -119.24 126.52 51.71 Favored 'General case' 0 N--CA 1.409 -2.488 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.244 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.52 -170.24 14.27 Favored Glycine 0 C--N 1.289 -2.061 0 C-N-CA 120.69 -0.766 . . . . 0.0 111.607 -178.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -98.66 -38.81 8.97 Favored 'General case' 0 C--N 1.309 -1.195 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 -177.139 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.5 mm -78.62 120.48 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.716 0 CA-C-N 114.668 -1.151 . . . . 0.0 109.098 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -123.36 6.33 9.04 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.488 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 25.8 p90 -143.29 165.4 27.57 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -171.265 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 34.4 mtp180 -129.09 143.19 50.78 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 169.126 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -113.6 130.21 56.42 Favored 'General case' 0 C--N 1.287 -2.135 0 C-N-CA 119.426 -0.909 . . . . 0.0 109.895 -178.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . 0.678 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 37.8 t -80.35 90.39 5.58 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 176.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.482 ' OD2' HG22 ' A' ' 131' ' ' THR . 16.9 t70 -97.21 -170.62 2.05 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 179.017 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.482 HG22 ' OD2' ' A' ' 130' ' ' ASP . 15.1 t -59.03 -32.36 69.67 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 123.485 0.714 . . . . 0.0 112.875 -172.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -75.86 -34.09 60.03 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 121.488 0.661 . . . . 0.0 110.393 178.012 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.478 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 140.0 -153.91 23.57 Favored Glycine 0 N--CA 1.417 -2.602 0 N-CA-C 107.81 -2.116 . . . . 0.0 107.81 -174.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.619 ' NE1' ' HB3' ' A' ' 85' ' ' CYS . 98.3 m95 -65.86 116.61 7.21 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 117.655 0.728 . . . . 0.0 111.326 176.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 54.4 p -74.74 171.13 14.49 Favored 'General case' 0 C--O 1.269 2.119 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.036 176.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 87.0 m-20 59.05 -158.3 0.31 Allowed 'General case' 0 CA--C 1.515 -0.391 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -136.58 -179.48 5.71 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 172.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.9 mt -57.5 121.21 46.67 Favored Pre-proline 0 C--N 1.273 -2.721 0 C-N-CA 123.945 0.898 . . . . 0.0 108.595 175.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -63.49 169.68 9.35 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 122.663 2.242 . . . . 0.0 112.386 -179.231 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.524 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 52.8 mt -95.83 139.89 18.17 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.856 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -173.608 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 38.3 t -126.59 136.57 52.71 Favored 'General case' 0 C--N 1.276 -2.628 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -130.64 154.55 47.78 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -178.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 4.2 p -70.64 147.96 11.07 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.614 HG23 ' HB2' ' A' ' 170' ' ' PHE . 2.3 m -67.57 107.58 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.521 176.412 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 89.0 mttt -89.9 137.16 32.57 Favored 'General case' 0 N--CA 1.436 -1.168 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.72 -178.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.8 m -102.89 138.14 40.17 Favored 'General case' 0 C--N 1.282 -2.328 0 N-CA-C 106.111 -1.811 . . . . 0.0 106.111 179.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . 0.457 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.0 mm? -63.0 148.22 92.89 Favored Pre-proline 0 N--CA 1.433 -1.275 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -177.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 26.8 Cg_exo -61.2 121.84 10.25 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 122.911 2.408 . . . . 0.0 110.571 175.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.6 p -93.22 151.82 3.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.2 p -88.68 -177.16 5.49 Favored 'General case' 0 N--CA 1.431 -1.385 0 C-N-CA 120.9 -0.32 . . . . 0.0 110.291 175.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -108.79 158.94 32.77 Favored Pre-proline 0 C--N 1.294 -1.832 0 C-N-CA 122.415 0.286 . . . . 0.0 111.412 -171.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.78 157.39 61.43 Favored 'Trans proline' 0 C--N 1.362 1.247 0 C-N-CA 122.779 2.32 . . . . 0.0 111.292 175.252 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -59.02 -57.25 13.91 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 113.737 1.014 . . . . 0.0 113.737 -175.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 56.6 m-80 -102.5 36.56 2.13 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -178.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -150.91 -154.56 6.56 Favored Glycine 0 N--CA 1.413 -2.851 0 C-N-CA 120.403 -0.903 . . . . 0.0 111.399 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . 0.671 ' HG3' HG23 ' A' ' 177' ' ' VAL . 17.5 ptmt -163.84 -177.55 5.18 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 123.658 0.783 . . . . 0.0 109.002 -178.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 55.2 mt -100.22 135.8 34.43 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.502 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.6 m -82.5 -33.71 11.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.539 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 7.2 m -82.7 79.21 9.17 Favored 'General case' 0 N--CA 1.425 -1.696 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.356 -173.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 15.9 m -77.09 75.29 3.66 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.751 178.34 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -125.77 94.36 4.1 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 114.628 -1.169 . . . . 0.0 109.37 -179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 38.0 tpp -157.3 86.85 0.96 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 176.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.445 ' CG ' ' HB2' ' A' ' 166' ' ' ARG . 8.5 pt-20 -150.66 165.52 17.21 Favored Pre-proline 0 C--N 1.288 -2.071 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 -179.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . 0.439 ' HD2' ' HB2' ' A' ' 163' ' ' GLU . 3.0 Cg_endo -44.44 -28.73 2.75 Favored 'Trans proline' 0 N--CA 1.485 0.978 0 C-N-CA 124.67 3.58 . . . . 0.0 116.127 -177.805 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -108.47 -44.83 4.0 Favored 'General case' 0 C--N 1.311 -1.084 0 C-N-CA 119.219 -0.992 . . . . 0.0 110.396 -177.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.445 ' HB2' ' CG ' ' A' ' 163' ' ' GLU . 4.7 mmp_? -87.42 95.38 9.99 Favored 'General case' 0 N--CA 1.427 -1.597 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.237 -177.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . 0.462 ' HB2' ' NE2' ' A' ' 169' ' ' HIS . 27.7 mt-10 -110.97 -177.78 3.3 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 105.469 -2.048 . . . . 0.0 105.469 174.53 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 68.7 m-85 -86.15 105.33 16.48 Favored 'General case' 0 C--N 1.295 -1.791 0 CA-C-O 121.58 0.705 . . . . 0.0 109.269 175.833 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.462 ' NE2' ' HB2' ' A' ' 167' ' ' GLU . 30.5 m170 -114.36 160.1 19.5 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -178.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.614 ' HB2' HG23 ' A' ' 144' ' ' VAL . 0.6 OUTLIER -53.99 120.85 6.93 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 174.141 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 122.17 -23.92 7.13 Favored Glycine 0 N--CA 1.428 -1.86 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -177.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 15.6 mm100 -70.53 145.32 50.92 Favored 'General case' 0 C--O 1.256 1.423 0 CA-C-O 121.656 0.741 . . . . 0.0 110.783 178.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -116.01 112.59 22.02 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 173.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 8.4 p -95.64 112.91 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.316 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.502 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 79.5 ttt180 -110.61 143.68 40.67 Favored 'General case' 0 C--N 1.28 -2.417 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.005 -175.229 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -114.18 159.65 19.87 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.053 -174.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.671 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.0 OUTLIER -129.8 154.06 39.75 Favored 'Isoleucine or valine' 0 CA--C 1.469 -2.148 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.746 179.907 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 82.7 m -115.22 140.07 49.4 Favored 'General case' 0 N--CA 1.395 -3.19 0 CA-C-N 114.158 -1.383 . . . . 0.0 108.787 174.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -67.97 161.64 26.12 Favored 'General case' 0 C--N 1.294 -1.841 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.286 177.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 17.3 t -55.12 117.39 3.44 Favored 'General case' 0 C--N 1.311 -1.09 0 O-C-N 124.167 0.917 . . . . 0.0 111.287 -173.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 113.41 -20.98 17.93 Favored Glycine 0 N--CA 1.429 -1.802 0 CA-C-N 115.066 -0.97 . . . . 0.0 111.743 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . 0.438 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 96.8 m-85 -104.2 157.36 17.18 Favored 'General case' 0 N--CA 1.432 -1.358 0 O-C-N 122.397 -0.472 . . . . 0.0 111.572 -177.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -124.17 154.35 40.21 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.9 tp -69.25 148.59 11.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 176.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 29.1 tt0 -55.91 -59.77 4.42 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 123.842 0.857 . . . . 0.0 110.758 177.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -134.16 -83.6 0.2 Allowed Glycine 0 N--CA 1.437 -1.283 0 C-N-CA 120.517 -0.849 . . . . 0.0 111.238 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . 0.455 ' OD2' ' HD2' ' A' ' 200' ' ' LYS . 74.2 m-20 -102.56 134.94 45.09 Favored 'General case' 0 CA--C 1.499 -0.985 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -85.33 -1.76 57.33 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.536 -178.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.526 ' O ' ' HG3' ' A' ' 200' ' ' LYS . 0.0 OUTLIER -134.42 143.08 47.36 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-O 121.253 0.549 . . . . 0.0 111.157 -175.878 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.457 ' HG3' ' H ' ' A' ' 200' ' ' LYS . 31.8 ttm -126.14 115.26 19.52 Favored 'General case' 0 N--CA 1.416 -2.167 0 C-N-CA 125.039 1.335 . . . . 0.0 108.07 178.232 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 8.1 m80 -94.62 154.9 17.13 Favored 'General case' 0 C--N 1.267 -3.013 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.045 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 45.0 t -98.76 142.42 30.33 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 13.7 p -119.52 -174.51 2.75 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 -173.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -56.56 -22.21 31.86 Favored 'General case' 0 N--CA 1.487 1.383 0 C-N-CA 125.317 1.447 . . . . 0.0 111.806 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -64.57 -21.01 66.58 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 115.005 -0.998 . . . . 0.0 111.338 -178.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 81.67 14.87 77.07 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 -174.049 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -141.04 177.83 7.79 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.428 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -81.16 147.06 30.21 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.14 -176.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 26.6 m -82.3 -29.62 31.0 Favored 'General case' 0 N--CA 1.422 -1.831 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.117 177.129 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.526 ' HG3' ' O ' ' A' ' 189' ' ' GLU . 6.4 mmpt? -98.47 166.12 11.51 Favored 'General case' 0 N--CA 1.441 -0.881 0 C-N-CA 117.974 -1.491 . . . . 0.0 112.913 177.037 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -96.74 163.84 12.83 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 104.365 -2.457 . . . . 0.0 104.365 171.121 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . 0.458 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 4.9 mtpm? -66.69 125.59 90.89 Favored Pre-proline 0 C--N 1.304 -1.388 0 C-N-CA 119.862 -0.735 . . . . 0.0 112.406 178.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.458 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 7.3 Cg_endo -89.46 -174.08 0.86 Allowed 'Trans proline' 0 N--CA 1.42 -2.838 0 C-N-CA 121.746 1.631 . . . . 0.0 109.767 171.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 20.5 pttm -149.67 175.94 11.11 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.438 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 73.6 m -113.26 113.9 25.96 Favored 'General case' 0 C--N 1.283 -2.287 0 O-C-N 123.683 0.615 . . . . 0.0 109.524 -178.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.5 m . . . . . 0 N--CA 1.422 -1.832 0 CA-C-N 113.765 -1.561 . . . . 0.0 109.005 -174.104 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo . . . . . 0 CA--C 1.533 0.47 0 CA-C-O 121.444 0.518 . . . . 0.0 111.728 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 33.9 m -79.37 -33.31 43.0 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 177.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.21 -92.72 0.55 Allowed Glycine 1 N--CA 1.394 -4.159 0 CA-C-N 114.104 -1.407 . . . . 0.0 109.717 172.748 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -174.8 133.54 0.5 Allowed Pre-proline 0 C--N 1.255 -3.543 0 N-CA-C 103.85 -2.648 . . . . 0.0 103.85 -175.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.476 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 86.9 Cg_endo -80.61 3.0 8.09 Favored 'Trans proline' 0 C--N 1.328 -0.502 0 C-N-CA 122.643 2.228 . . . . 0.0 113.899 -173.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.3 -166.08 17.26 Favored Glycine 0 C--N 1.287 -2.163 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 -175.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 21.7 t70 -145.1 151.25 38.2 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -177.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.4 t -120.98 130.33 24.9 Favored Pre-proline 0 N--CA 1.429 -1.503 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 177.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -78.83 -7.59 15.55 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.59 2.194 . . . . 0.0 111.908 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -96.64 19.0 13.05 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.482 -179.168 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 155.97 -119.07 0.89 Allowed Glycine 0 N--CA 1.42 -2.378 0 C-N-CA 119.941 -1.124 . . . . 0.0 111.995 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.7 t -168.6 -169.85 1.12 Allowed 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -176.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.408 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 45.4 p90 -143.48 163.28 33.56 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 177.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.1 m -124.61 162.83 23.27 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 106.349 -1.723 . . . . 0.0 106.349 178.299 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 15.4 mt -123.37 125.2 44.55 Favored 'General case' 0 C--N 1.279 -2.493 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.424 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 44.1 p -119.68 134.09 55.37 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 -176.184 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.31 25.72 42.62 Favored Glycine 0 C--N 1.312 -0.775 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.19 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 172.87 -35.71 0.13 Allowed Glycine 0 CA--C 1.486 -1.768 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 61.18 18.97 9.61 Favored 'General case' 0 CA--C 1.521 -0.144 0 C-N-CA 124.394 1.077 . . . . 0.0 112.2 178.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.54 ' O ' HG11 ' A' ' 108' ' ' VAL . 31.1 m -154.12 -167.3 0.07 OUTLIER 'Isoleucine or valine' 0 C--O 1.208 -1.103 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 -178.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 21.3 m-85 -105.42 42.71 1.2 Allowed 'General case' 0 C--N 1.311 -1.109 0 CA-C-N 119.392 0.996 . . . . 0.0 110.139 -176.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.704 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.1 pt-20 -86.23 179.14 6.97 Favored 'General case' 0 C--O 1.205 -1.251 0 CA-C-N 114.564 -1.198 . . . . 0.0 111.733 178.166 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.1 m-85 -74.9 136.18 41.47 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 122.017 -0.427 . . . . 0.0 111.391 177.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.09 6.93 70.9 Favored Glycine 0 C--N 1.31 -0.88 0 CA-C-N 115.914 -0.585 . . . . 0.0 113.034 177.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.704 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.8 p -97.9 145.64 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.062 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.424 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 59.4 mtpt -110.25 122.84 48.61 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 177.641 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.475 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -85.5 85.37 7.43 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.489 HG12 ' HB3' ' A' ' 126' ' ' TYR . 31.8 m -83.39 107.0 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.027 0 CA-C-O 122.812 1.291 . . . . 0.0 109.558 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . 0.408 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 31.8 m-85 -73.17 134.84 44.54 Favored 'General case' 0 C--N 1.276 -2.606 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.964 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.6 t -129.81 114.55 16.07 Favored 'General case' 0 N--CA 1.408 -2.529 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 87.2 m -66.66 161.68 22.81 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 115.596 -0.729 . . . . 0.0 112.518 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 5.0 t-20 -68.85 -173.54 0.49 Allowed 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 114.989 -1.005 . . . . 0.0 111.136 -177.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -58.38 -52.17 66.73 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 123.109 0.564 . . . . 0.0 111.902 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.04 12.56 63.81 Favored Glycine 0 N--CA 1.437 -1.297 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.99 -177.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.512 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.6 m-85 -129.44 159.09 37.33 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-N 117.157 0.478 . . . . 0.0 110.72 -177.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.79 152.84 45.52 Favored 'General case' 0 C--N 1.288 -2.102 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.479 ' HG ' ' HB2' ' A' ' 125' ' ' ASN . 0.5 OUTLIER -78.29 126.36 30.68 Favored 'General case' 0 C--N 1.281 -2.401 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 179.17 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.434 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.3 OUTLIER -108.01 130.61 55.05 Favored 'General case' 0 N--CA 1.418 -2.044 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -178.791 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 114.69 -169.41 12.86 Favored Glycine 0 C--N 1.292 -1.91 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -103.82 -31.77 9.64 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-O 121.52 0.676 . . . . 0.0 109.763 -179.108 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.428 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.9 mm -89.16 120.59 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.467 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.562 -178.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.479 ' HB2' ' HG ' ' A' ' 120' ' ' LEU . 3.7 p-10 -125.6 9.59 7.75 Favored 'General case' 0 C--O 1.203 -1.368 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.489 ' HB3' HG12 ' A' ' 111' ' ' VAL . 22.4 p90 -140.67 168.39 19.91 Favored 'General case' 0 C--N 1.282 -2.347 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -170.359 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.488 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 48.7 mtp180 -132.5 117.9 18.59 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 169.34 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -91.89 128.33 37.69 Favored 'General case' 0 C--N 1.296 -1.734 0 C-N-CA 118.881 -1.128 . . . . 0.0 109.969 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 47.8 t -84.62 109.74 18.21 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.183 -1.007 . . . . 0.0 109.652 175.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.429 ' OD2' HG22 ' A' ' 131' ' ' THR . 9.9 t70 -111.71 -164.35 0.91 Allowed 'General case' 0 C--N 1.287 -2.126 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.429 HG22 ' OD2' ' A' ' 130' ' ' ASP . 12.0 t -63.4 -21.35 66.24 Favored 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -174.567 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -82.32 -22.77 35.46 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-O 121.87 0.843 . . . . 0.0 109.551 177.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 118.55 -145.25 18.28 Favored Glycine 0 N--CA 1.419 -2.44 0 N-CA-C 107.227 -2.349 . . . . 0.0 107.227 -171.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -69.92 111.42 5.63 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 108.984 -0.746 . . . . 0.0 108.984 177.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 37.8 p -66.65 -57.23 7.62 Favored 'General case' 0 C--O 1.241 0.646 0 CA-C-O 121.394 0.616 . . . . 0.0 111.499 -177.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.488 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 4.9 m120 -75.94 169.96 17.17 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.733 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 22.0 m-20 -106.51 -178.2 3.58 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.8 mt -64.89 123.71 84.46 Favored Pre-proline 0 C--N 1.318 -0.791 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 177.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.428 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 35.5 Cg_endo -67.97 174.06 8.38 Favored 'Trans proline' 0 C--O 1.242 0.7 0 C-N-CA 122.867 2.378 . . . . 0.0 112.971 -179.103 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.434 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 63.1 mt -96.13 139.08 19.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 -176.475 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.512 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 33.9 t -128.21 125.21 38.53 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 178.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 13.7 tp10 -120.02 155.57 32.62 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -174.352 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 8.6 p -75.41 134.51 29.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.178 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.433 ' O ' ' HB2' ' A' ' 169' ' ' HIS . 83.0 t -60.21 123.91 13.6 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.711 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.171 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 51.2 mttm -106.12 158.39 16.85 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 120.944 0.402 . . . . 0.0 110.457 -175.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 60.6 m -117.46 161.6 19.32 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 2.2 pp -72.47 155.38 91.24 Favored Pre-proline 0 C--N 1.307 -1.259 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -78.23 126.02 7.47 Favored 'Trans proline' 0 N--CA 1.439 -1.683 0 C-N-CA 122.294 1.996 . . . . 0.0 113.152 -175.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.494 HG12 ' O ' ' A' ' 150' ' ' THR . 54.3 t -69.46 135.67 27.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 CA-C-N 114.041 -1.436 . . . . 0.0 110.349 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . 0.494 ' O ' HG12 ' A' ' 149' ' ' VAL . 11.5 p -93.7 170.85 9.27 Favored 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 171.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -93.46 156.75 39.54 Favored Pre-proline 0 C--N 1.267 -2.995 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -174.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -74.35 152.96 44.88 Favored 'Trans proline' 0 N--CA 1.428 -2.371 0 C-N-CA 120.761 0.974 . . . . 0.0 110.905 172.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -54.66 -44.34 73.17 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 114.72 1.378 . . . . 0.0 114.72 -172.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.8 m-80 -122.71 31.41 6.08 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 122.154 0.978 . . . . 0.0 108.746 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -139.57 -161.79 8.86 Favored Glycine 0 N--CA 1.428 -1.888 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 40.6 pttt -157.64 163.14 38.55 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 -178.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 49.3 mt -89.36 132.33 34.39 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-O 121.005 0.431 . . . . 0.0 110.029 -177.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.7 t -74.85 -48.22 34.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-O 122.182 0.991 . . . . 0.0 108.393 177.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.493 ' CB ' ' HA ' ' A' ' 174' ' ' VAL . 6.3 m -94.73 43.06 1.09 Allowed 'General case' 0 C--N 1.289 -2.039 0 CA-C-N 114.553 -1.203 . . . . 0.0 111.388 -175.611 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 32.0 t -68.5 102.29 1.42 Allowed 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.723 -0.217 . . . . 0.0 111.076 -177.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 43.06 78.81 0.05 OUTLIER 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 125.438 1.495 . . . . 0.0 113.923 177.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 17.0 ptp -85.36 -19.1 31.94 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.468 0.651 . . . . 0.0 110.261 -177.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -77.13 148.81 78.8 Favored Pre-proline 0 C--N 1.313 -0.991 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.588 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.6 -4.18 14.89 Favored 'Trans proline' 0 N--CA 1.479 0.665 0 C-N-CA 123.21 2.606 . . . . 0.0 111.156 178.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . 0.417 ' C ' ' H ' ' A' ' 167' ' ' GLU . 4.0 m-20 -93.59 -29.41 15.49 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 105.122 -2.177 . . . . 0.0 105.122 178.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 91.7 mtt180 69.32 -2.14 1.96 Allowed 'General case' 0 CA--C 1.501 -0.91 0 C-N-CA 127.287 2.235 . . . . 0.0 113.414 -177.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . 0.417 ' H ' ' C ' ' A' ' 165' ' ' ASP . 45.4 mt-10 -70.44 145.33 51.08 Favored 'General case' 0 C--N 1.274 -2.693 0 CA-C-N 113.53 -1.668 . . . . 0.0 107.326 172.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -90.74 126.32 35.96 Favored 'General case' 0 C--N 1.27 -2.881 0 N-CA-C 105.874 -1.899 . . . . 0.0 105.874 168.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.524 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 2.1 p-80 -145.46 168.72 19.87 Favored 'General case' 0 C--N 1.279 -2.47 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.675 -176.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 45.5 t80 -51.76 121.04 5.9 Favored 'General case' 0 C--O 1.242 0.695 0 O-C-N 124.31 1.006 . . . . 0.0 110.307 -176.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 123.49 -17.46 7.85 Favored Glycine 0 N--CA 1.427 -1.952 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.202 -175.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 25.3 mm-40 -78.67 135.34 37.17 Favored 'General case' 0 C--O 1.255 1.371 0 CA-C-O 121.716 0.77 . . . . 0.0 112.254 178.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -125.7 109.8 13.01 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 105.582 -2.007 . . . . 0.0 105.582 173.351 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.493 ' HA ' ' CB ' ' A' ' 159' ' ' SER . 53.6 t -107.4 122.61 61.85 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.687 -173.14 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.422 ' HG3' ' O ' ' A' ' 188' ' ' GLU . 24.0 ttp180 -111.66 161.51 16.17 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.322 177.163 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -130.73 162.47 29.39 Favored 'General case' 0 C--N 1.31 -1.15 0 C-N-CA 124.397 1.079 . . . . 0.0 110.296 -174.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.79 143.9 35.1 Favored 'Isoleucine or valine' 0 CA--C 1.471 -2.093 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.45 176.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 76.7 m -105.68 131.52 52.95 Favored 'General case' 0 N--CA 1.395 -3.216 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 173.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -54.1 164.36 0.65 Allowed 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.309 177.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 26.7 t -33.71 -47.88 0.26 Allowed 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 116.771 2.137 . . . . 0.0 116.771 -168.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -104.28 15.36 50.63 Favored Glycine 0 C--N 1.288 -2.136 0 C-N-CA 120.056 -1.069 . . . . 0.0 115.025 -173.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -120.09 162.14 19.79 Favored 'General case' 0 CA--C 1.497 -1.065 0 CA-C-N 118.344 1.072 . . . . 0.0 112.424 -176.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.447 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 25.5 pttm -123.28 154.2 39.16 Favored 'General case' 0 C--N 1.305 -1.357 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.474 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 2.8 tp -72.47 145.09 12.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 178.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -82.16 -71.16 0.5 Allowed 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 120.962 -0.295 . . . . 0.0 110.481 179.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.0 -89.58 0.63 Allowed Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.948 -177.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -136.36 159.99 40.1 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 105.284 -2.117 . . . . 0.0 105.284 -177.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.422 ' O ' ' HG3' ' A' ' 175' ' ' ARG . 1.0 OUTLIER -103.37 3.26 34.99 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 118.999 -1.08 . . . . 0.0 112.707 -171.979 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.578 ' O ' ' HG3' ' A' ' 200' ' ' LYS . 4.3 pt-20 -149.75 143.57 25.5 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 113.572 0.953 . . . . 0.0 113.572 -179.534 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.459 ' HB3' ' HB2' ' A' ' 200' ' ' LYS . 12.8 ptp -133.37 144.14 49.4 Favored 'General case' 0 C--N 1.315 -0.898 0 C-N-CA 124.146 0.978 . . . . 0.0 111.275 -176.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 49.4 t-80 -125.69 141.05 52.21 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.506 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 13.2 m -65.32 129.55 40.13 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 177.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . 0.41 ' OG ' ' HB3' ' A' ' 199' ' ' SER . 14.5 m -104.45 167.26 9.86 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.931 177.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -48.18 -37.23 15.22 Favored 'General case' 0 N--CA 1.496 1.874 0 C-N-CA 125.529 1.532 . . . . 0.0 113.535 -176.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -68.74 -16.01 63.68 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -176.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 99.33 27.79 7.95 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.195 -1.002 . . . . 0.0 113.248 178.287 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -150.21 179.2 8.3 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 122.391 -0.476 . . . . 0.0 110.356 176.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 77.5 m95 -84.84 135.77 33.95 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 123.924 0.765 . . . . 0.0 110.881 -176.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . 0.41 ' HB3' ' OG ' ' A' ' 193' ' ' SER . 9.5 p -73.26 -24.24 60.42 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.682 0.753 . . . . 0.0 111.136 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.578 ' HG3' ' O ' ' A' ' 189' ' ' GLU . 28.2 mmtp -94.9 179.88 5.08 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 115.026 -0.988 . . . . 0.0 112.909 -177.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -100.75 148.87 24.41 Favored 'General case' 0 C--N 1.292 -1.925 0 CA-C-N 113.557 -1.656 . . . . 0.0 110.735 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . 0.61 ' HE2' ' HD2' ' A' ' 203' ' ' PRO . 0.1 OUTLIER -75.03 107.98 4.76 Favored Pre-proline 0 C--N 1.323 -0.563 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 175.123 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.61 ' HD2' ' HE2' ' A' ' 202' ' ' LYS . 71.8 Cg_endo -88.81 174.25 4.0 Favored 'Trans proline' 0 N--CA 1.435 -1.915 0 C-N-CA 122.743 2.296 . . . . 0.0 114.898 -172.121 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 64.4 mttm -124.36 174.27 7.85 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -176.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.447 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 91.1 m -128.77 101.38 6.09 Favored 'General case' 0 C--N 1.29 -1.982 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 174.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 21.1 m . . . . . 0 C--N 1.294 -1.832 0 CA-C-N 114.226 -1.352 . . . . 0.0 108.679 -173.176 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo . . . . . 0 CA--C 1.542 0.908 0 CA-C-O 121.056 0.357 . . . . 0.0 112.008 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 61.7 m -82.67 -29.92 29.64 Favored 'General case' 0 CA--C 1.507 -0.675 0 CA-C-O 122.418 1.104 . . . . 0.0 108.228 177.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 113.2 -91.45 0.58 Allowed Glycine 0 N--CA 1.4 -3.737 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 173.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.8 t60 -175.1 135.26 0.51 Allowed Pre-proline 0 C--N 1.257 -3.453 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 -176.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.574 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 94.0 Cg_endo -80.9 2.04 8.86 Favored 'Trans proline' 0 C--N 1.324 -0.754 0 C-N-CA 122.364 2.043 . . . . 0.0 113.156 -175.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 94.42 176.07 38.81 Favored Glycine 0 C--N 1.287 -2.14 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -173.093 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -144.46 159.28 43.01 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 117.444 0.622 . . . . 0.0 109.453 -176.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.7 t -120.18 131.3 24.47 Favored Pre-proline 0 C--N 1.298 -1.645 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.25 -177.256 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -71.7 -19.12 28.1 Favored 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 122.337 2.025 . . . . 0.0 110.561 176.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -86.58 16.0 5.06 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 114.755 -1.112 . . . . 0.0 110.481 -174.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 164.78 -131.94 2.55 Favored Glycine 1 N--CA 1.396 -4.001 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.591 178.339 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.3 p -154.77 175.52 13.61 Favored 'General case' 0 C--N 1.288 -2.104 0 C-N-CA 124.182 0.993 . . . . 0.0 109.896 -173.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -144.95 154.07 42.2 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 171.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.8 m -126.13 162.14 26.04 Favored 'General case' 0 C--N 1.275 -2.648 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 17.6 mt -112.47 135.95 52.56 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 18.8 p -129.03 126.93 40.54 Favored 'General case' 0 C--N 1.281 -2.386 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.893 -178.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 90.47 29.23 14.55 Favored Glycine 0 C--N 1.302 -1.319 0 C-N-CA 120.407 -0.902 . . . . 0.0 111.978 179.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 172.12 -36.58 0.15 Allowed Glycine 0 N--CA 1.431 -1.699 0 C-N-CA 119.964 -1.112 . . . . 0.0 112.7 178.695 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 70.73 1.94 3.93 Favored 'General case' 0 N--CA 1.511 2.582 0 CA-C-O 122.206 1.003 . . . . 0.0 110.728 -178.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.46 ' O ' HG11 ' A' ' 108' ' ' VAL . 34.3 m -143.94 -171.24 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -173.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -105.45 45.41 0.97 Allowed 'General case' 0 C--N 1.304 -1.401 0 CA-C-O 121.269 0.557 . . . . 0.0 110.216 -176.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.693 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.7 pt-20 -83.01 177.65 8.52 Favored 'General case' 0 C--O 1.213 -0.857 0 CA-C-N 114.585 -1.189 . . . . 0.0 111.607 177.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 43.6 m-85 -77.42 130.92 37.68 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-O 120.941 0.401 . . . . 0.0 110.801 176.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.87 2.37 58.39 Favored Glycine 0 N--CA 1.437 -1.238 0 C-N-CA 120.575 -0.821 . . . . 0.0 112.555 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.693 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.7 p -94.77 145.89 7.49 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.285 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 19.7 mtpp -111.94 120.77 43.03 Favored 'General case' 0 C--N 1.286 -2.157 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -86.86 92.8 9.11 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 77.2 t -86.39 118.41 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.611 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -178.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -85.99 145.58 27.04 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.289 -178.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.9 t -144.34 110.66 5.52 Favored 'General case' 0 N--CA 1.407 -2.61 0 CA-C-O 122.208 1.004 . . . . 0.0 108.446 -179.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 41.7 m -71.22 158.81 35.75 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.813 -173.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.513 ' HB3' ' HD2' ' A' ' 118' ' ' TYR . 4.2 t-20 -60.24 171.9 0.94 Allowed 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 125.128 1.371 . . . . 0.0 111.33 -177.416 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -59.44 -41.87 90.6 Favored 'General case' 0 C--N 1.297 -1.685 0 C-N-CA 124.568 1.147 . . . . 0.0 110.017 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.433 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -86.63 19.82 26.66 Favored Glycine 0 CA--C 1.529 0.932 0 CA-C-N 115.368 -0.833 . . . . 0.0 113.739 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.583 ' HE1' HG22 ' A' ' 143' ' ' VAL . 97.9 m-85 -147.11 173.85 12.11 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.414 HE21 ' HB2' ' A' ' 119' ' ' GLN . 0.0 OUTLIER -143.68 165.44 27.64 Favored 'General case' 0 C--N 1.281 -2.403 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.601 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 5.3 tt -94.51 137.88 33.1 Favored 'General case' 0 C--N 1.28 -2.447 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -178.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -124.74 135.15 52.75 Favored 'General case' 0 C--N 1.292 -1.918 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 -177.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.66 159.5 15.39 Favored Glycine 0 N--CA 1.438 -1.191 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -78.99 -27.33 43.32 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.719 0.771 . . . . 0.0 109.085 -177.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.426 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 47.2 mm -89.76 132.78 33.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 114.814 -1.085 . . . . 0.0 108.311 -177.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -133.07 12.94 4.28 Favored 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -177.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . . . . . . . . . 2.8 p90 -152.65 169.21 23.26 Favored 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 -173.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.574 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 54.1 mtp180 -131.84 120.1 22.13 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 169.115 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -94.53 138.35 32.53 Favored 'General case' 0 C--N 1.287 -2.128 0 C-N-CA 118.893 -1.123 . . . . 0.0 110.565 177.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.0 t -89.69 104.35 16.92 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 118.881 -1.128 . . . . 0.0 109.61 174.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.444 ' OD2' HG22 ' A' ' 131' ' ' THR . 12.1 t70 -97.08 -172.22 2.39 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 176.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.444 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -67.25 -11.44 57.47 Favored 'General case' 0 C--N 1.293 -1.855 0 C-N-CA 123.259 0.623 . . . . 0.0 112.274 -174.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -94.6 -12.5 27.35 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.82 0.819 . . . . 0.0 109.412 176.558 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.15 -159.25 13.86 Favored Glycine 0 N--CA 1.431 -1.685 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -175.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.0 m95 -63.65 105.23 0.76 Allowed 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 120.894 0.378 . . . . 0.0 111.259 178.088 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 24.9 p -61.32 -64.89 0.8 Allowed 'General case' 0 C--O 1.241 0.652 0 C-N-CA 124.955 1.302 . . . . 0.0 112.87 -175.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.486 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.3 m120 -71.18 173.42 7.7 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.211 -177.099 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -106.55 176.43 5.17 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 175.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 77.5 mt -69.2 125.98 92.38 Favored Pre-proline 0 C--N 1.311 -1.085 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.426 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 55.0 Cg_endo -70.68 168.69 22.04 Favored 'Trans proline' 0 C--O 1.249 1.073 0 C-N-CA 122.719 2.279 . . . . 0.0 111.145 177.092 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.6 mm -97.93 129.53 47.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 120.436 -0.506 . . . . 0.0 111.245 -173.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 99.5 m -101.93 103.34 13.98 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 171.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -95.09 152.39 18.38 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 -179.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.583 HG22 ' HE1' ' A' ' 118' ' ' TYR . 3.2 t -76.69 145.51 10.2 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.514 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 -175.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 170' ' ' PHE . 5.9 m -73.71 108.39 5.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 174.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -104.75 127.2 52.45 Favored 'General case' 0 N--CA 1.412 -2.352 0 CA-C-N 114.45 -1.25 . . . . 0.0 111.095 -174.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.56 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 3.4 m -85.44 148.5 25.96 Favored 'General case' 0 C--N 1.282 -2.356 0 CA-C-N 113.738 -1.574 . . . . 0.0 110.078 -173.444 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 59.4 mt -56.36 132.46 76.19 Favored Pre-proline 0 C--N 1.319 -0.75 0 N-CA-C 112.677 0.621 . . . . 0.0 112.677 178.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_endo -62.49 111.4 1.3 Allowed 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 123.499 2.799 . . . . 0.0 112.391 -178.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 38.3 t -79.05 139.16 18.81 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.5 p -79.02 -75.9 0.22 Allowed 'General case' 0 N--CA 1.43 -1.447 0 O-C-N 123.868 0.73 . . . . 0.0 111.51 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 166.42 159.62 0.11 Allowed Pre-proline 0 C--O 1.24 0.59 0 C-N-CA 126.248 1.819 . . . . 0.0 107.054 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -73.73 171.81 17.07 Favored 'Trans proline' 0 CA--C 1.535 0.569 0 C-N-CA 121.519 1.479 . . . . 0.0 109.572 169.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -69.67 -62.57 1.33 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -177.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.5 m-80 -95.82 38.43 1.17 Allowed 'General case' 0 C--N 1.313 -1.01 0 O-C-N 121.562 -0.711 . . . . 0.0 110.488 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -155.1 -168.57 18.5 Favored Glycine 0 N--CA 1.426 -1.973 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.964 178.189 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 58.6 pttt -153.0 174.79 13.71 Favored 'General case' 0 C--N 1.307 -1.249 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 -178.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.408 HG12 ' CD1' ' A' ' 176' ' ' PHE . 52.5 mt -91.58 139.62 17.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -178.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.456 HG21 ' HB3' ' A' ' 175' ' ' ARG . 4.7 m -77.46 -37.17 24.55 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.576 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 178.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 28.6 t -115.95 79.64 1.33 Allowed 'General case' 0 N--CA 1.435 -1.199 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 32.3 m -77.98 74.2 4.54 Favored 'General case' 0 N--CA 1.43 -1.43 0 CA-C-O 121.751 0.786 . . . . 0.0 109.388 179.168 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -74.84 5.63 4.84 Favored 'General case' 0 C--O 1.211 -0.957 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.403 -175.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.687 ' O ' ' HA ' ' A' ' 166' ' ' ARG . 19.0 ptp -67.1 -15.27 63.61 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 124.356 1.062 . . . . 0.0 111.439 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.517 ' H ' ' HD2' ' A' ' 164' ' ' PRO . 24.4 mm-40 -125.46 -55.1 0.03 OUTLIER Pre-proline 0 N--CA 1.48 1.027 0 N-CA-C 115.687 1.736 . . . . 0.0 115.687 -178.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . 0.517 ' HD2' ' H ' ' A' ' 163' ' ' GLU . 11.6 Cg_endo -57.57 -27.15 75.6 Favored 'Trans proline' 0 C--N 1.371 1.732 0 C-N-CA 121.431 1.42 . . . . 0.0 111.536 177.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 23.0 t0 -127.76 -9.43 5.55 Favored 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -179.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.687 ' HA ' ' O ' ' A' ' 162' ' ' MET 0.253 72.8 mtt-85 62.83 -42.13 0.18 Allowed 'General case' 0 C--N 1.37 1.495 0 N-CA-C 117.543 2.423 . . . . 0.0 117.543 -179.328 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 -116.84 145.04 43.82 Favored 'General case' 1 C--N 1.22 -5.024 0 CA-C-N 114.84 -1.073 . . . . 0.0 108.999 -174.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -88.9 129.35 35.62 Favored 'General case' 0 C--N 1.295 -1.761 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 176.073 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 55.2 m80 -121.61 155.81 34.3 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 109.727 -0.472 . . . . 0.0 109.727 -175.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.515 ' HB2' HG23 ' A' ' 144' ' ' VAL . 81.7 t80 -49.68 121.09 4.78 Favored 'General case' 0 C--O 1.244 0.798 0 O-C-N 123.686 0.616 . . . . 0.0 110.56 175.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 132.28 -29.65 3.29 Favored Glycine 0 N--CA 1.42 -2.41 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 -177.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 20.8 mm-40 -63.24 128.85 37.73 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 179.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -118.06 82.66 1.87 Allowed 'General case' 0 N--CA 1.423 -1.813 0 N-CA-C 104.32 -2.474 . . . . 0.0 104.32 170.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.469 HG13 ' HG3' ' A' ' 190' ' ' MET . 14.9 p -77.63 111.56 14.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.004 -169.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.456 ' HB3' HG21 ' A' ' 158' ' ' VAL . 40.1 ttm180 -97.74 148.29 23.5 Favored 'General case' 0 N--CA 1.416 -2.159 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.716 -177.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.473 ' HZ ' ' SD ' ' A' ' 190' ' ' MET . 51.2 m-85 -115.46 150.98 35.61 Favored 'General case' 0 N--CA 1.42 -1.967 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 -179.38 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.413 ' HB ' HG12 ' A' ' 158' ' ' VAL . 13.7 p -126.49 141.05 47.08 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.749 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 178.273 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.4 m -99.64 163.59 12.43 Favored 'General case' 0 C--N 1.262 -3.207 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.001 -178.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -66.52 172.63 3.95 Favored 'General case' 0 CA--C 1.497 -1.066 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.204 179.227 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 21.8 m -42.99 -31.95 0.59 Allowed 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 116.335 1.976 . . . . 0.0 116.335 -172.033 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -126.42 24.02 5.64 Favored Glycine 0 C--N 1.289 -2.069 0 C-N-CA 119.376 -1.393 . . . . 0.0 113.377 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -118.42 151.94 36.83 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.815 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 50.9 pttt -115.27 157.03 24.33 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 -179.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.577 HD13 ' HA ' ' A' ' 188' ' ' GLU . 5.0 tt -86.1 143.59 11.17 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.506 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.224 175.403 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 7.0 tp10 -77.56 -68.16 0.65 Allowed 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -173.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -80.63 -109.61 0.3 Allowed Glycine 0 C--O 1.245 0.798 0 C-N-CA 120.766 -0.73 . . . . 0.0 111.976 -177.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -95.93 175.8 6.36 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 176.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.577 ' HA ' HD13 ' A' ' 184' ' ' ILE . 10.3 pt-20 -104.28 -19.09 14.22 Favored 'General case' 0 C--N 1.28 -2.435 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -177.316 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.451 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 5.3 pt-20 -141.45 150.21 41.98 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.053 -176.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.473 ' SD ' ' HZ ' ' A' ' 176' ' ' PHE . 0.1 OUTLIER -117.39 125.72 51.46 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.174 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -97.26 132.7 42.76 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 176.137 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . 0.469 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 48.7 t -80.39 136.8 36.44 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.114 179.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . 0.446 ' HB2' ' OD1' ' A' ' 195' ' ' ASP . 11.1 m -98.99 173.54 6.79 Favored 'General case' 0 N--CA 1.423 -1.792 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.643 179.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -67.41 -8.85 36.23 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 124.157 0.983 . . . . 0.0 112.47 -176.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . 0.446 ' OD1' ' HB2' ' A' ' 193' ' ' SER . 11.8 p-10 -94.25 4.99 53.13 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 122.223 -0.298 . . . . 0.0 111.406 179.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . 0.56 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 79.49 11.63 84.64 Favored Glycine 0 CA--C 1.526 0.73 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.486 178.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -117.92 150.76 38.68 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 122.345 -0.503 . . . . 0.0 110.3 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . 0.469 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 82.3 m95 -78.9 135.59 37.03 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.037 177.671 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 26.4 t -74.43 -16.91 60.86 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-O 121.19 0.519 . . . . 0.0 110.547 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.413 ' HB2' ' HA ' ' A' ' 190' ' ' MET . 24.5 mmtp -108.82 158.14 17.93 Favored 'General case' 0 CA--C 1.5 -0.978 0 O-C-N 122.123 -0.361 . . . . 0.0 110.551 178.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -97.58 170.44 9.02 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 123.477 0.486 . . . . 0.0 110.66 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 7.6 mmmm -69.06 115.8 35.43 Favored Pre-proline 0 CA--C 1.516 -0.354 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -178.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.451 ' HG2' HD11 ' A' ' 184' ' ' ILE . 78.0 Cg_endo -88.15 168.28 6.52 Favored 'Trans proline' 0 N--CA 1.446 -1.313 0 C-N-CA 122.862 2.375 . . . . 0.0 112.159 -179.355 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -115.73 165.93 12.51 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 86.6 m -114.71 109.83 18.81 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 172.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 30.8 m . . . . . 0 C--O 1.254 1.302 0 O-C-N 124.332 1.02 . . . . 0.0 109.444 -173.858 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo . . . . . 0 CA--C 1.535 0.543 0 CA-C-O 121.74 0.642 . . . . 0.0 110.866 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.0 m -86.65 -35.6 19.26 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 178.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 117.46 -88.53 0.46 Allowed Glycine 0 N--CA 1.404 -3.49 0 N-CA-C 109.821 -1.311 . . . . 0.0 109.821 174.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.5 t-80 -176.67 135.9 0.42 Allowed Pre-proline 0 C--N 1.255 -3.509 0 N-CA-C 104.458 -2.423 . . . . 0.0 104.458 -175.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.436 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 91.7 Cg_endo -82.15 -0.29 10.18 Favored 'Trans proline' 0 C--N 1.329 -0.494 0 C-N-CA 121.993 1.795 . . . . 0.0 112.791 -176.197 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 109.33 -155.82 15.9 Favored Glycine 0 N--CA 1.42 -2.387 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -177.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -156.02 157.41 36.1 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 178.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.5 t -122.91 127.51 25.69 Favored Pre-proline 0 C--N 1.293 -1.875 0 CA-C-N 118.226 0.467 . . . . 0.0 110.822 -177.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -65.47 -16.01 52.16 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 122.772 2.315 . . . . 0.0 111.64 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -86.7 -9.37 56.11 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.335 -178.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 173.14 -125.29 1.13 Allowed Glycine 0 N--CA 1.433 -1.549 0 C-N-CA 118.755 -1.688 . . . . 0.0 113.907 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.8 t -148.88 -169.76 3.45 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 -176.046 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -151.81 162.4 41.09 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 177.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -126.02 162.51 25.11 Favored 'General case' 0 C--N 1.291 -1.938 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.4 mt -113.93 138.74 49.92 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.411 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 26.5 p -132.68 137.64 47.02 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 -178.123 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 83.2 24.25 52.32 Favored Glycine 0 C--N 1.309 -0.921 0 N-CA-C 108.556 -1.818 . . . . 0.0 108.556 -173.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 145.6 154.3 6.12 Favored Glycine 1 N--CA 1.39 -4.398 0 N-CA-C 107.334 -2.306 . . . . 0.0 107.334 -177.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -108.6 29.07 7.75 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 177.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.418 ' O ' HG21 ' A' ' 108' ' ' VAL . 35.6 m -144.31 -175.17 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.055 0 CA-C-N 114.686 -1.143 . . . . 0.0 109.068 -173.418 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -108.4 47.13 0.92 Allowed 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 121.464 0.649 . . . . 0.0 109.543 -177.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.689 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.2 pt-20 -82.41 178.13 8.39 Favored 'General case' 0 C--O 1.213 -0.828 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.248 178.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -76.44 132.77 39.83 Favored 'General case' 0 C--N 1.289 -2.05 0 O-C-N 122.059 -0.401 . . . . 0.0 110.149 175.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.35 5.06 63.86 Favored Glycine 0 N--CA 1.431 -1.644 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.633 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.689 HG12 ' O ' ' A' ' 105' ' ' GLU . 10.4 p -96.69 144.4 10.56 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.924 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.411 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 20.5 mtpp -112.38 118.08 34.22 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -179.407 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -82.83 92.1 7.2 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 177.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.41 HG13 ' ND2' ' A' ' 125' ' ' ASN . 75.9 t -82.73 111.68 19.41 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.618 0 C-N-CA 123.942 0.897 . . . . 0.0 109.44 -178.632 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 -80.6 144.12 32.62 Favored 'General case' 0 C--N 1.293 -1.858 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.672 -179.225 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.1 t -145.87 112.43 5.9 Favored 'General case' 0 N--CA 1.418 -2.041 0 CA-C-N 115.048 -0.978 . . . . 0.0 108.677 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 83.0 m -70.46 163.24 27.19 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.127 -178.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 85.4 m-20 -68.38 174.36 4.12 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.514 178.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -59.96 -39.09 84.43 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 112.781 0.659 . . . . 0.0 112.781 -174.238 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -85.61 9.96 66.28 Favored Glycine 0 C--N 1.3 -1.43 0 C-N-CA 121.275 -0.488 . . . . 0.0 113.668 179.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -131.44 163.12 28.63 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -146.16 134.86 22.27 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 9.5 tt -70.3 138.46 51.53 Favored 'General case' 0 C--N 1.293 -1.873 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.621 -177.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.45 140.75 49.02 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.018 -172.322 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 108.37 -172.81 17.28 Favored Glycine 0 C--N 1.303 -1.252 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.272 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 30.0 mm-40 -99.68 -19.63 16.7 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 117.084 0.442 . . . . 0.0 111.18 -177.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.9 mm -98.59 135.99 31.32 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -178.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.41 ' ND2' HG13 ' A' ' 111' ' ' VAL . 2.6 p-10 -130.52 13.3 5.47 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.355 178.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.406 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 11.4 p90 -145.34 169.96 17.25 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -174.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.496 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 46.6 mtp180 -131.01 120.83 24.04 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 169.33 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -95.04 136.61 35.15 Favored 'General case' 0 C--N 1.28 -2.418 0 C-N-CA 119.228 -0.989 . . . . 0.0 110.223 178.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 27.1 t -92.61 109.19 20.6 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.923 -1.111 . . . . 0.0 109.473 173.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -110.3 -167.52 1.2 Allowed 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 105.004 -2.221 . . . . 0.0 105.004 175.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 14.8 t -67.03 -13.8 62.27 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 119.056 0.844 . . . . 0.0 111.409 -177.394 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -79.21 -15.68 57.67 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 121.745 0.784 . . . . 0.0 109.646 174.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 104.19 -154.62 17.64 Favored Glycine 0 N--CA 1.431 -1.69 0 N-CA-C 107.181 -2.368 . . . . 0.0 107.181 -173.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.9 m95 -64.36 106.72 1.17 Allowed 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 118.12 0.96 . . . . 0.0 108.535 172.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.0 p -63.52 -66.01 0.6 Allowed 'General case' 0 C--O 1.253 1.269 0 C-N-CA 124.001 0.92 . . . . 0.0 111.647 -174.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.496 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.6 m120 -67.09 167.88 11.16 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-N 114.84 -1.073 . . . . 0.0 109.036 -179.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 13.6 m-20 -100.7 -178.97 3.94 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 176.37 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 82.1 mt -72.13 120.69 81.73 Favored Pre-proline 0 C--N 1.313 -1.0 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 175.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.29 137.81 53.1 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 122.062 1.842 . . . . 0.0 110.911 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 69.7 mt -63.88 141.55 18.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.989 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 46.2 t -131.39 140.61 49.7 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -123.72 157.33 34.19 Favored 'General case' 0 N--CA 1.408 -2.551 0 CA-C-O 121.102 0.477 . . . . 0.0 110.324 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 5.7 p -75.1 137.9 22.06 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 177.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 97.5 t -58.55 117.52 1.82 Allowed 'Isoleucine or valine' 0 C--O 1.251 1.154 0 O-C-N 123.566 0.541 . . . . 0.0 110.18 -178.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 53.9 mttp -93.09 142.44 27.29 Favored 'General case' 0 N--CA 1.425 -1.704 0 CA-C-N 115.254 -0.885 . . . . 0.0 108.78 179.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.0 m -109.25 151.35 26.66 Favored 'General case' 0 C--N 1.278 -2.532 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -179.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 64.9 mt -56.17 137.45 74.22 Favored Pre-proline 0 C--N 1.319 -0.722 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.424 ' HA ' ' CD2' ' A' ' 168' ' ' TYR . 34.8 Cg_endo -66.71 94.87 0.33 Allowed 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 123.317 2.678 . . . . 0.0 111.6 179.202 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 9.5 p -69.41 142.78 15.61 Favored 'Isoleucine or valine' 0 C--O 1.25 1.119 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.01 -177.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 11.6 p -97.59 -166.25 1.36 Allowed 'General case' 0 N--CA 1.42 -1.961 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.882 177.45 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -119.61 156.35 53.64 Favored Pre-proline 0 C--N 1.297 -1.716 0 O-C-N 122.119 -0.363 . . . . 0.0 110.714 -171.04 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.4 175.36 6.03 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 122.224 1.949 . . . . 0.0 111.446 174.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . 0.498 ' CD ' ' H ' ' A' ' 153' ' ' GLU . 0.0 OUTLIER -82.72 -43.57 16.66 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 120.999 0.428 . . . . 0.0 111.068 -174.801 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . 0.452 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 55.9 m-80 -98.86 18.86 16.07 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.348 0.594 . . . . 0.0 110.488 -179.676 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -147.31 -166.34 12.41 Favored Glycine 0 N--CA 1.424 -2.118 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.664 -178.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 62.5 pttt -154.68 -179.42 7.98 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -177.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 50.0 mt -100.95 132.07 47.4 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.207 0 CA-C-N 117.745 0.248 . . . . 0.0 110.859 -177.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.573 HG12 HG22 ' A' ' 177' ' ' VAL . 2.3 m -78.02 -29.19 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 15.4 m -98.77 40.37 1.2 Allowed 'General case' 0 C--N 1.311 -1.101 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.954 -177.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 15.4 t -67.39 -27.29 66.97 Favored 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -102.16 97.76 8.02 Favored 'General case' 0 N--CA 1.422 -1.839 0 N-CA-C 105.982 -1.858 . . . . 0.0 105.982 170.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.422 ' SD ' ' HA ' ' A' ' 166' ' ' ARG . 0.0 OUTLIER -71.07 -60.13 2.4 Favored 'General case' 0 CA--C 1.498 -1.054 0 CA-C-O 121.794 0.807 . . . . 0.0 110.007 -172.747 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.432 ' HB2' ' HD2' ' A' ' 164' ' ' PRO . 10.0 pt-20 -161.09 165.75 16.5 Favored Pre-proline 0 C--N 1.314 -0.942 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 -175.388 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . 0.432 ' HD2' ' HB2' ' A' ' 163' ' ' GLU . 34.8 Cg_endo -65.41 1.88 1.84 Allowed 'Trans proline' 0 N--CA 1.49 1.322 0 C-N-CA 123.056 2.504 . . . . 0.0 114.091 178.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -108.05 -9.4 15.63 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-O 122.645 1.212 . . . . 0.0 108.063 178.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.422 ' HA ' ' SD ' ' A' ' 162' ' ' MET . 18.4 mmm180 57.61 30.37 18.7 Favored 'General case' 0 C--O 1.245 0.836 0 N-CA-C 117.287 2.328 . . . . 0.0 117.287 167.164 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . 0.528 ' HB2' ' CE1' ' A' ' 169' ' ' HIS . 60.1 mt-10 -126.26 170.33 11.98 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 171.087 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . 0.424 ' CD2' ' HA ' ' A' ' 148' ' ' PRO . 79.7 m-85 -93.84 123.34 37.13 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 174.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.528 ' CE1' ' HB2' ' A' ' 167' ' ' GLU . 37.4 m80 -130.95 164.62 24.92 Favored 'General case' 0 C--N 1.291 -1.953 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -178.161 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 92.5 t80 -58.07 111.61 1.24 Allowed 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 173.144 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 134.19 -23.76 3.65 Favored Glycine 0 N--CA 1.426 -1.981 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -174.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 81.0 mm-40 -78.53 140.51 38.54 Favored 'General case' 0 N--CA 1.429 -1.482 0 CA-C-O 121.339 0.59 . . . . 0.0 111.339 177.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -131.17 109.62 10.57 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 176.41 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 97.6 t -94.14 118.29 39.75 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.206 0 CA-C-N 115.472 -0.786 . . . . 0.0 110.578 -173.688 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.471 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 41.7 ttm180 -105.46 144.86 31.65 Favored 'General case' 0 N--CA 1.426 -1.654 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.604 176.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -114.24 159.27 20.33 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 123.586 0.754 . . . . 0.0 109.948 -176.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.573 HG22 HG12 ' A' ' 158' ' ' VAL . 0.0 OUTLIER -132.03 145.04 35.45 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.284 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.951 178.49 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 84.2 m -109.81 136.45 49.1 Favored 'General case' 0 C--N 1.268 -2.954 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 55.5 m-80 -60.51 164.76 4.2 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.082 178.299 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 24.1 m -48.05 108.19 0.16 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 124.799 1.312 . . . . 0.0 113.282 -175.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.78 -9.6 29.92 Favored Glycine 0 N--CA 1.421 -2.331 0 C-N-CA 120.543 -0.836 . . . . 0.0 112.737 177.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -109.36 155.49 21.16 Favored 'General case' 0 N--CA 1.423 -1.819 0 CA-C-N 117.219 0.51 . . . . 0.0 110.282 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.536 ' HE2' ' O ' ' A' ' 184' ' ' ILE . 18.7 ptmt -130.26 163.23 27.21 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.536 ' O ' ' HE2' ' A' ' 183' ' ' LYS . 3.7 tp -74.32 148.17 8.37 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.046 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -85.65 -74.29 0.41 Allowed 'General case' 0 C--N 1.289 -2.048 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.042 178.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -79.48 -97.88 0.28 Allowed Glycine 0 N--CA 1.442 -0.937 0 C-N-CA 121.043 -0.598 . . . . 0.0 112.443 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -118.19 150.92 38.6 Favored 'General case' 0 CA--C 1.484 -1.566 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 179.349 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -95.15 -1.92 50.91 Favored 'General case' 0 CA--C 1.499 -1.007 0 C-N-CA 120.155 -0.618 . . . . 0.0 111.049 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.481 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.5 pt-20 -146.35 146.72 30.77 Favored 'General case' 0 C--N 1.294 -1.844 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.437 -178.086 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.0 ptp -131.98 131.43 42.56 Favored 'General case' 0 C--N 1.298 -1.657 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.117 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 42.4 t-80 -102.83 138.52 39.61 Favored 'General case' 0 C--N 1.29 -1.989 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 177.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . 0.419 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 42.7 t -81.95 135.41 35.39 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.711 177.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.0 m -99.21 165.07 11.88 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 178.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -75.43 4.52 7.22 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.219 0.533 . . . . 0.0 111.621 -176.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -68.45 -32.51 72.58 Favored 'General case' 0 CA--C 1.507 -0.706 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.286 172.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 109.4 8.82 26.41 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 111.079 -0.808 . . . . 0.0 111.079 -175.562 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -142.06 173.23 11.7 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-O 120.691 0.282 . . . . 0.0 110.651 177.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . 0.419 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 66.2 m95 -82.95 148.25 27.73 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.056 -175.296 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 20.3 m -67.51 -25.27 65.76 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.654 0.74 . . . . 0.0 110.754 178.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.406 ' HA ' ' HD3' ' A' ' 200' ' ' LYS . 26.4 mmtp -124.63 148.88 47.65 Favored 'General case' 0 CA--C 1.487 -1.456 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.947 179.064 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -82.05 161.51 22.9 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 175.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . 0.413 ' HB2' ' HE2' ' A' ' 202' ' ' LYS . 10.5 ptmm? -63.51 137.95 97.23 Favored Pre-proline 0 N--CA 1.431 -1.396 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.6 -178.359 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.419 ' CG ' HD11 ' A' ' 184' ' ' ILE . 63.7 Cg_endo -86.89 -169.98 0.58 Allowed 'Trans proline' 0 N--CA 1.434 -1.985 0 C-N-CA 122.815 2.343 . . . . 0.0 113.919 -175.267 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . 0.49 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 61.2 tttp -134.42 158.61 43.44 Favored 'General case' 0 N--CA 1.424 -1.753 0 CA-C-N 113.948 -1.478 . . . . 0.0 107.669 -176.519 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.432 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 89.3 m -116.08 115.58 26.34 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 174.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.563 -175.51 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.49 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 33.0 Cg_endo . . . . . 0 CA--C 1.538 0.723 0 CA-C-O 121.107 0.378 . . . . 0.0 112.012 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.0 m -84.86 -32.62 23.12 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 121.891 0.853 . . . . 0.0 109.347 177.526 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.91 -92.05 0.53 Allowed Glycine 0 N--CA 1.405 -3.408 0 N-CA-C 109.336 -1.505 . . . . 0.0 109.336 175.337 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 30.2 t-80 -174.44 139.45 0.69 Allowed Pre-proline 0 C--N 1.265 -3.089 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 -176.371 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.458 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 88.1 Cg_endo -85.91 -0.1 8.48 Favored 'Trans proline' 0 N--CA 1.473 0.274 0 C-N-CA 122.093 1.862 . . . . 0.0 112.947 -175.222 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.446 ' HA3' HD11 ' A' ' 138' ' ' ILE . . . 109.59 -172.64 16.19 Favored Glycine 0 C--N 1.296 -1.692 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -176.06 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -146.96 163.61 35.64 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 179.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.8 t -141.32 139.19 18.55 Favored Pre-proline 0 C--N 1.3 -1.556 0 C-N-CA 120.532 -0.467 . . . . 0.0 111.528 -176.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -77.4 -12.7 16.99 Favored 'Trans proline' 0 CA--C 1.529 0.267 0 C-N-CA 122.696 2.264 . . . . 0.0 111.288 176.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -88.48 2.46 52.79 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.771 -175.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 159.59 -133.66 3.42 Favored Glycine 0 N--CA 1.41 -3.093 0 C-N-CA 120.213 -0.994 . . . . 0.0 111.859 179.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 14.1 p -148.85 -172.89 4.21 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -173.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -144.11 167.15 23.08 Favored 'General case' 0 N--CA 1.423 -1.779 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 173.18 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -131.59 157.76 42.78 Favored 'General case' 0 C--N 1.279 -2.457 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 178.207 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 22.7 mt -110.9 138.84 46.79 Favored 'General case' 0 C--N 1.265 -3.099 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.286 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.2 p -129.96 131.02 45.79 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.342 -178.094 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.18 16.19 45.0 Favored Glycine 0 CA--C 1.501 -0.797 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -175.046 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 147.77 160.46 8.95 Favored Glycine 1 N--CA 1.376 -5.305 0 N-CA-C 106.212 -2.755 . . . . 0.0 106.212 -175.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 -114.09 35.77 4.0 Favored 'General case' 0 C--N 1.25 -3.739 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 -179.579 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.445 ' O ' HG11 ' A' ' 108' ' ' VAL . 16.7 m -144.96 -173.82 0.49 Allowed 'Isoleucine or valine' 0 C--O 1.204 -1.291 0 CA-C-N 114.371 -1.286 . . . . 0.0 109.623 -175.126 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.458 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 29.5 m-85 -110.02 46.6 1.01 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 121.392 0.615 . . . . 0.0 109.554 -178.015 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.704 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.0 pt-20 -86.91 178.74 6.87 Favored 'General case' 0 C--O 1.212 -0.892 0 CA-C-N 114.909 -1.041 . . . . 0.0 111.427 178.209 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -75.54 132.26 40.6 Favored 'General case' 0 C--N 1.296 -1.752 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.223 177.44 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 90.69 10.49 63.19 Favored Glycine 0 N--CA 1.438 -1.194 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.969 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.704 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.5 p -102.29 148.07 8.2 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 176.67 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 52.4 mtpt -117.12 123.22 46.22 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 120.907 0.384 . . . . 0.0 110.532 -179.092 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.403 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.39 91.62 8.57 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.17 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.8 t -85.16 110.97 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.31 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -78.17 143.24 37.4 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 112.462 0.542 . . . . 0.0 112.462 -177.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.8 t -142.98 112.94 7.06 Favored 'General case' 0 N--CA 1.43 -1.445 0 CA-C-O 121.712 0.768 . . . . 0.0 109.461 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 89.8 m -65.81 162.17 19.41 Favored 'General case' 0 C--N 1.311 -1.09 0 N-CA-C 114.329 1.233 . . . . 0.0 114.329 -178.075 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -68.71 -179.97 1.57 Allowed 'General case' 0 N--CA 1.433 -1.293 0 C-N-CA 125.612 1.565 . . . . 0.0 109.892 178.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -59.95 -52.65 64.48 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 124.099 0.959 . . . . 0.0 111.145 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -86.81 33.1 3.81 Favored Glycine 0 C--N 1.308 -1.007 0 C-N-CA 120.426 -0.892 . . . . 0.0 113.791 -176.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.525 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 86.3 m-85 -150.54 170.43 19.13 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 123.725 0.81 . . . . 0.0 110.024 -177.142 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.406 HE21 ' HB2' ' A' ' 119' ' ' GLN . 0.0 OUTLIER -150.34 156.89 42.37 Favored 'General case' 0 N--CA 1.427 -1.617 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 176.659 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 8.2 tt -87.42 136.68 32.84 Favored 'General case' 0 C--N 1.27 -2.881 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -117.51 130.34 56.37 Favored 'General case' 0 N--CA 1.428 -1.54 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -176.578 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 120.97 172.14 14.45 Favored Glycine 0 N--CA 1.43 -1.733 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 -178.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 57.2 mm-40 -88.57 -25.43 22.5 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-O 121.256 0.55 . . . . 0.0 109.942 178.473 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.7 mm -87.44 127.78 40.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-N 114.604 -1.18 . . . . 0.0 108.528 -179.589 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -133.52 14.98 4.07 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.042 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.403 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 30.3 p90 -153.65 159.84 42.2 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-O 121.031 0.443 . . . . 0.0 110.558 -175.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 50.6 mtp180 -122.7 134.65 54.46 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 171.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -112.56 126.49 55.4 Favored 'General case' 0 C--N 1.278 -2.524 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -176.556 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 28.8 t -82.63 99.53 9.62 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 117.738 -1.585 . . . . 0.0 110.675 177.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.476 ' OD2' HG22 ' A' ' 131' ' ' THR . 14.1 t70 -95.87 -168.35 1.75 Allowed 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 175.112 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.476 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -64.65 -23.58 67.3 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -172.707 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -78.76 -28.13 44.76 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.778 0.799 . . . . 0.0 109.787 176.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 130.65 -154.35 20.66 Favored Glycine 0 N--CA 1.422 -2.257 0 N-CA-C 108.614 -1.795 . . . . 0.0 108.614 -175.07 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.402 ' CH2' HG13 ' A' ' 108' ' ' VAL . 97.5 m95 -65.06 112.47 3.37 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 117.112 0.456 . . . . 0.0 111.411 178.127 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 76.5 p -73.47 159.94 32.46 Favored 'General case' 0 C--O 1.271 2.227 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 175.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 89.3 m-20 63.4 -163.15 0.27 Allowed 'General case' 0 C--O 1.242 0.689 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . 0.458 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 17.1 t70 -141.25 -173.24 3.69 Favored 'General case' 0 C--N 1.283 -2.291 0 N-CA-C 106.114 -1.809 . . . . 0.0 106.114 173.488 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.458 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 67.1 mt -66.32 120.53 70.89 Favored Pre-proline 0 C--N 1.266 -3.027 0 C-N-CA 124.643 1.177 . . . . 0.0 108.727 179.753 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -68.31 139.25 45.16 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 122.238 1.958 . . . . 0.0 111.126 -179.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 73.6 mt -62.49 125.89 19.73 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 CA-C-O 121.742 0.782 . . . . 0.0 110.732 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.525 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 43.1 t -102.48 123.95 47.16 Favored 'General case' 0 N--CA 1.406 -2.652 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 176.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -105.09 154.47 20.11 Favored 'General case' 0 N--CA 1.413 -2.291 0 N-CA-C 107.859 -1.163 . . . . 0.0 107.859 -174.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 15.0 p -80.39 143.37 12.5 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.768 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.285 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.57 HG23 ' HB2' ' A' ' 170' ' ' PHE . 6.4 m -65.3 130.86 30.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 176.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.451 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 96.2 mttt -120.03 141.62 49.56 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.291 -174.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 29.4 m -108.92 160.06 16.3 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 124.199 0.937 . . . . 0.0 108.568 177.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . 0.414 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.0 mm? -76.63 149.69 81.22 Favored Pre-proline 0 N--CA 1.418 -2.074 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 2.9 Cg_exo -68.19 114.76 3.53 Favored 'Trans proline' 0 N--CA 1.442 -1.503 0 C-N-CA 122.679 2.253 . . . . 0.0 110.242 175.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.43 HG21 ' SD ' ' A' ' 190' ' ' MET . 41.5 t -71.36 147.19 11.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.142 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.27 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 22.8 p -71.57 -80.4 0.06 Allowed 'General case' 0 N--CA 1.435 -1.221 0 O-C-N 123.117 0.26 . . . . 0.0 111.353 -179.693 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.6 161.02 0.48 Allowed Pre-proline 0 C--O 1.24 0.587 0 C-N-CA 125.607 1.563 . . . . 0.0 107.612 177.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -78.84 -158.03 0.08 OUTLIER 'Trans proline' 0 CA--C 1.547 1.17 0 C-N-CA 121.555 1.503 . . . . 0.0 111.048 171.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . 0.463 ' CD ' ' H ' ' A' ' 153' ' ' GLU . 0.0 OUTLIER -99.91 -52.16 3.51 Favored 'General case' 0 C--N 1.31 -1.148 0 O-C-N 121.861 -0.524 . . . . 0.0 112.271 -175.668 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 61.8 m-80 -107.19 25.58 11.23 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.605 0.716 . . . . 0.0 110.141 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -151.13 -176.78 24.33 Favored Glycine 0 N--CA 1.417 -2.633 0 N-CA-C 110.297 -1.121 . . . . 0.0 110.297 -179.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 16.5 pttm -145.82 168.93 19.6 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 -179.334 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.465 ' HB ' ' OG ' ' A' ' 160' ' ' SER . 52.1 mt -91.6 141.84 13.9 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.463 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 2.5 m -90.98 -30.65 4.88 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 178.319 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.418 ' HA ' ' SD ' ' A' ' 162' ' ' MET . 10.4 m -98.85 36.79 1.61 Allowed 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.472 -174.075 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . 0.465 ' OG ' ' HB ' ' A' ' 157' ' ' ILE . 29.6 m -77.64 69.91 3.94 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 117.741 0.246 . . . . 0.0 111.179 -179.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 46.24 79.67 0.05 Allowed 'General case' 0 C--O 1.234 0.289 0 C-N-CA 124.807 1.243 . . . . 0.0 112.278 -177.597 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.418 ' SD ' ' HA ' ' A' ' 159' ' ' SER . 4.0 mpp? -56.9 -43.65 81.57 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-O 121.617 0.723 . . . . 0.0 109.665 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.479 ' HG3' ' HG2' ' A' ' 166' ' ' ARG . 9.0 pt-20 -118.71 138.65 26.16 Favored Pre-proline 0 C--N 1.298 -1.666 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 176.668 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -77.58 16.0 1.15 Allowed 'Trans proline' 0 N--CA 1.48 0.706 0 C-N-CA 123.039 2.493 . . . . 0.0 113.444 -175.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -105.09 -32.7 8.58 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 121.416 0.627 . . . . 0.0 109.905 -176.751 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.479 ' HG2' ' HG3' ' A' ' 163' ' ' GLU . 12.5 ptp180 -96.7 118.98 34.32 Favored 'General case' 0 N--CA 1.391 -3.391 0 C-N-CA 118.659 -1.216 . . . . 0.0 112.986 -174.131 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 30.4 mm-40 -82.64 168.88 16.85 Favored 'General case' 0 C--N 1.276 -2.625 0 CA-C-N 113.552 -1.658 . . . . 0.0 108.534 171.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . 0.451 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 79.6 m-85 -75.58 104.96 6.37 Favored 'General case' 0 C--N 1.293 -1.868 0 CA-C-O 121.506 0.669 . . . . 0.0 109.897 -179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 20.0 m170 -106.36 160.44 15.38 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 114.538 -1.21 . . . . 0.0 108.249 -175.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.57 ' HB2' HG23 ' A' ' 144' ' ' VAL . 65.0 t80 -50.02 123.99 9.25 Favored 'General case' 0 N--CA 1.47 0.539 0 O-C-N 123.287 0.367 . . . . 0.0 110.107 172.179 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 102.43 -0.83 49.87 Favored Glycine 0 N--CA 1.428 -1.839 0 C-N-CA 119.497 -1.335 . . . . 0.0 112.919 178.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 30.3 mm-40 -88.13 145.02 26.15 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 175.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -113.47 117.77 32.64 Favored 'General case' 0 C--N 1.281 -2.409 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.511 -179.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 54.5 t -98.71 101.24 11.87 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 176.305 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.463 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 16.2 ttm180 -93.45 145.98 24.1 Favored 'General case' 0 N--CA 1.415 -2.219 0 CA-C-N 114.906 -1.043 . . . . 0.0 110.54 -179.293 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.449 ' CD2' HG12 ' A' ' 157' ' ' ILE . 68.6 m-85 -114.89 156.15 25.52 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 14.6 p -137.01 139.84 43.76 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.212 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.6 m -95.5 138.75 32.73 Favored 'General case' 0 C--N 1.269 -2.934 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.237 -176.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . 0.468 ' O ' ' HD2' ' A' ' 182' ' ' TYR . 58.9 m-20 -82.72 165.42 19.95 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 -179.349 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.7 t 49.07 -142.55 0.55 Allowed 'General case' 0 CA--C 1.548 0.867 0 O-C-N 124.057 0.848 . . . . 0.0 110.805 178.265 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -93.49 32.44 5.76 Favored Glycine 0 N--CA 1.428 -1.865 0 C-N-CA 121.19 -0.529 . . . . 0.0 111.876 178.454 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . 0.468 ' HD2' ' O ' ' A' ' 179' ' ' ASN . 96.9 m-85 -84.23 160.49 20.78 Favored 'General case' 0 N--CA 1.443 -0.802 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.378 -179.216 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 25.6 pttm -126.54 155.03 43.03 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 2.6 tp -71.82 144.77 12.91 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 178.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -85.71 -65.85 0.96 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.363 179.092 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -86.26 -113.88 0.87 Allowed Glycine 0 N--CA 1.439 -1.162 0 N-CA-C 111.817 -0.513 . . . . 0.0 111.817 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.4 t70 -100.05 157.47 16.53 Favored 'General case' 0 C--N 1.297 -1.714 0 N-CA-C 106.827 -1.545 . . . . 0.0 106.827 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -93.51 -8.7 40.7 Favored 'General case' 0 N--CA 1.433 -1.283 0 C-N-CA 119.305 -0.958 . . . . 0.0 109.401 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.43 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 2.9 pt-20 -146.23 130.41 17.48 Favored 'General case' 0 N--CA 1.43 -1.442 0 CA-C-O 121.932 0.872 . . . . 0.0 112.835 178.698 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.43 ' SD ' HG21 ' A' ' 149' ' ' VAL . 12.8 ptp -102.01 143.16 32.21 Favored 'General case' 0 C--N 1.298 -1.669 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.514 177.182 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -113.66 150.11 33.69 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 2.4 m -74.04 123.18 23.87 Favored 'General case' 0 C--N 1.305 -1.335 0 O-C-N 123.685 0.615 . . . . 0.0 110.795 173.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . 0.423 ' HB2' ' OG ' ' A' ' 199' ' ' SER . 34.4 t -83.94 167.52 16.88 Favored 'General case' 0 N--CA 1.423 -1.795 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 176.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -71.81 -5.16 32.21 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 123.534 0.734 . . . . 0.0 111.351 -177.141 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -84.82 -18.87 33.6 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.412 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 88.81 27.46 24.04 Favored Glycine 0 N--CA 1.451 -0.309 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 -173.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 64.0 m-85 -131.94 161.55 32.82 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 179.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 91.8 m95 -77.87 131.06 37.35 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 176.464 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . 0.423 ' OG ' ' HB2' ' A' ' 193' ' ' SER . 15.0 m -68.04 -39.45 83.05 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-O 121.548 0.69 . . . . 0.0 110.064 -179.353 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 21.5 mmtp -96.33 150.27 20.76 Favored 'General case' 0 C--N 1.307 -1.247 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.75 177.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 22.9 mm-40 -86.3 166.23 15.81 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 176.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 28.3 ttmt -67.47 121.85 80.68 Favored Pre-proline 0 C--N 1.324 -0.519 0 C-N-CA 119.51 -0.876 . . . . 0.0 109.47 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -78.5 -174.86 2.44 Favored 'Trans proline' 0 N--CA 1.437 -1.834 0 C-N-CA 121.996 1.797 . . . . 0.0 111.759 179.183 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . 0.424 ' HG2' ' OE1' ' A' ' 153' ' ' GLU . 48.2 mttm -127.9 162.58 26.39 Favored 'General case' 0 C--N 1.287 -2.124 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.295 179.217 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 77.5 m -113.32 106.28 14.42 Favored 'General case' 0 C--N 1.281 -2.408 0 O-C-N 124.057 0.848 . . . . 0.0 109.137 170.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.5 m . . . . . 0 N--CA 1.431 -1.415 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.313 -173.759 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.447 ' HG2' ' HA ' ' A' ' 105' ' ' GLU . 33.9 Cg_endo . . . . . 0 CA--C 1.536 0.608 0 CA-C-O 121.113 0.38 . . . . 0.0 111.934 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.8 m -86.49 -33.69 20.27 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 176.085 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.74 -96.66 0.67 Allowed Glycine 0 N--CA 1.402 -3.593 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 173.035 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 56.0 t-80 -173.1 121.03 0.41 Allowed Pre-proline 0 C--N 1.263 -3.169 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -175.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.08 -30.79 13.05 Favored 'Trans proline' 0 C--O 1.219 -0.436 0 C-N-CA 121.909 1.74 . . . . 0.0 113.369 -171.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.22 176.13 14.34 Favored Glycine 0 CA--C 1.483 -1.936 0 N-CA-C 108.347 -1.901 . . . . 0.0 108.347 -176.468 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -134.7 -175.49 3.91 Favored 'General case' 0 C--N 1.289 -2.046 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -177.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 2.1 t -141.47 133.5 13.78 Favored Pre-proline 0 C--N 1.303 -1.43 0 CA-C-O 121.234 0.54 . . . . 0.0 112.131 -178.115 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -71.83 -18.1 28.53 Favored 'Trans proline' 0 C--O 1.238 0.513 0 C-N-CA 122.554 2.169 . . . . 0.0 111.389 175.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -86.72 -3.42 59.04 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.072 -176.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.474 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.89 -123.47 0.94 Allowed Glycine 0 N--CA 1.424 -2.157 0 C-N-CA 120.033 -1.079 . . . . 0.0 112.04 179.234 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 11.7 t -157.93 -166.48 1.98 Allowed 'General case' 0 C--N 1.285 -2.205 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 35.0 p90 -149.77 162.15 40.83 Favored 'General case' 0 N--CA 1.425 -1.695 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 177.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 7.0 m -128.34 161.41 29.47 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 -178.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 25.4 mt -117.11 128.6 55.29 Favored 'General case' 0 C--N 1.266 -3.042 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.439 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 32.0 p -123.76 135.17 53.67 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -175.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 105.95 -45.33 1.32 Allowed Glycine 0 C--N 1.305 -1.19 0 N-CA-C 111.69 -0.564 . . . . 0.0 111.69 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.464 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -131.9 -16.59 1.41 Allowed Glycine 0 C--O 1.219 -0.784 0 C-N-CA 120.263 -0.97 . . . . 0.0 113.524 -177.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 64.5 12.97 7.84 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 123.657 0.783 . . . . 0.0 113.014 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.516 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.4 m -145.95 -169.4 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 -177.201 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 33.8 m-85 -105.14 45.54 0.96 Allowed 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 118.692 0.678 . . . . 0.0 110.461 -178.232 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.721 ' O ' HG12 ' A' ' 108' ' ' VAL . 9.3 pt-20 -89.68 -176.18 4.9 Favored 'General case' 0 C--O 1.208 -1.094 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.884 178.231 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 47.0 m-85 -79.08 138.63 38.04 Favored 'General case' 0 C--N 1.31 -1.132 0 O-C-N 121.648 -0.657 . . . . 0.0 111.119 179.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 85.59 4.31 85.6 Favored Glycine 0 N--CA 1.439 -1.155 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.992 179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.721 HG12 ' O ' ' A' ' 105' ' ' GLU . 15.0 p -93.39 143.67 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.943 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 177.552 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.439 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 54.9 mtpt -108.08 118.38 36.6 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.368 178.669 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -83.08 91.87 7.29 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 175.575 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.421 HG12 ' CB ' ' A' ' 126' ' ' TYR . 32.3 m -91.83 117.58 35.44 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.405 0 CA-C-O 122.19 0.995 . . . . 0.0 108.735 -178.042 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 36.4 m-85 -84.42 146.71 27.51 Favored 'General case' 0 C--N 1.264 -3.143 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.918 -176.606 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.1 t -144.06 118.54 9.7 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-O 122.102 0.954 . . . . 0.0 108.919 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 3.8 m -75.12 160.93 29.87 Favored 'General case' 0 C--N 1.284 -2.25 0 CA-C-N 115.29 -0.868 . . . . 0.0 108.966 -176.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.474 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 75.4 m-20 -73.15 171.03 13.72 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 177.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -48.06 -49.37 31.72 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 124.553 1.141 . . . . 0.0 113.525 -176.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.548 ' HA2' ' CD2' ' A' ' 170' ' ' PHE . . . -80.61 8.46 54.8 Favored Glycine 0 C--N 1.309 -0.95 0 CA-C-N 116.025 -0.534 . . . . 0.0 113.37 -176.635 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.63 ' CE1' HG22 ' A' ' 143' ' ' VAL . 94.0 m-85 -130.71 150.61 51.81 Favored 'General case' 0 N--CA 1.434 -1.249 0 CA-C-O 121.501 0.667 . . . . 0.0 110.397 -178.478 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -119.08 163.5 16.92 Favored 'General case' 0 C--N 1.276 -2.614 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.47 HD11 ' HB2' ' A' ' 139' ' ' PRO . 13.4 tp -83.48 141.53 31.59 Favored 'General case' 0 C--N 1.282 -2.361 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 177.273 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.452 HD22 ' HA ' ' A' ' 121' ' ' LEU . 0.3 OUTLIER -112.72 116.94 30.92 Favored 'General case' 0 N--CA 1.408 -2.57 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 179.149 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.6 -169.33 13.14 Favored Glycine 0 C--N 1.276 -2.777 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.02 -174.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -100.53 -48.93 4.37 Favored 'General case' 0 C--N 1.287 -2.111 0 CA-C-N 114.926 -0.637 . . . . 0.0 109.304 -174.779 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.6 mm -68.0 126.67 28.27 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 CA-C-N 114.589 -1.187 . . . . 0.0 109.874 -176.085 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -122.91 3.13 9.42 Favored 'General case' 0 C--O 1.198 -1.654 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.219 176.346 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.421 ' CB ' HG12 ' A' ' 111' ' ' VAL . 20.9 p90 -138.28 161.85 35.84 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.068 -173.441 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 58.1 mtp180 -126.5 131.18 51.68 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 170.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -107.62 132.18 53.58 Favored 'General case' 0 C--N 1.279 -2.485 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 -177.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 43.1 t -81.02 104.5 11.57 Favored 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 118.02 -1.472 . . . . 0.0 110.303 176.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.516 ' OD1' HG22 ' A' ' 131' ' ' THR . 15.0 t70 -97.23 -169.43 1.85 Allowed 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.516 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.0 t -68.73 -17.02 63.98 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.631 0.729 . . . . 0.0 110.921 -175.614 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -87.9 -24.01 23.77 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.694 177.011 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 122.65 -154.03 16.95 Favored Glycine 0 N--CA 1.416 -2.646 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -174.335 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.431 ' CH2' HG13 ' A' ' 108' ' ' VAL . 93.9 m95 -63.34 115.1 4.27 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 55.4 p -76.66 168.87 19.32 Favored 'General case' 0 C--O 1.261 1.689 0 N-CA-C 109.287 -0.635 . . . . 0.0 109.287 176.531 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 61.53 -170.75 0.16 Allowed 'General case' 0 C--O 1.242 0.672 0 O-C-N 123.94 0.775 . . . . 0.0 111.918 177.438 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -112.64 171.29 7.61 Favored 'General case' 0 CA--C 1.469 -2.163 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 175.339 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.6 mt -67.57 113.4 14.0 Favored Pre-proline 0 C--N 1.297 -1.708 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 170.294 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.47 ' HB2' HD11 ' A' ' 120' ' ' LEU . 45.2 Cg_endo -66.46 131.69 27.06 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 122.052 1.835 . . . . 0.0 111.711 -176.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 69.3 mt -80.58 131.58 33.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.887 -176.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 74.3 m -103.52 149.56 24.74 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 174.191 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 8.7 mt-10 -125.49 168.37 13.73 Favored 'General case' 0 C--N 1.287 -2.117 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 174.226 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.63 HG22 ' CE1' ' A' ' 118' ' ' TYR . 99.6 t -67.65 143.3 15.51 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 177.028 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.446 ' HB ' ' HB2' ' A' ' 170' ' ' PHE . 72.6 t -61.5 130.7 25.99 Favored 'Isoleucine or valine' 0 C--O 1.242 0.668 0 N-CA-C 107.877 -1.156 . . . . 0.0 107.877 174.509 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.44 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 84.0 mttt -120.28 152.19 38.14 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 -175.264 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 59.0 m -118.42 160.04 22.4 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 64.4 mt -69.72 144.73 94.06 Favored Pre-proline 0 C--O 1.24 0.603 0 N-CA-C 112.282 0.475 . . . . 0.0 112.282 178.597 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -64.68 131.48 29.59 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 123.197 2.598 . . . . 0.0 112.449 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 44.2 t -90.94 136.82 23.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 179.245 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 15.3 p -73.55 -85.93 0.03 OUTLIER 'General case' 0 C--N 1.314 -0.965 0 CA-C-O 120.636 0.255 . . . . 0.0 111.55 178.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 177.0 150.24 0.35 Allowed Pre-proline 0 C--O 1.242 0.672 0 C-N-CA 125.627 1.571 . . . . 0.0 107.493 177.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . 0.413 ' HB3' ' O ' ' A' ' 203' ' ' PRO . 59.0 Cg_endo -77.88 171.16 17.75 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.008 1.805 . . . . 0.0 111.263 174.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -65.06 -59.96 3.55 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 114.645 1.35 . . . . 0.0 114.645 -174.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 44.2 m-80 -107.52 29.88 6.78 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-O 121.845 0.831 . . . . 0.0 110.161 -178.198 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.88 178.14 22.89 Favored Glycine 0 N--CA 1.419 -2.438 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 178.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 57.5 pttt -145.79 166.14 26.79 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.178 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.429 HG23 HG13 ' A' ' 174' ' ' VAL . 56.9 mt -83.69 134.13 27.62 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 CA-C-O 121.348 0.594 . . . . 0.0 111.005 -178.455 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 53.5 t -68.81 -43.1 82.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.131 -0.94 . . . . 0.0 109.595 178.044 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 35.0 t -79.67 82.7 5.74 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 121.676 0.75 . . . . 0.0 109.464 176.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 45.3 m -94.81 149.07 21.63 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.106 178.59 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 68.44 86.12 0.13 Allowed 'General case' 0 CA--C 1.501 -0.924 0 CA-C-O 122.637 1.208 . . . . 0.0 112.418 -177.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.504 ' O ' ' HA ' ' A' ' 166' ' ' ARG . 57.2 mmm -95.37 86.64 4.56 Favored 'General case' 0 N--CA 1.406 -2.666 0 CA-C-N 114.422 -1.263 . . . . 0.0 109.47 -179.079 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.599 ' H ' ' HD2' ' A' ' 164' ' ' PRO . 8.2 mm-40 -142.68 -41.5 0.01 OUTLIER Pre-proline 0 C--N 1.289 -2.057 0 CA-C-N 113.642 -1.617 . . . . 0.0 111.966 -178.255 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . 0.599 ' HD2' ' H ' ' A' ' 163' ' ' GLU . 7.4 Cg_endo -56.52 -22.76 44.47 Favored 'Trans proline' 0 C--N 1.373 1.828 0 CA-C-N 120.403 1.179 . . . . 0.0 111.02 166.681 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -125.66 -20.48 4.68 Favored 'General case' 0 C--O 1.213 -0.832 0 CA-C-N 116.024 -0.534 . . . . 0.0 109.777 178.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.504 ' HA ' ' O ' ' A' ' 162' ' ' MET . 24.2 mtp180 58.97 -81.57 0.02 OUTLIER 'General case' 0 C--N 1.362 1.129 0 N-CA-C 114.821 1.415 . . . . 0.0 114.821 -178.252 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -97.19 133.38 41.91 Favored 'General case' 1 C--N 1.243 -4.056 0 C-N-CA 126.403 1.881 . . . . 0.0 109.235 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 73.8 m-85 -61.32 110.03 1.3 Allowed 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.777 0.798 . . . . 0.0 112.79 -175.526 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.498 ' HB3' HG11 ' A' ' 143' ' ' VAL . 38.0 m80 -95.43 152.02 18.78 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 114.399 -1.273 . . . . 0.0 112.057 -178.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.548 ' CD2' ' HA2' ' A' ' 117' ' ' GLY . 0.9 OUTLIER -62.56 106.04 0.72 Allowed 'General case' 0 C--O 1.239 0.535 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 172.731 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 138.35 -12.53 3.52 Favored Glycine 0 N--CA 1.428 -1.884 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -174.681 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 31.7 mm-40 -99.34 160.74 14.06 Favored 'General case' 0 C--O 1.259 1.57 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 177.131 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -140.78 135.24 31.28 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 178.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.497 HG23 ' CH2' ' A' ' 198' ' ' TRP . 92.7 t -99.34 106.03 18.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.907 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.404 ' HA ' ' HA ' ' A' ' 189' ' ' GLU . 56.3 ttt180 -97.95 158.17 15.69 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 178.24 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -130.45 153.49 48.72 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -172.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.2 p -134.97 143.19 38.07 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 81.9 m -99.03 145.3 27.23 Favored 'General case' 0 C--N 1.283 -2.296 0 CA-C-N 115.607 -0.724 . . . . 0.0 112.218 -175.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -69.79 159.49 33.48 Favored 'General case' 0 N--CA 1.434 -1.257 0 CA-C-N 115.383 -0.826 . . . . 0.0 108.885 175.089 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 38.4 m -58.44 112.3 1.53 Allowed 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.805 -175.096 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 114.72 -13.43 20.3 Favored Glycine 0 N--CA 1.438 -1.218 0 CA-C-N 115.145 -0.934 . . . . 0.0 111.761 -178.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -107.83 160.96 15.33 Favored 'General case' 0 N--CA 1.433 -1.305 0 CA-C-O 120.876 0.369 . . . . 0.0 111.733 -177.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.533 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 22.3 pttm -131.24 152.75 50.2 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 178.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.569 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.4 tt -80.61 136.05 24.05 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.285 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.332 175.738 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 14.6 tp10 -75.0 -54.95 6.29 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.078 -176.502 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -91.38 -144.61 13.22 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.519 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -77.92 157.9 29.6 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.569 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.4 pt-20 -89.91 -5.63 56.58 Favored 'General case' 0 C--N 1.308 -1.212 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.557 -174.538 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.436 ' HG2' ' HG3' ' A' ' 188' ' ' GLU . 3.6 pt-20 -147.77 142.28 26.47 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.17 0.51 . . . . 0.0 111.977 -175.465 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.472 ' CG ' ' HB ' ' A' ' 174' ' ' VAL . 14.3 ptp -120.29 134.79 55.19 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.105 -0.952 . . . . 0.0 108.537 175.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 21.9 t-80 -112.36 147.01 37.29 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 110.56 -0.163 . . . . 0.0 110.56 -175.257 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . 0.404 ' HB3' ' HA ' ' A' ' 170' ' ' PHE . 1.5 m -70.68 120.01 15.66 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 116.663 -0.244 . . . . 0.0 110.542 173.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.1 m -98.7 163.95 12.43 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.836 178.104 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -47.17 -32.66 4.55 Favored 'General case' 0 N--CA 1.498 1.926 0 C-N-CA 126.533 1.933 . . . . 0.0 114.078 -178.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -73.1 -17.08 61.44 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 94.99 28.35 10.08 Favored Glycine 0 C--N 1.307 -1.069 0 C-N-CA 119.917 -1.135 . . . . 0.0 112.093 -178.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 2.5 p90 -140.62 172.05 13.25 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 110.176 -0.305 . . . . 0.0 110.176 176.45 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . 0.497 ' CH2' HG23 ' A' ' 174' ' ' VAL . 87.5 m95 -82.22 143.3 31.47 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 123.717 0.636 . . . . 0.0 111.129 -178.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 5.0 m -69.13 -6.46 28.72 Favored 'General case' 0 CA--C 1.549 0.937 0 C-N-CA 124.109 0.964 . . . . 0.0 111.245 178.197 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.459 ' HB2' ' HB3' ' A' ' 190' ' ' MET . 25.9 mmmt -140.52 150.99 44.41 Favored 'General case' 0 CA--C 1.482 -1.666 0 C-N-CA 123.863 0.865 . . . . 0.0 109.467 -178.315 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -89.65 157.62 17.94 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 104.561 -2.385 . . . . 0.0 104.561 169.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 25.9 ttpp -60.85 114.44 10.4 Favored Pre-proline 0 C--O 1.243 0.759 0 N-CA-C 114.479 1.289 . . . . 0.0 114.479 -172.062 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.436 ' HG2' HD11 ' A' ' 184' ' ' ILE . 90.3 Cg_endo -78.89 165.58 24.21 Favored 'Trans proline' 0 N--CA 1.435 -1.936 0 C-N-CA 123.113 2.542 . . . . 0.0 109.786 176.09 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.9 pttt -139.08 162.76 34.15 Favored 'General case' 0 C--N 1.285 -2.209 0 C-N-CA 120.005 -0.678 . . . . 0.0 111.543 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.533 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 73.6 m -96.29 121.4 38.04 Favored 'General case' 0 N--CA 1.406 -2.628 0 CA-C-N 114.455 -1.248 . . . . 0.0 110.052 179.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 13.4 m . . . . . 0 C--N 1.295 -1.775 0 C-N-CA 125.384 1.474 . . . . 0.0 108.181 -177.02 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo . . . . . 0 CA--C 1.538 0.703 0 CA-C-O 121.201 0.417 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 34.2 m -75.54 -37.18 60.21 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.674 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 120.41 -95.86 0.6 Allowed Glycine 0 N--CA 1.4 -3.742 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 173.608 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.2 t60 -173.26 123.67 0.43 Allowed Pre-proline 0 C--N 1.253 -3.596 0 N-CA-C 105.219 -2.141 . . . . 0.0 105.219 -175.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.496 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 81.3 Cg_endo -76.02 -3.52 13.96 Favored 'Trans proline' 0 C--O 1.213 -0.75 0 C-N-CA 122.766 2.31 . . . . 0.0 113.841 -171.519 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 112.97 -175.58 16.78 Favored Glycine 0 C--N 1.285 -2.295 0 N-CA-C 108.296 -1.921 . . . . 0.0 108.296 -176.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -152.92 118.52 5.31 Favored 'General case' 0 C--N 1.289 -2.023 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -176.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.1 t -91.22 133.85 30.91 Favored Pre-proline 0 C--N 1.304 -1.389 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -173.124 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -77.65 -13.73 16.17 Favored 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 122.725 2.283 . . . . 0.0 111.453 173.816 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -81.01 -10.32 59.72 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.934 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.535 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -178.41 -133.74 1.96 Allowed Glycine 0 N--CA 1.407 -3.299 0 C-N-CA 119.583 -1.294 . . . . 0.0 112.494 -178.746 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 21.0 p -143.39 -177.5 5.41 Favored 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -177.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 37.7 p90 -149.92 157.24 42.97 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 173.148 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.5 m -131.81 152.21 51.14 Favored 'General case' 0 C--N 1.289 -2.065 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.446 HD11 ' CE1' ' A' ' 104' ' ' PHE . 16.2 mt -106.12 131.49 53.32 Favored 'General case' 0 C--N 1.273 -2.731 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -177.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 20.5 p -123.01 137.92 54.82 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.0 -175.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 101.99 -56.96 0.66 Allowed Glycine 0 N--CA 1.436 -1.318 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 -177.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.485 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -110.04 -30.5 3.4 Favored Glycine 0 C--O 1.21 -1.383 0 C-N-CA 120.991 -0.623 . . . . 0.0 113.121 -178.216 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 42.0 m-80 70.6 11.4 7.28 Favored 'General case' 0 N--CA 1.506 2.329 0 C-N-CA 123.879 0.872 . . . . 0.0 110.96 -177.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.503 ' O ' HG11 ' A' ' 108' ' ' VAL . 24.3 m -148.8 -175.14 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.76 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 -179.385 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.446 ' CE1' HD11 ' A' ' 98' ' ' LEU . 24.4 m-85 -99.17 42.42 1.1 Allowed 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 119.25 0.932 . . . . 0.0 111.049 -176.151 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.718 ' O ' HG12 ' A' ' 108' ' ' VAL . 9.6 pt-20 -83.01 -179.67 7.51 Favored 'General case' 0 C--O 1.208 -1.128 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.877 177.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 48.6 m-85 -75.61 132.96 40.98 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.743 -0.598 . . . . 0.0 111.827 178.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.52 3.87 66.4 Favored Glycine 0 N--CA 1.435 -1.383 0 CA-C-N 115.695 -0.684 . . . . 0.0 112.842 177.583 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.718 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.9 p -90.28 143.7 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 C-N-CA 119.993 -0.683 . . . . 0.0 109.223 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.7 mtpt -107.81 119.36 39.24 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 178.47 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.44 93.3 9.1 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 177.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 79.4 t -85.37 113.94 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.506 0 C-N-CA 123.478 0.711 . . . . 0.0 109.231 -178.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -87.16 134.75 33.49 Favored 'General case' 0 C--N 1.282 -2.335 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.843 179.205 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -132.01 130.12 40.99 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -179.317 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 10.1 m -82.34 154.43 25.28 Favored 'General case' 0 C--N 1.278 -2.535 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.659 -173.117 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.535 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 86.5 m-20 -71.26 177.24 3.98 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-N 116.765 -0.198 . . . . 0.0 111.47 179.445 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . 0.412 ' O ' ' HB2' ' A' ' 194' ' ' ASP . 45.6 tt0 -52.41 -54.59 30.1 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 123.845 0.858 . . . . 0.0 112.021 -174.759 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.94 34.69 3.17 Favored Glycine 0 C--N 1.308 -0.992 0 C-N-CA 120.787 -0.72 . . . . 0.0 113.171 -179.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -147.09 156.4 42.97 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.103 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -133.91 169.1 17.59 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.446 HD11 ' HB2' ' A' ' 139' ' ' PRO . 15.4 tp -92.2 142.66 27.24 Favored 'General case' 0 C--N 1.28 -2.42 0 C-N-CA 119.574 -0.851 . . . . 0.0 109.006 177.622 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -124.58 122.49 37.72 Favored 'General case' 0 N--CA 1.414 -2.239 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 177.077 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.5 171.6 15.63 Favored Glycine 0 C--N 1.286 -2.201 0 C-N-CA 120.928 -0.653 . . . . 0.0 111.691 -176.608 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -95.91 -25.9 15.81 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.396 0.617 . . . . 0.0 109.808 -176.209 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.6 mm -90.2 137.36 21.69 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 23.0 p-10 -135.69 8.02 3.29 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 120.715 0.293 . . . . 0.0 110.639 179.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.5 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 28.8 p90 -146.29 171.35 15.11 Favored 'General case' 0 C--N 1.295 -1.796 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.067 -173.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.573 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 33.3 mtp180 -129.05 119.76 24.78 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 173.275 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -90.6 128.42 36.59 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.198 -1.001 . . . . 0.0 109.395 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 42.3 t -84.64 113.05 20.99 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 118.859 -1.136 . . . . 0.0 110.554 175.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -103.48 -172.33 2.09 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 177.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 10.8 t -64.19 -25.76 68.22 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.489 0.551 . . . . 0.0 112.489 -174.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -84.96 -23.94 28.54 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.13 0.491 . . . . 0.0 111.186 178.454 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 138.09 -158.01 24.59 Favored Glycine 0 N--CA 1.435 -1.381 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -177.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.413 ' CH2' HG13 ' A' ' 108' ' ' VAL . 93.4 m95 -68.57 113.04 5.74 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 178.441 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.2 p -64.49 -65.25 0.7 Allowed 'General case' 0 C--O 1.243 0.724 0 C-N-CA 123.049 0.54 . . . . 0.0 111.607 -176.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.573 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 4.1 m120 -72.38 167.82 19.72 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . 0.401 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 10.4 t70 -104.66 -171.65 1.96 Allowed 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 176.329 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.401 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 78.8 mt -72.92 121.6 85.48 Favored Pre-proline 0 C--N 1.274 -2.686 0 C-N-CA 124.497 1.119 . . . . 0.0 108.256 179.674 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.446 ' HB2' HD11 ' A' ' 120' ' ' LEU . 53.0 Cg_endo -69.69 160.7 48.73 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 122.027 1.818 . . . . 0.0 110.763 177.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.1 mm -95.91 124.64 48.66 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 CA-C-O 121.523 0.677 . . . . 0.0 110.95 -175.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 68.2 m -100.22 120.27 39.64 Favored 'General case' 0 C--N 1.271 -2.806 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 171.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 16.4 tp10 -102.36 146.1 28.54 Favored 'General case' 0 C--N 1.272 -2.777 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 -178.683 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.6 p -69.15 136.79 25.58 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.882 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.503 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.1 m -59.77 128.44 20.71 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 CA-C-O 121.22 0.533 . . . . 0.0 110.378 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 59.8 mttm -112.68 145.92 39.59 Favored 'General case' 0 C--N 1.292 -1.931 0 CA-C-N 115.183 -0.917 . . . . 0.0 109.56 -174.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.2 m -118.33 137.95 52.74 Favored 'General case' 0 C--N 1.277 -2.551 0 N-CA-C 106.157 -1.794 . . . . 0.0 106.157 -179.34 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 78.3 mt -62.32 143.42 95.63 Favored Pre-proline 0 C--N 1.313 -1.008 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -176.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -66.04 122.81 10.44 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.039 2.493 . . . . 0.0 110.408 177.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 51.7 t -76.33 149.25 6.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.941 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 6.3 p -68.95 -84.46 0.03 OUTLIER 'General case' 0 N--CA 1.439 -0.999 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.922 176.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 166.0 159.81 0.1 OUTLIER Pre-proline 0 CA--C 1.501 -0.94 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 177.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -72.28 156.11 55.36 Favored 'Trans proline' 0 N--CA 1.431 -2.167 0 CA-C-N 119.801 0.965 . . . . 0.0 109.89 171.094 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -64.92 -33.25 75.58 Favored 'General case' 0 C--N 1.28 -2.43 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -173.136 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -125.59 25.44 6.98 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-O 122.626 1.203 . . . . 0.0 109.045 -174.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.89 -155.8 6.59 Favored Glycine 0 N--CA 1.415 -2.738 0 CA-C-N 113.519 -1.673 . . . . 0.0 110.432 178.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . 0.514 ' HG3' HG23 ' A' ' 177' ' ' VAL . 24.1 pttm -157.79 174.41 15.34 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 107.947 -1.131 . . . . 0.0 107.947 179.37 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 41.7 mt -94.45 133.64 34.72 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.422 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.455 ' CG2' HG22 ' A' ' 177' ' ' VAL . 58.2 t -73.53 -48.45 41.13 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 177.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.9 m -79.62 85.4 5.35 Favored 'General case' 0 N--CA 1.429 -1.504 0 CA-C-N 115.019 -0.991 . . . . 0.0 109.021 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 37.0 t -121.71 -34.91 3.31 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.328 -175.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -113.25 91.17 3.55 Favored 'General case' 0 C--N 1.315 -0.92 0 O-C-N 121.924 -0.485 . . . . 0.0 110.919 -179.498 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 3.5 mpp? -112.87 -40.36 4.02 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.525 0.678 . . . . 0.0 109.994 178.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.409 ' HB2' ' H ' ' A' ' 166' ' ' ARG . 46.5 mt-10 -156.88 168.09 13.18 Favored Pre-proline 0 C--N 1.306 -1.317 0 N-CA-C 104.907 -2.257 . . . . 0.0 104.907 -178.147 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -75.98 -22.73 12.89 Favored 'Trans proline' 0 CA--C 1.545 1.044 0 C-N-CA 121.262 1.308 . . . . 0.0 110.78 169.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -94.77 -55.87 2.97 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -178.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.481 ' HD2' ' O ' ' A' ' 166' ' ' ARG 0.297 0.6 OUTLIER 37.85 75.36 0.07 Allowed 'General case' 0 N--CA 1.443 -0.803 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 179.058 . . . . . . . . 4 4 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . 0.515 ' HB2' ' NE2' ' A' ' 169' ' ' HIS . 48.3 mt-10 -80.73 140.2 35.7 Favored 'General case' 0 N--CA 1.423 -1.782 0 N-CA-C 105.851 -1.907 . . . . 0.0 105.851 172.384 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 80.5 m-85 -83.49 126.52 32.86 Favored 'General case' 0 C--N 1.271 -2.835 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 177.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.515 ' NE2' ' HB2' ' A' ' 167' ' ' GLU . 27.7 m170 -128.71 175.67 8.41 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 -175.679 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.503 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 70.8 t80 -53.93 135.42 42.44 Favored 'General case' 0 C--N 1.306 -1.302 0 O-C-N 124.185 0.928 . . . . 0.0 110.052 172.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 101.3 -27.3 21.17 Favored Glycine 0 N--CA 1.43 -1.752 0 C-N-CA 120.126 -1.035 . . . . 0.0 112.306 178.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 13.4 mm100 -68.14 147.21 52.62 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-N 117.28 0.54 . . . . 0.0 111.177 -178.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -128.44 116.13 19.26 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-N 114.457 -1.247 . . . . 0.0 107.794 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 69.5 t -100.18 110.31 26.97 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.928 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.237 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 64.1 ttt180 -97.07 155.64 16.71 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -178.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -128.27 161.87 28.34 Favored 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 123.669 0.787 . . . . 0.0 109.714 -174.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.514 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.1 OUTLIER -134.52 150.71 30.79 Favored 'Isoleucine or valine' 0 CA--C 1.474 -1.949 0 O-C-N 124.04 0.838 . . . . 0.0 109.111 178.659 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.2 m -110.83 137.5 48.41 Favored 'General case' 0 N--CA 1.395 -3.21 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 175.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -65.9 177.05 1.41 Allowed 'General case' 0 C--N 1.287 -2.136 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.853 -177.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 19.0 m -39.6 -36.11 0.37 Allowed 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 127.351 2.26 . . . . 0.0 116.823 -172.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -118.18 21.43 10.13 Favored Glycine 0 C--N 1.29 -2.005 0 C-N-CA 119.553 -1.308 . . . . 0.0 113.604 -178.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . 0.414 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 98.8 m-85 -126.92 156.36 41.59 Favored 'General case' 0 N--CA 1.436 -1.167 0 CA-C-N 117.754 0.777 . . . . 0.0 112.975 -177.17 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.453 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 25.0 pttm -124.96 153.07 43.31 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 179.105 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.3 tp -72.93 146.91 10.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.472 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 33.9 tt0 -83.04 -62.23 1.65 Allowed 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -103.15 -115.72 4.1 Favored Glycine 0 N--CA 1.446 -0.672 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -85.61 154.37 21.75 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -98.11 2.53 48.72 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 -178.277 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -155.79 149.61 25.24 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -176.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.0 ptp -126.82 126.14 42.87 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 114.945 -1.025 . . . . 0.0 111.331 179.154 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -95.76 148.28 22.74 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 177.096 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . 0.469 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 34.5 t -95.31 135.8 36.47 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 119.803 -0.759 . . . . 0.0 111.238 178.682 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 19.5 m -84.94 162.28 19.49 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 124.281 1.033 . . . . 0.0 109.294 177.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . 0.44 ' O ' HG11 ' A' ' 144' ' ' VAL . 4.5 p-10 -72.84 -7.72 52.14 Favored 'General case' 0 N--CA 1.495 1.813 0 CA-C-O 121.247 0.546 . . . . 0.0 112.29 -174.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . 0.439 ' HB2' ' CD2' ' A' ' 197' ' ' PHE . 2.8 m-20 -77.81 -12.59 59.99 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 174.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 89.74 39.98 6.07 Favored Glycine 0 N--CA 1.438 -1.188 0 CA-C-N 116.021 -0.536 . . . . 0.0 112.795 -179.147 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . 0.439 ' CD2' ' HB2' ' A' ' 195' ' ' ASP . 42.1 p90 -144.69 156.78 44.26 Favored 'General case' 0 C--N 1.318 -0.771 0 O-C-N 122.121 -0.634 . . . . 0.0 109.506 177.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . 0.469 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 81.9 m95 -76.12 128.85 35.83 Favored 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.4 m -63.07 -33.65 75.9 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.264 0.554 . . . . 0.0 110.078 -178.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.449 ' HD3' ' HA ' ' A' ' 200' ' ' LYS . 28.0 mmtp -108.68 148.35 30.56 Favored 'General case' 0 N--CA 1.429 -1.519 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.85 177.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -87.42 178.17 6.9 Favored 'General case' 0 C--N 1.289 -2.059 0 CA-C-N 114.835 -1.075 . . . . 0.0 110.683 -178.433 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 8.7 mmmm -59.84 120.34 49.05 Favored Pre-proline 0 N--CA 1.442 -0.855 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.283 177.165 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -90.49 178.89 1.97 Allowed 'Trans proline' 0 N--CA 1.427 -2.386 0 C-N-CA 122.467 2.111 . . . . 0.0 110.179 176.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -128.98 165.84 20.35 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.453 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 88.9 m -122.25 104.59 9.55 Favored 'General case' 0 N--CA 1.415 -2.205 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 172.108 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--N 1.297 -1.695 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.049 -174.728 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo . . . . . 0 CA--C 1.535 0.545 0 CA-C-O 121.404 0.502 . . . . 0.0 111.396 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 39.6 m -85.22 -33.85 22.15 Favored 'General case' 0 C--N 1.315 -0.921 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 177.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.72 -94.07 0.58 Allowed Glycine 0 N--CA 1.398 -3.848 0 CA-C-N 114.467 -1.242 . . . . 0.0 110.005 171.495 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 35.0 t-80 -175.07 123.9 0.36 Allowed Pre-proline 0 C--N 1.252 -3.649 0 N-CA-C 104.422 -2.436 . . . . 0.0 104.422 -174.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.431 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 74.4 Cg_endo -79.0 -23.61 7.67 Favored 'Trans proline' 0 C--N 1.329 -0.473 0 C-N-CA 122.031 1.821 . . . . 0.0 112.906 -175.193 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.1 176.77 20.45 Favored Glycine 0 CA--C 1.475 -2.459 0 N-CA-C 108.263 -1.935 . . . . 0.0 108.263 -175.159 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.1 t0 -136.87 155.15 50.16 Favored 'General case' 0 C--N 1.275 -2.663 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -176.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.4 t -99.57 127.2 34.84 Favored Pre-proline 0 C--N 1.294 -1.805 0 CA-C-O 120.836 0.35 . . . . 0.0 110.302 -176.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.9 -13.67 39.09 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.695 2.263 . . . . 0.0 112.3 -178.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.4 ' CD2' ' HB2' ' A' ' 141' ' ' CYS . 31.6 m-85 -94.62 1.48 55.6 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.72 -177.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.492 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 179.98 -129.94 1.42 Allowed Glycine 0 N--CA 1.416 -2.657 0 C-N-CA 119.234 -1.46 . . . . 0.0 112.482 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 22.0 p -149.13 -176.38 5.34 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 124.216 0.598 . . . . 0.0 110.0 -177.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -144.71 164.33 31.33 Favored 'General case' 0 C--N 1.313 -1.022 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 172.043 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.2 m -129.29 160.48 32.87 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 179.237 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.7 mt -117.51 125.01 50.13 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -179.121 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.467 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 21.7 p -117.86 137.87 52.49 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.442 -175.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 102.25 -47.72 1.13 Allowed Glycine 0 C--N 1.299 -1.497 0 N-CA-C 111.126 -0.789 . . . . 0.0 111.126 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.448 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -122.85 -21.17 2.68 Favored Glycine 0 N--CA 1.438 -1.168 0 C-N-CA 120.37 -0.919 . . . . 0.0 113.361 -178.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 64.25 14.72 8.89 Favored 'General case' 0 N--CA 1.5 2.048 0 C-N-CA 123.357 0.663 . . . . 0.0 112.666 -178.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.514 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.0 m -152.1 -172.89 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -178.232 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -99.9 43.87 1.04 Allowed 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 119.368 0.986 . . . . 0.0 111.061 -177.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.723 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.0 pt-20 -84.64 178.21 7.77 Favored 'General case' 0 C--O 1.205 -1.268 0 CA-C-N 114.681 -1.145 . . . . 0.0 111.983 178.225 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 34.8 m-85 -71.91 135.83 46.66 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 122.076 -0.39 . . . . 0.0 110.798 177.021 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.63 -7.65 71.14 Favored Glycine 0 N--CA 1.435 -1.378 0 C-N-CA 120.148 -1.025 . . . . 0.0 113.418 178.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.723 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -85.31 143.48 11.52 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 119.709 -0.797 . . . . 0.0 110.581 -176.274 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.467 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.8 mtpt -108.82 117.0 33.05 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.49 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -83.3 92.41 7.5 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.482 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 89.5 t -87.33 114.23 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.587 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -176.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 19.1 m-85 -86.33 139.32 31.09 Favored 'General case' 0 C--N 1.292 -1.923 0 CA-C-O 121.409 0.623 . . . . 0.0 111.013 -177.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -133.66 109.13 8.98 Favored 'General case' 0 N--CA 1.407 -2.587 0 CA-C-O 122.334 1.064 . . . . 0.0 109.387 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 12.8 m -67.57 153.17 44.31 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.423 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.492 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 86.8 m-20 -68.71 178.77 1.97 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.869 0.366 . . . . 0.0 111.558 -179.012 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -57.38 -37.21 72.3 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -176.166 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -86.61 18.16 35.67 Favored Glycine 0 C--N 1.304 -1.237 0 C-N-CA 120.68 -0.771 . . . . 0.0 113.322 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -145.79 166.34 26.19 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -175.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.429 HE21 ' HB2' ' A' ' 119' ' ' GLN . 0.7 OUTLIER -140.55 163.9 31.61 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.579 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -87.18 120.37 28.39 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 179.357 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.6 129.89 47.8 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 -178.154 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.8 -176.51 22.18 Favored Glycine 0 C--N 1.301 -1.366 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 -179.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -91.46 -38.58 12.47 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-O 121.316 0.579 . . . . 0.0 110.0 -179.052 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 46.5 mm -78.08 120.62 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.464 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -176.26 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -129.16 8.05 5.53 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -177.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.49 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 22.8 p90 -151.19 169.68 21.3 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 -174.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.581 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 57.8 mtp180 -129.14 122.57 30.11 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 173.472 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -94.65 127.29 40.51 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 119.557 -0.857 . . . . 0.0 110.316 178.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 47.4 t -83.27 113.1 20.46 Favored 'General case' 0 C--N 1.314 -0.975 0 C-N-CA 119.223 -0.991 . . . . 0.0 109.087 175.029 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.526 ' OD1' HG22 ' A' ' 131' ' ' THR . 8.4 t70 -110.3 -164.33 0.92 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.622 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.526 HG22 ' OD1' ' A' ' 130' ' ' ASP . 5.9 t -52.65 -33.45 46.98 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 -172.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -102.26 -10.39 19.59 Favored 'General case' 0 C--N 1.316 -0.875 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.83 -177.349 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 133.32 -153.96 21.01 Favored Glycine 0 N--CA 1.421 -2.346 0 N-CA-C 110.781 -0.927 . . . . 0.0 110.781 -178.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.409 ' CH2' HG13 ' A' ' 108' ' ' VAL . 86.2 m95 -67.65 119.93 13.21 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 122.527 0.331 . . . . 0.0 110.228 -178.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.0 p -71.58 -63.76 1.06 Allowed 'General case' 0 C--O 1.251 1.17 0 CA-C-O 121.544 0.687 . . . . 0.0 111.1 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.581 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.8 m120 -69.99 164.36 24.1 Favored 'General case' 0 CA--C 1.489 -1.383 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.828 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . 0.403 ' CG ' ' H ' ' A' ' 138' ' ' ILE . 12.1 t70 -103.35 -171.84 2.01 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 176.042 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.403 ' H ' ' CG ' ' A' ' 137' ' ' ASP . 64.1 mt -69.48 120.68 78.7 Favored Pre-proline 0 C--N 1.28 -2.427 0 C-N-CA 124.439 1.096 . . . . 0.0 109.625 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -69.77 172.76 12.06 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.558 2.172 . . . . 0.0 112.485 178.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 49.1 mm -109.36 130.5 62.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.051 -173.245 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.4 ' HB2' ' CD2' ' A' ' 93' ' ' PHE . 89.1 m -109.06 114.34 28.0 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 174.354 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -103.09 157.23 17.14 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 106.894 -1.521 . . . . 0.0 106.894 176.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 13.6 p -70.62 145.43 12.79 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.069 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.617 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 17.4 m -72.35 136.28 25.99 Favored 'Isoleucine or valine' 0 C--O 1.248 1.015 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 175.841 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 64.4 mmtt -105.8 151.82 24.0 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -174.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 39.6 m -114.91 145.77 41.85 Favored 'General case' 0 C--N 1.28 -2.43 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 176.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -61.75 145.89 91.44 Favored Pre-proline 0 N--CA 1.418 -2.05 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -179.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -69.95 125.1 11.66 Favored 'Trans proline' 0 N--CA 1.444 -1.431 0 C-N-CA 122.885 2.39 . . . . 0.0 111.532 -178.546 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.8 t -97.98 137.82 24.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 13.5 p -76.74 -81.7 0.08 Allowed 'General case' 0 C--N 1.314 -0.962 0 O-C-N 123.126 0.267 . . . . 0.0 110.96 177.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.07 156.22 0.24 Allowed Pre-proline 0 C--O 1.24 0.566 0 C-N-CA 125.403 1.481 . . . . 0.0 107.895 179.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . 0.479 ' HG2' ' HA3' ' A' ' 155' ' ' GLY . 37.1 Cg_endo -71.02 162.1 43.84 Favored 'Trans proline' 0 N--CA 1.459 -0.515 0 C-N-CA 121.966 1.777 . . . . 0.0 110.17 172.475 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -55.51 -44.99 77.15 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -174.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . 0.413 ' HB2' ' HB2' ' A' ' 205' ' ' CYS . 56.0 m-80 -116.45 28.0 8.85 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.242 0.544 . . . . 0.0 109.73 -177.333 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . 0.479 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -143.32 -174.6 15.72 Favored Glycine 0 N--CA 1.439 -1.162 0 C-N-CA 120.181 -1.009 . . . . 0.0 112.661 -179.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 31.7 pttt -152.9 161.02 43.06 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 123.193 0.597 . . . . 0.0 109.638 -176.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.463 HG23 HG13 ' A' ' 174' ' ' VAL . 58.2 mt -82.44 134.11 27.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 O-C-N 123.27 0.356 . . . . 0.0 110.773 -179.052 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.501 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.7 m -85.69 -32.14 6.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 CA-C-O 121.216 0.531 . . . . 0.0 110.585 -178.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 8.8 t -83.98 102.14 12.23 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.431 -172.273 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 45.2 m 65.09 -174.9 0.18 Allowed 'General case' 0 CA--C 1.549 0.919 0 C-N-CA 123.98 0.912 . . . . 0.0 110.948 -176.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -108.19 167.6 9.89 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.272 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 34.5 tpp -80.75 90.41 5.82 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-O 122.045 0.926 . . . . 0.0 110.214 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.433 ' C ' ' H ' ' A' ' 165' ' ' ASP . 34.4 mt-10 -128.13 152.0 77.0 Favored Pre-proline 0 C--N 1.298 -1.637 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 -178.705 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -77.72 13.76 1.6 Allowed 'Trans proline' 0 N--CA 1.479 0.64 0 C-N-CA 122.993 2.462 . . . . 0.0 110.378 177.213 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . 0.436 ' OD2' ' HD2' ' A' ' 166' ' ' ARG . 10.2 t70 -98.67 -39.04 8.87 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 114.364 -1.289 . . . . 0.0 108.877 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.436 ' HD2' ' OD2' ' A' ' 165' ' ' ASP . 18.6 mmm180 -78.19 103.03 7.88 Favored 'General case' 0 N--CA 1.42 -1.967 0 CA-C-N 114.932 -1.031 . . . . 0.0 111.195 -176.172 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -83.91 160.99 20.98 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 173.233 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . 0.461 ' HB3' ' HB2' ' A' ' 146' ' ' CYS . 97.5 m-85 -109.4 130.3 55.5 Favored 'General case' 0 C--N 1.284 -2.271 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 173.504 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 21.3 m80 -130.31 166.44 20.38 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -175.187 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.617 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 76.7 t80 -54.36 124.2 15.25 Favored 'General case' 0 C--O 1.247 0.945 0 C-N-CA 120.651 -0.42 . . . . 0.0 109.909 174.288 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 124.59 -26.43 5.71 Favored Glycine 0 N--CA 1.423 -2.218 0 C-N-CA 120.441 -0.885 . . . . 0.0 111.391 179.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 16.0 mm100 -59.08 131.56 51.39 Favored 'General case' 0 C--O 1.248 1.013 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -179.23 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -119.33 96.1 5.07 Favored 'General case' 0 N--CA 1.424 -1.735 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.463 HG13 HG23 ' A' ' 157' ' ' ILE . 73.4 t -88.89 101.6 12.09 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.25 -176.102 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.501 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 40.5 ttm180 -91.85 146.35 23.82 Favored 'General case' 0 N--CA 1.417 -2.084 0 CA-C-N 114.557 -1.201 . . . . 0.0 109.422 176.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -116.5 150.44 37.9 Favored 'General case' 0 N--CA 1.416 -2.135 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.6 p -129.84 142.45 43.83 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 177.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . 0.413 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 70.3 m -94.1 148.41 22.2 Favored 'General case' 0 C--N 1.264 -3.114 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.344 -177.238 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -62.33 158.15 18.06 Favored 'General case' 0 CA--C 1.495 -1.166 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.578 178.49 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 50.2 m -42.11 103.92 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.22 0 O-C-N 125.173 1.545 . . . . 0.0 113.891 -174.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 110.02 -10.56 31.78 Favored Glycine 0 N--CA 1.432 -1.625 0 C-N-CA 120.469 -0.872 . . . . 0.0 113.731 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . 0.413 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 77.4 m-85 -97.63 160.38 14.35 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 117.809 0.805 . . . . 0.0 111.611 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.21 148.46 52.46 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 -179.148 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.44 HD13 ' HA ' ' A' ' 188' ' ' GLU . 2.4 tt -79.77 144.99 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.148 0 CA-C-O 121.428 0.632 . . . . 0.0 110.817 -175.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -81.6 -65.27 1.03 Allowed 'General case' 0 C--N 1.294 -1.822 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.915 -176.534 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -78.52 -110.21 0.2 Allowed Glycine 0 C--N 1.309 -0.932 0 CA-C-N 116.117 -0.492 . . . . 0.0 112.978 -178.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -106.59 179.46 4.26 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 178.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.44 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.7 pt-20 -100.16 -11.9 20.06 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 118.974 0.806 . . . . 0.0 110.518 -174.288 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -152.61 164.38 37.79 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -173.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 15.2 ptp -133.79 136.89 44.8 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.079 176.176 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 44.6 t-80 -112.69 147.81 36.01 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 116.63 -0.259 . . . . 0.0 110.496 -178.104 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 61.1 m -75.08 121.2 21.67 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 123.067 0.547 . . . . 0.0 112.097 175.317 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 48.8 m -88.54 -175.23 4.88 Favored 'General case' 0 C--N 1.31 -1.136 0 C-N-CA 123.394 0.678 . . . . 0.0 110.205 174.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -51.81 -34.89 42.16 Favored 'General case' 0 N--CA 1.5 2.04 0 C-N-CA 125.073 1.349 . . . . 0.0 113.05 -178.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -78.06 -4.02 45.13 Favored 'General case' 0 C--N 1.309 -1.154 0 C-N-CA 123.347 0.659 . . . . 0.0 112.608 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 69.25 28.42 72.71 Favored Glycine 0 N--CA 1.444 -0.817 0 N-CA-C 108.051 -2.019 . . . . 0.0 108.051 -168.191 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 73.5 t80 -105.72 148.22 27.68 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-N 114.177 -1.012 . . . . 0.0 108.447 -176.16 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 83.6 m95 -81.97 123.67 29.08 Favored 'General case' 0 C--N 1.292 -1.906 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 10.9 m -62.4 -29.01 70.18 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 122.989 0.516 . . . . 0.0 111.837 -178.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 16.1 tppt? -118.93 155.75 30.76 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 107.078 -1.452 . . . . 0.0 107.078 -178.103 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -95.3 164.06 13.0 Favored 'General case' 0 C--N 1.288 -2.105 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 176.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 54.6 mtpt -54.42 115.87 9.48 Favored Pre-proline 0 C--N 1.319 -0.76 0 O-C-N 123.815 0.697 . . . . 0.0 112.586 -176.423 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.475 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 5.7 Cg_exo -78.06 162.56 28.86 Favored 'Trans proline' 0 N--CA 1.432 -2.093 0 C-N-CA 121.813 1.675 . . . . 0.0 111.231 177.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 50.7 tttp -109.0 157.94 18.19 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.563 -0.902 . . . . 0.0 108.563 -177.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.413 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 95.0 m -114.33 120.96 42.16 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 175.167 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 24.9 m . . . . . 0 C--N 1.307 -1.271 0 O-C-N 124.284 0.99 . . . . 0.0 109.318 -177.223 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.511 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 19.3 Cg_endo . . . . . 0 CA--C 1.532 0.412 0 CA-C-O 120.648 0.186 . . . . 0.0 112.308 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . 0.455 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 26.8 m -83.85 -26.55 29.38 Favored 'General case' 0 C--O 1.221 -0.44 0 CA-C-O 121.465 0.65 . . . . 0.0 110.245 176.323 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.8 -86.65 0.44 Allowed Glycine 0 CA--C 1.452 -3.888 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 170.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.2 t60 -175.03 131.41 0.44 Allowed Pre-proline 0 C--N 1.26 -3.32 0 N-CA-C 104.81 -2.292 . . . . 0.0 104.81 -174.349 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -82.0 6.42 5.7 Favored 'Trans proline' 0 N--CA 1.484 0.963 0 C-N-CA 122.627 2.218 . . . . 0.0 114.641 -172.014 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 108.89 -167.19 12.91 Favored Glycine 0 C--N 1.289 -2.046 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -176.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 9.5 t70 -154.97 155.47 34.27 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 1.7 t -129.51 129.54 23.21 Favored Pre-proline 0 C--N 1.297 -1.675 0 CA-C-O 120.757 0.313 . . . . 0.0 110.561 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -76.49 -10.05 18.79 Favored 'Trans proline' 0 C--O 1.223 -0.258 0 C-N-CA 122.523 2.148 . . . . 0.0 111.451 -179.588 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.483 ' HB2' ' HB2' ' A' ' 141' ' ' CYS . 28.4 m-85 -96.78 -52.11 4.03 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 122.213 1.006 . . . . 0.0 108.656 -179.478 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -106.49 -155.17 20.82 Favored Glycine 0 N--CA 1.401 -3.642 0 C-N-CA 119.78 -1.2 . . . . 0.0 112.502 -176.181 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.8 p -146.48 177.38 9.09 Favored 'General case' 0 C--N 1.261 -3.281 0 C-N-CA 125.226 1.411 . . . . 0.0 107.304 178.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.412 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 44.3 p90 -142.47 164.44 30.12 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.79 174.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -129.12 159.16 36.88 Favored 'General case' 0 C--N 1.284 -2.277 0 N-CA-C 106.641 -1.614 . . . . 0.0 106.641 -179.682 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.3 mt -118.25 119.09 33.63 Favored 'General case' 0 C--N 1.274 -2.713 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 177.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.497 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 37.3 p -116.49 136.85 52.64 Favored 'General case' 0 C--N 1.273 -2.759 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.551 -174.676 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 88.0 17.99 56.8 Favored Glycine 0 N--CA 1.429 -1.792 0 C-N-CA 119.593 -1.289 . . . . 0.0 111.107 -178.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 173.72 -31.85 0.1 Allowed Glycine 0 N--CA 1.436 -1.36 0 C-N-CA 119.229 -1.462 . . . . 0.0 113.596 -179.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 6.6 t30 66.28 9.73 6.61 Favored 'General case' 0 CA--C 1.556 1.175 0 CA-C-O 122.09 0.948 . . . . 0.0 111.728 -178.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.506 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.3 m -142.75 -168.92 0.37 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.459 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 -177.46 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -108.51 36.54 2.79 Favored 'General case' 0 C--O 1.25 1.092 0 CA-C-N 119.29 0.95 . . . . 0.0 110.796 -176.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.722 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.3 pt-20 -79.0 177.68 8.61 Favored 'General case' 0 C--O 1.195 -1.765 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.159 179.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . 0.462 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 48.2 m-85 -72.98 130.76 41.08 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 120.858 0.361 . . . . 0.0 111.641 178.771 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.42 -0.55 63.61 Favored Glycine 0 N--CA 1.437 -1.248 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.997 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.722 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.4 p -90.28 145.67 7.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.497 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 16.4 mtpp -109.75 127.18 54.45 Favored 'General case' 0 C--N 1.279 -2.486 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 179.745 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -88.76 85.19 6.72 Favored 'General case' 0 C--N 1.284 -2.272 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 175.467 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.484 HG12 ' CB ' ' A' ' 126' ' ' TYR . 29.4 m -87.07 114.64 26.52 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 CA-C-O 122.568 1.175 . . . . 0.0 109.461 -179.108 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . 0.412 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 31.4 m-85 -77.99 144.86 36.37 Favored 'General case' 0 C--N 1.27 -2.853 0 CA-C-N 115.098 -0.955 . . . . 0.0 110.833 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.2 t -142.02 118.08 10.64 Favored 'General case' 0 N--CA 1.413 -2.29 0 N-CA-C 107.108 -1.442 . . . . 0.0 107.108 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 38.0 m -75.34 158.51 32.69 Favored 'General case' 0 C--N 1.279 -2.479 0 O-C-N 121.992 -0.443 . . . . 0.0 110.651 -175.459 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 51.1 m-80 -77.65 -179.09 5.68 Favored 'General case' 0 CA--C 1.495 -1.151 0 C-N-CA 119.993 -0.683 . . . . 0.0 111.05 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -52.12 -52.73 49.71 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 124.099 0.874 . . . . 0.0 112.323 -176.306 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.481 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -83.94 25.29 5.41 Favored Glycine 0 C--N 1.304 -1.219 0 C-N-CA 120.625 -0.798 . . . . 0.0 113.831 -178.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.656 ' HE1' HG22 ' A' ' 143' ' ' VAL . 87.6 m-85 -144.31 152.01 40.16 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 122.268 -0.548 . . . . 0.0 110.08 -176.665 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.42 HE21 ' HB2' ' A' ' 119' ' ' GLN . 0.0 OUTLIER -126.78 162.05 26.76 Favored 'General case' 0 C--N 1.276 -2.613 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 -179.386 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 3.1 tt -93.06 128.24 38.88 Favored 'General case' 0 C--N 1.287 -2.114 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.07 -178.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -111.5 126.03 54.53 Favored 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 -177.364 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 113.52 164.79 15.76 Favored Glycine 0 C--N 1.286 -2.228 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -175.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 13.6 mm-40 -91.97 -31.48 15.6 Favored 'General case' 0 C--N 1.3 -1.543 0 CA-C-O 121.987 0.899 . . . . 0.0 109.382 -177.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.522 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 51.0 mm -82.57 127.47 39.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 178.328 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -122.42 2.8 9.69 Favored 'General case' 0 C--O 1.204 -1.339 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -177.221 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.484 ' CB ' HG12 ' A' ' 111' ' ' VAL . 10.8 p90 -143.54 164.08 31.36 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 120.506 -0.478 . . . . 0.0 109.817 -170.323 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 71.0 mtp180 -131.12 132.27 44.7 Favored 'General case' 0 C--N 1.289 -2.062 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 171.544 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -106.0 133.23 51.05 Favored 'General case' 0 C--N 1.284 -2.257 0 C-N-CA 118.533 -1.267 . . . . 0.0 110.773 -178.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . 0.462 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 39.7 t -75.72 96.88 3.7 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.439 ' OD1' HG22 ' A' ' 131' ' ' THR . 8.0 t70 -94.26 -175.05 3.54 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 178.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.454 ' HA ' ' CE1' ' A' ' 106' ' ' TYR . 13.9 t -68.28 -23.4 64.75 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-O 121.898 0.856 . . . . 0.0 109.889 -176.56 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -77.59 -39.06 46.87 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.613 177.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.455 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 145.21 -159.47 27.89 Favored Glycine 0 N--CA 1.421 -2.355 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -174.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 98.1 m95 -67.98 122.48 18.31 Favored 'General case' 0 C--N 1.309 -1.193 0 CA-C-N 117.639 0.719 . . . . 0.0 110.517 178.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 76.2 p -76.63 170.76 15.83 Favored 'General case' 0 C--O 1.265 1.885 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 74.4 m-20 61.91 -165.34 0.23 Allowed 'General case' 0 C--O 1.246 0.894 0 O-C-N 123.951 0.782 . . . . 0.0 111.474 174.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -122.53 168.83 11.66 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 80.6 mt -67.54 119.63 67.14 Favored Pre-proline 0 C--N 1.307 -1.252 0 O-C-N 123.247 0.342 . . . . 0.0 110.089 176.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.522 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 33.9 Cg_endo -65.99 150.09 85.69 Favored 'Trans proline' 0 C--O 1.251 1.147 0 C-N-CA 122.733 2.288 . . . . 0.0 110.527 177.317 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 61.8 mt -96.46 130.27 45.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-O 121.106 0.479 . . . . 0.0 111.034 -174.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.483 ' HB2' ' HB2' ' A' ' 93' ' ' PHE . 93.1 m -99.38 107.69 20.01 Favored 'General case' 0 C--N 1.284 -2.273 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 172.08 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -91.96 154.41 18.83 Favored 'General case' 0 N--CA 1.412 -2.362 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 177.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.656 HG22 ' HE1' ' A' ' 118' ' ' TYR . 4.5 t -80.02 141.36 15.39 Favored 'Isoleucine or valine' 0 C--N 1.256 -3.494 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -175.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.555 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 15.9 m -68.4 100.12 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-O 121.85 0.833 . . . . 0.0 109.987 -178.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.448 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 94.9 mttt -100.69 136.56 40.36 Favored 'General case' 0 N--CA 1.421 -1.879 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.053 -174.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 60.6 m -98.96 167.87 10.46 Favored 'General case' 0 C--N 1.291 -1.955 0 CA-C-N 114.321 -1.309 . . . . 0.0 109.056 -177.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 2.2 pp -79.73 154.92 75.96 Favored Pre-proline 0 N--CA 1.427 -1.612 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 178.239 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -79.64 118.82 3.92 Favored 'Trans proline' 0 N--CA 1.441 -1.564 0 C-N-CA 122.46 2.106 . . . . 0.0 111.719 -177.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.0 t -67.65 144.61 14.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.1 p -77.17 -83.54 0.07 Allowed 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 119.644 -0.217 . . . . 0.0 111.496 176.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 173.51 162.69 0.3 Allowed Pre-proline 0 N--CA 1.473 0.715 0 C-N-CA 125.171 1.388 . . . . 0.0 108.361 178.162 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . 0.46 ' HB3' ' HA ' ' A' ' 204' ' ' LYS . 72.6 Cg_endo -84.04 166.46 12.9 Favored 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 122.361 2.041 . . . . 0.0 110.997 170.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -72.11 -62.56 1.39 Allowed 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 114.099 1.148 . . . . 0.0 114.099 -176.333 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . 0.422 ' HB2' ' O ' ' A' ' 205' ' ' CYS . 43.7 m-80 -97.24 31.35 2.49 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 121.943 0.878 . . . . 0.0 110.075 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -150.87 -169.99 17.36 Favored Glycine 0 N--CA 1.422 -2.274 0 N-CA-C 109.081 -1.608 . . . . 0.0 109.081 179.59 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . 0.458 ' HG3' HG23 ' A' ' 177' ' ' VAL . 21.9 pttm -151.84 171.62 17.47 Favored 'General case' 0 C--N 1.289 -2.034 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.249 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 54.3 mt -90.87 135.09 27.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-O 120.951 0.405 . . . . 0.0 111.415 -178.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.474 ' CG2' HG22 ' A' ' 177' ' ' VAL . 57.0 t -70.83 -50.03 46.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 C-N-CA 124.214 1.006 . . . . 0.0 108.468 177.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 1.7 m -82.52 27.86 0.49 Allowed 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 124.558 1.143 . . . . 0.0 111.018 -176.513 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 7.2 p -68.5 -69.49 0.32 Allowed 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 -174.11 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -94.59 77.83 3.78 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 121.923 0.868 . . . . 0.0 113.216 -174.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.522 ' O ' ' HG2' ' A' ' 163' ' ' GLU . 62.6 mtm -90.09 -55.51 3.58 Favored 'General case' 0 C--N 1.293 -1.887 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 170.448 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.522 ' HG2' ' O ' ' A' ' 162' ' ' MET . 10.5 mm-40 -175.36 145.66 0.86 Allowed Pre-proline 0 CA--C 1.503 -0.855 0 C-N-CA 129.412 3.085 . . . . 0.0 104.935 175.316 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -84.29 -7.3 10.01 Favored 'Trans proline' 0 C--N 1.316 -1.137 0 C-N-CA 122.436 2.091 . . . . 0.0 111.787 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -97.62 -19.47 18.28 Favored 'General case' 0 CA--C 1.47 -2.117 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.261 -176.034 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -81.72 126.94 32.4 Favored 'General case' 0 N--CA 1.398 -3.036 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.204 -179.635 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -86.91 143.55 27.36 Favored 'General case' 0 C--N 1.272 -2.791 0 CA-C-N 114.783 -1.099 . . . . 0.0 109.279 -179.213 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . 0.448 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 74.4 m-85 -67.83 136.91 54.86 Favored 'General case' 0 C--O 1.2 -1.516 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 178.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.486 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 44.6 p-80 -153.21 171.44 18.51 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-O 118.675 -0.678 . . . . 0.0 109.19 -172.641 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.555 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 62.0 t80 -50.77 133.2 26.39 Favored 'General case' 0 C--O 1.239 0.528 0 O-C-N 123.732 0.645 . . . . 0.0 110.512 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 106.06 -26.99 18.91 Favored Glycine 0 N--CA 1.434 -1.48 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -177.369 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . 0.407 ' HA ' HE21 ' A' ' 172' ' ' GLN . 0.0 OUTLIER -76.12 140.43 41.8 Favored 'General case' 0 CA--C 1.503 -0.838 0 CA-C-O 121.629 0.728 . . . . 0.0 110.413 178.727 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.426 ' HB2' ' CD2' ' A' ' 191' ' ' HIS . . . -129.62 119.91 24.37 Favored 'General case' 0 C--N 1.279 -2.495 0 CA-C-N 114.139 -1.391 . . . . 0.0 107.315 176.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.495 HG23 ' CH2' ' A' ' 198' ' ' TRP . 68.1 t -93.65 108.38 20.45 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.992 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 176.021 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.451 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 76.2 ttt180 -103.24 156.29 17.82 Favored 'General case' 0 N--CA 1.409 -2.479 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -127.96 153.15 47.04 Favored 'General case' 0 C--N 1.291 -1.972 0 C-N-CA 123.179 0.591 . . . . 0.0 110.158 -170.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.474 HG22 ' CG2' ' A' ' 158' ' ' VAL . 0.1 OUTLIER -127.91 141.15 47.22 Favored 'Isoleucine or valine' 0 CA--C 1.467 -2.212 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.262 179.04 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 72.1 m -95.96 132.75 40.96 Favored 'General case' 0 N--CA 1.389 -3.487 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.08 176.238 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 -67.12 170.03 7.59 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 113.985 -1.462 . . . . 0.0 109.711 179.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 49.3 m -49.84 109.47 0.29 Allowed 'General case' 0 C--N 1.297 -1.7 0 O-C-N 124.394 1.059 . . . . 0.0 113.463 -174.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 97.16 18.21 29.68 Favored Glycine 0 N--CA 1.433 -1.527 0 CA-C-N 115.234 -0.894 . . . . 0.0 114.633 174.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -128.53 164.9 21.8 Favored 'General case' 0 C--O 1.241 0.645 0 CA-C-N 118.457 1.128 . . . . 0.0 112.572 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.503 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 56.7 pttt -122.12 154.84 36.86 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 106.741 -1.578 . . . . 0.0 106.741 178.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 5.4 tp -72.67 145.9 11.5 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 174.453 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -70.4 -69.73 0.34 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 120.983 0.421 . . . . 0.0 110.108 -177.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -109.65 -82.76 1.39 Allowed Glycine 0 N--CA 1.431 -1.66 0 C-N-CA 120.24 -0.981 . . . . 0.0 111.851 178.824 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -113.99 151.81 31.85 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -177.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.451 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 8.9 pt-20 -109.82 9.71 24.64 Favored 'General case' 0 C--N 1.3 -1.587 0 CA-C-N 118.448 0.567 . . . . 0.0 110.708 -179.333 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -148.73 130.35 14.96 Favored 'General case' 0 C--N 1.295 -1.788 0 CA-C-O 122.012 0.911 . . . . 0.0 113.315 -178.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.424 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 16.5 ptp -121.46 144.72 48.53 Favored 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.21 178.003 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . 0.426 ' CD2' ' HB2' ' A' ' 173' ' ' ALA . 34.5 m80 -117.25 147.77 42.24 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 120.469 0.176 . . . . 0.0 111.032 -179.411 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 4.9 m -76.17 115.92 16.37 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.475 172.61 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . 0.516 ' HB2' ' OD1' ' A' ' 195' ' ' ASP . 13.0 m -85.55 177.19 7.83 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.458 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -76.85 3.43 12.0 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 121.348 0.595 . . . . 0.0 112.272 -176.254 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . 0.516 ' OD1' ' HB2' ' A' ' 193' ' ' SER . 43.4 p-10 -92.61 -15.68 26.56 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 123.267 0.627 . . . . 0.0 109.755 177.077 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 90.93 19.47 43.14 Favored Glycine 0 N--CA 1.432 -1.603 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.586 -178.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -128.47 168.94 14.92 Favored 'General case' 0 C--N 1.314 -0.96 0 O-C-N 122.152 -0.617 . . . . 0.0 111.458 178.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . 0.495 ' CH2' HG23 ' A' ' 174' ' ' VAL . 85.9 m95 -82.46 131.03 35.22 Favored 'General case' 0 N--CA 1.436 -1.172 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.646 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 31.0 p -62.53 -29.66 70.72 Favored 'General case' 0 C--N 1.312 -1.025 0 C-N-CA 124.579 1.152 . . . . 0.0 113.108 -177.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 3.1 tppp? -126.17 158.18 36.25 Favored 'General case' 0 N--CA 1.432 -1.329 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -178.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -81.12 174.24 11.78 Favored 'General case' 0 C--N 1.312 -1.041 0 O-C-N 123.318 0.386 . . . . 0.0 110.033 -178.466 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . 0.418 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 37.5 mtpt -70.0 121.35 82.61 Favored Pre-proline 0 N--CA 1.438 -1.064 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.301 176.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -89.08 -162.36 0.13 Allowed 'Trans proline' 0 N--CA 1.431 -2.153 0 C-N-CA 122.388 2.059 . . . . 0.0 109.44 173.642 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . 0.46 ' HA ' ' HB3' ' A' ' 152' ' ' PRO . 18.0 ptpt -166.39 174.09 9.36 Favored 'General case' 0 N--CA 1.416 -2.141 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.504 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.503 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 80.7 m -114.03 128.89 56.58 Favored 'General case' 0 C--N 1.276 -2.607 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 177.727 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.8 m . . . . . 0 C--N 1.28 -2.432 0 O-C-N 124.49 1.118 . . . . 0.0 108.542 -172.642 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 39.7 Cg_endo . . . . . 0 CA--C 1.54 0.804 0 CA-C-O 121.245 0.435 . . . . 0.0 111.977 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 61.3 m -90.07 -32.5 16.68 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 122.148 0.975 . . . . 0.0 108.654 176.168 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 111.82 -83.84 0.34 Allowed Glycine 0 CA--C 1.455 -3.715 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 171.043 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 9.3 t60 -179.83 130.83 0.25 Allowed Pre-proline 0 C--N 1.267 -2.979 0 N-CA-C 104.928 -2.249 . . . . 0.0 104.928 -175.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.416 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 88.1 Cg_endo -84.12 1.48 8.74 Favored 'Trans proline' 0 N--CA 1.485 1.008 0 C-N-CA 122.677 2.251 . . . . 0.0 113.915 -172.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 94.19 179.75 38.25 Favored Glycine 0 N--CA 1.429 -1.831 0 N-CA-C 108.492 -1.843 . . . . 0.0 108.492 -173.112 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -140.7 -179.66 6.17 Favored 'General case' 0 C--N 1.29 -2.005 0 CA-C-N 117.628 0.714 . . . . 0.0 109.767 -178.178 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.0 t -126.53 138.47 32.49 Favored Pre-proline 0 C--N 1.307 -1.245 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -77.34 -20.89 12.2 Favored 'Trans proline' 0 CA--C 1.534 0.514 0 C-N-CA 122.537 2.158 . . . . 0.0 112.255 -179.097 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.402 ' O ' ' HB2' ' A' ' 115' ' ' ASN . 59.0 m-85 -80.82 -50.4 9.87 Favored 'General case' 0 CA--C 1.5 -0.967 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.477 -176.287 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -122.49 -136.45 4.89 Favored Glycine 0 N--CA 1.421 -2.338 0 C-N-CA 120.558 -0.829 . . . . 0.0 111.115 -178.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.7 p -148.21 -172.51 4.09 Favored 'General case' 0 C--N 1.294 -1.813 0 C-N-CA 123.594 0.758 . . . . 0.0 109.073 -178.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 38.5 p90 -145.01 163.76 33.23 Favored 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 120.381 -0.528 . . . . 0.0 109.984 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.6 m -135.75 158.91 43.22 Favored 'General case' 0 C--N 1.288 -2.084 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 178.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.423 HD11 ' CE1' ' A' ' 104' ' ' PHE . 18.1 mt -110.18 122.05 46.71 Favored 'General case' 0 C--N 1.28 -2.414 0 CA-C-O 120.94 0.4 . . . . 0.0 110.384 -178.029 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 19.2 p -114.43 136.27 53.19 Favored 'General case' 0 C--N 1.286 -2.162 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.924 -176.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 95.78 11.74 54.52 Favored Glycine 0 N--CA 1.43 -1.7 0 C-N-CA 120.035 -1.078 . . . . 0.0 112.174 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 171.59 -23.96 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 119.274 -1.441 . . . . 0.0 113.818 -178.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 65.4 17.3 10.92 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 113.051 0.76 . . . . 0.0 113.051 179.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.498 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.3 m -148.97 -176.23 0.41 Allowed 'Isoleucine or valine' 0 C--O 1.205 -1.242 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -175.726 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.423 ' CE1' HD11 ' A' ' 98' ' ' LEU . 41.2 m-85 -102.84 47.32 0.89 Allowed 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 118.299 0.5 . . . . 0.0 110.401 -179.452 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.712 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.8 pt-20 -88.44 179.54 6.29 Favored 'General case' 0 C--O 1.207 -1.147 0 CA-C-N 115.477 -0.783 . . . . 0.0 111.092 177.467 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -79.36 135.76 36.8 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.075 176.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 95.52 1.3 62.27 Favored Glycine 0 N--CA 1.434 -1.449 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.832 -179.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.712 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.5 p -97.54 150.67 4.53 Favored 'Isoleucine or valine' 0 C--O 1.246 0.908 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 14.6 mtpp -113.82 127.87 56.18 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 -179.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -90.34 93.05 9.17 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 175.773 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 44.0 t -88.19 114.95 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.662 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 -179.063 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 35.1 m-85 -85.15 133.48 34.2 Favored 'General case' 0 C--N 1.284 -2.246 0 CA-C-N 115.496 -0.775 . . . . 0.0 109.632 179.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 7.8 t -125.82 127.43 46.08 Favored 'General case' 0 N--CA 1.409 -2.508 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -177.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 79.6 m -75.32 159.99 30.83 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -179.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.402 ' HB2' ' O ' ' A' ' 93' ' ' PHE . 6.7 t-20 -69.53 -175.84 0.9 Allowed 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 114.053 -1.431 . . . . 0.0 109.487 178.148 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -67.1 -44.38 80.11 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 120.998 0.427 . . . . 0.0 111.081 -179.555 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.21 8.12 68.8 Favored Glycine 0 C--N 1.31 -0.878 0 CA-C-N 115.965 -0.561 . . . . 0.0 113.14 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.664 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 70.7 m-85 -127.95 160.64 31.26 Favored 'General case' 0 C--N 1.311 -1.073 0 O-C-N 122.534 -0.392 . . . . 0.0 110.955 178.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -145.33 144.26 30.62 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -178.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -75.6 126.95 32.01 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -174.657 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -110.79 130.92 55.44 Favored 'General case' 0 N--CA 1.421 -1.892 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 -177.391 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.02 174.81 20.18 Favored Glycine 0 C--N 1.301 -1.408 0 N-CA-C 111.528 -0.629 . . . . 0.0 111.528 -179.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -83.31 -36.22 24.62 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -179.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.416 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 49.5 mm -87.97 125.0 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.862 0 CA-C-N 113.977 -1.465 . . . . 0.0 109.247 -175.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -127.54 3.96 6.19 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.369 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.414 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 17.9 p90 -144.05 165.11 28.7 Favored 'General case' 0 N--CA 1.422 -1.848 0 C-N-CA 119.901 -0.72 . . . . 0.0 110.757 -171.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.416 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 45.9 mtp180 -126.19 132.79 51.71 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 106.217 -1.772 . . . . 0.0 106.217 173.093 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -108.76 134.15 51.86 Favored 'General case' 0 C--N 1.277 -2.586 0 C-N-CA 119.464 -0.895 . . . . 0.0 108.864 -177.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 17.5 t -85.74 99.96 11.69 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 118.292 -1.363 . . . . 0.0 109.403 177.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.448 ' OD2' HG22 ' A' ' 131' ' ' THR . 8.5 t70 -104.32 -167.84 1.41 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 177.123 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.448 HG22 ' OD2' ' A' ' 130' ' ' ASP . 9.6 t -65.14 -15.87 62.88 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 119.048 0.84 . . . . 0.0 111.633 -177.072 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -81.79 -13.49 57.64 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-O 121.697 0.76 . . . . 0.0 109.839 176.104 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 102.49 -157.46 18.24 Favored Glycine 0 N--CA 1.428 -1.847 0 N-CA-C 107.522 -2.231 . . . . 0.0 107.522 -174.445 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.411 ' CD2' ' HB3' ' A' ' 88' ' ' PRO . 94.6 m95 -62.28 106.64 0.77 Allowed 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 117.714 0.757 . . . . 0.0 110.405 173.766 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 62.3 p -71.8 171.48 11.57 Favored 'General case' 0 C--O 1.269 2.086 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.192 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 1.8 m-20 62.87 -158.57 0.32 Allowed 'General case' 0 C--O 1.245 0.83 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 172.029 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 29.0 t0 -141.11 173.03 11.87 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 173.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 70.1 mt -59.36 121.71 58.46 Favored Pre-proline 0 C--N 1.269 -2.915 0 C-N-CA 125.14 1.376 . . . . 0.0 108.352 175.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.416 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 38.2 Cg_endo -64.78 178.32 1.85 Allowed 'Trans proline' 0 C--O 1.251 1.17 0 C-N-CA 123.097 2.531 . . . . 0.0 113.614 -176.628 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 63.5 mt -98.37 129.52 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.066 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.69 -176.094 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.614 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 33.6 t -114.69 107.12 15.04 Favored 'General case' 0 C--N 1.273 -2.735 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 178.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -99.35 152.1 20.33 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-O 121.625 0.726 . . . . 0.0 110.933 -176.105 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.664 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 3.3 t -73.1 136.52 25.32 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.049 0 CA-C-N 113.902 -1.499 . . . . 0.0 108.609 -179.703 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.87 125.02 20.9 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.097 0 O-C-N 124.957 1.411 . . . . 0.0 108.064 177.052 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.522 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 45.6 mttp -122.9 162.62 21.88 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.382 -174.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 57.0 m -124.58 168.34 13.26 Favored 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 114.309 -1.314 . . . . 0.0 107.734 175.036 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 71.5 mt -74.73 143.59 78.76 Favored Pre-proline 0 C--N 1.307 -1.244 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -179.387 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.444 ' HA ' ' CE2' ' A' ' 168' ' ' TYR . 17.5 Cg_endo -62.73 122.36 10.65 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.945 2.43 . . . . 0.0 110.761 178.283 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 48.0 t -91.81 142.02 13.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.005 -175.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 21.0 p -79.95 -82.67 0.11 Allowed 'General case' 0 N--CA 1.43 -1.47 0 CA-C-N 116.727 -0.215 . . . . 0.0 110.907 176.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 176.49 165.7 0.45 Allowed Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 124.051 0.94 . . . . 0.0 108.724 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . 0.521 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 55.6 Cg_endo -76.57 160.93 34.63 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.024 1.816 . . . . 0.0 109.742 167.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -53.3 -50.77 64.21 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 114.287 1.218 . . . . 0.0 114.287 -175.055 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 55.6 m-80 -113.3 38.06 2.99 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -154.78 -167.43 16.56 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.918 -1.134 . . . . 0.0 112.53 177.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -153.04 170.24 20.95 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 -177.347 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.457 HG22 ' H ' ' A' ' 159' ' ' SER . 73.3 mt -86.02 137.67 20.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 177.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.52 HG21 ' HB3' ' A' ' 175' ' ' ARG . 14.5 m -69.11 -32.68 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-O 121.597 0.713 . . . . 0.0 110.872 -177.766 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.457 ' H ' HG22 ' A' ' 157' ' ' ILE . 24.3 t -113.25 -163.32 0.85 Allowed 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -178.099 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 28.9 p -151.69 -67.39 0.17 Allowed 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 121.022 -0.271 . . . . 0.0 111.076 177.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 60.58 23.75 13.48 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 124.526 1.131 . . . . 0.0 110.589 -178.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.477 ' CE ' ' HA ' ' A' ' 162' ' ' MET . 0.0 OUTLIER -99.53 87.52 3.61 Favored 'General case' 0 N--CA 1.428 -1.553 0 CA-C-O 121.697 0.76 . . . . 0.0 110.783 -174.709 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.406 ' HB2' ' CG ' ' A' ' 166' ' ' ARG . 48.9 mt-10 -129.33 159.39 69.43 Favored Pre-proline 0 C--N 1.294 -1.825 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 177.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -53.53 -34.93 74.67 Favored 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 122.81 2.34 . . . . 0.0 113.905 178.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -92.11 -23.58 19.4 Favored 'General case' 0 N--CA 1.476 0.843 0 CA-C-O 122.164 0.983 . . . . 0.0 109.768 -178.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.406 ' CG ' ' HB2' ' A' ' 163' ' ' GLU . 34.6 mmt180 -94.82 93.35 7.43 Favored 'General case' 0 N--CA 1.417 -2.11 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.989 -175.524 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -89.11 163.34 15.51 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 106.201 -1.778 . . . . 0.0 106.201 169.446 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . 0.489 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 67.4 m-85 -64.97 109.83 2.25 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 119.098 0.863 . . . . 0.0 110.628 179.453 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 28.1 m80 -98.02 161.45 13.72 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.534 -173.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -58.0 135.69 56.99 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.868 172.525 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 103.5 -18.26 48.39 Favored Glycine 0 N--CA 1.429 -1.803 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.62 -179.292 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.9 tp60 -76.96 128.83 35.24 Favored 'General case' 0 N--CA 1.398 -3.037 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -110.6 131.14 55.31 Favored 'General case' 0 N--CA 1.418 -2.027 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 172.468 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 189' ' ' GLU . 55.5 t -107.87 99.56 8.88 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.32 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.52 ' HB3' HG21 ' A' ' 158' ' ' VAL . 41.7 ttm180 -89.76 144.09 26.26 Favored 'General case' 0 N--CA 1.42 -1.928 0 CA-C-N 115.043 -0.981 . . . . 0.0 109.025 178.124 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.521 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 78.1 m-85 -113.93 160.42 18.82 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -178.171 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 12.9 p -139.53 150.45 22.52 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.946 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.057 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 63.9 m -109.7 157.64 18.9 Favored 'General case' 0 C--N 1.287 -2.123 0 O-C-N 123.39 0.431 . . . . 0.0 111.602 -175.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -78.41 170.7 16.21 Favored 'General case' 0 N--CA 1.439 -1.018 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.534 179.284 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 23.1 t -49.64 105.93 0.1 Allowed 'General case' 0 C--N 1.313 -1.013 0 C-N-CA 124.88 1.272 . . . . 0.0 112.918 -175.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 111.74 -15.08 26.75 Favored Glycine 0 N--CA 1.43 -1.719 0 CA-C-N 115.285 -0.87 . . . . 0.0 113.252 175.328 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . 0.462 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 93.5 m-85 -103.84 159.84 15.3 Favored 'General case' 0 N--CA 1.433 -1.323 0 CA-C-N 117.783 0.791 . . . . 0.0 111.353 -176.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 53.4 pttt -135.04 155.7 50.3 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 175.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.479 HD13 ' HA ' ' A' ' 188' ' ' GLU . 12.5 tt -81.95 141.98 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.57 0 C-N-CA 119.401 -0.92 . . . . 0.0 110.568 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -66.16 -79.02 0.05 OUTLIER 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 114.283 1.216 . . . . 0.0 114.283 -171.631 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -83.64 -92.87 0.67 Allowed Glycine 0 CA--C 1.496 -1.135 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.183 -175.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -94.32 173.71 7.5 Favored 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 178.453 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.479 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.7 pt-20 -122.82 4.83 9.43 Favored 'General case' 0 N--CA 1.438 -1.029 0 C-N-CA 120.613 -0.435 . . . . 0.0 110.205 178.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.471 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 7.1 pt-20 -163.46 120.02 1.77 Allowed 'General case' 0 N--CA 1.432 -1.345 0 CA-C-O 121.943 0.877 . . . . 0.0 112.144 -175.013 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 12.8 ptp -100.53 132.12 46.08 Favored 'General case' 0 C--N 1.281 -2.41 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.501 177.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 23.8 t-80 -107.24 143.46 35.43 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.918 -177.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 2.5 m -70.21 116.79 10.97 Favored 'General case' 0 CA--C 1.5 -0.946 0 C-N-CA 120.859 -0.336 . . . . 0.0 110.944 172.546 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 2.6 m -83.39 151.73 25.37 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -67.75 -8.92 39.53 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 121.17 0.51 . . . . 0.0 112.362 -175.079 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . 0.421 ' HB3' ' CE1' ' A' ' 197' ' ' PHE . 26.0 t70 -82.87 -16.81 46.11 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-O 121.279 0.562 . . . . 0.0 110.638 177.464 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 99.78 38.62 3.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.669 -0.777 . . . . 0.0 113.724 178.199 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . 0.421 ' CE1' ' HB3' ' A' ' 195' ' ' ASP . 44.7 p90 -149.08 156.18 41.83 Favored 'General case' 0 C--O 1.249 1.04 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.707 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 83.4 m95 -72.79 128.33 35.2 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 175.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.0 m -51.74 -36.65 47.89 Favored 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 123.047 0.539 . . . . 0.0 111.621 -178.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 28.3 mmtp -116.24 163.79 15.47 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 116.47 -0.332 . . . . 0.0 111.463 177.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -88.18 162.57 16.62 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.652 178.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . 0.442 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 0.2 OUTLIER -57.55 105.09 0.48 Allowed Pre-proline 0 CA--C 1.57 1.731 0 C-N-CA 125.667 1.587 . . . . 0.0 112.758 -176.548 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 5.3 Cg_endo -89.0 170.89 4.88 Favored 'Trans proline' 0 C--N 1.376 1.988 0 C-N-CA 124.005 3.136 . . . . 0.0 113.671 -176.708 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 20.1 pttm -135.06 162.21 33.13 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.046 -176.462 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.462 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 83.2 m -100.72 119.43 38.59 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 124.264 0.978 . . . . 0.0 108.537 177.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 25.5 m . . . . . 0 C--N 1.287 -2.128 0 O-C-N 124.441 1.088 . . . . 0.0 109.776 -174.188 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 105' ' ' GLU . 18.4 Cg_endo . . . . . 0 CA--C 1.543 0.938 0 CA-C-O 121.4 0.5 . . . . 0.0 111.882 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . 0.484 ' HB3' ' NE1' ' A' ' 134' ' ' TRP . 23.6 m -89.42 -27.3 20.49 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.035 0.445 . . . . 0.0 111.606 176.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.62 -83.14 0.32 Allowed Glycine 0 CA--C 1.456 -3.652 0 C-N-CA 120.292 -0.956 . . . . 0.0 111.249 170.405 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -175.66 129.21 0.39 Allowed Pre-proline 0 C--N 1.269 -2.934 0 N-CA-C 106.498 -1.667 . . . . 0.0 106.498 -176.002 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -82.81 7.97 4.86 Favored 'Trans proline' 0 N--CA 1.489 1.246 0 C-N-CA 123.231 2.62 . . . . 0.0 114.476 -171.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 120.69 164.92 12.59 Favored Glycine 0 C--N 1.292 -1.881 0 N-CA-C 108.316 -1.914 . . . . 0.0 108.316 -175.477 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -145.82 111.93 5.7 Favored 'General case' 0 C--N 1.293 -1.859 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -177.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 8.2 t -98.92 140.65 21.89 Favored Pre-proline 0 C--N 1.302 -1.479 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -172.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -85.38 -9.02 8.42 Favored 'Trans proline' 0 CA--C 1.536 0.607 0 C-N-CA 122.853 2.369 . . . . 0.0 111.548 173.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -94.81 16.41 15.95 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.251 0.548 . . . . 0.0 110.593 -176.149 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 156.43 -121.95 1.14 Allowed Glycine 0 N--CA 1.41 -3.072 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 t -171.85 -160.33 0.16 Allowed 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.652 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -149.94 164.82 34.43 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.364 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.8 m -125.33 160.76 28.55 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 178.268 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 19.0 mt -119.71 131.82 55.49 Favored 'General case' 0 C--N 1.277 -2.578 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -179.023 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 38.9 p -126.21 131.28 52.0 Favored 'General case' 0 C--N 1.286 -2.178 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -177.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 87.71 24.98 33.88 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 120.503 -0.856 . . . . 0.0 111.68 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 176.1 -37.8 0.1 OUTLIER Glycine 0 N--CA 1.434 -1.447 0 C-N-CA 119.93 -1.129 . . . . 0.0 112.799 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 67.39 11.36 8.34 Favored 'General case' 0 N--CA 1.498 1.925 0 C-N-CA 124.354 1.062 . . . . 0.0 109.694 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.504 ' O ' HG11 ' A' ' 108' ' ' VAL . 25.1 m -150.56 -168.38 0.12 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.085 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 -177.539 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 24.4 m-85 -104.75 38.25 1.95 Allowed 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 118.347 0.521 . . . . 0.0 110.788 -175.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.702 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.2 pt-20 -79.19 173.81 12.2 Favored 'General case' 0 C--O 1.195 -1.763 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.782 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . 0.492 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 41.8 m-85 -72.44 133.14 44.71 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.975 178.668 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.34 -0.1 71.09 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 115.739 -0.664 . . . . 0.0 113.064 178.293 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.702 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.5 p -89.45 148.77 4.31 Favored 'Isoleucine or valine' 0 C--O 1.243 0.763 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 178.753 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 55.4 mtpt -112.16 131.52 55.42 Favored 'General case' 0 C--N 1.283 -2.295 0 CA-C-N 115.848 -0.614 . . . . 0.0 109.362 177.657 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.494 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -94.96 94.93 8.3 Favored 'General case' 0 C--N 1.285 -2.213 0 CA-C-N 115.382 -0.826 . . . . 0.0 108.791 176.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 91.8 t -86.54 106.84 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.812 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . 0.499 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 18.4 t80 -74.14 138.19 43.7 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 123.495 0.718 . . . . 0.0 109.19 -177.559 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.2 t -142.07 114.68 8.48 Favored 'General case' 0 N--CA 1.43 -1.462 0 CA-C-O 122.097 0.951 . . . . 0.0 110.09 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 73.6 m -71.35 163.19 28.16 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 115.374 -0.83 . . . . 0.0 112.193 -179.382 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -73.42 -175.04 1.82 Allowed 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.862 178.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 33.4 tt0 -62.13 -45.93 91.25 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-O 121.228 0.537 . . . . 0.0 111.748 -177.324 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -79.82 4.32 66.0 Favored Glycine 0 C--N 1.313 -0.716 0 CA-C-N 115.879 -0.601 . . . . 0.0 114.285 -179.093 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.408 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.1 m-85 -129.77 166.25 20.27 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 -177.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 7.8 pt20 -150.49 160.87 43.47 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -178.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -77.59 133.94 38.34 Favored 'General case' 0 N--CA 1.424 -1.774 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.511 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -120.89 132.12 54.78 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 177.683 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 112.1 -170.14 13.44 Favored Glycine 0 N--CA 1.43 -1.76 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -178.746 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -100.77 -37.34 8.75 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.532 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 49.3 mm -80.97 125.53 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.071 0 CA-C-N 114.865 -1.061 . . . . 0.0 110.284 -177.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.407 ' HA ' ' HB3' ' A' ' 139' ' ' PRO . 2.8 p-10 -132.03 11.05 4.64 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.499 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.494 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 24.3 p90 -142.88 161.09 39.02 Favored 'General case' 0 C--N 1.312 -1.058 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -178.364 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 54.8 mtp180 -129.88 138.02 50.72 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 172.196 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -109.07 128.56 55.09 Favored 'General case' 0 C--N 1.281 -2.403 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.552 -178.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . 0.492 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 38.9 t -76.84 96.06 4.21 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.033 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.414 ' OD2' HG22 ' A' ' 131' ' ' THR . 11.2 t70 -103.12 -171.6 1.97 Allowed 'General case' 0 N--CA 1.426 -1.65 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 179.181 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.414 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.8 t -69.48 -20.35 63.74 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.054 0.454 . . . . 0.0 111.873 -173.05 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -82.02 -25.37 34.72 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 121.516 0.674 . . . . 0.0 109.5 175.171 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 130.11 -154.37 20.52 Favored Glycine 0 N--CA 1.422 -2.254 0 N-CA-C 108.291 -1.923 . . . . 0.0 108.291 -174.377 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.484 ' NE1' ' HB3' ' A' ' 85' ' ' CYS . 98.5 m95 -68.93 118.7 12.18 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 117.519 0.66 . . . . 0.0 110.977 178.572 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 75.7 p -70.42 166.16 20.97 Favored 'General case' 0 C--O 1.277 2.552 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 175.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 60.81 -162.94 0.26 Allowed 'General case' 0 C--O 1.246 0.896 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -129.72 -176.02 3.78 Favored 'General case' 0 C--N 1.283 -2.298 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 173.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 75.1 mt -63.42 117.8 37.76 Favored Pre-proline 0 C--N 1.278 -2.519 0 C-N-CA 124.219 1.008 . . . . 0.0 108.289 176.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.532 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 24.0 Cg_exo -55.7 158.36 13.67 Favored 'Trans proline' 0 C--O 1.251 1.172 0 C-N-CA 122.346 2.031 . . . . 0.0 111.904 178.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.511 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 46.6 mm -87.76 134.24 28.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 C-N-CA 120.192 -0.603 . . . . 0.0 109.885 -172.048 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.408 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 12.3 t -118.75 112.11 19.34 Favored 'General case' 0 C--N 1.28 -2.445 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.638 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -108.86 155.66 20.56 Favored 'General case' 0 C--N 1.278 -2.542 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -178.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.6 p -75.8 140.01 18.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.028 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 176.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.499 ' HB ' ' HB2' ' A' ' 170' ' ' PHE . 71.3 t -60.21 130.78 24.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 179.341 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -118.6 136.88 53.63 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -178.416 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 77.1 m -97.21 160.58 14.25 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.052 -177.638 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . 0.543 HD12 ' HD2' ' A' ' 148' ' ' PRO . 15.0 tp -71.75 125.91 91.58 Favored Pre-proline 0 N--CA 1.384 -3.725 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -178.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.543 ' HD2' HD12 ' A' ' 147' ' ' LEU . 14.2 Cg_endo -58.34 131.29 42.06 Favored 'Trans proline' 0 C--O 1.24 0.585 0 C-N-CA 123.839 3.026 . . . . 0.0 113.025 -176.091 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 40.7 t -93.51 139.59 17.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.0 p -74.98 -76.89 0.13 Allowed 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 111.657 0.243 . . . . 0.0 111.657 179.502 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.56 158.38 0.21 Allowed Pre-proline 0 CA--C 1.508 -0.665 0 N-CA-C 106.703 -1.592 . . . . 0.0 106.703 178.109 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -77.56 167.46 24.21 Favored 'Trans proline' 0 N--CA 1.447 -1.21 0 C-N-CA 121.388 1.392 . . . . 0.0 109.33 171.597 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . 0.507 ' OE1' ' HG3' ' A' ' 204' ' ' LYS . 0.1 OUTLIER -74.68 -46.83 35.32 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -173.109 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . 0.456 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 55.2 m-80 -106.45 23.76 13.66 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.766 0.793 . . . . 0.0 110.748 -177.682 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -145.07 -157.43 7.23 Favored Glycine 0 N--CA 1.421 -2.337 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.826 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 21.4 pttp -157.78 169.58 24.3 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 43.3 mt -95.94 124.87 48.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 CA-C-O 121.4 0.619 . . . . 0.0 111.199 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.4 ' CG2' HG22 ' A' ' 177' ' ' VAL . 80.7 t -67.64 -46.29 83.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 C-N-CA 124.486 1.114 . . . . 0.0 109.661 179.385 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 14.9 m -78.51 4.33 13.6 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 114.017 1.117 . . . . 0.0 114.017 -173.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 69.1 m -91.88 -27.2 18.09 Favored 'General case' 0 C--N 1.291 -1.961 0 C-N-CA 120.156 -0.618 . . . . 0.0 110.088 176.165 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -88.81 79.61 7.37 Favored 'General case' 0 N--CA 1.435 -1.188 0 CA-C-O 121.738 0.78 . . . . 0.0 111.125 -178.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.444 ' H ' ' H ' ' A' ' 163' ' ' GLU . 57.9 mtm -157.92 -31.32 0.08 Allowed 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 126.107 1.763 . . . . 0.0 107.042 178.492 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.444 ' H ' ' H ' ' A' ' 162' ' ' MET . 10.3 pt-20 -166.3 145.7 4.98 Favored Pre-proline 0 N--CA 1.441 -0.881 0 CA-C-N 114.168 -1.378 . . . . 0.0 107.95 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -81.61 -8.98 12.4 Favored 'Trans proline' 0 C--N 1.323 -0.777 0 C-N-CA 121.877 1.718 . . . . 0.0 112.485 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -80.88 -63.61 1.37 Allowed 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 -172.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . 0.322 4.7 ppt_? 23.65 83.18 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 117.809 2.522 . . . . 0.0 117.809 176.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -76.11 -12.24 60.08 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 115.281 -0.872 . . . . 0.0 111.263 178.153 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 68.2 m-85 68.08 85.08 0.14 Allowed 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 125.778 1.631 . . . . 0.0 110.58 -176.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 51.4 m170 -88.1 155.73 19.64 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.268 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.499 ' HB2' ' HB ' ' A' ' 144' ' ' VAL . 52.9 t80 -54.35 113.51 1.3 Allowed 'General case' 0 CA--C 1.509 -0.602 0 CA-C-O 121.484 0.659 . . . . 0.0 110.15 176.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . 0.417 ' H ' ' HB2' ' A' ' 192' ' ' CYS . . . 132.44 -25.33 3.83 Favored Glycine 0 N--CA 1.407 -3.243 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 -177.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . 0.488 HE21 ' HA ' ' A' ' 172' ' ' GLN . 0.0 OUTLIER -68.41 137.63 54.68 Favored 'General case' 0 C--O 1.256 1.402 0 CA-C-O 121.845 0.831 . . . . 0.0 111.747 -178.776 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -112.94 117.76 32.97 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 175.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.523 ' HB ' ' HG2' ' A' ' 190' ' ' MET . 53.3 t -99.47 105.32 17.28 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 CA-C-O 121.336 0.589 . . . . 0.0 110.089 -178.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.421 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 27.3 ttm180 -94.92 152.8 18.05 Favored 'General case' 0 N--CA 1.414 -2.237 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.694 178.13 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -125.04 157.63 35.73 Favored 'General case' 0 C--N 1.284 -2.249 0 C-N-CA 124.491 1.116 . . . . 0.0 108.869 -175.312 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.4 HG22 ' CG2' ' A' ' 158' ' ' VAL . 0.0 OUTLIER -131.37 151.44 35.62 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.958 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.912 175.636 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 7.7 m -118.06 135.2 54.33 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 114.136 -1.393 . . . . 0.0 108.154 173.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -62.63 161.39 12.3 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 124.233 0.958 . . . . 0.0 110.421 178.386 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 7.5 t -62.37 109.76 1.45 Allowed 'General case' 0 C--N 1.299 -1.597 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.323 -174.209 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 122.97 -19.93 7.72 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -177.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . 0.595 ' HB3' ' SG ' ' A' ' 205' ' ' CYS . 82.6 m-85 -107.69 160.86 15.38 Favored 'General case' 0 N--CA 1.429 -1.495 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.83 146.9 33.39 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.566 HD13 ' HA ' ' A' ' 188' ' ' GLU . 9.5 tt -80.72 140.02 17.26 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.808 0 CA-C-O 121.8 0.81 . . . . 0.0 111.513 -176.446 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -83.02 -51.02 7.93 Favored 'General case' 0 C--N 1.294 -1.829 0 CA-C-N 115.164 -0.925 . . . . 0.0 109.26 -176.112 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.58 -158.91 25.18 Favored Glycine 0 C--N 1.298 -1.573 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 173.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -79.74 160.36 26.26 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 122.283 -0.539 . . . . 0.0 110.108 177.485 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.566 ' HA ' HD13 ' A' ' 184' ' ' ILE . 10.5 pt-20 -91.17 9.33 31.55 Favored 'General case' 0 C--O 1.205 -1.241 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.362 -176.167 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.2 pt-20 -155.37 138.82 15.87 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 121.225 0.536 . . . . 0.0 111.431 -178.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.523 ' HG2' ' HB ' ' A' ' 174' ' ' VAL . 6.2 ptm -127.37 144.78 51.0 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 106.413 -1.699 . . . . 0.0 106.413 178.401 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 52.5 t-80 -126.48 142.33 51.57 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.593 -0.692 . . . . 0.0 110.742 -175.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . 0.417 ' HB2' ' H ' ' A' ' 171' ' ' GLY . 6.4 m -59.32 125.21 22.7 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 176.219 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 12.1 m -104.02 165.43 11.05 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.111 179.441 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -54.06 -30.59 48.73 Favored 'General case' 0 N--CA 1.498 1.943 0 C-N-CA 123.975 0.91 . . . . 0.0 111.901 179.481 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -54.98 -30.03 58.28 Favored 'General case' 0 C--N 1.313 -0.986 0 C-N-CA 124.906 1.282 . . . . 0.0 111.39 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . 0.512 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 98.06 11.73 48.4 Favored Glycine 0 CA--C 1.497 -1.057 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -174.123 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -130.54 -170.88 2.42 Favored 'General case' 0 N--CA 1.429 -1.475 0 CA-C-N 114.526 -0.837 . . . . 0.0 109.281 -178.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . 0.412 ' CE3' ' HG3' ' A' ' 190' ' ' MET . 85.7 m95 -96.25 154.14 17.42 Favored 'General case' 0 N--CA 1.426 -1.658 0 CA-C-O 121.094 0.473 . . . . 0.0 111.335 -175.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 13.7 p -75.14 -17.78 60.35 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.626 176.66 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.45 ' HD3' ' HA ' ' A' ' 200' ' ' LYS . 23.9 mmtp -128.62 159.03 36.84 Favored 'General case' 0 CA--C 1.492 -1.254 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.176 179.118 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -87.15 -175.86 5.47 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 3.8 tppp? -72.49 115.14 36.39 Favored Pre-proline 0 C--O 1.249 1.053 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 173.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.73 177.5 8.74 Favored 'Trans proline' 0 N--CA 1.43 -2.231 0 C-N-CA 121.755 1.636 . . . . 0.0 110.645 177.519 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . 0.507 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 23.7 ttmm -128.56 152.75 47.94 Favored 'General case' 0 C--N 1.275 -2.654 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.45 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.595 ' SG ' ' HB3' ' A' ' 182' ' ' TYR . 18.2 t -111.42 117.83 34.14 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 179.209 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--N 1.305 -1.342 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.33 -174.39 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 28.9 Cg_endo . . . . . 0 CA--C 1.543 0.931 0 CA-C-O 121.988 0.745 . . . . 0.0 111.786 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 63.8 m -81.64 -27.97 33.86 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-O 122.066 0.936 . . . . 0.0 109.144 177.134 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.95 -91.37 0.56 Allowed Glycine 0 N--CA 1.4 -3.712 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 173.213 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -179.4 125.5 0.24 Allowed Pre-proline 0 C--N 1.256 -3.47 0 N-CA-C 103.906 -2.627 . . . . 0.0 103.906 -176.113 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.547 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 72.3 Cg_endo -76.82 5.09 5.13 Favored 'Trans proline' 0 N--CA 1.488 1.204 0 C-N-CA 122.649 2.233 . . . . 0.0 113.343 -173.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 97.98 -160.38 20.84 Favored Glycine 0 N--CA 1.419 -2.453 0 N-CA-C 106.725 -2.55 . . . . 0.0 106.725 -173.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -155.31 -168.66 2.91 Favored 'General case' 0 C--N 1.281 -2.389 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.6 t -143.42 120.32 6.72 Favored Pre-proline 0 C--N 1.289 -2.055 0 CA-C-N 118.867 0.758 . . . . 0.0 110.596 -178.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.86 -0.08 9.83 Favored 'Trans proline' 0 CA--C 1.53 0.315 0 C-N-CA 122.831 2.354 . . . . 0.0 111.047 178.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -107.25 13.74 26.88 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.379 178.859 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 164.77 -128.38 1.79 Allowed Glycine 0 N--CA 1.422 -2.262 0 C-N-CA 119.516 -1.326 . . . . 0.0 112.684 179.036 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.3 p -151.52 173.54 14.48 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 123.322 0.649 . . . . 0.0 110.303 -174.097 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 35.9 p90 -140.62 161.48 37.65 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 169.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.9 m -127.0 159.99 32.46 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.438 HD11 ' CE1' ' A' ' 104' ' ' PHE . 20.8 mt -117.03 122.89 45.5 Favored 'General case' 0 C--N 1.28 -2.414 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 -179.167 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 29.8 p -115.55 122.08 44.59 Favored 'General case' 0 C--N 1.286 -2.162 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.557 -176.518 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 131.91 -54.98 0.77 Allowed Glycine 0 N--CA 1.421 -2.339 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -178.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -141.81 3.86 2.09 Favored Glycine 0 N--CA 1.437 -1.28 0 C-N-CA 120.14 -1.029 . . . . 0.0 113.316 -178.004 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 59.99 18.51 7.65 Favored 'General case' 0 N--CA 1.495 1.78 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.512 ' O ' HG11 ' A' ' 108' ' ' VAL . 30.4 m -147.48 -173.86 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 -174.032 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.438 ' CE1' HD11 ' A' ' 98' ' ' LEU . 26.9 m-85 -102.89 45.9 0.94 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 118.447 0.567 . . . . 0.0 109.665 -179.412 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.664 ' O ' HG12 ' A' ' 108' ' ' VAL . 13.0 pt-20 -86.57 -175.03 5.29 Favored 'General case' 0 C--O 1.211 -0.924 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.211 178.124 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -80.36 137.14 36.52 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.86 -0.525 . . . . 0.0 111.455 179.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 88.65 -0.97 83.39 Favored Glycine 0 N--CA 1.439 -1.129 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.849 178.723 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.664 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.4 p -90.08 147.53 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -176.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.4 mtpt -111.37 125.89 54.34 Favored 'General case' 0 N--CA 1.413 -2.281 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.706 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.402 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -89.57 93.25 9.42 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 174.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 54.1 t -88.2 116.43 30.08 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.454 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -179.315 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -87.52 141.59 28.51 Favored 'General case' 0 C--N 1.282 -2.341 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.109 -177.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.3 t -139.04 110.53 7.03 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-O 122.265 1.031 . . . . 0.0 108.488 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 33.2 m -68.75 163.03 24.96 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.114 -174.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -65.97 177.22 1.4 Allowed 'General case' 0 N--CA 1.444 -0.768 0 C-N-CA 124.31 1.044 . . . . 0.0 110.439 -178.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -58.92 -46.77 87.13 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 123.98 0.912 . . . . 0.0 112.086 -178.357 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.15 24.47 6.16 Favored Glycine 0 CA--C 1.524 0.609 0 C-N-CA 121.325 -0.464 . . . . 0.0 113.342 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -146.38 164.94 30.84 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 -177.134 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 10.4 pt20 -145.45 170.0 17.24 Favored 'General case' 0 C--N 1.275 -2.653 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 176.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.5 124.18 31.78 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 179.267 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.73 128.42 55.27 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 106.212 -1.773 . . . . 0.0 106.212 178.046 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 110.81 167.94 19.13 Favored Glycine 0 C--N 1.292 -1.886 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.605 -177.6 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -87.15 -26.57 23.53 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-O 121.816 0.817 . . . . 0.0 109.855 -175.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.425 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.9 mm -91.17 129.7 41.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.989 -1.005 . . . . 0.0 108.526 179.478 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 24.2 p-10 -130.81 9.62 4.98 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-O 120.845 0.355 . . . . 0.0 110.46 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.402 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 36.3 p90 -150.7 164.25 36.58 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.703 -173.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.547 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 45.3 mtp180 -123.66 134.47 53.74 Favored 'General case' 0 C--N 1.292 -1.915 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 173.313 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -110.13 134.03 52.6 Favored 'General case' 0 C--N 1.29 -1.987 0 C-N-CA 119.524 -0.87 . . . . 0.0 108.72 179.549 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.6 t -85.98 109.06 18.51 Favored 'General case' 0 C--N 1.292 -1.93 0 C-N-CA 118.998 -1.081 . . . . 0.0 110.076 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -102.78 -169.36 1.65 Allowed 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 177.422 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 15.0 t -66.19 -15.39 63.11 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 123.119 0.567 . . . . 0.0 112.074 -175.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -99.09 -7.0 27.37 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-O 121.446 0.641 . . . . 0.0 109.979 177.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 114.25 -163.12 12.2 Favored Glycine 0 N--CA 1.439 -1.133 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 90.9 m95 -62.67 109.0 1.27 Allowed 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 116.681 0.24 . . . . 0.0 110.842 177.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 30.6 p -59.11 -73.56 0.08 Allowed 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 125.265 1.426 . . . . 0.0 113.076 -176.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -73.57 177.88 5.06 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.857 -177.498 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -100.97 175.6 5.55 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.951 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 87.1 mt -70.16 125.4 91.97 Favored Pre-proline 0 C--N 1.309 -1.165 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.425 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 36.5 Cg_endo -65.76 172.1 8.75 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 122.716 2.277 . . . . 0.0 112.73 179.241 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 46.2 mm -101.77 124.94 55.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-O 121.231 0.539 . . . . 0.0 111.562 -173.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 94.7 m -97.71 99.29 10.64 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 174.335 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -92.19 146.08 24.0 Favored 'General case' 0 N--CA 1.416 -2.13 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.68 130.3 35.21 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.579 HG23 ' HB2' ' A' ' 170' ' ' PHE . 12.1 m -59.22 141.01 16.68 Favored 'Isoleucine or valine' 0 C--O 1.247 0.961 0 CA-C-O 121.138 0.494 . . . . 0.0 112.001 -176.575 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 83.4 mttt -121.12 136.94 54.88 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.081 -175.013 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 89.1 m -103.67 152.25 22.01 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 172.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 1.8 pp -60.39 154.05 56.09 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-O 120.868 0.366 . . . . 0.0 110.867 -177.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -78.12 102.95 1.62 Allowed 'Trans proline' 0 N--CA 1.441 -1.578 0 C-N-CA 122.504 2.136 . . . . 0.0 112.506 -176.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 7.7 p -73.36 134.28 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.301 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.534 177.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.1 p -75.62 -75.31 0.18 Allowed 'General case' 0 N--CA 1.439 -0.988 0 CA-C-N 116.162 -0.472 . . . . 0.0 112.217 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.408 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . 171.81 159.96 0.24 Allowed Pre-proline 0 C--O 1.239 0.51 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 -177.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . 0.464 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 56.5 Cg_endo -75.57 161.06 37.64 Favored 'Trans proline' 0 N--CA 1.443 -1.459 0 C-N-CA 121.263 1.309 . . . . 0.0 109.55 171.791 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -57.89 -41.5 82.69 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 114.414 1.265 . . . . 0.0 114.414 -172.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 56.0 m-80 -113.33 23.47 13.21 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.581 0.705 . . . . 0.0 110.041 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . 0.44 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -139.48 -163.3 9.46 Favored Glycine 0 N--CA 1.433 -1.536 0 C-N-CA 119.93 -1.129 . . . . 0.0 112.017 -178.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . 0.408 ' HA ' ' HB1' ' A' ' 151' ' ' ALA . 19.7 pttp -160.62 177.18 10.75 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -179.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.431 HG12 ' CE1' ' A' ' 176' ' ' PHE . 38.4 mt -95.47 140.42 17.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 123.278 0.361 . . . . 0.0 111.806 -175.545 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.47 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 3.8 m -92.13 -36.1 7.48 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 175.617 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.4 m -89.71 66.42 7.12 Favored 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 115.66 -0.7 . . . . 0.0 109.832 -177.055 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 45.6 m -82.99 89.87 6.94 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.305 1.05 . . . . 0.0 110.636 -177.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . 0.551 ' HA ' ' HG2' ' A' ' 164' ' ' PRO . . . -108.88 27.73 9.18 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.647 -177.652 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.562 ' HA ' ' HE2' ' A' ' 162' ' ' MET . 0.0 OUTLIER -67.01 -2.08 4.93 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 123.784 0.833 . . . . 0.0 112.968 -173.179 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.56 ' H ' ' HD2' ' A' ' 164' ' ' PRO . 48.2 mt-10 -140.54 -50.24 0.02 OUTLIER Pre-proline 0 C--N 1.305 -1.357 0 C-N-CA 124.02 0.928 . . . . 0.0 113.095 178.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . 0.56 ' HD2' ' H ' ' A' ' 163' ' ' GLU . 10.3 Cg_endo -55.74 -25.84 53.45 Favored 'Trans proline' 0 C--N 1.375 1.932 0 CA-C-N 121.011 1.397 . . . . 0.0 112.144 174.137 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 25.5 t0 -124.54 -9.22 7.41 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 176.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 51.3 mtt180 65.3 -45.67 0.36 Allowed 'General case' 0 C--N 1.363 1.162 0 C-N-CA 126.602 1.961 . . . . 0.0 115.965 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -121.65 -167.16 1.48 Allowed 'General case' 1 C--N 1.22 -5.063 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 -179.002 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -113.39 102.02 9.93 Favored 'General case' 0 C--N 1.289 -2.045 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 172.209 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -96.2 167.62 11.09 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.48 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.579 ' HB2' HG23 ' A' ' 144' ' ' VAL . 91.0 t80 -50.04 133.62 22.65 Favored 'General case' 0 N--CA 1.468 0.466 0 O-C-N 123.622 0.576 . . . . 0.0 111.019 178.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 111.69 -32.71 6.21 Favored Glycine 0 N--CA 1.427 -1.932 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 2.8 mp0 -69.66 114.9 8.3 Favored 'General case' 0 N--CA 1.416 -2.173 0 CA-C-O 122.287 1.041 . . . . 0.0 112.303 178.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -101.95 103.44 14.08 Favored 'General case' 0 N--CA 1.416 -2.128 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 174.35 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.562 HG13 ' HG3' ' A' ' 190' ' ' MET . 6.8 p -86.04 108.34 17.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.274 0 CA-C-O 121.579 0.704 . . . . 0.0 110.263 -175.227 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.47 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 43.2 ttp180 -100.12 147.29 25.83 Favored 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 115.537 -0.756 . . . . 0.0 109.476 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.464 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 74.2 m-85 -111.93 167.8 10.09 Favored 'General case' 0 C--N 1.293 -1.857 0 CA-C-O 121.784 0.802 . . . . 0.0 111.408 -177.333 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -136.99 151.65 27.52 Favored 'Isoleucine or valine' 0 CA--C 1.455 -2.678 0 CA-C-N 114.152 -1.385 . . . . 0.0 108.766 177.265 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 78.8 m -112.41 122.36 47.49 Favored 'General case' 0 N--CA 1.392 -3.348 0 O-C-N 124.474 1.109 . . . . 0.0 108.068 177.618 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 48.3 m-80 -53.92 168.73 0.19 Allowed 'General case' 0 C--N 1.307 -1.263 0 O-C-N 124.761 1.288 . . . . 0.0 112.301 -179.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 16.8 m -49.86 104.66 0.07 Allowed 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 125.273 1.429 . . . . 0.0 112.259 -175.673 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.01 3.16 31.75 Favored Glycine 0 N--CA 1.435 -1.409 0 C-N-CA 120.837 -0.697 . . . . 0.0 113.261 178.438 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -124.67 158.58 32.82 Favored 'General case' 0 CA--C 1.484 -1.564 0 CA-C-N 117.341 0.57 . . . . 0.0 110.725 178.61 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.516 ' HG2' ' OXT' ' A' ' 206' ' ' VAL . 25.2 pttm -133.39 162.23 32.4 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 106.757 -1.571 . . . . 0.0 106.757 179.239 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 4.4 tp -76.4 149.16 6.62 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -81.35 -59.12 2.74 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.987 179.584 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -115.96 -110.32 2.7 Favored Glycine 0 C--N 1.304 -1.205 0 C-N-CA 120.464 -0.874 . . . . 0.0 111.965 179.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . 0.537 ' CG ' ' HD3' ' A' ' 200' ' ' LYS . 1.5 p-10 -77.36 150.02 35.18 Favored 'General case' 0 C--O 1.193 -1.873 0 C-N-CA 124.161 0.984 . . . . 0.0 108.939 177.444 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -107.21 5.68 27.94 Favored 'General case' 0 C--N 1.296 -1.751 0 C-N-CA 121.009 -0.276 . . . . 0.0 110.871 -178.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -152.1 152.22 32.07 Favored 'General case' 0 C--N 1.308 -1.208 0 N-CA-C 113.57 0.952 . . . . 0.0 113.57 -172.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.562 ' HG3' HG13 ' A' ' 174' ' ' VAL . 0.0 OUTLIER -128.57 137.46 51.73 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.876 -1.056 . . . . 0.0 108.306 177.454 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 40.3 t-80 -105.49 130.02 53.65 Favored 'General case' 0 C--N 1.291 -1.953 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.124 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 51.3 t -70.74 113.93 8.31 Favored 'General case' 0 C--O 1.243 0.734 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 175.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 25.1 m -85.85 163.49 18.08 Favored 'General case' 0 N--CA 1.437 -1.086 0 C-N-CA 123.217 0.607 . . . . 0.0 111.689 -176.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -67.57 -10.87 55.91 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 -173.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . 0.407 ' HB2' ' CE2' ' A' ' 197' ' ' PHE . 19.4 m-20 -91.79 -0.99 57.56 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.402 0.62 . . . . 0.0 110.109 177.484 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 81.38 42.28 9.41 Favored Glycine 0 N--CA 1.436 -1.362 0 C-N-CA 120.993 -0.622 . . . . 0.0 113.282 179.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . 0.407 ' CE2' ' HB2' ' A' ' 195' ' ' ASP . 45.5 p90 -149.65 166.71 28.5 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 175.249 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.5 m95 -83.82 125.86 32.38 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 123.146 0.279 . . . . 0.0 110.484 -178.712 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 35.9 t -57.62 -38.98 75.88 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.597 177.068 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.537 ' HD3' ' CG ' ' A' ' 187' ' ' ASP . 1.8 mmpt? -101.91 178.6 4.57 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 115.718 -0.673 . . . . 0.0 111.039 177.5 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -113.69 178.78 4.16 Favored 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 179.4 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 51.5 mtpt -79.2 114.51 45.38 Favored Pre-proline 0 C--N 1.295 -1.802 0 C-N-CA 120.771 -0.372 . . . . 0.0 111.593 -179.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.49 -171.73 1.19 Allowed 'Trans proline' 0 N--CA 1.437 -1.812 0 C-N-CA 122.001 1.801 . . . . 0.0 110.898 176.354 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . 0.446 ' HG2' HG13 ' A' ' 206' ' ' VAL . 34.0 ttpt -141.66 153.48 44.74 Favored 'General case' 0 N--CA 1.405 -2.722 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.738 -175.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.435 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 81.1 m -104.81 121.54 43.86 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 174.648 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.516 ' OXT' ' HG2' ' A' ' 183' ' ' LYS . 25.0 m . . . . . 0 C--N 1.305 -1.365 0 O-C-N 124.191 0.932 . . . . 0.0 110.101 -175.387 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo . . . . . 0 CA--C 1.54 0.812 0 CA-C-O 121.423 0.51 . . . . 0.0 111.764 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 39.3 m -82.27 -36.23 27.28 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 122.264 1.031 . . . . 0.0 108.235 177.224 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 122.48 -92.62 0.48 Allowed Glycine 0 N--CA 1.406 -3.327 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 174.375 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.8 t60 -177.42 129.55 0.32 Allowed Pre-proline 0 C--N 1.261 -3.248 0 N-CA-C 103.991 -2.596 . . . . 0.0 103.991 -176.255 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.534 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 90.5 Cg_endo -80.24 2.55 8.38 Favored 'Trans proline' 0 C--N 1.327 -0.582 0 C-N-CA 122.446 2.098 . . . . 0.0 113.387 -173.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.48 -178.49 41.39 Favored Glycine 0 N--CA 1.422 -2.287 0 N-CA-C 109.037 -1.625 . . . . 0.0 109.037 -175.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -139.83 159.68 41.61 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-N 117.477 0.639 . . . . 0.0 110.177 -177.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 5.7 t -108.52 139.6 20.97 Favored Pre-proline 0 C--N 1.299 -1.59 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.632 -178.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 91' ' ' THR . 6.3 Cg_exo -82.41 -14.32 9.37 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.546 2.164 . . . . 0.0 111.155 178.396 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 45.5 m-85 -86.79 -1.22 57.59 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.642 -175.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 172.17 -131.89 2.26 Favored Glycine 0 N--CA 1.408 -3.226 0 N-CA-C 110.189 -1.164 . . . . 0.0 110.189 -178.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 35.8 p -145.62 -175.62 4.8 Favored 'General case' 0 C--N 1.289 -2.036 0 O-C-N 123.864 0.391 . . . . 0.0 110.012 -177.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -138.21 166.56 23.87 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 173.223 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -134.79 161.46 35.12 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.481 HD11 ' CE1' ' A' ' 104' ' ' PHE . 13.2 mt -119.14 124.16 46.16 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 -178.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.443 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 29.5 p -108.98 144.2 37.27 Favored 'General case' 0 C--N 1.284 -2.242 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 -177.727 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 102.64 -70.36 0.32 Allowed Glycine 0 N--CA 1.432 -1.598 0 C-N-CA 120.01 -1.09 . . . . 0.0 110.671 -178.19 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.488 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -110.47 -18.61 8.44 Favored Glycine 0 C--N 1.307 -1.08 0 C-N-CA 120.283 -0.96 . . . . 0.0 112.187 -178.313 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 42.3 m-80 64.04 22.62 12.99 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 123.336 0.655 . . . . 0.0 111.163 -178.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.513 ' O ' HG21 ' A' ' 108' ' ' VAL . 18.4 m -151.1 -171.75 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.198 -1.623 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -178.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.481 ' CE1' HD11 ' A' ' 98' ' ' LEU . 22.1 m-85 -101.9 43.99 1.04 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 119.095 0.862 . . . . 0.0 110.568 -177.025 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.669 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.7 pt-20 -84.11 -179.66 7.28 Favored 'General case' 0 C--O 1.206 -1.222 0 CA-C-N 114.476 -1.238 . . . . 0.0 111.663 178.357 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 40.2 m-85 -76.7 135.55 39.08 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 122.029 -0.419 . . . . 0.0 110.881 176.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.62 9.3 75.42 Favored Glycine 0 N--CA 1.44 -1.057 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.704 178.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.669 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.9 p -95.6 148.8 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.484 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.443 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.7 mtpt -115.17 121.96 44.59 Favored 'General case' 0 N--CA 1.415 -2.187 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.458 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -88.01 93.82 9.6 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 177.265 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 91.5 t -90.53 114.43 28.07 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.93 0 C-N-CA 124.414 1.086 . . . . 0.0 108.431 -177.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -84.76 139.44 31.96 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.511 -177.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.9 t -136.16 112.24 9.68 Favored 'General case' 0 N--CA 1.423 -1.796 0 CA-C-O 122.156 0.979 . . . . 0.0 109.943 -179.152 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 84.8 m -69.43 156.21 39.21 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.47 -0.786 . . . . 0.0 111.998 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 71.1 m-20 -67.7 172.93 4.69 Favored 'General case' 0 C--O 1.218 -0.573 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.069 176.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -53.33 -47.8 69.03 Favored 'General case' 0 C--N 1.313 -1.007 0 C-N-CA 124.022 0.929 . . . . 0.0 113.115 -174.132 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -85.02 15.35 44.17 Favored Glycine 0 C--N 1.307 -1.039 0 C-N-CA 120.803 -0.713 . . . . 0.0 113.784 -179.569 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -130.34 162.27 29.43 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.77 145.34 31.62 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 -179.701 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.5 tt -79.94 140.91 36.47 Favored 'General case' 0 C--N 1.279 -2.471 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.263 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.97 133.07 56.33 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -173.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 103.73 -169.41 18.08 Favored Glycine 0 C--N 1.306 -1.121 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.46 179.283 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 23.9 mt-10 -94.19 -47.45 6.64 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -178.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.0 mm -69.05 122.95 21.48 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 CA-C-N 114.464 -1.244 . . . . 0.0 109.626 -176.331 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -128.53 6.24 5.69 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.397 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 25.0 p90 -150.56 162.39 40.72 Favored 'General case' 0 N--CA 1.431 -1.408 0 C-N-CA 120.433 -0.507 . . . . 0.0 110.23 -173.857 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.534 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 39.9 mtp180 -121.78 132.97 54.89 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 106.226 -1.768 . . . . 0.0 106.226 173.235 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -108.7 128.9 55.27 Favored 'General case' 0 C--N 1.289 -2.035 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.7 t -85.35 107.33 17.3 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.087 -1.045 . . . . 0.0 109.642 177.116 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.418 ' CG ' ' H ' ' A' ' 131' ' ' THR . 34.1 t0 -103.86 -170.6 1.8 Allowed 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 178.27 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.418 ' H ' ' CG ' ' A' ' 130' ' ' ASP . 11.1 t -54.81 -29.49 54.71 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 124.56 1.144 . . . . 0.0 113.204 -177.033 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -81.82 -30.16 32.31 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 121.4 0.619 . . . . 0.0 110.382 176.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 132.86 -151.78 20.11 Favored Glycine 0 N--CA 1.42 -2.409 0 N-CA-C 108.744 -1.743 . . . . 0.0 108.744 -174.364 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 92.3 m95 -65.46 113.16 3.94 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 117.386 0.593 . . . . 0.0 109.778 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 22.3 p -64.65 -70.88 0.2 Allowed 'General case' 0 C--O 1.247 0.922 0 CA-C-O 121.6 0.714 . . . . 0.0 111.738 -178.326 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 -71.82 173.87 7.67 Favored 'General case' 0 CA--C 1.484 -1.559 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.959 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -110.01 -174.62 2.53 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -177.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.2 mt -66.58 118.56 55.25 Favored Pre-proline 0 C--O 1.244 0.814 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.405 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -64.61 155.93 63.96 Favored 'Trans proline' 0 N--CA 1.458 -0.614 0 C-N-CA 122.788 2.325 . . . . 0.0 111.706 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 67.5 mt -84.81 136.15 23.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.032 -177.657 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 43.7 t -126.06 138.75 53.73 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 176.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -127.56 157.32 40.49 Favored 'General case' 0 N--CA 1.414 -2.243 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -178.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 11.5 p -75.09 136.34 25.3 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.084 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.88 178.365 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.96 130.53 25.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 C-N-CA 123.303 0.641 . . . . 0.0 109.303 178.432 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.555 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 44.0 mttp -131.46 159.11 39.02 Favored 'General case' 0 CA--C 1.499 -1.007 0 CA-C-O 121.564 0.697 . . . . 0.0 112.64 -177.429 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 39.5 m -123.28 149.53 44.68 Favored 'General case' 0 N--CA 1.42 -1.974 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 176.312 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 80.5 mt -65.38 148.76 97.81 Favored Pre-proline 0 C--N 1.309 -1.154 0 N-CA-C 112.766 0.654 . . . . 0.0 112.766 -179.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -61.6 122.34 10.89 Favored 'Trans proline' 0 N--CA 1.459 -0.524 0 C-N-CA 123.199 2.599 . . . . 0.0 110.479 178.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 150' ' ' THR . 21.0 t -83.73 145.78 7.8 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -175.705 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . 0.539 ' O ' HG12 ' A' ' 149' ' ' VAL . 15.6 p -88.13 -164.93 1.19 Allowed 'General case' 0 N--CA 1.411 -2.425 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 171.53 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.532 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . -113.09 156.37 42.97 Favored Pre-proline 0 C--N 1.266 -3.057 0 O-C-N 121.511 -0.743 . . . . 0.0 110.392 -172.494 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . 0.415 ' HD3' ' CD2' ' A' ' 176' ' ' PHE . 28.9 Cg_endo -65.26 158.51 51.95 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 122.252 1.968 . . . . 0.0 110.276 173.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . 0.427 ' HG3' HD22 ' A' ' 154' ' ' ASN . 10.2 pt-20 -53.78 -36.43 62.4 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 114.463 1.282 . . . . 0.0 114.463 -174.554 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . 0.43 ' HB2' ' HB2' ' A' ' 205' ' ' CYS . 48.4 m-80 -127.7 36.1 4.4 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 121.789 0.804 . . . . 0.0 109.043 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 177' ' ' VAL . . . -152.7 -160.76 9.82 Favored Glycine 0 N--CA 1.429 -1.802 0 C-N-CA 119.628 -1.272 . . . . 0.0 113.231 178.103 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . 0.532 ' HA ' ' HB1' ' A' ' 151' ' ' ALA . 20.2 pttm -159.12 176.61 12.04 Favored 'General case' 0 C--N 1.319 -0.725 0 C-N-CA 123.936 0.894 . . . . 0.0 109.863 -177.889 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 59.8 mt -94.52 142.1 13.96 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 122.24 0.216 . . . . 0.0 110.705 -178.656 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.541 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 12.2 m -99.83 -23.57 4.4 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.615 0 CA-C-O 121.722 0.772 . . . . 0.0 110.479 179.055 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.502 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 33.4 m -108.18 133.61 52.2 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 114.742 1.386 . . . . 0.0 114.742 -168.496 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . 0.71 ' HA ' ' SD ' ' A' ' 162' ' ' MET . 58.2 m 55.13 34.79 23.36 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.953 1.464 . . . . 0.0 114.953 166.64 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -106.38 22.5 15.67 Favored 'General case' 0 C--N 1.305 -1.356 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 179.605 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.71 ' SD ' ' HA ' ' A' ' 160' ' ' SER . 3.7 mpp? -57.94 -43.68 86.51 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.503 -178.484 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.403 ' HB2' ' CG ' ' A' ' 166' ' ' ARG . 24.0 mm-40 -123.55 145.61 47.55 Favored Pre-proline 0 C--N 1.311 -1.084 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -82.67 -12.33 10.01 Favored 'Trans proline' 0 CA--C 1.547 1.154 0 C-N-CA 122.423 2.082 . . . . 0.0 113.188 -179.147 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -104.08 -10.29 18.12 Favored 'General case' 0 CA--C 1.487 -1.446 0 CA-C-O 121.138 0.494 . . . . 0.0 110.939 -174.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.403 ' CG ' ' HB2' ' A' ' 163' ' ' GLU . 0.1 OUTLIER -84.52 124.87 31.86 Favored 'General case' 0 N--CA 1.419 -1.993 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 -177.334 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 35.0 mt-10 -79.07 -173.98 3.85 Favored 'General case' 0 C--N 1.283 -2.308 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.306 179.229 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . 0.419 ' HE1' ' HB2' ' A' ' 160' ' ' SER . 98.4 m-85 -120.47 107.25 12.66 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.81 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.555 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 21.4 p-80 -96.5 171.1 8.77 Favored 'General case' 0 C--N 1.291 -1.968 0 C-N-CA 120.137 -0.625 . . . . 0.0 111.082 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 59.5 t80 -51.51 125.6 15.02 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 123.872 0.733 . . . . 0.0 110.948 179.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.48 -10.23 21.89 Favored Glycine 0 N--CA 1.424 -2.111 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -177.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.2 mm-40 -85.26 136.96 33.28 Favored 'General case' 0 N--CA 1.438 -1.072 0 CA-C-O 121.537 0.684 . . . . 0.0 112.041 -179.636 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -115.11 120.38 39.59 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 176.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.502 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 83.3 t -108.1 110.98 33.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.641 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 72.7 ttt180 -106.37 147.72 28.91 Favored 'General case' 0 N--CA 1.425 -1.696 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.415 ' CD2' ' HD3' ' A' ' 152' ' ' PRO . 60.9 m-85 -119.41 165.97 13.66 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-O 121.025 0.441 . . . . 0.0 111.134 -175.142 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.467 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.0 OUTLIER -130.28 156.65 42.52 Favored 'Isoleucine or valine' 0 CA--C 1.48 -1.715 0 CA-C-N 115.069 -0.969 . . . . 0.0 109.745 175.21 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 83.7 m -111.81 142.98 43.5 Favored 'General case' 0 C--N 1.278 -2.531 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 171.441 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -44.74 -80.68 0.01 OUTLIER 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 114.331 1.234 . . . . 0.0 114.331 -177.173 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 64.6 m -149.24 -42.05 0.14 Allowed 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 114.018 1.118 . . . . 0.0 114.018 -178.364 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -102.29 2.22 50.53 Favored Glycine 0 C--N 1.291 -1.928 0 C-N-CA 120.152 -1.023 . . . . 0.0 114.742 -174.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -110.35 175.73 5.32 Favored 'General case' 0 CA--C 1.487 -1.445 0 CA-C-N 117.643 0.721 . . . . 0.0 111.122 -176.33 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 37.6 pttt -136.63 152.56 50.57 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 173.427 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.497 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.9 tt -70.97 143.2 14.7 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.473 0 CA-C-O 121.821 0.82 . . . . 0.0 112.71 -176.706 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 19.2 tt0 -39.78 -59.63 1.13 Allowed 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 127.862 2.465 . . . . 0.0 113.061 179.046 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -145.24 -89.58 0.1 OUTLIER Glycine 0 CA--C 1.48 -2.122 0 C-N-CA 120.107 -1.044 . . . . 0.0 111.293 -177.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . 0.472 ' HB3' ' HG3' ' A' ' 200' ' ' LYS . 6.9 t0 -95.03 158.42 15.47 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.349 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.641 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 13.4 pt-20 -111.28 -9.48 14.29 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 121.084 -0.246 . . . . 0.0 110.772 -177.443 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.463 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 4.9 pt-20 -131.49 124.67 30.62 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-O 121.816 0.817 . . . . 0.0 112.869 -178.096 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 17.4 ptp -109.65 151.01 27.41 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.811 178.412 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 63.4 m80 -127.37 156.73 41.57 Favored 'General case' 0 CA--C 1.498 -1.043 0 C-N-CA 122.403 0.281 . . . . 0.0 110.66 -178.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 5.1 m -81.75 117.14 21.82 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.066 176.287 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 37.2 m -82.1 152.54 26.5 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.398 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -72.1 78.51 0.94 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 122.852 1.31 . . . . 0.0 112.257 -176.532 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -175.36 -47.16 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.627 0 CA-C-N 112.986 -1.915 . . . . 0.0 106.186 -179.175 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 121.28 66.34 0.25 Allowed Glycine 0 N--CA 1.427 -1.901 0 CA-C-N 114.547 -1.206 . . . . 0.0 112.21 -178.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 47.7 p90 -167.29 161.94 14.59 Favored 'General case' 0 C--O 1.248 0.979 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 176.58 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.9 m95 -85.15 139.46 31.68 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 124.005 0.816 . . . . 0.0 110.846 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.7 p -71.51 -18.64 62.27 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-N 115.515 -0.766 . . . . 0.0 112.252 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.584 ' HE3' ' O ' ' A' ' 201' ' ' GLU . 0.0 OUTLIER -123.94 153.49 41.13 Favored 'General case' 0 N--CA 1.426 -1.626 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 -179.879 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.584 ' O ' ' HE3' ' A' ' 200' ' ' LYS . 3.2 mp0 -77.55 168.4 20.05 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 106.532 -1.655 . . . . 0.0 106.532 177.261 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . 0.401 ' HB3' ' HE2' ' A' ' 202' ' ' LYS . 0.8 OUTLIER -68.89 114.91 26.14 Favored Pre-proline 0 C--N 1.311 -1.084 0 C-N-CA 119.915 -0.714 . . . . 0.0 109.722 176.566 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_endo -82.79 166.94 14.93 Favored 'Trans proline' 0 N--CA 1.431 -2.173 0 C-N-CA 121.95 1.766 . . . . 0.0 111.645 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . 0.416 ' HB2' ' HG2' ' A' ' 153' ' ' GLU . 9.8 ptpp? -131.08 179.06 6.22 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.16 -177.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.43 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 87.6 m -115.32 114.18 24.81 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 178.497 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.9 m . . . . . 0 C--N 1.302 -1.471 0 CA-C-N 114.796 -1.093 . . . . 0.0 109.692 -174.096 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.442 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 39.9 Cg_endo . . . . . 0 CA--C 1.538 0.711 0 CA-C-O 122.19 0.829 . . . . 0.0 110.772 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 64.9 m -92.41 -33.09 14.69 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.696 -1.138 . . . . 0.0 108.295 175.661 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.04 -91.79 0.58 Allowed Glycine 0 N--CA 1.402 -3.618 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 174.317 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 21.5 t-80 -174.7 132.61 0.49 Allowed Pre-proline 0 C--N 1.268 -2.973 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 -176.058 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.415 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 98.1 Cg_endo -81.97 5.75 6.12 Favored 'Trans proline' 0 N--CA 1.475 0.439 0 C-N-CA 122.363 2.042 . . . . 0.0 113.405 -172.492 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 113.58 -173.77 15.25 Favored Glycine 0 N--CA 1.43 -1.701 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -177.44 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -151.68 160.51 43.59 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 178.22 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.445 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 5.5 t -140.05 144.59 38.64 Favored Pre-proline 0 C--N 1.294 -1.809 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.723 -174.654 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 91' ' ' THR . 2.7 Cg_endo -83.09 -16.77 7.13 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 122.692 2.261 . . . . 0.0 110.611 174.12 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 40.4 m-85 -87.53 2.37 50.91 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.772 -175.018 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.523 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 164.4 -127.1 1.6 Allowed Glycine 0 N--CA 1.415 -2.726 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.756 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.2 t -161.08 -161.97 0.87 Allowed 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -178.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -155.02 159.43 40.31 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.942 -1.133 . . . . 0.0 107.942 177.45 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 16.2 m -121.34 163.35 18.78 Favored 'General case' 0 C--N 1.278 -2.527 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.456 HD11 ' CE1' ' A' ' 104' ' ' PHE . 20.6 mt -121.64 129.24 52.66 Favored 'General case' 0 C--N 1.284 -2.259 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -178.377 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.2 p -124.79 130.22 51.97 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.879 -176.071 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 94.33 20.97 28.4 Favored Glycine 0 C--N 1.303 -1.278 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.373 -178.63 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.94 -31.74 0.14 Allowed Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 119.907 -1.139 . . . . 0.0 113.128 177.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 6.7 m120 67.8 10.27 7.67 Favored 'General case' 0 N--CA 1.498 1.961 0 C-N-CA 123.267 0.627 . . . . 0.0 112.461 -177.1 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.532 ' O ' HG11 ' A' ' 108' ' ' VAL . 27.3 m -143.34 -171.67 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.501 -0.909 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 -176.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.456 ' CE1' HD11 ' A' ' 98' ' ' LEU . 23.4 m-85 -104.71 46.36 0.92 Allowed 'General case' 0 C--N 1.311 -1.083 0 CA-C-O 121.092 0.473 . . . . 0.0 110.162 -177.509 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.726 ' O ' HG12 ' A' ' 108' ' ' VAL . 14.9 pt-20 -87.88 175.74 7.67 Favored 'General case' 0 C--O 1.212 -0.884 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.408 178.016 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . 0.442 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 42.4 m-85 -74.69 131.57 40.98 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-O 121.088 0.47 . . . . 0.0 111.441 178.661 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 96.72 -1.13 61.42 Favored Glycine 0 N--CA 1.437 -1.239 0 CA-C-N 115.611 -0.722 . . . . 0.0 113.112 178.413 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.726 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.7 p -90.29 146.57 6.03 Favored 'Isoleucine or valine' 0 C--O 1.243 0.749 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 -179.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.3 mtpt -109.5 122.97 48.59 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.543 178.737 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.495 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.46 93.17 9.07 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 176.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 75.7 t -86.46 108.03 17.32 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.745 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . 0.513 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 66.4 t80 -78.3 140.55 38.82 Favored 'General case' 0 C--N 1.268 -2.942 0 CA-C-N 114.121 -1.4 . . . . 0.0 109.952 -174.59 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -143.48 132.38 22.78 Favored 'General case' 0 N--CA 1.438 -1.066 0 CA-C-O 121.9 0.857 . . . . 0.0 109.858 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 57.0 m -85.69 159.64 19.75 Favored 'General case' 0 C--N 1.284 -2.263 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.817 -176.198 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.523 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 54.9 m-20 -65.85 176.97 1.41 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.726 178.523 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -56.12 -49.3 74.27 Favored 'General case' 0 C--N 1.322 -0.598 0 C-N-CA 123.522 0.729 . . . . 0.0 112.396 -175.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.21 33.34 4.09 Favored Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.256 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 84.5 m-85 -146.56 158.21 43.86 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 124.224 1.01 . . . . 0.0 109.043 -178.33 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -136.1 169.75 17.12 Favored 'General case' 0 C--N 1.279 -2.457 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 177.129 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 10.5 tp -86.97 153.72 21.35 Favored 'General case' 0 C--N 1.287 -2.121 0 C-N-CA 119.259 -0.977 . . . . 0.0 108.397 178.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.05 125.31 31.11 Favored 'General case' 0 N--CA 1.415 -2.212 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 176.218 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 111.68 175.8 20.04 Favored Glycine 0 C--N 1.292 -1.876 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -176.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -94.73 -28.9 15.06 Favored 'General case' 0 CA--C 1.5 -0.943 0 CA-C-O 121.26 0.553 . . . . 0.0 111.0 -177.327 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.584 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 48.8 mm -81.1 129.78 36.95 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.178 -178.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -133.21 9.15 4.06 Favored 'General case' 0 C--O 1.213 -0.851 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 178.158 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.495 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 22.6 p90 -147.54 158.75 44.13 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.19 0.519 . . . . 0.0 110.425 -176.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 59.7 mtp180 -125.12 132.11 53.16 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 172.259 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -107.3 130.82 54.72 Favored 'General case' 0 C--N 1.275 -2.65 0 C-N-CA 119.408 -0.917 . . . . 0.0 109.715 -177.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 35.8 t -82.52 101.57 10.81 Favored 'General case' 0 N--CA 1.428 -1.536 0 C-N-CA 118.098 -1.441 . . . . 0.0 110.454 177.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.41 ' OD1' HG22 ' A' ' 131' ' ' THR . 6.4 t70 -98.79 -169.56 1.8 Allowed 'General case' 0 C--N 1.296 -1.718 0 N-CA-C 105.496 -2.038 . . . . 0.0 105.496 175.505 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.41 HG22 ' OD1' ' A' ' 130' ' ' ASP . 13.2 t -65.33 -24.36 67.24 Favored 'General case' 0 C--N 1.297 -1.694 0 CA-C-N 118.362 0.528 . . . . 0.0 110.965 -176.869 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -70.51 -24.18 62.78 Favored 'General case' 0 C--O 1.249 1.03 0 CA-C-O 122.105 0.955 . . . . 0.0 110.558 175.243 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 115.62 -148.11 18.91 Favored Glycine 0 N--CA 1.411 -2.985 0 N-CA-C 107.577 -2.209 . . . . 0.0 107.577 -172.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.454 ' CH2' HG13 ' A' ' 108' ' ' VAL . 97.4 m95 -71.12 112.78 7.54 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 117.235 0.518 . . . . 0.0 110.822 177.722 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 65.0 p -70.5 168.12 16.9 Favored 'General case' 0 C--O 1.269 2.116 0 N-CA-C 109.001 -0.741 . . . . 0.0 109.001 176.686 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 63.44 -163.1 0.27 Allowed 'General case' 0 C--O 1.242 0.674 0 O-C-N 124.07 0.856 . . . . 0.0 108.992 177.163 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -126.31 178.73 5.65 Favored 'General case' 0 C--N 1.279 -2.478 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 173.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 57.0 mt -67.2 119.77 67.21 Favored Pre-proline 0 C--N 1.298 -1.638 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 175.264 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.584 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 1.5 Cg_endo -58.18 165.09 7.6 Favored 'Trans proline' 0 C--O 1.24 0.606 0 C-N-CA 122.451 2.101 . . . . 0.0 111.834 177.762 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 61.8 mt -102.18 135.8 37.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.236 -172.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.432 ' SG ' ' CE2' ' A' ' 112' ' ' TYR . 90.2 m -103.28 148.47 25.79 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 171.699 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 4.9 tp10 -128.5 151.76 49.05 Favored 'General case' 0 C--N 1.266 -3.052 0 N-CA-C 105.261 -2.125 . . . . 0.0 105.261 174.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.554 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 7.3 p -71.45 147.35 10.97 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.607 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.131 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.61 HG23 ' HB2' ' A' ' 170' ' ' PHE . 11.6 m -67.18 121.92 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.911 0 C-N-CA 118.478 -1.289 . . . . 0.0 109.243 176.132 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.554 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 52.3 mtmt -115.97 142.91 46.17 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.307 -0.861 . . . . 0.0 111.312 -172.208 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 19.0 m -110.35 142.82 41.48 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 178.079 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . 0.483 ' HA ' ' HD3' ' A' ' 148' ' ' PRO . 4.1 mm? -60.95 144.42 90.51 Favored Pre-proline 0 N--CA 1.426 -1.661 0 N-CA-C 113.653 0.983 . . . . 0.0 113.653 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.483 ' HD3' ' HA ' ' A' ' 147' ' ' LEU . 31.4 Cg_exo -57.61 142.47 95.66 Favored 'Trans proline' 0 C--O 1.246 0.878 0 C-N-CA 123.493 2.796 . . . . 0.0 111.857 177.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.2 t -110.67 149.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 N-CA-C 107.448 -1.316 . . . . 0.0 107.448 -179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 16.9 p -80.72 -83.57 0.11 Allowed 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 122.131 0.172 . . . . 0.0 111.093 178.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.35 153.51 0.23 Allowed Pre-proline 0 C--O 1.237 0.44 0 C-N-CA 125.883 1.673 . . . . 0.0 106.729 179.515 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.14 160.94 46.04 Favored 'Trans proline' 0 N--CA 1.446 -1.3 0 C-N-CA 121.548 1.498 . . . . 0.0 111.574 175.118 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . 0.407 ' HG3' ' ND2' ' A' ' 154' ' ' ASN . 11.0 pt-20 -65.4 -32.68 74.44 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 114.582 1.326 . . . . 0.0 114.582 -173.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . 0.407 ' ND2' ' HG3' ' A' ' 153' ' ' GLU . 58.5 m-80 -126.26 32.79 5.14 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 121.777 0.799 . . . . 0.0 108.901 -179.226 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -156.59 -168.09 18.81 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.413 178.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 24.0 pttm -150.02 171.66 16.49 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 117.178 0.489 . . . . 0.0 109.705 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 53.5 mt -94.92 129.22 45.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.498 HG22 ' O ' ' A' ' 175' ' ' ARG . 10.5 m -82.09 -24.71 9.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-O 121.369 0.604 . . . . 0.0 110.569 -177.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 6.5 m -82.83 -6.83 59.62 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.307 -0.86 . . . . 0.0 110.409 -177.466 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 15.5 p 55.07 160.93 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.949 0 C-N-CA 126.378 1.871 . . . . 0.0 115.119 -178.239 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -87.29 117.67 26.2 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 176.471 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 65.8 mtm -65.29 -76.57 0.07 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.328 0.585 . . . . 0.0 110.197 -177.006 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -144.14 150.12 47.71 Favored Pre-proline 0 C--N 1.298 -1.654 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 178.665 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -63.86 -18.5 64.17 Favored 'Trans proline' 0 CA--C 1.547 1.141 0 C-N-CA 122.794 2.329 . . . . 0.0 113.684 -179.53 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -96.01 -25.14 16.04 Favored 'General case' 0 CA--C 1.501 -0.939 0 CA-C-O 121.085 0.469 . . . . 0.0 110.152 179.342 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 5.0 mmp_? -84.16 113.35 21.01 Favored 'General case' 0 N--CA 1.421 -1.921 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.698 -176.384 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -82.23 168.81 17.26 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.149 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -88.13 140.32 29.61 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 177.183 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.481 ' CD2' ' HG2' ' A' ' 145' ' ' LYS . 39.0 m170 -119.26 157.55 27.82 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 119.325 -0.369 . . . . 0.0 110.407 -172.143 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.61 ' HB2' HG23 ' A' ' 144' ' ' VAL . 85.7 t80 -35.15 127.75 0.54 Allowed 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 176.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 103.41 -30.31 10.58 Favored Glycine 0 N--CA 1.427 -1.943 0 CA-C-N 114.783 -1.099 . . . . 0.0 112.82 177.64 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -72.3 145.28 47.95 Favored 'General case' 0 N--CA 1.402 -2.827 0 CA-C-N 117.266 0.533 . . . . 0.0 110.248 -177.635 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -122.39 122.54 39.25 Favored 'General case' 0 N--CA 1.414 -2.241 0 CA-C-N 115.205 -0.907 . . . . 0.0 108.835 178.506 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 54.9 t -93.71 105.01 16.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.254 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 174.705 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.498 ' O ' HG22 ' A' ' 158' ' ' VAL . 19.3 ttp180 -103.37 146.64 28.18 Favored 'General case' 0 N--CA 1.402 -2.847 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -178.498 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 -117.13 166.76 11.85 Favored 'General case' 0 C--N 1.279 -2.485 0 CA-C-O 121.102 0.477 . . . . 0.0 109.945 -174.182 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.0 p -145.43 139.8 22.01 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.21 0 N-CA-C 107.961 -1.126 . . . . 0.0 107.961 174.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . 0.411 ' SG ' ' HB ' ' A' ' 184' ' ' ILE . 77.5 m -101.72 157.2 17.01 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -65.71 163.4 16.59 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 177.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 15.3 t -46.83 -33.45 4.48 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -169.453 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -108.52 18.04 32.97 Favored Glycine 0 C--N 1.289 -2.04 0 C-N-CA 120.427 -0.892 . . . . 0.0 114.203 -177.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -119.29 158.86 25.21 Favored 'General case' 0 CA--C 1.486 -1.519 0 CA-C-N 118.28 1.04 . . . . 0.0 110.795 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 14.8 pttm -120.14 150.97 39.76 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 178.316 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.424 HD13 ' HA ' ' A' ' 188' ' ' GLU . 8.3 tt -84.32 136.31 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.313 0 C-N-CA 119.279 -0.969 . . . . 0.0 108.902 174.485 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -86.65 -45.65 10.81 Favored 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.967 -1.015 . . . . 0.0 109.226 -174.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -78.46 -157.57 10.59 Favored Glycine 0 C--N 1.302 -1.33 0 N-CA-C 110.272 -1.131 . . . . 0.0 110.272 173.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . 0.451 ' HB3' ' HG3' ' A' ' 200' ' ' LYS . 17.1 t70 -82.04 169.34 16.82 Favored 'General case' 0 C--N 1.314 -0.977 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.132 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.424 ' HA ' HD13 ' A' ' 184' ' ' ILE . 13.1 pt-20 -81.44 -13.57 58.07 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-N 118.778 0.717 . . . . 0.0 110.865 -173.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -147.47 170.77 16.7 Favored 'General case' 0 N--CA 1.423 -1.779 0 CA-C-O 121.513 0.673 . . . . 0.0 111.431 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 13.0 ptp -141.8 125.66 17.09 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.911 175.372 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 1.9 m80 -98.54 147.27 24.95 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.526 178.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . 0.409 ' HB3' ' HA ' ' A' ' 170' ' ' PHE . 1.7 m -73.62 110.78 8.18 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.834 171.272 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 28.8 m -83.61 160.02 21.48 Favored 'General case' 0 N--CA 1.428 -1.574 0 O-C-N 123.925 0.766 . . . . 0.0 109.342 -179.269 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -70.37 1.56 4.84 Favored 'General case' 0 N--CA 1.486 1.34 0 CA-C-O 121.261 0.553 . . . . 0.0 112.423 -176.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -84.6 -17.53 38.44 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.376 174.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 90.1 23.3 32.71 Favored Glycine 0 CA--C 1.52 0.39 0 C-N-CA 120.288 -0.958 . . . . 0.0 110.865 -174.273 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -131.01 164.5 25.26 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 58.0 m95 -79.59 143.37 34.8 Favored 'General case' 0 N--CA 1.426 -1.642 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 174.638 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 18.1 m -63.77 -20.77 66.02 Favored 'General case' 0 CA--C 1.545 0.784 0 CA-C-O 121.153 0.502 . . . . 0.0 111.104 177.446 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.451 ' HG3' ' HB3' ' A' ' 187' ' ' ASP . 30.5 mmmt -133.74 158.78 42.44 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.058 -177.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 25.3 mm-40 -79.63 168.0 19.95 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 114.554 -1.203 . . . . 0.0 108.392 171.742 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 17.2 tptm -55.43 117.26 14.21 Favored Pre-proline 0 N--CA 1.439 -0.989 0 O-C-N 123.863 0.727 . . . . 0.0 110.02 176.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -87.5 158.4 7.94 Favored 'Trans proline' 0 N--CA 1.423 -2.639 0 C-N-CA 122.066 1.844 . . . . 0.0 111.663 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . 0.418 ' HG2' HG13 ' A' ' 206' ' ' VAL . 37.9 ttpt -122.42 149.08 44.32 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.709 -175.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.408 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 92.7 m -108.38 115.67 30.54 Favored 'General case' 0 C--N 1.297 -1.675 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 176.244 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . 0.418 HG13 ' HG2' ' A' ' 204' ' ' LYS . 9.4 m . . . . . 0 C--N 1.29 -1.981 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.126 -175.177 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo . . . . . 0 CA--C 1.534 0.477 0 CA-C-O 121.796 0.665 . . . . 0.0 110.612 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 59.5 m -88.23 -36.99 16.44 Favored 'General case' 0 N--CA 1.435 -1.204 0 CA-C-N 114.813 -1.085 . . . . 0.0 109.29 175.79 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 115.98 -87.72 0.44 Allowed Glycine 0 CA--C 1.463 -3.206 0 N-CA-C 110.081 -1.207 . . . . 0.0 110.081 174.34 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 3.5 t60 -177.72 127.77 0.29 Allowed Pre-proline 0 C--N 1.269 -2.922 0 N-CA-C 104.901 -2.259 . . . . 0.0 104.901 -175.642 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -79.99 12.26 2.52 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 123.043 2.495 . . . . 0.0 114.342 -171.909 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 106.03 -169.63 15.98 Favored Glycine 0 N--CA 1.424 -2.126 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -176.305 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -160.27 139.59 10.88 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 177.717 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.3 t -110.87 131.74 21.98 Favored Pre-proline 0 C--N 1.303 -1.449 0 C-N-CA 120.631 -0.428 . . . . 0.0 111.758 -175.85 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -70.02 -18.3 35.85 Favored 'Trans proline' 0 C--N 1.351 0.681 0 C-N-CA 122.826 2.351 . . . . 0.0 111.695 176.596 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -83.57 -2.5 56.18 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.329 -176.721 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.503 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.09 -124.49 1.04 Allowed Glycine 0 N--CA 1.414 -2.817 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.328 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 14.8 t -164.8 -165.27 0.89 Allowed 'General case' 0 C--N 1.285 -2.228 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.55 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.7 p90 -146.18 165.65 28.54 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.896 -0.503 . . . . 0.0 109.758 178.203 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -126.12 162.44 25.34 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.962 -1.495 . . . . 0.0 106.962 176.64 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 16.5 mt -114.88 132.91 56.37 Favored 'General case' 0 C--N 1.278 -2.51 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.314 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 19.9 p -128.9 128.48 43.9 Favored 'General case' 0 C--N 1.288 -2.066 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 -177.161 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 93.41 30.13 9.49 Favored Glycine 0 C--N 1.292 -1.863 0 C-N-CA 119.994 -1.098 . . . . 0.0 111.253 -178.302 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 164.17 -35.51 0.29 Allowed Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 119.705 -1.236 . . . . 0.0 111.974 177.396 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 68.85 14.25 8.91 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.547 0.739 . . . . 0.0 112.338 179.96 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.506 ' O ' HG11 ' A' ' 108' ' ' VAL . 29.3 m -147.74 -168.92 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.211 -0.951 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 -178.616 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -106.34 42.78 1.22 Allowed 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 119.118 0.872 . . . . 0.0 110.238 -178.115 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.719 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.8 pt-20 -79.27 173.91 12.11 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 114.641 -1.163 . . . . 0.0 111.588 178.262 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -75.98 127.59 33.3 Favored 'General case' 0 C--N 1.295 -1.762 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.059 176.201 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 104.17 -7.58 48.04 Favored Glycine 0 N--CA 1.435 -1.414 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.489 179.694 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.719 HG12 ' O ' ' A' ' 105' ' ' GLU . 13.9 p -87.76 148.9 4.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -178.32 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 55.9 mtpt -112.03 123.72 50.86 Favored 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.574 179.181 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.445 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.85 96.99 10.4 Favored 'General case' 0 C--N 1.291 -1.939 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 176.523 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.426 HG12 ' HB3' ' A' ' 126' ' ' TYR . 22.6 m -95.24 111.18 25.32 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.511 0 CA-C-O 122.564 1.174 . . . . 0.0 109.457 -179.168 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -78.92 148.96 32.5 Favored 'General case' 0 C--N 1.26 -3.32 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.813 -177.62 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.9 t -145.35 130.94 18.85 Favored 'General case' 0 N--CA 1.422 -1.839 0 CA-C-N 115.012 -0.995 . . . . 0.0 108.895 177.295 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 20.5 m -82.47 160.61 22.63 Favored 'General case' 0 C--N 1.284 -2.277 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.314 -175.732 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.503 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 71.1 m-20 -73.19 -178.06 2.75 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.952 178.812 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -53.31 -53.09 56.02 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 125.02 1.328 . . . . 0.0 113.375 -175.43 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.403 ' O ' HG23 ' A' ' 143' ' ' VAL . . . -88.25 31.81 4.64 Favored Glycine 0 C--N 1.305 -1.18 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.414 -177.542 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -146.1 153.65 40.94 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 -175.044 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -133.13 171.88 13.4 Favored 'General case' 0 C--N 1.272 -2.776 0 N-CA-C 105.923 -1.881 . . . . 0.0 105.923 175.663 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.449 HD11 ' HB2' ' A' ' 139' ' ' PRO . 13.1 tp -87.47 149.87 24.13 Favored 'General case' 0 C--N 1.282 -2.357 0 C-N-CA 119.135 -1.026 . . . . 0.0 108.563 179.216 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -122.51 121.83 37.48 Favored 'General case' 0 N--CA 1.408 -2.539 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 176.81 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.92 171.52 23.44 Favored Glycine 0 C--N 1.284 -2.33 0 C-N-CA 120.796 -0.716 . . . . 0.0 111.943 -175.434 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -86.27 -34.72 20.3 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.65 0.738 . . . . 0.0 109.495 -176.927 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.3 mm -77.97 126.67 38.43 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 CA-C-N 114.988 -1.006 . . . . 0.0 109.814 -175.925 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -127.57 1.93 6.19 Favored 'General case' 0 C--O 1.201 -1.454 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 176.899 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.445 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 18.2 p90 -136.51 162.43 33.12 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.42 -171.64 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 63.3 mtp180 -130.78 131.12 44.51 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 170.341 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -103.9 132.31 50.28 Favored 'General case' 0 C--N 1.292 -1.899 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.698 179.509 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 23.9 t -82.22 97.78 8.42 Favored 'General case' 0 N--CA 1.425 -1.681 0 C-N-CA 118.238 -1.385 . . . . 0.0 109.257 175.741 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -94.83 -173.41 2.98 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 106.673 -1.602 . . . . 0.0 106.673 178.163 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 14.1 t -67.01 -14.39 62.85 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.69 0.757 . . . . 0.0 111.277 -175.192 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -86.73 -28.64 22.94 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.017 177.953 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 132.13 -163.85 23.86 Favored Glycine 0 N--CA 1.436 -1.365 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 -175.405 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.469 ' CH2' HG13 ' A' ' 108' ' ' VAL . 98.5 m95 -63.62 113.55 3.4 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 117.85 0.825 . . . . 0.0 110.858 175.714 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 51.9 p -70.67 166.84 19.93 Favored 'General case' 0 C--O 1.267 2.006 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 177.542 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 62.24 -163.39 0.26 Allowed 'General case' 0 C--O 1.251 1.145 0 O-C-N 123.921 0.763 . . . . 0.0 109.383 178.061 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 37.6 t0 -131.59 177.88 7.17 Favored 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 174.419 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 71.7 mt -62.68 114.98 13.84 Favored Pre-proline 0 C--N 1.27 -2.873 0 C-N-CA 124.774 1.229 . . . . 0.0 108.036 175.193 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.449 ' HB2' HD11 ' A' ' 120' ' ' LEU . 29.1 Cg_endo -65.07 151.31 86.13 Favored 'Trans proline' 0 N--CA 1.447 -1.264 0 C-N-CA 122.479 2.119 . . . . 0.0 112.062 -177.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 48.2 mt -87.16 134.37 27.77 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.118 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.512 -174.165 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 93.5 m -107.82 148.13 29.95 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 171.165 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -129.8 144.85 51.51 Favored 'General case' 0 C--N 1.284 -2.266 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -179.824 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 117' ' ' GLY . 4.8 p -73.26 129.43 36.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 179.846 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.637 ' CG2' ' HB2' ' A' ' 170' ' ' PHE . 27.6 m -54.19 130.02 15.71 Favored 'Isoleucine or valine' 0 C--O 1.243 0.741 0 O-C-N 123.848 0.717 . . . . 0.0 112.209 -174.827 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.435 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 94.8 mttt -112.54 170.08 8.43 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.533 -175.985 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 3.0 p -150.41 158.82 44.58 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.052 176.33 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . 0.475 HD23 ' HD2' ' A' ' 148' ' ' PRO . 1.4 tt -55.48 131.6 70.76 Favored Pre-proline 0 N--CA 1.429 -1.515 0 C-N-CA 125.59 1.556 . . . . 0.0 111.992 -178.258 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.475 ' HD2' HD23 ' A' ' 147' ' ' LEU . 37.8 Cg_endo -69.08 100.6 0.74 Allowed 'Trans proline' 0 N--CA 1.445 -1.334 0 C-N-CA 122.846 2.364 . . . . 0.0 111.806 176.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 10.2 p -64.07 140.05 20.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.935 0 CA-C-N 115.428 -0.805 . . . . 0.0 108.948 176.607 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 15.6 p -73.12 -82.38 0.05 Allowed 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 113.177 0.806 . . . . 0.0 113.177 -174.529 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 175.45 162.62 0.41 Allowed Pre-proline 0 CA--C 1.517 -0.311 0 C-N-CA 124.771 1.228 . . . . 0.0 107.843 179.403 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -74.05 -178.16 3.69 Favored 'Trans proline' 0 N--CA 1.446 -1.301 0 C-N-CA 121.353 1.369 . . . . 0.0 110.254 170.57 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . 0.586 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.0 OUTLIER -93.15 -41.07 10.13 Favored 'General case' 0 C--N 1.289 -2.04 0 O-C-N 122.051 -0.406 . . . . 0.0 111.413 -176.394 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . 0.586 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 42.3 m-80 -107.59 21.12 17.92 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.529 0.68 . . . . 0.0 110.259 179.736 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -148.54 -172.68 18.65 Favored Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.677 -178.274 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 58.8 pttt -145.98 164.38 32.25 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 -176.621 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.436 HG22 ' H ' ' A' ' 159' ' ' SER . 63.5 mt -88.51 136.01 24.33 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 177.866 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 175' ' ' ARG . 11.5 m -84.73 -25.82 6.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.128 0.489 . . . . 0.0 110.81 -178.004 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.436 ' H ' HG22 ' A' ' 157' ' ' ILE . 21.4 t -128.58 92.4 3.41 Favored 'General case' 0 N--CA 1.432 -1.338 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.761 -174.98 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 32.2 t -148.78 97.54 2.73 Favored 'General case' 0 N--CA 1.426 -1.632 0 CA-C-O 121.108 0.48 . . . . 0.0 109.972 -178.627 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -100.09 90.88 4.53 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 176.364 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.434 ' CE ' ' HA ' ' A' ' 162' ' ' MET . 0.5 OUTLIER -84.22 84.3 7.67 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.815 0.817 . . . . 0.0 109.732 -177.825 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.464 ' HB2' ' HB2' ' A' ' 166' ' ' ARG . 45.8 mm-40 -109.1 163.42 17.04 Favored Pre-proline 0 C--N 1.296 -1.754 0 CA-C-N 114.311 -1.313 . . . . 0.0 108.67 -178.058 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.86 -12.61 19.86 Favored 'Trans proline' 0 C--O 1.221 -0.338 0 C-N-CA 121.954 1.77 . . . . 0.0 110.83 174.67 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -103.51 -38.74 7.03 Favored 'General case' 0 CA--C 1.494 -1.194 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.663 -178.145 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.464 ' HB2' ' HB2' ' A' ' 163' ' ' GLU . 9.9 mmt180 -98.43 100.33 11.58 Favored 'General case' 0 N--CA 1.416 -2.142 0 CA-C-N 115.195 -0.911 . . . . 0.0 113.45 -174.202 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.68 179.7 5.42 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 105.361 -2.088 . . . . 0.0 105.361 167.313 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . 0.435 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 95.1 m-85 -77.24 138.46 39.43 Favored 'General case' 0 C--N 1.296 -1.759 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.139 178.575 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.444 ' HA ' ' O ' ' A' ' 144' ' ' VAL . 36.0 m80 -136.31 169.61 17.37 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.642 -173.747 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.637 ' HB2' ' CG2' ' A' ' 144' ' ' VAL . 91.7 t80 -50.11 128.94 20.16 Favored 'General case' 0 C--O 1.24 0.573 0 O-C-N 124.2 0.937 . . . . 0.0 110.571 173.468 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 101.14 -14.08 58.52 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 119.972 -1.108 . . . . 0.0 112.751 175.95 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . 0.58 HE21 ' HA ' ' A' ' 172' ' ' GLN . 0.0 OUTLIER -77.19 143.45 39.02 Favored 'General case' 0 C--O 1.251 1.143 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.154 178.272 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -124.86 101.19 6.96 Favored 'General case' 0 C--N 1.285 -2.228 0 CA-C-N 114.767 -1.106 . . . . 0.0 108.859 -179.697 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.409 ' HB ' ' HG3' ' A' ' 190' ' ' MET . 69.2 t -81.38 96.62 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.648 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.252 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.6 ' O ' HG22 ' A' ' 158' ' ' VAL . 26.4 ttp180 -96.81 142.99 28.15 Favored 'General case' 0 N--CA 1.4 -2.936 0 CA-C-N 114.55 -1.204 . . . . 0.0 108.052 177.191 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -113.07 162.14 16.27 Favored 'General case' 0 C--N 1.278 -2.502 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -176.243 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 14.5 p -143.86 137.15 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.346 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 175.761 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . 0.432 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 80.8 m -92.7 152.37 19.56 Favored 'General case' 0 C--N 1.257 -3.438 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.586 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 51.2 m-80 -70.6 166.16 21.26 Favored 'General case' 0 CA--C 1.493 -1.22 0 C-N-CA 120.368 -0.533 . . . . 0.0 110.176 179.546 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 12.6 t -53.61 110.31 0.56 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 124.274 0.984 . . . . 0.0 111.163 -176.082 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 116.44 -13.88 15.59 Favored Glycine 0 N--CA 1.435 -1.383 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.706 179.307 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . 0.432 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 96.4 m-85 -110.7 163.25 13.94 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-N 117.482 0.641 . . . . 0.0 110.876 -179.007 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 18.1 ptmt -135.39 157.26 47.34 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.692 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.414 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.8 tt -84.98 137.53 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.766 0 CA-C-O 121.609 0.718 . . . . 0.0 111.127 -179.367 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -72.2 -53.48 12.51 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.091 -177.455 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -93.9 -134.8 7.38 Favored Glycine 0 C--N 1.296 -1.674 0 CA-C-N 115.506 -0.77 . . . . 0.0 112.087 -177.781 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -81.35 169.66 16.96 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 178.462 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.414 ' HA ' HD13 ' A' ' 184' ' ' ILE . 12.8 pt-20 -100.63 -15.76 17.65 Favored 'General case' 0 C--N 1.289 -2.048 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -176.338 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -144.19 138.32 28.01 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 113.073 0.768 . . . . 0.0 113.073 -175.394 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.409 ' HG3' ' HB ' ' A' ' 174' ' ' VAL . 13.8 ptp -117.45 130.2 56.31 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.66 -1.155 . . . . 0.0 108.713 174.883 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -102.49 137.19 41.06 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.965 -177.031 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . 0.476 ' HB2' ' CZ3' ' A' ' 198' ' ' TRP . 19.6 t -88.1 107.99 19.03 Favored 'General case' 0 C--O 1.253 1.274 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 174.515 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 21.7 m -102.81 -176.64 3.15 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 112.964 0.727 . . . . 0.0 112.964 -171.148 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -44.37 -39.32 4.56 Favored 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 126.148 1.779 . . . . 0.0 113.491 -176.973 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -63.54 -17.28 62.63 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.862 -177.047 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 78.57 32.91 40.23 Favored Glycine 0 N--CA 1.444 -0.83 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -174.092 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -144.11 171.92 13.62 Favored 'General case' 0 C--O 1.249 1.034 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 -179.544 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . 0.476 ' CZ3' ' HB2' ' A' ' 192' ' ' CYS . 81.9 m95 -87.32 137.6 32.2 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 175.778 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 44.7 m -83.35 -3.31 57.38 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.168 0.509 . . . . 0.0 111.941 179.881 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 20.2 mmtp -128.54 162.15 27.91 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.581 179.471 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -95.65 166.09 12.0 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.935 179.86 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . 0.449 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 9.8 tptm -65.34 116.97 35.71 Favored Pre-proline 0 CA--C 1.547 0.834 0 C-N-CA 123.337 0.655 . . . . 0.0 111.299 179.168 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.449 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 6.7 Cg_endo -90.54 177.87 2.17 Favored 'Trans proline' 0 CA--C 1.547 1.148 0 C-N-CA 122.658 2.238 . . . . 0.0 112.85 177.198 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . 0.542 ' HG3' ' OE2' ' A' ' 153' ' ' GLU . 22.1 ttmm -131.25 157.11 44.13 Favored 'General case' 0 C--N 1.318 -0.804 0 C-N-CA 124.319 1.048 . . . . 0.0 109.531 -177.238 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.429 ' HB2' ' HB2' ' A' ' 154' ' ' ASN . 87.8 m -104.06 119.22 38.47 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 173.857 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.296 -1.758 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.754 -174.693 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.4 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 31.7 Cg_endo . . . . . 0 CA--C 1.531 0.373 0 CA-C-O 121.665 0.611 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 57.9 m -88.43 -32.96 18.04 Favored 'General case' 0 N--CA 1.436 -1.125 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 176.332 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.99 -85.72 0.4 Allowed Glycine 0 CA--C 1.453 -3.839 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 171.58 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.2 t-80 -173.75 133.75 0.6 Allowed Pre-proline 0 C--N 1.266 -3.037 0 N-CA-C 105.411 -2.07 . . . . 0.0 105.411 -174.328 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.507 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 89.9 Cg_endo -87.24 -5.07 7.63 Favored 'Trans proline' 0 C--O 1.242 0.686 0 C-N-CA 122.252 1.968 . . . . 0.0 112.94 -176.364 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.499 ' HA3' HD11 ' A' ' 138' ' ' ILE . . . 126.38 -161.72 20.67 Favored Glycine 0 N--CA 1.42 -2.379 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 -178.375 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -158.48 150.52 21.53 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 104.711 -2.329 . . . . 0.0 104.711 177.86 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.9 t -131.53 127.04 21.43 Favored Pre-proline 0 C--N 1.301 -1.519 0 C-N-CA 119.746 -0.781 . . . . 0.0 111.994 -177.382 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -71.37 -16.6 31.06 Favored 'Trans proline' 0 CA--C 1.534 0.522 0 C-N-CA 122.541 2.161 . . . . 0.0 111.502 177.075 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 71.5 m-85 -83.45 -6.6 59.51 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.988 -177.458 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.44 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 171.89 -129.94 1.84 Allowed Glycine 0 N--CA 1.414 -2.79 0 C-N-CA 118.838 -1.648 . . . . 0.0 113.48 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.5 p -141.21 178.6 7.28 Favored 'General case' 0 C--N 1.286 -2.174 0 CA-C-N 114.989 -0.606 . . . . 0.0 111.288 -174.804 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.466 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 36.5 p90 -148.66 155.23 40.77 Favored 'General case' 0 N--CA 1.431 -1.383 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 171.327 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -123.98 153.15 41.69 Favored 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 107.766 -1.198 . . . . 0.0 107.766 -178.316 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -110.74 126.67 54.82 Favored 'General case' 0 C--N 1.271 -2.814 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -179.774 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.424 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 17.2 p -121.26 134.14 55.17 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.265 -176.508 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 108.14 -45.92 1.24 Allowed Glycine 0 C--N 1.311 -0.811 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.989 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.441 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -128.3 -18.21 1.88 Allowed Glycine 0 C--N 1.311 -0.842 0 C-N-CA 120.382 -0.913 . . . . 0.0 113.009 -179.901 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 63.27 16.55 9.54 Favored 'General case' 0 N--CA 1.494 1.731 0 C-N-CA 124.388 1.075 . . . . 0.0 110.868 179.993 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.513 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.6 m -148.41 -171.86 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.211 -0.965 0 N-CA-C 106.967 -1.494 . . . . 0.0 106.967 -178.912 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.507 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 32.6 m-85 -101.47 44.66 1.0 Allowed 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 118.794 0.725 . . . . 0.0 110.648 -177.486 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.69 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.2 pt-20 -86.51 -175.73 5.57 Favored 'General case' 0 C--O 1.207 -1.143 0 CA-C-N 114.837 -1.074 . . . . 0.0 111.468 177.638 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . 0.4 ' CE2' ' HB2' ' A' ' 84' ' ' PRO . 43.5 m-85 -81.05 139.65 35.59 Favored 'General case' 0 C--N 1.308 -1.226 0 O-C-N 121.686 -0.634 . . . . 0.0 111.085 178.786 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.44 4.29 80.55 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.655 -0.702 . . . . 0.0 112.529 179.122 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.69 HG12 ' O ' ' A' ' 105' ' ' GLU . 14.3 p -94.25 142.92 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 C-N-CA 119.763 -0.775 . . . . 0.0 109.123 -179.628 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.424 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -107.67 121.23 44.26 Favored 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.708 178.441 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -86.81 89.67 8.04 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 175.575 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 94.6 t -85.71 115.13 26.65 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.638 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -177.647 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . 0.466 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 43.2 m-85 -86.63 145.77 26.59 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 116.605 -0.271 . . . . 0.0 111.116 -177.061 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 10.1 t -145.44 116.74 7.95 Favored 'General case' 0 N--CA 1.427 -1.602 0 CA-C-O 122.404 1.097 . . . . 0.0 109.471 178.11 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 28.4 m -72.89 164.95 25.86 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 114.901 -1.045 . . . . 0.0 111.191 -174.887 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.44 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 81.0 m-20 -75.31 171.71 13.73 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.505 177.143 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -58.49 -39.4 79.9 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 113.269 0.84 . . . . 0.0 113.269 -174.331 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.425 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -75.39 12.41 7.55 Favored Glycine 0 CA--C 1.526 0.752 0 C-N-CA 120.838 -0.696 . . . . 0.0 113.063 179.733 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.67 ' HE1' HG22 ' A' ' 143' ' ' VAL . 83.5 m-85 -147.09 170.09 17.9 Favored 'General case' 0 N--CA 1.427 -1.582 0 C-N-CA 124.56 1.144 . . . . 0.0 108.95 -177.51 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.443 HE21 ' HB2' ' A' ' 119' ' ' GLN . 0.7 OUTLIER -140.58 173.5 11.43 Favored 'General case' 0 C--N 1.266 -3.058 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 175.699 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 6.9 tt -99.92 137.5 38.29 Favored 'General case' 0 C--N 1.27 -2.851 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -179.713 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.447 ' HB2' ' HB2' ' A' ' 142' ' ' GLU . 0.2 OUTLIER -127.52 135.83 50.89 Favored 'General case' 0 N--CA 1.423 -1.818 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -176.978 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 130.02 179.29 15.92 Favored Glycine 0 N--CA 1.421 -2.311 0 N-CA-C 110.065 -1.214 . . . . 0.0 110.065 178.397 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 61.7 mm-40 -95.88 -17.05 21.4 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 122.282 1.039 . . . . 0.0 109.078 177.102 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.6 mm -101.5 142.84 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.588 0 CA-C-N 114.184 -1.371 . . . . 0.0 108.233 179.032 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.7 p-10 -141.14 9.61 2.11 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-O 121.278 0.561 . . . . 0.0 109.517 177.795 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . . . . . . . . . 32.8 p90 -157.55 159.57 37.28 Favored 'General case' 0 N--CA 1.427 -1.602 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.747 -172.981 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 56.4 mtp180 -121.16 129.85 53.44 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 172.507 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -105.43 130.61 53.48 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -178.512 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 34.6 t -83.1 105.35 14.01 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 117.625 -1.63 . . . . 0.0 110.206 176.643 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.423 ' OD2' HG22 ' A' ' 131' ' ' THR . 22.5 t70 -94.38 -178.59 4.63 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 178.297 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.423 HG22 ' OD2' ' A' ' 130' ' ' ASP . 11.0 t -63.28 -22.49 66.91 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 121.728 0.775 . . . . 0.0 110.38 -177.729 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -76.59 -37.12 56.99 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.769 177.735 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 139.28 -159.49 25.69 Favored Glycine 0 N--CA 1.434 -1.462 0 N-CA-C 107.982 -2.047 . . . . 0.0 107.982 -173.938 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -66.38 122.99 18.77 Favored 'General case' 0 C--O 1.248 0.979 0 CA-C-N 118.258 1.029 . . . . 0.0 110.539 177.653 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 67.7 p -80.89 163.32 23.47 Favored 'General case' 0 N--CA 1.416 -2.167 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 175.814 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 61.74 -165.21 0.23 Allowed 'General case' 0 C--N 1.323 -0.582 0 O-C-N 124.017 0.823 . . . . 0.0 110.579 175.21 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -129.57 -179.92 5.45 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 175.678 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.499 HD11 ' HA3' ' A' ' 89' ' ' GLY . 62.3 mt -66.6 122.24 81.06 Favored Pre-proline 0 C--N 1.298 -1.648 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 173.245 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.55 158.15 54.59 Favored 'Trans proline' 0 C--O 1.243 0.742 0 C-N-CA 122.67 2.247 . . . . 0.0 111.416 179.275 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 68.0 mt -84.95 131.65 33.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 CA-C-O 121.03 0.443 . . . . 0.0 111.016 -174.051 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . . . . . . . . . 91.4 m -98.45 102.01 13.62 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 173.263 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.447 ' HB2' ' HB2' ' A' ' 121' ' ' LEU . 1.0 OUTLIER -87.88 154.5 20.47 Favored 'General case' 0 CA--C 1.461 -2.443 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.147 178.693 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.67 HG22 ' HE1' ' A' ' 118' ' ' TYR . 4.3 t -80.7 137.34 21.58 Favored 'Isoleucine or valine' 0 C--N 1.259 -3.367 0 CA-C-N 114.82 -1.082 . . . . 0.0 108.661 -177.197 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.6 HG23 ' HB2' ' A' ' 170' ' ' PHE . 3.7 m -69.83 98.34 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 CA-C-N 114.917 -1.038 . . . . 0.0 109.153 177.407 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.454 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 49.2 mttm -88.07 131.81 34.53 Favored 'General case' 0 N--CA 1.417 -2.094 0 CA-C-N 113.754 -1.566 . . . . 0.0 109.387 -176.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.43 ' O ' ' HB2' ' A' ' 168' ' ' TYR . 61.6 m -94.16 127.43 39.99 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 107.17 -1.419 . . . . 0.0 107.17 177.026 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -50.24 138.94 19.69 Favored Pre-proline 0 N--CA 1.438 -1.071 0 N-CA-C 114.655 1.354 . . . . 0.0 114.655 -176.264 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -69.7 123.38 10.07 Favored 'Trans proline' 0 N--CA 1.444 -1.425 0 C-N-CA 122.926 2.417 . . . . 0.0 112.304 -175.522 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 21.2 t -91.84 130.75 40.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.4 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.3 m -74.93 -67.96 0.59 Allowed 'General case' 0 N--CA 1.414 -2.268 0 C-N-CA 122.764 0.425 . . . . 0.0 111.16 -177.866 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 172.96 150.12 0.22 Allowed Pre-proline 0 CA--C 1.509 -0.599 0 C-N-CA 124.686 1.194 . . . . 0.0 108.079 -178.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -77.07 174.7 12.41 Favored 'Trans proline' 0 N--CA 1.446 -1.315 0 C-N-CA 121.836 1.691 . . . . 0.0 110.811 173.947 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -61.58 -51.78 67.14 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 114.215 1.191 . . . . 0.0 114.215 -174.913 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -123.29 23.27 9.14 Favored 'General case' 0 CA--C 1.496 -1.108 0 CA-C-O 122.032 0.92 . . . . 0.0 109.891 -172.411 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . 0.472 ' HA3' ' SG ' ' A' ' 205' ' ' CYS . . . -140.47 -178.15 16.76 Favored Glycine 0 C--N 1.281 -2.516 0 CA-C-N 114.071 -1.422 . . . . 0.0 109.906 178.716 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 47.6 pttt -143.91 162.52 35.91 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 -177.146 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.559 HG22 ' H ' ' A' ' 159' ' ' SER . 46.7 mt -92.25 135.98 25.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 -179.632 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' A' ' 175' ' ' ARG . 10.8 m -71.19 -23.14 22.98 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-O 121.872 0.844 . . . . 0.0 111.382 -175.281 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.559 ' H ' HG22 ' A' ' 157' ' ' ILE . 20.8 t -122.89 173.59 7.69 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 -178.849 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 71.0 m -162.48 -47.14 0.04 OUTLIER 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.52 0.676 . . . . 0.0 109.97 178.235 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -150.19 78.67 1.34 Allowed 'General case' 0 N--CA 1.44 -0.964 0 CA-C-O 121.85 0.833 . . . . 0.0 109.589 179.479 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.51 -23.24 34.72 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.486 -179.133 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -111.03 149.69 40.83 Favored Pre-proline 0 C--N 1.311 -1.079 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.133 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.63 -3.92 14.54 Favored 'Trans proline' 0 N--CA 1.482 0.839 0 C-N-CA 123.023 2.482 . . . . 0.0 110.842 177.621 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -89.06 -26.77 21.23 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 105.925 -1.88 . . . . 0.0 105.925 179.192 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 50.9 mtt180 71.69 -16.29 0.4 Allowed 'General case' 0 CA--C 1.497 -1.063 0 C-N-CA 127.426 2.29 . . . . 0.0 116.21 170.668 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 22.9 mm-40 -77.48 154.83 32.16 Favored 'General case' 0 C--N 1.249 -3.777 0 CA-C-N 114.761 -1.108 . . . . 0.0 109.34 176.999 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . 0.454 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 95.5 m-85 -92.78 134.45 35.05 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 176.755 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 23.3 m80 -129.28 161.5 30.08 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -174.469 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.6 ' HB2' HG23 ' A' ' 144' ' ' VAL . 87.1 t80 -51.9 107.74 0.22 Allowed 'General case' 0 N--CA 1.469 0.513 0 O-C-N 123.82 0.7 . . . . 0.0 110.675 174.54 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 139.05 -24.57 2.83 Favored Glycine 0 N--CA 1.433 -1.557 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -175.681 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -78.34 160.91 27.57 Favored 'General case' 0 N--CA 1.429 -1.523 0 CA-C-O 121.602 0.715 . . . . 0.0 112.897 -179.43 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.424 ' HA ' ' O ' ' A' ' 190' ' ' MET . . . -148.28 118.46 7.28 Favored 'General case' 0 N--CA 1.423 -1.775 0 CA-C-N 114.376 -1.283 . . . . 0.0 109.027 179.793 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.482 HG23 ' CH2' ' A' ' 198' ' ' TRP . 46.2 t -86.18 107.41 16.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.13 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.537 ' HB3' HG21 ' A' ' 158' ' ' VAL . 78.9 ttt180 -99.64 140.57 33.65 Favored 'General case' 0 N--CA 1.42 -1.954 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 178.067 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -114.49 161.09 18.45 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 -176.468 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 7.7 p -140.9 128.06 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.812 0 CA-C-N 115.22 -0.9 . . . . 0.0 109.931 175.948 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . 0.454 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 71.7 m -89.11 152.24 21.76 Favored 'General case' 0 C--N 1.276 -2.607 0 CA-C-N 114.915 -1.038 . . . . 0.0 110.138 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -68.9 -179.92 1.62 Allowed 'General case' 0 C--O 1.239 0.532 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.714 178.663 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 8.8 p -47.02 -39.67 13.14 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 115.945 1.832 . . . . 0.0 115.945 -172.097 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -109.51 15.5 32.25 Favored Glycine 0 C--N 1.286 -2.212 0 C-N-CA 120.328 -0.939 . . . . 0.0 113.239 -176.626 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . 0.454 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 96.5 m-85 -116.12 157.97 23.94 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-N 117.974 0.887 . . . . 0.0 111.571 -178.24 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -126.93 158.05 37.82 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 106.557 -1.645 . . . . 0.0 106.557 175.763 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.674 HD13 ' HA ' ' A' ' 188' ' ' GLU . 6.5 tt -91.28 139.45 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.23 0 C-N-CA 119.167 -1.013 . . . . 0.0 110.806 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -50.04 -58.95 4.42 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 126.08 1.752 . . . . 0.0 113.106 -177.657 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -128.64 -103.88 1.15 Allowed Glycine 0 CA--C 1.493 -1.331 0 C-N-CA 120.247 -0.978 . . . . 0.0 111.276 -178.394 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -80.52 159.12 25.62 Favored 'General case' 0 CA--C 1.486 -1.497 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 177.815 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.674 ' HA ' HD13 ' A' ' 184' ' ' ILE . 15.0 pt-20 -103.45 4.45 36.08 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.428 -0.909 . . . . 0.0 109.507 178.34 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -148.44 146.61 28.5 Favored 'General case' 0 N--CA 1.426 -1.654 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.018 -175.715 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.424 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 12.3 ptp -124.44 121.21 34.25 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.11 174.279 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 46.0 t-80 -98.77 145.41 26.97 Favored 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.069 -176.661 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 12.8 m -62.01 148.52 43.67 Favored 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 177.133 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 31.5 m -127.9 159.95 33.34 Favored 'General case' 0 N--CA 1.423 -1.813 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 173.074 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -69.97 -1.46 9.77 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -172.65 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -75.84 -15.91 60.16 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.039 0.447 . . . . 0.0 109.901 175.458 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 88.12 22.19 42.62 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -172.454 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -135.81 169.38 17.66 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -179.917 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . 0.482 ' CH2' HG23 ' A' ' 174' ' ' VAL . 78.1 m95 -87.13 151.42 23.22 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.818 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 39.6 t -71.1 -50.1 37.28 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 121.531 0.682 . . . . 0.0 109.186 177.739 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.409 ' HD3' ' HA ' ' A' ' 200' ' ' LYS . 25.4 mmtp -88.49 148.99 23.88 Favored 'General case' 0 N--CA 1.429 -1.499 0 CA-C-O 121.417 0.627 . . . . 0.0 111.623 -179.798 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -89.11 150.65 22.63 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 177.813 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . 0.433 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 27.3 ttpp -58.73 112.95 5.69 Favored Pre-proline 0 C--O 1.237 0.4 0 N-CA-C 114.443 1.275 . . . . 0.0 114.443 -173.306 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 18.0 Cg_exo -72.01 171.38 16.8 Favored 'Trans proline' 0 N--CA 1.451 -1.014 0 C-N-CA 123.395 2.73 . . . . 0.0 110.631 175.322 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.4 mttp -123.36 167.06 14.29 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -177.753 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.472 ' SG ' ' HA3' ' A' ' 155' ' ' GLY . 94.5 m -106.59 104.65 14.39 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 172.195 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 11.4 m . . . . . 0 C--N 1.296 -1.751 0 CA-C-N 114.782 -1.099 . . . . 0.0 112.327 -171.924 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo . . . . . 0 CA--C 1.536 0.611 0 CA-C-O 121.783 0.66 . . . . 0.0 111.082 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.5 m -82.5 -32.86 28.57 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.309 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.53 -85.86 0.4 Allowed Glycine 0 CA--C 1.458 -3.508 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 173.073 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 7.2 t60 179.42 130.43 0.23 Allowed Pre-proline 0 C--N 1.271 -2.818 0 N-CA-C 104.153 -2.536 . . . . 0.0 104.153 -176.056 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.4 -33.07 5.81 Favored 'Trans proline' 0 N--CA 1.474 0.363 0 C-N-CA 121.625 1.55 . . . . 0.0 112.744 -175.423 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 134.52 177.26 14.82 Favored Glycine 0 N--CA 1.419 -2.445 0 N-CA-C 107.021 -2.432 . . . . 0.0 107.021 -176.017 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -134.91 162.96 30.95 Favored 'General case' 0 C--N 1.287 -2.14 0 CA-C-N 118.36 1.08 . . . . 0.0 109.433 179.848 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.7 t -119.35 131.44 24.37 Favored Pre-proline 0 N--CA 1.416 -2.153 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.183 -178.516 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.02 -11.69 17.85 Favored 'Trans proline' 0 N--CA 1.459 -0.509 0 C-N-CA 122.563 2.176 . . . . 0.0 111.616 177.872 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -88.93 -2.89 58.81 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.216 -177.814 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.462 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 175.57 -128.02 1.34 Allowed Glycine 0 N--CA 1.414 -2.793 0 C-N-CA 118.961 -1.59 . . . . 0.0 113.63 -179.994 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.1 p -138.56 170.5 15.89 Favored 'General case' 0 C--N 1.291 -1.96 0 CA-C-N 114.841 -0.68 . . . . 0.0 110.972 -174.641 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.2 p90 -140.74 145.65 36.71 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 171.023 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.7 m -120.32 161.23 21.49 Favored 'General case' 0 C--N 1.271 -2.843 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -176.894 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.5 mt -119.56 120.97 38.29 Favored 'General case' 0 C--N 1.28 -2.448 0 CA-C-O 121.028 0.442 . . . . 0.0 109.867 -177.443 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.48 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 24.0 p -109.99 129.02 55.73 Favored 'General case' 0 C--N 1.285 -2.218 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.52 -175.383 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 113.38 -54.91 0.54 Allowed Glycine 0 N--CA 1.432 -1.593 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 179.073 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.429 ' H ' HG23 ' A' ' 108' ' ' VAL . . . -121.24 -12.63 5.67 Favored Glycine 0 C--N 1.305 -1.19 0 C-N-CA 119.965 -1.112 . . . . 0.0 113.335 -179.514 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 47.7 m-80 61.26 18.55 9.28 Favored 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 123.485 0.714 . . . . 0.0 112.22 -178.168 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.54 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.7 m -151.32 -174.48 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.206 -1.21 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -175.806 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -99.71 46.05 0.98 Allowed 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 118.732 0.696 . . . . 0.0 110.619 -177.339 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.691 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.1 pt-20 -86.91 179.79 6.65 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.632 177.019 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 41.2 m-85 -76.12 137.28 40.01 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 122.039 -0.413 . . . . 0.0 111.301 177.089 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.98 -7.96 70.11 Favored Glycine 0 N--CA 1.441 -0.969 0 CA-C-N 115.603 -0.726 . . . . 0.0 113.048 178.003 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.691 HG12 ' O ' ' A' ' 105' ' ' GLU . 12.9 p -87.14 146.8 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.881 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 -175.163 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.48 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.9 mtpt -110.25 125.84 53.53 Favored 'General case' 0 N--CA 1.419 -2.011 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.248 178.129 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -88.42 95.99 10.42 Favored 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 175.442 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 77.5 t -90.08 113.65 26.55 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.901 0 C-N-CA 123.988 0.915 . . . . 0.0 108.819 -177.451 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 48.0 m-85 -88.48 134.6 33.8 Favored 'General case' 0 C--N 1.285 -2.228 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.992 -178.948 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.1 t -142.82 124.04 14.6 Favored 'General case' 0 N--CA 1.428 -1.561 0 CA-C-O 122.067 0.937 . . . . 0.0 109.399 179.51 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.404 ' HB3' ' HB2' ' A' ' 118' ' ' TYR . 78.0 m -75.35 166.46 23.57 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.949 -174.064 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.462 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 85.2 m-20 -85.46 -177.03 6.34 Favored 'General case' 0 C--O 1.216 -0.698 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.295 178.393 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -42.93 -54.44 4.21 Favored 'General case' 0 C--N 1.311 -1.072 0 C-N-CA 126.163 1.785 . . . . 0.0 114.527 -177.435 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -92.41 17.34 57.64 Favored Glycine 0 C--N 1.299 -1.495 0 C-N-CA 119.497 -1.335 . . . . 0.0 112.859 -175.111 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.717 ' HE1' HG22 ' A' ' 143' ' ' VAL . 77.8 m-85 -133.95 147.32 51.04 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.182 -177.304 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.438 ' OE1' ' HB3' ' A' ' 142' ' ' GLU . 0.0 OUTLIER -136.3 160.07 39.84 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -178.849 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . 0.452 HD22 ' HB3' ' A' ' 125' ' ' ASN . 10.4 tp -83.7 141.44 31.47 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 118.915 -1.114 . . . . 0.0 109.947 -176.309 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.05 122.91 43.21 Favored 'General case' 0 N--CA 1.411 -2.381 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 179.177 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.66 -160.42 13.7 Favored Glycine 0 C--N 1.293 -1.855 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.77 -176.568 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -105.9 -48.31 3.65 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -179.129 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.5 mm -73.4 129.51 36.16 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.132 -173.458 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.452 ' HB3' HD22 ' A' ' 120' ' ' LEU . 2.5 p-10 -130.0 12.99 5.73 Favored 'General case' 0 C--O 1.213 -0.838 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 177.516 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.47 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 34.0 p90 -149.67 161.74 41.59 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.85 -176.48 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 44.3 mtp180 -127.46 131.78 50.13 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 172.069 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -108.06 131.98 54.03 Favored 'General case' 0 C--N 1.283 -2.301 0 C-N-CA 119.202 -0.999 . . . . 0.0 109.5 -178.405 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 21.6 t -81.4 99.27 8.62 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.829 -1.149 . . . . 0.0 109.155 176.533 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.425 ' OD2' HG22 ' A' ' 131' ' ' THR . 8.6 t70 -96.35 -167.13 1.52 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 178.447 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.425 HG22 ' OD2' ' A' ' 130' ' ' ASP . 9.0 t -59.37 -28.46 66.9 Favored 'General case' 0 C--N 1.31 -1.121 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 -174.733 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -85.95 -23.65 26.85 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.549 0.69 . . . . 0.0 110.213 179.596 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 128.96 -153.96 20.01 Favored Glycine 0 N--CA 1.421 -2.362 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -175.646 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -64.87 113.38 3.79 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -179.878 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 65.0 p -73.09 172.48 10.97 Favored 'General case' 0 C--O 1.27 2.154 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 176.188 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 63.6 m-20 59.68 -156.74 0.34 Allowed 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 175.984 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -141.15 -177.51 5.15 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 173.092 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 57.0 mt -65.73 116.88 36.17 Favored Pre-proline 0 C--N 1.273 -2.728 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 174.806 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.413 ' HB2' HD11 ' A' ' 120' ' ' LEU . 49.2 Cg_endo -68.61 160.83 47.77 Favored 'Trans proline' 0 C--O 1.246 0.91 0 C-N-CA 122.418 2.079 . . . . 0.0 112.308 -176.01 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 48.7 mm -90.67 131.52 37.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.364 -176.382 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.613 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 36.6 t -114.08 137.62 51.49 Favored 'General case' 0 C--N 1.282 -2.343 0 N-CA-C 105.752 -1.944 . . . . 0.0 105.752 175.697 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.438 ' HB3' ' OE1' ' A' ' 119' ' ' GLN . 9.7 tp10 -119.1 157.59 27.56 Favored 'General case' 0 C--N 1.277 -2.557 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 179.922 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.717 HG22 ' HE1' ' A' ' 118' ' ' TYR . 24.0 t -79.84 138.54 19.72 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.073 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 -178.908 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 70.6 t -60.01 122.01 9.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 124.305 1.003 . . . . 0.0 108.399 179.331 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.507 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 59.9 mttm -120.33 156.06 32.07 Favored 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.899 -178.815 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 80.1 m -108.65 -171.54 1.87 Allowed 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 123.825 0.85 . . . . 0.0 110.677 -179.827 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . 0.588 HD12 ' HD2' ' A' ' 148' ' ' PRO . 1.5 tp -95.56 134.34 24.39 Favored Pre-proline 0 N--CA 1.421 -1.913 0 O-C-N 122.027 -0.421 . . . . 0.0 110.023 -177.181 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.588 ' HD2' HD12 ' A' ' 147' ' ' LEU . 12.7 Cg_endo -58.2 121.51 10.12 Favored 'Trans proline' 0 CA--C 1.535 0.543 0 C-N-CA 123.23 2.62 . . . . 0.0 111.563 177.333 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 28.7 t -85.94 143.65 11.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 -177.975 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 19.5 p -77.98 -83.12 0.08 Allowed 'General case' 0 N--CA 1.42 -1.974 0 CA-C-N 116.806 -0.179 . . . . 0.0 111.308 175.436 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 170.96 156.56 0.21 Allowed Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 125.143 1.377 . . . . 0.0 107.757 179.604 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -69.79 162.93 40.18 Favored 'Trans proline' 0 C--N 1.353 0.816 0 C-N-CA 121.723 1.615 . . . . 0.0 110.896 172.915 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . 0.43 ' HG3' HD22 ' A' ' 154' ' ' ASN . 11.0 pt-20 -62.3 -50.6 71.02 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -174.926 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . 0.43 HD22 ' HG3' ' A' ' 153' ' ' GLU . 55.4 m-80 -113.76 38.17 3.04 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 -177.96 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -154.06 -164.41 12.75 Favored Glycine 0 N--CA 1.425 -2.051 0 CA-C-N 115.026 -0.988 . . . . 0.0 111.189 178.353 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -156.0 173.24 17.09 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -178.601 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 49.7 mt -88.98 134.73 27.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 CA-C-O 121.148 0.499 . . . . 0.0 110.499 -179.251 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 55.1 t -73.98 -43.38 52.27 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 C-N-CA 124.149 0.98 . . . . 0.0 109.455 178.779 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 2.1 m -84.18 87.92 7.19 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -179.86 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 11.2 p -83.66 -31.22 26.26 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.352 0.596 . . . . 0.0 112.086 -176.95 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -139.97 94.46 2.76 Favored 'General case' 0 C--N 1.309 -1.192 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.306 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . 0.465 ' HG2' ' HG2' ' A' ' 163' ' ' GLU . 1.6 pmm? -103.74 -35.91 8.05 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.476 -178.578 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.479 ' HG3' ' H ' ' A' ' 166' ' ' ARG . 8.9 pt-20 -148.89 146.78 22.39 Favored Pre-proline 0 N--CA 1.441 -0.907 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.236 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -79.0 0.68 9.81 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 122.851 2.367 . . . . 0.0 112.92 -178.769 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . 0.478 ' HB3' ' OE1' ' A' ' 163' ' ' GLU . 28.7 t70 -94.33 -33.78 13.07 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -178.425 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . 0.479 ' H ' ' HG3' ' A' ' 163' ' ' GLU . 14.5 mmm180 57.3 18.12 4.11 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 125.952 1.701 . . . . 0.0 115.36 174.978 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -91.24 -9.79 43.95 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-O 121.23 0.538 . . . . 0.0 110.065 -179.449 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 68.97 93.21 0.08 Allowed 'General case' 0 CA--C 1.49 -1.355 0 C-N-CA 126.143 1.777 . . . . 0.0 111.681 177.558 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.507 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 20.9 p-80 -96.34 159.52 14.9 Favored 'General case' 0 C--N 1.292 -1.904 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.623 -179.135 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 50.3 t80 -50.78 123.29 8.73 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 125.311 1.444 . . . . 0.0 109.59 176.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.62 -10.93 21.39 Favored Glycine 0 N--CA 1.425 -2.092 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.621 -178.068 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 28.0 mm-40 -89.65 143.64 26.64 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-N 117.805 0.802 . . . . 0.0 111.195 179.585 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -111.86 126.44 55.09 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.468 -1.242 . . . . 0.0 107.826 177.848 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.574 HG12 ' CG ' ' A' ' 190' ' ' MET . 0.3 OUTLIER -117.76 118.5 58.57 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.246 0 C-N-CA 119.249 -0.981 . . . . 0.0 108.384 178.73 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . . . . . . . . . 43.9 ttm180 -104.54 157.52 17.12 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 -179.275 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -129.12 154.35 46.79 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -176.031 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 11.5 p -135.82 152.13 30.47 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.158 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 179.581 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 74.8 m -105.48 146.29 29.74 Favored 'General case' 0 C--N 1.274 -2.716 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.871 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -65.88 172.93 3.23 Favored 'General case' 0 CA--C 1.503 -0.832 0 O-C-N 123.732 0.645 . . . . 0.0 110.473 -177.441 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 6.0 p -53.75 104.9 0.11 Allowed 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 124.317 1.047 . . . . 0.0 112.939 -177.764 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.18 -3.64 31.47 Favored Glycine 0 N--CA 1.433 -1.508 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.457 177.889 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -112.64 150.27 31.68 Favored 'General case' 0 N--CA 1.42 -1.946 0 O-C-N 122.162 -0.611 . . . . 0.0 110.397 179.89 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 65.0 pttt -123.36 160.3 27.06 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 -179.972 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.412 HD11 ' HB2' ' A' ' 203' ' ' PRO . 1.7 tp -76.18 142.2 14.72 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -179.787 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -88.5 -69.1 0.72 Allowed 'General case' 0 C--N 1.287 -2.114 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 -179.479 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -77.8 -128.22 0.42 Allowed Glycine 0 N--CA 1.437 -1.251 0 C-N-CA 120.615 -0.802 . . . . 0.0 111.717 176.964 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 203' ' ' PRO . 5.6 t70 -98.28 162.04 13.39 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 107.281 -1.378 . . . . 0.0 107.281 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -99.78 1.1 42.84 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 119.513 1.051 . . . . 0.0 112.23 -170.618 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -152.01 153.84 34.83 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 121.398 0.618 . . . . 0.0 112.475 -177.154 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.574 ' CG ' HG12 ' A' ' 174' ' ' VAL . 16.7 ptp -132.72 148.51 52.33 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.289 178.659 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 47.6 m80 -115.17 145.44 42.39 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.604 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 42.8 t -81.58 102.25 10.51 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 177.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 51.9 m -121.66 158.0 29.63 Favored 'General case' 0 N--CA 1.425 -1.688 0 N-CA-C 114.096 1.147 . . . . 0.0 114.096 -168.607 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 21.98 -76.87 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 129.483 3.113 . . . . 0.0 116.973 174.389 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -62.76 -21.2 65.66 Favored 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 125.014 1.325 . . . . 0.0 113.58 -172.059 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 101.73 20.72 12.38 Favored Glycine 0 N--CA 1.435 -1.42 0 C-N-CA 119.62 -1.276 . . . . 0.0 110.913 -175.819 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 21.9 p90 -146.67 173.18 12.58 Favored 'General case' 0 N--CA 1.426 -1.649 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 175.068 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 90.3 m95 -69.18 138.44 54.1 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 123.651 0.594 . . . . 0.0 111.62 -175.366 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 13.0 p -68.31 -33.4 74.26 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.656 178.841 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 59.5 mmtt -107.23 149.57 27.59 Favored 'General case' 0 N--CA 1.432 -1.352 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.617 -179.765 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -79.84 163.89 24.03 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 114.463 -1.244 . . . . 0.0 109.018 176.467 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 9.6 mtpm? -64.89 128.52 93.78 Favored Pre-proline 0 CA--C 1.502 -0.867 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.964 179.959 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.443 ' HB3' ' O ' ' A' ' 187' ' ' ASP . 95.3 Cg_endo -78.78 166.95 22.97 Favored 'Trans proline' 0 N--CA 1.434 -1.995 0 C-N-CA 122.247 1.964 . . . . 0.0 111.975 179.55 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 51.2 tttp -122.44 156.74 33.42 Favored 'General case' 0 N--CA 1.414 -2.268 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 -179.493 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 92.3 m -118.07 116.27 26.53 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 176.796 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 27.4 m . . . . . 0 C--N 1.301 -1.542 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.546 -176.571 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo . . . . . 0 CA--C 1.542 0.915 0 CA-C-O 120.948 0.312 . . . . 0.0 112.113 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.8 m -80.33 -31.9 37.97 Favored 'General case' 0 CA--C 1.502 -0.898 0 CA-C-O 122.262 1.03 . . . . 0.0 108.338 177.787 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 114.42 -87.97 0.46 Allowed Glycine 1 N--CA 1.395 -4.064 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 173.444 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 26.7 t-80 -176.47 133.22 0.4 Allowed Pre-proline 0 C--N 1.262 -3.213 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 -175.273 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.484 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 85.7 Cg_endo -81.91 1.04 9.49 Favored 'Trans proline' 0 N--CA 1.475 0.422 0 C-N-CA 122.58 2.187 . . . . 0.0 113.464 -174.819 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 100.72 -169.24 21.06 Favored Glycine 0 C--N 1.291 -1.96 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 -175.394 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -151.06 178.37 9.26 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 179.521 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 4.9 t -142.99 139.09 16.43 Favored Pre-proline 0 N--CA 1.427 -1.596 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.813 -176.984 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -74.97 -11.87 21.55 Favored 'Trans proline' 0 CA--C 1.534 0.5 0 C-N-CA 122.635 2.223 . . . . 0.0 111.349 176.227 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -89.63 -4.15 57.93 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.228 -177.021 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.572 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 173.83 -123.73 0.99 Allowed Glycine 0 N--CA 1.419 -2.444 0 C-N-CA 119.823 -1.18 . . . . 0.0 112.371 179.766 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.1 t -165.22 -163.25 0.67 Allowed 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.28 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.445 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 54.4 p90 -145.72 175.07 10.66 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 178.593 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.8 m -136.01 163.43 30.32 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 176.645 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 23.8 mt -118.94 120.89 38.61 Favored 'General case' 0 C--N 1.285 -2.22 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -178.885 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.413 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 26.1 p -114.13 128.75 56.52 Favored 'General case' 0 C--N 1.285 -2.21 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -175.411 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 97.36 19.67 24.93 Favored Glycine 0 C--N 1.299 -1.48 0 C-N-CA 119.849 -1.167 . . . . 0.0 111.149 -179.523 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.52 -32.16 0.15 Allowed Glycine 0 N--CA 1.43 -1.713 0 C-N-CA 118.911 -1.614 . . . . 0.0 114.417 179.445 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 65.93 19.45 11.26 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 123.205 0.602 . . . . 0.0 111.174 -176.242 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.465 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.3 m -149.23 -177.86 0.47 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.084 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -175.552 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 38.1 m-85 -103.88 47.8 0.87 Allowed 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 118.726 0.694 . . . . 0.0 110.171 -179.772 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.678 ' O ' HG12 ' A' ' 108' ' ' VAL . 10.7 pt-20 -83.63 177.8 8.24 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.311 -1.313 . . . . 0.0 111.554 179.226 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 45.5 m-85 -77.67 130.42 36.8 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.645 174.064 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 91.23 15.72 55.09 Favored Glycine 0 N--CA 1.434 -1.491 0 C-N-CA 120.203 -0.999 . . . . 0.0 112.377 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.678 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -106.38 149.5 9.77 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 176.06 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.413 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 55.2 mtpt -113.95 125.69 54.31 Favored 'General case' 0 N--CA 1.418 -2.048 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.485 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -90.01 89.27 7.63 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.225 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.472 HG12 ' HB3' ' A' ' 126' ' ' TYR . 28.5 m -84.91 112.28 21.74 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.981 0 CA-C-O 122.164 0.983 . . . . 0.0 109.565 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . 0.445 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 33.8 m-85 -78.92 142.21 36.94 Favored 'General case' 0 C--N 1.269 -2.9 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.123 -179.569 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.9 t -138.84 122.58 17.57 Favored 'General case' 0 N--CA 1.411 -2.422 0 CA-C-N 115.135 -0.938 . . . . 0.0 108.822 -179.639 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 88.0 m -73.68 160.8 31.04 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 115.487 -0.778 . . . . 0.0 112.0 -178.383 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.572 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 81.2 m-20 -76.44 -176.53 3.72 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.293 179.703 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -52.46 -48.52 65.8 Favored 'General case' 0 C--N 1.319 -0.745 0 C-N-CA 124.655 1.182 . . . . 0.0 113.491 -177.28 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -88.32 10.53 70.98 Favored Glycine 0 C--N 1.3 -1.437 0 C-N-CA 119.786 -1.197 . . . . 0.0 113.306 -177.971 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.538 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 93.6 m-85 -127.62 161.02 29.85 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 122.166 -0.608 . . . . 0.0 111.419 -175.753 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.49 150.43 43.75 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.026 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.21 133.03 39.01 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 -179.681 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -112.03 127.54 55.92 Favored 'General case' 0 N--CA 1.414 -2.241 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.143 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 117.2 -163.27 12.62 Favored Glycine 0 C--N 1.296 -1.666 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.811 -179.804 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -108.96 -30.05 8.29 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 178.632 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 48.7 mm -88.16 127.06 41.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.513 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -129.56 9.84 5.57 Favored 'General case' 0 C--O 1.202 -1.44 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.034 176.777 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.472 ' HB3' HG12 ' A' ' 111' ' ' VAL . 22.1 p90 -139.08 165.52 26.94 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.397 -171.916 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.542 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 52.2 mtp180 -128.57 126.82 41.11 Favored 'General case' 0 C--O 1.204 -1.311 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 171.395 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -98.17 133.11 43.05 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.542 -0.863 . . . . 0.0 109.947 179.187 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 36.2 t -89.86 110.62 21.54 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.31 174.555 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.42 ' CG ' ' H ' ' A' ' 131' ' ' THR . 36.1 t70 -113.44 -167.21 1.17 Allowed 'General case' 0 C--N 1.289 -2.033 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 175.485 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.42 ' H ' ' CG ' ' A' ' 130' ' ' ASP . 15.3 t -67.09 -20.53 65.81 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-O 122.319 1.057 . . . . 0.0 109.69 -179.318 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -70.22 -23.73 62.98 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 114.279 -1.328 . . . . 0.0 109.233 175.001 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 105.9 -154.87 16.93 Favored Glycine 0 N--CA 1.42 -2.39 0 N-CA-C 107.169 -2.373 . . . . 0.0 107.169 -173.313 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 96.1 m95 -65.33 99.18 0.38 Allowed 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 117.666 0.733 . . . . 0.0 109.83 172.776 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 43.6 p -58.64 -67.58 0.35 Allowed 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 124.74 1.216 . . . . 0.0 112.839 -173.009 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.542 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 3.0 m-20 -70.37 167.13 18.81 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.33 178.868 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 21.9 t0 -98.64 175.55 5.95 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.537 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 68.7 mt -63.92 121.83 73.52 Favored Pre-proline 0 C--N 1.273 -2.741 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 175.079 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -63.73 174.35 3.8 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 122.482 2.121 . . . . 0.0 112.791 -179.102 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 65.8 mt -98.9 140.73 17.81 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.927 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -175.307 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.538 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 42.4 t -128.92 119.5 24.48 Favored 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 -179.784 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 12.4 tp10 -103.14 140.9 36.74 Favored 'General case' 0 C--N 1.279 -2.476 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 -175.901 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.418 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 10.8 p -70.9 138.74 21.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 173.932 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 92.7 t -59.61 114.66 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.73 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 -176.371 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 169' ' ' HIS . 92.4 mttt -113.73 144.55 42.76 Favored 'General case' 0 N--CA 1.426 -1.67 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.274 -177.787 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 82.9 m -112.03 160.95 17.0 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 114.732 -1.122 . . . . 0.0 109.165 179.778 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 59.7 mt -64.82 138.19 97.39 Favored Pre-proline 0 C--N 1.318 -0.781 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -179.183 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -63.48 127.47 19.97 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.821 2.347 . . . . 0.0 111.103 179.376 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.4 t -85.21 142.42 13.25 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -179.788 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.9 p -67.45 -82.98 0.03 OUTLIER 'General case' 0 N--CA 1.425 -1.704 0 O-C-N 123.604 0.565 . . . . 0.0 111.223 177.412 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 168.41 159.52 0.16 Allowed Pre-proline 0 CA--C 1.513 -0.474 0 C-N-CA 125.554 1.542 . . . . 0.0 106.99 179.716 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_endo -82.88 169.11 13.46 Favored 'Trans proline' 0 N--CA 1.448 -1.196 0 C-N-CA 121.643 1.562 . . . . 0.0 111.352 173.688 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -60.54 -57.02 14.5 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -176.827 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -112.02 25.19 11.82 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.12 0.962 . . . . 0.0 109.798 -172.908 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -146.02 -172.03 16.01 Favored Glycine 0 C--N 1.284 -2.324 0 CA-C-N 114.421 -1.263 . . . . 0.0 110.984 179.04 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 17.0 pttm -149.79 169.12 21.83 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 178.504 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.561 HG12 ' CE2' ' A' ' 176' ' ' PHE . 62.8 mt -88.2 130.58 37.54 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.879 179.453 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.492 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 12.9 m -87.15 -29.04 5.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.324 0.583 . . . . 0.0 109.628 179.8 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.528 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 25.2 m -104.55 40.82 1.41 Allowed 'General case' 0 C--N 1.308 -1.233 0 CA-C-N 115.074 -0.966 . . . . 0.0 110.631 -174.812 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . 0.45 ' HA ' ' OH ' ' A' ' 168' ' ' TYR . 12.1 p -67.12 161.53 24.37 Favored 'General case' 0 N--CA 1.431 -1.4 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.2 -178.749 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -46.69 107.35 0.1 Allowed 'General case' 0 C--O 1.24 0.561 0 O-C-N 124.177 0.923 . . . . 0.0 111.805 -179.794 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 34.0 mtm -60.78 -52.47 64.96 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 114.486 -1.233 . . . . 0.0 108.934 179.054 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -129.18 149.82 73.71 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 104.664 -2.347 . . . . 0.0 104.664 174.963 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -74.82 -6.15 17.76 Favored 'Trans proline' 0 N--CA 1.478 0.58 0 C-N-CA 122.31 2.007 . . . . 0.0 110.998 179.058 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -91.08 -37.05 13.66 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 -179.894 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 23.1 mmm180 -92.68 89.16 6.55 Favored 'General case' 0 N--CA 1.427 -1.614 0 CA-C-N 114.426 -1.261 . . . . 0.0 108.058 179.726 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -84.48 174.08 10.34 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 114.49 -1.232 . . . . 0.0 110.888 -172.57 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . 0.45 ' OH ' ' HA ' ' A' ' 160' ' ' SER . 72.1 m-85 -68.93 113.39 6.3 Favored 'General case' 0 CA--C 1.476 -1.896 0 CA-C-O 121.194 0.521 . . . . 0.0 109.876 -179.008 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 145' ' ' LYS . 56.7 p-80 -130.44 167.93 17.81 Favored 'General case' 0 C--N 1.281 -2.395 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.038 -174.496 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 79.8 t80 -47.69 132.12 14.34 Favored 'General case' 0 CA--C 1.506 -0.73 0 O-C-N 124.418 1.074 . . . . 0.0 110.612 178.755 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 108.67 -26.11 17.11 Favored Glycine 0 N--CA 1.418 -2.55 0 C-N-CA 120.378 -0.915 . . . . 0.0 111.781 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -76.83 134.05 39.17 Favored 'General case' 0 N--CA 1.414 -2.247 0 CA-C-O 121.664 0.745 . . . . 0.0 110.524 -179.061 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -110.57 90.83 3.44 Favored 'General case' 0 C--N 1.269 -2.893 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 173.959 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.528 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 14.6 p -73.15 105.1 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.9 0 CA-C-O 121.706 0.765 . . . . 0.0 109.257 -176.127 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.514 ' HD2' ' OE2' ' A' ' 188' ' ' GLU . 12.4 ttp180 -97.11 152.73 18.49 Favored 'General case' 0 N--CA 1.411 -2.387 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.387 -175.503 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.561 ' CE2' HG12 ' A' ' 157' ' ' ILE . 81.7 m-85 -121.2 153.22 37.88 Favored 'General case' 0 N--CA 1.428 -1.563 0 C-N-CA 124.173 0.989 . . . . 0.0 109.151 -177.462 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.448 ' HB ' ' CG1' ' A' ' 158' ' ' VAL . 10.3 p -135.7 149.59 28.24 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . 0.438 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 76.6 m -90.06 141.07 29.04 Favored 'General case' 0 C--N 1.268 -2.959 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.464 178.314 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.9 m-20 -70.91 -52.6 19.06 Favored 'General case' 0 CA--C 1.477 -1.855 0 CA-C-N 115.298 -0.864 . . . . 0.0 112.338 -175.347 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . 0.445 ' HB3' ' CE2' ' A' ' 182' ' ' TYR . 34.3 t -116.01 -158.88 0.7 Allowed 'General case' 0 C--N 1.26 -3.287 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 -177.183 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -71.77 51.03 1.18 Allowed Glycine 0 C--O 1.229 -0.203 0 O-C-N 123.473 0.483 . . . . 0.0 113.294 -177.975 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . 0.445 ' CE2' ' HB3' ' A' ' 180' ' ' SER . 90.5 m-85 -103.51 170.64 7.83 Favored 'General case' 0 C--N 1.292 -1.913 0 C-N-CA 123.137 0.575 . . . . 0.0 109.539 177.463 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.458 ' O ' ' HA ' ' A' ' 205' ' ' CYS . 39.4 pttt -126.5 150.92 48.46 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 176.374 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 3.5 tp -65.31 142.68 16.57 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 CA-C-O 121.427 0.632 . . . . 0.0 110.025 176.096 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -67.23 -58.41 4.89 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.915 -178.362 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -120.96 -111.03 2.22 Favored Glycine 0 N--CA 1.42 -2.396 0 N-CA-C 110.589 -1.005 . . . . 0.0 110.589 -178.941 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -88.91 144.9 25.88 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 179.225 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.514 ' OE2' ' HD2' ' A' ' 175' ' ' ARG . 12.8 pt-20 -87.62 1.27 54.13 Favored 'General case' 0 C--O 1.205 -1.282 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.986 -176.045 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -145.16 151.18 38.05 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 121.191 0.52 . . . . 0.0 111.312 -179.186 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.492 ' HG3' HG13 ' A' ' 174' ' ' VAL . 0.0 OUTLIER -123.4 140.82 52.62 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 175.966 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 26.3 m80 -100.42 140.39 34.74 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.835 -0.346 . . . . 0.0 110.313 176.899 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 52.6 t -86.56 104.41 15.98 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 174.301 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 18.0 m -74.94 156.88 35.86 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-N 115.225 -0.898 . . . . 0.0 111.095 -177.524 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -68.63 1.84 2.89 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 124.794 1.238 . . . . 0.0 114.163 -174.371 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . 0.444 ' HB3' ' CE2' ' A' ' 197' ' ' PHE . 36.9 t70 -102.1 -17.37 16.06 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-O 121.33 0.586 . . . . 0.0 109.69 175.609 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 101.34 53.75 0.99 Allowed Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.766 -0.652 . . . . 0.0 112.935 179.912 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . 0.444 ' CE2' ' HB3' ' A' ' 195' ' ' ASP . 52.1 p90 -154.76 156.95 37.25 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.918 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 78.8 m95 -83.96 130.5 34.89 Favored 'General case' 0 N--CA 1.431 -1.394 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 175.39 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 7.7 m -63.8 -29.21 70.44 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.53 -179.81 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 4.0 mmmt -117.89 152.79 34.69 Favored 'General case' 0 N--CA 1.411 -2.395 0 O-C-N 121.943 -0.473 . . . . 0.0 110.882 -179.516 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -71.28 165.63 23.28 Favored 'General case' 0 C--O 1.252 1.205 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 174.875 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . 0.453 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 41.6 mtpt -61.32 125.3 83.83 Favored Pre-proline 0 N--CA 1.447 -0.602 0 C-N-CA 120.341 -0.544 . . . . 0.0 110.136 174.919 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -88.84 175.04 3.74 Favored 'Trans proline' 0 N--CA 1.419 -2.854 0 C-N-CA 121.791 1.661 . . . . 0.0 110.001 172.932 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 52.6 mttp -137.91 177.22 8.04 Favored 'General case' 0 C--N 1.284 -2.276 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 -177.073 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.458 ' HA ' ' O ' ' A' ' 183' ' ' LYS . 68.1 m -118.76 104.27 10.43 Favored 'General case' 0 C--N 1.283 -2.324 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 171.776 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 16.9 m . . . . . 0 C--N 1.291 -1.948 0 CA-C-N 114.306 -1.316 . . . . 0.0 111.337 -172.27 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.414 ' CG ' ' HA ' ' A' ' 105' ' ' GLU . 17.7 Cg_endo . . . . . 0 CA--C 1.536 0.595 0 CA-C-O 120.926 0.303 . . . . 0.0 112.269 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . 0.418 ' HB3' ' CD1' ' A' ' 134' ' ' TRP . 4.5 m -93.16 -24.56 18.19 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.242 0.544 . . . . 0.0 111.558 175.003 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.94 -93.55 0.59 Allowed Glycine 0 CA--C 1.46 -3.345 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 173.196 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 -170.23 132.77 1.02 Allowed Pre-proline 0 C--N 1.262 -3.201 0 N-CA-C 104.02 -2.585 . . . . 0.0 104.02 -175.478 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.504 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 87.9 Cg_endo -81.32 -19.81 7.58 Favored 'Trans proline' 0 C--N 1.332 -0.341 0 C-N-CA 121.637 1.558 . . . . 0.0 113.553 -173.189 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 130.1 -165.39 22.47 Favored Glycine 0 N--CA 1.426 -2.013 0 N-CA-C 110.186 -1.166 . . . . 0.0 110.186 -177.358 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -151.04 151.34 31.89 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 -178.659 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 9.1 t -131.07 127.5 22.0 Favored Pre-proline 0 C--N 1.303 -1.456 0 C-N-CA 120.338 -0.545 . . . . 0.0 110.553 179.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -72.46 -18.37 26.08 Favored 'Trans proline' 0 C--O 1.237 0.445 0 C-N-CA 122.523 2.149 . . . . 0.0 111.554 178.843 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.531 ' CB ' ' HB2' ' A' ' 141' ' ' CYS . 59.7 m-85 -78.92 -17.26 55.83 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.192 -177.461 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.472 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . -168.97 -126.76 0.87 Allowed Glycine 0 CA--C 1.477 -2.284 0 C-N-CA 120.212 -0.994 . . . . 0.0 111.167 -178.933 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.1 t -160.07 -169.87 2.65 Favored 'General case' 0 C--N 1.284 -2.243 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.651 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.431 ' HB3' ' CD2' ' A' ' 112' ' ' TYR . 37.8 p90 -147.11 165.46 29.89 Favored 'General case' 0 N--CA 1.432 -1.331 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 177.582 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.7 m -132.81 161.75 33.32 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 177.879 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 26.6 mt -109.93 137.54 47.57 Favored 'General case' 0 C--N 1.271 -2.837 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.47 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.536 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 11.1 p -134.11 141.6 47.2 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -173.979 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 100.33 -42.37 1.97 Allowed Glycine 0 C--N 1.303 -1.304 0 N-CA-C 108.148 -1.981 . . . . 0.0 108.148 -173.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.459 ' HA3' ' OE2' ' A' ' 105' ' ' GLU . . . -139.63 -143.09 4.33 Favored Glycine 0 N--CA 1.406 -3.358 0 N-CA-C 108.029 -2.028 . . . . 0.0 108.029 176.085 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -151.61 16.22 0.69 Allowed 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.41 1.1 . . . . 0.0 109.829 -178.51 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.531 ' O ' HG11 ' A' ' 108' ' ' VAL . 28.7 m -147.5 -170.57 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 -175.511 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.504 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 30.5 m-85 -96.17 39.11 1.16 Allowed 'General case' 0 C--N 1.307 -1.255 0 CA-C-O 121.99 0.9 . . . . 0.0 110.022 -177.832 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.661 ' O ' HG12 ' A' ' 108' ' ' VAL . 12.2 pt-20 -71.83 178.03 3.89 Favored 'General case' 0 C--O 1.202 -1.44 0 C-N-CA 127.197 2.199 . . . . 0.0 111.888 179.009 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . 0.546 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 27.6 m-85 -79.32 135.9 36.86 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-O 121.008 0.432 . . . . 0.0 110.971 176.49 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.24 3.24 82.34 Favored Glycine 0 N--CA 1.442 -0.91 0 C-N-CA 121.001 -0.618 . . . . 0.0 112.349 178.804 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.661 HG12 ' O ' ' A' ' 105' ' ' GLU . 8.5 p -92.75 142.81 12.6 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.39 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 179.549 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.536 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -107.52 126.82 53.0 Favored 'General case' 0 C--N 1.28 -2.437 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 177.682 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -89.32 87.98 7.32 Favored 'General case' 0 C--N 1.28 -2.436 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 174.896 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.508 HG12 ' HB3' ' A' ' 126' ' ' TYR . 30.0 m -84.97 116.78 29.07 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.383 0 CA-C-O 121.989 0.899 . . . . 0.0 109.403 -179.423 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . 0.431 ' CD2' ' HB3' ' A' ' 96' ' ' PHE . 33.9 m-85 -85.73 142.59 28.89 Favored 'General case' 0 C--N 1.27 -2.877 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.42 179.754 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.7 t -138.0 124.61 20.9 Favored 'General case' 0 N--CA 1.405 -2.725 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 -178.92 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 34.7 m -74.08 155.61 38.3 Favored 'General case' 0 C--N 1.288 -2.071 0 CA-C-N 115.3 -0.863 . . . . 0.0 112.262 -175.498 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.472 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 72.2 m-20 -68.09 173.81 4.35 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.175 178.482 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -50.75 -48.21 59.17 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 123.78 0.832 . . . . 0.0 112.547 -177.922 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.465 ' C ' HG22 ' A' ' 144' ' ' VAL . . . -89.8 30.88 5.53 Favored Glycine 0 N--CA 1.438 -1.222 0 C-N-CA 120.778 -0.725 . . . . 0.0 113.05 -178.417 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -146.65 157.4 43.7 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 122.177 -0.602 . . . . 0.0 109.555 -176.424 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.5 150.7 47.74 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 122.688 0.395 . . . . 0.0 110.334 177.076 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.99 117.21 15.51 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 -175.336 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -103.13 126.13 50.16 Favored 'General case' 0 N--CA 1.407 -2.593 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -178.876 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 120.33 176.54 15.77 Favored Glycine 0 C--N 1.29 -1.98 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.706 -177.551 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -93.77 -24.77 17.68 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.906 0.86 . . . . 0.0 109.02 -178.384 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.458 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 50.2 mm -104.03 129.22 56.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 114.851 -1.068 . . . . 0.0 109.213 -176.538 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -119.0 -2.49 10.8 Favored 'General case' 0 C--O 1.201 -1.493 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 177.611 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.508 ' HB3' HG12 ' A' ' 111' ' ' VAL . 39.8 p90 -138.46 162.18 35.13 Favored 'General case' 0 C--N 1.291 -1.936 0 CA-C-O 120.945 0.402 . . . . 0.0 110.526 -169.374 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 61.1 mtp180 -123.53 135.24 53.91 Favored 'General case' 0 C--N 1.282 -2.328 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 170.989 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -110.45 130.58 55.53 Favored 'General case' 0 C--N 1.284 -2.253 0 C-N-CA 119.046 -1.061 . . . . 0.0 110.215 -178.517 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . 0.546 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 36.9 t -75.99 98.96 4.41 Favored 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.328 0.585 . . . . 0.0 109.918 177.878 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.44 ' OD2' HG22 ' A' ' 131' ' ' THR . 20.3 t70 -100.14 -175.43 2.94 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 178.172 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.44 HG22 ' OD2' ' A' ' 130' ' ' ASP . 14.9 t -69.26 -19.49 63.92 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-O 121.997 0.904 . . . . 0.0 109.237 179.441 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -83.12 -12.79 56.69 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.304 -1.316 . . . . 0.0 109.326 179.831 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 110.37 -164.19 12.29 Favored Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -175.942 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.418 ' CD1' ' HB3' ' A' ' 85' ' ' CYS . 98.5 m95 -64.26 114.79 4.47 Favored 'General case' 0 C--O 1.248 0.978 0 CA-C-N 117.922 0.861 . . . . 0.0 109.88 175.363 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 68.6 p -71.29 164.87 24.86 Favored 'General case' 0 N--CA 1.417 -2.108 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 177.702 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 55.8 m-20 65.53 -158.87 0.28 Allowed 'General case' 0 C--O 1.245 0.826 0 O-C-N 123.843 0.714 . . . . 0.0 109.276 173.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -136.48 176.28 8.85 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 175.866 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.1 mt -64.29 120.44 64.81 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 124.271 0.982 . . . . 0.0 108.368 175.338 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.458 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 45.6 Cg_endo -67.68 176.52 4.99 Favored 'Trans proline' 0 C--O 1.248 1.024 0 C-N-CA 123.034 2.489 . . . . 0.0 112.583 -179.256 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.1 mm -111.71 137.0 46.08 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.512 0 CA-C-O 121.108 0.48 . . . . 0.0 110.318 -173.234 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.531 ' HB2' ' CB ' ' A' ' 93' ' ' PHE . 99.3 m -113.52 111.12 21.38 Favored 'General case' 0 C--N 1.279 -2.47 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 172.83 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -93.67 151.63 19.53 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 179.211 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 8.9 p -74.09 141.26 16.37 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.553 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . 0.506 HG23 ' HB2' ' A' ' 170' ' ' PHE . 15.6 m -67.09 101.14 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.776 0 CA-C-O 121.967 0.889 . . . . 0.0 110.024 177.843 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -85.18 123.51 30.77 Favored 'General case' 0 N--CA 1.407 -2.599 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.314 -179.919 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.518 ' HA ' ' O ' ' A' ' 196' ' ' GLY . 62.6 m -83.2 122.28 28.2 Favored 'General case' 0 C--N 1.273 -2.758 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 178.02 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 80.6 mt -53.36 131.69 52.94 Favored Pre-proline 0 C--N 1.313 -0.985 0 N-CA-C 113.629 0.974 . . . . 0.0 113.629 -175.693 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -56.44 121.03 9.31 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 123.33 2.687 . . . . 0.0 110.989 -178.575 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 14.5 p -89.28 149.48 4.01 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 CA-C-N 115.284 -0.871 . . . . 0.0 109.973 -175.878 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.4 p -81.73 -173.45 4.44 Favored 'General case' 0 N--CA 1.422 -1.837 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 175.245 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -123.37 155.63 64.98 Favored Pre-proline 0 C--N 1.285 -2.238 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 -172.802 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -77.35 169.72 20.73 Favored 'Trans proline' 0 CA--C 1.543 0.97 0 C-N-CA 121.92 1.746 . . . . 0.0 112.491 178.277 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -64.31 -57.5 9.21 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -178.816 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 88.7 m-20 -97.87 20.09 12.7 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-O 121.846 0.831 . . . . 0.0 110.269 -174.145 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -142.79 -173.27 14.41 Favored Glycine 0 N--CA 1.412 -2.903 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.985 179.878 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . 0.401 ' HG3' HG23 ' A' ' 177' ' ' VAL . 19.8 pttp -156.76 178.31 10.49 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -179.187 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 59.5 mt -101.09 138.35 25.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 CA-C-N 117.83 0.286 . . . . 0.0 111.066 -177.33 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.625 HG12 HG22 ' A' ' 177' ' ' VAL . 2.7 m -84.69 -33.64 8.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 177.426 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 6.1 m -95.78 48.62 1.13 Allowed 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 114.958 -1.019 . . . . 0.0 109.943 -174.584 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 25.5 m -70.29 94.44 0.93 Allowed 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.69 0.281 . . . . 0.0 110.264 -178.492 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 57.39 -166.02 0.15 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 123.996 0.919 . . . . 0.0 109.98 -175.219 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 63.2 mtm -135.94 -61.24 0.71 Allowed 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 106.179 -1.785 . . . . 0.0 106.179 173.233 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -129.82 151.23 77.82 Favored Pre-proline 0 C--N 1.291 -1.945 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 171.718 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -61.08 -15.23 38.05 Favored 'Trans proline' 0 N--CA 1.482 0.83 0 C-N-CA 122.948 2.432 . . . . 0.0 113.353 -177.455 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -104.92 -29.2 10.64 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 121.25 0.548 . . . . 0.0 110.661 179.565 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 30.3 mmm180 -93.39 99.48 11.98 Favored 'General case' 0 N--CA 1.429 -1.483 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.735 -175.844 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -76.11 -177.9 4.18 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.176 -179.513 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -67.69 130.98 44.68 Favored 'General case' 0 CA--C 1.502 -0.902 0 CA-C-O 120.984 0.421 . . . . 0.0 110.088 179.285 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 22.6 m170 -125.49 165.05 19.17 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -177.3 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.506 ' HB2' HG23 ' A' ' 144' ' ' VAL . 92.4 t80 -51.57 134.86 29.16 Favored 'General case' 0 C--O 1.239 0.526 0 O-C-N 123.885 0.741 . . . . 0.0 109.11 170.586 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 109.94 -10.05 31.89 Favored Glycine 0 N--CA 1.424 -2.103 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.732 -179.112 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 -99.55 159.29 15.14 Favored 'General case' 0 N--CA 1.433 -1.291 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.916 -178.842 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 190' ' ' MET . . . -138.73 123.98 19.21 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 175.688 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.547 HG23 ' CH2' ' A' ' 198' ' ' TRP . 85.0 t -87.68 109.71 19.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.051 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.047 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.481 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 41.2 ttm180 -96.71 142.57 28.58 Favored 'General case' 0 N--CA 1.416 -2.162 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 177.781 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -110.19 159.59 17.24 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 109.565 -0.532 . . . . 0.0 109.565 -177.294 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.625 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -130.76 139.79 50.33 Favored 'Isoleucine or valine' 0 CA--C 1.467 -2.247 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.675 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . 0.521 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 77.4 m -84.79 129.52 34.81 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 173.501 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -53.28 -51.63 61.69 Favored 'General case' 0 CA--C 1.48 -1.713 0 C-N-CA 124.76 1.224 . . . . 0.0 112.584 -175.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 13.3 t -123.63 -154.58 0.61 Allowed 'General case' 0 N--CA 1.402 -2.837 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 -177.052 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -74.22 51.11 2.06 Favored Glycine 0 N--CA 1.443 -0.838 0 O-C-N 123.588 0.555 . . . . 0.0 113.78 -176.468 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . 0.521 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 98.4 m-85 -100.89 168.39 9.66 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 176.114 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 50.6 pttt -121.41 146.05 47.29 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.794 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.759 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.8 tt -76.86 141.8 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.766 0 C-N-CA 119.691 -0.804 . . . . 0.0 110.276 176.403 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -53.75 -61.13 2.5 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 125.086 1.354 . . . . 0.0 113.228 -176.227 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -123.89 -97.81 1.27 Allowed Glycine 0 CA--C 1.496 -1.147 0 C-N-CA 120.33 -0.938 . . . . 0.0 112.814 -178.654 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -85.07 159.97 20.08 Favored 'General case' 0 CA--C 1.48 -1.728 0 N-CA-C 106.876 -1.527 . . . . 0.0 106.876 176.75 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.759 ' HA ' HD13 ' A' ' 184' ' ' ILE . 14.5 pt-20 -102.47 3.86 38.08 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 118.114 -1.434 . . . . 0.0 109.468 179.978 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . 0.476 ' HA ' ' O ' ' A' ' 174' ' ' VAL . 8.7 pt-20 -151.45 147.37 26.78 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-N 115.547 -0.751 . . . . 0.0 112.386 -176.216 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.486 ' O ' ' HA ' ' A' ' 173' ' ' ALA . 13.9 ptp -113.79 128.25 56.34 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.649 175.446 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 34.1 t-80 -110.56 146.56 35.85 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 116.746 -0.206 . . . . 0.0 110.473 -174.646 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 88.6 m -75.06 155.04 37.63 Favored 'General case' 0 C--O 1.241 0.642 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 178.436 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 60.6 m -126.17 171.46 10.86 Favored 'General case' 0 C--O 1.256 1.395 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 169.387 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -78.4 91.56 4.49 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.261 1.029 . . . . 0.0 112.496 -172.347 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 9.5 t70 174.22 -38.18 0.01 OUTLIER 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 113.15 -1.841 . . . . 0.0 106.293 176.508 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 146' ' ' CYS . . . 119.65 18.69 4.33 Favored Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.196 -179.534 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -109.65 158.13 18.38 Favored 'General case' 0 C--O 1.251 1.168 0 O-C-N 122.226 -0.573 . . . . 0.0 109.969 176.418 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . 0.547 ' CH2' HG23 ' A' ' 174' ' ' VAL . 87.6 m95 -87.31 144.69 26.67 Favored 'General case' 0 N--CA 1.423 -1.815 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 176.18 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 17.2 m -92.94 7.59 43.33 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-O 121.879 0.847 . . . . 0.0 110.926 -178.176 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.468 ' HB3' ' CB ' ' A' ' 190' ' ' MET . 0.8 OUTLIER -139.39 153.28 47.61 Favored 'General case' 0 N--CA 1.417 -2.102 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 177.096 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . 0.485 ' H ' ' CD ' ' A' ' 201' ' ' GLU . 0.2 OUTLIER -105.28 171.93 7.06 Favored 'General case' 0 C--N 1.279 -2.461 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 178.9 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . 0.454 ' HA ' ' HD3' ' A' ' 203' ' ' PRO . 45.8 mtpt -63.38 117.61 35.74 Favored Pre-proline 0 C--N 1.307 -1.258 0 N-CA-C 114.154 1.168 . . . . 0.0 114.154 -174.865 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 202' ' ' LYS . 5.4 Cg_exo -82.33 171.31 12.58 Favored 'Trans proline' 0 N--CA 1.445 -1.369 0 C-N-CA 122.793 2.329 . . . . 0.0 108.953 172.246 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . 0.463 ' O ' ' HA ' ' A' ' 184' ' ' ILE . 38.8 mtpt -122.38 174.55 6.95 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.966 -0.694 . . . . 0.0 109.432 179.681 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 57.3 m -115.39 107.56 15.37 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 173.19 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.4 m . . . . . 0 C--N 1.281 -2.413 0 CA-C-N 114.371 -1.286 . . . . 0.0 109.736 -173.638 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo . . . . . 0 N--CA 1.477 0.548 0 CA-C-O 121.078 0.366 . . . . 0.0 112.766 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 65.1 m -73.32 -27.15 61.36 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.547 0.689 . . . . 0.0 110.677 178.027 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.19 13.12 40.19 Favored Glycine 0 C--N 1.3 -1.417 0 CA-C-N 115.206 -0.907 . . . . 0.0 114.832 172.724 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 4.7 t60 68.77 125.37 0.03 OUTLIER Pre-proline 0 N--CA 1.489 1.484 0 C-N-CA 123.841 0.856 . . . . 0.0 108.931 -179.234 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.519 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 92.7 Cg_endo -75.97 7.77 3.09 Favored 'Trans proline' 0 N--CA 1.494 1.534 0 C-N-CA 123.059 2.506 . . . . 0.0 114.862 -171.998 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 97.94 -166.0 22.25 Favored Glycine 0 C--N 1.277 -2.715 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -175.514 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -143.37 140.21 30.38 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 -179.036 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.3 t -102.64 129.53 25.73 Favored Pre-proline 0 C--N 1.299 -1.624 0 CA-C-O 121.234 0.54 . . . . 0.0 110.829 -178.366 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.25 -11.55 25.0 Favored 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 122.544 2.163 . . . . 0.0 111.474 177.599 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -87.25 -3.02 59.03 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.518 -178.285 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.402 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 167.69 -120.85 0.93 Allowed Glycine 0 N--CA 1.43 -1.717 0 C-N-CA 120.271 -0.966 . . . . 0.0 111.797 179.235 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.4 t -151.49 -172.86 4.33 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 123.71 0.3 . . . . 0.0 110.361 179.447 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 36.6 p90 -146.13 156.42 43.42 Favored 'General case' 0 N--CA 1.436 -1.168 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 176.65 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 5.5 m -121.92 166.52 14.29 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 178.041 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.451 HD11 ' CE1' ' A' ' 104' ' ' PHE . 14.8 mt -120.14 128.83 53.78 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.897 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.441 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 33.7 p -115.91 135.72 53.72 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 -178.262 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 114.53 -65.04 0.29 Allowed Glycine 0 N--CA 1.429 -1.781 0 N-CA-C 110.361 -1.096 . . . . 0.0 110.361 -179.243 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -119.69 -5.93 10.72 Favored Glycine 0 C--N 1.309 -0.938 0 C-N-CA 119.98 -1.105 . . . . 0.0 113.143 -178.991 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 84.8 m-20 59.79 19.62 8.44 Favored 'General case' 0 N--CA 1.495 1.809 0 C-N-CA 123.04 0.536 . . . . 0.0 112.373 -178.079 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.502 ' O ' HG11 ' A' ' 108' ' ' VAL . 23.0 m -146.67 -171.12 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.203 -1.379 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -176.028 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.451 ' CE1' HD11 ' A' ' 98' ' ' LEU . 54.0 m-85 -106.42 39.41 1.83 Allowed 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 118.565 0.62 . . . . 0.0 110.635 -175.756 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.708 ' O ' HG12 ' A' ' 108' ' ' VAL . 11.5 pt-20 -85.43 -176.61 6.18 Favored 'General case' 0 C--O 1.202 -1.443 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.52 179.165 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 -75.63 137.29 40.64 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.935 -0.478 . . . . 0.0 111.143 177.702 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.35 4.93 73.23 Favored Glycine 0 N--CA 1.433 -1.536 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.962 178.132 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.708 HG12 ' O ' ' A' ' 105' ' ' GLU . 13.9 p -95.02 146.22 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.163 0 C-N-CA 119.854 -0.738 . . . . 0.0 109.179 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.441 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 56.3 mtpt -110.17 123.75 50.32 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.591 179.198 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.524 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -86.3 93.63 9.13 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 176.469 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 76.7 t -86.03 109.62 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.772 0 C-N-CA 123.972 0.909 . . . . 0.0 109.208 -177.803 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -82.99 139.22 33.42 Favored 'General case' 0 C--N 1.286 -2.17 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.773 -179.566 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 11.1 t -136.83 127.78 27.57 Favored 'General case' 0 N--CA 1.419 -1.994 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.738 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 82.3 m -81.31 160.18 24.25 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.822 -174.593 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.402 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 74.7 m-20 -72.46 177.21 4.76 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.9 175.926 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -56.57 -47.02 80.39 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -176.14 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -78.01 11.1 23.32 Favored Glycine 0 CA--C 1.522 0.495 0 CA-C-N 116.186 -0.461 . . . . 0.0 114.236 -178.876 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.612 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 82.5 m-85 -133.45 156.73 47.19 Favored 'General case' 0 C--N 1.311 -1.094 0 O-C-N 122.368 -0.489 . . . . 0.0 110.713 -179.195 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -143.44 147.97 35.4 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.006 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 7.2 tp -76.95 144.03 39.08 Favored 'General case' 0 C--N 1.29 -2.016 0 CA-C-O 120.978 0.418 . . . . 0.0 110.834 -173.158 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -121.82 125.38 46.36 Favored 'General case' 0 N--CA 1.425 -1.72 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -179.778 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 108.12 -176.28 20.34 Favored Glycine 0 C--N 1.291 -1.919 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -174.532 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -101.07 -24.95 14.21 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.363 0.602 . . . . 0.0 110.288 -179.726 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 50.2 mm -80.96 127.25 39.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -178.578 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -134.42 11.38 3.79 Favored 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 -178.561 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.524 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 32.8 p90 -149.01 167.71 25.08 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 -172.135 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.583 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 46.7 mtp180 -129.2 119.37 23.93 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 171.769 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -91.23 128.68 37.15 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.755 -0.778 . . . . 0.0 110.149 178.687 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 35.2 t -87.07 107.13 18.3 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.338 -0.945 . . . . 0.0 109.89 175.126 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.441 ' OD1' HG22 ' A' ' 131' ' ' THR . 7.2 t70 -100.61 -168.73 1.61 Allowed 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 176.342 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.441 HG22 ' OD1' ' A' ' 130' ' ' ASP . 11.1 t -69.84 -18.15 63.43 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 122.445 1.117 . . . . 0.0 109.176 178.279 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -80.67 -7.0 59.18 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 114.294 -1.321 . . . . 0.0 109.327 177.036 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 97.34 -158.57 21.08 Favored Glycine 0 N--CA 1.429 -1.77 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -176.316 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.405 ' CZ2' ' HD3' ' A' ' 88' ' ' PRO . 90.0 m95 -65.32 108.48 1.94 Allowed 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 175.963 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 30.0 p -64.05 -55.2 23.93 Favored 'General case' 0 C--N 1.317 -0.84 0 C-N-CA 123.705 0.802 . . . . 0.0 111.581 -176.251 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.583 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.3 m120 -78.64 167.22 21.56 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 114.857 -1.065 . . . . 0.0 109.04 -179.708 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -99.86 179.12 4.62 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 175.162 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 76.7 mt -65.63 118.98 56.45 Favored Pre-proline 0 C--N 1.325 -0.494 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 174.113 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.7 146.64 84.5 Favored 'Trans proline' 0 C--O 1.25 1.101 0 C-N-CA 122.322 2.015 . . . . 0.0 112.802 -176.292 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 66.0 mt -72.4 130.35 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.58 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.0 -179.783 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.612 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 45.3 t -121.48 142.42 50.07 Favored 'General case' 0 C--N 1.274 -2.678 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 176.354 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 6.1 tp10 -121.43 152.97 38.48 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -174.73 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.468 HG21 ' NE2' ' A' ' 169' ' ' HIS . 8.1 p -73.74 141.73 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.5 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.019 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 74.7 t -60.95 119.82 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.882 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.456 ' HA ' ' O ' ' A' ' 168' ' ' TYR . 52.8 mtmt -125.42 138.43 54.02 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.477 -177.504 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 2.1 p -110.75 160.61 16.56 Favored 'General case' 0 C--N 1.287 -2.112 0 CA-C-N 115.298 -0.865 . . . . 0.0 112.18 -179.186 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . 0.483 HD12 ' HD2' ' A' ' 148' ' ' PRO . 0.3 OUTLIER -77.97 135.6 62.87 Favored Pre-proline 0 N--CA 1.426 -1.65 0 C-N-CA 124.573 1.149 . . . . 0.0 111.302 -173.533 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.483 ' HD2' HD12 ' A' ' 147' ' ' LEU . 12.1 Cg_endo -55.97 126.87 23.84 Favored 'Trans proline' 0 C--O 1.244 0.784 0 C-N-CA 123.812 3.008 . . . . 0.0 112.661 179.304 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 10.8 p -91.21 150.31 3.8 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.128 -179.945 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 19.9 p -71.53 -88.34 0.02 OUTLIER 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 113.505 0.928 . . . . 0.0 113.505 -177.324 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 171.91 164.3 0.25 Allowed Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 179.738 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . 0.46 ' HD3' ' CD1' ' A' ' 176' ' ' PHE . 73.7 Cg_endo -78.45 166.02 24.61 Favored 'Trans proline' 0 N--CA 1.454 -0.849 0 C-N-CA 121.688 1.592 . . . . 0.0 110.419 171.624 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -64.94 -61.53 2.11 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 112.855 0.687 . . . . 0.0 112.855 -179.754 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 63.9 m-80 -91.34 35.56 0.93 Allowed 'General case' 0 C--O 1.247 0.963 0 O-C-N 121.773 -0.579 . . . . 0.0 111.24 179.709 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -156.85 -161.78 11.02 Favored Glycine 0 N--CA 1.425 -2.053 0 C-N-CA 120.145 -1.026 . . . . 0.0 112.384 178.263 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . . . . . . . . . 59.5 pttt -159.07 -178.48 7.26 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -178.394 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 58.2 mt -96.62 141.3 15.74 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 CA-C-N 117.577 0.171 . . . . 0.0 111.159 -178.604 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.55 HG12 HG22 ' A' ' 177' ' ' VAL . 3.3 m -88.77 -31.98 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.931 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 176.317 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 5.8 m -92.58 88.98 6.52 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 115.215 -0.902 . . . . 0.0 111.027 -176.07 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.0 m -55.51 136.83 49.64 Favored 'General case' 0 C--N 1.309 -1.152 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.585 179.695 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -65.98 171.35 4.56 Favored 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 116.013 -0.539 . . . . 0.0 112.408 -175.91 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.92 11.14 2.83 Favored 'General case' 0 C--O 1.207 -1.155 0 C-N-CA 123.381 0.672 . . . . 0.0 110.831 178.801 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . 0.337 49.4 mt-10 34.26 -77.23 0.0 OUTLIER Pre-proline 0 N--CA 1.487 1.423 0 C-N-CA 129.253 3.021 . . . . 0.0 119.07 173.094 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -59.4 -19.5 51.59 Favored 'Trans proline' 0 C--N 1.38 2.23 0 CA-C-N 122.34 1.872 . . . . 0.0 111.361 174.227 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -106.31 -38.35 6.26 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 175.864 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . 0.358 7.9 ppt_? 45.31 7.84 0.0 OUTLIER 'General case' 0 C--N 1.358 0.954 0 N-CA-C 118.041 2.608 . . . . 0.0 118.041 -172.911 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -103.19 135.44 44.84 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 107.931 -1.136 . . . . 0.0 107.931 175.719 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . 0.456 ' O ' ' HA ' ' A' ' 145' ' ' LYS . 73.2 m-85 -87.48 139.11 30.88 Favored 'General case' 0 C--N 1.287 -2.149 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.446 -173.288 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.468 ' NE2' HG21 ' A' ' 143' ' ' VAL . 54.9 t-80 -86.32 146.23 26.58 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.023 -0.99 . . . . 0.0 108.687 179.817 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 83.6 t80 -54.64 129.73 37.66 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.714 176.32 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 112.91 -22.17 16.85 Favored Glycine 0 N--CA 1.432 -1.602 0 C-N-CA 120.155 -1.021 . . . . 0.0 111.994 -178.006 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -70.35 150.88 45.85 Favored 'General case' 0 C--O 1.251 1.149 0 CA-C-O 120.87 0.367 . . . . 0.0 110.276 178.359 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -134.65 103.1 5.52 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.604 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 95.7 t -76.79 108.92 10.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.617 -178.025 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.465 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 29.5 ttp180 -101.49 142.2 33.22 Favored 'General case' 0 N--CA 1.407 -2.612 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.459 177.813 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . 0.46 ' CD1' ' HD3' ' A' ' 152' ' ' PRO . 62.8 m-85 -113.26 153.32 28.6 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.664 -174.809 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.55 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -121.29 152.54 24.75 Favored 'Isoleucine or valine' 0 CA--C 1.466 -2.275 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.996 179.296 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 67.9 m -99.51 138.87 35.99 Favored 'General case' 0 N--CA 1.403 -2.786 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 172.396 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -55.41 -52.41 63.67 Favored 'General case' 0 CA--C 1.486 -1.49 0 N-CA-C 114.192 1.182 . . . . 0.0 114.192 -175.131 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 58.9 m -150.33 -100.32 0.07 Allowed 'General case' 0 C--N 1.286 -2.153 0 C-N-CA 120.144 -0.622 . . . . 0.0 112.042 -177.005 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -87.5 44.68 3.29 Favored Glycine 0 CA--C 1.494 -1.254 0 CA-C-O 121.264 0.369 . . . . 0.0 112.343 -177.654 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -123.9 158.59 31.58 Favored 'General case' 0 N--CA 1.415 -2.2 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.531 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.446 ' O ' ' HD2' ' A' ' 183' ' ' LYS . 1.2 pptp? -132.01 143.13 49.85 Favored 'General case' 0 C--N 1.288 -2.066 0 O-C-N 123.878 0.736 . . . . 0.0 109.178 179.118 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.554 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.2 tt -71.57 142.47 15.4 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.26 0 CA-C-O 121.489 0.661 . . . . 0.0 111.626 -178.299 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -76.59 -57.08 4.06 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.735 -175.845 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -93.05 -126.42 4.16 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 120.277 -0.963 . . . . 0.0 111.954 -177.776 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -93.28 158.83 15.55 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 176.677 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.554 ' HA ' HD13 ' A' ' 184' ' ' ILE . 14.5 pt-20 -95.1 -7.81 38.33 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 118.915 -1.114 . . . . 0.0 110.976 -174.333 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -138.91 135.79 34.81 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.163 0.506 . . . . 0.0 112.339 -176.497 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.435 ' HB3' ' HB2' ' A' ' 200' ' ' LYS . 12.8 ptp -116.12 124.05 49.38 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.398 176.301 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 52.0 t-80 -97.95 135.99 38.87 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.702 -176.234 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 16.4 t -71.15 118.61 14.15 Favored 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.34 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 15.5 m -97.56 165.33 12.04 Favored 'General case' 0 N--CA 1.437 -1.112 0 O-C-N 123.606 0.567 . . . . 0.0 110.445 -175.756 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -65.51 -6.76 11.6 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 124.514 1.126 . . . . 0.0 112.316 -177.573 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -74.25 -22.2 59.43 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.565 175.532 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 92.44 14.51 55.53 Favored Glycine 0 N--CA 1.435 -1.418 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -174.521 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -136.6 176.81 8.37 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.587 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 88.1 m95 -84.78 152.28 23.78 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.92 -177.521 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 21.0 p -80.23 -14.58 58.31 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.508 179.835 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.435 ' HB2' ' HB3' ' A' ' 190' ' ' MET . 64.8 mmtt -124.36 165.98 16.75 Favored 'General case' 0 CA--C 1.477 -1.846 0 CA-C-O 122.141 0.972 . . . . 0.0 113.6 -173.957 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 74.6 mm-40 -91.47 166.44 12.86 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 113.053 -1.885 . . . . 0.0 109.337 176.322 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 6.1 mmmm -65.96 109.78 3.68 Favored Pre-proline 0 C--N 1.318 -0.787 0 O-C-N 124.053 0.846 . . . . 0.0 112.939 178.854 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -92.04 156.85 3.28 Favored 'Trans proline' 0 N--CA 1.424 -2.612 0 C-N-CA 122.42 2.08 . . . . 0.0 110.412 177.687 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . 0.443 ' HA ' ' HB3' ' A' ' 152' ' ' PRO . 19.1 ptpt -135.68 155.81 49.83 Favored 'General case' 0 C--N 1.287 -2.126 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.005 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 97.5 m -93.29 118.52 31.37 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 177.569 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 15.1 m . . . . . 0 C--N 1.291 -1.951 0 CA-C-N 114.007 -1.451 . . . . 0.0 107.326 -178.267 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.486 ' HB2' ' CE2' ' A' ' 106' ' ' TYR . 41.0 Cg_endo . . . . . 0 CA--C 1.534 0.505 0 CA-C-O 121.181 0.409 . . . . 0.0 111.642 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . 0.549 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 3.2 m -94.36 -17.9 22.11 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 122.1 0.952 . . . . 0.0 110.211 174.176 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.73 -87.72 0.54 Allowed Glycine 2 N--CA 1.391 -4.356 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 172.364 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.4 t-80 -171.85 138.24 1.02 Allowed Pre-proline 0 C--N 1.247 -3.854 0 N-CA-C 105.735 -1.95 . . . . 0.0 105.735 -172.739 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.517 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 91.9 Cg_endo -87.45 2.06 6.87 Favored 'Trans proline' 0 C--N 1.322 -0.837 0 C-N-CA 121.946 1.764 . . . . 0.0 112.764 -177.76 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.07 -166.37 13.1 Favored Glycine 0 N--CA 1.428 -1.875 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 -179.708 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -159.27 124.12 4.08 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 177.659 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.8 t -110.56 137.32 20.69 Favored Pre-proline 0 C--N 1.296 -1.735 0 CA-C-O 120.895 0.379 . . . . 0.0 111.749 -178.585 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -83.07 -10.11 10.39 Favored 'Trans proline' 0 CA--C 1.544 1.0 0 C-N-CA 122.742 2.295 . . . . 0.0 112.062 174.063 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -88.81 6.76 37.42 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.414 0.626 . . . . 0.0 111.143 -178.624 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.419 ' HA2' ' ND2' ' A' ' 115' ' ' ASN . . . 161.95 -123.86 1.24 Allowed Glycine 0 N--CA 1.415 -2.751 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.607 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.6 t -164.29 -159.72 0.5 Allowed 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 -178.592 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.6 p90 -152.88 165.53 35.17 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 176.987 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.0 m -127.83 159.52 34.61 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 177.906 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 20.1 mt -117.18 132.18 56.7 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 -178.54 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 16.5 p -125.53 129.77 50.39 Favored 'General case' 0 C--N 1.291 -1.95 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -176.388 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 84.57 27.74 34.68 Favored Glycine 0 C--N 1.313 -0.703 0 C-N-CA 120.353 -0.927 . . . . 0.0 111.653 -179.447 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 178.37 -45.81 0.09 OUTLIER Glycine 0 N--CA 1.433 -1.542 0 C-N-CA 119.69 -1.243 . . . . 0.0 112.8 -179.158 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 70.44 8.42 6.6 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 124.195 0.998 . . . . 0.0 109.965 -178.304 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.553 ' O ' HG11 ' A' ' 108' ' ' VAL . 25.2 m -148.82 -175.74 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.125 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 -177.864 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.517 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 23.5 m-85 -98.9 38.08 1.43 Allowed 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 118.995 0.816 . . . . 0.0 110.782 -176.296 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.72 ' O ' HG12 ' A' ' 108' ' ' VAL . 15.2 pt-20 -79.86 175.54 10.54 Favored 'General case' 0 C--O 1.195 -1.765 0 CA-C-N 114.568 -1.196 . . . . 0.0 111.815 -179.344 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . 0.534 ' HA ' ' SG ' ' A' ' 129' ' ' CYS . 43.0 m-85 -74.73 126.24 30.45 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 122.144 -0.347 . . . . 0.0 111.536 179.404 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 102.21 -1.22 50.66 Favored Glycine 0 N--CA 1.439 -1.16 0 CA-C-N 115.739 -0.664 . . . . 0.0 112.618 179.713 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.72 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.2 p -92.45 147.55 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.053 0 C-N-CA 120.068 -0.653 . . . . 0.0 109.626 -179.447 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . . . . . . . . . 54.8 mtpt -114.19 123.51 49.75 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 177.8 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.474 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -87.81 94.85 9.88 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 177.86 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 76.8 t -84.16 108.36 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.921 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -179.439 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . 0.51 ' HE1' ' SG ' ' A' ' 114' ' ' CYS . 37.6 t80 -74.82 140.99 44.32 Favored 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 123.563 0.745 . . . . 0.0 109.37 -177.012 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 3.3 t -144.3 111.49 5.9 Favored 'General case' 0 N--CA 1.426 -1.632 0 CA-C-O 121.919 0.866 . . . . 0.0 110.492 -179.637 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.51 ' SG ' ' HE1' ' A' ' 112' ' ' TYR . 74.7 m -71.46 162.17 29.86 Favored 'General case' 0 C--O 1.255 1.365 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.803 178.501 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.419 ' ND2' ' HA2' ' A' ' 94' ' ' GLY . 37.6 m-20 -74.99 -177.37 3.31 Favored 'General case' 0 C--O 1.211 -0.942 0 CA-C-N 115.817 -0.628 . . . . 0.0 109.905 175.582 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -66.86 -35.05 79.14 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -174.947 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.426 ' HA2' ' CD2' ' A' ' 170' ' ' PHE . . . -73.98 -6.19 72.64 Favored Glycine 0 C--N 1.311 -0.829 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.741 178.948 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.61 ' HE1' HG22 ' A' ' 143' ' ' VAL . 87.8 m-85 -129.88 167.91 17.43 Favored 'General case' 0 N--CA 1.441 -0.903 0 O-C-N 122.427 -0.455 . . . . 0.0 110.189 -176.615 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.408 HE21 ' HB2' ' A' ' 119' ' ' GLN . 0.3 OUTLIER -146.27 157.55 43.81 Favored 'General case' 0 C--N 1.289 -2.033 0 CA-C-O 120.908 0.385 . . . . 0.0 110.682 -178.325 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -78.93 125.78 29.83 Favored 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 178.236 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.589 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -115.45 134.26 55.26 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 178.2 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 109.03 -178.07 20.6 Favored Glycine 0 C--N 1.289 -2.036 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -178.501 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -96.46 -40.53 9.03 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 -178.699 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.582 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 46.8 mm -77.26 124.06 34.99 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-N 114.743 -1.117 . . . . 0.0 108.696 -178.271 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -131.54 9.27 4.66 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 -176.615 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 18.5 p90 -143.88 166.99 23.38 Favored 'General case' 0 N--CA 1.425 -1.689 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -174.978 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.5 ' HA ' ' HB2' ' A' ' 136' ' ' ASN . 63.3 mtp180 -131.95 122.58 25.82 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 171.345 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -91.84 124.8 36.24 Favored 'General case' 0 C--N 1.298 -1.649 0 C-N-CA 119.889 -0.724 . . . . 0.0 111.166 178.386 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . 0.534 ' SG ' ' HA ' ' A' ' 106' ' ' TYR . 36.0 t -80.0 105.03 10.98 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 108.231 -1.025 . . . . 0.0 108.231 175.2 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.437 ' OD2' HG22 ' A' ' 131' ' ' THR . 6.9 t70 -118.9 -169.92 1.82 Allowed 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -178.448 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.437 HG22 ' OD2' ' A' ' 130' ' ' ASP . 12.4 t -57.75 -26.01 61.25 Favored 'General case' 0 CA--C 1.563 1.45 0 C-N-CA 123.803 0.841 . . . . 0.0 112.266 -174.19 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -84.36 -24.86 29.53 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.882 0.848 . . . . 0.0 110.585 -179.731 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.549 ' HA2' ' SG ' ' A' ' 85' ' ' CYS . . . 125.52 -152.55 17.92 Favored Glycine 0 N--CA 1.419 -2.484 0 N-CA-C 106.811 -2.515 . . . . 0.0 106.811 -171.641 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -70.48 114.75 8.9 Favored 'General case' 0 N--CA 1.433 -1.321 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 175.281 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.3 p -64.94 -54.77 25.42 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.762 0.791 . . . . 0.0 111.456 -176.606 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.5 ' HB2' ' HA ' ' A' ' 127' ' ' ARG . 5.8 m120 -78.96 167.77 20.65 Favored 'General case' 0 C--N 1.296 -1.758 0 CA-C-N 114.703 -1.135 . . . . 0.0 108.619 -178.716 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -98.96 -179.91 4.42 Favored 'General case' 0 C--N 1.29 -2.018 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 175.004 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 63.1 mt -65.17 121.17 72.9 Favored Pre-proline 0 C--N 1.309 -1.175 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 177.526 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.582 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 23.2 Cg_exo -57.67 167.29 4.09 Favored 'Trans proline' 0 C--O 1.245 0.853 0 C-N-CA 122.709 2.273 . . . . 0.0 112.179 177.909 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.589 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 3.6 mp -94.27 132.25 38.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 -171.019 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 8.5 t -112.62 119.39 37.97 Favored 'General case' 0 N--CA 1.423 -1.792 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 176.233 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -108.96 156.02 20.19 Favored 'General case' 0 C--N 1.274 -2.717 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 178.566 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.659 ' O ' ' HG3' ' A' ' 145' ' ' LYS . 15.0 t -80.18 149.81 5.09 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.315 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 177.348 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 57.1 t -67.66 115.65 6.09 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.622 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 176.568 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.659 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 39.8 mtpt -123.23 157.67 32.58 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.799 -173.745 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.2 p -134.12 155.51 49.95 Favored 'General case' 0 C--N 1.286 -2.167 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.443 -179.228 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -55.69 147.09 42.77 Favored Pre-proline 0 N--CA 1.443 -0.807 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -177.086 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -71.77 129.9 16.16 Favored 'Trans proline' 0 N--CA 1.444 -1.43 0 C-N-CA 122.841 2.361 . . . . 0.0 111.914 -178.59 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 46.9 t -95.75 129.19 46.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.595 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 9.5 p -74.04 -73.93 0.21 Allowed 'General case' 0 N--CA 1.428 -1.551 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 178.215 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . 175.82 156.68 0.39 Allowed Pre-proline 0 C--N 1.328 -0.347 0 C-N-CA 125.034 1.334 . . . . 0.0 107.526 178.613 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . 0.425 ' HG2' ' HA3' ' A' ' 155' ' ' GLY . 10.9 Cg_endo -66.76 167.04 20.37 Favored 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 121.532 1.488 . . . . 0.0 109.605 170.852 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . 0.568 ' HG2' ' ND2' ' A' ' 154' ' ' ASN . 0.0 OUTLIER -62.52 -45.16 94.26 Favored 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -175.181 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . 0.568 ' ND2' ' HG2' ' A' ' 153' ' ' GLU . 42.7 m-80 -116.51 26.92 9.54 Favored 'General case' 0 CA--C 1.504 -0.813 0 CA-C-O 121.552 0.692 . . . . 0.0 109.689 179.881 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . 0.425 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -142.09 -171.7 13.18 Favored Glycine 0 N--CA 1.423 -2.211 0 C-N-CA 120.233 -0.984 . . . . 0.0 111.814 179.834 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . 0.415 ' HG3' HG23 ' A' ' 177' ' ' VAL . 44.2 pttt -153.26 171.1 19.06 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -177.39 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 53.2 mt -96.02 139.34 19.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 120.606 0.241 . . . . 0.0 111.372 -176.151 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.543 ' CG2' ' HB3' ' A' ' 175' ' ' ARG . 5.0 m -99.03 -28.32 3.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 CA-C-O 121.269 0.556 . . . . 0.0 110.09 178.305 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . 0.556 ' HB2' ' HA ' ' A' ' 174' ' ' VAL . 46.3 m -110.19 112.64 24.74 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.667 -0.697 . . . . 0.0 112.374 -172.041 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 66.8 m -152.19 112.14 4.02 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 175.729 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -70.6 95.71 1.12 Allowed 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 175.004 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 4.8 mmt -99.37 28.82 4.3 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.694 0.759 . . . . 0.0 110.004 -174.019 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.422 ' HB3' ' HD2' ' A' ' 164' ' ' PRO . 57.5 mm-40 -57.27 167.48 1.2 Allowed Pre-proline 0 C--N 1.307 -1.274 0 CA-C-N 113.492 -1.685 . . . . 0.0 108.693 174.752 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . 0.422 ' HD2' ' HB3' ' A' ' 163' ' ' GLU . 12.1 Cg_endo -55.42 -12.34 5.78 Favored 'Trans proline' 0 N--CA 1.5 1.906 0 C-N-CA 123.216 2.611 . . . . 0.0 114.177 178.502 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -94.73 -48.47 6.04 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 123.921 0.888 . . . . 0.0 109.182 -179.623 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . 0.28 3.0 ppt_? 39.39 32.75 0.09 Allowed 'General case' 0 C--O 1.239 0.532 0 N-CA-C 117.653 2.464 . . . . 0.0 117.653 -178.985 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -92.38 152.29 19.82 Favored 'General case' 0 N--CA 1.426 -1.661 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 173.893 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -80.67 130.44 35.1 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 176.888 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -135.08 160.41 38.44 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -178.737 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . 0.426 ' CD2' ' HA2' ' A' ' 117' ' ' GLY . 0.9 OUTLIER -61.55 114.67 3.38 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 172.259 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 135.3 -21.16 3.68 Favored Glycine 0 N--CA 1.427 -1.919 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 -176.198 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 25.7 tp60 -76.81 124.04 27.11 Favored 'General case' 0 N--CA 1.401 -2.89 0 C-N-CA 122.883 0.473 . . . . 0.0 109.986 178.271 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -112.07 118.07 34.38 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 171.262 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.556 ' HA ' ' HB2' ' A' ' 159' ' ' SER . 72.0 t -98.41 113.76 34.02 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -177.712 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.543 ' HB3' ' CG2' ' A' ' 158' ' ' VAL . 72.2 ttt180 -104.02 149.48 25.13 Favored 'General case' 0 N--CA 1.419 -1.99 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 -179.678 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 69.1 m-85 -122.45 162.74 21.12 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 121.579 0.704 . . . . 0.0 111.346 -174.455 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.415 HG23 ' HG3' ' A' ' 156' ' ' LYS . 0.0 OUTLIER -129.42 149.33 33.56 Favored 'Isoleucine or valine' 0 CA--C 1.475 -1.942 0 CA-C-N 113.998 -1.455 . . . . 0.0 109.644 174.097 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . 0.418 ' HB3' ' HB2' ' A' ' 182' ' ' TYR . 73.1 m -111.72 128.38 56.07 Favored 'General case' 0 N--CA 1.406 -2.674 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 176.062 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -50.45 159.74 0.47 Allowed 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 114.62 -1.173 . . . . 0.0 111.713 177.291 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 48.1 t -47.88 113.32 0.7 Allowed 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 114.918 -1.037 . . . . 0.0 112.42 -175.891 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 109.55 -17.3 30.95 Favored Glycine 0 N--CA 1.429 -1.796 0 C-N-CA 120.593 -0.813 . . . . 0.0 113.574 178.237 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . 0.418 ' HB2' ' HB3' ' A' ' 178' ' ' CYS . 95.7 m-85 -99.63 159.57 14.94 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 117.939 0.87 . . . . 0.0 110.965 -177.803 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 16.1 pttm -124.55 150.22 46.12 Favored 'General case' 0 N--CA 1.42 -1.958 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 175.615 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -74.93 133.58 31.21 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.468 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 174.807 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -77.47 -54.71 6.11 Favored 'General case' 0 C--N 1.282 -2.353 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -176.875 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -88.1 -134.65 4.7 Favored Glycine 0 C--N 1.301 -1.372 0 C-N-CA 120.958 -0.639 . . . . 0.0 111.836 177.558 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -87.36 158.7 18.97 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 178.83 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -96.37 6.17 49.34 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.067 -176.154 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -147.38 146.22 29.55 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 121.058 0.456 . . . . 0.0 111.981 -177.109 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.413 ' CE ' ' HA ' ' A' ' 202' ' ' LYS . 12.9 ptp -126.05 132.06 52.03 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.55 176.465 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 24.0 t-80 -105.84 136.09 46.11 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -177.876 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 8.6 t -74.22 124.55 26.6 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 177.338 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 27.1 t -97.18 171.55 8.38 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 122.91 0.484 . . . . 0.0 110.732 -176.361 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -68.14 -11.41 59.11 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 125.027 1.331 . . . . 0.0 114.439 -173.05 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . 0.514 ' HB3' ' CD1' ' A' ' 197' ' ' PHE . 29.3 t70 -94.23 -3.35 50.88 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-O 122.415 1.102 . . . . 0.0 109.959 177.68 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 82.81 49.81 4.93 Favored Glycine 0 N--CA 1.434 -1.497 0 C-N-CA 120.443 -0.884 . . . . 0.0 111.442 179.894 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . 0.514 ' CD1' ' HB3' ' A' ' 195' ' ' ASP . 3.1 p90 -151.77 158.97 44.05 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 178.322 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 87.4 m95 -76.38 135.22 39.49 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 176.551 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 16.9 p -61.1 -28.32 69.01 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.736 0.779 . . . . 0.0 111.291 -177.295 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . . . . . . . . . 40.0 mmtt -113.71 162.83 15.79 Favored 'General case' 0 N--CA 1.418 -2.042 0 CA-C-N 114.729 -1.123 . . . . 0.0 111.062 -178.946 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -75.38 172.28 12.76 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 105.845 -1.909 . . . . 0.0 105.845 172.483 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . 0.413 ' HA ' ' CE ' ' A' ' 190' ' ' MET . 3.1 ttpm? -85.2 116.4 65.32 Favored Pre-proline 0 N--CA 1.421 -1.922 0 C-N-CA 117.321 -1.751 . . . . 0.0 107.773 179.18 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -67.08 166.42 23.1 Favored 'Trans proline' 0 N--CA 1.453 -0.867 0 C-N-CA 122.774 2.316 . . . . 0.0 112.885 -174.733 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . 0.536 ' HG3' ' OE1' ' A' ' 153' ' ' GLU . 87.0 tttt -123.2 153.19 40.42 Favored 'General case' 0 C--N 1.286 -2.155 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.627 -173.627 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . . . . . . . . . 99.9 m -109.82 112.85 25.14 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 177.009 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--N 1.304 -1.381 0 CA-C-N 115.173 -0.921 . . . . 0.0 108.871 -177.127 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo . . . . . 0 CA--C 1.536 0.611 0 CA-C-O 121.783 0.659 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 56.6 m -90.28 -32.89 16.34 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.001 178.86 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 109.68 -78.02 0.23 Allowed Glycine 0 CA--C 1.457 -3.538 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.333 168.833 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 5.0 t60 179.93 128.49 0.24 Allowed Pre-proline 0 C--N 1.274 -2.705 0 N-CA-C 105.08 -2.193 . . . . 0.0 105.08 -176.811 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.416 ' HB2' ' HD3' ' A' ' 127' ' ' ARG . 72.3 Cg_endo -75.98 -0.99 10.88 Favored 'Trans proline' 0 N--CA 1.498 1.765 0 C-N-CA 123.647 2.898 . . . . 0.0 114.448 -172.236 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 118.66 179.64 16.93 Favored Glycine 0 N--CA 1.41 -3.093 0 N-CA-C 107.362 -2.295 . . . . 0.0 107.362 -173.495 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -150.16 160.26 43.8 Favored 'General case' 0 C--N 1.275 -2.641 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 -177.584 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 10.0 t -142.18 136.38 14.89 Favored Pre-proline 0 C--N 1.297 -1.676 0 C-N-CA 120.118 -0.633 . . . . 0.0 111.459 -176.778 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -79.67 -8.94 14.72 Favored 'Trans proline' 0 CA--C 1.533 0.432 0 C-N-CA 123.127 2.551 . . . . 0.0 112.022 176.631 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -93.23 4.28 54.26 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 121.315 0.579 . . . . 0.0 111.202 -176.858 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.627 ' HA2' ' OD1' ' A' ' 115' ' ' ASN . . . 170.19 -131.49 2.26 Favored Glycine 0 N--CA 1.401 -3.636 0 C-N-CA 120.278 -0.963 . . . . 0.0 110.921 -179.548 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.9 t -162.14 -166.64 1.45 Allowed 'General case' 0 C--N 1.277 -2.572 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -178.951 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.429 ' HA ' ' HA ' ' A' ' 112' ' ' TYR . 48.7 p90 -148.14 163.17 37.76 Favored 'General case' 0 C--N 1.305 -1.341 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 178.191 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.9 m -123.12 160.08 27.19 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 178.858 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 18.9 mt -119.7 117.15 27.49 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.865 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.524 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 30.8 p -107.03 130.9 54.59 Favored 'General case' 0 C--N 1.279 -2.496 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.441 -174.04 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 112.86 -67.44 0.24 Allowed Glycine 0 N--CA 1.424 -2.123 0 N-CA-C 110.871 -0.891 . . . . 0.0 110.871 -178.689 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -114.58 -8.84 15.57 Favored Glycine 0 C--N 1.314 -0.66 0 C-N-CA 120.109 -1.043 . . . . 0.0 113.335 -176.097 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . . . . . . . . . 47.9 m-80 61.1 18.63 9.2 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 123.253 0.621 . . . . 0.0 112.371 -178.334 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.498 ' O ' HG11 ' A' ' 108' ' ' VAL . 20.6 m -148.47 -176.73 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 -175.76 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -98.8 43.28 1.06 Allowed 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.13 0.491 . . . . 0.0 110.4 -177.237 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.653 ' O ' HG12 ' A' ' 108' ' ' VAL . 17.8 pt-20 -82.63 -175.95 6.02 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.772 -1.104 . . . . 0.0 111.549 177.394 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -80.71 140.26 35.68 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.393 175.285 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 89.12 -4.89 84.68 Favored Glycine 0 N--CA 1.443 -0.887 0 CA-C-N 115.77 -0.65 . . . . 0.0 113.298 177.691 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.653 HG12 ' O ' ' A' ' 105' ' ' GLU . 15.0 p -88.02 148.21 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.242 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -178.237 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.524 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 58.4 mtpt -109.87 128.93 55.65 Favored 'General case' 0 N--CA 1.414 -2.267 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 177.096 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -91.27 90.69 7.86 Favored 'General case' 0 C--N 1.281 -2.397 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 175.423 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.46 HG12 ' HB3' ' A' ' 126' ' ' TYR . 26.5 m -90.74 110.52 22.33 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-O 122.645 1.212 . . . . 0.0 109.461 -177.361 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . 0.429 ' HA ' ' HA ' ' A' ' 96' ' ' PHE . 27.5 m-85 -76.9 144.55 38.84 Favored 'General case' 0 C--N 1.272 -2.768 0 CA-C-N 115.074 -0.966 . . . . 0.0 112.324 -178.243 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 5.2 t -139.7 116.45 10.86 Favored 'General case' 0 N--CA 1.421 -1.912 0 CA-C-N 114.799 -1.091 . . . . 0.0 108.731 -179.28 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . . . . . . . . . 91.4 m -70.82 161.28 31.23 Favored 'General case' 0 C--N 1.298 -1.658 0 N-CA-C 113.63 0.974 . . . . 0.0 113.63 -179.307 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.627 ' OD1' ' HA2' ' A' ' 94' ' ' GLY . 4.9 m-20 -74.89 -176.73 3.01 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.003 -0.999 . . . . 0.0 110.955 177.552 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 35.7 tt0 -56.03 -49.92 72.36 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 123.68 0.792 . . . . 0.0 112.746 -177.599 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -89.44 19.01 42.5 Favored Glycine 0 N--CA 1.438 -1.217 0 C-N-CA 120.804 -0.712 . . . . 0.0 113.539 -177.802 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.69 ' CD1' ' HA ' ' A' ' 143' ' ' VAL . 87.2 m-85 -137.5 159.21 42.59 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 117.287 0.544 . . . . 0.0 110.488 -179.982 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . 0.534 ' OE1' ' HB3' ' A' ' 142' ' ' GLU . 0.0 OUTLIER -145.35 159.17 43.45 Favored 'General case' 0 N--CA 1.425 -1.714 0 C-N-CA 121.087 -0.245 . . . . 0.0 110.348 179.129 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.92 122.71 27.58 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 -176.902 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -107.9 127.62 53.9 Favored 'General case' 0 N--CA 1.414 -2.233 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 179.853 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 113.48 179.41 19.24 Favored Glycine 0 C--N 1.291 -1.93 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -178.182 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -94.49 -30.19 14.55 Favored 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.852 0.834 . . . . 0.0 108.77 -177.793 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . . . . . . . . . 49.2 mm -87.14 122.8 39.44 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.56 0 CA-C-N 114.922 -1.035 . . . . 0.0 109.101 -179.331 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -124.4 1.24 8.36 Favored 'General case' 0 C--O 1.203 -1.38 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 178.811 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.502 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 40.4 p90 -139.34 164.74 29.05 Favored 'General case' 0 C--N 1.288 -2.087 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -170.432 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . 0.416 ' HD3' ' HB2' ' A' ' 88' ' ' PRO . 43.1 mtp180 -127.87 133.63 49.35 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 171.706 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -103.98 128.14 51.53 Favored 'General case' 0 C--N 1.289 -2.043 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 -178.485 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 13.7 t -82.85 105.22 13.69 Favored 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 117.749 -1.58 . . . . 0.0 110.332 177.18 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.462 ' OD1' HG22 ' A' ' 131' ' ' THR . 9.1 t70 -97.84 -168.68 1.71 Allowed 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 177.483 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.462 HG22 ' OD1' ' A' ' 130' ' ' ASP . 15.3 t -66.83 -22.57 66.0 Favored 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 118.161 0.437 . . . . 0.0 111.468 -175.123 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -88.95 -9.29 52.03 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.681 0.753 . . . . 0.0 110.03 178.67 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . 114.72 -160.8 13.0 Favored Glycine 0 N--CA 1.428 -1.838 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -176.808 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . 0.416 ' CH2' HG13 ' A' ' 108' ' ' VAL . 96.9 m95 -64.22 113.57 3.66 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 122.543 0.337 . . . . 0.0 111.819 -179.044 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 66.3 p -73.61 176.03 6.56 Favored 'General case' 0 C--O 1.269 2.124 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.408 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 35.1 m-20 60.68 -149.08 0.43 Allowed 'General case' 0 C--O 1.244 0.787 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 179.281 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -144.2 -173.11 3.92 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 171.343 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 73.5 mt -66.01 119.29 60.18 Favored Pre-proline 0 C--N 1.272 -2.798 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 174.877 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -62.15 163.19 20.61 Favored 'Trans proline' 0 C--O 1.253 1.266 0 C-N-CA 122.686 2.257 . . . . 0.0 112.011 -178.918 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . . . . . . . . . 47.7 mm -93.83 123.72 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 CA-C-O 121.505 0.669 . . . . 0.0 109.939 -173.976 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.631 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 22.0 t -107.51 110.1 21.94 Favored 'General case' 0 C--N 1.263 -3.187 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 176.607 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.534 ' HB3' ' OE1' ' A' ' 119' ' ' GLN . 10.5 tp10 -101.2 150.77 22.62 Favored 'General case' 0 N--CA 1.409 -2.478 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -175.898 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.69 ' HA ' ' CD1' ' A' ' 118' ' ' TYR . 8.6 t -75.63 137.01 23.69 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.385 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.129 -177.696 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 42.9 t -67.96 112.15 2.88 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.933 0 N-CA-C 106.538 -1.652 . . . . 0.0 106.538 174.888 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . 0.432 ' HG3' ' O ' ' A' ' 143' ' ' VAL . 35.3 mtmm -129.86 161.57 30.51 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-N 115.5 -0.773 . . . . 0.0 108.951 -175.609 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 1.6 p -129.62 164.5 23.75 Favored 'General case' 0 C--N 1.271 -2.831 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.896 -178.138 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . . . . . . . . . 85.4 mt -70.63 142.38 88.67 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 113.931 1.085 . . . . 0.0 113.931 -175.67 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_endo -63.39 119.66 6.8 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 123.05 2.5 . . . . 0.0 110.178 175.811 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.7 t -80.29 151.84 4.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.249 -174.398 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . 0.425 ' O ' HD11 ' A' ' 157' ' ' ILE . 27.9 p -87.93 -159.08 0.5 Allowed 'General case' 0 N--CA 1.414 -2.24 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 170.971 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . . . . . . . . . . . -128.9 151.59 77.69 Favored Pre-proline 0 C--N 1.283 -2.306 0 O-C-N 121.142 -0.973 . . . . 0.0 109.53 -172.277 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . 0.453 ' HG2' ' HA3' ' A' ' 155' ' ' GLY . 24.0 Cg_endo -66.86 160.7 45.56 Favored 'Trans proline' 0 N--CA 1.454 -0.8 0 C-N-CA 122.055 1.836 . . . . 0.0 112.419 178.072 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -48.88 -45.79 41.64 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 126.0 1.72 . . . . 0.0 114.389 -175.516 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . . . . . . . . . 59.5 m-80 -126.84 27.15 6.06 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-O 122.077 0.941 . . . . 0.0 109.49 -178.477 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . 0.453 ' HA3' ' HG2' ' A' ' 152' ' ' PRO . . . -132.15 -169.41 12.3 Favored Glycine 0 N--CA 1.42 -2.382 0 CA-C-N 114.714 -1.13 . . . . 0.0 111.066 179.572 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . 0.481 ' HG3' HG23 ' A' ' 177' ' ' VAL . 45.3 pttt -157.94 171.78 19.65 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -177.746 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.425 HD11 ' O ' ' A' ' 150' ' ' THR . 58.6 mt -97.2 131.84 43.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 C-N-CA 122.022 0.129 . . . . 0.0 110.743 -177.613 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.581 HG12 HG22 ' A' ' 177' ' ' VAL . 3.5 m -75.19 -38.33 41.37 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.321 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.0 m -86.54 35.31 0.66 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 124.87 1.268 . . . . 0.0 109.134 -176.501 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 23.0 t -67.17 167.94 11.21 Favored 'General case' 0 N--CA 1.436 -1.139 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.529 -175.822 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . 67.32 96.22 0.06 Allowed 'General case' 0 CA--C 1.507 -0.7 0 CA-C-O 122.319 1.057 . . . . 0.0 110.921 -175.961 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 22.8 ttp -108.31 107.89 18.66 Favored 'General case' 0 N--CA 1.403 -2.821 0 N-CA-C 104.49 -2.411 . . . . 0.0 104.49 179.559 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -82.1 154.88 69.99 Favored Pre-proline 0 C--N 1.252 -3.631 0 CA-C-N 114.655 -1.157 . . . . 0.0 110.074 -170.772 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -56.94 -21.08 39.35 Favored 'Trans proline' 0 C--N 1.354 0.864 0 C-N-CA 123.22 2.613 . . . . 0.0 114.073 -178.581 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -98.53 -38.09 9.31 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 178.565 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 19.1 mmm180 -100.19 71.79 1.61 Allowed 'General case' 0 N--CA 1.415 -2.194 0 CA-C-N 114.937 -1.028 . . . . 0.0 111.353 -175.707 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -85.36 170.31 12.87 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 175.089 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . . . . . . . . . 62.0 m-85 -68.64 104.73 2.05 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.668 0.747 . . . . 0.0 111.557 -177.251 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -105.86 164.24 12.1 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 179.023 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 90.7 t80 -52.14 128.16 23.92 Favored 'General case' 0 C--N 1.317 -0.807 0 C-N-CA 123.123 0.569 . . . . 0.0 109.827 174.516 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 114.46 -33.95 5.15 Favored Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.382 -179.129 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . . . . . . . . . 14.2 mm100 -70.12 151.62 45.25 Favored 'General case' 0 C--O 1.259 1.557 0 CA-C-O 121.244 0.545 . . . . 0.0 109.825 179.863 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -135.09 131.16 36.59 Favored 'General case' 0 C--N 1.296 -1.733 0 CA-C-N 115.344 -0.843 . . . . 0.0 109.467 179.339 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 95.3 t -100.12 114.68 39.4 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 -178.594 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.575 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 43.2 ttm180 -101.49 142.99 32.05 Favored 'General case' 0 N--CA 1.419 -1.981 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 177.366 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 81.6 m-85 -111.99 160.52 17.38 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 123.138 0.575 . . . . 0.0 110.876 -176.613 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.581 HG22 HG12 ' A' ' 158' ' ' VAL . 0.1 OUTLIER -131.52 143.29 40.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 115.183 -0.917 . . . . 0.0 108.933 178.962 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 93.4 m -102.17 132.1 48.28 Favored 'General case' 0 C--N 1.276 -2.603 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 174.168 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 59.0 m-80 -61.09 163.12 6.38 Favored 'General case' 0 CA--C 1.491 -1.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.569 -178.715 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 10.9 m -46.89 106.67 0.09 Allowed 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 125.51 1.524 . . . . 0.0 112.569 -175.723 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . 115.79 -16.52 16.16 Favored Glycine 0 N--CA 1.435 -1.396 0 CA-C-N 115.343 -0.844 . . . . 0.0 113.323 178.99 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . 0.431 ' HB3' ' HB3' ' A' ' 205' ' ' CYS . 90.1 m-85 -103.8 155.07 18.89 Favored 'General case' 0 CA--C 1.495 -1.138 0 CA-C-N 117.269 0.535 . . . . 0.0 111.609 -177.664 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -125.16 147.34 49.08 Favored 'General case' 0 N--CA 1.423 -1.785 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 177.981 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . . . . . . . . . 9.1 tt -79.96 136.64 23.07 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.934 0 CA-C-O 121.802 0.811 . . . . 0.0 111.287 -177.296 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -81.87 -52.14 7.39 Favored 'General case' 0 C--N 1.292 -1.916 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.736 -177.707 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -86.4 -152.75 21.54 Favored Glycine 0 N--CA 1.433 -1.553 0 CA-C-N 114.97 -1.014 . . . . 0.0 111.042 178.487 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . 0.421 ' OD1' ' HD2' ' A' ' 200' ' ' LYS . 1.6 p-10 -92.7 163.11 13.88 Favored 'General case' 0 C--N 1.289 -2.024 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 177.955 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.575 ' O ' ' HA ' ' A' ' 175' ' ' ARG . 0.8 OUTLIER -99.87 3.74 44.75 Favored 'General case' 0 C--N 1.286 -2.181 0 C-N-CA 118.509 -1.277 . . . . 0.0 113.165 -171.683 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -144.39 121.81 11.67 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -173.986 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . 0.434 ' HB3' ' HB2' ' A' ' 200' ' ' LYS . 15.0 ptp -105.46 131.19 53.19 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.403 177.955 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . . . . . . . . . 25.1 t-80 -106.16 135.42 47.65 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.446 -176.952 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . . . . . . . . . 7.3 t -72.74 112.48 8.83 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.043 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . 0.424 ' OG ' ' HB3' ' A' ' 199' ' ' SER . 17.5 m -94.56 172.2 8.33 Favored 'General case' 0 N--CA 1.442 -0.856 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.289 -173.467 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -43.02 -43.1 4.11 Favored 'General case' 0 N--CA 1.495 1.775 0 C-N-CA 127.02 2.128 . . . . 0.0 114.538 -171.713 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -92.26 12.73 21.43 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 113.675 0.991 . . . . 0.0 113.675 -174.798 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 78.97 46.95 7.98 Favored Glycine 0 CA--C 1.496 -1.128 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.8 176.052 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 31.7 p90 -145.0 160.29 41.6 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 179.633 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -82.23 132.03 35.23 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 177.389 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . 0.424 ' HB3' ' OG ' ' A' ' 193' ' ' SER . 23.8 p -66.06 -22.49 66.43 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.551 0.691 . . . . 0.0 111.11 -178.945 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.434 ' HB2' ' HB3' ' A' ' 190' ' ' MET . 26.5 mmtp -120.75 151.0 40.11 Favored 'General case' 0 N--CA 1.419 -1.977 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.534 -177.829 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 73.0 mm-40 -89.42 166.53 13.66 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.211 176.928 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . 0.449 ' HE2' ' HB3' ' A' ' 202' ' ' LYS . 39.6 mtpt -63.95 119.04 51.63 Favored Pre-proline 0 C--N 1.319 -0.73 0 O-C-N 123.464 0.477 . . . . 0.0 111.057 179.513 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . 0.441 ' O ' ' HB3' ' A' ' 152' ' ' PRO . 95.4 Cg_endo -77.39 168.1 23.43 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 122.642 2.228 . . . . 0.0 112.056 179.973 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 37.1 ttpt -119.9 150.86 39.79 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.86 -176.653 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.431 ' HB3' ' HB3' ' A' ' 182' ' ' TYR . 83.8 m -110.93 118.72 36.87 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 177.388 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 30.4 m . . . . . 0 C--N 1.3 -1.555 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.574 -175.325 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo . . . . . 0 CA--C 1.537 0.666 0 CA-C-O 121.603 0.585 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 60.7 m -82.83 -32.89 27.33 Favored 'General case' 0 CA--C 1.504 -0.814 0 CA-C-O 122.005 0.907 . . . . 0.0 108.612 179.024 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 118.75 -87.85 0.43 Allowed Glycine 0 N--CA 1.396 -3.967 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.366 174.415 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 36.0 t-80 -175.02 135.39 0.52 Allowed Pre-proline 0 C--N 1.264 -3.135 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 -173.711 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.545 ' HD3' ' CD1' ' A' ' 104' ' ' PHE . 66.9 Cg_endo -93.69 -5.18 2.76 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.497 2.131 . . . . 0.0 113.031 -178.139 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 106.73 175.93 23.08 Favored Glycine 0 CA--C 1.485 -1.826 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 178.787 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -151.43 152.88 33.66 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 177.319 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.423 HG21 ' CZ ' ' A' ' 112' ' ' TYR . 9.6 t -125.18 141.12 37.72 Favored Pre-proline 0 C--N 1.29 -1.994 0 O-C-N 123.385 0.428 . . . . 0.0 112.043 -175.218 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -79.84 -12.69 13.36 Favored 'Trans proline' 0 CA--C 1.546 1.091 0 C-N-CA 122.913 2.409 . . . . 0.0 111.405 173.511 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -85.98 2.26 46.93 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 121.744 0.783 . . . . 0.0 110.861 -178.7 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.609 ' HA2' ' CG ' ' A' ' 115' ' ' ASN . . . 174.48 -126.56 1.21 Allowed Glycine 0 N--CA 1.402 -3.571 0 N-CA-C 110.007 -1.237 . . . . 0.0 110.007 -178.737 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.8 t -164.5 -166.23 1.06 Allowed 'General case' 0 C--N 1.27 -2.878 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.847 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -153.01 158.05 41.44 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 177.691 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.8 m -127.17 158.98 35.65 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 179.991 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.412 ' HB2' ' HA ' ' A' ' 102' ' ' ASN . 22.0 mt -116.55 127.49 54.56 Favored 'General case' 0 C--N 1.275 -2.669 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 -179.736 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.509 ' OG1' ' HB2' ' A' ' 109' ' ' LYS . 21.2 p -117.61 125.82 51.45 Favored 'General case' 0 C--N 1.29 -1.991 0 CA-C-O 121.311 0.577 . . . . 0.0 111.063 -175.728 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 121.55 -58.18 0.59 Allowed Glycine 0 N--CA 1.432 -1.602 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.306 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -130.82 -3.02 4.64 Favored Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.632 -0.794 . . . . 0.0 113.678 -177.868 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 102' ' ' ASN . . . . . 0.412 ' HA ' ' HB2' ' A' ' 98' ' ' LEU . 2.3 t30 54.13 29.29 10.15 Favored 'General case' 0 CA--C 1.559 1.315 0 C-N-CA 125.776 1.631 . . . . 0.0 112.016 -178.922 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.532 ' O ' HG11 ' A' ' 108' ' ' VAL . 18.7 m -149.74 -174.77 0.3 Allowed 'Isoleucine or valine' 0 C--O 1.209 -1.043 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 179.699 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.545 ' CD1' ' HD3' ' A' ' 88' ' ' PRO . 20.6 m-85 -100.8 44.48 1.01 Allowed 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 118.767 0.712 . . . . 0.0 110.359 -178.174 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.684 ' O ' HG12 ' A' ' 108' ' ' VAL . 9.7 pt-20 -85.06 177.59 7.86 Favored 'General case' 0 C--O 1.211 -0.967 0 CA-C-N 114.639 -1.164 . . . . 0.0 111.89 178.413 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 106' ' ' TYR . . . . . . . . . . . . . 30.8 m-85 -76.58 133.13 39.76 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.219 177.372 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.02 5.06 64.4 Favored Glycine 0 N--CA 1.438 -1.232 0 CA-C-N 115.791 -0.64 . . . . 0.0 112.679 179.85 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.684 HG12 ' O ' ' A' ' 105' ' ' GLU . 11.0 p -97.44 147.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 -179.92 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 109' ' ' LYS . . . . . 0.509 ' HB2' ' OG1' ' A' ' 99' ' ' THR . 57.4 mtpt -109.64 130.64 55.5 Favored 'General case' 0 N--CA 1.42 -1.938 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 177.249 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.527 ' O ' ' HA ' ' A' ' 126' ' ' TYR . . . -94.49 95.71 9.0 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 175.034 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 78.7 t -89.3 112.9 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.859 0 C-N-CA 123.768 0.827 . . . . 0.0 108.8 -178.327 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 112' ' ' TYR . . . . . 0.489 ' CB ' ' HG2' ' A' ' 139' ' ' PRO . 9.6 t80 -81.9 138.39 35.03 Favored 'General case' 0 C--N 1.276 -2.597 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -177.785 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 9.0 t -138.55 120.56 15.56 Favored 'General case' 0 N--CA 1.424 -1.739 0 CA-C-O 121.785 0.802 . . . . 0.0 109.309 177.64 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 114' ' ' CYS . . . . . 0.447 ' SG ' ' HE1' ' A' ' 112' ' ' TYR . 75.8 m -73.94 160.28 31.58 Favored 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.597 -179.244 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.609 ' CG ' ' HA2' ' A' ' 94' ' ' GLY . 82.2 m-20 -78.32 177.12 8.69 Favored 'General case' 0 C--O 1.212 -0.884 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.111 176.706 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . 0.476 ' HG3' ' OD2' ' A' ' 194' ' ' ASP . 39.9 tt0 -44.81 -46.62 10.73 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 124.956 1.303 . . . . 0.0 114.308 -177.305 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -84.91 5.33 82.96 Favored Glycine 0 C--N 1.311 -0.858 0 C-N-CA 120.309 -0.948 . . . . 0.0 114.048 -176.663 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.499 ' HB3' ' SG ' ' A' ' 141' ' ' CYS . 97.3 m-85 -130.61 164.28 25.29 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 -176.506 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 119' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -148.1 155.77 41.84 Favored 'General case' 0 C--N 1.289 -2.04 0 CA-C-O 120.988 0.423 . . . . 0.0 110.242 179.495 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 120' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -77.38 130.91 37.72 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 179.351 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.588 ' O ' ' HB ' ' A' ' 140' ' ' ILE . 0.2 OUTLIER -119.45 130.41 55.24 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.83 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 105.17 -175.07 21.82 Favored Glycine 0 C--N 1.295 -1.717 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.521 -179.597 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -91.8 -29.04 16.98 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-O 121.53 0.681 . . . . 0.0 109.646 -178.331 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 124' ' ' ILE . . . . . 0.569 ' O ' ' HB3' ' A' ' 139' ' ' PRO . 46.9 mm -82.95 114.51 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.553 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.869 -177.778 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 -130.42 7.67 4.95 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 179.896 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 126' ' ' TYR . . . . . 0.527 ' HA ' ' O ' ' A' ' 110' ' ' ALA . 17.8 p90 -151.57 156.43 40.46 Favored 'General case' 0 N--CA 1.425 -1.689 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.415 -173.446 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 127' ' ' ARG . . . . . . . . . . . . . 52.1 mtp180 -121.34 125.29 46.65 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 105.14 -2.17 . . . . 0.0 105.14 171.538 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -101.73 126.88 48.67 Favored 'General case' 0 C--N 1.275 -2.65 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.074 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . 0.459 ' SG ' ' HA2' ' A' ' 133' ' ' GLY . 25.5 t -86.03 100.81 12.41 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 118.498 -1.281 . . . . 0.0 110.075 176.166 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.424 ' OD1' HG22 ' A' ' 131' ' ' THR . 9.2 t70 -98.71 -165.28 1.22 Allowed 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 105.456 -2.053 . . . . 0.0 105.456 175.602 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.424 HG22 ' OD1' ' A' ' 130' ' ' ASP . 10.2 t -63.5 -22.95 67.18 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-N 119.131 0.878 . . . . 0.0 112.143 -177.02 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -80.23 -13.57 59.11 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.652 0.739 . . . . 0.0 110.692 176.357 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.459 ' HA2' ' SG ' ' A' ' 129' ' ' CYS . . . 105.49 -148.51 16.52 Favored Glycine 0 N--CA 1.421 -2.339 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -175.375 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 134' ' ' TRP . . . . . . . . . . . . . 85.0 m95 -69.13 109.55 4.09 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 176.908 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 28.9 p -61.14 -68.8 0.28 Allowed 'General case' 0 N--CA 1.438 -1.039 0 O-C-N 123.792 0.682 . . . . 0.0 111.48 -178.126 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 74.4 m-20 -75.62 177.13 7.02 Favored 'General case' 0 CA--C 1.489 -1.368 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.513 178.035 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 137' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -108.13 -168.91 1.43 Allowed 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 178.511 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . . . . . . . . . 67.2 mt -60.87 117.98 30.76 Favored Pre-proline 0 C--N 1.295 -1.775 0 O-C-N 123.986 0.804 . . . . 0.0 109.33 177.272 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 139' ' ' PRO . . . . . 0.569 ' HB3' ' O ' ' A' ' 124' ' ' ILE . 53.3 Cg_exo -52.77 165.99 0.99 Allowed 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.867 3.045 . . . . 0.0 113.916 178.644 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 140' ' ' ILE . . . . . 0.588 ' HB ' ' O ' ' A' ' 121' ' ' LEU . 3.6 mp -90.73 130.7 39.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.172 -174.801 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 141' ' ' CYS . . . . . 0.499 ' SG ' ' HB3' ' A' ' 118' ' ' TYR . 25.4 t -123.6 114.93 20.68 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.318 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 9.5 tp10 -110.41 149.79 29.76 Favored 'General case' 0 N--CA 1.405 -2.711 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 -177.961 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 9.6 p -73.69 143.53 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.898 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.572 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 144' ' ' VAL . . . . . . . . . . . . . 89.3 t -68.69 123.05 21.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 177.155 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 91.5 mttt -109.3 140.14 43.36 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.149 -176.421 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 57.5 m -102.13 144.66 30.41 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.9 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 147' ' ' LEU . . . . . 0.4 HD23 ' HD2' ' A' ' 148' ' ' PRO . 1.4 tt -49.59 130.03 19.4 Favored Pre-proline 0 N--CA 1.432 -1.36 0 C-N-CA 125.275 1.43 . . . . 0.0 110.748 179.491 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.563 ' HA ' ' CD2' ' A' ' 168' ' ' TYR . 12.4 Cg_endo -57.74 110.59 0.65 Allowed 'Trans proline' 0 N--CA 1.454 -0.813 0 C-N-CA 123.557 2.838 . . . . 0.0 113.35 -178.522 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 13.6 p -83.81 142.72 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 CA-C-N 115.176 -0.92 . . . . 0.0 108.865 177.397 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 10.2 p -105.22 -156.4 0.57 Allowed 'General case' 0 C--N 1.288 -2.069 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.37 176.172 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 151' ' ' ALA . . . . . 0.457 ' HB1' ' HA ' ' A' ' 156' ' ' LYS . . . -100.85 151.25 37.56 Favored Pre-proline 0 C--N 1.298 -1.649 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -170.636 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 152' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -75.62 170.24 20.64 Favored 'Trans proline' 0 N--CA 1.436 -1.906 0 C-N-CA 121.442 1.428 . . . . 0.0 110.914 175.25 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -50.41 -55.24 16.62 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 114.306 1.224 . . . . 0.0 114.306 -175.992 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 154' ' ' ASN . . . . . 0.436 ' HB2' ' O ' ' A' ' 205' ' ' CYS . 57.4 m-80 -113.95 27.04 9.82 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.19 0.519 . . . . 0.0 110.725 -177.544 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 155' ' ' GLY . . . . . . . . . . . . . . . -144.7 -173.1 15.71 Favored Glycine 0 N--CA 1.43 -1.702 0 C-N-CA 120.081 -1.057 . . . . 0.0 111.726 179.768 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 156' ' ' LYS . . . . . 0.457 ' HA ' ' HB1' ' A' ' 151' ' ' ALA . 50.3 pttt -153.33 172.67 16.68 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 -178.14 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 62.5 mt -86.04 132.1 32.91 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 CA-C-O 121.169 0.509 . . . . 0.0 111.058 -176.46 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.447 ' CG2' ' HB ' ' A' ' 177' ' ' VAL . 47.9 t -76.52 -40.31 33.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 C-N-CA 123.974 0.91 . . . . 0.0 108.907 177.172 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 159' ' ' SER . . . . . . . . . . . . . 4.0 m -84.08 32.28 0.49 Allowed 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.446 179.933 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 160' ' ' SER . . . . . . . . . . . . . 17.6 t -79.55 82.0 5.73 Favored 'General case' 0 N--CA 1.431 -1.406 0 CA-C-O 121.999 0.904 . . . . 0.0 112.568 -172.393 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 161' ' ' ALA . . . . . . . . . . . . . . . -115.7 72.76 0.81 Allowed 'General case' 0 N--CA 1.411 -2.375 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 169.973 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 162' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.76 82.84 8.15 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-O 122.293 1.044 . . . . 0.0 110.204 -176.682 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 57.1 mm-40 -122.21 155.0 62.14 Favored Pre-proline 0 C--N 1.282 -2.336 0 CA-C-N 113.376 -1.738 . . . . 0.0 108.035 -176.608 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 164' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -57.22 -25.19 63.3 Favored 'Trans proline' 0 CA--C 1.545 1.033 0 C-N-CA 123.115 2.544 . . . . 0.0 113.529 -179.211 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 165' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -92.19 -34.26 14.37 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.907 0.86 . . . . 0.0 109.82 -179.177 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 166' ' ' ARG . . . . . . . . . . . . . 6.2 mmp_? -81.7 81.38 7.77 Favored 'General case' 0 N--CA 1.422 -1.841 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.082 -177.824 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 167' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -103.46 165.54 10.97 Favored 'General case' 0 C--N 1.294 -1.84 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 176.203 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 168' ' ' TYR . . . . . 0.563 ' CD2' ' HA ' ' A' ' 148' ' ' PRO . 98.0 m-85 -78.71 103.41 8.63 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-O 121.661 0.743 . . . . 0.0 112.087 -174.594 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 27.7 m80 -98.38 155.47 17.21 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 114.506 -1.224 . . . . 0.0 107.966 -179.463 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 170' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -56.77 131.5 49.45 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 172.012 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . 0.438 ' H ' ' HB2' ' A' ' 192' ' ' CYS . . . 113.43 -15.03 22.64 Favored Glycine 0 N--CA 1.414 -2.768 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.234 -177.682 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 172' ' ' GLN . . . . . 0.426 ' O ' ' HA ' ' A' ' 191' ' ' HIS . 15.5 mm100 -74.58 134.38 42.13 Favored 'General case' 0 N--CA 1.423 -1.788 0 C-N-CA 120.223 -0.591 . . . . 0.0 111.976 179.55 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -115.15 94.34 4.69 Favored 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 173.562 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 66.2 t -81.61 109.02 15.36 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.84 0 CA-C-N 115.243 -0.889 . . . . 0.0 108.963 -176.121 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 175' ' ' ARG . . . . . 0.45 ' HA ' ' O ' ' A' ' 188' ' ' GLU . 14.5 ttp180 -97.1 156.27 16.45 Favored 'General case' 0 N--CA 1.411 -2.387 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 179.055 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 176' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -127.09 156.35 41.85 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 124.038 0.935 . . . . 0.0 109.399 -175.006 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.447 ' HB ' ' CG2' ' A' ' 158' ' ' VAL . 12.2 p -133.56 141.07 45.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.461 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 178' ' ' CYS . . . . . . . . . . . . . 80.5 m -102.54 153.63 19.89 Favored 'General case' 0 C--N 1.265 -3.105 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.961 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 179' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -64.62 163.46 13.68 Favored 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 119.972 -0.691 . . . . 0.0 110.153 176.73 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 180' ' ' SER . . . . . . . . . . . . . 15.8 m -43.54 -32.74 0.98 Allowed 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 116.37 1.989 . . . . 0.0 116.37 -170.724 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 181' ' ' GLY . . . . . . . . . . . . . . . -113.36 21.09 17.87 Favored Glycine 0 C--N 1.293 -1.847 0 C-N-CA 120.1 -1.047 . . . . 0.0 113.375 -179.048 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 182' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -122.32 151.06 41.53 Favored 'General case' 0 N--CA 1.432 -1.335 0 O-C-N 122.129 -0.63 . . . . 0.0 111.356 179.28 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -124.15 143.59 50.4 Favored 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.158 -178.93 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 184' ' ' ILE . . . . . 0.527 HD13 ' HA ' ' A' ' 188' ' ' GLU . 4.4 tt -74.87 140.55 17.3 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.928 0 CA-C-O 121.476 0.655 . . . . 0.0 111.288 -176.695 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 185' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -67.01 -64.57 0.83 Allowed 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.318 -177.261 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -103.41 -123.59 5.3 Favored Glycine 0 N--CA 1.436 -1.32 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.283 -179.558 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 187' ' ' ASP . . . . . 0.583 ' HB2' ' HG3' ' A' ' 200' ' ' LYS . 5.5 m-20 -91.63 153.4 19.73 Favored 'General case' 0 CA--C 1.491 -1.291 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -177.495 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 188' ' ' GLU . . . . . 0.527 ' HA ' HD13 ' A' ' 184' ' ' ILE . 14.2 pt-20 -91.65 -4.04 55.67 Favored 'General case' 0 C--O 1.205 -1.286 0 C-N-CA 119.944 -0.702 . . . . 0.0 111.174 -172.027 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 189' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -134.34 132.31 39.35 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 -177.72 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 190' ' ' MET . . . . . . . . . . . . . 14.4 ptp -112.68 123.54 50.53 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.304 -0.862 . . . . 0.0 109.271 174.881 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 191' ' ' HIS . . . . . 0.426 ' HA ' ' O ' ' A' ' 172' ' ' GLN . 16.4 t-80 -110.36 139.01 45.99 Favored 'General case' 0 C--N 1.279 -2.498 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.954 -177.317 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 192' ' ' CYS . . . . . 0.438 ' HB2' ' H ' ' A' ' 171' ' ' GLY . 22.0 m -62.64 130.14 43.69 Favored 'General case' 0 C--N 1.32 -0.705 0 O-C-N 123.657 0.598 . . . . 0.0 111.668 175.207 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 193' ' ' SER . . . . . . . . . . . . . 37.5 t -101.78 166.92 10.41 Favored 'General case' 0 C--N 1.312 -1.031 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.137 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 194' ' ' ASP . . . . . 0.476 ' OD2' ' HG3' ' A' ' 116' ' ' GLU . 6.3 t70 -52.41 -33.22 42.82 Favored 'General case' 0 N--CA 1.511 2.613 0 C-N-CA 124.236 1.014 . . . . 0.0 110.332 178.925 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 195' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -56.94 -26.21 59.14 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 113.75 -1.568 . . . . 0.0 111.742 179.807 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 196' ' ' GLY . . . . . . . . . . . . . . . 89.59 15.53 58.2 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -174.97 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 197' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -125.27 170.54 11.19 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.064 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 198' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -85.39 142.49 29.24 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 123.678 0.611 . . . . 0.0 110.944 -177.699 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 199' ' ' SER . . . . . . . . . . . . . 30.7 t -60.64 -50.29 74.11 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.725 176.593 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 200' ' ' LYS . . . . . 0.583 ' HG3' ' HB2' ' A' ' 187' ' ' ASP . 12.9 mmmm -104.61 156.14 18.23 Favored 'General case' 0 CA--C 1.485 -1.548 0 N-CA-C 108.771 -0.825 . . . . 0.0 108.771 174.227 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 201' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -89.06 171.73 9.63 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 170.546 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 202' ' ' LYS . . . . . . . . . . . . . 34.9 ttmt -61.9 122.25 70.67 Favored Pre-proline 0 C--O 1.243 0.724 0 CA-C-N 118.985 0.811 . . . . 0.0 110.492 -176.246 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 203' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.04 -173.49 1.9 Allowed 'Trans proline' 0 N--CA 1.437 -1.833 0 C-N-CA 122.039 1.826 . . . . 0.0 111.067 179.122 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 204' ' ' LYS . . . . . . . . . . . . . 66.0 mttm -126.58 160.88 29.39 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.118 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 205' ' ' CYS . . . . . 0.436 ' O ' ' HB2' ' A' ' 154' ' ' ASN . 97.4 m -116.62 105.19 12.17 Favored 'General case' 0 C--N 1.27 -2.887 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 170.852 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 206' ' ' VAL . . . . . . . . . . . . . 23.7 m . . . . . 0 C--N 1.286 -2.176 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.033 -173.547 . . . . . . . . 0 0 . 1 stop_ save_